<SEC-DOCUMENT>0001193125-23-092665.txt : 20230406
<SEC-HEADER>0001193125-23-092665.hdr.sgml : 20230406
<ACCEPTANCE-DATETIME>20230405202404
ACCESSION NUMBER:		0001193125-23-092665
CONFORMED SUBMISSION TYPE:	POS AM
PUBLIC DOCUMENT COUNT:		99
FILED AS OF DATE:		20230406
DATE AS OF CHANGE:		20230405

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			biote Corp.
		CENTRAL INDEX KEY:			0001819253
		STANDARD INDUSTRIAL CLASSIFICATION:	MEDICINAL CHEMICALS & BOTANICAL PRODUCTS [2833]
		IRS NUMBER:				851791125
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		POS AM
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-266433
		FILM NUMBER:		23804108

	BUSINESS ADDRESS:	
		STREET 1:		1875 W. WALNUT HILL LN #100
		CITY:			IRVING
		STATE:			TX
		ZIP:			75038
		BUSINESS PHONE:		972-486-9346

	MAIL ADDRESS:	
		STREET 1:		1875 W. WALNUT HILL LN #100
		CITY:			IRVING
		STATE:			TX
		ZIP:			75038

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Haymaker Acquisition Corp. III
		DATE OF NAME CHANGE:	20200727
</SEC-HEADER>
<DOCUMENT>
<TYPE>POS AM
<SEQUENCE>1
<FILENAME>d479690dposam.htm
<DESCRIPTION>POS AM
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8" ?>
<html xmlns:btmd="http://haymaker.com/20221231" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dei="http://xbrl.sec.gov/dei/2022" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:deprecated="http://www.xbrl.org/2009/arcrole/deprecated" xmlns:country="http://xbrl.sec.gov/country/2022" xmlns:currency="http://xbrl.sec.gov/currency/2022" xmlns:exch="http://xbrl.sec.gov/exch/2022" xmlns:naics="http://xbrl.sec.gov/naics/2022" xmlns:sic="http://xbrl.sec.gov/sic/2022" xmlns:stpr="http://xbrl.sec.gov/stpr/2022" xmlns:us-gaap="http://fasb.org/us-gaap/2022" xmlns:xl="http://www.xbrl.org/2003/XLink" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:us-gaap-supplement="http://fasb.org/us-gaap-sup/2022q3" xmlns:srt-supplement="http://fasb.org/srt-sup/2022q3" xmlns:srt="http://fasb.org/srt/2022" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:xbrll="http://www.xbrl.org/2003/linkbase" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns="http://www.w3.org/1999/xhtml">
<head>
<title>POS AM</title>
<meta content="text/html; charset=UTF-8" http-equiv="Content-Type"/>
</head>
<body style=""><div style='display: none'><ix:header><ix:hidden><ix:nonNumeric name="dei:DocumentType" id="hidden73945327" contextRef="P01_01_2022To12_31_2022">S-1</ix:nonNumeric><ix:nonNumeric name="dei:AmendmentFlag" contextRef="P01_01_2022To12_31_2022">false</ix:nonNumeric><ix:nonNumeric name="dei:EntityCentralIndexKey" contextRef="P01_01_2022To12_31_2022">0001819253</ix:nonNumeric><ix:nonNumeric name="dei:EntityAddressStateOrProvince" id="hidden73945344" contextRef="P01_01_2022To12_31_2022">TX</ix:nonNumeric><ix:nonNumeric name="dei:EntityAddressStateOrProvince" id="hidden73945345" contextRef="P01_01_2022To12_31_2022_BusinessContactMemberdeiEntityAddressesAddressTypeAxis">TX</ix:nonNumeric></ix:hidden><ix:references><link:schemaRef xlink:type="simple" xlink:href="btmd-20221231.xsd" /><link:linkbaseRef xlink:type="simple" xlink:href="btmd-20221231_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" /><link:linkbaseRef xlink:type="simple" xlink:href="btmd-20221231_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" /><link:linkbaseRef xlink:type="simple" xlink:href="btmd-20221231_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" /><link:linkbaseRef xlink:type="simple" xlink:href="btmd-20221231_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" /></ix:references><ix:resources><xbrli:context id="PAsOn12_31_2022" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001819253</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001819253</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001819253</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001819253</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P07_01_2014To07_01_2014" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001819253</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:startDate>2014-07-01</xbrli:startDate> <xbrli:endDate>2014-07-01</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P06_23_2022To06_23_2022" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001819253</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-06-23</xbrli:startDate> <xbrli:endDate>2022-06-23</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P05_27_2022To12_31_2022" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001819253</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-05-27</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn11_01_2022" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001819253</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-11-01</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To05_26_2022" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001819253</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-05-26</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn05_26_2022" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001819253</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-05-26</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="P07_27_2022To07_27_2022" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001819253</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-07-27</xbrli:startDate> <xbrli:endDate>2022-07-27</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001819253</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_ClassAVotingUnitsMemberusgaapCapitalUnitsByClassAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001819253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:CapitalUnitsByClassAxis" >btmd:ClassAVotingUnitsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_ClassAaNonVotingUnitsMemberusgaapCapitalUnitsByClassAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001819253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:CapitalUnitsByClassAxis" >btmd:ClassAaNonVotingUnitsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_ClassAaaNonVotingUnitsMemberusgaapCapitalUnitsByClassAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001819253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:CapitalUnitsByClassAxis" >btmd:ClassAaaNonVotingUnitsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_ClassAaaaNonVotingIncentiveUnitsMemberusgaapCapitalUnitsByClassAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001819253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:CapitalUnitsByClassAxis" >btmd:ClassAaaaNonVotingIncentiveUnitsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_UnsatisfiedTrainingObligationsMembersrtProductOrServiceAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001819253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis" >btmd:UnsatisfiedTrainingObligationsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_UnsatisfiedContractTermServicesMembersrtProductOrServiceAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001819253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis" >btmd:UnsatisfiedContractTermServicesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_UnsatisfiedPelletProceduresMembersrtProductOrServiceAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001819253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis" >btmd:UnsatisfiedPelletProceduresMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_PelletsMemberusgaapPublicUtilitiesInventoryAxis_ProductMembersrtProductOrServiceAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001819253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PublicUtilitiesInventoryAxis" >btmd:PelletsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis" >us-gaap:ProductMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_DietarySupplementsMemberusgaapPublicUtilitiesInventoryAxis_ProductMembersrtProductOrServiceAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001819253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis" >us-gaap:ProductMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:PublicUtilitiesInventoryAxis" >btmd:DietarySupplementsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_TrocarsMemberusgaapPropertyPlantAndEquipmentByTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001819253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis" >btmd:TrocarsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_LeaseholdImprovementsMemberusgaapPropertyPlantAndEquipmentByTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001819253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis" >us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_OfficeEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001819253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis" >us-gaap:OfficeEquipmentMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_SoftwareAndSoftwareDevelopmentCostsMemberusgaapPropertyPlantAndEquipmentByTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001819253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis" >us-gaap:SoftwareAndSoftwareDevelopmentCostsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_FurnitureAndFixturesMemberusgaapPropertyPlantAndEquipmentByTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001819253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis" >us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_ComputerEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001819253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis" >us-gaap:ComputerEquipmentMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_ConstructionInProgressMemberusgaapPropertyPlantAndEquipmentByTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001819253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis" >us-gaap:ConstructionInProgressMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_FirmMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001819253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis" >btmd:FirmMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_EmployeeMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001819253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis" >btmd:EmployeeMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_VendorMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001819253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis" >btmd:VendorMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_CommonClassBMemberusgaapStatementClassOfStockAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001819253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis" >us-gaap:CommonClassBMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_SpouseOfFounderChairmanAndBeneficialOwnerMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001819253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis" >btmd:SpouseOfFounderChairmanAndBeneficialOwnerMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_BankOfAmericaTermLoanMemberusgaapDebtInstrumentAxis_LineOfCreditMemberusgaapCreditFacilityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001819253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis" >us-gaap:LineOfCreditMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis" >btmd:BankOfAmericaTermLoanMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_ClassAMemberusgaapStatementClassOfStockAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001819253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis" >btmd:ClassAMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_ClassAaUnitsMemberusgaapStatementClassOfStockAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001819253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis" >btmd:ClassAaUnitsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_ClassAaaUnitsMemberusgaapStatementClassOfStockAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001819253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis" >btmd:ClassAaaUnitsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_ClassAaaaUnitsMemberusgaapStatementClassOfStockAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001819253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis" >btmd:ClassAaaaUnitsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_CommonClassAMemberusgaapStatementClassOfStockAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001819253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis" >us-gaap:CommonClassAMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_CommonClassVMemberusgaapStatementClassOfStockAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001819253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis" >btmd:CommonClassVMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_HaymakeriiiMembersrtConsolidatedEntitiesAxis_OtherBusinessCombinationMemberusgaapBusinessAcquisitionAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001819253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis" >btmd:HaymakeriiiMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis" >btmd:OtherBusinessCombinationMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_BioteMethodCustomerMemberbtmdNatureOfCustomerAxis_ServiceRevenueMemberbtmdSourceOfRevenueAxis_TrainingMemberbtmdSourceOfServiceRevenueAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001819253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="btmd:SourceOfServiceRevenueAxis" >btmd:TrainingMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="btmd:SourceOfRevenueAxis" >btmd:ServiceRevenueMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="btmd:NatureOfCustomerAxis" >btmd:BioteMethodCustomerMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_BioteMethodCustomerMemberbtmdNatureOfCustomerAxis_ContractTermServicesMemberbtmdSourceOfServiceRevenueAxis_ServiceRevenueMemberbtmdSourceOfRevenueAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001819253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="btmd:SourceOfRevenueAxis" >btmd:ServiceRevenueMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="btmd:NatureOfCustomerAxis" >btmd:BioteMethodCustomerMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="btmd:SourceOfServiceRevenueAxis" >btmd:ContractTermServicesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_BioteMethodCustomerMemberbtmdNatureOfCustomerAxis_PalletProceduresMemberbtmdSourceOfServiceRevenueAxis_ProductRevenueMemberbtmdSourceOfRevenueAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001819253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="btmd:NatureOfCustomerAxis" >btmd:BioteMethodCustomerMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="btmd:SourceOfRevenueAxis" >btmd:ProductRevenueMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="btmd:SourceOfServiceRevenueAxis" >btmd:PalletProceduresMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_HaymakeriiiMembersrtConsolidatedEntitiesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001819253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis" >btmd:HaymakeriiiMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_UnsatisfiedTrainingObligationsMembersrtProductOrServiceAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001819253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis" >btmd:UnsatisfiedTrainingObligationsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_UnsatisfiedContractTermServicesMembersrtProductOrServiceAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001819253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis" >btmd:UnsatisfiedContractTermServicesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_UnsatisfiedPelletProceduresMembersrtProductOrServiceAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001819253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis" >btmd:UnsatisfiedPelletProceduresMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_PelletsMemberusgaapPublicUtilitiesInventoryAxis_ProductMembersrtProductOrServiceAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001819253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PublicUtilitiesInventoryAxis" >btmd:PelletsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis" >us-gaap:ProductMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_DietarySupplementsMemberusgaapPublicUtilitiesInventoryAxis_ProductMembersrtProductOrServiceAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001819253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis" >us-gaap:ProductMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:PublicUtilitiesInventoryAxis" >btmd:DietarySupplementsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_TrocarsMemberusgaapPropertyPlantAndEquipmentByTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001819253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis" >btmd:TrocarsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_LeaseholdImprovementsMemberusgaapPropertyPlantAndEquipmentByTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001819253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis" >us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_OfficeEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001819253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis" >us-gaap:OfficeEquipmentMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_SoftwareAndSoftwareDevelopmentCostsMemberusgaapPropertyPlantAndEquipmentByTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001819253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis" >us-gaap:SoftwareAndSoftwareDevelopmentCostsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_FurnitureAndFixturesMemberusgaapPropertyPlantAndEquipmentByTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001819253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis" >us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_ComputerEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001819253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis" >us-gaap:ComputerEquipmentMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_CommonClassAMemberusgaapStatementClassOfStockAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001819253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis" >us-gaap:CommonClassAMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_CommonClassBMemberusgaapStatementClassOfStockAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001819253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis" >us-gaap:CommonClassBMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_ClassVCommonStockMemberusgaapStatementClassOfStockAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001819253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis" >btmd:ClassVCommonStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_PublicWarrantsMemberusgaapFinancialInstrumentAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001819253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis" >btmd:PublicWarrantsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis" >us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_PublicWarrantsMemberusgaapFinancialInstrumentAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001819253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis" >btmd:PublicWarrantsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_PrivatePlacementWarrantsMemberusgaapFinancialInstrumentAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001819253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis" >btmd:PrivatePlacementWarrantsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis" >us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_PrivatePlacementWarrantsMemberusgaapFinancialInstrumentAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001819253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis" >btmd:PrivatePlacementWarrantsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_EarnoutLiabilityMemberusgaapFinancialInstrumentAxis_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001819253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis" >btmd:EarnoutLiabilityMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis" >us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_EarnoutLiabilityMemberusgaapFinancialInstrumentAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001819253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis" >btmd:EarnoutLiabilityMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_MeasurementInputSharePriceMemberusgaapMeasurementInputTypeAxis_PrivatePlacementWarrantsMemberusgaapFinancialInstrumentAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001819253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis" >us-gaap:MeasurementInputSharePriceMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis" >btmd:PrivatePlacementWarrantsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_EarnoutLiabilityMemberusgaapFinancialInstrumentAxis_MeasurementInputSharePriceMemberusgaapMeasurementInputTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001819253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis" >us-gaap:MeasurementInputSharePriceMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis" >btmd:EarnoutLiabilityMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_ForeignCountryMemberusgaapIncomeTaxAuthorityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001819253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis" >us-gaap:ForeignCountryMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_FirmMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001819253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis" >btmd:FirmMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_EmployeeMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001819253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis" >btmd:EmployeeMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_VendorMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001819253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis" >btmd:VendorMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_BioteCorporationMembersrtOwnershipAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001819253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:OwnershipAxis" >btmd:BioteCorporationMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_EarnoutLiabilityMemberusgaapFinancialInstrumentAxis_MeasurementInputRiskFreeInterestRateMemberusgaapMeasurementInputTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001819253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis" >btmd:EarnoutLiabilityMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis" >us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_EarnoutLiabilityMemberusgaapFinancialInstrumentAxis_MeasurementInputOptionVolatilityMemberusgaapMeasurementInputTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001819253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis" >btmd:EarnoutLiabilityMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis" >us-gaap:MeasurementInputOptionVolatilityMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_MeasurementInputExpectedTermMemberusgaapMeasurementInputTypeAxis_PrivatePlacementWarrantsMemberusgaapFinancialInstrumentAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001819253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis" >btmd:PrivatePlacementWarrantsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis" >us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_CommonClassVMemberusgaapStatementClassOfStockAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001819253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis" >btmd:CommonClassVMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_LineOfCreditMemberusgaapCreditFacilityAxis_TruistTermLoanMemberusgaapDebtInstrumentAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001819253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis" >us-gaap:LineOfCreditMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis" >btmd:TruistTermLoanMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_CommonClassAMemberusgaapStatementClassOfStockAxis_HaymakeriiiMembersrtConsolidatedEntitiesAxis_RedeemableWarrantsMemberusgaapClassOfWarrantOrRightAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001819253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis" >btmd:HaymakeriiiMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis" >btmd:RedeemableWarrantsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis" >us-gaap:CommonClassAMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_MeasurementInputExercisePriceMemberusgaapMeasurementInputTypeAxis_PrivatePlacementWarrantsMemberusgaapFinancialInstrumentAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001819253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis" >btmd:PrivatePlacementWarrantsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis" >us-gaap:MeasurementInputExercisePriceMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_MeasurementInputRiskFreeInterestRateMemberusgaapMeasurementInputTypeAxis_PrivatePlacementWarrantsMemberusgaapFinancialInstrumentAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001819253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis" >btmd:PrivatePlacementWarrantsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis" >us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_MeasurementInputOptionVolatilityMemberusgaapMeasurementInputTypeAxis_PrivatePlacementWarrantsMemberusgaapFinancialInstrumentAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001819253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis" >btmd:PrivatePlacementWarrantsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis" >us-gaap:MeasurementInputOptionVolatilityMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_EarnoutLiabilityMemberusgaapFinancialInstrumentAxis_MeasurementInputExpectedTermMemberusgaapMeasurementInputTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001819253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis" >btmd:EarnoutLiabilityMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis" >us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_BusinessCombinationMemberusgaapBusinessAcquisitionAxis_CommonClassAMemberusgaapStatementClassOfStockAxis_SharePriceEqualsOrExceedsTwelvePointFivePerShareMemberusgaapVestingAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001819253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis" >btmd:BusinessCombinationMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis" >us-gaap:CommonClassAMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:VestingAxis" >btmd:SharePriceEqualsOrExceedsTwelvePointFivePerShareMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_BusinessCombinationMemberusgaapBusinessAcquisitionAxis_SharePriceEqualsOrExceedsFifteenPerShareMemberusgaapVestingAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001819253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis" >btmd:BusinessCombinationMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:VestingAxis" >btmd:SharePriceEqualsOrExceedsFifteenPerShareMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_BusinessCombinationMemberusgaapBusinessAcquisitionAxis_SharePriceEqualsOrExceedsSeventeenPointFivePerShareMemberusgaapVestingAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001819253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:VestingAxis" >btmd:SharePriceEqualsOrExceedsSeventeenPointFivePerShareMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis" >btmd:BusinessCombinationMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_HaymakeriiiMembersrtConsolidatedEntitiesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001819253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis" >btmd:HaymakeriiiMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_CommonClassAMemberusgaapStatementClassOfStockAxis_HaymakeriiiMembersrtConsolidatedEntitiesAxis_SharePriceEqualOrLessNinePointTwoRupeesPerDollarMemberusgaapMeasurementInputTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001819253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis" >btmd:HaymakeriiiMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis" >btmd:SharePriceEqualOrLessNinePointTwoRupeesPerDollarMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis" >us-gaap:CommonClassAMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis_TwoThousandTwentyTwoEquityIncentivePlanMemberusgaapPlanNameAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001819253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis" >btmd:TwoThousandTwentyTwoEquityIncentivePlanMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis" >us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_EmployeeStockOptionMemberusgaapAwardTypeAxis_TwoThousandTwentyTwoEquityIncentivePlanMemberusgaapPlanNameAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001819253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis" >btmd:TwoThousandTwentyTwoEquityIncentivePlanMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis" >us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_TwoThousandTwentyTwoEquityIncentivePlanMemberusgaapPlanNameAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001819253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis" >btmd:TwoThousandTwentyTwoEquityIncentivePlanMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_SpouseOfFounderChairmanAndBeneficialOwnerMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001819253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis" >btmd:SpouseOfFounderChairmanAndBeneficialOwnerMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_BankOfAmericaTermLoanMemberusgaapDebtInstrumentAxis_LineOfCreditMemberusgaapCreditFacilityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001819253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis" >us-gaap:LineOfCreditMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis" >btmd:BankOfAmericaTermLoanMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_ClassAVotingUnitsMemberusgaapCapitalUnitsByClassAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001819253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:CapitalUnitsByClassAxis" >btmd:ClassAVotingUnitsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_ClassAMemberusgaapStatementClassOfStockAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001819253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis" >btmd:ClassAMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_ClassAaUnitsMemberusgaapStatementClassOfStockAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001819253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis" >btmd:ClassAaUnitsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_ClassAaaUnitsMemberusgaapStatementClassOfStockAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001819253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis" >btmd:ClassAaaUnitsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_ClassAaaaUnitsMemberusgaapStatementClassOfStockAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001819253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis" >btmd:ClassAaaaUnitsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_HaymakeriiiMembersrtConsolidatedEntitiesAxis_OtherBusinessCombinationMemberusgaapBusinessAcquisitionAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001819253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis" >btmd:OtherBusinessCombinationMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis" >btmd:HaymakeriiiMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_RevolvingCreditFacilityMemberusgaapCreditFacilityAxis_TruistTermLoanMemberusgaapDebtInstrumentAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001819253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis" >us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis" >btmd:TruistTermLoanMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_CommonClassAMemberusgaapStatementClassOfStockAxis_SharePriceEqualOrExceedsTenRupeesPerDollarMemberusgaapMeasurementInputTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001819253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis" >btmd:SharePriceEqualOrExceedsTenRupeesPerDollarMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis" >us-gaap:CommonClassAMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_CommonClassAMemberusgaapStatementClassOfStockAxis_SharePriceEqualOrExceedsEighteenRupeesPerDollarMemberusgaapMeasurementInputTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001819253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis" >btmd:SharePriceEqualOrExceedsEighteenRupeesPerDollarMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis" >us-gaap:CommonClassAMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_CommonClassAMemberusgaapStatementClassOfStockAxis_HaymakeriiiMembersrtConsolidatedEntitiesAxis_SharePriceEqualOrExceedsEighteenRupeesPerDollarMemberusgaapMeasurementInputTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001819253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis" >btmd:SharePriceEqualOrExceedsEighteenRupeesPerDollarMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis" >btmd:HaymakeriiiMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis" >us-gaap:CommonClassAMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_DebtInstrumentRedemptionPeriodOneMemberusgaapDebtInstrumentRedemptionPeriodAxis_LineOfCreditMemberusgaapCreditFacilityAxis_MaximumMembersrtRangeAxis_TruistTermLoanMemberusgaapDebtInstrumentAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001819253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis" >us-gaap:DebtInstrumentRedemptionPeriodOneMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis" >us-gaap:LineOfCreditMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:RangeAxis" >srt:MaximumMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis" >btmd:TruistTermLoanMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_DebtInstrumentRedemptionPeriodTwoMemberusgaapDebtInstrumentRedemptionPeriodAxis_LineOfCreditMemberusgaapCreditFacilityAxis_MaximumMembersrtRangeAxis_TruistTermLoanMemberusgaapDebtInstrumentAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001819253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis" >us-gaap:LineOfCreditMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis" >us-gaap:DebtInstrumentRedemptionPeriodTwoMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:RangeAxis" >srt:MaximumMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis" >btmd:TruistTermLoanMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_DebtInstrumentRedemptionPeriodThreeMemberusgaapDebtInstrumentRedemptionPeriodAxis_LineOfCreditMemberusgaapCreditFacilityAxis_MaximumMembersrtRangeAxis_TruistTermLoanMemberusgaapDebtInstrumentAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001819253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis" >us-gaap:LineOfCreditMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:RangeAxis" >srt:MaximumMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis" >btmd:TruistTermLoanMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis" >us-gaap:DebtInstrumentRedemptionPeriodThreeMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_LineOfCreditMemberusgaapCreditFacilityAxis_MinimumMembersrtRangeAxis_TruistTermLoanMemberusgaapDebtInstrumentAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001819253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:RangeAxis" >srt:MinimumMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis" >us-gaap:LineOfCreditMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis" >btmd:TruistTermLoanMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_BioteMethodCustomerMemberbtmdNatureOfCustomerAxis_ServiceRevenueMemberbtmdSourceOfRevenueAxis_TrainingMemberbtmdSourceOfServiceRevenueAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001819253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="btmd:SourceOfServiceRevenueAxis" >btmd:TrainingMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="btmd:SourceOfRevenueAxis" >btmd:ServiceRevenueMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="btmd:NatureOfCustomerAxis" >btmd:BioteMethodCustomerMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_BioteMethodCustomerMemberbtmdNatureOfCustomerAxis_ContractTermServicesMemberbtmdSourceOfServiceRevenueAxis_ServiceRevenueMemberbtmdSourceOfRevenueAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001819253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="btmd:SourceOfRevenueAxis" >btmd:ServiceRevenueMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="btmd:NatureOfCustomerAxis" >btmd:BioteMethodCustomerMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="btmd:SourceOfServiceRevenueAxis" >btmd:ContractTermServicesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_BioteMethodCustomerMemberbtmdNatureOfCustomerAxis_PalletProceduresMemberbtmdSourceOfServiceRevenueAxis_ProductRevenueMemberbtmdSourceOfRevenueAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001819253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="btmd:NatureOfCustomerAxis" >btmd:BioteMethodCustomerMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="btmd:SourceOfRevenueAxis" >btmd:ProductRevenueMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="btmd:SourceOfServiceRevenueAxis" >btmd:PalletProceduresMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_HaymakeriiiMembersrtConsolidatedEntitiesAxis_PrivatePlacementWarrantsMemberusgaapClassOfWarrantOrRightAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001819253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis" >btmd:HaymakeriiiMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis" >btmd:PrivatePlacementWarrantsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_CommonClassAMemberusgaapStatementClassOfStockAxis_HaymakeriiiMembersrtConsolidatedEntitiesAxis_PrivatePlacementWarrantsMemberusgaapClassOfWarrantOrRightAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001819253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis" >btmd:HaymakeriiiMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis" >us-gaap:CommonClassAMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis" >btmd:PrivatePlacementWarrantsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_HaymakeriiiMembersrtConsolidatedEntitiesAxis_PublicWarrantsMemberusgaapClassOfWarrantOrRightAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001819253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis" >btmd:HaymakeriiiMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis" >btmd:PublicWarrantsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_HaymakeriiiMembersrtConsolidatedEntitiesAxis_PrivatePlacementWarrantsMemberusgaapClassOfWarrantOrRightAxis_SponseMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001819253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis" >btmd:SponseMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis" >btmd:HaymakeriiiMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis" >btmd:PrivatePlacementWarrantsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_AccountingStandardsUpdate201912MemberusgaapAdjustmentsForNewAccountingPronouncementsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001819253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis" >us-gaap:AccountingStandardsUpdate201912Member</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_ProductRevenueMembersrtProductOrServiceAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001819253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis" >btmd:ProductRevenueMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_ServiceRevenueMembersrtProductOrServiceAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001819253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis" >btmd:ServiceRevenueMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_PelletProceduresProductRevenueMembersrtProductOrServiceAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001819253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis" >btmd:PelletProceduresProductRevenueMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_DietarySupplementsMembersrtProductOrServiceAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001819253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis" >btmd:DietarySupplementsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_DisposableTrocarsProductRevenueMembersrtProductOrServiceAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001819253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis" >btmd:DisposableTrocarsProductRevenueMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_ShippingFeesProductRevenueMembersrtProductOrServiceAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001819253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis" >btmd:ShippingFeesProductRevenueMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_TrainingServiceRevenueMembersrtProductOrServiceAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001819253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis" >btmd:TrainingServiceRevenueMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_ContractTermServicesRevenueMembersrtProductOrServiceAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001819253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis" >btmd:ContractTermServicesRevenueMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_ProductRevenueMembersrtProductOrServiceAxis_USsrtStatementGeographicalAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001819253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis" >country:US</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis" >btmd:ProductRevenueMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_AllOtherCountryMembersrtStatementGeographicalAxis_ProductRevenueMembersrtProductOrServiceAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001819253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis" >btmd:ProductRevenueMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis" >btmd:AllOtherCountryMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_ServiceRevenueMembersrtProductOrServiceAxis_USsrtStatementGeographicalAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001819253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis" >country:US</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis" >btmd:ServiceRevenueMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_ShortTermContractWithCustomerMemberusgaapContractWithCustomerDurationAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001819253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:ContractWithCustomerDurationAxis" >us-gaap:ShortTermContractWithCustomerMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_CommonClassVMemberusgaapStatementClassOfStockAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001819253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis" >btmd:CommonClassVMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_FirmMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001819253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis" >btmd:FirmMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_LongTermContractWithCustomerMemberusgaapContractWithCustomerDurationAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001819253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:ContractWithCustomerDurationAxis" >us-gaap:LongTermContractWithCustomerMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_EmployeeMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001819253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis" >btmd:EmployeeMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_SpouseOfFounderChairmanAndBeneficialOwnerMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001819253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis" >btmd:SpouseOfFounderChairmanAndBeneficialOwnerMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001819253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:RetainedEarningsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_ParentMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001819253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:ParentMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001819253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_VendorMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001819253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis" >btmd:VendorMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_BankOfAmericaTermLoanMemberusgaapDebtInstrumentAxis_LineOfCreditMemberusgaapCreditFacilityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001819253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis" >us-gaap:LineOfCreditMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis" >btmd:BankOfAmericaTermLoanMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_BankOfAmericaTermLoanAndTruistTermLoanMemberusgaapDebtInstrumentAxis_LineOfCreditMemberusgaapCreditFacilityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001819253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis" >us-gaap:LineOfCreditMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis" >btmd:BankOfAmericaTermLoanAndTruistTermLoanMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_AssetsTotalMemberusgaapConcentrationRiskByBenchmarkAxis_InventoryMembersrtProductOrServiceAxis_SupplierConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001819253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis" >btmd:InventoryMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis" >us-gaap:AssetsTotalMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis" >us-gaap:SupplierConcentrationRiskMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_FourZeroOneKPlanMemberusgaapRetirementPlanNameAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001819253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:RetirementPlanNameAxis" >btmd:FourZeroOneKPlanMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_BioteMethodCustomerMemberbtmdNatureOfCustomerAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001819253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="btmd:NatureOfCustomerAxis" >btmd:BioteMethodCustomerMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_ProductRevenueMembersrtProductOrServiceAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001819253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis" >btmd:ProductRevenueMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_ServiceRevenueMembersrtProductOrServiceAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001819253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis" >btmd:ServiceRevenueMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_TrocarsMemberusgaapPropertyPlantAndEquipmentByTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001819253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis" >btmd:TrocarsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_OfficeEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001819253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis" >us-gaap:OfficeEquipmentMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_MinimumMembersrtRangeAxis_SoftwareDevelopmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001819253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis" >us-gaap:SoftwareDevelopmentMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:RangeAxis" >srt:MinimumMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_MaximumMembersrtRangeAxis_SoftwareDevelopmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001819253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis" >us-gaap:SoftwareDevelopmentMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:RangeAxis" >srt:MaximumMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_FurnitureAndFixturesMemberusgaapPropertyPlantAndEquipmentByTypeAxis_MinimumMembersrtRangeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001819253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis" >us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:RangeAxis" >srt:MinimumMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_FurnitureAndFixturesMemberusgaapPropertyPlantAndEquipmentByTypeAxis_MaximumMembersrtRangeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001819253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis" >us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:RangeAxis" >srt:MaximumMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_ComputerEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis_MinimumMembersrtRangeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001819253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis" >us-gaap:ComputerEquipmentMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:RangeAxis" >srt:MinimumMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_ComputerEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis_MaximumMembersrtRangeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001819253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis" >us-gaap:ComputerEquipmentMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:RangeAxis" >srt:MaximumMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_PelletProceduresProductRevenueMembersrtProductOrServiceAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001819253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis" >btmd:PelletProceduresProductRevenueMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_DietarySupplementsMembersrtProductOrServiceAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001819253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis" >btmd:DietarySupplementsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_DisposableTrocarsProductRevenueMembersrtProductOrServiceAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001819253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis" >btmd:DisposableTrocarsProductRevenueMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_ShippingFeesProductRevenueMembersrtProductOrServiceAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001819253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis" >btmd:ShippingFeesProductRevenueMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_TrainingServiceRevenueMembersrtProductOrServiceAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001819253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis" >btmd:TrainingServiceRevenueMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_ContractTermServicesRevenueMembersrtProductOrServiceAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001819253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis" >btmd:ContractTermServicesRevenueMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_ProductRevenueMembersrtProductOrServiceAxis_USsrtStatementGeographicalAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001819253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis" >country:US</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis" >btmd:ProductRevenueMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_AllOtherCountryMembersrtStatementGeographicalAxis_ProductRevenueMembersrtProductOrServiceAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001819253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis" >btmd:ProductRevenueMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis" >btmd:AllOtherCountryMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_ServiceRevenueMembersrtProductOrServiceAxis_USsrtStatementGeographicalAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001819253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis" >country:US</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis" >btmd:ServiceRevenueMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_AllOtherCountryMembersrtStatementGeographicalAxis_ServiceRevenueMembersrtProductOrServiceAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001819253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis" >btmd:AllOtherCountryMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis" >btmd:ServiceRevenueMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_ShortTermContractWithCustomerMemberusgaapContractWithCustomerDurationAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001819253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:ContractWithCustomerDurationAxis" >us-gaap:ShortTermContractWithCustomerMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_BioteManagementLlcMemberusgaapBusinessAcquisitionAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001819253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis" >btmd:BioteManagementLlcMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_CommonClassAMemberusgaapStatementClassOfStockAxis_HaymakeriiiMembersrtConsolidatedEntitiesAxis_RedeemableWarrantsMemberusgaapClassOfWarrantOrRightAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001819253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis" >us-gaap:CommonClassAMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis" >btmd:RedeemableWarrantsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis" >btmd:HaymakeriiiMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_TwoThousandTwentyTwoEquityIncentivePlanMemberusgaapPlanNameAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001819253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis" >btmd:TwoThousandTwentyTwoEquityIncentivePlanMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_RestrictedStockUnitsRSUMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001819253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" >us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_EmployeeStockOptionMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001819253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" >us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_ClassVCommonStockMemberusgaapStatementClassOfStockAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001819253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis" >btmd:ClassVCommonStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_PublicWarrantsMemberusgaapClassOfWarrantOrRightAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001819253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis" >btmd:PublicWarrantsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_PrivatePlacementWarrantsMemberusgaapClassOfWarrantOrRightAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001819253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis" >btmd:PrivatePlacementWarrantsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_EarnoutVotingSharesMemberusgaapStatementClassOfStockAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001819253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis" >btmd:EarnoutVotingSharesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_SponsorEarnOutSharesMemberusgaapStatementClassOfStockAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001819253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis" >btmd:SponsorEarnOutSharesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_FirmMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001819253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis" >btmd:FirmMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_ForeignCountryMemberusgaapIncomeTaxAuthorityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001819253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis" >us-gaap:ForeignCountryMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis_TwoThousandTwentyTwoEquityIncentivePlanMemberusgaapPlanNameAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001819253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis" >btmd:TwoThousandTwentyTwoEquityIncentivePlanMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis" >us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_EmployeeStockOptionMemberusgaapAwardTypeAxis_TwoThousandTwentyTwoEquityIncentivePlanMemberusgaapPlanNameAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001819253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis" >btmd:TwoThousandTwentyTwoEquityIncentivePlanMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis" >us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_BusinessCombinationMemberusgaapBusinessAcquisitionAxis_MaximumMembersrtRangeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001819253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis" >btmd:BusinessCombinationMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:RangeAxis" >srt:MaximumMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_CommonClassAMemberusgaapStatementClassOfStockAxis_HaymakeriiiMembersrtConsolidatedEntitiesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001819253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis" >us-gaap:CommonClassAMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis" >btmd:HaymakeriiiMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_CommonClassAMemberusgaapStatementClassOfStockAxis_HaymakeriiiMembersrtConsolidatedEntitiesAxis_SponseMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001819253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis" >us-gaap:CommonClassAMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis" >btmd:SponseMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis" >btmd:HaymakeriiiMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_CommonClassAMemberusgaapStatementClassOfStockAxis_SharePriceEqualOrExceedsTenRupeesPerDollarMemberusgaapMeasurementInputTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001819253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis" >btmd:SharePriceEqualOrExceedsTenRupeesPerDollarMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis" >us-gaap:CommonClassAMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_BankOfAmericaTermLoanMemberusgaapDebtInstrumentAxis_LineOfCreditMemberusgaapCreditFacilityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001819253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis" >btmd:BankOfAmericaTermLoanMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis" >us-gaap:LineOfCreditMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_LongTermContractWithCustomerMemberusgaapContractWithCustomerDurationAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001819253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:ContractWithCustomerDurationAxis" >us-gaap:LongTermContractWithCustomerMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_LeaseholdImprovementsMemberusgaapPropertyPlantAndEquipmentByTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001819253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis" >us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_MinimumMembersrtRangeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001819253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:RangeAxis" >srt:MinimumMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_MaximumMembersrtRangeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001819253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:RangeAxis" >srt:MaximumMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_BusinessCombinationMemberusgaapBusinessAcquisitionAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001819253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis" >btmd:BusinessCombinationMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_CommonClassVMemberusgaapStatementClassOfStockAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001819253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis" >btmd:CommonClassVMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_EmployeeMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001819253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis" >btmd:EmployeeMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_SpouseOfFounderChairmanAndBeneficialOwnerMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001819253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis" >btmd:SpouseOfFounderChairmanAndBeneficialOwnerMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_LineOfCreditMemberusgaapCreditFacilityAxis_TruistTermLoanMemberusgaapDebtInstrumentAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001819253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis" >us-gaap:LineOfCreditMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis" >btmd:TruistTermLoanMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001819253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:RetainedEarningsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_ParentMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001819253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:ParentMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_NoncontrollingInterestMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001819253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_HaymakeriiiMembersrtConsolidatedEntitiesAxis_OtherBusinessCombinationMemberusgaapBusinessAcquisitionAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001819253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis" >btmd:HaymakeriiiMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis" >btmd:OtherBusinessCombinationMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_BusinessCombinationMemberusgaapBusinessAcquisitionAxis_CommonClassAMemberusgaapStatementClassOfStockAxis_SharePriceEqualsOrExceedsTwelvePointFivePerShareMemberusgaapVestingAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001819253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis" >btmd:BusinessCombinationMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis" >us-gaap:CommonClassAMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:VestingAxis" >btmd:SharePriceEqualsOrExceedsTwelvePointFivePerShareMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_BusinessCombinationMemberusgaapBusinessAcquisitionAxis_SharePriceEqualsOrExceedsFifteenPerShareMemberusgaapVestingAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001819253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis" >btmd:BusinessCombinationMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:VestingAxis" >btmd:SharePriceEqualsOrExceedsFifteenPerShareMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_BusinessCombinationMemberusgaapBusinessAcquisitionAxis_SharePriceEqualsOrExceedsSeventeenPointFivePerShareMemberusgaapVestingAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001819253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:VestingAxis" >btmd:SharePriceEqualsOrExceedsSeventeenPointFivePerShareMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis" >btmd:BusinessCombinationMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_MaximumMembersrtRangeAxis_PhantomEquityRightsMemberusgaapAwardTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001819253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:RangeAxis" >srt:MaximumMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis" >btmd:PhantomEquityRightsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_MinimumMembersrtRangeAxis_PhantomEquityRightsMemberusgaapAwardTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001819253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:RangeAxis" >srt:MinimumMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis" >btmd:PhantomEquityRightsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_VendorMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001819253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis" >btmd:VendorMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_HaymakeriiiMembersrtConsolidatedEntitiesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001819253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis" >btmd:HaymakeriiiMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_CommonClassAMemberusgaapStatementClassOfStockAxis_SharePriceEqualOrExceedsEighteenRupeesPerDollarMemberusgaapMeasurementInputTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001819253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis" >btmd:SharePriceEqualOrExceedsEighteenRupeesPerDollarMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis" >us-gaap:CommonClassAMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_StandbyEquityPurchaseAgreementMemberusgaapTypeOfArrangementAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001819253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis" >btmd:StandbyEquityPurchaseAgreementMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_CommonClassAMemberusgaapStatementClassOfStockAxis_HaymakeriiiMembersrtConsolidatedEntitiesAxis_SharePriceEqualOrLessNinePointTwoRupeesPerDollarMemberusgaapMeasurementInputTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001819253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis" >us-gaap:CommonClassAMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis" >btmd:HaymakeriiiMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis" >btmd:SharePriceEqualOrLessNinePointTwoRupeesPerDollarMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_CommonClassAMemberusgaapStatementClassOfStockAxis_CommonStockMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001819253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis" >us-gaap:CommonClassAMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:CommonStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_HaymakeriiiMembersrtConsolidatedEntitiesAxis_PrivatePlacementWarrantsMemberusgaapClassOfWarrantOrRightAxis_SponseMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001819253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis" >btmd:SponseMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis" >btmd:HaymakeriiiMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis" >btmd:PrivatePlacementWarrantsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_HaymakeriiiMembersrtConsolidatedEntitiesAxis_PrivatePlacementWarrantsMemberusgaapClassOfWarrantOrRightAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001819253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis" >btmd:HaymakeriiiMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis" >btmd:PrivatePlacementWarrantsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_BankOfAmericaTermLoanAndTruistTermLoanMemberusgaapDebtInstrumentAxis_LineOfCreditMemberusgaapCreditFacilityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001819253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis" >us-gaap:LineOfCreditMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis" >btmd:BankOfAmericaTermLoanAndTruistTermLoanMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_FourZeroOneKPlanMemberusgaapRetirementPlanNameAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001819253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:RetirementPlanNameAxis" >btmd:FourZeroOneKPlanMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_CreditAvailabilityConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis_LiabilitiesTotalMemberusgaapConcentrationRiskByBenchmarkAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001819253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis" >us-gaap:LiabilitiesTotalMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis" >us-gaap:CreditAvailabilityConcentrationRiskMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_AssetsTotalMemberusgaapConcentrationRiskByBenchmarkAxis_InventoryMembersrtProductOrServiceAxis_SupplierConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001819253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis" >btmd:InventoryMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis" >us-gaap:AssetsTotalMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis" >us-gaap:SupplierConcentrationRiskMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_BusinessContactMemberdeiEntityAddressesAddressTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001819253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="dei:EntityAddressesAddressTypeAxis" >dei:BusinessContactMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_BioteMethodCustomerMemberbtmdNatureOfCustomerAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001819253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="btmd:NatureOfCustomerAxis" >btmd:BioteMethodCustomerMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To05_26_2022_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001819253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:RetainedEarningsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-05-26</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To05_26_2022_ParentMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001819253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:ParentMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-05-26</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To05_26_2022_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001819253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-05-26</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn05_26_2022_LineOfCreditMemberusgaapCreditFacilityAxis_TruistTermLoanMemberusgaapDebtInstrumentAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001819253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis" >us-gaap:LineOfCreditMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis" >btmd:TruistTermLoanMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-05-26</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn05_26_2022_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_PublicWarrantsMemberusgaapFinancialInstrumentAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001819253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis" >btmd:PublicWarrantsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis" >us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-05-26</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn05_26_2022_PublicWarrantsMemberusgaapFinancialInstrumentAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001819253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis" >btmd:PublicWarrantsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-05-26</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn05_26_2022_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_PrivatePlacementWarrantsMemberusgaapFinancialInstrumentAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001819253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis" >btmd:PrivatePlacementWarrantsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis" >us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-05-26</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn05_26_2022_PrivatePlacementWarrantsMemberusgaapFinancialInstrumentAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001819253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis" >btmd:PrivatePlacementWarrantsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-05-26</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn05_26_2022_EarnoutLiabilityMemberusgaapFinancialInstrumentAxis_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001819253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis" >btmd:EarnoutLiabilityMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis" >us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-05-26</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn05_26_2022_EarnoutLiabilityMemberusgaapFinancialInstrumentAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001819253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis" >btmd:EarnoutLiabilityMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-05-26</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn05_26_2022_MeasurementInputSharePriceMemberusgaapMeasurementInputTypeAxis_PrivatePlacementWarrantsMemberusgaapFinancialInstrumentAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001819253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis" >us-gaap:MeasurementInputSharePriceMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis" >btmd:PrivatePlacementWarrantsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-05-26</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn05_26_2022_EarnoutLiabilityMemberusgaapFinancialInstrumentAxis_MeasurementInputSharePriceMemberusgaapMeasurementInputTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001819253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis" >us-gaap:MeasurementInputSharePriceMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis" >btmd:EarnoutLiabilityMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-05-26</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn05_26_2022_MinorityInterestHoldersMembersrtOwnershipAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001819253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:OwnershipAxis" >btmd:MinorityInterestHoldersMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-05-26</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn05_26_2022_BioteCorporationMembersrtOwnershipAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001819253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:OwnershipAxis" >btmd:BioteCorporationMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-05-26</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn05_26_2022_EarnoutLiabilityMemberusgaapFinancialInstrumentAxis_MeasurementInputRiskFreeInterestRateMemberusgaapMeasurementInputTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001819253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis" >btmd:EarnoutLiabilityMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis" >us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-05-26</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn05_26_2022_EarnoutLiabilityMemberusgaapFinancialInstrumentAxis_MeasurementInputOptionVolatilityMemberusgaapMeasurementInputTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001819253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis" >btmd:EarnoutLiabilityMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis" >us-gaap:MeasurementInputOptionVolatilityMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-05-26</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn05_26_2022_MeasurementInputExpectedTermMemberusgaapMeasurementInputTypeAxis_PrivatePlacementWarrantsMemberusgaapFinancialInstrumentAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001819253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis" >btmd:PrivatePlacementWarrantsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis" >us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-05-26</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn05_26_2022_MeasurementInputExercisePriceMemberusgaapMeasurementInputTypeAxis_PrivatePlacementWarrantsMemberusgaapFinancialInstrumentAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001819253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis" >btmd:PrivatePlacementWarrantsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis" >us-gaap:MeasurementInputExercisePriceMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-05-26</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn05_26_2022_MeasurementInputRiskFreeInterestRateMemberusgaapMeasurementInputTypeAxis_PrivatePlacementWarrantsMemberusgaapFinancialInstrumentAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001819253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis" >btmd:PrivatePlacementWarrantsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis" >us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-05-26</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn05_26_2022_MeasurementInputOptionVolatilityMemberusgaapMeasurementInputTypeAxis_PrivatePlacementWarrantsMemberusgaapFinancialInstrumentAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001819253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis" >btmd:PrivatePlacementWarrantsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis" >us-gaap:MeasurementInputOptionVolatilityMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-05-26</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn05_26_2022_EarnoutLiabilityMemberusgaapFinancialInstrumentAxis_MeasurementInputExpectedTermMemberusgaapMeasurementInputTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001819253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis" >btmd:EarnoutLiabilityMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis" >us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-05-26</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn05_26_2022_PhantomEquityRightsMemberusgaapAwardTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001819253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis" >btmd:PhantomEquityRightsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-05-26</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn05_26_2022_MemberUnitsMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001819253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:MemberUnitsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-05-26</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn05_26_2022_CommonClassAMemberusgaapStatementClassOfStockAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001819253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis" >us-gaap:CommonClassAMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-05-26</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn05_26_2022_CommonClassVMemberusgaapStatementClassOfStockAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001819253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis" >btmd:CommonClassVMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-05-26</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn05_26_2022_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001819253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:RetainedEarningsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-05-26</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn05_26_2022_ParentMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001819253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:ParentMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-05-26</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn05_26_2022_DebtCommitmentLetterMemberusgaapDebtInstrumentAxis_HaymakeriiiMembersrtConsolidatedEntitiesAxis_SeniorSecuredRevolvingCreditFacilityMemberusgaapCreditFacilityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001819253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis" >btmd:SeniorSecuredRevolvingCreditFacilityMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis" >btmd:HaymakeriiiMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis" >btmd:DebtCommitmentLetterMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-05-26</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn05_26_2022_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001819253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-05-26</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn05_26_2022_NoncontrollingInterestMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001819253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-05-26</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn05_26_2022_DebtCommitmentLetterMemberusgaapDebtInstrumentAxis_HaymakeriiiMembersrtConsolidatedEntitiesAxis_SeniorSecuredTermLoanAFacilityMemberusgaapCreditFacilityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001819253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis" >btmd:HaymakeriiiMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis" >btmd:DebtCommitmentLetterMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis" >btmd:SeniorSecuredTermLoanAFacilityMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-05-26</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="P05_27_2022To12_31_2022_PrivatePlacementWarrantsMemberusgaapFinancialInstrumentAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001819253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis" >btmd:PrivatePlacementWarrantsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-05-27</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P05_27_2022To12_31_2022_EarnoutLiabilityMemberusgaapFinancialInstrumentAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001819253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis" >btmd:EarnoutLiabilityMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-05-27</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P05_27_2022To12_31_2022_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001819253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:RetainedEarningsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-05-27</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P05_27_2022To12_31_2022_ParentMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001819253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:ParentMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-05-27</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P05_27_2022To12_31_2022_NoncontrollingInterestMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001819253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-05-27</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P07_27_2022To07_27_2022_StandbyEquityPurchaseAgreementMemberusgaapTypeOfArrangementAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001819253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis" >btmd:StandbyEquityPurchaseAgreementMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-07-27</xbrli:startDate> <xbrli:endDate>2022-07-27</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn07_27_2022_StandbyEquityPurchaseAgreementMemberusgaapTypeOfArrangementAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001819253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis" >btmd:StandbyEquityPurchaseAgreementMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-07-27</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn07_27_2022_CommonClassAMemberusgaapStatementClassOfStockAxis_StandbyEquityPurchaseAgreementMemberusgaapTypeOfArrangementAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001819253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis" >us-gaap:CommonClassAMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis" >btmd:StandbyEquityPurchaseAgreementMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-07-27</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn07_27_2022_MaximumMembersrtRangeAxis_StandbyEquityPurchaseAgreementMemberusgaapTypeOfArrangementAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001819253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis" >btmd:StandbyEquityPurchaseAgreementMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:RangeAxis" >srt:MaximumMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-07-27</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn07_27_2022_StandbyEquityPurchaseAgreementMemberusgaapTypeOfArrangementAxis_YorkvilleAdvisorsGlobalLpMemberusgaapCreditFacilityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001819253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis" >btmd:YorkvilleAdvisorsGlobalLpMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis" >btmd:StandbyEquityPurchaseAgreementMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-07-27</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="P12_13_2021To12_13_2021_BioteManagementLlcMemberusgaapBusinessAcquisitionAxis_CommonClassAMemberusgaapStatementClassOfStockAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001819253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis" >us-gaap:CommonClassAMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis" >btmd:BioteManagementLlcMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-12-13</xbrli:startDate> <xbrli:endDate>2021-12-13</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P12_13_2021To12_13_2021_CommonClassAMemberusgaapStatementClassOfStockAxis_HaymakerAcquisitionCorpIiiMemberusgaapBusinessAcquisitionAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001819253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis" >btmd:HaymakerAcquisitionCorpIiiMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis" >us-gaap:CommonClassAMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-12-13</xbrli:startDate> <xbrli:endDate>2021-12-13</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P12_13_2021To12_13_2021_ClassVCommonStockMemberusgaapStatementClassOfStockAxis_HaymakerAcquisitionCorpIiiMemberusgaapBusinessAcquisitionAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001819253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis" >btmd:HaymakerAcquisitionCorpIiiMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis" >btmd:ClassVCommonStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-12-13</xbrli:startDate> <xbrli:endDate>2021-12-13</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P12_13_2021To12_13_2021_BusinessCombinationMemberusgaapBusinessAcquisitionAxis_HaymakeriiiMembersrtConsolidatedEntitiesAxis_MemberEarnOutUnitsMemberusgaapStatementClassOfStockAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001819253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis" >btmd:HaymakeriiiMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis" >btmd:MemberEarnOutUnitsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis" >btmd:BusinessCombinationMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-12-13</xbrli:startDate> <xbrli:endDate>2021-12-13</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P12_13_2021To12_13_2021_BusinessCombinationMemberusgaapBusinessAcquisitionAxis_HaymakeriiiMembersrtConsolidatedEntitiesAxis_SponsorEarnOutSharesMemberusgaapStatementClassOfStockAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001819253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis" >btmd:HaymakeriiiMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis" >btmd:BusinessCombinationMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis" >btmd:SponsorEarnOutSharesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-12-13</xbrli:startDate> <xbrli:endDate>2021-12-13</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P12_13_2021To12_13_2021_BusinessCombinationMemberusgaapBusinessAcquisitionAxis_EarnoutVotingSharesMemberusgaapStatementClassOfStockAxis_HaymakeriiiMembersrtConsolidatedEntitiesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001819253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis" >btmd:HaymakeriiiMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis" >btmd:BusinessCombinationMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis" >btmd:EarnoutVotingSharesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-12-13</xbrli:startDate> <xbrli:endDate>2021-12-13</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P12_13_2021To12_13_2021_BioteManagementLlcMemberusgaapBusinessAcquisitionAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001819253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis" >btmd:BioteManagementLlcMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-12-13</xbrli:startDate> <xbrli:endDate>2021-12-13</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P12_13_2021To12_13_2021_CommonClassAMemberusgaapStatementClassOfStockAxis_HaymakeriiiMembersrtConsolidatedEntitiesAxis_OtherBusinessCombinationMemberusgaapBusinessAcquisitionAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001819253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis" >us-gaap:CommonClassAMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis" >btmd:HaymakeriiiMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis" >btmd:OtherBusinessCombinationMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-12-13</xbrli:startDate> <xbrli:endDate>2021-12-13</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_13_2021_CommonClassAMemberusgaapStatementClassOfStockAxis_HaymakerAcquisitionCorpIiiMemberusgaapBusinessAcquisitionAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001819253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis" >btmd:HaymakerAcquisitionCorpIiiMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis" >us-gaap:CommonClassAMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-13</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_13_2021_CommonClassBMemberusgaapStatementClassOfStockAxis_HaymakerAcquisitionCorpIiiMemberusgaapBusinessAcquisitionAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001819253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis" >btmd:HaymakerAcquisitionCorpIiiMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis" >us-gaap:CommonClassBMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-13</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_13_2021_ClassVCommonStockMemberusgaapStatementClassOfStockAxis_HaymakerAcquisitionCorpIiiMemberusgaapBusinessAcquisitionAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001819253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis" >btmd:HaymakerAcquisitionCorpIiiMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis" >btmd:ClassVCommonStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-13</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn05_31_2019_BankOfAmericaTermLoanMemberusgaapDebtInstrumentAxis_LineOfCreditMemberusgaapCreditFacilityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001819253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis" >us-gaap:LineOfCreditMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis" >btmd:BankOfAmericaTermLoanMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2019-05-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="P05_01_2019To05_31_2019_BankOfAmericaTermLoanMemberusgaapDebtInstrumentAxis_LineOfCreditMemberusgaapCreditFacilityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001819253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis" >us-gaap:LineOfCreditMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis" >btmd:BankOfAmericaTermLoanMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2019-05-01</xbrli:startDate> <xbrli:endDate>2019-05-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P05_26_2022To05_26_2022_CommonClassVMemberusgaapStatementClassOfStockAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001819253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis" >btmd:CommonClassVMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-05-26</xbrli:startDate> <xbrli:endDate>2022-05-26</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P05_26_2022To05_26_2022_IncentiveUnitsMemberusgaapAwardTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001819253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis" >btmd:IncentiveUnitsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-05-26</xbrli:startDate> <xbrli:endDate>2022-05-26</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P05_26_2022To05_26_2022_PhantomEquityRightsMemberusgaapAwardTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001819253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis" >btmd:PhantomEquityRightsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-05-26</xbrli:startDate> <xbrli:endDate>2022-05-26</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P05_26_2022To05_26_2022_LineOfCreditMemberusgaapCreditFacilityAxis_TruistTermLoanMemberusgaapDebtInstrumentAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001819253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis" >us-gaap:LineOfCreditMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis" >btmd:TruistTermLoanMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-05-26</xbrli:startDate> <xbrli:endDate>2022-05-26</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P05_26_2022To05_26_2022_LineOfCreditMemberusgaapCreditFacilityAxis_MinimumMembersrtRangeAxis_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMemberusgaapVariableRateAxis_TruistTermLoanMemberusgaapDebtInstrumentAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001819253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:RangeAxis" >srt:MinimumMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis" >us-gaap:LineOfCreditMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis" >us-gaap:SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis" >btmd:TruistTermLoanMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-05-26</xbrli:startDate> <xbrli:endDate>2022-05-26</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P05_26_2022To05_26_2022_LineOfCreditMemberusgaapCreditFacilityAxis_MaximumMembersrtRangeAxis_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMemberusgaapVariableRateAxis_TruistTermLoanMemberusgaapDebtInstrumentAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001819253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis" >us-gaap:LineOfCreditMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis" >us-gaap:SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:RangeAxis" >srt:MaximumMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis" >btmd:TruistTermLoanMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-05-26</xbrli:startDate> <xbrli:endDate>2022-05-26</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P05_26_2022To05_26_2022_BaseRateMemberusgaapVariableRateAxis_LineOfCreditMemberusgaapCreditFacilityAxis_MinimumMembersrtRangeAxis_TruistTermLoanMemberusgaapDebtInstrumentAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001819253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:RangeAxis" >srt:MinimumMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis" >us-gaap:LineOfCreditMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis" >us-gaap:BaseRateMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis" >btmd:TruistTermLoanMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-05-26</xbrli:startDate> <xbrli:endDate>2022-05-26</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P05_26_2022To05_26_2022_BaseRateMemberusgaapVariableRateAxis_LineOfCreditMemberusgaapCreditFacilityAxis_MaximumMembersrtRangeAxis_TruistTermLoanMemberusgaapDebtInstrumentAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001819253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis" >us-gaap:LineOfCreditMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:RangeAxis" >srt:MaximumMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis" >us-gaap:BaseRateMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis" >btmd:TruistTermLoanMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-05-26</xbrli:startDate> <xbrli:endDate>2022-05-26</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn05_18_2022_DirectorMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_FounderAdvisoryAgreementMemberusgaapTypeOfArrangementAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001819253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis" >btmd:FounderAdvisoryAgreementMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis" >srt:DirectorMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-05-18</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn05_18_2022_ConsultantMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_NewIndependentContractorAgreementMemberusgaapTypeOfArrangementAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001819253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis" >btmd:NewIndependentContractorAgreementMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis" >btmd:ConsultantMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-05-18</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="P05_18_2022To05_18_2022_DirectorMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_FounderAdvisoryAgreementMemberusgaapTypeOfArrangementAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001819253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis" >btmd:FounderAdvisoryAgreementMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis" >srt:DirectorMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-05-18</xbrli:startDate> <xbrli:endDate>2022-05-18</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P05_18_2022To05_18_2022_ConsultantMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_NewIndependentContractorAgreementMemberusgaapTypeOfArrangementAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001819253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis" >btmd:NewIndependentContractorAgreementMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis" >btmd:ConsultantMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-05-18</xbrli:startDate> <xbrli:endDate>2022-05-18</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P03_26_2022To05_26_2022_IncentiveUnitsMemberusgaapAwardTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001819253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis" >btmd:IncentiveUnitsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-03-26</xbrli:startDate> <xbrli:endDate>2022-05-26</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P03_26_2022To05_26_2022_PhantomEquityRightsMemberusgaapAwardTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001819253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis" >btmd:PhantomEquityRightsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-03-26</xbrli:startDate> <xbrli:endDate>2022-05-26</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P05_31_2022To06_30_2022_MaximumMembersrtRangeAxis_PhantomEquityRightsMemberusgaapAwardTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001819253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis" >btmd:PhantomEquityRightsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:RangeAxis" >srt:MaximumMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-05-31</xbrli:startDate> <xbrli:endDate>2022-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P06_01_2022To06_30_2022_MinimumMembersrtRangeAxis_PhantomEquityRightsMemberusgaapAwardTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001819253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:RangeAxis" >srt:MinimumMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis" >btmd:PhantomEquityRightsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-06-01</xbrli:startDate> <xbrli:endDate>2022-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis_TwoThousandTwentyTwoEquityIncentivePlanMemberusgaapPlanNameAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001819253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis" >btmd:TwoThousandTwentyTwoEquityIncentivePlanMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis" >us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_MemberUnitsMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001819253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:MemberUnitsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001819253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:RetainedEarningsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001819253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_ParentMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001819253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:ParentMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_MemberUnitsMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001819253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:MemberUnitsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001819253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:RetainedEarningsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001819253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_ParentMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001819253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:ParentMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_CommonClassAMemberusgaapStatementClassOfStockAxis_CommonStockMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001819253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:CommonStockMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis" >us-gaap:CommonClassAMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_CommonClassVMemberusgaapStatementClassOfStockAxis_CommonStockMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001819253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis" >btmd:CommonClassVMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:CommonStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001819253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:RetainedEarningsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001819253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_ParentMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001819253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:ParentMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_NoncontrollingInterestMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001819253</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:unit id="Unit_USD" > <xbrli:measure>iso4217:USD</xbrli:measure> </xbrli:unit><xbrli:unit id="Unit_shares" > <xbrli:measure>xbrli:shares</xbrli:measure> </xbrli:unit><xbrli:unit id="Unit_Year" > <xbrli:measure>utr:Year</xbrli:measure> </xbrli:unit><xbrli:unit id="Unit_Day" > <xbrli:measure>utr:Day</xbrli:measure> </xbrli:unit><xbrli:unit id="Unit_pure" > <xbrli:measure>xbrli:pure</xbrli:measure> </xbrli:unit><xbrli:unit id="Unit_Month" > <xbrli:measure>utr:Month</xbrli:measure> </xbrli:unit><xbrli:unit id="Unit_USD_per_Share" > <xbrli:divide> <xbrli:unitNumerator> <xbrli:measure>iso4217:USD</xbrli:measure> </xbrli:unitNumerator> <xbrli:unitDenominator> <xbrli:measure>xbrli:shares</xbrli:measure> </xbrli:unitDenominator> </xbrli:divide> </xbrli:unit><xbrli:unit id="Unit_SEGMENT" > <xbrli:measure>btmd:SEGMENT</xbrli:measure> </xbrli:unit><xbrli:unit id="Unit_sqft" > <xbrli:measure>utr:sqft</xbrli:measure> </xbrli:unit><xbrli:unit id="Unit_VOTE" > <xbrli:measure>btmd:VOTE</xbrli:measure> </xbrli:unit><xbrli:unit id="Unit_vendor" > <xbrli:measure>btmd:vendor</xbrli:measure> </xbrli:unit><xbrli:unit id="Unit_CUSTOMER" > <xbrli:measure>btmd:CUSTOMER</xbrli:measure> </xbrli:unit></ix:resources></ix:header></div><div><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><div style="text-align: center; font-family: Times New Roman; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">As filed with the Securities and Exchange Commission April 5, 2023. </div></div></div></div><div style="text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Registration <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">No.&#160;333-266433</div> </div></div></div><div style="font-weight:bold;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"></div> </div> <div style="font-size: 4pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div> <div style="line-height: 1pt; margin-top: 0px; margin-bottom: 0px; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</div> <div style="line-height: 3pt; margin-top: 0px; margin-bottom: 0px; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 16pt; margin-top: 4pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 16pt; letter-spacing: 0px; top: 0px;;display:inline;">UNITED <div style="display:inline;">STATES</div> </div></div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 16pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 16pt; letter-spacing: 0px; top: 0px;;display:inline;">SECURITIES AND EXCHANGE COMMISSION </div></div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Washington, D.C. 20549 </div></div></div></div> <div style="font-weight:bold;display:inline;"> </div> <div style="font-size: 3pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div> <div style="text-align:center"><div style="line-height: 6pt; margin: 0px auto; border-bottom: 1pt solid rgb(0, 0, 0); width: 21%; text-align: center;">&#160;</div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 16pt; margin-top: 3pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 16pt; letter-spacing: 0px; top: 0px;;display:inline;">POST-<div style="display:inline;">EFFECTIVE</div> </div></div></div></div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:16pt; font-family:Times New Roman;font-weight:bold;text-align:center">AMENDMENT NO. 1 </div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 16pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 16pt; letter-spacing: 0px; top: 0px;;display:inline;">TO </div></div></div></div> <div style="font-weight:bold;display:inline;"> </div> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 16pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;">FORM <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><span style="-sec-ix-hidden:hidden73945327">S-1</span></div></div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 16pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 16pt; letter-spacing: 0px; top: 0px;;display:inline;">REGISTRATION STATEMENT </div></div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">UNDER </div></div></div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="null;text-indent: 0px;;font-style:italic;display:inline;">THE SECURITIES ACT OF 1933</div></div></div></div></div> <div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;"> </div></div></div> <div style="font-size: 3pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div> <div style="text-align:center"><div style="line-height: 6pt; margin: 0px auto; border-bottom: 1pt solid rgb(0, 0, 0); width: 21%; text-align: center;">&#160;</div></div> <div style="margin-top: 3pt; margin-bottom: 0pt; font-size: 22pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonNumeric name="dei:EntityRegistrantName" contextRef="P01_01_2022To12_31_2022">biote Corp.</ix:nonNumeric></div></div></div></div> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;"></div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">(Exact name of Registrant as specified in its charter) </div></div></div></div> <div style="font-size: 3pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="display:inline;"><div style="font-size: 3pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> <div style="text-align: center;;text-indent: 0px;"><div style="margin: 0pt auto 2pt; width: 21%; text-align: center; line-height: 6pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></div> <div style="font-size: 3pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="display:inline;"><div style="font-size: 3pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 8pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;">
<tr style="font-size: 0px;">
<td style="width: 34%;"></td>
<td style="vertical-align: bottom;"></td>
<td style="width: 32%;"></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td style="width: 32%;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;;text-align:center;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonNumeric name="dei:EntityIncorporationStateCountryCode" contextRef="P01_01_2022To12_31_2022" format="ixt-sec:stateprovnameen">Delaware</ix:nonNumeric></div></div></div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: top;;text-align:center;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonNumeric name="dei:EntityPrimarySicNumber" contextRef="P01_01_2022To12_31_2022">2833</ix:nonNumeric></div></div></div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: top;;text-align:center;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonNumeric name="dei:EntityTaxIdentificationNumber" contextRef="P01_01_2022To12_31_2022">85-1791125</ix:nonNumeric></div></div></div></div></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:top;text-align:center;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 8pt; font-family: &quot;Times New Roman&quot;; text-align: center; line-height: normal;"><div style="font-weight:bold;display:inline;">(State or other jurisdiction of</div></div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 8pt; font-family: &quot;Times New Roman&quot;; text-align: center; line-height: normal;"><div style="font-weight:bold;display:inline;">incorporation or organization)</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;text-align:center;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 8pt; font-family: &quot;Times New Roman&quot;; text-align: center; line-height: normal;"><div style="font-weight:bold;display:inline;">(Primary Standard Industrial</div></div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 8pt; font-family: &quot;Times New Roman&quot;; text-align: center; line-height: normal;"><div style="font-weight:bold;display:inline;">Classification Code Number)</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align: top;;text-align:center;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;">(I.R.S. Employer</div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-weight:bold;display:inline;">Identification Number)</div></div></td></tr></table> <div style="clear:both;max-height:0pt;;text-indent: 0px;"></div> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 3pt; letter-spacing: 0px; top: 0px;;display:inline;"></div></div> <div style="margin-top: 3pt; margin-bottom: 0pt; font-size: 9pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;"><ix:nonNumeric name="dei:EntityAddressAddressLine1" contextRef="P01_01_2022To12_31_2022">1875 W. Walnut Hill Ln #100</ix:nonNumeric> </div></div> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 9pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;"><ix:nonNumeric name="dei:EntityAddressCityOrTown" contextRef="P01_01_2022To12_31_2022">Irving</ix:nonNumeric>, <span style="-sec-ix-hidden:hidden73945344">TX</span> <ix:nonNumeric name="dei:EntityAddressPostalZipCode" contextRef="P01_01_2022To12_31_2022">75038</ix:nonNumeric> </div></div> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 9pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;">(<ix:nonNumeric name="dei:CityAreaCode" contextRef="P01_01_2022To12_31_2022">844</ix:nonNumeric>) <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonNumeric name="dei:LocalPhoneNumber" contextRef="P01_01_2022To12_31_2022">604-1246</ix:nonNumeric></div></div></div> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 8pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;">(Address, including zip code, and telephone number, including area code, of Registrant&#8217;s principal executive offices) </div></div> <div style="font-size: 3pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div> <div style="text-align:center"><div style="line-height: 6pt; margin: 0px auto; border-bottom: 1pt solid rgb(0, 0, 0); width: 21%; text-align: center;">&#160;</div></div> <div style="margin-top: 3pt; margin-bottom: 0pt; font-size: 9pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;"><ix:nonNumeric name="dei:ContactPersonnelName" contextRef="P01_01_2022To12_31_2022_BusinessContactMemberdeiEntityAddressesAddressTypeAxis">Teresa S. Weber</ix:nonNumeric> </div></div> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 9pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;">Chief Executive Officer </div></div> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 9pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;">biote Corp. </div></div> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 9pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;"><ix:nonNumeric name="dei:EntityAddressAddressLine1" contextRef="P01_01_2022To12_31_2022_BusinessContactMemberdeiEntityAddressesAddressTypeAxis">1875 W. Walnut Hill Ln #100</ix:nonNumeric> </div></div> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 9pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;"><ix:nonNumeric name="dei:EntityAddressCityOrTown" contextRef="P01_01_2022To12_31_2022_BusinessContactMemberdeiEntityAddressesAddressTypeAxis">Irving</ix:nonNumeric>, <span style="-sec-ix-hidden:hidden73945345">TX</span> <ix:nonNumeric name="dei:EntityAddressPostalZipCode" contextRef="P01_01_2022To12_31_2022_BusinessContactMemberdeiEntityAddressesAddressTypeAxis">75038</ix:nonNumeric> </div></div> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 9pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;">(<ix:nonNumeric name="dei:CityAreaCode" contextRef="P01_01_2022To12_31_2022_BusinessContactMemberdeiEntityAddressesAddressTypeAxis">312</ix:nonNumeric>) <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonNumeric name="dei:LocalPhoneNumber" contextRef="P01_01_2022To12_31_2022_BusinessContactMemberdeiEntityAddressesAddressTypeAxis">212-8079</ix:nonNumeric></div></div></div> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 8pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;">(Name, address, including zip code, and telephone number, including area code, of agent for service) </div></div> <div style="font-size: 3pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div> <div style="text-align:center"><div style="line-height: 6pt; margin: 0px auto; border-bottom: 1pt solid rgb(0, 0, 0); width: 21%; text-align: center;">&#160;</div></div> <div style="margin-top: 3pt; margin-bottom: 0pt; font-size: 9pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Copies to: </div></div></div></div> <div style="margin-top: 3pt; margin-bottom: 0pt; font-size: 9pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;">Ryan Sansom </div></div> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 9pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;">Peter Byrne </div></div> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 9pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;">Cooley LLP </div></div> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 9pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;">500 Boylston Street </div></div> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 9pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;">Boston, MA 02116-3736 </div></div> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 9pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;">(617) <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">937-2300</div></div></div> <div style="font-size: 3pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div> <div style="text-align:center"><div style="line-height: 6pt; margin: 0px auto; border-bottom: 1pt solid rgb(0, 0, 0); width: 21%; text-align: center;">&#160;</div></div> <div style="margin-top:3pt; margin-bottom:0pt; text-indent:4%; font-size:9pt; font-family:Times New Roman"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Approximate date of commencement of proposed sale to the public:</div></div> As soon as practicable after the effective date of this registration statement. </div> <div style="margin-top:3pt; margin-bottom:0pt; text-indent:4%; font-size:9pt; font-family:Times New Roman">If any of the securities being registered on this Form are to be offered on a delayed or continuous basis pursuant to Rule 415 under the Securities Act of 1933, as amended the &#8220;Securities Act,&#8221; check the following box.&#160;&#160;<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#9746;</div> </div> <div style="margin-top:3pt; margin-bottom:0pt; text-indent:4%; font-size:9pt; font-family:Times New Roman">If this Form is filed to register additional securities for an offering pursuant to Rule 462(b) under the Securities Act, please check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering.&#160;&#160;<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#9744;</div> </div> <div style="margin-top:3pt; margin-bottom:0pt; text-indent:4%; font-size:9pt; font-family:Times New Roman">If this Form is a post-effective amendment filed pursuant to Rule 462(c) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering.&#160;&#160;&#9744; </div> <div style="margin-top:3pt; margin-bottom:0pt; text-indent:4%; font-size:9pt; font-family:Times New Roman">If this Form is a post-effective amendment filed pursuant to Rule 462(d) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering.&#160;&#160;&#9744; </div> <div style="margin-top:3pt; margin-bottom:0pt; text-indent:4%; font-size:9pt; font-family:Times New Roman">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-accelerated</div> filer, a smaller reporting company or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company&#8221; and &#8220;emerging growth company&#8221; in Rule <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">12b-2</div> of the Exchange Act. </div> <div style="font-size: 3pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font-family: &quot;Times New Roman&quot;; font-size: 9pt; width: 100%; border: 0px; margin: 0px auto; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width:16%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td style="width:60%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td style="width:19%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td style="width:2%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<td style="vertical-align:bottom">Large&#160;Accelerated&#160;Filer</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#9744;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">Accelerated Filer</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#9744;</td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="2" style="height:3pt">&#160;</td>
<td colspan="2" style="height:3pt">&#160;</td>
<td colspan="2" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<td style="vertical-align:bottom"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"></div><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"></div><ix:nonNumeric name="dei:EntityFilerCategory" contextRef="P01_01_2022To12_31_2022" format="ixt-sec:entityfilercategoryen"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-accelerated</div> Filer</ix:nonNumeric></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#9746;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">Smaller&#160;Reporting&#160;Company</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonNumeric name="dei:EntitySmallBusiness" contextRef="P01_01_2022To12_31_2022" format="ixt-sec:boolballotbox">&#9746;</ix:nonNumeric></div></td></tr>
<tr style="font-size:1pt">
<td style="height:3pt">&#160;</td>
<td colspan="2" style="height:3pt">&#160;</td>
<td colspan="2" style="height:3pt">&#160;</td>
<td colspan="2" style="height:3pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">Emerging growth Company</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonNumeric name="dei:EntityEmergingGrowthCompany" contextRef="P01_01_2022To12_31_2022" format="ixt-sec:boolballotbox">&#9746;</ix:nonNumeric></div></td></tr></table> <div style="margin-top:3pt; margin-bottom:0pt; text-indent:4%; font-size:9pt; font-family:Times New Roman">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section&#160;7(a)(2)(B) of the Securities Act.&#160;&#160;<div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonNumeric name="dei:EntityExTransitionPeriod" contextRef="P01_01_2022To12_31_2022" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></div></div> <div style="font-size: 3pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div> <div style="text-align:center"><div style="line-height: 6pt; margin: 0px auto; border-bottom: 1pt solid rgb(0, 0, 0); width: 21%; text-align: center;">&#160;</div></div> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;"></div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 3pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">The post-effective amendment will become effective in accordance with the provisions of Section&#160;8(c) of the Securities Act of 1933, as amended. </div></div></div></div> <div style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> <div style="line-height: 1pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> <div style="line-height: 3pt; margin-top: 0pt; margin-bottom: 2pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> </div></div></div>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">EXPLANATORY NOTE </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This Post-Effective Amendment No.&#160;1 to the Registration Statement on Form <span style="white-space:nowrap">S-1</span> (File <span style="white-space:nowrap">No.&#160;333-266433)</span> (the &#8220;Registration Statement&#8221;) of biote Corp., as originally declared effective by the Securities and Exchange Commission (the &#8220;SEC&#8221;) on August&#160;5, 2022, is being filed pursuant to the undertakings in Item 17 of the Registration Statement to (i)&#160;include information contained in the Registrant&#8217;s Annual Report on Form <span style="white-space:nowrap">10-K</span> for the fiscal year ended December&#160;31, 2022 that was filed with the SEC on March&#160;29, 2023 and (ii)&#160;update certain other information in the Registration Statement. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The information included in this filing amends the Registration Statement and the prospectus contained therein. No additional securities are being registered under this Post-Effective Amendment No.&#160;1. All applicable registration fees were paid at the time of the original filing of the Registration Statement. </p>
</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Arial Narrow"><span style="color:#ff4338"><span style="font-weight:bold">The information in this preliminary prospectus is not complete and may be changed. Neither we nor the selling securityholder may sell these securities until the registration statement filed with the Securities and Exchange Commission is effective. This preliminary prospectus is not an offer to sell these securities and is not soliciting an offer to buy these securities in any jurisdiction where the offer or sale is not permitted. </span></span></p> <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"><span style="color:#ff4338"><span style="font-weight:bold">SUBJECT TO COMPLETION, DATED APRIL 5, 2023 </span></span></p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman;font-weight:bold;text-align:center">biote Corp. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman;font-weight:bold;text-align:center">Up to 5,000,000 Shares of Common Stock </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p><div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This prospectus relates to the resale of up to 5,000,000 shares (the &#8220;Shares&#8221;) of our Class&#160;A common stock, $0.0001 par value per share (the &#8220;Class&#160;A common stock&#8221;), by YA II PN, LTD., a Cayman Islands exempt limited partnership (the &#8220;Selling Securityholder&#8221;). The shares included in this prospectus consist of shares of Class&#160;A common stock that we have issued or that we may, in our discretion, elect to issue and sell to the Selling Securityholder, from time to time after the date of this prospectus, pursuant to a standby equity purchase agreement we entered into with the Selling Securityholder on July&#160;27, 2022 (the &#8220;Purchase Agreement&#8221;), in which the Selling Securityholder has committed to purchase from us, at our direction, up to 5,000,000 shares our Class&#160;A common stock, subject to terms and conditions specified in the Purchase Agreement. Concurrently to the Purchase Agreement, we issued 25,000 shares of Class&#160;A common stock to the Selling Securityholder on July&#160;27, 2022 as consideration for its irrevocable commitment to purchase shares of our Class&#160;A common stock at our election in our discretion, from time to time after the date of this prospectus, upon the terms and subject to the satisfaction of the conditions set forth in the Purchase Agreement. See the section entitled &#8220;Committed Equity Financing&#8221; for a description of the Purchase Agreement and the section entitled &#8220;Selling Securityholder&#8221; for additional information regarding the Selling Securityholder. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our registration of the securities covered by this prospectus does not mean that the Selling Securityholder will offer or sell any of the shares of Class&#160;A common stock. The Selling Securityholder may offer, sell or distribute all or a portion of their shares of Class&#160;A common stock publicly or through private transactions at prevailing market prices or at negotiated prices. We will not receive any proceeds from the sale of shares of Class&#160;A common stock by the Selling Securityholder pursuant to this prospectus. However, we expect to receive proceeds from sales of Class&#160;A common stock that we may elect to make to the Selling Securityholder pursuant to the Purchase Agreement, if any, from time to time in our discretion. See &#8220;Committed Equity Financing&#8221; for a description of how the price we may sell shares of Class&#160;A common stock to the Selling Securityholder is calculated pursuant to the Purchase Agreement. We provide more information about how the Selling Securityholder may sell or otherwise dispose of the shares of our Class&#160;A common stock in the section entitled &#8220;Plan of Distribution.&#8221; The Selling Securityholder is an &#8220;underwriter&#8221; within the meaning of Section&#160;2(a)(11) of the Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;). </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are an &#8220;emerging growth company&#8221; as defined in Section&#160;2(a) of the Securities Act, as modified by the Jumpstart Our Business Startups Act of 2012 (the &#8220;JOBS Act&#8221;) and a &#8220;smaller reporting company&#8221; as defined in Section&#160;10(f)(1) of Regulation <span style="white-space:nowrap">S-K,</span> and are subject to reduced public company reporting requirements. This prospectus complies with the requirements that apply to an issuer that is an emerging growth company. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our Class&#160;A common stock and Public Warrants are quoted on the Nasdaq Stock Market LLC under the symbols &#8220;BTMD&#8221; and &#8220;BTMDW,&#8221; respectively. On April 5, 2023, the last reported sales prices of our Class&#160;A common stock and Public Warrants were $5.88 and $0.41, respectively. </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p><div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:12pt; font-family:Times New Roman;font-weight:bold">Investing in our securities involves a high degree of risk. See the section entitled &#8220;<span style="text-decoration:underline"><a href="#toc479690_5">Risk Factors</a></span>&#8221; beginning on page 16 of this prospectus to read about factors you should consider before buying our securities. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman;font-weight:bold">Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or determined if this prospectus is truthful or complete. Any representation to the contrary is a criminal offense. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">The date of this prospectus is&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;, 2023. </p>
</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center" id="toc">TABLE OF CONTENTS </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">


<tr>

<td style="width:95%"></td>

<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Page</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#toc479690_1">ABOUT THIS PROSPECTUS</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#toc479690_2">CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">7</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#toc479690_3">PROSPECTUS SUMMARY</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">8</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#toc479690_4">THE OFFERING</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">14</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#toc479690_5">RISK FACTORS</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">16</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#toc479690_6">COMMITTED EQUITY FINANCING</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">63</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#toc479690_7">USE OF PROCEEDS</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">67</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#toc479690_8">MARKET INFORMATION FOR COMMON STOCK AND DIVIDEND POLICY</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">68</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#toc479690_9">BUSINESS</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">69</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#toc479690_10">MANAGEMENT&#8217;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">100</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#toc479690_11">MANAGEMENT</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">115</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#toc479690_12">EXECUTIVE COMPENSATION</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">122</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#toc479690_13">CERTAIN RELATIONSHIPS AND RELATED PARTY TRANSACTIONS</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">128</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#toc479690_14">PRINCIPAL SECURITYHOLDERS</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">132</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#toc479690_15">SELLING SECURITYHOLDER</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">135</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#toc479690_16">DESCRIPTION OF SECURITIES</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">137</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#toc479690_17">MATERIAL UNITED STATES FEDERAL INCOME TAX CONSEQUENCES</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">150</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#toc479690_18">PLAN OF DISTRIBUTION</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">157</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#toc479690_19">LEGAL MATTERS</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">159</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#toc479690_20">EXPERTS</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">159</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#toc479690_21">WHERE YOU CAN FIND MORE INFORMATION</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">159</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
</table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman;font-weight:bold">You should rely only on the information provided in this prospectus, as well as the information incorporated by reference into this prospectus and any applicable prospectus supplement. Neither we nor the Selling Securityholder have authorized anyone to provide you with different information. Neither we nor the Selling Securityholder are making an offer of these securities in any jurisdiction where the offer is not permitted. You should not assume that the information in this prospectus or any applicable prospectus supplement is accurate as of any date other than the date of the applicable document. Since the date of this prospectus and the documents incorporated by reference into this prospectus, our business, financial condition, results of operations and prospects may have changed. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">i </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center" id="toc479690_1">ABOUT THIS PROSPECTUS </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This prospectus is part of a registration statement on Form <span style="white-space:nowrap">S-1</span> that we filed with the Securities and Exchange Commission (the &#8220;SEC&#8221;) using the &#8220;shelf&#8221; registration process. Under this shelf registration process, the Selling Securityholder may, from time to time, sell the securities offered by them described in this prospectus. We will not receive any proceeds from the sale of the securities offered by the Selling Securityholder described in this prospectus. However, we expect to receive proceeds from sales of Class&#160;A common stock that we may elect to make to the Selling Securityholder pursuant to the Purchase Agreement, if any, from time to time in our discretion. The net proceeds from sales, if any, under the Purchase Agreement, will depend on the frequency and prices at which we sell shares of Common Stock to the Selling Securityholder after the date of this prospectus. See &#8220;Committed Equity Financing&#8221; for a description of how the price we may sell shares of Class&#160;A common stock to the Selling Securityholder is calculated pursuant to the Purchase Agreement. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Neither we nor the Selling Securityholder have authorized anyone to provide you with any information or to make any representations other than those contained in this prospectus or any applicable prospectus supplement or any free writing prospectuses prepared by or on behalf of us or to which we have referred you. Neither we nor the Selling Securityholder take responsibility for, or provide any assurance as to the reliability of, any other information that others may give you. Neither we nor the Selling Securityholder will make an offer to sell these securities in any jurisdiction where the offer or sale is not permitted. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may also provide a prospectus supplement or post-effective amendment to the registration statement to add information to, or update or change information contained in, this prospectus. You should read both this prospectus and any applicable prospectus supplement or post-effective amendment to the registration statement together with the additional information to which we refer you in the sections of this prospectus entitled &#8220;Where You Can Find More Information.&#8221; </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On May&#160;26, 2022 (the &#8220;Closing Date&#8221;), Haymaker Acquisition Corp. III, a Delaware corporation (&#8220;HYAC&#8221;), completed the transactions contemplated by that certain Business Combination Agreement, dated as of December&#160;13, 2021 (the &#8220;Business Combination Agreement&#8221;), by and among HYAC (the &#8220;Sponsor&#8221;), BioTE Holdings, LLC, a Nevada limited liability company (&#8220;Biote&#8221; and, together with its direct and indirect subsidiaries, the &#8220;Biote Companies&#8221;), BioTE Management, LLC, a Nevada limited liability company, Dr.&#160;Gary Donovitz, in his individual capacity, and Teresa S. Weber, in her capacity as the members&#8217; representative (in such capacity, the &#8220;Members&#8217; Representative&#8221;) of the members of Biote immediately prior to the closing (the &#8220;Closing&#8221;) of the transactions contemplated by the Business Combination Agreement (collectively, the &#8220;Members&#8221;). A description of the Business Combination (as defined below) and the terms of the Business Combination Agreement are included in the definitive proxy statement (File <span style="white-space:nowrap">No.&#160;001-40128)</span> (the &#8220;Proxy Statement&#8221;) filed by HYAC with the SEC on May&#160;5, 2022 in the section titled &#8220;Proposal No. <span style="white-space:nowrap">1-The</span> Business Combination Proposal.&#8221; </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">At the Closing, (i)&#160;Biote transferred to the Company (as defined below) 9,161,771 Class&#160;A common units of Biote (&#8220;Biote Units&#8221;), which was equal to the number of shares of HYAC&#8217;s Class&#160;A common stock, par value $0.0001 per share (&#8220;HYAC Class&#160;A Common Stock&#8221;), issued and outstanding as of immediately prior to the Closing (after giving effect to redemptions by HYAC&#8217;s public stockholders of 30,525,729 shares of HYAC Class&#160;A Common Stock prior to the Closing and the conversion of HYAC&#8217;s Class&#160;B common stock, par value $0.0001 per share (&#8220;HYAC Class&#160;B Common Stock&#8221;)) into shares of HYAC Class&#160;A Common Stock and (ii)&#160;HYAC issuance of 58,565,824 shares of newly authorized Class&#160;V voting stock, par value $0.0001 per share (&#8220;Class&#160;V voting stock&#8221; and, together with the Class&#160;A common stock, the &#8220;Common Stock&#8221;), which number of shares of Class&#160;V voting stock was equal to the number of Biote Units retained by the Members immediately following the Closing (the &#8220;Retained Biote Units&#8221;), and which shares of Class&#160;V voting stock were distributed to Biote&#8217;s Members, resulting in the Combined Company being organized in an <span style="white-space:nowrap">&#8220;Up-C&#8221;</span> structure. The transactions contemplated by the Business Combination Agreement are referred to herein as the &#8220;Business Combination.&#8221; </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">1 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Also at Closing, (x)&#160;in exchange for Biote issuing to the Company 9,161,771 Biote Units (the &#8220;Closing Biote Units&#8221;), HYAC transferred cash in an amount equal to (i)&#160;the cash in the trust account and any cash held by HYAC outside of the trust account, less (ii)&#160;the amounts required by the redemptions of Class&#160;A common stock by the public stockholders, which was equal to $305.5&#160;million and (y)&#160;the Biote Companies received aggregate proceeds of $125.0&#160;million from the Debt Financing (as defined below) (the aggregate amounts described in (x)&#160;and (y) of $137.3&#160;million, are referred to as the &#8220;Closing Date Cash&#8221;) in accordance with and in the priority set forth in the Business Combination Agreement and as described further in the Proxy Statement. There was no cash consideration paid to Members at Closing. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Upon the Closing, HYAC as the registrant changed its name to &#8220;biote Corp.&#8221; </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Unless the context otherwise requires, the terms &#8220;we,&#8221; &#8220;us,&#8221; &#8220;our,&#8221; and the &#8220;Company&#8221; refers to biote Corp. and its consolidated subsidiaries, including Biote, following the Closing, and references to &#8220;HYAC&#8221; refer to Haymaker Acquisition Corp. III at or prior to the Closing. All references herein to the &#8220;Board&#8221; refer to the board of directors of the Company after giving effect to the Business Combination. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">2 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">CERTAIN DEFINED TERMS </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Unless the context indicates otherwise, the following terms have the following meanings when used in this prospectus: </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<span style="font-style:italic">Affiliate</span>&#8221; of any particular Person means any other Person controlling, controlled by, or under common control with such Person, where &#8220;<span style="font-style:italic">control</span>&#8221; means the possession, directly or indirectly, of the power to direct the management and policies of a Person, whether through the ownership of voting securities, its capacity as a sole or managing member, or otherwise. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">&#8220;Biote&#8221;</span> means BioTE Holdings, LLC, unless otherwise noted, a Delaware limited liability company after the plan of conversion filed with the Nevada Secretary of State. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<span style="font-style:italic">Biote A&amp;R OA</span>&#8221; means the Second Amended and Restated Operating Agreement of entered into at the Closing by and among the Combined Company, Biote and the Members, which, among other things, permitted the issuance and ownership of Biote Units as contemplated to be issued and owned following the Closing, designate the Combined Company as the sole manager of Biote, provide for the Exchange Rights, set forth the rights and preferences of the Biote Units, and establish the ownership of the Biote Units by the persons or entities indicated in the Biote A&amp;R OA, in each case, as more fully described in the Biote A&amp;R OA. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<span style="font-style:italic">Biote Companies</span>&#8221; means Biote, together with all of its direct and indirect subsidiaries. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<span style="font-style:italic">Biote Medical</span>&#8221; means BioTE Medical, LLC. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<span style="font-style:italic">Bylaws</span>&#8221; means the amended and restated bylaws of the Company, dated as of February&#160;21, 2023. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<span style="font-style:italic">Charter</span>&#8221; means the second amended and restated certificate of incorporation of the Company, dated as of the Closing Date. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<span style="font-style:italic">Class</span><span style="font-style:italic"></span><span style="font-style:italic">&#160;A Units</span>&#8221; means the Class&#160;A Units (as defined in the Biote A&amp;R OA) issued and outstanding immediately prior to the consummation of the Recapitalization. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<span style="font-style:italic">Class</span><span style="font-style:italic"></span><span style="font-style:italic">&#160;AA Units</span>&#8221; means the Class&#160;AA Units (as defined in the Biote A&amp;R OA) issued and outstanding immediately prior to the consummation of the Recapitalization. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<span style="font-style:italic">Class</span><span style="font-style:italic"></span><span style="font-style:italic">&#160;AAA Units</span>&#8221; means the Class&#160;AAA Units (as defined in the Biote A&amp;R OA) issued and outstanding immediately prior to the consummation of the Recapitalization. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<span style="font-style:italic">Class</span><span style="font-style:italic"></span><span style="font-style:italic">&#160;AAAA Units</span>&#8221; means the Class&#160;AAAA Units (as defined in the Biote A&amp;R OA) issued and outstanding immediately prior to the consummation of the Recapitalization. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<span style="font-style:italic">Class</span><span style="font-style:italic"></span><span style="font-style:italic">&#160;B Common Stock Conversion</span>&#8221; means, in connection with the Closing, the conversion of all then-outstanding shares of Class&#160;B common stock into shares of Class&#160;A common stock on a <span style="white-space:nowrap"><span style="white-space:nowrap">one-for-one</span></span> basis. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<span style="font-style:italic">Closing Date</span>&#8221; means May&#160;26, 2022. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<span style="font-style:italic">Combined Company</span>&#8221; means biote Corp. and its consolidated subsidiaries, including Biote, following the Closing. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<span style="font-style:italic">Common Stock</span>&#8221; means the Class&#160;A common stock and Class&#160;V voting stock. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<span style="font-style:italic">Credit Agreement</span>&#8221; means the Credit Agreement, dated as of May&#160;26, 2022, by and among BioTE Medical, Biote, the guarantors identified therein, the lenders party thereto from time to time, Truist Bank, as </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">3 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Administrative Agent, Swingline Lender and Issuing Bank, Bank of America, N.A. and Wells Fargo Bank, National Association, as <span style="white-space:nowrap">Co-Syndication</span> Agents, Truist Securities, Inc., BofA Securities, Inc. and Wells Fargo Securities, LLC as Joint Lead Arrangers and Joint Bookrunners. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<span style="font-style:italic">Debt Financing</span>&#8221; means the Term Loan, the Revolving Loans and the Credit Agreement, collectively. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<span style="font-style:italic">Earnout Voting Shares</span>&#8221; means 10,000,000 shares of Class&#160;V voting stock distributed to the Members by Biote. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<span style="font-style:italic">Exchange Rights</span>&#8221; means, beginning on the six month anniversary of the Closing, the rights of the Members to have their Retained Biote Units redeemed, together with one share of Class&#160;V voting stock and subject to certain conditions, in exchange for either one share of Class&#160;A common stock or in certain circumstances, at the election of the Company in its capacity as the sole manager of Biote, the cash equivalent of the market value of one share of Class&#160;A common stock, pursuant to the terms and conditions of the Biote A&amp;R OA. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<span style="font-style:italic">Equity Securities</span>&#8221; means, with respect to any Person, all of the shares of capital stock or equity of (or other ownership or profit interests in) such Person, all of the warrants, options or other rights for the purchase or acquisition from such Person of shares of capital stock or equity of (or other ownership or profit interests in) such Person, all of the securities convertible into or exchangeable for shares of capital stock or equity of (or other ownership or profit interests in) such Person or warrants, rights or options for the purchase or acquisition from such Person of such shares or equity (or such other interests), restricted stock awards, restricted stock units, equity appreciation rights, phantom equity rights, profit participation and all of the other ownership or profit interests of such Person (including partnership or member interests therein), whether voting or nonvoting. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<span style="font-style:italic">Founder Holders</span>&#8221; means each of the Sponsor, Steven J. Heyer and Andrew R. Heyer. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<span style="font-style:italic">Founder Shares</span>&#8221; means the shares of Class&#160;B common stock held by the Founder Holders, which such shares of Class&#160;B common stock automatically converted into an equal number of shares of Class&#160;A common stock in connection with the Closing. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<span style="font-style:italic">Governmental Entity</span>&#8221; means any nation or government, any state, province, county, municipal or other political subdivision thereof, any entity exercising executive, legislative, tribal, judicial, regulatory or administrative functions of or pertaining to government, including any court, arbitrator (public or private) or other body or administrative, regulatory or quasi-judicial authority, agency, department, board, commission or instrumentality of any federal, state, local or foreign jurisdiction, or any self-regulated organization or other <span style="white-space:nowrap">non-governmental</span> regulatory authority (to the extent that the rules, regulations or orders of such organization or authority have the force of law). </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<span style="font-style:italic">Holdings</span>&#8221; means BioTE Holdings, LLC and its consolidated subsidiaries. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<span style="font-style:italic">HYAC</span>&#8221; means Haymaker Acquisition Corp. III prior to the Business Combination. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<span style="font-style:italic">Initial Shares</span>&#8221; means an aggregate of 58,565,824 Retained Biote Units (and any Equity Securities into which such units may be exchanged), proportionately amongst the Members based on their respective percentage interests held in Biote as of immediately after the Closing. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<span style="font-style:italic">Investor Rights Agreement</span>&#8221; means the Investor Rights Agreement entered into at the Closing, by and among the Company, the Sponsor, the Members&#8217; Representative and certain other parties. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<span style="font-style:italic">IPO</span>&#8221; means Haymaker Acquisition Corp. III.&#8217;s initial public offering, consummated on March&#160;4, 2021, through the sale of 31,750,000 units at $10.00 per unit (including 1,750,000 units that were issued upon the partial exercise of the IPO underwriters&#8217; overallotment option, which closed on March&#160;5, 2021). </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<span style="font-style:italic">Member Earnout Units</span>&#8221; means the 10,000,000 Retained Biote Units held by the Members at the Closing. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">4 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<span style="font-style:italic">Nasdaq Independent</span>&#8221; means a person who shall qualify as an &#8220;independent director&#8221; as such term is defined under Nasdaq Stock Market Rule 5605(a)(2) (or any successor rule) and applicable SEC rules and regulations, as of (i)&#160;the time of the nomination of such director pursuant to Section&#160;2.1 and (ii)&#160;the time of any vote, decision or recommendation made by such director as a member of the board. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<span style="font-style:italic">Person</span>&#8221; means any natural person, sole proprietorship, partnership, joint venture, trust, unincorporated association, corporation, limited liability company, entity or Governmental Entity. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<span style="font-style:italic">Phantom Equity Acknowledgement</span>&#8221; means the acknowledgement that each Phantom Equity Holder entered into effective as of the Closing, which, among other things, confirms the number of shares of Class&#160;A common stock to be issued to such Phantom Equity Holder pursuant to biote Corp. 2022 Equity Incentive Plan (the &#8220;Incentive Plan&#8221;) in satisfaction of his or her phantom equity rights and the vesting schedule for such shares. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<span style="font-style:italic">Phantom Equity Holder</span>&#8221; means each holder of phantom equity in any of Biote or its direct or indirect subsidiaries. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<span style="font-style:italic">Purchase Agreement</span>&#8221; means that certain standby equity purchase agreement, by and between biote Corp. and YA II PN, LTD. dated as of July&#160;27, 2022. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">&#8220;Recapitalization&#8221;</span> means the recapitalization that occurred immediately prior the Closing, pursuant to which all its Class&#160;A Units, Class&#160;AA Units, Class&#160;AAA Units and Class&#160;AAAA Units held by the Members were to be converted or exchanged (whether by direct exchange, merger or otherwise) into a number of equity interests in Biote designated as &#8220;Class&#160;A Common Units&#8221; resulting in the Members holding a single class of Biote Units. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<span style="font-style:italic">Revolving Loans</span>&#8221; means the $50,000,000 senior secured revolving credit facility provided for in the Credit Agreement. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<span style="font-style:italic">Securities Act</span>&#8221; means the Securities Act of 1933, as amended. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<span style="font-style:italic">Sponsor Earnout Shares</span>&#8221; means 1,587,500 shares of Class&#160;A common stock held by the Sponsor after giving effect to the Class&#160;B Common Stock Conversion. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<span style="font-style:italic">Tax Receivable Agreement</span>&#8221; means the tax receivable agreement entered into simultaneously with the Closing by and among the Combined Company, Biote, the Members and the Members&#8217; Representative, which provides for, among other things, payment by the Combined Company to the Members of 85% of the U.S. federal, state and local income tax savings realized by the Combined Company as a result of the increases in tax basis and certain other tax benefits related to the transactions contemplated under the Business Combination Agreement and the redemption of Retained Biote Units in exchange for Class&#160;A common stock or cash (as more fully described in the Tax Receivable Agreement). </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<span style="font-style:italic">Term Loan</span>&#8221; means the $125,000,000 senior secured term loan A credit facility provided for in the Credit Agreement, which was borrowed in full on the Closing Date. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<span style="font-style:italic">Underwriter Units</span>&#8221; means the 1,750,000 units issued to the Underwriters in a concurrent private placement in connection with the IPO. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<span style="font-style:italic">Underwriters</span>&#8221; means Citigroup Global Markets Inc. and Cantor Fitzgerald&#160;&amp; Co., as representatives of the several underwriters in the IPO. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<span style="font-style:italic">Warrant Agent</span>&#8221; means Continental Stock Transfer&#160;&amp; Trust Company in its capacity as warrant agent under the Warrant Agreement. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">5 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<span style="font-style:italic">Warrant Agreement</span>&#8221; means that certain Warrant Agreement, dated as of March&#160;1, 2021, by and between HYAC and Continental Stock Transfer&#160;&amp; Trust Company, a New York corporation, as warrant agent. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<span style="font-style:italic">Working Capital Loans</span>&#8221; means funds that the Sponsor or an affiliate of the Sponsor, or certain of the HYAC&#8217;s officers and directors may, but are not obligated to, loan HYAC as may be required in order to finance transaction costs in connection with the Business Combination. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;<span style="font-style:italic">Yorkville</span>&#8221; means YA II PN, LTD., a Cayman Islands exempt limited partnership. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">6 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center" id="toc479690_2">CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This registration statement contains forward-looking statements. These forward-looking statements relate to expectations for future financial performance, business strategies, or expectations for the Company&#8217;s business. These forward-looking statements include, but are not limited to, statements regarding the Company&#8217;s or its management team&#8217;s expectations, hopes, beliefs, intentions, or strategies regarding the future. In addition, any statements that refer to projections, forecasts, or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking statements. The forward-looking statements are contained principally in the sections titled &#8220;Prospectus Summary&#8221; &#8220;Risk Factors,&#8221; &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations,&#8221; &#8220;Business&#8221; and elsewhere in this prospectus. In some cases, you can identify forward-looking statements by terms such as &#8220;may,&#8221; &#8220;can,&#8221; &#8220;should,&#8221; &#8220;will,&#8221; &#8220;estimate,&#8221; &#8220;plan,&#8221; &#8220;project,&#8221; &#8220;forecast,&#8221; &#8220;intend,&#8221; &#8220;expect,&#8221; &#8220;hope,&#8221; &#8220;anticipate,&#8221; &#8220;believe,&#8221; &#8220;seek,&#8221; &#8220;target,&#8221; &#8220;continue,&#8221; &#8220;could,&#8221; &#8220;might,&#8221; &#8220;ongoing,&#8221; &#8220;potential,&#8221; &#8220;predict,&#8221; &#8220;would&#8221; or similar expressions. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">These forward-looking statements are based on information available as of the date of this prospectus, and our management&#8217;s current expectations, forecasts and assumptions, and involve a number of judgments, risks and uncertainties. Accordingly, forward-looking statements should not be relied upon as representing the Company&#8217;s views as of any subsequent date. The Company does not undertake any obligation to update forward-looking statements to reflect events or circumstances after the date they were made, whether as a result of new information, future events or otherwise, except as may be required under applicable securities laws. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">You should not place undue reliance on these forward-looking statements. As a result of a number of known and unknown risks and uncertainties, the Company&#8217;s actual results or performance may be materially different from those expressed or implied by these forward-looking statements. Some factors that could cause actual results to differ include: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the success of our dietary supplements to attain significant market acceptance among clinics, practitioners and their patients; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">our customers&#8217; reliance on certain third parties to support the manufacturing of <span style="white-space:nowrap">bio-identical</span> hormones for prescribers; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">our and our customers&#8217; sensitivity to regulatory, economic, environmental and competitive conditions in certain geographic regions; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">our ability to increase the use by practitioners and clinics of the Biote Method at the rate that we anticipate or at all; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">our ability to grow our business; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the significant competition we face in our industry; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">our limited operating history; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">our ability to protect our intellectual property; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the unpredictability of the effects of the <span style="white-space:nowrap">COVID-19</span> pandemic; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the heavy regulatory oversight in our industry; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">changes in applicable laws or regulations; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the inability to profitably expand in existing markets and into new markets; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the possibility that we may be adversely impacted by other economic, business and/or competitive factors; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">future exchange and interest rates; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">other risks and uncertainties indicated in this registration statement, including those under &#8220;Risk Factors&#8221; herein, and other filings the Company has made, or will make, with the Securities and Exchange Commission (the &#8220;SEC&#8221;). </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">7 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<div style="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center" id="toc479690_3">PROSPECTUS SUMMARY </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">The following summary highlights selected information contained elsewhere in this prospectus and does not contain all of the information that you should consider in making your investment decision. Before investing in our securities, you should carefully read this entire prospectus, including our consolidated financial statements and the related notes included in this prospectus and the information set forth under the headings &#8220;Risk Factors&#8221; and &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations.&#8221; </span></p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Our Company </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We operate a high-growth practice-building business within the hormone optimization space. Similar to a franchise model, we provide the necessary components to enable Biote-certified practitioners to establish, build, and successfully implement a program designed to optimize hormone levels using personalized solutions for their patient populations. The Biote Method is a comprehensive, <span style="white-space:nowrap"><span style="white-space:nowrap">end-to-end</span></span> practice building platform that provides Biote-certified practitioners with the following components specifically developed for practitioners in the hormone optimization space: Biote Method education, training and certification, practice management software, inventory management software, and information regarding available hormone replacement therapy (&#8220;HRT&#8221;) products, as well as digital and <span style="white-space:nowrap"><span style="white-space:nowrap">point-of-care</span></span> marketing support. We also sell a complementary Biote-branded line of dietary supplements. We generate revenues by charging the Biote-partnered clinics fees associated with the support Biote provides for HRT and from the sale of Biote-branded dietary supplements. By virtue of our historical performance over the 11 years ended December&#160;31, 2022, we believe that our business model has been successful, remains differentiated, and is well positioned for future growth. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">By incorporating the Biote Method in their practices, we enable practitioners to participate in the large and growing hormone optimization space. Bioidentical hormone therapy, which is offered by Biote-certified practitioners, is one segment of the large HRT market. It is estimated that, as of 2020, the total U.S. market opportunity for HRT products, available in various forms, exceeds $7&#160;billion and is expected to grow 7% annually through 2026. We believe our business opportunity in providing educational and practice management services is large and will similarly grow. Growth in this field is expected to be fueled by &#8220;aging&#8221; demographics and expanding consumer demand for medical information and treatment options to address hormonal imbalances. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Patient symptoms associated with menopause in women and andropause in men, such as hot flashes, night sweats, depressed mood, low libido, weight gain, and issues with concentration and focus, while negatively impacting quality of life, may also be associated with higher risks for chronic diseases attributable to declining hormone levels, including cardiovascular disease, osteoporosis and breast cancer. Approximately 13.8&#160;million men over age 45 in the United States are affected by hypogonadism and only about 1.3&#160;million (9%) of those affected undergo testosterone treatment. An average of 27&#160;million women between the ages of 45 and 64, or 20% of the American workforce, experience menopause every year. Despite the prevalence of <span style="white-space:nowrap">symptoms-84%</span> of women report menopausal symptoms that interfere with their lives-only 58% have discussed menopause with a health provider, and only 28%, or approximately 13&#160;million, undergo HRT (and of that 28%, only 31%, or approximately 4&#160;million, undergo bioidentical HRT). By 2030, over 1.2&#160;billion women, 14% of the global population, will be in menopause or post-menopause. Yet, despite the growing number of women experiencing menopause, they remain an underserved population. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">One key driver of this unmet medical need is the lack of knowledge and experience of treating physicians. For many practitioners, the last time they received meaningful instruction on treating menopause and andropause was during medical school. Based on a 2018 article by Jennifer Wolff, entitled &#8220;What Doctors Don&#8217;t Know About Menopause,&#8221; among newer doctors surveyed in 2015, 80% of medical residents reported feeling &#8220;barely comfortable&#8221; discussing or treating menopause. While this knowledge gap applies to training, we believe it also applies to the understanding of treatment alternatives, access to new therapies, methods to drive efficiencies in a hormone optimization practice and finally, how to profitably treat this growing population. </p>
</div></div>

 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">8 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<div style="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">To capitalize on this large and underserved market opportunity, we developed a highly differentiated practice-building platform to enable practitioners to treat the hormone imbalance symptoms experienced by their patients. The Biote Method has been designed specifically for practitioners who focus on treating perimenopause in women; post-menopause in women; and andropause/hypogonadism in men. It is constructed to bridge the existing gaps which exist in education and treatment options, while improving the efficiency of practitioners&#8217; business operations and the hormone health of their aging patient base. Over the past 11 years, we have built our platform to provide highly differentiated education and training, practice support resources and inventory management tools that would be difficult for a practice to otherwise attain on their own. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We empower Biote-certified practitioners by requiring rigorous <span style="white-space:nowrap">in-person</span> training, testing and certification for all Biote-certified practitioners and office staff wishing to use the Biote Method in their practice. Our practitioner instructors are among the nation&#8217;s most experienced clinical experts in hormonal therapy, including multiple modalities of HRT such as creams, gels, patches, pills, injections and compounded bioidentical hormone pellets. We teach clinicians how to identify early indicators of hormone-related aging conditions, and we believe we are the top practitioner educators by virtue of our experience over 11 years, with over 3&#160;million hormone optimization procedures performed by Biote-certified practitioners to date, including approximately 300,000 active patients. We offer training centrally and regionally to provide consistent and ongoing technical education. On an ongoing basis, we provide access to <span style="white-space:nowrap"><span style="white-space:nowrap">around-the-clock</span></span> clinical and technical support for Biote-certified practitioners. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">To offer a turnkey platform, we leverage the data Biote-certified practitioners collect using our BioTracker software for regulatory and record management to seamlessly assess a simple procedure-based revenue model that encompasses fees for the education, training, <span style="white-space:nowrap">re-training,</span> comprehensive administrative services and support and pass-through cost of pellets that practitioners may choose to provide as part of the Biote Method. We believe our revenue model represents an objective method to assess fees across the varying size and sophistication of our Biote-certified practitioners and clinics beginning with the first day of training and continuing throughout the treatment of each practitioner&#8217;s patient. Additionally, this revenue model provides our Biote-certified practitioners with consistency and predictability, notwithstanding the variability in services required to support their practices during any given period. Our revenue model also offers efficiency and transparency for inventory management, as each procedure is electronically recorded through our technology platform without requiring additional workflow. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Biote Method&#8217;s proprietary clinical decision support software (&#8220;CDS&#8221;) assists physicians in establishing individualized dosing for patients. Our BioTracker software and business tools allow practitioners to efficiently manage the record management, product acquisition, inventory logistics and the business end of a robust hormone optimization practice. We provide Biote-partnered clinics access to <span style="white-space:nowrap">FDA-registered</span> outsourcing facilities that can supply a wide array of hormone optimization products for Biote-certified practitioner patients. We provide information to Biote-certified practitioners regarding how to integrate with our BioTracker software. Our BioTracker software allows Biote-certified practitioners to manage orders and maintain accurate inventory records to keep their regulatory and business systems up to date. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Beyond the breadth and depth of our commercial and operational platform, the Biote name has achieved strong brand recognition among practitioners and patients in the communities we serve, as illustrated by QY Research&#8217;s market research publication entitled &#8220;South&#160;&amp; North America Hormone Replacement Therapy Market Insights and Forecast to 2026.&#8221; Practitioners undertaking the Biote Method can be confident that our exclusive training and practice building tools will prepare them to provide excellent and differentiated care to patients. This has led to high practitioner satisfaction and above 90% retention rate among Biote-certified practitioners. We are contracted with and provide comprehensive support to over 6,400 practitioners that have adopted the Biote Method in their practices. Leveraging our brand strength, we offer marketing assistance, including office signage and patient education materials, to every Biote-certified practitioner within our network. </p>
</div></div>

 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">9 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<div style="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We believe by virtue of their participation in our robust training and practice certification, Biote-certified practitioners are well informed on all aspects of hormone optimization. We believe our brand advantage with both practitioners and patients is a key element of our commercial growth strategy, and an asset that we intend to leverage to expand our business. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Complementing the Biote Method is our expanding line of private-labeled dietary supplements to address hormone, vitamin, and physiological deficiencies that regularly manifest in an aging population. This business segment appeals to practitioners&#8217; patient demographic and enables patients the opportunity to receive practitioner-recommended Biote-branded dietary supplements to support healthy aging. By leveraging our existing Biote-certified practitioner base to sell and distribute our Biote-branded dietary supplements, we believe we have created an efficient and complementary business. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We also designed the Biote Method to permit beneficial practice economics for our Biote-partnered clinics. Our educational training and practice management platform helps enable Biote-partnered clinics to execute this <span style="white-space:nowrap">all-cash</span> model with minimal reimbursement risk. This contrasts to consistently decreasing reimbursement rates for most other treatments and therapies offered by physician offices. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have a track record of consistently achieving accelerated and highly profitable growth. Our four-year revenue compound annual growth rate (&#8220;CAGR&#8221;) from 2016-2020 was 22%. Our revenue was $165.0&#160;million and $139.4&#160;million for the years ended December&#160;31, 2022 and 2021, respectively. Net income was $1.3&#160;million and $32.6&#160;million for the years ended December&#160;31, 2022 and 2021, respectively. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Corporate Information </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">HYAC was incorporated in the State of Delaware on July&#160;6, 2020 as a special purpose acquisition company under the name Haymaker Acquisition Corp. III. Holdings is a Delaware limited liability company formed on March&#160;31, 2019. On March&#160;4, 2021, HYAC completed its IPO. On May&#160;26, 2022, the Business Combination with Holdings was consummated, resulting in Biote being organized in an <span style="white-space:nowrap">&#8220;Up-C&#8221;</span> structure, and HYAC as the registrant changed its name to &#8220;biote Corp<span style="font-style:italic">.</span>&#8221; Biote&#8217;s headquarters are located at 1875 W. Walnut Hill Ln #100 Irving, Texas 75038. Our telephone number is (844) <span style="white-space:nowrap">604-1246,</span> and our website address is www.biote.com. The information contained on, or that can be accessed through, our website is not incorporated by reference in this prospectus and does not form a part of this prospectus. The reference to our website address does not constitute incorporation by reference of the information contained at or available through our website, and you should not consider it to be a part of this registration statement. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Committed Equity Financing </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On July&#160;27, 2022, we entered into the Purchase Agreement, with Yorkville. Pursuant to the Purchase Agreement, we have the right to sell to Yorkville up to 5,000,000 shares of our Class&#160;A common stock, subject to certain limitations and conditions set forth in the Purchase Agreement, from time to time during the term of the Purchase Agreement. Sales of Class&#160;A common stock to Yorkville under the Purchase Agreement, and the timing of any such sales, are at our option, and we are under no obligation to sell any securities to Yorkville under the Purchase Agreement. In accordance with our obligations under the Purchase Agreement, we have filed the registration statement that includes this prospectus with the SEC to register under the Securities Act the resale by Yorkville of up to 5,000,000 shares of Class&#160;A common stock, consisting of 25,000 shares of Class&#160;A common stock that we issued to Yorkville in consideration of its commitment to purchase shares of Class&#160;A common stock at our election under to the Purchase Agreement (the &#8220;Commitment Shares&#8221;), and up to 4,975,000 shares of Class&#160;A common stock that we may elect, in our sole discretion, to issue and sell to Yorkville, from time to time under the Purchase Agreement. </p>
</div></div>

 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">10 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<div style="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Upon the satisfaction of the conditions to Yorkville&#8217;s purchase obligation set forth in the Purchase Agreement, including that the registration statement of which this prospectus forms a part be declared effective by the SEC and the final form of this prospectus is filed with the SEC, we will have the right, but not the obligation, from time to time at our discretion until the first day of the month following the <span style="white-space:nowrap">36-month</span> period after the date of the Purchase Agreement, to direct Yorkville to purchase a specified amount of shares of Class&#160;A common stock (each such sale, an &#8220;Advance&#8221;) by delivering written notice to Yorkville (each, an &#8220;Advance Notice&#8221;). While there is no mandatory minimum amount for any Advance, it may not exceed the greater of (i)&#160;an amount equal to thirty percent (30%) of the Daily Volume Traded on the trading day immediately preceding an Advance Notice, or (ii) 1,000,000 shares of Class&#160;A common stock. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The per share purchase price for the shares of Class&#160;A common stock, if any, that we elect to sell to the Selling Securityholder in an Advance pursuant to the Purchase Agreement will be determined by reference to the volume weighted average price of our Class&#160;A common stock (the &#8220;VWAP&#8221;) and calculated in accordance with the Purchase Agreement, less a variable discount of 3%, provided however that the Company may establish a minimum acceptable price in each Advance Notice below which it shall not be obligated to make any sales to the Selling Securityholder. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">There is no upper limit on the price per share that Yorkville could be obligated to pay for the Class&#160;A common stock we may elect to sell to it in any Advance. The purchase price per share of Class&#160;A common stock that we may elect to sell to Yorkville in an Advance under the Purchase Agreement will be equitably adjusted for any reorganization, recapitalization, <span style="white-space:nowrap">non-cash</span> dividend, stock split, reverse stock split or other similar transaction. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We will control the timing and amount of any sales of Class&#160;A common stock to Yorkville. Actual sales of shares of our Class&#160;A common stock to Yorkville under the Purchase Agreement will depend on a variety of factors to be determined by us from time to time, which may include, among other things, market conditions, the trading price of our Class&#160;A common stock and determinations by us as to the appropriate sources of funding for our business and its operations. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may not issue or sell any shares of Class&#160;A common stock to Yorkville under the Purchase Agreement which, when aggregated with all other shares of Class&#160;A common stock then beneficially owned by Yorkville and its Affiliates (as calculated pursuant to Section&#160;13(d) of the Securities Exchange Act of 1934, as amended, and Rule <span style="white-space:nowrap">13d-3</span> promulgated thereunder), would result in Yorkville beneficially owning more than 4.99% of the outstanding shares of Class&#160;A common stock (the &#8220;Beneficial Ownership Limitation&#8221;). </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The net proceeds under the Purchase Agreement to us will depend on the frequency and prices at which we sell shares of our stock to Yorkville. We expect that any proceeds received by us from such sales to Yorkville will be used for working capital and general corporate purposes. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Yorkville has agreed that it and its Affiliates will not engage in any short sales of the Class&#160;A common stock nor enter into any transaction that establishes a net short position in the Class&#160;A common stock during the term of the Purchase Agreement. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Purchase Agreement will automatically terminate on the earliest to occur of (i)&#160;the first day of the month next following the <span style="white-space:nowrap">36-month</span> anniversary of the date of the Purchase Agreement or (ii)&#160;the date on which the Selling Securityholder shall have purchased from us under the Purchase Agreement 5,000,000 shares of our Class&#160;A common stock. We have the right to terminate the Purchase Agreement at no cost or penalty upon five (5)&#160;trading days&#8217; prior written notice to Yorkville, provided that there are no outstanding Advance Notices and all outstanding amounts owed to Yorkville are repaid. We and Yorkville may also agree to terminate the Purchase Agreement by mutual written consent. Neither we nor Yorkville may assign or transfer our respective rights and </p>
</div></div>

 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">11 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<div style="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
obligations under the Purchase Agreement, and no provision of the Purchase Agreement may be modified or waived by us or Yorkville other than by an instrument in writing signed by both parties. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As consideration for Yorkville&#8217;s commitment to purchase shares of Class&#160;A common stock at our direction upon the terms and subject to the conditions set forth in the Purchase Agreement, upon execution of the Purchase Agreement, we issued 25,000 shares of Class&#160;A common stock to Yorkville. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Purchase Agreement contains customary representations, warranties, conditions and indemnification obligations of the parties. The representations, warranties and covenants contained in such agreements were made only for purposes of such agreements and as of specific dates, were solely for the benefit of the parties to such agreements and may be subject to limitations agreed upon by the contracting parties. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of July&#160;28, 2022, excluding the Commitment Shares, there were 67,727,595 shares of common stock outstanding, consisting of 9,161,771 shares of our Class&#160;A common stock and 58,565,824 shares of our Class&#160;V voting stock, of which 9,515,519 shares of common stock were held by <span style="white-space:nowrap">non-affiliates,</span> consisting of 5,301,991 shares of our Class&#160;A common stock and 4,213,528 shares of our Class&#160;V voting stock. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If all of the 5,000,000 shares offered by Yorkville for resale under the registration statement that includes this prospectus were issued and outstanding as of the date hereof (without taking into account the 4.99% Beneficial Ownership Limitation), such shares would represent approximately 6.9% of the total number of shares of our Common Stock outstanding and approximately 52.5% of the total number of outstanding shares held by <span style="white-space:nowrap">non-affiliates,</span> in each case as of July&#160;28, 2022. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">There are substantial risks to our stockholders as a result of the sale and issuance of Class&#160;A common stock to Yorkville under the Purchase Agreement. These risks include the potential for substantial dilution and significant declines in our stock price. See the section entitled &#8220;Risk Factors.&#8221; Issuances of our Class&#160;A common stock in this offering will not affect the rights or privileges of our existing stockholders, except that the economic and voting interests of each of our existing stockholders will be diluted as a result of any such issuance. Although the number of shares of Class&#160;A common stock that our existing stockholders own will not decrease as a result of sales, if any, under the Purchase Agreement, the shares owned by our existing stockholders will represent a smaller percentage of our total outstanding shares after any such issuance to Yorkville. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For more detailed information regarding the Purchase Agreement, see the section entitled &#8220;Committed Equity Financing.&#8221; </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Emerging Growth Company Status </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are an &#8220;emerging growth company<span style="font-style:italic">,</span>&#8221; as defined in Section&#160;2(a) of the Securities Act, as modified by the JOBS Act, and we may take advantage of certain exemptions from various reporting requirements that are applicable to other public companies that are not emerging growth companies, including, but not limited to, not being required to comply with the auditor attestation requirements of Section&#160;404 of the Sarbanes-Oxley Act of 2002, as amended (the &#8220;Sarbanes-Oxley Act&#8221;), reduced disclosure obligations regarding executive compensation in our periodic reports and proxy statements, and exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and stockholder approval of any golden parachute payments not previously approved. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Further, Section&#160;102(b)(1) of the JOBS Act exempts emerging growth companies from being required to comply with new or revised financial accounting standards until private companies (that is, those that have not had a registration statement under the Securities Act declared effective or do not have a class of securities registered under the Securities Exchange Act of 1934, as amended the &#8220;Exchange Act&#8221;), are required to comply </p>
</div></div>

 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">12 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<div style="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
with the new or revised financial accounting standards. The JOBS Act provides that a company can elect to opt out of the extended transition period and comply with the requirements that apply to <span style="white-space:nowrap">non-emerging</span> growth companies but any such election to opt out is irrevocable. We have elected not to opt out of such extended transition period which means that when a standard is issued or revised and it has different application dates for public or private companies, we, as an emerging growth company, can adopt the new or revised standard at the time private companies adopt the new or revised standard. This may make comparison of our financial statements with another public company which is neither an emerging growth company nor an emerging growth company which has opted out of using the extended transition period difficult or impossible because of the potential differences in accounting standards used. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We will remain an emerging growth company until the earlier of (1)&#160;the last day of the fiscal year (a)&#160;following the fifth anniversary of the completion of the IPO, (b)&#160;in which we have total annual gross revenue of at least $1.235&#160;billion, or (c)&#160;in which we are deemed to be a large accelerated filer, which means the market value of our Class&#160;A common stock held by <span style="white-space:nowrap">non-affiliates</span> equaled or exceeded $700&#160;million as of the prior June&#160;30, and (2)&#160;the date on which we have issued more than $1.0&#160;billion in <span style="white-space:nowrap">non-convertible</span> debt securities during the prior three-year period. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Additionally, we are a &#8220;smaller reporting company&#8221; as defined in Item 10(f)(1) of Regulation <span style="white-space:nowrap">S-K.</span> Smaller reporting companies may take advantage of certain reduced disclosure obligations, including, among other things, providing only two years of audited financial statements. We will remain a smaller reporting company until the last day of the fiscal year in which (1)&#160;the market value of our common stock held by <span style="white-space:nowrap">non-affiliates</span> equaled or exceeded $250&#160;million as of the end of the prior June 30th, or (2)&#160;our annual revenues equaled or exceeded $100&#160;million during such completed fiscal year and the market value of our common stock held by <span style="white-space:nowrap">non-affiliates</span> equaled or exceeded $700&#160;million as of the prior June 30th. </p>
</div></div>

 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">13 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<div style="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center" id="toc479690_4">THE OFFERING </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="vertical-align:TOP">
<td style="width:38%"> <p style=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Issuer </p></td>
<td>biote Corp. (f/k/a Haymaker Acquisition Corporation III). </td></tr></table> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="vertical-align:TOP">
<td style="width:38%"> <p style=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Shares of Class&#160;A common stock Offered by the Selling Securityholder </p></td>
<td>5,000,000 shares of Class&#160;A common stock, consisting of (i) 25,000 Commitment Shares; and (ii)&#160;up to 4,975,000 shares we may elect, in our discretion, to issue and sell to the Selling Securityholder under the Purchase Agreement from time to time. </td></tr></table> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="vertical-align:TOP">
<td style="width:38%"> <p style=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Shares of Common Stock Outstanding prior to the exercise of all Warrants </p></td>
<td>9,161,771 shares of Class&#160;A common stock and 58,565,824 shares of Class&#160;V voting stock (as of July&#160;28, 2022). </td></tr></table> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="vertical-align:TOP">
<td style="width:38%"> <p style=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Shares of Common Stock Outstanding After Giving Effect to the Issuance of the Shares Registered for Resale Hereunder </p></td>
<td>14,161,771 shares of Class&#160;A common stock and 58,565,824 shares of Class&#160;V voting stock (based on total shares outstanding as of July&#160;28, 2022). </td></tr></table> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="vertical-align:TOP">
<td style="width:38%"> <p style=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Use of Proceeds </p></td>
<td>We will not receive any proceeds from the resale of shares of Class&#160;A common stock included in this prospectus by the Selling Securityholder. However, we expect to receive proceeds from sales of Class&#160;A common stock that we may elect to make to the Selling Securityholder pursuant to the Purchase Agreement, if any, from time to time in our discretion. The net proceeds from sales, if any, under the Purchase Agreement, will depend on the frequency and prices at which we sell shares of Common Stock to the Selling Securityholder after the date of this prospectus. See &#8220;Committed Equity Financing&#8221; for a description of how the price we may sell shares of Class&#160;A common stock to the Selling Securityholder is calculated pursuant to the Purchase Agreement. </td></tr></table> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr>
<td style="width:38%">&#160;</td>
<td align="left" style="vertical-align:top">We expect to use the net proceeds that we receive from sales of our Class&#160;A common stock to the Selling Securityholder, if any, under the Purchase Agreement for working capital and general corporate purposes. See the section titled &#8220;Use of Proceeds.&#8221; </td></tr></table> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="vertical-align:TOP">
<td style="width:38%"> <p style=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Market for Class&#160;A common stock </p></td>
<td>Our Class&#160;A common stock is listed on the Nasdaq Stock Market LLC under the symbol &#8220;BTMD&#8221;. </td></tr></table> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="vertical-align:TOP">
<td style="width:38%"> <p style=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Risk Factors </p></td>
<td>See the section entitled &#8220;Risk Factors&#8221; and other information included in this prospectus for a discussion of factors you should consider before investing in our securities. </td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The number of shares of Common Stock to be outstanding is based on 67,727,595 shares of Common Stock outstanding as of July&#160;28, 2022 and excludes: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">11,965,873 shares of Class&#160;A common stock available for future issuance under the Incentive Plan; </p></td></tr></table>
</div></div>

 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">14 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<div style="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">797,724 shares available for future issuance under the biote Corp. 2022 Employee Stock Purchase Plan (the &#8220;ESPP&#8221;); </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">5,566,666 shares issuable upon the exercise of outstanding private warrants to purchase Class&#160;A common stock (the &#8220;Private Placement Warrants&#8221;), with an exercise price of $11.50 per share; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">7,937,500 shares issuable upon the exercise of outstanding public warrants to purchase Class&#160;A common stock, (the &#8220;Public Warrants,&#8221; together with the Private Placement Warrants the &#8220;Warrants&#8221;) with an exercise price of $11.50 per share; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">25,000 Commitment Shares issued to the Selling Securityholder upon signing the Purchase Agreement; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">4,975,000 shares of Class&#160;A common stock that we may elect, in our sole discretion, to issue and sell to Yorkville, from time to time under the Purchase Agreement. </p></td></tr></table>
</div></div>

 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">15 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center" id="toc479690_5">RISK FACTORS </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Investing in our securities involves risks. You should consider carefully the risks and uncertainties described below, together with all of the other information in this prospectus, including the section titled &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221; and the financial statements and notes to the financial statements included herein, before deciding whether to purchase any of our securities. If any of these risks actually occur, our business, results of operations, financial condition, and prospects could be materially and adversely affected. Unless otherwise indicated, references in these risk factors to our business being harmed will include harm to our business, reputation, brand, financial condition, results of operations, and prospects. In such event, the market price of our securities could decline, and you could lose all or part of your investment. You should carefully consider the following risk factors in addition to the other information included in this prospectus, including matters addressed in the section entitled &#8220;Cautionary Note Regarding Forward-Looking Statements.&#8221; We may face additional risks and uncertainties that are not presently known to us, or that we currently deem immaterial, which may also impair our business or financial condition. The following discussion should be read in conjunction with the financial statements and notes to the financial statements included herein. Unless otherwise indicated or the context otherwise requires, references in this section to &#8220;we&#8221;, &#8220;us&#8221; and &#8220;our&#8221; generally refer to Biote in the present tense or the Combined Company from and after the Business Combination. </span></p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Summary of Risk Factors </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following is a summary of the risk factors our business faces. The list below is not exhaustive, and investors should read this &#8220;Risk Factors&#8221; section in full. Some of the risks we face include: </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Summary of Risks Related to this Offering </span></p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">It is not possible to predict the actual number of shares we will sell under the Purchase Agreement to the Selling Securityholder, or the actual gross proceeds resulting from those sales. Further, we may not have access to the full amount available under the Purchase Agreement with the Selling Securityholder. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">The sale and issuance of our Class&#160;A common stock to the Selling Securityholder will cause dilution to our existing stockholders, and the sale of the shares of Class&#160;A common stock acquired by the Selling Securityholder, or the perception that such sales may occur, could cause the price of our Class&#160;A common stock to fall. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Investors who buy shares of Class&#160;A common stock at different times will likely pay different prices. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Our management team will have broad discretion over the use of the net proceeds from our sale of shares of Class&#160;A common stock to the Selling Securityholder, if any, and you may not agree with how we use the proceeds and the proceeds may not be invested successfully. </p></td></tr></table> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Summary of Risks Related to Our Industry and Business </span></p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Our success will depend upon whether the Biote Method and our Biote-branded dietary supplements attain significant market acceptance among clinics, practitioners and their patients. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Outsourcing facilities that produce bioidentical hormone pellets that we offer training on in the Biote Method and failure by those parties to adequately perform their obligations could harm our business. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">We and Biote-certified practitioners and Biote-partnered clinics are reliant on AnazaoHealth Corporation, Right Value Drug Stores, LLC. and F.H. Investments, Inc. to support the manufacturing of <span style="white-space:nowrap">bio-identical</span> hormones for prescribers. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Biote-certified practitioners and Biote-partnered clinics are concentrated in certain geographic regions, which makes us sensitive to regulatory, economic, environmental and competitive conditions in those regions. </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">16 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">The frequency of use by practitioners and clinics of the Biote Method may not increase at the rate that we anticipate or at all. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Adoption of the Biote Method depends upon appropriate practitioner training, and inadequate training may lead to negative patient outcomes and adversely affect our business. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">The continuing development of our training depends upon our maintaining strong working relationships with Biote-certified practitioners and other medical personnel. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">We believe our long-term value as a company will be greater if we focus on growth, which may negatively impact our results of operations in the near term. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">We face significant competition, and if we are unable to compete effectively, we may not be able to achieve or maintain expected levels of market penetration and market share, which could have a material adverse effect on our business, financial condition and results of operations. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">We have a limited history operating a practice-building business for practitioners in the hormone optimization space, which may make it difficult for an investor to evaluate the success of our business to date and to assess our future viability. </p></td></tr></table> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Summary of Risks Related to Intellectual Property </span></p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">If we are unable to obtain and maintain patent protection for any products or methods we develop, or if the scope of the patent protection obtained is not sufficiently broad, our competitors could develop and commercialize products similar or identical to our Biote-branded dietary supplements, and our ability to successfully commercialize any products we may develop may be adversely affected. If we are not able to maintain freedom to operate for our products from third-party intellectual property rights, our ability to commercialize products may be limited unless we secure a license to such rights. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">We may become a party to intellectual property litigation or administrative proceedings that could be costly and could interfere with our ability to sell and market the Biote Method and our Biote-branded dietary supplements. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">If we are unable to protect the confidentiality of our other proprietary information, our business and competitive position may be harmed. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">We may be subject to claims that we or our employees, consultants or contractors have wrongfully used, disclosed or otherwise misappropriated the intellectual property of a third-party, including trade secrets or <span style="white-space:nowrap">know-how,</span> or are in breach of <span style="white-space:nowrap">non-competition</span> or <span style="white-space:nowrap">non-solicitation</span> agreements with our competitors or claims asserting an ownership interest in intellectual property we regard as our own. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">We may be subject to claims challenging our intellectual property. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">If our trademarks and trade names are not adequately protected, then we may not be able to build brand recognition in our markets and our business may be adversely affected. </p></td></tr></table> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Summary of Risks Related to Regulation </span></p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">We market dietary supplements and convenience kits, which are regulated by the U.S. Food and Drug Administration (the &#8220;FDA&#8221;), and are subject to certain requirements under the Federal Food, Drug, and Cosmetic Act (the &#8220;FDCA&#8221;) and the laws enforced by the Federal Trade Commission (the &#8220;FTC&#8221;). Our failure to meet those requirements could cause us to cease certain of our business activities and may involve the payment of financial penalties. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">We have developed and market a method and training program where the practitioner may prescribe a compounded bioidentical hormone. Compounded drugs are regulated by the FDA and are subject to certain requirements under the FDCA. Failure of compounding entities to meet those requirements could cause us to cease certain of our business activities and may involve the payment of financial penalties. </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">17 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Compounded preparations and the pharmacy compounding industry are subject to regulatory scrutiny, which may impair our growth and sales. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">If a compounded drug formulation provided through a compounding pharmacy or an outsourcing facility leads to patient injury or death or results in a product recall, we may be exposed to significant liabilities and reputational harm. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">If the FDA takes regulatory action to implement any of the National Academies of Sciences, Engineering, and Medicine (the &#8220;NASEM&#8221;) recommendations for compounded bioidentical hormones, this may have a substantial effect on the ability of the outsourcing facilities to compound the hormone pellets utilized by Biote-certified practitioners, which would have a substantially negative impact on Biote&#8217;s revenue and business operations. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Our internal controls over financial reporting currently do not meet all of the standards contemplated by Section&#160;404 of the Sarbanes-Oxley Act, and a material weakness resulted in the restatement of previously issued financial statements. Failure to achieve and maintain an effective system of disclosure controls and internal control over financial reporting could impair our ability to produce timely and accurate financial statements or comply with applicable regulations. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">If we are unable to maintain our listing on the Nasdaq Stock Market LLC (&#8220;Nasdaq&#8221;), it could become more difficult to sell our Class&#160;A common stock and Public Warrants in the public market. </p></td></tr></table> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Summary of Risks Related to Ownership of Our Securities </span></p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Because there are no current plans to pay cash dividends on our Class&#160;A common stock for the foreseeable future, you may not receive any return on investment unless you sell our Class&#160;A common stock for a price greater than that which you paid for it. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">We may require additional capital to support business growth, and if capital is not available to us or is available only by diluting existing stockholders, our business, operating results and financial condition may suffer. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Anti-takeover provisions contained in the Charter and the Bylaws, as well as provisions of Delaware law, could impair a takeover attempt. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Future sales, or the perception of future sales, by the Company or its stockholders in the public market, the issuance of rights to purchase the Company&#8217;s Class&#160;A common stock, including pursuant to the Incentive Plan and the ESPP, and future exercises of registration rights could result in the additional dilution of the percentage ownership of the Company&#8217;s stockholders and cause the market price for the Company&#8217;s Class&#160;A common stock to decline. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">We may be subject to periodic claims and litigation, including the Donovitz Litigation (as defined herein), that could result in unexpected expenses and could ultimately be resolved against us. </p></td></tr></table> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Risks Related to this Offering </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">It is not possible to predict the actual number of shares we will sell under the Purchase Agreement to the Selling Securityholder, or the actual gross proceeds resulting from those sales. Further, we may not have access to the full amount available under the Purchase Agreement with the Selling Securityholder. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On July&#160;27, 2022, we entered into the Purchase Agreement with the Selling Securityholder, pursuant to which the Selling Securityholder has committed to purchase up to 5,000,000 shares of our Class&#160;A common stock, subject to certain limitations and conditions set forth in the Purchase Agreement. The shares of our Class&#160;A common stock that may be issued under the Purchase Agreement may be sold by us to the Selling Securityholder at our discretion from time to time. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">18 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We generally have the right to control the timing and amount of any sales of our shares of Class&#160;A common stock to the Selling Securityholder under the Purchase Agreement. Sales of our Class&#160;A common stock, if any, to the Selling Securityholder under the Purchase Agreement will depend upon market conditions and other factors to be determined by us. We may ultimately decide to sell to the Selling Securityholder all, some or none of the shares of our Class&#160;A common stock that may be available for us to sell to the Selling Securityholder pursuant to the Purchase Agreement. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Because the purchase price per share to be paid by the Selling Securityholder for the shares of Class&#160;A common stock that we may elect to sell to the Selling Securityholder under the Purchase Agreement, if any, will fuctuate based on the market prices of our Class&#160;A common stock prior to each Advance made pursuant to the Purchase Agreement, if any, it is not possible for us to predict, as of the date of this prospectus and prior to any such sales, the number of shares of Class&#160;A common stock that we will sell to the Selling Securityholder under the Purchase Agreement, the purchase price per share that the Selling Securityholder will pay for shares purchased from us under the Purchase Agreement, or the aggregate gross proceeds that we will receive from those purchases by the Selling Securityholder under the Purchase Agreement, if any. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are not required or permitted to issue any shares of Class&#160;A common stock under the Purchase Agreement if such issuance would breach our obligations under the rules or regulations of our Trading Market. In addition, the Selling Securityholder will not be required to purchase any shares of our Class&#160;A common stock if such sale would result in the Selling Securityholder&#8217;s beneficial ownership exceeding 4.99% of the then issued and outstanding Class&#160;A common stock. Our inability to access a part or all of the amount available under the Purchase Agreement, in the absence of any other financing sources, could have a material adverse effect on our business. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">The sale and issuance of our Class&#160;A common stock to the Selling Securityholder will cause dilution to our existing stockholders, and the sale of the shares of Class&#160;A common stock acquired by the Selling Securityholder, or the perception that such sales may occur, could cause the price of our Class&#160;A common stock to fall. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The purchase price for the shares that we may sell to the Selling Securityholder under the Purchase Agreement will fluctuate based on the price of our Class&#160;A common stock. Depending on a number of factors, including market liquidity, sales of such shares may cause the trading price of our Class&#160;A common stock to fall. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If and when we do sell shares to the Selling Securityholder, the Selling Securityholder may resell all, some, or none of those shares at its discretion, subject to the terms of the Purchase Agreement. Therefore, sales to the Selling Securityholder by us could result in substantial dilution to the interests of other holders of our Class&#160;A common stock. Additionally, the sale of a substantial number of shares of our Class&#160;A common stock to the Selling Securityholder, or the anticipation of such sales, could make it more difficult for us to sell equity or equity-related securities in the future at a desirable time and price. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Investors who buy shares of Class&#160;A common stock at different times will likely pay different prices. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the Purchase Agreement, we control the timing and amount of any sales of Class&#160;A common stock to the Selling Securityholder. If and when we do elect to sell shares of our Class&#160;A common stock to the Selling Securityholder pursuant to the Purchase Agreement, the Selling Securityholder may resell all, some or none of such shares in its discretion and at different prices, subject to the terms of the Purchase Agreement. As a result, investors who purchase shares from the Selling Securityholder in this offering at different times will likely pay different prices for those shares, and so may experience different levels of dilution and in some cases substantial dilution and different outcomes in their investment results. Investors may experience a decline in the value of the shares they purchase from the Selling Securityholder in this offering as a result of future sales made by us to the Selling Securityholder at prices lower than the prices such investors paid for their shares in this offering. In addition, if we sell a substantial number of shares to the Selling Securityholder under the Purchase </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">19 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Agreement, or if investors expect that we will do so, the actual sales of shares or the mere existence of our arrangement with the Selling Securityholder may make it more difficult for us to sell equity or equity-related securities in the future at a desirable time and price. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Our management team will have broad discretion over the use of the net proceeds from our sale of shares of Class&#160;A common stock to the Selling Securityholder, if any, and you may not agree with how we use the proceeds and the proceeds may not be invested successfully. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our management team will have broad discretion as to the use of the net proceeds from our sale of shares of Class&#160;A common stock to the Selling Securityholder, if any, and we could use such proceeds for purposes other than those contemplated at the time of commencement of this offering. Accordingly, you will be relying on the judgment of our management team with regard to the use of those net proceeds, and you will not have the opportunity, as part of your investment decision, to assess whether the proceeds are being used appropriately. It is possible that, pending their use, we may invest those net proceeds in a way that does not yield a favorable, or any, return for us. The failure of our management team to use such funds effectively could have a material adverse effect on our business, financial condition, operating results and cash flows. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Risks Related to Our Industry and Business </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Our success will depend upon whether the Biote Method and our Biote-branded dietary supplements attain significant market acceptance among clinics, practitioners and their patients. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our success will depend on the acceptance of the hormone optimization methods we teach in our training. We cannot predict how quickly clinics, practitioners or their patients will accept the Biote Method (as further described in the section entitled &#8220;Business&#8221;) or, if accepted, how frequently it will be used. The methods that we currently recommend and any methods we recommend in the future may never gain broad market acceptance. Demonstrated HRT health risks or side effects, as well as negative publicity relating to the same, could negatively impact the perception of patient benefit and generate resistance and opposition from practitioners, which could limit adoption of the Biote Method and have a material adverse impact on our business. To date, a substantial majority of our sales and revenue have been derived from a limited number of clinics and independent, third-party physicians and nurse practitioners who are certified under our training program (the &#8220;Biote-certified practitioners&#8221;). </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our future growth and profitability will largely depend on our ability to increase practitioner awareness of our practice-building platform as well as our Biote-branded dietary supplements, and on the willingness of clinics, practitioners and their patients to adopt them. Practitioners may not adopt the Biote Method unless they determine, based on experience, clinical data, medical society recommendations and other analyses, that our methods and the Biote-branded dietary supplements are appropriate for their patients. Healthcare practitioners must believe that our practice-building platform and Biote-branded dietary supplements offer benefits over alternatives. Even if we are able to raise awareness, practitioners may be slow in changing their medical treatment practices and may be hesitant to use the Biote Method. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Practitioners independently determine the type of treatment that will be utilized and provided to their patients. We focus our sales, marketing and education efforts primarily in the hormone optimization space and aim to educate Biote-certified practitioners regarding the patient population that would benefit from the Biote Method. Despite our efforts, we cannot assure you that we will achieve broad market acceptance among these practitioners or, more generally, that practitioners will adopt the Biote Method at all. Further, changes in the regulatory or enforcement landscape may be a factor in practitioners choosing certain methods for their patients, for example, medication compounded by a compounding pharmacy or outsourcing facility. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For example, some Biote-certified practitioners may choose to utilize the Biote Method and our Biote-branded dietary supplements on only a subset of their total patient population or may not adopt our offerings at </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">20 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
all. If we are not able to effectively demonstrate that the use of the Biote Method and our Biote-branded dietary supplements is beneficial in a broad range of their patients, adoption of our offerings will be limited and may not occur as rapidly as we anticipate or at all, which would have a material adverse effect on our business, financial condition and results of operations. We cannot assure you that the Biote Method or our Biote-branded dietary supplements will achieve broad market acceptance among clinics and practitioners. Additionally, even if the Biote Method and our Biote-branded dietary supplements achieve initial market acceptance, they may not maintain that market acceptance over time if competing methods, procedures or technologies are considered more cost-effective or otherwise superior. Any failure of our offerings to generate sufficient demand or to achieve meaningful market acceptance and penetration will harm our future prospects and have a material adverse effect on our business, financial condition and results of operations. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Further, if the Biote Method or our Biote-branded dietary supplements do not generate sufficient patient demand for the Biote-certified practitioners or clinics we partner with (&#8220;Biote-partnered clinics&#8221;), we may be unable to attract or retain contracts with practitioners or clinics to use the Biote Method or sell our Biote-branded dietary supplements. If we are unable to attract or retain contracts with practitioners or clinics, our business, results of operations and financial condition could be adversely affected. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Outsourcing facilities that produce bioidentical hormone pellets that we offer training on in the Biote Method and failure by those parties to adequately perform their obligations could harm our business. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Outsourcing facilities manufacture the products that we recommend as part of our training. The facilities used to compound and distribute bioidentical hormone pellets, which may be prescribed by Biote-certified practitioners, are registered with the FDA as 503B outsourcing facilities. We do not control or direct the compounding or manufacturing processes used by these outsourcing facilities. We use contract manufacturers to produce the formulations of the dietary supplements we develop and sell under Biote&#8217;s private label, and we rely on those manufacturers for compliance with the applicable regulatory requirements. As such, we have no control over the ability of third parties to maintain adequate quality control, quality assurance and qualified personnel. If the FDA or a comparable international regulatory authority does not approve these facilities for the manufacture of these products or if it withdraws any such approval in the future, we may need to identify alternative manufacturing facilities, which would significantly impact our ability to meet consumer demand. In addition, our inability to identify or enter into satisfactory arrangements with any such alternative manufacturing facilities may result in a material adverse effect on our business, financial condition and results of operations. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Further, our reliance on third-party dietary supplement contract manufacturers entails risks, including: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">inability to meet certain product specifications and quality requirements consistently; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">delay or inability to procure or expand sufficient manufacturing capacity; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">issues related to <span style="white-space:nowrap">scale-up</span> of manufacturing; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">costs and validation of new equipment and facilities required for <span style="white-space:nowrap">scale-up;</span> </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">third-party manufacturers may not be able to execute necessary manufacturing procedures and other logistical support requirements appropriately; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">third-party manufacturers may fail to comply with current good manufacturing practice (&#8220;cGMP&#8221;) requirements and other requirements by the FDA or other comparable regulatory authorities; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">inability for us or Biote-certified practitioners and Biote-partnered clinics to negotiate manufacturing agreements with third parties under commercially reasonable terms, if at all; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">breach, termination or <span style="white-space:nowrap">non-renewal</span> of manufacturing agreements with third parties in a manner or at a time that is costly or damaging to us or Biote-certified practitioners and Biote-partnered clinics; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">third-party manufacturers may not devote sufficient resources to the products that we recommend as part of our training or our Biote-branded dietary supplements; </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">21 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">we may not own, or may have to share, the intellectual property rights to any improvements made by third-party manufacturers in the manufacturing process for our Biote-branded dietary supplements; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">operations of third-party manufacturers or our suppliers could be disrupted by conditions unrelated to our business or operations, including the bankruptcy of the manufacturer or supplier; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">logistics carrier disruptions or increased costs that are beyond our control. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any adverse developments affecting manufacturing operations for our Biote-branded dietary supplements may result in lot failures, inventory shortages, shipment delays, product withdrawals or recalls or other interruptions in the supply of these products, which could prevent their delivery to Biote-certified practitioners or Biote-partnered clinics. We may also have to write off inventory, incur other charges and expenses to replace dietary supplements that fail to meet specifications, undertake costly remediation efforts, or seek more costly manufacturing alternatives. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any of these events could impact our ability to successfully commercialize any future products that we recommend as part of our training and our current or any future Biote-branded dietary supplements. Some of these events could be the basis for FDA action, including injunction, request for recall, seizure, or total or partial suspension of production. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">We and Biote-certified practitioners and Biote-partnered clinics are reliant on AnazaoHealth Corporation, Right Value Drug Stores, LLC. and F.H. Investments, Inc. to support the manufacturing of <span style="white-space:nowrap">bio-identical</span> hormones for prescribers. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We entered into a Pharmacy Services Agreement with AnazaoHealth Corporation, or AnazaoHealth, on October&#160;30, 2020 (the &#8220;AnazaoHealth Pharmacy Services Agreement&#8221;), an Outsourcing Facility Services Agreement with Right Value Drug Stores, LLC d/b/a Carie Boyd&#8217;s Prescription Shop, or Carie Boyd&#8217;s on August&#160;1, 2020 (the &#8220;Outsourcing Facility Services Agreement&#8221;), and a Pharmacy Services Agreement with F.H. Investments, Inc. d/b/a Asteria Health, Asteria Health, on October&#160;28, 2021, to build relationships to support Biote-certified practitioners by offering an option for the compounded bioidentical hormones that the practitioners may order or prescribe (the &#8220;Asteria Health Pharmacy Services Agreement&#8221;). AnazaoHealth, Carie Boyd&#8217;s, and Asteria Health are operators of <span style="white-space:nowrap">FDA-registered</span> 503B outsourcing facilities. While Biote-certified practitioners have the option to use a variety of different outsourcing facilities, AnazaoHealth, Carie Boyd&#8217;s and Asteria Health are the primary outsourcing facilities of the compound testosterone and estradiol implantable subcutaneous pellets used by Biote-certified practitioners as part of the Biote Method. However, we do not control or direct the compounding or manufacturing processes of these 503B outsourcing facilities. We also do not control the time and resources AnazaoHealth, Carie Boyd&#8217;s or Asteria Health devotes to compounding of testosterone and estradiol implantable subcutaneous pellets. If AnazaoHealth, Carie Boyd&#8217;s or Asteria Health are unable to successfully fulfill a Biote-certified practitioner&#8217;s product orders, or if the state licenses held by AnazaoHealth, Carie Boyd&#8217;s or Asteria Health to ship medications for office use throughout the United States are revoked, expire or otherwise not maintained, it could adversely impact the practices of Biote-certified Practitioners or Biote-partnered clinics, which could in turn have a material adverse effect on our business, financial condition and results of operations. Other changes in state and federal regulatory and enforcement with respect to compounded drugs may also affect AnazaoHealth, Carie Boyd&#8217;s and Asteria Health, and, in turn, have the potential to harm the practices of Biote-certified practitioners or Biote-partnered clinics or our business. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any termination of the AnazaoHealth Pharmacy Services Agreement, the Outsourcing Facility Services Agreement, or the Asteria Health Pharmacy Services Agreement could have an adverse effect on the practices of Biote-certified Practitioners or Biote-partnered clinics our business, financial condition and results of operations. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the future, we may also seek to develop relationships with other outsourcing facilities to support the manufacturing of bioidentical hormones for Biote-certified practitioners and Biote-partnered clinics in the United States and internationally, with an initial focus on expansion into Puerto Rico, Argentina, Brazil, Colombia, </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">22 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Mexico, Canada and the Dominican Republic, as permitted by law. If we fail to develop new relationships with any other outsourcing facilities we seek to engage, including in new markets in the United States and internationally, fail to manage or incentivize these facilities effectively, or if these facilities are not successful in their sales and marketing efforts, our ability to support to Biote-certified practitioners and Biote-partnered clinics, and to generate revenue, cash flow and earnings growth could suffer, which could have a material adverse effect on our business, financial condition and results of operations. Moreover, these agreements may be <span style="white-space:nowrap">non-exclusive,</span> and some of these facilities may also have cooperative relationships with certain of our competitors. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Biote-certified practitioners and Biote-partnered clinics are concentrated in certain geographic regions, which makes us sensitive to regulatory, economic, environmental and competitive conditions in those regions. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We generate revenues by charging the Biote-partnered clinics fees associated with the support Biote provides for HRT and from the sale of Biote-branded dietary supplements. During the year ended December&#160;31, 2022, over 64% of our revenue was generated in Texas, Oklahoma, New Mexico, Colorado, Arkansas, Louisiana, Mississippi, Alabama, Georgia and Florida. Such geographic concentration makes us particularly sensitive to regulatory, economic, environmental and competitive conditions in those states. Any material changes in those factors in those states could have a material adverse effect on our business, financial condition and results of operations. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may not be successful in expanding into new geographic areas within the United States or internationally. In addition, as we expand into new geographic areas, we may not be able to dedicate enough time or resources to maintain our market share in our core geographic areas, and our business may be negatively impacted. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">The frequency of use by practitioners and clinics of the Biote Method may not increase at the rate that we anticipate or at all. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">One of our key objectives is to continue to increase utilization, or the adoption and frequency of use, of both the Biote Method and our Biote-branded dietary supplements by new and existing Biote-certified practitioners and Biote-partnered clinics. If utilization by our existing and newly trained Biote-certified practitioners of the Biote Method and the Biote-branded dietary supplements we sell does not occur or does not occur as quickly as we anticipate, we could experience a material adverse effect on our business, financial condition and results of operations. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Adoption of the Biote Method depends upon appropriate practitioner training, and inadequate training may lead to negative patient outcomes and adversely affect our business. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our success depends in part on the patient selection criteria of Biote-certified practitioners and proper execution of methods discussed in training sessions conducted by our training faculty. However, the practice of medicine is the domain of the Biote-certified practitioners, who rely on their previous medical training and experience, and we cannot guarantee that Biote-certified practitioners will effectively utilize the Biote Method. Patient outcomes may not be consistent across Biote-certified practitioners and Biote-partnered clinics. This result may negatively impact the perception of patient benefit and limit adoption of the Biote Method, and could result in litigation against us, in each case which would have a material adverse effect on our business, financial condition and results of operations. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">The continuing development of our training depends upon our maintaining strong working relationships with Biote-certified practitioners and other medical personnel. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The development, marketing and sale of our training depend upon our maintaining working relationships with Biote-certified practitioners and other medical personnel. We rely on these relationships to provide us with </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">23 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
considerable knowledge and experience regarding the development, marketing and sale of our training. For example, Biote-certified practitioners assist us in marketing and as researchers, consultants and public speakers. If we cannot maintain our strong working relationships and continue to receive such advice and input, the development and marketing of our training could suffer, which could have a material adverse effect on our business, financial condition and results of operations. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">We believe our long-term value as a company will be greater if we focus on growth, which may negatively impact our results of operations in the near term. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We believe our long-term value as a company will be greater if we focus on longer-term growth over short-term results. As a result, our results of operations may be negatively impacted in the near term relative to a strategy focused on maximizing short-term profitability. Significant expenditures on marketing efforts, acquisitions and international expansion may not ultimately grow our business or lead to expected long-term results. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have experienced substantial growth in our operations, and we expect to experience continued growth in our business. For example, we plan to increase our headcount from 2023 through 2025. This growth has placed, and will continue to place, significant demands on our management and our operational infrastructure. Any growth that we experience in the future could require us to expand our sales and marketing personnel and general and administrative infrastructure. In addition to the need to scale our organization, future growth will impose significant added responsibilities on management, including the need to identify, recruit, train and integrate additional employees. We cannot assure you that any increases in scale will be successfully implemented or that appropriate personnel will be available to facilitate the growth of our business. Rapid expansion in personnel could mean that less experienced people market and sell the Biote Method and our Biote-branded dietary supplements, which could result in inefficiencies and unanticipated costs, lowered quality standards and disruptions to our operations. Rapid and significant growth may strain our administrative and operational infrastructure and could require significant capital expenditures that may divert financial resources from other projects, such as research and development of potential future offerings. In addition, our ability to grow may be adversely impacted due to factors beyond our control, which could have a material adverse effect on our business, reputation, financial performance, financial condition and results of operations, and could expose us to liability. Our failure to manage growth effectively could have a material and adverse effect on our business, financial condition and results of operations. To manage the growth of our operations, we must establish appropriate and scalable operational and financial systems, procedures and controls and build and maintain a qualified finance, administrative and operations staff. If we are unable to manage our growth effectively, including by failing to implement necessary procedures, transition to new processes or hire necessary personnel, we may fail to execute our business strategy which would have a material adverse effect on our business, results of operations and financial condition. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">We face significant competition, and if we are unable to compete effectively, we may not be able to achieve or maintain expected levels of market penetration and market share, which could have a material adverse effect on our business, financial condition and results of operations. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The medical practice-building market and dietary supplement industry are highly competitive, subject to rapid change and significantly affected by new offerings and other market activities of industry participants. For example, in the dietary supplement space, we are competing with more than 30 brands of dietary supplements, including that of Evexipel, Pellecome, <span style="white-space:nowrap">Pro-Pell,</span> Sottopelle, BodyLogicMD, HTCA and Nature&#8217;s Way, that are either available direct to consumer online, through more conventional retailers and department stores and/or sold through practitioners. If we are unable to compete effectively, we will not be able to establish our training and Biote-branded dietary supplements in the marketplace, which would have a material adverse effect on our business, financial condition and results of operations. Further, large, well-capitalized pharmaceutical companies may enter the medical practice-building market in the hormone optimization space or dietary supplements market </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">24 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
and would be able to spend more on development of their offerings, marketing, sales, compliance and other initiatives than we can. Some of our competitors may have: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">significantly greater name recognition; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">broader or deeper relations with healthcare professionals and clinics; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">more established dietary supplement distribution networks; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">additional lines of dietary supplements and the ability to offer rebates or bundle products to offer greater discounts or other incentives to gain a competitive advantage; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">greater experience in conducting research and development, and marketing for their products; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">greater financial and human resources for development, sales and marketing and patent prosecution of our offerings. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our continued success depends on our ability to: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">develop innovative training as well as Biote-branded dietary supplements that aim to address patient needs; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">adapt to regulatory and enforcement changes over time; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">expand our sales force across key markets to increase the number of Biote-certified practitioners; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">leverage our Biote-branded dietary supplements; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">accelerate the expansion of our business into new markets; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">attract and retain skilled research, development, sales and clinical personnel; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">cost-effectively market and sell our training and our Biote-branded dietary supplements; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">obtain, maintain, enforce and defend our intellectual property rights and operate our business without infringing, misappropriating or otherwise violating the intellectual property rights of others. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We can provide no assurance that we will be successful in developing new training, methods, or Biote-branded dietary supplements or commercializing them in ways that achieve market acceptance. Moreover, any significant delays in the development or commercialization of new training, methods or dietary supplements may significantly impede our ability to enter or compete in a given market and may reduce the sales that we are able to generate, which could have a material adverse effect on our business, financial condition and results of operations. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">We have a limited history operating a practice-building business for practitioners in the hormone optimization space, which may make it difficult for an investor to evaluate the success of our business to date and to assess our future viability. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have a limited history operating a practice-building business for practitioners in the hormone optimization space. We commenced operations in 2012, and our operations to date have been largely focused on organizing and staffing our company, business planning, raising capital, developing the Biote Method and our training, refining our relationships with outsourcing facilities that can compound the bioidentical hormone pellet products that Biote-certified practitioners may prescribe, as well as manufacturers who produce our Biote-branded dietary supplements. Our limited operating history and evolving business make it difficult to evaluate our current business and future prospects and increase the risk of your investment. Any predictions you make about our future success or viability may not be as accurate as they could be if we had a longer operating history or a history of commercializing the Biote Method and our Biote-branded dietary supplements. In addition, as an early-stage company with a limited operating history, we may encounter unforeseen expenses, difficulties, complications, delays and other known and unknown factors which may result in our inability to maintain profitability. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">25 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Our quarterly results may fluctuate significantly and may not fully reflect the underlying performance of our business. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our results of operations and key metrics discussed elsewhere in this registration statement may vary significantly in the future and <span style="white-space:nowrap"><span style="white-space:nowrap">period-to-period</span></span> comparisons of our operating results and key metrics may not provide a full picture of our performance. Accordingly, the results of any one quarter or year should not be relied upon as an indication of future performance. Our quarterly financial results and metrics may fluctuate as a result of a variety of factors, many of which are outside of our control, and as a result they may not fully reflect the underlying performance of our business. These quarterly fluctuations may negatively affect the value of our securities. Factors that may cause these fluctuations include, without limitation: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the level of demand for either the Biote Method or our Biote-branded dietary supplements, which may vary significantly from period to period; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">our ability to attract new Biote-partnered clinics and Biote-certified practitioners; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the addition or loss of one or more of our Biote-partnered clinics or Biote-certified practitioners, including as the result of acquisitions or consolidations; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the timing of recognition of revenues; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the amount and timing of operating expenses; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">general economic, industry and market conditions, both domestically and internationally, including any economic downturns and adverse impacts resulting from public health crises, increases in inflation and interest rates and/or the military conflict between Russia and Ukraine; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the timing of our billing and collections; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Biote-partnered clinic and Biote-certified practitioner renewal, expansion, and adoption rates; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">increases or decreases in the number of patients that are served by Biote-certified practitioners or Biote-partnered clinics, or pricing changes upon any renewals of Biote-certified practitioner or Biote-partnered clinic agreements; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">changes in our pricing policies or those of our competitors; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the timing and success of new offerings by us or our competitors or any other change in the competitive dynamics of our industry, including consolidation among competitors, practitioners, clinics or outsourcing facilities; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">extraordinary expenses such as litigation or other dispute-related expenses or settlement payments; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">sales tax and other tax determinations by authorities in the jurisdictions in which we conduct business; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the impact of new accounting pronouncements and the adoption thereof; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">fluctuations in stock-based compensation expenses; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">expenses in connection with mergers, acquisitions or other strategic transactions; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">changes in regulatory and licensing requirements; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the amount and timing of expenses related to our expansion to markets outside the United States; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the timing of expenses related to the development or acquisition of technologies or businesses and potential future charges for impairment of goodwill or intangibles from acquired companies. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Further, in future periods, our revenue growth could slow or our revenues could decline for a number of reasons, including slowing demand for either the Biote Method or our Biote-branded dietary supplements, increasing competition, a decrease in the growth of our overall market, or our failure, for any reason, to continue to capitalize on growth opportunities. In addition, our growth rate may slow in the future as our market </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">26 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
penetration rates increase. As a result, our revenues, operating results and cash flows may fluctuate significantly on a quarterly basis and revenue growth rates may not be sustainable and may decline in the future, and we may not be able to achieve or sustain profitability in future periods, which could harm our business and cause the market price of our Class&#160;A common stock to decline. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">If we are unable to attract and retain executive officers, key employees and other qualified personnel, or are unable to attract and retain contracts with Biote-certified practitioners, our ability to compete could be harmed. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our success depends on our ability to attract and retain our executive officers, key employees and other qualified personnel, and as a relatively small company with key talent residing in a limited number of employees, our operations and prospects may be severely disrupted if we lost any one or more of their services. As we build our brand, expand into new domestic and international territories and become more well known, there is increased risk that competitors or other companies will seek to hire our personnel. While some of our employees are bound by <span style="white-space:nowrap">non-competition</span> agreements, these may prove to be unenforceable. The failure to attract, integrate, train, motivate and retain these personnel could seriously harm our business and prospects. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, we are highly dependent on the services of several of our executive officers and other senior technical and management personnel, including Teresa S. Weber, our Chief Executive Officer, Marc D. Beer, our Executive Chairman, Samar Kamdar, our Chief Financial Officer, Dr.&#160;Ross McQuivey, our Chief Medical Officer, Mary Elizabeth Conlon, our Vice President, Business Development&#160;&amp; General Counsel, and Cary Paulette, our Chief Revenue Officer, who would be difficult to replace. If these or other key personnel were to depart, we may not be able to successfully attract and retain senior leadership necessary to grow our business. We do not maintain key person life insurance with respect to any member of management or other employee. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Further, our success depends in part upon our ability to attract, train and retain contracts with practitioners and clinics. We have invested substantial time and resources in building our base of Biote-certified practitioners and Biote-partnered clinics. If we are unable to attract and retain contracts with practitioners and clinics capable of meeting our business needs and expectations, our business and brand image may be impaired. Any failure to grow our practitioner base of Biote-certified practitioners or any material increase in turnover rates of our Biote-certified practitioners may adversely affect our business, results of operations and financial condition. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">The healthcare industry is highly regulated, and government authorities may determine that we have failed to comply with applicable laws, rules or regulations. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The healthcare industry, including the healthcare and other services that we and Biote-certified practitioners provide, are subject to extensive and complex federal, state and local laws, rules and regulations, compliance with which imposes substantial costs on us. Of particular importance are the provisions summarized as follows: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">federal laws (including the False Claims Act, 31 U.S.C. &#167; 3729 (the &#8220;False Claims Act&#8221;)) that prohibit entities and individuals from intentionally (or with reckless disregard or deliberate ignorance) presenting or causing to be presented false or fraudulent claims to government-funded programs, or improperly retaining known overpayments; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">a provision of the Social Security Act of 1935, as amended, commonly referred to as the federal Anti-Kickback Statute, as amended (the &#8220;federal Anti-Kickback Statute&#8221;), that prohibits the knowing and willful offer, payment, solicitation or receipt of any bribe, kickback, rebate or other remuneration, in cash or in kind, in return for the referral or recommendation of patients for, or for the purchasing, leasing, ordering or arranging for, items and services for which payment may be made, in whole or in part, by federal healthcare programs; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">similar state law provisions pertaining to anti-kickback, fee splitting, self-referral and false claims, and other fraud and abuse issues which typically are not limited to relationships involving government-</p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">27 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:9%">&#160;</td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">
funded programs. In some cases these laws prohibit or regulate additional conduct beyond what federal law affects, including applicability to items and services paid by commercial insurers and private pay patients. Penalties for violating these laws can range from fines to criminal sanctions; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">provisions of 18 U.S.C. &#167; 1347 that prohibit knowingly and willfully executing a scheme or artifice to defraud a healthcare benefit program or falsifying, concealing or covering up a material fact or making any materially false, fictitious or fraudulent statement in connection with the delivery of or payment for healthcare benefits, items or services; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">FDA marketing and promotion restrictions, as well as several other types of state and federal healthcare fraud and abuse laws have been applied in recent years to restrict certain marketing practices in the healthcare industry; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">federal and state laws related to confidentiality, privacy and security of personal information such as the Health Insurance Portability and Accountability Act of 1996 (&#8220;HIPAA&#8221;), including protected health information (&#8220;PHI&#8221;), that limit the manner in which we may use and disclose that information, impose obligations to safeguard that information and require that we notify our customers in the event of a breach; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">state laws that prohibit general business corporations from practicing medicine, controlling physicians&#8217; medical decisions or engaging in certain practices, such as splitting fees with physicians. </p></td></tr></table> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">We plan to expand our operations to new markets outside the United States, creating a variety of operational challenges. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Although we currently work with numerous clinics that are multi-national in scope, our current business is primarily focused on clinics and practitioners in the United States. A component of our growth strategy involves expanding our operations outside the United States, including expansion into Puerto Rico, Argentina, Brazil, Colombia, Mexico, Canada and the Dominican Republic, as permitted by law. We may face difficulties as we expand our operations into new domestic and international markets in which we have limited or no prior operating experience. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our growth strategy for expanding our operations outside the United States will require significant resources and management attention and will subject us to regulatory, economic and political risks that are different from those in the United States, including: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the need to localize and adapt our platform for specific countries, including translation into foreign languages and obtaining local regulatory and legal guidance with associated expenses; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">data privacy laws that require customer data to be stored and processed in a designated territory; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">difficulties in staffing and managing international operations and working with international partners; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">different pricing environments, longer sales cycles and longer accounts receivable payment cycles and collections issues; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">new and different sources of competition; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">weaker protection for intellectual property and other legal rights than in the United States and practical difficulties in enforcing intellectual property and other rights outside of the United States; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">laws and business practices favoring local competitors; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">compliance challenges related to the complexity of multiple, conflicting and changing governmental laws and regulations, including employment, tax, privacy and data protection laws and regulations; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">increased financial accounting and reporting burdens and complexities; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">restrictions on the transfer of funds; </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">28 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">fluctuations in currency exchange rates, which could increase the price of the products that we recommend as part of our training and of our Biote-branded dietary supplements outside of the United States, increase the expenses of our international operations and expose us to international currency exchange rate risk; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">adverse tax consequences; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">unstable regional and economic political conditions. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, due to potential costs from any international expansion efforts and potentially higher supplier costs outside of the United States, our international operations may operate with a lower margin profile. As a result, our margins may fluctuate as we expand our operations internationally. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As we move to expand our business into Central and South America, our success will depend, in large part, on our ability to identify and work with international distributors. If our international distributors are unable to expand our business or are unable to provide an adequate training program, our business could be harmed. Our failure to manage any of these risks successfully, or to comply with these laws and regulations, could harm our operations, reduce our sales and harm our business, operating results and financial condition. For example, in certain countries, particularly those with developing economies, certain business practices that are prohibited by laws and regulations applicable to us, such as the Foreign Corrupt Practices Act, may be more commonplace. Although we have policies and procedures designed to ensure compliance with these laws and regulations, our employees, contractors and agents, as well as partners involved in our international sales, may take actions in violation of our policies. Any such violation could have an adverse effect on our business and reputation. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Some of the outsourcing facilities we work with also have international operations and are subject to the risks described above. Even if we are able to successfully manage the risks of international operations, our business may be adversely affected if these facilities are not able to successfully manage these risks. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">We may not be able to achieve or maintain satisfactory pricing and margins for our training and the Biote Method or the Biote-branded dietary supplements we sell. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Companies in our industry have a history of price competition, and we can give no assurance that we will be able to achieve satisfactory prices for the Biote Method, or our Biote-branded dietary supplements, or maintain prices at the levels we have historically achieved. If we are forced to lower the price we charge for the Biote Method or our Biote-branded dietary supplements, our revenue and gross margins will decrease, which will adversely affect our ability to invest in and grow our business. If we are unable to maintain our prices, or if our costs increase and we are unable to offset such increase with an increase in our prices, our margins could erode. We will continue to be subject to significant pricing pressure, which could materially and adversely impact our business, financial condition and results of operations. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Unforeseen and unpredictable factors affecting the operations of the FDA, U.S. Drug Enforcement Administration (the &#8220;DEA&#8221;) and other government agencies, such as changes in funding for the FDA, DEA and other government agencies, could hinder their ability to hire and retain key leadership and other personnel, or otherwise delay inspections of the 503B outsourcing facilities of our third-party dietary supplement contract manufacturers, which could negatively impact practitioners and our business. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The ability of the FDA, the DEA and other governmental agencies to conduct their regulatory duties and activities, including reviewing and approving future products, can be affected by a variety of factors, including government budget and funding levels, ability to hire and retain key personnel and accept the payment of user fees, and statutory, regulatory, and policy changes. Average review and response times at the agency have fluctuated in recent years as a result. In addition, government funding of other government agencies that fund research and development activities is subject to the political process, which is inherently fluid and unpredictable. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">29 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Since March 2020, when international and domestic inspections were largely placed on hold, the FDA has been working to resume routine surveillance and inspections on a prioritized basis and may experience delays in their regulatory activities. The FDA has developed a rating system to assist in determining when and where it is safest to conduct prioritized domestic inspections and resumed inspections in China and India in 2021. Regulatory authorities outside the United States may adopt similar restrictions or other policy measures in response to public health crises. If a prolonged government shutdown occurs, or if global health concerns continue to prevent the FDA or comparable international regulatory authorities from conducting their regular inspections, reviews, or other regulatory activities, it could significantly impact the ability of the FDA or comparable international regulatory authorities to timely inspect the facilities of our third-party suppliers, which could have a material adverse effect on our business. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">The size of the markets for our current and future offerings has not been established with precision and may be smaller than we estimate. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Biote-certified practitioners primarily focus their treatments on women experiencing symptoms due to hormonal imbalance before, during, and after menopause, and men experiencing symptoms of hypogonadism and male sex hormone deficiency. It is estimated that, as of 2020, the total U.S. market opportunity for HRT products, available in various forms, exceeds $7&#160;billion and is expected to grow 7% annually through 2026. We believe our business opportunity in providing educational and practice management services is large and will similarly grow. Our estimates of our total addressable markets for our current offerings and those under development are based on a number of internal and third-party estimates, including, without limitation, the number of practitioners we can offer our training and Biote-branded dietary supplements to and the assumed prices at which we can sell offerings in markets that have not been established or that we have not yet entered. While we believe our assumptions and the data underlying our estimates are reasonable, these assumptions and estimates may not be correct and the conditions supporting our assumptions or estimates may change at any time, thereby reducing the predictive accuracy of these estimates. As a result, our estimates of the total addressable market for our current or future offerings may prove to be incorrect. If the actual number of a Biote-certified practitioner&#8217;s or Biote-partnered clinic&#8217;s patients who would benefit from the Biote Method or our Biote-branded dietary supplements, the price at which we can sell training and Biote-branded dietary supplements, or the total addressable market for the Biote Method or our Biote-branded dietary supplements is smaller than we have estimated, it may impair our sales growth and have a material adverse impact on our business, financial condition and results of operations. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Our forecasted operating and financial results rely upon assumptions and analyses developed by us. If these assumptions and analyses prove to be incorrect, our actual operating and financial results may be significantly below our forecasts. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Whether actual operating and financial results and business developments will be consistent with our expectations, assumptions and analyses as reflected in our forecasted operating and financial results depends on a number of factors, many of which are outside of our control, including, but not limited to: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">whether we can obtain sufficient capital to grow our business; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">our ability to manage our growth; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">whether we can manage relationships with 503B outsourcing facilities and dietary supplement contract manufacturers, and other key suppliers; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">demand for the Biote Method and our Biote-branded dietary supplements; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the timing and costs of new and existing marketing and promotional efforts; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">competition, including from established and future competitors; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">our ability to retain existing key management, to integrate recent hires and to attract, retain and motivate qualified personnel; </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">30 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the overall strength and stability of the economies in the markets in which we operate or intend to operate in the future; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">regulatory, legislative and political changes. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Unfavorable changes in any of these or other factors, most of which are beyond our control, could materially and adversely affect our business, prospects, financial condition, and results of operations. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">If our estimates or judgments relating to our critical accounting policies prove to be incorrect, our results of operations could be adversely affected. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The preparation of financial statements in conformity with U.S. generally accepted accounting principles (&#8220;U.S. GAAP&#8221;) requires management to make estimates and assumptions that affect the amounts reported in our consolidated financial statements and accompanying notes appearing elsewhere in this registration statement. We base our estimates on historical experience and on various other assumptions that we believe to be reasonable under the circumstances. The results of these estimates form the basis for making judgments about the carrying values of assets, liabilities and equity, and the amount of revenue and expenses. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our significant accounting policies are described in Note 2 to our audited consolidated financial statements included elsewhere in this registration statement. We believe that the accounting policies described reflect our most critical accounting policies and estimates (including with respect to revenue recognition and the valuation of inventory), which represent those that involve a significant degree of judgment and complexity. Accordingly, we believe these policies are critical in fully understanding and evaluating our reported financial condition and results of operations. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our results of operations may be adversely affected if our assumptions change or if actual circumstances differ from those in our assumptions, which could cause our results of operations to fall below the expectations of securities analysts and investors, resulting in a decline in the market price of our Class&#160;A common stock. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic"><span style="white-space:nowrap">Off-label</span> promotion may result in civil and criminal fines and other penalties, as well as product liability suits, which could be costly to our business. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Biote does not manufacture or distribute any drug products. Nevertheless, if the FDA determines that our practitioner training, including our paid consultants&#8217; educational materials, constitutes <span style="white-space:nowrap">off-label</span> drug promotion, it could subject us or our business partners to enforcement action, including warning letters, untitled letters, fines and penalties, including criminal fines and/or prosecution. If we are found to have inappropriately marketed or promoted any drugs, we may become subject to significant liability. The federal government has levied large civil and criminal fines and/or other penalties against companies for alleged improper promotion and has investigated, prosecuted and/or enjoined several companies from engaging in <span style="white-space:nowrap">off-label</span> promotion. If we become subject to civil or criminal fines or other penalties, or product liability suits, such fines, penalties or lawsuits could have a material adverse effect on our business, financial condition and results of operations. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Certain direct and indirect subsidiaries of Biote entered into that certain credit agreement which contains affirmative, negative and financial covenants that may limit its flexibility in operating its businesses. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On May&#160;26, 2022, certain direct and indirect subsidiaries of Biote entered into that certain Credit Agreement (the &#8220;Credit Agreement&#8221;) with BioTE Medical, LLC (the &#8220;BioTE Medical&#8221;) as borrower, and Truist Bank, as administrative agent, in connection with the Closing of the Business Combination. The Credit Agreement provides to borrower a $125.0&#160;million five-year senior secured term loan A facility (the &#8220;Term Loan&#8221;) and a $50.0&#160;million revolving line of credit. The proceeds of the Credit Agreement have been used to repay existing debt, pay fees and expenses in connection with the Business Combination, and for general corporate purposes. The Credit Agreement contains affirmative, negative and financial covenants that could limit the manner in </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">31 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
which Biote conducts its business, and Biote may be unable to expand or fully pursue its business strategies, engage in favorable business activities, or finance future operations or capital needs. Biote&#8217;s ability to comply with the covenants under the Credit Agreement may be affected by events beyond its control, and it may not be able to comply with those covenants. A breach of any of the covenants contained in the Credit Agreement could result in a default under the Credit Agreement, which could cause all of the outstanding indebtedness under the facility to become immediately due and payable. If Biote is unable to generate sufficient cash to repay its debt obligations under the Credit Agreement when they become due and payable, either as such obligations become due, when they mature, or in the event of a default, Biote may not be able to obtain additional debt or equity financing on favorable terms, if at all, which could have a material adverse effect on our business, financial condition and results of operations. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Further, borrowings under the Credit Agreement are at variable rates of interest and expose us to interest rate risk. In recent months, global inflation and other factors have resulted in an increase in interest rates generally, which has impacted our borrowing costs. If interest rates were to continue to increase, our debt service obligations on the variable rate indebtedness referred to above would increase even if the principal amount borrowed remained the same, and our net income and cash flows will correspondingly decrease. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Product liability lawsuits against us could cause us to incur substantial liabilities and to limit commercialization of any products that we offer or may develop. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We face an inherent risk of product liability exposure. If we cannot successfully defend ourselves against claims that the products that we recommend as part of our training or our Biote-branded dietary supplements caused injuries, we will incur substantial liabilities. Regardless of merit or eventual outcome, liability claims may result in: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">decreased demand for the Biote Method and our Biote-branded dietary supplements; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">decreased demand for any new methods, training, or products that we may develop; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">injury to our reputation and significant negative media attention; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">significant costs to defend the related litigation, including the risk that any Biote-certified practitioners who may face such related litigation may in turn seek to recover from us; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">substantial monetary awards paid to patients; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">loss of revenue; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">exhaustion of any available insurance and our capital resources; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">reduced resources for our management to pursue our business strategy; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the inability to commercialize any methods, training, or products that we may develop. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Although we maintain product liability insurance coverage, such insurance may not be adequate to cover all liabilities that we may incur and we may need to increase our insurance coverage. Insurance coverage is increasingly expensive. We may not be able to maintain insurance coverage at a reasonable cost or in an amount adequate to satisfy any liability that may arise. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Further, a Biote-certified practitioner&#8217;s failure to follow our training and the Biote Method, or accepted medical practices in any stage of treatment may result in lawsuits against us. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">If we experience significant disruptions in our information technology systems, our business may be adversely affected. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We depend on our information technology systems for the efficient functioning of our business, including to support Biote Method, our <span style="white-space:nowrap"><span style="white-space:nowrap">end-to-end</span></span> platform to enable Biote-certified practitioners to establish, build, and </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">32 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
successfully operate a Biote-partnered clinic for optimizing hormone levels in their specific aging patient population, the distribution and maintenance of our Biote-branded dietary supplements, as well as for accounting, data storage, compliance, purchasing and inventory management. Our information technology systems may be subject to computer viruses, ransomware or other malware, attacks by computer hackers, failures during the process of upgrading or replacing software, databases or components thereof, power outages, damage or interruption from fires or other natural disasters, hardware failures, telecommunication failures and user errors, among other malfunctions. We could be subject to any number of unintentional events that could involve a third-party gaining unauthorized access to our systems, which could disrupt our operations, corrupt our data or result in release of our confidential information. Technological interruptions could disrupt our operations, including our ability to project inventory requirements, manage our supply chain and otherwise adequately service our Biote-partnered clinics and Biote-certified practitioners or disrupt their ability use the Biote Method and our Biote-branded dietary supplements for treatments. In the event we experience significant disruptions, we may be unable to repair our systems in an efficient and timely manner. Accordingly, such events may disrupt or reduce the efficiency of our entire operation and have a material adverse effect on our business, financial condition and results of operations. To the extent that any disruption or security breach were to result in a loss of, or damage to, our data or applications, or inappropriate disclosure of confidential or proprietary information, we could incur liability and the further development and commercialization of the Biote Method and our Biote-branded dietary supplements could be delayed or disrupted. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are increasingly dependent on complex information technology to manage our infrastructure. Our information systems require an ongoing commitment of significant resources to maintain, protect and enhance our existing systems. Failure to maintain or protect our information systems and data integrity effectively could have a material adverse effect on our business, financial condition and results of operations. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">We may engage in strategic transactions that could impact our liquidity, increase our expenses and present significant distractions to our management. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">From time to time, we may consider strategic transactions, such as acquisitions of companies, asset purchases and <span style="white-space:nowrap">out-licensing</span> or <span style="white-space:nowrap">in-licensing</span> of intellectual property, products or technologies. Any future transactions could increase our near and long-term expenditures, result in potentially dilutive issuances of our securities, including our Class&#160;A common stock, or the incurrence of debt, contingent liabilities, amortization expenses or acquired <span style="white-space:nowrap">in-process</span> research and development expenses, any of which could affect our financial condition, liquidity and results of operations. Additional potential transactions that we may consider in the future include a variety of business arrangements, including spin-offs, strategic partnerships, joint ventures, restructurings, divestitures, business combinations and investments. Future acquisitions may also require us to obtain additional financing, which may not be available on favorable terms or at all. These transactions may never be successful and may require significant time and attention of management. In addition, the integration of any business that we may acquire in the future may disrupt our existing business and may be a complex, risky and costly endeavor for which we may never realize the full benefits of the acquisition. Accordingly, although we may not undertake or successfully complete any additional transactions of the nature described above, any additional transactions that we do complete could have a material adverse effect on our business, results of operations, financial condition and prospects. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Our insurance policies are expensive and only protect us from some business risks, which will leave us exposed to significant uninsured liabilities. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We carry business interruption coverage to mitigate certain potential losses, but this insurance is limited in amount and may not be sufficient in type or amount to cover us against claims related to our operations. We cannot be certain that such potential losses will not exceed our policy limits, insurance will continue to be available to us on economically reasonable terms, or at all, or any insurer will not deny coverage as to any future claim. In addition, we may be subject to changes in our insurance policies, including premium increases or the imposition of large deductible or <span style="white-space:nowrap">co-insurance</span> requirements. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">33 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Further, we do not carry insurance for all categories of risk that our business may encounter. Some of the policies we currently maintain include products and completed operations liability, business personal property and directors&#8217; and officers&#8217; insurance. We do not know, however, if we will be able to maintain insurance with adequate levels of coverage. Any significant uninsured liability may require us to pay substantial amounts, which would materially and adversely affect our business, financial condition and results of operations. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Our employees, independent contractors, consultants, Biote-certified practitioners, Biote-partnered clinics, medical advisors and suppliers may engage in misconduct or other improper activities, including <span style="white-space:nowrap">non-compliance</span> with professional and regulatory standards and requirements, which could have a material adverse effect on our business. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are exposed to the risk that our employees, independent contractors, consultants, Biote-certified practitioners, Biote-partnered clinics, medical advisors and suppliers may engage in misconduct or other improper activities. Misconduct by these parties could include intentional, reckless and/or negligent conduct or disclosure of unauthorized activities to us that violates: (i)&#160;FDA laws and regulations or those of comparable international regulatory authorities, including those laws that require the reporting of true, complete and accurate information to the FDA, (ii)&#160;compounding and manufacturing standards, (iii)&#160;federal and state data privacy, security, fraud and abuse and other healthcare laws and regulations established and enforced by comparable international regulatory authorities, or (iv)&#160;laws that require the true, complete and accurate reporting of financial information or data. It is not always possible to identify and deter misconduct by employees and third parties, and the precautions we take to detect and prevent this activity may not be effective in controlling unknown or unmanaged risks or losses or in protecting us from governmental investigations or other actions or lawsuits stemming from a failure to be in compliance with such laws or regulations. Additionally, we are subject to the risk that a person or government could allege such fraud or other misconduct, even if none occurred. If any such actions are instituted against us, and we are not successful in defending ourselves or asserting our rights, those actions could have a significant impact on our business and results of operations, including the imposition of significant fines or other sanctions. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Extreme weather conditions, natural disasters, and other catastrophic events, including those caused by climate change, could negatively impact our results of operations and financial condition. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Extreme weather conditions and volatile changes in weather conditions in the areas in which our offices, suppliers, Biote-partnered clinics, dietary supplement third-party manufacturers, and suppliers are located could adversely affect our results of operations and financial condition. Moreover, natural disasters such as earthquakes, hurricanes, tsunamis, floods, monsoons or wildfires, public health crises, such as pandemics and epidemics (including, for example, the <span style="white-space:nowrap">COVID-19</span> pandemic), political crises, such as terrorist attacks, war and other political instability, or other catastrophic events, whether occurring in the United States or abroad, and their related consequences and effects, including energy shortages, could disrupt our operations, the operations of our vendors and other suppliers or result in economic instability that could negatively impact practitioner or clinic spending, any or all of which would negatively impact our results of operations and financial condition. In particular, these types of events could impact our global supply chain, including the ability of manufacturers to produce our Biote-branded dietary supplement products to Biote-partnered clinics or Biote-certified practitioners from or to the impacted region(s). For instance, in 2022 we experienced hurricane-related closures of 140 medical clinics in Florida and Puerto Rico, two of our key markets. If such closures continue or we experience similar closures in the future, there could be a material adverse effect on our business, financial condition and results of operations. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Adverse developments affecting the financial services industry, such as actual events or concerns involving liquidity, defaults or <span style="white-space:nowrap">non-performance</span> by financial institutions could adversely affect our current financial condition and projected business operations. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Actual events involving limited liquidity, defaults, <span style="white-space:nowrap">non-performance</span> or other adverse developments that affect financial institutions, transactional counterparties or other companies in the financial services industry or </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">34 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
the financial services industry generally, or concerns or rumors about any events of these kinds or other similar risks, have in the past and may in the future lead to market-wide liquidity problems. For example, on March&#160;10, 2023, the Federal Deposit Insurance Corporation (&#8220;FDIC&#8221;) took control and was appointed receiver of Silicon Valley Bank. Similarly, on March&#160;12, 2023, Signature Bank and Silvergate Capital Corp. were each swept into receivership. Although the FDIC announced that all deposits with these banks would be fully insured, there continues to be uncertainty in the markets regarding the stability of regional banks and the safety of deposits in excess of the FDIC insured deposit limits. If other banks and financial institutions enter receivership or become insolvent in the future in response to financial conditions affecting the banking system and financial markets, our ability to access our existing cash may be threatened. The FDIC only insures accounts in amounts up to $250,000 per depositor per insured bank, and we currently have cash deposited in certain financial institutions significantly in excess of FDIC insured levels. If any of the banking institutions in which we have deposited funds ultimately fails, we may lose our deposits over $250,000. The loss of our deposits may have a material adverse effect on our business and financial condition. The ultimate outcome of these events cannot be predicted, but these events could have a material adverse effect on our business. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Market and economic conditions may negatively impact the Company&#8217;s business, financial condition and stock price. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Concerns over inflation, energy costs, geopolitical issues, including the ongoing conflict between Russia and Ukraine, unstable global credit markets and financial conditions, and volatile oil prices could lead to periods of significant economic instability, diminished liquidity and credit availability, declines in consumer confidence and discretionary spending, diminished expectations for the global economy and expectations of slower global economic growth going forward. For example, in December 2022, the U.S. Consumer Price Index (CPI), which measures a wide-ranging basket of goods and services, rose 6.5% from the same month a year ago. The Company&#8217;s general business strategy may be adversely affected by any such inflationary fluctuations, economic downturns, volatile business environments and continued unstable or unpredictable economic and market conditions. Additionally, rising costs of goods and services purchased by the Company, including its raw materials used in manufacturing its product, may have an adverse effect on the Company&#8217;s gross margins and profitability in future periods. Increased inflation rates can adversely affect us by increasing our costs, including labor and employee benefit costs. Any significant increases in inflation and related increase in interest rates could have a material adverse effect on our business, results of operations and financial condition. If economic and market conditions continue to deteriorate or do not improve, it may make any necessary debt or equity financing more difficult to complete, more costly and more dilutive to the Company&#8217;s stockholders. Failure to secure any necessary financing in a timely manner or on favorable terms could have a material adverse effect on the Company&#8217;s financial performance and stock price or could require the Company to delay or abandon development other business plans. In addition, there is a risk that one or more of the Company&#8217;s current and future service providers, manufacturers, suppliers, and other facilities, and other partners could be negatively affected by such difficult economic factors, which could adversely affect the Company&#8217;s ability to attain its operating goals on schedule and on budget or meet its business and financial objectives. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Risks Related to Intellectual Property </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">If we are unable to obtain and maintain patent protection for any products or methods we develop, or if the scope of the patent protection obtained is not sufficiently broad, our competitors could develop and commercialize products similar or identical to our Biote-branded dietary supplements, and our ability to successfully commercialize any products we may develop may be adversely affected. If we are not able to maintain freedom to operate for our products from third-party intellectual property rights, our ability to commercialize products may be limited unless we secure a license to such rights. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our success depends in part on our ability to obtain and maintain patent and other intellectual property protection in the United States and other countries with respect to our Biote-branded dietary supplements. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">35 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We rely on a combination of contractual provisions, confidentiality procedures and copyright, trademark, trade secret and other intellectual property rights to protect the proprietary aspects of our brands, technologies, and data. These legal measures afford only limited protection, and competitors or others may gain access to or use our intellectual property and proprietary information. Our success will depend, in part, on preserving our trade secrets, maintaining the security of our data and <span style="white-space:nowrap">know-how,</span> obtaining and maintaining patents and obtaining other intellectual property rights. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may not be able to obtain and maintain intellectual property or other proprietary rights necessary to our business or in a form that provides us with a competitive advantage. For example, our trade secrets, data and know-how could be subject to unauthorized use, misappropriation or disclosure to unauthorized parties, despite our efforts to enter into confidentiality agreements with our employees, consultants, contractors, clients and other vendors who have access to such information and could otherwise become known or be independently discovered by third parties. In addition, the patent prosecution process is expensive, time-consuming and complex, and we may not be able to file, prosecute, maintain, enforce or license all necessary or desirable patent applications at a reasonable cost, in a timely manner, or in all jurisdictions where protection may be commercially advantageous, or we may not be able to protect our intellectual property at all. Despite our efforts to protect our intellectual property, unauthorized parties may be able to obtain and use information that we regard as proprietary. It is also possible that we will fail to identify patentable aspects of our research and development output in time to obtain patent protection. Although we enter into <span style="white-space:nowrap">non-disclosure</span> and confidentiality agreements with parties who have access to confidential or patentable aspects of our research and development output, such as our employees, consultants, contractors, collaborators, Biote-certified practitioners, Biote-partnered clinics, vendors and other third parties, any of these parties may breach the agreements and disclose such output before a patent application is filed, thereby jeopardizing our ability to seek patent protection. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our other intellectual property, including our trademarks, could also be challenged, invalidated, infringed and circumvented by third parties, and our trademarks could also be diluted, declared generic or found to be infringing on other marks, in which case we could be forced to <span style="white-space:nowrap">re-brand</span> our Biote-branded dietary supplements, resulting in loss of brand recognition and requiring us to devote resources to advertising and marketing new brands, and suffer other competitive harm. Third parties may also adopt trademarks similar to ours, which could harm our brand identity and lead to market confusion. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may in the future also be subject to claims by our former employees, consultants or contractors asserting an ownership right in our patents or patent applications, as a result of the work they performed on our behalf. Although we generally require all of our employees, consultants, contractors and any other collaborators who have access to our proprietary <span style="white-space:nowrap">know-how,</span> information or technology to assign or grant similar rights to their inventions to us, we cannot be certain that we have executed such agreements with all parties who may have contributed to our intellectual property, nor can we be certain that our agreements with such parties will be upheld in the face of a potential challenge, or that they will not be breached, for which we may not have an adequate remedy. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Failure to obtain and maintain patents, trademarks and other intellectual property rights necessary to our business and failure to protect, monitor and control the use of our intellectual property rights could negatively impact our ability to compete and cause us to incur significant expenses. The intellectual property laws and other statutory and contractual arrangements in the United States and other jurisdictions we depend upon may not provide sufficient protection in the future to prevent the infringement, use, violation or misappropriation of our patents, trademarks, data, technology and other intellectual property, and may not provide an adequate remedy if our intellectual property rights are infringed, misappropriated or otherwise violated. Any of the foregoing could have a material adverse effect on our competitive position, business, financial conditions, results of operations and prospects. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">36 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">We may become a party to intellectual property litigation or administrative proceedings that could be costly and could interfere with our ability to sell and market the Biote Method and our Biote-branded dietary supplements. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our industry has been characterized by extensive litigation regarding patents, trademarks, trade secrets and other intellectual property rights, and companies in the industry have used intellectual property litigation to gain a competitive advantage. It is possible that we may be accused of misappropriating third parties&#8217; trade secrets. Additionally, our Biote-branded dietary supplements are produced by third-party vendors and may include components that are outside of our direct control. Our competitors may have applied for or obtained, or may in the future apply for or obtain, patents or trademarks that will prevent, limit or otherwise interfere with our ability to use and sell the Biote Method, or use, sell and/or export our Biote-branded dietary supplements, or our ability to use product names. Moreover, in recent years, individuals and groups that are <span style="white-space:nowrap">non-practicing</span> entities, commonly referred to as &#8220;patent trolls,&#8221; have purchased patents and other intellectual property assets for the purpose of making claims of infringement in order to extract settlements. From time to time, we may receive threatening letters, notices or &#8220;invitations to license,&#8221; or may be the subject of claims that the Biote Method, our Biote-branded dietary supplements and business operations infringe or violate the intellectual property rights of others. The defense of these matters can be time consuming, costly to defend in litigation, divert management&#8217;s attention and resources, damage our reputation and brand and cause us to incur significant expenses or make substantial payments. Vendors from whom we purchase products may not indemnify us in the event that such products accused of infringing a third-party&#8217;s patent or trademark or of misappropriating a third-party&#8217;s trade secret, or any indemnification granted by such vendors may not be sufficient to address any liability and costs we incur as a result of such claims. Additionally, we may be obligated to indemnify Biote-partnered clinics, Biote-certified practitioners or business partners in connection with litigation and to obtain licenses, which could further exhaust our resources. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Even if we believe a third-party&#8217;s intellectual property claims are without merit, there is no assurance that a court would find in our favor, including on questions of infringement, validity, enforceability or priority of patents. The strength of our defenses will depend on the patents asserted, the interpretation of these patents, and our ability to invalidate the asserted patents. A court of competent jurisdiction could hold that these third-party patents are valid, enforceable and infringed, which could materially and adversely affect our ability to commercialize any products or technology we may develop and any other products or technologies covered by the asserted third-party patents. In order to successfully challenge the validity of any such U.S. patent in federal court, we would need to overcome a presumption of validity. As this burden is a high one requiring us to present clear and convincing evidence as to the invalidity of any such U.S. patent claim, there is no assurance that a court of competent jurisdiction would invalidate the claims of any such U.S. patent. Conversely, the patent owner need only prove infringement by a preponderance of the evidence, which is a lower burden of proof. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Further, if patents, trademarks or trade secrets are successfully asserted against us, this may harm our business and result in injunctions preventing us from selling the Biote Method and our Biote-branded dietary supplements, or result in obligations to pay license fees, damages, attorney fees and court costs, which could be significant. In addition, if we are found to willfully infringe third-party patents or trademarks or to have misappropriated trade secrets, we could be required to pay treble damages in addition to other penalties. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Although patent, trademark, trade secret and other intellectual property disputes have often been settled through licensing or similar arrangements, costs associated with such arrangements may be substantial and could include ongoing royalties. We may be unable to obtain necessary licenses, if any, on satisfactory terms, if at all. In addition, if any license we obtain is <span style="white-space:nowrap">non-exclusive,</span> we may not be able to prevent our competitors and other third parties from using the intellectual property or technology covered by such license to compete with us. Any of these events could materially and adversely affect our business, financial condition and results of operations. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Similarly, interference or derivation proceedings provoked by third parties or brought by the U.S. Patent and Trademark Office (the &#8220;USPTO&#8221;), may be necessary to determine priority with respect to our patents, patent </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">37 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
applications, trademarks or trademark applications. We may also become involved in other proceedings, such as reexamination, <span style="font-style:italic">inter partes</span> review, derivation or opposition proceedings before the USPTO or other jurisdictional body relating to our intellectual property rights or the intellectual property rights of others. Adverse determinations in a judicial or administrative proceeding or failure to obtain necessary licenses could prevent third-party suppliers from manufacturing our Biote-branded dietary supplements, which would have a significant adverse impact on our business, financial condition and results of operations. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Additionally, we have filed and may in the future file lawsuits or initiate other proceedings to protect or enforce our intellectual property rights, which could be expensive, time consuming and unsuccessful. We are currently party to two open litigation matters involving terminated practices and practitioners who we filed suit against to enforce post-termination contractual obligations where the defendants offered a competing hormone pellet therapy within the contractual <span style="white-space:nowrap">two-year</span> restrictive period without paying our requisite <span style="white-space:nowrap">buy-out</span> or residual benefit fee. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Competitors may infringe our issued patents or other intellectual property, which we may not always be able to detect. To counter infringement or unauthorized use, we may be required to file infringement claims, which can be expensive and time-consuming. Any claims we assert against perceived infringers could provoke these parties to assert counterclaims against us alleging that we infringe their intellectual property or alleging that our intellectual property is invalid or unenforceable. Grounds for a validity challenge could be an alleged failure to meet any of several statutory requirements, including lack of novelty, obviousness or <span style="white-space:nowrap">non-enablement.</span> Grounds for an unenforceability assertion could be an allegation that someone connected with prosecution of the patent withheld relevant information from the USPTO, or made a misleading statement, during prosecution. Third parties may raise challenges to the validity of certain of our owned patent claims before administrative bodies in the United States or abroad, even outside the context of litigation. Such mechanisms include <span style="white-space:nowrap">re-examination,</span> post-grant review, <span style="font-style:italic">inter partes</span> review, interference proceedings, derivation proceedings and equivalent proceedings in international jurisdictions (e.g., opposition proceedings). In any such lawsuit or other proceedings, a court or other administrative body may decide that a patent of ours is invalid or unenforceable, in whole or in part, construe the patent&#8217;s claims narrowly or refuse to stop the other party from using the technology at issue on the grounds that our patents do not cover the technology in question. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The outcome following legal assertions of invalidity and unenforceability is unpredictable. If a third-party were to prevail on a legal assertion of invalidity or unenforceability, we would lose at least part, and perhaps all, of the protection on products that we may develop. If our patents are found to be valid and infringed, a court may refuse to grant injunctive relief against the infringer and instead grant us monetary damages and/or ongoing royalties. Such monetary compensation may be insufficient to adequately offset the damage to our business caused by the infringer&#8217;s competition in the market. An adverse result in any litigation or other proceeding could put one or more of our patents at risk of being invalidated or interpreted narrowly. Any of these events could materially and adversely affect our business, financial condition and results of operations. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Even if resolved in our favor, litigation or other proceedings relating to intellectual property claims may cause us to incur significant expenses and could distract our personnel from their normal responsibilities. In addition, there could be public announcements of the results of hearings, motions or other interim proceedings or developments, and if securities analysts or investors perceive these results to be negative, it could have a substantial adverse effect on the price of our Class&#160;A common stock. Such litigation or proceedings could substantially increase our operating losses and reduce the resources available for development activities or any future sales, marketing or distribution activities. We may not have sufficient financial or other resources to conduct such litigation or proceedings adequately. Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation, there is a risk that some of our confidential or sensitive information could be compromised by disclosure in the event of litigation. Uncertainties resulting from the initiation and continuation of patent and other intellectual property litigation or other proceedings could have a material adverse effect on our business, financial condition and results of operations. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">38 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">If we are unable to protect the confidentiality of our other proprietary information, our business and competitive position may be harmed. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition to patent protection, we also rely on other proprietary rights, including protection of trade secrets, and other proprietary information that is not patentable or that we elect not to patent. However, trade secrets can be difficult to protect and some courts are less willing or unwilling to protect trade secrets. To maintain the confidentiality of our trade secrets and proprietary information, we rely heavily on confidentiality provisions that we have in contracts with our employees, consultants, contractors, Biote-certified practitioners, collaborators and others upon the commencement of their relationship with us. We cannot guarantee that we have entered into such agreements with each party that may have or have had access to our trade secrets or proprietary technology and processes. We may not be able to prevent the unauthorized disclosure or use of our technical knowledge or other trade secrets by such third parties, despite the existence generally of these confidentiality restrictions. These contracts may not provide meaningful protection for our trade secrets, <span style="white-space:nowrap">know-how</span> or other proprietary information in the event of any unauthorized use, misappropriation or disclosure of such trade secrets, <span style="white-space:nowrap">know-how</span> or other proprietary information. There can be no assurance that such third parties will not breach their agreements with us, that we will have adequate remedies for any breach, or that our trade secrets will not otherwise become known or independently developed by competitors. Despite the protections we do place on our intellectual property or other proprietary rights, monitoring unauthorized use and disclosure of our intellectual property is difficult, and we do not know whether the steps we have taken to protect our intellectual property or other proprietary rights will be adequate. Enforcing a claim that a party illegally disclosed or misappropriated a trade secret is difficult, expensive and time-consuming, and the outcome is unpredictable. The laws of many countries will not protect our intellectual property or other proprietary rights to the same extent as the laws of the United States. Consequently, we may be unable to prevent our proprietary technology from being exploited in the United States and abroad, which could affect our ability to expand in domestic and international markets or require costly efforts to protect our technology. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">To the extent our intellectual property or other proprietary information protection is incomplete, we are exposed to a greater risk of direct competition. A third-party could, without authorization, copy or otherwise obtain and use our Biote-branded dietary supplements, technology, or develop similar technology. Our competitors could purchase our Biote-branded dietary supplements and attempt to replicate some or all of the competitive advantages we derive from our development efforts or design around our protected technology. Our failure to secure, protect and enforce our intellectual property rights could substantially harm the value of our Biote-branded dietary supplements, as well as the value of our brand and business. The theft or unauthorized use or publication of our trade secrets and other confidential business information could reduce the differentiation of our Biote-branded dietary supplements and harm our business, the value of our investment in development or business acquisitions could be reduced and third parties might make claims against us related to losses of their confidential or proprietary information. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Further, it is possible that others will independently develop the same or similar technology or otherwise obtain access to our unpatented technology, and in such cases, we could not assert any trade secret rights against such parties. Costly and time-consuming litigation could be necessary to enforce and determine the scope of our trade secret rights and related confidentiality and <span style="white-space:nowrap">non-disclosure</span> provisions. If we fail to obtain or maintain trade secret protection, or if our competitors obtain our trade secrets or independently develop technology similar to ours or competing technologies, our competitive market position could be materially and adversely affected. In addition, some courts are less willing or unwilling to protect trade secrets, and agreement terms that address <span style="white-space:nowrap">non-competition</span> are difficult to enforce in many jurisdictions and might not be enforceable in certain cases. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We also seek to preserve the integrity and confidentiality of our data and other confidential information by maintaining physical security of our premises and physical and electronic security of our information technology systems. While we have confidence in these individuals, organizations and systems, agreements or security measures may be breached and detecting the disclosure or misappropriation of confidential information and enforcing a claim that a party illegally disclosed or misappropriated confidential information is difficult, </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">39 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
expensive and time-consuming, and the outcome is unpredictable. Further, we may not be able to obtain adequate remedies for any breach. Any of the foregoing could materially and adversely affect our business, financial condition and results of operations. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">We may be subject to claims that we or our employees, consultants or contractors have wrongfully used, disclosed or otherwise misappropriated the intellectual property of a third-party, including trade secrets or <span style="white-space:nowrap">know-how,</span> or are in breach of <span style="white-space:nowrap">non-competition</span> or <span style="white-space:nowrap">non-solicitation</span> agreements with our competitors or claims asserting an ownership interest in intellectual property we regard as our own. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Many of our employees, consultants and contractors were previously employed at or engaged by other medical device, biotechnology or pharmaceutical companies, including our competitors or potential competitors. Some of these employees, consultants and contractors may have executed proprietary rights, <span style="white-space:nowrap">non-disclosure</span> and <span style="white-space:nowrap">non-competition</span> agreements in connection with such previous employment. Although we try to ensure that our employees, consultants and contractors do not use the intellectual property, proprietary information, <span style="white-space:nowrap">know-how</span> or trade secrets of others in their work for us, we may be subject to claims that we or these individuals have, inadvertently or otherwise, used, disclosed or otherwise misappropriated intellectual property, including trade secrets or other proprietary information, of their former employers or our competitors or potential competitors. Additionally, we may be subject to claims from third parties challenging our ownership interest in intellectual property we regard as our own, based on claims that our employees, consultants or contractors have breached an obligation to assign inventions to another employer, to a former employer, or to another person or entity. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Litigation may be necessary to defend against such claims, and it may be necessary or we may desire to enter into a license to settle any such claim; however, there can be no assurance that we would be able to obtain a license on commercially reasonable terms, if at all. If our defense to those claims fails, in addition to paying monetary damages, we may lose valuable intellectual property rights or personnel. For example, a court could prohibit us from using technologies or features that are essential to the Biote Method or our Biote-branded dietary supplements, if such technologies or features are found to incorporate or be derived from the trade secrets or other proprietary information of the former employer. Even if we are successful in defending against such claims, litigation could result in substantial costs and be a distraction to management. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">An inability to incorporate technologies or features that are important or essential to the Biote Method and our Biote-branded dietary supplements could have a material adverse effect on our business, financial condition and results of operations, and may prevent us from providing our training and selling our Biote-branded dietary supplements. Any litigation or the threat thereof may adversely affect our ability to hire employees or contract with independent sales representatives. A loss of key personnel or their work product could hamper or prevent our ability to commercialize the products that we recommend as part of our training and our Biote-branded dietary supplements, which could have an adverse effect on our business, financial condition and results of operations. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">We may be subject to claims challenging our intellectual property. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We or our licensors may be subject to claims that former consultants, contractors or other third parties have an interest in our trade secrets or other intellectual property as an inventor or <span style="white-space:nowrap">co-inventor.</span> While it is our policy to require our employees, consultants and contractors who may be involved in the conception or development of intellectual property to execute agreements assigning such intellectual property to us, we may be unsuccessful in executing such an agreement with each party who, in fact, conceives or develops intellectual property that we regard as our own. The assignment of intellectual property rights may not be self-executing, or the assignment agreements may be breached, and we may be forced to bring claims against third parties, or defend claims that they may bring against us, to determine the ownership of what we regard as our intellectual property. If we or our licensors fail in defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights, such as exclusive ownership of, or right to use, intellectual property that is important to our Biote-branded dietary supplements. Any such events could have a material adverse effect on our business, financial condition and results of operations. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">40 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">If our trademarks and trade names are not adequately protected, then we may not be able to build brand recognition in our markets and our business may be adversely affected. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We rely on trademarks, service marks, trade names and brand names to distinguish our training and Biote-branded dietary supplements from our competitors and have registered or applied to register these trademarks. Our registered or unregistered trademarks, service marks, trade names and brand names may be challenged, infringed, diluted, circumvented or declared generic or determined to be infringing on other marks. Additionally, we cannot assure you that our trademark applications will be approved. During trademark registration proceedings, we may receive rejections. Although we are given an opportunity to respond to those rejections, we may be unable to overcome such rejections. In addition, in proceedings before the USPTO and comparable agencies in many international jurisdictions, third parties are given an opportunity to oppose pending trademark applications and to seek to cancel registered trademarks. Opposition or cancellation proceedings may be filed against our trademarks, and our trademarks may not survive such proceedings. In the event that our trademarks are successfully challenged, we could be forced to rebrand our Biote-branded dietary supplements, which could result in loss of brand recognition and could require us to devote significant resources towards advertising and marketing new brands. At times, competitors may adopt trade names or trademarks similar to ours, thereby impeding our ability to build brand identity and possibly leading to market confusion. In some cases, we may need to litigate claims to enforce our rights in our marks to avoid market confusion. Certain of our current or future trademarks may become so well known by the public that their use becomes generic and they lose trademark protection. Over the long term, if we are unable to establish name recognition based on our trademarks and trade names, then we may not be able to compete effectively and our business, financial condition and results of operations may be adversely affected. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Risks Related to Regulation </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">We market dietary supplements and convenience kits, which are regulated by the FDA, and are subject to certain requirements under the FDCA and the laws enforced by the FTC. Our failure to meet those requirements could cause us to cease certain of our business activities and may involve the payment of financial penalties. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We sell dietary supplements and convenience kits, which are regulated by the FDA. Each of these product categories have differing requirements that must be followed to ensure compliance with the FDCA and regulations promulgated thereunder, and failure to do so may result in the products being misbranded or adulterated. If we are found to have manufactured, distributed, sold, or labeled any products in violation of the FDCA, we may face significant penalties which may result in a material adverse effect on our business, financial condition, and results of operations. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The FTC enforces the Federal Trade Commission Act (the &#8220;FTCA&#8221;) and related regulations, which governs the advertising associated with the promotion and sale of our Biote-branded dietary supplements to prevent misleading or deceptive claims. For advertisements relating to dietary supplements, the FTC typically requires all factual claims, both express and implied, to be substantiated by competent and reliable scientific evidence. The FTC has promulgated policies and guidance that apply to advertising for dietary supplements that may be costly to comply with. The FDA may also determine that a particular dietary supplement or ingredient that we may market presents an unacceptable health risk. If that occurs, we could be required to cease distribution of and/or recall Biote-branded dietary supplements containing that ingredient. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The FDA or FTC may also determine that certain labeling, advertising and promotional claims, statements or activities with respect to a dietary supplement are not in compliance with applicable laws and regulations and may determine that a particular statement is an unapproved health claim, a drug claim, a false or misleading claim, or a deceptive advertising claim. Any such determination or any other failure to comply with FDA, FTCA or other regulatory requirements could prevent us from marketing our Biote-branded dietary supplements as a dietary supplement and subject us to administrative, civil or criminal penalties. The FTC has instituted numerous enforcement actions against dietary supplement companies for making false or misleading advertising claims and </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">41 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
for failing to adequately substantiate claims made in advertising. These enforcement actions have often resulted in warning letters, consent decrees and the payment of civil penalties and/or restitution by the companies involved. Should the FTC determine that our claims are false or misleading or unsubstantiated, we could be subject to FTC enforcement action and may face significant penalties which may result in a material adverse effect on our business, financial condition, and results of operations. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">We have developed and market a method and training program where the practitioner may prescribe a compounded bioidentical hormone. Compounded drugs are regulated by the FDA and are subject to certain requirements under the FDCA. Failure of compounding entities to meet those requirements could cause us to cease certain of our business activities and may involve the payment of financial penalties. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">While we do not sell compounded or prescription drugs, we have developed and market a method and training program where the practitioner may prescribe a compounded bioidentical hormone that is made by a third-party 503B outsourcing facility and requires compliance with the FDCA, and failure to do so may result in the products being misbranded or adulterated. Amendments to the FDCA in 2013 created Section&#160;503B, which creates a category of compounding pharmacies known as &#8220;outsourcing facilities&#8221; which are subject to certain FDCA requirements, including the requirement to adhere to cGMP regulations, though it exempts such facilities from certain of the FDCA requirements that otherwise apply to drug manufacturers. Understanding and complying with these laws and regulations may require substantial time, money, and effort. While we have only established relationships with 503B outsourcing facilities to support practitioners, if we are found to have manufactured, distributed, marketed, sold, or labeled any products in violation of the FDCA, we may face significant penalties which may result in a material adverse effect on our business, financial condition, and results of operations. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Compounded preparations and the pharmacy compounding industry are subject to regulatory scrutiny, which may impair our growth and sales. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Formulations prepared and dispensed by compounding pharmacies are not approved by the FDA. As we are a medical marketing and training company, we do not manufacture or compound pharmaceutical products. However, we contract with <span style="white-space:nowrap">FDA-registered</span> 503B outsourcing facilities to build relationships to support Biote-certified practitioners by offering an option for the compounding of bioidentical hormone pellets that the practitioner may order to prescribe. These pellets, compounded by 503B outsourcing facilities, are not subject to the FDA new drug approval process. Certain compounding pharmacies have been the subject of widespread negative media coverage in recent years. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Additionally, the outsourcing facilities with which we have relationships must comply with applicable provision of the FDCA and its implementing regulations. They may only distribute compounded drugs either pursuant to a patient-specific prescription or in response to an order from a healthcare provider, such as a hospital, that is not for an identified individual patient (e.g., for office stock). Further, such outsourcing facilities are inspected by the FDA according to a risk-based schedule, and must meet certain other conditions, such as reporting adverse events and providing the FDA with certain information about the products they compound. When the FDA finds that a manufacturer has violated FDA regulations, the FDA may notify the manufacturer of such violations in the form of a warning letter. The FDA also will issue an FDA Form 483 at the conclusion of an inspection if an investigator has observed a violative condition relating to the manufacturing and storage conditions of any drug product that may result in the product being adulterated, or any other regulatory <span style="white-space:nowrap">non-compliance</span> such as inadequate reporting or record-keeping. The outsourcing facilities with which we have relationships have each received warning letters and FDA Form 483s from the FDA. If the FDA takes enforcement action against outsourcing facilities with which we have relationships, it may have a material adverse impact on our business, results of operations and financial conditions. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Additionally, state laws and regulations may differ from the FDCA. We and the 503B outsourcing facilities are required to comply with state laws and regulations in the states where we and they do business. Efforts to </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">42 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
ensure compliance with these laws may require ongoing substantial cost. For example, some of the 503B outsourcing facilities with which we have relationships have received unfavorable enforcement actions from state regulators for <span style="white-space:nowrap">non-compliance.</span> Failure to comply with applicable state laws and regulations could expose us and these 503B outsourcing facilities to significant penalties which may harm our business, results of operations and financial condition. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">If a compounded drug formulation provided through a compounding pharmacy or an outsourcing facility leads to patient injury or death or results in a product recall, we may be exposed to significant liabilities and reputational harm. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We could be adversely affected if compounded pellets are subject to negative publicity. We could also be adversely affected if compounded pellets sold by any compounding outsourcing facilities, prove to be, or are asserted to be, harmful to patients or are otherwise subject to negative publicity. For example, in 2015, the FDA required labeling changes for prescription testosterone replacement therapy to warn of increased risk of heart attacks and strokes. There are a number of factors that could result in the injury or death of a patient who receives a compounded formulation, including quality issues, manufacturing or labeling flaws, improper packaging or unanticipated or improper uses of the products, any of which could result from human or other error. Any of these situations could lead to a recall of, or safety alert relating to, one or more of the products we recommend as part of our training. Similarly, to the extent any of the components of approved drugs or other ingredients used by the outsourcing facilities with whom we have relationships have quality or other problems that adversely affect the finished compounded preparations, our sales could be adversely affected. For example, some of the contracted outsourcing facilities have been the subject of civil suits alleging patient harm as a result of an improper formulation unrelated to the products we recommend. If a product which we recommend as part of our training becomes the subject of a civil or criminal suit, we may be subject to significant liability for any damages suffered by the plaintiffs and associated costs and penalties. Defending against any such actions can be costly, time-consuming and may require significant financial and personnel resources. Therefore, even if we are successful in defending against any such actions that may be brought against us, our business may be impaired. In addition, in the ordinary course of business, a voluntarily recall of one of the products we recommend as part of our training or may be instituted in response to a practitioner or clinic complaint. Because of our dependence upon medical and patient perceptions, any adverse publicity associated with illness or other adverse effects resulting from the use or misuse of the compounded products we recommend as part of our training or any other compounded formulations made or sold by other companies, could have a material adverse impact on our business, results of operations and financial condition. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">If the FDA takes regulatory action to implement any of the NASEM recommendations for compounded bioidentical hormones, this may have a substantial effect on the ability of the outsourcing facilities to compound the hormone pellets utilized by Biote-certified practitioners, which would have a substantially negative impact on Biote&#8217;s revenue and business operations. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In fall 2018, the FDA commissioned the NASEM to appoint an ad hoc committee to examine the clinical utility of treating patients with compounded bioidentical hormones. The NASEM committee held a series of open and closed sessions from March 2019 to April 2020, to examine data, research, and stakeholder input in order to form conclusions and recommendations regarding the clinical utility of these products. On July&#160;1, 2020, the NASEM committee published its report, wherein it concluded that there is a lack of high-quality clinical evidence to demonstrate the safety and effectiveness of these products and, accordingly, that there is insufficient evidence to support the overall clinical utility of these products as treatment for menopause and male hypogonadism symptoms. The NASEM Committee recommended restricted use of these products, assessments of their difficulty to compound, and additional education, state and federal regulatory oversight, and research. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">More specifically, NASEM Committee made six recommendations to the FDA: (1)&#160;Restrict the use of compounded bioidentical hormone preparations; (2)&#160;Review select bioidentical hormone therapies and dosage forms as candidates for the FDA Difficult to Compound List; (3)&#160;Improve education for prescribers and </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">43 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
pharmacists who market, prescribe, compound, and dispense these preparations; (4)&#160;Additional federal and state-level oversight should be implemented to better address public health and clinical concerns regarding the safety and effectiveness of these preparations; (5)&#160;Collect and disclose conflicts of interest; and (6)&#160;Strengthen and expand the evidence base on the safety, effectiveness, and use of these preparations. NASEM&#8217;s report is purely advisory and <span style="white-space:nowrap">non-binding</span> on the FDA. Biote cannot predict whether or not the FDA will accept the recommendations made in the NASEM report in whole, in part, or whether the FDA will reject NASEM&#8217;s recommendations. If the FDA were to take regulatory action to implement any of NASEM&#8217;s recommendations, in whole or in part, this may have a substantial effect on the ability of the outsourcing facilities to compound the hormone pellets utilized by Biote-certified practitioners as part of the Biote Method, and, in turn, have a substantially negative impact on Biote&#8217;s revenue and business operations. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Failure to comply with the FDCA and analogous state laws and regulations can result in administrative, civil, criminal penalties. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The FDA, acting under the scope of the FDCA and its implementing regulations, has broad authority to regulate the manufacture, distribution, and labeling of many products, including medical devices, cosmetics, drugs, and food, including dietary supplements <span style="white-space:nowrap">(FDA-regulated</span> products). The FDCA prohibits, among other things, the introduction or delivery for introduction into interstate commerce of any <span style="white-space:nowrap">FDA-regulated</span> product that is adulterated or misbranded, as well as the adulteration or misbranding of any <span style="white-space:nowrap">FDA-regulated</span> product while the product is in interstate commerce. However, the FDCA does not regulate the practice of medicine. Drugs that are compounded pursuant to a practitioner&#8217;s orders are considered to be the result of a compounding pharmacy or practitioner combining, mixing, or altering ingredients to create a medication tailored for the needs of a particular patient, and are not regulated as new drugs under the FDCA. We have developed relationships with 503B outsourcing facilities who compound bioidentical pellets to support Biote-certified practitioners who prescribe such products. If any of these compounded bioidentical hormone pellets are determined to be unapproved new drugs or are determined to be adulterated or misbranded under the FDCA, we could be subject to enforcement action by the FDA. If any of our operations are found to have violated the FDCA or any other federal, state, or local statute or regulation that may apply to us and our business, we could face significant penalties including the seizure of product, civil, criminal, and administrative penalties, damages, fines, disgorgement, imprisonment, contractual damages, reputational harm, and diminished profits and future earnings. Defending against any such actions can be costly, time-consuming and may require significant financial and personnel resources. Therefore, even if we are successful in defending against any such actions that may be brought against us, our business may be significantly impaired. Additionally, the FDA or analogous state agencies could determine that we or the outsourcing facilities with whom we have relationships are not in compliance with the FDCA or analogous or related state laws applicable to outsourcing facilities, which could significantly impact our business. Further, the FDA could recommend a voluntary recall, or issue a public health notification or safety notification about one or more of the products we recommend in training, which could materially harm our business, financial condition, and results of operations. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">If we fail to comply with FDA or state regulations governing our Biote-branded dietary supplements, our business could suffer. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We also market Biote-branded dietary supplements that are regulated by the FDA or state regulatory authorities. We may need to develop and maintain a robust compliance and quality program to ensure that the products that we market comply with all applicable laws and regulation, including the FDCA. If we are found to have manufactured, distributed, sold, or labeled any products in violation of the FDCA, we may face significant penalties which may result in a material adverse effect on our business, financial condition, and results of operations. For example, in May 2017, we received a warning letter from the FDA concerning both cGMP violations observed during a 2016 FDA inspection of our facility, and unapproved new drug claims that were made for certain of our dietary supplement products (the &#8220;Warning Letter&#8221;). Although our response to the </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">44 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Warning Letter resulted in a closeout by the FDA in May 2018, we cannot assure you that we will not receive warning letters or other regulatory action by the FDA on the same or similar violations in the future. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">If we fail to comply with FDA regulations governing our medical device products, our business could suffer. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We also offer for sale to practitioners two convenience kits for use with hormone optimization therapies, one for male patients and one for female patients. These kits largely contain commercially available products, including only disposable supplies (e.g., gloves, antiseptic, gauze, disposable trocar, etc.) assembled in a sterile package. The products contained in the kits are sourced, assembled, and supplied by Medline Industries, LP, with the components, including the Class&#160;1 disposable trocars, being manufactured by various other component suppliers. Trocars and convenience kits are medical devices that are regulated by the FDA. Because we previously manufactured and sold reusable and disposable trocars, we registered with the FDA as a repackager, relabeler and specification developer, and we currently list the trocars we previously manufactured and the convenience kits we currently sell in compliance with FDA registration and listing requirements. We may need to develop and maintain a robust compliance and quality program to ensure that the convenience kits we sell comply with all applicable laws and regulation, including the FDCA and other regulatory requirements thereunder including for example cGMPs and Medical Device Reporting (&#8220;MDR&#8221;) where applicable. If the FDA determines that the convenience kits we sell require 510(k) clearance, or are otherwise considered unapproved medical devices, we may be in violation of the FDCA. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Additionally, we offer our proprietary clinical decision support (&#8220;CDS&#8221;) software to practitioners to provide information from published literature and clinical guidelines to assist practitioners in providing precise, patient-specific treatment options at various intervals through a patient&#8217;s therapy. The FDA has recently issued a <span style="white-space:nowrap">non-binding</span> final CDS guidance that significantly narrows what the agency considers <span style="white-space:nowrap">non-device</span> CDS. If the FDA determines that our CDS is a medical device under the FDCA, the FDA may determine that our algorithm requires premarket approval or clearance, and may determine that unless and until we obtain such premarket approval or clearance that we are distributing an unapproved medical device in violation of the FDCA. If we are found to have manufactured, distributed, sold, or labeled any medical devices in violation of the FDCA, we may face significant penalties which may result in a material adverse effect on our business, financial condition, and results of operations. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">If we fail to comply with healthcare and other governmental regulations, we could face substantial penalties and our business, financial condition and results of operations could be adversely affected. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our relationships with Biote-certified practitioners, Biote-partnered clinics, outsourcing facilities, and suppliers may subject us to a variety of healthcare laws including, among others, laws that prohibit fraud and abuse, including the federal Anti-Kickback Statute, the False Claims Act, the healthcare fraud provisions of HIPAA, and state anti-kickback statutes that prohibit any person from offering, soliciting, receiving, or providing remuneration in exchange for the referral of patients or the purchase, order, or recommendation of any good or service and fee splitting laws, which prohibit a practitioner from dividing compensation for their professional services with a person who did not render the service. Violations of these laws are punishable by substantial penalties and other remedies, including monetary fines, civil penalties, administrative remedies, criminal sanctions (in the case of the federal Anti-Kickback Statute and certain state anti-kickback laws) and forfeiture of amounts collected in violation of such laws. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Additionally, most states do not allow business corporations to employ practitioners to provide professional services. This prohibition against the &#8220;corporate practice of medicine&#8221; is aimed at preventing corporations such as us from exercising control over the medical judgments or decisions of practitioners. While some states have broad exceptions to the corporate practice of medicine, the state licensure statutes and regulations and agency and court decisions that enumerate the specific corporate practice rules vary considerably from state to state and are enforced by both the courts and regulatory authorities, each with broad discretion. If regulatory authorities or other parties in any jurisdiction successfully assert that we are engaged in the unauthorized corporate practice of </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">45 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
medicine, we could be required to restructure our contractual and other arrangements. Further, violation of these laws may result in sanctions imposed against us, Biote-certified practitioners and/or Biote-partnered clinics through licensure proceedings. Similarly, our compensation arrangement with Biote-certified practitioners and/or Biote-partnered clinics may implicate state <span style="white-space:nowrap">fee-splitting</span> prohibitions, which prohibit providers from sharing a portion of their professional fees collected with third parties. Additionally, our relationships with healthcare providers may subject us to HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act (&#8220;HITECH&#8221;), which impose certain requirements relating to the privacy, security and transmission of PHI on certain healthcare providers, health plans and healthcare clearinghouses, and their business associates and their subcontractors that access or otherwise process individually identifiable health information for or on behalf of a covered entity as well as their covered subcontractors. We could also be subject to analogous state healthcare data privacy laws, which may not always be preempted by HIPAA. We are subject to laws relating to the collection, use, retention, security, and transfer of personally identifiable information about its users around the world. Much of the personal information that we collect is regulated by multiple laws. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Because of the breadth of these laws and the complexity of statutory and regulatory exemptions, it is possible that some of our activities could be subject to challenge under one or more of such laws. Any action brought against us for violations of these laws or regulations, even if successfully defended, could cause us to incur significant legal expenses and divert our management&#8217;s attention from the operation of our business. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In a regulatory climate that is uncertain, our operations may be subject to direct and indirect adoption, expansion or reinterpretation of various healthcare laws and regulations. Compliance with these and/or future healthcare laws and regulations may require us to change our practices at an undeterminable and possibly significant initial monetary and annual expense. These additional monetary expenditures may increase future overhead, which could have a material adverse effect on our results of operations. Additionally, the introduction of new training, and Biote-branded dietary supplements may require us to comply with additional laws and regulations. Compliance may require obtaining appropriate licenses or certificates, increasing our security measures, and expending additional resources to monitor developments in applicable rules and ensure compliance. The failure to adequately comply with these and/or future healthcare laws and regulations may delay or possibly prevent any new training and products from being offered to Biote-certified practitioners, Biote-partnered clinics and their patients, which could have a material adverse effect on our business, financial condition, and results of operations. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our success depends on our relationships with Biote-certified practitioners and Biote-partnered clinics, and, therefore, our operations are subject to federal and state healthcare fraud and abuse, referral and reimbursement laws and regulations. If our operations are found to be in violation of any of the federal and state healthcare laws or any other current or future fraud and abuse or other healthcare laws and regulations that apply to us, including applicable healthcare fraud statutes, we may be subject to penalties. Penalties under these laws may be severe, and include without limitation treble damages, significant criminal, civil and administrative penalties, attorneys&#8217; fees and fines, injunctions, as well as contractual damages and reputational harm. We could also be required to modify, curtail or cease our operations. Any of the foregoing consequences could seriously harm our business and our financial results and enforcement of the foregoing laws could have a material adverse effect on our business. Also, these measures may be interpreted or applied by a prosecutorial, regulatory or judicial authority in a manner that could require us to make changes in our operations or incur substantial defense and settlement expenses. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Our relationships with Biote-certified practitioners and Biote-partnered clinics in connection with our current and future business activities may be subject to healthcare fraud and abuse laws and health information privacy and security laws, which could expose us to significant criminal sanctions, civil penalties, contractual damages, reputational harm, administrative burdens and diminished profits and future earnings. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our current and future arrangements with Biote-certified practitioners and Biote-partnered clinics may expose us to broadly applicable federal and state fraud and abuse and other federal and state healthcare laws and regulations that may constrain Biote&#8217;s business or financial arrangements and relationships. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">46 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Restrictions under applicable federal and state healthcare laws and regulations may include the following: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">State healthcare fraud and abuse laws that prohibit any person from offering, paying, soliciting or receiving any remuneration, directly or indirectly, in cash or in kind, for the referral of patients or other items or services to or with licensed healthcare providers, subject to limited exceptions. Some state fraud and abuse laws apply to items or services reimbursed by any third-party payor, including commercial insurers, some apply only to state healthcare program payors, while other state laws apply regardless of payor, including funds paid out of pocket by a patient. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">State corporate practice of &#8220;medicine&#8221; prohibitions that restrict unlicensed persons from engaging licensed professionals to render professional services to the public or from interfering with or influencing a licensed practitioner&#8217;s professional judgment. Certain activities other than those directly related to the delivery of healthcare services to patients may be considered an element of the practice of medicine in many states. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">State <span style="white-space:nowrap">fee-splitting</span> prohibitions, which prohibit licensed healthcare professionals from sharing a portion of their professional fees collected from their professional services with unlicensed third parties. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">HIPAA, as amended by the HITECH and their implementing regulations, also imposes obligations, including mandatory contractual terms, on covered entities, which are health plans, healthcare clearinghouses, and certain healthcare providers, as those terms are defined by HIPAA, and their respective business associates and their subcontractors, with respect to safeguarding the privacy, security and transmission of individually identifiable health information. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Although Biote does not bill or receive any reimbursement from any third-party payor, to the extent that any Biote-certified practitioners and Biote-partnered clinic with whom we partner accepts health insurance for their services, we could be subject to additional laws, including without limitation the federal Anti-Kickback Statute, False Claims Act and the healthcare fraud provisions of HIPAA. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Further, the California Consumer Privacy Act of 2018 (&#8220;CCPA&#8221;) applies to personal information of consumers, business representatives, and employees, and requires businesses to provide specific disclosures in privacy notices and honor requests of California residents to exercise certain privacy rights. The CCPA provides for civil penalties of up to $7,500 per violation and allows private litigants affected by certain data breaches to recover significant statutory damages. Although the CCPA may exempt some data processed in certain contexts, the CCPA increases compliance costs and potential liability with respect to other personal data we maintain about California residents. In addition, the California Privacy Rights Act of 2020 (&#8220;CPRA&#8221;), which became operative on January&#160;1, 2023, expands the CCPA&#8217;s requirements, giving California residents the ability to limit use of certain sensitive personal data, along with establishing a new regulatory agency to implement and enforce the law. Other states, such as Virginia, Colorado, Utah, and Connecticut have also passed comprehensive privacy laws, and similar laws are being considered in several other states, as well as at the federal and local levels. While these states, like the CCPA, also exempt some data processed in the context of clinical trials, these developments further complicate compliance efforts, and increase legal risk and compliance costs for us, the third parties upon whom we rely, and our customers. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Efforts to ensure that our current and future business arrangements with third parties will comply with applicable healthcare and data privacy laws and regulations will involve substantial ongoing costs and may require us to undertake or implement additional policies or measures. The scope of the foregoing state laws and the interpretations of them vary by jurisdiction and are enforced by local courts and regulatory authorities, each with broad discretion. We may face claims and proceedings by private parties, and claims, investigations and other proceedings by governmental authorities, relating to allegations that our business practices do not comply with current or future statutes, regulations or case law involving applicable fraud and abuse or other healthcare laws and regulations, and it is possible that courts or governmental authorities may conclude that our arrangements with the Biote-certified practitioners, Biote-partnered clinics or our sales force are not consistent with such laws, or that we may find it necessary or appropriate to settle any such claims or other proceedings. In </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">47 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
connection with any such claims, proceedings, or settlements, we may be subject to significant penalties, including civil, criminal and administrative penalties, damages, fines, disgorgement, imprisonment, exclusion from participation in government funded healthcare programs, such as Medicare and Medicaid, integrity oversight and reporting obligations, contractual damages, reputational harm, diminished profits and future earnings and the curtailment or restructuring of our operations. Defending against any such actions can be costly, time-consuming and may require significant financial and personnel resources. Therefore, even if we are successful in defending against any such actions that may be brought against us, our business may be impaired. Further, if any Biote-certified practitioners or Biote-partnered clinics with whom we expect to do business are found to be not in compliance with applicable laws, they may be subject to criminal, civil or administrative sanctions. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">If our information technology systems or data is or were compromised, we could experience adverse consequences resulting from such compromise, including, but not limited to, interruptions to our operations, claims that we breached our data protection obligations, decreased use of the Biote Method, loss of Biote-partnered clinics or Biote-certified practitioners or sales, and harm to our reputation. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Operating our business (including the Biote Method) involves the collection, storage, transmission, disclosure and other processing of proprietary, confidential and sensitive information, as well as the personal information of patients that we may receive from clinics. We may rely upon third-party service providers, such as identity verification and payment processing providers, for our information processing-related activities. We may share or receive sensitive information with or from third parties. In an effort to protect sensitive information, we have implemented security measures designed to protect against security incidents and protect sensitive information. However, advances in information technology capabilities, increasingly sophisticated tools and methods used by hackers, cyber terrorists and other threat actors, new or other developments, and intentional or accidental exposures of sensitive information by those with authorized access to our network, may result in our failure or inability to adequately protect sensitive information. We may expend significant resources or modify our business activities in an effort to protect our information and against security incidents. Certain information privacy and security obligations may require us to implement and maintain specific security measures, industry-standard or reasonable security measures to protect our information technology systems and information. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are subject to a variety of evolving threats including, but not limited to, hacking, malware, computer viruses, unauthorized access, phishing or social engineering attacks, ransomware attacks, credential stuffing attacks, <span style="white-space:nowrap"><span style="white-space:nowrap">denial-of-service</span></span> attacks, supply-chain attacks, software bugs, information technology malfunction, software or hardware failures, loss of data, theft of data, misuse of data, telecommunications failures, earthquakes, fire, flood, exploitation of software vulnerabilities, and other real or perceived threats. Any of these incidents could lead to interruptions or shutdowns of our IT systems, loss or corruption of data or unauthorized access to, or disclosure of personal data or other sensitive information. Ransomware attacks, including those from organized criminal threat actors, nation-states and nation-state supported actors, are becoming increasingly prevalent and severe and can lead to significant interruptions, delays, or outages in our operations, loss of data, loss of income, significant extra expenses to restore data or systems, reputational loss and the diversion of funds. To alleviate the financial, operational and reputational impact of a ransomware attack it may be preferable to make extortion payments, but we may be unwilling or unable to do so. Cyberattacks could also result in the theft of our intellectual property, damage to our IT systems or disruption of our ability to make financial reports, and other public disclosures required of public companies. We have been subject to attempted cyber, phishing, or social engineering attacks in the past and may continue to be subject to such attacks and other cybersecurity incidents in the future. If we gain greater visibility, we may face a higher risk of being targeted by cyberattacks. Advances in information technology capabilities, new technological discoveries, or other developments are likely to result in cyberattacks becoming more sophisticated and more difficult to detect. We and third parties upon whom we rely for our information technology systems and information, may experience such cyberattacks and may not have the resources or technical sophistication to anticipate or prevent all threats. Moreover, techniques used to obtain unauthorized access to systems change frequently and may not be known until launched. Security breaches can also occur as a result of <span style="white-space:nowrap">non-technical</span> issues, including intentional or inadvertent actions by our </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">48 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
personnel and third-party service providers (including their personnel). Any of the previously identified or similar threats could cause a security incident. A security incident could result in unauthorized, unlawful or accidental acquisition, modification, destruction, loss, alteration, encryption, disclosure of or access to information. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Applicable information privacy and security obligations may require us to notify relevant stakeholders of security incidents. Such disclosures are costly, and the disclosures or the failure to comply with such requirements, could lead to adverse impacts. If we (or a third-party upon whom we rely) experience a security incident or are perceived to have experienced a security incident, we may experience adverse consequences. These consequences may include: government enforcement actions (for example, investigations, fines, penalties, audits, and inspections); additional reporting requirements and/or oversight; restrictions on processing data (including personal data); litigation (including class claims); indemnification obligations; negative publicity; reputational harm; monetary fund diversions; interruptions in our operations (including availability of data); financial loss; and other similar harms. Security incidents and attendant consequences may cause Biote-partnered clinics or Biote-certified practitioners to stop using the Biote Method and Biote-branded dietary supplements and may deter new clinics and practitioners from using the Biote Method and Biote-branded dietary supplements and negatively impact our ability to grow and operate our business. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">While we maintain cyber errors and omissions insurance coverage that covers certain aspects of cyber risks, these losses may not be adequately covered by insurance or other contractual rights available to us. The successful assertion of one or more large claims against us that exceed or are not covered by our insurance coverage or changes in our insurance policies, including premium increases or the imposition of large deductible or <span style="white-space:nowrap">co-insurance</span> requirements, could have an adverse effect on our business, financial condition, and results of operations. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Furthermore, we may be required to disclose personal data pursuant to demands from individuals, privacy advocates, regulators, government agencies, and law enforcement agencies in various jurisdictions with conflicting privacy and security laws. Any disclosure or refusal to disclose personal data may result in a breach of privacy and data protection policies, notices, laws, rules, court orders, and regulations and could result in proceedings or actions against us in the same or other jurisdictions, damage to our reputation and brand, and inability to provide our trainings and Biote-branded dietary supplements to clinics and practitioners in certain jurisdictions. Additionally, changes in the laws and regulations that govern our collection, use, and disclosure of certain data could impose additional requirements with respect to the retention and security of customer data, could limit our marketing activities, and have an adverse effect on our business, reputation, brand, financial condition, and results of operations. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Following the consummation of the Business Combination, we have incurred, and we expect to continue to incur, significant increased expenses and administrative burdens as a public company, which could negatively impact its business, financial condition and results of operations. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Following the consummation of the Business Combination, we have faced increased legal, accounting, administrative and other costs and expenses in connection with operation as a public company which Biote did not incur as a private company. Our significantly increased expenses and administrative burdens as a public company could have an adverse effect on its business, financial condition and results of operation. The Sarbanes-Oxley Act of 2002, as amended (the &#8220;Sarbanes-Oxley Act&#8221;), including the requirements of Section&#160;404, as well as rules and regulations subsequently implemented by the SEC, the Dodd-Frank Wall Street Reform and Consumer Protection Act of 2010, as amended (the &#8220;Dodd-Frank Act&#8221;) and the rules and regulations promulgated and to be promulgated thereunder, and the securities exchanges, impose additional reporting and other obligations on public companies. Compliance with public company requirements has increased, and may continue to increase, costs and make certain activities more time-consuming. A number of those requirements requires us to carry out activities that Biote has not done previously. For example, we have adopted new charters for our board committees and new internal controls and disclosure controls and procedures. In addition, expenses </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">49 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
associated with SEC reporting requirements and stock exchange listing requirements have been, and will continue to be, incurred. Furthermore, if any issues in complying with those requirements are identified (for example, if the auditors identify a material weakness or significant deficiency in the internal control over financial reporting), we could incur additional costs rectifying those issues, and the existence of those issues could adversely affect our reputation or investor perceptions of it. It may also be more expensive to obtain director and officer liability insurance. Risks associated with our status as a public company may make it more difficult to attract and retain qualified persons to serve on our board of directors or as executive officers. The additional reporting and other obligations imposed by these rules and regulations may continue to increase legal and financial compliance costs and the costs of related legal, accounting and administrative activities. These increased costs require us to divert a significant amount of money that could otherwise be used to expand the business and achieve strategic objectives. Additionally, advocacy efforts by stockholders and third parties may also prompt additional changes in governance and reporting requirements, which could further increase costs. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Our internal controls over financial reporting currently do not meet all of the standards contemplated by Section&#160;404 of the Sarbanes-Oxley Act, and a material weakness resulted in the restatement of previously issued financial statements. Failure to achieve and maintain an effective system of disclosure controls and internal control over financial reporting could impair our ability to produce timely and accurate financial statements or comply with applicable regulations. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We will eventually be required to provide management&#8217;s attestation on internal controls over financial reporting. The standards required for a public company under Section&#160;404(a) of the Sarbanes-Oxley Act are significantly more stringent than those required of us as a privately held company prior to the Business Combination. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A material weakness is a deficiency, or combination of deficiencies, in internal control over financial reporting, such that there is a reasonable possibility that a material misstatement of the annual or interim financial statements will not be prevented or detected on a timely basis. In the course of preparing our financial statements for the fiscal years ended December&#160;31, 2020 and 2019, our management identified a material weakness in the aggregate in our internal control over financial reporting. Specifically, we determined that we did not have appropriate accounting competence and capabilities to properly record in our financial statements certain complex and <span style="white-space:nowrap">non-routine</span> accounting issues, particularly related to revenue recognition, financial instruments, and equity. This resulted in incorrect accounting entries that were identified and corrected through the audit of our fiscal years ended December&#160;31, 2020 and 2019. In addition, this material weakness resulted in errors in the financial statements and related disclosures in our Quarterly Reports on Form <span style="white-space:nowrap">10-Q</span> for the quarters ended June&#160;30, 2022 and September&#160;30, 2022, which we have restated as described in the Quarterly Reports on Form <span style="white-space:nowrap">10-Q/A</span> for each of the affected quarters, each filed on March&#160;29, 2023. This material weakness has not been remediated as of the date of this registration statement. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In order to remediate this material weakness in the aggregate, we plan to continue to hire personnel with public company experience and provide additional training for our personnel on internal controls as our company continues to grow, and engage external consultants to assist in the development and improvement of methodologies, policies and procedures designed to ensure adequate internal control over financial reporting, including the technical application of U.S. GAAP and evaluating segregation of duties. Although we believe these measures will remediate this material weakness, there can be no assurance that the material weakness will be remediated on a timely basis or at all, or that additional material weaknesses will not be identified in the future. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our current controls and any new controls that we develop may also become inadequate because of changes in conditions in our business. Further, weaknesses in our disclosure controls and internal control over financial reporting may be discovered in the future. Any failure to develop or maintain effective controls or any difficulties encountered in their implementation or improvement could harm our results of operations or cause us to fail to meet our reporting obligations and may result in a restatement of our financial statements for prior periods. Any </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">50 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
failure to implement and maintain effective internal control over financial reporting also could adversely affect the results of periodic management evaluations and annual independent registered public accounting firm attestation reports regarding the effectiveness of our internal control over financial reporting that we will eventually be required to include in our periodic reports that will be filed with the SEC. Ineffective disclosure controls and procedures and internal control over financial reporting could also cause investors to lose confidence in our reported financial and other information. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As a result, the market price of our Class&#160;A common stock could be negatively affected, and we could become subject to investigations by the stock exchange on which our securities are listed, the SEC or other regulatory authorities, which could require additional financial and management resources. In addition, if we are unable to continue to meet these requirements, we may not be able to <span style="white-space:nowrap">re-list</span> on Nasdaq. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our independent registered public accounting firm is not required to formally attest to the effectiveness of our internal control over financial reporting until after we are no longer an &#8220;emerging growth company&#8221; as defined in the Jumpstart Our Business Startups Act of 2012 (the &#8220;JOBS Act&#8221;). At such time, our independent registered public accounting firm may issue a report that is adverse in the event it is not satisfied with the level at which our internal control over financial reporting is then documented, designed or operating. Any failure to maintain effective disclosure controls and internal control over financial reporting could have an adverse effect on our business and results of operations and could cause a decline in the price of our Class&#160;A common stock. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">We recently restated our financial statements for certain prior periods, which resulted in unanticipated costs. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As previously announced, we concluded that our previously issued consolidated financial statements as of and for the quarters ended June&#160;30, 2022 and September&#160;30, 2022 (the &#8220;Affected Periods&#8221;) should no longer be relied upon. As a result, we restated the financial statements for the Affected Periods. The restatements of our financial statements for the Affected Periods were due, in part, to an error in the calculation of its earnout valuation, resulting in an overstatement of our earnout liability and our gain (loss) from change in fair value of earnout liability. We also determined that we should attribute changes in fair value of our warrant and earnout liabilities to our operating subsidiary, BioTE Holdings, LLC (&#8220;Holdings&#8221;), whereas these changes had previously been attributed to the Company in the due to an error related to the calculation of the fair value of our contingent earnout liability in each of the Affected Periods. We determined that attributing these changes in fair value to Holdings more appropriately reflects the economics of the net income allocation to equity interests in our condensed consolidated financial statements in accordance with Accounting Standards Codification 810, given our <span style="white-space:nowrap">&#8220;Up-C&#8221;</span> structure. As a result, we corrected the error in our condensed consolidated financial statements as of and for the period ended June&#160;30, 2022 and restated our financial statements for the quarters ended June&#160;30, 2022 and September&#160;30, 2022 to reflect a reduction in our basic and diluted income (loss) per common share, as a pro rata portion of gain (loss) from changes in fair value of the warrant and earnout liabilities attributed to noncontrolling interests of Holdings. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As a result, we incurred unanticipated costs for accounting and legal fees in connection with the restatements. The restatements may negatively impact the trading price of our securities and make it more difficult for us to raise capital on acceptable terms, or at all, which could have a material adverse effect on our business, results of operations and financial condition. See also &#8220;Controls and Procedures.&#8221; </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Resales of shares of common stock could depress the market price of our common stock. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of December&#160;31, 2022, 69,808,711 shares (which includes 10,000,000 Earnout Voting Shares and 1,587,500 Sponsor Earnout Shares) shares of our common stock are outstanding, consisting of 11,242,887 shares of Class&#160;A common stock and 58,565,824 shares of Class&#160;V voting stock. Following the Business Combination, shares held by HYAC&#8217;s public stockholders have been freely tradeable, and the shares held by the Sponsor and the Members, following their exercise of Exchange Rights, are freely tradeable as of the <span style="white-space:nowrap">six-month</span> anniversary of the Closing, subject to applicable securities laws. We have also registered all shares of Class&#160;A common stock </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">51 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
that we may issue under the Incentive Plan or the ESPP. Once we register these shares, they can be freely sold in the public market upon issuance, subject to volume limitations applicable to Affiliates. As a result, there may be a large number of shares of Class&#160;A common stock sold in the market. These sales of shares of Class&#160;A common stock, or the perception of these sales, may depress the market price of our Class&#160;A common stock. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">If the benefits from the Business Combination do not meet the expectations of investors, stockholders or financial analysts, the market price of our securities may decline. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If the benefits from the Business Combination do not meet the expectations of investors or securities analysts, the market price of our securities may decline. For example, from the Closing Date through March&#160;15, 2023, our stock price fluctuated from a low of $2.00 to a high of $10.51. Fluctuations in the price of our securities could contribute to the loss of all or part of your investment. Immediately prior to the Business Combination, there was not a public market for Biote&#8217;s stock and trading in the shares of our Class&#160;A common stock was not active. Accordingly, the valuation ascribed to Biote and our Class&#160;A common stock in the Business Combination may not be indicative of the price that will prevail in the trading market following the Business Combination. The trading price of our securities could be volatile and subject to wide fluctuations in response to various factors, some of which are beyond our control. Any of the factors listed below could adversely affect your investment in our securities, and our securities may trade at prices significantly below the price you paid for them. In these circumstances, the trading price of our securities may not recover and may experience a further decline. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Factors affecting the trading price of our securities following the Business Combination may include: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">actual or anticipated fluctuations in our quarterly financial results or the quarterly financial results of companies perceived to be similar to us; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">changes in the market&#8217;s expectations about our operating results; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the public&#8217;s reaction to our press releases, our other public announcements and our filings with the SEC; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">speculation in the press or investment community; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">success of competitors; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">our operating results failing to meet the expectation of securities analysts or investors in a particular period; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">changes in financial estimates and recommendations by securities analysts concerning the Biote or the market in general; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">operating and stock price performance of other companies that investors deem comparable to the Biote; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">our ability to market new and enhanced products on a timely basis; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">changes in laws and regulations affecting our business; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">commencement of, or involvement in, litigation involving the Biote, including the Donovitz Litigation (as defined herein); </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">changes in Biote&#8217;s capital structure, such as future issuances of securities or the incurrence of additional debt; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the volume of shares of our Class&#160;A common stock available for public sale; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">our ability to maintain the listing of our securities on Nasdaq; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">any major change of officers or directors; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">sales of substantial amounts of Class&#160;A common stock by our directors, officers or significant stockholders or the perception that such sales could occur; and </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">52 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">general economic and political conditions such as recessions, interest rates, fuel prices, international currency fluctuations and acts of war or terrorism. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Broad market and industry factors may materially harm the market price of our securities irrespective of our operating performance. The stock market in general has experienced price and volume fluctuations that have often been unrelated or disproportionate to the operating performance of the particular companies affected. The trading prices and valuations of these stocks, and of our securities, may not be predictable. A loss of investor confidence in the market for the stocks of other companies that investors perceive to be similar to Biote could depress our stock price regardless of our business, prospects, financial condition or results of operations. A decline in the market price of our securities also could adversely affect our ability to issue additional securities and our ability to obtain additional financing in the future. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the past, securities class action litigation has often been initiated against companies following periods of volatility in their stock price. This type of litigation could result in substantial costs and divert our management&#8217;s attention and resources and could also require us to make substantial payments to satisfy judgments or to settle litigation. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">We are an &#8220;emerging growth company&#8221; and a &#8220;smaller reporting company&#8221; and we take advantage of certain exemptions from disclosure requirements available to emerging growth companies and/or smaller reporting companies, this could make our securities less attractive to investors and may make it more difficult to compare our performance with other public companies. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are an &#8220;emerging growth company&#8221; within the meaning of the Securities Act, as modified by the JOBS Act, and we take advantage of certain exemptions from various reporting requirements that are applicable to other public companies that are not emerging growth companies including, but not limited to, not being required to comply with the auditor internal controls attestation requirements of Section&#160;404 of the Sarbanes-Oxley Act, reduced disclosure obligations regarding executive compensation in our periodic reports and proxy statements, and exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and stockholder approval of any golden parachute payments not previously approved. As a result, our stockholders may not have access to certain information they may deem important. We could be an emerging growth company for up to five years following our initial public offering, although circumstances could cause us to lose that status earlier, including if the market value of our Class&#160;A common stock held by <span style="white-space:nowrap">non-affiliates</span> exceeds $700&#160;million as of any June&#160;30 before that time, in which case we would no longer be an emerging growth company as of the following December 31. We cannot predict whether investors will find our securities less attractive because we may rely on these exemptions. If some investors find our securities less attractive as a result of our reliance on these exemptions, the trading prices of our securities may be lower than they otherwise would be, there may be a less active trading market for our securities and the trading prices of our securities may be more volatile. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Further, Section&#160;102(b)(1) of the JOBS Act exempts emerging growth companies from being required to comply with new or revised financial accounting standards until private companies (that is, those that have not had a Securities Act registration statement declared effective or do not have a class of securities registered under the Exchange Act) are required to comply with the new or revised financial accounting standards. The JOBS Act provides that a company can elect to opt out of the extended transition period and comply with the requirements that apply to <span style="white-space:nowrap">non-emerging</span> growth companies but any such an election to opt out is irrevocable. We have elected not to opt out of such extended transition period which means that when a standard is issued or revised and it has different application dates for public or private companies, we, as an emerging growth company, can adopt the new or revised standard at the time private companies adopt the new or revised standard. This may make comparison of our financial statements with another public company which is neither an emerging growth company nor an emerging growth company which has opted out of using the extended transition period difficult or impossible because of the potential differences in accounting standards used. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Additionally, we are a &#8220;smaller reporting company&#8221; as defined in Item 10(f)(1) of Regulation <span style="white-space:nowrap">S-K.</span> Smaller reporting companies may take advantage of certain reduced disclosure obligations, including, among other </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">53 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
things, providing only two years of audited financial statements. We will remain a smaller reporting company until the last day of the fiscal year in which (1)&#160;the market value of our common stock held by <span style="white-space:nowrap">non-affiliates</span> exceeds $250&#160;million as of the prior June 30th, or (2)&#160;our annual revenues exceeded $100&#160;million during such completed fiscal year and the market value of our common stock held by <span style="white-space:nowrap">non-affiliates</span> exceeds $700&#160;million as of the prior June 30th. To the extent we take advantage of such reduced disclosure obligations, it may also make comparison of our financial statements with other public companies difficult or impossible. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">If we are unable to maintain our listing on Nasdaq, it could become more difficult to sell our Class&#160;A common stock and Public Warrants in the public market. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our Class&#160;A common stock is listed on Nasdaq. To maintain our listing on this market, we must meet Nasdaq&#8217;s listing maintenance standards. On July&#160;20, 2022, Nasdaq suspended trading of our Class&#160;A common stock and Public Warrants for failure to meet certain initial listing requirements and indicated it intended to pursue delisting our Class&#160;A common stock and Public Warrants once all applicable appeal and review periods expired. On August&#160;25, 2022, Nasdaq approved our application to relist our Class&#160;A common stock and Public Warrants and we began trading on August&#160;29, 2022. If we are unable to continue to meet Nasdaq&#8217;s listing maintenance standards for any reason, our Class&#160;A common stock and Public Warrants could be delisted from Nasdaq. If delisted, we may seek to list our securities on a different stock exchange or, if one or more broker-dealer market makers comply with applicable requirements, the <span style="white-space:nowrap"><span style="white-space:nowrap">over-the-counter</span></span> (OTC) market. Listing on such other market or exchange could reduce the liquidity of our Class&#160;A common stock and Public Warrants. If our Class&#160;A common stock and Public Warrants were to trade in the OTC market, an investor would find it more difficult to dispose of, or to obtain accurate quotations for the price of, the Class&#160;A common stock. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A delisting from The Nasdaq Global Market and failure to obtain listing on another market or exchange would subject our Class&#160;A common stock and Public Warrants to <span style="white-space:nowrap">so-called</span> penny stock rules that impose additional sales practice and market-making requirements on broker-dealers who sell or make a market in such securities. Consequently, removal from Nasdaq and failure to obtain listing on another market or exchange could affect the ability or willingness of broker-dealers to sell or make a market in our Class&#160;A common stock and the ability of purchasers of our Class&#160;A common stock to sell their securities in the secondary market. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On March&#160;15, 2023, the closing price of our Class&#160;A common stock was $5.15 per share. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Future resales of Class&#160;A common stock may cause the market price of our securities to drop significantly, even if our business is doing well. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The <span style="white-space:nowrap">lock-up</span> restrictions agreed to in connection with the A&amp;R IRA have expired, except with respect to the Member Earnout Units, which <span style="white-space:nowrap">lock-up</span> restrictions will expire on such later date the Member Earnout Units are earned in accordance with the Business Combination Agreement. As such, each Retained Holdings Unit and corresponding share of Class&#160;V voting stock held by the Members (other than the Member Earnout Units) may be redeemed at any time, upon the exercise of such Members&#8217; Exchange Rights, in exchange for either one share of Class&#160;A common stock or, at the election of the Company in its capacity as the sole manager of Biote, the cash equivalent of the market value of one share of Class&#160;A common stock, pursuant to the terms and conditions of the Second Amended and Restated Operating Agreement of Biote (the &#8220;Holdings A&amp;R OA&#8221;). Assuming the full exercise of the Exchange Rights by all of the Members (including with respect to the Member Earnout Units), the Members would own approximately 83.9% of our Class&#160;A common stock, with two such members each beneficially owning 33.4% of our Class&#160;A common stock as of December&#160;31, 2022. Except with respect to the Member Earnout Units, the Members are no longer restricted from selling the shares of Class&#160;A common stock held by them following their exercise of Members&#8217; Exchange Rights, other than by applicable securities laws. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, the Sponsor is no longer restricted from transferring, selling, assigning or otherwise disposing of (a)&#160;its shares of Class&#160;A common stock (other than the Sponsor Earnout Shares, which may not be transferred, sold assigned or otherwise disposed of until the Sponsor Earnout Shares are earned) or (b)&#160;its Private Placement </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">54 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Warrants (as defined herein) (or the underlying shares of Class&#160;A common stock) issued pursuant to that certain Private Placement Warrants Purchase Agreement, dated March&#160;1, 2021, by and between the Company and the Sponsor. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Further we and each of our officers, directors and selling stockholders executed <span style="white-space:nowrap">lock-up</span> agreements in which they agreed not to offer, sell, agree to sell, directly or indirectly, or otherwise dispose of any shares of Class&#160;A common stock or any securities convertible into or exchangeable for shares of Class&#160;A common stock without the prior written consent of the underwriters for a period of 90 days after January&#160;6, 2023, subject to customary exceptions. We do not, however, expect to receive <span style="white-space:nowrap">lock-up</span> agreements from any other stockholders, including Dr.&#160;Gary Donovitz, who beneficially held 33.2% of shares of our common stock outstanding as of March&#160;15, 2023. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As such, sales of a substantial number of shares of Class&#160;A common stock in the public market could occur at any time. These sales, or the perception in the market that the holders of a large number of shares intend to sell shares, could cause the market price of our Class&#160;A common stock to decline or increase the volatility in the market price of our Class&#160;A common stock. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Risks Related to Ownership of Our Securities </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Because there are no current plans to pay cash dividends on our Class&#160;A common stock for the foreseeable future, you may not receive any return on investment unless you sell our Class&#160;A common stock for a price greater than that which you paid for it. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may retain future earnings, if any, for future operations, expansion and debt repayment and we have no current plans to pay any cash dividends for the foreseeable future. Any decision to declare and pay dividends as a public company in the future will be made at the discretion our Board and will depend on, among other things, our results of operations, financial condition, cash requirements, contractual restrictions and other factors that our Board may deem relevant. In addition, our ability to pay dividends may be limited by covenants of any existing and future outstanding indebtedness we or our subsidiaries incur. As a result, you may not receive any return on an investment in our Class&#160;A common stock unless you sell your shares of Class&#160;A common stock for a price greater than that which you paid for it. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">We may require additional capital to support business growth, and if capital is not available to us or is available only by diluting existing stockholders, our business, operating results and financial condition may suffer. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We require significant capital to continue to develop and grow our business, including with respect to the design, development, marketing, distribution and sale of the Biote Method and Biote-branded dietary supplements. We may need additional capital to pursue our business objectives and respond to business opportunities, challenges or unforeseen circumstances, and we cannot be certain that additional financing will be available, which could limit our ability to grow and jeopardize our ability to continue our business operations. We fund our capital needs primarily from available working capital; however, the timing of available working capital and capital funding needs may not always coincide, and the levels of working capital may not fully cover capital funding requirements. From time to time, we may need to supplement our working capital from operations with proceeds from financing activities. For instance, on July&#160;27, 2022, we entered into a standby equity purchase agreement (the &#8220;SEPA&#8221;) with Yorkville, whereby we have the right, but not the obligation, to sell to Yorkville up to 5,000,000 shares of our Class&#160;A common stock at our request, subject to terms and conditions specified in the SEPA. We expect to continue to opportunistically seek access to additional funds by utilizing the SEPA. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">To the extent that current and anticipated future sources of liquidity are insufficient to fund our future business activities and requirements, we may need to engage in equity or debt financings to secure additional </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">55 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
funds. If we raise additional funds through further issuances of equity or convertible debt securities, our existing stockholders could suffer significant dilution, and any new securities we issue could have rights, preferences and privileges superior to those of holders of our Class&#160;A common stock. The amount of dilution due to equity-based compensation of our employees and other additional issuances could be substantial. Additionally, any debt financing secured by us in the future could involve restrictive covenants relating to our capital raising activities and other financial and operational matters, which may make it more difficult for us to obtain additional capital and to pursue business opportunities. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Further, there can be no assurance that further deterioration in credit and financial markets and confidence in economic conditions will not occur. A severe or prolonged economic downturn could result in a variety of risks to our business, including weakened demand for any product candidates we may develop and our ability to raise additional capital when needed on acceptable terms, if at all. A weak or declining economy could also strain our suppliers, possibly resulting in supply disruption. If the equity and credit markets deteriorate, it may make any necessary debt or equity financing more difficult, more costly, and more dilutive. Failure to secure any necessary financing in a timely manner and on favorable terms could impair our ability to achieve our growth strategy, could harm our financial performance and stock price and could require us to delay or abandon our business plans. In addition, there is a risk that our current or future suppliers, service providers, manufacturers or other partners may not survive such difficult economic times, which could directly affect our ability to attain our operating goals on schedule and on budget. We cannot anticipate all of the ways in which the current economic climate and financial market conditions could adversely impact our business. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Anti-takeover provisions contained in the Charter and Bylaws, as well as provisions of Delaware law, could impair a takeover attempt. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Provisions in our Charter and Bylaws, as well as provisions under Delaware law, could make acquiring us more difficult, may limit attempts by stockholders to replace or remove our management, may limit stockholders&#8217; ability to obtain a favorable judicial forum for disputes with the us or our directors, officers, or employees, and may limit the market price of our Class&#160;A common stock. These provisions may make more difficult the removal of management and may discourage transactions that otherwise could involve payment of a premium over prevailing market prices for our securities. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Future sales, or the perception of future sales, by the Company or its stockholders in the public market, the issuance of rights to purchase the Company&#8217;s Class&#160;A common stock, including pursuant to the Incentive Plan and the ESPP, and future exercises of registration rights could result in the additional dilution of the percentage ownership of the Company&#8217;s stockholders and cause the market price for the Company&#8217;s Class&#160;A common stock to decline. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of March&#160;15, 2023, 70,320,563 shares (which includes 10,000,000 Earnout Voting Shares and 1,587,000 Sponsor Earnout Shares) of our common stock are outstanding, consisting of 19,707,997 shares of Class&#160;A common stock and 50,612,566 shares of Class&#160;V voting stock. Assuming the full exercise of the Exchange Rights by all of the Members (including with respect to the Member Earnout Units), and after giving effect to the secondary offering of shares of Class&#160;A common stock by certain stockholders pursuant to the registration statement on Form <span style="white-space:nowrap">S-1,</span> declared effective by the SEC on January&#160;4, 2023, the Members would have owned approximately 72.0% of our Class&#160;A common stock, with one such Member beneficially owning approximately 33.2% of our Class&#160;A common stock, as of March&#160;15, 2023. The Members are not restricted from selling the shares of Class&#160;A common stock held by them following their exercise of Members&#8217; Exchange Rights, other than by applicable securities laws. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, we have registered up to 16,651,347 shares of Class&#160;A common stock that we may issue under the Incentive Plan and the ESPP. We have registered 5,000,000 shares of Class&#160;A common stock for resale related to the SEPA with Yorkville, including 130,559 shares of Class&#160;A common stock issued and outstanding as of March&#160;15, 2023 and 4,869,441 shares of Class&#160;A common stock that may be issued pursuant to the SEPA in </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">56 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
the future. Once we issue these shares, they can be freely sold in the public market upon issuance, subject to volume limitations applicable to Affiliates. As a result, there may be a large number of shares of Class&#160;A common stock sold in the market. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The sale of shares of the Company&#8217;s Class&#160;A common stock, convertible securities or other securities in the public market, or the perception that such sales could occur, could harm the prevailing market price of shares of the Company&#8217;s Class&#160;A common stock. These sales, or the possibility that these sales may occur, also might make it more difficult for the Company to sell securities in the future at a time and at a price that it deems appropriate. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, if the Company sells shares of its Class&#160;A common stock, convertible securities or other securities, investors may be materially diluted by subsequent sales. Such sales may also result in material dilution to the Company&#8217;s existing stockholders, and new investors could gain rights, preferences, and privileges senior to the holders of the Company&#8217;s Class&#160;A common stock, including the Company&#8217;s Class&#160;A common stock issued in connection with the Business Combination. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the Incentive Plan, the Company is authorized to grant equity awards to its employees, directors and consultants. In addition, pursuant to the ESPP, the Company is authorized to sell shares to its employees. The Company initially reserved 15% of the shares of Class&#160;A common stock outstanding on a fully-diluted basis upon the Closing for future issuance under the Incentive Plan, plus 3,887,750 shares of Class&#160;A common stock necessary to satisfy payments to Phantom Equity Holders under the Phantom Equity Acknowledgments (such 3,887,750 shares of Class&#160;A common stock will not again become available for issuance under the Incentive Plan and will not be subject to the automatic annual increases described below). In addition, the Company initially reserved 1% of the shares of Class&#160;A common stock outstanding on a fully-diluted basis upon the Closing for future issuance under the ESPP. The Incentive Plan and ESPP provide for annual automatic increases in the number of shares reserved thereunder, beginning on January&#160;1, 2023. As a result of such annual increases, the Company&#8217;s stockholders may experience additional dilution, which could cause the price of the Company&#8217;s Class&#160;A common stock to fall. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the future, the Company may also issue its securities in connection with investments or acquisitions. The amount of shares of the Company&#8217;s Class&#160;A common stock issued in connection with an investment or acquisition could constitute a material portion of the Company&#8217;s then-outstanding shares of Class&#160;A common stock. Any issuance of additional securities in connection with investments or acquisitions may result in additional dilution to the Company&#8217;s stockholders. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">We may be subject to periodic claims and litigation, including the Donovitz Litigation (as defined below), that could result in unexpected expenses and could ultimately be resolved against us. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">From time to time, we may be involved in litigation and other proceedings, including matters related to product liability claims, stockholder class action and derivative claims, commercial disputes, copyright infringement, trademark challenges, and other intellectual property claims, as well as trade, regulatory, employment, and other claims related to our business. Any of these proceedings could result in significant settlement amounts, damages, fines, or other penalties, divert financial and management resources, and result in significant legal fees. An unfavorable outcome of any particular proceeding could exceed the limits of our insurance policies or the carriers may decline to fund such final settlements and/or judgments and could have an adverse impact on our business, financial condition, and results of operations. In addition, any proceeding could negatively impact our reputation among our practitioners and clinics and our brand image. The Company is currently involved in the Donovitz Litigation (See Item 3 Legal Proceedings). The outcome of the Donovitz Litigation, regardless of the merits, is inherently uncertain. At this point in time, the Company cannot predict the length of the Donovitz Litigation or the ultimate liability, if any, which may arise therefrom. In addition, litigation and related matters are costly and may divert the attention of the Company&#8217;s management and other resources that would otherwise be engaged in other activities. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">57 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Risks Related to our Organizational Structure </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Our only material asset is our ownership interest in Holdings, and accordingly we depend on distributions from Holdings to pay distributions, dividends on our Class&#160;A common stock, taxes and other expenses, and make any payments required to be made by us under the Tax Receivable Agreement (the &#8220;TRA&#8221;). </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are a holding company and have no material assets other than our ownership of the Holdings Units. We are not expected to have independent means of generating revenue or cash flow, and our ability to pay distributions, dividends on our Class&#160;A common stock, taxes and other expenses, and make any payments required to be made by us under the TRA will be dependent upon the financial results and cash flows of Holdings. The earnings from, or other available assets of, Holdings may not be sufficient to pay dividends or make distributions or loans to enable us to pay any dividends on our Class&#160;A common stock or satisfy our other financial obligations. There can be no assurance that Holdings will generate sufficient cash flow to distribute funds to us or that applicable state law and contractual restrictions, including negative covenants under debt instruments, will permit such distributions. If Holdings does not distribute sufficient funds to us to pay our taxes or other liabilities, we may default on contractual obligations or have to borrow additional funds. In the event that we are required to borrow additional funds it could adversely affect our liquidity and subject us to additional restrictions imposed by lenders. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Holdings will continue to be treated as a partnership for U.S. federal income tax purposes and, as such, generally will not be subject to any entity-level U.S. federal income tax. Instead, taxable income or loss will be allocated, for U.S. federal income tax purposes, to the holders of Holdings Units, including us. Accordingly, we will be required to pay U.S. federal income taxes on our allocable share of the net taxable income of Holdings. Under the terms of the Holdings A&amp;R OA, Holdings is obligated to make tax distributions to holders of Holdings Units (including us) calculated at certain assumed rates. In addition to tax expenses, we also will incur expenses related to our operations, some of which expenses will be reimbursed by Holdings. We intend to cause Holdings to make ordinary distributions and tax distributions to the holders of Holdings Units on a pro rata basis in amounts sufficient to cover all applicable taxes, relevant operating expenses (to the extent not already payable or reimbursable by Holdings pursuant to the Holdings A&amp;R OA), payments under the TRA and dividends, if any, declared by us. However, as discussed herein, Holdings&#8217; ability to make such distributions may be subject to various limitations and restrictions, including, but not limited to, retention of amounts necessary to satisfy the obligations of the Company and its subsidiaries (the &#8220;BioTE Companies&#8221;) and restrictions on distributions that would violate any applicable restrictions contained in Holdings&#8217; debt agreements, or any applicable law, or that would have the effect of rendering Holdings insolvent. To the extent we are unable to make payments under the TRA for any reason, such payments will be deferred and will accrue interest until paid, provided, however, that nonpayment for a specified period and/or under certain circumstances may constitute a material breach of a material obligation under the TRA and therefore accelerate payments under the TRA, which could be substantial. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Additionally, although Holdings generally will not be subject to any entity-level U.S. federal income tax, it may be liable under certain U.S. federal income tax legislation for any adjustments to its tax return, absent an election to the contrary. In the event Holdings&#8217; calculations of taxable income are incorrect, Holdings and/or its Members, including us, in later years may be subject to material liabilities pursuant to this U.S. federal income tax legislation and its related guidance. We anticipate that the distributions we receive from Holdings may, in certain periods, exceed our actual liabilities and our obligations to make payments under the TRA. The Board, in its sole discretion, will make any determination from time to time with respect to the use of any such excess cash so accumulated, which may include, among other uses, to pay dividends on our Class&#160;A common stock. We will have no obligation to distribute such cash (or other available cash other than any declared dividend) to our public stockholders. We may, if necessary, undertake ameliorative actions, which may include pro rata or <span style="white-space:nowrap">non-pro</span> rata reclassifications, combinations, subdivisions or adjustments of outstanding Holdings Units, to maintain <span style="white-space:nowrap"><span style="white-space:nowrap">one-for-one</span></span> parity between Holdings Units held by us and shares of our Class&#160;A common stock. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">58 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Pursuant to the TRA, we will be required to pay to the Members 85% of the net income tax savings that we realize as a result of increases in tax basis of the BioTE Companies&#8217; assets resulting from the Business Combination and the redemptions of the Retained Holdings Units in exchange for shares of Class&#160;A common stock (or cash) pursuant to the Holdings A&amp;R OA and tax benefits related to the TRA, including tax benefits attributable to payments under the TRA, and those payments may be substantial. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In connection with the Business Combination, the Selling Member will be deemed for U.S. federal (and applicable state and local) income tax purposes to have sold Holdings Units to the Company for the Cash Consideration and rights under the TRA (the &#8220;Purchase&#8221;) and the Members may in the future have their Holdings Units (including the Earnout Units, if any, that have vested in accordance with the Business Combination Agreement), together with the cancelation of an equal number of shares of Class&#160;V voting stock, redeemed in exchange for shares of our Class&#160;A common stock (or cash) pursuant to the Holdings A&amp;R OA, subject to certain conditions and transfer restrictions as set forth therein and in the A&amp;R IRA. These sales and exchanges are expected to result in increases in our allocable share of the tax basis of the tangible and intangible assets of the BioTE Companies. These increases in tax basis may increase (for income tax purposes) depreciation and amortization deductions allocable to us and therefore reduce the amount of income or franchise tax that we would otherwise be required to pay in the future had such sales and exchanges never occurred, although the U.S. Internal Revenue Service (the &#8220;IRS&#8221;) or any applicable foreign, state or local tax authority may challenge all or part of that tax basis increase, and a court could sustain such a challenge. We have entered into the TRA, which generally provides for the payment by us of 85% of certain net tax benefits, if any, that we realize (or in certain cases are deemed to realize) as a result of these increases in tax basis and tax benefits related to the transactions contemplated under the Business Combination Agreement and the redemption of Retained Holdings Units in exchange for Class&#160;A common stock (or cash) pursuant to the Holdings A&amp;R OA and tax benefits attributable to payments under the TRA. These payments are our obligation and are not an obligation of the BioTE Companies. The actual increase in our allocable share of tax basis in the BioTE Companies&#8217; assets, as well as the amount and timing of any payments under the TRA, will vary depending upon a number of factors, including the timing of exchanges, the market price of the Class&#160;A common stock at the time of the exchange and the amount and timing of the recognition of our income. While many of the factors that will determine the amount of payments that we will make under the TRA are outside of our control, we expect that the payments we will make under the TRA will be substantial and could have a material adverse effect on our financial condition. Any payments we make under the TRA generally will reduce the amount of overall cash flow that might have otherwise been available to us. To the extent that we are unable to make timely payments under the TRA for any reason, the unpaid amounts will be deferred and will accrue interest until paid; however, nonpayment for a specified period and/or under certain circumstances may constitute a material breach of a material obligation under the TRA and therefore accelerate payments due under the TRA, as further described below. Furthermore, our future obligation to make payments under the TRA could make us a less attractive target for an acquisition, particularly in the case of an acquirer that cannot use some or all of the tax benefits that may be deemed realized under the TRA. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">In certain cases, payments under the TRA may exceed the actual tax benefits we realize. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Payments under the TRA will be based on the tax reporting positions that we determine, and the IRS or another taxing authority may challenge all or any part of the tax basis increases, as well as other tax positions that we take, and a court may sustain such a challenge. In the event that any tax benefits initially claimed by us are disallowed, the Members will not be required to reimburse us for any excess payments that may previously have been made under the TRA, for example, due to adjustments resulting from examinations by the IRS or other taxing authorities. Rather, excess payments made to Members will be applied against and reduce any future cash payments otherwise required to be made to such Members, if any, after the determination of such excess. However, a challenge to any tax benefits initially claimed by us may not arise for a number of years following the initial time of such payment and, even if challenged earlier, such excess cash payment may be greater than the amount of future cash payments that we might otherwise be required to make under the terms of the TRA and, as a result, there might not be future cash payments against which such excess can be applied. As a result, in certain circumstances we could make payments under the TRA in excess of our actual income or franchise tax savings, which could materially impair our financial condition. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">59 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">In certain cases, payments under the TRA may be accelerated or significantly exceed the actual benefits we realize in respect of the tax attributes subject to the TRA. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The TRA provides that, in the event that (i)&#160;we exercise our early termination rights under the TRA, (ii)&#160;certain changes of control occur (as described in the TRA), (iii) we, in certain circumstances, fail to make a payment required to be made pursuant to the TRA by the applicable final payment date, which <span style="white-space:nowrap">non-payment</span> continues for 30 days following such final payment date or (iv)&#160;we materially breach any of our material obligations under the TRA, which breach continues without cure for 30 days following receipt by us of written notice thereof (unless, in the case of clauses (iii)&#160;and (iv), certain liquidity exceptions apply) our obligations under the TRA will accelerate and we will be required to make a <span style="white-space:nowrap">lump-sum</span> cash payment to the applicable parties to the TRA equal to the present value of all forecasted future payments that would have otherwise been made under the TRA, which <span style="white-space:nowrap">lump-sum</span> payment would be based on certain assumptions, including those relating to our future taxable income. The change of control payment to the Members could be substantial and could exceed the actual tax benefits that we receive as a result of acquiring Holdings Units from the Members because the amounts of such payments would be calculated assuming that we would have been able to use the potential tax benefits each year for the remainder of the amortization periods applicable to the basis increases, and that tax rates applicable to us would be the same as they were in the year of the termination. Decisions made in the course of running our business, such as with respect to mergers, asset sales, other forms of business combinations or other changes in control, may influence the timing and amount of payments that are received by the holders of Retained Holdings Units under the TRA. For example, the earlier disposition of assets following an exchange or acquisition transaction will generally accelerate payments under the TRA and increase the present value of such payments, and the disposition of assets before an exchange or acquisition transaction will increase an existing owner&#8217;s tax liability without giving rise to any rights of holders of Retained Holdings Units to receive payments under the TRA. There may be a material negative effect on our liquidity if the payments under the TRA exceed the actual income or franchise tax savings that we realize in respect of the tax attributes subject to the TRA or if distributions to us by Holdings are not sufficient to permit us to make payments under the TRA after we have paid taxes and other expenses. Furthermore, our obligations to make payments under the TRA could make us a less attractive target for an acquisition, particularly in the case of an acquirer that cannot use some or all of the tax benefits that are deemed realized under the TRA. We may need to incur additional indebtedness to finance payments under the TRA to the extent our cash resources are insufficient to meet our obligations under the TRA as a result of timing discrepancies or otherwise which may have a material adverse effect on our financial condition. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">We may not be able to realize all or a portion of the tax benefits that are expected to result from the acquisition of Retained Holdings Units from Biote Members. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the TRA, we will share tax savings resulting from (A)&#160;the amortization of the anticipated <span style="white-space:nowrap">step-up</span> in tax basis in the BioTE Companies&#8217; assets as a result of (i)&#160;the Purchase and (ii)&#160;the redemption of Retained Holdings Units in exchange for shares of Class&#160;A common stock or cash pursuant to the Holdings A&amp;R OA and (B)&#160;certain other related transactions with the Members. The amount of any such tax savings attributable to the Purchase and future exchanges will be paid 85% to the applicable Members and retained 15% by us. Any such amounts payable will only be due once the relevant tax savings have been realized by us, unless our obligations under the TRA are accelerated. Our ability to realize, and benefit from, these tax savings depends on a number of assumptions, including that we will earn sufficient taxable income each year during the period over which the deductions arising from any such basis increases and payments are available and that there are no adverse changes in applicable law or regulations. If our actual taxable income were insufficient to fully utilize such tax benefits or there were adverse changes in applicable law or regulations, we may be unable to realize all or a portion of these expected benefits and our cash flows and stockholders&#8217; equity could be negatively affected. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">60 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Risks Related to Taxes </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Taxing authorities may successfully assert that we should have collected or in the future should collect sales and use, gross receipts, value added or similar taxes and may successfully impose additional obligations on us, and any such assessments or obligations could adversely affect our business, financial condition and results of operations. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The application of indirect taxes, such as sales and use tax, value-added tax, goods and services tax, business tax and gross receipts tax, to platform businesses is a complex and evolving issue. Many of the fundamental statutes and regulations that impose these taxes were established before the adoption and growth of the Internet and <span style="white-space:nowrap">e-commerce.</span> Significant judgment is required on an ongoing basis to evaluate applicable tax obligations and, as a result, amounts recorded are estimates and are subject to adjustments. In many cases, the ultimate tax determination is uncertain because it is not clear how new and existing statutes might apply to our business. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may face various indirect tax audits in various U.S. jurisdictions. In certain jurisdictions, we collect and remit indirect taxes. However, tax authorities may raise questions about or challenge or disagree with our calculation, reporting or collection of taxes and may require us to collect taxes in jurisdictions in which we do not currently do so or to remit additional taxes and interest, and could impose associated penalties and fees. For example, after the U.S. Supreme Court decision in South Dakota v. Wayfair Inc., certain states have adopted, or started to enforce, laws that may require the calculation, collection and remittance of taxes on sales in their jurisdictions, even if we do not have a physical presence in such jurisdictions. A successful assertion by one or more tax authorities requiring us to collect taxes in jurisdictions in which we do not currently do so or to collect additional taxes in a jurisdiction in which we currently collect taxes, could result in substantial tax liabilities, including taxes on past sales, as well as penalties and interest, could harm our business, financial condition and results of operations. Although we have reserved for potential payments of possible past tax liabilities in our financial statements, if these liabilities exceed such reserves, our financial condition will be harmed. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As a result of these and other factors, the ultimate amount of tax obligations owed may differ from the amounts recorded in our financial statements and any such difference may adversely impact our results of operations in future periods in which we change our estimates of our tax obligations or in which the ultimate tax outcome is determined. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Unanticipated changes in effective tax rates or adverse outcomes resulting from examination of our income or other tax returns could adversely affect our financial condition and results of operations. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are subject to income taxes in the United States, and our domestic tax liabilities are subject to the allocation of expenses in differing jurisdictions. Our future effective tax rates could be subject to volatility or adversely affected by a number of factors, including: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">changes in the valuation of our deferred tax assets and liabilities; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">expected timing and amount of the release of any tax valuation allowances; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">tax effects of stock-based compensation; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">costs related to intercompany restructurings; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">changes in tax laws, regulations or interpretations thereof; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">lower than anticipated future earnings in jurisdictions where we have lower statutory tax rates and higher than anticipated future earnings in jurisdictions where we have higher statutory tax rates. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, we may be subject to audits of our income, sales and other transaction taxes by U.S. federal and state authorities. Outcomes from these audits could adversely affect our financial condition and results of operations. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">61 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Increases in our income tax rates, changes in income tax laws or disagreements with tax authorities may adversely affect our business, financial condition or results of operations. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Increases in our income tax rates or other changes in income tax laws in the United States or any jurisdiction in which we operate could reduce our <span style="white-space:nowrap">after-tax</span> income and adversely affect our business, financial condition or results of operations. Existing tax laws in the United States have been, and in the future could be, subject to significant change. For example, the Inflation Reduction Act of 2022 was recently enacted, which includes a one percent excise tax on share buybacks imposed on the corporation repurchasing such stock, effective for tax years beginning after 2022. Future regulatory guidance from taxing authorities or other executive or Congressional actions in the United States or other jurisdictions may be forthcoming. These or other changes in the relevant tax regimes, including changes in how existing tax laws are interpreted or enforced, may adversely affect our business, financial condition or results of operations. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We also will be subject to regular reviews, examinations and audits by the IRS and other taxing authorities with respect to income and <span style="white-space:nowrap">non-income-based</span> taxes. Economic and political pressures to increase tax revenues in jurisdictions in which we operate, or the adoption of new or reformed tax legislation or regulation, may make resolving tax disputes more difficult and the final resolution of tax audits and any related litigation can differ from our historical provisions and accruals, resulting in an adverse impact on our business, financial condition or results of operations. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">62 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center" id="toc479690_6">COMMITTED EQUITY FINANCING </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On July&#160;27, 2022, we entered into the Purchase Agreement, with Yorkville. Pursuant to the Purchase Agreement, we have the right to sell to Yorkville up to 5,000,000 shares of our Class&#160;A common stock, subject to certain limitations and conditions set forth in the Purchase Agreement, from time to time during the term of the Purchase Agreement. Sales of Class&#160;A common stock to Yorkville under the Purchase Agreement, and the timing of any such sales, are at our option, and we are under no obligation to sell any securities to Yorkville under the Purchase Agreement. In accordance with our obligations under the Purchase Agreement, we have filed the registration statement that includes this prospectus with the SEC to register under the Securities Act the resale by Yorkville of up to 5,000,000 shares of Class&#160;A common stock, consisting of 25,000 shares of Class&#160;A common stock that we issued to Yorkville in consideration of its commitment to purchase shares of Class&#160;A common stock at our election under to the Purchase Agreement, and up to 4,975,000 shares of Class&#160;A common stock that we may elect, in our sole discretion, to issue and sell to Yorkville, from time to time under the Purchase Agreement. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Upon the satisfaction of the conditions to Yorkville&#8217;s purchase obligation set forth in the Purchase Agreement, including that the registration statement of which this prospectus forms a part be declared effective by the SEC and the final form of this prospectus is filed with the SEC, we will have the right, but not the obligation, from time to time at our discretion until the first day of the month following the <span style="white-space:nowrap">36-month</span> period after the date of the Purchase Agreement, to direct Yorkville to purchase an Advance by delivering an Advance Notice. While there is no mandatory minimum amount for any Advance, it may not exceed the greater of (i)&#160;an amount equal to thirty percent (30%) of the Daily Volume Traded on the trading day immediately preceding an Advance Notice, or (ii) 1,000,000 shares of Class&#160;A common stock. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The per share purchase price for the shares of Class&#160;A common stock, if any, that we elect to sell to the Selling Securityholder in an Advance pursuant to the Purchase Agreement will be determined by reference to the VWAP and calculated in accordance with the Purchase Agreement, less a variable discount of 3%, provided however that the Company may establish a minimum acceptable price in each Advance Notice below which it shall not be obligated to make any sales to the Selling Securityholder. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">There is no upper limit on the price per share that Yorkville could be obligated to pay for the Class&#160;A common stock we may elect to sell to it in any Advance. The purchase price per share of Class&#160;A common stock that we may elect to sell to Yorkville in an Advance under the Purchase Agreement will be equitably adjusted for any reorganization, recapitalization, <span style="white-space:nowrap">non-cash</span> dividend, stock split, reverse stock split or other similar transaction. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We will control the timing and amount of any sales of Class&#160;A common stock to Yorkville. Actual sales of shares of our Class&#160;A common stock to Yorkville under the Purchase Agreement will depend on a variety of factors to be determined by us from time to time, which may include, among other things, market conditions, the trading price of our Class&#160;A common stock and determinations by us as to the appropriate sources of funding for our business and its operations. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may not issue or sell any shares of Class&#160;A common stock to Yorkville under the Purchase Agreement which, when aggregated with all other shares of Class&#160;A common stock then beneficially owned by Yorkville and its Affiliates (as calculated pursuant to Section&#160;13(d) of the Exchange Act, and Rule <span style="white-space:nowrap">13d-3</span> promulgated thereunder), would result in Yorkville beneficially owning more than the Beneficial Ownership Limitation. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The net proceeds under the Purchase Agreement to us will depend on the frequency and prices at which we sell shares of our stock to Yorkville. We expect that any proceeds received by us from such sales to Yorkville will be used for working capital and general corporate purposes. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Yorkville has agreed that it and its Affiliates will not engage in any short sales of the Class&#160;A common stock nor enter into any transaction that establishes a net short position in the Class&#160;A common stock during the term of the Purchase Agreement. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">63 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Purchase Agreement will automatically terminate on the earliest to occur of (i)&#160;the first day of the month next following the <span style="white-space:nowrap">36-month</span> anniversary of the date of the Purchase Agreement or (ii)&#160;the date on which the Selling Securityholder shall have purchased from us under the Purchase Agreement 5,000,000 shares of our Class&#160;A common stock. We have the right to terminate the Purchase Agreement at no cost or penalty upon five (5)&#160;trading days&#8217; prior written notice to Yorkville, provided that there are no outstanding Advance Notices and all outstanding amounts owed to Yorkville are repaid. We and Yorkville may also agree to terminate the Purchase Agreement by mutual written consent. Neither we nor Yorkville may assign or transfer our respective rights and obligations under the Purchase Agreement, and no provision of the Purchase Agreement may be modified or waived by us or Yorkville other than by an instrument in writing signed by both parties. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As consideration for Yorkville&#8217;s commitment to purchase shares of Class&#160;A common stock at our direction upon the terms and subject to the conditions set forth in the Purchase Agreement, upon execution of the Purchase Agreement, we issued 25,000 shares of Class&#160;A common stock to Yorkville. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Purchase Agreement contains customary representations, warranties, conditions and indemnification obligations of the parties. The representations, warranties and covenants contained in such agreements were made only for purposes of such agreements and as of specific dates, were solely for the benefit of the parties to such agreements and may be subject to limitations agreed upon by the contracting parties. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Advances of Class&#160;A common stock Under the Purchase Agreement </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Advances </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We will have the right, but not the obligation, from time to time at our discretion, until the first day of the month following the <span style="white-space:nowrap">36-month</span> period after the date of the Purchase Agreement, to direct Yorkville to purchase up to a specified maximum amount of shares of Class&#160;A common stock as set forth in the Purchase Agreement by delivering an Advance Notice an Advance Notice Date, so long as the amount under any single Advance does not exceed the greater of (i)&#160;an amount equal to thirty percent (30%) of the Daily Volume Traded on the trading day immediately preceding an Advance Notice, or (ii) 1,000,000 shares of Class&#160;A common stock. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Conditions to Each Advance </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Selling Securityholder&#8217;s obligation to accept Advance Notices that are timely delivered by us under the Purchase Agreement and to purchase shares of our Class&#160;A common stock in Advances under the Purchase Agreement, are subject to the satisfaction, at the applicable Advance Notice Date, of the conditions precedent thereto set forth in the Purchase Agreement, all of which are entirely outside of the Selling Securityholder&#8217;s control, which conditions include the following: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the accuracy in all material respects of the representations and warranties of the Company included in the Purchase Agreement; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the Company having performed, satisfied and complied in all material respects with all covenants, agreements and conditions required by the Purchase Agreement to be performed, satisfied or complied with by the Company; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the registration statement that includes this prospectus (and any one or more additional registration statements filed with the SEC that include shares of Class&#160;A common stock that may be issued and sold by the Company to the Selling Securityholder under the Purchase Agreement) having been declared effective under the Securities Act by the SEC, and the Selling Securityholder being able to utilize this prospectus (and any other prospectus included in any one or more additional registration statements filed with the SEC) to resell all of the shares of Class&#160;A common stock issuable pursuant to such Advance Notice (and included in any such additional prospectuses); </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the SEC shall not have issued any stop order suspending the effectiveness of the registration statement that includes this prospectus (or any one or more additional registration statements filed with the SEC </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">64 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:9%">&#160;</td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">
that include shares of Class&#160;A common stock that may be issued and sold by the Company to the Selling Securityholder under the Purchase Agreement) or prohibiting or suspending the use of this prospectus (or any other prospectus included in any one or more additional registration statements filed with the SEC), and the absence of any suspension of qualification or exemption from qualification of the Class&#160;A common stock for offering or sale in any jurisdiction; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">all reports, notices and other documents required to have been filed by the Company with the SEC during the preceding twelve-month period pursuant to the reporting requirements of the Exchange Act shall have been timely filed; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">trading in the Class&#160;A common stock shall not have been suspended by the SEC or Nasdaq (or, in the case of an Advance Notice, the Principal Market, as such term is defined in the Purchase Agreement), the Company shall not have received any final and <span style="white-space:nowrap">non-appealable</span> notice threatening the continued quotation of the Class&#160;A common stock, except as disclosed in any documents filed with the SEC prior to the date of this prospectus; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the Company shall have materially complied with all applicable federal, state and local governmental laws, rules, regulations and ordinances in connection with the execution, delivery and performance of the Purchase Agreement; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">all of the shares of Class&#160;A common stock that may be issued pursuant to the Advance Notice shall have been approved for listing or quotation on Nasdaq (or, in the case of an Advance Notice, the Principal Market), subject only to notice of issuance; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">no condition, occurrence, state of facts or event constituting a Material Outside Event (as such term is defined in the Purchase Agreement) shall have occurred and be continuing; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the receipt by the Selling Securityholder of the legal opinion as required under the Purchase Agreement. </p></td></tr></table> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Termination of the Purchase Agreement </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Unless earlier terminated as provided in the Purchase Agreement, the Purchase Agreement will terminate automatically on the earliest to occur of: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the first day of the month next following the <span style="white-space:nowrap">36-month</span> anniversary of the date of the Purchase Agreement; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the date on which the Selling Securityholder shall have purchased 5,000,000 shares of Class&#160;A common stock under the Purchase Agreement; </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We also have the right to terminate the Purchase Agreement at any time, at no cost or penalty, upon five&#160;(5)&#160;trading days&#8217; prior written notice to the Selling Securityholder, provided that there are no outstanding Advance Notices under which we are yet to issue Class&#160;A common stock. We and the Selling Securityholder may also terminate the Purchase Agreement at any time by mutual written consent. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">No Short-Selling by the Selling Securityholder </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Selling Securityholder has agreed that it and its Affiliates will not engage in any short sales during the term of the Purchase Agreement and will not enter into any transaction that establishes a net short position with respect to the Class&#160;A common stock. The Purchase Agreement stipulates that the Selling Securityholder may sell our Class&#160;A common stock to be issued pursuant to an Advance Notice, following receipt of the Advance Notice, but prior to receiving such shares and may sell other Class&#160;A common stock acquired pursuant to the Purchase Agreement that the Selling Securityholder has continuously held from a prior date of acquisition. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">65 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Effect of Sales of our Class&#160;A common stock under the Purchase Agreement on our Stockholders </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">All shares of Class&#160;A common stock that may be issued or sold by us to the Selling Securityholder under the Purchase Agreement that are being registered under the Securities Act for resale by the Selling Securityholder in this offering are expected to be freely tradable. The shares of Class&#160;A common stock being registered for resale in this offering may be issued and sold by us to the Selling Securityholder from time to time at our discretion over the term of the Purchase Agreement. The resale by the Selling Securityholder of a significant amount of shares registered for resale in this offering at any given time, or the perception that these sales may occur, could cause the market price of our Class&#160;A common stock to decline and to be highly volatile. Sales of our Class&#160;A common stock, if any, to the Selling Securityholder under the Purchase Agreement will depend upon market conditions and other factors to be determined by us. We may ultimately decide to sell to the Selling Securityholder all, some or none of the shares of our Class&#160;A common stock that may be available for us to sell to the Selling Securityholder pursuant to the Purchase Agreement. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If and when we do elect to sell shares of our Class&#160;A common stock to the Selling Securityholder pursuant to the Purchase Agreement, the Selling Securityholder may resell all, some or none of such shares in its discretion and at different prices subject to the terms of the Purchase Agreement. As a result, investors who purchase shares from the Selling Securityholder in this offering at different times will likely pay different prices for those shares, and so may experience different levels of dilution and in some cases substantial dilution and different outcomes in their investment results. Investors may experience a decline in the value of the shares they purchase from the Selling Securityholder in this offering as a result of future sales made by us to the Selling Securityholder at prices lower than the prices such investors paid for their shares in this offering. In addition, if we sell a substantial number of shares to the Selling Securityholder under the Purchase Agreement, or if investors expect that we will do so, the actual sales of shares or the mere existence of our arrangement with the Selling Securityholder may make it more difficult for us to sell equity or equity-related securities in the future at a desirable time and price. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Because the purchase price per share to be paid by the Selling Securityholder for the shares of Class&#160;A common stock that we may elect to sell to the Selling Securityholder under the Purchase Agreement, if any, will fluctuate based on the market prices of our Class&#160;A common stock during the applicable Pricing Period, as of the date of this prospectus we cannot reliably predict the number of shares of Class&#160;A common stock that we will sell to the Selling Securityholder under the Purchase Agreement, the actual purchase price per share to be paid by the Selling Securityholder for those shares, or the actual gross proceeds to be raised by us from those sales, if any. As of July&#160;28, 2022, there were 67,727,595 shares of common stock outstanding (excluding the Commitment Shares), consisting of 9,161,771 shares of our Class&#160;A common stock and 58,565,824 shares of our Class&#160;V voting stock, of which 9,515,519 shares of common stock were held by <span style="white-space:nowrap">non-affiliates,</span> consisting of 5,301,991 shares of our Class&#160;A common stock and 4,213,528 shares of our Class&#160;V voting stock. If all of the 5,000,000 shares offered by Yorkville for resale under the registration statement that includes this prospectus were issued and outstanding as of the date hereof (without taking into account the 4.99% Beneficial Ownership Limitation), such shares would represent approximately 6.9% of the total number of shares of our Common Stock outstanding and approximately 52.5% of the total number of outstanding shares held by <span style="white-space:nowrap">non-affiliates,</span> in each case as of July&#160;28, 2022. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The issuance, if any, of our Class&#160;A common stock to the Selling Securityholder pursuant to the Purchase Agreement would not affect the rights or privileges of our existing stockholders, except that the economic and voting interests of each of our existing stockholders would be diluted. Although the number of shares of our Class&#160;A common stock that our existing stockholders own would not decrease as a result of sales, if any, under the Purchase Agreement, the shares of our Class&#160;A common stock owned by our existing stockholders would represent a smaller percentage of our total outstanding shares of our Class&#160;A common stock after any such issuance. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">66 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center" id="toc479690_7">USE OF PROCEEDS </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">All of the shares of our Class&#160;A common stock offered by the Selling Securityholder pursuant to this prospectus will be sold by the Selling Securityholder for their respective accounts. We will not receive any of the direct proceeds from these sales. However, we expect to receive proceeds under the Purchase Agreement from sales of Class&#160;A common stock that we may elect to make to the Selling Securityholder pursuant to the Purchase Agreement, if any, from time to time in our discretion. See the section titled &#8220;Plan of Distribution&#8221; elsewhere in this prospectus for more information. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We expect to use any proceeds that we receive under the Purchase Agreement for working capital and general corporate purposes. As of the date of this prospectus, we cannot specify with certainty all of the particular uses, and the respective amounts we may allocate to those uses, for any net proceeds we receive. Accordingly, we will retain broad discretion over the use of these proceeds. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">67 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center" id="toc479690_8">MARKET INFORMATION FOR COMMON STOCK AND DIVIDEND POLICY </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Market Information </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Prior to the closing of our business combination, HYAC common stock, units and warrants were listed on Nasdaq under the symbols &#8220;HYAC,&#8221; &#8220;HYACU&#8221; and &#8220;HYACW,&#8221; respectively. On May&#160;27, 2022, our Class&#160;A common stock and public warrants began trading on Nasdaq under the symbols &#8220;BTMD&#8221; and &#8220;BTMDW,&#8221; respectively. We no longer have any outstanding units. As of March&#160;15, 2023, there were 19,707,997 shares of Class&#160;A common stock issued and outstanding and 50,612,566 shares of our Class&#160;V voting stock (the &#8220;Class&#160;V voting stock&#8221;) issued and outstanding. No market exists for the Class&#160;V voting stock. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Holders </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of March&#160;15, 2023, there were 43 holders of record of our Class&#160;A common stock, 9 holders of record of our Class&#160;V voting stock and 1 holder of record of our Public Warrants. The actual number of stockholders is greater than this number of record holders, and includes stockholders who are beneficial owners, but whose shares are held in street name by brokers and other nominees. This number of holders of record also does not include stockholders whose shares may be held in trust by other entities. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Dividend Policy </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have never declared or paid any cash dividends on our capital stock and do not anticipate paying any cash dividends in the foreseeable future. Payment of cash dividends, if any, in the future will be at the discretion of our board of directors and will depend on then-existing conditions, including our financial condition, operating results, contractual restrictions, capital requirements, business prospects and other factors our board of directors may deem relevant. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">68 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center" id="toc479690_9">BUSINESS </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Unless the context otherwise requires, all references in this section to &#8220;Biote&#8221; refer to Biote and its subsidiaries prior to the consummation of the Business Combination, or the Company from and after the Business Combination in the present tense. Biote&#8217;s business and the industry in which Biote operates is subject to a high degree of uncertainty and risk due to a variety of factors, including those described in the section titled &#8220;Risk Factors&#8221; and elsewhere in this prospectus. These and other factors could cause results to differ materially from those expressed in the estimates made by the independent parties and by Biote. </span></p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Overview </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We operate a high-growth practice-building business within the hormone optimization space. Similar to a franchise model, we provide the necessary components to enable Biote-certified practitioners to establish, build, and successfully implement a program designed to optimize hormone levels using personalized solutions for their patient populations. The Biote Method is a comprehensive, <span style="white-space:nowrap"><span style="white-space:nowrap">end-to-end</span></span> practice building platform that provides Biote-certified practitioners with the following components specifically developed for practitioners in the hormone optimization space: Biote Method education, training and certification, practice management software, inventory management software, and information regarding available HRT products, as well as digital and <span style="white-space:nowrap"><span style="white-space:nowrap">point-of-care</span></span> marketing support. We also sell a complementary Biote-branded line of dietary supplements. We generate revenues by charging the Biote-partnered clinics fees associated with the support Biote provides for HRT and from the sale of Biote-branded dietary supplements. By virtue of our historical performance over the 11&#160;years ended December&#160;31, 2022, we believe that our business model has been successful, remains differentiated, and is well positioned for future growth. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">By incorporating the Biote Method in their practices, we enable practitioners to participate in the large and growing hormone optimization space. Bioidentical hormone therapy, which is offered by Biote-certified practitioners, is one segment of the large HRT market. It is estimated that, as of 2020, the total U.S. market opportunity for HRT products, available in various forms, exceeds $7&#160;billion and is expected to grow 7% annually through 2026. We believe our business opportunity in providing educational and practice management services is large and will similarly grow. Growth in this field is expected to be fueled by &#8220;aging&#8221; demographics and expanding consumer demand for medical information and treatment options to address hormonal imbalances. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Patient symptoms associated with menopause in women and andropause in men, such as hot flashes, night sweats, depressed mood, low libido, weight gain, and issues with concentration and focus, while negatively impacting quality of life, may also be associated with higher risks for chronic diseases attributable to declining hormone levels, including cardiovascular disease, osteoporosis and breast cancer. Approximately 13.8&#160;million men over age 45 in the United States are affected by hypogonadism and only about 1.3&#160;million (9%) of those affected undergo testosterone treatment. An average of 27&#160;million women between the ages of 45 and 64, or 20% of the American workforce, experience menopause every year. Despite the prevalence of <span style="white-space:nowrap">symptoms-84%</span> of women report menopausal symptoms that interfere with their lives-only 58% have discussed menopause with a health provider, and only 28%, or approximately 13&#160;million, undergo HRT (and of that 28%, only 31%, or approximately 4&#160;million, undergo bioidentical HRT). By 2030, over 1.2&#160;billion women, 14% of the global population, will be in menopause or post-menopause. Yet, despite the growing number of women experiencing menopause, they remain an underserved population. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">One key driver of this unmet medical need is the lack of knowledge and experience of treating physicians. For many practitioners, the last time they received meaningful instruction on treating menopause and andropause was during medical school. Based on a 2018 article by Jennifer Wolff, entitled &#8220;What Doctors Don&#8217;t Know About Menopause,&#8221; among newer doctors surveyed in 2015, 80% of medical residents reported feeling &#8220;barely comfortable&#8221; discussing or treating menopause. While this knowledge gap applies to training, we believe it also applies to the understanding of treatment alternatives, access to new therapies, methods to drive efficiencies in a hormone optimization practice and finally, how to profitably treat this growing population. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">69 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">To capitalize on this large and underserved market opportunity, we developed a highly differentiated practice-building platform to enable practitioners to treat the hormone imbalance symptoms experienced by their patients. The Biote Method has been designed specifically for practitioners who focus on treating perimenopause in women; post-menopause in women; and andropause/hypogonadism in men. It is constructed to bridge the existing gaps which exist in education and treatment options, while improving the efficiency of practitioners&#8217; business operations and the hormone health of their aging patient base. Over the past 11 years, we have built our platform to provide highly differentiated education and training, practice support resources and inventory management tools that would be difficult for a practice to otherwise attain on their own. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We empower Biote-certified practitioners by requiring rigorous <span style="white-space:nowrap">in-person</span> training, testing and certification for all Biote-certified practitioners and office staff wishing to use the Biote Method in their practice. Our practitioner instructors are among the nation&#8217;s most experienced clinical experts in hormonal therapy, including multiple modalities of HRT such as creams, gels, patches, pills, injections and compounded bioidentical hormone pellets. We teach clinicians how to identify early indicators of hormone-related aging conditions, and we believe we are the top practitioner educators by virtue of our experience over 11 years, with over 3&#160;million hormone optimization procedures performed by Biote-certified practitioners to date, including approximately 300,000 active patients. We offer training centrally and regionally to provide consistent and ongoing technical education. On an ongoing basis, we provide access to <span style="white-space:nowrap"><span style="white-space:nowrap">around-the-clock</span></span> clinical and technical support for Biote-certified practitioners. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">To offer a turnkey platform, we leverage the data Biote-certified practitioners collect using our BioTracker software for regulatory and record management to seamlessly assess a simple procedure-based revenue model that encompasses fees for the education, training, <span style="white-space:nowrap">re-training,</span> comprehensive administrative services and support and pass-through cost of pellets that practitioners may choose to provide as part of the Biote Method. We believe our revenue model represents an objective method to assess fees across the varying size and sophistication of our Biote-certified practitioners and clinics beginning with the first day of training and continuing throughout the treatment of each practitioner&#8217;s patient. Additionally, this revenue model provides our Biote-certified practitioners with consistency and predictability, notwithstanding the variability in services required to support their practices during any given period. Our revenue model also offers efficiency and transparency for inventory management, as each procedure is electronically recorded through our technology platform without requiring additional workflow. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Biote Method&#8217;s proprietary CDS assists physicians in establishing individualized dosing for patients. Our BioTracker software and business tools allow practitioners to efficiently manage the record management, product acquisition, inventory logistics and the business end of a robust hormone optimization practice. We provide Biote-partnered clinics access to <span style="white-space:nowrap">FDA-registered</span> outsourcing facilities that can supply a wide array of hormone optimization products for Biote-certified practitioner patients. We provide information to Biote-certified practitioners regarding how to integrate with our BioTracker software. Our BioTracker software allows Biote-certified practitioners to manage orders and maintain accurate inventory records to keep their regulatory and business systems up to date. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Beyond the breadth and depth of our commercial and operational platform, the Biote name has achieved strong brand recognition among practitioners and patients in the communities we serve, as illustrated by QY Research&#8217;s market research publication entitled &#8220;South&#160;&amp; North America Hormone Replacement Therapy Market Insights and Forecast to 2026.&#8221; Practitioners undertaking the Biote Method can be confident that our exclusive training and practice building tools will prepare them to provide excellent and differentiated care to patients. This has led to high practitioner satisfaction and above 90% retention rate among Biote-certified practitioners. We are contracted with and provide comprehensive support to over 6,400 practitioners that have adopted the Biote Method in their practices. Leveraging our brand strength, we offer marketing assistance, including office signage and patient education materials, to every Biote-certified practitioner within our network. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We believe by virtue of their participation in our robust training and practice certification, Biote-certified practitioners are well informed on all aspects of hormone optimization. We believe our brand advantage with </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">70 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
both practitioners and patients is a key element of our commercial growth strategy, and an asset that we intend to leverage to expand our business. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Complementing the Biote Method is our expanding line of private-labeled dietary supplements to address hormone, vitamin, and physiological deficiencies that regularly manifest in an aging population. This business segment appeals to practitioners&#8217; patient demographic and enables patients the opportunity to receive practitioner-recommended Biote-branded dietary supplements to support healthy aging. By leveraging our existing Biote-certified practitioner base to sell and distribute our Biote-branded dietary supplements, we believe we have created an efficient and complementary business. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We also designed the Biote Method to permit beneficial practice economics for our Biote-partnered clinics. Our educational training and practice management platform helps enable Biote-partnered clinics to execute this <span style="white-space:nowrap">all-cash</span> model with minimal reimbursement risk. This contrasts to consistently decreasing reimbursement rates for most other treatments and therapies offered by physician offices. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have a track record of consistently achieving accelerated and highly profitable growth. Our four-year revenue CAGR from 2016-2020 was 22%. Our revenue was $165.0&#160;million and $139.4&#160;million for the years ended December&#160;31, 2022 and 2021, respectively. Net income was $1.3&#160;million and $32.6&#160;million for the years ended December&#160;31, 2022 and 2021, respectively. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">The Clinical Need to Treat Hormone Imbalance </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Biote-certified practitioners primarily focus their treatments on women experiencing symptoms due to hormonal imbalance before, during, and after menopause, and men experiencing symptoms of hypogonadism and male sex hormone deficiency. According to a 2015 study entitled &#8220;Use of Compounded Hormone Therapy in the United States: Report of The North American Menopause Society Survey,&#8221; by Margery L.S. Gass, Cynthia A. Stuenkel, Wulf H. Utian, Andrea LaCroix, James H. Liu and Jan L. Shifren, it is estimated that as many as 200&#160;million Americans are affected by hormonal imbalance and approximately 80% are untreated, according to a 2014 study entitled &#8220;Systematic Literature Review of the Epidemiology of Nongenetic Forms of Hypogonadism in Adult Males&#8221; by Victoria Zarotsky, et al. The corresponding treatment market for hormone replacement therapies is large and diverse, both in terms of the number of products, the number of suppliers, the type of administration and regulatory requirements for producing and distributing these products. Bioidentical optimization, which provides hormone supplementation that can be administered to patients just two or three times per year, is a highly differentiated segment of this market. Biote-certified practitioners perform about 80% of their hormone optimization procedures on female patients and approximately 20% of such procedures on male patients. As the U.S. population continues to age, we believe the number of patients seeking relief from the symptoms of hormone imbalance will continue to grow.<span style="font-weight:bold">)</span> </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Menopausal Symptoms Segment (Female) </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Approximately <span style="white-space:nowrap">40-50&#160;million</span> women in the U.S. will experience hot flashes, a symptom of menopause, according to a study entitled &#8220;Psychosocial and Socioeconomic Burden of Vasomotor Symptoms in Menopause: A Comprehensive Review&#8221; by Wulf H. Utian. Based on a study entitled &#8220;Change in Follicle- Stimulating and Estradiol Across the Menopausal Transition: Effect of Age at the Final Menstrual Period&#8221; by John F. Randolph, et al., Women experience a 67% reduction in estradiol between their <span style="white-space:nowrap">mid-40s</span> and <span style="white-space:nowrap">mid-50s.</span> Testosterone, a prevalent sex hormone in the female body also starts decreasing early, and by age 40, a woman has lost half of her testosterone production. Based on a 2018 article by Shelly Emling, entitled &#8220;Menopause Symptoms Can Last Decades,&#8221; this decline in hormone production and the resulting imbalance between estrogen and testosterone levels results in menopause symptoms that can continue for 10 years or more. According to a 1984 study, entitled </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">71 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
&#8220;The Effects of Subcutaneous Hormone Implants During Climacteric&#8221; by Linda Cardozo, et al., these menopause symptoms include, but are not limited to: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">


<tr>

<td style="width:51%"></td>

<td style="vertical-align:bottom;width:2%"></td>
<td style="width:47%"></td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style="margin-top:0pt; margin-bottom:0pt; margin-left:4.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#8226;&#8195;&#8202;Hot flashes</p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; margin-left:4.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#8226;&#8195;&#8202;Night sweats / excessive sweating</p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; margin-left:4.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#8226;&#8195;&#8202;Sleep disturbance</p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; margin-left:4.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#8226;&#8195;&#8202;Irritability / anxiety</p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; margin-left:4.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#8226;&#8195;&#8202;Depressed mood</p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:1pt; margin-left:4.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#8226;&#8195;&#8202;Brain fog</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"> <p style="margin-top:0pt; margin-bottom:0pt; margin-left:4.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#8226;&#8195;&#8202;Low libido</p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; margin-left:4.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#8226;&#8195;&#8202;Vaginal dryness</p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; margin-left:4.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#8226;&#8195;&#8202;Fatigue / exhaustion</p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; margin-left:4.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#8226;&#8195;&#8202;Joint / muscle ache</p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; margin-left:4.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#8226;&#8195;&#8202;Weight gain</p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:1pt; margin-left:4.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#8226;&#8195;&#8202;Decrease in bone density</p></td></tr>
</table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Beyond immediate symptoms, medical evidence exists linking untreated hormone imbalance with more serious health risks. A substantial collection of studies and analyses reported in the medical literature further illustrates the association between HRT and a deceased risk of heart disease, breast cancer, osteoporosis, and neurodegenerative diseases. For example, Dr.&#160;Rebecca&#160;L. Glaser, a prominent breast cancer surgeon, studied the incidence of breast cancer during 10 years of treating menopausal women with testosterone. In a study entitled &#8220;Incidence of Invasive Breast Cancer in Women Treated with Testosterone Implants: A Prospective <span style="white-space:nowrap">10-year</span> Cohort Study,&#8221; she concluded that testosterone was demonstrated to be associated with a 39% reduction in the incidence of invasive breast cancer compared to the <span style="white-space:nowrap">age-matched</span> SEER expected incidence. Additionally, a study entitled &#8220;Efficacy of Pharmacological Therapies for the Prevention of Fractures in Postmenopausal Women: A Network Meta-Analysis&#8221; by Patricia Barrionuevo, et al. published a systemic analysis of pharmacological therapies for prevention of fractures in postmenopausal women and concluded that estrogen with progesterone produces reductions in hip fractures, <span style="white-space:nowrap">non-vertebral</span> fractures and vertebral fractures. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Menopause treatment options involving hormones are most frequently comprised of estrogen, testosterone and/or progesterone. Hormones are available in a broad range of formulations administered as oral tablets, injectable, gels, creams, pellet implants and vaginal devices. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold"><span style="font-style:italic">Oral Estrogen +/- Progesterone formulations</span></span>-Routinely prescribed as estrogen tablets or estrogen plus progesterone tablets (depending on uterus status), parenteral and oral dosage forms are the most widely prescribed HRT products. Practitioners can choose to prescribe from a number of oral estrogens, with the most popular being estradiol, estrone, estropipate and conjugated estrogens. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold"><span style="font-style:italic">Testosterone Therapy</span></span>-The use of testosterone for the treatment of female menopause symptoms has been well established for more than 70 years, as evidenced by a 1949 study entitled &#8220;Indications for Hormonal Pellets in the Therapy of Endocrine and Gynecic Disorders&#8221; by Robert B. Greenblatt&#160;&amp; Susan R. Roland. Despite this scientific and clinical evidence, there is no <span style="white-space:nowrap">FDA-approved</span> testosterone<span style="font-weight:bold"><span style="font-style:italic"> </span></span>therapy for use in females. Practitioners desiring to use testosterone for their female patients need to choose between prescribing <span style="white-space:nowrap">off-label</span> use<span style="font-weight:bold"><span style="font-style:italic"> </span></span>of testosterone products approved exclusively for male use, or testosterone products custom-formulated and compounded by pharmacies for use in female patients which is consistent with the Biote Method. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The lack of testosterone products approved for women contrasts with the extensive peer-reviewed literature that consists of studies showing that testosterone levels drop in women with age, particularly in menopause, and that testosterone supplementation improves sexual health and addresses symptoms associated with menopause. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Cochrane Review analysis of trials addressing therapy targeting hypoactive female sexual desire disorder, and two meta-analyses published by Chiara Achilli, et al. and Rakibul M Islam, et al., entitled &#8220;Efficacy and Safety of Transdermal Testosterone in Postmenopausal Women with Hypoactive Sexual Desire Disorder: A Systematic Review and Meta-analysis&#8221; and &#8220;Safety and Efficacy of Testosterone for Women: A Systematic Review and Meta-analysis of Randomised Controlled Trial Data,&#8221; respectively, all concluded that testosterone therapy produces statistically significant improvement in multiple measures relating to menopausal women&#8217;s </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">72 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
sexual heath. In addition, preliminary studies, including &#8220;Mechanisms of Testosterone Deficiency-related Endothelial Dysfunction&#8221; by Alexios S. Antonopoulos&#160;&amp; Charalambos Antoniades, &#8220;Testosterone Therapy and Cardiovascular Risk: Advances and Controversies&#8221; by Abraham Morgentaler, et al. and &#8220;Breast Cancer Incidence Reduction in Women Treated with Subcutaneous Testosterone: Testosterone Therapy and Breast Cancer Incidence Study&#8221; by Dr.&#160;Gary&#160;S. Donovitz&#160;&amp; Mandy Cotton, report marked improvements in other menopausal symptoms and potential beneficial effects on cardiovascular risk, breast cancer risk, bone growth, depressed mood, and exhaustion. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Hypogonadism&#160;&amp; Sex Hormone Segment (Male) </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Male hypogonadism is a deficiency in testosterone. It is characterized by serum testosterone levels of less than 300 ng/dL in combination with at least one clinical sign or symptom, according to a 2010 study by Peeyush Kumar, et al., entitled &#8220;Male hypogonadism: Symptoms and Treatment.&#8221; In the period through their 20s, male testosterone levels are approximately 700 ng/dL or higher (in a range of <span style="white-space:nowrap">600-1300</span> ng/dL) as presented in a study entitled &#8220;Reference Ranges for Testosterone in Men Generated Using Liquid Chromatography Tandem Mass Spectrometry in a Community-Based Sample of Healthy Nonobese Young Men in the Framingham Heart Study and Applied to Three Geographically Distinct Cohorts&#8221; by Shalender Bhasin, et al. In men, testosterone levels decline <span style="white-space:nowrap">1-1.5%</span> per year after age thirty, according to &#8220;Age, disease, and changing sex hormone levels in middle-aged men: results of the Massachusetts Male Aging Study&#8221; by Anna Gray, Henry A Feldman, John B. McKinlay and Christopher Longcope. Multiple studies on hypogonadism, including &#8220;Age Trends in the Level of Serum Testosterone and Other Hormones in Middle-Aged Men: Longitudinal Results from the Massachusetts Male Aging Study&#8221; by Henry A. Feldman, et al. and &#8220;Prevalence of Hypogonadism in Males Aged at Least 45 years: The HIM Study&#8221; by Thomas Mulligan, et al., estimate the prevalence of low testosterone (total testosterone less than 300 ng/dL) is as high as 38.7% in males over 45. Not every male experiences testosterone decline at the same rate or to the same level, but over time, all males experience testosterone level decrease. Men experience a 44% average reduction in testosterone between ages 30 and 74, according to the Cleveland Clinic. Testosterone deficiency is a clinical syndrome that relates to a man&#8217;s symptoms and physical signs, not necessarily to the specific level detected in a blood test. There are many men suffering from testosterone deficiency who may not have laboratory values less than 300 ng/dL. The primary signs of low testosterone include: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">


<tr>

<td style="width:51%"></td>

<td style="vertical-align:bottom;width:2%"></td>
<td style="width:47%"></td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style="margin-top:0pt; margin-bottom:0pt; margin-left:4.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#8226;&#8195;&#8202;Decrease in libido</p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; margin-left:4.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#8226;&#8195;&#8202;Memory, focus and concentration issues</p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:1pt; margin-left:4.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#8226;&#8195;&#8202;Sarcopeia or muscle loss</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"> <p style="margin-top:0pt; margin-bottom:0pt; margin-left:4.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#8226;&#8195;&#8202;Decrease bone mineral density</p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:1pt; margin-left:4.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#8226;&#8195;&#8202;Erectile Dysfunction (ED)</p></td></tr>
</table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A 2019 study entitled &#8220;Testosterone Therapy in Men with Hypogonadism Prevents Progression from Prediabetes to Type 2 Diabetes: Eight-year Data from a Registry Study&#8221; published by Aksam Yassin, et al. supports the use of testosterone as a treatment for diabetes in hypogonadal men. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Hormone Imbalance: The Treatment Challenge </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Hormone imbalance symptoms experienced by aging men and women can be highly bothersome, and negatively impact quality of life. Current demographics indicate the number of adults experiencing menopause and andropause symptoms is large and expanding. Under the best of circumstances, the surge in people requiring medical care might overwhelm available resources. Adding to this situation, significant gaps exist that exacerbate the treatment challenge: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Practitioner education in the diagnosis and treatment of menopause and andropause symptoms is frequently dated, leaving them unprepared on how to best manage these patients with optimal and contemporary therapies. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">While extensive peer-reviewed literature extolling the benefits of testosterone therapy exists, <span style="white-space:nowrap">FDA-approved</span> medications exist for males only. </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">73 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">There is low awareness among both medical and public audiences of alternative hormone optimization therapies. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Given pressing workloads and declining reimbursements, physicians have little practical incentives to invest their time and resources (or that of their staff) in exploring new treatment modalities. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Taken together, we believe these factors have resulted in a medical system often <span style="white-space:nowrap">ill-prepared</span> to treat menopause and andropause and patients, particularly women, needlessly suffering its symptoms. We believe that the Biote Method is well designed to help partnered clinics overcome these challenges. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">What We Offer </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Biote Business Model/Solution </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have developed a comprehensive platform for Biote-certified practitioners to establish and operate a personalized hormone optimization program in their practices. Biote-certified practitioners seek to optimize imbalances in their patients&#8217; hormone, vitamin, and mineral levels and may prescribe bioidentical hormone therapies and/or recommend dietary supplements to accomplish this end. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We believe our competitive advantage lies in the breadth and completeness of our offering, which supports practices in pursuing excellence in all facets of patient care. We provide partnered clinics with <span style="white-space:nowrap"><span style="white-space:nowrap">up-to-date</span></span> scientific education delivered by highly experienced practitioner instructors. Our training content is based on a scientifically rigorous approach and is continually updated. We further provide Biote-certified practitioners with the clinical mentorship, practice support resources, inventory management tools and marketing capability necessary to operate an efficient hormone optimization practice. Biote-certified practitioners can access <span style="white-space:nowrap">FDA-registered</span> outsourcing facilities that can supply hormone optimization therapies should practitioners determine such treatment is appropriate for their patients. Further, our practice management software allows Biote-certified practitioners to efficiently order, track and manage hormone optimization product inventory, and meet other administrative requirements. Our BioTracker software is integrated with the outsourcing facilities&#8217; own software to facilitate ordering and inventory control. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Biote-certified practitioners who are trained in the Biote Method may prescribe bioidentical compounded hormone pellets prepared by independent third-party compounding pharmacies, known as outsourcing facilities, which are governed by Section&#160;503B of the FDCA. Section&#160;503B includes requirements regarding registration and reporting, use of bulk drug substances in compounding, a prohibition on compounding copies of <span style="white-space:nowrap">FDA-approved</span> drugs and wholesaling, and certain requirements for labeling, among others. Entities registering as outsourcing facilities are subject to current good manufacturing practices (&#8220;cGMP&#8221;) requirements and regular FDA inspections, among other requirements. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Drugs compounded by outsourcing facilities in compliance with Section&#160;503B are exempt from the new drug approval requirements of the FDCA and certain labeling requirements of the FDCA. This means that FDA does not review or verify the safety or effectiveness of compounded products distributed or dispensed by outsourcing facilities; rather Section&#160;503B of the FDCA establishes standards for manufacturing processes and controls applicable to outsourcing facilities as a means to ensure drug quality. Section&#160;503B outsourcing facilities are subject to FDA inspection and are inspected by FDA on a risk-based schedule. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Biote contracts with operators of certain <span style="white-space:nowrap">FDA-registered</span> 503B outsourcing facilities, namely AnazaoHealth Corporation, or AnazaoHealth, Right Value Drug Stores, LLC d/b/a Carie Boyd&#8217;s Prescription Shop, or Carie Boyd&#8217;s, and F.H. Investments, Inc. d/b/a Asteria Health. While Biote-certified practitioners have the option to use a variety of different outsourcing facilities, AnazaoHealth, Carie Boyd&#8217;s and Asteria Health are the primary outsourcing facilities for the compounded testosterone and estradiol implantable subcutaneous pellets used by Biote-certified practitioners as part of the Biote Method. It is Biote&#8217;s understanding that these 503B outsourcing facilities make these compounded drugs from bulk substances that comport with FDA&#8217;s final guidance on its </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">74 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
interim policy on bulk substances. However, we do not control or direct the compounding or manufacturing processes of these 503B outsourcing facilities. While Biote generates revenue by charging the Biote-partnered clinics procedure-based fees associated with the Biote-provided <span style="white-space:nowrap"><span style="white-space:nowrap">end-to-end</span></span> platform for running an efficient practice that includes tracking compounded products ordered from 503B outsourcing facilities, as well as other services, Biote does not receive compensation for the sale of bioidentical pellets from these 503B outsourcing facilities to Biote-certified practitioners. For more information about compounding facilities, please see the section entitled &#8220;Regulation of Compounded Drug Products.&#8221; </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our Biote-branded dietary supplements are a natural extension of our practice-building business and represent approximately 20% of our annual revenues. We sell dietary supplements that may support hormone, vitamin and physiological balances in an aging population. Our Biote-branded dietary supplements provide Biote-certified practitioners with an opportunity to further balance other important aspects of a patient&#8217;s profile and simultaneously increase practice revenue. Biote-partnered clinics directly purchase Biote-branded dietary supplements from us, and our third-party logistics (&#8220;3PL&#8221; suppliers fill and ship directly to the ordering practice. The Biote-partnered clinic then sets their own pricing in compliance with our applicable policies and sells Biote-branded dietary supplements directly to patients. We have leveraged out existing commercial infrastructure and relationships with Biote-certified practitioners to build our Biote-branded dietary supplement business. As a result, as of December 2022, approximately 93% of Biote-branded dietary supplements were sold through Biote-certified practitioners. Approximately 77% of our partnered clinics offer Biote-branded dietary supplements, for an average supplement volume per practice of approximately $11,500 as of 2022. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Hormone Therapy </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Biote Method is purpose built to enable Biote-certified practitioners to treat hormone imbalance using bioidentical estrogen and testosterone products as necessary. The term bioidentical refers to hormone formulations that match the hormones of the human body. Estradiol (the most active estrogen), progesterone and testosterone can be produced as bioidentical formulations. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">Estradiol </span>is FDA approved and commercially available under several different brand names. Examples include Vivelle Dot (patch), Estrogel, Elestrin, Evamist, Vagifem, Estring and FemRing. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">Testosterone </span>can be formulated for use by both women and men. However, <span style="white-space:nowrap">FDA-approved</span> testosterone products exist exclusively for males. Testopel is an example. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">Progesterone </span>is FDA approved, and available commercially as a capsule of micronized progesterone in peanut (or olive) oil. Progesterone is also available in patch and cream formulations. Prometrium is an example. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Hormones that are not bioidentical are commonly known as synthetic hormone formulations. Examples of synthetic hormones include conjugated equine estrogens, oral contraceptive pills, medroxyprogesterone (Provera) and methyltestosterone. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Biote Method is focused on promoting the use of bioidentical hormones to provide optimized clinical results using bioidentical estrogen, progesterone and testosterone rather than synthetic, chemically-modified versions of the hormone. The Biote Method encourages practitioners to begin each patient treatment with comprehensive lab testing, which includes checking testosterone, thyroid and vitamin levels. Patients complete symptom questionnaires to enable practitioners to appropriately gauge symptom scores. These questionnaires and lab results are evaluated by the practitioner, along with patient data such as age, weight, medical history and desired outcomes. The Biote software then can assist Biote-certified practitioners in developing patient-specific treatment options. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Biote-certified practitioners utilize a wide variety of hormone therapies. In addition to bioidentical hormone pellets, practitioners may also choose to administer hormone therapy to their patients via topical methods </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">75 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
(creams, gels, patches), oral methods (sublingual tablets, pills) or injections, depending on the practitioners&#8217; medical assessment of their patients&#8217; clinical needs. Creams, lotions and patches are prescribed on a per patient basis and obtained from pharmacies. If the physician chooses to utilize pellets, they generally administer the pellets that they obtain from 503B outsourcing facilities through &#8220;in office&#8221; procedures. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In a 2014 study published in the Journal of Sexual Medicine, pellet therapy was chosen by 17% of 382 male patients when presented with the choice of the following methods of hormone therapy: gels, injections and implantable subcutaneous pellets. Further, according to a 2013 study published in the same journal, of 113 men who underwent subcutaneous testosterone pellet therapy, 52.2% had switched to pellet therapy from topical gel therapy and 35.4% had switched from injection therapy. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">The Biote Difference </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">Biote training and certification program&#8212;</span>For many practitioners, medical school was the last time they received instruction in menopause, andropause and hormone deficiency. In fact, according to a 2018 article, in a survey of more than 1,000 medical professionals, only 57% reported being <span style="white-space:nowrap"><span style="white-space:nowrap">&#8220;up-to-date&#8221;</span></span> on information regarding HRT for menopause symptoms. Effectively managing hormone levels is an involved, complex and highly data-intensive process. We believe that contemporary medical training is a critical element of our platform and seek to bridge any gap in a practitioner&#8217;s experience and clinical education. To become a Biote-certified practitioner, we carefully vet healthcare providers to ensure they possess the necessary commitment, patient population and office staff needed to build a successful hormone optimization practice. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Prospective practitioners and their staff attend a <span style="white-space:nowrap">two-day</span> Biote Method training program. The training includes didactic lectures designed to educate practitioners on the latest science of HRT. The training program also includes <span style="white-space:nowrap">in-clinic</span> training during which practitioners gain experience performing hormone replacement procedures in a supervised setting. We also understand the importance of staff interaction in any patient experience and require each prospective Biote-partnered clinic&#8217;s office staff to attend training regarding the best practices for maintaining a hormone therapy practice. We believe that this comprehensive training program, as well as continuing education and mentoring, is critical to the successful establishment of new Biote-certified practitioners. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition to completing training, Biote-certified practitioners must: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Be in good standing with their respective state professional licensing board; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Successfully pass a post-training certification exam / requirements; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Utilize our BioTracker platform to comply with the U.S. Drug Enforcement Administration&#8217;s (the &#8220;DEA&#8221;) inventory control regulations for all scheduled drugs; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Use our proprietary technology, including training materials, therapy instruction and training videos to facilitate optimal therapy and patient outcomes. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">Biote training facilities</span><span style="font-weight:bold"></span><span style="font-weight:bold">&#160;&amp; faculty&#8212;</span>We operate one national and five regional training facilities for Biote-certified practitioners, healthcare providers and medical staff. The <span style="white-space:nowrap">10-person</span> practitioner clinical faculty and 15&#160;medical advisors provide <span style="white-space:nowrap">on-site</span> and virtual educational programs, seminars, training, refresher courses in hormone optimization, vitamin and Biote-branded dietary supplement guidance, and other topics. As of December 2022, over 6,400 providers in more than 3,600 clinics nationwide have successfully completed our rigorous curriculum and clinical training program. Upon completion, each Biote-certified practitioner is teamed with an experienced Biote-certified practitioner who is committed to providing mentorship and guidance, including with respect to regulatory compliance, education and new research updates. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">Biote BioTracker system&#8212;</span>We require Biote-partnered clinics to keep patient and inventory records, which was accomplished historically with manually-completed paper copies. To help our practitioners automate this </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">76 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
process, we offer as part of our platform the BioTracker system, which provides inventory management services to enable Biote-partnered clinics to comply with federal (DEA) and applicable state regulations for the hormones that Biote-certified practitioners may order from 503B outsourcing facilities. Our BioTracker software is integrated with the outsourcing facilities&#8217; software to facilitate ordering and inventory control. As each Biote-partnered clinic stores and dispenses these hormones, this software performs the critical function of monitoring and tracking the necessary detail regarding the administration of controlled substances. BioTracker also provides robust data analytics which allows the practitioner to effectively manage their processes and internal records. We also leverage this data to electronically transmit to us the number of hormone optimization pellet insertion procedures performed, affording us the most direct way to seamlessly assess a fair, transparent and consistent fee for our Biote Method, including the education, training, <span style="white-space:nowrap">re-training</span> and comprehensive services and support. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">Biote Clinical Decision Support software&#8212;</span>The CDS is part of our offerings available to Biote-certified practitioners. The CDS programs assist practitioners in identifying potential patient-specific treatment options and provides these practitioners with access to publications and guidelines that serve as independently verifiable bases for treatment recommendations. The practitioner enters a patient&#8217;s clinical markers into the program, and an algorithm based on the published literature with clinical data and clinical guidelines suggests potential individualized treatment option for the practitioner&#8217;s evaluation and consideration. While Biote-certified practitioners may consider the treatment options identified by the CDS, responsibility for treatment decisions remains solely with the practitioners in the exercise of their independent medical judgment. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">Biote-branded Dietary Supplements&#8212;</span>Our expanding Biote-branded dietary supplements business sells dietary supplements that may support hormone, vitamin and physiological balances in an aging population. We introduced our line of Biote-branded dietary supplements in 2013 with two specific dietary supplement products, DIM SGS+ and ADK 5. The line has since grown to include 19 dietary supplements, priced between $20.25 and $99. We offer wholesale sales directly to over 2,200 Biote-certified practitioners through our own eCommerce site, efficiently leveraging the core Biote provider platform. Practitioners then <span style="white-space:nowrap">re-sell</span> to their patients through online stores or <span style="white-space:nowrap">in-clinic.</span> As of December 2022, 77% of Biote-partnered clinics also offer our Biote-branded dietary supplement products. Biote-branded dietary supplement sales accounted for approximately 19.5% of our revenue in both 2022 and 2021. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In 2021, we launched a <span style="white-space:nowrap"><span style="white-space:nowrap">direct-to-patient</span></span> eCommerce platform whereby practitioners can invite their patients to buy Biote-branded dietary supplement products online via their own online store. Enhancements to the <span style="white-space:nowrap"><span style="white-space:nowrap">direct-to-patient</span></span> platform included a subscription service that launched in early 2022 for added convenience to patients, and to help drive reoccurring revenue for both us and Biote-partnered clinics. Our team plans to continue researching new formulations, product expansion opportunities and architecting an innovation pipeline that will offer solutions and revenue expansion for our practitioners and for Biote. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We believe that as awareness of our Biote brand name associated with our supplements continues to increase, so too will the incidence of our Biote-branded dietary supplements being sold in online stores. In the broader global dietary supplement market, by 2025, it is estimated that approximately 26% of sales will be generated through online markets, mirroring trends across global retail trade. We are preparing for this shift with the introduction of an online <span style="white-space:nowrap"><span style="white-space:nowrap">direct-to-patient</span></span> store in conjunction with expanding our digital marketing outreach. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Our Competitive Strengths </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We believe we are a leader in the practice-building market focused on the hormone optimization space as evidenced by our size as compared to competitors. We have designed the Biote Method to offer practitioners an <span style="white-space:nowrap"><span style="white-space:nowrap">end-to-end</span></span> platform to enable them to successfully establish and grow a profitable hormone therapy practice. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">Proprietary <span style="white-space:nowrap"><span style="white-space:nowrap">end-to-end</span></span> hormone optimization platform&#8212;</span>The Biote Method provides a comprehensive solution that quickly enables new clinics to effectively start and run an efficient bioidentical HRT practice. Our <span style="white-space:nowrap">two-day</span> mandatory, practitioner-paid training program educates the practitioner on clinical and back-office </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">77 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
aspects of treating patients. Biote&#8217;s CDS identifies treatment options while customized practice management and data software enable efficient workflow and inventory and vendor management. By virtue of the breadth and quality of the systems and services provided by the Biote Method, we believe our platform is differentiated within our industry and represents a competitive advantage. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">Accretive practice economics&#8212;</span>Our relationship with Biote-certified practitioners delivers positive practice economics. As of July 2021, Biote-partnered clinics generated average profits of approximately $100,000 per year from the hormone optimization space. In an environment of expanding patient needs due to an aging population and declining reimbursement for patient care related costs, extending quality of care while providing a profitable revenue stream are compelling contributors to practitioners joining the Biote network. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">Size compared to competition and brand awareness among practitioners&#8212;</span>With more than 3,600 clinics, 6,400 Biote-certified practitioners and 3&#160;million procedures performed to date, and over 400,000 active patients, we believe we are approximately 11 times larger than our nearest competitor. We believe that our patient education materials reinforce the commitment by our Biote-certified practitioners to be medically and technically well-prepared to effectively address patients&#8217; symptoms by providing individualized treatment to help patients &#8220;achieve their best self&#8221;. We believe that Biote-certified practitioners identify with the Biote brand because we provide a reliable education and business platform and enable them to build a profitable practice area. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">Complementary product lines augment growth&#8212;</span>In addition to our practice building business, our growth opportunities are also driven by our Biote-branded dietary supplement products. These Biote-branded dietary supplements support consumer health with differentiated formulations. Biote-branded dietary supplements are contract manufactured to approved specifications by a select group of experienced supplement manufacturers. These supplements are primarily sold by Biote-certified practitioners as well as on a <span style="white-space:nowrap"><span style="white-space:nowrap">direct-to-consumer</span></span> basis, extending their consumer appeal beyond the HRT patient base. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">Proven leadership team with expansive industry experience&#8212;</span>We have a highly experienced leadership team comprised of senior corporate leaders from within global healthcare and consumer markets. Our team has demonstrated skill in scaling our business model <span style="white-space:nowrap">to-date.</span> We believe we possess the skills and knowledge to complete our national expansion and capitalize on the growing category awareness. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Practitioner Growth, Sales, Brand and Marketing </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Clinic and Practitioner Growth </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of December 2022, we contract with over 6,400 Biote-certified practitioners in approximately 3,600 partnered clinics, and many Biote-certified practitioners are also patients. In 2022, we contracted with 740 new partnered clinics, bringing the total number of partnered clinics to 3,600. The 740 new partnered clinics account for 27% of our 2022 revenue growth. Since we started in 2012, our commercial footprint has expanded to 10 core states, which, as of December 2022, generated 64% of our revenue: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">


<tr>

<td style="width:51%"></td>

<td style="vertical-align:bottom;width:2%"></td>
<td style="width:47%"></td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style="margin-top:0pt; margin-bottom:0pt; margin-left:4.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#8226;&#8195;&#8202;Alabama</p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; margin-left:4.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#8226;&#8195;&#8202;Arkansas</p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; margin-left:4.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#8226;&#8195;&#8202;Colorado</p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; margin-left:4.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#8226;&#8195;&#8202;Florida</p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:1pt; margin-left:4.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#8226;&#8195;&#8202;Georgia</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"> <p style="margin-top:0pt; margin-bottom:0pt; margin-left:4.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#8226;&#8195;&#8202;Louisiana</p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; margin-left:4.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#8226;&#8195;&#8202;Mississippi</p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; margin-left:4.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#8226;&#8195;&#8202;New Mexico</p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; margin-left:4.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#8226;&#8195;&#8202;Oklahoma</p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:1pt; margin-left:4.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#8226;&#8195;&#8202;Texas</p></td></tr>
</table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We employ targeted methodologies that consider practice demographics and practitioner prescribing history to identify the best potential practitioners within each area of medical specialty and geography. We also utilize these analytics in determining optimal geographies for new sales territories. Although there are approximately </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">78 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
1.2&#160;million total providers in the United States, we target practitioners who are already prescribing alternative HRT patient care-related and having conversations with patients about hormone-related symptoms that impact patient health and wellbeing. This target set includes practitioners in OB/GYN, family and general practice, urology, and internal medicine. In our experience, patients most often seek out practitioners within these distinct specialties when experiencing menopause or andropause symptoms. In 2019, there were approximately 260,000 practitioners in the United States within our targeted specialties. Of this group, we currently target the top three deciles from the relevant specialties, which represents approximately 78,000 practitioners. Practitioners in these four specialties have appropriate patient demographics and have proven they can be developed into capable hormone optimization practices. Our own business experience confirms that more than half of our revenue in 2021 was generated from two provider specialties: family and general practice and OB/GYN. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We believe medical practitioners choose our company for three primary reasons: 1) our intensive, onsite and virtual education and training, and ongoing mentorship, is unique and highly valued; 2) our proprietary, <span style="white-space:nowrap"><span style="white-space:nowrap">end-to-end</span></span> business platform enables efficient practice <span style="white-space:nowrap">start-up</span> and management; and 3) through the Biote cash pay model, the average Biote-partnered clinic generates meaningful incremental, comparatively high margin profit to their legacy profitability. Our <span style="white-space:nowrap">all-cash,</span> minimal reimbursement model is cost-effective for patients across income levels while delivering strong profits to our partnered clinics. As of 2019, 50% of Biote-certified practitioners&#8217; patients had an annual household income of less than $100,000. We believe this demonstrates the affordability of the procedures and their accessibility to patients of varying income levels, and the scale of the addressable consumer market. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We derive the majority of our revenue through service fees that encompass the comprehensive platform and wraparound support we provide our Biote-partnered clinics. These service fees are realized when Biote-certified practitioners perform HRT procedures utilizing pellets dispensed in office. During the year ended December&#160;31, 2022, these service fees generated approximately 80% of our revenue. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This procedure-based revenue model provides our Biote-certified practitioners with consistency and predictability and is not dependent on the volume of bioidentical hormone pellets ordered by practitioners or the number of patients that may visit a clinic. Although there is a correlation between our revenue model and the hormone optimization procedure involving the use of bioidentical hormone pellets, the fees that we charge our Biote-partnered clinics are designed to cover the wide array of education, training, <span style="white-space:nowrap">re-training,</span> comprehensive administrative services and support and pass-through cost of pellets that practitioners may prescribe as part of the Biote Method. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Sales </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our company began in Texas in 2012 and, since that time, has expanded into the geographically adjacent states. As of December 2022, we have an over <span style="white-space:nowrap">120-person</span> sales force, structured to attract new Biote-certified practitioners while simultaneously supporting the productivity within existing partnered clinics. As of December 2022, the regional sales team consists of 97 liaisons and practice development managers (&#8220;PDMs&#8221;) and are led locally by a regional manager. Liaisons are charged with identifying <span style="white-space:nowrap">non-Biote-certified</span> practitioners and educating them on value in attending the comprehensive <span style="white-space:nowrap">two-day</span> training program to become a Biote-certified practitioner. The role of the PDM is to act as a resource and facilitate the practice management of the Biote Method in both new and existing partnered clinics. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Throughout the initial years of our rapid growth, high practitioner and patient satisfaction made referrals from satisfied practitioners and patients one of our most important marketing tools. Many patients of Biote-certified practitioners or Biote-partnered clinics share their experiences with friends, family, and other practitioners. Biote-certified practitioners often report the positive clinical results and powerful patient descriptions of their hormone optimization experience. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">79 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Brand </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Biote brand has been cultivated over 11 years to reinforce a &#8220;science-based, patient focused&#8221; approach to our practice building model. We believe that the quality of our platform, our size and scale differential, combined with strong brand placement throughout <span style="white-space:nowrap"><span style="white-space:nowrap">point-of-care</span></span> delivery has enabled us to establish Biote as a highly recognized brand in the hormone optimization space. By the end of 2022, more than 3&#160;million patient procedures had been performed by Biote-certified practitioners. We believe the patient experiences generated through the Biote Method are both strong and unique in our competitive environment. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For practitioners, we believe that those who choose to engage with Biote understand that we offer them a practice-building platform that is highly refined and delivers the critical elements necessary to build a successful hormone optimization practice. Each facet of the Biote Method&#8217;s <span style="white-space:nowrap"><span style="white-space:nowrap">end-to-end</span></span> platform reinforces our commitment to developing practitioner excellence. Biote-certified practitioners thus understand the value of operating their practice under the Biote brand and are highly loyal. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For patients visiting a Biote-certified practitioner, our brand represents an opportunity for them to be the &#8220;best version of themselves&#8221;. Patients can be confident that their Biote-certified practitioner will have a keen, informed focus on their unique symptoms and provide top notch medical care accordingly. Patients see the Biote logo and imagery at every step along the way, from the practitioner&#8217;s website to the decal on the door. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We believe that the acceptance and strength of the Biote brand has enabled us to successfully launch and build our companion Biote-branded dietary supplement line. Practitioners frequently prescribe supplements as adjunct to hormone therapy. As of December 2022, approximately 77% of Biote-partnered clinics also sell Biote-branded dietary supplement products. As patients trust the recommendations of their practitioner, our Biote-branded dietary supplements are likewise trusted and purchased. As a company, we benefit from this continued brand leverage. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Marketing </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Clinic / Practitioner Marketing </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our primary objective in marketing to healthcare providers is to inform them of the value in becoming a Biote-certified practitioner. We accomplish this through referrals from existing Biote-certified practitioners to their healthcare provider relationships, a dedicated sales force, and through digital and traditional marketing channels. We target specific healthcare providers based on their specialty, prescribing data, demographic information and location match with our existing geographic footprint and targeted new geographic markets. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In 2019, there were 260,000 practitioners in the United States within our targeted specialties: family and general practice (108,000); obstetricians and gynecologists (39,000); internal medicine (104,000); and urologists (9,000). These are the specialties that patients typically initially contact when experiencing the symptoms associated with menopause and andropause. As a result, these practitioners are actively searching for a therapeutic solution to the health challenges faced by their existing patients. Currently, approximately 70% of our customer base is comprised of OB/GYN, family and general practice, urology and internal medicine practices. We believe this target mix accurately reflects our potential by specialty, and we expect similar trends moving forward. As such, our practitioner-focused marketing efforts are directed accordingly. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Lead generation through sales force efforts remains our highest priority channel. To that end, we plan to meaningfully expand the number of sales representatives calling on practitioners within targeted specialties in both current and new geographies. From a central marketing perspective, we have carefully built comprehensive omnichannel expertise and leverage evidence-&#160;based content to drive differentiated Biote branding. All tactical execution of marketing and promotion is handled internally. We have invested significantly in building our digital marketing capabilities, we are utilizing this extensive capability to generate practitioner leads and have </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">80 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
established media capabilities across all digital channels. We believe the scale and breadth of our marketing capabilities to be a significant competitive advantage that will be very difficult to duplicate. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Consumer Marketing </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Consumer outreach is a growing portion of our marketing. We believe that the Biote brand is highly differentiated and leverageable across key consumer channels. We direct consumers that are actively seeking care to Biote-certified practitioners via the &#8220;Find A Provider&#8221; feature on our company website. Through our growing digital outreach capabilities, we connect with consumers seeking general information to Biote-certified practitioners for more information. This not only builds incremental patient starts, but also extends strong practitioner loyalty to our company. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Our Corporate Growth Strategy </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">U.S. Geographic Expansion </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Since our initial founding in Texas, we have demonstrated a strong ability to scale. During the year ended December&#160;31, 2022, we conducted over 64% of our business in Texas, Oklahoma, New Mexico, Colorado, Arkansas, Louisiana, Mississippi, Alabama, Georgia and Florida. Informed by both data and our past success, we are confident in our ability to further expand our U.S. geographic footprint. For example, in 2022, we grew the size of our sales force by approximately 50% to over 120 customer-facing representatives. In 2023, we plan to expand our field sales and support staff to add liaisons in critical locations, add new geographies and expand our training capacity to meet the increased rate of new Biote-partnered clinics. In order to efficiently identify new growth opportunities, we use demographic and practitioner-level data such as identifying prescription patterns and prescription purchasing data to assist in understanding the needs of new practices. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">International <span style="white-space:nowrap">Scale-up</span> </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The market for private-label dietary supplement products, and the training and support requirements for practitioners outside of the United States is well-established and growing. According to the Mater Data Forecast&#8217;s &#8220;Global Hormone Replacement Therapy Market Size, Share, Trends, <span style="white-space:nowrap">COVID-19</span> Impact&#160;&amp; Growth Analysis Report-Segmented By Type, Route of Administration&#160;&amp; Region-Industry Forecast (2022 to 2027),&#8221; as of April 2021, 57% of the current global market for hormone products exists outside of North America. We believe there is a significant potential opportunity for our practice building platform in a core group of Latin American countries, in Europe and potentially in Asia, which some market analysts project to be the fastest growing market globally. We believe market acceptance is well established in these geographies and targeted population demographics are favorable. We believe this will allow our streamlined tools and education to find a market in these regions. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We believe that international expansion may require a different access model, such as a license model, which may require the utilization of one or more local distributors with established practitioner relationships. We </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">81 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
are in the process of evaluating international expansion on a <span style="white-space:nowrap"><span style="white-space:nowrap">market-by-market</span></span> basis with the intention to determine the most appropriate <span style="white-space:nowrap"><span style="white-space:nowrap">go-to-market</span></span> strategy and to enter select international market entries in 2023. </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:84%;border:0;margin:0 auto">


<tr>

<td style="width:57%"></td>

<td style="vertical-align:bottom;width:3%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:3%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:3%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom;white-space:nowrap"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman;font-weight:bold">Country/Territory</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Total</span><br /><span style="font-weight:bold">Population</span><br /><span style="font-weight:bold">(2019)</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Population</span><br /><span style="font-weight:bold">Over 65</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Historical</span><br /><span style="font-weight:bold">or<br />Projected</span><br /><span style="font-weight:bold">Biote<br />Market</span><br /><span style="font-weight:bold">Entrance</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">United States</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">328.3&#160;million</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">54.8&#160;million</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">2012</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Puerto Rico</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">3.2&#160;million</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.7&#160;million</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">2016</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Mexico</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">127.6&#160;million</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">9.8&#160;million</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">2018</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Canada</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">37.6&#160;million</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">6.9&#160;million</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">2018</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Dominican Republic</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">10.7&#160;million</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.8&#160;million</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">2022</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Brazil</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">211.0&#160;million</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">20.4&#160;million</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">2024E</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Columbia</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">50.3&#160;million</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">4.6&#160;million</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">2024E</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Argentina</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">44.9&#160;million</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">5.2&#160;million</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">2024E</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
</table> <p style="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(1)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">As of March 2023. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We recognize the challenges and potential risk associated with simultaneously expanding in multiple geographies. As such, our U.S. growth strategy is the most strategically and financially vital. Ensuring that the US plan is <span style="white-space:nowrap">on-track</span> and moving toward success will be our primary focus prior to launching international expansion. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our current presence outside of the continental United States is in Puerto Rico, Mexico, and the Dominican Republic where we enjoy a fast growing but still nascent business. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Clinical Research Support </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The clinical research program supports our education programs through systematic literature reviews and analysis of patient therapy effects in clinical practice. By leveraging existing literature and existing data, we will strengthen our educational programs. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In 2021, we published a nine-year retrospective breast cancer study in the European Journal of Breast Health. This study demonstrated testosterone is breast protective. Testosterone and/or testosterone/estradiol delivered subcutaneously significantly reduced the incidence of breast cancer. Additionally, in 2021, we published a safety review of seven years of adverse events data regarding the use of subcutaneous hormone therapy. This study showed an overall complication rate of less than 1%. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In 2022, we made significant strides in understanding hormone replacement therapy for women, specifically testosterone therapy, as highlighted in a comprehensive literature review published in the Journal of Personalized Medicine titled &#8220;A Personal Perspective on Testosterone Therapy in Women&#8211;What We Know in 2022.&#8221; This review clarified the lack of scientific evidence for the safety concerns surrounding testosterone therapy in women, paving the way for further research and potential <span style="white-space:nowrap">FDA-approved</span> therapies. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Moreover, a supportive commentary titled &#8220;Testosterone Therapy in Women: A Clinical Challenge&#8221; published in Obstetrics and Gynecology in 2022 reinforced the benefits of subcutaneously administered testosterone in appropriately selected women to treat menopausal symptoms. This commentary emphasized the need to overcome the negative narratives and focus on the potential positive impact of testosterone therapy for women&#8217;s health. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This and other peer-reviewed medical literature has the strongest influence on defining the proper suggestions for clinical practice when focused on the data from controlled clinical trials. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">82 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In parallel, we are engaging with clinical practices to define how to access, analyze and publish their clinical findings. Over the past decade, the FDA and academic communities have targeted real-world evidence as critical to understanding the effects of therapy and process in clinical practice, a trend that we can utilize to teach Biote-certified practitioners about optimal use of hormone therapies. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">New Product Development </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are committed to advancing healthcare through product improvement. We constantly evaluate the potential for advanced education and tools to support the hormone optimization market. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our Biote-branded dietary supplement business has grown at a 22% CAGR between 2019 and 2022. In addition to generating continued growth through new patients added via our geographic expansion and through <span style="white-space:nowrap"><span style="white-space:nowrap">direct-to-consumer</span></span> channels, we believe there is an important growth opportunity to expand the size of our Biote-branded dietary supplement portfolio through new product launches and increased education of Biote-certified practitioners on these products. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Strategic Acquisitions and Product Offerings </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have historically reinvested our revenue to fund our geographic expansion. Over the next three years, we plan to accelerate that expansion to grow our practice-building business in the hormone optimization market. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We also believe that by becoming a public company, the resources and access to public markets will provide us with the financial leverage to become strategically acquisitive. We currently evaluate selective business development opportunities as they present themselves, while simultaneously strategizing on moves that we believe could benefit our model and our stockholders. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Employees </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of December&#160;31, 2022, we had 186 employees, across 11 departments. This includes five employees on the executive team, 136 in sales and marketing, and seven in finance and operations. We believe our employee relations are good. None of our employees work under any collective bargaining agreements. All of our employment and consulting agreements include employees&#8217; and consultants&#8217; covenants with respect to confidentiality, noncompetition, nonsolicitation and assignment to us of intellectual property rights developed in the course of their employment with us. However, there can be no assurance that these agreements will be enforceable or that they will provide us with adequate protection. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are committed to creating, nurturing and sustaining an inclusive culture where differences drive innovative solutions to meet the needs of our practitioners and partnered clinics, their patients, and our employees. We believe that having varied perspectives helps generate better ideas to solve the complex healthcare problems of a <span style="white-space:nowrap">changing-and</span> increasingly diverse-world. A diverse, equitable and inclusive workforce is a critical focus of the Company. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Organizationally, we are progressing our diversity recruiting and advancement goals by: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Targeting diverse job boards that market to diverse candidate pools </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Targeting networking/user groups that are diverse in nature </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Developing an employer brand that conveys our diversity, equality and inclusion commitment and initiatives </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Creating and continually improving company policies that appeal to diverse candidates </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">83 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Offering future talent acquisition recruiters the opportunity to attend and complete a thorough diversity certification course </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Nurturing a respectful and encouraging workplace </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Providing professional development assessments and opportunities to support skill and career growth </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">These initiatives represent the next steps in our diversity, equity and inclusion commitments. With time and consistent focus, we are building a truly inclusive and equitable workplace. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Supply Chain for Dietary Supplements and Pellet Insertion Kits </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our supply chain management enables precise planning of near-term and long-term business growth because we have full visibility into the production and distribution of resources that influence capacity planning. We sell 18 custom-branded dietary supplements, manufactured to exacting specifications by six U.S.-based suppliers. Currently, no one supplier manufactures more than seven products within our portfolio. We have chosen and continually evaluate our dietary supplement suppliers based on multiple factors including: 1) reputation and experience in the dietary supplement space; 2) expertise they bring to a specific product category; 3) ability to consistently execute all aspects of the manufacturing and packaging process to Biote quality standards; 4) <span style="white-space:nowrap">on-time</span> order fulfillment; and 5) cost. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We strive for supplier consistency within our supply chain. However, we do not hesitate to change or add new suppliers when there is potential to either improve our dietary supplement product offerings or gain operational leverage through better cost position and/or supplier service levels. We aim to maintain rigid quality control standards, ensuring the products and services of every dietary supplement and ingredient supplier and vendor meet or exceed our expectations. While all dietary supplement products are currently single source manufactured, we have identified potential <span style="white-space:nowrap">back-up</span> suppliers for contingency situations, should they arise. While no single dietary supplement product is sufficiently large enough to justify dual source of supply, we regularly evaluate this decision from a risk management perspective and will add second source dietary supplement suppliers when appropriate. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our Biote-branded dietary supplement inventory and shipping are executed by a 3PL partner. Our current structure is with B2B as our 3PL ships Biote-branded dietary supplements directly to Biote-certified practitioners, who in turn, sell directly to patients. As our business scales, we envision that our dietary supplement distribution mix will also evolve. We expect to add more Biote-certified practitioners and that a growing percentage of our dietary supplement sales will be <span style="white-space:nowrap"><span style="white-space:nowrap">direct-to-consumer.</span></span> We anticipate this will result in fulfillment shifting to a much greater volume of more frequent, smaller orders&#8212;directly to patients. While these shifts will occur over time, we are currently planning for the necessary changes to our 3PL structure, including adding one or more shipping locations, to successfully manage this expansion. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We also offer for sale to practitioners two sterile pellet insertion kits for use with hormone optimization therapies, one for male patients and one for female patients. These kits largely contain commercially available products, including disposable supplies (gloves, antiseptic, gauze, disposable trocar, etc.) assembled in a sterile package. The products contained in the kits are sourced, assembled, and supplied by a third-party with whom we have an agreement. Sales of these products are modest as most clinics currently choose to assemble these parts <span style="white-space:nowrap">in-house.</span> </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Administering hormone therapy via subcutaneous placement of hormone pellets is a procedure performed by health care providers in the office. Once the patient&#8217;s individualized dose is established, a local anesthetic is applied to the upper buttock or flank. A small incision (about <span style="white-space:nowrap">3-4mm</span> in length) is made and the pellets (about the size of a grain of rice) are inserted into the subcutaneous fat using <span style="white-space:nowrap">a-trocar</span> insertion device. Upon placement of the pellets and removal of the trocar insertion device, wound closure tape is placed over the incision. A protective </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">84 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
dressing is then placed over the wound closure tape. Experienced practitioners typically complete the pellet insertion process in four to seven minutes, depending on the number of pellets inserted. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Biote-certified practitioners utilize a wide variety of hormone therapies. In addition to bioidentical hormone pellets, practitioners may also choose to administer hormone therapy to their patients via topical methods (creams, gels, patches), oral methods (sublingual tablets, pills), or injections depending on the practitioners&#8217; medical assessment of their patients&#8217; clinical needs. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In a 2014 study published in the Journal of Sexual Medicine, pellet therapy was chosen by 17% of 382 male patients when presented with the choice of the following methods of hormone therapy: gels, injections, and implantable subcutaneous pellets. Further, according to a 2013 study published in the same journal, of 113 men who underwent a subcutaneous testosterone pellets therapy, 52.5% had switched to subcutaneous pellet therapy from topical gel therapy and 35.4% had switched from injection therapy. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We manage and monitor our supply chain, in part, via a Sales and Operations Planning Process (&#8220;S&amp;OP&#8221;). This has a goal of continually iterating a capital-efficient supply chain that underpins practitioners&#8217; confidence in providing care for their patients. This process collects inputs from the following as part of our direct responsibility for planning and sourcing: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Feedback from dietary supplement suppliers we talk to regularly regarding inventory availability and fulfillment performance </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Sales and finance teams that monitor sales volumes, and develop product pricing structures </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Marketing teams that monitor sales and inventory metrics, developing promotional events to optimize revenue and inventory investment </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">New dietary supplement product development teams that create new offerings to bring to market, based on industry trends and customer needs </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">These and other inputs are reconciled monthly as part of the S&amp;OP process to ensure that expected market demand, product forecasts, orders and dietary supplement production delivery are tightly aligned across all involved functions, including sales, marketing, finance and operations. This process helps ensure that product inventories are managed to appropriate levels, simultaneously enabling targeted customer service levels and optimized inventory costs. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our Biote-branded dietary supplement supply chain has remained highly stable over the past two years. As a preventative measure due to global supply chain disruptions, we increased our safety stock (minimum required inventory on hand) from three weeks to four weeks. For the foreseeable future, we will continue to monitor the marketplace and assess potential dietary supplement supply chain changes and alter our strategy accordingly. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Intellectual Property </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We develop and continue to refine our CDS and proprietary formulations for our Biote-branded dietary supplements. We believe the completeness of our offerings represents a sustainable competitive advantage and is but one contributing factor to our high rate of practice retention. While their existence is not a trade secret, their details, as well as the investment and practice experience required by a competitor to reproduce them represents a barrier of entry in that respect. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Patents </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of December&#160;31, 2022, we owned three issued U.S. design patents related to trocars. The first filed of these three patents, D773,664, is subject to a <span style="white-space:nowrap">14-year</span> term and will expire on December&#160;6, 2030. The remaining two patents, D791,322 and D800,307, are subject to a <span style="white-space:nowrap">15-year</span> term and will expire on July&#160;4, 2032, and </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">85 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
October&#160;17, 2032, respectively. We pursued these patents to protect the unique design qualities of the trocars recommended for use in our education and training. However, we are no longer using our design patents as specifications for trocar manufacturing, opting instead to purchase and market trocar convenience kits that include commercially available and sourced disposable trocars. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Trademarks </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of December&#160;31, 2022, our trademark portfolio comprises 24 trademark registrations or active trademark applications worldwide. Such portfolio includes nine U.S. trademark registrations, 11 <span style="white-space:nowrap">non-U.S.</span> trademark registrations, three pending <span style="white-space:nowrap">non-U.S.</span> trademark applications and one pending U.S. trademark applications. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Trade Secrets </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition to our reliance on trademark protection for our brand and tradename, we also rely on trade secrets, <span style="white-space:nowrap">know-how,</span> confidentiality agreements and continuing technological innovation to develop and maintain our competitive position. New employee hires, as well as vendors and consultants, are required to sign contractual agreements to protect our confidential information from disclosure. We take various physical security and cybersecurity measures, including having policies in place to prevent data breaches and help prevent our confidential information from being transferred to unsecured systems. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Competition </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Although we have competitors, we believe that no current competitor has the strength and size of our practice-building business within the hormone optimization space. We believe our company is significantly larger than our next competitors in a highly fragmented space. The below chart details our principal competitors&#8217; offerings compared to Biote (based on publicly available information): </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8.5pt;width:100%;border:0;margin:0 auto">


<tr>

<td style="width:23%"></td>

<td style="vertical-align:bottom;width:1%"></td>
<td></td>

<td style="vertical-align:bottom;width:1%"></td>
<td></td>

<td style="vertical-align:bottom;width:1%"></td>
<td></td>

<td style="vertical-align:bottom;width:1%"></td>
<td></td>

<td style="vertical-align:bottom;width:1%"></td>
<td></td>

<td style="vertical-align:bottom;width:1%"></td>
<td></td>

<td style="vertical-align:bottom;width:1%"></td>
<td></td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:top" align="center"><span style="font-weight:bold">Company Name</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top" align="center">Biote</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top" align="center">Evexipel</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top" align="center">Sottopelle</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top" align="center">BodyLogicMD</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top" align="center">Pellecome</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top" align="center">HTCA</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top" align="center"><span style="white-space:nowrap">Pro-pell</span></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8.5pt">
<td style="vertical-align:top" align="center"><span style="font-weight:bold">Number&#160;of&#160;Practice&#8217;s&#160;Locations</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top" align="center">3,600</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top" align="center">300</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top" align="center">150</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top" align="center">45</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top" align="center">100</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top" align="center">120</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top" align="center">150</td></tr>
<tr style="font-size:1pt">
<td style="height:3.75pt"></td>
<td style="height:3.75pt" colspan="2"></td>
<td style="height:3.75pt" colspan="2"></td>
<td style="height:3.75pt" colspan="2"></td>
<td style="height:3.75pt" colspan="2"></td>
<td style="height:3.75pt" colspan="2"></td>
<td style="height:3.75pt" colspan="2"></td>
<td style="height:3.75pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8.5pt">
<td style="vertical-align:top" align="center"><span style="font-weight:bold">Geographic Area</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top" align="center">North America</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top" align="center">U.S.</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top" align="center">U.S.&#160;South<br />America</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top" align="center">28 States</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top" align="center">Most U.S.<br />States</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top" align="center">Most<br /> <p style="margin-bottom:1pt; margin-top:0pt; font-size:8.5pt; font-family:Times New Roman;text-align:center">U.S.<br />States</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top" align="center">29 States</td></tr>
<tr style="font-size:1pt">
<td style="height:3.75pt"></td>
<td style="height:3.75pt" colspan="2"></td>
<td style="height:3.75pt" colspan="2"></td>
<td style="height:3.75pt" colspan="2"></td>
<td style="height:3.75pt" colspan="2"></td>
<td style="height:3.75pt" colspan="2"></td>
<td style="height:3.75pt" colspan="2"></td>
<td style="height:3.75pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8.5pt">
<td style="vertical-align:top" align="center"><span style="font-weight:bold">Services Provided</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top" align="center">BHRT<br />Education,<br />Training, and<br />Inventory<br />Management</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top" align="center">Pellet Therapy<br />Education</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top" align="center">Pellet<br />Therapy<br />Education</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top" align="center">BHRT<br />Modalities<br />and<br />Wellness<br />Program<br />Franchise</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top" align="center">Pellet<br />Training,<br />Pellet<br />Insertion<br />Devices</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top" align="center">Pellet<br />Therapy<br />Education</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top" align="center">Pellet<br />Training,<br />Compounding<br />Pharmacy<br />Items</td></tr>
<tr style="font-size:1pt">
<td style="height:3.75pt"></td>
<td style="height:3.75pt" colspan="2"></td>
<td style="height:3.75pt" colspan="2"></td>
<td style="height:3.75pt" colspan="2"></td>
<td style="height:3.75pt" colspan="2"></td>
<td style="height:3.75pt" colspan="2"></td>
<td style="height:3.75pt" colspan="2"></td>
<td style="height:3.75pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8.5pt">
<td style="vertical-align:top" align="center"><span style="font-weight:bold">Products Sold</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top" align="center">Training<br />Classes,<br />Dietary<br />Supplements&#160;&amp;<br />Convenience</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top" align="center">Training<br />Classes,<br />Dietary<br />Supplements&#160;&amp;<br />Convenience<br />Kits</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top" align="center">Training<br />Classes&#160;&amp;<br />Pellets</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top" align="center">Memberships<br />to Provider<br />offices</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top" align="center">Training<br />Classes,<br />Dietary<br />Supplements&#160;&amp;<br />Convenience<br />Kits</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top" align="center">Training<br />Classes</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top" align="center">Training,<br />Pellets,<br />Supplements</td></tr>
</table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The dietary supplement space is a large, fragmented and highly competitive industry, with few barriers to entry for both branded dietary supplements sold through practitioners as well as direct to consumer online and through conventional retailers and department stores. For instance, of our competitors listed above, Evexipel, Pellecome, and <span style="white-space:nowrap">Pro-Pell</span> maintain their own branded dietary supplements that they sell through affiliated practitioners and Sottopelle, BodyLogicMD and HTCA sell their branded dietary supplements direct to consumers online. Further, an internet search for providers of DIM, a popular dietary supplement, illustrates more than 20 other accessible brands, including Nature&#8217;s Way and The Vitamin Shoppe, available online and sold through conventional retailers and department stores such as The Vitamin Shoppe, Walmart, and Target. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">86 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Despite the significant availability of dietary supplements, the contents of different brands vary substantially leaving to the consumers to ensure that their purchase matches their physiologic needs. In contrast to other competitors, our Biote-branded dietary supplements are primarily sold and recommended by Biote-certified practitioners. As of December 2022, approximately 77% of Biote-partnered clinics also sell Biote-branded dietary supplement products. We believe consumers primarily choose our Biote-branded dietary supplements as they are recommended by their practitioner. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Government Regulations/Healthcare Laws </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Government Regulation </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our business is the development and instruction in the Biote Method to practitioners who then become certified in the Biote Method. We offer training courses in our Biote Method and access to a network of other providers who have been trained in the Biote Method. The Biote Method involves educating and training medical providers in the analysis of patient hormone wellness. The Biote-certified practitioner will use both our proprietary user platform and his or her own independent medical judgment to assess patient wellness and make recommendations to improve wellness. This assessment may result in the Biote-certified practitioner&#8217;s prescription for drugs, including compounded bioidentical hormones and/or recommendation of dietary supplements. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The healthcare industry in the United States is subject to extensive regulation by a number of governmental entities at the federal, state and local level. The healthcare regulatory landscape is also subject to frequent change. Laws and regulations in the healthcare industry are extremely complex and, in many instances, the industry does not have the benefit of significant regulatory or judicial interpretation. Moreover, our business is impacted not only by those laws and regulations that are directly applicable to us but also by certain laws and regulations that are applicable to vendors, medical providers, outsourcing facilities and traditional compounding pharmacies. While our management believes that we are in substantial compliance with all of the existing laws and regulations applicable to us as stated below, such laws and regulations are subject to rapid change and often are uncertain and inconsistent in their application. As controversies continue to arise in the healthcare industry, federal and state regulation and enforcement priorities in this area may increase, the impact of which cannot be predicted. There can be no assurance that we will not be subject to scrutiny or challenge under one or more of these laws or that any such challenge would not be successful. Any such challenge, whether or not successful, could have a material adverse effect upon our business and results of operations. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Among the various federal and state laws and regulations which may govern or impact our current and planned operations are the following: </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Regulation of Dietary Supplements </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Biote-certified practitioners who are trained in the Biote Method may recommend dietary supplements. We are a private-labeler of dietary supplements. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the FDCA, &#8220;dietary supplements&#8221; are defined as vitamins, minerals, herbs, other botanicals, amino acids and other dietary substances that are used to supplement the diet, as well as concentrates, constituents, extracts, metabolites, or combinations of such dietary ingredients. The FDCA and its amendments, such as the Food Safety Modernization Act and the Dietary Supplement Health and Education Act of 1994 (the &#8220;DSHEA&#8221;), provide the FDA with the authority to regulate dietary supplements and the dietary ingredients in the supplement products and ensure that they comply with the requirements for identity, purity, quality, strength, and composition. The FDA has the authority to regulate the entire lifecycle of a dietary supplement product, and regulates the formulation, development, manufacture, packaging, labeling, holding, promotion, sale, and distribution of dietary supplements. Under the FDCA, introduction into interstate commerce of misbranded, adulterated, or otherwise unlawful <span style="white-space:nowrap">FDA-regulated</span> products is prohibited. Violations such as <span style="white-space:nowrap">non-compliance</span> </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">87 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
with the FDA labeling requirements, false or misleading statements on a product&#8217;s labeling, or <span style="white-space:nowrap">non-compliant</span> nutrient declarations can render a product misbranded. In addition, violations such as inclusion of prohibited or dangerous ingredients, production in facilities that do not comply with the cGMP requirements, or production under insanitary conditions can render a product adulterated. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, a dietary supplement product can become adulterated if it includes a new dietary ingredient and the product does not comply with the requirements for new dietary ingredients. A new dietary ingredient is a dietary ingredient that was not marketed in the United States before October&#160;15, 1994. Under the DSHEA, manufacturers and distributors of dietary supplements containing new dietary ingredients must submit a new dietary ingredient notification, unless the ingredient has been present in the food supply as an article used for food in a form in which the food has not been chemically altered. A new dietary ingredient notification must provide the FDA with evidence of a &#8220;history of use or other evidence of safety&#8221; that establishes that use of the dietary ingredient &#8220;will reasonably be expected to be safe.&#8221; A new dietary ingredient notification must be submitted to the FDA at least 75 days before the new dietary ingredient can be marketed. There can be no assurance that the FDA will accept evidence purporting to establish the safety of any new dietary ingredients that we may want to market, and the FDA&#8217;s refusal to accept such evidence could prevent the marketing of such dietary ingredients. In addition, there is no definitive list of dietary ingredients that are exempt from the new dietary ingredient notification requirement. There is no guarantee that the FDA will agree with us that all of our dietary ingredients comply with this requirement. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In determining whether a product should be regulated as a dietary supplement, the FDA reviews the objective intent of a product&#8217;s manufacturer and/or distributor, as evidenced by the manufacturer and/or distributor&#8217;s expressed or implied labeling claims, advertising matter, and oral and written statements, to determine the product&#8217;s classification. The FDA may classify a product as a drug, food, or supplement depending on the objective intent. For example, claims to cure diseases can render a product a drug that is subject to FDA&#8217;s drug requirements, such as the requirement to submit to the FDA a new drug application prior to marketing the product. However, certain &#8220;health claims,&#8221; which are claims that have been reviewed and approved by the FDA associating a nutrient with risk-reduction, but not treatment, of a disease or health-related condition may be included on dietary supplement product&#8217;s labeling. In addition, &#8220;statements of nutritional support,&#8221; including <span style="white-space:nowrap">so-called</span> &#8220;structure/function claims,&#8221; can be included in labeling without the FDA&#8217;s review of the statement. Such statements may describe how a particular dietary ingredient affects the structure, function or general well-being of the body, or the mechanism of action by which a dietary ingredient may affect the structure, function or well-being of the body, but such statements may not claim that a dietary supplement will reduce the risk or incidence of a disease unless such claim has been reviewed and approved by the FDA. A company that uses a statement of nutritional support in labeling must possess evidence&#8211;at the time that the statement is made&#8211;substantiating that the statement is truthful and not misleading. Such statements must be submitted to the FDA no later than thirty days after first marketing the product with the certification that the company possesses the necessary evidence and must be accompanied by an <span style="white-space:nowrap">FDA-mandated</span> label disclaimer tied to the statement, indicating that &#8220;This statement has not been evaluated by the FDA. This product is not intended to diagnose, treat, cure or prevent any disease.&#8221; There is no assurance, however, that the FDA will agree with our positions on these matters, and it may interpret a claim as an unauthorized health claim, in which case we may not be able to use the claim for our products, and we may be subject to enforcement actions stemming from the claims that render a dietary supplement misbranded or cause a product to become an unapproved new drug under the FDCA. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As authorized by the FDCA, the FDA has adopted and implemented cGMPs, specifically for dietary supplements. These cGMPs impose extensive process controls on the manufacture, holding, labeling, packaging, and distribution of dietary supplements and the components of dietary supplements. They require that every dietary supplement be made in accordance with a master manufacturing record with all dietary ingredients verified by identity testing before use; that each step in manufacture, holding, labeling, packaging, and distribution be defined with written standard operating procedures, monitored, and documented; and that any deviation in manufacture, holding, labeling, packaging, or distribution be contemporaneously documented, assessed by a quality-control expert, and corrected through documented corrective action steps (whether through </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">88 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
an intervention that restores the product to the specifications in the master manufacturing record or to document destruction of the <span style="white-space:nowrap">non-conforming</span> product). The cGMPs are designed to ensure documentation, including testing results that confirm the identity, purity, quality, strength, and composition of finished dietary supplements. In addition, cGMPs require a company to make and keep written records of every product complaint that is related to cGMPs. The regulations directly affect all who manufacture the dietary supplements that we sell and our distribution of dietary supplements. The FDA may deem any dietary supplement adulterated, whether presenting a risk of illness or injury or not, based on a failure to comply with any one or more process controls in the cGMP regulations. If deemed adulterated, a dietary supplement may not be lawfully distributed and may have to be recalled from the market. It is possible that the FDA will find one or more of the process controls for our products to be inadequate and may require corrective action, may render any one or more of the dietary supplements we sell unlawful for sale, or may result in a judicial order that may impair our ability to market and sell dietary supplements. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The FDA also requires product labels to include phone numbers or addresses for reporting of adverse events, and requires serious adverse event reporting for all supplements. An &#8220;adverse event&#8221; is defined by statute to include &#8220;any health-related event associated with the use of a dietary supplement that is adverse.&#8221; While all adverse event complaints received must be recorded in accordance with the cGMPs discussed above, only serious adverse events must be reported to the FDA. A &#8220;serious adverse event&#8221; is an adverse event that: results in death, a life-threatening experience, inpatient hospitalization, a persistent or significant disability or incapacity, or a congenital anomaly or birth defect; or requires, based on reasonable medical judgment, a medical or surgical intervention to prevent an outcome described above. When a manufacturer, packer, or distributor whose name appears on the product label of a dietary supplement receives any report of a serious adverse event associated with the use of the dietary supplement in the United States, the company must submit a &#8220;serious adverse event report&#8221; on MedWatch Form 3500A. The report must be filed within 15 business days of receipt of information regarding the adverse event. All adverse event reports, whether serious or not, must be recorded and kept in company records under the cGMP rules. A company must maintain records of each report of any adverse event (both serious and <span style="white-space:nowrap">non-serious)</span> for a minimum of 6 years. These records should include any documents related to the report, including: the company&#8217;s serious adverse event report to the FDA with attachments; any new medical information about the serious adverse event received; all reports to the FDA of new medical information related to the serious adverse event; and any communications between the company and any other person(s) who provided information related to the adverse event. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the FDCA, the FDA also has the authority to inspect facilities that manufacture, process, pack, hold, or otherwise further the introduction of dietary supplement products into interstate commerce. The FDA typically reviews the facilities and the products that are manufactured, processed, packed, or held in those facilities for compliance with the requirements under the FDCA and its implementing regulations. If the FDA finds <span style="white-space:nowrap">non-compliance</span> during the inspection, the FDA may issue a Form 483 Notice of Inspectional Observations that lists and explains the deficiencies that the FDA identified during the inspection. Facilities then must implement corrective actions and provide responses to the FDA; if the FDA finds the corrective actions and responses to be satisfactory, the FDA will close out the inspection. <span style="white-space:nowrap">Non-compliance</span> with any of the FDA requirements under the FDCA can result in enforcement actions, including civil and criminal penalties. The FDA may send warning letters, untitled letters, or <span style="white-space:nowrap"><span style="white-space:nowrap"><span style="white-space:nowrap"><span style="white-space:nowrap"><span style="white-space:nowrap">it-has-come-to-our-attention</span></span></span></span></span> letters, make public announcements about illegal products, require mandatory or recommend voluntary recalls, or it may place the violative company and its products on the Import Alert, thereby stopping all applicable incoming shipments. For more serious or repeat violations, the FDA may seek more drastic remedies such as seizures, disgorgement, or injunctions. Criminal violations can result in fines or incarceration. Enforcement actions from the FDA can severely interfere with a company&#8217;s ability to conduct its business and can also negatively impact the company&#8217;s ability to operate in the future. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The FTC requires advertising for any product, including dietary supplements, to be truthful, not misleading, and properly substantiated. For advertisements relating to dietary supplements, the FDA typically requires a substantiation standard of competent and reliable scientific evidence for all express and implied claims. The FTC has promulgated policies and guidance that apply to advertising for food and dietary supplements. Advertisers </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">89 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
must possess adequate substantiation for the product claims before disseminating advertisements. The FTC also regulates other aspects of consumer purchases including, but not limited to, promotional offers, telemarketing, continuity plans, and &#8220;free&#8221; offers. The FTC has instituted numerous enforcement actions against dietary supplement companies for making false or misleading advertising claims and for failing to adequately substantiate claims made in advertising. These enforcement actions have often resulted in warning letters, consent decrees and the payment of civil penalties and/or restitution by the companies involved. Should the FTC determine that our claims are false or misleading or unsubstantiated, we could be subject to FTC enforcement action. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our business is also subject to regulation under various state and local laws that include provisions governing, among other things, the formulation, manufacturing, packaging, labeling, advertising and distribution of dietary supplements. For example, under Proposition 65 in the State of California, there is a list of substances that are deemed to pose a risk of carcinogenicity or birth defects at or above certain levels. If any such ingredient exceeds the permissible levels in a dietary supplement, cosmetic, or drug, the product may be lawfully sold in California only if accompanied by a prominent warning label alerting consumers that the product contains an ingredient linked to cancer or birth-defect risk. Private actions as well as California attorney general actions may be brought against <span style="white-space:nowrap">non-compliant</span> parties and can result in substantial costs and fines. In addition, there are state consumer protection statutes that allow consumers to bring lawsuits against marketers of <span style="white-space:nowrap">FDA-regulated</span> products. For example, California has a law called the &#8220;Consumers Legal Remedies Act&#8221; (Cal. Civ. Code &#167; 1750 et seq.) that allows private parties to assert a class action claim for false or deceptive advertising. It is typically asserted in combination with claims for false advertising and unfair competition under the California Business and Professions Code. California law firms specializing in this type of consumer class action claims have recently been targeting dietary supplement and OTC homeopathic drug makers and sellers of products sold in California, claiming injury based on the products&#8217; failure to deliver results as claimed in product labeling and promotion. Many other states, such as New York and Illinois, have similar laws and we may become the subject of lawsuits filed under such laws, which tend to be plaintiff-friendly. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Congress continues to enact new laws or amend the existing laws that are applicable to some of our business. From time to time in the future, we may become subject to additional laws or regulations administered by the FDA; the FTC; or by other federal, state, or local regulatory authorities; to the repeal of laws or regulations, or to more stringent interpretations of current laws or regulations. We are not able to predict the nature of such future laws, regulations, repeals or interpretations, and we cannot predict what effect additional governmental regulation, if and when it occurs, would have on our business in the future. Such developments could, however, require reformulation of certain products to meet new standards, recalls or discontinuance of certain products not able to be reformulated, additional record-keeping requirements, increased documentation of the properties of certain products, additional or different labeling, additional scientific substantiation, additional personnel or other new requirements. Any such developments could have a material adverse effect on our business. There can be no assurance that, if more stringent statutes are enacted for dietary supplements, or if more stringent regulations are promulgated, we will be able to comply with such statutes or regulations or that compliance won&#8217;t first require us to incur substantial expense. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Regulation of Compounded Drug Products </span></p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Section&#160;503B Outsourcing Facilities </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Biote-certified practitioners who are trained in the Biote Method may prescribe bioidentical compounded hormone pellets prepared by independent third-party compounding pharmacies, known as outsourcing facilities. Outsourcing facilities must be registered with the FDA under Section&#160;503B of the FDCA. Outsourcing facilities are primarily regulated by Section&#160;503B, however, outsourcing facilities may also be subject to state statutes and regulations governing the practice of pharmacy, and the Controlled Substances Act (the &#8220;CSA&#8221;) and corresponding state-controlled substance regulations, as applicable. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">90 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Food, Drug</span><span style="font-style:italic"></span><span style="font-style:italic">&#160;&amp; Cosmetic Act</span>. Under Section&#160;503B of the FDCA, outsourcing facilities are permitted to compound large quantities of drug formulations pursuant to a practitioner&#8217;s order, and to distribute drug formulations without a patient-specific prescription for office administration or for the purpose of dispensing. Section&#160;503B includes requirements regarding registration and reporting, use of bulk drug substances, a prohibition on wholesaling and compounding copies of <span style="white-space:nowrap">FDA-approved</span><span style="font-style:italic"> </span>drugs, and certain requirements for labeling, among others. Entities registering as outsourcing facilities are subject to cGMP requirements and regular FDA inspections, among other requirements. FDA has issued a series of draft and final guidance which further explain FDA&#8217;s positions on the requirements of certain portions of Section&#160;503B. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Drugs compounded by outsourcing facilities in compliance with Section&#160;503B are exempt from the new drug approval requirements of the FDCA and certain labeling requirements. This means that FDA does not verify the safety or effectiveness of compounded products distributed by outsourcing facilities; rather Section&#160;503B of the FDCA establishes standards for manufacturing processes and controls to ensure drug quality applicable to outsourcing facilities. Drugs compounded by outsourcing facilities also lack an FDA finding of manufacturing quality before such drugs are marketed. Section&#160;503B outsourcing facilities are subject to FDA inspection and are inspected by FDA on a risk-based schedule. <span style="white-space:nowrap">Non-compliance</span> with FDA requirements can result in FDA enforcement actions. FDA may send warning letters or untitled letters; make public announcements about illegal products; request recalls; or it may place the violative company and its products on Import Alert, thereby stopping all applicable incoming shipments. For more serious or repeat violations, FDA may seek more drastic remedies such as seizures, disgorgement, injunctions, or prosecution. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">State Regulation</span>. Outsourcing facilities are primarily regulated by the FDCA, however, certain states impose state licensing requirements on outsourcing facilities and may, where applicable, require that such<span style="font-style:italic"> </span>facilities comply with applicable state statutes and regulations governing the preparation of drug products. Depending on the state, outsourcing facilities may be subject to further inspection by state regulatory authorities. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Controlled Substance Act</span>. The CSA regulates the manufacture, importation, possession, use, and distribution of certain substances. These controlled substances are categorized into one of five schedules, and their placement is based upon the substance&#8217;s medical use, potential for abuse, and safety or dependence liability. Controlled substances are subject to extensive regulation by the DEA, as well as state and local regulatory agencies, regarding procurement, manufacture, storage, shipment, sale, and use. These regulations add additional complications and costs to the storage, use, sale and distribution of such products. All pharmacies, including outsourcing facilities, that handle controlled substances must register with DEA and ensure compliance with the CSA as it relates to the controlled substances in the pharmacy&#8217;s possession. All pharmacies, including outsourcing facilities, that are registered with DEA are subject to inspection by DEA. Failure to comply with the CSA may result in civil and criminal liabilities. </p> <p style="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Regulation of Medical Devices </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the United States, FDA defines a medical device as an instrument, apparatus, implement, machine, contrivance, implant, in vitro reagent or other similar or related article, including any component part or accessory, which is (i)&#160;intended for use in the diagnosis of disease or other conditions, or in the cure, mitigation, treatment, or prevention of disease, in man or other animals, or (ii)&#160;intended to affect the structure or any function of the body of man or other animals and which does not achieve any of its primary intended purposes through chemical action within or on the body of man or other animals and which is not dependent upon being metabolized for the achievement of any of its primary intended purposes. Medical devices are subject to extensive regulation by the FDA under the FDCA and its implementing regulations, and other federal and state statutes and regulations. The laws and regulations govern, among other things, medical device design and development, <span style="white-space:nowrap">pre-clinical</span> and clinical testing, <span style="white-space:nowrap">pre-market</span> clearance, authorization or approval, establishment registration and product listing, product manufacturing, product packaging and labeling, product storage, advertising and promotion, product distribution, recalls and field actions, servicing and post-market clinical </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">91 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
surveillance. A number of U.S. states also impose licensing and compliance regimes on companies that manufacture or distribute prescription devices into or within the state. </p> <p style="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Trocar Convenience Kits </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The FDA classifies medical devices into three classes based on risk. The level of regulatory control increases from Class&#160;I (lowest risk), to Class&#160;II (moderate risk), to Class&#160;III (highest risk). Marketing of most Class&#160;II and III medical devices within the United States must be preceded either by <span style="white-space:nowrap">(a)&#160;pre-market</span> notification and FDA clearance pursuant to Section&#160;510(k) of the FDCA or (b)&#160;the granting of <span style="white-space:nowrap">pre-market</span> approval (&#8220;PMA&#8221;). Both 510(k) notifications and PMA applications must be submitted to the FDA with significant user fees, although reduced fees for small businesses are available. Class&#160;I devices are generally exempt from <span style="white-space:nowrap">pre-market</span> review and notification, as are some moderate-risk Class&#160;II devices. Most Class&#160;II devices are subject to the requirement to submit a 510(k) notification and receive a clearance for marketing. Manufacturers of all classes of devices must comply with the FDA&#8217;s Quality System Regulation (&#8220;QSR&#8221;), establishment registration, medical device listing, labeling requirements, and MDR regulations, which are collectively referred to as medical device general controls. Class&#160;II devices may also be subject to special controls such as performance standards, post-market surveillance, FDA guidelines, or particularized labeling. Some Class&#160;I and Class&#160;II devices can be exempted by regulation from the requirement of compliance with substantially all of the QSR. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">FDA regulations for medical devices include requirements to (a)&#160;register medical devices establishments and (b)&#160;list marketed medical devices in the FDA medical device database. We are registered with FDA for our facility as a repackager/relabeler and a specification developer and our Class&#160;I disposable and reusable trocars which are included in convenience kits for sale to our customers are listed on FDA&#8217;s device database. We currently market only disposable trocar convenience kits. The convenience kits include commercially available and sourced disposable trocar with obdurator and tip protector; a sterile tray; sterile, latex free, CSR wrap; a medicine cup; latex free gloves, a Syringe and needles; alcohol prep pad; chlorhexidine gluconate and isopropyl alcohol skin antiseptic swab stick; compound benzoin tincture vial; a fenestrated drape; gauze dressings; a plastic forceps; a scalpel, tape strips, and transparent dressing. These convenience kits are assembled by Medline Industries, LP, with the components, including the trocars, being manufactured by various other component suppliers. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A &#8220;convenience kit&#8221; is defined in 21 CFR 801.3 as &#8220;two or more different medical devices packaged together for the convenience of the user.&#8221; FDA interprets this to mean a convenience kit is a device that contains two or more different medical devices packaged together and intended to remain packaged together and not to be replaced, substituted, repackaged, sterilized, or otherwise processed or modified before being used by an end user. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Most medical devices, including the devices within a convenience kit, must undergo <span style="white-space:nowrap">pre-market</span> review by and receive clearance, authorization, or approval from the FDA prior to commercialization, unless the device is of a type exempted from such review by statute, regulation, or an FDA exercise of enforcement discretion. However, if a convenience kit falls under enforcement discretion such that it is not required to obtain a premarket clearance, the convenience kit must not modify the intended use(s) of the individual kit components. If the labeling of the kit suggests an intended use for components that differs from the approved uses, the FDA may require premarket review. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under FDA&#8217;s Convenience Kits Interim Regulatory Guidance, FDA exercises enforcement discretion and thereby does not require premarket clearance for convenience kits, as it is FDA&#8217;s current thinking that such clearance may not be necessary to ensure protection of the public health. Accordingly, unless and until there is formal rulemaking on this issue, FDA intends to exercise its enforcement discretion, i.e. not require 510(k) clearance, for convenience kits if they are consistent with the &#8220;Types of Convenience Kits&#8221; list. To qualify for the enforcement discretion guidance and not be required to obtain premarket clearance, these kits must consist of components that do not alter the intended use of the individual kit components; only contain components that are </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">92 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
legally marketed preamendments devices, exempt from premarket notification, or have been found to be substantially equivalent through premarket notification process; and where the assembler/manufacturer is able to reasonably conclude that any further processing of the kit and its components does not significantly affect the safety or effectiveness of any of its components. </p> <p style="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">State Oversight of Convenience Kits </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The distribution of convenience kits is also regulated by certain states, some of which impose state licensure requirements as a resident or nonresident distributor. That is, even if a facility does not handle the physical distribution of the convenience kit, the facility could still be required to obtain a state distributor license if the facility causes the convenience kit to be distributed or furthers the marketing of the convenience kit. We cause the convenience kits to be distributed and further the marketing of the same, therefore, we hold a resident device distributor license with the Texas Department of State Health Services. We also cause the distribution of convenience kits into several other states, some of which require Biote, as a nonresident facility, to hold a nonresident device distributor license. Accordingly, we also hold all applicable and required nonresident distributor licenses. </p> <p style="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Clinical Decision Support Software </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As stated above, our proprietary CDS provides Biote-certified practitioners with information from published literature and clinical guidelines to assist practitioners in evaluating patient-specific treatment options. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">FDA has become increasingly active in addressing the regulation of computer software functions intended for use in healthcare settings. FDA has the authority to regulate a software function as a medical device if it falls within the definition of a &#8220;device&#8221; under the FDCA. However, FDA has exercised enforcement discretion for software said to be &#8220;low risk.&#8221; </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The 21st Century Cures Act clarified FDA&#8217;s authority to regulate software functions as medical devices by amending the definition of &#8220;device&#8221; in the FDCA to exclude certain software functions, including clinical decision support software that meet certain criteria. In December 2017, FDA issued a draft guidance document describing FDA&#8217;s proposed interpretation of the exemption under the 21st Century Cures Act for CDS software. FDA issued a revised draft of this CDS software guidance document in September 2019. Under the 21st Century Cures Act and FDA CDS guidance, certain software functions are excluded from FDA&#8217;s definition of &#8220;device&#8221; when they meet all the following criteria: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:5%;vertical-align:top" align="left">1.</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">not intended to acquire, process, or analyze a medical image or a signal from an in vitro diagnostic device or a pattern or signal from a signal acquisition system; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:5%;vertical-align:top" align="left">2.</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">intended for the purpose of displaying, analyzing, or printing medical information about a patient or other medical information (such as peer-reviewed clinical studies and clinical practice guidelines); </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:5%;vertical-align:top" align="left">3.</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">intended for the purpose of supporting or providing recommendations to a healthcare professional about prevention, diagnosis, or treatment of a disease or condition; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:5%;vertical-align:top" align="left">4.</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">intended for the purpose of enabling such healthcare professional to independently review the basis for such recommendations that such software presents so that it is not the intent that such healthcare professional rely primarily on any of such recommendations to make a clinical diagnosis or treatment decision regarding an individual patient. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Although we believe that our technologies and software are not subject to active FDA regulation, there is a risk that the FDA could disagree. There is also a risk that FDA could finalize its guidance for CDS software in such a way that it excludes our software and technologies from the scope of the CDS software exclusion under the 21st Century Cures Act. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">93 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If the FDA determines that any of our current or future services, technologies or software applications, including our CDS software, are regulated by the FDA as medical devices, we would become subject to various statutes, regulations and policies enforced by the FDA and other governmental authorities, including both <span style="white-space:nowrap">pre-market</span> and post-market requirements, and we would need to bring the affected services, technologies, and/or software into compliance with such requirements. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Other Laws </span></p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Regulation of Advertising </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The FTC regulates advertising pursuant to its authority to prevent &#8220;unfair or deceptive acts or practices in or affecting commerce&#8221; under the Federal Trade Commission Act (the &#8220;FTCA&#8221;). The FTC will find an advertisement to be deceptive if it contains a representation or omission of fact that is likely to mislead consumers acting reasonably under the circumstances, and the representation or omission is material and if the advertiser does not possess and rely upon a reasonable basis, such as competent and reliable evidence, substantiating the claim. The FTC may attack unfair or deceptive advertising practices through either an administrative adjudication or judicial enforcement action, including preliminary or permanent injunction. The FTC may also seek consumer redress from the advertiser in instances of dishonest or fraudulent conduct. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, the FDA regulates the advertising of prescription drugs. Promotional materials for prescription compounded drugs may not be false or misleading. Failure to comply with FDA requirements can result in a prescription drug being deemed misbranded under the FDCA. This can result in administrative or judicial penalties, including civil penalties, injunctions, or in extreme instances, criminal prosecution. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Moreover, states have similar unfair and deceptive acts and practices statutes (sometimes called &#8220;little FTC Acts&#8221; or &#8220;UDAP&#8221; statutes). They vary, but often the state regulator can seek monetary relief along with an order of discontinuance. Under certain state UDAP laws, consumers can bring private claims against companies who disseminate false or deceptive advertising claims. Although those UDAP statutes often provide for statutory damages in the case of individual consumers, more often such cases take the form of class actions, which can lead to damages awards and awards of attorney&#8217;s fees. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Finally, federal and state laws also give causes of action to competitors to seek injunctive and monetary relief for false and misleading advertising statements. Any person who is or may be likely to be damaged by false or misleading advertising statements may bring an action in federal court pursuant to the Lanham Act, &#167; 43(a). Proven damages may be trebled and attorney&#8217;s fees and costs may be awarded in appropriate cases. There are state analogs of this sort of unfair competition statute as well. </p> <p style="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Corporate Practice of Medicine Laws; Fee Splitting </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We contract with Biote-certified practitioners to provide them with access to our services. These contractual relationships are subject to various state laws that prohibit fee splitting or the practice of a healthcare profession by lay entities or persons that are intended to prevent unlicensed persons from interfering with or influencing a practitioner&#8217;s professional judgment, known as the corporate practice of medicine. Activities other than those directly related to the delivery of healthcare may be considered an element of the practice of medicine in many states. Under the corporate practice of medicine prohibition of certain states, decisions and activities that may be performed by unlicensed individuals or entities and perceived as impacting the clinical decision-making of licensed professionals such as policy and procedure development, contracting, setting rates and the hiring and management of clinical personnel may implicate the restrictions on the corporate practice of medicine. Similarly, certain compensation arrangements between licensed professionals and unlicensed individuals and entities can implicate state <span style="white-space:nowrap">fee-splitting</span> prohibitions, which prohibit providers from sharing a portion of their professional fees collected with third parties. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">State corporate practice of medicine and <span style="white-space:nowrap">fee-splitting</span> laws and rules vary from state to state and are not always consistent across various healthcare professions within the same state. In addition, these requirements are </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">94 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
subject to broad interpretation and enforcement by state regulators. Some of these requirements may apply to our business even if we do not have a physical presence in the state, based solely on our relationship with a practitioner licensed in the state. Thus, regulatory authorities or other parties, including Biote-certified practitioners, may assert that we are engaged in the corporate practice of medicine or that our contractual arrangements with Biote-certified practitioners or their practice groups constitute unlawful fee splitting. In such event, failure to comply could lead to adverse judicial or administrative action against us and/or Biote-certified practitioners, civil, criminal or administrative penalties, receipt of <span style="white-space:nowrap"><span style="white-space:nowrap">cease-and-desist</span></span> orders from state regulators, loss of provider licenses, the need to make changes to the terms of engagement of our Biote-certified practitioners that interfere with our business, and other materially adverse consequences. </p> <p style="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Licenses and Accreditations </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We, as well as the Biote-certified practitioners, may be subject to professional and private licensing, certification and accreditation requirements. These include, but are not limited to, requirements imposed by Medicare, Medicaid, state licensing authorities, voluntary accrediting organizations and third-party private payors. Receipt and renewal of such licenses, certifications and accreditations are often based on inspections, surveys, audits, investigations or other reviews, some of which may require affirmative compliance actions by us to ensure we are accurately representing our services that could be burdensome and expensive. The applicable standards may change in the future. There can be no assurance that we will be able to maintain all necessary licenses or certifications in good standing or that they will not be required to incur substantial costs in doing so. The failure to maintain all necessary licenses, certifications and accreditations in good standing, or the expenditure of substantial funds to maintain them, could have an adverse effect on our business. </p> <p style="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">U.S. State Healthcare Fraud and Abuse Laws </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Many states, including certain states in which we conduct our business, prohibit any person from offering, paying, soliciting or receiving any remuneration, directly or indirectly, in cash or in kind, for the referral of patients or other items or services to or with licensed healthcare providers, subject to limited exceptions. The scope of these laws and the interpretations of them vary by jurisdiction and are enforced by local courts and regulatory authorities, each with broad discretion. Some state fraud and abuse laws apply to items or services reimbursed by any third-party payor, including commercial insurers, some apply only to state healthcare program payors, while other state laws apply regardless of payor, including funds paid out of pocket by a patient. A determination of liability under such state fraud and abuse laws could result in fines and penalties and restrictions on our ability to operate in these jurisdictions. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The federal Anti-Kickback Statute prohibits the knowing and willful offer, payment, solicitation or receipt of any form of remuneration to induce the referral of a patient or the purchase, lease or order (or the arranging for or recommending of the purchase, lease or order) of healthcare items or services paid for by federal healthcare programs, including Medicare or Medicaid. A violation does not require proof that a person had actual knowledge of the statute or specific intent to violate the statute, and court decisions under the Anti-Kickback Statute have consistently held that the law is violated where one purpose of a payment is to induce or reward referrals. Violation of the federal Anti-Kickback Statute could result in felony conviction, administrative penalties, liability (including penalties) under the False Claims Act and/or exclusion from federal healthcare programs. A number of states have enacted anti-kickback laws that sometimes apply not only to state-sponsored healthcare programs, but also to items or services that are paid for by private insurance and <span style="white-space:nowrap">self-pay</span> patients. State anti-kickback laws can vary considerably in their applicability and scope and sometimes have fewer statutory and regulatory exceptions than does the federal law. We consider the importance of anti-kickback laws when structuring company operations and relationships. That said, we cannot ensure that the applicable regulatory authorities will not determine that some of our arrangements with physicians violate the Anti-Kickback Statute or other applicable laws. An adverse determination could subject us to different liabilities, including criminal penalties, civil monetary penalties and exclusion from participation in Medicare, Medicaid or other healthcare programs, any of which could have a material adverse effect on our business, financial condition or results of operations. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">95 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the Civil Monetary Penalties Law, a person (including an organization) is prohibited from knowingly presenting or causing to be presented to any United States officer, employee, agent, or department, or any state agency, a claim for payment for medical or other items or services where the person knows or should know (a)&#160;the items or services were not provided as described in the coding of the claim, (b)&#160;the claim is a false or fraudulent claim, (c)&#160;the claim is for a service furnished by an unlicensed physician, (d)&#160;the claim is for medical or other items or service furnished by a person or an entity that is in a period of exclusion from the program, or (e)&#160;the items or services are medically unnecessary items or services. Penalties range from $20,000 to $100,000 per violation up to $20,000 per claim, treble damages, and exclusion from federal healthcare programs. The Civil Monetary Penalties Law also prohibits a person from transferring any remuneration to a Medicare or Medicaid beneficiary that the person knows or should know is likely to influence the beneficiary&#8217;s selection of a particular provider of Medicare or Medicaid payable items or services. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The federal False Claims Act imposes civil penalties for knowingly submitting or causing the submission of a false or fraudulent claim for payment to a government-sponsored program, such as Medicare and Medicaid. Violations of the False Claims Act present civil liability of treble damages plus a penalty of at least $21,563 per false claim. The False Claims Act has &#8220;whistleblower&#8221; or &#8220;qui tam&#8221; provisions that allow individuals to commence a civil action in the name of the government, and the whistleblower is entitled to share in any subsequent recovery (plus attorney&#8217;s fees). Many states also have enacted civil statutes that largely mirror the federal False Claims Act but allow states to impose penalties in a state court. The existence of the False Claims Act, under which <span style="white-space:nowrap">so-called</span> qui tam plaintiffs can allege liability for a wide range of regulatory noncompliance, increases the potential for such actions to be brought and has increased the potential financial exposure for such actions. These actions are costly and time-consuming to defend. </p> <p style="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">U.S. State and Federal Health Information Privacy and Security Laws </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">There are numerous U.S. federal and state laws and regulations related to the privacy and security of personal identifiable information (&#8220;PII&#8221;), including health information. The HIPAA is a federal law that required the creation of national standards to protect sensitive patient health information from being disclosed without the patient&#8217;s consent or knowledge. In particular, HIPAA establishes privacy and security standards that limit the use and disclosure of PHI, and require the implementation of administrative, physical, and technical safeguards to ensure the confidentiality, integrity and availability of PHI in electronic form. Biote-certified practitioners and their clinics may be regulated as covered entities under HIPAA. We may be a business associate of our covered entity clients when we are working on behalf of our covered entity clients and providing services to those clients. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">To the extent we qualify as a business associate, we will also be regulated by HIPAA and may be required to provide satisfactory written assurances to our covered entity clients through written business associate agreements that we will provide our services in accordance with HIPAA. Failure to comply with these contractual agreements could lead to loss of clients, contractual liability to our clients, and direct action by HHS Office for Civil Rights, including monetary penalties. Violations of HIPAA may result in significant civil and criminal penalties, including a tiered system of civil monetary penalties that range from $100 to $50,000 per violation, with a cap of $1.5&#160;million per year for identical violations. However, a single breach incident can result in violations of multiple standards. Under the breach notification rule, covered entities must notify affected individuals without unreasonable delay in the case of a breach of unsecured PHI, which may compromise the privacy, security or integrity of the PHI. In addition, notification must be provided to HHS and the local media in cases where a breach affects more than 500 individuals. Breaches affecting fewer than 500 individuals must be reported to HHS on an annual basis. HIPAA also requires a business associate to notify its covered entity clients of breaches by the business associate without unreasonable delay and no later than 60 days from the discovery of the breach. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">State attorneys general also have the right to prosecute HIPAA violations committed against residents of their states. While HIPAA does not create a private right of action that would allow individuals to sue in civil court for a HIPAA violation, its standards have been used as the basis for the duty of care in state civil suits, such </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">96 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
as those for negligence or recklessness in misusing personal information. It also tasks HHS with establishing a methodology whereby harmed individuals who were the victims of breaches of unsecured PHI may receive a percentage of the Civil Monetary Penalty fine paid by the violator. In light of the HIPAA Omnibus Final Rule, recent enforcement activity, and statements from HHS, we expect increased federal and state HIPAA privacy and security enforcement efforts. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Many states where we operate and where patients treated by Biote-certified practitioners reside also have laws that protect the privacy and security of sensitive and personal information, including health information. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">These laws may be similar to or even more protective than HIPAA and other federal privacy laws. For example, the laws of the State of California that govern personal information and medical information such as the California Consumer Protection Act or the California Confidentiality of Medical Information Act, in which we operate, are more restrictive than HIPAA. Where state laws are more protective than HIPAA, we must comply with the state laws we are subject to, in addition to HIPAA. In certain cases, it may be necessary to modify our planned operations and procedures to comply with these more stringent state laws. Not only may some of these state laws impose fines and penalties upon violators, but, unlike HIPAA, some may afford private rights of action to individuals who believe their personal information has been misused. In addition, state laws are changing rapidly, and there have been proposals for a new federal privacy law or federal breach notification law, to which we may be subject. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition to HIPAA and state health information privacy laws, we may be subject to other state and federal privacy laws, including laws that prohibit unfair privacy and security acts or practices and deceptive statements about privacy and security and laws that place specific requirements on certain types of activities, such as data security and texting. The FTC and states&#8217; attorneys general have brought enforcement actions and prosecuted some data breach cases as unfair and/or deceptive acts or practices under the FTC Act and similar state laws. FTC jurisdiction in data privacy and security cases is concurrent with the HHS Office for Civil Rights&#8217; jurisdiction with respect to HIPAA. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In recent years, there have been a number of well-publicized data breaches involving the improper use and disclosure of PII and PHI. Many states have responded to these incidents by enacting laws requiring holders of personal information to maintain safeguards and to take certain actions in response to a data breach, such as providing prompt notification of the breach to affected individuals and state officials and provide credit monitoring services and/or other relevant services to impacted individuals. In addition, under HIPAA and pursuant to the related contracts that we may enter into with Biote-certified practitioners or Biote-partnered clinics who are covered entities, we must report breaches of unsecured PHI to them following discovery of the breach within a set timeframe. Notification must also be made in certain circumstances to affected individuals, federal and state authorities, media, and other relevant parties. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Legal Proceedings </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">From time to time, we may be involved in various legal proceedings and subject to claims that arise in the ordinary course of business. Although the results of litigation and claims are inherently unpredictable and uncertain, we are not currently a party to any legal proceedings the outcome of which, if determined adversely to us, are believed to, either individually or taken together, have a material adverse effect on our business, operating results, cash flows or financial condition. Regardless of the outcome, litigation has the potential to have an adverse impact on us due to defense costs and possible settlement expenses, diversion of management resources and other factors. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Donovitz Litigation </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company is currently involved in litigation described below with one of the Company&#8217;s stockholders, Dr.&#160;Gary&#160;S. Donovitz (&#8220;Donovitz&#8221;) (the &#8220;Donovitz Litigation&#8221;). The outcome of the Donovitz Litigation, </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">97 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
regardless of the merits, is inherently uncertain. At this point in time, the Company cannot predict the length of the Donovitz Litigation or the ultimate liability, if any, which may arise therefrom. In addition, litigation and related matters are costly and may divert the attention of the Company&#8217;s management and other resources that would otherwise be engaged in other activities. However, the Donovitz Litigation is not expected to have a material adverse effect on the consolidated results of operations or financial position of the Company. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On June&#160;23, 2022, Donovitz sued Haymaker Sponsor, LLC, the Company&#8217;s outside legal counsel, and certain Company executive officers and directors in the District Court of Dallas County, Texas. Donovitz alleges that the defendants made a variety of false promises regarding Donovitz&#8217;s future role in the Company, the protection of Donovitz&#8217;s interests, and the continuance of Donovitz&#8217;s seminars and training programs subsequent to the completion of the Business Combination. Otherwise, Donovitz claims he would not have agreed to the arrangements that led to the completion of the Business Combination and related transactions. Donovitz generally alleges fraud, fraudulent inducement, negligent misrepresentation, a breach of the covenant of good faith and fair dealing, breaches of fiduciary duties, and/or aiding and abetting those alleged breaches against the defendants (the &#8220;Donovitz Claims&#8221;). Donovitz seeks monetary relief exceeding $1.0&#160;million, including, but not limited to, actual damages to be determined at trial, punitive damages, attorneys&#8217; fees, costs, expenses, and prejudgment and post-judgment interest, and equitable relief, including, but not limited to, profit disgorgement, fee forfeiture, recession, and constructive trust. While not a direct party to the lawsuit, the Company believes that the allegations contained in the petition are without merit and intends to participate in the defense of the litigation. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On July&#160;11, 2022, the Company sued Donovitz in the Delaware Court of Chancery, pursuing injunctive relief to prevent Donovitz from proceeding with the litigation over the Donovitz Claims in Texas. The Company seeks to enforce (a)&#160;the Company&#8217;s certificate of incorporation, which mandates that stockholders must bring certain actions, including some or all of the Donovitz Claims, exclusively in Delaware, and (b)&#160;the Business Combination Agreement, by which Donovitz consented to the exclusive jurisdiction of the Delaware Court of Chancery and agreed that Delaware law governs any related claims, including some or all of the Donovitz Claims. Pending a ruling from the Delaware Court of Chancery, Donovitz agreed to stay all answer dates in that lawsuit in Texas. Then, on March&#160;23, 2023, Donovitz filed an amended answer and counterclaims alleging what appear to be the same as the Donovitz Claims originally filed in Texas. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On August&#160;2, 2022, the Company sued Donovitz, Lani Hammonds Donovitz, and Lani D. Consulting in the District Court of Dallas County, Texas, seeking injunctive relief to enforce <span style="white-space:nowrap">non-disparagement</span> obligations of that certain founder advisory agreement with Donovitz and the independent contractor agreement with Lani Hammonds Donovitz, both of which were entered into by the subject parties in connection with the Business Combination. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On August&#160;23, 2022, the defendants filed an answer, which included affirmative defenses to the Company&#8217;s claims and certain counterclaims and third-party claims against certain executive officers of the Company. The affirmative defenses included repudiation, fraud, breach of contract, unclean hands, and laches. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The counterclaims and third-party claims included claims for fraud, breach of fiduciary duty, breach of contract, and defamation, as well as other related claims. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company successfully obtained a temporary restraining order to enforce the <span style="white-space:nowrap">non-disparagement</span> obligations of Donovitz and Lani Hammonds Donovitz. The parties subsequently entered into an agreed order that the temporary restraining order will stay in effect until the entry of a final judgment. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A jury trial was scheduled to commence on January&#160;3, 2023, to address the Company&#8217;s request for a permanent injunction, as well as adjudicate the affirmative defenses, with all remaining claims, counterclaims and third-party claims to be tried at a later date. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">98 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">After the filing of this lawsuit, the Company amended its claim in the Delaware Court of Chancery to also seek an injunction to prevent Donovitz from proceeding with certain of the affirmative defenses, counterclaims, and third-party claims filed by the defendants on August&#160;23, 2022. On November&#160;4, 2022, the Delaware Court of Chancery denied that request for injunctive relief, permitting the Texas lawsuit filed by the Company and all affirmative defenses and claims asserted therein to proceed in Texas. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Subsequently, the parties agreed that the trial on the Company&#8217;s claim for breach of contract, including its request for a permanent injunction, will be consolidated with a trial on the previously filed counterclaims and third-party claims. Prior to that agreement being reached, Donovitz and Lani Hammonds Donovitz filed an amended pleading which did not include any of their previously asserted affirmative defenses or assert any new affirmative defenses. It was also agreed that if Donovitz and or Lani Hammonds Donovitz seek leave to add any affirmative defenses before the final trial, at most they would be allowed to assert laches, unclean hands or mistake, and only if they can convince the trial court that any or all of those affirmative defenses would have qualified as claims that could have been non suited at the time they filed their amended pleading asserting no affirmative defenses. A jury trial is scheduled to commence on September&#160;11, 2023. The temporary restraining order entered against Gary Donovitz and Lani Hammonds Donovitz remains in effect until the entry of a final judgment. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">99 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center" id="toc479690_10">MANAGEMENT&#8217;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION </p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">AND RESULTS OF OPERATIONS </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Unless the context otherwise requires, all references in this section to the &#8220;Company,&#8221; &#8220;we,&#8221; &#8220;us, or &#8220;our&#8221; refer to the business of the Biote Companies prior to the consummation of the Business Combination. Throughout this section, unless otherwise noted, &#8220;Biote&#8221; refers to BioTE Holdings, LLC and its consolidated subsidiaries. </span></p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">You should read the following discussion and analysis of our financial condition and results of operations together with our financial statements and the related notes appearing elsewhere in this registration statement. This discussion contains forward-looking statements that reflect our plans, estimates, and beliefs that involve risks and uncertainties. As a result of many factors, such as those set forth under the &#8220;Risk Factors&#8221; and &#8220;Cautionary Statement Regarding Forward-Looking Statements&#8221; sections and elsewhere in this registration statement, our actual results may differ materially from those anticipated in these forward-looking statements. </span></p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Overview </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We operate a high growth practice-building business within the hormone optimization space. Similar to a franchise model, we provide the necessary components to enable Biote-certified practitioners to establish, build, and successfully implement a program designed to optimize hormone levels using personalized solutions for their aging patient populations. The Biote Method is a comprehensive, <span style="white-space:nowrap"><span style="white-space:nowrap">end-to-end</span></span> practice building platform that provides Biote-certified practitioners with the components specifically developed for practitioners in the hormone optimization space: Biote Method education, training and certification, practice management software, inventory management software, and information regarding available hormone replacement therapy (&#8220;HRT&#8221;) products, as well as digital and <span style="white-space:nowrap"><span style="white-space:nowrap">point-of-care</span></span> marketing support. We also sell a complementary Biote-branded line of dietary supplements. We generate revenue by charging the Biote-partnered clinics fees associated with the support Biote provides for HRT and from the sale of Biote-branded dietary supplements. By virtue of our historical performance over the past 11 years, we believe that our business model has been successful, remains differentiated, and is well positioned for future growth. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our <span style="white-space:nowrap"><span style="white-space:nowrap">go-to-market</span></span> strategy focuses on: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left"><span style="font-weight:bold">Increase the number of Biote-certified practitioners</span>. Our primary objective in marketing to healthcare providers is to inform them of the value in joining the Biote network. We accomplish this through provider referrals, a dedicated sales force, and through digital and traditional marketing channels. We target specific physicians based on their specialty, prescribing data, demographic information and location match with our existing geographic footprint. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left"><span style="font-weight:bold">Grow the practice of our Biote-certified practitioners and Biote-partnered clinics</span>. When the practices of our Biote-certified practitioners and Biote-partnered clinics grow, we grow. We help our Biote-certified practitioners and Biote-partnered clinics grow by, among other things: </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">providing mentorship, practice management and marketing capability necessary to operate an efficient hormone optimization practice; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">providing high-quality Biote-branded dietary supplement products; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">providing Biote-certified practitioners and Biote-partnered clinics a full array of wellness education and marketing materials; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">directing consumers that are actively seeking care to Biote-certified practitioners via the &#8220;Find A Provider&#8221; feature on our company website; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">utilizing our growing digital outreach capabilities to connect with consumers seeking general information. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left"><span style="font-weight:bold">Increasing sales of Biote-branded dietary supplements</span>. Our Biote-branded dietary supplement line currently includes 19 dietary supplements that we offer to our Biote-certified practitioners through our </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">100 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:9%">&#160;</td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">
eCommerce site, efficiently leveraging our core Biote provider platform. Practitioners then <span style="white-space:nowrap">re-sell</span> Biote-branded dietary supplements to their patients, enabling patients to receive physician-guided therapies to manage the related effects of aging. In August 2021, we launched a <span style="white-space:nowrap"><span style="white-space:nowrap">direct-to-patient</span></span> eCommerce platform whereby practitioners can invite their patients to buy Biote-branded dietary supplements online via our online store. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The hormone pellet products used by Biote-certified practitioners are manufactured by third-party compounding pharmacies and shipped directly to Biote-certified practitioners. Custody of the pellets is with Biote-certified practitioners. However, the pellets are recorded as inventory on our financial statements from the date of shipment until such time as they are administered in a patient treatment as monitored and recorded in our BioTracker system as an additional service for administrative convenience of Biote-certified practitioners and Biote-partnered clinics. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">These products have a finite life ranging from six to twelve months. We assume the risk of loss due to expiration, damage or otherwise. Additionally, the products offered in our Biote-branded dietary supplement portfolio are produced by third-party manufacturers located in the United States. Prior to 2021, our Biote-branded dietary supplements were dropped-shipped directly to our customers from our vendors. Beginning in 2021, Biote contracted with a third-party to provide warehousing, <span style="white-space:nowrap">co-packing</span> and logistics services for our Biote-branded dietary supplements. As such our consolidated balance sheets as of December&#160;31, 2022 and December&#160;31, 2021 reflect inventories relating to these items. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Revenue generated from individual Biote-partnered clinics varies significantly. This variability is due to many factors. These include: tenure of its practitioners as Biote-certified practitioners; the number of certified practitioners in an individual clinic; the number of patients served by a clinic; the clinic&#8217;s patient demographics; and the clinic&#8217;s geographic location and population density. The master services agreements (&#8220;MSAs&#8221;) we enter into with Biote-partnered clinics contain tiered pricing provisions for the management fees. These provisions provide for decreasing management fees owed to us based on the number of new patients treated. This can result in declines in revenue we realize from management fees from existing Biote-partnered clinics unless these are offset by revenue generated from newly acquired Biote-partnered clinics which begin at higher fee levels under the MSA. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our revenue was $165.0&#160;million and $139.4&#160;million, our net income was $1.3&#160;million and $32.6&#160;million, and our Adjusted EBITDA was $50.1&#160;million and $40.2&#160;million, for the years ended December&#160;31, 2022 and 2021, respectively. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Recent Developments </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Impact of the <span style="white-space:nowrap">COVID-19</span> Pandemic and Other Trends </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In March 2020, the World Health Organization declared the <span style="white-space:nowrap">COVID-19</span> outbreak a pandemic (the <span style="white-space:nowrap">&#8220;COVID-19</span> pandemic&#8221;), and the virus continues to spread in areas where we partner with Biote-certified practitioners and Biote-partnered clinics and sell our dietary supplements. Several public health organizations have recommended, and many local governments have implemented, certain measures to slow and limit the transmission of the virus, including shelter in place and social distancing ordinances, which have resulted in a significant deterioration of economic conditions in many of the states in which we operate. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The impact of the <span style="white-space:nowrap">COVID-19</span> pandemic and the related disruptions caused to the global economy did not have a material impact on our business during the years ended December&#160;31, 2022 and 2021. We experienced a decrease in Biote-partnered clinic demand and Biote-branded dietary supplement shipments in the second quarter of fiscal year 2020. This decrease was primarily the result of closures or reduced capacity at Biote-partnered clinics in various geographies within the United States. During the second half of fiscal year 2020, clinic demand returned to <span style="white-space:nowrap"><span style="white-space:nowrap">pre-COVID-19</span></span> pandemic levels. During this and subsequent periods, we have not experienced any material disruptions in our supply chain or in our ability to fulfill orders as a result of the <span style="white-space:nowrap">COVID-19</span> pandemic. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">101 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Further, global economic conditions have been worsening, with disruptions to, and volatility in, the credit and financial markets in the U.S. and worldwide resulting from the effects of <span style="white-space:nowrap">COVID-19</span> and otherwise. If these conditions persist and deepen, we could experience an inability to access additional capital or our liquidity could otherwise be impacted. If we are unable to raise capital when needed or on attractive terms, we would be forced to delay, reduce or eliminate our research and development programs and/or other efforts. A recession or additional market corrections resulting from the impact of the evolving effects of the <span style="white-space:nowrap">COVID-19</span> pandemic could materially affect our business and the value of our securities. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Additionally, the recent trends towards rising inflation may also materially adversely affect our business and corresponding financial position and cash flows. Inflationary factors, such as increases in the cost of our clinical trial materials and supplies, interest rates and overhead costs may adversely affect our operating results. Rising interest and inflation rates also present a recent challenge impacting the U.S. economy and could make it more difficult for us to obtain traditional financing on acceptable terms, if at all, in the future. Although we do not believe that inflation has had a material impact on our financial position or results of operations to date, we may experience increases in the near future (especially if inflation rates continue to rise) on our operating costs, including our labor costs and research and development costs, due to supply chain constraints, consequences associated with <span style="white-space:nowrap">COVID-19</span> and the ongoing conflict between Russia and Ukraine, and employee availability and wage increases, which may result in additional stress on our working capital resources. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Business Combination </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On May&#160;26, 2022, BioTE Holdings, LLC (&#8220;Holdings,&#8221; inclusive of its direct and indirect subsidiaries, the &#8220;BioTE Companies,&#8221; and as to its members, the &#8220;Members&#8221;) completed a series of transactions (the &#8220;Business Combination&#8221;) with Haymaker Acquisition Corp. III (&#8220;Haymaker&#8221;), Haymaker Sponsor III LLC (the &#8220;Sponsor&#8221;), BioTE Management, LLC, Dr.&#160;Gary&#160;S. Donovitz, in his individual capacity, and Teresa S. Weber, in her capacity as the Members&#8217; representative (in such capacity, the &#8220;Members&#8217; Representative&#8221;) pursuant to the business combination agreement (the &#8220;Business Combination Agreement&#8221;) dated December&#160;13, 2021. The Business Combination was accounted for as a common control transaction, in accordance with U.S. generally accepted accounting principles (&#8220;U.S. GAAP&#8221;). Under this method of accounting, Haymaker&#8217;s acquisition of the BioTE Companies was accounted for at their historical carrying values, and the BioTE Companies were deemed the predecessor entity. This method of accounting is similar to a reverse recapitalization whereby the Business Combination was treated as the equivalent of the BioTE Companies issuing stock for the net assets of Haymaker, accompanied by a recapitalization. The net assets of Haymaker are stated at historical cost, with no goodwill or other intangible assets recorded. Operations prior to the Business Combination are those of the BioTE Companies. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Following the Closing of the Business Combination, the Company is organized in an <span style="white-space:nowrap">&#8220;Up-C&#8221;</span> structure in which the business of the Company is operated by Holdings and its subsidiaries, and Biote&#8217;s only material direct asset consists of membership interests in Holdings. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In connection with the Business Combination, on the Closing Date, BioTE Medical entered into a credit agreement with Truist Bank and Truist Securities, Inc. providing for (i)&#160;the Revolving Loans, a $50.0&#160;million senior secured revolving credit facility in favor of BioTE Medical and (ii)&#160;the Term Loan, a $125.0&#160;million senior secured term loan A facility in favor of BioTE Medical, which was borrowed in full at the Closing Date. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Components of Results of Operations </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Revenue </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We sell Biote-partnered clinics the Biote Method, the components of which are specifically developed for practitioners in the hormone optimization space: Biote Method education, training and certification, practice management resources, inventory management resources, and digital and <span style="white-space:nowrap"><span style="white-space:nowrap">point-of-care-marketing</span></span> support. Our </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">102 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
revenue represents fees paid for the training, marketing support, practice development, equipment, IP licensing, and product sales of Biote-branded dietary supplements, physician-prescribed procedures, and pellet procedure convenience kits, or trocars. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our revenue fluctuates in response to a combination of factors, including the following: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">sales volumes; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the mix of male and female patients treated by Biote-certified practitioners, as treatment for males generates more revenue per patient than treatment for females; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">our overall product mix of dietary supplements sold; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the effects of competition on market share; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">new Biote-partnered clinics acquired as customers, less any existing clinics lost as customers (&#8220;net new clinics&#8221;); </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">number of procedures performed by practitioners; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">medical industry acceptance of hormone optimization generally as a solution to unmet medical needs; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the number of business days in a particular reporting period, including as a result of holidays; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">weather disruptions impacting medical offices&#8217; ability to maintain regular operating schedules; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the effects of competition and competitive pricing strategies; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">governmental regulations influencing our markets; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">global and regional economic cycles. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Generally, our MSAs require us to provide (1)&#160;initial training to practitioners on the Biote Method, (2)&#160;inventory management services and (3)&#160;other contract-term marketing and practice development services (including recurring training and licenses of Biote IP). Historically, we have provided the optional free lease of reusable trocars by Biote-certified practitioners. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Substantially all of our revenue originates from sales to clinic locations in the United States. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Product Revenue </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Product revenue includes both pellets, in connection with the service described above, and the related inventory management services provided to clinics. Product revenue is recognized at the point in time when the clinic obtains ownership of the pellet, which we determined to be when the Biote-certified practitioner performs the procedure to implant the pellet into their patient. The consideration allocated to this performance obligation is a procedure-based service fee which we refer to as procedure revenue. Our product revenue also includes revenue earned from sales of pellet insertion kits and Biote-branded dietary supplements. Revenue from the sale of pellet insertion kits and Biote-branded dietary supplements is recognized when the clinic or clinic&#8217;s patient (supplements only) obtains control of the product and is generally at the time of shipment from our distribution facility or supplier. Any shipping or handling fees paid by clinics are also recorded within product revenue. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Service Revenue </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Service revenue is revenue earned from fees paid by Biote-partnered clinics for training services and other contract term services pursuant to our MSAs. While the option to receive and right to use the reusable trocars through the term of the contract represents an embedded lease, we have adopted the practical expedient within ASC 842 to combine the lease and <span style="white-space:nowrap">non-lease</span> components and account for the combined component under ASC 606 (as defined below). </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">103 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For Biote Method arrangements, we recognize revenue for trainings and for management services over time. For initial trainings, progress is measured by the number of training sessions completed, and for contract-term services, progress is measured on a time-elapsed basis. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The training completion and time-elapsed bases represent the most reliable measure of transfer of control to the clinic for trainings and contract-term services, respectively. Revenue is deferred for amounts billed or received prior to delivery of the services. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Cost of Revenue </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Cost of service revenue consists primarily of costs incurred to deliver trainings to Biote-partnered clinics. Cost of product revenues include the pass-through cost of pellets purchased from outsourcing facilities, the cost of pellet insertion kits and Biote-branded dietary supplements purchased from manufacturing facilities, and the shipping and handling costs incurred to deliver these products to Biote-partnered clinics. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Commissions </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Commissions consist primarily of fees paid to a third-party sales force and fees paid to Biote-partnered clinics that participate in our clinic mentor program (our &#8220;Mentor Program&#8221;), which pairs experienced Biote-certified practitioners with newly contracted practitioners. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Commissions paid to the Company&#8217;s third-party sales forces relate to market support and development activities undertaken to increase sales through the acquisition of new Biote-partnered clinics and growth from existing clinics. These are not considered incremental costs to obtain a clinic contract. As a result of investing in growing our internal sales capabilities beginning in 2019, we rely less on third-party sales forces and our commissions have decreased over time. We expect external commissions expenses to continue to decrease as we focus our growth initiatives based on an internal sales force model. However, the employee salaries we pay to our internal sales force are considered compensation expense and allocated to Selling, general and administrative expense. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Marketing </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Marketing consists primarily of advertising expenses, other <span style="white-space:nowrap">non-advertising</span> marketing and training program costs, and management services costs. These costs are all expensed as incurred. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Selling, General and Administrative Expense </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Selling, general and administrative expense consists primarily of software licensing and maintenance and the cost of employees who engage in corporate functions, such as finance and accounting, information technology, human resources, legal, and executive management. Selling, general and administrative expense also includes rent occupancy costs, office expenses, recruiting expenses, entertainment allocations, depreciation and amortization, share-based compensation, transaction related expenses, other general overhead costs, insurance premiums, professional service fees, research and development and costs related to regulatory and legal matters. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Interest Expense </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Interest expense consists primarily of cash and <span style="white-space:nowrap">non-cash</span> interest under our term loan facility and commitment fees for our unused line of credit. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Gain from Change in Fair Value of Warrant Liability </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Gain from change in fair value of warrant liability consists of the change in fair value of the warrant liability from the Closing Date to the balance sheet date. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">104 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Gain from Change in Fair Value of Earnout Liability </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Gain from change in fair value of earnout liability consists of the change in fair value of the Member and Sponsor earnouts from the Closing Date to the balance sheet date. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Loss from extinguishment of debt </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Loss from extinguishment of debt consists of the remaining unamortized portion of the debt issuance costs related to the Bank of America Credit Agreement (as defined below) written off upon repayment in connection with the Business Combination. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Other Income / Expense </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Other income and other expense consist of the foreign currency exchange gains and losses for sales denominated in foreign currencies, interest income and other income or payments not appropriately classified as operating expenses. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Income Taxes </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are subject to federal and state income taxes in the United States and taxes in foreign jurisdictions in which we operate. We recognize deferred tax assets and liabilities based on temporary differences between the financial reporting and income tax bases of assets and liabilities using statutory rates. We regularly assess the need to record a valuation allowance against net deferred tax assets if, based upon the available evidence, it is more likely than not that some or all of the deferred tax assets will not be realized. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">105 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Results of Operations </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Comparison of the years ended December&#160;31, 2022 and 2021 </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The table and discussion below present our results for the years ended December&#160;31, 2022 and 2021: </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">


<tr>

<td style="width:63%"></td>

<td style="vertical-align:bottom;width:3%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:3%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:3%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:3%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="6" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Year Ended<br />December&#160;31,</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="6" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Increase/(Decrease)</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="border-bottom:1.00pt solid #000000;vertical-align:bottom;white-space:nowrap"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman"><span style="font-weight:bold"></span><span style="font-weight:bold"><span style="font-style:italic">(U.S. dollars, in thousands)</span></span><span style="font-weight:bold"></span></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">2022</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">2021</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;white-space:nowrap"><span style="font-weight:bold">$</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">%</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Revenue:</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Product revenue</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">163,133</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">137,598</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">25,535</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">18.6</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Service revenue</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1,824</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1,798</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">26</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1.4</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total revenue</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">164,957</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">139,396</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">25,561</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">18.3</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cost of revenue (excluding depreciation and amortization included in selling, general and administrative, below)</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cost of products</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">51,990</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">46,298</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">5,692</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">12.3</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cost of services</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">2,585</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">2,519</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">66</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">2.6</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cost of revenue</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">54,575</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">48,817</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">5,758</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">11.8</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt;background-color:#cceeff">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Commissions</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">974</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">2,056</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">(1,082</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">(52.6</td>
<td style="white-space:nowrap;vertical-align:bottom">%)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Marketing</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">4,628</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">4,908</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">(280</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">(5.7</td>
<td style="white-space:nowrap;vertical-align:bottom">%)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt;background-color:#cceeff">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Selling, general and administrative</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">165,502</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">49,054</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">116,448</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">237.4</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Income (loss) from operations</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(60,722</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">34,561</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(95,283</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(275.7</td>
<td style="white-space:nowrap;vertical-align:bottom">%)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other income (expense), net:</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest expense</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(5,091</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(1,673</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(3,418</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">204.3</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Gain from change in fair value of warrant liability</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">5,127</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">5,127</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.0</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Gain from change in fair value of earnout liability</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">61,770</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">61,770</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.0</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loss from extinguishment of debt</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(445</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(445</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.0</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other income</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1,073</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">17</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1,056</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">*</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total other income (expense), net</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">62,434</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(1,656</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">64,090</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">*</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Income before provision for income taxes</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1,712</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">32,905</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(31,193</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(94.8</td>
<td style="white-space:nowrap;vertical-align:bottom">%)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt;background-color:#cceeff">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Income tax expense (benefit)</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">388</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">286</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">102</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">35.7</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net income</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1,324</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">32,619</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(31,295</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(95.9</td>
<td style="white-space:nowrap;vertical-align:bottom">%)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
</table> <p style="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">*</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left"><span style="font-style:italic">Not a meaningful change</span> </p></td></tr></table> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Revenue </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Revenue for the year ended December&#160;31, 2022 increased by $25.6&#160;million to $165.0&#160;million, or 18.3% as compared to the year ended December&#160;31, 2021. The increase was primarily driven by a $24.7&#160;million increase of procedure and Biote-branded dietary supplement revenue. Procedures performed increased by 17.8% versus the prior year resulting in a $19.5&#160;million increase in procedure revenue. During the year ended December&#160;31, 2022, the number of active clinics billed increased by 13% over the year ended December&#160;31, 2021. Biote-branded dietary supplement sales increased by 19.0% or $5.2&#160;million over the same period in the prior year. Service revenue increased by 1.4% over the same period in the prior year resulting from an increase in the number of training sessions during the year ended December&#160;31, 2022 compared to the year ended December&#160;31, 2021. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Cost of revenue </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Cost of revenue for the year ended December&#160;31, 2022 increased by $5.8&#160;million, to $54.6&#160;million, or 11.8% as compared to the year ended December&#160;31, 2021. The increase was primarily due to the net impact of higher volumes at sustained unit costs. Cost of procedures increased by $4.6&#160;million for the period, consisting of </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">106 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
$4.8&#160;million attributable to volume increases in pellets dispensed which was offset by a reduction of $0.2&#160;million related to broken, damaged, or expired pellets. Biote branded dietary supplement costs increased $0.5&#160;million or 3.5%, due to higher sales volume. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Commissions </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Commissions expense for the year ended December&#160;31, 2022 decreased by $1.1&#160;million to $1.0&#160;million, or 52.6%, as compared to the year ended December&#160;31, 2021. The decrease is primarily driven by our shift to an internal sales force to generate product demand. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Marketing </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Marketing expense for the year ended December&#160;31, 2022 decreased by $0.3&#160;million to $4.6&#160;million, or 5.7%, as compared to the year ended December&#160;31, 2021. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Selling, General and Administrative </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Selling, general and administrative expense for the year ended December&#160;31, 2022 increased by $116.4&#160;million to $165.5&#160;million, or 237.4%, as compared to the year ended December&#160;31, 2021. This increase was primarily driven by stock compensation expense of $82.2&#160;million. This expense represented the cumulative impact of unrecognized compensation expense for stockholders upon completion of the Business Combination as well as subsequent vesting of certain shares awarded. An additional component of the increase was $21.6&#160;million of transaction-related expenses related to the Business Combination and other associated capital structure transactions recognized during the period. These consisted of the excess closing costs of the Business Combination over the Business Combination proceeds received; costs associated with sponsor share transfers and certain compensation paid resulting from the transaction. The increase also included a $7.2&#160;million increase in payroll and related expenses due to increases in sales incentives consistent with sales growth for the period and additional sales and management hiring; $0.7&#160;million of travel and entertainment expenses due to increases in sales force headcount. Depreciation and amortization expenses increased by $0.8&#160;million attributable to assets placed in service at the beginning of the year. Additionally, professional fees and insurance costs increased during the period by $6.2&#160;million mainly attributable to increases in costs associated with being a public company. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Interest Expense </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Interest expense for the year ended December&#160;31, 2022 increased by $3.4&#160;million to $5.1&#160;million, or 204.3%, as compared to the year ended December&#160;31, 2021. The increase is primarily a result of the higher debt balance outstanding from the new debt issued as part of closing the Business Combination as well as higher interest rates incurred during the period. Interest expense relates primarily to interest on an outstanding note payable and amortization of origination fees. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Gain from Change in Fair Value of Warrant Liability </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The gain from the change in fair value of our warrant liability of $5.1&#160;million was primarily a result of the decrease in the trading price of our Public Warrants listed on Nasdaq to $0.30 per share on December&#160;31, 2022 from $0.68 per share on the closing of the Business Combination, May&#160;26, 2022. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Gain from Change in Fair Value of Earnout Liability </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Upon the closing of the Business Combination on the Closing Date, we recognized an earnout liability of $93.9&#160;million and subsequently remeasured the earnout liability to its fair value of $32.1&#160;million as of December&#160;31, 2022. The gain from the change in fair value of our earnout liability of $61.8&#160;million was primarily </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">107 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
a result of the decrease in the closing price of our Class&#160;A common stock listed on Nasdaq to $3.73 per share on December&#160;31, 2022 from $9.02 per share on the Closing Date. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Other Income </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Other income for the year ended December&#160;31, 2022 increased by $1.1&#160;million to $1.1&#160;million as compared to the year ended December&#160;31, 2021. The increase was primarily due to interest income earned on higher on hand cash balances and currency fluctuations during the period. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Income Tax Expense (Benefit) </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Income tax expense for the year ended December&#160;31, 2022 decreased by $0.1&#160;million as compared to the year ended December&#160;31, 2021. This increase reflects the taxability of the income attributable to Biote that prior to the Business Combination was taxable to the Company&#8217;s Members offset by a tax benefit from certain <span style="white-space:nowrap">one-time</span> expenses related to the Business Combination that will be attributed to Biote. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="white-space:nowrap">Non-GAAP</span> Measures </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Adjusted EBITDA is a <span style="white-space:nowrap">non-GAAP</span> performance measure that provides supplemental information that we believe is useful to analysts and investors to evaluate the company&#8217;s ongoing results of operations when considered alongside net income, (the most directly comparable U.S. GAAP measure). </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We use Adjusted EBITDA as alternative measures to evaluate our operational performance. We calculate Adjusted EBITDA by excluding from net income: interest expense; depreciation and amortization expenses; and income taxes. Additionally, we exclude certain expenses we believe are not indicative of our ongoing operations or operational performance. We present Adjusted EBITDA because it is a key measure used by our management to evaluate our operating performance, generate future operating plans and determining payments under compensation programs. Accordingly, we believe that Adjusted EBITDA provides useful information to investors and others in understanding and evaluating our operating results in the same manner as our management. However, <span style="white-space:nowrap">non-GAAP</span> financial information is presented for supplemental informational purposes only, has limitations as an analytical tool and should not be considered in isolation or as a substitute for financial information presented in accordance with U.S. GAAP. Some of these limitations are as follows: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">although depreciation and amortization are <span style="white-space:nowrap">non-cash</span> charges, the assets being depreciated and amortized may have to be replaced in the future, and Adjusted EBITDA does not reflect cash capital expenditure requirements for such replacements or for new capital expenditure requirements; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Adjusted EBITDA does not reflect changes in, or cash requirements for, our working capital needs; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Adjusted EBITDA does not reflect tax payments that may represent a reduction in cash available to us. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, Adjusted EBITDA is subject to inherent limitations as it reflects the exercise of judgment by Biote&#8217;s management about which expenses are excluded or included. Other companies, including companies in our industry, may calculate Adjusted EBITDA or similarly titled <span style="white-space:nowrap">non-GAAP</span> measures differently or may use other measures to evaluate their performance, all of which could reduce the usefulness of our Adjusted EBITDA as a tool for comparison. Investors are encouraged to review the reconciliation, and not to rely on any single financial measure to evaluate our business. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">108 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following is a reconciliation of net income (loss) to Adjusted EBITDA (in thousands) for the years ended December&#160;31, 2022 and 2021: </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto">


<tr>

<td style="width:72%"></td>

<td style="vertical-align:bottom;width:6%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:6%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="6" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Year Ended<br />December&#160;31,</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">2022</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">2021</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt;background-color:#cceeff">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net income</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">$</td>
<td style="vertical-align:bottom" align="right">1,324</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">$</td>
<td style="vertical-align:bottom" align="right">32,619</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest expense</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">5,091</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1,673</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Income tax expense</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">388</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">286</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Depreciation and amortization</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">2,199</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1,400</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loss from extinguishment of debt and other <span style="white-space:nowrap">non-operating</span> items</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(628</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(17</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Share-based compensation expense</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">82,180</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Transaction-related expenses</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">21,627</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">2,387</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Litigation and other</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">4,843</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1,869</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Gain from change in fair value of warrant liability</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(5,127</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Gain from change in fair value of earnout liability</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(61,770</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Adjusted EBITDA</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">50,127</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">40,218</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td></tr>
</table> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Liquidity and Capital Resources </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We derive liquidity primarily from debt and equity financing activities. As of December&#160;31, 2022, our balance of cash and cash equivalents was $79.2&#160;million, which is an increase of $52.5&#160;million, or 196.0%, compared to December&#160;31, 2021. Our total outstanding debt principal balance as of December&#160;31, 2022 was $121.9&#160;million, which represents an increase of $84.4&#160;million over the total outstanding debt principal balance as of December&#160;31, 2021 of $37.5&#160;million. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our primary sources of cash are our cash flow from operations, less amounts paid to fund operating expenses, and working capital requirements related to inventory, accounts payable and accounts receivable, and general and administrative expenditures. We primarily use cash to fund our debt service obligations, fund operations, meet working capital requirements, capital expenditures and strategic investments. As of December&#160;31, 2022, we had cash and cash equivalents of $79.2&#160;million and a $50&#160;million revolving line of credit. Based on past performance and current expectations, we believe that our current available sources of funds (including cash and cash equivalents plus proceeds from the Business Combination and debt financing) will be adequate to finance our operations, working capital requirements, capital expenditures, debt servicing obligations, and potential dividends for at least the next twelve months. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Since our inception, we have financed our operations and capital expenditures primarily through capital investment from our founder and other members, debt financing in the form of short-term lines of credit and long-term notes payable, and net cash inflows from operations. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We expect our operating and capital expenditures to increase as we increase headcount, expand our operations and grow our clinic base. If additional funds are required to support our working capital requirements, acquisitions or other purposes, we may seek to raise funds through additional debt or equity financings or from other sources. If we raise additional funds through the issuance of equity or convertible debt securities, the percentage ownership of our equity holders could be significantly diluted, and these newly issued securities may have rights, preferences or privileges senior to those of existing equity holders. If we raise additional funds by obtaining loans from third parties, the terms of those financing arrangements may include negative covenants or other restrictions on our business that could impair our operating flexibility and also require us to incur additional interest expense. We can provide no assurance that additional financing will be available at all or, if available, that we would be able to obtain additional financing on terms favorable to us. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">109 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The exercise price of our Warrants is $11.50 per Warrant. We believe the likelihood that Warrant holders will exercise their Warrants, and therefore the amount of cash proceeds that we would receive, is dependent upon the trading price of our Class&#160;A common stock, which was $5.15 per share on March&#160;15, 2023. If the trading price for our Class&#160;A common stock is less than $11.50 per share, we believe holders of our Public Warrants and Private Placement Warrants will be unlikely to exercise their Warrants. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our ability to raise additional capital through the sale of equity or convertible debt securities could be significantly impacted by the resale of shares of Class&#160;A common stock by selling securityholders pursuant to the registration statement on Form <span style="white-space:nowrap">S-1</span> filed with the SEC on June&#160;17, 2022, which could result in a significant decline in the trading price of our Class&#160;A common stock and potentially hinder our ability to raise capital at terms that are acceptable to us or at all. In addition, debt financing and equity financing, if available, may involve agreements that include covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures or declaring dividends. If we are unable to raise additional funds through equity or debt financings when needed, we may be required to delay, limit, or substantially reduce our operations. Our future capital requirements and the adequacy of available funds will depend on many factors, including those set forth in the section titled &#8220;Risk Factors&#8221; included in this registration statement. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Cash Flows </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table summarizes our consolidated cash flows for the years ended December&#160;31, 2022 and 2021: </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:92%;border:0;margin:0 auto">


<tr>

<td style="width:60%"></td>

<td style="vertical-align:bottom;width:4%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:4%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:4%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:4%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="6" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Year Ended<br />December&#160;31,</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="6" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Increase/(Decrease)</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">2022</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">2021</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;white-space:nowrap"><span style="font-weight:bold">$</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">%</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman;font-weight:bold">Consolidated Statements of Cash Flows Data:</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net cash (used in) provided by operating activities</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(9,157</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">33,720</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(42,877</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(127.2</td>
<td style="white-space:nowrap;vertical-align:bottom">%)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net cash used in investing activities</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(1,838</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(3,807</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1,969</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">51.7</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net cash provided by (used in) financing activities</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">63,460</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(20,343</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">83,803</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">412.0</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
</table> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Operating Activities </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Comparison of the years ended December&#160;31, 2022 and 2021 </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Cash flows from operating activities for the year ended December&#160;31, 2022 decreased $42.9&#160;million as compared to the year ended December&#160;31, 2021. Net income, adjusted for <span style="white-space:nowrap">non-cash</span> expenses such as depreciation and amortization, provisions for bad debts, stock compensation, change in fair value of warrants and earnout liabilities, and provisions for obsolete inventories, among others, resulted in a net decrease of $15.9&#160;million as compared to the prior period. Additionally, our working capital investment in our Biote-branded supplement inventory increased by $4.1&#160;million as compared to the prior period. This resulted from the initial investment in our third-party fulfillment centers during the year ended December&#160;31, 2021. These net changes were offset by a $2.3&#160;million increase in working capital from advances and prepayments made to certain vendors and increases in accounts receivable of $0.8&#160;million. Additionally, $31.1&#160;million of transaction closing costs were assumed as accrued expenses and subsequently paid upon completion of the reverse-merger with Haymaker which reduced cash flow from operating activities. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Investing Activities </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Comparison of the years ended December&#160;31, 2022 and 2021 </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Net cash used in investing activities for the year ended December&#160;31, 2022 decreased by $2.0&#160;million as compared to the year ended December&#160;31, 2021. This decrease was primarily driven by a reduction in purchases of property and equipment of $1.1&#160;million, primarily reusable trocars. Additionally capitalized software development costs decreased by $0.9&#160;million. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">110 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Financing Activities </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Comparison of the years ended December&#160;31, 2022 and 2021 </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Net cash provided by financing activities for the year ended December&#160;31, 2022 increased $83.8&#160;million as compared to the year ended December&#160;31, 2021. The increase is primarily due to the completion of the Business Combination with Haymaker. This included $12.3&#160;million of cash proceeds from the Business Combination and $125.0&#160;million of debt issue proceeds. These were offset by payments to retire existing debt of $37.5&#160;million, principal payment of $3.1&#160;million on the Truist debt, and $12.4&#160;million of transaction and debt issuance costs. Other items included a decrease in distributions to Members of $1.5&#160;million. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Critical Accounting Policies and Estimates </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The preparation of financial statements and related disclosures in accordance with U.S. GAAP requires our management to make judgments, assumptions and estimates that affect the amounts reported in our accompanying consolidated financial statements and the accompanying notes included elsewhere in this registration statement. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our management bases its estimates and judgments on historical experience, current economic and industry conditions and on various other factors that are believed to be reasonable under the circumstances. Actual results may differ from these estimates under different assumptions or conditions. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The methods, estimates, and judgments that we use in applying our accounting policies have a significant impact on the results that we report in our consolidated financial statements. Some of our accounting policies require us to make difficult and subjective judgments, often as a result of the need to make estimates regarding matters that are inherently uncertain. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our most critical accounting estimates include revenue recognition, the valuation of inventory, the valuation of stock compensation, the valuation of earnout liability and the valuation of warrant liability. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our significant accounting policies are described in <span style="font-style:italic">Note 2</span> to our consolidated financial statements. We believe that the accounting policies described reflect our most critical accounting policies and estimates, which represent those that involve a significant degree of judgment and complexity. Accordingly, we believe these policies are critical in fully understanding and evaluating our reported financial condition and results of operations. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Revenue Recognition </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We adopted Financial Accounting Standards Board (&#8220;FASB&#8221;) Accounting Standard Update (&#8220;ASU&#8221;) <span style="white-space:nowrap">2014-09,</span> <span style="font-style:italic">Revenue from Contracts with Customers</span>, and subsequent amendments (collectively, &#8220;ASC 606&#8221;), on January&#160;1, 2019. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">To determine revenue recognition for arrangements within the scope of ASC 606, we perform the following five steps: (1)&#160;identify the contract(s) with a clinic; (2)&#160;identify the performance obligations in the contract; (3)&#160;determine the transaction price; (4)&#160;allocate the transaction price to the performance obligations in the contract; and (5)&#160;recognize revenue when (or as) we satisfy performance obligations. We recognize revenue when the control of the promised goods or services is transferred to Biote-partnered clinics in an amount that reflects the consideration we expect to receive in exchange for such goods or services. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The majority of our revenue is derived from our long-term service agreements for Biote-partnered clinics of the Biote Method. In determining the transaction price, we evaluate whether the price is subject to discounts or adjustments to determine the net consideration to which we expect to be entitled. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">111 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Revenue is recognized when control of the product or service is transferred to the clinic (i.e., when our performance obligation is satisfied), which varies between the different performance obligations within the contract. In determining whether control has transferred for a product, we consider if there is a present right to payment and legal title, and whether risks and rewards of ownership have transferred to the clinic. For services, we consider whether we have an enforceable right to payment and when the clinic receives the benefits of our performance. Refer to Note 2 to our consolidated financial statements for additional discussion of our revenue recognition policy. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Inventories </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our inventories consist of physician-prescribed pellets used by Biote-certified practitioners in partnered clinics and Biote-branded dietary supplements which are sold and distributed to the Biote-partnered clinics and their patients. Custody of the pellets remains with Biote-certified practitioners. The pellets are presented as inventory on our financial statements from the date of shipment until such time as they are administered in a treatment by a Biote-certified practitioner on their patient for the convenience of Biote-certified practitioners and Biote-partnered clinics. Beginning the quarter ended June&#160;30, 2021, we maintained our Biote-branded dietary supplement inventory at a third-party facility that provides Biote with <span style="white-space:nowrap">co-packing</span> and logistics services in the distribution of these products. From April&#160;1, 2019 through March&#160;31, 2021, we did not maintain our own stock of inventories on these products. During that time period these were distributed to Biote-partnered clinics via drop shipment arrangements with our respective vendors. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Inventories are valued at the lower of cost or net realizable value. We regularly review our inventories and write down our inventories for estimated losses due to obsolescence or expiration. The allowance for pellets is determined based on the age of the specific manufacturing lots of the product and its remaining life until expiration. Dietary supplements are evaluated at the product level based on sales of our products in the recent past and/or expected future demand. Future demand is affected by market conditions, new products and strategic plans, each of which is subject to change with little or no forewarning. In estimating obsolescence, we utilize information that includes projecting future demand. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The need for strategic inventory levels to ensure competitive delivery performance to our Biote-partnered clinics are balanced against the risk of inventory obsolescence due to clinic requirements. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Share-Based Compensation </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Share-based compensation awards previously granted by Holdings were valued using a Monte-Carlo simulation as of the grant date because the value of the awards was dependent on future distributions to be received from a change in control or qualifying liquidity event. The significant assumptions used in the valuation include the constant risk-free rate, constant volatility factor and the Geometric Brownian Motion. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Earnout Liability </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our earnout liability was valued using a Monte-Carlo simulation in order to simulate the future path of our stock price over the earnout period. The carrying amount of the liability may fluctuate significantly and actual amounts paid may be materially different from the liability&#8217;s estimate value. The significant assumptions used in the valuation include the Company&#8217;s stock price, volatility and the drift rate. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Warrant Liability </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We value the 5,566,666 private placement warrants sold to the Sponsor (the &#8220;Private Placement Warrants&#8221;) using a Monte-Carlo simulation in order to simulate the future path of our stock price over the term of the Private Placement Warrants. The carrying amount of the liability may fluctuate significantly and actual amounts paid may be materially different from the liability&#8217;s estimated value. The significant assumptions used in the valuation include the Company&#8217;s stock price, exercise price, risk-free rate, volatility and term. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">112 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="white-space:nowrap">Off-Balance</span> Sheet Commitments and Arrangements </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of December&#160;31, 2022, we did not have any <span style="white-space:nowrap">off-balance</span> sheet arrangements as defined in Item&#160;303(a)(4)(ii) of Regulation <span style="white-space:nowrap">S-K.</span> </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Contractual Obligations </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our principal contractual obligations and commitments consist of obligations to pay loan principal and interest under our long-term debt agreement and obligations under our operating lease agreement. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Refer to Note 8 and Note 10 to our consolidated financial statements for a discussion of the nature and timing of our obligations under these agreements. The future amount and timing of interest payments under our long-term debt agreement are expected to vary with the amount and then-prevailing contractual interest rates of our debt, which are discussed in Note 8 to our consolidated financial statements. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Recently Issued and Adopted Accounting Pronouncements </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">See Note 2 to our consolidated financial statements for a discussion of accounting pronouncements recently adopted and recently issued accounting pronouncements not yet adopted and their potential impact to our financial statements. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">JOBS Act Accounting Election </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are an emerging growth company, as defined in Section&#160;2(a) of the Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;), as modified by the JOBS Act. Section&#160;107 of the JOBS Act provides that an emerging growth company can take advantage of an extended transition period provided in Section&#160;7(a)(2)(B) of the Securities Act for complying with new or revised accounting standards applicable to public companies, allowing them to delay the adoption of those standards until those standards would otherwise apply to private companies. We have elected to use this extended transition period under the JOBS Act. As a result, following the Business Combination, our consolidated financial statements may not be comparable to the financial statements of companies that are required to comply with the effective dates for new or revised accounting standards that are applicable to public companies, which may make our common stock less attractive to investors. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We will remain an emerging growth company under the JOBS Act until the earliest of (i)&#160;March&#160;4, 2026, (ii) the last date of our fiscal year in which we have total annual gross revenue of at least $1.235&#160;billion, (iii)&#160;the date on which we are deemed to be a &#8220;large accelerated filer&#8221; under the rules of the SEC with at least $700.0&#160;million of outstanding securities held by <span style="white-space:nowrap">non-affiliates</span> or (iv)&#160;the date on which we have issued more than $1.0&#160;billion in <span style="white-space:nowrap">non-convertible</span> debt securities during the previous three years. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Quantitative and Qualitative Disclosures about Market Risk </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are exposed to market risks in the ordinary course of our business, including the effects of interest rate changes and inflation. Information relating to quantitative and qualitative disclosures about these market risks is set forth below. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Interest Rate Fluctuation Risk </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The primary objective of our investment activities is to maintain cash reserves to meet the capital requirements of our operations and our contractual obligations. In future periods, we will continue to evaluate our investment policy in order to ensure that we continue to meet our overall objectives. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are exposed to interest rate risk in relation to our long-term debt outstanding. As is more fully described in Note 8 to the consolidated financial statements elsewhere in this registration statement, our outstanding </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">113 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
<span style="white-space:nowrap">long-term</span> debt has a variable rate of interest, which is primarily based on the Standard Overnight Financing Rate. We estimate that an increase of 100 basis points in the interest rates related to our long-term debt would increase our annualized interest expense by $1.2&#160;million. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We do not engage in any strategies to limit our exposure to this interest rate risk. In addition to the interest rate risk related to our current borrowings, changes in interest rates could affect the interest we pay under any future borrowings on the line of credit available to us under our long-term debt agreement. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The variable interest rate on our long-term debt has increased since our last fiscal year, to a rate of 6.92304% as of December&#160;31, 2022 from a rate of 3.1% as of December&#160;31, 2021. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Inflation </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We do not believe that inflation has had a material effect on our business, financial condition, or results of operations. We continue to monitor the impact of inflation in order to minimize its effects through pricing strategies, productivity improvements and cost reductions. If our costs were to become subject to significant inflationary pressures, we may not be able to fully offset such higher costs through price increases. Our inability or failure to do so could harm our business, financial condition, and results of operations. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">114 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center" id="toc479690_11">MANAGEMENT </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Management and Board of Directors </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table sets forth certain information, including ages as of March&#160;27, 2023, of our executive officers and members of the Board. </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">


<tr>

<td style="width:37%"></td>

<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:1%"></td>
<td style="width:59%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;white-space:nowrap"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Name</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Age</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Position(s)</p></td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Marc D. Beer</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">58</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">Class&#160;III Director</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Dana Jacoby</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">48</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">Class&#160;I Director</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Mark Cone</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">60</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">Class&#160;II Director</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Steven J. Heyer</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">70</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">Class&#160;II Director</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Andrew R. Heyer</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">65</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">Class&#160;I Director</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Debra L. Morris</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">64</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">Class&#160;II Director</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Teresa S. Weber</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">70</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">Chief Executive Officer, Class&#160;III Director</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Samar Kamdar</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">43</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">Chief Financial Officer</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Mary Elizabeth Conlon</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">43</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">Vice&#160;President,&#160;Business&#160;Development&#160;&amp;&#160;General&#160;Counsel</td></tr>
</table> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Executive Officers </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following is a brief biography of each of Biote&#8217;s executive officers and key employees. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold"><span style="font-style:italic">Teresa S. Weber</span></span>, <span style="font-style:italic">Chief Executive Officer, Director</span>. Ms.&#160;Teresa&#160;S. Weber has served as the Chief Executive Officer of Biote since March 2019 and on its Board of Managers since June 2018. Prior to joining Biote, Ms.&#160;Weber served as the Chief Executive Officer of Amen Clinics, Inc., an outpatient healthcare clinic company, from January 2015 to March 2019. Ms.&#160;Weber has also been a partner and consultant at Mattioli Weber Consulting, a marketing, service and retain consulting firm, since June 2013. She holds an M.S. in Management from Purdue University and a B.S. in Economics from New College Florida. Ms.&#160;Weber is qualified to serve as a director due to her significant leadership experience. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold"><span style="font-style:italic">Samar Kamdar,</span></span> <span style="font-style:italic">Chief Financial Officer</span>. Mr.&#160;Kamdar has served as the Chief Financial Officer since August 2022. Prior to joining Biote, Mr.&#160;Kamdar served as the Chief Financial Officer of Slync, Inc. (d/b/a Slync.io), a logistical technology company from September 2021 to June 2022. Prior to joining Slync.io, Mr.&#160;Kamdar served as the Chief Financial Officer of TaxAct Inc., a tax preparation software company from August 2018 to August 2021. Prior to joining TaxAct Inc., Mr.&#160;Kamdar served as the Vice President of Finance of Crossmark, Inc., a sales and marketing services company that operates within the consumer goods industry from September 2014 until August 2018. Mr.&#160;Kamdar holds a B.S. in electrical engineering from Baylor University and a M.B.A. from the University of Texas, McCombs School of Business. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold"><span style="font-style:italic">Mary Elizabeth Conlon</span></span><span style="font-style:italic">, Vice President, Business Development</span><span style="font-style:italic"></span><span style="font-style:italic">&#160;&amp; General Counsel</span>. Ms.&#160;Mary Elizabeth Conlon has served as the Vice President, Business Development and General Counsel of Biote since June 2021. Prior to joining Biote, Ms.&#160;Conlon founded The Conlon Law Firm, P.C., where she practiced law from January 2012 to June 2021. Prior to that, Ms.&#160;Conlon was named partner at Travis, Calhoun&#160;&amp; Conlon, P.C., where she practiced law from September 2004. Ms.&#160;Conlon holds a J.D. from Baylor Law School and a B.A. in Communications from Baylor University. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="white-space:nowrap">Non-Employee</span> Directors </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold"><span style="font-style:italic">Marc D. Beer</span></span>, <span style="font-style:italic">Executive Chairman, Director</span>. Mr.&#160;Marc Beer has served as the Chairman of the Board of Managers of Biote since January 2021. Mr.&#160;Beer has also served as the Chairman of the Board of Origami Surgical LLC since April 2020 and as the Chairman of the Board of LumeNXT LLC since August 2018 as well. Prior to that, Mr.&#160;Beer <span style="white-space:nowrap">co-founded</span> Renovia Inc. in August 2016, where he previously held the positions of Chairman of the Board and Chief Executive Officer and continues to serve as a strategic advisor. Before starting </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">115 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Renovia Inc., Mr.&#160;Beer was the Chairman of the Board of Minerva Neurosciences, Inc. (NASDAQ:NERV) from December 2013 to January 2018. Mr.&#160;Beer holds a BS from Miami University. Mr.&#160;Beer is qualified to serve as a director due to his significant leadership background and industry experience. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold"><span style="font-style:italic">Dana Jacoby</span></span>, <span style="font-style:italic">Director</span>. Ms.&#160;Dana Jacoby has served as a member of the Board of Managers of Biote since August 2021. Prior to Biote, Ms.&#160;Jacoby served as the Chief Executive Officer of Specialty Networks Consulting from November 2015 to December 2020. In October 2017, Ms.&#160;Jacoby founded Vector Medical Group, where she continues to serve as Chief Executive Officer. Ms.&#160;Jacoby holds an M.S. in Business and Healthcare, Master of Health Systems from the Robert Wood Johnson Medical School at the University of Medicine and Dentistry of New Jersey and a B.S. in Political Science and Public Relations from Louisiana State University. Ms.&#160;Jacoby is qualified to serve as a director due to her extensive leadership experience and background in the industry. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold"><span style="font-style:italic">S. Mark Cone</span></span>, <span style="font-style:italic">Director</span>. Dr.&#160;Mark Cone has served as a member of the Board of Managers of Biote since August 2021. Dr.&#160;Cone has also served as the Market President of Privia Health&#8217;s South Texas market (Nasdaq: PRVA) since October 2015 and as the President of Privia Medical Group Gulf Coast since October 2015. Additionally, since December 2013, Dr.&#160;Cone has served as Vice President of the Board of Directors of the U.S. Women&#8217;s Health Alliance and since October 2020, as Chairman of the Board of Global Women&#8217;s Health Providers, a Cedar Gate Technologies company. Prior to these positions, Dr.&#160;Cone was the CEO of Complete MD Solutions, a physician management company from December 2014 to October 2015. He holds an M.D. from Baylor College of Medicine and a Bachelor of Science in Biology and Medicine from Texas A&amp;M University. Dr.&#160;Cone is qualified to serve as a director due to his extensive industry and leadership experience. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold"><span style="font-style:italic">Andrew R. Heyer,</span></span> our President and a Director since July 2020 is a finance professional with over 40 years of experience investing in the consumer and consumer-related products and services industries, as well as a senior banker in leveraged finance during which time his clients included many large private equity firms. Mr.&#160;Heyer served as President and Director of Haymaker Acquisition Corp. II (&#8220;Haymaker II&#8221;) until it completed its business combination in December 2020 with GPM and ARKO Holdings Ltd. (&#8220;ARKO Holdings&#8221;), which together merged under a new holding company, ARKO Corp. (Nasdaq: ARKO) as part of the business combination, and has remained on the board since such time. Mr.&#160;Heyer was President and Director of Haymaker I until it completed its business combination with OneSpaWorld Holdings in March 2019, and has since remained on its board since such time. Currently, Mr.&#160;Heyer is the Chief Executive Officer and founder of Mistral Equity Partners (&#8220;Mistral&#8221;), a private equity fund manager founded in 2007 that invests in the consumer industry. Prior to founding Mistral in 2007, from 2000 to 2007, Mr.&#160;Heyer served as a Founding Managing Partner of Trimaran Capital Partners, a $1.3&#160;billion private equity fund. Mr.&#160;Heyer was formerly a vice chairman of CIBC World Markets Corp. and a <span style="white-space:nowrap">co-head</span> of the CIBC Argosy Merchant Banking Funds from 1995 to 2001. Prior to joining CIBC World Markets Corp. in 1995, Mr.&#160;Heyer was a founder and Managing Director of The Argosy Group L.P. from 1985 to 1995. Before Argosy, from 1984 to 1985, Mr.&#160;Heyer was a Managing Director at Drexel Burnham Lambert Incorporated and, previous to that, he worked at Shearson/American Express. Mr.&#160;Heyer currently serves on the board of Tastemaker Acquisition Corp. (Nasdaq: TMKR), a SPAC which completed its $276&#160;million initial public offering on January&#160;12, 2021 and is searching for a target business in the restaurant, hospitality and related technology and service sectors. Mr.&#160;Heyer also currently serves as President and a Director of Haymaker Acquisition Corp. IV, a SPAC that has not yet completed its initial public offering, a Director of AF Acquisition Corp. (Nasdaq: AFAQ), a SPAC that completed its $224&#160;million initial public offering on March&#160;23, 2021, and a Director of Coliseum Acquisition Corp. (Nasdaq: MITA), a SPAC that completed its $150&#160;million initial public offering on June&#160;25, 2021. In addition, Mr.&#160;Heyer serves as an advisor to the board of directors of Ascendant Digital Acquisition Corp. III (NYSE: ACDI), a SPAC that completed its $300&#160;million initial public offering on November&#160;15, 2021. From 1993 through 2009, Mr.&#160;Heyer also served on the board of The Hain Celestial Group, Inc. (Nasdaq: HAIN), a natural and organic food and products company, rejoining the board from 2012 to April 2019. Mr.&#160;Heyer also serves on the board of several private companies owned in whole or in part by Mistral, including Worldwise, Inc., a pet accessories business from 2011 to the present, and The Lovesac Company, Inc. (Nasdaq: LOVE), a branded omni-channel retailer of technology-forward furniture, from 2010 to the present. Mr.&#160;Heyer has also served on the board of Insomnia Cookies, a </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">116 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
retailer of desserts open primarily in the evening and nighttime, and on the investment committee of AF Ventures, an investor in high-growth consumer product companies. In the past, Mr.&#160;Heyer has served as a director of XpresSpa Group, Inc. from 2016 to 2019, Las Vegas Sands Corp., a casino company, from 2006 to 2008, El Pollo Loco Holdings, Inc., a casual Mexican restaurant, from 2005 to 2008, and Reddy Ice Holdings, Inc., a manufacturer of packaged ice products, from 2003 to 2006. Mr.&#160;Heyer received his B.Sc. and M.B.A. from the Wharton School of the University of Pennsylvania, graduating magna cum laude. Mr.&#160;Heyer is the brother of Mr.&#160;Steven Heyer, our Chief Executive Officer. Mr.&#160;Heyer is qualified to serve as a director due to his extensive finance, investment and operations experience, particularly in the consumer and consumer-related products and services industries. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold"><span style="font-style:italic">Steven J. Heyer,</span></span> our Chief Executive Officer and Executive Chairman since July 2020, has over 40 years of experience in the consumer and consumer-related products and services industries, leading a range of companies and brands. Mr.&#160;Heyer has applied his experience and analytical skills in a variety of leadership positions across diverse industry groups, including broadcast media, consumer products, and hotel and leisure companies. Over the past ten years, he has been acting as an advisor and director to, and investor in, several private companies across the consumer subsectors of health and wellness, restaurants, technology, marketing services and technology and furniture. Mr.&#160;Heyer currently serves as Chief Executive Officer and a Director of Haymaker Acquisition Corp. IV, a SPAC that has not yet completed its initial public offering. Mr.&#160;Heyer served as the Chief Executive Officer and Chairman of Haymaker II until it completed its business combination in December 2020 with GPM Investments, LLC (&#8220;GPM&#8221;) and ARKO Holdings, which together merged under a new holding company, ARKO Corp. (Nasdaq: ARKO) as part of the business combination, and has remained on its board since such time as a director. Mr.&#160;Heyer was Chief Executive Officer and Chairman of Haymaker I from its formation until it completed its business combination with OneSpaWorld Holdings (Nasdaq: OSW) in March 2019. Since its business combination, he has served as Vice Chairman on the board of directors of OneSpaWorld Holdings. Mr.&#160;Heyer&#8217;s operating experiences include: leading the turnaround of Outback Steakhouse as an advisor (from 2010 to 2012); as Chief Executive Officer of Starwood Hotels&#160;&amp; Resorts Worldwide (from 2004 until 2007); as President and Chief Operating Officer of The Coca-Cola Company (from 2001 to 2004); as a member of the boards of Coca-Cola FEMSA, and Coca-Cola Enterprises (all from 2001 to 2004); as President and Chief Operating Officer of Turner Broadcasting System, Inc., and a member of AOL Time Warner&#8217;s Operating Committee (from 1994 to 2001); as President and Chief Operating Officer of Young&#160;&amp; Rubicam Advertising Worldwide (from 1992 to 1994); and before that spending 15 years at Booz Allen&#160;&amp; Hamilton, ultimately becoming Senior Vice President and Managing Partner. For the last five years, Mr.&#160;Heyer has served on the boards of Lazard Ltd, Lazard Group, and Atkins Nutritionals Inc. (each as further described below) as well as investing in a private capacity in early stage and venture consumer and consumer media companies. Mr.&#160;Heyer has extensive board experience, including: the board of Atkins Nutritionals Inc. until 2017, when it was acquired by Conyers Park Acquisition Corp, a publicly traded special purpose acquisition company; Lazard Ltd and Lazard Group (2005 to present); the board of WPP Group, a publicly traded digital, internet, and traditional advertising company (2000 to 2004); the board of Equifax, the publicly traded consumer credit reporting and insights company (2002 through 2003); the board of Omnicare, Inc., a supplier of pharmaceutical care to the elderly (2008 through 2015); the board of Vitrue, Inc., a provider of social marketing publishing technologies (2007 through 2012); and the board of Internet Security Systems, Inc. a provider of internet security software, appliance, and services (2004 through 2005). In March 2011, Harry&#160;&amp; David Holdings, Inc. (&#8220;Harry&#160;&amp; David&#8221;), a company where Mr.&#160;Heyer had been Chief Executive Officer from 2010 until February 2011, filed a prearranged Chapter 11 plan under the U.S. Bankruptcy Code. Subsequently, Harry&#160;&amp; David filed a reorganization plan in bankruptcy court in May 2011 and emerged from bankruptcy in September 2011. Mr.&#160;Heyer received his B.S. from Cornell University and an M.B.A. from New York University. Mr.&#160;Heyer is the brother of Mr.&#160;Andrew Heyer, our President. Mr.&#160;Heyer is qualified to serve as a director due to his extensive operations, management and business background, particularly in the consumer and consumer-related products and services industries. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold"><span style="font-style:italic">Debra L. Morris</span></span>,<span style="font-weight:bold"><span style="font-style:italic"> </span></span><span style="font-style:italic">Director</span>. Ms.&#160;Morris has served as a member of our Board since November 2022. Ms.&#160;Morris served as the executive vice president and chief financial officer of Apria, Inc. (Nasdaq: APR) from March 2013 through October 2022. Effective May&#160;15, 2020, Ms.&#160;Morris serves as a Director for Alternative </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">117 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Logistics Technologies, Holdco, LLC (a.k.a EverDriven) where she serves as the chair of the audit committee. Ms.&#160;Morris has served as a director of Rexford Industrial (REXR) since December 2020, where she also serves on the audit, compensation and nomination and governance committees. Prior to that, Ms.&#160;Morris served as Chief Financial Officer of Americas for Sitel Worldwide Corporation from February 2010 to February 2013. Prior to that she served as a Partner of Tatum LLC from 2004 to 2010 and as a Director from 2008 to 2010 and provided interim and permanent Chief Financial Officer services for companies contracted with Tatum LLC including LifeMasters Supported SelfCare and RelaDyne. Ms.&#160;Morris holds a B.S. in Business Administration from Colby Sawyer College in New London, New Hampshire. Ms.&#160;Morris is qualified to serve as a director due to her extensive experience serving on public company boards. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Family Relationships </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">There are no family relationships among any of our executive officers or directors with the exception of Mr.&#160;Steven Heyer and Mr.&#160;Andrew Heyer, who are brothers. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Classified Board of Directors </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our business affairs are managed under the direction of the Board. The Board consists of six directors and is divided into three staggered classes of directors. At each annual meeting of its stockholders, a class of directors will be elected for a three-year term to succeed the same class whose term is then expiring, as follows, or in each case until their respective successors are elected and qualified, or until their earlier resignation, removal or death, or in each case until their respective successors are elected and qualified, or until their earlier resignation, removal or death: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the Class&#160;I directors, whose terms will expire in 2023, are Andrew R. Heyer and Dana Jacoby; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the Class&#160;II directors, whose terms will expire in 2024, are Steven J. Heyer, S. Mark Cone, and Debra L. Morris; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the Class&#160;III directors, whose terms will expire in 2025, are, Marc Beer and Terry Weber. </p></td></tr></table> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Director Independence </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our Corporate Governance Guidelines require a majority of Board members to be independent. Our Board has determined that all Board members, other than Mr.&#160;Beer and Ms.&#160;Weber, are independent under applicable rules of The Nasdaq Stock Market LLC (&#8220;Nasdaq&#8221;). Mr.&#160;Beer is not deemed to be independent under Nasdaq rules by virtue of his role as our Executive Chairman. Ms.&#160;Weber is not deemed to be independent under Nasdaq rules by virtue of her role as our Chief Executive Officer. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Committees of the Board of Directors </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The standing committees of our Board currently include an audit committee, a compensation committee and nominating and corporate governance committee. Each of the committees report to the Board as they deem appropriate and as the Board may request. The composition, duties and responsibilities of these committees are set forth below. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Audit Committee </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Audit Committee consists of Messrs. Andrew Heyer and Steven Heyer and Mses. Jacoby and Morris, with Mr.&#160;Andrew Heyer serving as chairperson. Our Board has determined that Mr.&#160;Andrew Heyer qualifies as our &#8220;audit committee financial expert,&#8221; as that term is defined in Item 407(d)(5) of Regulation <span style="white-space:nowrap">S-K.</span> The principal functions of the Audit Committee include, among other things: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">assisting Board oversight of (1)&#160;the integrity of our financial statements, (2)&#160;our compliance with legal and regulatory requirements, (3)&#160;our independent registered public accounting firm&#8217;s qualifications and </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">118 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:9%">&#160;</td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">
independence, and (4)&#160;the performance of our internal audit function and independent registered public accounting firm; the appointment, compensation, retention, replacement, and oversight of the work of the independent auditors and any other independent registered public accounting firm engaged by us; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left"><span style="white-space:nowrap">pre-approving</span> all audit and <span style="white-space:nowrap">non-audit</span> services to be provided by the independent auditors or any other registered public accounting firm engaged by us, and establishing <span style="white-space:nowrap">pre-approval</span> policies and procedures; reviewing and discussing with the independent registered public accounting firm all relationships the auditors have with us in order to evaluate their continued independence; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">setting clear policies for audit partner rotation in compliance with applicable laws and regulations; obtaining and reviewing a report, at least annually, from the independent registered public accounting firm describing (1)&#160;the independent registered public accounting firm&#8217;s internal quality-control procedures and (2) any material issues raised by the most recent internal quality-control review, or peer review, of the audit firm, or by any inquiry or investigation by governmental or professional authorities, within the preceding five years respecting one or more independent audits carried out by the firm and any steps taken to deal with such issues; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">meeting to review and discuss our annual audited financial statements and quarterly financial statements with management and the independent auditor, including reviewing our specific disclosures under &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221;; reviewing and approving any related party transaction required to be disclosed pursuant to Item 404 of Regulation <span style="white-space:nowrap">S-K</span> prior to us entering into such transaction; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">reviewing with management, the independent auditor, and our legal advisors, as appropriate, any legal, regulatory or compliance matters, including any correspondence with regulators or government agencies and any employee complaints or published reports that raise material issues regarding our financial statements or accounting policies and any significant changes in accounting standards or rules promulgated by the Financial Accounting Standards Board, the SEC or other regulatory authorities. </p></td></tr></table> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Compensation Committee </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Compensation Committee consists of Ms.&#160;Jacoby and Messrs. Cone and Andrew Heyer, with Ms.&#160;Jacoby serving as the chairperson. The principal functions of the Compensation Committee include, among other things: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">reviewing and approving on an annual basis the corporate goals and objectives relevant to our Chief Executive Officer&#8217;s compensation evaluating our Chief Executive Officer&#8217;s performance in light of such goals and objectives and determining and approving the remuneration (if any) of our Chief Executive Officer based on such evaluation; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">reviewing and making recommendations to our Board with respect to the compensation, and any incentive compensation and equity-based plans that are subject to Board approval of all of our other officers; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">reviewing our executive compensation policies and plans; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">implementing and administering our incentive compensation equity-based remuneration plans; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">assisting management in complying with our proxy statement and annual report disclosure requirements; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">approving all special perquisites, special cash payments and other special compensation and benefit arrangements for our officers and employees; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">producing a report on executive compensation to be included in our annual proxy statement; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">reviewing, evaluating and recommending changes, if appropriate, to the remuneration for directors. </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">119 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Nominating and Corporate Governance Committee </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Nominating and Corporate Governance Committee consists of Messrs. Steven Heyer and Beer and Dr.&#160;Cone, with Mr.&#160;Steven Heyer serving as the chairperson. The principal functions of the Nominating and Corporate Governance Committee include, among other things: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">screening and reviewing individuals qualified to serve as directors, consistent with criteria approved by our Board, and recommending to our Board of Director candidates for nomination for election at annual meetings of stockholders or to fill vacancies on our Board; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">developing and recommending to our Board and overseeing implementation of our Corporate Governance Guidelines; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">coordinating and overseeing the annual self-evaluation of the Board of Directors, its committees, individual directors and management in the governance of the Company; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">reviewing on a regular basis our overall corporate governance and recommending improvements as and when necessary. </p></td></tr></table> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Board Leadership Structure </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our Bylaws provide our Board with the flexibility to combine or separate the positions of chairperson of the Board and Chief Executive Officer to reflect our evolving needs and strategy, changes in our Board&#8217;s composition and leadership needs, as well as other factors, including the views of our stockholders and other stakeholders. Our Corporate Governance Guidelines specify that our Board will select our Chief Executive Officer and chairperson of our Board in the manner that it determines to be in the best interests of our stockholders. We do not believe there should be a fixed rule regarding the positions of Chief Executive Officer and chairperson being held by different individuals, or whether the chairperson should be an employee of the Company or should be elected from among the <span style="white-space:nowrap">non-employee</span> directors. The needs of the Company and the individuals available to assume these roles may require different outcomes at different times, and our Board believes that retaining flexibility in these decisions is in the best interests of the Company and its stockholders. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to its charter, the Nominating and Corporate Governance Committee periodically reviews this matter and make recommendations to our Board. The Nominating and Corporate Governance Committee has recommended, and our Board of directors has determined, that the roles of Chief Executive Officer and chairperson of our Board of directors should be separate. The role of chairperson is currently held by Mr.&#160;Beer, a <span style="white-space:nowrap">non-employee</span> director. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Role of the Board in Risk Oversight </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A key function of our Board is informed oversight of our risk management process. In particular, our Board is responsible for monitoring and assessing strategic risk exposure, including a determination of the nature and level of risk appropriate for the Company. Our Board does not have a standing risk management committee, but rather administers this oversight function directly through our Board as a whole, as well as through various standing committees of our Board that address risks inherent in their respective areas of oversight. Our Board and its committees consider specific risk topics, including risks associated with our strategic plan, business operations, capital structure, information technology, data privacy and cyber security. It is the responsibility of the committee chairpersons to report findings regarding material risk exposures to our Board as quickly as possible. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our Audit Committee has the responsibility to consider and discuss with management and the auditors, as appropriate, our guidelines and policies with respect to financial risk management and financial risk assessment, including our major financial risk exposures and the steps taken by management to monitor and control these exposures. Areas of focus for our Audit Committee include our policies and other matters relating to our </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">120 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
investments, cash management and foreign exchange management, major financial risk exposures, the adequacy and effectiveness of our information security policies and practices and the internal controls regarding information security, and the steps taken by management to monitor and mitigate or otherwise control these exposures and to identify future risks. Our Compensation Committee assesses and monitors whether any of our compensation policies and programs has the potential to encourage excessive risk-taking, including risks related to executive compensation and overall compensation and benefit strategies, plans, arrangements, practices and policies. Our Nominating and Corporate Governance Committee monitors the effectiveness of our Corporate Governance Guidelines, including whether they are successful in preventing illegal or improper liability-creating conduct. The Nominating and Corporate Governance Committee also oversees and reviews with management our major legal compliance risk exposures and the steps management has taken to monitor or mitigate such exposures. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In connection with its reviews of our business operations and corporate functions, our Board addresses the primary risks associated with those operations and corporate functions. In addition, our Board reviews the risks associated with our business strategies periodically throughout the year as part of its consideration of undertaking any such business strategies. While our Board and its committees oversee risk management strategy, management is responsible for implementing and supervising <span style="white-space:nowrap"><span style="white-space:nowrap">day-to-day</span></span> risk management processes and reporting to our Board and its committees on such matters. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Code of Conduct and Ethics </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have adopted a code of ethics (the &#8220;Code of Ethics&#8221;) applicable to our directors, executive officers and employees that complies with the rules and regulations of Nasdaq, which is available on the Governance section of our investor relations website at <span style="font-style:italic">ir.biote.com</span>. In addition, we intend to post on our website all disclosures that are required by law or the Nasdaq listing standards concerning any amendments to, or waivers from, any provision of the Code of Ethics. The reference to our website address does not constitute incorporation by reference of the information contained at or available through our website, and you should not consider it to be a part of this registration statement. We also intend to disclose any amendments to or waivers of certain provisions of our Code of Ethics in a Current Report on Form <span style="white-space:nowrap">8-K.</span> You may review these documents by accessing public filings at the SEC&#8217;s web site at www.sec.gov. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">121 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center" id="toc479690_12">EXECUTIVE COMPENSATION </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This section discusses the material components of the executive compensation program for our named executive officers who are identified in the 2022 Summary Compensation Table below, who are also the named executive officers of Biote. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Overview </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have opted to comply with the executive compensation disclosure rules applicable to emerging growth companies, as the Company is an emerging growth company. The scaled down disclosure rules require compensation disclosure for our principal executive officer and its two most highly compensated executive officers other than the principal executive officer whose total compensation for 2022 exceeded $100,000 and who were serving as executive officers as of December&#160;31, 2022. We refer to these individuals as &#8220;named executive officers.&#8221; For 2022, our named executive officers were: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Teresa S. Weber, Biote&#8217;s Chief Executive Officer; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Samar Kamdar, Chief Financial Officer; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Mary Elizabeth Conlon, Vice President, Business Development&#160;&amp; General Counsel. </p></td></tr></table> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">2022 Compensation of Named Executive Officers </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Summary Compensation Table </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table sets forth information for each of the last two completed fiscal years regarding compensation awarded to or earned by our Chief Executive Officer and the two other most highly compensated executive officers, or collectively, the named executive officers, during the fiscal years indicated: </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">


<tr>

<td style="width:41%"></td>

<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom;white-space:nowrap"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman;font-weight:bold">Name and Principal Position</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Year</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Salary<sup style="font-size:75%; vertical-align:top">(1)</sup></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Stock</span><br /><span style="font-weight:bold">Awards<sup style="font-size:75%; vertical-align:top">(2)</sup></span><br /><span style="font-weight:bold">($)</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Option</span><br /><span style="font-weight:bold">Awards<sup style="font-size:75%; vertical-align:top">(2)</sup></span><br /><span style="font-weight:bold">($)</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold"><span style="white-space:nowrap">Non-Equity</span></span><br /><span style="font-weight:bold">Incentive Plan</span><br /><span style="font-weight:bold">Compensation<sup style="font-size:75%; vertical-align:top">(5)</sup></span><br /><span style="font-weight:bold">($)</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">All Other</span><br /><span style="font-weight:bold">Compensation<sup style="font-size:75%; vertical-align:top">(3)</sup></span><br /><span style="font-weight:bold">($)</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Total ($)</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Teresa S. Weber</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">2022</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">541,392</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">340,160</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">2,689,432</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">3,158,852</td>
<td style="white-space:nowrap;vertical-align:bottom"><sup style="font-size:75%; vertical-align:top">(4)</sup>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">6,729,835</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Chief Executive Officer</span></p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">2021</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1,472,530</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1,799</td>
<td style="white-space:nowrap;vertical-align:bottom"><sup style="font-size:75%; vertical-align:top">(8)</sup>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1,474,329</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Samar Kamdar<sup style="font-size:75%; vertical-align:top">(6)</sup></p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">2022</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">118,462</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">595,945</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">44,940</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">3,556</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">762,890</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Chief Financial Officer</span></p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">2021</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Mary Elizabeth Conlon<sup style="font-size:75%; vertical-align:top">(7)</sup></p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">2022</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">355,038</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">291,212</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">110,811</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">9,150</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">766,211</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Vice President, Business Development&#160;&amp; General Counsel</span></p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">2021</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">167,308</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1,436,555</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">35,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">2,423</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1,641,286</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
</table> <p style="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(1)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Salary amounts represent actual amounts earned during the applicable year. See &#8220;&#8212;Narrative to the Summary Compensation Table&#8212;Annual Base Salary&#8221; below. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(2)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Amounts represent the aggregate grant date fair value of the awards granted to our named executive officers during the years indicated as computed in accordance with Accounting Standards Codification Topic 718 (&#8220;ASC 718&#8221;). For additional information on these awards, please see &#8220;&#8212;Outstanding Equity Awards at Fiscal <span style="white-space:nowrap">Year-End.&#8221;</span> </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(3)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">The amounts in this column represent Biote&#8217;s matching contributions to the named executive officer&#8217;s 401(k) plan. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(4)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Amount includes $2,808,342 of performance-based cash bonuses awarded to Ms.&#160;Weber during the fiscal year ended December&#160;31, 2022 in connection with the Closing of the Business Combination. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(5)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Amounts reflect target performance-based cash bonuses awarded to our named executive officers. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(6)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Mr.&#160;Kamdar was appointed as the Company&#8217;s Chief Financial Officer, effective August&#160;24, 2022. Amounts in the table reflect actual compensation awarded to Mr.&#160;Kamdar and are not annualized. </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">122 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(7)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Ms.&#160;Conlon was appointed as the Company&#8217;s Vice President, Business Development&#160;&amp; General Counsel in June 2021. Amounts in the table reflect actual compensation awarded to Ms.&#160;Conlon and are not annualized. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(8)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">For Ms.&#160;Weber, the amounts in this column also include reimbursements for participation in certain professional association activities incurred for our year ended December&#160;31, 2021. </p></td></tr></table> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Narrative to the Summary Compensation Table </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Annual Base Salary </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our named executive officers receive a base salary to compensate them for services rendered to us. The base salary payable to each named executive officer is intended to provide a fixed component of compensation reflecting the executive&#8217;s skill set, experience, role and responsibilities. None of our named executive officers is currently party to an employment agreement or other agreement or arrangement that provides for automatic or scheduled increases in base salary. See &#8220;&#8212;Employment Arrangements&#8221; for additional information. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table sets forth the annual base salaries for our named executive officers for 2021 and 2022. </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto">


<tr>

<td style="width:74%"></td>

<td style="vertical-align:bottom;width:3%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:3%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="border-bottom:1.00pt solid #000000;vertical-align:bottom;white-space:nowrap"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold">Name</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">2021&#160;Base</span><br /><span style="font-weight:bold">Salary</span><br /><span style="font-weight:bold">($)</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">2022&#160;Base</span><br /><span style="font-weight:bold">Salary</span><br /><span style="font-weight:bold">($)</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Teresa S. Weber</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">400,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">575,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Samar Kamdar<sup style="font-size:75%; vertical-align:top">(1)</sup></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">N/A</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">350,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Mary Elizabeth Conlon<sup style="font-size:75%; vertical-align:top">(2)</sup></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">300,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">395,400</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
</table> <p style="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(1)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Mr.&#160;Kamdar was appointed as the Company&#8217;s Chief Financial Officer, effective August&#160;24, 2022. The base salary reflected for Mr.&#160;Kamdar represents his annualized salary. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(2)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Ms.&#160;Conlon was appointed as the Company&#8217;s Vice President, Business Development&#160;&amp; General Counsel in June 2021. </p></td></tr></table> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic"><span style="white-space:nowrap">Non-Equity</span> Incentive Plan Compensation </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We seek to motivate and reward our executives for achievements relative to our corporate goals and expectations for each fiscal year. In accordance with the terms of their respective employment agreements, our named executive officers are eligible to receive discretionary annual bonuses of up to a percentage of each executive&#8217;s gross base salary based on individual performance, company performance or as otherwise determined appropriate, as determined by the Compensation Committee of the Board. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Board previously approved specified company and individual performance metrics for annual bonuses for our executives for fiscal 2022 as well as target bonuses for certain executives of the Company. Mr.&#160;Kamdar was eligible to receive a <span style="white-space:nowrap">pro-rated</span> bonus award for the portion of 2022 during which he was employed by us. The Compensation Committee has reviewed the Company&#8217;s fiscal year 2022 corporate performance, reflecting a 100% achievement of the 2022 Corporate Goals, and deemed it advisable to approve a bonus pool in the amount of $87,109 for <span style="white-space:nowrap">non-executive</span> employees, based on the 2022 Corporate Goals Achievement, for the payment of 2022 cash performance bonuses to <span style="white-space:nowrap">non-executive</span> employees of the Company. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table sets forth the bonus amounts for our named executive officers for 2022. </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:68%;border:0;margin:0 auto">


<tr>

<td style="width:82%"></td>

<td style="vertical-align:bottom;width:4%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="border-bottom:1.00pt solid #000000;vertical-align:bottom;white-space:nowrap"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold">Name</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">2022&#160;Bonus</span><br /><span style="font-weight:bold">Amount</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Teresa S. Weber<sup style="font-size:75%; vertical-align:top">(1)</sup></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">3,158,852</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Samar Kamdar<sup style="font-size:75%; vertical-align:top">(2)</sup></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">4,940</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Mary Elizabeth Conlon</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">110,811</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
</table> <p style="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(1)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Amount includes $2,808,342 of performance-based cash bonuses awarded to Ms.&#160;Weber during the fiscal year ended December&#160;31, 2022 in connection with the Closing of the Business Combination. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(2)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Mr.&#160;Kamdar was appointed as the Company&#8217;s Chief Financial Officer, effective August&#160;24, 2022. </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">123 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Equity-Based Incentive Awards </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our equity-based incentive awards granted to our named executive officers are designed to align our interests and those of our stockholders with those of our employees and consultants, including our executive officers. As of the date of this registration statement, stock awards and stock option awards were the only form of equity awards we have granted to any of our executive officers. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We use stock options as an incentive for long-term compensation to our executive officers because the stock options allow our executive officers to profit from this form of equity compensation only if our stock price increases relative to the stock option&#8217;s exercise price, which exercise price is set at the fair market value of our Common Stock on the date of grant. Vesting of equity awards is generally tied to each officer&#8217;s continuous service with us and serves as an additional retention measure. We may grant equity awards at such times as the Board or Compensation Committee determines appropriate. Our executives generally are awarded an initial grant in the form of a stock option award in connection with their commencement of employment with us. Additional grants may occur periodically in order to specifically incentivize executives with respect to achieving certain corporate goals or to reward executives for exceptional performance. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of the date of this registration statement, we have granted all stock options pursuant to our 2022 Equity Incentive Plan. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">All options are granted with an exercise price per share that is no less than the fair market value of our Common Stock on the date of grant of such award. Our stock option awards generally vest over a four-year period and may be subject to acceleration of vesting and exercisability under certain termination and change in control events. See &#8220;&#8212;Outstanding Equity Awards at Fiscal <span style="white-space:nowrap">Year-End.&#8221;</span> </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Outstanding Equity Awards at Fiscal <span style="white-space:nowrap">Year-End</span> </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table presents information regarding outstanding equity awards held by our named executive officers as of December&#160;31, 2022. All awards were granted pursuant to the Incentive Plan. </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt;width:100%;border:0;margin:0 auto">


<tr>

<td style="width:40%"></td>

<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="14" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Option Awards</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="6" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Stock Awards</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="border-bottom:1.00pt solid #000000;vertical-align:bottom;white-space:nowrap"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold">Name</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Number&#160;of</span><br /><span style="font-weight:bold">Securities</span><br /><span style="font-weight:bold">Underlying</span><br /><span style="font-weight:bold">Unexercised</span><br /><span style="font-weight:bold">Options (#)</span><br /><span style="font-weight:bold">Exercisable</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Number&#160;of</span><br /><span style="font-weight:bold">Securities</span><br /><span style="font-weight:bold">Underlying</span><br /><span style="font-weight:bold">Unexercised</span><br /><span style="font-weight:bold">Options (#)</span><br /><span style="font-weight:bold">Unexercisable</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Option</span><br /><span style="font-weight:bold">Exercise</span><br /><span style="font-weight:bold">Price<sup style="font-size:75%; vertical-align:top">(1)</sup>&#160;($)</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Option</span><br /><span style="font-weight:bold">Expiration</span><br /><span style="font-weight:bold">Date</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Number&#160;of</span><br /><span style="font-weight:bold">Shares or</span><br /><span style="font-weight:bold">Units of</span><br /><span style="font-weight:bold">Stock that</span><br /><span style="font-weight:bold">Have Not</span><br /><span style="font-weight:bold">Vested (#)</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Market&#160;Value</span><br /><span style="font-weight:bold">of Shares</span><br /><span style="font-weight:bold">or Units of</span><br /><span style="font-weight:bold">Stock that</span><br /><span style="font-weight:bold">Have Not</span><br /><span style="font-weight:bold">Vested<sup style="font-size:75%; vertical-align:top">(2)</sup> ($)</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt;background-color:#cceeff">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Teresa S. Weber</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">1,137,430</td>
<td style="white-space:nowrap;vertical-align:bottom"><sup style="font-size:75%; vertical-align:top">(3)</sup>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">$</td>
<td style="vertical-align:bottom" align="right">4.00</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">9/14/2032</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">85,040</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">317,199</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Samar Kamdar<sup style="font-size:75%; vertical-align:top">(4)</sup></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">250,000</td>
<td style="white-space:nowrap;vertical-align:bottom"><sup style="font-size:75%; vertical-align:top">(3)</sup>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">$</td>
<td style="vertical-align:bottom" align="right">4.00</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">9/14/2032</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt;background-color:#cceeff">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Mary Elizabeth Conlon</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">123,161</td>
<td style="white-space:nowrap;vertical-align:bottom"><sup style="font-size:75%; vertical-align:top">(3)</sup>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">$</td>
<td style="vertical-align:bottom" align="right">4.00</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">9/14/2032</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">63,606</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">237,250</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
</table> <p style="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(1)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">All of the option awards listed in the table were granted with an exercise price per share that is no less than the fair market value of our Class&#160;A common stock on the date of grant of such award, as determined in good faith by the Board. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(2)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">The market value of unvested shares is calculated by multiplying the number of unvested shares by the closing market price of our Class&#160;A common stock on Nasdaq on December&#160;30, 2022, the last trading day of the year, which was $3.73 per share. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(3)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">50% of the shares vest on the second-year anniversary of the vesting commencement date, with the remainder of the shares vesting in 24 equal monthly installments thereafter, subject to the recipient&#8217;s continuous service through each applicable vesting date. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(4)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Mr.&#160;Kamdar was appointed as the Company&#8217;s Chief Financial Officer, effective August&#160;24, 2022. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">See &#8220;&#8212;Potential Payments and Benefits upon Termination or Change of Control&#8221; for a description of vesting acceleration applicable to stock options held by our named executive officers. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">124 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may in the future, on an annual basis or otherwise, grant additional equity awards to our executive officers pursuant to our Incentive Plans. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Benefits and Perquisites </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We provide benefits to our named executive officers on the same basis as provided to all of our employees, including health, dental and vision insurance; life insurance; accidental death and dismemberment insurance; employee assistance program; life planning, financial and legal resources; and worldwide emergency travel assistance. We do not maintain any executive-specific benefit or executive perquisite programs other than as provided in the agreements described in the section immediately below. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Other than the director and officer insurance coverage we maintain for our directors and officers, we do not maintain any executive-specific health and welfare benefit or perquisites. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Health and Welfare Benefits and Perquisites </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We provide benefits to our named executive officers on the same basis as provided to all of our employees, including: health, dental and vision insurance; life insurance; accidental death and dismemberment insurance; life planning financial and legal resources; and worldwide emergency travel assistance. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">401(k) Plan </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Biote&#8217;s named executive officers are eligible to participate in a defined contribution retirement plan that provides eligible U.S. employees with an opportunity to save for retirement on a tax advantaged basis. Eligible employees may contribute a portion of their annual compensation to the 401(k) Plan, subject to the maximum annual amounts as set periodically by the IRS. The Company makes a safe harbor, <span style="white-space:nowrap">non-elective</span> contribution to the 401(k) Plan equal to 3% of each participant&#8217;s eligible employee compensation. Safe harbor contributions vest immediately for each participant. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Employment Arrangements </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Below are descriptions of our employment agreements and arrangements with our named executive officers. The agreements generally provide for <span style="white-space:nowrap">at-will</span> employment without any specific term and set forth the named executive officer&#8217;s initial base salary and annual target bonus. Each named executive officer is also eligible to participate in all employee benefit plans that are generally available to our employees. Furthermore, each of our named executive officers has executed our standard employee confidential information and invention assignment agreement, which includes, among other things, <span style="white-space:nowrap">non-solicitation</span> and <span style="white-space:nowrap">non-competition</span> provisions. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Teresa S. Weber </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Biote Medical entered into a services agreement with Ms.&#160;Weber effective as of May&#160;26, 2022. Ms.&#160;Weber&#8217;s services agreement provides that she will serve as the Chief Executive Officer of Biote and BioTE Management, LLC, and as a member of the Board, receive an annual base salary of $575,000 and be eligible for a discretionary annual cash bonus, with a target of 100% of base salary based on annual performance standards to be established and determined by Biote in its sole discretion. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, Ms.&#160;Weber&#8217;s services agreement provides for severance benefits upon an involuntary termination. Ms.&#160;Weber&#8217;s amended and restated employment agreement provides that if Ms.&#160;Weber&#8217;s employment is terminated without cause or with good reason she shall receive (a)&#160;continuation of her then-current base salary plus (b)&#160;payment of monthly COBRA premiums for continuation coverage under her medical, dental and life insurance plans coverage (if any) as in effect on the day prior to the effective date of her termination, for a period of 18 months if such termination is in connection with a change in control event, or 12 </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">125 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
months if such termination is not in connection with a change in control event. In addition, in the event such termination is in connection with a change in control event, Ms.&#160;Weber shall also receive a monthly payment in an amount equal to 1/12th of her then-current target bonus for a period of 18 months. Such payments are contingent on Ms.&#160;Weber&#8217;s execution and nonrevocation of an effective written release of claims and the COBRA premium payments shall cease in the event Ms.&#160;Weber (i)&#160;becomes eligible for substantially equivalent health insurance coverage in connection with new employment or self-employment or (ii)&#160;ceases to be eligible for COBRA continuation coverage. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Samar Kamdar </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On July&#160;15, 2022, Biote Medical entered into an employment agreement with Samar Kamdar, which was amended on August&#160;24, 2022. The employment agreement provides for Mr.&#160;Kamdar&#8217;s <span style="white-space:nowrap">at-will</span> employment as the Chief Financial Officer for a term commencing on August&#160;24, 2022 and continuing until terminated by either the Company or Mr.&#160;Kamdar. Under the terms of the Employment Agreement, Mr.&#160;Kamdar will be entitled to: (i)&#160;an annualized base salary of $350,000 per year; (ii)&#160;an annual bonus of up to 40% of his base salary; (iii)&#160;an initial grant of 250,000 stock options pursuant to the Company&#8217;s Incentive Plan and eligibility to participate in the Incentive Plan; and (iv)&#160;eligibility to participate in the Company&#8217;s employee benefit plans and programs in accordance with the terms and conditions of the applicable plans and programs. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, Mr.&#160;Kamdar&#8217;s employment agreement provides that if Mr.&#160;Kamdar&#8217;s employment is terminated without cause or with good reason he shall receive (i)&#160;continuation of his then-current base salary plus (ii)&#160;payment of monthly COBRA premiums for continuation coverage under his medical, dental and life insurance plans coverage (if any) as in effect on the day prior to the effective date of his termination, for a period of 12 months if such termination is in connection with a change in control event, or 9 months if such termination is not in connection with a change in control event. In addition, in the event such termination is in connection with a change in control event, Mr.&#160;Kamdar shall also receive a monthly payment an amount equal to 1/12th of his then-current target bonus for a period of 12 months. Such payments are contingent on Mr.&#160;Kamdar&#8217;s execution and nonrevocation of an effective written release of claims and the COBRA premium payments shall cease in the event Mr.&#160;Kamdar (i)&#160;becomes eligible for substantially equivalent health insurance coverage in connection with new employment or self-employment or (ii)&#160;ceases to be eligible for COBRA continuation coverage. Biote has also entered into an indemnification agreement with Mr.&#160;Kamdar on the same terms as it has with its other directors and executive officers. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Mary Elizabeth Conlon </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On May&#160;31, 2022, Biote Medical entered into an employment agreement with Mary Elizabeth Conlon, effective as of May&#160;26, 2022. Ms.&#160;Conlon&#8217;s employment agreement provides that she will serve as Biote&#8217;s Vice President, Business Development&#160;&amp; General Counsel, receive an annual base salary of $395,400 and be eligible for a discretionary annual cash bonus, with a target of 40% of base salary based on annual performance standards to be established and determined by Biote in its sole discretion. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, Ms.&#160;Conlon&#8217;s employment agreement provides that if Ms.&#160;Conlon&#8217;s employment is terminated without cause or with good reason she shall receive (a)&#160;continuation of her then-current base salary plus (b)&#160;payment of monthly COBRA premiums for continuation coverage under her medical, dental and life insurance plans coverage (if any) as in effect on the day prior to the effective date of her termination, for a period of 12 months if such termination is in connection with a change in control event, or 9 months if such termination is not in connection with a change in control event. In addition, in the event such termination is in connection with a change in control event, Ms.&#160;Conlon shall also receive a monthly payment an amount equal to 1/12th of her then-current target bonus for a period of 12 months. Such payments are contingent on Ms.&#160;Conlon&#8217;s execution and nonrevocation of an effective written release of claims and the COBRA premium payments shall cease in the event Ms.&#160;Conlon (i)&#160;becomes eligible for substantially equivalent health insurance coverage in connection with new employment or self-employment or (ii)&#160;ceases to be eligible for COBRA continuation </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">126 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
coverage. Biote has also entered into an indemnification agreement with Ms.&#160;Conlon on the same terms as it has with its other directors and executive officers. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Marc Beer </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Biote Medical entered into an executive chair agreement with Mr. Beer effective as of May 26, 2022, providing for Mr. Beer to serve as Biote&#8217;s Executive Chairman of the Board, receive a cash fee of $242,000 and be eligible for a discretionary annual cash bonus, with a target of 100% of cash fee based on financial performance standards of the Company to be established and determined by Biote in its sole discretion. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Potential Payments Upon Termination or Change in Control </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The employment agreements for our named executive officers provide for severance and change in control benefits as described above under &#8220;&#8212;Employment Arrangements.&#8221; </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Equity Benefit Plans </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Equity-based compensation has been and will continue to be an important foundation in executive compensation packages as Biote believes it is important to maintain a strong link between executive incentives and the creation of stockholder value. Biote believes that performance and equity-based compensation can be an important component of the total executive compensation package for maximizing stockholder value while, at the same time, attracting, motivating and retaining high-quality executives. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">127 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center" id="toc479690_13">CERTAIN RELATIONSHIPS AND RELATED PARTY TRANSACTIONS </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Other than compensation and indemnification arrangements for our directors and executive officers, which are described elsewhere in this registration statement, the following is a description of each transaction since January&#160;1, 2021 and each currently proposed transaction in which: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">HYAC or Biote has been or is to be a participant; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the amounts involved exceeded or exceeds the lesser of (i) $120,000 or (ii)&#160;one percent of the average of our total assets on a consolidated basis at year end for the past two fiscal years; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">any of our directors, executive officers or holders of more than five percent of our outstanding capital stock, or any immediate family member of, or person sharing the household with, any of these individuals or entities, had or will have a direct or indirect material interest. </p></td></tr></table> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">HYAC&#8217;s Related Party Transactions </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On July&#160;6, 2020, the Sponsor paid $25,000 to cover certain of HYAC&#8217;s offering costs in exchange for 8,625,000 shares of Class&#160;B common stock, 687,500 of which were subsequently forfeited in connection with the partial exercise of the over-allotment option by the underwriters in order for the Sponsor to maintain ownership of 20.0% of the issued and outstanding shares of the Company. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Sponsor purchased an aggregate of 5,566,666 private placement warrants, exercisable for one share of Class&#160;A common stock at $11.50 per share for an aggregate purchase price of $8,350,000, or $1.50 per warrant, in a private placement that occurred simultaneously with HYAC&#8217;s IPO, consummated on March&#160;4, 2021. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Prior to the Business Combination, HYAC utilized office space at 501 Madison Avenue, Floor 12, New York, New York 10022 from our Sponsor. HYAC paid an affiliate of our Sponsor $20,000 per month for office space, utilities, secretarial and administrative services provided to our directors and officers. Upon completion of the Business Combination, HYAC ceased paying these monthly fees. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Sponsor agreed to loan HYAC up to $300,000 to be used for a portion of the expenses of the IPO. These loans were <span style="white-space:nowrap">non-interest</span> bearing, unsecured and were due at the earlier of December&#160;31, 2020 or the closing of the IPO. The loan was fully paid off at the completion of the IPO on March&#160;4, 2021. On February&#160;28, 2022, HYAC issued an unsecured promissory note in the principal amount of $350,000 to the Sponsor. This loan is <span style="white-space:nowrap">non-interest</span> bearing. At the election of the Sponsor, all or a portion of the unpaid principal amount of such note may be converted into private placement warrants of Biote at a price of $1.50 per warrant. The principal balance of the promissory note was due on the Closing Date. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Biote&#8217;s Related Party Transactions </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Employment Relationships </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Mandy Cotten, the daughter of Dr.&#160;Gary&#160;S. Donovitz, Biote&#8217;s founder, former chairman and one of our five&#160;percent or greater stockholders, was employed by BioTE Medical as a Clinic Director from September&#160;1, 2015 to June&#160;14, 2022. Mandy Cotten also provided services as a proctor and, from January&#160;1, 2021 to June&#160;14, 2022, Mandy Cotten also managed Biote&#8217;s therapy hotline. Mandy Cotten&#8217;s compensation included an annual salary of $137,000 in addition to a potential bonus based on services performed for Biote. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">BioTE Medical granted Mandy Cotten phantom equity for her contributions as key personnel pursuant to that certain Phantom Equity Rights Grant Notice and Award Agreement, dated January&#160;1, 2021, by and between BioTE Medical and Mandy Cotten (the &#8220;Cotten Phantom Equity Award&#8221;), which were forfeited as a result of her departure on June&#160;9, 2022. Pursuant to the Cotten Phantom Equity Award, Mandy Cotten was entitled to receive a stated percentage of the net sales proceeds of a change in control paid or payable to Biote or Biote&#8217;s Members. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">128 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
BioTE Medical&#8217;s board of managers determined that the net sale proceeds from the Business Combination was $555,000,000, and that such amount would be satisfied through the issuance of, in the aggregate, approximately 138,750 shares of the Company&#8217;s Class&#160;A common stock to Mandy Cotten, to be issued in eight equal quarterly installments following the Closing of the Business Combination; however, the Cotten Phantom Equity Award was forfeited as a result of her departure on June&#160;9, 2022. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Lani Hammonds-Donovitz, the wife of Dr.&#160;Gary&#160;S. Donovitz, Biote&#8217;s founder, former chairman and one of our five percent or greater stockholders, was employed by BioTE Medical from January&#160;1, 2021 through April&#160;30, 2021 as Director, Business Development &#8211; Research. Effective May&#160;1, 2021, Ms.&#160;Donovitz became an independent contractor of BioTE Medical pursuant to that certain Independent Contractor Agreement with Lani D. Consulting, a company affiliated with Ms.&#160;Hammonds-Donovitz, which was terminated immediately prior to the Closing. Total compensation received by Ms.&#160;Donovitz and Lani D. Consulting was $157,639 and $265,936 for the years ended December&#160;31, 2022 and 2021. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Founder Advisory Agreement </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On May&#160;18, 2022, BioTE Medical and Dr.&#160;Gary&#160;S. Donovitz, MD, the founder of BioTE Medical (the &#8220;Founder Advisor&#8221;), entered into a Founder Advisory Agreement, effective as of the Closing (the &#8220;Founder Advisory Agreement&#8221;). Pursuant to the Founder Advisory Agreement, the Founder Advisor transitioned from an officer and manager of BioTE Medical into the role of Founder Advisor and Senior Advisor (as defined in the Founder Advisory Agreement) as of the Closing. Pursuant to the Founder Advisory Agreement, Founder Advisor provides strategic advisory services to BioTE Medical for a period of four years, unless terminated earlier pursuant to the terms of the Founder Advisory Agreement, and receives an annual fee equal to $300,000 per year, continued coverage under BioTE Medical&#8217;s employee benefits and reimbursement for reasonable business expenses. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Independent Contractor Agreement </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On May&#160;18, 2022, BioTE Medical entered into an Independent Contractor Agreement with Lani D. Consulting, a company affiliated with Lani Hammonds Donovitz, the wife of Dr.&#160;Gary&#160;S. Donovitz, MD, Biote&#8217;s founder and one of our five percent or greater stockholders (the &#8220;<span style="font-weight:bold"><span style="font-style:italic">New Independent Contractor Agreement</span></span>&#8221;). Immediately upon the Closing, the New Independent Contractor Agreement replaced the Independent Contractor Agreement, dated as of May&#160;3, 2021, between Lani D. Consulting and BioTE Medical. Pursuant to the New Independent Contractor Agreement, Lani D. Consulting will provide certain services to BioTE Medical for a period of four years, unless terminated earlier pursuant to the terms of the New Independent Contractor Agreement, and will receive an annual fee equal to $250,000 per year and reimbursement for reasonable business expenses. The New Independent Contractor Agreement was terminated effective September&#160;9, 2022. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Related Party Transactions in Connection with the Business Combination </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Tax Receivable Agreement </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Simultaneously with the Closing, Biote entered into a tax receivable agreement (the &#8220;TRA&#8221;) with Holdings, the Members and the Members&#8217; Representative. Pursuant to the TRA, Biote generally will be required to pay to the Members 85% of certain net tax benefits, if any, that we realize (or in certain cases are deemed to realize) as a result of the increases in tax basis and tax benefits related to the transactions contemplated under the Business Combination Agreement and the redemption of Retained Holdings Units in exchange for Class&#160;A common stock (or cash) pursuant to the Holdings A&amp;R OA, and tax benefits attributable to payments under the TRA. The term of the TRA will continue until all such tax benefits have been utilized or expired unless Biote exercises its right to terminate the TRA for an amount representing the present value of anticipated future tax benefits under the TRA (calculated under certain assumptions) or certain other acceleration events occur. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">129 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Sponsor Letter </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In connection with the execution of the Business Combination Agreement, certain of HYAC&#8217;s then current officers and directors, the Sponsor, Biote, Holdings and the Members&#8217; Representative entered into the &#8220;Sponsor Letter&#8221;, pursuant to which, among other things, the Sponsor agreed to (i)&#160;vote, at any duly called meeting of stockholders of the Company, in favor of the Business Combination Agreement and the transactions contemplated thereby, (ii)&#160;subject to certain exceptions, not to effect any sale or distribution of any of its shares of Class&#160;B common stock or private placement warrants and (iii)&#160;waive any and all anti-dilution rights described in the current charter or otherwise with respect to the shares of Class&#160;B common stock held by the Sponsor that may be implicated by the Business Combination such that the Class&#160;B common stock Conversion will occur as discussed herein (and as more fully described in the Sponsor Letter). </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">A&amp;R Investor Rights Agreement </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">At the Closing, Biote, the Members, the Sponsor, the Members&#8217; Representative and certain other parties entered into an investor rights agreement, which was amended and restated on July&#160;19, 2022, and which we refer to as the A&amp;R IRA. Pursuant to the terms of the A&amp;R IRA, among other things, (i)&#160;that certain Registration Rights Agreement, by and between HYAC and certain security holders, dated March&#160;1, 2021, entered into in connection with HYAC&#8217;s IPO, was terminated, (ii)&#160;the Company provided certain registration rights for the shares of Class&#160;A common stock held (or underlying certain securities held) by the Members, the Sponsor, and certain other parties, (iii)&#160;the Members agreed not to, subject to certain exceptions, transfer, sell, assign or otherwise dispose of the shares of Class&#160;A common stock, Class&#160;V voting stock and the Holdings Units held by such Members, as applicable, for six months following the Closing, and the Member Earnout Units until the date such securities have been earned in accordance with the Business Combination Agreement and (iv)&#160;the Sponsor agreed not to, subject to certain exceptions, transfer, sell, assign or otherwise dispose of its (a)&#160;shares of Class&#160;A common stock (other than the Sponsor Earnout Shares, as defined therein) for six months following the Closing, (b)&#160;Sponsor Earnout Shares until the date such securities have been earned in accordance with the Business Combination Agreement and (c)&#160;warrants issued to the Sponsor pursuant to that certain Private Placement Warrants Purchase Agreement, dated March&#160;1, 2021, by and between the Company and the Sponsor, and the underlying shares of Class&#160;A common stock, for 30 days following the Closing Date (such <span style="white-space:nowrap">lock-up</span> period superseding the <span style="white-space:nowrap">lock-up</span> period set forth in the Insider Letter (as defined in the A&amp;R IRA)), in each case, as more fully described in the A&amp;R IRA). All <span style="white-space:nowrap">lock-up</span> restrictions, other than those related to the Member Earnout Units and the Sponsor Earnout Shares, have now expired. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The foregoing description of the A&amp;R IRA does not purport to be complete and is qualified in its entirety by the full text of the A&amp;R IRA, a copy of which is attached as Exhibit 10.3 hereto. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Second Amended and Restated Operating Agreement of Biote </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">At the Closing, Biote, Holdings and the Members entered into the Holdings A&amp;R OA, which, among other things, permitted the issuance and ownership of Holdings Units as contemplated to be issued and owned upon the consummation of the Business Combination, designated Biote as the sole manager of Holdings, provided for the Exchange Rights, set forth the rights and preferences of the Class&#160;A common units of Holdings (&#8220;Holdings Units&#8221;), and established the ownership of the Holdings Units by the persons or entities indicated in the Holdings A&amp;R OA. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The foregoing description of the Holdings A&amp;R OA does not purport to be complete and is qualified in its entirety by the full text of the Holdings A&amp;R OA, a copy of which is attached as Exhibit 10.5 hereto. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Director and Officer Indemnification </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Charter contains provisions limiting the liability of directors and provides that the Biote will indemnify each of its directors and officers to the fullest extent permitted under Delaware law. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">130 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have entered into indemnification agreements with each of our directors and executive officers. The indemnification agreements provide that Biote will indemnify each of its directors and executive officers against any and all expenses incurred by that director, executive officer, or other key employee because of his or her status as one of the Biote&#8217;s directors or executive officers to the fullest extent permitted by Delaware law, our Charter and our Bylaws. In addition, the indemnification agreements provide that, to the fullest extent permitted by Delaware law, the Biote will advance all expenses incurred by its directors and executive officers in connection with a legal proceeding involving his or her status as a director, executive officer, or key employee. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Policies and Procedures for Related Person Transactions </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Board adopted a written related person transaction policy that sets forth the policies and procedures for the review and approval or ratification of related person transactions (the &#8220;RPT Policy&#8221;). The RPT policy requires that a &#8220;related person&#8221; (as defined in paragraph (a)&#160;of Item 404 of Regulation <span style="white-space:nowrap">S-K)</span> must promptly disclose to the our general counsel any &#8220;related person transaction&#8221; (defined as any transaction that is reportable under Item 404(a) of Regulation <span style="white-space:nowrap">S-K</span> in which we are or will be a participant and the amount involved exceeds $120,000 and in which any related person has or will have a direct or indirect material interest) and all material facts with respect thereto. The general counsel will promptly communicate such information to the Audit Committee or another independent body of our Board. No related person transaction will be entered into without the approval or ratification of our Audit Committee or another independent body of our Board. Directors interested in a related person transaction will be required to recuse themselves from any such vote. The RPT Policy does not specify the standards to be applied by its Audit Committee or another independent body of the Board in determining whether or not to approve or ratify a related person transaction, although such determinations are made in accordance with Delaware law. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">131 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center" id="toc479690_14">PRINCIPAL SECURITYHOLDERS </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table sets forth information with respect to the beneficial ownership of our shares as of March&#160;15, 2023 by: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">each of our named executive officers; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">each of our directors; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">all of our current directors and executive officers as a group; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">each person known by us to be the beneficial owner of more than 5% of our Common Stock. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have determined beneficial ownership in accordance with the rules and regulations of the SEC and the information is not necessarily indicative of beneficial ownership for any other purpose. This table is based upon information supplied by officers, directors and principal stockholders and Schedules 13G or 13D filed with the SEC. Except as indicated by the footnotes below, we believe, based on information furnished to us, that the persons and entities named in the table below have sole voting and sole investment power with respect to all shares that they beneficially own, subject to applicable community property laws. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Applicable percentage ownership is based on 70,320,563 shares of Common Stock outstanding as of March&#160;15, 2023, which includes 10,000,000 Earnout Voting Shares and 1,587,400 Sponsor Earnout Shares. In computing the number of shares beneficially owned by a person and the percentage ownership of such person, we deemed to be outstanding all shares subject to options held by the person that are currently exercisable, or exercisable or would vest based on service-based vesting conditions within 60 days of March&#160;15, 2023. However, except as described above, we did not deem such shares outstanding for the purpose of computing the percentage ownership of any other person. </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto">


<tr>

<td style="width:69%"></td>

<td style="vertical-align:bottom;width:7%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:7%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="border-bottom:1.00pt solid #000000;vertical-align:bottom;white-space:nowrap"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold">Name of Beneficial Owner<sup style="font-size:75%; vertical-align:top">(1)</sup></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Number of</span><br /><span style="font-weight:bold">Shares</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Percentage</span><br /><span style="font-weight:bold">of Shares</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold"></span><span style="font-weight:bold"><span style="font-style:italic">Directors and Executive Officers:</span></span><span style="font-weight:bold"></span></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Steven J. Heyer<sup style="font-size:75%; vertical-align:top">(2)</sup></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">2,191,962</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">3.1</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Andrew R. Heyer<sup style="font-size:75%; vertical-align:top">(3)</sup></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">3,730,329</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">5.2</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Dana Jacoby<sup style="font-size:75%; vertical-align:top">(4)</sup></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">33,317</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">*</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Marc D. Beer<sup style="font-size:75%; vertical-align:top">(5)</sup></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">2,967,092</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">4.2</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">S. Mark Cone<sup style="font-size:75%; vertical-align:top">(6)</sup></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">116,667</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">*</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Debra L. Morris<sup style="font-size:75%; vertical-align:top">(7)</sup></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">40,565</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">*</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Teresa S. Weber<sup style="font-size:75%; vertical-align:top">(8)</sup></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">2,967,092</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">4.2</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Samar Kamdar</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">13,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">*</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Mary Elizabeth Conlon<sup style="font-size:75%; vertical-align:top">(9)</sup></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">133,269</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">*</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman;font-weight:bold">All directors and executive officers as a group (9 individuals)</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">12,193,293</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">16.6</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold"></span><span style="font-weight:bold"><span style="font-style:italic">Greater than Five Percent Holders:</span></span><span style="font-weight:bold"></span></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Dr.&#160;Gary&#160;S. Donovitz<sup style="font-size:75%; vertical-align:top">(10)</sup></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">23,343,672</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">33.2</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Donovitz Family Irrevocable Trust<sup style="font-size:75%; vertical-align:top">(11)</sup></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">18,072,607</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">25.7</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Boston Partners<sup style="font-size:75%; vertical-align:top">(12)</sup></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">988,528</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1.4</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Roystone Entities<sup style="font-size:75%; vertical-align:top">(13)</sup></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">3,520,951</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">5.0</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
</table> <p style="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">*</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Less than 1%. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(1)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Unless otherwise stated, the business address of each of these entities or individuals is 1875 W Walnut Hill Ln #100, Irving, TX 75038, United States. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(2)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Consists of (i) 729,856 shares of Class&#160;A common stock (which includes 126,132 Sponsor Earnout Shares), (ii) 1,442,737 Private Placement Warrants and (iii) 19,369 shares of Class&#160;A common stock issuable upon the exercise of options within 60 days of March&#160;15, 2023. </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">132 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(3)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Consists of (i) (a) 1,473,513 shares of Class&#160;A common stock (which includes 237,369 Sponsor Earnout Shares), (b) 957,568 Private Placement Warrants and (c) 19,369 shares of Class&#160;A common stock issuable upon the exercise of options within 60 days of March&#160;15, 2023 held by Mr.&#160;Andrew Heyer, (ii) (a) 345,201 shares of Class&#160;A common stock (which includes 42,375 Sponsor Earnout Shares) and (b) 204,281 Private Placement Warrants held by Heyer Investment Management, LLC, (iii) (a) 61,298 shares of Class&#160;A common stock (which includes 10,593 Sponsor Earnout Shares) and (b) 51,070 Private Placement Warrants held by Harris Reid Heyer Trust, (iv) (a) 61,298 shares of Class&#160;A common stock (which includes 10,593 Sponsor Earnout Shares) and (b) 51,070 Private Placement Warrants held by James Heyer Trust, (v) (a) 61,298 shares of Class&#160;A common stock (which includes 10,593 Sponsor Earnout Shares) and (b) 51,070 Private Placement Warrants held by Peter Justin Heyer Trust, (vi) (a) 61,298 shares of Class&#160;A common stock (which includes 10,593 Sponsor Earnout Shares) and (b) 51,070 Private Placement Warrants held by William Heyer Trust, and (vii) (a) 153,250 shares of Class&#160;A common stock (which includes 26,484 Sponsor Earnout Shares) and (b) 127,675 Private Placement Warrants held by the Mindy B. Heyer 2021 Grantor Retained Annuity Trust. Mr.&#160;Andrew Heyer is (i)&#160;a trustee of each of Harris Reid Heyer Trust, James Heyer Trust, Peter Justin Heyer Trust, and William Heyer Trust; and (ii)&#160;the managing member of Heyer Investment Management, LLC, and has voting and dispositive power of the securities held by such entities. Accordingly, Mr.&#160;Andrew Heyer may be deemed to have or share beneficial ownership of such securities. In addition, Mr.&#160;Andrew Heyer&#8217;s spouse is the sole trustee, grantor and recipient of annuity payments of the Mindy B. Heyer 2021 Grantor Retained Annuity Trust. Mr.&#160;Andrew Heyer disclaims beneficial ownership of the securities held by the Mindy B. Heyer 2021 Grantor Retained Annuity Trust, and the filing of this report should not be deemed an admission that Mr.&#160;Andrew Heyer is the beneficial owner of such securities. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(4)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Consists of (i) 23,473 shares of Class&#160;A common stock and (ii) 9,844 restricted stock units (&#8220;RSUs&#8221;) vesting within 60 days of March&#160;15, 2023. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(5)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Consists of 2,967,092 shares of Class&#160;A common stock underlying Class&#160;V voting stock (which includes 654,387 Earnout Voting Shares). </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(6)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Consists of (i) 106,823 shares of Class&#160;A common stock and (ii) 9,844 RSUs vesting within 60 days of March&#160;15, 2023. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(7)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Consists of (i) 30,000 shares of Class&#160;A common stock and (ii) 10,565 shares of Class&#160;A common stock issuable upon the exercise of options within 60 days of March&#160;15, 2023. Ms.&#160;Morris was appointed as a member of the Board on November&#160;3, 2022. All information regarding compensation and awards in this section reflects the compensation of Ms.&#160;Morris as a director from and after November&#160;3, 2022. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(8)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Consists of 2,967,092 shares of Class&#160;A common stock underlying Class&#160;V voting stock (which includes 654,387 Earnout Voting Shares). </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(9)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Consists of (i) 93,894 shares of Class&#160;A common stock and (ii) 39,375 RSUs vesting within 60 days of March&#160;15, 2023. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(10)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Consists of: (i) 848,726 shares of Class&#160;A common stock underlying Class&#160;V voting stock (which includes 144,918 Earnout Voting Shares) held by BioTE Management, LLC, of which Dr.&#160;Donovitz is the sole member; and (ii) 22,494,946 shares of Class&#160;A common stock underlying Class&#160;V voting stock (which includes 3,840,969 Earnout Voting Shares) held by the Gary S. Donovitz 2012 Irrevocable Trust (formerly Marci M. Donovitz Trust), of which Dr.&#160;Donovitz is the trustee. Dr.&#160;Donovitz exercises sole voting and dispositive power over the shares held by the trust. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(11)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Consists of 18,072,607 shares of Class&#160;A common stock underlying Class&#160;V voting stock (which includes 3,985,887 Earnout Voting Shares) held by the Donovitz Family Irrevocable Trust, of which Marci Donovitz is the trustee and beneficial owner. The business address of the Donovitz Family Irrevocable Trust is Synergy Wealth Partners, 600 N Shepherd Drive, Suite 200, Houston, TX 77007. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(12)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Information based on the Schedule 13G filed with the SEC on February&#160;7, 2023. The shares of Class&#160;A common stock beneficially owned by Boston Partners, represent approximately 5.0% of the outstanding shares of Class&#160;A common stock. The business address of Boston Partners is One Beacon Street, 30th Floor, Boston, MA 02108. </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">133 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(13)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Information based on the Schedule 13G, Form 3 and Form 4 filed with the SEC on February&#160;17, 2023, which report beneficial ownership for each of: (i)&#160;Roystone Capital Management LP (&#8220;Roystone Management&#8221;); (ii) Roystone Capital Holdings LLC (&#8220;Roystone Capital&#8221;); (iii) Guines LLC and (iv)&#160;Richard Barrerra (together with Roystone Management, Roystone Capital and Guines LLC, the &#8220;Roystone Entities&#8221;). These filings indicate that (i)&#160;Guines LLC holds (a) 3,088,896 shares of Class&#160;A common stock (which includes 117,330 Sponsor Earnout Shares) and (b) 432,055 Private Placement Warrants, (ii)&#160;each of the entities or individuals listed above has shared power to vote and dispose of such shares of Class&#160;A common stock or Private Placement Warrants and (iii)&#160;none of the entities or individuals listed above has sole power to vote or dispose of such shares of Class&#160;A common stock or Private Placement Warrants. The shares of Class&#160;A common stock and the shares of Class&#160;A common stock underlying the Private Placement Warrants beneficially owned by the Roystone Entities, in the aggregate, represent approximately 17.5% of the outstanding shares of Class&#160;A common stock. The business address of the Roystone Entities is 767 Third Avenue, 29th Floor, New York, NY 10017. </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">134 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center" id="toc479690_15">SELLING SECURITYHOLDER </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This prospectus relates to the offer and sale by Yorkville of up to 5,000,000 shares of Class&#160;A common stock that have been and may be issued by us to Yorkville under the Purchase Agreement. For additional information regarding the shares of Class&#160;A common stock included in this prospectus, see the section entitled &#8220;Committed Equity Financing&#8221; above. We are registering the shares of Common Stock included in this prospectus pursuant to the provisions of the Purchase Agreement we entered into with Yorkville on July&#160;27, 2022 in order to permit the Selling Securityholder to offer the shares included in this prospectus for resale from time to time. Except for the transactions contemplated by the Purchase Agreement, and as set forth in the section entitled &#8220;Plan of Distribution&#8221; in this prospectus, Yorkville has not had any material relationship with us within the past three years. As used in this prospectus, the term &#8220;Selling Securityholder&#8221; and &#8220;Yorkville&#8221; mean YA II PN, LTD., a Cayman Islands exempt limited partnership. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The table below presents information regarding the Selling Securityholder and the shares of Common Stock that may be resold by the Selling Securityholder from time to time under this prospectus. This table is prepared based on information supplied to us by the Selling Securityholder, and reflects holdings as of July&#160;28, 2022. The number of shares in the column &#8220;Maximum Number of Shares of Common Stock to be Offered Pursuant to this Prospectus&#8221; represents all of the shares of Common Stock being offered for resale by the Selling Securityholder under this prospectus. The Selling Securityholder may sell some, all or none of the shares being offered for resale in this offering. We do not know how long the Selling Securityholder will hold the shares before selling them, and we are not aware of any existing arrangements between the Selling Securityholder and any other stockholder, broker, dealer, underwriter or agent relating to the sale or distribution of the shares of our Common Stock being offered for resale by this prospectus. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Beneficial ownership is determined in accordance with Rule <span style="white-space:nowrap">13d-3(d)</span> promulgated by the SEC under the Exchange Act, and includes shares of Common Stock with respect to which the Selling Securityholder has sole or shared voting and investment power. The percentage of shares of Common Stock beneficially owned by the Selling Securityholder prior to the offering shown in the table below is based on an aggregate of 67,727,595 shares of our Common Stock outstanding on July&#160;28, 2022. Because the purchase price to be paid by the Selling Securityholder for shares of Common Stock, if any, that we may elect to sell to the Selling Securityholder in one or more Advances from time to time under the Purchase Agreement will be determined on the applicable Advance Dates for such Advances, the actual number of shares of Class&#160;A common stock that we may sell to the Selling Securityholder under the Purchase Agreement may be fewer than the number of shares being offered for resale under this prospectus. The fourth column assumes the resale by the Selling Securityholder of all of the shares of Class&#160;A common stock being offered for resale pursuant to this prospectus. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have determined beneficial ownership in accordance with the rules of the SEC. Except as indicated by the footnotes below, we believe, based on the information furnished to us, that the Selling Securityholder has sole voting and investment power with respect to all shares of Class&#160;A common stock that they beneficially own, subject to applicable community property laws. Except as otherwise described below, based on the information provided to us by the Selling Securityholder, the Selling Securityholder is not a broker-dealer or an affiliate of a broker-dealer. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Up to 13,504,166 shares of Class&#160;A common stock issuable upon the exercise of the Warrants are not included in the table below, unless specifically indicated in the footnotes therein. </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt;width:100%;border:0;margin:0 auto">


<tr>

<td style="width:38%"></td>

<td style="vertical-align:bottom;width:8%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:8%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:8%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:8%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:8%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="6" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Number&#160;of&#160;Shares&#160;of<br />Common</span><br /><span style="font-weight:bold">Stock&#160;Beneficially&#160;Owned</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" rowspan="2">&#160;&#160;</td>
<td colspan="2" rowspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Maximum&#160;Number<br />of</span><br /><span style="font-weight:bold">Shares of Common</span><br /><span style="font-weight:bold">Stock&#160;Being&#160;Offered</span></td>
<td style="vertical-align:bottom" rowspan="2">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="6" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Shares of Common Stock<br />Beneficially</span><br /><span style="font-weight:bold">Owned&#160;After&#160;the&#160;Offered&#160;Shares&#160;of</span><br /><span style="font-weight:bold">Common Stock are Sold</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom;white-space:nowrap"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman;font-weight:bold">Name of Selling Securityholder</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Number</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Percent</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Number</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Percent</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">YA II PN, LTD.</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">25,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">*</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">5,000,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
</table> <p style="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">*</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Less than one percent. </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">135 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(1)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Represents the 25,000 shares of Common Stock we issued to Yorkville on July&#160;27, 2022 as Commitment Shares in consideration for entering into the Purchase Agreement with us. In accordance with Rule <span style="white-space:nowrap">13d-3(d)</span> under the Exchange Act, we have excluded from the number of shares beneficially owned prior to the offering all of the shares that Yorkville may be required to purchase under the Purchase Agreement, because the issuance of such shares is at our discretion and is subject to conditions contained in the Purchase Agreement, the satisfaction of which are entirely outside of Yorkville&#8217;s control, including the registration statement that includes this prospectus becoming and remaining effective. Furthermore, the Advances of Common Stock under the Purchase Agreement are subject to certain agreed upon maximum amount limitations set forth in the Purchase Agreement. Also, the Purchase Agreement prohibits us from issuing and selling any shares of our Common Stock to Yorkville to the extent such shares, when aggregated with all other shares of our Common Stock then beneficially owned by Yorkville, would cause Yorkville&#8217;s beneficial ownership of our Common Stock to exceed the 4.99% Beneficial Ownership Limitation. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(2)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Applicable percentage ownership is based on 67,727,595 shares of our Common Stock outstanding as of July&#160;28, 2022 (excluding the Commitment Shares). </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(3)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Assumes the sale of all shares being offered pursuant to this prospectus. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(4)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Yorkville is a fund managed by Yorkville Advisors Global, LP (&#8220;Yorkville LP&#8221;). Yorkville Advisors Global II, LLC (&#8220;Yorkville LLC&#8221;) is the General Partner of Yorkville LP. All investment decisions for YA II PN, LTD are made by Yorkville LLC&#8217;s President and Managing Member, Mr.&#160;Mark Angelo. The business address of YA is 1012 Springfield Avenue, Mountainside, NJ 07092. </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">136 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center" id="toc479690_16">DESCRIPTION OF SECURITIES </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">The following summary of the material terms of our securities is not intended to be a complete description of all of the rights and preferences of such securities. Because it is only a summary, it does not contain all of the information that may be important to you, and is qualified by reference to our Charter, the Bylaws, the Investor Rights Agreement and the Warrant Agreement, which are exhibits to the registration statement of which this prospectus is a part. We urge you to read each of the Charter, the Bylaws, the Investor Rights Agreement and the Warrant Agreement, which are filed as exhibits to this registration statement, in their entirety for a complete description of the rights and preferences of our securities. </span></p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Authorized and Outstanding Stock </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our Charter authorizes the issuance of 718,000,000 shares, consisting of 708,000,000 shares of common stock, including (i) 600,000,000 shares of Class&#160;A common stock, (ii) 8,000,000 shares of Class&#160;B common stock, and (iii) 100,000,000 shares of Class&#160;V voting stock, and 10,000,000 shares of preferred stock. The outstanding shares of our common stock are, and the shares of Common Stock issuable upon exercise of the Warrants or pursuant to the Exchange Rights will be, duly authorized, validly issued, fully paid and <span style="white-space:nowrap">non-assessable.</span> These numbers of holders do not include DTC participants or beneficial owners holding shares through nominee names. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The number of Sponsor Earnout Shares (the Sponsor Earnout Units together with the Sponsor Earnout Shares, the Earnout Voting Shares and the Member Earnout Units, the &#8220;Earnout Securities&#8221;), are subject to certain restrictions and potential forfeiture pending the achievement (if any) of certain earnout targets pursuant to the terms of the Business Combination Agreement or the occurrence of a Change of Control. The Earnout Securities have voting rights but no right to dividends or distributions (except for certain tax distributions from Biote in accordance with the Biote A&amp;R OA) until such restrictions and potential forfeiture have lapsed. One third of each of the Member Earnout Units, Earnout Voting Shares, Sponsor Earnout Shares and Sponsor Earnout Units will vest upon the occurrence of each of the following events: (i)&#160;the first time, prior to the Earnout Deadline, the VWAP equals or exceeds $12.50 per share for 20 consecutive trading days of any 30 consecutive trading day period following the Closing, (ii)&#160;the first time, prior to the Earnout Deadline, the VWAP equals or exceeds $15.00 per share for 20 trading days of any 30 consecutive trading day period following the Closing, and (iii)&#160;the first time, prior to the Earnout Deadline, the VWAP equals or exceeds $17.50 per share for 20 trading days of any 30 consecutive trading day period following the Closing. If a definitive agreement with respect to a Change of Control is entered into on or prior to the Earnout Deadline, then effective as of immediately prior to closing of such Change of Control, unless previously vested pursuant to clauses (i)&#160;through (iii) of the preceding sentence, each of the Member Earnout Units, Earnout Voting Shares, Sponsor Earnout Shares and Sponsor Earnout Units will vest. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Beginning on the six month anniversary of the Closing, each Retained Biote Unit held by the Members may be redeemed, together with one share of Class&#160;V voting stock and subject to certain conditions, in exchange for either one share of Class&#160;A common stock or in certain circumstances, at the election of the Company in its capacity as the sole manager of Biote, the cash equivalent of the market value of one share of Class&#160;A common stock, pursuant to the terms and conditions of the Biote A&amp;R OA. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Common Stock </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our Common Stock consists of shares of Class&#160;A common stock, Class&#160;B common stock and Class&#160;V voting stock. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Voting Power </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Except as otherwise required by law or the Charter (including any preferred stock designation), the holders of common stock exclusively possess all voting power with respect to the Company. Except as otherwise </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">137 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
required by law or the Charter (including any preferred stock designation), the holders of shares of common stock are entitled to one vote per share on each matter properly submitted to the stockholders on which the holders of the common stock are entitled to vote. Except as otherwise required by law or the Charter (including any preferred stock designation), at any annual or special meeting of the stockholders of the Company, holders of the Class&#160;A common stock and holders of the Class&#160;V voting stock, voting together as a single class, have the exclusive right to vote for the election of directors and on all other matters properly submitted to a vote of the stockholders. Notwithstanding the foregoing, except as otherwise required by law or the Charter (including any preferred stock designation), holders of shares of any series of common stock are not entitled to vote on any amendment to the Charter (including any amendment to any preferred stock designation) that relates solely to the terms of one or more outstanding series of preferred stock or other series of common stock if the holders of such affected series of preferred stock or common stock, as applicable, are entitled exclusively, either separately or together with the holders of one or more other such series, to vote thereon pursuant to the Charter (including any preferred stock designation) or the Delaware General Corporate Law (the &#8220;DGCL&#8221;). </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Class&#160;B Common Stock </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Except as otherwise required by law or the Charter (including any preferred stock designation), for so long as any shares of Class&#160;B common stock shall remain outstanding, the Company shall not, without the prior vote or written consent of the holders of a majority of the shares of Class&#160;B common stock then outstanding, voting separately as a single class, amend, alter or repeal any provision of the Charter, whether by merger, consolidation or otherwise, if such amendment, alteration or repeal would alter or change the powers, preferences or relative, participating, optional or other or special rights of the Class&#160;B common stock. Any action required or permitted to be taken at any meeting of the holders of Class&#160;B common stock may be taken without a meeting, without prior notice and without a vote, if a consent or consents in writing, setting forth the action so taken, shall be signed by the holders of the outstanding Class&#160;B common stock having not less than the minimum number of votes that would be necessary to authorize or take such action at a meeting at which all shares of Class&#160;B common stock were present and voted and shall be delivered to the Company by delivery to its registered office in the State of Delaware, its principal place of business, or to the Secretary of the Company or another officer or agent of the Company having custody of the book in which minutes of proceedings of stockholders are recorded. Delivery made to the Company&#8217;s registered office shall be by hand or by certified or registered mail, return receipt requested. Prompt written notice of the taking of corporate action without a meeting by less than unanimous written consent of the holders of Class&#160;B common stock shall, to the extent required by law, be given to those holders of Class&#160;B common stock who have not consented in writing and who, if the action had been taken at a meeting, would have been entitled to notice of the meeting if the record date for notice of such meeting had been the date that written consents signed by a sufficient number of holders of Class&#160;B common stock to take the action were delivered to the Company. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Dividends </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our &#8220;Economic Common Stock&#8221; means Class&#160;A common stock together with Class&#160;B common stock. Subject to applicable law, the rights, if any, of the holders of any outstanding series of preferred stock and the provisions of the Charter, holders of shares of Economic Common Stock will be entitled to receive dividends and other distributions (payable in cash, property or capital stock of the Company), when, as and if declared thereon by our Board from time to time out of any assets or funds of the Company legally available therefor and shall share equally on a per share basis in such dividends and distributions. Dividends or distributions of cash, property or shares of capital stock of the Company may not be declared or paid on the Class&#160;V voting stock. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Liquidation, Dissolution and Winding Up </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Subject to applicable law, the rights, if any, of the holders of any outstanding series of preferred stock and the provisions of the Charter, in the event of the voluntary or involuntary liquidation, dissolution, distribution of assets or <span style="white-space:nowrap">winding-up</span> of the Company, after payment or provision for payment of the debts and other liabilities of </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">138 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
the Company, the holders of shares of Economic Common Stock shall be entitled to receive all the remaining assets of the Company available for distribution to its stockholders, ratably in proportion to the number of shares of Economic Common Stock held by them. The holders of shares of Class&#160;V voting stock will not be entitled to receive, with respect of such shares, any assets of the Company in excess of the par value thereof, in the event of any voluntary or involuntary liquidation, dissolution or winding up of the affairs of the Company. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Preemptive or Other Rights </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our stockholders have no preemptive or other subscription rights and there are no sinking fund or redemption provisions applicable to our common stock. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Election of Directors </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our Board is divided into three classes, with only one class of directors being elected in each year and each class (except for those directors appointed prior to the first annual meeting of stockholders of the Combined Company) generally serving a term of three years. As described in our Charter, our initial Class&#160;I directors will serve until the next annual meeting of stockholders following the Closing, initial Class&#160;II directors will serve until the second annual meeting of stockholders following the Closing and initial Class&#160;III directors will serve until the third annual meeting of stockholders. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Preferred Stock </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Charter provides that shares of preferred stock may be issued from time to time in one or more series. Our Board is authorized to fix the voting rights, if any, designations, powers, preferences, the relative, participating, optional or other special rights and any qualifications, limitations and restrictions thereof, applicable to the shares of each series. Our Board is able, without stockholder approval, to issue preferred stock with voting and other rights that could adversely affect the voting power and other rights of the holders of the common stock and could have anti-takeover effects. The ability of our Board to issue preferred stock without stockholder approval could have the effect of delaying, deferring or preventing a change of control of us or the removal of existing management. We have no preferred stock outstanding at the date hereof. Although we do not currently intend to issue any shares of preferred stock, we cannot assure you that we will not do so in the future. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Warrants </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Public Stockholders&#8217; Warrants </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each whole warrant entitles the registered holder to purchase one share of Class&#160;A common stock at a price of $11.50 per share, subject to adjustment as discussed below, provided that we have an effective registration statement under the Securities Act covering the shares of Class&#160;A common stock issuable upon exercise of the warrants and a current prospectus relating to them is available (or we permit holders to exercise their warrants on a cashless basis under the circumstances specified in the Warrant Agreement) and such shares are registered, qualified or exempt from registration under the securities, or blue sky, laws of the state of residence of the holder. Pursuant to the Warrant Agreement, a warrant holder may exercise its warrants only for a whole number of shares of Class&#160;A common stock. This means only a whole warrant may be exercised at a given time by a warrant holder. No fractional warrants will be issued upon separation of the units and only whole warrants will trade. Accordingly, unless you purchase at least four units, you will not be able to receive or trade a whole warrant. The warrants will expire five years after the Closing Date, at 5:00 p.m., New York City time, or earlier upon redemption or liquidation. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are not obligated to deliver any shares of Class&#160;A common stock pursuant to the exercise of a warrant and have no obligation to settle such warrant exercise unless a registration statement under the Securities Act with respect to the shares of Class&#160;A common stock underlying the warrants is then effective and a prospectus </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">139 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
relating thereto is current, subject to our satisfying our obligations described below with respect to registration. No warrant is exercisable and we are not obligated to issue shares of Class&#160;A common stock upon exercise of a warrant unless Class&#160;A common stock issuable upon such warrant exercise has been registered, qualified or deemed to be exempt under the securities laws of the state of residence of the registered holder of the warrants. In the event that the conditions in the two immediately preceding sentences are not satisfied with respect to a warrant, the holder of such warrant is not entitled to exercise such warrant and such warrant may have no value and expire worthless. In no event are we required to net cash settle any warrant, except as described in the following paragraph. In the event that a registration statement is not effective for the exercised warrants, the purchaser of a unit containing such warrant will have paid the full purchase price for the unit solely for the share of Class&#160;A common stock underlying such unit. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the Warrant Agreement, we have agreed that we will use our best efforts to maintain the effectiveness of a registration statement, and a current prospectus relating thereto, until the expiration of the warrants in accordance with the provisions of the Warrant Agreement. Notwithstanding the above, if our Class&#160;A common stock are at the time of any exercise of a warrant not listed on a national securities exchange such that they satisfy the definition of a &#8220;covered security&#8221; under Section&#160;18(b)(1) of the Securities Act, we may, at our option, require holders of Public Warrants who exercise their warrants to do so on a &#8220;cashless basis&#8221; in accordance with Section&#160;3(a)(9) of the Securities Act and, in the event we so elect, we will not be required to file or maintain in effect a registration statement, and in the event we do not so elect, we will use our best efforts to register or qualify the shares under applicable blue sky laws to the extent an exemption is not available. In such event, each holder would pay the exercise price by surrendering the warrants for that number of shares of Class&#160;A common stock equal to the lesser of (A)&#160;the quotient obtained by dividing (x)&#160;the product of the number of shares of Class&#160;A common stock underlying the warrants, multiplied by the excess of the &#8220;fair market value&#8221; (defined below) less the exercise price of the warrants by (y)&#160;the fair market value and (B) 0.361. The &#8220;fair market value&#8221; as used in this paragraph shall mean the volume weighted average price of the Class&#160;A common stock for the 10&#160;trading days ending on the trading day prior to the date on which the notice of exercise is received by the Warrant Agent. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Redemption of Warrants When the Price Per Share of Class&#160;A common stock Equals or Exceeds $18.00 </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Once the warrants become exercisable, we may call the warrants for redemption (except as described herein with respect to the private placement warrants): </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">in whole and not in part; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">at a price of $0.01 per warrant; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">upon a minimum of 30 days&#8217; prior written notice of redemption (the <span style="white-space:nowrap">&#8220;30-day</span> redemption period&#8221;) to each warrantholder; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">if, and only if, the closing price of the Class&#160;A common stock equals or exceeds $18.00 per share (as adjusted for adjustments to the number of shares issuable upon exercise or the exercise price of a warrant as described under the heading &#8220;Warrants-Public Stockholders&#8217; Warrants-Anti-Dilution Adjustments&#8221;) for any 20 trading days within a <span style="white-space:nowrap">30-trading</span> day period ending on the third trading day prior to the date on which we send the notice of redemption to the warrantholders. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We will not redeem the warrants as described above unless a registration statement under the Securities Act covering the issuance of the shares of the Class&#160;A common stock issuable upon exercise of the warrants is then effective and a current prospectus relating to those shares of the Class&#160;A common stock is available throughout the <span style="white-space:nowrap">30-day</span> redemption period. We may exercise our redemption right even if we are unable to register or qualify the underlying securities for sale under all applicable state securities laws. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have established the last of the redemption criterion discussed above to prevent a redemption call unless there is at the time of the call a significant premium to the warrant exercise price. If the foregoing conditions are </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">140 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
satisfied and we issue a notice of redemption of the warrants, each warrant holder will be entitled to exercise his, her or its warrant prior to the scheduled redemption date. However, the price of the Class&#160;A common stock may fall below the $18.00 redemption trigger price (as adjusted for adjustments to the number of shares issuable upon exercise or the exercise price of a warrant as described under the heading &#8220;Warrants-Public Stockholders&#8217; Warrants-Anti-Dilution Adjustments&#8221;) as well as the $11.50 warrant exercise price after the redemption notice is issued. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Redemption of Warrants When the Price Per Share of Class&#160;A Common Stock Equals or Exceeds $10.00 </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Once the warrants become exercisable, we may redeem the warrants: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">in whole and not in part; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">at $0.10 per warrant upon a minimum of 30 days&#8217; prior written notice of redemption provided that holders will be able to exercise their warrants on a cashless basis prior to redemption and receive that number of shares of the Class&#160;A common stock to be determined by reference to the table below, based on the redemption date and the &#8220;fair market value&#8221; of shares of the Class&#160;A common stock (as defined below) except as otherwise described below; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">if, and only if, the closing price of shares of the Class&#160;A common stock equals or exceeds $10.00 per share (as adjusted for adjustments to the number of shares issuable upon exercise or the exercise price of a warrant as described under the heading &#8220;Warrants-Public Stockholders&#8217; Warrants-Anti-Dilution Adjustments&#8221;) for any 20 trading days within the <span style="white-space:nowrap">30-trading</span> day period ending on the third trading day prior to the date on which we send the notice of redemption to the warrantholders; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">if the closing price of the Class&#160;A common stock for any 20 trading days within a <span style="white-space:nowrap">30-trading</span> day period ending on the third trading day prior to the date on which we send the notice of redemption to the warrant holders is less than $18.00 per share (as adjusted for adjustments to the number of shares issuable upon exercise or the exercise price of a warrant as described under the heading &#8220;Warrants-Public Stockholders&#8217; Warrants-Anti-Dilution Adjustments&#8221;), the private placement warrants must also be concurrently called for redemption on the same terms as the outstanding public warrants, as described above. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Beginning on the date the notice of redemption is given until the warrants are redeemed or exercised, holders may elect to exercise their warrants on a cashless basis. The numbers in the table below represent the number of shares of the Class&#160;A common stock that a warrantholder will receive upon such cashless exercise in connection with a redemption by us pursuant to this redemption feature, based on the &#8220;<span style="text-decoration:underline">fair market value</span>&#8221; of shares of the Class&#160;A common stock on the corresponding redemption date (assuming holders elect to exercise their warrants and such warrants are not redeemed for $0.10 per warrant), determined for these purposes based on the volume weighted average price of shares of the Class&#160;A common stock during the 10 trading days immediately following the date on which the notice of redemption is sent to the holders of warrants, and the number of months that the corresponding redemption date precedes the expiration date of the warrants, each as set forth in the table below. We will provide our warrantholders with the final fair market value no later than one business day after the <span style="white-space:nowrap">10-trading</span> day period described above ends. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the Warrant Agreement, references above to shares of our Class&#160;A common stock shall include any security other than shares of our Class&#160;A common stock into which the shares of our Class&#160;A common stock have been converted or exchanged for in the event we are not the surviving company in our initial business combination. The numbers in the table below will not be adjusted when determining the number of such securities to issue upon exercise of the warrants if we are not the surviving entity following our initial business combination. However, the share prices set forth in the column headings of the table below will be adjusted as of any date on which the number of shares issuable upon exercise of a warrant or the exercise price of a warrant is adjusted as set forth under the heading &#8220;Anti-Dilution Adjustments&#8221; below. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">141 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If the number of shares issuable upon exercise of a warrant is adjusted, the adjusted share prices in the column headings will equal the share prices immediately prior to such adjustment, multiplied by a fraction, the numerator of which is the number of shares deliverable upon exercise of a warrant immediately prior to such adjustment and the denominator of which is the number of shares deliverable upon exercise of a warrant as so adjusted. The number of shares in the table below shall be adjusted in the same manner and at the same time as the number of shares issuable upon exercise of a warrant. If the exercise price of a warrant is adjusted, (a)&#160;in the case of an adjustment pursuant to the sixth paragraph under the heading &#8220;Anti-Dilution Adjustments&#8221; below, the adjusted share prices in the column headings will equal the unadjusted share price multiplied by a fraction, the numerator of which is the higher of the Market Value and the Newly Issued Price as set forth under the heading &#8220;Anti-Dilution Adjustments&#8221; and the denominator of which is $10.00 and (b)&#160;in the case of an adjustment pursuant to the third paragraph under the heading &#8220;Anti-Dilution Adjustments&#8221; below, the adjusted share prices in the column headings will equal the unadjusted share price less the decrease in the exercise price of a warrant pursuant to such exercise price adjustment. </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">


<tr>

<td style="width:46%"></td>

<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td rowspan="2" style="vertical-align:bottom;white-space:nowrap"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold">Redemption Date</p> <p style="margin-top:0pt; margin-bottom:1pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman;font-weight:bold">(period to expiration of warrants)</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="34" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Fair Market Value of Shares of our Class&#160;A common stock</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold"></span>&#8804;<span style="font-weight:bold"></span><span style="font-weight:bold">$10.00</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">$11.00</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">$12.00</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">$13.00</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">$14.00</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">$15.00</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">$16.00</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">$17.00</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold"></span>&#8805;<span style="font-weight:bold"></span><span style="font-weight:bold">$18.00</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">60 months</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.237</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.259</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.278</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.295</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.311</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.325</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.338</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.350</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.361</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">57 months</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.233</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.255</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.275</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.293</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.309</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.324</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.338</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.350</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.361</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">54 months</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.229</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.251</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.272</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.291</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.307</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.323</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.337</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.350</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.361</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">51 months</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.225</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.248</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.269</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.288</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.305</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.321</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.336</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.349</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.361</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">48 months</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.220</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.243</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.265</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.285</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.303</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.320</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.335</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.349</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.361</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">45 months</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.214</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.239</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.261</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.282</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.301</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.318</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.334</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.348</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.361</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">42 months</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.208</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.234</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.257</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.278</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.298</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.316</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.333</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.348</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.361</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">39 months</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.202</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.228</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.252</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.275</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.295</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.314</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.331</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.347</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.361</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">36 months</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.195</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.222</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.247</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.271</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.292</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.312</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.330</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.346</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.361</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">33 months</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.187</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.215</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.241</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.266</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.288</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.309</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.328</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.345</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.361</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">30 months</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.179</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.208</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.235</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.261</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.284</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.306</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.326</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.345</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.361</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">27 months</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.170</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.199</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.228</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.255</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.280</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.303</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.324</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.343</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.361</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">24 months</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.159</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.190</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.220</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.248</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.274</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.299</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.322</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.342</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.361</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">21 months</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.148</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.179</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.210</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.240</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.268</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.295</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.319</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.341</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.361</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">18 months</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.135</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.167</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.200</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.231</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.261</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.289</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.315</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.339</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.361</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">15 months</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.120</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.153</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.187</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.220</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.253</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.283</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.311</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.337</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.361</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">12 months</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.103</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.137</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.172</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.207</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.242</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.275</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.306</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.335</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.361</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">9 months</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.083</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.117</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.153</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.191</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.229</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.266</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.300</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.332</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.361</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">6 months</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.059</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.092</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.130</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.171</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.213</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.254</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.292</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.328</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.361</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">3 months</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.030</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.060</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.100</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.145</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.193</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.240</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.284</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.324</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.361</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">0 months</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.042</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.115</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.179</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.233</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.281</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.324</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.361</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
</table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The exact fair market value and redemption date may not be set forth in the table above, in which case, if the fair market value is between two values in the table or the redemption date is between two redemption dates in the table, the number of shares of the Class&#160;A common stock to be issued for each warrant exercised will be determined by a straight-line interpolation between the number of shares set forth for the higher and lower fair market values and the earlier and later redemption dates, as applicable, based on a <span style="white-space:nowrap">365-</span> or <span style="white-space:nowrap">366-day</span> year, as applicable. For an example where the exact fair market value and redemption date are not as set forth in the table above, if the volume weighted average price of shares of our Class&#160;A common stock during the 10 trading days immediately following the date on which the notice of redemption is sent to the holders of the warrants is $13.50 per share, and at such time there are 38 months until the expiration of the warrants, holders may choose to, in connection with this redemption feature, exercise their warrants for 0.284 shares of our Class&#160;A common stock for each whole warrant. In no event will the warrants be exercisable on a cashless basis in connection with this redemption feature for more than 0.361 shares of the Class&#160;A common stock per warrant (subject to adjustment). Finally, as reflected in the table above, if the warrants are out of the money and about to expire, they cannot be exercised on a cashless basis in connection with a redemption by us pursuant to this redemption feature, since they will not be exercisable for any shares of the Class&#160;A common stock. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">142 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This redemption feature differs from the typical warrant redemption features used in many other blank check offerings, which typically only provide for a redemption of warrants for cash (other than the private placement warrants) when the trading price for the shares of our Class&#160;A common stock exceeds $18.00 per share for a specified period of time. Our redemption feature is structured to allow for all of the outstanding warrants to be redeemed when the shares of our Class&#160;A common stock are trading at or above $10.00 per share, which may be at a time when the trading price of shares of our Class&#160;A common stock is below the exercise price of the warrants. We have established this redemption feature to provide us with the flexibility to redeem the warrants without the warrants having to reach the $18.00 per share threshold set forth above under &#8220;Redemption of Warrants When the Price Per Share of Class&#160;A common stock Equals or Exceeds $18.00.&#8221; Holders choosing to exercise their warrants in connection with a redemption pursuant to this feature will, in effect, receive a number of shares for their warrants based on an option pricing model with a fixed volatility input as of the date of the Company&#8217;s IPO prospectus. This redemption right provides us with an additional mechanism by which to redeem all of the outstanding warrants and therefore provides us with certainty as to our capital structure as the warrants would no longer be outstanding if redeemed. The redemption right will allow us to quickly proceed with a redemption of the warrants if we determine it is in our best interest to do so. As such, we would redeem the warrants in this manner when we believe it is in our best interest to update our capital structure to remove the warrants and pay the redemption price to the warrant holders. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As stated above, we have the right to redeem the warrants when the shares of our Class&#160;A common stock are trading at a price equal to or exceeding $10.00, which is below the exercise price of $11.50. This right will provide us certainty with respect to our capital structure and cash position while providing warrant holders with the opportunity to exercise their warrants on a cashless basis for the applicable number of shares. If we choose to redeem the warrants when the shares of the Class&#160;A common stock are trading at a price below the exercise price of the warrants, this could result in the warrant holders receiving fewer shares of our Class&#160;A common stock than they would have received if they had chosen to wait to exercise their warrants for shares of our Class&#160;A common stock if and when such shares of the Class&#160;A common stock were trading at a price higher than the exercise price of $11.50. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">No fractional shares of the Class&#160;A common stock will be issued upon exercise. If, upon exercise, a holder would be entitled to receive a fractional interest in a share, we will round down to the nearest whole number of shares of the Class&#160;A common stock to be issued to the holder. If, at the time of redemption, the warrants are exercisable for a security other than the shares of the Class&#160;A common stock pursuant to the Warrant Agreement, the warrants may be exercised for such security. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Exercise Limitations </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A holder of a warrant may notify us in writing in the event it elects to be subject to a requirement that such holder will not have the right to exercise such warrant, to the extent that after giving effect to such exercise, such person (together with such person&#8217;s Affiliates), to the Warrant Agent&#8217;s actual knowledge, would beneficially own in excess of 4.9% or 9.8% (as specified by the holder) of the Class&#160;A common stock outstanding immediately after giving effect to such exercise. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Anti-Dilution Adjustments </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If the number of outstanding shares of Class&#160;A common stock is increased by a stock dividend payable in shares of Class&#160;A common stock, or by a <span style="white-space:nowrap">split-up</span> of common stock or other similar event, then, on the effective date of such stock dividend, <span style="white-space:nowrap">split-up</span> or similar event, the number of shares of Class&#160;A common stock issuable on exercise of each warrant will be increased in proportion to such increase in the outstanding shares of common stock. A rights offering to holders of common stock entitling holders to purchase Class&#160;A common stock at a price less than the fair market value will be deemed a stock dividend of a number of shares of Class&#160;A common stock equal to the product of (i)&#160;the number of shares of Class&#160;A common stock actually sold in such rights offering (or issuable under any other Equity Securities sold in such rights offering that are convertible into or </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">143 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
exercisable for Class&#160;A common stock) and (ii)&#160;the quotient of (x)&#160;the price per share of Class&#160;A common stock paid in such rights offering and (y)&#160;the fair market value. For these purposes (i)&#160;if the rights offering is for securities convertible into or exercisable for shares of Class&#160;A common stock, in determining the price payable for Class&#160;A common stock, there will be taken into account any consideration received for such rights, as well as any additional amount payable upon exercise or conversion and (ii)&#160;fair market value means the volume weighted average price of shares of Class&#160;A common stock as reported during the 10 trading day period ending on the trading day prior to the first date on which the Class&#160;A common stock trades on the applicable exchange or in the applicable market, regular way, without the right to receive such rights. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, if we, at any time while the warrants are outstanding and unexpired, pay a dividend or make a distribution in cash, securities or other assets to the holders of Class&#160;A common stock on account of such Class&#160;A common stock (or other securities into which the warrants are convertible), other than (a)&#160;as described above, (b)&#160;certain ordinary cash dividends, (c)&#160;to satisfy the redemption rights of the holders of Class&#160;A common stock in connection with a proposed initial business combination or extension of the time period in which we must complete an initial business combination, or (d)&#160;in connection with the redemption of our public shares upon our failure to complete our initial business combination, then the warrant exercise price will be decreased, effective immediately after the effective date of such event, by the amount of cash and/or the fair market value of any securities or other assets paid on each share of Class&#160;A common stock in respect of such event. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If the number of outstanding shares of Class&#160;A common stock is decreased by a consolidation, combination, reverse stock split or reclassification of Class&#160;A common stock or other similar event, then, on the effective date of such consolidation, combination, reverse stock split, reclassification or similar event, the number of shares of Class&#160;A common stock issuable on exercise of each warrant will be decreased in proportion to such decrease in outstanding shares of Class&#160;A common stock. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Whenever the number of shares of Class&#160;A common stock purchasable upon the exercise of the warrants is adjusted, as described above, the warrant exercise price will be adjusted by multiplying the warrant exercise price immediately prior to such adjustment by a fraction (x)&#160;the numerator of which will be the number of shares of Class A common stock purchasable upon the exercise of the warrants immediately prior to such adjustment, and (y)&#160;the denominator of which will be the number of shares of Class&#160;A common stock so purchasable immediately thereafter. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In case of any reclassification or reorganization of the outstanding Class&#160;A common stock (other than those described above or that solely affects the par value of such Class&#160;A common stock), or in the case of any merger or consolidation of us with or into another corporation (other than a consolidation or merger in which we are the continuing corporation and that does not result in any reclassification or reorganization of our outstanding Class&#160;A common stock), or in the case of any sale or conveyance to another corporation or entity of the assets or other property of us as an entirety or substantially as an entirety in connection with which we are dissolved, the holders of the warrants will thereafter have the right to purchase and receive, upon the basis and upon the terms and conditions specified in the warrants and in lieu of the Class&#160;A common stock immediately theretofore purchasable and receivable upon the exercise of the rights represented thereby, the kind and amount of shares of Class&#160;A common stock or other securities or property (including cash) receivable upon such reclassification, reorganization, merger or consolidation, or upon a dissolution following any such sale or transfer, that the holder of the warrants would have received if such holder had exercised their warrants immediately prior to such event. If less than 70% of the consideration receivable by the holders of Class&#160;A common stock in such a transaction is payable in the form of Class&#160;A common stock in the successor entity that is listed for trading on a national securities exchange or is quoted in an established <span style="white-space:nowrap"><span style="white-space:nowrap">over-the-counter</span></span> market, or is to be so listed for trading or quoted immediately following such event, and if the registered holder of the warrant properly exercises the warrant within thirty days following public disclosure of such transaction, the warrant exercise price will be reduced as specified in the Warrant Agreement based on the Black-Scholes Warrant Value (as defined in the Warrant Agreement) of the warrant. The purpose of such exercise price reduction is to provide additional value to holders of the warrants when an extraordinary transaction occurs during the exercise period of the warrants pursuant to which the holders of the warrants otherwise do not receive the full potential value of the warrants. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">144 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The warrants have been issued in registered form under the Warrant Agreement. The Warrant Agreement provides that the terms of the warrants may be amended without the consent of any holder to cure any ambiguity or correct any defective provision, and that all other modifications or amendments will require the vote or written consent of the holders of a majority of the then outstanding public warrants, and, solely with respect to any amendment to the terms of the private placement warrants, a majority of the then outstanding private placement warrants. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The warrants may be exercised upon surrender of the warrant certificate on or prior to the expiration date at the offices of the Warrant Agent, with the exercise form on the reverse side of the warrant certificate completed and executed as indicated, accompanied by full payment of the exercise price (or on a cashless basis, if applicable), by certified or official bank check payable to us, for the number of warrants being exercised. The warrant holders do not have the rights or privileges of holders of common stock and any voting rights until they exercise their warrants and receive Class&#160;A common stock. After the issuance of Class&#160;A common stock upon exercise of the warrants, each holder will be entitled to one vote for each share held of record on all matters to be voted on by stockholders. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">No fractional shares will be issued upon exercise of the warrants. If, upon exercise of the warrants, a holder would be entitled to receive a fractional interest in a share, we will, upon exercise, round the number of shares of Class&#160;A common stock to be issued to the warrant holder down to the nearest whole number. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have agreed that, subject to applicable law, any action, proceeding or claim against us arising out of or relating in any way to the Warrant Agreement will be brought and enforced in the courts of the State of New York or the United States District Court for the Southern District of New York, and we irrevocably submit to such jurisdiction, which jurisdiction will be the exclusive forum for any such action, proceeding or claim. This provision applies to claims under the Securities Act but does not apply to claims under the Exchange Act or any claim for which the federal district courts of the United States of America are the sole and exclusive forum. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Private Placement Warrants </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The private placement warrants (including the Class&#160;A common stock issuable upon exercise of the private placement warrants) are not redeemable by us so long as they are held by the Sponsor or its permitted transferees. The initial purchasers, or their permitted transferees, have the option to exercise the private placement warrants on a cashless basis. Except as described in this section, the private placement warrants have terms and provisions that are identical to those of the warrants sold as part of the units in the IPO, including that they may be redeemed for shares of Class&#160;A common stock. If the private placement warrants are held by holders other than the initial purchasers or their permitted transferees, the private placement warrants will be redeemable by us in all redemption scenarios and exercisable by the holders on the same basis as the warrants included in the units sold in the IPO. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Except as described under &#8220;<span style="font-style:italic">Public Stockholders&#8217; Warrants-Redemption of Warrants When the Price Per Share of Class</span><span style="font-style:italic"></span><span style="font-style:italic">&#160;A Common Stock Equals or Exceeds $10.00</span>,&#8221; if holders of the private placement warrants elect to exercise them on a cashless basis, they would pay the exercise price by surrendering his, her or its warrants for that number of shares of Class&#160;A common stock equal to the quotient obtained by dividing (x)&#160;the product of the number of shares of Class&#160;A common stock underlying the warrants, multiplied by the excess of the &#8220;fair market value&#8221; of our Class&#160;A common stock (defined below) over the exercise price of the warrants by (y)&#160;the fair market value. The &#8220;fair market value&#8221; will mean the average closing price of the Class&#160;A common stock for the 10 trading days ending on the third trading day prior to the date on which the notice of warrant exercise is sent to the Warrant Agent. The reason that we have agreed that these warrants will be exercisable on a cashless basis so long as they are held by the initial purchasers or their permitted transferees is because it is not known at this time whether they will be affiliated with us following a business combination. If they remain affiliated with us, their ability to sell our securities in the open market will be significantly limited. We have policies in place that prohibit insiders from selling our securities except during specific periods of time. Even during such periods of </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">145 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
time when insiders will be permitted to sell our securities, an insider cannot trade in our securities if he or she is in possession of material <span style="white-space:nowrap">non-public</span> information. Accordingly, unlike public stockholders who could exercise their warrants and sell the shares of Class&#160;A common stock received upon such exercise freely in the open market in order to recoup the cost of such exercise, the insiders could be significantly restricted from selling such securities. As a result, we believe that allowing the holders to exercise such warrants on a cashless basis is appropriate. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Dividends </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have not paid any cash dividends on our common stock to date and do not intend to pay cash dividends prior to the completion of a business combination. The payment of cash dividends in the future will be dependent upon our revenues and earnings, if any, capital requirements and general financial condition. The payment of any cash dividends is within the discretion of our Board. Our Board is not currently contemplating and does not anticipate declaring any stock dividends in the foreseeable future. Further, if we incur any indebtedness, our ability to declare dividends may be limited by restrictive covenants we may agree to in connection therewith. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Transfer Agent and Warrant Agent </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The transfer agent for our common stock and Warrant Agent for our warrants is Continental Stock Transfer&#160;&amp; Trust Company. We have agreed to indemnify Continental Stock Transfer&#160;&amp; Trust Company in its roles as transfer agent and Warrant Agent, its agents and each of its stockholders, directors, officers and employees against all claims and losses that may arise out of acts performed or omitted for its activities in that capacity, except for any liability due to any gross negligence, willful misconduct or bad faith of the indemnified person or entity. Continental Stock Transfer&#160;&amp; Trust Company has agreed that it has no right of <span style="white-space:nowrap">set-off</span> or any right, title, interest or claim of any kind to, or to any monies in, the trust account, and has irrevocably waived any right, title, interest or claim of any kind to, or to any monies in, the trust account that it may have now or in the future. Accordingly, any indemnification provided will only be able to be satisfied, or a claim will only be able to be pursued, solely against us and our assets outside the trust account and not against the any monies in the trust account or interest earned thereon. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Certain Anti-Takeover Provisions of Delaware Law and the Combined Company&#8217;s Charter and Bylaws </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are currently subject to the provisions of Section&#160;203 of the DGCL, which we refer to as &#8220;Section&#160;203,&#8221; regulating corporate takeovers. This statute prevents certain Delaware corporations, under certain circumstances, from engaging in a &#8220;business combination&#8221; with: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">a stockholder who owns 15% or more of our outstanding voting stock (otherwise known as an &#8220;interested stockholder&#8221;); </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">an Affiliate of an interested stockholder; or </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">an associate of an interested stockholder, for three years following the date that the stockholder became an interested stockholder. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A &#8220;business combination&#8221; includes a merger or sale of more than 10% of our assets. However, the above provisions of Section&#160;203 do not apply if: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">our Board approves the transaction that made the stockholder an &#8220;interested stockholder,&#8221; prior to the date of the transaction; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">after the completion of the transaction that resulted in the stockholder becoming an interested stockholder, that stockholder owned at least 85% of our voting stock outstanding at the time the transaction commenced, other than statutorily excluded shares of common stock; or </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">on or subsequent to the date of the transaction, the business combination is approved by our Board and authorized at a meeting of our stockholders, and not by written consent, by an affirmative vote of at least <span style="white-space:nowrap">two-thirds</span> of the outstanding voting stock not owned by the interested stockholder. </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">146 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Charter opts out of Section&#160;203 of the DGCL. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Charter contains certain limitations on convening special stockholder meetings. In addition, the prior charter and the Charter do not provide for cumulative voting in the election of directors. Our Board is empowered to elect a director to fill a vacancy created by the expansion of the Board or the resignation, death, or removal of a director in certain circumstances; and our advance notice provisions require that stockholders must comply with certain procedures in order to nominate candidates to our Board or to propose matters to be acted upon at a stockholders&#8217; meeting. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our authorized but unissued common stock and preferred stock are available for future issuances without stockholder approval and could be utilized for a variety of corporate purposes, including future offerings to raise additional capital, acquisitions and employee benefit plans. The existence of authorized but unissued and unreserved common stock and preferred stock could render more difficult or discourage an attempt to obtain control of us by means of a proxy contest, tender offer, merger or otherwise. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Forum Selection Clause </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our Charter provides that, unless we consent in writing to the selection of an alternative forum, the Court of Chancery of the State of Delaware shall be the sole and exclusive forum for any stockholder (including a beneficial owner) to bring: (i)&#160;any derivative action or proceeding brought on behalf of the Combined Company; (ii)&#160;any action asserting a claim of breach of fiduciary duty owed by any of the Combined Company&#8217;s directors, officers or other employees of the Combined Company to the Combined Company or its stockholders; (iii)&#160;any action asserting a claim against the Combined Company, its directors, officers or employees arising pursuant to any provision of the DGCL or the Charter or Bylaws; or (iv)&#160;any action asserting a claim against the Combined Company, its directors, officers or employees governed by the internal affairs doctrine and, if brought outside of Delaware, the stockholder bringing the suit will be deemed to have consented to service of process on such stockholder&#8217;s counsel except any action (A)&#160;as to which the Court of Chancery determines that there is an indispensable party not subject to the jurisdiction of the Court of Chancery (and the indispensable party does not consent to the personal jurisdiction of the Court of Chancery within ten days following such determination), (B) which is vested in the exclusive jurisdiction of a court or forum other than the Court of Chancery or (C)&#160;for which the Court of Chancery does not have subject matter jurisdiction. Unless the Combined Company consents in writing to the selection of an alternative forum, the federal district courts of the United States of America shall be the sole and exclusive forum for the resolution of any complaint asserting a cause of action arising under the Securities Act. Under the Securities Act, federal and state courts have concurrent jurisdiction over all suits brought to enforce any duty or liability created by the Securities Act, and stockholders cannot waive compliance with the federal securities laws and the rules and regulations thereunder. Accordingly, there is uncertainty as to whether a court would enforce such a forum selection provision as written in connection with claims arising under the Securities Act. Notwithstanding the foregoing, the forum selection clause will not apply to suits brought to enforce any liability or duty created by the Exchange Act or any other claim for which the federal district courts of the United States of America shall be the sole and exclusive forum. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Rule 144 </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to Rule 144 promulgated by the SEC under the Securities Act, as may be amended from time to time (&#8220;Rule 144&#8221;), a person who has beneficially owned restricted shares of our common stock or warrants for at least six months would be entitled to sell their securities provided that, (i)&#160;such person is not deemed to have been one of our Affiliates at the time of, or at any time during the three months preceding, a sale and (ii)&#160;we are subject to the Exchange Act periodic reporting requirements for at least three months before the sale and have filed all required reports under Section&#160;13 or 15(d) of the Exchange Act during the 12 months (or such shorter period as we were required to file reports) preceding the sale. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Persons who have beneficially owned restricted shares of our common stock or warrants for at least six months but who are our Affiliates at the time of, or at any time during the three months preceding, a sale, would </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">147 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
be subject to additional restrictions, by which such person would be entitled to sell within any three-month period only a number of securities that does not exceed the greater of: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">1% of the total number of shares of Class&#160;A common stock then outstanding, or 317,500 shares as of the date of this registration statement; or </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the average weekly reported trading volume of the Class&#160;A common stock during the four calendar weeks preceding the filing of a notice on Form 144 with respect to the sale. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Sales by our Affiliates under Rule 144 are also limited by manner of sale provisions and notice requirements and to the availability of current public information about us. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Restrictions on the Use of Rule 144 by Shell Companies or Former Shell Companies </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Rule 144 is not available for the resale of securities initially issued by shell companies (other than business combination related shell companies) or issuers that have been at any time previously a shell company. However, Rule 144 also includes an important exception to this prohibition if the following conditions are met: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the issuer of the securities that was formerly a shell company has ceased to be a shell company; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the issuer of the securities is subject to the reporting requirements of Section&#160;13 or 15(d) of the Exchange Act; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the issuer of the securities has filed all Exchange Act reports and materials required to be filed, as applicable, during the preceding 12 months (or such shorter period that the issuer was required to file such reports and materials), other than Current Reports on Form <span style="white-space:nowrap">8-K;</span> and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">at least one year has elapsed from the time that the issuer filed current Form 10 type information with the SEC reflecting its status as an entity that is not a shell company. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of the date of this registration statement, we had 9,161,771 shares of Class&#160;A common stock outstanding. Of these shares, 1,224,271 shares sold in our IPO are freely tradable without restriction or further registration under the Securities Act, except for any shares purchased by one of our Affiliates within the meaning of Rule&#160;144. All of the 7,937,500 Founder Shares are restricted securities under Rule 144, in that they were issued in private transactions not involving a public offering. Because the Business Combination was approved, the shares of our common stock we issue to the Members pursuant to the Business Combination Agreement are restricted securities for purposes of Rule 144. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of the date of this registration statement, there are 13,504,166 Warrants of the Company outstanding, consisting of 7,937,500 public warrants originally sold as part of the units issued in the IPO and 5,566,666 private placement warrants held by the Sponsor. Each warrant is exercisable for one share of Class&#160;A common stock, in accordance with the terms of the Warrant Agreement governing the warrants. The public warrants are freely tradable. In addition, we will be obligated to file no later than 15 business days after the Closing a registration statement under the Securities Act covering the 7,937,500 shares of Class&#160;A common stock that may be issued upon the exercise of the public warrants, and cause the registration statement to become effective and maintain the effectiveness of such registration statement until the expiration of the warrants. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Investor Rights </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company, the Members, the Sponsor, the Members&#8217; Representative and certain other parties are party to an Investor Rights Agreement, pursuant to which, among other things, (i)&#160;the Registration Rights Agreement were terminated, (ii)&#160;the <span style="white-space:nowrap">lock-up</span> period set forth in the Investor Rights Agreement superseded the <span style="white-space:nowrap">lock-up</span> period set forth in the Insider Letter, (iii)&#160;the Company provided certain registration rights for the shares of Class&#160;A common stock held by the Members, the Sponsor, and certain other parties, (iv)&#160;the Members agreed not to, subject to certain exceptions, transfer, sell, assign or otherwise dispose of the shares of Class&#160;A common stock, </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">148 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
shares of Class&#160;V voting stock and Biote Units held by such Members for six months following the Closing, and the Member Earnout Units until the date such securities have been earned in accordance with the Business Combination Agreement and (v)&#160;the Sponsor agreed not to, subject to certain exceptions, transfer, sell, assign or otherwise dispose of its (a)&#160;shares of Class&#160;A common stock (other than the Sponsor Earnout Shares) for six months following the Closing, (b)&#160;Sponsor Earnout Shares until the date such securities have been earned in accordance with the Business Combination Agreement and (c)&#160;warrants issued to the Sponsor pursuant to that certain Private Placement Warrants Purchase Agreement, dated March&#160;1, 2021, by and between the Company and the Sponsor, and the underlying shares of Class&#160;A common stock, for 30 days following the Closing Date (in each case, as more fully described in the Investor Rights Agreement). However, the Company chose, and may in the future choose, to release one or more Selling Securityholders from the applicable <span style="white-space:nowrap">lock-up</span> periods, after determining it was, or will be, in our stockholders&#8217; and our best interests, which allows for earlier sales of shares of Class&#160;A common stock in the public market and could have a negative impact on the price of the Company&#8217;s Class&#160;A common stock. For example, as of July&#160;18, 2022, we had a small public float of approximately 1.2&#160;million shares of Class&#160;A common stock and needed to increase our public float in order to comply with Nasdaq listing standards. For these reasons or other unforeseen developments, we may determine that it is in our stockholders&#8217; and our best interests to release one or more selling stockholders in the future from their applicable <span style="white-space:nowrap">lock-up</span> obligations. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Listing of Securities </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our Class&#160;A common stock and Public Warrants are listed on the Nasdaq Stock Market LLC under the symbols &#8220;BTMD&#8221; and &#8220;BTMDW,&#8221; respectively. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">149 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center" id="toc479690_17">MATERIAL UNITED STATES FEDERAL INCOME TAX CONSEQUENCES </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following discussion is a summary of certain U.S. federal income tax considerations generally applicable to the ownership and disposition of our Class&#160;A common stock and Warrants, which we refer to collectively as our securities. This summary is based upon U.S. federal income tax law as of the date of this prospectus, which is subject to change or differing interpretations, possibly with retroactive effect. This summary does not discuss all aspects of U.S. federal income taxation that may be important to particular investors in light of their individual circumstances, including investors subject to special tax rules (e.g., financial institutions, insurance companies, broker-dealers, dealers or traders in securities, <span style="white-space:nowrap">tax-exempt</span> organizations (including private foundations), qualified retirement plans, taxpayers that have elected <span style="white-space:nowrap"><span style="white-space:nowrap">mark-to-market</span></span> accounting, S corporations, partnerships and pass-through entities for U.S. federal income tax purposes (and investors in such entities); regulated investment companies, real estate investment trusts, passive foreign investment companies, controlled foreign corporations, U.S. Holders (as defined below) that hold Class&#160;A common stock or Warrants as part of a straddle, hedge, conversion, or other integrated transaction for U.S. federal income tax purposes or that received our Class&#160;A common stock or Warrants as compensation, holders that own, or are deemed to own, more than 5% of our capital stock (except to the extent specifically set forth below), former citizens or long-term residents of the United States, or U.S. Holders that have a functional currency other than the U.S. dollar), all of whom may be subject to tax rules that differ materially from those summarized below. This summary does not discuss U.S. federal <span style="white-space:nowrap">non-income</span> tax consequences (e.g., estate or gift tax), any state, local, or <span style="white-space:nowrap">non-U.S.</span> tax considerations, the Medicare contribution tax, the alternative minimum tax, or the special tax accounting rules under Section&#160;451(b) of the Code. In addition, this summary is limited to investors that will hold our securities as &#8220;<span style="font-style:italic">capital assets</span>&#8221; (generally, property held for investment) under the Code, and that acquire our Class&#160;A common stock and Warrants for cash pursuant to this prospectus. No ruling from the IRS or opinion of counsel has been or will be sought regarding any matter discussed herein. No assurance can be given that the IRS would not assert, or that a court would not sustain, a position contrary to any of the tax aspects set forth below. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For purposes of this summary, a &#8220;<span style="font-style:italic">U.S. Holder</span>&#8221; is a beneficial holder of our securities that, for U.S. federal income tax purposes is: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">an individual who is a U.S. citizen or resident of the United States, as determined for U.S. federal income tax purposes; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">a corporation or other entity treated as a corporation for United States federal income tax purposes created in, or organized under the law of, the United States or any state or political subdivision thereof; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">an estate the income of which is includible in gross income for U.S. federal income tax purposes regardless of its source; or </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">a trust (A)&#160;the administration of which is subject to the primary supervision of a United States court and which has one or more United States persons (within the meaning of Section&#160;7701(a)(30) of the Code) who have the authority to control all substantial decisions of the trust or (B)&#160;that has in effect a valid election under applicable U.S. Department of Treasury regulations (the &#8220;Treasury Regulations&#8221;) to be treated as a United States person for U.S. federal income tax purposes. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If a partnership (including any entity or arrangement treated as a partnership for U.S. federal income tax purposes) holds our securities, the tax treatment of a partner, member or other beneficial owner in such partnership will generally depend upon the status of the partner, member or other beneficial owner, the activities of the partnership and certain determinations made at the partner, member or other beneficial owner level. If you are a partner, member or other beneficial owner of a partnership holding our securities, you are urged to consult your tax advisor regarding the tax consequences of the ownership and disposition of our securities. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">THIS DISCUSSION OF U.S. FEDERAL INCOME TAX CONSIDERATIONS IS FOR GENERAL INFORMATION PURPOSES ONLY AND IS NOT TAX ADVICE. PROSPECTIVE HOLDERS SHOULD CONSULT THEIR TAX ADVISORS CONCERNING THE U.S. FEDERAL INCOME TAX </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">150 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
CONSEQUENCES TO THEM OF OWNING AND DISPOSING OF OUR SECURITIES, AS WELL AS THE APPLICATION OF ANY, STATE, LOCAL AND <span style="white-space:nowrap">NON-U.S.</span> INCOME, ESTATE AND OTHER TAX CONSIDERATIONS AND THE EFFECT OF ANY TAX TREATIES. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">U.S. Federal Income Tax Considerations For U.S. Holders </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Taxation of Distributions </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If we pay distributions or make constructive distributions (other than certain distributions of our capital stock or rights to acquire our capital stock) to U.S. Holders of shares of our Class&#160;A common stock, such distributions generally will constitute dividends for U.S. federal income tax purposes to the extent paid from our current or accumulated earnings and profits, as determined under U.S. federal income tax principles. Distributions in excess of our current and accumulated earnings and profits will constitute a return of capital that will be applied against and reduce (but not below zero) the U.S. Holder&#8217;s adjusted tax basis in our Class&#160;A common stock. Any remaining excess will be treated as gain realized on the sale or other disposition of the Class&#160;A common stock and will be treated as described under &#8220;<span style="font-style:italic">U.S. Federal Income Tax Considerations For U.S. Holders-Gain or Loss on Sale, Taxable Exchange or Other Taxable Disposition of Class</span><span style="font-style:italic"></span><span style="font-style:italic">&#160;A Common Stock</span>&#8221; below. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Dividends we pay to a U.S. Holder that is a taxable corporation will generally qualify for the dividends received deduction if the requisite holding period is satisfied. With certain exceptions (including dividends treated as investment income for purposes of investment interest deduction limitations), and provided certain holding period requirements are met, dividends we pay to a <span style="white-space:nowrap">non-corporate</span> U.S. Holder will generally constitute &#8220;<span style="font-style:italic">qualified dividends</span>&#8221; that will be subject to tax at the maximum tax rate accorded to long-term capital gains. If the applicable holding period requirements are not satisfied, a corporation may not be able to qualify for the dividends received deduction and would have taxable income equal to the entire dividend amount, and <span style="white-space:nowrap">non-corporate</span> U.S. holders may be subject to tax on such dividend at ordinary income tax rates instead of the preferential rates that apply to qualified dividend income. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Gain or Loss on Sale, Taxable Exchange or Other Taxable Disposition of Class&#160;A Common Stock </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A U.S. Holder generally will recognize gain or loss on the sale, taxable exchange or other taxable disposition of our Class&#160;A common stock. Any such gain or loss generally will be capital gain or loss, and will be long-term capital gain or loss if the U.S. Holder&#8217;s holding period for the Class&#160;A common stock so disposed of exceeds one year. The amount of gain or loss recognized generally will be equal to the difference between (1)&#160;the sum of the amount of cash and the fair market value of any property received by the U.S. Holder in such disposition and (2)&#160;the U.S. Holder&#8217;s adjusted tax basis in its Class&#160;A common stock so disposed of. A U.S. Holder&#8217;s adjusted tax basis in its Class&#160;A common stock generally will equal the U.S. Holder&#8217;s acquisition cost for such Class&#160;A common stock (or, in the case of Class&#160;A common stock received upon exercise of a Warrant, the U.S. Holder&#8217;s initial basis for such Class&#160;A common stock, as discussed below), less any prior distributions treated as a return of capital. If a U.S. Holder received Class&#160;A common stock in a taxable exchange for property other than cash, the U.S. Holder&#8217;s acquisition cost generally will be the fair market value of the Class&#160;A common stock received in the exchange. Long-term capital gains recognized by <span style="white-space:nowrap">non-corporate</span> U.S. Holders generally are eligible for reduced rates of U.S. federal income tax. If the U.S. Holder&#8217;s holding period for the Class&#160;A common stock so disposed of is one year or less, any gain on such sale or other taxable disposition would be subject to short-term capital gain treatment and generally would be subject to U.S. federal income tax at ordinary income tax rates. The deductibility of capital losses is subject to limitations. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Exercise of a Warrant </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Except as discussed below with respect to the cashless exercise of a Warrant, a U.S. Holder generally will not recognize taxable gain or loss upon the exercise of a Warrant for cash. The U.S. Holder&#8217;s initial tax basis in the share of our Class&#160;A common stock received upon exercise of the Warrant will generally be an amount equal </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">151 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
to the sum of the U.S. Holder&#8217;s acquisition cost of the Warrant and the exercise price of such Warrant. It is unclear whether a U.S. Holder&#8217;s holding period for the Class&#160;A common stock received upon exercise of the warrant would commence on the date of exercise of the Warrant or the day following the date of exercise of the Warrant; however, in either case the holding period will not include the period during which the U.S. Holder held the Warrants. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The tax consequences of a cashless exercise of a Warrant are not clear under current tax law. A cashless exercise may be nontaxable, either because the exercise is not a realization event or because the exercise is treated as a recapitalization for U.S. federal income tax purposes. In either situation, a U.S. Holder&#8217;s initial tax basis in the Class&#160;A common stock received generally should equal the holder&#8217;s adjusted tax basis in the Warrant. If the cashless exercise were treated as not being a realization event, it is unclear whether a U.S. Holder&#8217;s holding period for the Class&#160;A common stock would commence on the date of exercise of the Warrant or the day following the date of exercise of the Warrant; in either case, the holding period would not include the period during which the U.S. Holder held the Warrant. If, instead, the cashless exercise were treated as a recapitalization, the holding period of the Class&#160;A common stock generally would include the holding period of the Warrant. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">It is also possible that a cashless exercise of a Warrant could be treated in part as a taxable exchange in which gain or loss is recognized. In such event, a U.S. Holder could be deemed to have surrendered a portion of the Warrants being exercised having a value equal to the exercise price of such Warrants in satisfaction of such exercise price. Although not free from doubt, such U.S. Holder generally should recognize capital gain or loss in an amount equal to the difference between the fair market value of the Warrants deemed surrendered to satisfy the exercise price and the U.S. Holder&#8217;s adjusted tax basis in such Warrants. In this case, a U.S. Holder&#8217;s initial tax basis in the Class&#160;A common stock received would equal the sum of the exercise price and the U.S. holder&#8217;s adjusted tax basis in the Warrants exercised. It is unclear whether a U.S. Holder&#8217;s holding period for the Class&#160;A common stock would commence on the date of exercise of the warrant or the day following the date of exercise of the Warrant; in either case, the holding period would not include the period during which the U.S. Holder held the Warrant. Due to the uncertainty and absence of authority on the U.S. federal income tax treatment of a cashless exercise, including when a U.S. Holder&#8217;s holding period would commence with respect to the Class&#160;A common stock received, U.S. Holders are urged to consult their tax advisors regarding the tax consequences of a cashless exercise of a Warrant. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Sale, Exchange, Redemption or Expiration of a Warrant </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Upon a sale, exchange (other than by exercise), redemption, or expiration of a Warrant, a U.S. Holder will recognize taxable gain or loss in an amount equal to the difference between (1)&#160;the amount realized upon such disposition or expiration and (2)&#160;the U.S. Holder&#8217;s adjusted tax basis in the Warrant. A U.S. Holder&#8217;s adjusted tax basis in its Warrants will generally equal the U.S. Holder&#8217;s acquisition cost, increased by the amount of any constructive distributions included in income by such U.S. Holder (as described below under &#8220;<span style="font-style:italic">U.S. Federal Income Tax Considerations For U.S. Holders-Possible Constructive Distributions</span>&#8221;). Such gain or loss generally will be treated as long-term capital gain or loss if the Warrant is held by the U.S. Holder for more than one year at the time of such disposition or expiration. If a Warrant is allowed to lapse unexercised, a U.S. Holder will generally recognize a capital loss equal to such holder&#8217;s adjusted tax basis in the Warrant. The deductibility of capital losses is subject to certain limitations. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Possible Constructive Distributions </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The terms of each Warrant provide for an adjustment to the number of shares of Class&#160;A common stock for which the Warrant may be exercised or to the exercise price of the Warrant in certain events, as discussed in the section of this prospectus entitled &#8220;<span style="font-style:italic">Description of Securities-Warrants-Anti-Dilution Adjustments.</span>&#8221; An adjustment which has the effect of preventing dilution generally should not be a taxable event. Nevertheless, a U.S. Holder of Warrants would be treated as receiving a constructive distribution from us if, for example, the adjustment increases the holder&#8217;s proportionate interest in our assets or earnings and profits (e.g., through an </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">152 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
increase in the number of shares of Class&#160;A common stock that would be obtained upon exercise) as a result of a distribution of cash to the holders of shares of our Class&#160;A common stock which is taxable to such holders as a distribution. Such constructive distribution would be subject to tax as described above under &#8220;<span style="font-style:italic">U.S. Federal Income Tax Considerations For U.S. Holders-Taxation of Distributions</span>&#8221; in the same manner as if such U.S. Holder received a cash distribution from us on Class&#160;A common stock equal to the fair market value of such increased interest. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Information Reporting and Backup Withholding </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In general, information reporting requirements may apply to dividends paid to a U.S. Holder and to the proceeds of the sale or other disposition of shares of Class&#160;A common stock and Warrants, unless the U.S. Holder is an exempt recipient. Backup withholding (currently at a rate of 24%) may apply to such payments if the U.S. Holder fails to provide a taxpayer identification number, a certification of exempt status or has been notified by the IRS that it is subject to backup withholding (and such notification has not been withdrawn). </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Backup withholding is not an additional tax. Any amounts withheld under the backup withholding rules will be allowed as a credit against a U.S. Holder&#8217;s U.S. federal income tax liability and may entitle such holder to a refund, provided the required information is timely furnished to the IRS. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">U.S. Federal Income Tax Considerations For <span style="white-space:nowrap">Non-U.S.</span> Holders </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As used herein, the term &#8220;<span style="font-style:italic"><span style="white-space:nowrap">non-U.S.</span> Holder</span>&#8221; means a beneficial owner of Class&#160;A common stock or Warrants, who or that is for U.S. federal income tax purposes: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">a <span style="white-space:nowrap">non-resident</span> alien individual; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">a foreign corporation or </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">an estate or trust that is not a U.S. Holder; </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">but generally does not include an individual who is present in the United States for 183 days or more in the taxable year of disposition (except to the extent specifically set forth below). If you are such an individual, you should consult your tax advisor regarding the U.S. federal income tax consequences of the acquisition, ownership or sale or other disposition of our securities. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Taxation of Distributions </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In general, any distributions (including constructive distributions) we make to a <span style="white-space:nowrap">non-U.S.</span> Holder of our Class&#160;A common stock, to the extent paid out of our current or accumulated earnings and profits (as determined under U.S. federal income tax principles), will constitute dividends for U.S. federal income tax purposes. Subject to the withholding requirements under Sections 1471 through 1474 of the Code and the U.S. Treasury regulations and administrative guidance issued thereunder, collectively &#8220;<span style="font-style:italic">FATCA</span>,&#8221; and, provided such dividends are not effectively connected with the <span style="white-space:nowrap">non-U.S.</span> Holder&#8217;s conduct of a trade or business within the United States, we will be required to withhold tax from the gross amount of the dividend at a rate of 30%, unless such <span style="white-space:nowrap">non-U.S.</span> Holder is eligible for a reduced rate of withholding tax under an applicable income tax treaty and provides proper certification of its eligibility for such reduced rate (usually on an IRS Form <span style="white-space:nowrap">W-8BEN</span> or <span style="white-space:nowrap"><span style="white-space:nowrap">W-8BEN-E,</span></span> as applicable). In the case of any constructive dividend (as described below under &#8220;<span style="font-style:italic">U.S. Federal Income Tax Considerations For <span style="white-space:nowrap">Non-U.S.</span> Holders-Possible Constructive Distributions</span>&#8221;), it is possible that this tax would be withheld from any amount owed to a <span style="white-space:nowrap">non-U.S.</span> Holder by the applicable withholding agent, including cash distributions on other property or sale proceeds from Warrants or other property subsequently paid or credited to such holder. Any distribution not constituting a dividend will be treated first as reducing (but not below zero) the <span style="white-space:nowrap">non-U.S.</span> Holder&#8217;s adjusted tax basis in its shares of our Class&#160;A common stock and, to the extent such distribution exceeds the <span style="white-space:nowrap">non-U.S.</span> Holder&#8217;s adjusted tax basis, as gain realized from the sale or other disposition </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">153 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
of the Class&#160;A common stock, which will be treated as described under &#8220;<span style="font-style:italic">U.S. Federal Income Tax Considerations For <span style="white-space:nowrap">Non-U.S.</span> Holders-Gain on Sale, Taxable Exchange or Other Taxable Disposition of Class</span><span style="font-style:italic"></span><span style="font-style:italic">&#160;A Common Stock and Warrants</span>&#8221; below. In addition, if we determine that we are likely to be classified as a &#8220;<span style="font-style:italic">United States real property holding corporation</span>&#8221; (see &#8220;<span style="font-style:italic">U.S. Federal Income Tax Considerations For <span style="white-space:nowrap">Non-U.S.</span> Holders-Gain on Sale, Exchange or Other Taxable Disposition of Class</span><span style="font-style:italic"></span><span style="font-style:italic">&#160;A Common Stock and Warrants</span>&#8221; below), we will withhold 15% of any distribution that exceeds our current and accumulated earnings and profits. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Dividends we pay to a <span style="white-space:nowrap">non-U.S.</span> Holder that are effectively connected with such <span style="white-space:nowrap">non-U.S.</span> Holder&#8217;s conduct of a trade or business within the United States (or if a tax treaty applies are attributable to a U.S. permanent establishment or fixed base maintained by the <span style="white-space:nowrap">non-U.S.</span> Holder) will generally not be subject to the U.S. withholding tax described above, provided such <span style="white-space:nowrap">non-U.S.</span> Holder complies with certain certification and disclosure requirements (generally by providing an IRS Form <span style="white-space:nowrap">W-8ECI).</span> Instead, such dividends generally will be subject to U.S. federal income tax, net of certain deductions, at the same graduated individual or corporate rates applicable to U.S. Holders. If the <span style="white-space:nowrap">non-U.S.</span> Holder is a corporation, dividends that are effectively connected income may also be subject to a &#8220;<span style="font-style:italic">branch profits tax</span>&#8221; at a rate of 30% (or such lower rate as may be specified by an applicable income tax treaty). </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Exercise, Lapse or Redemption of a Warrant </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The U.S. federal income tax treatment of a <span style="white-space:nowrap">non-U.S.</span> Holder&#8217;s exercise of a Warrant will generally correspond to the U.S. federal income tax treatment of the exercise, lapse or redemption of a Warrant by a U.S. Holder, as described under &#8220;<span style="font-style:italic">U.S. Federal Income Tax Considerations For U.S. Holders-Exercise of a Warrant</span>&#8221; and &#8220;<span style="font-style:italic">U.S. Federal Income Tax Considerations For U.S. Holders-Sale, Exchange, Redemption or Expiration of a Warrant&#8221;</span> above, although to the extent a cashless exercise results in a taxable exchange, the tax consequences to the <span style="white-space:nowrap">non-U.S.</span> Holder would be the same as those described below in &#8220;<span style="font-style:italic">U.S. Federal Income Tax Considerations For <span style="white-space:nowrap">Non-U.S.Holders-Gain</span> on Sale, Exchange or Other Taxable Disposition of Class</span><span style="font-style:italic"></span><span style="font-style:italic">&#160;A Common Stock and Warrants</span>.&#8221; </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Gain on Sale, Exchange or Other Taxable Disposition of Class&#160;A Common Stock and Warrants </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A <span style="white-space:nowrap">non-U.S.</span> Holder generally will not be subject to U.S. federal income or withholding tax in respect of gain recognized on a sale, taxable exchange or other taxable disposition of our Class&#160;A common stock or Warrants or an expiration or redemption of our Warrants, unless: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the gain is effectively connected with the conduct of a trade or business by the <span style="white-space:nowrap">non-U.S.</span> Holder within the United States (and, if an applicable tax treaty so requires, is attributable to a U.S. permanent establishment or fixed base maintained by the <span style="white-space:nowrap">non-U.S.</span> Holder); </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the <span style="white-space:nowrap">non-U.S.</span> Holder is an individual who is present in the United States for 183 days or more in the taxable year of disposition and certain other conditions are met; or </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">we are or have been a &#8220;<span style="font-style:italic">United States real property holding corporation</span>&#8221; for U.S. federal income tax purposes at any time during the shorter of the five-year period ending on the date of disposition or the period that the <span style="white-space:nowrap">non-U.S.</span> Holder held our Class&#160;A common stock or Warrants and, in the case where shares of our Class&#160;A common stock are regularly traded on an established securities market, the <span style="white-space:nowrap">non-U.S.</span> Holder has owned, directly or constructively, more than 5% of our Class&#160;A common stock at any time within the shorter of the five-year period preceding the disposition or such <span style="white-space:nowrap">Non-U.S.</span> holder&#8217;s holding period for the shares of our Class&#160;A common stock. There can be no assurance that our Class&#160;A common stock will be treated as regularly traded on an established securities market for this purpose. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Gain described in the first bullet point above will be subject to tax at generally applicable U.S. federal income tax rates as if the <span style="white-space:nowrap">non-U.S.</span> Holder were a U.S. resident for U.S. federal income tax purposes. Any gain described in the first bullet point above of a <span style="white-space:nowrap">non-U.S.</span> Holder that is a foreign corporation may also be subject to </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">154 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
an additional &#8220;<span style="font-style:italic">branch profits tax</span>&#8221; at a 30% rate (or lower applicable income tax treaty rate). Gain described in the second bullet point above will generally be subject to a flat 30% U.S. federal income tax. <span style="white-space:nowrap">Non-U.S.</span> Holders are urged to consult their tax advisors regarding possible eligibility for benefits under income tax treaties. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If the third bullet point above applies to a <span style="white-space:nowrap">non-U.S.</span> Holder and applicable exceptions are not available, gain recognized by such holder on the sale, exchange or other disposition of our Class&#160;A common stock or Warrants will be subject to tax at generally applicable U.S. federal income tax rates. In addition, a buyer of our Class&#160;A common stock or Warrants from such holder may be required to withhold U.S. income tax at a rate of 15% of the amount realized upon such disposition. We will be classified as a United States real property holding corporation if the fair market value of our &#8220;<span style="font-style:italic">United States real property interests</span>&#8221; equals or exceeds 50% of the sum of the fair market value of our worldwide real property interests plus our other assets used or held for use in a trade or business, as determined for U.S. federal income tax purposes. We do not believe we currently are or will become a United States real property holding corporation, however there can be no assurance in this regard. <span style="white-space:nowrap">Non-U.S.</span> Holders are urged to consult their tax advisors regarding the application of these rules. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Possible Constructive Distributions </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The terms of each Warrant provide for an adjustment to the number of shares of Class&#160;A common stock for which the Warrant may be exercised or to the exercise price of the Warrant in certain events, as discussed in the section of this prospectus captioned &#8220;<span style="font-style:italic">Description of Securities-Warrants-Anti-Dilution Adjustments.</span>&#8221; An adjustment which has the effect of preventing dilution generally should not be a taxable event. Nevertheless, a <span style="white-space:nowrap">non-U.S.</span> Holder of Warrants would be treated as receiving a constructive distribution from us if, for example, the adjustment increases the holder&#8217;s proportionate interest in our assets or earnings and profits (e.g., through an increase in the number of shares of Class&#160;A common stock that would be obtained upon exercise) as a result of a distribution of cash to the holders of shares of our Class&#160;A common stock which is taxable to such holders as a distribution. A <span style="white-space:nowrap">non-U.S.</span> Holder would be subject to U.S. federal income tax withholding as described above under &#8220;<span style="font-style:italic">U.S. Federal Income Tax Considerations For <span style="white-space:nowrap">Non-U.S.</span> Holders-Taxation of Distributions</span>&#8221; under that section in the same manner as if such <span style="white-space:nowrap">non-U.S.</span> Holder received a cash distribution from us on Class&#160;A common stock equal to the fair market value of such increased interest. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Foreign Account Tax Compliance Act </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">FATCA imposes withholding tax at a rate of 30% in certain circumstances on dividends (including constructive dividends) in respect of our securities which are held by or through certain foreign financial institutions (which is defined broadly for this purpose and includes investment funds), unless any such institution (1)&#160;enters into, and complies with, an agreement with the IRS to report, on an annual basis, information with respect to interests in, and accounts maintained by, the institution that are owned by certain U.S. persons and by certain <span style="white-space:nowrap">non-U.S.</span> entities that are wholly or partially owned by U.S. persons and to withhold on certain payments, or (2)&#160;if required under an intergovernmental agreement between the United States and an applicable foreign country, reports such information to its local tax authority, which will exchange such information with the U.S. authorities. An intergovernmental agreement between the United States and an applicable foreign country may modify these requirements. Accordingly, the entity through which our securities are held will affect the determination of whether such withholding is required. Similarly, FATCA imposes withholding tax at a rate of 30% in certain circumstances on dividend (including constructive dividends) in respect of our securities which are held by or thought certain <span style="white-space:nowrap">non-financial</span> foreign entities unless such entity either (1)&#160;certifies to us or the applicable withholding agent that such entity does not have any &#8220;<span style="font-style:italic">substantial United States owners</span>&#8221; or (2)&#160;provides certain information regarding the entity&#8217;s &#8220;<span style="font-style:italic">substantial United States owners,</span>&#8221; which will in turn be provided to the U.S. Department of Treasury. Withholding under FATCA was scheduled to apply to payments of gross proceeds from the sale or other disposition of property that produces U.S.-source interest or dividends, however, the IRS has issued proposed regulations (the preamble to which states that taxpayers may rely upon the proposed regulations until final regulations are issued) that would generally not apply FATCA withholding requirements to gross proceeds from sales or other disposition proceeds from our units, shares of Class&#160;A </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">155 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
common stock and Warrants. Prospective investors should consult their tax advisors regarding the possible implications of FATCA on their investment in our securities. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Information Reporting and Backup Withholding </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Information returns will be filed with the IRS in connection with payments of distributions and the proceeds from a sale or other disposition of shares of Class&#160;A common stock and Warrants to <span style="white-space:nowrap">non-U.S.</span> Holders. A <span style="white-space:nowrap">non-U.S.</span> Holder may have to comply with certification procedures to establish that it is not a United States person in order to avoid backup withholding requirements. The certification procedures required to claim a reduced rate of withholding under a treaty generally will satisfy the certification requirements necessary to avoid the backup withholding as well. Backup withholding is not an additional tax. The amount of any backup withholding from a payment to a <span style="white-space:nowrap">non-U.S.</span> Holder will be allowed as a credit against such holder&#8217;s U.S. federal income tax liability and may entitle such holder to a refund, provided that the required information is timely furnished to the IRS. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">156 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center" id="toc479690_18">PLAN OF DISTRIBUTION </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The shares of Class&#160;A common stock offered by this prospectus are being offered by the Selling Securityholder, Yorkville. The shares may be sold or distributed from time to time by the Selling Securityholder directly to one or more purchasers or through brokers, dealers, or underwriters who may act solely as agents at market prices prevailing at the time of sale, at prices related to the prevailing market prices, at negotiated prices, or at fixed prices, which may be changed. We will not receive any of the proceeds from the sale of the securities by the Selling Securityholder. However, we expect to receive proceeds from sales of Class&#160;A common stock that we may elect to make to the Selling Securityholder pursuant to the Purchase Agreement, if any, from time to time in our discretion. The net proceeds from sales, if any, under the Purchase Agreement, will depend on the frequency and prices at which we sell shares of Common Stock to the Selling Securityholder after the date of this prospectus. See &#8220;Committed Equity Financing&#8221; for a description of how the price we may sell shares of Class&#160;A common stock to the Selling Securityholder is calculated pursuant to the Purchase Agreement. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The sale of the shares of our Common Stock offered by this prospectus could be effected in one or more of the following methods: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">ordinary brokers&#8217; transactions; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">transactions involving cross or block trades; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">through brokers, dealers, or underwriters who may act solely as agents; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">&#8220;at the market&#8221; into an existing market for our Common Stock; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">in other ways not involving market makers or established business markets, including direct sales to purchasers or sales effected through agents; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">in privately negotiated transactions; or </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">any combination of the foregoing. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In order to comply with the securities laws of certain states, if applicable, the shares may be sold only through registered or licensed brokers or dealers. In addition, in certain states, the shares may not be sold unless they have been registered or qualified for sale in the state or an exemption from the state&#8217;s registration or qualification requirement is available and complied with. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Yorkville is an &#8220;underwriter&#8221; within the meaning of Section&#160;2(a)(11) of the Securities Act. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Yorkville has informed us that it intends to use one or more registered broker-dealers to effectuate all sales, if any, of our Common Stock that it may acquire from us pursuant to the Purchase Agreement. Such sales will be made at prices and at terms then prevailing or at prices related to the then current market price. Such registered broker-dealer may, in some circumstances (for instance if such registered broker-dealer&#8217;s involvement is not limited to receiving commission not in excess of the usual and customary distributors&#8217; or sellers&#8217; commissions), be considered to be an underwriter within the meaning of Section&#160;2(a)(11) of the Securities Act. Yorkville has informed us that each such broker-dealer may receive commissions from Yorkville for executing such sales for Yorkville and, if so, such commissions will not exceed customary brokerage commissions. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Brokers, dealers, underwriters or agents participating in the distribution of the shares of our Common Stock offered by this prospectus may receive compensation in the form of commissions, discounts, or concessions from the purchasers, for whom the broker-dealers may act as agent, of the shares sold by the Selling Securityholder through this prospectus. The compensation paid to any such particular broker-dealer by any such purchasers of shares of our Common Stock sold by the Selling Securityholder may be less than or in excess of customary commissions. Neither we nor the Selling Securityholder can presently estimate the amount of compensation that any agent will receive from any purchasers of shares of our Common Stock sold by the Selling Securityholder. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">157 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We know of no existing arrangements between the Selling Securityholder or any other stockholder, broker, dealer, underwriter or agent relating to the sale or distribution of the shares of our Common Stock offered by this prospectus. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may from time to time file with the SEC one or more supplements to this prospectus or amendments to the registration statement of which this prospectus forms a part to amend, supplement or update information contained in this prospectus, including, if and when required under the Securities Act, to disclose certain information relating to a particular sale of shares offered by this prospectus by the Selling Securityholder, including with respect to any compensation paid or payable by the Selling Securityholder to any brokers, dealers, underwriters or agents that participate in the distribution of such shares by the Selling Securityholder, and any other related information required to be disclosed under the Securities Act. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We will pay the expenses incident to the registration under the Securities Act of the offer and sale of the shares of our Common Stock covered by this prospectus by the Selling Securityholder. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As consideration for its irrevocable commitment to purchase our Common Stock under the Purchase Agreement, we have agreed to issue to Yorkville 25,000 shares of our Common Stock as Commitment Shares upon execution of the Purchase Agreement. In addition, we have paid Yorkville a structuring fee of $15,000 in connection with the structuring and due diligence of the transactions by Yorkville under the Purchase Agreement. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We also have agreed to indemnify Yorkville and certain other persons against certain liabilities in connection with the offering of shares of our Common Stock offered hereby, including liabilities arising under the Securities Act or, if such indemnity is unavailable, to contribute amounts required to be paid in respect of such liabilities. Yorkville has agreed to indemnify us against liabilities under the Securities Act that may arise from certain written information furnished to us by Yorkville specifically for use in this prospectus or, if such indemnity is unavailable, to contribute amounts required to be paid in respect of such liabilities. Insofar as indemnification for liabilities arising under the Securities Act may be permitted to our directors, officers, and controlling persons, we have been advised that in the opinion of the SEC this indemnification is against public policy as expressed in the Securities Act and is therefore, unenforceable. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We estimate that the total expenses for the offering will be approximately $0.3&#160;million. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Yorkville has represented to us that at no time prior to the date of the Purchase Agreement has Yorkville or any entity managed or controlled by Yorkville, engaged in or effected, in any manner whatsoever, directly or indirectly, for its own account or for the account of any of its affiliates, any short sale or any transaction, which establishes a net short position with respect to our Common Stock. Yorkville has agreed that during the term of the Purchase Agreement, none of Yorkville, its officers, its sole member, or any entity managed or controlled by Yorkville, will enter into or effect, directly or indirectly, any of the foregoing transactions for its own account or for the account of any other such person or entity. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have advised the Selling Securityholder that it is required to comply with Regulation M promulgated under the Exchange Act. With certain exceptions, Regulation M precludes the Selling Securityholder, any affiliated purchasers, and any broker-dealer or other person who participates in the distribution from bidding for or purchasing, or attempting to induce any person to bid for or purchase any security which is the subject of the distribution until the entire distribution is complete. Regulation M also prohibits any bids or purchases made in order to stabilize the price of a security in connection with the distribution of that security. All of the foregoing may affect the marketability of the securities offered by this prospectus. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This offering will terminate on the date that all shares of our Common Stock offered by this prospectus have been sold by the Selling Securityholder. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our Common Stock is currently listed on Nasdaq under the symbol &#8220;BTMD&#8221;. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">158 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center" id="toc479690_19">LEGAL MATTERS </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The validity of any securities offered by this prospectus will be passed upon for us by Cooley LLP. </p> <p style="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center" id="toc479690_20">EXPERTS </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The consolidated financial statements of BioTE Holdings, LLC as of December&#160;31, 2022 and 2021, and for the years then ended included in this Prospectus, have been audited by Deloitte&#160;&amp; Touche LLP, an independent registered public accounting firm, as stated in their report. Such financial statements are included in reliance upon the report of such firm given their authority as experts in accounting and auditing. </p> <p style="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center" id="toc479690_21">WHERE YOU CAN FIND MORE INFORMATION </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We file annual, quarterly and current reports, proxy statements and other information with the SEC. We have also filed a registration statement on Form <span style="white-space:nowrap">S-1,</span> including exhibits, under the Securities Act of 1933, as amended, with respect to the Class&#160;A common stock offered by this prospectus. This prospectus is part of the registration statement, but does not contain all of the information included in the registration statement or the exhibits. Our SEC filings are available to the public on the internet at a website maintained by the SEC located at http://www.sec.gov. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We also maintain an Internet website at www.biote.com. Through our website, we make available, free of charge, the following documents as soon as reasonably practicable after they are electronically filed with, or furnished to, the SEC: our Annual Reports on Form <span style="white-space:nowrap">10-K;</span> our proxy statements for our annual and special shareholder meetings; our Quarterly Reports on Form <span style="white-space:nowrap">10-Q;</span> our Current Reports on Form <span style="white-space:nowrap">8-K;</span> Forms 3, 4 and 5 and Schedules 13D; and amendments to those documents. The information contained on, or that may be accessed through, our website is not part of, and is not incorporated into, this prospectus. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">159 </p>

</div></div>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" /><div style='display: none'><ix:header><ix:hidden><ix:nonNumeric name="us-gaap:LeaseExpirationDate1" id="hidden73946198" contextRef="P07_01_2014To07_01_2014">2023-06-30</ix:nonNumeric><ix:nonNumeric name="btmd:CapitalizedSoftwareEstimatedUsefulLives" id="hidden73945767" contextRef="P01_01_2022To12_31_2022_MinimumMembersrtRangeAxis">P3Y</ix:nonNumeric><ix:nonNumeric name="btmd:CapitalizedSoftwareEstimatedUsefulLives" id="hidden73945768" contextRef="P01_01_2022To12_31_2022_MaximumMembersrtRangeAxis">P8Y</ix:nonNumeric><ix:nonNumeric name="btmd:EarnoutDeadlineDate" id="hidden73946098" contextRef="P01_01_2022To12_31_2022_BusinessCombinationMemberusgaapBusinessAcquisitionAxis">2027-05-26</ix:nonNumeric><ix:nonNumeric name="us-gaap:CommonStockSharesAuthorizedUnlimited" id="hidden73945433" contextRef="P01_01_2022To12_31_2022">Unlimited</ix:nonNumeric><ix:nonNumeric name="us-gaap:CommonStockSharesAuthorizedUnlimited" id="hidden73945434" contextRef="P01_01_2021To12_31_2021">Unlimited</ix:nonNumeric><ix:nonNumeric name="us-gaap:BusinessAcquisitionDescriptionOfAcquiredEntity" id="hidden73945879" contextRef="P01_01_2022To12_31_2022_HaymakeriiiMembersrtConsolidatedEntitiesAxis_OtherBusinessCombinationMemberusgaapBusinessAcquisitionAxis">The TRA provides that, in the event that (i) the Company exercises its early termination rights under the TRA, (ii) certain changes of control occur (as described in the TRA), (iii) the Company, in certain circumstances, fails to make a payment required to be made pursuant to the TRA by the applicable final payment date, which non-payment continues for 30 days following such final payment date or (iv) the Company materially breaches any of its material obligations under the TRA, which breach continues without cure for 30 days following receipt by the Company of written notice thereof (unless, in the case of clauses (iii) and (iv), certain liquidity exceptions apply) the Company&#8217;s obligations under the TRA will accelerate and the Company will be required to make a lump-sum cash payment to the applicable parties to the TRA equal to the present value of all forecasted future payments that would have otherwise been made under the TRA, which lump-sum payment would be based on certain assumptions, including those relating to our future taxable income. </ix:nonNumeric><ix:nonNumeric name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="hidden73946171" contextRef="P01_01_2022To12_31_2022_MinimumMembersrtRangeAxis_PhantomEquityRightsMemberusgaapAwardTypeAxis">P1Y</ix:nonNumeric><ix:nonNumeric name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="hidden73946172" contextRef="P06_01_2022To06_30_2022_MinimumMembersrtRangeAxis_PhantomEquityRightsMemberusgaapAwardTypeAxis">P1Y</ix:nonNumeric><ix:nonNumeric name="btmd:LineOfCreditFacilityMaturityMonthAndYear" id="hidden73946021" contextRef="P01_01_2022To12_31_2022_BankOfAmericaTermLoanMemberusgaapDebtInstrumentAxis_LineOfCreditMemberusgaapCreditFacilityAxis">2024-05</ix:nonNumeric><ix:nonNumeric name="btmd:ConsecutiveTradingDays" id="hidden73945778" contextRef="P07_27_2022To07_27_2022">P3D</ix:nonNumeric><ix:nonNumeric name="us-gaap:DebtInstrumentCovenantDescription" id="hidden73946027" contextRef="P01_01_2022To12_31_2022_LineOfCreditMemberusgaapCreditFacilityAxis_TruistTermLoanMemberusgaapDebtInstrumentAxis">In addition, the Credit Agreement is subject to (i) a maximum total net leverage ratio and (ii) a minimum fixed charge coverage ratio. The Company must maintain a total net leverage ratio of less than or equal to (i) 4.25:1.00, with respect to the fiscal quarter ending September 30, 2022 through and including the fiscal quarter ending March 31, 2023, (ii) 4.00:1.00, with respect to the fiscal quarter ending June 30, 2023 through and including March 31, 2024, and (iii) 3.75:1.00 thereafter. Beginning with the third fiscal quarter of 2022, the Company must not permit the Consolidated Fixed Charge Coverage Ratio to be less than 1.25:1.00. Both financial covenants are tested quarterly.</ix:nonNumeric></ix:hidden><ix:references><link:schemaRef xlink:type="simple" xlink:href="btmd-20221231.xsd" /><link:linkbaseRef xlink:type="simple" xlink:href="btmd-20221231_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" /><link:linkbaseRef xlink:type="simple" xlink:href="btmd-20221231_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" /><link:linkbaseRef xlink:type="simple" xlink:href="btmd-20221231_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" /><link:linkbaseRef xlink:type="simple" xlink:href="btmd-20221231_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" /></ix:references></ix:header></div><div><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><div id="index" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">INDEX TO CONSOLIDATED FINANCIAL STATEMENTS </div></div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;">
<tr style="font-size: 0px;">
<td style="width: 96%; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 1%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><a href="#fin479690_1">Report of Independent Registered Public Accounting Firm (PCAOB ID No.&#160;34)</a></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">F-2</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><a href="#fin479690_2">Consolidated Balance Sheets</a></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">F-3</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><a href="#fin479690_3">Consolidated Statements of Income and Comprehensive Income</a></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">F-4</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><a href="#fin479690_4">Consolidated Statements of Stockholders&#8217; Equity (Deficit)</a></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">F-5</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><a href="#fin479690_5">Consolidated Statements of Cash Flows</a></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">F-7</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><a href="#fin479690_6">Notes to Consolidated Financial Statements</a></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">F-8</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr></table><div style="clear:both;max-height:0pt;;text-indent: 0px;"></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-1 </div></div></div></div><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div><hr style="color:#999999;height:3px;width:100%"/><div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><div id="fin479690_1" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM </div></div></div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">To the stockholders and the Board of Directors of biote Corp. </div><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">Opinion on the Financial Statements </div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have audited the accompanying consolidated balance sheets of biote Corp. and subsidiaries (the &#8220;Company&#8221;) as of December&#160;31, 2022 and 2021, the related consolidated statements of income and comprehensive income, stockholders&#8217; equity (deficit), and cash flows for the years then ended, and the related notes (collectively referred to as the &#8220;financial statements&#8221;). In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company as of December&#160;31, 2022 and 2021, and the results of its operations and its cash flows for the years then ended, in conformity with accounting principles generally accepted in the United States of America. </div><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">Basis for Opinion </div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">These financial statements are the responsibility of the Company&#8217;s management. Our responsibility is to express an opinion on the Company&#8217;s financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits, we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company&#8217;s internal control over financial reporting. Accordingly, we express no such opinion. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">/s/ Deloitte&#160;&amp; Touche LLP </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Dallas, Texas </div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">March&#160;29, 2023 </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have served as the Company&#8217;s auditor since 2021. </div><div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">F-2 </div></div></div><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div><hr style="color:#999999;height:3px;width:100%"/><div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div></div> <div><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">biote Corp. </div></div></div></div><div id="fin479690_2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">CONSOLIDATED BALANCE SHEETS </div></div></div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(in thousands, except share amounts) </div></div></div><div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt;width:100%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:77%"></td>
<td style="vertical-align:bottom;width:5%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:5%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,<br/> 2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,<br/> 2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 9pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Assets</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 9pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Current assets:</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 9pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Cash</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:Cash" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">79,231</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:Cash" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">26,766</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 9pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Accounts receivable, net</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AccountsReceivableNetCurrent" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">6,948</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AccountsReceivableNetCurrent" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">5,231</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 9pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Inventory, net</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:InventoryNet" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">11,183</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:InventoryNet" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">9,615</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 9pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Other current assets</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">3,816</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">5,473</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 9pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total current assets</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AssetsCurrent" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">101,178</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AssetsCurrent" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">47,085</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 9pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Property and equipment, net</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,504</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">2,335</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 9pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Capitalized software, net</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:CapitalizedComputerSoftwareNet" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">5,073</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:CapitalizedComputerSoftwareNet" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">4,554</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 9pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Operating lease <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">right-of-use</div></div> assets</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">2,052</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">356</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 9pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Deferred tax asset</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:DeferredIncomeTaxAssetsNet" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,838</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 9pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total assets</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:Assets" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">111,645</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:Assets" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">54,330</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt;background-color:#cceeff">
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 9pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Liabilities and Stockholders&#8217; Equity (Deficit)</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 9pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Current liabilities:</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 9pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Accounts payable</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AccountsPayableCurrent" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">4,112</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AccountsPayableCurrent" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">4,349</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 9pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Accrued expenses</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AccruedLiabilitiesCurrent" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">6,274</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AccruedLiabilitiesCurrent" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">6,011</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 9pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Term loan, current</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:LongTermDebtCurrent" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">6,250</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:LongTermDebtCurrent" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">5,000</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 9pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Deferred revenue, current</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ContractWithCustomerLiabilityCurrent" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,965</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ContractWithCustomerLiabilityCurrent" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,705</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 9pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Operating lease liabilities, current</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityCurrent" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">165</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityCurrent" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">248</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 9pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total current liabilities</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:LiabilitiesCurrent" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">18,766</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:LiabilitiesCurrent" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">17,313</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 9pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Term loan, net of current portion</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:LongTermDebtNoncurrent" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">112,086</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:LongTermDebtNoncurrent" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">31,963</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 9pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Deferred revenue, net of current portion</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ContractWithCustomerLiabilityNoncurrent" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">926</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ContractWithCustomerLiabilityNoncurrent" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">802</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 9pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Operating lease liabilities, net of current portion</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityNoncurrent" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,927</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityNoncurrent" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">127</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 9pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Warrant liability</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:WarrantsAndRightsOutstanding" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">4,104</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 9pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Earnout liability</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:DerivativeLiabilitiesNoncurrent" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">32,110</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 9pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total liabilities</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:Liabilities" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">169,919</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:Liabilities" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">50,205</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 9pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Commitments and contingencies (See Note 18)</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><ix:nonFraction name="us-gaap:CommitmentsAndContingencies" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" xsi:nil="true"></ix:nonFraction></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><ix:nonFraction name="us-gaap:CommitmentsAndContingencies" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" xsi:nil="true"></ix:nonFraction></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 9pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Stockholders&#8217; Equity (Deficit)</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 9pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Class&#160;A, AA, AAA, and AAAA units, <ix:nonFraction name="us-gaap:CommonStockNoParValue" contextRef="PAsOn12_31_2022_ClassAaUnitsMemberusgaapStatementClassOfStockAxis" unitRef="Unit_USD_per_Share" decimals="INF" scale="0" format="ixt-sec:numwordsen"><ix:nonFraction name="us-gaap:CommonStockNoParValue" contextRef="PAsOn12_31_2022_ClassAaaUnitsMemberusgaapStatementClassOfStockAxis" unitRef="Unit_USD_per_Share" decimals="INF" scale="0" format="ixt-sec:numwordsen"><ix:nonFraction name="us-gaap:CommonStockNoParValue" contextRef="PAsOn12_31_2022_ClassAaaaUnitsMemberusgaapStatementClassOfStockAxis" unitRef="Unit_USD_per_Share" decimals="INF" scale="0" format="ixt-sec:numwordsen"><ix:nonFraction name="us-gaap:CommonStockNoParValue" contextRef="PAsOn12_31_2022_ClassAMemberusgaapStatementClassOfStockAxis" unitRef="Unit_USD_per_Share" decimals="INF" scale="0" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> par value, <div style="letter-spacing: 0px; top: 0px;;display:inline;"><span style="-sec-ix-hidden:hidden73945433">unlimited</span></div> <span style="-sec-ix-hidden:hidden73945434">units</span> authorized; <ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="PAsOn12_31_2022_ClassAaUnitsMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt-sec:numwordsen"><ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="PAsOn12_31_2022_ClassAaaUnitsMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt-sec:numwordsen"><ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="PAsOn12_31_2022_ClassAaaaUnitsMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt-sec:numwordsen"><ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="PAsOn12_31_2022_ClassAMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> and <ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="PAsOn12_31_2021_ClassAaUnitsMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="PAsOn12_31_2021_ClassAaaUnitsMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="PAsOn12_31_2021_ClassAaaaUnitsMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="PAsOn12_31_2021_ClassAMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal">1,013,197</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> units issued, <ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="PAsOn12_31_2022_ClassAaUnitsMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt-sec:numwordsen"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="PAsOn12_31_2022_ClassAaaUnitsMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt-sec:numwordsen"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="PAsOn12_31_2022_ClassAaaaUnitsMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt-sec:numwordsen"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="PAsOn12_31_2022_ClassAMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> and <ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="PAsOn12_31_2021_ClassAaUnitsMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="PAsOn12_31_2021_ClassAaaUnitsMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="PAsOn12_31_2021_ClassAaaaUnitsMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="PAsOn12_31_2021_ClassAMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal">982,800</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> units outstanding as of December&#160;31, 2022 and December&#160;31, 2021, respectively</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 9pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Preferred stock, $<ix:nonFraction name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="PAsOn12_31_2021" unitRef="Unit_USD_per_Share" decimals="INF" scale="0" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="PAsOn12_31_2022" unitRef="Unit_USD_per_Share" decimals="INF" scale="0" format="ixt:num-dot-decimal">0.0001</ix:nonFraction></ix:nonFraction> par value, <ix:nonFraction name="us-gaap:PreferredStockSharesAuthorized" contextRef="PAsOn12_31_2021" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:PreferredStockSharesAuthorized" contextRef="PAsOn12_31_2022" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal">10,000,000</ix:nonFraction></ix:nonFraction> shares authorized; <ix:nonFraction name="us-gaap:PreferredStockSharesIssued" contextRef="PAsOn12_31_2021" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt-sec:numwordsen"><ix:nonFraction name="us-gaap:PreferredStockSharesOutstanding" contextRef="PAsOn12_31_2022" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt-sec:numwordsen"><ix:nonFraction name="us-gaap:PreferredStockSharesOutstanding" contextRef="PAsOn12_31_2021" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt-sec:numwordsen"><ix:nonFraction name="us-gaap:PreferredStockSharesIssued" contextRef="PAsOn12_31_2022" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> shares issued or outstanding</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:PreferredStockValue" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:PreferredStockValue" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 9pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Class&#160;A common stock, $<ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="PAsOn12_31_2021_CommonClassAMemberusgaapStatementClassOfStockAxis" unitRef="Unit_USD_per_Share" decimals="INF" scale="0" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="PAsOn12_31_2022_CommonClassAMemberusgaapStatementClassOfStockAxis" unitRef="Unit_USD_per_Share" decimals="INF" scale="0" format="ixt:num-dot-decimal">0.0001</ix:nonFraction></ix:nonFraction> par value, <ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="PAsOn12_31_2021_CommonClassAMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="PAsOn12_31_2022_CommonClassAMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal">600,000,000</ix:nonFraction></ix:nonFraction> shares authorized; <ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="PAsOn12_31_2022_CommonClassAMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal">11,242,887</ix:nonFraction> and <ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="PAsOn12_31_2021_CommonClassAMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt-sec:numwordsen">no</ix:nonFraction> shares issued, <ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="PAsOn12_31_2022_CommonClassAMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal">9,655,387</ix:nonFraction> and <ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="PAsOn12_31_2021_CommonClassAMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt-sec:numwordsen">no</ix:nonFraction> shares outstanding as of December&#160;31, 2022 and December&#160;31, 2021, respectively</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:CommonStockValue" contextRef="PAsOn12_31_2022_CommonClassAMemberusgaapStatementClassOfStockAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">1</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 9pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Class&#160;B common stock, $<ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="PAsOn12_31_2021_CommonClassBMemberusgaapStatementClassOfStockAxis" unitRef="Unit_USD_per_Share" decimals="INF" scale="0" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="PAsOn12_31_2022_CommonClassBMemberusgaapStatementClassOfStockAxis" unitRef="Unit_USD_per_Share" decimals="INF" scale="0" format="ixt:num-dot-decimal">0.0001</ix:nonFraction></ix:nonFraction> par value, <ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="PAsOn12_31_2021_CommonClassBMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="PAsOn12_31_2022_CommonClassBMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal">8,000,000</ix:nonFraction></ix:nonFraction> shares authorized; <ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="PAsOn12_31_2021_CommonClassBMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt-sec:numwordsen"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="PAsOn12_31_2022_CommonClassBMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt-sec:numwordsen"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="PAsOn12_31_2021_CommonClassBMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt-sec:numwordsen"><ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="PAsOn12_31_2022_CommonClassBMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> shares issued or outstanding as of December&#160;31, 2022 and December&#160;31, 2021</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:CommonStockValue" contextRef="PAsOn12_31_2022_CommonClassBMemberusgaapStatementClassOfStockAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:CommonStockValue" contextRef="PAsOn12_31_2021_CommonClassBMemberusgaapStatementClassOfStockAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 9pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Class&#160;V voting stock, $<ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="PAsOn12_31_2021_CommonClassVMemberusgaapStatementClassOfStockAxis" unitRef="Unit_USD_per_Share" decimals="INF" scale="0" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="PAsOn12_31_2022_CommonClassVMemberusgaapStatementClassOfStockAxis" unitRef="Unit_USD_per_Share" decimals="INF" scale="0" format="ixt:num-dot-decimal">0.0001</ix:nonFraction></ix:nonFraction> par value, <ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="PAsOn12_31_2021_CommonClassVMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="PAsOn12_31_2022_CommonClassVMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal">100,000,000</ix:nonFraction></ix:nonFraction> shares authorized; <ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="PAsOn12_31_2022_CommonClassVMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal">58,565,824</ix:nonFraction> and <ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="PAsOn12_31_2021_CommonClassVMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt-sec:numwordsen">no</ix:nonFraction> shares issued, <ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="PAsOn12_31_2022_CommonClassVMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal">48,565,824</ix:nonFraction> and <ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="PAsOn12_31_2021_CommonClassVMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt-sec:numwordsen">no</ix:nonFraction> shares outstanding as of December&#160;31, 2022 and December&#160;31, 2021, respectively</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:CommonStockValue" contextRef="PAsOn12_31_2022_CommonClassVMemberusgaapStatementClassOfStockAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">5</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 9pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Additional <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">paid-in</div> capital</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AdditionalPaidInCapital" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AdditionalPaidInCapital" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 9pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Retained earnings (Accumulated deficit)</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">44,460</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">4,165</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 9pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Accumulated other comprehensive loss</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">5</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">40</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 9pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">biote Corp.&#8217;s stockholders&#8217; equity (deficit)</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">44,459</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">4,125</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 9pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><ix:nonFraction name="us-gaap:CommonStockNoParValue" contextRef="PAsOn12_31_2021_ClassAaUnitsMemberusgaapStatementClassOfStockAxis" unitRef="Unit_USD_per_Share" decimals="INF" scale="0" format="ixt-sec:numwordsen"><ix:nonFraction name="us-gaap:CommonStockNoParValue" contextRef="PAsOn12_31_2021_ClassAaaUnitsMemberusgaapStatementClassOfStockAxis" unitRef="Unit_USD_per_Share" decimals="INF" scale="0" format="ixt-sec:numwordsen"><ix:nonFraction name="us-gaap:CommonStockNoParValue" contextRef="PAsOn12_31_2021_ClassAaaaUnitsMemberusgaapStatementClassOfStockAxis" unitRef="Unit_USD_per_Share" decimals="INF" scale="0" format="ixt-sec:numwordsen"><ix:nonFraction name="us-gaap:CommonStockNoParValue" contextRef="PAsOn12_31_2021_ClassAMemberusgaapStatementClassOfStockAxis" unitRef="Unit_USD_per_Share" decimals="INF" scale="0" format="ixt-sec:numwordsen">No</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction>ncontrolling interest</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:MinorityInterest" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">13,815</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:MinorityInterest" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 9pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total stockholders&#8217; equity (deficit)</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">58,274</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">4,125</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 9pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total liabilities and stockholders&#8217; equity (deficit)</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">111,645</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">54,330</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table><div style="margin-top:6pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman;text-align:center">The accompanying notes are an integral part of these consolidated financial statements. </div><div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">F-3 </div></div></div><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div><hr style="color:#999999;height:3px;width:100%"/><div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div></div> <div><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">biote Corp. </div></div></div></div><div id="fin479690_3" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">CONSOLIDATED STATEMENTS OF INCOME AND COMPREHENSIVE INCOME </div></div></div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;">(in thousands, except share and per share amounts)</div></div></div><div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:80%"></td>
<td style="vertical-align:bottom;width:3%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:3%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Year Ended December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Revenue:</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Produ</div>ct revenue</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P01_01_2022To12_31_2022_ProductRevenueMembersrtProductOrServiceAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">163,133</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P01_01_2021To12_31_2021_ProductRevenueMembersrtProductOrServiceAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">137,598</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Service revenue</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P01_01_2022To12_31_2022_ServiceRevenueMembersrtProductOrServiceAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,824</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P01_01_2021To12_31_2021_ServiceRevenueMembersrtProductOrServiceAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,798</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total revenue</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">164,957</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">139,396</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Cost of revenue (excluding depreciation and amortization included in selling, general and administrative, below)</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Cost of products</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization" contextRef="P01_01_2022To12_31_2022_ProductRevenueMembersrtProductOrServiceAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">51,990</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization" contextRef="P01_01_2021To12_31_2021_ProductRevenueMembersrtProductOrServiceAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">46,298</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Cost of services</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization" contextRef="P01_01_2022To12_31_2022_ServiceRevenueMembersrtProductOrServiceAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">2,585</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization" contextRef="P01_01_2021To12_31_2021_ServiceRevenueMembersrtProductOrServiceAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">2,519</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Cost of revenue</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">54,575</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">48,817</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Commissions</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:SalesCommissionsAndFees" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">974</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:SalesCommissionsAndFees" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">2,056</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Marketing</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:MarketingExpense" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">4,628</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:MarketingExpense" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">4,908</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Selling, general and administrative</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:SellingGeneralAndAdministrativeExpense" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">165,502</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:SellingGeneralAndAdministrativeExpense" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">49,054</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Income (loss) from operations</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">60,722</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">34,561</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Other income (expense), net:</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Interest expense</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:InterestIncomeExpenseNonoperatingNet" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">5,091</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:InterestIncomeExpenseNonoperatingNet" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">1,673</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Gain from change in fair value of warrant liability</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:FairValueAdjustmentOfWarrants" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">5,127</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Gain from change in fair value of earnout liability</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="btmd:GainLossFromChangeInFairValueOfEarnoutLiability" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">61,770</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Loss from extinguishment of debt</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:GainsLossesOnExtinguishmentOfDebt" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">445</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Other income</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:OtherNonoperatingIncome" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,073</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:OtherNonoperatingIncome" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">17</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total other income (expense), net</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:NonoperatingIncomeExpense" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">62,434</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:NonoperatingIncomeExpense" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">1,656</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Income before provision for income taxes</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,712</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">32,905</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Income tax expense</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">388</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">286</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Net income</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ProfitLoss" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,324</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ProfitLoss" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">32,619</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Less: Net income attributable to noncontrolling interest</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">2,293</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Net income (loss) attributable to biote Corp. stockholders</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">969</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Other comprehensive income (loss):</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Foreign currency translation adjustments</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">1</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">17</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Other comprehensive income (loss)</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">1</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">17</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Comprehensive income</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ComprehensiveIncomeNetOfTax" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,323</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ComprehensiveIncomeNetOfTax" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">32,602</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Net income (loss) per common share</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Basic</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD_per_Share" decimals="2" scale="0" sign="-" format="ixt:num-dot-decimal">0.12</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Diluted</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:EarningsPerShareDiluted" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD_per_Share" decimals="2" scale="0" sign="-" format="ixt:num-dot-decimal">0.12</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Weighted average common shares outstanding</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Basic</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal">8,059,371</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Diluted</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal">8,059,371</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr></table><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">The accompanying notes are an integral part of these consolidated financial statements. </div><div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">F-4 </div></div><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div><hr style="color:#999999;height:3px;width:100%"/><div style="text-align: left;; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;;font-size: .83em;"><a href="#toc">Table of Contents</a></div></div></div> <div><div><div style="background-color:white;display: inline;"><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">biote Corp. </div></div></div></div><div id="fin479690_4" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">CONSOLIDATED STATEMENTS OF STOCKHOLDERS&#8217; EQUITY (DEFICIT) </div></div></div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(in thousands, except share amounts) </div></div></div><div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt;width:100%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:39%"></td>
<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Members&#8217; Equity</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Class&#160;A</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Common&#160;Stock</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Class&#160;V</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Voting&#160;Stock</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td rowspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" rowspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Additional<br/> <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Paid-in</div><br/> Capital</div></div></td>
<td rowspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td rowspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" rowspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Retained<br/> Earnings /<br/> (Accumulated<br/> Deficit)</div></div></td>
<td rowspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td rowspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" rowspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Accumulated<br/> Other<br/> Comprehensive<br/> Income (Loss)</div></div></td>
<td rowspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td rowspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" rowspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Total<br/> Stockholders&#8217;<br/> Equity<br/> (Deficit)<br/> Attributable<br/> to<br/> biote&#160;Corp.</div></div></td>
<td rowspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td rowspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" rowspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Non<br/> controlling<br/> Interest</div></div></td>
<td rowspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td rowspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" rowspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Total<br/> Stockholders&#8217;<br/> Equity<br/> (Deficit)</div></div></td>
<td rowspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Units</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Amount</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Shares</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Amount</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Shares</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Amount</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 9pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Balance at December&#160;31, 2020</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:PartnersCapitalAccountUnits" contextRef="PAsOn12_31_2020_MemberUnitsMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal">982,800</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="PAsOn12_31_2020_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">17,052</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="PAsOn12_31_2020_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">23</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="PAsOn12_31_2020_ParentMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">17,075</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">17,075</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 9pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Distributions</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:DividendsCommonStock" contextRef="P01_01_2021To12_31_2021_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">11,402</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:DividendsCommonStock" contextRef="P01_01_2021To12_31_2021_ParentMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">11,402</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:DividendsCommonStock" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">11,402</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 9pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Net income</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ProfitLoss" contextRef="P01_01_2021To12_31_2021_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">32,619</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ProfitLoss" contextRef="P01_01_2021To12_31_2021_ParentMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">32,619</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ProfitLoss" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">32,619</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 9pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Other comprehensive loss</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" contextRef="P01_01_2021To12_31_2021_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">17</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" contextRef="P01_01_2021To12_31_2021_ParentMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">17</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">17</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 9pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Balance&#160;at&#160;December&#160;31, 2021</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:PartnersCapitalAccountUnits" contextRef="PAsOn12_31_2021_MemberUnitsMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal">982,800</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="PAsOn12_31_2021_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">4,165</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="PAsOn12_31_2021_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">40</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="PAsOn12_31_2021_ParentMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">4,125</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">4,125</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">The accompanying notes are an integral part of these consolidated financial statements. </div><div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">F-5 </div></div></div></div><div></div></div><div><div style="background-color:white;display: inline;"><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div><hr style="color:#999999;height:3px;width:100%"/><div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div></div></div></div> <div><div><div style="background-color:white;display: inline;"><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">biote Corp. </div></div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">CONSOLIDATED STATEMENTS OF STOCKHOLDERS&#8217; EQUITY (DEFICIT) </div></div></div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(in thousands, except share amounts) </div></div></div><div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt;width:100%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:32%"></td>
<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Members&#8217;</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Equity</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Class&#160;A</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Common&#160;Stock</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Class&#160;V</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Voting Stock</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td rowspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" rowspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Additional<br/> <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Paid-in</div></div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Capital</div></div></td>
<td rowspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td rowspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" rowspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Retained<br/> Earnings /<br/> (Accumulated<br/> Deficit)</div></div></td>
<td rowspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td rowspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" rowspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Accumulated<br/> Other<br/> Comprehensive<br/> Income (Loss)</div></div></td>
<td rowspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td rowspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" rowspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Total<br/> Stockholders&#8217;<br/> Equity<br/> (Deficit)<br/> Attributable<br/> to<br/> biote&#160;Corp.</div></div></td>
<td rowspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td rowspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" rowspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Non-<br/> controlling<br/> Interest</div></div></td>
<td rowspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td rowspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" rowspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Total<br/> Stockholders&#8217;<br/> Equity<br/> (Deficit)</div></div></td>
<td rowspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Units</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Amount</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Shares</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Amount</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Shares</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Amount</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 9pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Balance at December&#160;31, 2021</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:PartnersCapitalAccountUnits" contextRef="PAsOn12_31_2021_MemberUnitsMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal">982,800</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="PAsOn12_31_2021_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">4,165</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="PAsOn12_31_2021_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">40</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="PAsOn12_31_2021_ParentMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">4,125</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">4,125</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 9pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Distributions</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:DividendsCommonStock" contextRef="P01_01_2022To12_31_2022_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">9,575</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:DividendsCommonStock" contextRef="P01_01_2022To12_31_2022_ParentMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">9,575</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:DividendsCommonStock" contextRef="P01_01_2022To12_31_2022_NoncontrollingInterestMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">3,311</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:DividendsCommonStock" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">12,886</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 9pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Net income through May&#160;26, 2022</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ProfitLoss" contextRef="P01_01_2022To05_26_2022_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">9,143</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ProfitLoss" contextRef="P01_01_2022To05_26_2022_ParentMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">9,143</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ProfitLoss" contextRef="P01_01_2022To05_26_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">9,143</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 9pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Other comprehensive income through May&#160;26, 2022</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" contextRef="P01_01_2022To05_26_2022_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">1</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" contextRef="P01_01_2022To05_26_2022_ParentMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">1</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" contextRef="P01_01_2022To05_26_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">1</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 9pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Business Combination: Reverse recapitalization on May&#160;26, 2022</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="btmd:PartnersCapitalAccountReverseRecapitalizationUnits" contextRef="PAsOn05_26_2022_MemberUnitsMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="0" scale="0" sign="-" format="ixt:num-dot-decimal">982,800</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="btmd:StockholdersEquityIncludingPortionAttributableToNonControllingInterestSharesReverseRecapitalization" contextRef="PAsOn05_26_2022_CommonClassAMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal">7,574,271</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="btmd:StockholdersEquityIncludingPortionAttributableToNonControllingInterestReverseRecapitalization" contextRef="PAsOn05_26_2022_CommonClassAMemberusgaapStatementClassOfStockAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">1</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="btmd:StockholdersEquityIncludingPortionAttributableToNonControllingInterestSharesReverseRecapitalization" contextRef="PAsOn05_26_2022_CommonClassVMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal">48,565,824</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="btmd:StockholdersEquityIncludingPortionAttributableToNonControllingInterestReverseRecapitalization" contextRef="PAsOn05_26_2022_CommonClassVMemberusgaapStatementClassOfStockAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">5</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="btmd:StockholdersEquityIncludingPortionAttributableToNonControllingInterestReverseRecapitalization" contextRef="PAsOn05_26_2022_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">113,628</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="btmd:StockholdersEquityIncludingPortionAttributableToNonControllingInterestReverseRecapitalization" contextRef="PAsOn05_26_2022_ParentMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">113,622</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="btmd:StockholdersEquityIncludingPortionAttributableToNonControllingInterestReverseRecapitalization" contextRef="PAsOn05_26_2022" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">113,622</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 9pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Business Combination: Noncontrolling interest on May&#160;26, 2022</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="btmd:StockholdersEquityAttributableToNonControllingInterestBusinessCombination" contextRef="PAsOn05_26_2022_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">3,619</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="btmd:StockholdersEquityAttributableToNonControllingInterestBusinessCombination" contextRef="PAsOn05_26_2022_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">34</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="btmd:StockholdersEquityAttributableToNonControllingInterestBusinessCombination" contextRef="PAsOn05_26_2022_ParentMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">3,653</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="btmd:StockholdersEquityAttributableToNonControllingInterestBusinessCombination" contextRef="PAsOn05_26_2022_NoncontrollingInterestMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">3,653</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 9pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Business Combination: Capitalized transaction costs</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="btmd:StockholdersEquityBussinessCombinationCapitalizedTransactionCosts" contextRef="P01_01_2022To12_31_2022_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">12,282</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="btmd:StockholdersEquityBussinessCombinationCapitalizedTransactionCosts" contextRef="P01_01_2022To12_31_2022_ParentMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">12,282</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="btmd:StockholdersEquityBussinessCombinationCapitalizedTransactionCosts" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">12,282</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 9pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Net loss after May&#160;26, 2022</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:ProfitLoss" contextRef="P05_27_2022To12_31_2022_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">969</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:ProfitLoss" contextRef="P05_27_2022To12_31_2022_ParentMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">969</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:ProfitLoss" contextRef="P05_27_2022To12_31_2022_NoncontrollingInterestMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">6,850</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:ProfitLoss" contextRef="P05_27_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">7,819</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 9pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Other comprehensive loss after May&#160;26, 2022</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" contextRef="P05_27_2022To12_31_2022_NoncontrollingInterestMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">1</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" contextRef="P05_27_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">1</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 9pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Share-based compensation</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="P01_01_2022To12_31_2022_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">82,180</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="P01_01_2022To12_31_2022_ParentMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">82,180</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">82,180</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 9pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Settlement of phantom equity rights</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="btmd:StockIssuedDuringPeriodValueSettlementOfEquityRights" contextRef="P01_01_2022To12_31_2022_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">7,250</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="btmd:StockIssuedDuringPeriodValueSettlementOfEquityRights" contextRef="P01_01_2022To12_31_2022_ParentMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">7,250</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="btmd:StockIssuedDuringPeriodValueSettlementOfEquityRights" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">7,250</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 9pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Vesting of RSUs</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="btmd:StockIssuedDuringPeriodSharesVestingOfRestrictedStockUnit" contextRef="P01_01_2022To12_31_2022_CommonClassAMemberusgaapStatementClassOfStockAxis_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal">1,950,557</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="btmd:StockIssuedDuringPeriodValueVestingOfRestrictedStockUnit" contextRef="P01_01_2022To12_31_2022_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">424</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="btmd:StockIssuedDuringPeriodValueVestingOfRestrictedStockUnit" contextRef="P01_01_2022To12_31_2022_ParentMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">424</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="btmd:StockIssuedDuringPeriodValueVestingOfRestrictedStockUnit" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">424</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 9pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Issuance of shares under SEPA</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="P01_01_2022To12_31_2022_CommonClassAMemberusgaapStatementClassOfStockAxis_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal">130,559</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="P01_01_2022To12_31_2022_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">561</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="P01_01_2022To12_31_2022_ParentMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">561</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">561</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 9pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Balance at December&#160;31, 2022</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="PAsOn12_31_2022_CommonClassAMemberusgaapStatementClassOfStockAxis_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal">9,655,387</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="PAsOn12_31_2022_CommonClassAMemberusgaapStatementClassOfStockAxis_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">1</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="PAsOn12_31_2022_CommonClassVMemberusgaapStatementClassOfStockAxis_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal">48,565,824</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="PAsOn12_31_2022_CommonClassVMemberusgaapStatementClassOfStockAxis_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">5</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="PAsOn12_31_2022_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">44,460</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="PAsOn12_31_2022_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">5</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="PAsOn12_31_2022_ParentMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">44,459</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="PAsOn12_31_2022_NoncontrollingInterestMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">13,815</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">58,274</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">The accompanying notes are an integral part of these consolidated financial statements. </div><div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">F-6 </div></div></div><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div><hr style="color:#999999;height:3px;width:100%"/><div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div></div></div></div> <div><div><div style="background-color:white;display: inline;"><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">biote Corp. </div></div></div></div><div id="fin479690_5" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">CONSOLIDATED STATEMENTS OF CASH FLOWS </div></div></div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;">(in thousands)</div></div></div><div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9.5pt;width:100%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:80%"></td>
<td style="vertical-align:bottom;width:4%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:4%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Year&#160;Ended&#160;December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;2022&#160;&#160;&#160;&#160;&#160;&#160;</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;2021&#160;&#160;&#160;&#160;&#160;&#160;</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt;background-color:#cceeff">
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 9.5pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Operating Activities</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 9.5pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Net income</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ProfitLoss" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,324</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ProfitLoss" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">32,619</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 9.5pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Adjustments to reconcile net income to net cash (used in) provided by operating</div><div style="margin-top: 0pt; margin-bottom: 1pt; margin-left: 1em; text-indent: -1em; font-size: 9.5pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">activities:</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 9.5pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Depreciation and amortization</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:DepreciationDepletionAndAmortization" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">2,199</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:DepreciationDepletionAndAmortization" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,400</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 9.5pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Bad debt expense (recoveries)</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:ProvisionForDoubtfulAccounts" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">155</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ProvisionForDoubtfulAccounts" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">240</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 9.5pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Amortization of debt issuance costs</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AmortizationOfFinancingCosts" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">589</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AmortizationOfFinancingCosts" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">222</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 9.5pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Provision for obsolete inventory</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:InventoryWriteDown" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">140</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:InventoryWriteDown" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">471</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 9.5pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-cash</div> lease expense</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="btmd:NonCashLeaseExpense" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">240</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="btmd:NonCashLeaseExpense" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">226</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 9.5pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-cash</div> sponsor share transfers</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="btmd:NonCashSponsorShareTransfers" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">7,216</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 9.5pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-cash</div> fees under SEPA</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="btmd:NonCashFeesUnderSepa" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">119</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 9.5pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Share-based compensation expense</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">82,180</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 9.5pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Gain from change in fair value of warrant liability</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:FairValueAdjustmentOfWarrants" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">5,127</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 9.5pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Gain from change in fair value of earnout liability</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="btmd:FairValueAdjustmentOfEarnoutLiability" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">61,770</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 9.5pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Loss from extinguishment of debt</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:GainsLossesOnExtinguishmentOfDebt" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">445</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 9.5pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Deferred income taxes</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:DeferredIncomeTaxesAndTaxCredits" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">743</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 9.5pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Changes in operating assets and liabilities:</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 9.5pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Accounts receivable</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsReceivable" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,562</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsReceivable" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">752</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 9.5pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Inventory</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInInventories" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,708</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInInventories" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">5,762</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 9.5pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Other current assets</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInOtherCurrentAssets" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">2,284</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:IncreaseDecreaseInOtherCurrentAssets" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">34</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 9.5pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Accounts payable</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsPayable" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">416</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsPayable" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,605</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 9.5pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Deferred revenue</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:IncreaseDecreaseInDeferredRevenue" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">384</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInDeferredRevenue" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">373</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 9.5pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Accrued expenses</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInAccruedLiabilities" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">30,841</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:IncreaseDecreaseInAccruedLiabilities" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">4,029</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 9.5pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Operating lease liabilities</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">219</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">239</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 9.5pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Net cash (used in) provided by operating activities</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">9,157</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">33,720</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt;background-color:#cceeff">
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 9.5pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Investing Activities</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 9.5pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Purchases of property and equipment</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">333</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,448</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 9.5pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Purchases of capitalized software</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:PaymentsForSoftware" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,505</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:PaymentsForSoftware" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">2,359</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 9.5pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Net cash used in investing activities</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInInvestingActivities" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">1,838</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInInvestingActivities" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">3,807</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt;background-color:#cceeff">
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 9.5pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Financing Activities</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 9.5pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Proceeds from the Business Combination</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="btmd:ProceedsFromBusinessCombination" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">12,282</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 9.5pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Principal repayments on term loan</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="btmd:PrincipalRepaymentsOnTermLoan" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">4,375</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="btmd:PrincipalRepaymentsOnTermLoan" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">5,000</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 9.5pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Borrowings on term loan</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="btmd:BorrowingsOnTermLoan" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">125,000</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 9.5pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Extinguishment of Bank of America term loan</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:PaymentsOfDebtExtinguishmentCosts" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">36,250</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 9.5pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Debt issuance costs</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:PaymentsOfDebtIssuanceCosts" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">4,036</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 9.5pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Settlement of phantom equity rights</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="btmd:PaymentsOfSettlementOfPhantomEquityRight" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">7,250</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 9.5pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Settlement of RSUs</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="btmd:PaymentsOfSettlementOfRestrictedStockUnits" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">424</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 9.5pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Distributions</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:PaymentsOfDividends" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">12,886</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:PaymentsOfDividends" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">11,402</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 9.5pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Capitalized transaction costs</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:PaymentsOfStockIssuanceCosts" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">8,341</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:PaymentsOfStockIssuanceCosts" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">3,941</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 9.5pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Proceeds from issuance of shares under SEPA</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="btmd:ProceedsFromIssuanceOfSharesUnderSepa" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">442</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 9.5pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">SEPA transaction costs</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="btmd:PaymentsToSEPATransactionCosts" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">702</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 9.5pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Net cash provided by (used in) financing activities</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">63,460</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">20,343</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 9.5pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Effect of exchange rate changes on cash and cash equivalents</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">12</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 9.5pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Net increase in cash and cash equivalents</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">52,465</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">9,558</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 9.5pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Cash and cash equivalents at beginning of period</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">26,766</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">17,208</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 9.5pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Cash and cash equivalents at end of period</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">79,231</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">26,766</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 9.5pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Supplemental Disclosure of Cash Flow Information</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 9.5pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Cash paid for interest</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:InterestPaidNet" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">4,426</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:InterestPaidNet" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,462</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 9.5pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Cash paid for income taxes</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:IncomeTaxesPaid" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">282</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:IncomeTaxesPaid" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">171</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 9.5pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-cash</div> investing and financing activities</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 9.5pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Capital expenditures and capitalized software included in accounts payable</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">49</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">282</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 9.5pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-cash</div> SEPA transaction costs</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="btmd:NonCashSEPATransactionCosts" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">119</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr></table><div style="margin-top:12pt; margin-bottom:0pt; font-size:9.5pt; font-family:Times New Roman;text-align:center">The accompanying notes are an integral part of these consolidated financial statements. </div><div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">F-7 </div></div></div></div><div></div></div><div><div style="background-color:white;display: inline;"><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div><hr style="color:#999999;height:3px;width:100%"/><div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div></div></div></div> <div><div><div style="background-color:white;display: inline;"><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">biote Corp. </div></div></div></div><div id="fin479690_6" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS </div></div></div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;">(amounts in thousands, except share and per share amounts)</div></div></div><div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div><ix:nonNumeric name="us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock" contextRef="P01_01_2022To12_31_2022" escape="true">
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">1.</div></div></td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: left; line-height: normal;"><div style="font-weight:bold;display:inline;">DESCRIPTION OF BUSINESS AND BASIS OF PRESENTATION </div></div></td></tr></table><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Description of Business</div></div>&#8212;biote Corp. (inclusive of its consolidated subsidiaries, the &#8220;Company&#8221; or &#8220;Biote&#8221;) is a Delaware incorporated company headquartered in Irving, Texas. The Company was founded in 2012 and trains physicians and nurse practitioners in hormone optimization using <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">bio-identical</div> hormone replacement pellet therapy in men and women experiencing hormonal imbalance. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Basis of Presentation</div></div>&#8212;The consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (&#8220;U.S. GAAP&#8221;). The consolidated financial statements include the accounts of Biote and its subsidiaries. All intercompany balances and transactions have been eliminated in consolidation. The Company recognizes noncontrolling interest related to its less-than-wholly-owned subsidiary as equity in the consolidated financial statements separate from the parent entity&#8217;s equity. The net income attributable to noncontrolling interest is included in net income in the consolidated statements of income and comprehensive income. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div></div></div>&#8212;As of December&#160;31, 2022 and December&#160;31, 2021, the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> pandemic and the related disruptions caused to the global economy did not have a material impact on the Company&#8217;s business. However, the duration and intensity of the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> pandemic and any resulting disruption to the Company&#8217;s operations remains somewhat uncertain, and the Company will continue to assess the impact of the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> pandemic on its financial position. Further, global economic conditions have been worsening, with disruptions to, and volatility in, the credit and financial markets in the U.S. and worldwide resulting from the effects of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> and otherwise. If these conditions persist and deepen, the Company could experience an inability to access additional capital or its liquidity could otherwise be impacted. If the Company is unable to raise capital when needed or on attractive terms, it would be forced to delay, reduce or eliminate its research and development programs and/or other efforts. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Business Combination</div></div>&#8212;On May&#160;26, 2022 (the &#8220;Closing Date&#8221;), BioTE Holdings, LLC (&#8220;Holdings,&#8221; inclusive of its direct and indirect subsidiaries, the &#8220;BioTE Companies,&#8221; and as to its members, the &#8220;Members&#8221;) completed a series of transactions (the &#8220;Business Combination&#8221;) with Haymaker Acquisition Corp. III (&#8220;Haymaker&#8221;), Haymaker Sponsor III LLC (the &#8220;Sponsor&#8221;), BioTE Management, LLC, Dr.&#160;Gary&#160;S. Donovitz, in his individual capacity, and Teresa S. Weber, in her capacity as the Members&#8217; representative (in such capacity, the &#8220;Members&#8217; Representative&#8221;) pursuant to the business combination agreement (the &#8220;Business Combination Agreement&#8221;) dated December&#160;13, 2021 (the &#8220;Closing&#8221;), which is discussed in more detail in Note 3. As a result of the Business Combination, Haymaker was renamed &#8220;biote Corp.&#8221; </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Business Combination was accounted for as a common control transaction, in accordance with U.S. GAAP. Under this method of accounting, Haymaker&#8217;s acquisition of the BioTE Companies was accounted for at their historical carrying values, and the BioTE Companies were deemed the predecessor entity. This method of accounting is similar to a reverse recapitalization whereby the Business Combination was treated as the equivalent of the BioTE Companies issuing stock for the net assets of Haymaker, accompanied by a recapitalization. The net assets of Haymaker are stated at historical cost, with no goodwill or other intangible assets recorded. Operations prior to the Business Combination are those of the BioTE Companies. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Following the Closing of the Business Combination, the Company is organized in an <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">&#8220;Up-C&#8221;</div> structure in which the business of the Company is operated by Holdings and its subsidiaries, and Biote&#8217;s only material direct asset consists of equity interests in Holdings. The consolidated financial statements of Holdings and its subsidiaries have been determined to be the predecessor for accounting and reporting purposes for the period prior to the Business Combination. </div></ix:nonNumeric><div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">F-8 </div></div></div><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div><hr style="color:#999999;height:3px;width:100%"/><div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><ix:nonNumeric name="us-gaap:SignificantAccountingPoliciesTextBlock" contextRef="P01_01_2022To12_31_2022" escape="true" continuedAt="TextSelection_73945680">
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2.</div></div></td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: left; line-height: normal;"><div style="font-weight:bold;display:inline;">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES </div></div></td></tr></table><ix:nonNumeric name="us-gaap:UseOfEstimates" contextRef="P01_01_2022To12_31_2022" escape="true"><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Use of Estimates&#8212;</div></div>The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. The Company regularly evaluates estimates and assumptions related to assets, liabilities, costs, expenses, contingent liabilities, share-based compensation and research and development costs. The Company bases its estimates and assumptions on historical experience and on various other factors that it believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results could differ from those estimates. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In the opinion of the Company, the accompanying consolidated financial statements contain all adjustments, consisting of only normal recurring adjustments, necessary for a fair presentation of its financial position and its results of operations, changes in stockholders&#8217; equity (deficit) and cash flows. </div></ix:nonNumeric><ix:nonNumeric name="us-gaap:FairValueMeasurementPolicyPolicyTextBlock" contextRef="P01_01_2022To12_31_2022" escape="true"><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Fair Value Measurements</div></div>&#8212;The guidance in FASB ASC 820, <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Fair Value Measurements and Disclosures </div></div>(&#8220;ASC 820&#8221;), defines fair value and establishes a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements) and the lowest priority to unobservable inputs (Level 3 measurements). The three levels of the fair value hierarchy are described below: </div><div style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Level</div></div><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"></div><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">&#160;1</div></div>&#8212;Inputs are quoted prices (unadjusted) in active markets for identical assets or liabilities that the reporting entity has the ability to access at the measurement date. </div><div style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Level 2</div></div>&#8212;Valuations based on quoted prices in markets that are not active or for which all significant inputs are observable, either directly or indirectly. </div><div style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Level</div></div><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"></div><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">&#160;3</div></div>&#8212;Prices or valuations that require inputs that are both significant to the fair value measurement and unobservable. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">See Note 12 for further detail. </div></ix:nonNumeric><ix:nonNumeric name="us-gaap:SegmentReportingPolicyPolicyTextBlock" contextRef="P01_01_2022To12_31_2022" escape="true"><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Segment Information</div></div>&#8212;Operating segments are defined as components of an enterprise about which separate financial information is available that is evaluated regularly by the chief operating decision maker in deciding how to allocate resources and in assessing performance. The Company&#8217;s chief operating decision maker is the chief executive officer. The Company has one business activity and there are no segment managers who are held accountable for operations, operating results, and plans for levels or components below the consolidated unit level. Accordingly, the Company has <ix:nonFraction name="us-gaap:NumberOfOperatingSegments" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_SEGMENT" decimals="0" scale="0" format="ixt-sec:numwordsen">one </ix:nonFraction>operating segment and, therefore, <ix:nonFraction name="us-gaap:NumberOfReportableSegments" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_SEGMENT" decimals="0" scale="0" format="ixt-sec:numwordsen">one </ix:nonFraction>reportable segment. </div></ix:nonNumeric><ix:nonNumeric name="us-gaap:CashAndCashEquivalentsPolicyTextBlock" contextRef="P01_01_2022To12_31_2022" escape="true"><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Cash</div></div>&#8212;As of December&#160;31, 2022 and 2021, cash consists primarily of checking and savings deposits. The Company maintains deposits primarily with two financial institutions, which may at times exceed amounts covered by insurance provided by the U.S. Federal Deposit Insurance Corporation (&#8220;FDIC&#8221;). The Company has not experienced any losses related to amounts in excess of FDIC limits. The Company does not hold any cash equivalents, which would consist of highly liquid investments with original maturities of three months or less at the time of purchase. </div></ix:nonNumeric><ix:nonNumeric name="us-gaap:ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy" contextRef="P01_01_2022To12_31_2022" escape="true" continuedAt="TextSelection_73945705"><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Accounts Receivable and Allowance for Doubtful Accounts</div></div>&#8212;Accounts receivable are recorded net of allowances for doubtful accounts. Accounts receivable consist primarily of invoiced amounts to clinics that are not yet paid. On a periodic basis, management evaluates its accounts receivable and determines whether to provide an allowance or if any accounts should be written off based on past history of write-offs, collections, and current credit conditions. The Company maintains an allowance for doubtful accounts to provide for uncollectible amounts based on historical collection experience and an analysis of the aging of receivables. Management provides for probable uncollectible amounts through a charge to earnings and a credit to a valuation allowance based on its assessment of the current status of individual accounts. Balances still outstanding after </div><div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"><ix:exclude>F-9</ix:exclude></div></ix:nonNumeric></ix:nonNumeric></div></div><ix:continuation id="TextSelection_73945705" continuedAt="TextSelectionAppend_73945705_1"><ix:continuation id="TextSelection_73945680" continuedAt="TextSelectionAppend_73945680_1"><ix:exclude><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_73945680_1" continuedAt="TextSelectionAppend_73945680_2"><ix:exclude><hr style="color:#999999;height:3px;width:100%"/></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_73945680_2" continuedAt="TextSelectionAppend_73945680_3"><ix:exclude><div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div></ix:exclude></ix:continuation></ix:continuation></div></div></div> <div><div><div style="background-color:white;display: inline;"><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><ix:continuation id="TextSelectionAppend_73945680_3" continuedAt="TextSelectionAppend_73945680_4"><ix:continuation id="TextSelectionAppend_73945705_1"><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">management has exhausted all reasonable collection efforts are written off through a charge to the valuation allowance and a credit to accounts receivable. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Bad debt expense is classified in selling, general, and administrative expense within the consolidated statements of income and comprehensive income. The Company generally does not require any security or collateral to support its receivables. <ix:nonNumeric name="us-gaap:AccountsReceivableAllowanceForCreditLossTableTextBlock" contextRef="P01_01_2022To12_31_2022" escape="true" continuedAt="TextSelection_73945728">A rollforward of the allowance for doubtful accounts is as follows (in thousands): </ix:nonNumeric></div><ix:continuation id="TextSelection_73945728"><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:68%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:86%"></td>
<td style="vertical-align:bottom;width:6%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">As of December&#160;31, 2020</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,157</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Provisions charged to operating results</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:ProvisionForDoubtfulAccounts" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">240</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Account <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">write-off</div> and recoveries</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="btmd:ProvisonForDoubfulDebtAcoountsWriteOffAndRecoveries" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">9</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">As of December&#160;31, 2021</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,406</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">As of December&#160;31, 2021</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,406</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Provisions charged to operating results</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ProvisionForDoubtfulAccounts" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">155</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Account <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">write-off</div> and recoveries</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="btmd:ProvisonForDoubfulDebtAcoountsWriteOffAndRecoveries" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">277</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">As of December&#160;31, 2022</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">974</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table></ix:continuation></ix:continuation><ix:nonNumeric name="us-gaap:InventoryPolicyTextBlock" contextRef="P01_01_2022To12_31_2022" escape="true"><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Inventory</div></div>&#8212;Inventory is carried at the lower of cost or net realizable value using the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">first-in,</div> <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">first-out</div> (FIFO) method. Inventory consists of bioidentical hormone pellets and dietary supplements. Bioidentical hormone pellets contain bioidentical testosterone or estrogen used to achieve hormone balance. Dietary supplements are high-grade vitamins used to enhance pellet therapy. The Company reviews its inventory balances and writes down its inventory for estimated obsolescence or excess inventory equal to the difference between the cost of inventory and the estimated net realizable value based upon assumptions about future demand and market conditions. Inventory write-downs are recorded within cost of products. Management recorded a reserve for obsolescence of inventory related to inventory which has expired. See Note 5 for further details. </div></ix:nonNumeric><ix:nonNumeric name="btmd:OtherCurrentAssetsPolicyTextBlock" contextRef="P01_01_2022To12_31_2022" escape="true"><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Other Current Assets</div></div>&#8212;<ix:nonNumeric name="us-gaap:ScheduleOfOtherCurrentAssetsTableTextBlock" contextRef="P01_01_2022To12_31_2022" escape="true" continuedAt="TextSelection_73945729">As of December&#160;31, 2022 and December&#160;31, 2021, the Company&#8217;s total other current assets consist of the following: </ix:nonNumeric></div><ix:continuation id="TextSelection_73945729"><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:66%"></td>
<td style="vertical-align:bottom;width:11%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:11%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,<br/> 2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,<br/> 2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Prepaid expenses</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:PrepaidExpenseCurrent" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">2,939</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:PrepaidExpenseCurrent" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">847</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Advances</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AdvancesOnInventoryPurchases" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">877</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AdvancesOnInventoryPurchases" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">685</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Capitalized transaction costs</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:DeferredOfferingCosts" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">3,941</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total other current assets</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">3,816</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">5,473</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table></ix:continuation><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Prepaid expenses include software and technology licensing agreements, insurance premiums and other advance payments for services to be received over the next 12 months. Advances are comprised of deposit payments to vendors for inventory purchase orders to be received in the next 12 months. The capitalized transaction costs as of December&#160;31, 2021 relate to costs incurred that were directly related to the Business Combination as described in Note 1. </div></ix:nonNumeric><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"><ix:exclude>F-10</ix:exclude></div></ix:continuation></div></div><ix:continuation id="TextSelectionAppend_73945680_4" continuedAt="TextSelectionAppend_73945680_5"><ix:exclude><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_73945680_5" continuedAt="TextSelectionAppend_73945680_6"><ix:exclude><hr style="color:#999999;height:3px;width:100%"/></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_73945680_6" continuedAt="TextSelectionAppend_73945680_7"><ix:exclude><div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div></ix:exclude></ix:continuation><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><ix:continuation id="TextSelectionAppend_73945680_7" continuedAt="TextSelectionAppend_73945680_8"><ix:nonNumeric name="us-gaap:PropertyPlantAndEquipmentPolicyTextBlock" contextRef="P01_01_2022To12_31_2022" escape="true"><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Property and Equipment, Net</div></div>&#8212;Property and equipment are stated at cost less accumulated depreciation. Depreciation is calculated using the straight-line method and is recorded in Selling, general, and administrative expense over the estimated useful lives of the assets. <ix:nonNumeric name="btmd:DisclosureInTabularFormOfEstimatedUsefulLivesOfPropertyPlantAndEquipmentTableTextBlock" contextRef="P01_01_2022To12_31_2022" escape="true" continuedAt="TextSelection_73945730">The estimated useful lives of property and equipment are as follows: </ix:nonNumeric></div><ix:continuation id="TextSelection_73945730"><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:48%"></td>
<td style="vertical-align:bottom;width:3%"></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Estimated&#160;Useful Life (in years)</div></div></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Trocars</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;text-align:center;"><ix:nonNumeric name="us-gaap:PropertyPlantAndEquipmentUsefulLife" contextRef="P01_01_2022To12_31_2022_TrocarsMemberusgaapPropertyPlantAndEquipmentByTypeAxis" format="ixt-sec:duryear">5</ix:nonNumeric></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Leasehold improvements</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;text-align:center;"><ix:nonNumeric name="us-gaap:PropertyPlantAndEquipmentEstimatedUsefulLives" contextRef="P01_01_2022To12_31_2022_LeaseholdImprovementsMemberusgaapPropertyPlantAndEquipmentByTypeAxis">Shorter of lease term or useful life of the<br/> improvement</ix:nonNumeric></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Office equipment</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;text-align:center;"><ix:nonNumeric name="us-gaap:PropertyPlantAndEquipmentUsefulLife" contextRef="P01_01_2022To12_31_2022_OfficeEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis" format="ixt-sec:duryear">5</ix:nonNumeric></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Computer software</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;text-align:center;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonNumeric name="us-gaap:PropertyPlantAndEquipmentUsefulLife" contextRef="P01_01_2022To12_31_2022_MinimumMembersrtRangeAxis_SoftwareDevelopmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis" format="ixt-sec:duryear">3</ix:nonNumeric>-<ix:nonNumeric name="us-gaap:PropertyPlantAndEquipmentUsefulLife" contextRef="P01_01_2022To12_31_2022_MaximumMembersrtRangeAxis_SoftwareDevelopmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis" format="ixt-sec:duryear">5</ix:nonNumeric></div></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Furniture and fixtures</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;text-align:center;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonNumeric name="us-gaap:PropertyPlantAndEquipmentUsefulLife" contextRef="P01_01_2022To12_31_2022_FurnitureAndFixturesMemberusgaapPropertyPlantAndEquipmentByTypeAxis_MinimumMembersrtRangeAxis" format="ixt-sec:duryear">5</ix:nonNumeric>-<ix:nonNumeric name="us-gaap:PropertyPlantAndEquipmentUsefulLife" contextRef="P01_01_2022To12_31_2022_FurnitureAndFixturesMemberusgaapPropertyPlantAndEquipmentByTypeAxis_MaximumMembersrtRangeAxis" format="ixt-sec:duryear">7</ix:nonNumeric></div></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Computer equipment</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;text-align:center;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonNumeric name="us-gaap:PropertyPlantAndEquipmentUsefulLife" contextRef="P01_01_2022To12_31_2022_ComputerEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis_MinimumMembersrtRangeAxis" format="ixt-sec:duryear">3</ix:nonNumeric>-<ix:nonNumeric name="us-gaap:PropertyPlantAndEquipmentUsefulLife" contextRef="P01_01_2022To12_31_2022_ComputerEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis_MaximumMembersrtRangeAxis" format="ixt-sec:duryear">5</ix:nonNumeric></div></td></tr></table></ix:continuation><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">See Note 6 for further details. </div></ix:nonNumeric><ix:nonNumeric name="us-gaap:InternalUseSoftwarePolicy" contextRef="P01_01_2022To12_31_2022" escape="true"><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Capitalized Software, Net</div></div>&#8212;Capitalization of costs related to internally developed software begins when the preliminary project stage is completed and it is probable that the project will be completed and used for its intended function. Once an application has reached the development stage, internal and external costs, if direct and incremental, are capitalized until the software is substantially complete and ready for its intended use. Capitalization ceases upon completion of all substantial testing. The Company also capitalizes costs related to specific upgrades and enhancements when it is probable the expenditures will result in additional features and functionality. Maintenance costs are expensed as incurred. Internal use software is amortized on a straight-line basis over its estimated useful life, generally <span style="-sec-ix-hidden:hidden73945767">three</span> to <span style="-sec-ix-hidden:hidden73945768">eight</span> years. Capitalized software is included within capitalized software, net on the consolidated balance sheet. See Note 7 for further details. </div></ix:nonNumeric><ix:nonNumeric name="us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" contextRef="P01_01_2022To12_31_2022" escape="true"><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Impairment of Long-Lived Assets</div></div>&#8212;Long-lived assets, such as property and equipment and capitalized software, are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of the asset may not be recoverable. The carrying amount of a long-lived asset is not recoverable if it exceeds the sum of the undiscounted future cash flows expected to result from the use and eventual disposition of the asset. The amount of impairment loss, if any, is measured as the difference between the carrying value of the asset and its estimated fair value. Fair value is determined through various valuation techniques, including discounted cash flow models, quoted market values, and third-party independent appraisals, as considered necessary. <ix:nonFraction name="us-gaap:ImpairmentOfLongLivedAssetsHeldForUse" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt-sec:numwordsen"><ix:nonFraction name="us-gaap:ImpairmentOfLongLivedAssetsHeldForUse" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt-sec:numwordsen">No </ix:nonFraction></ix:nonFraction>impairment charges have been recorded during the years ended December&#160;31, 2022 and 2021. </div></ix:nonNumeric><ix:nonNumeric name="us-gaap:LesseeLeasesPolicyTextBlock" contextRef="P01_01_2022To12_31_2022" escape="true" continuedAt="TextSelection_73945711"><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Leases</div></div>&#8212;At the inception of an arrangement, the Company determines whether the arrangement is or contains a lease based on the unique facts and circumstances present in the arrangement including the use of an identified asset(s) and the Company&#8217;s control over the use of that identified asset. The Company elected, as allowed under Financial Accounting Standards Board (&#8220;FASB&#8221;) Accounting Standard Update (&#8220;ASU&#8221;) <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2016-02,</div> <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Leases </div></div>(&#8220;ASC&#160;842&#8221;), to not recognize leases with a lease term of one year or less on its balance sheet. Leases with a term greater than one year are recognized on the balance sheet as <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">right-of-use</div></div> (&#8220;ROU&#8221;) assets and current and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-current</div> lease liabilities, as applicable. As of December&#160;31, 2022 and December&#160;31, 2021, the Company does not have any financing leases. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Lease liabilities and their corresponding ROU assets are initially recorded based on the present value of lease payments over the expected remaining lease term. Certain adjustments to the ROU asset may be required for items such as incentives, prepaid lease payments, or initial direct costs. When an option to extend the lease exists, a determination is made whether that option is reasonably certain of exercise based on economic factors present at the measurement date and as circumstances may change. Lease cost for operating leases is recognized on a straight-line basis over the lease term as an operating expense. Variable lease costs are expensed as incurred as an operating expense. </div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"><ix:exclude>F-11</ix:exclude></div></ix:nonNumeric></ix:continuation></div></div><ix:continuation id="TextSelection_73945711" continuedAt="TextSelectionAppend_73945711_1"><ix:continuation id="TextSelectionAppend_73945680_8" continuedAt="TextSelectionAppend_73945680_9"><ix:exclude><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_73945680_9" continuedAt="TextSelectionAppend_73945680_10"><ix:exclude><hr style="color:#999999;height:3px;width:100%"/></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_73945680_10" continuedAt="TextSelectionAppend_73945680_11"><ix:exclude><div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div></ix:exclude></ix:continuation></ix:continuation></div></div></div> <div><div><div style="background-color:white;display: inline;"><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><ix:continuation id="TextSelectionAppend_73945680_11" continuedAt="TextSelectionAppend_73945680_12"><ix:continuation id="TextSelectionAppend_73945711_1"><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As the rates implicit in the Company&#8217;s leases have not historically been readily determinable, the Company utilizes the appropriate incremental borrowing rate, which is the rate the Company would incur to borrow on a collateralized basis over a similar term an amount equal to the lease payments in a similar economic environment over the lease term. To estimate our incremental borrowing rate, a credit rating applicable to the Company is estimated using a synthetic credit rating analysis since the Company does not currently have a rating agency-based credit rating. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In accordance with ASC 842, contracts containing a lease should be split into three categories: lease components, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-lease</div> components, and activities or costs that do not transfer a distinct good or service <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">(&#8220;non-components&#8221;).</div> The fixed and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">in-substance</div> fixed contract consideration (including any consideration related to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-components)</div> must be allocated, based on the respective relative fair values, to the lease components and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-lease</div> components. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Entities may elect not to separate lease and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-lease</div> components. Accordingly, entities making this election would account for each lease component and related <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-lease</div> component together as a single lease component. The Company has elected to account for lease and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-lease</div> components together as a single lease component for all underlying assets and allocate all of the contract consideration to the lease component only. See Note 15 for further details. </div></ix:continuation><ix:nonNumeric name="us-gaap:IncomeTaxPolicyTextBlock" contextRef="P01_01_2022To12_31_2022" escape="true"><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Income Taxes</div></div>&#8212;The Company accounts for income taxes under the asset and liability method pursuant to ASC&#160;740, Income Taxes. Under this method, the Company recognizes deferred tax assets and liabilities for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating loss and tax credit carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We recognize deferred tax assets to the extent that we believe that these assets are more likely than not to be realized. In making such a determination, we consider all available positive and negative evidence, including future reversals of existing taxable temporary differences, projected future taxable income, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">tax-planning</div> strategies, and results of recent operations. If we determine that we would be able to realize our deferred tax assets in the future in excess of their net recorded amount, we would make an adjustment to the deferred tax asset valuation allowance, which would reduce the provision for income taxes. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We record uncertain tax positions in accordance with ASC 740 on the basis of a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">two-step</div> process in which (1)&#160;we determine whether it is more likely than not that the tax positions will be sustained on the basis of the technical merits of the position and (2)&#160;for those tax positions that meet the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">more-likely-than-not</div> recognition threshold, we recognize the largest amount of tax benefit that is more than 50&#160;percent likely to be realized upon ultimate settlement with the related tax authority. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We recognize interest and penalties related to unrecognized tax benefits on the income tax expense line in the accompanying consolidated statements of income and comprehensive income. </div></ix:nonNumeric><ix:nonNumeric name="btmd:DebtIssuanceCostsPolicyTextBlock" contextRef="P01_01_2022To12_31_2022" escape="true"><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Debt Issuance Costs</div></div>&#8212;Costs incurred in connection with the issuance of the Company&#8217;s long-term debt have been recorded as a direct reduction of the debt and amortized over the life of the associated debt as a component of interest expense using the straight-line method, which is not materially different compared to the effective interest m<div style="display:inline;">ethod.</div> </div></ix:nonNumeric><ix:nonNumeric name="btmd:WarrantLiabilitiesPolicyTextBlock" contextRef="P01_01_2022To12_31_2022" escape="true" continuedAt="TextSelection_73945714"><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Warrant Liabilities</div></div>&#8212;The Company accounts for warrants as either equity-classified or liability-classified instruments based on an assessment of the warrant&#8217;s specific terms and applicable authoritative guidance in ASC&#160;480, <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Distinguishing Liabilities from Equity</div></div> (&#8220;ASC 480&#8221;) and ASC 815, <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Derivatives and Hedging</div></div> (&#8220;ASC&#160;815&#8221;). The assessment considers whether the warrants are freestanding financial instruments pursuant to ASC&#160;480, <div style="display:inline;">meet</div> </div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"><ix:exclude>F-12</ix:exclude></div></ix:nonNumeric></ix:continuation></div></div><ix:continuation id="TextSelection_73945714" continuedAt="TextSelectionAppend_73945714_1"><ix:continuation id="TextSelectionAppend_73945680_12" continuedAt="TextSelectionAppend_73945680_13"><ix:exclude><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_73945680_13" continuedAt="TextSelectionAppend_73945680_14"><ix:exclude><hr style="color:#999999;height:3px;width:100%"/></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_73945680_14" continuedAt="TextSelectionAppend_73945680_15"><ix:exclude><div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div></ix:exclude></ix:continuation></ix:continuation><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><ix:continuation id="TextSelectionAppend_73945680_15" continuedAt="TextSelectionAppend_73945680_16"><ix:continuation id="TextSelectionAppend_73945714_1"><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">the definition of a liability pursuant to ASC 480, and whether the warrants meet all of the requirements for equity classification under ASC 815, including whether the warrants are indexed to the Company&#8217;s own common stock, among other conditions for equity classification. This assessment, which requires the use of professional judgment, is conducted at the time of warrant issuance and as of each subsequent quarterly period end date while the warrants are outstanding. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For issued or modified warrants that meet all of the criteria for equity classification, the warrants are required to be recorded as a component of additional <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">paid-in</div> capital at the time of issuance. For issued or modified warrants that do not meet all the criteria for equity classification, the warrants are required to be recorded as a liability at their initial fair value on the date of issuance, and remeasured each balance sheet date thereafter. The Company&#8217;s warrants did not meet the criteria for equity classification and are recorded as liabilities. Changes in the estimated fair value of the warrants are recognized as a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-cash</div> gain or loss in the statements of income and comprehensive income. See Note 10 for further detail. </div></ix:continuation><ix:nonNumeric name="btmd:EarnoutLiabilityPolicyTextBlock" contextRef="P01_01_2022To12_31_2022" escape="true"><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Earnout Liability</div></div>&#8212;In connection with the Business Combination, the Members and the Sponsor received shares that will vest upon the achievement of certain share price targets. The earnout shares are classified as a liability in the Company&#8217;s consolidated balance sheet because it does not qualify as being indexed to the Company&#8217;s own stock. The earnout liability was initially measured at fair value at the Closing Date and subsequently remeasured at the end of each reporting period. The change in fair value of the earnout liability is recorded in the consolidated statement of income and comprehensive income. See Note 11 for further detail. </div></ix:nonNumeric><ix:nonNumeric name="us-gaap:StockholdersEquityPolicyTextBlock" contextRef="P01_01_2022To12_31_2022" escape="true" continuedAt="TextSelection_73945716"><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Stockholders&#8217; Equity (Deficit)</div></div>&#8212;Prior to consummation of the Business Combination, the Company&#8217;s capital structure included voting units (Class A), <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-voting</div> units (Class AA and AAA), and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-voting</div> incentive units (Class AAAA), with no limit to the number of units that may be issued. Class&#160;A units had <ix:nonFraction name="btmd:CommonUnitsVotingRightsPercentage" contextRef="PAsOn12_31_2022_ClassAVotingUnitsMemberusgaapCapitalUnitsByClassAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal">100</ix:nonFraction>% of the voting rights, and there is no par value assigned to any of the classes of units. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to the Business Combination Agreement and immediately prior to the Business Combination&#8217;s consummation, the Company effectuated a recapitalization whereby all Class&#160;A, Class&#160;AA, Class&#160;AAA and Class&#160;AAAA units held by Holdings&#8217; Members were converted (whether by direct exchange, merger or otherwise) into Class&#160;A <div style="display:inline;">Common Units.</div> </div><ix:nonNumeric name="us-gaap:ScheduleOfCapitalUnitsTextBlock" contextRef="P01_01_2022To12_31_2022" escape="true"><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of December&#160;31, 2021, the following members&#8217; equity units were issued and outstanding: </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:68%"></td>
<td style="vertical-align:bottom;width:5%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:5%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31, 2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.5pt;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; font-size: 8pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Members&#8217; Equity</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Issued</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Outstanding</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Class&#160;A (Voting)</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:CommonUnitIssued" contextRef="PAsOn12_31_2021_ClassAVotingUnitsMemberusgaapCapitalUnitsByClassAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal">16,721</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:CommonUnitOutstanding" contextRef="PAsOn12_31_2021_ClassAVotingUnitsMemberusgaapCapitalUnitsByClassAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal">16,721</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Class&#160;AA <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">(Non-voting)</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:CommonUnitIssued" contextRef="PAsOn12_31_2021_ClassAaNonVotingUnitsMemberusgaapCapitalUnitsByClassAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal">903,079</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:CommonUnitOutstanding" contextRef="PAsOn12_31_2021_ClassAaNonVotingUnitsMemberusgaapCapitalUnitsByClassAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal">903,079</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Class&#160;AAA <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">(Non-voting)</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:CommonUnitIssued" contextRef="PAsOn12_31_2021_ClassAaaNonVotingUnitsMemberusgaapCapitalUnitsByClassAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal">60,000</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:CommonUnitOutstanding" contextRef="PAsOn12_31_2021_ClassAaaNonVotingUnitsMemberusgaapCapitalUnitsByClassAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal">60,000</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Class&#160;AAAA <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">(Non-voting</div> incentive units)</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:CommonUnitIssued" contextRef="PAsOn12_31_2021_ClassAaaaNonVotingIncentiveUnitsMemberusgaapCapitalUnitsByClassAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal">33,397</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:CommonUnitOutstanding" contextRef="PAsOn12_31_2021_ClassAaaaNonVotingIncentiveUnitsMemberusgaapCapitalUnitsByClassAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal">3,000</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:CommonUnitIssued" contextRef="PAsOn12_31_2021" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal">1,013,197</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:CommonUnitOutstanding" contextRef="PAsOn12_31_2021" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal">982,800</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table></ix:nonNumeric><ix:nonNumeric name="us-gaap:ScheduleOfStockByClassTextBlock" contextRef="P01_01_2022To12_31_2022" escape="true"><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of December&#160;31, 2022, the following shares of common stock were issued and outstanding: </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:11pt;width:76%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:64%"></td>
<td style="vertical-align:bottom;width:3%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:3%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31, 2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.5pt;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; font-size: 8pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Stockholders&#8217; Equity</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Issued</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Outstanding</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt;background-color:#cceeff">
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Class&#160;A common stock</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="PAsOn12_31_2022_CommonClassAMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal">11,242,887</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="PAsOn12_31_2022_CommonClassAMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal">9,655,387</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Class&#160;B common stock</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="PAsOn12_31_2022_CommonClassBMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="PAsOn12_31_2022_CommonClassBMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt;background-color:#cceeff">
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Class&#160;V voting stock</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="PAsOn12_31_2022_ClassVCommonStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal">58,565,824</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="PAsOn12_31_2022_ClassVCommonStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal">48,565,824</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="PAsOn12_31_2022" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal">69,808,711</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="PAsOn12_31_2022" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal">58,221,211</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table></ix:nonNumeric><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"><ix:exclude>F-13</ix:exclude></div></ix:nonNumeric></ix:continuation></div></div><ix:continuation id="TextSelection_73945716" continuedAt="TextSelectionAppend_73945716_1"><ix:continuation id="TextSelectionAppend_73945680_16" continuedAt="TextSelectionAppend_73945680_17"><ix:exclude><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_73945680_17" continuedAt="TextSelectionAppend_73945680_18"><ix:exclude><hr style="color:#999999;height:3px;width:100%"/></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_73945680_18" continuedAt="TextSelectionAppend_73945680_19"><ix:exclude><div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div></ix:exclude></ix:continuation></ix:continuation></div></div></div> <div><div><div style="background-color:white;display: inline;"><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><ix:continuation id="TextSelectionAppend_73945680_19" continuedAt="TextSelectionAppend_73945680_20"><ix:continuation id="TextSelectionAppend_73945716_1"><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company made operating distributions to Members of Holdings and taxing authorities on the Members&#8217; behalf totaling $<ix:nonFraction name="us-gaap:LimitedPartnersCapitalAccountDistributionAmount" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">12,886</ix:nonFraction> and $<ix:nonFraction name="us-gaap:LimitedPartnersCapitalAccountDistributionAmount" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">11,402</ix:nonFraction> during the years ended December&#160;31, 2022 and 2021, <div style="display:inline;">respectively.</div> </div></ix:continuation><ix:nonNumeric name="btmd:StandbyEquityPurchaseAgreementPolicyTextBlock" contextRef="P01_01_2022To12_31_2022" escape="true"><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;">Standby Equity Purchase Agreement </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On July&#160;27, 2022, the Company entered into a Standby Equity Purchase Agreement (the &#8220;SEPA&#8221;) with YA II PN, Ltd. (&#8220;Yorkville&#8221;). Yorkville is a fund managed by Yorkville Advisors Global, LP, headquartered in Mountainside, New Jersey. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company has the right, but not the obligation, from time to time at the Company&#8217;s discretion until the first day of the month following the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonNumeric name="btmd:TerminationPeriodOfPurchaseAgreement" contextRef="P07_27_2022To07_27_2022_StandbyEquityPurchaseAgreementMemberusgaapTypeOfArrangementAxis" format="ixt-sec:durmonth">36</ix:nonNumeric>-month</div> anniversary of the date of the SEPA (unless earlier terminated), to direct Yorkville to purchase a specified amount of shares of Class&#160;A common stock (each such sale, an &#8220;Advance&#8221;) by delivering written notice to Yorkville (each, an &#8220;Advance Notice&#8221;). The shares of Class&#160;A common stock purchased pursuant to an Advance will be purchased at a price equal to <ix:nonFraction name="btmd:PercentageOfCommonStockPurchasePrice" contextRef="P07_27_2022To07_27_2022_StandbyEquityPurchaseAgreementMemberusgaapTypeOfArrangementAxis" unitRef="Unit_pure" decimals="INF" scale="-2" format="ixt:num-dot-decimal">97.0</ix:nonFraction>% of the lowest daily VWAP of the Class&#160;A common stock during the <span style="-sec-ix-hidden:hidden73945778">three</span> consecutive trading days commencing on the date of delivery of a given Advance Notice. &#8220;VWAP&#8221; means, for any trading day, the daily volume weighted average price of the Company&#8217;s common stock for such date as reported by Bloomberg L.P. during regular trading hours. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">While there is <ix:nonFraction name="btmd:MandatoryMinimumAmountForIndividualAdvance" contextRef="PAsOn07_27_2022_StandbyEquityPurchaseAgreementMemberusgaapTypeOfArrangementAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt-sec:numwordsen">no</ix:nonFraction> mandatory minimum amount for any individual Advance, it may not exceed the greater of (i)&#160;an amount equal to thirty percent (<ix:nonFraction name="btmd:MaximumValueOfDailyVolumeTradedThresholdPercentage" contextRef="P07_27_2022To07_27_2022_StandbyEquityPurchaseAgreementMemberusgaapTypeOfArrangementAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal">30</ix:nonFraction>%) of the daily volume traded on the trading day immediately preceding an Advance Notice, or (ii) <ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="PAsOn07_27_2022_CommonClassAMemberusgaapStatementClassOfStockAxis_StandbyEquityPurchaseAgreementMemberusgaapTypeOfArrangementAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal">1,000,000</ix:nonFraction> shares of Class&#160;A common stock. No more than <ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="PAsOn07_27_2022_MaximumMembersrtRangeAxis_StandbyEquityPurchaseAgreementMemberusgaapTypeOfArrangementAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal">5,000,000</ix:nonFraction> shares of Class&#160;A common stock, including the Commitment Shares (as defined below) may be sold pursuant to the SEPA. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Yorkville&#8217;s obligation to continue to purchase shares of Class&#160;A common stock pursuant to the SEPA is subject to a number of conditions. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As consideration for Yorkville&#8217;s commitment to purchase Class&#160;A common stock at the Company&#8217;s direction upon the terms and subject to the conditions set forth in the SEPA, upon execution of the SEPA, the Company issued <ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="PAsOn07_27_2022_StandbyEquityPurchaseAgreementMemberusgaapTypeOfArrangementAxis_YorkvilleAdvisorsGlobalLpMemberusgaapCreditFacilityAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal">25,000</ix:nonFraction> shares of Class&#160;A common stock to Yorkville (the &#8220;Commitment Shares&#8221;). During the year ended December&#160;31, 2022, the Company sold <ix:nonFraction name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" contextRef="P01_01_2022To12_31_2022_StandbyEquityPurchaseAgreementMemberusgaapTypeOfArrangementAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal">105,559</ix:nonFraction> shares to Yorkville under the SEPA for cash proceeds of $<ix:nonFraction name="btmd:ProceedsFromSettlementOfSEPA" contextRef="P01_01_2022To12_31_2022_StandbyEquityPurchaseAgreementMemberusgaapTypeOfArrangementAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">442</ix:nonFraction>. </div></ix:nonNumeric><ix:nonNumeric name="btmd:NoncontrollingInterestPolicyTextBlock" contextRef="P01_01_2022To12_31_2022" escape="true"><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Noncontrolling Interest</div></div>&#8212;Pursuant to the Business Combination, as described in Note 3, the Company is organized in an <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">&#8220;Up-C&#8221;</div> structure with the Company owning only a portion of its consolidated subsidiaries. The portion of the consolidated subsidiaries not owned by the Company and any related activity is presented as noncontrolling interest in the consolidated financial statements. The noncontrolling interests, together with their corresponding shares of Class&#160;V voting stock, can be exchanged for Class&#160;A common stock in Biote or, at the election of the Company, cash. Because redemptions for cash is solely within the control of the Company, noncontrolling interest is presented in permanent equity. </div></ix:nonNumeric><ix:nonNumeric name="us-gaap:RevenueRecognitionPolicyTextBlock" contextRef="P01_01_2022To12_31_2022" escape="true" continuedAt="TextSelection_73945719"><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Revenue Recognition</div></div>&#8212;The Company accounts for revenue in accordance with FASB, Accounting Standards <div style="display:inline;">Update</div> (&#8220;ASU&#8221;) <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">No.&#160;2014-09,</div> <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Revenue from Contracts with Customers</div></div>, as amended, (Topic 606). Revenue is measured based on the consideration specified in a contract with a customer. The Company recognizes revenue when it satisfies a performance obligation by transferring control of a product or service to a customer. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Taxes assessed by a governmental authority that are both imposed on and concurrent with a specific revenue-producing transaction, that are collected by the Company from a customer, are excluded from revenue. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Shipping and handling costs associated with outbound freight after control of a product has transferred to a customer are accounted for as fulfillment costs and are included in cost of products in the statements of income and comprehensive income. Shipping and handling costs billed to customers are considered part of the transaction price and are recognized as revenue with the underlying product sales for dietary supplements and trocars. </div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"><ix:exclude>F-14</ix:exclude></div></ix:nonNumeric></ix:continuation></div></div><ix:continuation id="TextSelection_73945719" continuedAt="TextSelectionAppend_73945719_1"><ix:continuation id="TextSelectionAppend_73945680_20" continuedAt="TextSelectionAppend_73945680_21"><ix:exclude><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_73945680_21" continuedAt="TextSelectionAppend_73945680_22"><ix:exclude><hr style="color:#999999;height:3px;width:100%"/></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_73945680_22" continuedAt="TextSelectionAppend_73945680_23"><ix:exclude><div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div></ix:exclude></ix:continuation></ix:continuation><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><ix:continuation id="TextSelectionAppend_73945719_1" continuedAt="TextSelectionAppend_73945719_2"><ix:continuation id="TextSelectionAppend_73945680_23" continuedAt="TextSelectionAppend_73945680_24"><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following is a description of the principal contract activities, disaggregated by the contract type, from which the Company generates its revenue. </div><div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">The Biote Method </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company generates revenues through standard service agreements with customers who participate in the Biote Method. The Biote Method is a bioidentical hormone replacement therapy which has been developed as a treatment designed to alleviate hormone imbalances. Under this agreement, the Company provides a bundle of goods and services to customers, including initial training to medical practitioners, bioidentical hormone pellets and software tools used for inventory management and dosing, and ongoing practice development and marketing support services, which includes a license to use the Company&#8217;s trademarks and trade names in the customer&#8217;s marketing materials. The initial contract term is three years, and customers have the option to renew for additional <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">one-year</div> periods. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For the bundled goods and services, the Company accounts for individual products and services separately if they are distinct, i.e., if a product or service is separately identifiable from other items in the bundled package and if a customer can benefit from it on its own or with other resources that are readily available to the customer. The Company has identified three distinct obligations in its standard service agreement: initial training, pellet procedures (including sales of bioidentical hormone pellets, use of inventory management software to monitor pellet inventory, and use of the Company&#8217;s blood dosing website to determine the appropriate pellets to use in each procedure), contract-term services (including ongoing practice development and marketing support, options to receive reusable trocars, and the right to use the reusable trocars through the term of the contract, if the option is exercised). The third obligation includes a combined lease/nonlease component for which the Company has adopted the practical expedient within ASC 842 which allows lessors to combine lease and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-lease</div> components that have the same pattern of transfer to the customer-lessee and account for the combined component under the guidance relevant to the predominant portion of the component. By applying this expedient, the Company applies Topic 606 to the combined component. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The consideration in the contract is allocated between separate products and services in the bundle based on the stand-alone selling prices of each good and service. The stand-alone selling prices are determined based on the prices at which the Company separately sells the initial training and the pellet procedures. Judgment is required to determine the standalone selling price for each distinct performance obligation. For items that are not sold separately and for which the Company has not established a standalone selling price, the Company allocates consideration based on the residual approach. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company recognizes revenue for initial training over time as the customer completes the training. Training sessions generally occur over the course of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2-3</div> consecutive days at or near the time of contract inception. The Customer is charged an initial fixed-rate fee for this training. Customers pay in full for the initial training at the time of contract inception. The standalone selling price of these services is based on the lowest price offered by the Company for the services. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company recognizes revenue for pellet procedures at the point in time the procedures are performed by the practitioner, which is when control of the pellets transfers to the customer. Consideration for these services is in the form of a management fee assessed for each procedure performed, which includes a volume-based tiered pricing schedule. The standalone selling price for these services requires judgment and is estimated based on the Company&#8217;s historical experience with prices offered to similar customers throughout the initial term of the contract. Billings in excess of the standalone selling price constitute a premium charged to customers early in a relationship and are deferred and recognized when or as the remaining goods and services are transferred to the customer. Fees are billed and paid on a semimonthly basis. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company recognizes revenue for contract-term services on a straight-line basis over the initial term of the contract, which aligns with the Company&#8217;s satisfaction of the performance obligation. The Company allocates the residual consideration to this performance obligation, which is consistent with the allocation objective. </div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"><ix:exclude>F-15</ix:exclude></div></ix:continuation></ix:continuation></div></div><ix:continuation id="TextSelectionAppend_73945719_2" continuedAt="TextSelectionAppend_73945719_3"><ix:continuation id="TextSelectionAppend_73945680_24" continuedAt="TextSelectionAppend_73945680_25"><ix:exclude><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_73945680_25" continuedAt="TextSelectionAppend_73945680_26"><ix:exclude><hr style="color:#999999;height:3px;width:100%"/></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_73945680_26" continuedAt="TextSelectionAppend_73945680_27"><ix:exclude><div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div></ix:exclude></ix:continuation></ix:continuation></div></div></div> <div><div><div style="background-color:white;display: inline;"><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><ix:continuation id="TextSelectionAppend_73945719_3" continuedAt="TextSelectionAppend_73945719_4"><ix:continuation id="TextSelectionAppend_73945680_27" continuedAt="TextSelectionAppend_73945680_28"><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Dietary Supplements </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Dietary supplements are supplements that customer practitioners resell to patients that aid the patients with maintaining hormone balances. The Company recognizes revenue for these, net of any discounts given, when control transfers to the customer, which is generally the point of shipment from the Company&#8217;s distributor. Products are billed at standalone selling price for the dietary supplements and invoiced at shipment. </div><div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Disposable Trocars </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Disposable Trocars are manual surgical instruments intended for use by Biote-certified practitioners. These tools are used to implant the bioidentical hormone pellets into the customers&#8217; patients. The Company recognizes revenue at the time control transfers, which is generally the point of shipment from the distributor. Products are billed at the standalone selling price for the trocars and invoiced at shipment. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Revenue disaggregated by the nature of the product or service and by geography is included within Note 4: Revenue Recognition. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of the years ended December&#160;31, 2022 and 2021, the Company had allocated $<ix:nonFraction name="us-gaap:RevenueRemainingPerformanceObligation" contextRef="PAsOn12_31_2022_BioteMethodCustomerMemberbtmdNatureOfCustomerAxis_ServiceRevenueMemberbtmdSourceOfRevenueAxis_TrainingMemberbtmdSourceOfServiceRevenueAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">104</ix:nonFraction> and $<ix:nonFraction name="us-gaap:RevenueRemainingPerformanceObligation" contextRef="PAsOn12_31_2021_BioteMethodCustomerMemberbtmdNatureOfCustomerAxis_ServiceRevenueMemberbtmdSourceOfRevenueAxis_TrainingMemberbtmdSourceOfServiceRevenueAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">67</ix:nonFraction> respectively, of consideration to the unsatisfied initial training obligations, and $<ix:nonFraction name="us-gaap:RevenueRemainingPerformanceObligation" contextRef="PAsOn12_31_2022_BioteMethodCustomerMemberbtmdNatureOfCustomerAxis_ContractTermServicesMemberbtmdSourceOfServiceRevenueAxis_ServiceRevenueMemberbtmdSourceOfRevenueAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,655</ix:nonFraction> and $<ix:nonFraction name="us-gaap:RevenueRemainingPerformanceObligation" contextRef="PAsOn12_31_2021_BioteMethodCustomerMemberbtmdNatureOfCustomerAxis_ContractTermServicesMemberbtmdSourceOfServiceRevenueAxis_ServiceRevenueMemberbtmdSourceOfRevenueAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,393</ix:nonFraction>, respectively, of consideration to the unsatisfied contract-term service obligations provided to the Biote Method customers. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Consideration allocated to initial training due to deposits paid upfront is presented within deferred revenue on the consolidated balance sheets and is expected to be recognized as revenue within one year, as the training is complete. Consideration allocated to contract-term services is presented within deferred revenue and deferred revenue, long-term for the amounts expected to be recognized within one year and longer than one year, respectively. As of the years ended December&#160;31, 2022 and 2021 the amount of consideration allocated to contract-term services presented within deferred revenue was $<ix:nonFraction name="us-gaap:ContractWithCustomerLiabilityCurrent" contextRef="PAsOn12_31_2022_BioteMethodCustomerMemberbtmdNatureOfCustomerAxis_ContractTermServicesMemberbtmdSourceOfServiceRevenueAxis_ServiceRevenueMemberbtmdSourceOfRevenueAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,028</ix:nonFraction> and $<ix:nonFraction name="us-gaap:ContractWithCustomerLiabilityCurrent" contextRef="PAsOn12_31_2021_BioteMethodCustomerMemberbtmdNatureOfCustomerAxis_ContractTermServicesMemberbtmdSourceOfServiceRevenueAxis_ServiceRevenueMemberbtmdSourceOfRevenueAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">849</ix:nonFraction>, respectively, and the amount presented within deferred revenue, long-term was $<ix:nonFraction name="us-gaap:ContractWithCustomerLiabilityNoncurrent" contextRef="PAsOn12_31_2022_BioteMethodCustomerMemberbtmdNatureOfCustomerAxis_ContractTermServicesMemberbtmdSourceOfServiceRevenueAxis_ServiceRevenueMemberbtmdSourceOfRevenueAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">627</ix:nonFraction> and $<ix:nonFraction name="us-gaap:ContractWithCustomerLiabilityNoncurrent" contextRef="PAsOn12_31_2021_BioteMethodCustomerMemberbtmdNatureOfCustomerAxis_ContractTermServicesMemberbtmdSourceOfServiceRevenueAxis_ServiceRevenueMemberbtmdSourceOfRevenueAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">544</ix:nonFraction>, respectively. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Consideration allocated to the premiums within the management fee for pellet procedures is presented within deferred revenue current and deferred revenue, long-term for amounts expected to be recognized within one year and longer than one year, respectively. As of the years ended December&#160;31, 2022 and 2021 the amount of these premiums within deferred revenue was $<ix:nonFraction name="us-gaap:ContractWithCustomerLiabilityCurrent" contextRef="PAsOn12_31_2022_BioteMethodCustomerMemberbtmdNatureOfCustomerAxis_PalletProceduresMemberbtmdSourceOfServiceRevenueAxis_ProductRevenueMemberbtmdSourceOfRevenueAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">833</ix:nonFraction> and $<ix:nonFraction name="us-gaap:ContractWithCustomerLiabilityCurrent" contextRef="PAsOn12_31_2021_BioteMethodCustomerMemberbtmdNatureOfCustomerAxis_PalletProceduresMemberbtmdSourceOfServiceRevenueAxis_ProductRevenueMemberbtmdSourceOfRevenueAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">789</ix:nonFraction>, respectively, and the amount within deferred revenue, long-term was $<ix:nonFraction name="us-gaap:ContractWithCustomerLiabilityNoncurrent" contextRef="PAsOn12_31_2022_BioteMethodCustomerMemberbtmdNatureOfCustomerAxis_PalletProceduresMemberbtmdSourceOfServiceRevenueAxis_ProductRevenueMemberbtmdSourceOfRevenueAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">299</ix:nonFraction> and $<ix:nonFraction name="us-gaap:ContractWithCustomerLiabilityNoncurrent" contextRef="PAsOn12_31_2021_BioteMethodCustomerMemberbtmdNatureOfCustomerAxis_PalletProceduresMemberbtmdSourceOfServiceRevenueAxis_ProductRevenueMemberbtmdSourceOfRevenueAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">258</ix:nonFraction>, respectively. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company has also elected the practical expedient in ASC 606 to not disclose consideration allocated to contracts with an original term of one year or less, which includes contracts for <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">point-in-time</div></div> sales of dietary supplements, disposable trocars, and pellet procedures. Pellet procedures are included in the Company&#8217;s Biote Method service agreement, which has a three-year stated term, but as revenues are recognized at a point in time, there are no minimum purchase volumes, and the contract allows for cancellation with ninety days&#8217; notice from the customer, there are no pellet procedure obligations that are satisfied over a period greater than one year. </div><div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Contract Assets and Liabilities </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Customer receivables are made up of consideration to which the Company has an unconditional right to payment, regardless of whether the Company has satisfied the performance obligations in the contract. All customer receivables are presented within accounts receivable, net of allowance for doubtful accounts in the consolidated balance sheets. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Contract assets are the Company&#8217;s right to consideration for goods or services that the entity has transferred to the customer when that right is conditioned on something other than the passage of time. The Company does not have any contract assets for the years ended December&#160;31, 2022 and 2021. </div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"><ix:exclude>F-16</ix:exclude></div></ix:continuation></ix:continuation></div></div><ix:continuation id="TextSelectionAppend_73945719_4" continuedAt="TextSelectionAppend_73945719_5"><ix:continuation id="TextSelectionAppend_73945680_28" continuedAt="TextSelectionAppend_73945680_29"><ix:exclude><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_73945680_29" continuedAt="TextSelectionAppend_73945680_30"><ix:exclude><hr style="color:#999999;height:3px;width:100%"/></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_73945680_30" continuedAt="TextSelectionAppend_73945680_31"><ix:exclude><div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div></ix:exclude></ix:continuation></ix:continuation><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><ix:continuation id="TextSelectionAppend_73945680_31" continuedAt="TextSelectionAppend_73945680_32"><ix:continuation id="TextSelectionAppend_73945719_5"><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Contract liabilities are the Company&#8217;s obligation to transfer goods or services to a customer for which the Company has received consideration or has an unconditional right to receive consideration. The Company&#8217;s contract liabilities include deposits for initial training and contract-term services paid in advance which have not been recognized as revenue during the period. Contract liabilities are presented within deferred revenue and deferred revenue, long-term in the consolidated balance sheets. Contract liabilities are classified as current liabilities for the amount of revenue that the Company expects to recognize within one year of the reporting date. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Changes in contract liabilities between each period are attributable to fees paid by new customers, revenue recognized for completed trainings, and revenue recognized for the Company&#8217;s over-time satisfaction of contract-term services. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company does not have a history of material returns or refunds, and generally does not offer warranties or guarantees for any products or services. Expected returns and refunds are recorded as a reduction of revenue and are $<ix:nonFraction name="btmd:ExpectedReturnsAndRefundsToCustomers" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">0</ix:nonFraction> and $<ix:nonFraction name="btmd:ExpectedReturnsAndRefundsToCustomers" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">0</ix:nonFraction> for the years ended December&#160;31, 2022 and 2021, respectively. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A reconciliation of the beginning and ending contract liabilities is included within Note 4: Revenue Recognition. </div></ix:continuation><ix:nonNumeric name="btmd:CostOfRevenuePolicyTextBlock" contextRef="P01_01_2022To12_31_2022" escape="true"><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Cost of Revenue</div></div>&#8212;Cost of services primarily consist of the costs incurred to deliver trainings to Biote Method customers. Cost of products includes the cost of pellets purchased from compounding pharmacies and sold to customers of the Biote Method, the cost of trocars and dietary supplements purchased from manufacturing facilities or third-party <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">co-packers,</div> and the shipping and handling costs incurred to deliver these products to the customers. </div></ix:nonNumeric><ix:nonNumeric name="us-gaap:MarketRiskBenefitPolicyTextBlock" contextRef="P01_01_2022To12_31_2022" escape="true"><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Marketing</div></div>&#8212;<div style="display:inline;">Mark</div>eting expense includes advertising costs, marketing events, and program costs. These costs are expensed as incurred. </div></ix:nonNumeric><ix:nonNumeric name="us-gaap:SellingGeneralAndAdministrativeExpensesPolicyTextBlock" contextRef="P01_01_2022To12_31_2022" escape="true"><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Selling, General, and Administrative</div></div>&#8212;Selling, general, and administrative expense consists primarily of software licensing and maintenance and the cost of employees who engage in corporate functions, such as finance and accounting, information technology, human resources, legal, and executive management. Selling, general, and administrative expense also includes rent occupancy costs, office expenses, recruiting expenses, entertainment allocations, depreciation and amortization, other general overhead costs, insurance premiums, professional service fees, research and development, and costs related to regulatory and litigation m<div style="display:inline;">atters.</div> </div></ix:nonNumeric><ix:nonNumeric name="us-gaap:PensionAndOtherPostretirementPlansPolicy" contextRef="P01_01_2022To12_31_2022" escape="true"><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">Employee Retirement Plans&#8212; </div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Defined Contribution Retirement Plans </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Effective January&#160;1, 2021, the Company offers participation in the BioTE Medical, LLC (&#8221;BioTE Medical&#8221;) 401(k) Plan (the &#8220;401(k) Plan&#8221;), a defined contribution plan providing retirement benefits to eligible employees. Eligible employees may contribute a portion of their annual compensation to the 401(k) Plan, subject to the maximum annual amounts as set periodically by the IRS. The Company makes a safe harbor, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-elective</div> contribution to the 401(k) Plan equal to <ix:nonFraction name="us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" contextRef="P01_01_2022To12_31_2022_FourZeroOneKPlanMemberusgaapRetirementPlanNameAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal">3</ix:nonFraction>% of each participant&#8217;s eligible employee compensation. Safe harbor contributions vest immediately for each participant. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">During the years ended December&#160;31, 2022 and 2021, the Company made $<ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="P01_01_2022To12_31_2022_FourZeroOneKPlanMemberusgaapRetirementPlanNameAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">915</ix:nonFraction> and $<ix:nonFraction name="us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount" contextRef="P01_01_2021To12_31_2021_FourZeroOneKPlanMemberusgaapRetirementPlanNameAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">335</ix:nonFraction>, respectively, in safe harbor contributions under the 401(k) Plan, which are presented within Selling, general and administrative expense in the consolidated statements of income and comprehensive income. </div></ix:nonNumeric><ix:nonNumeric name="us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy" contextRef="P01_01_2022To12_31_2022" escape="true" continuedAt="TextSelection_73945724"><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Share-Based Compensation</div></div>&#8212;Holdings previously granted Class&#160;AAAA units (&#8220;incentive units&#8221;) and phantom equity rights (collectively, the &#8220;equity awards&#8221;) to certain key members of management. The equity awards were entitled to share in the distributions of Holdings from a change in control or qualifying liquidity event. The equity awards are accounted for under ASC 718, <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Compensation&#8212;Stock Compensation</div></div>, and classified in <div style="display:inline;">equity.</div> </div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"><ix:exclude>F-17</ix:exclude></div></ix:nonNumeric></ix:continuation></div></div><ix:continuation id="TextSelection_73945724" continuedAt="TextSelectionAppend_73945724_1"><ix:continuation id="TextSelectionAppend_73945680_32" continuedAt="TextSelectionAppend_73945680_33"><ix:exclude><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_73945680_33" continuedAt="TextSelectionAppend_73945680_34"><ix:exclude><hr style="color:#999999;height:3px;width:100%"/></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_73945680_34" continuedAt="TextSelectionAppend_73945680_35"><ix:exclude><div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div></ix:exclude></ix:continuation></ix:continuation></div></div></div> <div><div><div style="background-color:white;display: inline;"><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><ix:continuation id="TextSelectionAppend_73945680_35" continuedAt="TextSelectionAppend_73945680_36"><ix:continuation id="TextSelectionAppend_73945724_1"><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company has elected to recognize forfeitures at the time they occur. The fair value of the equity awards was determined using a Monte-Carlo simulation as of the grant date. The awards begin to vest on the date of a change in control or qualifying event. The Business Combination constituted such a qualifying event triggering the performance condition in the awards. <ix:nonFraction name="btmd:MaximumValueOfDailyVolumeTradedThresholdPercentage" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_pure" decimals="0" scale="-2" format="ixt-sec:numwordsen">No </ix:nonFraction>compensation cost was recognized historically until the Closing of the Business Combination as a qualifying event was not previously deemed probable to occur. See Note 14 for further <div style="display:inline;">details.</div></div></ix:continuation><ix:nonNumeric name="us-gaap:CommissionsPolicy" contextRef="P01_01_2022To12_31_2022" escape="true"><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Commissions</div></div>&#8212;Commissions consist primarily of fees paid to a third-party sales force, internal sales force, and partner clinics which participate in the Company&#8217;s new clinic mentor program. Commissions paid to the Company&#8217;s internal and third-party sales forces relate to market support and development activities undertaken to drive channel sales through existing customers and are not considered incremental costs to obtain a customer contract. For the years ended December&#160;31, 2022 and 2021 expenses incurred for these commission programs were $<ix:nonFraction name="us-gaap:SalesCommissionsAndFees" contextRef="P01_01_2022To12_31_2022_BioteMethodCustomerMemberbtmdNatureOfCustomerAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">124</ix:nonFraction> and $<ix:nonFraction name="us-gaap:SalesCommissionsAndFees" contextRef="P01_01_2021To12_31_2021_BioteMethodCustomerMemberbtmdNatureOfCustomerAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">317</ix:nonFraction>, respectively. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Commissions paid to clinics under the Company&#8217;s mentorship program represent amounts paid to existing clinics which provide services to help new customers complete onboarding and other startup activities and are only incurred after contract initiation. These costs are expensed as incurred, consistent with other contract fulfillment costs. For the years ended December&#160;31, 2022 and 2021 commissions paid under this program were $<ix:nonFraction name="us-gaap:CapitalizedContractCostAmortization" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,098</ix:nonFraction> and $<ix:nonFraction name="us-gaap:CapitalizedContractCostAmortization" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,738</ix:nonFraction>, respectively. </div></ix:nonNumeric><ix:nonNumeric name="us-gaap:ConcentrationRiskCreditRisk" contextRef="P01_01_2022To12_31_2022" escape="true"><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Concentrations</div></div>&#8212;Financial instruments that potentially subject the Company to concentrations of credit risk consist primarily of cash, accounts receivable, credit agreements, and inventory purchases. The Company&#8217;s cash balances exceed those that are federally insured. To date, the Company has not recognized any losses caused by uninsured balances. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of December&#160;31, 2022 and December&#160;31, 2021, <ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="P01_01_2022To12_31_2022_CreditAvailabilityConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis_LiabilitiesTotalMemberusgaapConcentrationRiskByBenchmarkAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal">100</ix:nonFraction>% of the Company&#8217;s outstanding debt and available line of credit was from one lender. A failure of the counterparty to perform could result in the loss of access to the available borrowing capacity under the line of credit. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Inventory purchases from <ix:nonFraction name="btmd:NumberOfInventoryVendors" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_vendor" decimals="0" scale="0" format="ixt-sec:numwordsen"><ix:nonFraction name="btmd:NumberOfInventoryVendors" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_vendor" decimals="0" scale="0" format="ixt-sec:numwordsen">three</ix:nonFraction></ix:nonFraction> vendors totaled approximately <ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="P01_01_2022To12_31_2022_AssetsTotalMemberusgaapConcentrationRiskByBenchmarkAxis_InventoryMembersrtProductOrServiceAxis_SupplierConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal">87</ix:nonFraction>% and <ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="P01_01_2021To12_31_2021_AssetsTotalMemberusgaapConcentrationRiskByBenchmarkAxis_InventoryMembersrtProductOrServiceAxis_SupplierConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal">94</ix:nonFraction>% for the years ended December&#160;31, 2022 and 2021, respectively. Due to the nature of the markets and availability of alternative suppliers, the Company does not believe the loss of any one vendor would have a material adverse impact on the Company&#8217;s financial position, results of operations or cash flows for any significant period of time. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Significant customers are those which represent more than 10% of the Company&#8217;s total revenue or gross accounts receivable balance. The Company did <ix:nonFraction name="btmd:NumberOfCustomersAccountedForTenPercentOrMoreAggregateRevenue" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_CUSTOMER" decimals="0" scale="0" format="ixt-sec:numwordsen"><ix:nonFraction name="btmd:NumberOfCustomersAccountedForTenPercentOrMoreAggregateRevenue" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_CUSTOMER" decimals="0" scale="0" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction>t have any customers that accounted for 10% or more of total revenues for the years ended December&#160;31, 2022 and 2021. The Company did <ix:nonFraction name="btmd:NumberOfCustomersAccountedForTenPercentOrMoreAccountsReceivable" contextRef="PAsOn12_31_2021" unitRef="Unit_CUSTOMER" decimals="0" scale="0" format="ixt-sec:numwordsen"><ix:nonFraction name="btmd:NumberOfCustomersAccountedForTenPercentOrMoreAccountsReceivable" contextRef="PAsOn12_31_2022" unitRef="Unit_CUSTOMER" decimals="0" scale="0" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction>t have any customers that accounted for more than 10% of the outstanding gross accounts receivable as of December&#160;31, 2022 or December&#160;31, 2021. </div></ix:nonNumeric><ix:nonNumeric name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" contextRef="P01_01_2022To12_31_2022" escape="true" continuedAt="TextSelection_73945727"><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Recently Adopted Accounting Pronouncements</div></div>&#8212;In December 2019, the FASB issued ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2019-12,</div> <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Income Taxes (Topic 740)&#8212;Simplifying the Accounting for Income Taxes</div></div>, which simplifies the accounting for income taxes by removing certain exceptions to the general principles of ASC 740, <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Income Taxes</div></div>. The amendments also improve consistent application of and simplify U.S. GAAP for other areas of ASC 740 by clarifying and amending existing guidance. ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2019-12</div> is effective for fiscal years beginning after December&#160;15, 2021, and for interim periods beginning after December&#160;15, 2022. The Company has <ix:nonNumeric name="us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted" contextRef="PAsOn12_31_2022_AccountingStandardsUpdate201912MemberusgaapAdjustmentsForNewAccountingPronouncementsAxis" format="ixt:fixed-true">adopted</ix:nonNumeric> the standard as of <ix:nonNumeric name="us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate" contextRef="PAsOn12_31_2022_AccountingStandardsUpdate201912MemberusgaapAdjustmentsForNewAccountingPronouncementsAxis" format="ixt:date-monthname-day-year-en">January 1, 2022</ix:nonNumeric>, and there was <ix:nonNumeric name="us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect" contextRef="PAsOn12_31_2022_AccountingStandardsUpdate201912MemberusgaapAdjustmentsForNewAccountingPronouncementsAxis" format="ixt:fixed-true">no</ix:nonNumeric> material impact to the financial statements. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Recent Accounting Pronouncements Not Yet Adopted</div></div>&#8212;In June 2016, the FASB issued ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2016-13,</div> <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Measurement of Credit Losses on Financial Instruments</div></div> (&#8220;ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2016-13&#8221;).</div> The main objective of the update is to provide financial statement users with more decision-useful information about the expected credit losses on financial instruments and other commitments to extend credit held by companies at each reporting date. For trade </div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"><ix:exclude>F-18</ix:exclude></div></ix:nonNumeric></ix:continuation></div></div><ix:continuation id="TextSelection_73945727" continuedAt="TextSelectionAppend_73945727_1"><ix:continuation id="TextSelectionAppend_73945680_36" continuedAt="TextSelectionAppend_73945680_37"><ix:exclude><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_73945680_37" continuedAt="TextSelectionAppend_73945680_38"><ix:exclude><hr style="color:#999999;height:3px;width:100%"/></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_73945680_38" continuedAt="TextSelectionAppend_73945680_39"><ix:exclude><div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div></ix:exclude></ix:continuation></ix:continuation><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><ix:continuation id="TextSelectionAppend_73945680_39"><ix:continuation id="TextSelectionAppend_73945727_1"><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">and other receivables, held to maturity debt securities, and other instruments, companies will be required to use a new forward-looking &#8220;expected losses&#8221; model that generally will result in the recognition of allowances for losses earlier than under current accounting guidance. Further, the FASB issued ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2019-04,</div> ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2019-05</div> and ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2019-11</div> to provide additional guidance on the credit losses standard. The standard will be adopted using the modified retrospective approach. ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2016-13</div> is effective for annual and interim periods beginning after December&#160;15, 2022, with early adoption permitted. The Company is evaluating the potential impact of adopting ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2016-13</div> on its consolidated financial statements and related disclosures. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In August 2020, the FASB issued ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2020-06,</div><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;"> Debt&#8212;Debt with Conversion and Other Options <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">(Subtopic&#160;470-20)</div> and Derivatives and Hedging&#8212;Contracts in Entity&#8217;s Own Equity (Subtopic <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">815-40):</div> Accounting for Convertible Instruments and Contracts in an Entity&#8217;s Own Equity</div></div> (&#8220;ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2020-06&#8221;).</div> <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">ASU&#160;2020-06</div> changes how entities account for convertible instruments and contracts in an entity&#8217;s own equity and simplifies the accounting for convertible instruments by removing certain separation models for convertible instruments. ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2020-06</div> also modifies the guidance on diluted earnings per share calculations. The amendments are effective for fiscal years beginning after December&#160;15, 2023, including interim periods within those fiscal years. The Company is currently evaluating the impact of this standard on its consolidated financial statements and related disclosures. </div></ix:continuation></ix:continuation><div style="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&#160;</div><ix:nonNumeric name="us-gaap:BusinessCombinationDisclosureTextBlock" contextRef="P01_01_2022To12_31_2022" escape="true" continuedAt="TextSelection_73945681">
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">3.</div></div></td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: left; line-height: normal;"><div style="font-weight:bold;display:inline;">BUSINESS COMBINATION </div></div></td></tr></table><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">At the Closing, (i)&#160;Holdings transferred to the Company <ix:nonFraction name="us-gaap:BusinessCombinationConsiderationTransferred1" contextRef="P12_13_2021To12_13_2021_BioteManagementLlcMemberusgaapBusinessAcquisitionAxis_CommonClassAMemberusgaapStatementClassOfStockAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">9,161,771</ix:nonFraction> Class&#160;A common units of Holdings (&#8220;Holdings Units&#8221;), which was equal to the number of shares of Haymaker&#8217;s Class&#160;A common stock, par value $<ix:nonFraction name="us-gaap:BusinessAcquisitionSharePrice" contextRef="PAsOn12_13_2021_CommonClassAMemberusgaapStatementClassOfStockAxis_HaymakerAcquisitionCorpIiiMemberusgaapBusinessAcquisitionAxis" unitRef="Unit_USD_per_Share" decimals="INF" scale="0" format="ixt:num-dot-decimal">0.0001</ix:nonFraction> per share (&#8220;Class&#160;A common stock&#8221;), issued and outstanding as of immediately prior to the Closing (after giving effect to redemptions by Haymaker&#8217;s public stockholders of <ix:nonFraction name="us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" contextRef="P12_13_2021To12_13_2021_CommonClassAMemberusgaapStatementClassOfStockAxis_HaymakerAcquisitionCorpIiiMemberusgaapBusinessAcquisitionAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal">30,525,729</ix:nonFraction> shares of Class&#160;A common stock prior to the Closing and the conversion of Haymaker&#8217;s Class&#160;B common stock, par value $<ix:nonFraction name="us-gaap:BusinessAcquisitionSharePrice" contextRef="PAsOn12_13_2021_CommonClassBMemberusgaapStatementClassOfStockAxis_HaymakerAcquisitionCorpIiiMemberusgaapBusinessAcquisitionAxis" unitRef="Unit_USD_per_Share" decimals="INF" scale="0" format="ixt:num-dot-decimal">0.0001</ix:nonFraction> per share (&#8220;Class&#160;B common stock&#8221;) into shares of Class&#160;A common stock and (ii)&#160;Haymaker issued <ix:nonFraction name="us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" contextRef="P12_13_2021To12_13_2021_ClassVCommonStockMemberusgaapStatementClassOfStockAxis_HaymakerAcquisitionCorpIiiMemberusgaapBusinessAcquisitionAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal">58,565,824</ix:nonFraction> shares of newly authorized Class&#160;V voting stock, par value $<ix:nonFraction name="us-gaap:BusinessAcquisitionSharePrice" contextRef="PAsOn12_13_2021_ClassVCommonStockMemberusgaapStatementClassOfStockAxis_HaymakerAcquisitionCorpIiiMemberusgaapBusinessAcquisitionAxis" unitRef="Unit_USD_per_Share" decimals="INF" scale="0" format="ixt:num-dot-decimal">0.0001</ix:nonFraction> per share (&#8220;Class&#160;V voting stock&#8221;), which number of shares of Class&#160;V voting stock was equal to the number of Holdings Units retained by the Members immediately following the Closing (the &#8220;Retained Holdings Units&#8221;), and which shares of Class&#160;V voting stock were distributed to the Members, resulting in the Company being organized in an <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">&#8220;Up-C&#8221;</div> structure. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Also at Closing, (x)&#160;in exchange for the Closing Holdings Units, Haymaker transferred cash in an amount equal to (i)&#160;the cash in the trust account and any cash held by Haymaker outside of the trust account, less (ii)&#160;the amounts required by the redemptions of Class&#160;A common stock by the public stockholders, which was equal to $<ix:nonFraction name="us-gaap:PaymentsToAcquireBusinessesGross" contextRef="P12_13_2021To12_13_2021_BioteManagementLlcMemberusgaapBusinessAcquisitionAxis_CommonClassAMemberusgaapStatementClassOfStockAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">305.5</ix:nonFraction>&#160;million and (y)&#160;the BioTE Companies received aggregate proceeds of $<ix:nonFraction name="us-gaap:ProceedsFromPreviousAcquisition" contextRef="P12_13_2021To12_13_2021_BioteManagementLlcMemberusgaapBusinessAcquisitionAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">125</ix:nonFraction>&#160;million from the Debt Financing (as defined below) (the aggregate amounts described in (x)&#160;and (y) of $<ix:nonFraction name="us-gaap:PaymentsToAcquireBusinessesGross" contextRef="P12_13_2021To12_13_2021_BioteManagementLlcMemberusgaapBusinessAcquisitionAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">137.3</ix:nonFraction>&#160;million, the &#8220;Closing Date Cash&#8221;) in accordance with and in the priority set forth in the Business Combination Agreement and as described further in the Proxy Statement. There was <ix:nonFraction name="us-gaap:BusinessCombinationConsiderationTransferred1" contextRef="P01_01_2022To12_31_2022_BioteManagementLlcMemberusgaapBusinessAcquisitionAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt-sec:numwordsen">no </ix:nonFraction>cash consideration paid to Members at Closing. </div><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">Recapitalization </div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Immediately prior to the Closing, Holdings (i)&#160;effectuated a recapitalization, pursuant to which all its Class&#160;A units, Class&#160;AA units, Class&#160;AAA units and Class&#160;AAAA units held by the Members were converted or exchanged (whether by direct exchange, merger or otherwise) into a number of equity interests in the Company designated as &#8220;Class&#160;A Common Units&#8221; in the amounts determined in accordance with Holdings&#8217; Second Amended and Restated Operating Agreement (the &#8220;Holdings A&amp;R OA&#8221;), which was entered into prior to the Closing, the result of which was that the Members hold a single class of Holdings Units as of immediately prior to the Closing and (ii)&#160;converted into a Delaware limited liability company. </div><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">Consideration </div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">At the Closing and in consideration for the acquisition of Holdings Units, Haymaker and the BioTE Companies, pursuant to the Business Combination Agreement and the Trust Agreement (as defined in the Business Combination Agreement), disbursed the Closing Date Cash to Holdings. </div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"><ix:exclude>F-19</ix:exclude></div></ix:nonNumeric></div></div><ix:continuation id="TextSelection_73945681" continuedAt="TextSelectionAppend_73945681_1"><ix:exclude><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_73945681_1" continuedAt="TextSelectionAppend_73945681_2"><ix:exclude><hr style="color:#999999;height:3px;width:100%"/></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_73945681_2" continuedAt="TextSelectionAppend_73945681_3"><ix:exclude><div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div></ix:exclude></ix:continuation></div></div></div> <div><div><div style="background-color:white;display: inline;"><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><ix:continuation id="TextSelectionAppend_73945681_3" continuedAt="TextSelectionAppend_73945681_4"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">Earnout </div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On the Closing Date (a)&#160;the Members on a pro rata basis subjected (i) <ix:nonFraction name="us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" contextRef="P12_13_2021To12_13_2021_BusinessCombinationMemberusgaapBusinessAcquisitionAxis_HaymakeriiiMembersrtConsolidatedEntitiesAxis_MemberEarnOutUnitsMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal">10,000,000</ix:nonFraction> Retained Holdings Units held by them (the &#8220;Member Earnout Units&#8221;) and (ii) <ix:nonFraction name="us-gaap:BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable" contextRef="P12_13_2021To12_13_2021_BusinessCombinationMemberusgaapBusinessAcquisitionAxis_EarnoutVotingSharesMemberusgaapStatementClassOfStockAxis_HaymakeriiiMembersrtConsolidatedEntitiesAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">10,000,000</ix:nonFraction> shares of Class&#160;V voting stock distributed to them by the BioTE Companies (the &#8220;Earnout Voting Shares&#8221;), (b) the Sponsor subjected <ix:nonFraction name="us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" contextRef="P12_13_2021To12_13_2021_BusinessCombinationMemberusgaapBusinessAcquisitionAxis_HaymakeriiiMembersrtConsolidatedEntitiesAxis_SponsorEarnOutSharesMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal">1,587,500</ix:nonFraction> shares of Class&#160;A common stock held by it after giving effect to the Class&#160;B common stock Conversion (the &#8220;Sponsor Earnout Shares&#8221;), and (c)&#160;Haymaker subjected a number of Holdings Units equal to the number of Sponsor Earnout Shares (the &#8220;Sponsor Earnout Units,&#8221; and, together with the Sponsor Earnout Shares, the Earnout Voting Shares and the Member Earnout Units, the &#8220;Earnout Securities&#8221;), to certain restrictions and potential forfeiture pending the achievement (if any) of certain earnout targets or milestones pursuant to the terms of the Business Combination Agreement or the occurrence of a Change of Control (as defined in the Business Combination Agreement). </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Beginning on the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">six-month</div> anniversary of the Closing, each Retained Biote Unit held by the Members may be redeemed, together with one share of Class&#160;V voting stock and subject to certain conditions, in exchange for either one share of Class&#160;A common stock or in certain circumstances, at the election of the Company in its capacity as the sole manager of Holdings, the cash equivalent of the market value of one share of Class&#160;A common stock, pursuant to the terms and conditions of the Holdings A&amp;R OA (such exchange rights, as further described in the Holdings A&amp;R OA, the &#8220;Exchange Rights&#8221;). See Note 11 for further detail. </div><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">Other Agreements&#8212;Business Combination </div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Business Combination Agreement contemplated the execution of various additional agreements and instruments, including, among others, the following: </div><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;">Tax Receivable Agreement </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">At Closing, Biote entered into a tax receivable agreement (the &#8220;TRA&#8221;) with Holdings, the Members and the Members&#8217; Representative, which provides for, among other things, payment by the Company to the Members of <ix:nonFraction name="btmd:IncomeTaxPercentageOfFederalStateAndLocalIncomeTaxSavings" contextRef="P01_01_2022To12_31_2022_HaymakeriiiMembersrtConsolidatedEntitiesAxis_OtherBusinessCombinationMemberusgaapBusinessAcquisitionAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal">85</ix:nonFraction>% of the U.S. federal, state and local income tax savings realized by the Company as a result of the increases in tax basis and certain other tax benefits related to any transactions contemplated under the Business Combination Agreement and any redemption of Retained Holdings Units in exchange for Class&#160;A common stock or cash (as more fully described in the TRA). These payments are an obligation of Biote and not of the BioTE Companies. Biote&#8217;s only material asset following the Business Combination is its ownership interest in Holdings and, accordingly, the Company will depend on distributions from Holdings to make any payments required to be made by the Company under the TRA. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The term of the TRA will continue until all such tax benefits have been utilized or expired unless the Company exercises its right to terminate the TRA for an amount representing the present value of anticipated future tax benefits under the TRA or certain other acceleration events occur. The actual increase in the Company&#8217;s allocable share of tax basis in the BioTE Companies&#8217; assets, as well as the amount and timing of any payments under the TRA, will vary depending upon a number of factors, including the timing of redemptions of shares of Retained Holdings Units, the market price of shares of the Class&#160;A common stock at the time of the exchange, the extent to which such exchanges are taxable and the amount and timing of the Company&#8217;s income. Any payments the Company makes under the TRA will generally reduce the amount of overall cash flow that might have otherwise been available to the Company. To the extent that the Company is unable to make timely payments under the TRA for any reason, the unpaid amounts will be deferred and will accrue interest until paid; however, nonpayment for a specified period and/or under certain circumstances may constitute a material breach of a material obligation under the TRA and therefore accelerate payments due under the TRA. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="-sec-ix-hidden:hidden73945879">The TRA provides that, in the event that (i)&#160;the Company exercises its early termination rights under the TRA, (ii)&#160;certain changes of control occur (as described in the TRA), (iii) the Company, in certain circumstances, fails</span> </div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"><ix:exclude>F-20</ix:exclude></div></ix:continuation></div></div><ix:continuation id="TextSelectionAppend_73945681_4" continuedAt="TextSelectionAppend_73945681_5"><ix:exclude><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_73945681_5" continuedAt="TextSelectionAppend_73945681_6"><ix:exclude><hr style="color:#999999;height:3px;width:100%"/></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_73945681_6" continuedAt="TextSelectionAppend_73945681_7"><ix:exclude><div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div></ix:exclude></ix:continuation><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><ix:continuation id="TextSelectionAppend_73945681_7" continuedAt="TextSelectionAppend_73945681_8"><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">to make a payment required to be made pursuant to the TRA by the applicable final payment date, which <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-payment</div> continues for 30 days following such final payment date or (iv)&#160;the Company materially breaches any of its material obligations under the TRA, which breach continues without cure for 30 days following receipt by the Company of written notice thereof (unless, in the case of clauses (iii)&#160;and (iv), certain liquidity exceptions apply) the Company&#8217;s obligations under the TRA will accelerate and the Company will be required to make a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">lump-sum</div> cash payment to the applicable parties to the TRA equal to the present value of all forecasted future payments that would have otherwise been made under the TRA, which <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">lump-sum</div> payment would be based on certain assumptions, including those relating to our future taxable income. As of December&#160;31, 2022 and December&#160;31, 2021, there have been no exchanges, and therefore, <ix:nonFraction name="btmd:TaxReceivableAgreementLiability" contextRef="PAsOn12_31_2021_HaymakeriiiMembersrtConsolidatedEntitiesAxis_OtherBusinessCombinationMemberusgaapBusinessAcquisitionAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt-sec:numwordsen"><ix:nonFraction name="btmd:TaxReceivableAgreementLiability" contextRef="PAsOn12_31_2022_HaymakeriiiMembersrtConsolidatedEntitiesAxis_OtherBusinessCombinationMemberusgaapBusinessAcquisitionAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt-sec:numwordsen">no </ix:nonFraction></ix:nonFraction>liability is recorded related to the TRA. </div><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;">Second Amended and Restated Operating Agreement of Holdings </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">At the Closing, the Company, Holdings and the Members entered into the Holdings A&amp;R OA, which, among other things, (i)&#160;provided for a recapitalization of the ownership structure of Holdings, whereby following the execution of the Holdings A&amp;R OA, the ownership structure of Holdings consists solely of the Holdings Units, (ii)&#160;designated the Company as the sole manager of Holdings (iii)&#160;provides that on the Exchange Date (as defined in the Holdings A&amp;R OA) (unless otherwise waived by the Company, or, with respect to the Initial Shares (as defined therein), following the registration under the Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;), of such shares), each Retained Biote Unit held by the Members may be redeemed in exchange, subject to certain conditions, for either one share of Class&#160;A common stock or, at the election of the Company in its capacity as the sole manager of Holdings, the cash equivalent of the market value of one share of Class&#160;A common stock (the &#8220;Exchange Rights&#8221;), and (iv)&#160;otherwise amended and restated the rights and preferences of the Holdings Units, in each case, as more fully described in the Holdings A&amp;R OA. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In connection with the execution of the Business Combination Agreement, certain of Haymaker&#8217;s officers and directors, Haymaker, the Sponsor, Holdings and the Members&#8217; Representative entered into a letter agreement (the &#8220;Sponsor Letter&#8221;), pursuant to which, among other things, the Sponsor agreed to (i)&#160;vote, at any duly called meeting of stockholders of the Company, in favor of the Business Combination Agreement and the transactions contemplated thereby, (ii)&#160;subject to certain exceptions, not to effect any sale or distribution of any of its shares of Class&#160;B common stock or private placement warrants and (iii)&#160;waive any and all anti-dilution rights described in Haymaker&#8217;s amended and restated certificate of incorporation or otherwise with respect to the shares of Class&#160;B common stock held by the Sponsor that may be implicated by the Business Combination such that the Class&#160;B common stock Conversion will occur as discussed therein. </div><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;">Investor Rights Agreement </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">At the Closing, the Company, the Members, the Sponsor, the Members&#8217; Representative and certain other parties entered into an Investor Rights Agreement (the &#8220;IRA&#8221;). Pursuant to the terms of the IRA, among other things, (i)&#160;that certain Registration Rights Agreement, by and between Haymaker and certain security holders, dated March&#160;1, 2021, entered into in connection with Haymaker&#8217;s initial public offering, was terminated, (ii)&#160;the Company provided certain registration rights for the shares of Class&#160;A common stock held (or underlying certain securities held) by the Members, the Sponsor, and certain other parties, (iii)&#160;the Members agreed not to, subject to certain exceptions, transfer, sell, assign or otherwise dispose of the shares of Class&#160;A common stock, Class&#160;V voting stock and the Holdings Units held by such Members, as applicable, for six months following the Closing, and the Member Earnout Units (as defined therein) until the date such securities have been earned in accordance with the Business Combination Agreement and (iv)&#160;the Sponsor agreed not to, subject to certain exceptions, transfer, sell, assign or otherwise dispose of its (a)&#160;shares of Class&#160;A common stock (other than the Sponsor Earnout Shares, as defined therein) for six months following the Closing, (b)&#160;Sponsor Earnout Shares until the date such securities have been earned in accordance with the Business Combination Agreement and (c)&#160;warrants issued to the Sponsor pursuant to that certain Private Placement Warrants Purchase Agreement, dated March&#160;1, 2021, by and between the Company and the Sponsor, and the underlying shares of Class&#160;A common stock, for </div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"><ix:exclude>F-21</ix:exclude></div></ix:continuation></div></div></div><ix:continuation id="TextSelectionAppend_73945681_8" continuedAt="TextSelectionAppend_73945681_9"><div></div></ix:continuation></div><ix:continuation id="TextSelectionAppend_73945681_9" continuedAt="TextSelectionAppend_73945681_10"><div><div style="background-color:white;display: inline;"><ix:exclude><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div></ix:exclude><ix:exclude><hr style="color:#999999;height:3px;width:100%"/></ix:exclude><ix:exclude><div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div></ix:exclude></div></div></ix:continuation></div> <div><div><div style="background-color:white;display: inline;"><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><ix:continuation id="TextSelectionAppend_73945681_10"><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><ix:nonNumeric name="btmd:CommonStockTransfersThresholdTradingDays" contextRef="P12_13_2021To12_13_2021_CommonClassAMemberusgaapStatementClassOfStockAxis_HaymakeriiiMembersrtConsolidatedEntitiesAxis_OtherBusinessCombinationMemberusgaapBusinessAcquisitionAxis" format="ixt-sec:durday">30</ix:nonNumeric>&#160;days following the Closing Date (such <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">lock-up</div> period superseding the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">lock-up</div> period set forth in the Insider Letter (as defined in the IRA)), in each case, as more fully described in the IRA). </div><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;">Indemnification Agreements </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In connection with the Closing, the Company entered into indemnification agreements (each, an &#8220;Indemnification Agreement&#8221;) with its directors and executive officers. Each Indemnification Agreement provides for indemnification and advancements by the Company of certain expenses and costs if the basis of the indemnitee&#8217;s involvement in a matter was by reason of the fact that the indemnitee is or was a director, officer, employee, or agent of the Company or any of its subsidiaries or was serving at the Company&#8217;s request in an official capacity for another entity, in each case to the fullest extent permitted by the laws of the State of Delaware. </div><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;">Credit Agreements </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On the Closing Date, certain direct and indirect subsidiaries of Biote entered into that certain Credit Agreement, dated as of May&#160;26, 2022 (the &#8220;Credit Agreement&#8221;; any capitalized terms used but not defined herein have the meanings assigned to such terms in the Credit Agreement), by and among, inter alios, Holdings, BioTE Medical, LLC, (&#8220;BioTE Medical&#8221;), BioTe IP, LLC, (&#8220;BioTe IP&#8221; and, together with Holdings and BioTE Medical, collectively, the &#8220;Loan Parties&#8221;), certain lenders party thereto from time to time (the &#8220;Lenders&#8221;), and Truist Bank, as administrative agent for the Lenders (&#8220;Administrative Agent&#8221;). The Credit Agreement provides for (i)&#160;a $<ix:nonFraction name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" contextRef="PAsOn05_26_2022_DebtCommitmentLetterMemberusgaapDebtInstrumentAxis_HaymakeriiiMembersrtConsolidatedEntitiesAxis_SeniorSecuredRevolvingCreditFacilityMemberusgaapCreditFacilityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">50,000</ix:nonFraction> senior secured revolving credit facility (the &#8220;Revolving Loans&#8221;) and (ii)&#160;a $<ix:nonFraction name="us-gaap:DebtInstrumentFaceAmount" contextRef="PAsOn05_26_2022_DebtCommitmentLetterMemberusgaapDebtInstrumentAxis_HaymakeriiiMembersrtConsolidatedEntitiesAxis_SeniorSecuredTermLoanAFacilityMemberusgaapCreditFacilityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">125,000</ix:nonFraction> senior secured term loan A credit facility, which was borrowed in full on the Closing Date (the &#8220;Term Loan&#8221; and, together with the Revolving Loans, collectively, the &#8220;Loans&#8221;, such transactions together the &#8220;Debt Financing&#8221;). BioTE Medical used the proceeds of the Debt Financing to refinance and replace an existing credit facility pursuant to a credit agreement, dated as of May&#160;17, 2019, with Bank of America, N.A and for general corporate purposes. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Loans are also subject to customary events of default. Events of default under the Credit Agreement include (subject to grace periods in certain instances): (i) the failure by any Loan Party to timely make payments due under the Credit Agreement; (ii)&#160;material misrepresentations or misstatements in any representation or warranty by any Loan Party when made; (iii)&#160;failure by any Loan Party to comply with the covenants under the Credit Agreement and other related agreements; (iv)&#160;certain defaults under a specified amount of other indebtedness of Holdings or its subsidiaries; (v)&#160;insolvency or bankruptcy-related events with respect to Holdings or any of its subsidiaries; (vi)&#160;certain undischarged, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-appealable</div> judgments above a specified threshold against Holdings or any of its subsidiaries; (vii)&#160;certain ERISA-related events reasonably expected to result in liability above a specified threshold to Holdings and its subsidiaries taken as a whole; (viii)&#160;any loan documents or a material part of the liens under the loan documents ceasing to be, or being asserted by Holdings or its subsidiaries not to be, in full force and effect; (ix)&#160;any loan party or subsidiary denying that it has further obligations under any Loan Document; (x)&#160;any obligations under the loan documents ceasing to constitute senior indebtedness; and (x)&#160;the occurrence of a change of control. If an event of default has occurred and continues beyond any applicable cure period, Administrative Agent may (i)&#160;accelerate all outstanding obligations under the Credit Agreement or (ii)&#160;terminate the commitments, amongst other remedies. Additionally, BioTE Medical may not borrow under the Loans while an event of default is continuing. See Note 9 for further detail. </div></ix:continuation><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">F-22 </div></div></div><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div><hr style="color:#999999;height:3px;width:100%"/><div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><ix:nonNumeric name="us-gaap:RevenueFromContractWithCustomerTextBlock" contextRef="P01_01_2022To12_31_2022" escape="true" continuedAt="TextSelection_73945682">
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">4.</div></div></td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: left; line-height: normal;"><div style="font-weight:bold;display:inline;">REVENUE RECOGNITION </div></div></td></tr></table><ix:nonNumeric name="us-gaap:DisaggregationOfRevenueTableTextBlock" contextRef="P01_01_2022To12_31_2022" escape="true"><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Revenue recognized for each revenue stream is as follows: </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:84%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:39%"></td>
<td style="vertical-align:bottom;width:4%"></td>
<td style="width:33%"></td>
<td style="vertical-align:bottom;width:4%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:4%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td rowspan="2" style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.5pt;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; font-size: 8pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Financial Statement Caption</div></div></td>
<td rowspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td rowspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 8pt; font-family: &quot;Times New Roman&quot;; text-align: center; line-height: normal;"><div style="font-weight:bold;display:inline;">Revenue Stream</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Year Ended</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Product revenue:</div></div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">Pellet procedures</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P01_01_2022To12_31_2022_PelletProceduresProductRevenueMembersrtProductOrServiceAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">128,952</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P01_01_2021To12_31_2021_PelletProceduresProductRevenueMembersrtProductOrServiceAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">109,465</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">Dietary supplements</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P01_01_2022To12_31_2022_DietarySupplementsMembersrtProductOrServiceAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">32,412</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P01_01_2021To12_31_2021_DietarySupplementsMembersrtProductOrServiceAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">27,241</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">Disposable trocars</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P01_01_2022To12_31_2022_DisposableTrocarsProductRevenueMembersrtProductOrServiceAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,698</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P01_01_2021To12_31_2021_DisposableTrocarsProductRevenueMembersrtProductOrServiceAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">860</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">Shipping fees</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P01_01_2022To12_31_2022_ShippingFeesProductRevenueMembersrtProductOrServiceAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">71</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P01_01_2021To12_31_2021_ShippingFeesProductRevenueMembersrtProductOrServiceAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">32</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;">Total product revenue</div></div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P01_01_2022To12_31_2022_ProductRevenueMembersrtProductOrServiceAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">163,133</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P01_01_2021To12_31_2021_ProductRevenueMembersrtProductOrServiceAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">137,598</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Service revenue:</div></div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">Training</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P01_01_2022To12_31_2022_TrainingServiceRevenueMembersrtProductOrServiceAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">973</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P01_01_2021To12_31_2021_TrainingServiceRevenueMembersrtProductOrServiceAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">859</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">Contract-term services</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P01_01_2022To12_31_2022_ContractTermServicesRevenueMembersrtProductOrServiceAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">851</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P01_01_2021To12_31_2021_ContractTermServicesRevenueMembersrtProductOrServiceAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">939</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;">Total service revenue</div></div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P01_01_2022To12_31_2022_ServiceRevenueMembersrtProductOrServiceAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,824</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P01_01_2021To12_31_2021_ServiceRevenueMembersrtProductOrServiceAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,798</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;">Total revenue</div></div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">164,957</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">139,396</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Revenue recognized by geographic region is as follows: </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:84%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:39%"></td>
<td style="vertical-align:bottom;width:4%"></td>
<td style="width:33%"></td>
<td style="vertical-align:bottom;width:4%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:4%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td rowspan="2" style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.5pt;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; font-size: 8pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Financial Statement Caption</div></div></td>
<td rowspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td rowspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 8pt; font-family: &quot;Times New Roman&quot;; text-align: center; line-height: normal;"><div style="font-weight:bold;display:inline;">Country</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">For the Year Ended<br/> December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Product revenue:</div></div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">United States</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P01_01_2022To12_31_2022_ProductRevenueMembersrtProductOrServiceAxis_USsrtStatementGeographicalAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">162,742</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P01_01_2021To12_31_2021_ProductRevenueMembersrtProductOrServiceAxis_USsrtStatementGeographicalAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">137,349</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">All other</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P01_01_2022To12_31_2022_AllOtherCountryMembersrtStatementGeographicalAxis_ProductRevenueMembersrtProductOrServiceAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">391</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P01_01_2021To12_31_2021_AllOtherCountryMembersrtStatementGeographicalAxis_ProductRevenueMembersrtProductOrServiceAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">249</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;">Total product revenue</div></div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P01_01_2022To12_31_2022_ProductRevenueMembersrtProductOrServiceAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">163,133</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P01_01_2021To12_31_2021_ProductRevenueMembersrtProductOrServiceAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">137,598</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Service revenue:</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">United States</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P01_01_2022To12_31_2022_ServiceRevenueMembersrtProductOrServiceAxis_USsrtStatementGeographicalAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,781</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P01_01_2021To12_31_2021_ServiceRevenueMembersrtProductOrServiceAxis_USsrtStatementGeographicalAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,798</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">All other</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P01_01_2022To12_31_2022_AllOtherCountryMembersrtStatementGeographicalAxis_ServiceRevenueMembersrtProductOrServiceAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">43</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;">Total service revenue</div></div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P01_01_2022To12_31_2022_ServiceRevenueMembersrtProductOrServiceAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,824</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P01_01_2021To12_31_2021_ServiceRevenueMembersrtProductOrServiceAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,798</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;">Total revenue</div></div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">164,957</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">139,396</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table></ix:nonNumeric><ix:nonNumeric name="us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock" contextRef="P01_01_2022To12_31_2022" escape="true"><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Significant changes in contract liability balances are as follows: </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:92%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:60%"></td>
<td style="vertical-align:bottom;width:5%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:5%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:5%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:5%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="14" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Year Ended December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.5pt;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; font-size: 8pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Description of change</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Deferred<br/> Revenue</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Deferred<br/> Revenue,</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Long-term</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Deferred<br/> Revenue</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Deferred<br/> Revenue,</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Long-term</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Revenue recognized that was included in the contract liability balance at the beginning of the period</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:ContractWithCustomerLiabilityRevenueRecognized" contextRef="P01_01_2022To12_31_2022_ShortTermContractWithCustomerMemberusgaapContractWithCustomerDurationAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">1,710</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:ContractWithCustomerLiabilityRevenueRecognized" contextRef="P01_01_2021To12_31_2021_ShortTermContractWithCustomerMemberusgaapContractWithCustomerDurationAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">2,048</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Increases due to cash received, excluding amounts recognized as revenue during the period</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="btmd:ContractWithCustomerLiabilityIncreasesDueToCashReceivedExcludingAmountsRecognizedAsRevenue" contextRef="P01_01_2022To12_31_2022_ShortTermContractWithCustomerMemberusgaapContractWithCustomerDurationAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,342</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="btmd:ContractWithCustomerLiabilityIncreasesDueToCashReceivedExcludingAmountsRecognizedAsRevenue" contextRef="P01_01_2022To12_31_2022_LongTermContractWithCustomerMemberusgaapContractWithCustomerDurationAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">760</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="btmd:ContractWithCustomerLiabilityIncreasesDueToCashReceivedExcludingAmountsRecognizedAsRevenue" contextRef="P01_01_2021To12_31_2021_ShortTermContractWithCustomerMemberusgaapContractWithCustomerDurationAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,022</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="btmd:ContractWithCustomerLiabilityIncreasesDueToCashReceivedExcludingAmountsRecognizedAsRevenue" contextRef="P01_01_2021To12_31_2021_LongTermContractWithCustomerMemberusgaapContractWithCustomerDurationAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">652</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Transfers between current and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-current</div> liabilities due to the expected revenue recognition period</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="btmd:ContractWithCustomerLiabilityTransfersBetweenCurrentAndNonCurrentLiabilitiesDueToExpectedRevenueRecognitionPeriod" contextRef="P01_01_2022To12_31_2022_ShortTermContractWithCustomerMemberusgaapContractWithCustomerDurationAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">460</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="btmd:ContractWithCustomerLiabilityTransfersBetweenCurrentAndNonCurrentLiabilitiesDueToExpectedRevenueRecognitionPeriod" contextRef="P01_01_2022To12_31_2022_LongTermContractWithCustomerMemberusgaapContractWithCustomerDurationAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">460</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="btmd:ContractWithCustomerLiabilityTransfersBetweenCurrentAndNonCurrentLiabilitiesDueToExpectedRevenueRecognitionPeriod" contextRef="P01_01_2021To12_31_2021_ShortTermContractWithCustomerMemberusgaapContractWithCustomerDurationAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">697</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="btmd:ContractWithCustomerLiabilityTransfersBetweenCurrentAndNonCurrentLiabilitiesDueToExpectedRevenueRecognitionPeriod" contextRef="P01_01_2021To12_31_2021_LongTermContractWithCustomerMemberusgaapContractWithCustomerDurationAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">697</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total increase (decrease) in contract liabilities</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" contextRef="P01_01_2022To12_31_2022_ShortTermContractWithCustomerMemberusgaapContractWithCustomerDurationAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">92</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" contextRef="P01_01_2022To12_31_2022_LongTermContractWithCustomerMemberusgaapContractWithCustomerDurationAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">300</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" contextRef="P01_01_2021To12_31_2021_ShortTermContractWithCustomerMemberusgaapContractWithCustomerDurationAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">329</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" contextRef="P01_01_2021To12_31_2021_LongTermContractWithCustomerMemberusgaapContractWithCustomerDurationAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">45</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table></ix:nonNumeric><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Consideration allocated to initial training due to deposits paid upfront is presented within deferred revenue on the consolidated balance sheets and is expected to be recognized as revenue within one year as the training is performed. Consideration allocated to contract-term services is presented within deferred revenue and deferred </div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"><ix:exclude>F-23</ix:exclude></div></ix:nonNumeric></div></div><ix:continuation id="TextSelection_73945682" continuedAt="TextSelectionAppend_73945682_1"><ix:exclude><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_73945682_1" continuedAt="TextSelectionAppend_73945682_2"><ix:exclude><hr style="color:#999999;height:3px;width:100%"/></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_73945682_2" continuedAt="TextSelectionAppend_73945682_3"><ix:exclude><div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div></ix:exclude></ix:continuation></div></div></div> <div><div><div style="background-color:white;display: inline;"><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><ix:continuation id="TextSelectionAppend_73945682_3"><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">revenue, long-term for the amounts expected to be recognized within one year and longer than one year, respectively. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Consideration allocated to the premiums within the management fee for pellet procedures is presented within deferred revenue current and deferred revenue, long-term for amounts expected to be recognized within one year and longer than one year, respectively. </div><ix:nonNumeric name="btmd:SummaryOfConsiderationAllocatedToPerformanceObligationsTableTextBlock" contextRef="P01_01_2022To12_31_2022" escape="true"><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Consideration allocated to performance obligations are as follows: </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:68%"></td>
<td style="vertical-align:bottom;width:10%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:10%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,<br/> 2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,<br/> 2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Unsatisfied training obligations&#8212;Current</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ContractWithCustomerLiabilityCurrent" contextRef="PAsOn12_31_2022_UnsatisfiedTrainingObligationsMembersrtProductOrServiceAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">104</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ContractWithCustomerLiabilityCurrent" contextRef="PAsOn12_31_2021_UnsatisfiedTrainingObligationsMembersrtProductOrServiceAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">67</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Unsatisfied contract-term services&#8212;Current</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ContractWithCustomerLiabilityCurrent" contextRef="PAsOn12_31_2022_UnsatisfiedContractTermServicesMembersrtProductOrServiceAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,028</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ContractWithCustomerLiabilityCurrent" contextRef="PAsOn12_31_2021_UnsatisfiedContractTermServicesMembersrtProductOrServiceAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">849</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Unsatisfied contract-term services&#8212;Long-term</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ContractWithCustomerLiabilityNoncurrent" contextRef="PAsOn12_31_2022_UnsatisfiedContractTermServicesMembersrtProductOrServiceAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">627</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ContractWithCustomerLiabilityNoncurrent" contextRef="PAsOn12_31_2021_UnsatisfiedContractTermServicesMembersrtProductOrServiceAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">544</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Total allocated to unsatisfied contract-term services</div></div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ContractWithCustomerLiability" contextRef="PAsOn12_31_2022_UnsatisfiedContractTermServicesMembersrtProductOrServiceAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,655</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ContractWithCustomerLiability" contextRef="PAsOn12_31_2021_UnsatisfiedContractTermServicesMembersrtProductOrServiceAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,393</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Unsatisfied pellet procedures&#8212;Current</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ContractWithCustomerLiabilityCurrent" contextRef="PAsOn12_31_2022_UnsatisfiedPelletProceduresMembersrtProductOrServiceAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">833</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ContractWithCustomerLiabilityCurrent" contextRef="PAsOn12_31_2021_UnsatisfiedPelletProceduresMembersrtProductOrServiceAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">789</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Unsatisfied pellet procedures&#8212;Long-term</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ContractWithCustomerLiabilityNoncurrent" contextRef="PAsOn12_31_2022_UnsatisfiedPelletProceduresMembersrtProductOrServiceAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">299</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ContractWithCustomerLiabilityNoncurrent" contextRef="PAsOn12_31_2021_UnsatisfiedPelletProceduresMembersrtProductOrServiceAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">258</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Total allocated to unsatisfied pellet procedures</div></div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ContractWithCustomerLiability" contextRef="PAsOn12_31_2022_UnsatisfiedPelletProceduresMembersrtProductOrServiceAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,132</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ContractWithCustomerLiability" contextRef="PAsOn12_31_2021_UnsatisfiedPelletProceduresMembersrtProductOrServiceAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,047</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Total deferred revenue&#8212;Current</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ContractWithCustomerLiabilityCurrent" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,965</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ContractWithCustomerLiabilityCurrent" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,705</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Total deferred revenue&#8212;Long-term</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ContractWithCustomerLiabilityNoncurrent" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">926</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ContractWithCustomerLiabilityNoncurrent" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">802</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table></ix:nonNumeric><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company does not have a history of material returns or refunds and generally does not offer warranties or guarantees for any products or services. Expected returns and refunds are recorded as a reduction of revenue and are $<ix:nonFraction name="btmd:ReductionOfRevenue" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">0</ix:nonFraction> and $<ix:nonFraction name="btmd:ReductionOfRevenue" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">0</ix:nonFraction> for the years ended December&#160;31, 2022 and 2021, respectively. </div></ix:continuation><div style="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&#160;</div><ix:nonNumeric name="us-gaap:InventoryDisclosureTextBlock" contextRef="P01_01_2022To12_31_2022" escape="true">
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">5.</div></div></td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: left; line-height: normal;"><div style="font-weight:bold;display:inline;">INVENTORY, NET </div></div></td></tr></table><ix:nonNumeric name="us-gaap:ScheduleOfInventoryCurrentTableTextBlock" contextRef="P01_01_2022To12_31_2022" escape="true"><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Inventory, net consists of the following: </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:66%"></td>
<td style="vertical-align:bottom;width:10%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:10%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,<br/> 2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,<br/> 2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Product inventory&#8212;Pellets</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:InventoryGross" contextRef="PAsOn12_31_2022_PelletsMemberusgaapPublicUtilitiesInventoryAxis_ProductMembersrtProductOrServiceAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">6,213</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:InventoryGross" contextRef="PAsOn12_31_2021_PelletsMemberusgaapPublicUtilitiesInventoryAxis_ProductMembersrtProductOrServiceAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">6,318</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Less: Obsolete and expired pellet allowance</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:InventoryAdjustments" contextRef="PAsOn12_31_2022_PelletsMemberusgaapPublicUtilitiesInventoryAxis_ProductMembersrtProductOrServiceAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,298</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:InventoryAdjustments" contextRef="PAsOn12_31_2021_PelletsMemberusgaapPublicUtilitiesInventoryAxis_ProductMembersrtProductOrServiceAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,356</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Pellet inventory, net</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:InventoryNet" contextRef="PAsOn12_31_2022_PelletsMemberusgaapPublicUtilitiesInventoryAxis_ProductMembersrtProductOrServiceAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">4,915</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:InventoryNet" contextRef="PAsOn12_31_2021_PelletsMemberusgaapPublicUtilitiesInventoryAxis_ProductMembersrtProductOrServiceAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">4,962</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Product inventory&#8212;Dietary supplements</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:InventoryGross" contextRef="PAsOn12_31_2022_DietarySupplementsMemberusgaapPublicUtilitiesInventoryAxis_ProductMembersrtProductOrServiceAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">6,283</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:InventoryGross" contextRef="PAsOn12_31_2021_DietarySupplementsMemberusgaapPublicUtilitiesInventoryAxis_ProductMembersrtProductOrServiceAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">4,849</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Less: Obsolete and expired dietary supplement allowance</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:InventoryAdjustments" contextRef="PAsOn12_31_2022_DietarySupplementsMemberusgaapPublicUtilitiesInventoryAxis_ProductMembersrtProductOrServiceAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">15</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:InventoryAdjustments" contextRef="PAsOn12_31_2021_DietarySupplementsMemberusgaapPublicUtilitiesInventoryAxis_ProductMembersrtProductOrServiceAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">196</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Dietary supplement inventory, net</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:InventoryNet" contextRef="PAsOn12_31_2022_DietarySupplementsMemberusgaapPublicUtilitiesInventoryAxis_ProductMembersrtProductOrServiceAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">6,268</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:InventoryNet" contextRef="PAsOn12_31_2021_DietarySupplementsMemberusgaapPublicUtilitiesInventoryAxis_ProductMembersrtProductOrServiceAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">4,653</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Inventory, net</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:InventoryNet" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">11,183</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:InventoryNet" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">9,615</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table></ix:nonNumeric></ix:nonNumeric><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">F-24 </div></div></div><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div><hr style="color:#999999;height:3px;width:100%"/><div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><ix:nonNumeric name="us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock" contextRef="P01_01_2022To12_31_2022" escape="true">
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">6.</div></div></td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: left; line-height: normal;"><div style="font-weight:bold;display:inline;">PROPERTY AND EQUIPMENT, NET </div></div></td></tr></table><ix:nonNumeric name="us-gaap:PropertyPlantAndEquipmentTextBlock" contextRef="P01_01_2022To12_31_2022" escape="true"><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Property and equipment, net consists of the following: </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:66%"></td>
<td style="vertical-align:bottom;width:11%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:11%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,<br/> 2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,<br/> 2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Trocars</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="PAsOn12_31_2022_TrocarsMemberusgaapPropertyPlantAndEquipmentByTypeAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">4,645</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="PAsOn12_31_2021_TrocarsMemberusgaapPropertyPlantAndEquipmentByTypeAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">4,448</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Leasehold improvements</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="PAsOn12_31_2022_LeaseholdImprovementsMemberusgaapPropertyPlantAndEquipmentByTypeAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,028</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="PAsOn12_31_2021_LeaseholdImprovementsMemberusgaapPropertyPlantAndEquipmentByTypeAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">254</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Office equipment</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="PAsOn12_31_2022_OfficeEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">238</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="PAsOn12_31_2021_OfficeEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">223</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Computer software</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="PAsOn12_31_2022_SoftwareAndSoftwareDevelopmentCostsMemberusgaapPropertyPlantAndEquipmentByTypeAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">140</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="PAsOn12_31_2021_SoftwareAndSoftwareDevelopmentCostsMemberusgaapPropertyPlantAndEquipmentByTypeAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">135</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Furniture and fixtures</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="PAsOn12_31_2022_FurnitureAndFixturesMemberusgaapPropertyPlantAndEquipmentByTypeAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">161</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="PAsOn12_31_2021_FurnitureAndFixturesMemberusgaapPropertyPlantAndEquipmentByTypeAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">119</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Computer equipment</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="PAsOn12_31_2022_ComputerEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">102</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="PAsOn12_31_2021_ComputerEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">97</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Construction in process</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="PAsOn12_31_2021_ConstructionInProgressMemberusgaapPropertyPlantAndEquipmentByTypeAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">705</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Property and equipment</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">6,314</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">5,981</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Less: Accumulated depreciation</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">4,810</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">3,646</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Property and equipment, net</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,504</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">2,335</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table></ix:nonNumeric><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Total depreciation expense related to property and equipment was $<ix:nonFraction name="us-gaap:Depreciation" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,164</ix:nonFraction> and $<ix:nonFraction name="us-gaap:Depreciation" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">713</ix:nonFraction> for the years ended December&#160;31, 2022 and 2021. Total depreciation expense was included in Selling, general and administrative expense in the consolidated statements of income and comprehensive income. The Company has not acquired any property and equipment under finance leases. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company&#8217;s property and equipment are all held within the United States. </div></ix:nonNumeric><div style="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&#160;</div><ix:nonNumeric name="us-gaap:ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock" contextRef="P01_01_2022To12_31_2022" escape="true">
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">7.</div></div></td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: left; line-height: normal;"><div style="font-weight:bold;display:inline;">CAPITALIZED SOFTWARE, NET </div></div></td></tr></table><ix:nonNumeric name="btmd:SummaryOfCapitalizedSoftwareNetTableTextBlock" contextRef="P01_01_2022To12_31_2022" escape="true"><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Capitalized software, net consists of the following: </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:66%"></td>
<td style="vertical-align:bottom;width:11%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:11%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,<br/> 2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,<br/> 2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Website costs</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="btmd:CapitalizedSoftwareWebsiteCosts" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">4,142</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="btmd:CapitalizedSoftwareWebsiteCosts" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">3,571</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Development in process</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="btmd:CapitalizedSoftwareDevelopmentInProcess" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">3,277</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="btmd:CapitalizedSoftwareDevelopmentInProcess" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">2,294</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Less: Accumulated amortization</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:CapitalizedComputerSoftwareAccumulatedAmortization" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">2,346</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:CapitalizedComputerSoftwareAccumulatedAmortization" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,311</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Capitalized software, net</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:CapitalizedComputerSoftwareNet" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">5,073</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:CapitalizedComputerSoftwareNet" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">4,554</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table></ix:nonNumeric><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Total amortization expense for capitalized software was $<ix:nonFraction name="us-gaap:CapitalizedComputerSoftwareAmortization1" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,035</ix:nonFraction> and $<ix:nonFraction name="us-gaap:CapitalizedComputerSoftwareAmortization1" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">687</ix:nonFraction> for the years ended December&#160;31, 2022 and 2021, respectively. Total amortization expense was included in Selling, general and administrative expense in the consolidated statements of income and comprehensive income. </div></ix:nonNumeric><div style="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&#160;</div><ix:nonNumeric name="us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" contextRef="P01_01_2022To12_31_2022" escape="true">
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">8.</div></div></td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: left; line-height: normal;"><div style="font-weight:bold;display:inline;">ACCRUED EXPENSES </div></div></td></tr></table><ix:nonNumeric name="us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock" contextRef="P01_01_2022To12_31_2022" escape="true"><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Accrued expenses consist of the following: </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:66%"></td>
<td style="vertical-align:bottom;width:11%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:11%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,<br/> 2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,<br/> 2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Accrued professional fees</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AccruedProfessionalFeesCurrent" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">354</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AccruedProfessionalFeesCurrent" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,192</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Accrued employee-related costs</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:EmployeeRelatedLiabilitiesCurrent" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">4,221</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:EmployeeRelatedLiabilitiesCurrent" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">2,213</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Accrued merchant fees</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="btmd:AccruedMerchantFeesCurrent" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">184</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Accrued interest</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:InterestPayableCurrent" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">27</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Legal accrual</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="btmd:LegalAccrualCurrent" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,302</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Other</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:OtherAccruedLiabilitiesCurrent" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,699</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:OtherAccruedLiabilitiesCurrent" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,093</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Accrued expenses</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AccruedLiabilitiesCurrent" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">6,274</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AccruedLiabilitiesCurrent" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">6,011</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table></ix:nonNumeric></ix:nonNumeric><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">F-25 </div></div></div><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div><hr style="color:#999999;height:3px;width:100%"/><div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div></div></div></div> <div><div><div style="background-color:white;display: inline;"><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><ix:nonNumeric name="us-gaap:DebtDisclosureTextBlock" contextRef="P01_01_2022To12_31_2022" escape="true" continuedAt="TextSelection_73945687">
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">9.</div></div></td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: left; line-height: normal;"><div style="font-weight:bold;display:inline;">LONG-TERM DEBT </div></div></td></tr></table><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Bank of America Term Loan </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In May 2019, the Company entered into a credit arrangement (the &#8220;Bank of America Credit Agreement&#8221;) with a financial institution for a term loan for $<ix:nonFraction name="us-gaap:DebtInstrumentFaceAmount" contextRef="PAsOn05_31_2019_BankOfAmericaTermLoanMemberusgaapDebtInstrumentAxis_LineOfCreditMemberusgaapCreditFacilityAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">50,000</ix:nonFraction> (the &#8220;Bank of America Term Loan&#8221;), which bore an interest rate quoted as <ix:nonNumeric name="us-gaap:DebtInstrumentInterestRateTerms" contextRef="P01_01_2022To12_31_2022_BankOfAmericaTermLoanMemberusgaapDebtInstrumentAxis_LineOfCreditMemberusgaapCreditFacilityAxis">LIBOR + 300 Basis Points (BPS)</ix:nonNumeric>. As of December&#160;31, 2022 and December&#160;31, 2021, the outstanding principal on the Bank of America Term Loan was $<ix:nonFraction name="us-gaap:LongTermDebt" contextRef="PAsOn12_31_2022_BankOfAmericaTermLoanMemberusgaapDebtInstrumentAxis_LineOfCreditMemberusgaapCreditFacilityAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">0</ix:nonFraction> and $<ix:nonFraction name="us-gaap:LongTermDebt" contextRef="PAsOn12_31_2021_BankOfAmericaTermLoanMemberusgaapDebtInstrumentAxis_LineOfCreditMemberusgaapCreditFacilityAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">37,500</ix:nonFraction>, respectively. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Bank of America Credit Agreement also included a line of credit arrangement, under which the Company could borrow up to $<ix:nonFraction name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" contextRef="PAsOn12_31_2022_BankOfAmericaTermLoanMemberusgaapDebtInstrumentAxis_LineOfCreditMemberusgaapCreditFacilityAxis" unitRef="Unit_USD" decimals="INF" scale="3" format="ixt:num-dot-decimal">10,000</ix:nonFraction>. The line was set to expire in <div style="display:inline;"><span style="-sec-ix-hidden:hidden73946021">May of 2024</span></div> and was secured by all assets of the Company. The Company did <ix:nonFraction name="us-gaap:LineOfCredit" contextRef="PAsOn12_31_2021_BankOfAmericaTermLoanMemberusgaapDebtInstrumentAxis_LineOfCreditMemberusgaapCreditFacilityAxis" unitRef="Unit_USD" decimals="INF" scale="3" format="ixt-sec:numwordsen"><ix:nonFraction name="us-gaap:LineOfCredit" contextRef="PAsOn12_31_2022_BankOfAmericaTermLoanMemberusgaapDebtInstrumentAxis_LineOfCreditMemberusgaapCreditFacilityAxis" unitRef="Unit_USD" decimals="INF" scale="3" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction>t draw on the line of credit during the years ended December&#160;31, 2022 and 2021. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In connection with obtaining the Bank of America Credit Agreement in May of 2019, the Company incurred lender&#8217;s fees and related attorney&#8217;s fees of $<ix:nonFraction name="us-gaap:InterestExpenseDebt" contextRef="P05_01_2019To05_31_2019_BankOfAmericaTermLoanMemberusgaapDebtInstrumentAxis_LineOfCreditMemberusgaapCreditFacilityAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,108</ix:nonFraction>. The Company capitalized these costs and was amortizing these to interest expense over the maturity of the Bank of America Term Loan. The balance on the Bank of America Term Loan is presented in the consolidated balance sheet net of the related debt issuance costs. Amortization expense related to the debt issuance costs on the Bank of America Credit Agreement was $<ix:nonFraction name="us-gaap:AmortizationOfFinancingCosts" contextRef="P01_01_2022To12_31_2022_BankOfAmericaTermLoanMemberusgaapDebtInstrumentAxis_LineOfCreditMemberusgaapCreditFacilityAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">91</ix:nonFraction> and $<ix:nonFraction name="us-gaap:AmortizationOfFinancingCosts" contextRef="P01_01_2021To12_31_2021_BankOfAmericaTermLoanMemberusgaapDebtInstrumentAxis_LineOfCreditMemberusgaapCreditFacilityAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">222</ix:nonFraction> for the years ended December&#160;31, 2022 and 2021, respectively. At June&#160;30, 2022, the remaining unamortized Bank of America debt issuance costs of $<ix:nonFraction name="us-gaap:GainsLossesOnExtinguishmentOfDebt" contextRef="P01_01_2022To12_31_2022_BankOfAmericaTermLoanMemberusgaapDebtInstrumentAxis_LineOfCreditMemberusgaapCreditFacilityAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">445</ix:nonFraction> were written off as a loss from extinguishment of debt in the Company&#8217;s consolidated statements of income and comprehensive income upon extinguishment of the Bank of America Credit Agreement. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In connection with the Business Combination, the Company entered into a new loan agreement as described below. A portion of the funds obtained from the new agreement were used to repay the Bank of America Term Loan in full. </div><div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Truist Term Loan </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On the Closing Date, the Company entered into a new loan agreement with Truist Bank (the &#8220;Credit Agreement&#8221; and with respect to the term loan within, the &#8220;Term Loan&#8221;) for $<ix:nonFraction name="us-gaap:DebtInstrumentFaceAmount" contextRef="PAsOn05_26_2022_LineOfCreditMemberusgaapCreditFacilityAxis_TruistTermLoanMemberusgaapDebtInstrumentAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">125,000</ix:nonFraction>. Interest on borrowings under the Credit Agreement is based on either, at the Company&#8217;s election, the Standard Overnight Financing Rate plus an applicable margin of <ix:nonFraction name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" contextRef="P05_26_2022To05_26_2022_LineOfCreditMemberusgaapCreditFacilityAxis_MinimumMembersrtRangeAxis_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMemberusgaapVariableRateAxis_TruistTermLoanMemberusgaapDebtInstrumentAxis" unitRef="Unit_pure" decimals="3" scale="-2" format="ixt:num-dot-decimal">2.5</ix:nonFraction>% or <ix:nonFraction name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" contextRef="P05_26_2022To05_26_2022_LineOfCreditMemberusgaapCreditFacilityAxis_MaximumMembersrtRangeAxis_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMemberusgaapVariableRateAxis_TruistTermLoanMemberusgaapDebtInstrumentAxis" unitRef="Unit_pure" decimals="4" scale="-2" format="ixt:num-dot-decimal">2.75</ix:nonFraction>% or the Base Rate plus an applicable margin of <ix:nonFraction name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" contextRef="P05_26_2022To05_26_2022_BaseRateMemberusgaapVariableRateAxis_LineOfCreditMemberusgaapCreditFacilityAxis_MinimumMembersrtRangeAxis_TruistTermLoanMemberusgaapDebtInstrumentAxis" unitRef="Unit_pure" decimals="3" scale="-2" format="ixt:num-dot-decimal">1.5</ix:nonFraction>% or <ix:nonFraction name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" contextRef="P05_26_2022To05_26_2022_BaseRateMemberusgaapVariableRateAxis_LineOfCreditMemberusgaapCreditFacilityAxis_MaximumMembersrtRangeAxis_TruistTermLoanMemberusgaapDebtInstrumentAxis" unitRef="Unit_pure" decimals="4" scale="-2" format="ixt:num-dot-decimal">1.75</ix:nonFraction>%. At December&#160;31, 2022, the interest rate charged to the Company was approximately <ix:nonFraction name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" contextRef="PAsOn12_31_2022_LineOfCreditMemberusgaapCreditFacilityAxis_TruistTermLoanMemberusgaapDebtInstrumentAxis" unitRef="Unit_pure" decimals="INF" scale="-2" format="ixt:num-dot-decimal">6.92</ix:nonFraction>%. The Term Loam requires principal payments of approximately $<ix:nonFraction name="us-gaap:DebtInstrumentPeriodicPaymentPrincipal" contextRef="P01_01_2022To12_31_2022_LineOfCreditMemberusgaapCreditFacilityAxis_TruistTermLoanMemberusgaapDebtInstrumentAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,563</ix:nonFraction> in <ix:nonNumeric name="us-gaap:DebtInstrumentFrequencyOfPeriodicPayment" contextRef="P01_01_2022To12_31_2022_LineOfCreditMemberusgaapCreditFacilityAxis_TruistTermLoanMemberusgaapDebtInstrumentAxis">quarterly</ix:nonNumeric> installments on the last day of each calendar quarter, commencing on September&#160;30, 2022, with repayment of the outstanding amount of the note due on maturity, which occurs on <ix:nonNumeric name="us-gaap:LongTermDebtMaturityDate" contextRef="PAsOn12_31_2022_LineOfCreditMemberusgaapCreditFacilityAxis_TruistTermLoanMemberusgaapDebtInstrumentAxis" format="ixt:date-monthname-day-year-en">May 26, 2027</ix:nonNumeric>. As of December&#160;31, 2022, the outstanding principal on the Term Loan was $<ix:nonFraction name="us-gaap:LongTermDebt" contextRef="PAsOn12_31_2022_LineOfCreditMemberusgaapCreditFacilityAxis_TruistTermLoanMemberusgaapDebtInstrumentAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">121,875</ix:nonFraction>. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to the Credit Agreement, BioTE Medical may borrow under the &#8220;Revolving Loans&#8221; from time to time up to the total commitment of $<ix:nonFraction name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" contextRef="PAsOn12_31_2022_RevolvingCreditFacilityMemberusgaapCreditFacilityAxis_TruistTermLoanMemberusgaapDebtInstrumentAxis" unitRef="Unit_USD" decimals="INF" scale="3" format="ixt:num-dot-decimal">50,000</ix:nonFraction>. The Company has <ix:nonFraction name="us-gaap:ProceedsFromLinesOfCredit" contextRef="P01_01_2022To12_31_2022_LineOfCreditMemberusgaapCreditFacilityAxis_TruistTermLoanMemberusgaapDebtInstrumentAxis" unitRef="Unit_USD" decimals="INF" scale="3" format="ixt-sec:numwordsen">no</ix:nonFraction>t drawn on the line of credit during the year ended December&#160;31, 2022. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Credit Agreement is secured by substantially all of the assets of the Company and is subject to, among other provisions, customary covenants regarding indebtedness, liens, negative pledges, restricted payments, certain prepayments of indebtedness, investments, fundamental changes, disposition of assets, sale and lease-back transactions, transactions with affiliates, amendments of or waivers with respect to restricted debt and permitted activities of the Company. <span style="-sec-ix-hidden:hidden73946027">In addition, the Credit Agreement is subject to (i)&#160;a maximum total net leverage ratio and (ii)&#160;a minimum fixed charge coverage ratio. The Company must maintain a total net leverage ratio of less than or equal to (i) <ix:nonFraction name="us-gaap:RatioOfIndebtednessToNetCapital1" contextRef="PAsOn12_31_2022_DebtInstrumentRedemptionPeriodOneMemberusgaapDebtInstrumentRedemptionPeriodAxis_LineOfCreditMemberusgaapCreditFacilityAxis_MaximumMembersrtRangeAxis_TruistTermLoanMemberusgaapDebtInstrumentAxis" unitRef="Unit_pure" decimals="2" scale="0" format="ixt:num-dot-decimal">4.25</ix:nonFraction>:1.00, with respect to the fiscal quarter ending September&#160;30, 2022 through and including the fiscal quarter ending March&#160;31, 2023, (ii) <ix:nonFraction name="us-gaap:RatioOfIndebtednessToNetCapital1" contextRef="PAsOn12_31_2022_DebtInstrumentRedemptionPeriodTwoMemberusgaapDebtInstrumentRedemptionPeriodAxis_LineOfCreditMemberusgaapCreditFacilityAxis_MaximumMembersrtRangeAxis_TruistTermLoanMemberusgaapDebtInstrumentAxis" unitRef="Unit_pure" decimals="2" scale="0" format="ixt:num-dot-decimal">4.00</ix:nonFraction>:1.00, with respect to the fiscal quarter ending June&#160;30, 2023 through and including March&#160;31, 2024, and (iii) <ix:nonFraction name="us-gaap:RatioOfIndebtednessToNetCapital1" contextRef="PAsOn12_31_2022_DebtInstrumentRedemptionPeriodThreeMemberusgaapDebtInstrumentRedemptionPeriodAxis_LineOfCreditMemberusgaapCreditFacilityAxis_MaximumMembersrtRangeAxis_TruistTermLoanMemberusgaapDebtInstrumentAxis" unitRef="Unit_pure" decimals="2" scale="0" format="ixt:num-dot-decimal">3.75</ix:nonFraction>:1.00 thereafter. Beginning with the third fiscal quarter of 2022, the Company must not permit the Consolidated Fixed Charge Coverage Ratio to be less than <ix:nonFraction name="btmd:FixedChargeCoverageRatio" contextRef="PAsOn12_31_2022_LineOfCreditMemberusgaapCreditFacilityAxis_MinimumMembersrtRangeAxis_TruistTermLoanMemberusgaapDebtInstrumentAxis" unitRef="Unit_pure" decimals="2" scale="0" format="ixt:num-dot-decimal">1.25</ix:nonFraction>:1.00.</span> </div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"><ix:exclude>F-26</ix:exclude> </div></ix:nonNumeric></div></div></div><ix:continuation id="TextSelection_73945687" continuedAt="TextSelectionAppend_73945687_1"><div></div></ix:continuation></div><div><div style="background-color:white;display: inline;"><ix:continuation id="TextSelectionAppend_73945687_1" continuedAt="TextSelectionAppend_73945687_2"><ix:exclude><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_73945687_2" continuedAt="TextSelectionAppend_73945687_3"><ix:exclude><hr style="color:#999999;height:3px;width:100%"/></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_73945687_3" continuedAt="TextSelectionAppend_73945687_4"><ix:exclude><div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div></ix:exclude></ix:continuation><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><ix:continuation id="TextSelectionAppend_73945687_4"><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Both financial covenants are tested quarterly. <ix:nonNumeric name="us-gaap:DebtInstrumentCovenantCompliance" contextRef="P01_01_2022To12_31_2022_LineOfCreditMemberusgaapCreditFacilityAxis_TruistTermLoanMemberusgaapDebtInstrumentAxis">The Company was in compliance with all required covenants associated with the Credit Agreement as of December 31, 2022.</ix:nonNumeric> </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In connection with obtaining the Credit Agreement in May of 2022, the Company incurred lender&#8217;s fees and related attorney&#8217;s fees of approximately $<ix:nonFraction name="us-gaap:DebtRelatedCommitmentFeesAndDebtIssuanceCosts" contextRef="P05_26_2022To05_26_2022_LineOfCreditMemberusgaapCreditFacilityAxis_TruistTermLoanMemberusgaapDebtInstrumentAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">4,036</ix:nonFraction>. The Company capitalized these costs and is amortizing these to interest expense over the term of the Term Loan. The balance on the Term Loan is presented in the consolidated balance sheet net of the related debt issuance costs. Amortization expense related to the debt issuance costs on the Credit Agreement was $<ix:nonFraction name="us-gaap:AmortizationOfFinancingCosts" contextRef="P01_01_2022To12_31_2022_LineOfCreditMemberusgaapCreditFacilityAxis_TruistTermLoanMemberusgaapDebtInstrumentAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">498</ix:nonFraction> for the year ended December&#160;31, 2022. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The total amortization of debt issuance costs, inclusive of those related to both the Bank of America Credit Agreement and the Credit Agreement, was $<ix:nonFraction name="us-gaap:AmortizationOfFinancingCosts" contextRef="P01_01_2022To12_31_2022_BankOfAmericaTermLoanAndTruistTermLoanMemberusgaapDebtInstrumentAxis_LineOfCreditMemberusgaapCreditFacilityAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">589</ix:nonFraction> and $<ix:nonFraction name="us-gaap:AmortizationOfFinancingCosts" contextRef="P01_01_2021To12_31_2021_BankOfAmericaTermLoanAndTruistTermLoanMemberusgaapDebtInstrumentAxis_LineOfCreditMemberusgaapCreditFacilityAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">222</ix:nonFraction> for the years ended December&#160;31, 2022 and 2021, respectively. </div><ix:nonNumeric name="us-gaap:ScheduleOfDebtTableTextBlock" contextRef="P01_01_2022To12_31_2022" escape="true"><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The outstanding debt as of December&#160;31, 2022 and 2021 is classified in the consolidated balance sheets as follows: </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:65%"></td>
<td style="vertical-align:bottom;width:9%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:9%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,<br/> 2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,<br/> 2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Term loan</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:DebtInstrumentCarryingAmount" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">121,875</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:DebtInstrumentCarryingAmount" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">37,500</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Less: Current portion</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="btmd:TeamLoanCurrentPortionBeforeUnamortizedDebtIssuanceCosts" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">6,250</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="btmd:TeamLoanCurrentPortionBeforeUnamortizedDebtIssuanceCosts" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">5,000</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="btmd:TeamLoanNonCurrentPortionBeforeUnamortizedDebtIssuanceCosts" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">115,625</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="btmd:TeamLoanNonCurrentPortionBeforeUnamortizedDebtIssuanceCosts" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">32,500</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Less: Unamortized debt issuance costs</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:DeferredFinanceCostsNet" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">3,539</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:DeferredFinanceCostsNet" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">537</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Term loan, net of current portion</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:LongTermDebtNoncurrent" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">112,086</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:LongTermDebtNoncurrent" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">31,963</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table></ix:nonNumeric><ix:nonNumeric name="us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" contextRef="P01_01_2022To12_31_2022" escape="true"><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Future maturities of long-term debt, excluding debt issuance costs, are as follows: </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:68%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:83%"></td>
<td style="vertical-align:bottom;width:7%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">2023</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">6,250</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">2024</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">6,250</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">2025</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">6,250</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">2026</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">6,250</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">2027</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">96,875</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:LongTermDebt" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">121,875</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table></ix:nonNumeric></ix:continuation><div style="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&#160;</div><ix:nonNumeric name="btmd:WarrantLiabilityTextBlock" contextRef="P01_01_2022To12_31_2022" escape="true" continuedAt="TextSelection_73945688">
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">10.</div></div></td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: left; line-height: normal;"><div style="font-weight:bold;display:inline;">WARRANT LIABILITY </div></div></td></tr></table><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In connection with its initial public offering, Haymaker issued Public Warrants as part of the units sold through the offering (&#8220;Public Warrant&#8221;) as well as private placement warrants (&#8220;Private Placement Warrant&#8221;) to its Sponsor, the terms of which are further described below. </div><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">Public Warrants </div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Each whole Public Warrant is exercisable to purchase one share of Class&#160;A common stock, and only whole warrants are exercisable. The Public Warrants became exercisable on June&#160;25, 2022, <ix:nonNumeric name="btmd:ClassOfWarrantOrRightRedemptionThresholdConsecutiveTradingDays" contextRef="P01_01_2022To12_31_2022_CommonClassAMemberusgaapStatementClassOfStockAxis_HaymakeriiiMembersrtConsolidatedEntitiesAxis_RedeemableWarrantsMemberusgaapClassOfWarrantOrRightAxis" format="ixt-sec:durday">30</ix:nonNumeric> days after the completion of the Business Combination. Each whole Public Warrant entitles the holder to purchase <ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="PAsOn12_31_2022_CommonClassAMemberusgaapStatementClassOfStockAxis_HaymakeriiiMembersrtConsolidatedEntitiesAxis_RedeemableWarrantsMemberusgaapClassOfWarrantOrRightAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt-sec:numwordsen">one</ix:nonFraction> share of Class&#160;A common stock at an exercise price of $<ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="PAsOn12_31_2022_HaymakeriiiMembersrtConsolidatedEntitiesAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal">11.50</ix:nonFraction>. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to the warrant agreement, a warrant holder may exercise its warrants only for a whole number of shares of Class&#160;A common stock. This means that only a whole warrant may be exercised at any given time by a warrant holder. No fractional warrants were issued upon separation of the units and only whole warrants were traded, requiring a purchase of at least four units to receive or trade a whole warrant. The warrants will expire on <ix:nonNumeric name="us-gaap:WarrantsAndRightsOutstandingMaturityDate" contextRef="PAsOn12_31_2022_HaymakeriiiMembersrtConsolidatedEntitiesAxis" format="ixt:date-monthname-day-year-en">May 26, 2027</ix:nonNumeric>, <ix:nonNumeric name="us-gaap:WarrantsAndRightsOutstandingTerm" contextRef="PAsOn12_31_2022_HaymakeriiiMembersrtConsolidatedEntitiesAxis" format="ixt-sec:durwordsen">five years</ix:nonNumeric> after the completion of the Business Combination, or earlier upon redemption or liquidation. </div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"><ix:exclude>F-27</ix:exclude></div></ix:nonNumeric></div></div><ix:continuation id="TextSelection_73945688" continuedAt="TextSelectionAppend_73945688_1"><ix:exclude><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_73945688_1" continuedAt="TextSelectionAppend_73945688_2"><ix:exclude><hr style="color:#999999;height:3px;width:100%"/></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_73945688_2" continuedAt="TextSelectionAppend_73945688_3"><ix:exclude><div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div></ix:exclude></ix:continuation></div></div></div> <div><div><div style="background-color:white;display: inline;"><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><ix:continuation id="TextSelectionAppend_73945688_3" continuedAt="TextSelectionAppend_73945688_4"><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If the shares issuable upon exercise of the warrants are not registered under the Securities Act within <ix:nonNumeric name="btmd:ClassOfWarrantsOrRightsTransfersRestrictionOnNumberOfDaysFromTheDateOfBusinessCombination" contextRef="P01_01_2022To12_31_2022_CommonClassAMemberusgaapStatementClassOfStockAxis_HaymakeriiiMembersrtConsolidatedEntitiesAxis" format="ixt-sec:durday">60</ix:nonNumeric> business days following the Business Combination, the Company will be required to permit holders to exercise their warrants on a cashless basis. However, no warrant will be exercisable for cash or on a cashless basis, and the Company will not be obligated to issue any shares to holders seeking to exercise their warrants, unless the issuance of the shares upon such exercise is registered or qualified under the securities laws of the state of the exercising holder, unless an exemption is available. In the event that the conditions in the immediately preceding sentence are not satisfied with respect to a warrant, the holder of such warrant will not be entitled to exercise such warrant and such warrant may have no value and expire worthless. In no event will the Company be required to net cash settle any warrant. In the event that a registration statement is not effective for the exercised warrants, the purchaser of a unit containing such warrant will have paid the full purchase price for the unit solely for the share of Class&#160;A common stock underlying such unit. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company has agreed that as soon as practicable, but in no event later than <ix:nonNumeric name="btmd:ClassOfWarrantOrRightThresholdPeriodForExerciseFromDateOfClosingPublicOffering" contextRef="P01_01_2022To12_31_2022_CommonClassAMemberusgaapStatementClassOfStockAxis_HaymakeriiiMembersrtConsolidatedEntitiesAxis" format="ixt-sec:durday">15</ix:nonNumeric> business days, after the closing of the Business Combination, the Company will use its reasonable best efforts to file with the SEC a registration statement for the registration, under the Securities Act, of the shares of Class&#160;A common stock issuable upon exercise of the warrants. The Company will use its reasonable best efforts to cause the same to become effective within <ix:nonNumeric name="btmd:NumberOfDaysFollowingItsInitialBusinessCombinationUntilTheExpirationOfTheWarrants" contextRef="P01_01_2022To12_31_2022_HaymakeriiiMembersrtConsolidatedEntitiesAxis" format="ixt-sec:durday">60</ix:nonNumeric> business days following the Business Combination and to maintain the effectiveness of such registration statement, and a current prospectus relating thereto, until the expiration of the warrants in accordance with the provisions of the warrant agreement. Notwithstanding the above, if the Company&#8217;s Class&#160;A common stock is at the time of any exercise of a warrant not listed on a national securities exchange such that it satisfies the definition of a &#8220;covered security&#8221; under Section&#160;18(b)(1) of the Securities Act, the Company may, at its option, require holders of Public Warrants who exercise their warrants to do so on a &#8220;cashless basis&#8221; in accordance with Section&#160;3(a)(9) of the Securities Act and, in the event the Company so elects, the Company will not be required to file or maintain in effect a registration statement, but the Company will be required to use its best efforts to register or qualify the shares under applicable blue sky laws to the extent an exemption is not available. </div><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;">Redemption of warrants when the price per Class&#160;A share equals or exceeds $<ix:nonFraction name="us-gaap:SharePrice" contextRef="PAsOn12_31_2022_CommonClassAMemberusgaapStatementClassOfStockAxis_SharePriceEqualOrExceedsEighteenRupeesPerDollarMemberusgaapMeasurementInputTypeAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal">18.00</ix:nonFraction> </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Once the warrants become exercisable, the Company may call the warrants for redemption: </div><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left;">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-align: left; line-height: normal;">in whole and not in part; </div></td></tr></table><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left;">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-align: left; line-height: normal;">at a price of $<ix:nonFraction name="btmd:ClassOfWarrantsRedemptionPricePerUnit" contextRef="PAsOn12_31_2022_HaymakeriiiMembersrtConsolidatedEntitiesAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal">0.01</ix:nonFraction> per warrant; </div></td></tr></table><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left;">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-align: left; line-height: normal;">upon not less than <ix:nonNumeric name="btmd:NumberOfConsecutiveTradingDaysForDeterminingSharePrice" contextRef="P01_01_2022To12_31_2022_HaymakeriiiMembersrtConsolidatedEntitiesAxis" format="ixt-sec:durday">30</ix:nonNumeric> days&#8217; prior written notice of redemption (which we refer to as the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="display:inline;">30</div>-day</div> redemption period) to each warrant holder; and </div></td></tr></table><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left;">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-align: left; line-height: normal;">if, and only if, the last reported sale price of the Class&#160;A common stock equals or exceeds $<ix:nonFraction name="us-gaap:SharePrice" contextRef="PAsOn12_31_2022_CommonClassAMemberusgaapStatementClassOfStockAxis_SharePriceEqualOrExceedsEighteenRupeesPerDollarMemberusgaapMeasurementInputTypeAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal">18.00</ix:nonFraction> per share (as adjusted for stock splits, stock capitalizations, reorganizations, recapitalizations and the like) for any <ix:nonNumeric name="btmd:NumberOfConsecutiveTradingDaysForDeterminingSharePrice" contextRef="P01_01_2022To12_31_2022_CommonClassAMemberusgaapStatementClassOfStockAxis_SharePriceEqualOrExceedsEighteenRupeesPerDollarMemberusgaapMeasurementInputTypeAxis" format="ixt-sec:durday">20</ix:nonNumeric> trading days within a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="display:inline;">30</div>-trading</div> day period ending on the third trading day prior to the date on which we send the notice of redemption to the warrant holders. </div></td></tr></table><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;">Redemption of warrants when the price per Class&#160;A share equals or exceeds $<ix:nonFraction name="us-gaap:SharePrice" contextRef="PAsOn12_31_2022_CommonClassAMemberusgaapStatementClassOfStockAxis_SharePriceEqualOrExceedsTenRupeesPerDollarMemberusgaapMeasurementInputTypeAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal">10.00</ix:nonFraction> </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Once the warrants become exercisable, the Company may call the warrants for redemption: </div><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left;">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-align: left; line-height: normal;">in whole and not in part; </div></td></tr></table><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left;">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-align: left; line-height: normal;">at $<ix:nonFraction name="btmd:ClassOfWarrantsRedemptionPricePerUnit" contextRef="PAsOn12_31_2022_CommonClassAMemberusgaapStatementClassOfStockAxis_SharePriceEqualOrExceedsTenRupeesPerDollarMemberusgaapMeasurementInputTypeAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal">0.10</ix:nonFraction> per warrant upon a minimum of <ix:nonNumeric name="btmd:ClassOfWarrantOrRightThresholdPeriodForExerciseFromDateOfClosingPublicOffering" contextRef="P01_01_2022To12_31_2022_CommonClassAMemberusgaapStatementClassOfStockAxis_SharePriceEqualOrExceedsTenRupeesPerDollarMemberusgaapMeasurementInputTypeAxis" format="ixt-sec:durday">30</ix:nonNumeric> days&#8217; prior written notice of redemption provided that holders will be able to exercise their warrants on a cashless basis prior to redemption and receive that number of shares of our Class&#160;A common stock to be determined based on the redemption date and the &#8220;fair market value&#8221; of shares of our Class&#160;A common stock except as otherwise described below; </div></td></tr></table><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left;">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-align: left; line-height: normal;">if, and only if, the closing price of shares of our Class&#160;A common stock equals or exceeds $<ix:nonFraction name="us-gaap:SharePrice" contextRef="PAsOn12_31_2022_CommonClassAMemberusgaapStatementClassOfStockAxis_SharePriceEqualOrExceedsTenRupeesPerDollarMemberusgaapMeasurementInputTypeAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal">10.00</ix:nonFraction> per share (as adjusted for stock splits, stock dividends, reorganizations, recapitalizations and the like) for </div></td></tr></table><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"><ix:exclude>F-28</ix:exclude> </div></ix:continuation></div></div><ix:continuation id="TextSelectionAppend_73945688_4" continuedAt="TextSelectionAppend_73945688_5"><ix:exclude><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_73945688_5" continuedAt="TextSelectionAppend_73945688_6"><ix:exclude><hr style="color:#999999;height:3px;width:100%"/></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_73945688_6" continuedAt="TextSelectionAppend_73945688_7"><ix:exclude><div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div></ix:exclude></ix:continuation><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><ix:continuation id="TextSelectionAppend_73945688_7" continuedAt="TextSelectionAppend_73945688_8">
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:9%">&#160;</td>
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt; line-height: normal;">any <ix:nonNumeric name="btmd:ClassOfWarrantOrRightMinimumNoticePeriodForRedemption" contextRef="P01_01_2022To12_31_2022_CommonClassAMemberusgaapStatementClassOfStockAxis_SharePriceEqualOrExceedsTenRupeesPerDollarMemberusgaapMeasurementInputTypeAxis" format="ixt-sec:durday">20</ix:nonNumeric> trading days within the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">30-trading</div> day period ending on the third trading day prior to the date on which we send the notice of redemption to the warrant holders; and </div></td></tr></table><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left;">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-align: left; line-height: normal;"><ix:nonNumeric name="btmd:PrivatePlacementWarrantsRedemptionDescription" contextRef="P01_01_2022To12_31_2022">if the closing price of our Class A common stock for any 20 trading days within a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">30-trading</div> day period ending on the third trading day prior to the date on which we send the notice of redemption to the warrant holders is less than $18.00 per share (as adjusted for stock splits, stock dividends, reorganizations, recapitalizations and the like), the Private Placement Warrants must also be concurrently called for redemption on the same terms as the outstanding Public Warrants.</ix:nonNumeric> </div></td></tr></table><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, if (x)&#160;the Company issues additional shares of Class&#160;A common stock or equity-linked securities for capital raising purposes in connection with the Closing of the Business Combination at an issue price or effective issue price of less than $<ix:nonFraction name="btmd:ShareRedemptionTriggerPrice" contextRef="PAsOn12_31_2022_CommonClassAMemberusgaapStatementClassOfStockAxis_HaymakeriiiMembersrtConsolidatedEntitiesAxis_SharePriceEqualOrLessNinePointTwoRupeesPerDollarMemberusgaapMeasurementInputTypeAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal">9.20</ix:nonFraction> per share of Class&#160;A common stock (with such issue price or effective issue price to be determined in good faith by the Company&#8217;s board of directors and, in the case of any such issuance to the Sponsor or its affiliates, without taking into account any founder shares held by the Sponsor or such affiliates, as applicable, prior to such issuance) (the &#8220;Newly Issued Price&#8221;), (y) the aggregate gross proceeds from such issuances represent more than <ix:nonFraction name="btmd:MinimumGrossProceedsRequiredFromIssuanceOfEquity" contextRef="PAsOn12_31_2022_CommonClassAMemberusgaapStatementClassOfStockAxis_HaymakeriiiMembersrtConsolidatedEntitiesAxis_SharePriceEqualOrLessNinePointTwoRupeesPerDollarMemberusgaapMeasurementInputTypeAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal">60</ix:nonFraction>% of the total equity proceeds, inclusive of interest earned on equity held in trust, available for the funding of the Business Combination on the date of the consummation of the Business Combination (net of redemptions), and (z)&#160;the volume weighted average trading price of the Company&#8217;s common stock during the <ix:nonNumeric name="btmd:ClassOfWarrantOrRightMinimumNoticePeriodForRedemption" contextRef="P01_01_2022To12_31_2022_CommonClassAMemberusgaapStatementClassOfStockAxis_HaymakeriiiMembersrtConsolidatedEntitiesAxis_SharePriceEqualOrLessNinePointTwoRupeesPerDollarMemberusgaapMeasurementInputTypeAxis" format="ixt-sec:durday">20</ix:nonNumeric> trading day period starting on the trading day prior to the day on which the Business Combination is consummated (such price, the &#8220;Market Value&#8221;) is below $<ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="PAsOn12_31_2022_CommonClassAMemberusgaapStatementClassOfStockAxis_HaymakeriiiMembersrtConsolidatedEntitiesAxis_SharePriceEqualOrLessNinePointTwoRupeesPerDollarMemberusgaapMeasurementInputTypeAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal">9.20</ix:nonFraction> per share, the exercise price of the warrants will be adjusted (to the nearest cent) to be equal to <ix:nonFraction name="btmd:ClassOfWarrantOrRightExercisePriceAdjustmentPercentageHigherOfMarketValue" contextRef="PAsOn12_31_2022_CommonClassAMemberusgaapStatementClassOfStockAxis_HaymakeriiiMembersrtConsolidatedEntitiesAxis_SharePriceEqualOrLessNinePointTwoRupeesPerDollarMemberusgaapMeasurementInputTypeAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal">115</ix:nonFraction>% of the higher of the Market Value and the Newly Issued Price, and the $<ix:nonFraction name="btmd:ShareRedemptionTriggerPrice" contextRef="PAsOn12_31_2022_CommonClassAMemberusgaapStatementClassOfStockAxis_HaymakeriiiMembersrtConsolidatedEntitiesAxis_SharePriceEqualOrExceedsEighteenRupeesPerDollarMemberusgaapMeasurementInputTypeAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal">18.00</ix:nonFraction> per share redemption trigger price described above will be adjusted (to the nearest cent) to be equal to <ix:nonFraction name="btmd:ClassOfWarrantOrRightExercisePriceAdjustmentPercentageHigherOfMarketValue" contextRef="PAsOn12_31_2022_CommonClassAMemberusgaapStatementClassOfStockAxis_HaymakeriiiMembersrtConsolidatedEntitiesAxis_SharePriceEqualOrExceedsEighteenRupeesPerDollarMemberusgaapMeasurementInputTypeAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal">180</ix:nonFraction>% of the higher of the Market Value and the Newly Issued Price. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company&#8217;s Public Warrants are treated as liabilities and recorded at fair value in the Warrant liability line of the consolidated balance sheet. Any changes in fair value are recorded in the changes in fair value of warrants line of the consolidated statements of income and comprehensive income. Please see Note 12 for further detail. <ix:nonFraction name="btmd:PublicWarrantsRedeemed" contextRef="PAsOn12_31_2021_HaymakeriiiMembersrtConsolidatedEntitiesAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt-sec:numwordsen">No</ix:nonFraction> Public Warrants have been redeemed as of December&#160;31, 2022 or December&#160;31, 2021. </div><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">Private Placement Warrants </div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Sponsor purchased an aggregate of <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="P01_01_2022To12_31_2022_HaymakeriiiMembersrtConsolidatedEntitiesAxis_PrivatePlacementWarrantsMemberusgaapClassOfWarrantOrRightAxis_SponseMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal">5,333,333</ix:nonFraction> Private Placement Warrants at a price of $<ix:nonFraction name="us-gaap:SharesIssuedPricePerShare" contextRef="PAsOn12_31_2022_HaymakeriiiMembersrtConsolidatedEntitiesAxis_PrivatePlacementWarrantsMemberusgaapClassOfWarrantOrRightAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal">1.50</ix:nonFraction> per whole warrant in a private placement that occurred simultaneously with the closing of Haymaker&#8217;s initial public offering. Subsequently, the Sponsor purchased an additional <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="P01_01_2022To12_31_2022_HaymakeriiiMembersrtConsolidatedEntitiesAxis_PrivatePlacementWarrantsMemberusgaapClassOfWarrantOrRightAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal">233,333</ix:nonFraction> Private Placement Warrants for an aggregate purchase price of $<ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" contextRef="P01_01_2022To12_31_2022_HaymakeriiiMembersrtConsolidatedEntitiesAxis_PrivatePlacementWarrantsMemberusgaapClassOfWarrantOrRightAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">350,000</ix:nonFraction> in conjunction with the partial exercise of the underwriters&#8217; overallotment option. Each whole Private Placement Warrant was exercisable for one share of the Company&#8217;s Class&#160;A common stock at a price of $<ix:nonFraction name="us-gaap:SharesIssuedPricePerShare" contextRef="PAsOn12_31_2022_CommonClassAMemberusgaapStatementClassOfStockAxis_HaymakeriiiMembersrtConsolidatedEntitiesAxis_PrivatePlacementWarrantsMemberusgaapClassOfWarrantOrRightAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal">11.50</ix:nonFraction> per share. The Private Placement Warrants were <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-redeemable</div> and exercisable on a cashless basis so long as they are held by the Sponsor or its permitted transferees. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Private Placement Warrants (including the Class&#160;A common stock issuable upon exercise of the Private Placement Warrants) were not transferable, assignable or saleable until <ix:nonNumeric name="btmd:ClassOfWarrantOrRightThresholdPeriodForExerciseFromDateOfClosingPublicOffering" contextRef="P01_01_2022To12_31_2022_CommonClassAMemberusgaapStatementClassOfStockAxis_HaymakeriiiMembersrtConsolidatedEntitiesAxis_SponseMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" format="ixt-sec:durday">30</ix:nonNumeric> days after the completion of the Business Combination and they are not redeemable so long as they are held by the Sponsor or its permitted transferees. Otherwise, the Private Placement Warrants had terms and provisions that were identical to those of the Public Warrants, including as to exercise price, exercisability and exercise period. If the Private Placement Warrants are held by holders other than the Sponsor or its permitted transferees, the Private Placement Warrants will be redeemable by the Company and exercisable by the holders on the same basis as the Public Warrants. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If holders of the Private Placement Warrants elect to exercise them on a cashless basis, they would pay the exercise price by surrendering their warrants for that number of shares of Class&#160;A common stock equal to the quotient obtained by dividing (x)&#160;the product of the number of shares of Class&#160;A common stock underlying the warrants, multiplied by the difference between the exercise price of the warrants and the &#8220;fair market value&#8221; (defined below) by (y)&#160;the fair market value. The &#8220;fair market value&#8221; shall mean the average reported last sale price of the Class&#160;A common stock for the 10 trading days ending on the third trading day prior to the date on which the notice of warrant exercise is sent to the warrant agent. </div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"><ix:exclude>F-29</ix:exclude> </div></ix:continuation></div></div><ix:continuation id="TextSelectionAppend_73945688_8" continuedAt="TextSelectionAppend_73945688_9"><ix:exclude><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_73945688_9" continuedAt="TextSelectionAppend_73945688_10"><ix:exclude><hr style="color:#999999;height:3px;width:100%"/></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_73945688_10" continuedAt="TextSelectionAppend_73945688_11"><ix:exclude><div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div></ix:exclude></ix:continuation></div></div></div> <div><div><div style="background-color:white;display: inline;"><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><ix:continuation id="TextSelectionAppend_73945688_11"><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On December&#160;31, 2022, there were <ix:nonFraction name="us-gaap:ClassOfWarrantOrRightOutstanding" contextRef="PAsOn12_31_2022_HaymakeriiiMembersrtConsolidatedEntitiesAxis_PublicWarrantsMemberusgaapClassOfWarrantOrRightAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal">7,937,466</ix:nonFraction> Public Warrants and <ix:nonFraction name="us-gaap:ClassOfWarrantOrRightOutstanding" contextRef="PAsOn12_31_2022_HaymakeriiiMembersrtConsolidatedEntitiesAxis_PrivatePlacementWarrantsMemberusgaapClassOfWarrantOrRightAxis_SponseMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal">5,566,666</ix:nonFraction> Private Placement Warrants outstanding. The Company accounts for the Public Warrants and Private Placement Warrants in accordance with the guidance contained in ASC <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">815-40.</div> Such guidance provides that because the warrants do not meet the criteria for equity treatment thereunder, each warrant must be recorded as a liability. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The warrant liabilities are subject to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">re-measurement</div> at each balance sheet date. With each such <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">re-measurement,</div> the warrant liabilities are adjusted to current fair value, with the change in fair value recognized in the Company&#8217;s consolidated statements of income and comprehensive income. The Company reassesses the classification at each balance sheet date. If the classification changes as a result of events during the period, the warrants will be reclassified as of the date of the event that causes the reclassification. No such events requiring a change in classification of the warrants have occurred through December&#160;31, 2022. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company&#8217;s Private Placement Warrants are treated as liabilities and recorded at fair value in the Warrant liability line of the balance sheet. Any changes in fair value are recorded in the changes in fair value of warrants line of the consolidated statement of income and comprehensive income. Please see Note 12 for further detail. </div></ix:continuation><div style="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&#160;</div><ix:nonNumeric name="btmd:EarnoutLiabilityTextBlock" contextRef="P01_01_2022To12_31_2022" escape="true">
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">11.</div></div></td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: left; line-height: normal;"><div style="font-weight:bold;display:inline;">EARNOUT LIABILITY </div></div></td></tr></table><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Certain of the Company&#8217;s equity holders are entitled to vest in up to <ix:nonFraction name="btmd:NumberOfEarnoutSecuritiesShareholderEntitledToVestIfCertainSharePriceTargetsAchieved" contextRef="P01_01_2022To12_31_2022_BusinessCombinationMemberusgaapBusinessAcquisitionAxis_MaximumMembersrtRangeAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal">11,587,500</ix:nonFraction> Earnout Securities if certain share price targets (the &#8220;Triggering Events&#8221;) are achieved by <span style="-sec-ix-hidden:hidden73946098">May&#160;26, 2027</span> (the &#8220;Earnout Deadline&#8221;). The Triggering Events each entitle the eligible equity holders to a certain number of shares per Triggering Event. The Triggering Events are as follows: </div><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:5%;vertical-align:top;text-align:left;">(i)</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: left; line-height: normal;">the first time, prior to the Earnout Deadline, that the volume-weighted average share price of Biote&#8217;s Class&#160;A common stock (&#8220;VWAP&#8221;) equals or exceeds $<ix:nonFraction name="us-gaap:SharePrice" contextRef="PAsOn12_31_2022_BusinessCombinationMemberusgaapBusinessAcquisitionAxis_CommonClassAMemberusgaapStatementClassOfStockAxis_SharePriceEqualsOrExceedsTwelvePointFivePerShareMemberusgaapVestingAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal">12.50</ix:nonFraction> per share (the &#8220;Price Target 1&#8221;) for twenty (<ix:nonNumeric name="btmd:CommonStockTransfersThresholdTradingDays" contextRef="P01_01_2022To12_31_2022_BusinessCombinationMemberusgaapBusinessAcquisitionAxis_CommonClassAMemberusgaapStatementClassOfStockAxis_SharePriceEqualsOrExceedsTwelvePointFivePerShareMemberusgaapVestingAxis" format="ixt-sec:durday">20</ix:nonNumeric>)&#160;trading days of any thirty (<ix:nonNumeric name="btmd:NumberOfConsecutiveTradingDaysForDeterminingTheSharePrice" contextRef="P01_01_2022To12_31_2022_BusinessCombinationMemberusgaapBusinessAcquisitionAxis_CommonClassAMemberusgaapStatementClassOfStockAxis_SharePriceEqualsOrExceedsTwelvePointFivePerShareMemberusgaapVestingAxis" format="ixt-sec:durday">30</ix:nonNumeric>)&#160;consecutive trading day period following the Closing, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">one-third</div> (1/3) of the Earnout Securities shall be vested and no longer subject to forfeiture and other transfer restrictions (the &#8220;Earnout Restrictions&#8221;); </div></td></tr></table><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:5%;vertical-align:top;text-align:left;">(ii)</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: left; line-height: normal;">the first time, prior to the Earnout Deadline, that the VWAP equals or exceeds $<ix:nonFraction name="us-gaap:SharePrice" contextRef="PAsOn12_31_2022_BusinessCombinationMemberusgaapBusinessAcquisitionAxis_SharePriceEqualsOrExceedsFifteenPerShareMemberusgaapVestingAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal">15.00</ix:nonFraction> per share (the &#8220;Price Target 2&#8221;) for twenty (<ix:nonNumeric name="btmd:CommonStockTransfersThresholdTradingDays" contextRef="P01_01_2022To12_31_2022_BusinessCombinationMemberusgaapBusinessAcquisitionAxis_SharePriceEqualsOrExceedsFifteenPerShareMemberusgaapVestingAxis" format="ixt-sec:durday">20</ix:nonNumeric>)&#160;trading days of any thirty (<ix:nonNumeric name="btmd:NumberOfConsecutiveTradingDaysForDeterminingTheSharePrice" contextRef="P01_01_2022To12_31_2022_BusinessCombinationMemberusgaapBusinessAcquisitionAxis_SharePriceEqualsOrExceedsFifteenPerShareMemberusgaapVestingAxis" format="ixt-sec:durday">30</ix:nonNumeric>)&#160;consecutive trading day period following the Closing, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">one-third</div> (1/3) of the Earnout Securities shall be vested and no longer subject to the Earnout Restrictions; </div></td></tr></table><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:5%;vertical-align:top;text-align:left;">(iii)</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: left; line-height: normal;">the first time, prior to the Earnout Deadline, that the VWAP equals or exceeds $<ix:nonFraction name="us-gaap:SharePrice" contextRef="PAsOn12_31_2022_BusinessCombinationMemberusgaapBusinessAcquisitionAxis_SharePriceEqualsOrExceedsSeventeenPointFivePerShareMemberusgaapVestingAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal">17.50</ix:nonFraction> per share (the &#8220;Price Target 3&#8221;) for twenty (<ix:nonNumeric name="btmd:CommonStockTransfersThresholdTradingDays" contextRef="P01_01_2022To12_31_2022_BusinessCombinationMemberusgaapBusinessAcquisitionAxis_SharePriceEqualsOrExceedsSeventeenPointFivePerShareMemberusgaapVestingAxis" format="ixt-sec:durday">20</ix:nonNumeric>)&#160;trading days of any thirty (<ix:nonNumeric name="btmd:NumberOfConsecutiveTradingDaysForDeterminingTheSharePrice" contextRef="P01_01_2022To12_31_2022_BusinessCombinationMemberusgaapBusinessAcquisitionAxis_SharePriceEqualsOrExceedsSeventeenPointFivePerShareMemberusgaapVestingAxis" format="ixt-sec:durday">30</ix:nonNumeric>)&#160;consecutive trading day period following the Closing, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">one-third</div> (1/3) of the Earnout Securities shall be vested and no longer subject to the Earnout Restrictions; and </div></td></tr></table><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:5%;vertical-align:top;text-align:left;">(iv)</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: left; line-height: normal;">if the Company completes a change of control prior to the Earnout Deadline, then all remaining unvested Earnout Securities shall vest and no longer be subject to the Earnout Restrictions. </div></td></tr></table><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company&#8217;s Earnout liability is recorded at fair value in the consolidated balance sheet. Any changes in fair value are recorded in the changes in earnout liability line of the consolidated statement of income and comprehensive income. Please see Note 12 for further detail. </div><div style="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&#160;</div></ix:nonNumeric><ix:nonNumeric name="us-gaap:FairValueDisclosuresTextBlock" contextRef="P01_01_2022To12_31_2022" escape="true" continuedAt="TextSelection_73945690">
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">12.</div></div></td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: left; line-height: normal;"><div style="font-weight:bold;display:inline;">FAIR VALUE MEASUREMENTS </div></div></td></tr></table><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">To the extent that valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair value requires more judgment. Accordingly, the degree of judgment exercised by the Company in determining fair value is greatest for instruments categorized in Level&#160;3. A financial instrument&#8217;s level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement. </div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"><ix:exclude>F-30</ix:exclude> </div></ix:nonNumeric></div></div><ix:continuation id="TextSelection_73945690" continuedAt="TextSelectionAppend_73945690_1"><ix:exclude><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_73945690_1" continuedAt="TextSelectionAppend_73945690_2"><ix:exclude><hr style="color:#999999;height:3px;width:100%"/></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_73945690_2" continuedAt="TextSelectionAppend_73945690_3"><ix:exclude><div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div></ix:exclude></ix:continuation><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><ix:continuation id="TextSelectionAppend_73945690_3" continuedAt="TextSelectionAppend_73945690_4"><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Fair value is a market-based measure considered from the perspective of a market participant rather than an entity-specific measure. Therefore, even when market assumptions are not readily available, the Company&#8217;s own assumptions are set to reflect those that market participants would use in pricing the asset or liability at the measurement date. The Company uses prices and inputs that are current as of the measurement date, including during periods of market dislocation. In periods of market dislocation, the observability of prices and inputs may be reduced for many instruments. This condition could cause an instrument to be reclassified from Level&#160;1 to Level&#160;2 or Level&#160;2 to Level&#160;3. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company&#8217;s financial instruments consist of accounts receivable, accounts payable, accrued expenses, and short- and long-term debt. The carrying value of accounts receivable, accounts payable, accrued expenses and short-term debt are considered a reasonable estimate of their fair value, due to the short-term maturity of these instruments. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company&#8217;s debt instruments are carried at amortized cost in its consolidated balance sheets, which may differ from their respective fair values. The fair values of the Company&#8217;s term loan and revolving line of credit generally approximate their carrying values. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company&#8217;s Warrant liability and Earnout liability are recorded at fair value on a recurring basis. </div><ix:nonNumeric name="us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock" contextRef="P01_01_2022To12_31_2022" escape="true"><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following table presents the Company&#8217;s fair value hierarchy for financial assets and liabilities: </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:92%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:60%"></td>
<td style="vertical-align:bottom;width:6%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:6%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:6%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:6%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="14" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Fair&#160;Value&#160;Measurements&#160;as&#160;of&#160;December&#160;31,&#160;2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;Level&#160;1&#160;&#160;</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;Level&#160;2&#160;&#160;</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;Level&#160;3&#160;&#160;</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;Total&#160;&#160;</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Liabilities:</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Public Warrants</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:FinancialLiabilitiesFairValueDisclosure" contextRef="PAsOn12_31_2022_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_PublicWarrantsMemberusgaapFinancialInstrumentAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">2,381</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:FinancialLiabilitiesFairValueDisclosure" contextRef="PAsOn12_31_2022_PublicWarrantsMemberusgaapFinancialInstrumentAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">2,381</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Private Placement Warrants</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:FinancialLiabilitiesFairValueDisclosure" contextRef="PAsOn12_31_2022_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_PrivatePlacementWarrantsMemberusgaapFinancialInstrumentAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,723</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:FinancialLiabilitiesFairValueDisclosure" contextRef="PAsOn12_31_2022_PrivatePlacementWarrantsMemberusgaapFinancialInstrumentAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,723</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Earnout liability</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:FinancialLiabilitiesFairValueDisclosure" contextRef="PAsOn12_31_2022_EarnoutLiabilityMemberusgaapFinancialInstrumentAxis_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">32,110</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:FinancialLiabilitiesFairValueDisclosure" contextRef="PAsOn12_31_2022_EarnoutLiabilityMemberusgaapFinancialInstrumentAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">32,110</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:12pt">&#160;</td>
<td colspan="16" style="height:12pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="14" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Fair Value Measurements as of May&#160;26, 2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Level&#160;1</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Level&#160;2</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Level&#160;3</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Total</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Liabilities:</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Public Warrants</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:FinancialLiabilitiesFairValueDisclosure" contextRef="PAsOn05_26_2022_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_PublicWarrantsMemberusgaapFinancialInstrumentAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">5,397</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:FinancialLiabilitiesFairValueDisclosure" contextRef="PAsOn05_26_2022_PublicWarrantsMemberusgaapFinancialInstrumentAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">5,397</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Private Placement Warrants</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:FinancialLiabilitiesFairValueDisclosure" contextRef="PAsOn05_26_2022_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_PrivatePlacementWarrantsMemberusgaapFinancialInstrumentAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">3,834</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:FinancialLiabilitiesFairValueDisclosure" contextRef="PAsOn05_26_2022_PrivatePlacementWarrantsMemberusgaapFinancialInstrumentAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">3,834</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Earnout liability</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:FinancialLiabilitiesFairValueDisclosure" contextRef="PAsOn05_26_2022_EarnoutLiabilityMemberusgaapFinancialInstrumentAxis_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">93,880</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:FinancialLiabilitiesFairValueDisclosure" contextRef="PAsOn05_26_2022_EarnoutLiabilityMemberusgaapFinancialInstrumentAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">93,880</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr></table></ix:nonNumeric><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">There were no movements between levels during the year ended December&#160;31, 2022. These instruments were not outstanding on the Company&#8217;s books for the year ended December&#160;31, 2021. </div><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">Level&#160;3 Disclosures </div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Private Placement Warrants </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As described in Note 10, the Company&#8217;s Private Placement Warrants were initially issued by Haymaker and were thus acquired by the Company through the consummation of the Business Combination. Accordingly, the initial measurement date of the Private Placement Warrants for the Company was the Closing Date. The Private Placement Warrants were valued using a Monte Carlo simulation. Calculating the fair value of the Private Placement Warrants requires the input of subjective assumptions. Other reasonable assumptions could provide differing results. The carrying amount of the liability may fluctuate significantly, and actual amounts at settlement may be materially different from the liability&#8217;s estimated value. </div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"><ix:exclude>F-31</ix:exclude> </div></ix:continuation></div></div><ix:continuation id="TextSelectionAppend_73945690_4" continuedAt="TextSelectionAppend_73945690_5"><ix:exclude><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_73945690_5" continuedAt="TextSelectionAppend_73945690_6"><ix:exclude><hr style="color:#999999;height:3px;width:100%"/></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_73945690_6" continuedAt="TextSelectionAppend_73945690_7"><ix:exclude><div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div></ix:exclude></ix:continuation></div></div></div> <div><div><div style="background-color:white;display: inline;"><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><ix:continuation id="TextSelectionAppend_73945690_7"><ix:nonNumeric name="us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" contextRef="P01_01_2022To12_31_2022" escape="true" continuedAt="TextSelection_73945744"><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following table provides the significant inputs to the Monte Carlo simulation for the fair value of the Private Placement Warrants as of December&#160;31, 2022 and the Closing Date: </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:71%"></td>
<td style="vertical-align:bottom;width:10%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:9%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">As of</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">May&#160;26,</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Stock price</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:SaleOfStockPricePerShare" contextRef="PAsOn12_31_2022_MeasurementInputSharePriceMemberusgaapMeasurementInputTypeAxis_PrivatePlacementWarrantsMemberusgaapFinancialInstrumentAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal">3.73</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:SaleOfStockPricePerShare" contextRef="PAsOn05_26_2022_MeasurementInputSharePriceMemberusgaapMeasurementInputTypeAxis_PrivatePlacementWarrantsMemberusgaapFinancialInstrumentAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal">9.02</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Exercise price</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" contextRef="PAsOn12_31_2022_MeasurementInputExercisePriceMemberusgaapMeasurementInputTypeAxis_PrivatePlacementWarrantsMemberusgaapFinancialInstrumentAxis" unitRef="Unit_pure" decimals="2" scale="0" format="ixt:num-dot-decimal">11.50</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" contextRef="PAsOn05_26_2022_MeasurementInputExercisePriceMemberusgaapMeasurementInputTypeAxis_PrivatePlacementWarrantsMemberusgaapFinancialInstrumentAxis" unitRef="Unit_pure" decimals="2" scale="0" format="ixt:num-dot-decimal">11.50</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Risk-free rate</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" contextRef="PAsOn12_31_2022_MeasurementInputRiskFreeInterestRateMemberusgaapMeasurementInputTypeAxis_PrivatePlacementWarrantsMemberusgaapFinancialInstrumentAxis" unitRef="Unit_pure" decimals="3" scale="-2" format="ixt:num-dot-decimal">4.0</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" contextRef="PAsOn05_26_2022_MeasurementInputRiskFreeInterestRateMemberusgaapMeasurementInputTypeAxis_PrivatePlacementWarrantsMemberusgaapFinancialInstrumentAxis" unitRef="Unit_pure" decimals="3" scale="-2" format="ixt:num-dot-decimal">2.7</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Volatility</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" contextRef="PAsOn12_31_2022_MeasurementInputOptionVolatilityMemberusgaapMeasurementInputTypeAxis_PrivatePlacementWarrantsMemberusgaapFinancialInstrumentAxis" unitRef="Unit_pure" decimals="3" scale="-2" format="ixt:num-dot-decimal">42.2</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" contextRef="PAsOn05_26_2022_MeasurementInputOptionVolatilityMemberusgaapMeasurementInputTypeAxis_PrivatePlacementWarrantsMemberusgaapFinancialInstrumentAxis" unitRef="Unit_pure" decimals="3" scale="-2" format="ixt:num-dot-decimal">13.4</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Term (in years)</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonNumeric name="us-gaap:WarrantsAndRightsOutstandingTerm" contextRef="PAsOn12_31_2022_MeasurementInputExpectedTermMemberusgaapMeasurementInputTypeAxis_PrivatePlacementWarrantsMemberusgaapFinancialInstrumentAxis" format="ixt-sec:duryear">4.4</ix:nonNumeric></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonNumeric name="us-gaap:WarrantsAndRightsOutstandingTerm" contextRef="PAsOn05_26_2022_MeasurementInputExpectedTermMemberusgaapMeasurementInputTypeAxis_PrivatePlacementWarrantsMemberusgaapFinancialInstrumentAxis" format="ixt-sec:duryear">5.0</ix:nonNumeric></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr></table></ix:nonNumeric><div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Earnout Liability </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Earnout liability was valued using a Monte Carlo simulation in order to project the future path of the Company&#8217;s stock price over the earnout period. The carrying amount of the liability may fluctuate significantly, and actual amounts paid may be materially different from the liability&#8217;s estimated value. </div><ix:continuation id="TextSelection_73945744"><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following table provides the significant inputs to the Monte Carlo simulation for the fair value of the Earnout liability as of December&#160;31, 2022 and the Closing Date, the date of initial measurement: </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:71%"></td>
<td style="vertical-align:bottom;width:12%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:11%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">As of</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,<br/> 2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">May&#160;26,<br/> 2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Stock price</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:SaleOfStockPricePerShare" contextRef="PAsOn12_31_2022_EarnoutLiabilityMemberusgaapFinancialInstrumentAxis_MeasurementInputSharePriceMemberusgaapMeasurementInputTypeAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal">3.73</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:SaleOfStockPricePerShare" contextRef="PAsOn05_26_2022_EarnoutLiabilityMemberusgaapFinancialInstrumentAxis_MeasurementInputSharePriceMemberusgaapMeasurementInputTypeAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal">9.02</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Risk-free rate</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" contextRef="PAsOn12_31_2022_EarnoutLiabilityMemberusgaapFinancialInstrumentAxis_MeasurementInputRiskFreeInterestRateMemberusgaapMeasurementInputTypeAxis" unitRef="Unit_pure" decimals="3" scale="-2" format="ixt:num-dot-decimal">4.1</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" contextRef="PAsOn05_26_2022_EarnoutLiabilityMemberusgaapFinancialInstrumentAxis_MeasurementInputRiskFreeInterestRateMemberusgaapMeasurementInputTypeAxis" unitRef="Unit_pure" decimals="3" scale="-2" format="ixt:num-dot-decimal">2.7</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Volatility</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" contextRef="PAsOn12_31_2022_EarnoutLiabilityMemberusgaapFinancialInstrumentAxis_MeasurementInputOptionVolatilityMemberusgaapMeasurementInputTypeAxis" unitRef="Unit_pure" decimals="3" scale="-2" format="ixt:num-dot-decimal">70.0</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" contextRef="PAsOn05_26_2022_EarnoutLiabilityMemberusgaapFinancialInstrumentAxis_MeasurementInputOptionVolatilityMemberusgaapMeasurementInputTypeAxis" unitRef="Unit_pure" decimals="3" scale="-2" format="ixt:num-dot-decimal">60.0</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Term (in years)</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonNumeric name="us-gaap:WarrantsAndRightsOutstandingTerm" contextRef="PAsOn12_31_2022_EarnoutLiabilityMemberusgaapFinancialInstrumentAxis_MeasurementInputExpectedTermMemberusgaapMeasurementInputTypeAxis" format="ixt-sec:duryear">4.4</ix:nonNumeric></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonNumeric name="us-gaap:WarrantsAndRightsOutstandingTerm" contextRef="PAsOn05_26_2022_EarnoutLiabilityMemberusgaapFinancialInstrumentAxis_MeasurementInputExpectedTermMemberusgaapMeasurementInputTypeAxis" format="ixt-sec:duryear">5.0</ix:nonNumeric></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr></table></ix:continuation><ix:nonNumeric name="btmd:ScheduleOfChangesInTheFairValueOfWarrantLiabilitiesTableTextBlock" contextRef="P01_01_2022To12_31_2022" escape="true"><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following table presents the changes in fair value of the Company&#8217;s Level&#160;3 financial instruments that are measured at fair value as of December&#160;31, 2022 and the Closing Date, the date of initial measurement: </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:84%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:65%"></td>
<td style="vertical-align:bottom;width:5%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:5%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:5%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Private<br/> Placement</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Warrants</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Earnout<br/> Liability</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Total</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Fair value as of May&#160;26, 2022 (initial measurement)</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:FinancialLiabilitiesFairValueDisclosure" contextRef="PAsOn05_26_2022_PrivatePlacementWarrantsMemberusgaapFinancialInstrumentAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">3,834</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:FinancialLiabilitiesFairValueDisclosure" contextRef="PAsOn05_26_2022_EarnoutLiabilityMemberusgaapFinancialInstrumentAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">93,880</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:FinancialLiabilitiesFairValueDisclosure" contextRef="PAsOn05_26_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">97,714</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Gain from change in fair value</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:FairValueOptionChangesInFairValueGainLoss1" contextRef="P05_27_2022To12_31_2022_PrivatePlacementWarrantsMemberusgaapFinancialInstrumentAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">2,111</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:FairValueOptionChangesInFairValueGainLoss1" contextRef="P05_27_2022To12_31_2022_EarnoutLiabilityMemberusgaapFinancialInstrumentAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">61,770</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:FairValueOptionChangesInFairValueGainLoss1" contextRef="P05_27_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">63,881</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Fair value as of December&#160;31, 2022</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:FinancialLiabilitiesFairValueDisclosure" contextRef="PAsOn12_31_2022_PrivatePlacementWarrantsMemberusgaapFinancialInstrumentAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,723</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:FinancialLiabilitiesFairValueDisclosure" contextRef="PAsOn12_31_2022_EarnoutLiabilityMemberusgaapFinancialInstrumentAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">32,110</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:FinancialLiabilitiesFairValueDisclosure" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">33,833</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr></table></ix:nonNumeric></ix:continuation><div style="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&#160;</div><ix:nonNumeric name="us-gaap:MinorityInterestDisclosureTextBlock" contextRef="P01_01_2022To12_31_2022" escape="true" continuedAt="TextSelection_73945691">
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">13.</div></div></td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: left; line-height: normal;"><div style="font-weight:bold;display:inline;">NONCONTROLLING INTEREST </div></div></td></tr></table><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In connection with the Closing of the Business Combination on the Closing Date, certain Members of Holdings (the &#8220;Minority Interest Holders&#8221;) retained an approximately <ix:nonFraction name="us-gaap:MinorityInterestOwnershipPercentageByNoncontrollingOwners" contextRef="PAsOn05_26_2022_MinorityInterestHoldersMembersrtOwnershipAxis" unitRef="Unit_pure" decimals="3" scale="-2" format="ixt:num-dot-decimal">86.5</ix:nonFraction>% membership interest in Holdings and Biote received an approximately <ix:nonFraction name="us-gaap:MinorityInterestOwnershipPercentageByParent" contextRef="PAsOn05_26_2022_BioteCorporationMembersrtOwnershipAxis" unitRef="Unit_pure" decimals="3" scale="-2" format="ixt:num-dot-decimal">13.5</ix:nonFraction>% ownership interest in Holdings. As a result of share issuances subsequent to the Closing of the Business Combination, Biote&#8217;s ownership of Holdings, was approximately <ix:nonFraction name="us-gaap:MinorityInterestOwnershipPercentageByParent" contextRef="PAsOn12_31_2022_BioteCorporationMembersrtOwnershipAxis" unitRef="Unit_pure" decimals="3" scale="-2" format="ixt:num-dot-decimal">16.6</ix:nonFraction>% as of December&#160;31, 2022. The Minority Interest Holders may from time to time, after the Closing Date, exchange with Biote, such holders&#8217; units in Holdings for an equal number of shares of Biote&#8217;s Class&#160;A common stock. As a result, Biote&#8217;s ownership interest in Holdings will continue to increase. The Minority Interest Holders&#8217; ownership interests are accounted for as noncontrolling interests in the Company&#8217;s consolidated financial statements. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Because the Business Combination was accounted for similar to a reverse recapitalization, the noncontrolling interest was initially recorded based on the Minority Interest Holders&#8217; ownership interest in the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-combination</div> carrying value of Holdings&#8217; equity, including net income (loss) for the periods prior to the Closing Date included in accumulated deficit as of the Closing Date. Subsequent to the Business Combination, the Minority Interest Holders&#8217; interest in the net income (loss) of Holdings after the Closing Date is allocated to noncontrolling interest. </div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"><ix:exclude>F-32</ix:exclude> </div></ix:nonNumeric></div></div><ix:continuation id="TextSelection_73945691" continuedAt="TextSelectionAppend_73945691_1"><ix:exclude><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_73945691_1" continuedAt="TextSelectionAppend_73945691_2"><ix:exclude><hr style="color:#999999;height:3px;width:100%"/></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_73945691_2" continuedAt="TextSelectionAppend_73945691_3"><ix:exclude><div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div></ix:exclude></ix:continuation><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><ix:continuation id="TextSelectionAppend_73945691_3"><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In connection with the Business Combination, Biote issued the Minority Interest Holders an aggregate of <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="P01_01_2022To12_31_2022_CommonClassVMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal">48,565,824</ix:nonFraction> shares of Class&#160;V voting stock. The Class&#160;V voting stock provides no economic rights in Biote to the holder thereof; however, <ix:nonNumeric name="us-gaap:CommonStockVotingRights" contextRef="P01_01_2022To12_31_2022_CommonClassVMemberusgaapStatementClassOfStockAxis">each holder of Class V voting stock is entitled to vote with the holders of Class A common stock of Biote, with each share of Class V voting stock entitling the holder to <ix:nonFraction name="btmd:CommonStockNumberOfVotesEntitledPerShare" contextRef="P01_01_2022To12_31_2022_CommonClassVMemberusgaapStatementClassOfStockAxis" unitRef="Unit_VOTE" decimals="0" scale="0" format="ixt-sec:numwordsen">one</ix:nonFraction> vote per share of Class V voting stock at the time of such vote (subject to customary conversion rate adjustments for stock splits, stock dividends and reclassifications).</ix:nonNumeric> </div><div style="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&#160;</div></ix:continuation><ix:nonNumeric name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" contextRef="P01_01_2022To12_31_2022" escape="true" continuedAt="TextSelection_73945692">
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">14.</div></div></td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: left; line-height: normal;"><div style="font-weight:bold;display:inline;">SHARE-BASED COMPENSATION </div></div></td></tr></table><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">At the Closing of the Business Combination, Holdings&#8217; share-based compensation awards (as such terms are defined below) were converted into equity in Biote. Share information below has been converted from historical disclosure based on the equivalent shares received in the Business Combination. </div><div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Incentive Units </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Holdings previously issued incentive units, which entitled the holder to participate in the net transaction proceeds from a change in control or qualifying liquidity event. Incentive units equivalent to <ix:nonFraction name="btmd:ShareBasedCompensationArrangementVestingOfIncentiveUnits" contextRef="P01_01_2021To12_31_2021_CommonClassVMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal">987,275</ix:nonFraction> shares of Class&#160;V voting stock were vested as of December&#160;31, 2021, and the Closing of the Business Combination triggered the vesting of the remaining incentive units equivalent to <ix:nonFraction name="btmd:ShareBasedCompensationArrangementVestingOfIncentiveUnits" contextRef="P05_26_2022To05_26_2022_CommonClassVMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal">6,356,178</ix:nonFraction> shares of Class&#160;V voting stock. <ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="P03_26_2022To05_26_2022_IncentiveUnitsMemberusgaapAwardTypeAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt-sec:numwordsen">No</ix:nonFraction> compensation cost was recognized historically until the Closing of the Business Combination, and $<ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="P05_26_2022To05_26_2022_IncentiveUnitsMemberusgaapAwardTypeAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">50,026</ix:nonFraction> of share-based compensation expense was recognized at Closing related to the incentive units. As of December&#160;31, 2022, there are no incentive units outstanding. </div><div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Restricted Stock Units (Including Phantom Equity Rights) </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Holdings also previously authorized the grant of phantom equity rights, which entitled the holder to participate in the net transaction proceeds from a change in control or qualifying liquidity event. For current employees as of the Closing Date, these awards vest quarterly over a period of <span style="-sec-ix-hidden:hidden73946171">one</span> or <ix:nonNumeric name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" contextRef="P01_01_2022To12_31_2022_MaximumMembersrtRangeAxis_PhantomEquityRightsMemberusgaapAwardTypeAxis" format="ixt-sec:durwordsen">two years</ix:nonNumeric> after a change in control or qualifying liquidity event, and each holder is entitled to receive a stated percentage of the net transaction proceeds in excess of certain thresholds in accordance with the terms of their respective award agreement. Awards related to former employees vest at the time of a change in control or qualifying liquidity event, and each holder is entitled to receive a stated percentage of the net transaction proceeds in excess of certain thresholds or a maximum amount in accordance with the terms of their respective award agreement. The Closing of the Business Combination met the performance condition in the phantom equity rights. <ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="P03_26_2022To05_26_2022_PhantomEquityRightsMemberusgaapAwardTypeAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt-sec:numwordsen">No</ix:nonFraction> compensation cost was recognized historically until the Closing of the Business Combination. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The phantom equity rights are equity-classified awards. The grant date fair value of the phantom equity rights was determined using a Monte-Carlo simulation. The significant assumptions used in valuation include the constant risk-free rate, constant volatility factor and the Geometric Brownian Motion. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">At the Closing of the Business Combination, Holdings&#8217; phantom equity rights related to former employees vested, and we recognized share-based compensation expense of $<ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="P05_26_2022To05_26_2022_PhantomEquityRightsMemberusgaapAwardTypeAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">4,339</ix:nonFraction> related to these awards with an offsetting increase to equity based on the awards&#8217; grant-date fair value. At Closing, the Company exercised its option to settle the awards for cash in the amount of $<ix:nonFraction name="us-gaap:SettlementLiabilitiesCurrent" contextRef="PAsOn05_26_2022_PhantomEquityRightsMemberusgaapAwardTypeAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">7,250</ix:nonFraction>. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">At the Closing of the Business Combination, Holdings&#8217; phantom equity rights related to current employees were replaced with <ix:nonFraction name="us-gaap:ConversionOfStockSharesConverted1" contextRef="P05_26_2022To05_26_2022_PhantomEquityRightsMemberusgaapAwardTypeAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal">3,887,750</ix:nonFraction> restricted stock units (&#8220;RSUs&#8221;) of Biote. The RSUs will continue to vest according to their original terms, quarterly over a period of <span style="-sec-ix-hidden:hidden73946172">one</span> or <ix:nonNumeric name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" contextRef="P05_31_2022To06_30_2022_MaximumMembersrtRangeAxis_PhantomEquityRightsMemberusgaapAwardTypeAxis" format="ixt-sec:durwordsen">two years</ix:nonNumeric> after the Closing of the Business Combination. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Since the Closing of the Business Combination, the Company continues to grant RSUs to certain employees under the <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">2022 Equity Incentive Plan</div></div> adopted on May&#160;26, 2022. New RSUs issued are valued at the Company&#8217;s </div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"><ix:exclude>F-33</ix:exclude> </div></ix:nonNumeric></div></div><ix:continuation id="TextSelection_73945692" continuedAt="TextSelectionAppend_73945692_1"><ix:exclude><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_73945692_1" continuedAt="TextSelectionAppend_73945692_2"><ix:exclude><hr style="color:#999999;height:3px;width:100%"/></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_73945692_2" continuedAt="TextSelectionAppend_73945692_3"><ix:exclude><div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div></ix:exclude></ix:continuation></div></div></div> <div><div><div style="background-color:white;display: inline;"><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><ix:continuation id="TextSelectionAppend_73945692_3"><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">stock price on the date of grant. <ix:nonNumeric name="us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" contextRef="P01_01_2022To12_31_2022" escape="true" continuedAt="TextSelection_73945746">The following table summarizes RSU activity during the year ended December&#160;31, 2022: </ix:nonNumeric></div><ix:continuation id="TextSelection_73945746"><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:68%"></td>
<td style="vertical-align:bottom;width:7%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:7%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Shares</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Weighted-<br/> Average</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Grant-Date</div><br/> Fair Value</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">RSUs outstanding at December&#160;31, 2021</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" contextRef="PAsOn12_31_2021_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis_TwoThousandTwentyTwoEquityIncentivePlanMemberusgaapPlanNameAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal">3,887,750</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" contextRef="PAsOn12_31_2021_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis_TwoThousandTwentyTwoEquityIncentivePlanMemberusgaapPlanNameAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal">8.85</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Granted</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" contextRef="P01_01_2022To12_31_2022_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis_TwoThousandTwentyTwoEquityIncentivePlanMemberusgaapPlanNameAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal">85,040</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" contextRef="P01_01_2022To12_31_2022_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis_TwoThousandTwentyTwoEquityIncentivePlanMemberusgaapPlanNameAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal">4.00</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Forfeited</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" contextRef="P01_01_2022To12_31_2022_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis_TwoThousandTwentyTwoEquityIncentivePlanMemberusgaapPlanNameAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal">296,250</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" contextRef="P01_01_2022To12_31_2022_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis_TwoThousandTwentyTwoEquityIncentivePlanMemberusgaapPlanNameAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal">8.71</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Vested</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" contextRef="P01_01_2022To12_31_2022_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis_TwoThousandTwentyTwoEquityIncentivePlanMemberusgaapPlanNameAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal">2,053,700</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" contextRef="P01_01_2022To12_31_2022_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis_TwoThousandTwentyTwoEquityIncentivePlanMemberusgaapPlanNameAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal">8.24</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">RSUs outstanding at December&#160;31, 2022</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" contextRef="PAsOn12_31_2022_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis_TwoThousandTwentyTwoEquityIncentivePlanMemberusgaapPlanNameAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal">1,622,840</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" contextRef="PAsOn12_31_2022_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis_TwoThousandTwentyTwoEquityIncentivePlanMemberusgaapPlanNameAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal">9.41</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr></table></ix:continuation><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company recognized share-based compensation expense of $<ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="P01_01_2022To12_31_2022_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis_TwoThousandTwentyTwoEquityIncentivePlanMemberusgaapPlanNameAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">26,647</ix:nonFraction> during the year ended December&#160;31, 2022, related to RSUs, which included a cumulative <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">catch-up</div> of unrecognized share-based compensation expense for service provided from the grant date to the Closing of the Business Combination. As of December&#160;31, 2022, there was $<ix:nonFraction name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" contextRef="PAsOn12_31_2022_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis_TwoThousandTwentyTwoEquityIncentivePlanMemberusgaapPlanNameAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">3,688</ix:nonFraction> of unrecognized share-based compensation expense related to unvested RSUs. This expense is expected to be recognized over a weighted-average remaining vesting period of <ix:nonNumeric name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" contextRef="P01_01_2022To12_31_2022_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis_TwoThousandTwentyTwoEquityIncentivePlanMemberusgaapPlanNameAxis" format="ixt-sec:duryear">1.0</ix:nonNumeric> year. </div><div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Stock Options </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Subsequent to the Closing of the Business Combination, the Company began to grant stock options to certain employees, directors, and consultants under the <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">2022 Equity Incentive Plan</div></div> adopted on May&#160;26, 2022. <ix:nonNumeric name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" contextRef="P01_01_2022To12_31_2022" escape="true" continuedAt="TextSelection_73945747">The following table summarizes stock option activity during the year ended December&#160;31, 2022: </ix:nonNumeric></div><ix:continuation id="TextSelection_73945747"><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:84%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:57%"></td>
<td style="vertical-align:bottom;width:8%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:8%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:8%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Shares</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Weighted-<br/> Average</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Exercise&#160;Price</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Weighted-<br/> Average</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Remaining</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Contractual<br/> Term</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(Years)</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Options outstanding at December&#160;31, 2021</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Granted</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="P01_01_2022To12_31_2022_TwoThousandTwentyTwoEquityIncentivePlanMemberusgaapPlanNameAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal">5,165,328</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" contextRef="P01_01_2022To12_31_2022_TwoThousandTwentyTwoEquityIncentivePlanMemberusgaapPlanNameAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal">3.86</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Forfeited</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" contextRef="P01_01_2022To12_31_2022_TwoThousandTwentyTwoEquityIncentivePlanMemberusgaapPlanNameAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal">122,700</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" contextRef="P01_01_2022To12_31_2022_TwoThousandTwentyTwoEquityIncentivePlanMemberusgaapPlanNameAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal">3.73</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Options outstanding at December&#160;31, 2022</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="PAsOn12_31_2022_TwoThousandTwentyTwoEquityIncentivePlanMemberusgaapPlanNameAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal">5,042,628</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="PAsOn12_31_2022_TwoThousandTwentyTwoEquityIncentivePlanMemberusgaapPlanNameAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal">3.86</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonNumeric name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" contextRef="P01_01_2022To12_31_2022_TwoThousandTwentyTwoEquityIncentivePlanMemberusgaapPlanNameAxis" format="ixt-sec:duryear">9.5</ix:nonNumeric></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Options exercisable December&#160;31, 2022</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" contextRef="PAsOn12_31_2022_TwoThousandTwentyTwoEquityIncentivePlanMemberusgaapPlanNameAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal">131,461</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" contextRef="PAsOn12_31_2022_TwoThousandTwentyTwoEquityIncentivePlanMemberusgaapPlanNameAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal">3.99</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonNumeric name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" contextRef="P01_01_2022To12_31_2022_TwoThousandTwentyTwoEquityIncentivePlanMemberusgaapPlanNameAxis" format="ixt-sec:duryear">2.1</ix:nonNumeric></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr></table></ix:continuation><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company recognized share-based compensation expense of $<ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="P01_01_2022To12_31_2022_EmployeeStockOptionMemberusgaapAwardTypeAxis_TwoThousandTwentyTwoEquityIncentivePlanMemberusgaapPlanNameAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,168</ix:nonFraction> during the year ended December&#160;31, 2022 related to stock options. As of December&#160;31, 2022, there was $<ix:nonFraction name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" contextRef="PAsOn12_31_2022_EmployeeStockOptionMemberusgaapAwardTypeAxis_TwoThousandTwentyTwoEquityIncentivePlanMemberusgaapPlanNameAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">10,156</ix:nonFraction> of unrecognized share-based compensation expense related to unvested stock options. This expense is expected to be recognized over a weighted-average remaining vesting period of <ix:nonNumeric name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" contextRef="P01_01_2022To12_31_2022_EmployeeStockOptionMemberusgaapAwardTypeAxis_TwoThousandTwentyTwoEquityIncentivePlanMemberusgaapPlanNameAxis" format="ixt-sec:duryear">3.4</ix:nonNumeric> years. </div><ix:nonNumeric name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" contextRef="P01_01_2022To12_31_2022" escape="true"><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The weighted-average assumptions used to estimate the fair value of stock options granted during the year ended December&#160;31, 2022 were as follows: </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:68%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:90%"></td>
<td style="vertical-align:bottom;width:6%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Expected term (in years)</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonNumeric name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" contextRef="P01_01_2022To12_31_2022_TwoThousandTwentyTwoEquityIncentivePlanMemberusgaapPlanNameAxis" format="ixt-sec:duryear">6.0</ix:nonNumeric></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Volatility</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" contextRef="P01_01_2022To12_31_2022_TwoThousandTwentyTwoEquityIncentivePlanMemberusgaapPlanNameAxis" unitRef="Unit_pure" decimals="3" scale="-2" format="ixt:num-dot-decimal">60.0</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Risk-free rate</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" contextRef="P01_01_2022To12_31_2022_TwoThousandTwentyTwoEquityIncentivePlanMemberusgaapPlanNameAxis" unitRef="Unit_pure" decimals="3" scale="-2" format="ixt:num-dot-decimal">3.5</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Dividend yield</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" contextRef="P01_01_2022To12_31_2022_TwoThousandTwentyTwoEquityIncentivePlanMemberusgaapPlanNameAxis" unitRef="Unit_pure" decimals="3" scale="-2" format="ixt:num-dot-decimal">0.0</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr></table></ix:nonNumeric></ix:continuation><div style="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&#160;</div><ix:nonNumeric name="us-gaap:LesseeOperatingLeasesTextBlock" contextRef="P01_01_2022To12_31_2022" escape="true" continuedAt="TextSelection_73945693">
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">15.</div></div></td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: left; line-height: normal;"><div style="font-weight:bold;display:inline;">LEASES </div></div></td></tr></table><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On July&#160;1, 2014, BioTE Medical entered into a contract to lease office space in the Las Colinas Business Center in Irving, TX. Subsequent to execution of the contract, the Company revised the lease to include additional space </div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"><ix:exclude>F-34</ix:exclude> </div></ix:nonNumeric></div></div></div><ix:continuation id="TextSelection_73945693" continuedAt="TextSelectionAppend_73945693_1"><div></div></ix:continuation></div><div><div style="background-color:white;display: inline;"><ix:continuation id="TextSelectionAppend_73945693_1" continuedAt="TextSelectionAppend_73945693_2"><ix:exclude><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_73945693_2" continuedAt="TextSelectionAppend_73945693_3"><ix:exclude><hr style="color:#999999;height:3px;width:100%"/></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_73945693_3" continuedAt="TextSelectionAppend_73945693_4"><ix:exclude><div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div></ix:exclude></ix:continuation><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><ix:continuation id="TextSelectionAppend_73945693_4" continuedAt="TextSelectionAppend_73945693_5"><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">and extend the lease term through <span style="-sec-ix-hidden:hidden73946198">June&#160;30, 2023</span>. <ix:nonNumeric name="us-gaap:LesseeOperatingLeaseOptionToExtend" contextRef="P01_01_2022To12_31_2022">On November 1, 2022, the Company executed an extension of lease office space to extend through November 30, 2028.</ix:nonNumeric> This extension included an additional <ix:nonFraction name="btmd:AreaOfOfficeSpace" contextRef="PAsOn11_01_2022" unitRef="Unit_sqft" decimals="INF" scale="0" format="ixt:num-dot-decimal">3,700</ix:nonFraction> square feet of space that would be available for use in December of 2023, which would be included in monthly rent payments at this date accordingly. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company recognizes operating lease costs on a straight-line basis over the lease term within Selling, general and administrative expense in the consolidated statement of income and comprehensive income. <ix:nonNumeric name="btmd:SummaryOfLeaseCostsRecognizedUnderAsc842AndSupplementalCashFlowInformationForLeasesTableTextBlock" contextRef="P01_01_2022To12_31_2022" escape="true" continuedAt="TextSelection_73945749">The following table contains a summary of the operating lease costs recognized under ASC 842 and supplemental cash flow information for leases for the years ended December&#160;31, 2022 and 2021: </ix:nonNumeric></div><ix:continuation id="TextSelection_73945749"><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:80%"></td>
<td style="vertical-align:bottom;width:5%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:5%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Year Ended</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Fixed lease expense</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:OperatingLeaseCost" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">278</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:OperatingLeaseCost" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">244</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total lease cost</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:LeaseCost" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">278</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:LeaseCost" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">244</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Other information:</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Cash paid for amounts included in the measurement of lease liabilities</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:OperatingLeasePayments" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">257</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:OperatingLeasePayments" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">257</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Right-of-use</div></div> assets obtained in exchange for new operating lease liabilities</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,936</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr></table></ix:continuation><ix:nonNumeric name="btmd:SummaryBalanceSheetClassificationOfOperatingLeasesAndWeightedAverageRemainingLeaseTermAndDiscountRateTableTextBlock" contextRef="P01_01_2022To12_31_2022" escape="true"><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following table summarizes the balance sheet classification of the Company&#8217;s operating leases, amounts of ROU assets and lease liabilities, the weighted average remaining lease term, and the weighted average discount rate for the Company&#8217;s operating leases: </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:66%"></td>
<td style="vertical-align:bottom;width:14%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:13%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,<br/> 2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,<br/> 2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Lease assets</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Operating lease <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">right-of-use</div></div> assets</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">2,052</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">356</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total lease assets</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="btmd:LeaseAssets" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">2,052</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="btmd:LeaseAssets" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">356</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Lease liabilities</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Current:</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Operating lease liabilities</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityCurrent" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">165</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityCurrent" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">248</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-current:</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Operating lease liabilities</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityNoncurrent" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,927</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityNoncurrent" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">127</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total lease liabilities</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:OperatingLeaseLiability" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">2,092</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:OperatingLeaseLiability" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">375</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Weighted-average remaining lease term&#8212;operating leases (years)</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonNumeric name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" contextRef="PAsOn12_31_2022" format="ixt-sec:duryear">5.92</ix:nonNumeric></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonNumeric name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" contextRef="PAsOn12_31_2021" format="ixt-sec:duryear">1.50</ix:nonNumeric></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Weighted-average discount rate&#8212;operating leases</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" contextRef="PAsOn12_31_2022" unitRef="Unit_pure" decimals="4" scale="-2" format="ixt:num-dot-decimal">8.48</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" contextRef="PAsOn12_31_2021" unitRef="Unit_pure" decimals="4" scale="-2" format="ixt:num-dot-decimal">3.75</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr></table></ix:nonNumeric><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"><ix:exclude>F-35</ix:exclude> </div></ix:continuation></div></div><ix:continuation id="TextSelectionAppend_73945693_5" continuedAt="TextSelectionAppend_73945693_6"><ix:exclude><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_73945693_6" continuedAt="TextSelectionAppend_73945693_7"><ix:exclude><hr style="color:#999999;height:3px;width:100%"/></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_73945693_7" continuedAt="TextSelectionAppend_73945693_8"><ix:exclude><div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div></ix:exclude></ix:continuation></div></div></div> <div><div><div style="background-color:white;display: inline;"><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><ix:continuation id="TextSelectionAppend_73945693_8"><ix:nonNumeric name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock" contextRef="P01_01_2022To12_31_2022" escape="true"><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following table summarizes the payments by date for the Company&#8217;s operating lease, which is then reconciled to our total lease obligation, as of December&#160;31, 2022: </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:68%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:87%"></td>
<td style="vertical-align:bottom;width:6%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">2023</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">337</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">2024</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">448</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">2025</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">464</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">2026</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">480</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">2027</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">497</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Thereafter</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">470</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total lease payments</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">2,696</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Less: Interest</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">604</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Present value of lease liabilities</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:OperatingLeaseLiability" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">2,092</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table></ix:nonNumeric></ix:continuation><div style="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&#160;</div><ix:nonNumeric name="us-gaap:IncomeTaxDisclosureTextBlock" contextRef="P01_01_2022To12_31_2022" escape="true" continuedAt="TextSelection_73945694">
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">16.</div></div></td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: left; line-height: normal;"><div style="font-weight:bold;display:inline;">INCOME TAXES </div></div></td></tr></table><ix:nonNumeric name="us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" contextRef="P01_01_2022To12_31_2022" escape="true"><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Income (loss) before provision for income taxes consisted of the following (in thousands): </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:76%"></td>
<td style="vertical-align:bottom;width:5%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:5%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Year Ended</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Domestic</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">2,221</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">33,191</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Foreign</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">509</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">286</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Income before provision for income taxes</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,712</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">32,905</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table></ix:nonNumeric><ix:nonNumeric name="us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" contextRef="P01_01_2022To12_31_2022" escape="true"><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The income tax provision for the year ended December&#160;31, 2022 and 2021 consists of the following: </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:80%"></td>
<td style="vertical-align:bottom;width:6%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:6%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Year Ended</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Current income tax provision (benefit):</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Federal</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:CurrentFederalTaxExpenseBenefit" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">749</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">State and Local</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:CurrentStateAndLocalTaxExpenseBenefit" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">377</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:CurrentStateAndLocalTaxExpenseBenefit" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">286</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Foreign</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:CurrentForeignTaxExpenseBenefit" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">5</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total current expense (benefit):</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:CurrentIncomeTaxExpenseBenefit" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,131</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:CurrentIncomeTaxExpenseBenefit" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">286</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Deferred income tax provision (benefit):</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Federal</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:DeferredFederalIncomeTaxExpenseBenefit" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">714</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">State and Local</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">29</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Foreign</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total deferred expense (benefit):</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:DeferredIncomeTaxExpenseBenefit" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">743</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total income tax provision (benefit)</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">388</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">286</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table></ix:nonNumeric><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"><ix:exclude>F-36</ix:exclude> </div></ix:nonNumeric></div></div><ix:continuation id="TextSelection_73945694" continuedAt="TextSelectionAppend_73945694_1"><ix:exclude><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_73945694_1" continuedAt="TextSelectionAppend_73945694_2"><ix:exclude><hr style="color:#999999;height:3px;width:100%"/></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_73945694_2" continuedAt="TextSelectionAppend_73945694_3"><ix:exclude><div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div></ix:exclude></ix:continuation><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><ix:continuation id="TextSelectionAppend_73945694_3" continuedAt="TextSelectionAppend_73945694_4"><ix:nonNumeric name="us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" contextRef="P01_01_2022To12_31_2022" escape="true"><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A reconciliation of the federal income tax rate to the Company&#8217;s effective tax rate for the year ended December&#160;31, 2022 and 2021 is as follows: </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:79%"></td>
<td style="vertical-align:bottom;width:5%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:4%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Year Ended</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Statutory federal income tax rate</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_pure" decimals="4" scale="-2" format="ixt:num-dot-decimal">21.00</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_pure" decimals="4" scale="-2" format="ixt:num-dot-decimal">21.00</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">State taxes, net of federal benefit</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_pure" decimals="4" scale="-2" format="ixt:num-dot-decimal">18.20</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_pure" decimals="4" scale="-2" format="ixt:num-dot-decimal">0.87</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Nontaxable partnership income</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">-<ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxExemptIncome" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_pure" decimals="4" scale="-2" sign="-" format="ixt:num-dot-decimal">41.39</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">-<ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxExemptIncome" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_pure" decimals="4" scale="-2" sign="-" format="ixt:num-dot-decimal">21.00</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Foreign rate differential</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">-<ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_pure" decimals="4" scale="-2" sign="-" format="ixt:num-dot-decimal">2.71</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_pure" decimals="4" scale="-2" format="ixt:num-dot-decimal">0.00</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Change in valuation allowance</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_pure" decimals="4" scale="-2" format="ixt:num-dot-decimal">27.55</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_pure" decimals="4" scale="-2" format="ixt:num-dot-decimal">0.00</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_pure" decimals="4" scale="-2" format="ixt:num-dot-decimal">22.65</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_pure" decimals="4" scale="-2" format="ixt:num-dot-decimal">0.87</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table></ix:nonNumeric><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company&#8217;s significant rate reconciliation items are driven primarily by state taxes, permanent differences associated with Holdings&#8217; flowthrough income and the recognition of a valuation allowance. </div><ix:nonNumeric name="us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" contextRef="P01_01_2022To12_31_2022" escape="true"><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company&#8217;s net deferred tax assets (liabilities) as of December&#160;31, 2022 and 2021 is as follows: </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:80%"></td>
<td style="vertical-align:bottom;width:5%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:5%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Year Ended</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Deferred tax assets:</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Outside basis difference in partnership</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:DeferredTaxAssetsInvestments" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,173</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Net operating loss carryforwards</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">164</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Intangibles</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">978</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total deferred tax assets</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:DeferredTaxAssetsGross" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">2,315</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Valuation allowance</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:DeferredTaxAssetsValuationAllowance" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">477</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Deferred tax assets, net of allowance</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:DeferredTaxAssetsNet" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,838</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table></ix:nonNumeric><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of December&#160;31, 2022, the Company had a foreign net operating losses of $<ix:nonFraction name="us-gaap:OperatingLossCarryforwards" contextRef="PAsOn12_31_2022_ForeignCountryMemberusgaapIncomeTaxAuthorityAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">0.5</ix:nonFraction>&#160;million, which begin to expire in <ix:nonNumeric name="btmd:OperatingLossCarryforwardsExpirationYear" contextRef="P01_01_2022To12_31_2022_ForeignCountryMemberusgaapIncomeTaxAuthorityAxis">2032</ix:nonNumeric>. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In assessing the realization of deferred tax assets, management considers whether it is more likely than not that some portion or all of the deferred tax assets will not be realized. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income during the periods in which temporary differences representing future deductible amounts become deductible. Management considers the scheduled reversal of deferred tax assets, projected future taxable income and tax planning strategies in making this assessment. After consideration of all the information available, management has recorded a valuation allowance against the foreign net operating losses and the portion of outside basis difference related to Holdings&#8217; permanent book/tax differences. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The calculation of our tax liabilities involves dealing with uncertainties in the application of complex tax laws and regulations for both federal taxes and the many states in which we operate or do business in. ASC 740 states that a tax benefit from an uncertain tax position may be recognized when it is more likely than not that the position will be sustained upon examination, including resolutions of any related appeals or litigation processes, on the basis of the technical merits. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We record uncertain tax positions as liabilities in accordance with ASC 740 and adjust these liabilities when our judgment changes as a result of the evaluation of new information not previously available. Because of the complexity of some of these uncertainties, the ultimate resolution may result in a payment that is materially </div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"><ix:exclude>F-37</ix:exclude> </div></ix:continuation></div></div><ix:continuation id="TextSelectionAppend_73945694_4" continuedAt="TextSelectionAppend_73945694_5"><ix:exclude><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_73945694_5" continuedAt="TextSelectionAppend_73945694_6"><ix:exclude><hr style="color:#999999;height:3px;width:100%"/></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_73945694_6" continuedAt="TextSelectionAppend_73945694_7"><ix:exclude><div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div></ix:exclude></ix:continuation></div></div></div> <div><div><div style="background-color:white;display: inline;"><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><ix:continuation id="TextSelectionAppend_73945694_7"><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">different from our current estimate of the unrecognized tax benefit liabilities. These differences will be reflected as increases or decreases to income tax expense in the period in which new information is available. As of December&#160;31, 2022 and 2021 we have <ix:nonFraction name="us-gaap:UnrecognizedTaxBenefits" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt-sec:numwordsen"><ix:nonFraction name="us-gaap:UnrecognizedTaxBenefits" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction>t recorded any uncertain tax positions in our financial statements. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company files tax returns as prescribed by the tax laws of the jurisdictions in which it operates. In the normal course of business, the Company is subject to examination by federal and state jurisdictions, where applicable. <ix:nonNumeric name="us-gaap:IncomeTaxExaminationDescription" contextRef="P01_01_2022To12_31_2022">There are currently no pending tax examinations. The Company&#8217;s tax years are still open under statute from December 31, 2019, to the present.</ix:nonNumeric> The resolution of tax matters is not expected to have a material effect on the Company&#8217;s consolidated financial statements. </div><div style="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&#160;</div></ix:continuation><ix:nonNumeric name="us-gaap:EarningsPerShareTextBlock" contextRef="P01_01_2022To12_31_2022" escape="true" continuedAt="TextSelection_73945695">
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">17.</div></div></td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: left; line-height: normal;"><div style="font-weight:bold;display:inline;">NET LOSS PER COMMON SHARE </div></div></td></tr></table><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The computation of basic and diluted net loss per common share is based on net loss attributable to Biote stockholders divided by the basic and diluted weighted average number of shares of Class&#160;A common stock outstanding, each for the period subsequent to the consummation of the Business Combination. <ix:nonNumeric name="us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" contextRef="P01_01_2022To12_31_2022" escape="true" continuedAt="TextSelection_73945756">The following table sets forth the computation of net loss per common share: </ix:nonNumeric></div><ix:continuation id="TextSelection_73945756"><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:68%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:80%"></td>
<td style="vertical-align:bottom;width:14%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Year Ended</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,<br/> 2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Net loss per common share</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Numerator:</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Net loss attributable to biote Corp. stockholders (basic and diluted)</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">969</ix:nonFraction></ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Denominator:</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Weighted average shares outstanding (basic and diluted)</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal">8,059,371</ix:nonFraction></ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Net loss per common share</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Basic</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD_per_Share" decimals="2" scale="0" sign="-" format="ixt:num-dot-decimal">0.12</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Diluted</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:EarningsPerShareDiluted" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD_per_Share" decimals="2" scale="0" sign="-" format="ixt:num-dot-decimal">0.12</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr></table></ix:continuation><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On the Closing Date, the Company completed the Business Combination which materially impacted the number of shares outstanding, and the Company was organized in an <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Up-C</div> structure. Net loss per common share information for the year ended December&#160;31, 2022 has been presented on a prospective basis and reflects only the net loss attributable to holders of Biote&#8217;s Class&#160;A common stock, as well as both basic and diluted weighted average Class&#160;A common stock outstanding, for the period from the Closing Date through December&#160;31, 2022. Net loss per common share information prior to the Closing Date is not presented since the ownership structure of Holdings is not a common unit of ownership of the Company, and the resulting values would not be meaningful to the users of the consolidated financial statements. Net loss per common share is not separately presented for Class&#160;V voting stock since it has no economic rights to the income or loss of the Company. Class&#160;V voting stock is considered in the calculation of dilutive net loss per common share on an <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">if-converted</div> basis as these shares, together with the related Holdings Units, have Exchange Rights into Class&#160;A common stock that could result in additional Class&#160;A common stock being issued. All other potentially dilutive securities are determined based on the treasury stock method. See Note 1 for more information regarding the Business Combination. </div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"><ix:exclude>F-38</ix:exclude> </div></ix:nonNumeric></div></div><ix:continuation id="TextSelection_73945695" continuedAt="TextSelectionAppend_73945695_1"><ix:exclude><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_73945695_1" continuedAt="TextSelectionAppend_73945695_2"><ix:exclude><hr style="color:#999999;height:3px;width:100%"/></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_73945695_2" continuedAt="TextSelectionAppend_73945695_3"><ix:exclude><div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div></ix:exclude></ix:continuation><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><ix:continuation id="TextSelectionAppend_73945695_3"><ix:nonNumeric name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" contextRef="P01_01_2022To12_31_2022" escape="true"><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company excluded the following potential shares, presented based on amounts outstanding at each period end, from the computation of diluted weighted average shares outstanding for the periods indicated because including them would have had an antidilutive effect: </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:68%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:80%"></td>
<td style="vertical-align:bottom;width:5%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Year Ended</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,<br/> 2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">RSUs</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="P01_01_2022To12_31_2022_RestrictedStockUnitsRSUMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal">1,622,840</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Stock Options</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="P01_01_2022To12_31_2022_EmployeeStockOptionMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal">5,042,628</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Class&#160;V Voting Stock</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="P01_01_2022To12_31_2022_ClassVCommonStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal">48,565,824</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Public Warrants</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="P01_01_2022To12_31_2022_PublicWarrantsMemberusgaapClassOfWarrantOrRightAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal">7,937,466</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Private Placement Warrants</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="P01_01_2022To12_31_2022_PrivatePlacementWarrantsMemberusgaapClassOfWarrantOrRightAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal">5,566,666</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Earnout Voting Shares</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="P01_01_2022To12_31_2022_EarnoutVotingSharesMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal">10,000,000</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Sponsor Earnout Shares</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="P01_01_2022To12_31_2022_SponsorEarnOutSharesMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal">1,587,500</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal">80,322,924</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table></ix:nonNumeric></ix:continuation><div style="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&#160;</div><ix:nonNumeric name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" contextRef="P01_01_2022To12_31_2022" escape="true" continuedAt="TextSelection_73945696">
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">18.</div></div></td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: left; line-height: normal;"><div style="font-weight:bold;display:inline;">COMMITMENTS AND CONTINGENCIES </div></div></td></tr></table><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Litigation Risk </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">From time to time, the Company may become involved in various legal actions arising in the ordinary course of business. Management is of the opinion that the ultimate liability, if any, from these actions will not have a material effect on its financial condition or results of operations. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company is currently involved in litigation described below with one of the Company&#8217;s stockholders, Dr.&#160;Gary&#160;S. Donovitz (&#8220;Donovitz&#8221;) (the &#8220;Donovitz Litigation&#8221;). The outcome of the Donovitz Litigation, regardless of the merits, is inherently uncertain. At this point in time, the Company cannot predict the length of the Donovitz Litigation or the ultimate liability, if any, which may arise therefrom. In addition, litigation and related matters are costly and may divert the attention of the Company&#8217;s management and other resources that would otherwise be engaged in other activities. However, the Donovitz Litigation is not expected to have a material adverse effect on the consolidated results of operations or financial position of the Company. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On <ix:nonNumeric name="us-gaap:LossContingencyLawsuitFilingDate" contextRef="P01_01_2022To12_31_2022">June 23, 2022</ix:nonNumeric>, <ix:nonNumeric name="us-gaap:LossContingencyNameOfPlaintiff" contextRef="P06_23_2022To06_23_2022">Donovitz</ix:nonNumeric> sued <ix:nonNumeric name="us-gaap:LossContingencyNameOfDefendant" contextRef="P06_23_2022To06_23_2022">Haymaker Sponsor, LLC</ix:nonNumeric>, the Company&#8217;s outside legal counsel, and certain Company executive officers and directors in the District Court of Dallas County, Texas. Donovitz alleges that the defendants made a variety of false promises regarding Donovitz&#8217;s future role in the Company, the protection of Donovitz&#8217;s interests, and the continuance of Donovitz&#8217;s seminars and training programs subsequent to the completion of the Business Combination. Otherwise, Donovitz claims he would not have agreed to the arrangements that led to the completion of the Business Combination and related transactions. Donovitz generally alleges fraud, negligent misrepresentation, a breach of the covenant of good faith and fair dealing, and breaches of fiduciary duties against the defendants (the &#8220;Donovitz Claims&#8221;). Donovitz seeks monetary relief exceeding $<ix:nonFraction name="us-gaap:LossContingencyDamagesSoughtValue" contextRef="P06_23_2022To06_23_2022" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">1.0</ix:nonFraction>&#160;million, including, but not limited to, actual damages, damages to be determined at trial, punitive damages, attorneys&#8217; fees, and equitable relief such as profit disgorgement, fee forfeiture, recession, and constructive trust. While not a direct party to the lawsuit, the Company believes that the allegations contained in the complaint are without merit and intends to participate in the defense of the litigation. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On July&#160;11, 2022, the Company sued Donovitz in the Delaware Court of Chancery, pursuing injunctive relief to prevent Donovitz from proceeding with the litigation over the Donovitz Claims in Texas. The Company seeks to enforce (a)&#160;the Company&#8217;s certificate of incorporation, which mandates that stockholders must bring certain actions, including some or all of the Donovitz Claims, exclusively in Delaware, and (b)&#160;the Business Combination Agreement, by which Donovitz consented to the exclusive jurisdiction of the Delaware Court of Chancery and agreed that Delaware law governs any related claims, including some or all of the Donovitz Claims. Pending a ruling from the Delaware Court of Chancery, Donovitz agreed to stay all answer dates in that </div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"><ix:exclude>F-39</ix:exclude> </div></ix:nonNumeric></div></div><ix:continuation id="TextSelection_73945696" continuedAt="TextSelectionAppend_73945696_1"><ix:exclude><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_73945696_1" continuedAt="TextSelectionAppend_73945696_2"><ix:exclude><hr style="color:#999999;height:3px;width:100%"/></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_73945696_2" continuedAt="TextSelectionAppend_73945696_3"><ix:exclude><div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div></ix:exclude></ix:continuation></div></div></div> <div><div><div style="background-color:white;display: inline;"><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><ix:continuation id="TextSelectionAppend_73945696_3"><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">lawsuit in Texas. Then, on March&#160;23, 2023, Donovitz filed an amended answer and counterclaims alleging what appear to be the same as the Donovitz Claims originally filed in Texas. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On August&#160;2, 2022, the Company sued Donovitz, Lani Hammonds Donovitz, and Lani D. Consulting in the District Court of Dallas County, Texas, seeking injunctive relief to enforce <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-disparagement</div> obligations of that certain founder advisory agreement with Donovitz and the independent contractor agreement with Lani Hammonds Donovitz, both of which were entered into by the subject parties in connection with the Business Combination. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On August&#160;23, 2022, the defendants filed an answer, which included affirmative defenses to the Company&#8217;s claims and certain counterclaims and third-party claims against certain executive officers of the Company. The affirmative defenses included repudiation, fraud, breach of contract, unclean hands, and laches. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The counterclaims and third-party claims included claims for fraud, breach of fiduciary duty, breach of contract, and defamation, as well as other related claims. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company successfully obtained a temporary restraining order to enforce the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-disparagement</div> obligations of Donovitz and Lani Hammonds Donovitz. The parties subsequently entered into an agreed order that the temporary restraining order will stay in effect until the entry of a final judgment. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A jury trial was scheduled to commence on January&#160;3, 2023, to address the Company&#8217;s request for a permanent injunction, as well as adjudicate the affirmative defenses, with all remaining claims, counterclaims and third-party claims to be tried at a later date. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">After the filing of this lawsuit, the Company amended its claim in the Delaware Court of Chancery to also seek an injunction to prevent Donovitz from proceeding with certain of the affirmative defenses, counterclaims, and third-party claims filed by the defendants on August&#160;23, 2022. On November&#160;4, 2022, the Delaware Court of Chancery denied that request for injunctive relief, permitting the Texas lawsuit filed by the Company and all affirmative defenses and claims asserted therein to proceed in Texas. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Subsequently, the parties agreed that the trial on the Company&#8217;s claim for breach of contract, including its request for a permanent injunction, will be consolidated with a trial on the previously filed counterclaims and third-party claims. Prior to that agreement being reached, Donovitz and Lani Hammonds Donovitz filed an amended pleading which did not include any of their previously asserted affirmative defenses or assert any new affirmative defenses. It was also agreed that if Donovitz and or Lani Hammonds Donovitz seek leave to add any affirmative defenses before the final trial, at most they would be allowed to assert laches, unclean hands or mistake, and only if they can convince the trial court that any or all of those affirmative defenses would have qualified as claims that could have been non suited at the time they filed their amended pleading asserting no affirmative defenses. A jury trial is scheduled to commence on September&#160;11, 2023. The temporary restraining order entered against Gary Donovitz and Lani Hammonds Donovitz remains in effect until the entry of a final judgment. </div><div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Tax Distributions </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">To the extent the Company has funds legally available, the board of directors will approve distributions to each stockholder on a quarterly basis, in an amount per share that, when added to all other distributions made to such stockholder with respect to the previous calendar year, equals the estimated federal and state income tax liabilities applicable to such stockholder as the result of its, his or her ownership of the units and the associated net taxable income allocated with respect to such units for the previous calendar year. </div></ix:continuation><div style="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&#160;</div><ix:nonNumeric name="us-gaap:RelatedPartyTransactionsDisclosureTextBlock" contextRef="P01_01_2022To12_31_2022" escape="true" continuedAt="TextSelection_73945697">
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">19.</div></div></td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: left; line-height: normal;"><div style="font-weight:bold;display:inline;">RELATED-PARTY TRANSACTIONS </div></div></td></tr></table><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company utilizes a professional services firm to perform accounting and tax services for the Company. Trusts whose beneficiaries are the children of a partner of the firm hold shares of our Class&#160;V voting stock. Fees </div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"><ix:exclude>F-40</ix:exclude> </div></ix:nonNumeric></div></div><ix:continuation id="TextSelection_73945697" continuedAt="TextSelectionAppend_73945697_1"><ix:exclude><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_73945697_1" continuedAt="TextSelectionAppend_73945697_2"><ix:exclude><hr style="color:#999999;height:3px;width:100%"/></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_73945697_2" continuedAt="TextSelectionAppend_73945697_3"><ix:exclude><div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div></ix:exclude></ix:continuation><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><ix:continuation id="TextSelectionAppend_73945697_3"><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">paid to the firm were $<ix:nonFraction name="us-gaap:ProfessionalFees" contextRef="P01_01_2022To12_31_2022_FirmMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">31</ix:nonFraction> and $<ix:nonFraction name="us-gaap:ProfessionalFees" contextRef="P01_01_2021To12_31_2021_FirmMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">456</ix:nonFraction> during the years ended December&#160;31, 2022 and 2021, respectively. Amounts due to the firm as of December&#160;31, 2022 and December&#160;31, 2021 were $<ix:nonFraction name="us-gaap:DueToRelatedPartiesCurrentAndNoncurrent" contextRef="PAsOn12_31_2022_FirmMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">0</ix:nonFraction> and $<ix:nonFraction name="us-gaap:DueToRelatedPartiesCurrentAndNoncurrent" contextRef="PAsOn12_31_2021_FirmMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">0</ix:nonFraction>, respectively. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A former employee of the Company is the beneficiary of a trust which holds shares of our Class&#160;V voting stock, as well as being the child of the Company&#8217;s founder who beneficially owns shares of our Class&#160;V voting stock. Compensation paid to the former employee was $<ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="P01_01_2022To12_31_2022_EmployeeMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">100</ix:nonFraction> and $<ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="P01_01_2021To12_31_2021_EmployeeMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">201</ix:nonFraction> for the years ended December&#160;31, 2022 and 2021, respectively. Amounts due to the former employee were $<ix:nonFraction name="us-gaap:DueToRelatedPartiesCurrentAndNoncurrent" contextRef="PAsOn12_31_2022_EmployeeMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">0</ix:nonFraction> and $<ix:nonFraction name="us-gaap:DueToRelatedPartiesCurrentAndNoncurrent" contextRef="PAsOn12_31_2021_EmployeeMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">0</ix:nonFraction> as of December&#160;31, 2022 and December&#160;31, 2021, respectively. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition to their previous employment by the Company, the above referenced former employee also owns a clinic which was a customer of the Company. Revenues recognized from sales to this customer were $<ix:nonFraction name="us-gaap:DeferredRevenueRevenueRecognized1" contextRef="P01_01_2022To12_31_2022_EmployeeMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">458</ix:nonFraction> and $<ix:nonFraction name="us-gaap:DeferredRevenueRevenueRecognized1" contextRef="P01_01_2021To12_31_2021_EmployeeMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">744</ix:nonFraction> for the years ended December&#160;31, 2022 and 2021, respectively. Amounts due from this customer were $<ix:nonFraction name="us-gaap:DueFromCustomerAcceptances" contextRef="PAsOn12_31_2022_EmployeeMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">0</ix:nonFraction> and $<ix:nonFraction name="us-gaap:DueFromCustomerAcceptances" contextRef="PAsOn12_31_2021_EmployeeMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">57</ix:nonFraction> as of December&#160;31, 2022 and December&#160;31, 2021, respectively. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A former employee of the Company is the spouse of the Company&#8217;s founder who beneficially owns shares of our Class&#160;V voting stock. Compensation paid to the former employee was $<ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="P01_01_2022To12_31_2022_SpouseOfFounderChairmanAndBeneficialOwnerMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">158</ix:nonFraction> and $<ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="P01_01_2021To12_31_2021_SpouseOfFounderChairmanAndBeneficialOwnerMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">285</ix:nonFraction> for the years ended December&#160;31, 2022 and 2021, respectively. Amounts due to the former employee were $<ix:nonFraction name="us-gaap:DueToEmployeesCurrentAndNoncurrent" contextRef="PAsOn12_31_2022_SpouseOfFounderChairmanAndBeneficialOwnerMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">0</ix:nonFraction> and $<ix:nonFraction name="us-gaap:DueToEmployeesCurrentAndNoncurrent" contextRef="PAsOn12_31_2021_SpouseOfFounderChairmanAndBeneficialOwnerMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">0</ix:nonFraction> as of December&#160;31, 2022 and December&#160;31, 2021, respectively. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company purchases dietary supplements inventories from a vendor in which the Company&#8217;s founder holds a minority interest. Inventory purchases from this vendor were $<ix:nonFraction name="btmd:InventoryPurchases" contextRef="P01_01_2022To12_31_2022_VendorMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,304</ix:nonFraction> and $<ix:nonFraction name="btmd:InventoryPurchases" contextRef="P01_01_2021To12_31_2021_VendorMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">888</ix:nonFraction> for the years ended December&#160;31, 2022 and 2021, respectively. Amounts due to the vendor were $<ix:nonFraction name="us-gaap:DueToRelatedPartiesCurrentAndNoncurrent" contextRef="PAsOn12_31_2022_VendorMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">151</ix:nonFraction> and $<ix:nonFraction name="us-gaap:DueToRelatedPartiesCurrentAndNoncurrent" contextRef="PAsOn12_31_2021_VendorMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">0</ix:nonFraction> as of December&#160;31, 2022 and December&#160;31, 2021, respectively. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On May&#160;18, 2022, BioTE Medical and Dr.&#160;Gary&#160;S. Donovitz entered into a founder advisory agreement, effective as of, and contingent upon, the Closing. Pursuant to the founder advisory agreement, Dr.&#160;Gary&#160;S. Donovitz transitioned from an officer and manager of BioTE Medical into the role of Founder Advisor and Senior Advisor (as defined in the founder advisory agreement) as of the Closing. Pursuant to the founder advisory agreement, Dr.&#160;Gary&#160;S. Donovitz provides strategic advisory services to BioTE Medical for a period of <ix:nonNumeric name="btmd:AgreementTerm" contextRef="P05_18_2022To05_18_2022_DirectorMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_FounderAdvisoryAgreementMemberusgaapTypeOfArrangementAxis" format="ixt-sec:durwordsen">four years</ix:nonNumeric> from the Closing, unless terminated earlier pursuant to the terms of the founder advisory agreement, and will receive an annual fee equal to $<ix:nonFraction name="btmd:AnnualAdviosryFeesPayable" contextRef="PAsOn05_18_2022_DirectorMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_FounderAdvisoryAgreementMemberusgaapTypeOfArrangementAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">300</ix:nonFraction> per year, continued coverage under BioTE Medical&#8217;s employee benefits and reimbursement for reasonable and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-approved</div> business expenses. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On May&#160;18, 2022, BioTE Medical entered into an independent contractor agreement with Lani D. Consulting, a company affiliated with Lani Hammonds Donovitz, the wife of Dr.&#160;Gary&#160;S. Donovitz (the &#8220;New Independent Contractor Agreement&#8221;). Immediately upon the Closing, the New Independent Contractor Agreement replaced the independent contractor agreement dated as of May&#160;3, 2021, between Lani D. Consulting and BioTE Medical. Pursuant to the New Independent Contractor Agreement, Lani D. Consulting provides certain services to BioTE Medical for a period of <ix:nonNumeric name="btmd:AgreementTerm" contextRef="P05_18_2022To05_18_2022_ConsultantMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_NewIndependentContractorAgreementMemberusgaapTypeOfArrangementAxis" format="ixt-sec:durwordsen">four years</ix:nonNumeric> from the Closing, unless terminated earlier pursuant to the terms of the New Independent Contractor Agreement, and will receive an annual fee equal to $<ix:nonFraction name="btmd:AnnualAdviosryFeesPayable" contextRef="PAsOn05_18_2022_ConsultantMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_NewIndependentContractorAgreementMemberusgaapTypeOfArrangementAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">250</ix:nonFraction> per year and reimbursement for reasonable and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-approved</div> business expenses. BioTE Medical terminated Ms.&#160;Donovitz for cause, effective September&#160;9, 2022. </div></ix:continuation><div style="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&#160;</div><ix:nonNumeric name="us-gaap:SubsequentEventsTextBlock" contextRef="P01_01_2022To12_31_2022" escape="true">
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">20.</div></div></td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: left; line-height: normal;"><div style="font-weight:bold;display:inline;">SUBSEQUENT EVENTS </div></div></td></tr></table><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company evaluated subsequent events from December&#160;31, 2022, the date of these consolidated financial statements, through March&#160;29, 2023, which represents the date the consolidated financial statements were issued, for events requiring adjustment to or disclosure in these consolidated financial statements. There are no material events that require adjustment to or disclosure in these consolidated financial statements. </div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div></ix:nonNumeric><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">F-41 </div></div></div></div></div></div>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="line-height:2.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:2.00pt solid #000000">&#160;</p> <p style="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&#160;</p> <p style="font-size:24pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt;margin-bottom:0pt;text-align:center">


<img src="g479690g00z01.jpg" alt="LOGO" />
 </p> <p style="font-size:320pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&#160;</p> <p style="line-height:4.5pt;margin-top:0pt;margin-bottom:2pt;border-bottom:2.00pt solid #000000">&#160;</p>
</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">PART II </p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">Information Not Required in Prospectus </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Item&#160;13. Other Expenses of Issuance and Distribution. </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following is an estimate of the expenses (all of which are to be paid by the registrant) that we may incur in connection with the securities being registered hereby. All amounts shown are estimates except for the SEC registration fee. </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:68%;border:0;margin:0 auto">


<tr>

<td style="width:79%"></td>

<td style="vertical-align:bottom;width:6%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Amount</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">SEC registration fee</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1,812.29</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Legal fees and expenses*</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">125,000.00</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accounting fees and expenses*</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">25,000.00</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Printing fees*</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">125,000.00</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Miscellaneous fees and expenses*</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">20,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total expenses</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">296,812.29</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
</table> <p style="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">*</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Estimated solely for the purposes of this Item 13. Actual expenses may vary. </p></td></tr></table> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Item&#160;14. Indemnification of Directors and Officers. </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&#160;145(a) of the DGCL provides, in general, that a corporation may indemnify any person who was or is a party to or is threatened to be made a party to any threatened, pending or completed action, suit or proceeding, whether civil, criminal, administrative or investigative (other than an action by or in the right of the corporation), because he or she is or was a director, officer, employee or agent of the corporation, or is or was serving at the request of the corporation as a director, officer, employee or agent of another corporation, partnership, joint venture, trust or other enterprise, against expenses (including attorneys&#8217; fees), judgments, fines and amounts paid in settlement actually and reasonably incurred by the person in connection with such action, suit or proceeding, if he or she acted in good faith and in a manner he or she reasonably believed to be in or not opposed to the best interests of the corporation and, with respect to any criminal action or proceeding, had no reasonable cause to believe his or her conduct was unlawful. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&#160;145(b) of the DGCL provides, in general, that a corporation may indemnify any person who was or is a party or is threatened to be made a party to any threatened, pending or completed action or suit by or in the right of the corporation to procure a judgment in its favor because the person is or was a director, officer, employee or agent of the corporation, or is or was serving at the request of the corporation as a director, officer, employee or agent of another corporation, partnership, joint venture, trust or other enterprise, against expenses (including attorneys&#8217; fees) actually and reasonably incurred by the person in connection with the defense or settlement of such action or suit if he or she acted in good faith and in a manner he or she reasonably believed to be in or not opposed to the best interests of the corporation, except that no indemnification shall be made with respect to any claim, issue or matter as to which he or she shall have been adjudged to be liable to the corporation unless and only to the extent that the Court of Chancery or other adjudicating court determines that, despite the adjudication of liability but in view of all of the circumstances of the case, he or she is fairly and reasonably entitled to indemnity for such expenses that the Court of Chancery or other adjudicating court shall deem proper. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&#160;145(g) of the DGCL provides, in general, that a corporation may purchase and maintain insurance on behalf of any person who is or was a director, officer, employee or agent of the corporation, or is or was serving at the request of the corporation as a director, officer, employee or agent of another corporation, partnership, joint venture, trust or other enterprise against any liability asserted against such person and incurred by such person in any such capacity, or arising out of his or her status as such, whether or not the corporation would have the power to indemnify the person against such liability under Section&#160;145 of the DGCL. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">II-1 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Additionally, our second amended and restated certificate of incorporation (the &#8220;Charter&#8221;) provides that our officers and directors will be indemnified by us to the fullest extent authorized by Delaware law, as it now exists or may in the future be amended. In addition, our Charter provides that our directors will not be personally liable for monetary damages to us or our stockholders for breaches of their fiduciary duty as directors, unless they violated their duty of loyalty to us or our stockholders, acted in bad faith, knowingly or intentionally violated the law, authorized unlawful payments of dividends, unlawful stock purchases or unlawful redemptions, or derived an improper personal benefit from their actions as directors. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have entered into agreements with our officers and directors to provide contractual indemnification in addition to the indemnification provided for in the Charter. Our Bylaws also permit us to secure insurance on behalf of any officer, director or employee for any liability arising out of his or her actions, regardless of whether Delaware law would permit such indemnification. We have purchased a policy of directors&#8217; and officers&#8217; liability insurance that insures our officers and directors against the cost of defense, settlement or payment of a judgment in some circumstances and insures us against our obligations to indemnify our officers and directors. Our officers and directors have agreed to waive (and any other persons who may become an officer or director prior to the initial business combination will also be required to waive) any right, title, interest or claim of any kind in or to any monies in the trust account, and not to seek recourse against the trust account for any reason whatsoever, including with respect to such indemnification. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">These provisions may discourage stockholders from bringing a lawsuit against our directors for breach of their fiduciary duty. These provisions also may have the effect of reducing the likelihood of derivative litigation against officers and directors, even though such an action, if successful, might otherwise benefit us and our stockholders. Furthermore, a stockholder&#8217;s investment may be adversely affected to the extent we pay the costs of settlement and damage awards against officers and directors pursuant to these indemnification provisions. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Insofar as indemnification for liabilities arising under the Securities Act may be permitted to directors, officers, or control persons, in the opinion of the SEC, such indemnification is against public policy as expressed in the Securities Act and is therefore unenforceable. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Item&#160;15. Recent Sales of Unregistered Securities. </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Transaction Consideration </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On the Closing Date, as consideration for consummating the Business Combination in accordance with the Business Combination Agreement, we issued 58,565,824 shares of newly authorized Class&#160;V Voting Stock to the Members, which number of shares of Class&#160;V Voting Stock was equal to the number of Biote Units retained by the Members immediately following the Closing. 10,000,000 of these shares of Class&#160;V Voting Stock are subject to forfeiture if the earnout Triggering Events are not achieved. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Standby Equity Purchase Agreement </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On July&#160;27, 2022, the Company issued 25,000 shares of Class&#160;A Common Stock to Yorkville upon execution of the Purchase Agreement in consideration of Yorkville&#8217;s entry into the Purchase Agreement, pursuant to which, subject to certain conditions, Yorkville has certain obligations to purchase shares of Common Stock from the Company. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On September&#160;16, 2022, we received cash proceeds of approximately $0.2&#160;million in connection with the issuance of 40,000 shares of Class&#160;A common stock under the SEPA. On October&#160;20, 2022, we received cash proceeds of approximately $0.3&#160;million in connection with the issuance of 65,559 shares of Class&#160;A common stock. We expect to use any net proceeds from such sales for working capital and general corporate purposes. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Settlement Agreement </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On January&#160;6, 2023, we issued 375,000 shares of Class&#160;A common stock pursuant to the settlement of litigation with a former employee, for which we did not receive proceeds. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">II-2 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Each of the foregoing issuances were issued in reliance on the exemption from registration requirements thereof provided by Section&#160;4(a)(2) of the Securities Act and/or Regulation D promulgated thereunder as a transaction by an issuer not involving a public offering. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Item&#160;16. Exhibits. </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">


<tr>

<td></td>

<td style="vertical-align:bottom;width:4%"></td>
<td style="width:92%"></td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#160;&#160;2.1&#8224;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1819253/000119312521356831/d225433dex21.htm">Business Combination Agreement, dated as of December&#160;13, 2021, by and among the Company, Haymaker Sponsor III LLC, Dr.&#160;Gary Donovitz, in his capacity, and Teresa S. Weber, in her capacity as the Members&#8217; Representative (incorporated by reference to Exhibit 2.1 of Haymaker Acquisition Corp. III&#8217;s Current Report on Form <span style="white-space:nowrap">8-K</span> (File <span style="white-space:nowrap">No.&#160;001-40128)</span> filed with the SEC on December&#160;14, 2021). </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#160;&#160;3.1</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/0001819253/000119312522166249/d342736dex31.htm">Second Amended and Restated Certificate of Incorporation of biote Corp. (Incorporated by reference to Exhibit 3.1 to the Company&#8217;s Current Report on Form <span style="white-space:nowrap">8-K</span> (File <span style="white-space:nowrap">No.&#160;001-40128)</span> filed by the Company with the SEC on June&#160;2, 2022).</a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#160;&#160;3.2</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1819253/000119312523044861/d459867dex31.htm">Amended and Restated Bylaws of biote Corp. (Incorporated by reference to Exhibit 3.1 to the Company&#8217;s Current Report on Form <span style="white-space:nowrap">8-K</span> (File <span style="white-space:nowrap">No.&#160;001-40128)</span> filed by the Company with the SEC on February&#160;22, 2023).</a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#160;&#160;4.1</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/0001819253/000119312522166249/d342736dex41.htm">Form of Warrant Certificate (Incorporated by reference to Exhibit 4.1 to the Company&#8217;s Current Report on Form <span style="white-space:nowrap">8-K</span> (File <span style="white-space:nowrap">No.&#160;001-40128)</span> filed by the Company with the SEC on June&#160;2, 2022).</a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#160;&#160;4.2</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/0001819253/000119312521071532/d97629dex41.htm">Warrant Agreement, dated March&#160;1, 2021, by and between the Company and Continental Stock Transfer&#160;&amp; Trust Company, as Warrant Agent (incorporated by reference to exhibit 4.1 of the Company&#8217;s Current Report on Form <span style="white-space:nowrap">8-K</span> (File <span style="white-space:nowrap">No.&#160;001-40128)</span> filed with the SEC on March&#160;5, 2021).</a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#160;&#160;5.1**</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1819253/000119312522176642/d256890dex51.htm">Opinion of Cooley, LLP. </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">10.1#</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1819253/000095017023010664/btmd-ex10_1.htm"><span style="white-space:nowrap">Non-Employee</span> Director Compensation Policy. (Incorporated by reference to Exhibit 10.1 to the Company&#8217;s Annual Report on Form <span style="white-space:nowrap">10-K</span> (File <span style="white-space:nowrap">No.&#160;001-40128)</span> filed by the Company with the SEC on March&#160;29, 2023). </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">10.2</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/0001819253/000119312522166249/d342736dex101.htm">Tax Receivable Agreement, dated as of May&#160;26, 2022, by and among the Company, BioTE Holdings, LLC and the persons named therein. (incorporated by reference to Exhibit 10.1 of the Company&#8217;s Current Report on Form <span style="white-space:nowrap">8-K</span> (File <span style="white-space:nowrap">No.&#160;001-40128)</span> filed with the SEC on June&#160;2, 2022). </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">10.3</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/0001819253/000119312522166249/d342736dex102.htm">Investor Rights Agreement, dated as of May&#160;26, 2022, by and among the Company, the Members, the Members&#8217; Representative, Haymaker Sponsor III LLC and certain other parties thereto (incorporated by reference to Exhibit 10.2 of the Company&#8217;s Current Report on Form <span style="white-space:nowrap">8-K</span> (File <span style="white-space:nowrap">No.&#160;001-40128)</span> filed with the SEC on June&#160;2, 2022).</a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">10.4</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1819253/000119312522196992/d374974dex101.htm">Amended and Restated Investor Rights Agreement, dated as of July&#160;19, 2022, by and among the Company, the Members, the Members&#8217; Representative, Haymaker Sponsor III LLC and certain other parties thereto (incorporated by reference to Exhibit 10.1 to the Company&#8217;s Current Report on Form <span style="white-space:nowrap">8-K</span> (File <span style="white-space:nowrap">No.&#160;001-40128)</span> filed by the Company with the SEC on July&#160;19, 2022).</a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">10.5</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/0001819253/000119312522166249/d342736dex103.htm">Second Amended and Restated Operating Agreement of BioTE Holdings, LLC (incorporated by reference to Exhibit 10.3 of the Company&#8217;s Current Report on Form <span style="white-space:nowrap">8-K</span> (File <span style="white-space:nowrap">No.&#160;001-40128)</span> filed with the SEC on June&#160;2, 2022). </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">10.6#</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/0001819253/000119312522166249/d342736dex104.htm">Form of Indemnification Agreement (incorporated by reference to Exhibit 10.4 of the Company&#8217;s Current Report on Form <span style="white-space:nowrap">8-K</span> (File <span style="white-space:nowrap">No.&#160;001-40128)</span> filed with the SEC on June&#160;2, 2022). </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">10.7#</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1819253/000119312522166249/d342736dex105.htm">Services Agreement, dated May&#160;26, 2022, by and between BioTE Medical, LLC and Teresa S. Weber. (incorporated by reference to Exhibit 10.5 of the Company&#8217;s Current Report on Form <span style="white-space:nowrap">8-K</span> <span style="white-space:nowrap">(File&#160;No.&#160;001-40128)</span> filed with the SEC on June&#160;2, 2022).</a></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">II-3 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">


<tr>

<td></td>

<td style="vertical-align:bottom;width:4%"></td>
<td style="width:90%"></td></tr>

<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">10.8#</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1819253/000119312522176642/d256890dex106.htm">Services Agreement, effective as of May&#160;26, 2022, by and between BioTE Medical, LLC and Marc Beer. (Incorporated by reference to Exhibit 10.6 to the Company&#8217;s registration statement on Form <span style="white-space:nowrap">S-1</span> (File <span style="white-space:nowrap">No.&#160;333-265714)</span> filed by the Company with the SEC on June&#160;17, 2022).</a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">10.9#</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1819253/000119312522176642/d256890dex107.htm">Amended and Restated Employment Agreement, effective as of May&#160;26, 2022, by and between BioTE Medical, LLC and Robbin Gibbins (incorporated by reference to Exhibit 10.7 to the Company&#8217;s registration statement on Form <span style="white-space:nowrap">S-1</span> (File <span style="white-space:nowrap">No.&#160;333-265714)</span> filed by the Company with the SEC on June&#160;17, 2022). </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">10.10#</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1819253/000119312522176642/d256890dex108.htm">Employment Agreement, effective as of June&#160;10, 2022, by and between BioTE Medical, LLC and Ross McQuivey, M.D. (Incorporated by reference to Exhibit 10.8 to the Company&#8217;s registration statement on Form <span style="white-space:nowrap">S-1</span> (File <span style="white-space:nowrap">No.&#160;333-265714)</span> filed by the Company with the SEC on June&#160;17, 2022). </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">10.11#</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1819253/000119312522176642/d256890dex109.htm">Employment Agreement, effective as of May&#160;26, 2022, by and between BioTE Medical, LLC and Mary Elizabeth Conlon (Incorporated by reference to Exhibit 10.9 to the Company&#8217;s registration statement on Form <span style="white-space:nowrap">S-1</span> (File <span style="white-space:nowrap">No.&#160;333-265714)</span> filed by the Company with the SEC on June&#160;17, 2022). </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">10.12#</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1819253/000119312522166249/d342736dex106.htm">Executive Employment Agreement, dated May&#160;26, 2022, by and between BioTE Medical, LLC and Cary Paulette (incorporated by reference to Exhibit 10.6 of the Company&#8217;s Current Report on <span style="white-space:nowrap">Form&#160;8-K</span> (File <span style="white-space:nowrap">No.&#160;001-40128)</span> filed with the SEC on June&#160;2, 2022). </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">10.13#</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1819253/000095017022024970/btmd-ex10_1.htm">Employment Agreement, effective July&#160;15, 2022, by and between BioTE Medical, LLC and Samar Kamdar (incorporated by reference to Exhibit 10.1 to the Company&#8217;s Quarterly Report on Form <span style="white-space:nowrap">10-Q</span> (File <span style="white-space:nowrap">No.&#160;001-40128)</span> filed by the Company with the SEC on November&#160;14, 2022). </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">10.14#</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1819253/000095017022024970/btmd-ex10_2.htm">Amendment to Employment Agreement, effective August&#160;24, 2022, by and between BioTE Medical, LLC and Samar Kamdar (Incorporated by reference to Exhibit 10.2 to the Company&#8217;s Quarterly Report on Form <span style="white-space:nowrap">10-Q</span> (File <span style="white-space:nowrap">No.&#160;001-40128)</span> filed by the Company with the SEC on November&#160;14, 2022). </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">10.15#</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1819253/000095017022024970/btmd-ex10_3.htm">Transition Agreement, effective August&#160;31, 2022, by and between BioTE Medical, LLC and Robbin Gibbins. (Incorporated by reference to Exhibit 10.3 to the Company&#8217;s Quarterly Report on <span style="white-space:nowrap">Form&#160;10-Q</span> (File <span style="white-space:nowrap">No.&#160;001-40128)</span> filed by the Company with the SEC on November&#160;14, 2022). </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">10.16</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1819253/000119312522204281/d323810dex101.htm">Standby Equity Purchase Agreement, by and between biote Corp. and YA II PN, LTD (Incorporated by reference to Exhibit 10.1 to the Company&#8217;s Current Report on Form <span style="white-space:nowrap">8-K</span> (File <span style="white-space:nowrap">No.&#160;001-40128)</span> filed by the Company with the SEC on July&#160;28, 2022). </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">10.17#</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1819253/000095017023010664/btmd-ex10_17.htm">biote Corp. 2022 Equity Incentive Plan. (Incorporated by reference to Exhibit 10.17 to the Company&#8217;s Annual Report on Form <span style="white-space:nowrap">10-K</span> (File <span style="white-space:nowrap">No.&#160;001-40128)</span> filed by the Company with the SEC on March&#160;29, 2023). </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">10.18#</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1819253/000119312522211291/d380602dex992.htm">biote Corp. 2022 Employee Stock Purchase Plan (Incorporated by reference to Exhibit 99.2 of the Company&#8217;s Registration Statement on Form <span style="white-space:nowrap">S-8</span> filed on August&#160;3, 2022). </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">10.19#</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1819253/000119312522211291/d380602dex993.htm">Form of Stock Option Grant Notice (Incorporated by reference to Exhibit 99.3 of the Company&#8217;s Registration Statement on Form <span style="white-space:nowrap">S-8</span> filed on August&#160;3, 2022). </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">10.20#</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1819253/000119312522211291/d380602dex994.htm">Form of RSU Award Grant Notice (Incorporated by reference to Exhibit 99.4 of the Company&#8217;s Registration Statement on Form <span style="white-space:nowrap">S-8</span> filed on August&#160;3, 2022). </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">10.21</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/0001819253/000119312521071532/d97629dex11.htm">Underwriting Agreement, dated March&#160;1, 2021, by and among Haymaker Acquisition Corp. III, Citigroup Global Markets Inc. and Cantor Fitzgerald&#160;&amp; Co., as representative of the several underwriters (Incorporated by reference to exhibit 1.1 of the Company&#8217;s Current Report on Form <span style="white-space:nowrap">8-K</span> (File <span style="white-space:nowrap">No.&#160;001-40128)</span> filed with the SEC on March&#160;5, 2021). </a></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">II-4 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">


<tr>

<td></td>

<td style="vertical-align:bottom;width:5%"></td>
<td style="width:88%"></td></tr>

<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">10.22</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1819253/000119312521071532/d97629dex105.htm">Private Placement Warrants Purchase Agreement, dated March&#160;1, 2021, by and between Haymaker Acquisition Corp. III and Haymaker Sponsor III LLC (Incorporated by reference to exhibit 10.5 of the Company&#8217;s Current Report on Form <span style="white-space:nowrap">8-K</span> (File <span style="white-space:nowrap">No.&#160;001-40128)</span> filed with the SEC on March&#160;5, 2021). </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">21.1</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/0001819253/000119312522166249/d342736dex211.htm">List of Subsidiaries (Incorporated by reference to Exhibit 21.1 of the Company&#8217;s Current Report on Form <span style="white-space:nowrap">8-K</span> (File <span style="white-space:nowrap">No.&#160;001-40128)</span> filed with the SEC on June&#160;2, 2022). </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">23.1*</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="d479690dex231.htm">Consent of Deloitte&#160;&amp; Touche LLP. </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">23.3**</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1819253/000119312522176642/d256890dex51.htm">Consent of Cooley, LLP (Included on Exhibit 5.1). </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">24*</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="#sig">Power of Attorney (Included on signature page hereto). </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">101.INS*</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Inline XBRL Instance Document</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">101.SCH*</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Inline XBRL Taxonomy Extension Schema Document</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">101.CAL*</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Inline XBRL Taxonomy Extension Calculation Linkbase Document</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">101.DEF*</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Inline XBRL Taxonomy Extension Definition Linkbase Document</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">101.LAB*</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Inline XBRL Taxonomy Extension Label Linkbase Document</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">101.PRE*</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Inline XBRL Taxonomy Extension Presentation Linkbase Document</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">104*</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Cover Page Interactive Data File (formatted as Inline XBRL)</td></tr>
</table> <p style="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">*</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Filed herewith. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">**</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Previously filed. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">&#8224;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Certain portions of this exhibit have been omitted pursuant to Regulation <span style="white-space:nowrap">S-K</span> Item (601)(b)(10). </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">#</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Indicates management contract or compensatory plan or arrangement. </p></td></tr></table> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Item&#160;17. Undertakings. </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) The undersigned registrant hereby undertakes: </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(1) To file, during any period in which offers or sales are being made, a post-effective amendment to this registration statement: </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(i) to include any prospectus required by Section&#160;10(a)(3) of the Securities Act; </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(ii) to reflect in the prospectus any facts or events arising after the effective date of the registration statement (or the most recent post-effective amendment thereof) which, individually or in the aggregate, represent a fundamental change in the information set forth in the registration statement. Notwithstanding the foregoing, any increase or decrease in volume of securities offered (if the total dollar value of securities offered would not exceed that which was registered) and any deviation from the low or high end of the estimated maximum offering range may be reflected in the form of prospectus filed with the Securities and Exchange Commission (the &#8220;Commission&#8221;) pursuant to Rule 424(b) if, in the aggregate, the changes in volume and price represent no more than 20&#160;percent change in the maximum aggregate offering price set forth in the &#8220;Calculation of Registration Fee&#8221; table in the effective registration statement; and </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(iii) to include any material information with respect to the plan of distribution not previously disclosed in the registration statement or any material change to such information in the registration statement; </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">provided</span>, <span style="font-style:italic">however</span>, that: Paragraphs (a)(1)(i), (a)(1)(ii) and (a)(1)(iii) of this section do not apply if the information required to be included in a post-effective amendment by those paragraphs is contained in reports filed with or furnished to the Commission by the registrant pursuant to Section&#160;13 or Section&#160;15(d) of </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">II-5 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
the Securities and Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;), that are incorporated by reference in the registration statement, or is contained in a form of prospectus filed pursuant to Rule 424(b) that is part of the registration statement. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(2) That, for the purpose of determining any liability under the Securities Act, each such post-effective amendment shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(3) To remove from registration by means of a post-effective amendment any of the securities being registered which remain unsold at the termination of the offering. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(4) That, for the purpose of determining liability under the Securities Act to any purchaser: </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(i) Each prospectus filed by the registrant pursuant to Rule 424(b)(3) shall be deemed to be part of the registration statement as of the date the filed prospectus was deemed part of and included in the registration statement; and </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(ii) Each prospectus required to be filed pursuant to Rule 424(b)(2), (b)(5) or (b)(7) as part of a registration statement in reliance on Rule 430B relating to an offering made pursuant to Rule 415(a)(1)(i), (vii) or (x)&#160;for the purpose of providing the information required by Section&#160;10(a) of the Securities Act shall be deemed to be part of and included in the registration statement as of the earlier of the date such form of prospectus is first used after effectiveness or the date of the first contract of sale of securities in the offering described in the prospectus. As provided in Rule 430B, for liability purposes of the issuer and any person that is at that date an underwriter, such date shall be deemed to be a new effective date of the registration statement relating to the securities in the registration statement to which that prospectus relates, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof. Provided, however, that no statement made in a registration statement or prospectus that is part of the registration statement or made in a document incorporated or deemed incorporated by reference into the registration statement or prospectus that is part of the registration statement will, as to a purchaser with a time of contract of sale prior to such effective date, supersede or modify any statement that was made in the registration statement or prospectus that was part of the registration statement or made in any such document immediately prior to such effective date. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(5) That, for the purpose of determining liability of the registrant under the Securities Act to any purchaser in the initial distribution of the securities, the undersigned registrant undertakes that in a primary offering of securities of the undersigned registrant pursuant to this registration statement, regardless of the underwriting method used to sell the securities to the purchaser, if the securities are offered or sold to such purchaser by means of any of the following communications, the undersigned registrant will be a seller to the purchaser and will be considered to offer or sell such securities to such purchaser: </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(i) Any preliminary prospectus or prospectus of the undersigned registrant relating to the offering required to be filed pursuant to Rule 424; </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(ii) Any free writing prospectus relating to the offering prepared by or on behalf of the undersigned registrant or used or referred to by the undersigned registrant; </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(iii) The portion of any other free writing prospectus relating to the offering containing material information about the undersigned registrant or its securities provided by or on behalf of the undersigned registrant; and </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(iv) Any other communication that is an offer in the offering made by the undersigned registrant to the purchaser. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">II-6 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) Insofar as indemnification for liabilities arising under the Securities Act may be permitted to directors, officers and controlling persons of the Registrant pursuant to the foregoing provisions, or otherwise, the Registrant has been advised that in the opinion of the SEC such indemnification is against public policy as expressed in the Securities Act and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the Registrant of expenses incurred or paid by a director, officer or controlling person of the Registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered, the Registrant will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the Securities Act and will be governed by the final adjudication of such issue. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">II-7 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center" id="sig">SIGNATURES </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Act of 1933, the registrant has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized in the City of Irving, State of Texas on April&#160;5, 2023. </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p><div>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:40%;border:0;margin-left:auto">


<tr>

<td style="width:7%"></td>

<td style="vertical-align:bottom;width:1%"></td>
<td style="width:92%"></td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top" colspan="3">BIOTE CORP.</td></tr>
<tr style="font-size:1pt">
<td style="height:12pt"></td>
<td style="height:12pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">By:</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">/s/ Teresa S. Weber</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><span style="font-weight:bold">Name: Teresa S. Weber</span></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><span style="font-weight:bold">Title: Chief Executive Officer</span></td></tr>
</table></div> <p style="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">POWER OF ATTORNEY </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">KNOW ALL MEN BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints each of Teresa S. Weber and Samar Kamdar, as his or her true and lawful <span style="white-space:nowrap"><span style="white-space:nowrap">attorney-in-fact,</span></span> with full power of substitution and resubstitution for him or her and in his or her name, place and stead, in any and all capacities to sign any and all amendments including post-effective amendments to this registration statement and any and all registration statements filed pursuant to Rule 462 under the Securities Act of 1933, as amended, and to file the same, with all exhibits thereto, and other documents in connection therewith, with the SEC, hereby ratifying and confirming all that said <span style="white-space:nowrap"><span style="white-space:nowrap">attorney-in-fact</span></span> or his substitute, each acting alone, may lawfully do or cause to be done by virtue thereof. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Act of 1933, as amended, this Registration Statement has been signed below by the following persons in the capacities and on the dates indicated. </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0">


<tr>

<td style="width:45%"></td>

<td style="vertical-align:bottom;width:1%"></td>
<td style="width:35%"></td>

<td style="vertical-align:bottom;width:2%"></td>
<td style="width:18%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom" align="center"><span style="font-weight:bold">Name</span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom" align="center"><span style="font-weight:bold">Position</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="center"><span style="font-weight:bold">Date</span></td></tr>


<tr style="font-size:1pt">
<td style="height:12pt"></td>
<td style="height:12pt" colspan="2"></td>
<td style="height:12pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Teresa S. Weber</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Teresa S. Weber</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top" align="center">Chief Executive Officer, Director</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;white-space:nowrap" align="center">April&#160;5, 2023</td></tr>
<tr style="font-size:1pt">
<td style="height:12pt"></td>
<td style="height:12pt" colspan="2"></td>
<td style="height:12pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Samar Kamdar</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Samar Kamdar</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top" align="center">Chief Financial Officer</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;white-space:nowrap" align="center">April&#160;5, 2023</td></tr>
<tr style="font-size:1pt">
<td style="height:12pt"></td>
<td style="height:12pt" colspan="2"></td>
<td style="height:12pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Marc D. Beer</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Marc D. Beer</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top" align="center">Director, Chair</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;white-space:nowrap" align="center">April&#160;5, 2023</td></tr>
<tr style="font-size:1pt">
<td style="height:12pt"></td>
<td style="height:12pt" colspan="2"></td>
<td style="height:12pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Dana Jacoby</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Dana Jacoby</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top" align="center">Director</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;white-space:nowrap" align="center">April&#160;5, 2023</td></tr>
<tr style="font-size:1pt">
<td style="height:12pt"></td>
<td style="height:12pt" colspan="2"></td>
<td style="height:12pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Mark Cone</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Mark Cone</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top" align="center">Director</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;white-space:nowrap" align="center">April&#160;5, 2023</td></tr>
<tr style="font-size:1pt">
<td style="height:12pt"></td>
<td style="height:12pt" colspan="2"></td>
<td style="height:12pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Steven J. Heyer</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Steven J. Heyer</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top" align="center">Director</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;white-space:nowrap" align="center">April&#160;5, 2023</td></tr>
<tr style="font-size:1pt">
<td style="height:12pt"></td>
<td style="height:12pt" colspan="2"></td>
<td style="height:12pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Andrew R. Heyer</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Andrew R. Heyer</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top" align="center">Director</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;white-space:nowrap" align="center">April&#160;5, 2023</td></tr>
<tr style="font-size:1pt">
<td style="height:12pt"></td>
<td style="height:12pt" colspan="2"></td>
<td style="height:12pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Debra L. Morris</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Debra L. Morris</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top" align="center">Director</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;white-space:nowrap" align="center">April&#160;5, 2023</td></tr>
</table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">II-8 </p>

</div></div>

</body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>2
<FILENAME>d479690dex231.htm
<DESCRIPTION>EX-23.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-23.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 23.1 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We consent to the use in this Registration Statement No.&nbsp;333-266433 on Form <FONT STYLE="white-space:nowrap">S-1</FONT> of our report dated
March&nbsp;29, 2023, relating to the consolidated financial statements of biote Corp and subsidiaries. We also consent to the reference to us under the heading &#147;Experts&#148; in such Registration Statement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">/s/ Deloitte &amp; Touche LLP </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Dallas, TX </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">April 5, 2023 </P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>3
<FILENAME>btmd-20221231.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<!--Generated by DFIN XBRL Instance Document - http://www.dfinsolutions.com/ - Version R3.0 - on 06-April-2023 [03:21:32] {AM}-->
<schema targetNamespace="http://haymaker.com/20221231" elementFormDefault="qualified" xmlns:btmd="http://haymaker.com/20221231" xmlns="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xl="http://www.xbrl.org/2003/XLink" xmlns:us-gaap="http://fasb.org/us-gaap/2022" xmlns:country="http://xbrl.sec.gov/country/2022" xmlns:currency="http://xbrl.sec.gov/currency/2022" xmlns:dei="http://xbrl.sec.gov/dei/2022" xmlns:exch="http://xbrl.sec.gov/exch/2022" xmlns:naics="http://xbrl.sec.gov/naics/2022" xmlns:sic="http://xbrl.sec.gov/sic/2022" xmlns:us-types="http://fasb.org/us-types/2022" xmlns:stpr="http://xbrl.sec.gov/stpr/2022" xmlns:deprecated="http://www.xbrl.org/2009/arcrole/fact-explanatoryFact" xmlns:srt="http://fasb.org/srt/2022" xmlns:srt-types="http://fasb.org/srt-types/2022" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:us-gaap-supplement="http://fasb.org/us-gaap-sup/2022q3" xmlns:srt-supplement="http://fasb.org/srt-sup/2022q3">
<annotation>
<appinfo>
<link:roleType roleURI="http://haymaker.com/role/Cover" id="Cover">
<link:definition>1001 - Document -  Cover</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://haymaker.com/role/ConsolidatedBalanceSheets" id="ConsolidatedBalanceSheets">
<link:definition>1002 - Statement -  CONSOLIDATED BALANCE SHEETS</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://haymaker.com/role/ConsolidatedBalanceSheetsParenthetical" id="ConsolidatedBalanceSheetsParenthetical">
<link:definition>1003 - Statement -  CONSOLIDATED BALANCE SHEETS (Parenthetical)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://haymaker.com/role/ConsolidatedStatementsOfIncomeAndComprehensiveIncome" id="ConsolidatedStatementsOfIncomeAndComprehensiveIncome">
<link:definition>1004 - Statement -  CONSOLIDATED STATEMENTS OF INCOME AND COMPREHENSIVE INCOME</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://haymaker.com/role/ConsolidatedStatementsOfStockholdersEquityDeficit" id="ConsolidatedStatementsOfStockholdersEquityDeficit">
<link:definition>1005 - Statement -  CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (DEFICIT)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://haymaker.com/role/ConsolidatedStatementsOfCashFlows" id="ConsolidatedStatementsOfCashFlows">
<link:definition>1006 - Statement -  CONSOLIDATED STATEMENTS OF CASH FLOWS</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://haymaker.com/role/DescriptionOfBusinessAndBasisOfPresentation" id="DescriptionOfBusinessAndBasisOfPresentation">
<link:definition>1007 - Disclosure -  Description of Business and Basis of Presentation</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://haymaker.com/role/SummaryOfSignificantAccountingPolicies" id="SummaryOfSignificantAccountingPolicies">
<link:definition>1008 - Disclosure -  Summary of Significant Accounting Policies</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://haymaker.com/role/BusinessCombination" id="BusinessCombination">
<link:definition>1009 - Disclosure -  Business Combination</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://haymaker.com/role/RevenueRecognition" id="RevenueRecognition">
<link:definition>1010 - Disclosure -  Revenue Recognition</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://haymaker.com/role/InventoryNet" id="InventoryNet">
<link:definition>1011 - Disclosure -  Inventory, Net</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://haymaker.com/role/PropertyAndEquipmentNet" id="PropertyAndEquipmentNet">
<link:definition>1012 - Disclosure -  Property and Equipment, Net</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://haymaker.com/role/CapitalizedSoftwareNet" id="CapitalizedSoftwareNet">
<link:definition>1013 - Disclosure -  Capitalized Software, Net</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://haymaker.com/role/AccruedExpenses" id="AccruedExpenses">
<link:definition>1014 - Disclosure -  Accrued Expenses</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://haymaker.com/role/LongTermDebt" id="LongTermDebt">
<link:definition>1015 - Disclosure -  Long-Term Debt</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://haymaker.com/role/WarrantLiability" id="WarrantLiability">
<link:definition>1016 - Disclosure -  Warrant Liability</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://haymaker.com/role/EarnoutLiability" id="EarnoutLiability">
<link:definition>1017 - Disclosure -  Earnout Liability</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://haymaker.com/role/FairValueMeasurements" id="FairValueMeasurements">
<link:definition>1018 - Disclosure -  Fair Value Measurements</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://haymaker.com/role/NoncontrollingInterest" id="NoncontrollingInterest">
<link:definition>1019 - Disclosure -  Noncontrolling Interest</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://haymaker.com/role/ShareBasedCompensation" id="ShareBasedCompensation">
<link:definition>1020 - Disclosure -  Share-Based Compensation</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://haymaker.com/role/Leases" id="Leases">
<link:definition>1021 - Disclosure -  Leases</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://haymaker.com/role/IncomeTaxes" id="IncomeTaxes">
<link:definition>1022 - Disclosure -  Income Taxes</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://haymaker.com/role/NetLossPerCommonShare" id="NetLossPerCommonShare">
<link:definition>1023 - Disclosure -  Net Loss Per Common Share</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://haymaker.com/role/CommitmentsAndContingencies" id="CommitmentsAndContingencies">
<link:definition>1024 - Disclosure -  Commitments and Contingencies</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://haymaker.com/role/RelatedPartyTransactions" id="RelatedPartyTransactions">
<link:definition>1025 - Disclosure -  Related-Party Transactions</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://haymaker.com/role/SubsequentEvents" id="SubsequentEvents">
<link:definition>1026 - Disclosure -  Subsequent Events</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://haymaker.com/role/SummaryOfSignificantAccountingPoliciesPolicies" id="SummaryOfSignificantAccountingPoliciesPolicies">
<link:definition>1027 - Disclosure -  Summary of Significant Accounting Policies (Policies)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://haymaker.com/role/SummaryOfSignificantAccountingPoliciesTables" id="SummaryOfSignificantAccountingPoliciesTables">
<link:definition>1028 - Disclosure -  Summary of Significant Accounting Policies (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://haymaker.com/role/RevenueRecognitionTables" id="RevenueRecognitionTables">
<link:definition>1029 - Disclosure -  Revenue Recognition (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://haymaker.com/role/InventoryNetTables" id="InventoryNetTables">
<link:definition>1030 - Disclosure -  Inventory, Net (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://haymaker.com/role/PropertyAndEquipmentNetTables" id="PropertyAndEquipmentNetTables">
<link:definition>1031 - Disclosure -  Property and Equipment, Net (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://haymaker.com/role/CapitalizedSoftwareNetTables" id="CapitalizedSoftwareNetTables">
<link:definition>1032 - Disclosure -  Capitalized Software, Net (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://haymaker.com/role/AccruedExpensesTables" id="AccruedExpensesTables">
<link:definition>1033 - Disclosure -  Accrued Expenses (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://haymaker.com/role/LongTermDebtTables" id="LongTermDebtTables">
<link:definition>1034 - Disclosure -  Long-Term Debt (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://haymaker.com/role/FairValueMeasurementsTables" id="FairValueMeasurementsTables">
<link:definition>1035 - Disclosure -  Fair Value Measurements (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://haymaker.com/role/ShareBasedCompensationTables" id="ShareBasedCompensationTables">
<link:definition>1036 - Disclosure -  Share-Based Compensation (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://haymaker.com/role/LeasesTables" id="LeasesTables">
<link:definition>1037 - Disclosure -  Leases (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://haymaker.com/role/IncomeTaxesTables" id="IncomeTaxesTables">
<link:definition>1038 - Disclosure -  Income Taxes (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://haymaker.com/role/NetLossPerCommonShareTables" id="NetLossPerCommonShareTables">
<link:definition>1039 - Disclosure -  Net Loss Per Common Share (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://haymaker.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" id="SummaryOfSignificantAccountingPoliciesAdditionalInformationDetails">
<link:definition>1040 - Disclosure -  Summary of Significant Accounting Policies - Additional Information (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://haymaker.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfRollforwardOfTheAllowanceForDoubtfulAccountsDetails" id="SummaryOfSignificantAccountingPoliciesSummaryOfRollforwardOfTheAllowanceForDoubtfulAccountsDetails">
<link:definition>1041 - Disclosure -  Summary of Significant Accounting Policies - Summary of Rollforward of the Allowance for Doubtful Accounts (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://haymaker.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfTotalOtherCurrentAssetsDetails" id="SummaryOfSignificantAccountingPoliciesSummaryOfTotalOtherCurrentAssetsDetails">
<link:definition>1042 - Disclosure -  Summary of Significant Accounting Policies - Summary of Total Other Current Assets (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://haymaker.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfEstimatedUsefulLivesOfPropertyAndEquipmentDetails" id="SummaryOfSignificantAccountingPoliciesSummaryOfEstimatedUsefulLivesOfPropertyAndEquipmentDetails">
<link:definition>1043 - Disclosure -  Summary of Significant Accounting Policies - Summary of Estimated Useful Lives of Property and Equipment (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://haymaker.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfMembersEquityUnitsIssuedAndOutstandingDetails" id="SummaryOfSignificantAccountingPoliciesSummaryOfMembersEquityUnitsIssuedAndOutstandingDetails">
<link:definition>1044 - Disclosure -  Summary of Significant Accounting Policies - Summary of Members' Equity Units Issued and Outstanding (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://haymaker.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfCommonStockIssuedAndOutstandingDetails" id="SummaryOfSignificantAccountingPoliciesSummaryOfCommonStockIssuedAndOutstandingDetails">
<link:definition>1045 - Disclosure -  Summary of Significant Accounting Policies - Summary of Common Stock Issued and Outstanding (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://haymaker.com/role/BusinessCombinationAdditionalInformationDetails" id="BusinessCombinationAdditionalInformationDetails">
<link:definition>1046 - Disclosure -  Business Combination - Additional Information (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://haymaker.com/role/RevenueRecognitionScheduleOfRevenuesRecognizedForEachRevenueStreamDetails" id="RevenueRecognitionScheduleOfRevenuesRecognizedForEachRevenueStreamDetails">
<link:definition>1047 - Disclosure -  Revenue Recognition - Schedule of Revenues Recognized for Each Revenue Stream (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://haymaker.com/role/RevenueRecognitionScheduleOfRevenuesRecognizedByGeographicRegionDetails" id="RevenueRecognitionScheduleOfRevenuesRecognizedByGeographicRegionDetails">
<link:definition>1048 - Disclosure -  Revenue Recognition - Schedule of Revenues Recognized by Geographic Region (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://haymaker.com/role/RevenueRecognitionSummaryOfSignificantChangesInContractLiabilityBalancesDetails" id="RevenueRecognitionSummaryOfSignificantChangesInContractLiabilityBalancesDetails">
<link:definition>1049 - Disclosure -  Revenue Recognition - Summary of Significant Changes in Contract Liability Balances (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://haymaker.com/role/RevenueRecognitionSummaryOfConsiderationAllocatedToPerformanceObligationsDetails" id="RevenueRecognitionSummaryOfConsiderationAllocatedToPerformanceObligationsDetails">
<link:definition>1050 - Disclosure -  Revenue Recognition - Summary of Consideration Allocated to Performance Obligations (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://haymaker.com/role/RevenueRecognitionAdditionalInformationDetails" id="RevenueRecognitionAdditionalInformationDetails">
<link:definition>1051 - Disclosure -  Revenue Recognition - Additional Information (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://haymaker.com/role/InventoryNetScheduleOfInventoryNetDetails" id="InventoryNetScheduleOfInventoryNetDetails">
<link:definition>1052 - Disclosure -  Inventory, Net - Schedule of Inventory, Net (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://haymaker.com/role/PropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetails" id="PropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetails">
<link:definition>1053 - Disclosure -  Property and Equipment, Net - Schedule of Property and Equipment, Net (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://haymaker.com/role/PropertyAndEquipmentNetAdditionalInformationDetails" id="PropertyAndEquipmentNetAdditionalInformationDetails">
<link:definition>1054 - Disclosure -  Property and Equipment, Net - Additional Information (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://haymaker.com/role/CapitalizedSoftwareNetSummaryOfCapitalizedSoftwareNetDetails" id="CapitalizedSoftwareNetSummaryOfCapitalizedSoftwareNetDetails">
<link:definition>1055 - Disclosure -  Capitalized Software, Net - Summary of Capitalized Software, Net (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://haymaker.com/role/CapitalizedSoftwareNetAdditionalInformationDetails" id="CapitalizedSoftwareNetAdditionalInformationDetails">
<link:definition>1056 - Disclosure -  Capitalized Software, Net - Additional Information (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://haymaker.com/role/AccruedExpensesScheduleOfAccruedExpensesDetails" id="AccruedExpensesScheduleOfAccruedExpensesDetails">
<link:definition>1057 - Disclosure -  Accrued Expenses - Schedule of Accrued Expenses (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://haymaker.com/role/LongTermDebtAdditionalInformationDetails" id="LongTermDebtAdditionalInformationDetails">
<link:definition>1058 - Disclosure -  Long-Term Debt - Additional Information (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://haymaker.com/role/LongTermDebtScheduleOfOutstandingDebtDetails" id="LongTermDebtScheduleOfOutstandingDebtDetails">
<link:definition>1059 - Disclosure -  Long-Term Debt - Schedule of Outstanding Debt (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://haymaker.com/role/LongTermDebtScheduleOfFutureMaturitiesOfLongTermDebtDetails" id="LongTermDebtScheduleOfFutureMaturitiesOfLongTermDebtDetails">
<link:definition>1060 - Disclosure -  Long-Term Debt - Schedule of Future Maturities of Long-term Debt (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://haymaker.com/role/WarrantLiabilityAdditionalInformationDetails" id="WarrantLiabilityAdditionalInformationDetails">
<link:definition>1061 - Disclosure -  Warrant Liability - Additional Information (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://haymaker.com/role/EarnoutLiabilityAdditionalInformationDetails" id="EarnoutLiabilityAdditionalInformationDetails">
<link:definition>1062 - Disclosure -  Earnout Liability - Additional Information (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://haymaker.com/role/FairValueMeasurementsScheduleOfFairValueHierarchyForFinancialAssetsAndLiabilitiesDetails" id="FairValueMeasurementsScheduleOfFairValueHierarchyForFinancialAssetsAndLiabilitiesDetails">
<link:definition>1063 - Disclosure -  Fair Value Measurements - Schedule of Fair Value Hierarchy for Financial Assets and Liabilities (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://haymaker.com/role/FairValueMeasurementsSummaryOfSignificantInputsToMonteCarloSimulationForFairValueOfPrivatePlacementWarrantsDetails" id="FairValueMeasurementsSummaryOfSignificantInputsToMonteCarloSimulationForFairValueOfPrivatePlacementWarrantsDetails">
<link:definition>1064 - Disclosure -  Fair Value Measurements - Summary of Significant Inputs to Monte Carlo Simulation for Fair Value of Private Placement Warrants (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://haymaker.com/role/FairValueMeasurementsSummaryOfSignificantInputsToMonteCarloSimulationForFairValueOfEarnoutLiabilityDetails" id="FairValueMeasurementsSummaryOfSignificantInputsToMonteCarloSimulationForFairValueOfEarnoutLiabilityDetails">
<link:definition>1065 - Disclosure -  Fair Value Measurements - Summary of Significant Inputs to Monte Carlo Simulation for Fair Value of Earnout Liability (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://haymaker.com/role/FairValueMeasurementsSummaryOfChangesInTheFairValueOfCompanysLevel3FinancialInstrumentsDetails" id="FairValueMeasurementsSummaryOfChangesInTheFairValueOfCompanysLevel3FinancialInstrumentsDetails">
<link:definition>1066 - Disclosure -  Fair Value Measurements - Summary of Changes in the Fair Value of Company's Level 3 Financial Instruments (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://haymaker.com/role/NoncontrollingInterestAdditionalInformationDetails" id="NoncontrollingInterestAdditionalInformationDetails">
<link:definition>1067 - Disclosure -  Noncontrolling Interest - Additional Information (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://haymaker.com/role/ShareBasedCompensationAdditionalInformationDetails" id="ShareBasedCompensationAdditionalInformationDetails">
<link:definition>1068 - Disclosure -  Share-Based Compensation - Additional Information (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://haymaker.com/role/ShareBasedCompensationSummaryOfRestrictedStockUnitActivityDetails" id="ShareBasedCompensationSummaryOfRestrictedStockUnitActivityDetails">
<link:definition>1069 - Disclosure -  Share-Based Compensation - Summary of Restricted Stock Unit Activity (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://haymaker.com/role/ShareBasedCompensationSummaryOfStockOptionActivityDetails" id="ShareBasedCompensationSummaryOfStockOptionActivityDetails">
<link:definition>1070 - Disclosure -  Share-Based Compensation - Summary of Stock Option Activity (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://haymaker.com/role/ShareBasedCompensationSummaryOfWeightedAverageAssumptionsUsedToEstimateFairValueOfStockOptionsGrantedDetails" id="ShareBasedCompensationSummaryOfWeightedAverageAssumptionsUsedToEstimateFairValueOfStockOptionsGrantedDetails">
<link:definition>1071 - Disclosure -  Share-Based Compensation - Summary of Weighted-Average Assumptions used to Estimate Fair Value of Stock Options Granted (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://haymaker.com/role/LeasesAdditionalInformationDetails" id="LeasesAdditionalInformationDetails">
<link:definition>1072 - Disclosure -  Leases - Additional Information (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://haymaker.com/role/LeasesSummaryOfOperatingLeaseCostsRecognizedUnderAsc842AndSupplementalCashFlowInformationForLeasesDetails" id="LeasesSummaryOfOperatingLeaseCostsRecognizedUnderAsc842AndSupplementalCashFlowInformationForLeasesDetails">
<link:definition>1073 - Disclosure -  Leases - Summary of Operating Lease Costs Recognized under ASC 842 and Supplemental Cash Flow Information for Leases (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://haymaker.com/role/LeasesSummaryBalanceSheetClassificationOfOperatingLeasesAndWeightedAverageRemainingLeaseTermAndDiscountRateDetails" id="LeasesSummaryBalanceSheetClassificationOfOperatingLeasesAndWeightedAverageRemainingLeaseTermAndDiscountRateDetails">
<link:definition>1074 - Disclosure -  Leases - Summary Balance Sheet Classification of Operating Leases and Weighted Average Remaining Lease Term and Discount Rate (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://haymaker.com/role/LeasesSummaryOfPaymentsByDateForOperatingLeaseDetails" id="LeasesSummaryOfPaymentsByDateForOperatingLeaseDetails">
<link:definition>1075 - Disclosure -  Leases - Summary of Payments by Date for Operating Lease (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://haymaker.com/role/IncomeTaxesAdditionalInformationDetails" id="IncomeTaxesAdditionalInformationDetails">
<link:definition>1076 - Disclosure -  Income Taxes - Additional Information (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://haymaker.com/role/IncomeTaxesScheduleOfIncomeLossBeforeProvisionForIncomeTaxesDetails" id="IncomeTaxesScheduleOfIncomeLossBeforeProvisionForIncomeTaxesDetails">
<link:definition>1077 - Disclosure -  Income Taxes - Schedule of Income (Loss) Before Provision for Income Taxes (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://haymaker.com/role/IncomeTaxesScheduleOfIncomeTaxProvisionDetails" id="IncomeTaxesScheduleOfIncomeTaxProvisionDetails">
<link:definition>1078 - Disclosure -  Income Taxes - Schedule of Income Tax Provision (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://haymaker.com/role/IncomeTaxesScheduleOfReconciliationOfTheFederalIncomeTaxRateToTheCompanyEffectiveTaxRateDetails" id="IncomeTaxesScheduleOfReconciliationOfTheFederalIncomeTaxRateToTheCompanyEffectiveTaxRateDetails">
<link:definition>1079 - Disclosure -  Income Taxes - Schedule of Reconciliation of the Federal Income Tax Rate to the Company Effective Tax Rate (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://haymaker.com/role/IncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails" id="IncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails">
<link:definition>1080 - Disclosure -  Income Taxes - Deferred Tax Assets and Liabilities (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://haymaker.com/role/NetLossPerCommonShareScheduleOfComputationOfNetLossPerCommonShareDetails" id="NetLossPerCommonShareScheduleOfComputationOfNetLossPerCommonShareDetails">
<link:definition>1081 - Disclosure -  Net Loss Per Common Share - Schedule of Computation of Net Loss Per Common Share (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://haymaker.com/role/NetLossPerCommonShareScheduleOfComputationOfDilutedWeightedAverageSharesOutstandingDetails" id="NetLossPerCommonShareScheduleOfComputationOfDilutedWeightedAverageSharesOutstandingDetails">
<link:definition>1082 - Disclosure -  Net Loss Per Common Share - Schedule of Computation of Diluted Weighted Average Shares Outstanding (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://haymaker.com/role/CommitmentsAndContingenciesAdditionalInformationDetails" id="CommitmentsAndContingenciesAdditionalInformationDetails">
<link:definition>1083 - Disclosure -  Commitments and Contingencies - Additional Information (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://haymaker.com/role/RelatedPartyTransactionsAdditionalInformationDetails" id="RelatedPartyTransactionsAdditionalInformationDetails">
<link:definition>1084 - Disclosure -  Related-Party Transactions - Additional Information (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:linkbaseRef xlink:type="simple" xlink:href="btmd-20221231_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
<link:linkbaseRef xlink:type="simple" xlink:href="btmd-20221231_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
<link:linkbaseRef xlink:type="simple" xlink:href="btmd-20221231_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
<link:linkbaseRef xlink:type="simple" xlink:href="btmd-20221231_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
</appinfo>
</annotation>
<import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
<import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
<import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" />
<import namespace="http://fasb.org/us-gaap/2022" schemaLocation="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd" />
<import namespace="http://xbrl.sec.gov/country/2022" schemaLocation="https://xbrl.sec.gov/country/2022/country-2022.xsd" />
<import namespace="http://xbrl.sec.gov/currency/2022" schemaLocation="https://xbrl.sec.gov/currency/2022/currency-2022.xsd" />
<import namespace="http://xbrl.sec.gov/exch/2022" schemaLocation="https://xbrl.sec.gov/exch/2022/exch-2022.xsd" />
<import namespace="http://xbrl.sec.gov/naics/2022" schemaLocation="https://xbrl.sec.gov/naics/2022/naics-2022.xsd" />
<import namespace="http://xbrl.sec.gov/sic/2022" schemaLocation="https://xbrl.sec.gov/sic/2022/sic-2022.xsd" />
<import namespace="http://xbrl.sec.gov/stpr/2022" schemaLocation="https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd" />
<import namespace="http://www.xbrl.org/2009/role/negated" schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd" />
<import namespace="http://www.xbrl.org/2009/role/net" schemaLocation="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd" />
<import namespace="http://www.xbrl.org/2009/arcrole/fact-explanatoryFact" schemaLocation="http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd" />
<import namespace="http://xbrl.sec.gov/dei/2022" schemaLocation="https://xbrl.sec.gov/dei/2022/dei-2022.xsd" />
<import namespace="http://fasb.org/us-types/2022" schemaLocation="https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd" />
<import namespace="http://fasb.org/srt-types/2022" schemaLocation="https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd" />
<import namespace="http://fasb.org/srt/2022" schemaLocation="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd" />
<import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd" />
<import namespace="http://fasb.org/us-gaap-sup/2022q3" schemaLocation="https://xbrl.fasb.org/us-gaap/2022q3/us-gaap-sup-2022q3.xsd" />
<import namespace="http://fasb.org/srt-sup/2022q3" schemaLocation="https://xbrl.fasb.org/srt/2022q3/srt-sup-2022q3.xsd" />
<element name="CommonClassVMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="btmd_CommonClassVMember" substitutionGroup="xbrli:item" />
<element name="ClassAMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="btmd_ClassAMember" substitutionGroup="xbrli:item" />
<element name="ClassAaUnitsMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="btmd_ClassAaUnitsMember" substitutionGroup="xbrli:item" />
<element name="ClassAaaUnitsMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="btmd_ClassAaaUnitsMember" substitutionGroup="xbrli:item" />
<element name="ClassAaaaUnitsMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="btmd_ClassAaaaUnitsMember" substitutionGroup="xbrli:item" />
<element name="ProductRevenueMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="btmd_ProductRevenueMember" substitutionGroup="xbrli:item" />
<element name="ServiceRevenueMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="btmd_ServiceRevenueMember" substitutionGroup="xbrli:item" />
<element name="GainLossFromChangeInFairValueOfEarnoutLiability" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="btmd_GainLossFromChangeInFairValueOfEarnoutLiability" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="StockholdersEquityAttributableToNonControllingInterestBusinessCombination" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="btmd_StockholdersEquityAttributableToNonControllingInterestBusinessCombination" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="StockholdersEquityBussinessCombinationCapitalizedTransactionCosts" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="btmd_StockholdersEquityBussinessCombinationCapitalizedTransactionCosts" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="StockIssuedDuringPeriodValueSettlementOfEquityRights" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="btmd_StockIssuedDuringPeriodValueSettlementOfEquityRights" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="StockIssuedDuringPeriodValueVestingOfRestrictedStockUnit" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="btmd_StockIssuedDuringPeriodValueVestingOfRestrictedStockUnit" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="StockIssuedDuringPeriodSharesVestingOfRestrictedStockUnit" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="btmd_StockIssuedDuringPeriodSharesVestingOfRestrictedStockUnit" substitutionGroup="xbrli:item" />
<element name="PartnersCapitalAccountReverseRecapitalizationUnits" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="btmd_PartnersCapitalAccountReverseRecapitalizationUnits" substitutionGroup="xbrli:item" />
<element name="StockholdersEquityIncludingPortionAttributableToNonControllingInterestReverseRecapitalization" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="btmd_StockholdersEquityIncludingPortionAttributableToNonControllingInterestReverseRecapitalization" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="StockholdersEquityIncludingPortionAttributableToNonControllingInterestSharesReverseRecapitalization" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="btmd_StockholdersEquityIncludingPortionAttributableToNonControllingInterestSharesReverseRecapitalization" substitutionGroup="xbrli:item" />
<element name="PrincipalRepaymentsOnTermLoan" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="btmd_PrincipalRepaymentsOnTermLoan" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="BorrowingsOnTermLoan" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="btmd_BorrowingsOnTermLoan" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="ProceedsFromBusinessCombination" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="btmd_ProceedsFromBusinessCombination" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="PaymentsOfSettlementOfPhantomEquityRight" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="btmd_PaymentsOfSettlementOfPhantomEquityRight" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="PaymentsOfSettlementOfRestrictedStockUnits" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="btmd_PaymentsOfSettlementOfRestrictedStockUnits" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="ProceedsFromIssuanceOfSharesUnderSepa" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="btmd_ProceedsFromIssuanceOfSharesUnderSepa" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="PaymentsToSEPATransactionCosts" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="btmd_PaymentsToSEPATransactionCosts" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="NonCashSponsorShareTransfers" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="btmd_NonCashSponsorShareTransfers" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="NonCashFeesUnderSepa" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="btmd_NonCashFeesUnderSepa" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="FairValueAdjustmentOfEarnoutLiability" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="btmd_FairValueAdjustmentOfEarnoutLiability" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="NonCashLeaseExpense" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="btmd_NonCashLeaseExpense" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="NonCashSEPATransactionCosts" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="btmd_NonCashSEPATransactionCosts" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="WarrantLiabilityTextBlock" type="dtr-types:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="btmd_WarrantLiabilityTextBlock" substitutionGroup="xbrli:item" />
<element name="EarnoutLiabilityTextBlock" type="dtr-types:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="btmd_EarnoutLiabilityTextBlock" substitutionGroup="xbrli:item" />
<element name="OtherCurrentAssetsPolicyTextBlock" type="dtr-types:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="btmd_OtherCurrentAssetsPolicyTextBlock" substitutionGroup="xbrli:item" />
<element name="DebtIssuanceCostsPolicyTextBlock" type="dtr-types:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="btmd_DebtIssuanceCostsPolicyTextBlock" substitutionGroup="xbrli:item" />
<element name="WarrantLiabilitiesPolicyTextBlock" type="dtr-types:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="btmd_WarrantLiabilitiesPolicyTextBlock" substitutionGroup="xbrli:item" />
<element name="EarnoutLiabilityPolicyTextBlock" type="dtr-types:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="btmd_EarnoutLiabilityPolicyTextBlock" substitutionGroup="xbrli:item" />
<element name="StandbyEquityPurchaseAgreementPolicyTextBlock" type="dtr-types:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="btmd_StandbyEquityPurchaseAgreementPolicyTextBlock" substitutionGroup="xbrli:item" />
<element name="NoncontrollingInterestPolicyTextBlock" type="dtr-types:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="btmd_NoncontrollingInterestPolicyTextBlock" substitutionGroup="xbrli:item" />
<element name="CostOfRevenuePolicyTextBlock" type="dtr-types:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="btmd_CostOfRevenuePolicyTextBlock" substitutionGroup="xbrli:item" />
<element name="DisclosureInTabularFormOfEstimatedUsefulLivesOfPropertyPlantAndEquipmentTableTextBlock" type="dtr-types:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="btmd_DisclosureInTabularFormOfEstimatedUsefulLivesOfPropertyPlantAndEquipmentTableTextBlock" substitutionGroup="xbrli:item" />
<element name="SummaryOfConsiderationAllocatedToPerformanceObligationsTableTextBlock" type="dtr-types:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="btmd_SummaryOfConsiderationAllocatedToPerformanceObligationsTableTextBlock" substitutionGroup="xbrli:item" />
<element name="SummaryOfCapitalizedSoftwareNetTableTextBlock" type="dtr-types:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="btmd_SummaryOfCapitalizedSoftwareNetTableTextBlock" substitutionGroup="xbrli:item" />
<element name="ScheduleOfChangesInTheFairValueOfWarrantLiabilitiesTableTextBlock" type="dtr-types:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="btmd_ScheduleOfChangesInTheFairValueOfWarrantLiabilitiesTableTextBlock" substitutionGroup="xbrli:item" />
<element name="SummaryOfLeaseCostsRecognizedUnderAsc842AndSupplementalCashFlowInformationForLeasesTableTextBlock" type="dtr-types:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="btmd_SummaryOfLeaseCostsRecognizedUnderAsc842AndSupplementalCashFlowInformationForLeasesTableTextBlock" substitutionGroup="xbrli:item" />
<element name="SummaryBalanceSheetClassificationOfOperatingLeasesAndWeightedAverageRemainingLeaseTermAndDiscountRateTableTextBlock" type="dtr-types:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="btmd_SummaryBalanceSheetClassificationOfOperatingLeasesAndWeightedAverageRemainingLeaseTermAndDiscountRateTableTextBlock" substitutionGroup="xbrli:item" />
<element name="ClassAVotingUnitsMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="btmd_ClassAVotingUnitsMember" substitutionGroup="xbrli:item" />
<element name="InventoryMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="btmd_InventoryMember" substitutionGroup="xbrli:item" />
<element name="NatureOfCustomerAxis" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="btmd_NatureOfCustomerAxis" substitutionGroup="xbrldt:dimensionItem" />
<element name="NatureOfCustomerDomain" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="btmd_NatureOfCustomerDomain" substitutionGroup="xbrli:item" />
<element name="BioteMethodCustomerMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="btmd_BioteMethodCustomerMember" substitutionGroup="xbrli:item" />
<element name="SourceOfRevenueAxis" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="btmd_SourceOfRevenueAxis" substitutionGroup="xbrldt:dimensionItem" />
<element name="SourceOfRevenueDomain" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="btmd_SourceOfRevenueDomain" substitutionGroup="xbrli:item" />
<element name="SourceOfServiceRevenueAxis" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="btmd_SourceOfServiceRevenueAxis" substitutionGroup="xbrldt:dimensionItem" />
<element name="SourceOfServiceRevenueDomain" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="btmd_SourceOfServiceRevenueDomain" substitutionGroup="xbrli:item" />
<element name="TrainingMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="btmd_TrainingMember" substitutionGroup="xbrli:item" />
<element name="ContractTermServicesMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="btmd_ContractTermServicesMember" substitutionGroup="xbrli:item" />
<element name="PalletProceduresMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="btmd_PalletProceduresMember" substitutionGroup="xbrli:item" />
<element name="FourZeroOneKPlanMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="btmd_FourZeroOneKPlanMember" substitutionGroup="xbrli:item" />
<element name="StandbyEquityPurchaseAgreementMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="btmd_StandbyEquityPurchaseAgreementMember" substitutionGroup="xbrli:item" />
<element name="YorkvilleAdvisorsGlobalLpMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="btmd_YorkvilleAdvisorsGlobalLpMember" substitutionGroup="xbrli:item" />
<element name="CapitalizedSoftwareEstimatedUsefulLives" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="btmd_CapitalizedSoftwareEstimatedUsefulLives" substitutionGroup="xbrli:item" />
<element name="CommonUnitsVotingRightsPercentage" type="dtr-types:percentItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="btmd_CommonUnitsVotingRightsPercentage" substitutionGroup="xbrli:item" />
<element name="PercentageOfCommonStockPurchasePrice" type="dtr-types:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="btmd_PercentageOfCommonStockPurchasePrice" substitutionGroup="xbrli:item" />
<element name="TerminationPeriodOfPurchaseAgreement" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="btmd_TerminationPeriodOfPurchaseAgreement" substitutionGroup="xbrli:item" />
<element name="ConsecutiveTradingDays" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="btmd_ConsecutiveTradingDays" substitutionGroup="xbrli:item" />
<element name="MandatoryMinimumAmountForIndividualAdvance" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="btmd_MandatoryMinimumAmountForIndividualAdvance" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="MaximumValueOfDailyVolumeTradedThresholdPercentage" type="dtr-types:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="btmd_MaximumValueOfDailyVolumeTradedThresholdPercentage" substitutionGroup="xbrli:item" />
<element name="ProceedsFromSettlementOfSEPA" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="btmd_ProceedsFromSettlementOfSEPA" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="ExpectedReturnsAndRefundsToCustomers" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="btmd_ExpectedReturnsAndRefundsToCustomers" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="NumberOfInventoryVendors" type="xbrli:integerItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="btmd_NumberOfInventoryVendors" substitutionGroup="xbrli:item" />
<element name="NumberOfCustomersAccountedForTenPercentOrMoreAggregateRevenue" type="xbrli:integerItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="btmd_NumberOfCustomersAccountedForTenPercentOrMoreAggregateRevenue" substitutionGroup="xbrli:item" />
<element name="NumberOfCustomersAccountedForTenPercentOrMoreAccountsReceivable" type="xbrli:integerItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="btmd_NumberOfCustomersAccountedForTenPercentOrMoreAccountsReceivable" substitutionGroup="xbrli:item" />
<element name="ProvisonForDoubfulDebtAcoountsWriteOffAndRecoveries" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="btmd_ProvisonForDoubfulDebtAcoountsWriteOffAndRecoveries" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="TrocarsMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="btmd_TrocarsMember" substitutionGroup="xbrli:item" />
<element name="ClassAaNonVotingUnitsMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="btmd_ClassAaNonVotingUnitsMember" substitutionGroup="xbrli:item" />
<element name="ClassAaaNonVotingUnitsMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="btmd_ClassAaaNonVotingUnitsMember" substitutionGroup="xbrli:item" />
<element name="ClassAaaaNonVotingIncentiveUnitsMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="btmd_ClassAaaaNonVotingIncentiveUnitsMember" substitutionGroup="xbrli:item" />
<element name="ClassVCommonStockMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="btmd_ClassVCommonStockMember" substitutionGroup="xbrli:item" />
<element name="MemberEarnOutUnitsMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="btmd_MemberEarnOutUnitsMember" substitutionGroup="xbrli:item" />
<element name="EarnoutVotingSharesMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="btmd_EarnoutVotingSharesMember" substitutionGroup="xbrli:item" />
<element name="SponsorEarnOutSharesMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="btmd_SponsorEarnOutSharesMember" substitutionGroup="xbrli:item" />
<element name="DebtCommitmentLetterMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="btmd_DebtCommitmentLetterMember" substitutionGroup="xbrli:item" />
<element name="HaymakeriiiMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="btmd_HaymakeriiiMember" substitutionGroup="xbrli:item" />
<element name="HaymakerAcquisitionCorpIiiMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="btmd_HaymakerAcquisitionCorpIiiMember" substitutionGroup="xbrli:item" />
<element name="BusinessCombinationMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="btmd_BusinessCombinationMember" substitutionGroup="xbrli:item" />
<element name="BioteManagementLlcMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="btmd_BioteManagementLlcMember" substitutionGroup="xbrli:item" />
<element name="OtherBusinessCombinationMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="btmd_OtherBusinessCombinationMember" substitutionGroup="xbrli:item" />
<element name="SeniorSecuredRevolvingCreditFacilityMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="btmd_SeniorSecuredRevolvingCreditFacilityMember" substitutionGroup="xbrli:item" />
<element name="SeniorSecuredTermLoanAFacilityMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="btmd_SeniorSecuredTermLoanAFacilityMember" substitutionGroup="xbrli:item" />
<element name="CommonStockTransfersThresholdTradingDays" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="btmd_CommonStockTransfersThresholdTradingDays" substitutionGroup="xbrli:item" />
<element name="IncomeTaxPercentageOfFederalStateAndLocalIncomeTaxSavings" type="dtr-types:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="btmd_IncomeTaxPercentageOfFederalStateAndLocalIncomeTaxSavings" substitutionGroup="xbrli:item" />
<element name="TaxReceivableAgreementLiability" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="btmd_TaxReceivableAgreementLiability" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="PelletProceduresProductRevenueMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="btmd_PelletProceduresProductRevenueMember" substitutionGroup="xbrli:item" />
<element name="DietarySupplementsMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="btmd_DietarySupplementsMember" substitutionGroup="xbrli:item" />
<element name="DisposableTrocarsProductRevenueMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="btmd_DisposableTrocarsProductRevenueMember" substitutionGroup="xbrli:item" />
<element name="ShippingFeesProductRevenueMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="btmd_ShippingFeesProductRevenueMember" substitutionGroup="xbrli:item" />
<element name="TrainingServiceRevenueMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="btmd_TrainingServiceRevenueMember" substitutionGroup="xbrli:item" />
<element name="ContractTermServicesRevenueMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="btmd_ContractTermServicesRevenueMember" substitutionGroup="xbrli:item" />
<element name="AllOtherCountryMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="btmd_AllOtherCountryMember" substitutionGroup="xbrli:item" />
<element name="ContractWithCustomerLiabilityIncreasesDueToCashReceivedExcludingAmountsRecognizedAsRevenue" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="btmd_ContractWithCustomerLiabilityIncreasesDueToCashReceivedExcludingAmountsRecognizedAsRevenue" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="ContractWithCustomerLiabilityTransfersBetweenCurrentAndNonCurrentLiabilitiesDueToExpectedRevenueRecognitionPeriod" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="btmd_ContractWithCustomerLiabilityTransfersBetweenCurrentAndNonCurrentLiabilitiesDueToExpectedRevenueRecognitionPeriod" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="UnsatisfiedTrainingObligationsMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="btmd_UnsatisfiedTrainingObligationsMember" substitutionGroup="xbrli:item" />
<element name="UnsatisfiedContractTermServicesMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="btmd_UnsatisfiedContractTermServicesMember" substitutionGroup="xbrli:item" />
<element name="UnsatisfiedPelletProceduresMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="btmd_UnsatisfiedPelletProceduresMember" substitutionGroup="xbrli:item" />
<element name="ReductionOfRevenue" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="btmd_ReductionOfRevenue" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="PelletsMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="btmd_PelletsMember" substitutionGroup="xbrli:item" />
<element name="CapitalizedSoftwareWebsiteCosts" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="btmd_CapitalizedSoftwareWebsiteCosts" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="CapitalizedSoftwareDevelopmentInProcess" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="btmd_CapitalizedSoftwareDevelopmentInProcess" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="AccruedMerchantFeesCurrent" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="btmd_AccruedMerchantFeesCurrent" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="LegalAccrualCurrent" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="btmd_LegalAccrualCurrent" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="BankOfAmericaTermLoanMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="btmd_BankOfAmericaTermLoanMember" substitutionGroup="xbrli:item" />
<element name="TruistTermLoanMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="btmd_TruistTermLoanMember" substitutionGroup="xbrli:item" />
<element name="BankOfAmericaTermLoanAndTruistTermLoanMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="btmd_BankOfAmericaTermLoanAndTruistTermLoanMember" substitutionGroup="xbrli:item" />
<element name="LineOfCreditFacilityMaturityMonthAndYear" type="xbrli:gYearMonthItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="btmd_LineOfCreditFacilityMaturityMonthAndYear" substitutionGroup="xbrli:item" />
<element name="FixedChargeCoverageRatio" type="xbrli:pureItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="btmd_FixedChargeCoverageRatio" substitutionGroup="xbrli:item" />
<element name="TeamLoanCurrentPortionBeforeUnamortizedDebtIssuanceCosts" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="btmd_TeamLoanCurrentPortionBeforeUnamortizedDebtIssuanceCosts" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="TeamLoanNonCurrentPortionBeforeUnamortizedDebtIssuanceCosts" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="btmd_TeamLoanNonCurrentPortionBeforeUnamortizedDebtIssuanceCosts" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="RedeemableWarrantsMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="btmd_RedeemableWarrantsMember" substitutionGroup="xbrli:item" />
<element name="PrivatePlacementWarrantsMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="btmd_PrivatePlacementWarrantsMember" substitutionGroup="xbrli:item" />
<element name="PublicWarrantsMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="btmd_PublicWarrantsMember" substitutionGroup="xbrli:item" />
<element name="SharePriceEqualOrExceedsTenRupeesPerDollarMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="btmd_SharePriceEqualOrExceedsTenRupeesPerDollarMember" substitutionGroup="xbrli:item" />
<element name="SharePriceEqualOrExceedsEighteenRupeesPerDollarMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="btmd_SharePriceEqualOrExceedsEighteenRupeesPerDollarMember" substitutionGroup="xbrli:item" />
<element name="SharePriceEqualOrLessNinePointTwoRupeesPerDollarMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="btmd_SharePriceEqualOrLessNinePointTwoRupeesPerDollarMember" substitutionGroup="xbrli:item" />
<element name="SponseMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="btmd_SponseMember" substitutionGroup="xbrli:item" />
<element name="ClassOfWarrantOrRightRedemptionThresholdConsecutiveTradingDays" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="btmd_ClassOfWarrantOrRightRedemptionThresholdConsecutiveTradingDays" substitutionGroup="xbrli:item" />
<element name="ClassOfWarrantOrRightThresholdPeriodForExerciseFromDateOfClosingPublicOffering" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="btmd_ClassOfWarrantOrRightThresholdPeriodForExerciseFromDateOfClosingPublicOffering" substitutionGroup="xbrli:item" />
<element name="ClassOfWarrantsOrRightsTransfersRestrictionOnNumberOfDaysFromTheDateOfBusinessCombination" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="btmd_ClassOfWarrantsOrRightsTransfersRestrictionOnNumberOfDaysFromTheDateOfBusinessCombination" substitutionGroup="xbrli:item" />
<element name="NumberOfDaysFollowingItsInitialBusinessCombinationUntilTheExpirationOfTheWarrants" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="btmd_NumberOfDaysFollowingItsInitialBusinessCombinationUntilTheExpirationOfTheWarrants" substitutionGroup="xbrli:item" />
<element name="ClassOfWarrantsRedemptionPricePerUnit" type="dtr-types:perShareItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="btmd_ClassOfWarrantsRedemptionPricePerUnit" substitutionGroup="xbrli:item" />
<element name="NumberOfConsecutiveTradingDaysForDeterminingSharePrice" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="btmd_NumberOfConsecutiveTradingDaysForDeterminingSharePrice" substitutionGroup="xbrli:item" />
<element name="ShareRedemptionTriggerPrice" type="dtr-types:perShareItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="btmd_ShareRedemptionTriggerPrice" substitutionGroup="xbrli:item" />
<element name="PrivatePlacementWarrantsRedemptionDescription" type="xbrli:stringItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="btmd_PrivatePlacementWarrantsRedemptionDescription" substitutionGroup="xbrli:item" />
<element name="MinimumGrossProceedsRequiredFromIssuanceOfEquity" type="dtr-types:percentItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="btmd_MinimumGrossProceedsRequiredFromIssuanceOfEquity" substitutionGroup="xbrli:item" />
<element name="ClassOfWarrantOrRightMinimumNoticePeriodForRedemption" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="btmd_ClassOfWarrantOrRightMinimumNoticePeriodForRedemption" substitutionGroup="xbrli:item" />
<element name="ClassOfWarrantOrRightExercisePriceAdjustmentPercentageHigherOfMarketValue" type="dtr-types:percentItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="btmd_ClassOfWarrantOrRightExercisePriceAdjustmentPercentageHigherOfMarketValue" substitutionGroup="xbrli:item" />
<element name="PublicWarrantsRedeemed" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="btmd_PublicWarrantsRedeemed" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="SharePriceEqualsOrExceedsTwelvePointFivePerShareMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="btmd_SharePriceEqualsOrExceedsTwelvePointFivePerShareMember" substitutionGroup="xbrli:item" />
<element name="SharePriceEqualsOrExceedsFifteenPerShareMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="btmd_SharePriceEqualsOrExceedsFifteenPerShareMember" substitutionGroup="xbrli:item" />
<element name="SharePriceEqualsOrExceedsSeventeenPointFivePerShareMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="btmd_SharePriceEqualsOrExceedsSeventeenPointFivePerShareMember" substitutionGroup="xbrli:item" />
<element name="NumberOfEarnoutSecuritiesShareholderEntitledToVestIfCertainSharePriceTargetsAchieved" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="btmd_NumberOfEarnoutSecuritiesShareholderEntitledToVestIfCertainSharePriceTargetsAchieved" substitutionGroup="xbrli:item" />
<element name="EarnoutDeadlineDate" type="xbrli:dateItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="btmd_EarnoutDeadlineDate" substitutionGroup="xbrli:item" />
<element name="NumberOfConsecutiveTradingDaysForDeterminingTheSharePrice" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="btmd_NumberOfConsecutiveTradingDaysForDeterminingTheSharePrice" substitutionGroup="xbrli:item" />
<element name="EarnoutLiabilityMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="btmd_EarnoutLiabilityMember" substitutionGroup="xbrli:item" />
<element name="MinorityInterestHoldersMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="btmd_MinorityInterestHoldersMember" substitutionGroup="xbrli:item" />
<element name="BioteCorporationMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="btmd_BioteCorporationMember" substitutionGroup="xbrli:item" />
<element name="CommonStockNumberOfVotesEntitledPerShare" type="xbrli:integerItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="btmd_CommonStockNumberOfVotesEntitledPerShare" substitutionGroup="xbrli:item" />
<element name="TwoThousandTwentyTwoEquityIncentivePlanMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="btmd_TwoThousandTwentyTwoEquityIncentivePlanMember" substitutionGroup="xbrli:item" />
<element name="IncentiveUnitsMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="btmd_IncentiveUnitsMember" substitutionGroup="xbrli:item" />
<element name="PhantomEquityRightsMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="btmd_PhantomEquityRightsMember" substitutionGroup="xbrli:item" />
<element name="ShareBasedCompensationArrangementVestingOfIncentiveUnits" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="btmd_ShareBasedCompensationArrangementVestingOfIncentiveUnits" substitutionGroup="xbrli:item" />
<element name="AreaOfOfficeSpace" type="xbrli:decimalItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="btmd_AreaOfOfficeSpace" substitutionGroup="xbrli:item" />
<element name="OtherInformationAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="btmd_OtherInformationAbstract" substitutionGroup="xbrli:item" />
<element name="AssetsLesseeAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="btmd_AssetsLesseeAbstract" substitutionGroup="xbrli:item" />
<element name="LeaseAssets" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="btmd_LeaseAssets" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="LiabilitiesLesseeAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="btmd_LiabilitiesLesseeAbstract" substitutionGroup="xbrli:item" />
<element name="OperatingLossCarryforwardsExpirationYear" type="xbrli:gYearItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="btmd_OperatingLossCarryforwardsExpirationYear" substitutionGroup="xbrli:item" />
<element name="FirmMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="btmd_FirmMember" substitutionGroup="xbrli:item" />
<element name="EmployeeMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="btmd_EmployeeMember" substitutionGroup="xbrli:item" />
<element name="SpouseOfFounderChairmanAndBeneficialOwnerMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="btmd_SpouseOfFounderChairmanAndBeneficialOwnerMember" substitutionGroup="xbrli:item" />
<element name="VendorMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="btmd_VendorMember" substitutionGroup="xbrli:item" />
<element name="ConsultantMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="btmd_ConsultantMember" substitutionGroup="xbrli:item" />
<element name="FounderAdvisoryAgreementMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="btmd_FounderAdvisoryAgreementMember" substitutionGroup="xbrli:item" />
<element name="NewIndependentContractorAgreementMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="btmd_NewIndependentContractorAgreementMember" substitutionGroup="xbrli:item" />
<element name="InventoryPurchases" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="btmd_InventoryPurchases" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="AgreementTerm" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="btmd_AgreementTerm" substitutionGroup="xbrli:item" />
<element name="AnnualAdviosryFeesPayable" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="btmd_AnnualAdviosryFeesPayable" substitutionGroup="xbrli:item" xbrli:balance="credit" />
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>4
<FILENAME>btmd-20221231_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<!--Generated by DFIN XBRL Instance Document - http://www.dfinsolutions.com/ - Version R3.0 - on 06-April-2023 [03:21:32] {AM}-->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
<roleRef xlink:type="simple" xlink:href="btmd-20221231.xsd#ConsolidatedBalanceSheets" roleURI="http://haymaker.com/role/ConsolidatedBalanceSheets" />
<roleRef xlink:type="simple" xlink:href="btmd-20221231.xsd#ConsolidatedStatementsOfIncomeAndComprehensiveIncome" roleURI="http://haymaker.com/role/ConsolidatedStatementsOfIncomeAndComprehensiveIncome" />
<roleRef xlink:type="simple" xlink:href="btmd-20221231.xsd#ConsolidatedStatementsOfCashFlows" roleURI="http://haymaker.com/role/ConsolidatedStatementsOfCashFlows" />
<roleRef xlink:type="simple" xlink:href="btmd-20221231.xsd#SummaryOfSignificantAccountingPoliciesSummaryOfTotalOtherCurrentAssetsDetails" roleURI="http://haymaker.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfTotalOtherCurrentAssetsDetails" />
<roleRef xlink:type="simple" xlink:href="btmd-20221231.xsd#RevenueRecognitionSummaryOfSignificantChangesInContractLiabilityBalancesDetails" roleURI="http://haymaker.com/role/RevenueRecognitionSummaryOfSignificantChangesInContractLiabilityBalancesDetails" />
<roleRef xlink:type="simple" xlink:href="btmd-20221231.xsd#RevenueRecognitionSummaryOfConsiderationAllocatedToPerformanceObligationsDetails" roleURI="http://haymaker.com/role/RevenueRecognitionSummaryOfConsiderationAllocatedToPerformanceObligationsDetails" />
<roleRef xlink:type="simple" xlink:href="btmd-20221231.xsd#InventoryNetScheduleOfInventoryNetDetails" roleURI="http://haymaker.com/role/InventoryNetScheduleOfInventoryNetDetails" />
<roleRef xlink:type="simple" xlink:href="btmd-20221231.xsd#PropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetails" roleURI="http://haymaker.com/role/PropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetails" />
<roleRef xlink:type="simple" xlink:href="btmd-20221231.xsd#CapitalizedSoftwareNetSummaryOfCapitalizedSoftwareNetDetails" roleURI="http://haymaker.com/role/CapitalizedSoftwareNetSummaryOfCapitalizedSoftwareNetDetails" />
<roleRef xlink:type="simple" xlink:href="btmd-20221231.xsd#AccruedExpensesScheduleOfAccruedExpensesDetails" roleURI="http://haymaker.com/role/AccruedExpensesScheduleOfAccruedExpensesDetails" />
<roleRef xlink:type="simple" xlink:href="btmd-20221231.xsd#LongTermDebtScheduleOfOutstandingDebtDetails" roleURI="http://haymaker.com/role/LongTermDebtScheduleOfOutstandingDebtDetails" />
<roleRef xlink:type="simple" xlink:href="btmd-20221231.xsd#LongTermDebtScheduleOfFutureMaturitiesOfLongTermDebtDetails" roleURI="http://haymaker.com/role/LongTermDebtScheduleOfFutureMaturitiesOfLongTermDebtDetails" />
<roleRef xlink:type="simple" xlink:href="btmd-20221231.xsd#LeasesSummaryOfOperatingLeaseCostsRecognizedUnderAsc842AndSupplementalCashFlowInformationForLeasesDetails" roleURI="http://haymaker.com/role/LeasesSummaryOfOperatingLeaseCostsRecognizedUnderAsc842AndSupplementalCashFlowInformationForLeasesDetails" />
<roleRef xlink:type="simple" xlink:href="btmd-20221231.xsd#LeasesSummaryBalanceSheetClassificationOfOperatingLeasesAndWeightedAverageRemainingLeaseTermAndDiscountRateDetails" roleURI="http://haymaker.com/role/LeasesSummaryBalanceSheetClassificationOfOperatingLeasesAndWeightedAverageRemainingLeaseTermAndDiscountRateDetails" />
<roleRef xlink:type="simple" xlink:href="btmd-20221231.xsd#LeasesSummaryOfPaymentsByDateForOperatingLeaseDetails" roleURI="http://haymaker.com/role/LeasesSummaryOfPaymentsByDateForOperatingLeaseDetails" />
<roleRef xlink:type="simple" xlink:href="btmd-20221231.xsd#IncomeTaxesScheduleOfIncomeLossBeforeProvisionForIncomeTaxesDetails" roleURI="http://haymaker.com/role/IncomeTaxesScheduleOfIncomeLossBeforeProvisionForIncomeTaxesDetails" />
<roleRef xlink:type="simple" xlink:href="btmd-20221231.xsd#IncomeTaxesScheduleOfIncomeTaxProvisionDetails" roleURI="http://haymaker.com/role/IncomeTaxesScheduleOfIncomeTaxProvisionDetails" />
<roleRef xlink:type="simple" xlink:href="btmd-20221231.xsd#IncomeTaxesScheduleOfReconciliationOfTheFederalIncomeTaxRateToTheCompanyEffectiveTaxRateDetails" roleURI="http://haymaker.com/role/IncomeTaxesScheduleOfReconciliationOfTheFederalIncomeTaxRateToTheCompanyEffectiveTaxRateDetails" />
<roleRef xlink:type="simple" xlink:href="btmd-20221231.xsd#IncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails" roleURI="http://haymaker.com/role/IncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails" />
<roleRef xlink:type="simple" xlink:href="btmd-20221231.xsd#NetLossPerCommonShareScheduleOfComputationOfNetLossPerCommonShareDetails" roleURI="http://haymaker.com/role/NetLossPerCommonShareScheduleOfComputationOfNetLossPerCommonShareDetails" />
<calculationLink xlink:type="extended" xlink:role="http://haymaker.com/role/ConsolidatedStatementsOfIncomeAndComprehensiveIncome">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" use="optional" order="1" weight="-1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaap_ProfitLoss" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="loc_us-gaap_ProfitLoss" use="optional" order="2" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ProfitLoss" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" use="optional" order="3" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="loc_us-gaap_OperatingIncomeLoss" use="optional" order="4" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" use="optional" order="5" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization" xlink:label="loc_us-gaap_CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="loc_us-gaap_CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization" use="optional" order="6" weight="-1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SalesCommissionsAndFees" xlink:label="loc_us-gaap_SalesCommissionsAndFees" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="loc_us-gaap_SalesCommissionsAndFees" use="optional" order="7" weight="-1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketingExpense" xlink:label="loc_us-gaap_MarketingExpense" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="loc_us-gaap_MarketingExpense" use="optional" order="8" weight="-1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense" use="optional" order="9" weight="-1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaap_NonoperatingIncomeExpense" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="loc_us-gaap_NonoperatingIncomeExpense" use="optional" order="10" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:label="loc_us-gaap_InterestIncomeExpenseNonoperatingNet" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense" xlink:to="loc_us-gaap_InterestIncomeExpenseNonoperatingNet" use="optional" order="11" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="loc_us-gaap_FairValueAdjustmentOfWarrants" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense" xlink:to="loc_us-gaap_FairValueAdjustmentOfWarrants" use="optional" order="12" weight="-1" />
<loc xlink:type="locator" xlink:href="btmd-20221231.xsd#btmd_GainLossFromChangeInFairValueOfEarnoutLiability" xlink:label="loc_btmd_GainLossFromChangeInFairValueOfEarnoutLiability" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense" xlink:to="loc_btmd_GainLossFromChangeInFairValueOfEarnoutLiability" use="optional" order="13" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt" use="optional" order="14" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncome" xlink:label="loc_us-gaap_OtherNonoperatingIncome" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense" xlink:to="loc_us-gaap_OtherNonoperatingIncome" use="optional" order="15" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ProfitLoss" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit" use="optional" order="16" weight="-1" />
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://haymaker.com/role/ConsolidatedStatementsOfIncomeAndComprehensiveIncome">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaap_ProfitLoss" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="loc_us-gaap_ProfitLoss" use="optional" order="17" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ProfitLoss" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" use="optional" order="18" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="loc_us-gaap_OperatingIncomeLoss" use="optional" order="19" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" use="optional" order="20" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization" xlink:label="loc_us-gaap_CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="loc_us-gaap_CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization" use="optional" order="21" weight="-1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SalesCommissionsAndFees" xlink:label="loc_us-gaap_SalesCommissionsAndFees" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="loc_us-gaap_SalesCommissionsAndFees" use="optional" order="22" weight="-1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketingExpense" xlink:label="loc_us-gaap_MarketingExpense" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="loc_us-gaap_MarketingExpense" use="optional" order="23" weight="-1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense" use="optional" order="24" weight="-1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaap_NonoperatingIncomeExpense" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="loc_us-gaap_NonoperatingIncomeExpense" use="optional" order="25" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:label="loc_us-gaap_InterestIncomeExpenseNonoperatingNet" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense" xlink:to="loc_us-gaap_InterestIncomeExpenseNonoperatingNet" use="optional" order="26" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="loc_us-gaap_FairValueAdjustmentOfWarrants" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense" xlink:to="loc_us-gaap_FairValueAdjustmentOfWarrants" use="optional" order="27" weight="-1" />
<loc xlink:type="locator" xlink:href="btmd-20221231.xsd#btmd_GainLossFromChangeInFairValueOfEarnoutLiability" xlink:label="loc_btmd_GainLossFromChangeInFairValueOfEarnoutLiability" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense" xlink:to="loc_btmd_GainLossFromChangeInFairValueOfEarnoutLiability" use="optional" order="28" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt" use="optional" order="29" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncome" xlink:label="loc_us-gaap_OtherNonoperatingIncome" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense" xlink:to="loc_us-gaap_OtherNonoperatingIncome" use="optional" order="30" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ProfitLoss" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit" use="optional" order="31" weight="-1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" use="optional" order="32" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:to="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" use="optional" order="33" weight="1" />
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://haymaker.com/role/ConsolidatedStatementsOfCashFlows">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" use="optional" order="1" weight="1" />
<loc xlink:type="locator" xlink:href="btmd-20221231.xsd#btmd_ProceedsFromBusinessCombination" xlink:label="loc_btmd_ProceedsFromBusinessCombination" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="loc_btmd_ProceedsFromBusinessCombination" use="optional" order="2" weight="1" />
<loc xlink:type="locator" xlink:href="btmd-20221231.xsd#btmd_PrincipalRepaymentsOnTermLoan" xlink:label="loc_btmd_PrincipalRepaymentsOnTermLoan" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="loc_btmd_PrincipalRepaymentsOnTermLoan" use="optional" order="3" weight="-1" />
<loc xlink:type="locator" xlink:href="btmd-20221231.xsd#btmd_BorrowingsOnTermLoan" xlink:label="loc_btmd_BorrowingsOnTermLoan" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="loc_btmd_BorrowingsOnTermLoan" use="optional" order="4" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfDebtExtinguishmentCosts" xlink:label="loc_us-gaap_PaymentsOfDebtExtinguishmentCosts" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaap_PaymentsOfDebtExtinguishmentCosts" use="optional" order="5" weight="-1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfDebtIssuanceCosts" xlink:label="loc_us-gaap_PaymentsOfDebtIssuanceCosts" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaap_PaymentsOfDebtIssuanceCosts" use="optional" order="6" weight="-1" />
<loc xlink:type="locator" xlink:href="btmd-20221231.xsd#btmd_PaymentsOfSettlementOfPhantomEquityRight" xlink:label="loc_btmd_PaymentsOfSettlementOfPhantomEquityRight" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="loc_btmd_PaymentsOfSettlementOfPhantomEquityRight" use="optional" order="7" weight="-1" />
<loc xlink:type="locator" xlink:href="btmd-20221231.xsd#btmd_PaymentsOfSettlementOfRestrictedStockUnits" xlink:label="loc_btmd_PaymentsOfSettlementOfRestrictedStockUnits" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="loc_btmd_PaymentsOfSettlementOfRestrictedStockUnits" use="optional" order="8" weight="-1" />
<loc xlink:type="locator" xlink:href="btmd-20221231.xsd#btmd_ProceedsFromIssuanceOfSharesUnderSepa" xlink:label="loc_btmd_ProceedsFromIssuanceOfSharesUnderSepa" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="loc_btmd_ProceedsFromIssuanceOfSharesUnderSepa" use="optional" order="9" weight="1" />
<loc xlink:type="locator" xlink:href="btmd-20221231.xsd#btmd_PaymentsToSEPATransactionCosts" xlink:label="loc_btmd_PaymentsToSEPATransactionCosts" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="loc_btmd_PaymentsToSEPATransactionCosts" use="optional" order="10" weight="-1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfDividends" xlink:label="loc_us-gaap_PaymentsOfDividends" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaap_PaymentsOfDividends" use="optional" order="11" weight="-1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaap_PaymentsOfStockIssuanceCosts" use="optional" order="12" weight="-1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" use="optional" order="13" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" use="optional" order="14" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaap_ProfitLoss" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_ProfitLoss" use="optional" order="15" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization" use="optional" order="16" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProvisionForDoubtfulAccounts" xlink:label="loc_us-gaap_ProvisionForDoubtfulAccounts" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_ProvisionForDoubtfulAccounts" use="optional" order="17" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfFinancingCosts" xlink:label="loc_us-gaap_AmortizationOfFinancingCosts" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_AmortizationOfFinancingCosts" use="optional" order="18" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryWriteDown" xlink:label="loc_us-gaap_InventoryWriteDown" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_InventoryWriteDown" use="optional" order="19" weight="1" />
<loc xlink:type="locator" xlink:href="btmd-20221231.xsd#btmd_NonCashLeaseExpense" xlink:label="loc_btmd_NonCashLeaseExpense" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_btmd_NonCashLeaseExpense" use="optional" order="20" weight="1" />
<loc xlink:type="locator" xlink:href="btmd-20221231.xsd#btmd_NonCashFeesUnderSepa" xlink:label="loc_btmd_NonCashFeesUnderSepa" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_btmd_NonCashFeesUnderSepa" use="optional" order="21" weight="1" />
<loc xlink:type="locator" xlink:href="btmd-20221231.xsd#btmd_NonCashSponsorShareTransfers" xlink:label="loc_btmd_NonCashSponsorShareTransfers" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_btmd_NonCashSponsorShareTransfers" use="optional" order="22" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_ShareBasedCompensation" use="optional" order="23" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="loc_us-gaap_FairValueAdjustmentOfWarrants" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_FairValueAdjustmentOfWarrants" use="optional" order="24" weight="1" />
<loc xlink:type="locator" xlink:href="btmd-20221231.xsd#btmd_FairValueAdjustmentOfEarnoutLiability" xlink:label="loc_btmd_FairValueAdjustmentOfEarnoutLiability" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_btmd_FairValueAdjustmentOfEarnoutLiability" use="optional" order="25" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt" use="optional" order="26" weight="-1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxesAndTaxCredits" xlink:label="loc_us-gaap_DeferredIncomeTaxesAndTaxCredits" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_DeferredIncomeTaxesAndTaxCredits" use="optional" order="27" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" use="optional" order="28" weight="-1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories" use="optional" order="29" weight="-1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherCurrentAssets" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherCurrentAssets" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherCurrentAssets" use="optional" order="30" weight="-1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable" use="optional" order="31" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:label="loc_us-gaap_IncreaseDecreaseInDeferredRevenue" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_IncreaseDecreaseInDeferredRevenue" use="optional" order="32" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities" use="optional" order="33" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" use="optional" order="34" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" use="optional" order="35" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" use="optional" order="36" weight="-1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForSoftware" xlink:label="loc_us-gaap_PaymentsForSoftware" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="loc_us-gaap_PaymentsForSoftware" use="optional" order="37" weight="-1" />
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://haymaker.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfTotalOtherCurrentAssetsDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="loc_us-gaap_PrepaidExpenseCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="loc_us-gaap_PrepaidExpenseCurrent" use="optional" order="1" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdvancesOnInventoryPurchases" xlink:label="loc_us-gaap_AdvancesOnInventoryPurchases" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="loc_us-gaap_AdvancesOnInventoryPurchases" use="optional" order="2" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredOfferingCosts" xlink:label="loc_us-gaap_DeferredOfferingCosts" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="loc_us-gaap_DeferredOfferingCosts" use="optional" order="3" weight="1" />
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://haymaker.com/role/RevenueRecognitionSummaryOfSignificantChangesInContractLiabilityBalancesDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" use="optional" order="1" weight="-1" />
<loc xlink:type="locator" xlink:href="btmd-20221231.xsd#btmd_ContractWithCustomerLiabilityIncreasesDueToCashReceivedExcludingAmountsRecognizedAsRevenue" xlink:label="loc_btmd_ContractWithCustomerLiabilityIncreasesDueToCashReceivedExcludingAmountsRecognizedAsRevenue" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:to="loc_btmd_ContractWithCustomerLiabilityIncreasesDueToCashReceivedExcludingAmountsRecognizedAsRevenue" use="optional" order="2" weight="-1" />
<loc xlink:type="locator" xlink:href="btmd-20221231.xsd#btmd_ContractWithCustomerLiabilityTransfersBetweenCurrentAndNonCurrentLiabilitiesDueToExpectedRevenueRecognitionPeriod" xlink:label="loc_btmd_ContractWithCustomerLiabilityTransfersBetweenCurrentAndNonCurrentLiabilitiesDueToExpectedRevenueRecognitionPeriod" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:to="loc_btmd_ContractWithCustomerLiabilityTransfersBetweenCurrentAndNonCurrentLiabilitiesDueToExpectedRevenueRecognitionPeriod" use="optional" order="3" weight="-1" />
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://haymaker.com/role/RevenueRecognitionSummaryOfConsiderationAllocatedToPerformanceObligationsDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiability" xlink:label="loc_us-gaap_ContractWithCustomerLiability" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityCurrent" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ContractWithCustomerLiability" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent" use="optional" order="1" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ContractWithCustomerLiability" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent" use="optional" order="2" weight="1" />
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://haymaker.com/role/InventoryNetScheduleOfInventoryNetDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNet" xlink:label="loc_us-gaap_InventoryNet" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryGross" xlink:label="loc_us-gaap_InventoryGross" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryNet" xlink:to="loc_us-gaap_InventoryGross" use="optional" order="1" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryAdjustments" xlink:label="loc_us-gaap_InventoryAdjustments" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryNet" xlink:to="loc_us-gaap_InventoryAdjustments" use="optional" order="2" weight="-1" />
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://haymaker.com/role/PropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross" use="optional" order="1" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" use="optional" order="2" weight="-1" />
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://haymaker.com/role/CapitalizedSoftwareNetSummaryOfCapitalizedSoftwareNetDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalizedComputerSoftwareNet" xlink:label="loc_us-gaap_CapitalizedComputerSoftwareNet" />
<loc xlink:type="locator" xlink:href="btmd-20221231.xsd#btmd_CapitalizedSoftwareWebsiteCosts" xlink:label="loc_btmd_CapitalizedSoftwareWebsiteCosts" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CapitalizedComputerSoftwareNet" xlink:to="loc_btmd_CapitalizedSoftwareWebsiteCosts" use="optional" order="1" weight="1" />
<loc xlink:type="locator" xlink:href="btmd-20221231.xsd#btmd_CapitalizedSoftwareDevelopmentInProcess" xlink:label="loc_btmd_CapitalizedSoftwareDevelopmentInProcess" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CapitalizedComputerSoftwareNet" xlink:to="loc_btmd_CapitalizedSoftwareDevelopmentInProcess" use="optional" order="2" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalizedComputerSoftwareAccumulatedAmortization" xlink:label="loc_us-gaap_CapitalizedComputerSoftwareAccumulatedAmortization" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CapitalizedComputerSoftwareNet" xlink:to="loc_us-gaap_CapitalizedComputerSoftwareAccumulatedAmortization" use="optional" order="3" weight="-1" />
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://haymaker.com/role/AccruedExpensesScheduleOfAccruedExpensesDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:to="loc_us-gaap_AccruedProfessionalFeesCurrent" use="optional" order="1" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" use="optional" order="2" weight="1" />
<loc xlink:type="locator" xlink:href="btmd-20221231.xsd#btmd_AccruedMerchantFeesCurrent" xlink:label="loc_btmd_AccruedMerchantFeesCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:to="loc_btmd_AccruedMerchantFeesCurrent" use="optional" order="3" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestPayableCurrent" xlink:label="loc_us-gaap_InterestPayableCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:to="loc_us-gaap_InterestPayableCurrent" use="optional" order="4" weight="1" />
<loc xlink:type="locator" xlink:href="btmd-20221231.xsd#btmd_LegalAccrualCurrent" xlink:label="loc_btmd_LegalAccrualCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:to="loc_btmd_LegalAccrualCurrent" use="optional" order="5" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent" use="optional" order="6" weight="1" />
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://haymaker.com/role/LongTermDebtScheduleOfOutstandingDebtDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtNoncurrent" xlink:label="loc_us-gaap_LongTermDebtNoncurrent" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredFinanceCostsNet" xlink:label="loc_us-gaap_DeferredFinanceCostsNet" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebtNoncurrent" xlink:to="loc_us-gaap_DeferredFinanceCostsNet" use="optional" order="1" weight="-1" />
<loc xlink:type="locator" xlink:href="btmd-20221231.xsd#btmd_TeamLoanNonCurrentPortionBeforeUnamortizedDebtIssuanceCosts" xlink:label="loc_btmd_TeamLoanNonCurrentPortionBeforeUnamortizedDebtIssuanceCosts" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebtNoncurrent" xlink:to="loc_btmd_TeamLoanNonCurrentPortionBeforeUnamortizedDebtIssuanceCosts" use="optional" order="2" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentCarryingAmount" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_btmd_TeamLoanNonCurrentPortionBeforeUnamortizedDebtIssuanceCosts" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount" use="optional" order="3" weight="1" />
<loc xlink:type="locator" xlink:href="btmd-20221231.xsd#btmd_TeamLoanCurrentPortionBeforeUnamortizedDebtIssuanceCosts" xlink:label="loc_btmd_TeamLoanCurrentPortionBeforeUnamortizedDebtIssuanceCosts" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_btmd_TeamLoanNonCurrentPortionBeforeUnamortizedDebtIssuanceCosts" xlink:to="loc_btmd_TeamLoanCurrentPortionBeforeUnamortizedDebtIssuanceCosts" use="optional" order="4" weight="1" />
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://haymaker.com/role/LeasesSummaryOfOperatingLeaseCostsRecognizedUnderAsc842AndSupplementalCashFlowInformationForLeasesDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseCost" xlink:label="loc_us-gaap_LeaseCost" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseCost" xlink:label="loc_us-gaap_OperatingLeaseCost" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LeaseCost" xlink:to="loc_us-gaap_OperatingLeaseCost" use="optional" order="1" weight="1" />
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://haymaker.com/role/LeasesSummaryBalanceSheetClassificationOfOperatingLeasesAndWeightedAverageRemainingLeaseTermAndDiscountRateDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability" xlink:label="loc_us-gaap_OperatingLeaseLiability" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeaseLiability" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent" use="optional" order="1" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeaseLiability" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" use="optional" order="2" weight="1" />
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://haymaker.com/role/LeasesSummaryBalanceSheetClassificationOfOperatingLeasesAndWeightedAverageRemainingLeaseTermAndDiscountRateDetails">
<loc xlink:type="locator" xlink:href="btmd-20221231.xsd#btmd_LeaseAssets" xlink:label="loc_btmd_LeaseAssets" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_btmd_LeaseAssets" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset" use="optional" order="3" weight="1" />
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://haymaker.com/role/LeasesSummaryOfPaymentsByDateForOperatingLeaseDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" use="optional" order="1" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" use="optional" order="2" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" use="optional" order="3" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" use="optional" order="4" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" use="optional" order="5" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" use="optional" order="6" weight="1" />
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://haymaker.com/role/IncomeTaxesScheduleOfIncomeLossBeforeProvisionForIncomeTaxesDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" use="optional" order="1" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" use="optional" order="2" weight="1" />
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://haymaker.com/role/IncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="loc_us-gaap_DeferredTaxAssetsNet" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="loc_us-gaap_DeferredTaxAssetsGross" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsNet" xlink:to="loc_us-gaap_DeferredTaxAssetsGross" use="optional" order="1" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsInvestments" xlink:label="loc_us-gaap_DeferredTaxAssetsInvestments" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross" xlink:to="loc_us-gaap_DeferredTaxAssetsInvestments" use="optional" order="2" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" use="optional" order="3" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:label="loc_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross" xlink:to="loc_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" use="optional" order="4" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsNet" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance" use="optional" order="5" weight="-1" />
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://haymaker.com/role/ConsolidatedBalanceSheets">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets" xlink:to="loc_us-gaap_AssetsCurrent" use="optional" order="1" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Cash" xlink:label="loc_us-gaap_Cash" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="loc_us-gaap_Cash" use="optional" order="2" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent" use="optional" order="3" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNet" xlink:label="loc_us-gaap_InventoryNet" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="loc_us-gaap_InventoryNet" use="optional" order="4" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" use="optional" order="5" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet" use="optional" order="6" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalizedComputerSoftwareNet" xlink:label="loc_us-gaap_CapitalizedComputerSoftwareNet" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets" xlink:to="loc_us-gaap_CapitalizedComputerSoftwareNet" use="optional" order="7" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset" use="optional" order="8" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxAssetsNet" xlink:label="loc_us-gaap_DeferredIncomeTaxAssetsNet" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets" xlink:to="loc_us-gaap_DeferredIncomeTaxAssetsNet" use="optional" order="9" weight="1" />
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://haymaker.com/role/ConsolidatedBalanceSheets">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaap_Liabilities" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaap_Liabilities" use="optional" order="10" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities" xlink:to="loc_us-gaap_LiabilitiesCurrent" use="optional" order="11" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaap_AccountsPayableCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="loc_us-gaap_AccountsPayableCurrent" use="optional" order="12" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent" use="optional" order="13" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtCurrent" xlink:label="loc_us-gaap_LongTermDebtCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="loc_us-gaap_LongTermDebtCurrent" use="optional" order="14" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityCurrent" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent" use="optional" order="15" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent" use="optional" order="16" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtNoncurrent" xlink:label="loc_us-gaap_LongTermDebtNoncurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities" xlink:to="loc_us-gaap_LongTermDebtNoncurrent" use="optional" order="17" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent" use="optional" order="18" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" use="optional" order="19" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantsAndRightsOutstanding" xlink:label="loc_us-gaap_WarrantsAndRightsOutstanding" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities" xlink:to="loc_us-gaap_WarrantsAndRightsOutstanding" use="optional" order="20" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeLiabilitiesNoncurrent" xlink:label="loc_us-gaap_DerivativeLiabilitiesNoncurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities" xlink:to="loc_us-gaap_DerivativeLiabilitiesNoncurrent" use="optional" order="21" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" use="optional" order="22" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MinorityInterest" xlink:label="loc_us-gaap_MinorityInterest" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="loc_us-gaap_MinorityInterest" use="optional" order="23" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="loc_us-gaap_StockholdersEquity" use="optional" order="24" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="loc_us-gaap_CommonStockValue" use="optional" order="25" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaap_AdditionalPaidInCapital" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="loc_us-gaap_AdditionalPaidInCapital" use="optional" order="26" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit" use="optional" order="27" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" use="optional" order="28" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaap_PreferredStockValue" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="loc_us-gaap_PreferredStockValue" use="optional" order="29" weight="1" />
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://haymaker.com/role/NetLossPerCommonShareScheduleOfComputationOfNetLossPerCommonShareDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:to="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" use="optional" order="1" weight="1" />
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://haymaker.com/role/NetLossPerCommonShareScheduleOfComputationOfNetLossPerCommonShareDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" use="optional" order="2" weight="1" />
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://haymaker.com/role/IncomeTaxesScheduleOfIncomeTaxProvisionDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:to="loc_us-gaap_CurrentIncomeTaxExpenseBenefit" use="optional" order="1" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentFederalTaxExpenseBenefit" xlink:label="loc_us-gaap_CurrentFederalTaxExpenseBenefit" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:to="loc_us-gaap_CurrentFederalTaxExpenseBenefit" use="optional" order="2" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:label="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:to="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" use="optional" order="3" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentForeignTaxExpenseBenefit" xlink:label="loc_us-gaap_CurrentForeignTaxExpenseBenefit" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:to="loc_us-gaap_CurrentForeignTaxExpenseBenefit" use="optional" order="4" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit" use="optional" order="5" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:to="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" use="optional" order="6" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:to="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" use="optional" order="7" weight="1" />
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://haymaker.com/role/LongTermDebtScheduleOfFutureMaturitiesOfLongTermDebtDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebt" xlink:label="loc_us-gaap_LongTermDebt" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" use="optional" order="1" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" use="optional" order="2" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" use="optional" order="3" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" use="optional" order="4" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" use="optional" order="5" weight="1" />
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://haymaker.com/role/IncomeTaxesScheduleOfReconciliationOfTheFederalIncomeTaxRateToTheCompanyEffectiveTaxRateDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" use="optional" order="1" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" use="optional" order="2" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxExemptIncome" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxExemptIncome" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxExemptIncome" use="optional" order="3" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" use="optional" order="4" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" use="optional" order="5" weight="1" />
</calculationLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>5
<FILENAME>btmd-20221231_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<!--Generated by DFIN XBRL Instance Document - http://www.dfinsolutions.com/ - Version R3.0 - on 06-April-2023 [03:21:32] {AM}-->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:xbrldt="http://xbrl.org/2005/xbrldt">
<roleRef xlink:type="simple" xlink:href="btmd-20221231.xsd#Cover" roleURI="http://haymaker.com/role/Cover" />
<roleRef xlink:type="simple" xlink:href="btmd-20221231.xsd#ConsolidatedBalanceSheets" roleURI="http://haymaker.com/role/ConsolidatedBalanceSheets" />
<roleRef xlink:type="simple" xlink:href="btmd-20221231.xsd#ConsolidatedBalanceSheetsParenthetical" roleURI="http://haymaker.com/role/ConsolidatedBalanceSheetsParenthetical" />
<roleRef xlink:type="simple" xlink:href="btmd-20221231.xsd#ConsolidatedStatementsOfIncomeAndComprehensiveIncome" roleURI="http://haymaker.com/role/ConsolidatedStatementsOfIncomeAndComprehensiveIncome" />
<roleRef xlink:type="simple" xlink:href="btmd-20221231.xsd#ConsolidatedStatementsOfStockholdersEquityDeficit" roleURI="http://haymaker.com/role/ConsolidatedStatementsOfStockholdersEquityDeficit" />
<roleRef xlink:type="simple" xlink:href="btmd-20221231.xsd#SummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" roleURI="http://haymaker.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" />
<roleRef xlink:type="simple" xlink:href="btmd-20221231.xsd#SummaryOfSignificantAccountingPoliciesSummaryOfEstimatedUsefulLivesOfPropertyAndEquipmentDetails" roleURI="http://haymaker.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfEstimatedUsefulLivesOfPropertyAndEquipmentDetails" />
<roleRef xlink:type="simple" xlink:href="btmd-20221231.xsd#SummaryOfSignificantAccountingPoliciesSummaryOfMembersEquityUnitsIssuedAndOutstandingDetails" roleURI="http://haymaker.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfMembersEquityUnitsIssuedAndOutstandingDetails" />
<roleRef xlink:type="simple" xlink:href="btmd-20221231.xsd#SummaryOfSignificantAccountingPoliciesSummaryOfCommonStockIssuedAndOutstandingDetails" roleURI="http://haymaker.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfCommonStockIssuedAndOutstandingDetails" />
<roleRef xlink:type="simple" xlink:href="btmd-20221231.xsd#BusinessCombinationAdditionalInformationDetails" roleURI="http://haymaker.com/role/BusinessCombinationAdditionalInformationDetails" />
<roleRef xlink:type="simple" xlink:href="btmd-20221231.xsd#RevenueRecognitionScheduleOfRevenuesRecognizedForEachRevenueStreamDetails" roleURI="http://haymaker.com/role/RevenueRecognitionScheduleOfRevenuesRecognizedForEachRevenueStreamDetails" />
<roleRef xlink:type="simple" xlink:href="btmd-20221231.xsd#RevenueRecognitionScheduleOfRevenuesRecognizedByGeographicRegionDetails" roleURI="http://haymaker.com/role/RevenueRecognitionScheduleOfRevenuesRecognizedByGeographicRegionDetails" />
<roleRef xlink:type="simple" xlink:href="btmd-20221231.xsd#RevenueRecognitionSummaryOfSignificantChangesInContractLiabilityBalancesDetails" roleURI="http://haymaker.com/role/RevenueRecognitionSummaryOfSignificantChangesInContractLiabilityBalancesDetails" />
<roleRef xlink:type="simple" xlink:href="btmd-20221231.xsd#RevenueRecognitionSummaryOfConsiderationAllocatedToPerformanceObligationsDetails" roleURI="http://haymaker.com/role/RevenueRecognitionSummaryOfConsiderationAllocatedToPerformanceObligationsDetails" />
<roleRef xlink:type="simple" xlink:href="btmd-20221231.xsd#InventoryNetScheduleOfInventoryNetDetails" roleURI="http://haymaker.com/role/InventoryNetScheduleOfInventoryNetDetails" />
<roleRef xlink:type="simple" xlink:href="btmd-20221231.xsd#PropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetails" roleURI="http://haymaker.com/role/PropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetails" />
<roleRef xlink:type="simple" xlink:href="btmd-20221231.xsd#LongTermDebtAdditionalInformationDetails" roleURI="http://haymaker.com/role/LongTermDebtAdditionalInformationDetails" />
<roleRef xlink:type="simple" xlink:href="btmd-20221231.xsd#WarrantLiabilityAdditionalInformationDetails" roleURI="http://haymaker.com/role/WarrantLiabilityAdditionalInformationDetails" />
<roleRef xlink:type="simple" xlink:href="btmd-20221231.xsd#EarnoutLiabilityAdditionalInformationDetails" roleURI="http://haymaker.com/role/EarnoutLiabilityAdditionalInformationDetails" />
<roleRef xlink:type="simple" xlink:href="btmd-20221231.xsd#FairValueMeasurementsScheduleOfFairValueHierarchyForFinancialAssetsAndLiabilitiesDetails" roleURI="http://haymaker.com/role/FairValueMeasurementsScheduleOfFairValueHierarchyForFinancialAssetsAndLiabilitiesDetails" />
<roleRef xlink:type="simple" xlink:href="btmd-20221231.xsd#FairValueMeasurementsSummaryOfSignificantInputsToMonteCarloSimulationForFairValueOfPrivatePlacementWarrantsDetails" roleURI="http://haymaker.com/role/FairValueMeasurementsSummaryOfSignificantInputsToMonteCarloSimulationForFairValueOfPrivatePlacementWarrantsDetails" />
<roleRef xlink:type="simple" xlink:href="btmd-20221231.xsd#FairValueMeasurementsSummaryOfSignificantInputsToMonteCarloSimulationForFairValueOfEarnoutLiabilityDetails" roleURI="http://haymaker.com/role/FairValueMeasurementsSummaryOfSignificantInputsToMonteCarloSimulationForFairValueOfEarnoutLiabilityDetails" />
<roleRef xlink:type="simple" xlink:href="btmd-20221231.xsd#FairValueMeasurementsSummaryOfChangesInTheFairValueOfCompanysLevel3FinancialInstrumentsDetails" roleURI="http://haymaker.com/role/FairValueMeasurementsSummaryOfChangesInTheFairValueOfCompanysLevel3FinancialInstrumentsDetails" />
<roleRef xlink:type="simple" xlink:href="btmd-20221231.xsd#NoncontrollingInterestAdditionalInformationDetails" roleURI="http://haymaker.com/role/NoncontrollingInterestAdditionalInformationDetails" />
<roleRef xlink:type="simple" xlink:href="btmd-20221231.xsd#ShareBasedCompensationAdditionalInformationDetails" roleURI="http://haymaker.com/role/ShareBasedCompensationAdditionalInformationDetails" />
<roleRef xlink:type="simple" xlink:href="btmd-20221231.xsd#ShareBasedCompensationSummaryOfRestrictedStockUnitActivityDetails" roleURI="http://haymaker.com/role/ShareBasedCompensationSummaryOfRestrictedStockUnitActivityDetails" />
<roleRef xlink:type="simple" xlink:href="btmd-20221231.xsd#ShareBasedCompensationSummaryOfStockOptionActivityDetails" roleURI="http://haymaker.com/role/ShareBasedCompensationSummaryOfStockOptionActivityDetails" />
<roleRef xlink:type="simple" xlink:href="btmd-20221231.xsd#ShareBasedCompensationSummaryOfWeightedAverageAssumptionsUsedToEstimateFairValueOfStockOptionsGrantedDetails" roleURI="http://haymaker.com/role/ShareBasedCompensationSummaryOfWeightedAverageAssumptionsUsedToEstimateFairValueOfStockOptionsGrantedDetails" />
<roleRef xlink:type="simple" xlink:href="btmd-20221231.xsd#IncomeTaxesAdditionalInformationDetails" roleURI="http://haymaker.com/role/IncomeTaxesAdditionalInformationDetails" />
<roleRef xlink:type="simple" xlink:href="btmd-20221231.xsd#NetLossPerCommonShareScheduleOfComputationOfNetLossPerCommonShareDetails" roleURI="http://haymaker.com/role/NetLossPerCommonShareScheduleOfComputationOfNetLossPerCommonShareDetails" />
<roleRef xlink:type="simple" xlink:href="btmd-20221231.xsd#NetLossPerCommonShareScheduleOfComputationOfDilutedWeightedAverageSharesOutstandingDetails" roleURI="http://haymaker.com/role/NetLossPerCommonShareScheduleOfComputationOfDilutedWeightedAverageSharesOutstandingDetails" />
<roleRef xlink:type="simple" xlink:href="btmd-20221231.xsd#CommitmentsAndContingenciesAdditionalInformationDetails" roleURI="http://haymaker.com/role/CommitmentsAndContingenciesAdditionalInformationDetails" />
<roleRef xlink:type="simple" xlink:href="btmd-20221231.xsd#RelatedPartyTransactionsAdditionalInformationDetails" roleURI="http://haymaker.com/role/RelatedPartyTransactionsAdditionalInformationDetails" />
<roleRef xlink:type="simple" xlink:href="btmd-20221231.xsd#ConsolidatedStatementsOfCashFlows" roleURI="http://haymaker.com/role/ConsolidatedStatementsOfCashFlows" />
<roleRef xlink:type="simple" xlink:href="btmd-20221231.xsd#DescriptionOfBusinessAndBasisOfPresentation" roleURI="http://haymaker.com/role/DescriptionOfBusinessAndBasisOfPresentation" />
<roleRef xlink:type="simple" xlink:href="btmd-20221231.xsd#SummaryOfSignificantAccountingPolicies" roleURI="http://haymaker.com/role/SummaryOfSignificantAccountingPolicies" />
<roleRef xlink:type="simple" xlink:href="btmd-20221231.xsd#BusinessCombination" roleURI="http://haymaker.com/role/BusinessCombination" />
<roleRef xlink:type="simple" xlink:href="btmd-20221231.xsd#RevenueRecognition" roleURI="http://haymaker.com/role/RevenueRecognition" />
<roleRef xlink:type="simple" xlink:href="btmd-20221231.xsd#InventoryNet" roleURI="http://haymaker.com/role/InventoryNet" />
<roleRef xlink:type="simple" xlink:href="btmd-20221231.xsd#PropertyAndEquipmentNet" roleURI="http://haymaker.com/role/PropertyAndEquipmentNet" />
<roleRef xlink:type="simple" xlink:href="btmd-20221231.xsd#CapitalizedSoftwareNet" roleURI="http://haymaker.com/role/CapitalizedSoftwareNet" />
<roleRef xlink:type="simple" xlink:href="btmd-20221231.xsd#AccruedExpenses" roleURI="http://haymaker.com/role/AccruedExpenses" />
<roleRef xlink:type="simple" xlink:href="btmd-20221231.xsd#LongTermDebt" roleURI="http://haymaker.com/role/LongTermDebt" />
<roleRef xlink:type="simple" xlink:href="btmd-20221231.xsd#WarrantLiability" roleURI="http://haymaker.com/role/WarrantLiability" />
<roleRef xlink:type="simple" xlink:href="btmd-20221231.xsd#EarnoutLiability" roleURI="http://haymaker.com/role/EarnoutLiability" />
<roleRef xlink:type="simple" xlink:href="btmd-20221231.xsd#FairValueMeasurements" roleURI="http://haymaker.com/role/FairValueMeasurements" />
<roleRef xlink:type="simple" xlink:href="btmd-20221231.xsd#NoncontrollingInterest" roleURI="http://haymaker.com/role/NoncontrollingInterest" />
<roleRef xlink:type="simple" xlink:href="btmd-20221231.xsd#ShareBasedCompensation" roleURI="http://haymaker.com/role/ShareBasedCompensation" />
<roleRef xlink:type="simple" xlink:href="btmd-20221231.xsd#Leases" roleURI="http://haymaker.com/role/Leases" />
<roleRef xlink:type="simple" xlink:href="btmd-20221231.xsd#IncomeTaxes" roleURI="http://haymaker.com/role/IncomeTaxes" />
<roleRef xlink:type="simple" xlink:href="btmd-20221231.xsd#NetLossPerCommonShare" roleURI="http://haymaker.com/role/NetLossPerCommonShare" />
<roleRef xlink:type="simple" xlink:href="btmd-20221231.xsd#CommitmentsAndContingencies" roleURI="http://haymaker.com/role/CommitmentsAndContingencies" />
<roleRef xlink:type="simple" xlink:href="btmd-20221231.xsd#RelatedPartyTransactions" roleURI="http://haymaker.com/role/RelatedPartyTransactions" />
<roleRef xlink:type="simple" xlink:href="btmd-20221231.xsd#SubsequentEvents" roleURI="http://haymaker.com/role/SubsequentEvents" />
<roleRef xlink:type="simple" xlink:href="btmd-20221231.xsd#SummaryOfSignificantAccountingPoliciesPolicies" roleURI="http://haymaker.com/role/SummaryOfSignificantAccountingPoliciesPolicies" />
<roleRef xlink:type="simple" xlink:href="btmd-20221231.xsd#SummaryOfSignificantAccountingPoliciesTables" roleURI="http://haymaker.com/role/SummaryOfSignificantAccountingPoliciesTables" />
<roleRef xlink:type="simple" xlink:href="btmd-20221231.xsd#InventoryNetTables" roleURI="http://haymaker.com/role/InventoryNetTables" />
<roleRef xlink:type="simple" xlink:href="btmd-20221231.xsd#PropertyAndEquipmentNetTables" roleURI="http://haymaker.com/role/PropertyAndEquipmentNetTables" />
<roleRef xlink:type="simple" xlink:href="btmd-20221231.xsd#CapitalizedSoftwareNetTables" roleURI="http://haymaker.com/role/CapitalizedSoftwareNetTables" />
<roleRef xlink:type="simple" xlink:href="btmd-20221231.xsd#AccruedExpensesTables" roleURI="http://haymaker.com/role/AccruedExpensesTables" />
<roleRef xlink:type="simple" xlink:href="btmd-20221231.xsd#LongTermDebtTables" roleURI="http://haymaker.com/role/LongTermDebtTables" />
<roleRef xlink:type="simple" xlink:href="btmd-20221231.xsd#RevenueRecognitionTables" roleURI="http://haymaker.com/role/RevenueRecognitionTables" />
<roleRef xlink:type="simple" xlink:href="btmd-20221231.xsd#FairValueMeasurementsTables" roleURI="http://haymaker.com/role/FairValueMeasurementsTables" />
<roleRef xlink:type="simple" xlink:href="btmd-20221231.xsd#ShareBasedCompensationTables" roleURI="http://haymaker.com/role/ShareBasedCompensationTables" />
<roleRef xlink:type="simple" xlink:href="btmd-20221231.xsd#LeasesTables" roleURI="http://haymaker.com/role/LeasesTables" />
<roleRef xlink:type="simple" xlink:href="btmd-20221231.xsd#SummaryOfSignificantAccountingPoliciesSummaryOfRollforwardOfTheAllowanceForDoubtfulAccountsDetails" roleURI="http://haymaker.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfRollforwardOfTheAllowanceForDoubtfulAccountsDetails" />
<roleRef xlink:type="simple" xlink:href="btmd-20221231.xsd#IncomeTaxesTables" roleURI="http://haymaker.com/role/IncomeTaxesTables" />
<roleRef xlink:type="simple" xlink:href="btmd-20221231.xsd#SummaryOfSignificantAccountingPoliciesSummaryOfTotalOtherCurrentAssetsDetails" roleURI="http://haymaker.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfTotalOtherCurrentAssetsDetails" />
<roleRef xlink:type="simple" xlink:href="btmd-20221231.xsd#RevenueRecognitionAdditionalInformationDetails" roleURI="http://haymaker.com/role/RevenueRecognitionAdditionalInformationDetails" />
<roleRef xlink:type="simple" xlink:href="btmd-20221231.xsd#PropertyAndEquipmentNetAdditionalInformationDetails" roleURI="http://haymaker.com/role/PropertyAndEquipmentNetAdditionalInformationDetails" />
<roleRef xlink:type="simple" xlink:href="btmd-20221231.xsd#CapitalizedSoftwareNetSummaryOfCapitalizedSoftwareNetDetails" roleURI="http://haymaker.com/role/CapitalizedSoftwareNetSummaryOfCapitalizedSoftwareNetDetails" />
<roleRef xlink:type="simple" xlink:href="btmd-20221231.xsd#CapitalizedSoftwareNetAdditionalInformationDetails" roleURI="http://haymaker.com/role/CapitalizedSoftwareNetAdditionalInformationDetails" />
<roleRef xlink:type="simple" xlink:href="btmd-20221231.xsd#AccruedExpensesScheduleOfAccruedExpensesDetails" roleURI="http://haymaker.com/role/AccruedExpensesScheduleOfAccruedExpensesDetails" />
<roleRef xlink:type="simple" xlink:href="btmd-20221231.xsd#LongTermDebtScheduleOfOutstandingDebtDetails" roleURI="http://haymaker.com/role/LongTermDebtScheduleOfOutstandingDebtDetails" />
<roleRef xlink:type="simple" xlink:href="btmd-20221231.xsd#NetLossPerCommonShareTables" roleURI="http://haymaker.com/role/NetLossPerCommonShareTables" />
<roleRef xlink:type="simple" xlink:href="btmd-20221231.xsd#LeasesAdditionalInformationDetails" roleURI="http://haymaker.com/role/LeasesAdditionalInformationDetails" />
<roleRef xlink:type="simple" xlink:href="btmd-20221231.xsd#LeasesSummaryBalanceSheetClassificationOfOperatingLeasesAndWeightedAverageRemainingLeaseTermAndDiscountRateDetails" roleURI="http://haymaker.com/role/LeasesSummaryBalanceSheetClassificationOfOperatingLeasesAndWeightedAverageRemainingLeaseTermAndDiscountRateDetails" />
<roleRef xlink:type="simple" xlink:href="btmd-20221231.xsd#LeasesSummaryOfPaymentsByDateForOperatingLeaseDetails" roleURI="http://haymaker.com/role/LeasesSummaryOfPaymentsByDateForOperatingLeaseDetails" />
<roleRef xlink:type="simple" xlink:href="btmd-20221231.xsd#LeasesSummaryOfOperatingLeaseCostsRecognizedUnderAsc842AndSupplementalCashFlowInformationForLeasesDetails" roleURI="http://haymaker.com/role/LeasesSummaryOfOperatingLeaseCostsRecognizedUnderAsc842AndSupplementalCashFlowInformationForLeasesDetails" />
<roleRef xlink:type="simple" xlink:href="btmd-20221231.xsd#IncomeTaxesScheduleOfIncomeTaxProvisionDetails" roleURI="http://haymaker.com/role/IncomeTaxesScheduleOfIncomeTaxProvisionDetails" />
<roleRef xlink:type="simple" xlink:href="btmd-20221231.xsd#IncomeTaxesScheduleOfReconciliationOfTheFederalIncomeTaxRateToTheCompanyEffectiveTaxRateDetails" roleURI="http://haymaker.com/role/IncomeTaxesScheduleOfReconciliationOfTheFederalIncomeTaxRateToTheCompanyEffectiveTaxRateDetails" />
<roleRef xlink:type="simple" xlink:href="btmd-20221231.xsd#IncomeTaxesScheduleOfIncomeLossBeforeProvisionForIncomeTaxesDetails" roleURI="http://haymaker.com/role/IncomeTaxesScheduleOfIncomeLossBeforeProvisionForIncomeTaxesDetails" />
<roleRef xlink:type="simple" xlink:href="btmd-20221231.xsd#IncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails" roleURI="http://haymaker.com/role/IncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails" />
<roleRef xlink:type="simple" xlink:href="btmd-20221231.xsd#LongTermDebtScheduleOfFutureMaturitiesOfLongTermDebtDetails" roleURI="http://haymaker.com/role/LongTermDebtScheduleOfFutureMaturitiesOfLongTermDebtDetails" />
<arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" />
<arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" />
<arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" />
<arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" />
<arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" />
<arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/notAll" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#notAll" />
<definitionLink xlink:type="extended" xlink:role="http://haymaker.com/role/Cover">
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentInformationLineItems" xlink:label="loc_dei_DocumentInformationLineItems_112" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType" xlink:label="loc_dei_DocumentType_104" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_112" xlink:to="loc_dei_DocumentType_104" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey" xlink:label="loc_dei_EntityCentralIndexKey_118" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_112" xlink:to="loc_dei_EntityCentralIndexKey_118" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory" xlink:label="loc_dei_EntityFilerCategory_122" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_112" xlink:to="loc_dei_EntityFilerCategory_122" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness" xlink:label="loc_dei_EntitySmallBusiness_123" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_112" xlink:to="loc_dei_EntitySmallBusiness_123" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_dei_EntityEmergingGrowthCompany_126" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_112" xlink:to="loc_dei_EntityEmergingGrowthCompany_126" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityExTransitionPeriod" xlink:label="loc_dei_EntityExTransitionPeriod_127" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_112" xlink:to="loc_dei_EntityExTransitionPeriod_127" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_dei_EntityIncorporationStateCountryCode_133" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_112" xlink:to="loc_dei_EntityIncorporationStateCountryCode_133" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_dei_EntityTaxIdentificationNumber_134" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_112" xlink:to="loc_dei_EntityTaxIdentificationNumber_134" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_dei_EntityAddressAddressLine1_135" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_112" xlink:to="loc_dei_EntityAddressAddressLine1_135" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_dei_EntityAddressCityOrTown_137" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_112" xlink:to="loc_dei_EntityAddressCityOrTown_137" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_dei_EntityAddressStateOrProvince_138" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_112" xlink:to="loc_dei_EntityAddressStateOrProvince_138" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_dei_EntityAddressPostalZipCode_139" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_112" xlink:to="loc_dei_EntityAddressPostalZipCode_139" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode" xlink:label="loc_dei_CityAreaCode_140" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_112" xlink:to="loc_dei_CityAreaCode_140" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber" xlink:label="loc_dei_LocalPhoneNumber_141" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_112" xlink:to="loc_dei_LocalPhoneNumber_141" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentInformationTable" xlink:label="loc_dei_DocumentInformationTable_149" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_dei_DocumentInformationLineItems_112" xlink:to="loc_dei_DocumentInformationTable_149" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_107" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_dei_DocumentInformationTable_149" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_107" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_103" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_107" xlink:to="loc_us-gaap_EquityComponentDomain_103" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_103_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_107" xlink:to="loc_us-gaap_EquityComponentDomain_103_default" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_110" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_dei_DocumentInformationTable_149" xlink:to="loc_us-gaap_StatementClassOfStockAxis_110" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_105" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_110" xlink:to="loc_us-gaap_ClassOfStockDomain_105" use="optional" order="20" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_105_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_110" xlink:to="loc_us-gaap_ClassOfStockDomain_105_default" use="optional" order="21" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressesAddressTypeAxis" xlink:label="loc_dei_EntityAddressesAddressTypeAxis_1242" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_dei_DocumentInformationTable_149" xlink:to="loc_dei_EntityAddressesAddressTypeAxis_1242" use="optional" order="22" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AddressTypeDomain" xlink:label="loc_dei_AddressTypeDomain_1243" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_EntityAddressesAddressTypeAxis_1242" xlink:to="loc_dei_AddressTypeDomain_1243" use="optional" order="23" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AddressTypeDomain" xlink:label="loc_dei_AddressTypeDomain_1243_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_EntityAddressesAddressTypeAxis_1242" xlink:to="loc_dei_AddressTypeDomain_1243_default" use="optional" order="24" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_BusinessContactMember" xlink:label="loc_dei_BusinessContactMember_1244" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_AddressTypeDomain_1243" xlink:to="loc_dei_BusinessContactMember_1244" use="optional" order="25" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag" xlink:label="loc_dei_AmendmentFlag_111" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_112" xlink:to="loc_dei_AmendmentFlag_111" use="optional" order="26" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName" xlink:label="loc_dei_EntityRegistrantName_117" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_112" xlink:to="loc_dei_EntityRegistrantName_117" use="optional" order="27" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityPrimarySicNumber" xlink:label="loc_dei_EntityPrimarySicNumber_1240" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_112" xlink:to="loc_dei_EntityPrimarySicNumber_1240" use="optional" order="28" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_ContactPersonnelName" xlink:label="loc_dei_ContactPersonnelName_1241" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_112" xlink:to="loc_dei_ContactPersonnelName_1241" use="optional" order="29" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://haymaker.com/role/ConsolidatedBalanceSheets">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_162" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_153" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_162" xlink:to="loc_us-gaap_StatementTable_153" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_152" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_153" xlink:to="loc_us-gaap_StatementClassOfStockAxis_152" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_155" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_152" xlink:to="loc_us-gaap_ClassOfStockDomain_155" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_155_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_152" xlink:to="loc_us-gaap_ClassOfStockDomain_155_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonClassAMember" xlink:label="loc_us-gaap_CommonClassAMember_154" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_155" xlink:to="loc_us-gaap_CommonClassAMember_154" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonClassBMember" xlink:label="loc_us-gaap_CommonClassBMember_163" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_155" xlink:to="loc_us-gaap_CommonClassBMember_163" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="btmd-20221231.xsd#btmd_CommonClassVMember" xlink:label="loc_btmd_CommonClassVMember_170" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_155" xlink:to="loc_btmd_CommonClassVMember_170" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaap_AssetsAbstract_156" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_162" xlink:to="loc_us-gaap_AssetsAbstract_156" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaap_AssetsCurrentAbstract_158" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_156" xlink:to="loc_us-gaap_AssetsCurrentAbstract_158" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Cash" xlink:label="loc_us-gaap_Cash_160" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_158" xlink:to="loc_us-gaap_Cash_160" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNet" xlink:label="loc_us-gaap_InventoryNet_174" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_158" xlink:to="loc_us-gaap_InventoryNet_174" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_179" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_158" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_179" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent_184" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_158" xlink:to="loc_us-gaap_AssetsCurrent_184" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_168" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_158" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_168" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_177" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_156" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_177" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxAssetsNet" xlink:label="loc_us-gaap_DeferredIncomeTaxAssetsNet_182" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_156" xlink:to="loc_us-gaap_DeferredIncomeTaxAssetsNet_182" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets_187" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_156" xlink:to="loc_us-gaap_Assets_187" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_166" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_156" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_166" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalizedComputerSoftwareNet" xlink:label="loc_us-gaap_CapitalizedComputerSoftwareNet_172" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_156" xlink:to="loc_us-gaap_CapitalizedComputerSoftwareNet_172" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_164" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_162" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_164" use="optional" order="20" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_159" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_164" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_159" use="optional" order="21" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaap_AccountsPayableCurrent_161" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_159" xlink:to="loc_us-gaap_AccountsPayableCurrent_161" use="optional" order="22" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityCurrent" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_180" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_159" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_180" use="optional" order="23" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_185" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_159" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_185" use="optional" order="24" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent_189" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_159" xlink:to="loc_us-gaap_LiabilitiesCurrent_189" use="optional" order="25" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_169" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_159" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_169" use="optional" order="26" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtCurrent" xlink:label="loc_us-gaap_LongTermDebtCurrent_175" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_159" xlink:to="loc_us-gaap_LongTermDebtCurrent_175" use="optional" order="27" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_178" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_164" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_178" use="optional" order="28" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantsAndRightsOutstanding" xlink:label="loc_us-gaap_WarrantsAndRightsOutstanding_183" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_164" xlink:to="loc_us-gaap_WarrantsAndRightsOutstanding_183" use="optional" order="29" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeLiabilitiesNoncurrent" xlink:label="loc_us-gaap_DerivativeLiabilitiesNoncurrent_188" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_164" xlink:to="loc_us-gaap_DerivativeLiabilitiesNoncurrent_188" use="optional" order="30" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaap_Liabilities_191" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_164" xlink:to="loc_us-gaap_Liabilities_191" use="optional" order="31" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtNoncurrent" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_167" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_164" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_167" use="optional" order="32" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_173" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_164" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_173" use="optional" order="33" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaap_CommitmentsAndContingencies_193" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_164" xlink:to="loc_us-gaap_CommitmentsAndContingencies_193" use="optional" order="34" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_194" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_164" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_194" use="optional" order="35" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaap_PreferredStockValue_157" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_194" xlink:to="loc_us-gaap_PreferredStockValue_157" use="optional" order="36" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue_165" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_194" xlink:to="loc_us-gaap_CommonStockValue_165" use="optional" order="37" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_181" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_194" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_181" use="optional" order="38" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_186" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_194" xlink:to="loc_us-gaap_StockholdersEquity_186" use="optional" order="39" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MinorityInterest" xlink:label="loc_us-gaap_MinorityInterest_190" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_194" xlink:to="loc_us-gaap_MinorityInterest_190" use="optional" order="40" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaap_AdditionalPaidInCapital_171" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_194" xlink:to="loc_us-gaap_AdditionalPaidInCapital_171" use="optional" order="41" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_176" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_194" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_176" use="optional" order="42" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_192" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_194" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_192" use="optional" order="43" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_195" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_164" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_195" use="optional" order="44" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://haymaker.com/role/ConsolidatedBalanceSheetsParenthetical">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_203" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_205" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_203" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_205" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaap_PreferredStockSharesIssued_207" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_203" xlink:to="loc_us-gaap_PreferredStockSharesIssued_207" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_209" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_203" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_209" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorizedUnlimited" xlink:label="loc_us-gaap_CommonStockSharesAuthorizedUnlimited_211" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_203" xlink:to="loc_us-gaap_CommonStockSharesAuthorizedUnlimited_211" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockNoParValue" xlink:label="loc_us-gaap_CommonStockNoParValue_213" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_203" xlink:to="loc_us-gaap_CommonStockNoParValue_213" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_215" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_203" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_215" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_216" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_203" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_216" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_199" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_203" xlink:to="loc_us-gaap_StatementTable_199" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_198" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_199" xlink:to="loc_us-gaap_StatementClassOfStockAxis_198" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_201" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_198" xlink:to="loc_us-gaap_ClassOfStockDomain_201" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_201_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_198" xlink:to="loc_us-gaap_ClassOfStockDomain_201_default" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonClassBMember" xlink:label="loc_us-gaap_CommonClassBMember_204" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_201" xlink:to="loc_us-gaap_CommonClassBMember_204" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="btmd-20221231.xsd#btmd_CommonClassVMember" xlink:label="loc_btmd_CommonClassVMember_206" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_201" xlink:to="loc_btmd_CommonClassVMember_206" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="btmd-20221231.xsd#btmd_ClassAMember" xlink:label="loc_btmd_ClassAMember_208" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_201" xlink:to="loc_btmd_ClassAMember_208" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="btmd-20221231.xsd#btmd_ClassAaUnitsMember" xlink:label="loc_btmd_ClassAaUnitsMember_210" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_201" xlink:to="loc_btmd_ClassAaUnitsMember_210" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="btmd-20221231.xsd#btmd_ClassAaaUnitsMember" xlink:label="loc_btmd_ClassAaaUnitsMember_212" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_201" xlink:to="loc_btmd_ClassAaaUnitsMember_212" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="btmd-20221231.xsd#btmd_ClassAaaaUnitsMember" xlink:label="loc_btmd_ClassAaaaUnitsMember_214" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_201" xlink:to="loc_btmd_ClassAaaaUnitsMember_214" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonClassAMember" xlink:label="loc_us-gaap_CommonClassAMember_200" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_201" xlink:to="loc_us-gaap_CommonClassAMember_200" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_202" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_203" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_202" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaap_CommonStockSharesIssued_217" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_203" xlink:to="loc_us-gaap_CommonStockSharesIssued_217" use="optional" order="20" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_218" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_203" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_218" use="optional" order="21" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://haymaker.com/role/ConsolidatedStatementsOfIncomeAndComprehensiveIncome">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_233" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_225" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_233" xlink:to="loc_us-gaap_StatementTable_225" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srt_ProductOrServiceAxis_222" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_225" xlink:to="loc_srt_ProductOrServiceAxis_222" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_223" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_222" xlink:to="loc_srt_ProductsAndServicesDomain_223" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_223_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_222" xlink:to="loc_srt_ProductsAndServicesDomain_223_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="btmd-20221231.xsd#btmd_ProductRevenueMember" xlink:label="loc_btmd_ProductRevenueMember_230" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_223" xlink:to="loc_btmd_ProductRevenueMember_230" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="btmd-20221231.xsd#btmd_ServiceRevenueMember" xlink:label="loc_btmd_ServiceRevenueMember_237" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_223" xlink:to="loc_btmd_ServiceRevenueMember_237" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenuesAbstract" xlink:label="loc_us-gaap_RevenuesAbstract_226" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_233" xlink:to="loc_us-gaap_RevenuesAbstract_226" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_228" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenuesAbstract_226" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_228" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_243" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_233" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_243" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss_245" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_233" xlink:to="loc_us-gaap_OperatingIncomeLoss_245" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract_247" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_233" xlink:to="loc_us-gaap_NonoperatingIncomeExpenseAbstract_247" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:label="loc_us-gaap_InterestIncomeExpenseNonoperatingNet_229" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_247" xlink:to="loc_us-gaap_InterestIncomeExpenseNonoperatingNet_229" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_242" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_247" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_242" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncome" xlink:label="loc_us-gaap_OtherNonoperatingIncome_244" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_247" xlink:to="loc_us-gaap_OtherNonoperatingIncome_244" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_246" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_247" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_246" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="loc_us-gaap_FairValueAdjustmentOfWarrants_236" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_247" xlink:to="loc_us-gaap_FairValueAdjustmentOfWarrants_236" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="btmd-20221231.xsd#btmd_GainLossFromChangeInFairValueOfEarnoutLiability" xlink:label="loc_btmd_GainLossFromChangeInFairValueOfEarnoutLiability_240" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_247" xlink:to="loc_btmd_GainLossFromChangeInFairValueOfEarnoutLiability_240" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_248" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_233" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_248" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_249" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_233" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_249" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaap_ProfitLoss_250" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_233" xlink:to="loc_us-gaap_ProfitLoss_250" use="optional" order="20" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_251" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_233" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_251" use="optional" order="21" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortizationAbstract" xlink:label="loc_us-gaap_CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortizationAbstract_235" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_233" xlink:to="loc_us-gaap_CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortizationAbstract_235" use="optional" order="22" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization" xlink:label="loc_us-gaap_CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization_227" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortizationAbstract_235" xlink:to="loc_us-gaap_CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization_227" use="optional" order="23" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SalesCommissionsAndFees" xlink:label="loc_us-gaap_SalesCommissionsAndFees_239" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_233" xlink:to="loc_us-gaap_SalesCommissionsAndFees_239" use="optional" order="24" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketingExpense" xlink:label="loc_us-gaap_MarketingExpense_241" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_233" xlink:to="loc_us-gaap_MarketingExpense_241" use="optional" order="25" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_252" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_233" xlink:to="loc_us-gaap_NetIncomeLoss_252" use="optional" order="26" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossTaxPortionAttributableToParentAbstract" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossTaxPortionAttributableToParentAbstract_253" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_233" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossTaxPortionAttributableToParentAbstract_253" use="optional" order="27" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_238" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossTaxPortionAttributableToParentAbstract_253" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_238" use="optional" order="28" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax_231" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossTaxPortionAttributableToParentAbstract_253" xlink:to="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax_231" use="optional" order="29" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_254" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_233" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_254" use="optional" order="30" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaap_EarningsPerShareAbstract_255" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_233" xlink:to="loc_us-gaap_EarningsPerShareAbstract_255" use="optional" order="31" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic" xlink:label="loc_us-gaap_EarningsPerShareBasic_221" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareAbstract_255" xlink:to="loc_us-gaap_EarningsPerShareBasic_221" use="optional" order="32" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="loc_us-gaap_EarningsPerShareDiluted_232" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareAbstract_255" xlink:to="loc_us-gaap_EarningsPerShareDiluted_232" use="optional" order="33" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_256" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_233" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_256" use="optional" order="34" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_224" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_256" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_224" use="optional" order="35" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_234" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_256" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_234" use="optional" order="36" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://haymaker.com/role/ConsolidatedStatementsOfStockholdersEquityDeficit">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_276" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PartnersCapitalAccountUnits" xlink:label="loc_us-gaap_PartnersCapitalAccountUnits_266" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_276" xlink:to="loc_us-gaap_PartnersCapitalAccountUnits_266" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_271" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_276" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_271" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaap_SharesOutstanding_298" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_276" xlink:to="loc_us-gaap_SharesOutstanding_298" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_261" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_276" xlink:to="loc_us-gaap_StatementTable_261" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_268" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_261" xlink:to="loc_us-gaap_StatementClassOfStockAxis_268" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_265" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_268" xlink:to="loc_us-gaap_ClassOfStockDomain_265" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_265_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_268" xlink:to="loc_us-gaap_ClassOfStockDomain_265_default" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="btmd-20221231.xsd#btmd_CommonClassVMember" xlink:label="loc_btmd_CommonClassVMember_269" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_265" xlink:to="loc_btmd_CommonClassVMember_269" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonClassAMember" xlink:label="loc_us-gaap_CommonClassAMember_262" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_265" xlink:to="loc_us-gaap_CommonClassAMember_262" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RestatementAxis" xlink:label="loc_srt_RestatementAxis_273" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_261" xlink:to="loc_srt_RestatementAxis_273" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RestatementDomain" xlink:label="loc_srt_RestatementDomain_260" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RestatementAxis_273" xlink:to="loc_srt_RestatementDomain_260" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RestatementDomain" xlink:label="loc_srt_RestatementDomain_260_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RestatementAxis_273" xlink:to="loc_srt_RestatementDomain_260_default" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_259" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_261" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_259" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_263" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_259" xlink:to="loc_us-gaap_EquityComponentDomain_263" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_263_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_259" xlink:to="loc_us-gaap_EquityComponentDomain_263_default" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MemberUnitsMember" xlink:label="loc_us-gaap_MemberUnitsMember_267" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_263" xlink:to="loc_us-gaap_MemberUnitsMember_267" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_272" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_263" xlink:to="loc_us-gaap_CommonStockMember_272" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaap_RetainedEarningsMember_275" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_263" xlink:to="loc_us-gaap_RetainedEarningsMember_275" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_278" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_263" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_278" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ParentMember" xlink:label="loc_us-gaap_ParentMember_280" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_263" xlink:to="loc_us-gaap_ParentMember_280" use="optional" order="20" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncontrollingInterestMember" xlink:label="loc_us-gaap_NoncontrollingInterestMember_282" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_263" xlink:to="loc_us-gaap_NoncontrollingInterestMember_282" use="optional" order="21" />
<loc xlink:type="locator" xlink:href="btmd-20221231.xsd#btmd_StockholdersEquityAttributableToNonControllingInterestBusinessCombination" xlink:label="loc_btmd_StockholdersEquityAttributableToNonControllingInterestBusinessCombination_287" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_276" xlink:to="loc_btmd_StockholdersEquityAttributableToNonControllingInterestBusinessCombination_287" use="optional" order="22" />
<loc xlink:type="locator" xlink:href="btmd-20221231.xsd#btmd_StockholdersEquityBussinessCombinationCapitalizedTransactionCosts" xlink:label="loc_btmd_StockholdersEquityBussinessCombinationCapitalizedTransactionCosts_288" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_276" xlink:to="loc_btmd_StockholdersEquityBussinessCombinationCapitalizedTransactionCosts_288" use="optional" order="23" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_290" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_276" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_290" use="optional" order="24" />
<loc xlink:type="locator" xlink:href="btmd-20221231.xsd#btmd_StockIssuedDuringPeriodValueSettlementOfEquityRights" xlink:label="loc_btmd_StockIssuedDuringPeriodValueSettlementOfEquityRights_291" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_276" xlink:to="loc_btmd_StockIssuedDuringPeriodValueSettlementOfEquityRights_291" use="optional" order="25" />
<loc xlink:type="locator" xlink:href="btmd-20221231.xsd#btmd_StockIssuedDuringPeriodValueVestingOfRestrictedStockUnit" xlink:label="loc_btmd_StockIssuedDuringPeriodValueVestingOfRestrictedStockUnit_292" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_276" xlink:to="loc_btmd_StockIssuedDuringPeriodValueVestingOfRestrictedStockUnit_292" use="optional" order="26" />
<loc xlink:type="locator" xlink:href="btmd-20221231.xsd#btmd_StockIssuedDuringPeriodSharesVestingOfRestrictedStockUnit" xlink:label="loc_btmd_StockIssuedDuringPeriodSharesVestingOfRestrictedStockUnit_293" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_276" xlink:to="loc_btmd_StockIssuedDuringPeriodSharesVestingOfRestrictedStockUnit_293" use="optional" order="27" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_294" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_276" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_294" use="optional" order="28" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_295" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_276" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_295" use="optional" order="29" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DividendsCommonStock" xlink:label="loc_us-gaap_DividendsCommonStock_277" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_276" xlink:to="loc_us-gaap_DividendsCommonStock_277" use="optional" order="30" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaap_ProfitLoss_281" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_276" xlink:to="loc_us-gaap_ProfitLoss_281" use="optional" order="31" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_283" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_276" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_283" use="optional" order="32" />
<loc xlink:type="locator" xlink:href="btmd-20221231.xsd#btmd_PartnersCapitalAccountReverseRecapitalizationUnits" xlink:label="loc_btmd_PartnersCapitalAccountReverseRecapitalizationUnits_284" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_276" xlink:to="loc_btmd_PartnersCapitalAccountReverseRecapitalizationUnits_284" use="optional" order="33" />
<loc xlink:type="locator" xlink:href="btmd-20221231.xsd#btmd_StockholdersEquityIncludingPortionAttributableToNonControllingInterestReverseRecapitalization" xlink:label="loc_btmd_StockholdersEquityIncludingPortionAttributableToNonControllingInterestReverseRecapitalization_285" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_276" xlink:to="loc_btmd_StockholdersEquityIncludingPortionAttributableToNonControllingInterestReverseRecapitalization_285" use="optional" order="34" />
<loc xlink:type="locator" xlink:href="btmd-20221231.xsd#btmd_StockholdersEquityIncludingPortionAttributableToNonControllingInterestSharesReverseRecapitalization" xlink:label="loc_btmd_StockholdersEquityIncludingPortionAttributableToNonControllingInterestSharesReverseRecapitalization_286" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_276" xlink:to="loc_btmd_StockholdersEquityIncludingPortionAttributableToNonControllingInterestSharesReverseRecapitalization_286" use="optional" order="35" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://haymaker.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProductInformationLineItems" xlink:label="loc_us-gaap_ProductInformationLineItems_567" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="loc_us-gaap_NumberOfOperatingSegments_524" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProductInformationLineItems_567" xlink:to="loc_us-gaap_NumberOfOperatingSegments_524" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfProductInformationTable" xlink:label="loc_us-gaap_ScheduleOfProductInformationTable_527" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ProductInformationLineItems_567" xlink:to="loc_us-gaap_ScheduleOfProductInformationTable_527" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalUnitsByClassAxis" xlink:label="loc_us-gaap_CapitalUnitsByClassAxis_512" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfProductInformationTable_527" xlink:to="loc_us-gaap_CapitalUnitsByClassAxis_512" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalUnitClassDomain" xlink:label="loc_us-gaap_CapitalUnitClassDomain_507" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CapitalUnitsByClassAxis_512" xlink:to="loc_us-gaap_CapitalUnitClassDomain_507" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalUnitClassDomain" xlink:label="loc_us-gaap_CapitalUnitClassDomain_507_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CapitalUnitsByClassAxis_512" xlink:to="loc_us-gaap_CapitalUnitClassDomain_507_default" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="btmd-20221231.xsd#btmd_ClassAVotingUnitsMember" xlink:label="loc_btmd_ClassAVotingUnitsMember_534" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CapitalUnitClassDomain_507" xlink:to="loc_btmd_ClassAVotingUnitsMember_534" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srt_ProductOrServiceAxis_536" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfProductInformationTable_527" xlink:to="loc_srt_ProductOrServiceAxis_536" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_505" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_536" xlink:to="loc_srt_ProductsAndServicesDomain_505" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_505_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_536" xlink:to="loc_srt_ProductsAndServicesDomain_505_default" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="btmd-20221231.xsd#btmd_InventoryMember" xlink:label="loc_btmd_InventoryMember_530" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_505" xlink:to="loc_btmd_InventoryMember_530" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="btmd-20221231.xsd#btmd_NatureOfCustomerAxis" xlink:label="loc_btmd_NatureOfCustomerAxis_543" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfProductInformationTable_527" xlink:to="loc_btmd_NatureOfCustomerAxis_543" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="btmd-20221231.xsd#btmd_NatureOfCustomerDomain" xlink:label="loc_btmd_NatureOfCustomerDomain_504" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_btmd_NatureOfCustomerAxis_543" xlink:to="loc_btmd_NatureOfCustomerDomain_504" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="btmd-20221231.xsd#btmd_NatureOfCustomerDomain" xlink:label="loc_btmd_NatureOfCustomerDomain_504_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_btmd_NatureOfCustomerAxis_543" xlink:to="loc_btmd_NatureOfCustomerDomain_504_default" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="btmd-20221231.xsd#btmd_BioteMethodCustomerMember" xlink:label="loc_btmd_BioteMethodCustomerMember_514" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_btmd_NatureOfCustomerDomain_504" xlink:to="loc_btmd_BioteMethodCustomerMember_514" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="btmd-20221231.xsd#btmd_SourceOfRevenueAxis" xlink:label="loc_btmd_SourceOfRevenueAxis_545" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfProductInformationTable_527" xlink:to="loc_btmd_SourceOfRevenueAxis_545" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="btmd-20221231.xsd#btmd_SourceOfRevenueDomain" xlink:label="loc_btmd_SourceOfRevenueDomain_509" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_btmd_SourceOfRevenueAxis_545" xlink:to="loc_btmd_SourceOfRevenueDomain_509" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="btmd-20221231.xsd#btmd_SourceOfRevenueDomain" xlink:label="loc_btmd_SourceOfRevenueDomain_509_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_btmd_SourceOfRevenueAxis_545" xlink:to="loc_btmd_SourceOfRevenueDomain_509_default" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="btmd-20221231.xsd#btmd_ServiceRevenueMember" xlink:label="loc_btmd_ServiceRevenueMember_513" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_btmd_SourceOfRevenueDomain_509" xlink:to="loc_btmd_ServiceRevenueMember_513" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="btmd-20221231.xsd#btmd_ProductRevenueMember" xlink:label="loc_btmd_ProductRevenueMember_537" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_btmd_SourceOfRevenueDomain_509" xlink:to="loc_btmd_ProductRevenueMember_537" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="btmd-20221231.xsd#btmd_SourceOfServiceRevenueAxis" xlink:label="loc_btmd_SourceOfServiceRevenueAxis_547" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfProductInformationTable_527" xlink:to="loc_btmd_SourceOfServiceRevenueAxis_547" use="optional" order="20" />
<loc xlink:type="locator" xlink:href="btmd-20221231.xsd#btmd_SourceOfServiceRevenueDomain" xlink:label="loc_btmd_SourceOfServiceRevenueDomain_515" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_btmd_SourceOfServiceRevenueAxis_547" xlink:to="loc_btmd_SourceOfServiceRevenueDomain_515" use="optional" order="21" />
<loc xlink:type="locator" xlink:href="btmd-20221231.xsd#btmd_SourceOfServiceRevenueDomain" xlink:label="loc_btmd_SourceOfServiceRevenueDomain_515_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_btmd_SourceOfServiceRevenueAxis_547" xlink:to="loc_btmd_SourceOfServiceRevenueDomain_515_default" use="optional" order="22" />
<loc xlink:type="locator" xlink:href="btmd-20221231.xsd#btmd_TrainingMember" xlink:label="loc_btmd_TrainingMember_510" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_btmd_SourceOfServiceRevenueDomain_515" xlink:to="loc_btmd_TrainingMember_510" use="optional" order="23" />
<loc xlink:type="locator" xlink:href="btmd-20221231.xsd#btmd_ContractTermServicesMember" xlink:label="loc_btmd_ContractTermServicesMember_535" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_btmd_SourceOfServiceRevenueDomain_515" xlink:to="loc_btmd_ContractTermServicesMember_535" use="optional" order="24" />
<loc xlink:type="locator" xlink:href="btmd-20221231.xsd#btmd_PalletProceduresMember" xlink:label="loc_btmd_PalletProceduresMember_542" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_btmd_SourceOfServiceRevenueDomain_515" xlink:to="loc_btmd_PalletProceduresMember_542" use="optional" order="25" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_549" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfProductInformationTable_527" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_549" use="optional" order="26" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_506" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_549" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_506" use="optional" order="27" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_506_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_549" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_506_default" use="optional" order="28" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditAvailabilityConcentrationRiskMember" xlink:label="loc_us-gaap_CreditAvailabilityConcentrationRiskMember_532" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_506" xlink:to="loc_us-gaap_CreditAvailabilityConcentrationRiskMember_532" use="optional" order="29" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplierConcentrationRiskMember" xlink:label="loc_us-gaap_SupplierConcentrationRiskMember_541" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_506" xlink:to="loc_us-gaap_SupplierConcentrationRiskMember_541" use="optional" order="30" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_551" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfProductInformationTable_527" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_551" use="optional" order="31" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_529" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_551" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_529" use="optional" order="32" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_529_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_551" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_529_default" use="optional" order="33" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesTotalMember" xlink:label="loc_us-gaap_LiabilitiesTotalMember_520" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_529" xlink:to="loc_us-gaap_LiabilitiesTotalMember_520" use="optional" order="34" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsTotalMember" xlink:label="loc_us-gaap_AssetsTotalMember_539" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_529" xlink:to="loc_us-gaap_AssetsTotalMember_539" use="optional" order="35" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanNameAxis" xlink:label="loc_us-gaap_RetirementPlanNameAxis_553" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfProductInformationTable_527" xlink:to="loc_us-gaap_RetirementPlanNameAxis_553" use="optional" order="36" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanNameDomain" xlink:label="loc_us-gaap_RetirementPlanNameDomain_531" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RetirementPlanNameAxis_553" xlink:to="loc_us-gaap_RetirementPlanNameDomain_531" use="optional" order="37" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanNameDomain" xlink:label="loc_us-gaap_RetirementPlanNameDomain_531_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RetirementPlanNameAxis_553" xlink:to="loc_us-gaap_RetirementPlanNameDomain_531_default" use="optional" order="38" />
<loc xlink:type="locator" xlink:href="btmd-20221231.xsd#btmd_FourZeroOneKPlanMember" xlink:label="loc_btmd_FourZeroOneKPlanMember_526" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanNameDomain_531" xlink:to="loc_btmd_FourZeroOneKPlanMember_526" use="optional" order="39" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_555" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfProductInformationTable_527" xlink:to="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_555" use="optional" order="40" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="loc_us-gaap_TypeOfAdoptionMember_525" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_555" xlink:to="loc_us-gaap_TypeOfAdoptionMember_525" use="optional" order="41" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="loc_us-gaap_TypeOfAdoptionMember_525_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_555" xlink:to="loc_us-gaap_TypeOfAdoptionMember_525_default" use="optional" order="42" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingStandardsUpdate201912Member" xlink:label="loc_us-gaap_AccountingStandardsUpdate201912Member_521" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TypeOfAdoptionMember_525" xlink:to="loc_us-gaap_AccountingStandardsUpdate201912Member_521" use="optional" order="43" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_557" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfProductInformationTable_527" xlink:to="loc_us-gaap_TypeOfArrangementAxis_557" use="optional" order="44" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_508" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_557" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_508" use="optional" order="45" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_508_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_557" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_508_default" use="optional" order="46" />
<loc xlink:type="locator" xlink:href="btmd-20221231.xsd#btmd_StandbyEquityPurchaseAgreementMember" xlink:label="loc_btmd_StandbyEquityPurchaseAgreementMember_522" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_508" xlink:to="loc_btmd_StandbyEquityPurchaseAgreementMember_522" use="optional" order="47" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityAxis" xlink:label="loc_us-gaap_CreditFacilityAxis_559" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfProductInformationTable_527" xlink:to="loc_us-gaap_CreditFacilityAxis_559" use="optional" order="48" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityDomain" xlink:label="loc_us-gaap_CreditFacilityDomain_519" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CreditFacilityAxis_559" xlink:to="loc_us-gaap_CreditFacilityDomain_519" use="optional" order="49" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityDomain" xlink:label="loc_us-gaap_CreditFacilityDomain_519_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CreditFacilityAxis_559" xlink:to="loc_us-gaap_CreditFacilityDomain_519_default" use="optional" order="50" />
<loc xlink:type="locator" xlink:href="btmd-20221231.xsd#btmd_YorkvilleAdvisorsGlobalLpMember" xlink:label="loc_btmd_YorkvilleAdvisorsGlobalLpMember_518" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CreditFacilityDomain_519" xlink:to="loc_btmd_YorkvilleAdvisorsGlobalLpMember_518" use="optional" order="51" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_561" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfProductInformationTable_527" xlink:to="loc_us-gaap_StatementClassOfStockAxis_561" use="optional" order="52" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_523" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_561" xlink:to="loc_us-gaap_ClassOfStockDomain_523" use="optional" order="53" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_523_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_561" xlink:to="loc_us-gaap_ClassOfStockDomain_523_default" use="optional" order="54" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonClassAMember" xlink:label="loc_us-gaap_CommonClassAMember_517" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_523" xlink:to="loc_us-gaap_CommonClassAMember_517" use="optional" order="55" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_563" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfProductInformationTable_527" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_563" use="optional" order="56" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_528" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_563" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_528" use="optional" order="57" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_528_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_563" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_528_default" use="optional" order="58" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_565" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfProductInformationTable_527" xlink:to="loc_srt_RangeAxis_565" use="optional" order="59" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_511" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_565" xlink:to="loc_srt_RangeMember_511" use="optional" order="60" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_511_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_565" xlink:to="loc_srt_RangeMember_511_default" use="optional" order="61" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_516" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_511" xlink:to="loc_srt_MinimumMember_516" use="optional" order="62" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_538" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_511" xlink:to="loc_srt_MaximumMember_538" use="optional" order="63" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NumberOfReportableSegments" xlink:label="loc_us-gaap_NumberOfReportableSegments_540" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProductInformationLineItems_567" xlink:to="loc_us-gaap_NumberOfReportableSegments_540" use="optional" order="64" />
<loc xlink:type="locator" xlink:href="btmd-20221231.xsd#btmd_CapitalizedSoftwareEstimatedUsefulLives" xlink:label="loc_btmd_CapitalizedSoftwareEstimatedUsefulLives_544" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProductInformationLineItems_567" xlink:to="loc_btmd_CapitalizedSoftwareEstimatedUsefulLives_544" use="optional" order="65" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:label="loc_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_546" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProductInformationLineItems_567" xlink:to="loc_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_546" use="optional" order="66" />
<loc xlink:type="locator" xlink:href="btmd-20221231.xsd#btmd_CommonUnitsVotingRightsPercentage" xlink:label="loc_btmd_CommonUnitsVotingRightsPercentage_550" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProductInformationLineItems_567" xlink:to="loc_btmd_CommonUnitsVotingRightsPercentage_550" use="optional" order="67" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LimitedPartnersCapitalAccountDistributionAmount" xlink:label="loc_us-gaap_LimitedPartnersCapitalAccountDistributionAmount_552" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProductInformationLineItems_567" xlink:to="loc_us-gaap_LimitedPartnersCapitalAccountDistributionAmount_552" use="optional" order="68" />
<loc xlink:type="locator" xlink:href="btmd-20221231.xsd#btmd_PercentageOfCommonStockPurchasePrice" xlink:label="loc_btmd_PercentageOfCommonStockPurchasePrice_554" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProductInformationLineItems_567" xlink:to="loc_btmd_PercentageOfCommonStockPurchasePrice_554" use="optional" order="69" />
<loc xlink:type="locator" xlink:href="btmd-20221231.xsd#btmd_TerminationPeriodOfPurchaseAgreement" xlink:label="loc_btmd_TerminationPeriodOfPurchaseAgreement_556" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProductInformationLineItems_567" xlink:to="loc_btmd_TerminationPeriodOfPurchaseAgreement_556" use="optional" order="70" />
<loc xlink:type="locator" xlink:href="btmd-20221231.xsd#btmd_ConsecutiveTradingDays" xlink:label="loc_btmd_ConsecutiveTradingDays_558" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProductInformationLineItems_567" xlink:to="loc_btmd_ConsecutiveTradingDays_558" use="optional" order="71" />
<loc xlink:type="locator" xlink:href="btmd-20221231.xsd#btmd_MandatoryMinimumAmountForIndividualAdvance" xlink:label="loc_btmd_MandatoryMinimumAmountForIndividualAdvance_560" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProductInformationLineItems_567" xlink:to="loc_btmd_MandatoryMinimumAmountForIndividualAdvance_560" use="optional" order="72" />
<loc xlink:type="locator" xlink:href="btmd-20221231.xsd#btmd_MaximumValueOfDailyVolumeTradedThresholdPercentage" xlink:label="loc_btmd_MaximumValueOfDailyVolumeTradedThresholdPercentage_562" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProductInformationLineItems_567" xlink:to="loc_btmd_MaximumValueOfDailyVolumeTradedThresholdPercentage_562" use="optional" order="73" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaap_CommonStockSharesIssued_564" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProductInformationLineItems_567" xlink:to="loc_us-gaap_CommonStockSharesIssued_564" use="optional" order="74" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_568" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProductInformationLineItems_567" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_568" use="optional" order="75" />
<loc xlink:type="locator" xlink:href="btmd-20221231.xsd#btmd_ProceedsFromSettlementOfSEPA" xlink:label="loc_btmd_ProceedsFromSettlementOfSEPA_569" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProductInformationLineItems_567" xlink:to="loc_btmd_ProceedsFromSettlementOfSEPA_569" use="optional" order="76" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRemainingPerformanceObligation" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligation_570" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProductInformationLineItems_567" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligation_570" use="optional" order="77" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityCurrent" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_571" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProductInformationLineItems_567" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_571" use="optional" order="78" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_572" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProductInformationLineItems_567" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_572" use="optional" order="79" />
<loc xlink:type="locator" xlink:href="btmd-20221231.xsd#btmd_ExpectedReturnsAndRefundsToCustomers" xlink:label="loc_btmd_ExpectedReturnsAndRefundsToCustomers_573" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProductInformationLineItems_567" xlink:to="loc_btmd_ExpectedReturnsAndRefundsToCustomers_573" use="optional" order="80" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_574" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProductInformationLineItems_567" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_574" use="optional" order="81" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_575" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProductInformationLineItems_567" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_575" use="optional" order="82" />
<loc xlink:type="locator" xlink:href="btmd-20221231.xsd#btmd_NumberOfInventoryVendors" xlink:label="loc_btmd_NumberOfInventoryVendors_576" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProductInformationLineItems_567" xlink:to="loc_btmd_NumberOfInventoryVendors_576" use="optional" order="83" />
<loc xlink:type="locator" xlink:href="btmd-20221231.xsd#btmd_NumberOfCustomersAccountedForTenPercentOrMoreAggregateRevenue" xlink:label="loc_btmd_NumberOfCustomersAccountedForTenPercentOrMoreAggregateRevenue_577" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProductInformationLineItems_567" xlink:to="loc_btmd_NumberOfCustomersAccountedForTenPercentOrMoreAggregateRevenue_577" use="optional" order="84" />
<loc xlink:type="locator" xlink:href="btmd-20221231.xsd#btmd_NumberOfCustomersAccountedForTenPercentOrMoreAccountsReceivable" xlink:label="loc_btmd_NumberOfCustomersAccountedForTenPercentOrMoreAccountsReceivable_578" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProductInformationLineItems_567" xlink:to="loc_btmd_NumberOfCustomersAccountedForTenPercentOrMoreAccountsReceivable_578" use="optional" order="85" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" xlink:label="loc_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch_579" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProductInformationLineItems_567" xlink:to="loc_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch_579" use="optional" order="86" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:label="loc_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount_580" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProductInformationLineItems_567" xlink:to="loc_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount_580" use="optional" order="87" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SalesCommissionsAndFees" xlink:label="loc_us-gaap_SalesCommissionsAndFees_581" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProductInformationLineItems_567" xlink:to="loc_us-gaap_SalesCommissionsAndFees_581" use="optional" order="88" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalizedContractCostAmortization" xlink:label="loc_us-gaap_CapitalizedContractCostAmortization_582" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProductInformationLineItems_567" xlink:to="loc_us-gaap_CapitalizedContractCostAmortization_582" use="optional" order="89" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate" xlink:label="loc_us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate_583" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProductInformationLineItems_567" xlink:to="loc_us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate_583" use="optional" order="90" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted" xlink:label="loc_us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted_584" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProductInformationLineItems_567" xlink:to="loc_us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted_584" use="optional" order="91" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect" xlink:label="loc_us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect_585" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProductInformationLineItems_567" xlink:to="loc_us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect_585" use="optional" order="92" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://haymaker.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfEstimatedUsefulLivesOfPropertyAndEquipmentDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_611" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_600" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_611" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_600" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_603" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_611" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_603" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_604" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_603" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_604" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_605" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_604" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_605" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_605_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_604" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_605_default" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="btmd-20221231.xsd#btmd_TrocarsMember" xlink:label="loc_btmd_TrocarsMember_606" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_605" xlink:to="loc_btmd_TrocarsMember_606" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_610" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_605" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_610" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OfficeEquipmentMember" xlink:label="loc_us-gaap_OfficeEquipmentMember_612" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_605" xlink:to="loc_us-gaap_OfficeEquipmentMember_612" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SoftwareDevelopmentMember" xlink:label="loc_us-gaap_SoftwareDevelopmentMember_613" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_605" xlink:to="loc_us-gaap_SoftwareDevelopmentMember_613" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_614" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_605" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_614" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComputerEquipmentMember" xlink:label="loc_us-gaap_ComputerEquipmentMember_615" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_605" xlink:to="loc_us-gaap_ComputerEquipmentMember_615" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_609" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_603" xlink:to="loc_srt_RangeAxis_609" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_601" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_609" xlink:to="loc_srt_RangeMember_601" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_601_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_609" xlink:to="loc_srt_RangeMember_601_default" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_602" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_601" xlink:to="loc_srt_MinimumMember_602" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_608" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_601" xlink:to="loc_srt_MaximumMember_608" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives_607" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_611" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives_607" use="optional" order="17" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://haymaker.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfMembersEquityUnitsIssuedAndOutstandingDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalUnitLineItems" xlink:label="loc_us-gaap_CapitalUnitLineItems_623" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCapitalUnitsTable" xlink:label="loc_us-gaap_ScheduleOfCapitalUnitsTable_619" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CapitalUnitLineItems_623" xlink:to="loc_us-gaap_ScheduleOfCapitalUnitsTable_619" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalUnitsByClassAxis" xlink:label="loc_us-gaap_CapitalUnitsByClassAxis_620" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCapitalUnitsTable_619" xlink:to="loc_us-gaap_CapitalUnitsByClassAxis_620" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalUnitClassDomain" xlink:label="loc_us-gaap_CapitalUnitClassDomain_618" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CapitalUnitsByClassAxis_620" xlink:to="loc_us-gaap_CapitalUnitClassDomain_618" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalUnitClassDomain" xlink:label="loc_us-gaap_CapitalUnitClassDomain_618_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CapitalUnitsByClassAxis_620" xlink:to="loc_us-gaap_CapitalUnitClassDomain_618_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="btmd-20221231.xsd#btmd_ClassAVotingUnitsMember" xlink:label="loc_btmd_ClassAVotingUnitsMember_622" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CapitalUnitClassDomain_618" xlink:to="loc_btmd_ClassAVotingUnitsMember_622" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="btmd-20221231.xsd#btmd_ClassAaNonVotingUnitsMember" xlink:label="loc_btmd_ClassAaNonVotingUnitsMember_625" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CapitalUnitClassDomain_618" xlink:to="loc_btmd_ClassAaNonVotingUnitsMember_625" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="btmd-20221231.xsd#btmd_ClassAaaNonVotingUnitsMember" xlink:label="loc_btmd_ClassAaaNonVotingUnitsMember_626" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CapitalUnitClassDomain_618" xlink:to="loc_btmd_ClassAaaNonVotingUnitsMember_626" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="btmd-20221231.xsd#btmd_ClassAaaaNonVotingIncentiveUnitsMember" xlink:label="loc_btmd_ClassAaaaNonVotingIncentiveUnitsMember_627" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CapitalUnitClassDomain_618" xlink:to="loc_btmd_ClassAaaaNonVotingIncentiveUnitsMember_627" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonUnitIssued" xlink:label="loc_us-gaap_CommonUnitIssued_621" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CapitalUnitLineItems_623" xlink:to="loc_us-gaap_CommonUnitIssued_621" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonUnitOutstanding" xlink:label="loc_us-gaap_CommonUnitOutstanding_624" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CapitalUnitLineItems_623" xlink:to="loc_us-gaap_CommonUnitOutstanding_624" use="optional" order="10" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://haymaker.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfCommonStockIssuedAndOutstandingDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockLineItems" xlink:label="loc_us-gaap_ClassOfStockLineItems_636" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_631" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfStockLineItems_636" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_631" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_632" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_631" xlink:to="loc_us-gaap_StatementClassOfStockAxis_632" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_633" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_632" xlink:to="loc_us-gaap_ClassOfStockDomain_633" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_633_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_632" xlink:to="loc_us-gaap_ClassOfStockDomain_633_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonClassAMember" xlink:label="loc_us-gaap_CommonClassAMember_630" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_633" xlink:to="loc_us-gaap_CommonClassAMember_630" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonClassBMember" xlink:label="loc_us-gaap_CommonClassBMember_635" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_633" xlink:to="loc_us-gaap_CommonClassBMember_635" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="btmd-20221231.xsd#btmd_ClassVCommonStockMember" xlink:label="loc_btmd_ClassVCommonStockMember_638" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_633" xlink:to="loc_btmd_ClassVCommonStockMember_638" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaap_CommonStockSharesIssued_634" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_636" xlink:to="loc_us-gaap_CommonStockSharesIssued_634" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_637" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_636" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_637" use="optional" order="9" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://haymaker.com/role/BusinessCombinationAdditionalInformationDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_682" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_646" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_682" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_646" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_648" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_646" xlink:to="loc_us-gaap_StatementClassOfStockAxis_648" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_650" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_648" xlink:to="loc_us-gaap_ClassOfStockDomain_650" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_650_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_648" xlink:to="loc_us-gaap_ClassOfStockDomain_650_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonClassAMember" xlink:label="loc_us-gaap_CommonClassAMember_643" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_650" xlink:to="loc_us-gaap_CommonClassAMember_643" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="btmd-20221231.xsd#btmd_ClassVCommonStockMember" xlink:label="loc_btmd_ClassVCommonStockMember_663" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_650" xlink:to="loc_btmd_ClassVCommonStockMember_663" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="btmd-20221231.xsd#btmd_MemberEarnOutUnitsMember" xlink:label="loc_btmd_MemberEarnOutUnitsMember_668" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_650" xlink:to="loc_btmd_MemberEarnOutUnitsMember_668" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="btmd-20221231.xsd#btmd_EarnoutVotingSharesMember" xlink:label="loc_btmd_EarnoutVotingSharesMember_673" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_650" xlink:to="loc_btmd_EarnoutVotingSharesMember_673" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonClassBMember" xlink:label="loc_us-gaap_CommonClassBMember_657" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_650" xlink:to="loc_us-gaap_CommonClassBMember_657" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="btmd-20221231.xsd#btmd_SponsorEarnOutSharesMember" xlink:label="loc_btmd_SponsorEarnOutSharesMember_678" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_650" xlink:to="loc_btmd_SponsorEarnOutSharesMember_678" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_659" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_646" xlink:to="loc_us-gaap_DebtInstrumentAxis_659" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_652" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_659" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_652" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_652_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_659" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_652_default" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="btmd-20221231.xsd#btmd_DebtCommitmentLetterMember" xlink:label="loc_btmd_DebtCommitmentLetterMember_654" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_652" xlink:to="loc_btmd_DebtCommitmentLetterMember_654" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidatedEntitiesAxis" xlink:label="loc_srt_ConsolidatedEntitiesAxis_664" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_646" xlink:to="loc_srt_ConsolidatedEntitiesAxis_664" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidatedEntitiesDomain" xlink:label="loc_srt_ConsolidatedEntitiesDomain_653" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ConsolidatedEntitiesAxis_664" xlink:to="loc_srt_ConsolidatedEntitiesDomain_653" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidatedEntitiesDomain" xlink:label="loc_srt_ConsolidatedEntitiesDomain_653_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ConsolidatedEntitiesAxis_664" xlink:to="loc_srt_ConsolidatedEntitiesDomain_653_default" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="btmd-20221231.xsd#btmd_HaymakeriiiMember" xlink:label="loc_btmd_HaymakeriiiMember_647" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ConsolidatedEntitiesDomain_653" xlink:to="loc_btmd_HaymakeriiiMember_647" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_669" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_646" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_669" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_641" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_669" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_641" use="optional" order="20" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_641_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_669" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_641_default" use="optional" order="21" />
<loc xlink:type="locator" xlink:href="btmd-20221231.xsd#btmd_HaymakerAcquisitionCorpIiiMember" xlink:label="loc_btmd_HaymakerAcquisitionCorpIiiMember_642" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_641" xlink:to="loc_btmd_HaymakerAcquisitionCorpIiiMember_642" use="optional" order="22" />
<loc xlink:type="locator" xlink:href="btmd-20221231.xsd#btmd_BusinessCombinationMember" xlink:label="loc_btmd_BusinessCombinationMember_672" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_641" xlink:to="loc_btmd_BusinessCombinationMember_672" use="optional" order="23" />
<loc xlink:type="locator" xlink:href="btmd-20221231.xsd#btmd_BioteManagementLlcMember" xlink:label="loc_btmd_BioteManagementLlcMember_656" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_641" xlink:to="loc_btmd_BioteManagementLlcMember_656" use="optional" order="24" />
<loc xlink:type="locator" xlink:href="btmd-20221231.xsd#btmd_OtherBusinessCombinationMember" xlink:label="loc_btmd_OtherBusinessCombinationMember_677" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_641" xlink:to="loc_btmd_OtherBusinessCombinationMember_677" use="optional" order="25" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAxis" xlink:label="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAxis_674" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_646" xlink:to="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAxis_674" use="optional" order="26" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsDomain" xlink:label="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsDomain_655" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAxis_674" xlink:to="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsDomain_655" use="optional" order="27" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsDomain" xlink:label="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsDomain_655_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAxis_674" xlink:to="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsDomain_655_default" use="optional" order="28" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityAxis" xlink:label="loc_us-gaap_CreditFacilityAxis_679" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_646" xlink:to="loc_us-gaap_CreditFacilityAxis_679" use="optional" order="29" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityDomain" xlink:label="loc_us-gaap_CreditFacilityDomain_645" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CreditFacilityAxis_679" xlink:to="loc_us-gaap_CreditFacilityDomain_645" use="optional" order="30" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityDomain" xlink:label="loc_us-gaap_CreditFacilityDomain_645_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CreditFacilityAxis_679" xlink:to="loc_us-gaap_CreditFacilityDomain_645_default" use="optional" order="31" />
<loc xlink:type="locator" xlink:href="btmd-20221231.xsd#btmd_SeniorSecuredRevolvingCreditFacilityMember" xlink:label="loc_btmd_SeniorSecuredRevolvingCreditFacilityMember_644" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CreditFacilityDomain_645" xlink:to="loc_btmd_SeniorSecuredRevolvingCreditFacilityMember_644" use="optional" order="32" />
<loc xlink:type="locator" xlink:href="btmd-20221231.xsd#btmd_SeniorSecuredTermLoanAFacilityMember" xlink:label="loc_btmd_SeniorSecuredTermLoanAFacilityMember_658" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CreditFacilityDomain_645" xlink:to="loc_btmd_SeniorSecuredTermLoanAFacilityMember_658" use="optional" order="33" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationConsiderationTransferred1" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferred1_651" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_682" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferred1_651" use="optional" order="34" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" xlink:label="loc_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_666" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_682" xlink:to="loc_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_666" use="optional" order="35" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable_671" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_682" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable_671" use="optional" order="36" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionSharePrice" xlink:label="loc_us-gaap_BusinessAcquisitionSharePrice_661" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_682" xlink:to="loc_us-gaap_BusinessAcquisitionSharePrice_661" use="optional" order="37" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromPreviousAcquisition" xlink:label="loc_us-gaap_ProceedsFromPreviousAcquisition_685" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_682" xlink:to="loc_us-gaap_ProceedsFromPreviousAcquisition_685" use="optional" order="38" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_686" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_682" xlink:to="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_686" use="optional" order="39" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_687" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_682" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_687" use="optional" order="40" />
<loc xlink:type="locator" xlink:href="btmd-20221231.xsd#btmd_CommonStockTransfersThresholdTradingDays" xlink:label="loc_btmd_CommonStockTransfersThresholdTradingDays_688" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_682" xlink:to="loc_btmd_CommonStockTransfersThresholdTradingDays_688" use="optional" order="41" />
<loc xlink:type="locator" xlink:href="btmd-20221231.xsd#btmd_IncomeTaxPercentageOfFederalStateAndLocalIncomeTaxSavings" xlink:label="loc_btmd_IncomeTaxPercentageOfFederalStateAndLocalIncomeTaxSavings_676" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_682" xlink:to="loc_btmd_IncomeTaxPercentageOfFederalStateAndLocalIncomeTaxSavings_676" use="optional" order="42" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionDescriptionOfAcquiredEntity" xlink:label="loc_us-gaap_BusinessAcquisitionDescriptionOfAcquiredEntity_681" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_682" xlink:to="loc_us-gaap_BusinessAcquisitionDescriptionOfAcquiredEntity_681" use="optional" order="43" />
<loc xlink:type="locator" xlink:href="btmd-20221231.xsd#btmd_TaxReceivableAgreementLiability" xlink:label="loc_btmd_TaxReceivableAgreementLiability_683" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_682" xlink:to="loc_btmd_TaxReceivableAgreementLiability_683" use="optional" order="44" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireBusinessesGross" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross_684" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_682" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesGross_684" use="optional" order="45" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://haymaker.com/role/RevenueRecognitionScheduleOfRevenuesRecognizedForEachRevenueStreamDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueLineItems" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_696" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueTable" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_693" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_696" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_693" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srt_ProductOrServiceAxis_692" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_693" xlink:to="loc_srt_ProductOrServiceAxis_692" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_691" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_692" xlink:to="loc_srt_ProductsAndServicesDomain_691" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_691_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_692" xlink:to="loc_srt_ProductsAndServicesDomain_691_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="btmd-20221231.xsd#btmd_PelletProceduresProductRevenueMember" xlink:label="loc_btmd_PelletProceduresProductRevenueMember_695" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_691" xlink:to="loc_btmd_PelletProceduresProductRevenueMember_695" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="btmd-20221231.xsd#btmd_DietarySupplementsMember" xlink:label="loc_btmd_DietarySupplementsMember_698" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_691" xlink:to="loc_btmd_DietarySupplementsMember_698" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="btmd-20221231.xsd#btmd_DisposableTrocarsProductRevenueMember" xlink:label="loc_btmd_DisposableTrocarsProductRevenueMember_699" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_691" xlink:to="loc_btmd_DisposableTrocarsProductRevenueMember_699" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="btmd-20221231.xsd#btmd_ShippingFeesProductRevenueMember" xlink:label="loc_btmd_ShippingFeesProductRevenueMember_700" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_691" xlink:to="loc_btmd_ShippingFeesProductRevenueMember_700" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="btmd-20221231.xsd#btmd_ProductRevenueMember" xlink:label="loc_btmd_ProductRevenueMember_701" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_691" xlink:to="loc_btmd_ProductRevenueMember_701" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="btmd-20221231.xsd#btmd_TrainingServiceRevenueMember" xlink:label="loc_btmd_TrainingServiceRevenueMember_702" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_691" xlink:to="loc_btmd_TrainingServiceRevenueMember_702" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="btmd-20221231.xsd#btmd_ContractTermServicesRevenueMember" xlink:label="loc_btmd_ContractTermServicesRevenueMember_703" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_691" xlink:to="loc_btmd_ContractTermServicesRevenueMember_703" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="btmd-20221231.xsd#btmd_ServiceRevenueMember" xlink:label="loc_btmd_ServiceRevenueMember_704" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_691" xlink:to="loc_btmd_ServiceRevenueMember_704" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_694" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_696" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_694" use="optional" order="13" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://haymaker.com/role/RevenueRecognitionScheduleOfRevenuesRecognizedByGeographicRegionDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueLineItems" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_717" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueTable" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_711" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_717" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_711" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srt_ProductOrServiceAxis_709" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_711" xlink:to="loc_srt_ProductOrServiceAxis_709" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_707" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_709" xlink:to="loc_srt_ProductsAndServicesDomain_707" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_707_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_709" xlink:to="loc_srt_ProductsAndServicesDomain_707_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="btmd-20221231.xsd#btmd_ProductRevenueMember" xlink:label="loc_btmd_ProductRevenueMember_713" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_707" xlink:to="loc_btmd_ProductRevenueMember_713" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="btmd-20221231.xsd#btmd_ServiceRevenueMember" xlink:label="loc_btmd_ServiceRevenueMember_716" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_707" xlink:to="loc_btmd_ServiceRevenueMember_716" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis" xlink:label="loc_srt_StatementGeographicalAxis_715" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_711" xlink:to="loc_srt_StatementGeographicalAxis_715" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srt_SegmentGeographicalDomain_710" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_715" xlink:to="loc_srt_SegmentGeographicalDomain_710" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srt_SegmentGeographicalDomain_710_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_715" xlink:to="loc_srt_SegmentGeographicalDomain_710_default" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_US" xlink:label="loc_country_US_708" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_710" xlink:to="loc_country_US_708" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="btmd-20221231.xsd#btmd_AllOtherCountryMember" xlink:label="loc_btmd_AllOtherCountryMember_714" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_710" xlink:to="loc_btmd_AllOtherCountryMember_714" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_712" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_717" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_712" use="optional" order="12" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://haymaker.com/role/RevenueRecognitionSummaryOfSignificantChangesInContractLiabilityBalancesDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueLineItems" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_725" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueTable" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_722" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_725" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_722" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerDurationAxis" xlink:label="loc_us-gaap_ContractWithCustomerDurationAxis_720" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_722" xlink:to="loc_us-gaap_ContractWithCustomerDurationAxis_720" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerDurationDomain" xlink:label="loc_us-gaap_ContractWithCustomerDurationDomain_721" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ContractWithCustomerDurationAxis_720" xlink:to="loc_us-gaap_ContractWithCustomerDurationDomain_721" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerDurationDomain" xlink:label="loc_us-gaap_ContractWithCustomerDurationDomain_721_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ContractWithCustomerDurationAxis_720" xlink:to="loc_us-gaap_ContractWithCustomerDurationDomain_721_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermContractWithCustomerMember" xlink:label="loc_us-gaap_ShortTermContractWithCustomerMember_724" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ContractWithCustomerDurationDomain_721" xlink:to="loc_us-gaap_ShortTermContractWithCustomerMember_724" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermContractWithCustomerMember" xlink:label="loc_us-gaap_LongTermContractWithCustomerMember_727" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ContractWithCustomerDurationDomain_721" xlink:to="loc_us-gaap_LongTermContractWithCustomerMember_727" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_723" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_725" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_723" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="btmd-20221231.xsd#btmd_ContractWithCustomerLiabilityIncreasesDueToCashReceivedExcludingAmountsRecognizedAsRevenue" xlink:label="loc_btmd_ContractWithCustomerLiabilityIncreasesDueToCashReceivedExcludingAmountsRecognizedAsRevenue_726" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_725" xlink:to="loc_btmd_ContractWithCustomerLiabilityIncreasesDueToCashReceivedExcludingAmountsRecognizedAsRevenue_726" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="btmd-20221231.xsd#btmd_ContractWithCustomerLiabilityTransfersBetweenCurrentAndNonCurrentLiabilitiesDueToExpectedRevenueRecognitionPeriod" xlink:label="loc_btmd_ContractWithCustomerLiabilityTransfersBetweenCurrentAndNonCurrentLiabilitiesDueToExpectedRevenueRecognitionPeriod_728" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_725" xlink:to="loc_btmd_ContractWithCustomerLiabilityTransfersBetweenCurrentAndNonCurrentLiabilitiesDueToExpectedRevenueRecognitionPeriod_728" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_729" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_725" xlink:to="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_729" use="optional" order="10" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://haymaker.com/role/RevenueRecognitionSummaryOfConsiderationAllocatedToPerformanceObligationsDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueLineItems" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_737" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueTable" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_734" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_737" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_734" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srt_ProductOrServiceAxis_733" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_734" xlink:to="loc_srt_ProductOrServiceAxis_733" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_732" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_733" xlink:to="loc_srt_ProductsAndServicesDomain_732" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_732_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_733" xlink:to="loc_srt_ProductsAndServicesDomain_732_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="btmd-20221231.xsd#btmd_UnsatisfiedTrainingObligationsMember" xlink:label="loc_btmd_UnsatisfiedTrainingObligationsMember_736" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_732" xlink:to="loc_btmd_UnsatisfiedTrainingObligationsMember_736" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="btmd-20221231.xsd#btmd_UnsatisfiedContractTermServicesMember" xlink:label="loc_btmd_UnsatisfiedContractTermServicesMember_739" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_732" xlink:to="loc_btmd_UnsatisfiedContractTermServicesMember_739" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="btmd-20221231.xsd#btmd_UnsatisfiedPelletProceduresMember" xlink:label="loc_btmd_UnsatisfiedPelletProceduresMember_741" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_732" xlink:to="loc_btmd_UnsatisfiedPelletProceduresMember_741" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityCurrent" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_735" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_737" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_735" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_738" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_737" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_738" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiability" xlink:label="loc_us-gaap_ContractWithCustomerLiability_740" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_737" xlink:to="loc_us-gaap_ContractWithCustomerLiability_740" use="optional" order="10" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://haymaker.com/role/InventoryNetScheduleOfInventoryNetDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryLineItems" xlink:label="loc_us-gaap_InventoryLineItems_758" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryAdjustments" xlink:label="loc_us-gaap_InventoryAdjustments_754" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InventoryLineItems_758" xlink:to="loc_us-gaap_InventoryAdjustments_754" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNet" xlink:label="loc_us-gaap_InventoryNet_757" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InventoryLineItems_758" xlink:to="loc_us-gaap_InventoryNet_757" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryCurrentTable" xlink:label="loc_us-gaap_InventoryCurrentTable_751" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_InventoryLineItems_758" xlink:to="loc_us-gaap_InventoryCurrentTable_751" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srt_ProductOrServiceAxis_748" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_InventoryCurrentTable_751" xlink:to="loc_srt_ProductOrServiceAxis_748" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_749" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_748" xlink:to="loc_srt_ProductsAndServicesDomain_749" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_749_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_748" xlink:to="loc_srt_ProductsAndServicesDomain_749_default" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProductMember" xlink:label="loc_us-gaap_ProductMember_752" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_749" xlink:to="loc_us-gaap_ProductMember_752" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PublicUtilitiesInventoryAxis" xlink:label="loc_us-gaap_PublicUtilitiesInventoryAxis_755" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_InventoryCurrentTable_751" xlink:to="loc_us-gaap_PublicUtilitiesInventoryAxis_755" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PublicUtilitiesInventoryTypeDomain" xlink:label="loc_us-gaap_PublicUtilitiesInventoryTypeDomain_753" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PublicUtilitiesInventoryAxis_755" xlink:to="loc_us-gaap_PublicUtilitiesInventoryTypeDomain_753" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PublicUtilitiesInventoryTypeDomain" xlink:label="loc_us-gaap_PublicUtilitiesInventoryTypeDomain_753_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PublicUtilitiesInventoryAxis_755" xlink:to="loc_us-gaap_PublicUtilitiesInventoryTypeDomain_753_default" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="btmd-20221231.xsd#btmd_DietarySupplementsMember" xlink:label="loc_btmd_DietarySupplementsMember_756" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PublicUtilitiesInventoryTypeDomain_753" xlink:to="loc_btmd_DietarySupplementsMember_756" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="btmd-20221231.xsd#btmd_PelletsMember" xlink:label="loc_btmd_PelletsMember_750" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PublicUtilitiesInventoryTypeDomain_753" xlink:to="loc_btmd_PelletsMember_750" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryGross" xlink:label="loc_us-gaap_InventoryGross_747" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InventoryLineItems_758" xlink:to="loc_us-gaap_InventoryGross_747" use="optional" order="13" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://haymaker.com/role/PropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_767" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_761" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_767" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_761" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_763" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_767" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_763" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_762" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_763" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_762" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_764" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_762" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_764" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_764_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_762" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_764_default" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="btmd-20221231.xsd#btmd_TrocarsMember" xlink:label="loc_btmd_TrocarsMember_765" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_764" xlink:to="loc_btmd_TrocarsMember_765" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_768" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_764" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_768" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OfficeEquipmentMember" xlink:label="loc_us-gaap_OfficeEquipmentMember_770" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_764" xlink:to="loc_us-gaap_OfficeEquipmentMember_770" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" xlink:label="loc_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_771" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_764" xlink:to="loc_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_771" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_772" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_764" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_772" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComputerEquipmentMember" xlink:label="loc_us-gaap_ComputerEquipmentMember_773" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_764" xlink:to="loc_us-gaap_ComputerEquipmentMember_773" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConstructionInProgressMember" xlink:label="loc_us-gaap_ConstructionInProgressMember_774" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_764" xlink:to="loc_us-gaap_ConstructionInProgressMember_774" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_766" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_767" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_766" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_769" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_767" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_769" use="optional" order="14" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://haymaker.com/role/LongTermDebtAdditionalInformationDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="loc_us-gaap_DebtInstrumentLineItems_826" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTable" xlink:label="loc_us-gaap_DebtInstrumentTable_808" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_826" xlink:to="loc_us-gaap_DebtInstrumentTable_808" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_811" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_808" xlink:to="loc_us-gaap_DebtInstrumentAxis_811" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_806" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_811" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_806" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_806_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_811" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_806_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="btmd-20221231.xsd#btmd_BankOfAmericaTermLoanMember" xlink:label="loc_btmd_BankOfAmericaTermLoanMember_809" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_806" xlink:to="loc_btmd_BankOfAmericaTermLoanMember_809" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="btmd-20221231.xsd#btmd_TruistTermLoanMember" xlink:label="loc_btmd_TruistTermLoanMember_816" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_806" xlink:to="loc_btmd_TruistTermLoanMember_816" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="btmd-20221231.xsd#btmd_BankOfAmericaTermLoanAndTruistTermLoanMember" xlink:label="loc_btmd_BankOfAmericaTermLoanAndTruistTermLoanMember_820" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_806" xlink:to="loc_btmd_BankOfAmericaTermLoanAndTruistTermLoanMember_820" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityAxis" xlink:label="loc_us-gaap_CreditFacilityAxis_798" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_808" xlink:to="loc_us-gaap_CreditFacilityAxis_798" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityDomain" xlink:label="loc_us-gaap_CreditFacilityDomain_804" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CreditFacilityAxis_798" xlink:to="loc_us-gaap_CreditFacilityDomain_804" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityDomain" xlink:label="loc_us-gaap_CreditFacilityDomain_804_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CreditFacilityAxis_798" xlink:to="loc_us-gaap_CreditFacilityDomain_804_default" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevolvingCreditFacilityMember" xlink:label="loc_us-gaap_RevolvingCreditFacilityMember_814" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CreditFacilityDomain_804" xlink:to="loc_us-gaap_RevolvingCreditFacilityMember_814" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditMember" xlink:label="loc_us-gaap_LineOfCreditMember_803" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CreditFacilityDomain_804" xlink:to="loc_us-gaap_LineOfCreditMember_803" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableRateAxis" xlink:label="loc_us-gaap_VariableRateAxis_818" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_808" xlink:to="loc_us-gaap_VariableRateAxis_818" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableRateDomain" xlink:label="loc_us-gaap_VariableRateDomain_799" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_VariableRateAxis_818" xlink:to="loc_us-gaap_VariableRateDomain_799" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableRateDomain" xlink:label="loc_us-gaap_VariableRateDomain_799_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_VariableRateAxis_818" xlink:to="loc_us-gaap_VariableRateDomain_799_default" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BaseRateMember" xlink:label="loc_us-gaap_BaseRateMember_815" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableRateDomain_799" xlink:to="loc_us-gaap_BaseRateMember_815" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember" xlink:label="loc_us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember_805" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableRateDomain_799" xlink:to="loc_us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember_805" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentRedemptionPeriodAxis" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis_822" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_808" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis_822" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_807" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis_822" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_807" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_807_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis_822" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_807_default" use="optional" order="20" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentRedemptionPeriodTwoMember" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodTwoMember_812" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_807" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodTwoMember_812" use="optional" order="21" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentRedemptionPeriodOneMember" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodOneMember_800" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_807" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodOneMember_800" use="optional" order="22" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentRedemptionPeriodThreeMember" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodThreeMember_819" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_807" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodThreeMember_819" use="optional" order="23" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_824" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_808" xlink:to="loc_srt_RangeAxis_824" use="optional" order="24" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_801" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_824" xlink:to="loc_srt_RangeMember_801" use="optional" order="25" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_801_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_824" xlink:to="loc_srt_RangeMember_801_default" use="optional" order="26" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_813" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_801" xlink:to="loc_srt_MaximumMember_813" use="optional" order="27" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_802" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_801" xlink:to="loc_srt_MinimumMember_802" use="optional" order="28" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_810" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_826" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_810" use="optional" order="29" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateTerms" xlink:label="loc_us-gaap_DebtInstrumentInterestRateTerms_817" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_826" xlink:to="loc_us-gaap_DebtInstrumentInterestRateTerms_817" use="optional" order="30" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_828" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_826" xlink:to="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_828" use="optional" order="31" />
<loc xlink:type="locator" xlink:href="btmd-20221231.xsd#btmd_LineOfCreditFacilityMaturityMonthAndYear" xlink:label="loc_btmd_LineOfCreditFacilityMaturityMonthAndYear_829" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_826" xlink:to="loc_btmd_LineOfCreditFacilityMaturityMonthAndYear_829" use="optional" order="32" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturityDate" xlink:label="loc_us-gaap_LongTermDebtMaturityDate_831" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_826" xlink:to="loc_us-gaap_LongTermDebtMaturityDate_831" use="optional" order="33" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCredit" xlink:label="loc_us-gaap_LineOfCredit_832" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_826" xlink:to="loc_us-gaap_LineOfCredit_832" use="optional" order="34" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromLinesOfCredit" xlink:label="loc_us-gaap_ProceedsFromLinesOfCredit_833" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_826" xlink:to="loc_us-gaap_ProceedsFromLinesOfCredit_833" use="optional" order="35" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentCovenantDescription" xlink:label="loc_us-gaap_DebtInstrumentCovenantDescription_834" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_826" xlink:to="loc_us-gaap_DebtInstrumentCovenantDescription_834" use="optional" order="36" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentCovenantCompliance" xlink:label="loc_us-gaap_DebtInstrumentCovenantCompliance_835" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_826" xlink:to="loc_us-gaap_DebtInstrumentCovenantCompliance_835" use="optional" order="37" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RatioOfIndebtednessToNetCapital1" xlink:label="loc_us-gaap_RatioOfIndebtednessToNetCapital1_836" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_826" xlink:to="loc_us-gaap_RatioOfIndebtednessToNetCapital1_836" use="optional" order="38" />
<loc xlink:type="locator" xlink:href="btmd-20221231.xsd#btmd_FixedChargeCoverageRatio" xlink:label="loc_btmd_FixedChargeCoverageRatio_837" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_826" xlink:to="loc_btmd_FixedChargeCoverageRatio_837" use="optional" order="39" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpenseDebt" xlink:label="loc_us-gaap_InterestExpenseDebt_838" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_826" xlink:to="loc_us-gaap_InterestExpenseDebt_838" use="optional" order="40" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtRelatedCommitmentFeesAndDebtIssuanceCosts" xlink:label="loc_us-gaap_DebtRelatedCommitmentFeesAndDebtIssuanceCosts_839" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_826" xlink:to="loc_us-gaap_DebtRelatedCommitmentFeesAndDebtIssuanceCosts_839" use="optional" order="41" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:label="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_821" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_826" xlink:to="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_821" use="optional" order="42" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentPeriodicPaymentPrincipal" xlink:label="loc_us-gaap_DebtInstrumentPeriodicPaymentPrincipal_823" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_826" xlink:to="loc_us-gaap_DebtInstrumentPeriodicPaymentPrincipal_823" use="optional" order="43" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFrequencyOfPeriodicPayment" xlink:label="loc_us-gaap_DebtInstrumentFrequencyOfPeriodicPayment_825" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_826" xlink:to="loc_us-gaap_DebtInstrumentFrequencyOfPeriodicPayment_825" use="optional" order="44" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebt" xlink:label="loc_us-gaap_LongTermDebt_827" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_826" xlink:to="loc_us-gaap_LongTermDebt_827" use="optional" order="45" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfFinancingCosts" xlink:label="loc_us-gaap_AmortizationOfFinancingCosts_840" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_826" xlink:to="loc_us-gaap_AmortizationOfFinancingCosts_840" use="optional" order="46" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_841" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_826" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_841" use="optional" order="47" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_842" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_826" xlink:to="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_842" use="optional" order="48" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://haymaker.com/role/WarrantLiabilityAdditionalInformationDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="loc_us-gaap_ClassOfWarrantOrRightLineItems_890" />
<loc xlink:type="locator" xlink:href="btmd-20221231.xsd#btmd_ClassOfWarrantOrRightRedemptionThresholdConsecutiveTradingDays" xlink:label="loc_btmd_ClassOfWarrantOrRightRedemptionThresholdConsecutiveTradingDays_864" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_890" xlink:to="loc_btmd_ClassOfWarrantOrRightRedemptionThresholdConsecutiveTradingDays_864" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="loc_us-gaap_ClassOfWarrantOrRightTable_873" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_890" xlink:to="loc_us-gaap_ClassOfWarrantOrRightTable_873" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_862" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_873" xlink:to="loc_us-gaap_StatementClassOfStockAxis_862" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_870" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_862" xlink:to="loc_us-gaap_ClassOfStockDomain_870" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_870_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_862" xlink:to="loc_us-gaap_ClassOfStockDomain_870_default" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonClassAMember" xlink:label="loc_us-gaap_CommonClassAMember_865" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_870" xlink:to="loc_us-gaap_CommonClassAMember_865" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_876" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_873" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_876" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_875" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_876" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_875" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_875_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_876" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_875_default" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="btmd-20221231.xsd#btmd_RedeemableWarrantsMember" xlink:label="loc_btmd_RedeemableWarrantsMember_868" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_875" xlink:to="loc_btmd_RedeemableWarrantsMember_868" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="btmd-20221231.xsd#btmd_PrivatePlacementWarrantsMember" xlink:label="loc_btmd_PrivatePlacementWarrantsMember_878" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_875" xlink:to="loc_btmd_PrivatePlacementWarrantsMember_878" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="btmd-20221231.xsd#btmd_PublicWarrantsMember" xlink:label="loc_btmd_PublicWarrantsMember_882" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_875" xlink:to="loc_btmd_PublicWarrantsMember_882" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidatedEntitiesAxis" xlink:label="loc_srt_ConsolidatedEntitiesAxis_880" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_873" xlink:to="loc_srt_ConsolidatedEntitiesAxis_880" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidatedEntitiesDomain" xlink:label="loc_srt_ConsolidatedEntitiesDomain_874" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ConsolidatedEntitiesAxis_880" xlink:to="loc_srt_ConsolidatedEntitiesDomain_874" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidatedEntitiesDomain" xlink:label="loc_srt_ConsolidatedEntitiesDomain_874_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ConsolidatedEntitiesAxis_880" xlink:to="loc_srt_ConsolidatedEntitiesDomain_874_default" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="btmd-20221231.xsd#btmd_HaymakeriiiMember" xlink:label="loc_btmd_HaymakeriiiMember_869" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ConsolidatedEntitiesDomain_874" xlink:to="loc_btmd_HaymakeriiiMember_869" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="loc_us-gaap_MeasurementInputTypeAxis_884" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_873" xlink:to="loc_us-gaap_MeasurementInputTypeAxis_884" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_872" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_884" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_872" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_872_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_884" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_872_default" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="btmd-20221231.xsd#btmd_SharePriceEqualOrExceedsTenRupeesPerDollarMember" xlink:label="loc_btmd_SharePriceEqualOrExceedsTenRupeesPerDollarMember_871" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_872" xlink:to="loc_btmd_SharePriceEqualOrExceedsTenRupeesPerDollarMember_871" use="optional" order="20" />
<loc xlink:type="locator" xlink:href="btmd-20221231.xsd#btmd_SharePriceEqualOrExceedsEighteenRupeesPerDollarMember" xlink:label="loc_btmd_SharePriceEqualOrExceedsEighteenRupeesPerDollarMember_879" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_872" xlink:to="loc_btmd_SharePriceEqualOrExceedsEighteenRupeesPerDollarMember_879" use="optional" order="21" />
<loc xlink:type="locator" xlink:href="btmd-20221231.xsd#btmd_SharePriceEqualOrLessNinePointTwoRupeesPerDollarMember" xlink:label="loc_btmd_SharePriceEqualOrLessNinePointTwoRupeesPerDollarMember_883" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_872" xlink:to="loc_btmd_SharePriceEqualOrLessNinePointTwoRupeesPerDollarMember_883" use="optional" order="22" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_886" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_873" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_886" use="optional" order="23" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_861" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_886" xlink:to="loc_us-gaap_RelatedPartyDomain_861" use="optional" order="24" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_861_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_886" xlink:to="loc_us-gaap_RelatedPartyDomain_861_default" use="optional" order="25" />
<loc xlink:type="locator" xlink:href="btmd-20221231.xsd#btmd_SponseMember" xlink:label="loc_btmd_SponseMember_866" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_861" xlink:to="loc_btmd_SponseMember_866" use="optional" order="26" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementScenarioAxis" xlink:label="loc_srt_StatementScenarioAxis_888" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_873" xlink:to="loc_srt_StatementScenarioAxis_888" use="optional" order="27" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="loc_srt_ScenarioUnspecifiedDomain_867" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementScenarioAxis_888" xlink:to="loc_srt_ScenarioUnspecifiedDomain_867" use="optional" order="28" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="loc_srt_ScenarioUnspecifiedDomain_867_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementScenarioAxis_888" xlink:to="loc_srt_ScenarioUnspecifiedDomain_867_default" use="optional" order="29" />
<loc xlink:type="locator" xlink:href="btmd-20221231.xsd#btmd_ClassOfWarrantOrRightThresholdPeriodForExerciseFromDateOfClosingPublicOffering" xlink:label="loc_btmd_ClassOfWarrantOrRightThresholdPeriodForExerciseFromDateOfClosingPublicOffering_877" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_890" xlink:to="loc_btmd_ClassOfWarrantOrRightThresholdPeriodForExerciseFromDateOfClosingPublicOffering_877" use="optional" order="30" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_881" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_890" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_881" use="optional" order="31" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_885" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_890" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_885" use="optional" order="32" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantsAndRightsOutstandingMaturityDate" xlink:label="loc_us-gaap_WarrantsAndRightsOutstandingMaturityDate_887" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_890" xlink:to="loc_us-gaap_WarrantsAndRightsOutstandingMaturityDate_887" use="optional" order="33" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="loc_us-gaap_WarrantsAndRightsOutstandingTerm_889" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_890" xlink:to="loc_us-gaap_WarrantsAndRightsOutstandingTerm_889" use="optional" order="34" />
<loc xlink:type="locator" xlink:href="btmd-20221231.xsd#btmd_ClassOfWarrantsOrRightsTransfersRestrictionOnNumberOfDaysFromTheDateOfBusinessCombination" xlink:label="loc_btmd_ClassOfWarrantsOrRightsTransfersRestrictionOnNumberOfDaysFromTheDateOfBusinessCombination_891" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_890" xlink:to="loc_btmd_ClassOfWarrantsOrRightsTransfersRestrictionOnNumberOfDaysFromTheDateOfBusinessCombination_891" use="optional" order="35" />
<loc xlink:type="locator" xlink:href="btmd-20221231.xsd#btmd_NumberOfDaysFollowingItsInitialBusinessCombinationUntilTheExpirationOfTheWarrants" xlink:label="loc_btmd_NumberOfDaysFollowingItsInitialBusinessCombinationUntilTheExpirationOfTheWarrants_892" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_890" xlink:to="loc_btmd_NumberOfDaysFollowingItsInitialBusinessCombinationUntilTheExpirationOfTheWarrants_892" use="optional" order="36" />
<loc xlink:type="locator" xlink:href="btmd-20221231.xsd#btmd_ClassOfWarrantsRedemptionPricePerUnit" xlink:label="loc_btmd_ClassOfWarrantsRedemptionPricePerUnit_893" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_890" xlink:to="loc_btmd_ClassOfWarrantsRedemptionPricePerUnit_893" use="optional" order="37" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaap_SharePrice_895" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_890" xlink:to="loc_us-gaap_SharePrice_895" use="optional" order="38" />
<loc xlink:type="locator" xlink:href="btmd-20221231.xsd#btmd_NumberOfConsecutiveTradingDaysForDeterminingSharePrice" xlink:label="loc_btmd_NumberOfConsecutiveTradingDaysForDeterminingSharePrice_896" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_890" xlink:to="loc_btmd_NumberOfConsecutiveTradingDaysForDeterminingSharePrice_896" use="optional" order="39" />
<loc xlink:type="locator" xlink:href="btmd-20221231.xsd#btmd_ShareRedemptionTriggerPrice" xlink:label="loc_btmd_ShareRedemptionTriggerPrice_898" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_890" xlink:to="loc_btmd_ShareRedemptionTriggerPrice_898" use="optional" order="40" />
<loc xlink:type="locator" xlink:href="btmd-20221231.xsd#btmd_PrivatePlacementWarrantsRedemptionDescription" xlink:label="loc_btmd_PrivatePlacementWarrantsRedemptionDescription_899" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_890" xlink:to="loc_btmd_PrivatePlacementWarrantsRedemptionDescription_899" use="optional" order="41" />
<loc xlink:type="locator" xlink:href="btmd-20221231.xsd#btmd_MinimumGrossProceedsRequiredFromIssuanceOfEquity" xlink:label="loc_btmd_MinimumGrossProceedsRequiredFromIssuanceOfEquity_900" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_890" xlink:to="loc_btmd_MinimumGrossProceedsRequiredFromIssuanceOfEquity_900" use="optional" order="42" />
<loc xlink:type="locator" xlink:href="btmd-20221231.xsd#btmd_ClassOfWarrantOrRightMinimumNoticePeriodForRedemption" xlink:label="loc_btmd_ClassOfWarrantOrRightMinimumNoticePeriodForRedemption_901" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_890" xlink:to="loc_btmd_ClassOfWarrantOrRightMinimumNoticePeriodForRedemption_901" use="optional" order="43" />
<loc xlink:type="locator" xlink:href="btmd-20221231.xsd#btmd_ClassOfWarrantOrRightExercisePriceAdjustmentPercentageHigherOfMarketValue" xlink:label="loc_btmd_ClassOfWarrantOrRightExercisePriceAdjustmentPercentageHigherOfMarketValue_902" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_890" xlink:to="loc_btmd_ClassOfWarrantOrRightExercisePriceAdjustmentPercentageHigherOfMarketValue_902" use="optional" order="44" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_903" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_890" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_903" use="optional" order="45" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="loc_us-gaap_SharesIssuedPricePerShare_904" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_890" xlink:to="loc_us-gaap_SharesIssuedPricePerShare_904" use="optional" order="46" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueIssuedForServices_905" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_890" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueIssuedForServices_905" use="optional" order="47" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding_906" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_890" xlink:to="loc_us-gaap_ClassOfWarrantOrRightOutstanding_906" use="optional" order="48" />
<loc xlink:type="locator" xlink:href="btmd-20221231.xsd#btmd_PublicWarrantsRedeemed" xlink:label="loc_btmd_PublicWarrantsRedeemed_907" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_890" xlink:to="loc_btmd_PublicWarrantsRedeemed_907" use="optional" order="49" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://haymaker.com/role/EarnoutLiabilityAdditionalInformationDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesLineItems" xlink:label="loc_us-gaap_LossContingenciesLineItems_930" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesTable" xlink:label="loc_us-gaap_LossContingenciesTable_918" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LossContingenciesLineItems_930" xlink:to="loc_us-gaap_LossContingenciesTable_918" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_919" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_918" xlink:to="loc_us-gaap_StatementClassOfStockAxis_919" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_916" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_919" xlink:to="loc_us-gaap_ClassOfStockDomain_916" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_916_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_919" xlink:to="loc_us-gaap_ClassOfStockDomain_916_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonClassAMember" xlink:label="loc_us-gaap_CommonClassAMember_914" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_916" xlink:to="loc_us-gaap_CommonClassAMember_914" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VestingAxis" xlink:label="loc_us-gaap_VestingAxis_922" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_918" xlink:to="loc_us-gaap_VestingAxis_922" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VestingDomain" xlink:label="loc_us-gaap_VestingDomain_915" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_VestingAxis_922" xlink:to="loc_us-gaap_VestingDomain_915" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VestingDomain" xlink:label="loc_us-gaap_VestingDomain_915_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_VestingAxis_922" xlink:to="loc_us-gaap_VestingDomain_915_default" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="btmd-20221231.xsd#btmd_SharePriceEqualsOrExceedsTwelvePointFivePerShareMember" xlink:label="loc_btmd_SharePriceEqualsOrExceedsTwelvePointFivePerShareMember_920" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VestingDomain_915" xlink:to="loc_btmd_SharePriceEqualsOrExceedsTwelvePointFivePerShareMember_920" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="btmd-20221231.xsd#btmd_SharePriceEqualsOrExceedsFifteenPerShareMember" xlink:label="loc_btmd_SharePriceEqualsOrExceedsFifteenPerShareMember_923" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VestingDomain_915" xlink:to="loc_btmd_SharePriceEqualsOrExceedsFifteenPerShareMember_923" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="btmd-20221231.xsd#btmd_SharePriceEqualsOrExceedsSeventeenPointFivePerShareMember" xlink:label="loc_btmd_SharePriceEqualsOrExceedsSeventeenPointFivePerShareMember_926" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VestingDomain_915" xlink:to="loc_btmd_SharePriceEqualsOrExceedsSeventeenPointFivePerShareMember_926" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_925" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_918" xlink:to="loc_srt_RangeAxis_925" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_912" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_925" xlink:to="loc_srt_RangeMember_912" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_912_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_925" xlink:to="loc_srt_RangeMember_912_default" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_913" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_912" xlink:to="loc_srt_MaximumMember_913" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_928" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_918" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_928" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_910" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_928" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_910" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_910_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_928" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_910_default" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="btmd-20221231.xsd#btmd_BusinessCombinationMember" xlink:label="loc_btmd_BusinessCombinationMember_911" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_910" xlink:to="loc_btmd_BusinessCombinationMember_911" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="btmd-20221231.xsd#btmd_NumberOfEarnoutSecuritiesShareholderEntitledToVestIfCertainSharePriceTargetsAchieved" xlink:label="loc_btmd_NumberOfEarnoutSecuritiesShareholderEntitledToVestIfCertainSharePriceTargetsAchieved_921" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_930" xlink:to="loc_btmd_NumberOfEarnoutSecuritiesShareholderEntitledToVestIfCertainSharePriceTargetsAchieved_921" use="optional" order="20" />
<loc xlink:type="locator" xlink:href="btmd-20221231.xsd#btmd_EarnoutDeadlineDate" xlink:label="loc_btmd_EarnoutDeadlineDate_924" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_930" xlink:to="loc_btmd_EarnoutDeadlineDate_924" use="optional" order="21" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaap_SharePrice_927" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_930" xlink:to="loc_us-gaap_SharePrice_927" use="optional" order="22" />
<loc xlink:type="locator" xlink:href="btmd-20221231.xsd#btmd_CommonStockTransfersThresholdTradingDays" xlink:label="loc_btmd_CommonStockTransfersThresholdTradingDays_929" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_930" xlink:to="loc_btmd_CommonStockTransfersThresholdTradingDays_929" use="optional" order="23" />
<loc xlink:type="locator" xlink:href="btmd-20221231.xsd#btmd_NumberOfConsecutiveTradingDaysForDeterminingTheSharePrice" xlink:label="loc_btmd_NumberOfConsecutiveTradingDaysForDeterminingTheSharePrice_931" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_930" xlink:to="loc_btmd_NumberOfConsecutiveTradingDaysForDeterminingTheSharePrice_931" use="optional" order="24" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://haymaker.com/role/FairValueMeasurementsScheduleOfFairValueHierarchyForFinancialAssetsAndLiabilitiesDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_945" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_934" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_945" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_934" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="loc_us-gaap_FinancialInstrumentAxis_938" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_934" xlink:to="loc_us-gaap_FinancialInstrumentAxis_938" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_939" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_938" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_939" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_939_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_938" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_939_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="btmd-20221231.xsd#btmd_PublicWarrantsMember" xlink:label="loc_btmd_PublicWarrantsMember_935" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_939" xlink:to="loc_btmd_PublicWarrantsMember_935" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="btmd-20221231.xsd#btmd_PrivatePlacementWarrantsMember" xlink:label="loc_btmd_PrivatePlacementWarrantsMember_941" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_939" xlink:to="loc_btmd_PrivatePlacementWarrantsMember_941" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="btmd-20221231.xsd#btmd_EarnoutLiabilityMember" xlink:label="loc_btmd_EarnoutLiabilityMember_944" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_939" xlink:to="loc_btmd_EarnoutLiabilityMember_944" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_942" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_934" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_942" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_936" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_942" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_936" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_936_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_942" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_936_default" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_940" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_936" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_940" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_946" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_936" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_946" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialLiabilitiesFairValueDisclosure" xlink:label="loc_us-gaap_FinancialLiabilitiesFairValueDisclosure_937" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_945" xlink:to="loc_us-gaap_FinancialLiabilitiesFairValueDisclosure_937" use="optional" order="13" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://haymaker.com/role/FairValueMeasurementsSummaryOfSignificantInputsToMonteCarloSimulationForFairValueOfPrivatePlacementWarrantsDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_959" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_949" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_959" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_949" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="loc_us-gaap_FinancialInstrumentAxis_950" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_949" xlink:to="loc_us-gaap_FinancialInstrumentAxis_950" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_955" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_950" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_955" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_955_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_950" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_955_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="btmd-20221231.xsd#btmd_PrivatePlacementWarrantsMember" xlink:label="loc_btmd_PrivatePlacementWarrantsMember_952" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_955" xlink:to="loc_btmd_PrivatePlacementWarrantsMember_952" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="loc_us-gaap_MeasurementInputTypeAxis_956" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_949" xlink:to="loc_us-gaap_MeasurementInputTypeAxis_956" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_954" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_956" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_954" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_954_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_956" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_954_default" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputSharePriceMember" xlink:label="loc_us-gaap_MeasurementInputSharePriceMember_953" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_954" xlink:to="loc_us-gaap_MeasurementInputSharePriceMember_953" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputExercisePriceMember" xlink:label="loc_us-gaap_MeasurementInputExercisePriceMember_958" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_954" xlink:to="loc_us-gaap_MeasurementInputExercisePriceMember_958" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:label="loc_us-gaap_MeasurementInputRiskFreeInterestRateMember_961" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_954" xlink:to="loc_us-gaap_MeasurementInputRiskFreeInterestRateMember_961" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputOptionVolatilityMember" xlink:label="loc_us-gaap_MeasurementInputOptionVolatilityMember_962" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_954" xlink:to="loc_us-gaap_MeasurementInputOptionVolatilityMember_962" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputExpectedTermMember" xlink:label="loc_us-gaap_MeasurementInputExpectedTermMember_963" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_954" xlink:to="loc_us-gaap_MeasurementInputExpectedTermMember_963" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_951" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_959" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_951" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="loc_us-gaap_WarrantsAndRightsOutstandingTerm_957" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_959" xlink:to="loc_us-gaap_WarrantsAndRightsOutstandingTerm_957" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:label="loc_us-gaap_WarrantsAndRightsOutstandingMeasurementInput_960" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_959" xlink:to="loc_us-gaap_WarrantsAndRightsOutstandingMeasurementInput_960" use="optional" order="16" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://haymaker.com/role/FairValueMeasurementsSummaryOfSignificantInputsToMonteCarloSimulationForFairValueOfEarnoutLiabilityDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_976" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_966" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_976" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_966" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="loc_us-gaap_FinancialInstrumentAxis_967" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_966" xlink:to="loc_us-gaap_FinancialInstrumentAxis_967" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_972" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_967" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_972" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_972_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_967" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_972_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="btmd-20221231.xsd#btmd_EarnoutLiabilityMember" xlink:label="loc_btmd_EarnoutLiabilityMember_969" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_972" xlink:to="loc_btmd_EarnoutLiabilityMember_969" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="loc_us-gaap_MeasurementInputTypeAxis_973" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_966" xlink:to="loc_us-gaap_MeasurementInputTypeAxis_973" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_971" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_973" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_971" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_971_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_973" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_971_default" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputSharePriceMember" xlink:label="loc_us-gaap_MeasurementInputSharePriceMember_970" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_971" xlink:to="loc_us-gaap_MeasurementInputSharePriceMember_970" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:label="loc_us-gaap_MeasurementInputRiskFreeInterestRateMember_975" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_971" xlink:to="loc_us-gaap_MeasurementInputRiskFreeInterestRateMember_975" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputOptionVolatilityMember" xlink:label="loc_us-gaap_MeasurementInputOptionVolatilityMember_978" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_971" xlink:to="loc_us-gaap_MeasurementInputOptionVolatilityMember_978" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputExpectedTermMember" xlink:label="loc_us-gaap_MeasurementInputExpectedTermMember_979" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_971" xlink:to="loc_us-gaap_MeasurementInputExpectedTermMember_979" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_968" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_976" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_968" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:label="loc_us-gaap_WarrantsAndRightsOutstandingMeasurementInput_974" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_976" xlink:to="loc_us-gaap_WarrantsAndRightsOutstandingMeasurementInput_974" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="loc_us-gaap_WarrantsAndRightsOutstandingTerm_977" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_976" xlink:to="loc_us-gaap_WarrantsAndRightsOutstandingTerm_977" use="optional" order="15" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://haymaker.com/role/FairValueMeasurementsSummaryOfChangesInTheFairValueOfCompanysLevel3FinancialInstrumentsDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_989" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_982" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_989" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_982" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="loc_us-gaap_FinancialInstrumentAxis_985" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_982" xlink:to="loc_us-gaap_FinancialInstrumentAxis_985" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_986" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_985" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_986" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_986_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_985" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_986_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="btmd-20221231.xsd#btmd_PrivatePlacementWarrantsMember" xlink:label="loc_btmd_PrivatePlacementWarrantsMember_983" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_986" xlink:to="loc_btmd_PrivatePlacementWarrantsMember_983" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="btmd-20221231.xsd#btmd_EarnoutLiabilityMember" xlink:label="loc_btmd_EarnoutLiabilityMember_987" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_986" xlink:to="loc_btmd_EarnoutLiabilityMember_987" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialLiabilitiesFairValueDisclosure" xlink:label="loc_us-gaap_FinancialLiabilitiesFairValueDisclosure_984" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_989" xlink:to="loc_us-gaap_FinancialLiabilitiesFairValueDisclosure_984" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueOptionChangesInFairValueGainLoss1" xlink:label="loc_us-gaap_FairValueOptionChangesInFairValueGainLoss1_988" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_989" xlink:to="loc_us-gaap_FairValueOptionChangesInFairValueGainLoss1_988" use="optional" order="8" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://haymaker.com/role/NoncontrollingInterestAdditionalInformationDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MinorityInterestLineItems" xlink:label="loc_us-gaap_MinorityInterestLineItems_1004" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners" xlink:label="loc_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners_993" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MinorityInterestLineItems_1004" xlink:to="loc_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners_993" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MinorityInterestTable" xlink:label="loc_us-gaap_MinorityInterestTable_998" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_MinorityInterestLineItems_1004" xlink:to="loc_us-gaap_MinorityInterestTable_998" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_OwnershipAxis" xlink:label="loc_srt_OwnershipAxis_997" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_MinorityInterestTable_998" xlink:to="loc_srt_OwnershipAxis_997" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_OwnershipDomain" xlink:label="loc_srt_OwnershipDomain_999" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_OwnershipAxis_997" xlink:to="loc_srt_OwnershipDomain_999" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_OwnershipDomain" xlink:label="loc_srt_OwnershipDomain_999_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_OwnershipAxis_997" xlink:to="loc_srt_OwnershipDomain_999_default" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="btmd-20221231.xsd#btmd_MinorityInterestHoldersMember" xlink:label="loc_btmd_MinorityInterestHoldersMember_996" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_OwnershipDomain_999" xlink:to="loc_btmd_MinorityInterestHoldersMember_996" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="btmd-20221231.xsd#btmd_BioteCorporationMember" xlink:label="loc_btmd_BioteCorporationMember_1001" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_OwnershipDomain_999" xlink:to="loc_btmd_BioteCorporationMember_1001" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_1002" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_MinorityInterestTable_998" xlink:to="loc_us-gaap_StatementClassOfStockAxis_1002" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_995" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_1002" xlink:to="loc_us-gaap_ClassOfStockDomain_995" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_995_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_1002" xlink:to="loc_us-gaap_ClassOfStockDomain_995_default" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="btmd-20221231.xsd#btmd_CommonClassVMember" xlink:label="loc_btmd_CommonClassVMember_994" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_995" xlink:to="loc_btmd_CommonClassVMember_994" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MinorityInterestOwnershipPercentageByParent" xlink:label="loc_us-gaap_MinorityInterestOwnershipPercentageByParent_1000" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MinorityInterestLineItems_1004" xlink:to="loc_us-gaap_MinorityInterestOwnershipPercentageByParent_1000" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_1003" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MinorityInterestLineItems_1004" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_1003" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockVotingRights" xlink:label="loc_us-gaap_CommonStockVotingRights_1005" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MinorityInterestLineItems_1004" xlink:to="loc_us-gaap_CommonStockVotingRights_1005" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="btmd-20221231.xsd#btmd_CommonStockNumberOfVotesEntitledPerShare" xlink:label="loc_btmd_CommonStockNumberOfVotesEntitledPerShare_1006" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MinorityInterestLineItems_1004" xlink:to="loc_btmd_CommonStockNumberOfVotesEntitledPerShare_1006" use="optional" order="15" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://haymaker.com/role/ShareBasedCompensationAdditionalInformationDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1031" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1010" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1031" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1010" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_1018" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1010" xlink:to="loc_us-gaap_StatementClassOfStockAxis_1018" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_1014" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_1018" xlink:to="loc_us-gaap_ClassOfStockDomain_1014" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_1014_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_1018" xlink:to="loc_us-gaap_ClassOfStockDomain_1014_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="btmd-20221231.xsd#btmd_CommonClassVMember" xlink:label="loc_btmd_CommonClassVMember_1013" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_1014" xlink:to="loc_btmd_CommonClassVMember_1013" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaap_PlanNameAxis_1023" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1010" xlink:to="loc_us-gaap_PlanNameAxis_1023" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_1019" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_1023" xlink:to="loc_us-gaap_PlanNameDomain_1019" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_1019_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_1023" xlink:to="loc_us-gaap_PlanNameDomain_1019_default" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="btmd-20221231.xsd#btmd_TwoThousandTwentyTwoEquityIncentivePlanMember" xlink:label="loc_btmd_TwoThousandTwentyTwoEquityIncentivePlanMember_1009" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_1019" xlink:to="loc_btmd_TwoThousandTwentyTwoEquityIncentivePlanMember_1009" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_1026" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1010" xlink:to="loc_us-gaap_AwardTypeAxis_1026" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1016" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_1026" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1016" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1016_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_1026" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1016_default" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="btmd-20221231.xsd#btmd_IncentiveUnitsMember" xlink:label="loc_btmd_IncentiveUnitsMember_1015" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1016" xlink:to="loc_btmd_IncentiveUnitsMember_1015" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="btmd-20221231.xsd#btmd_PhantomEquityRightsMember" xlink:label="loc_btmd_PhantomEquityRightsMember_1021" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1016" xlink:to="loc_btmd_PhantomEquityRightsMember_1021" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_1024" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1016" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_1024" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_1027" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1016" xlink:to="loc_us-gaap_EmployeeStockOptionMember_1027" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_1029" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1010" xlink:to="loc_srt_RangeAxis_1029" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_1011" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_1029" xlink:to="loc_srt_RangeMember_1011" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_1011_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_1029" xlink:to="loc_srt_RangeMember_1011_default" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_1012" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_1011" xlink:to="loc_srt_MinimumMember_1012" use="optional" order="20" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_1020" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_1011" xlink:to="loc_srt_MaximumMember_1020" use="optional" order="21" />
<loc xlink:type="locator" xlink:href="btmd-20221231.xsd#btmd_ShareBasedCompensationArrangementVestingOfIncentiveUnits" xlink:label="loc_btmd_ShareBasedCompensationArrangementVestingOfIncentiveUnits_1017" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1031" xlink:to="loc_btmd_ShareBasedCompensationArrangementVestingOfIncentiveUnits_1017" use="optional" order="22" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_1022" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1031" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_1022" use="optional" order="23" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SettlementLiabilitiesCurrent" xlink:label="loc_us-gaap_SettlementLiabilitiesCurrent_1025" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1031" xlink:to="loc_us-gaap_SettlementLiabilitiesCurrent_1025" use="optional" order="24" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConversionOfStockSharesConverted1" xlink:label="loc_us-gaap_ConversionOfStockSharesConverted1_1028" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1031" xlink:to="loc_us-gaap_ConversionOfStockSharesConverted1_1028" use="optional" order="25" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_1030" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1031" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_1030" use="optional" order="26" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_1032" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1031" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_1032" use="optional" order="27" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_1033" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1031" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_1033" use="optional" order="28" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://haymaker.com/role/ShareBasedCompensationSummaryOfRestrictedStockUnitActivityDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1046" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1037" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1046" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1037" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_1041" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1037" xlink:to="loc_us-gaap_AwardTypeAxis_1041" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1039" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_1041" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1039" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1039_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_1041" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1039_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_1038" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1039" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_1038" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaap_PlanNameAxis_1044" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1037" xlink:to="loc_us-gaap_PlanNameAxis_1044" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_1042" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_1044" xlink:to="loc_us-gaap_PlanNameDomain_1042" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_1042_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_1044" xlink:to="loc_us-gaap_PlanNameDomain_1042_default" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="btmd-20221231.xsd#btmd_TwoThousandTwentyTwoEquityIncentivePlanMember" xlink:label="loc_btmd_TwoThousandTwentyTwoEquityIncentivePlanMember_1036" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_1042" xlink:to="loc_btmd_TwoThousandTwentyTwoEquityIncentivePlanMember_1036" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_1040" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1046" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_1040" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_1043" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1046" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_1043" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_1045" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1046" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_1045" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_1047" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1046" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_1047" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_1049" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1046" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_1049" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_1050" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1046" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_1050" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_1051" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1046" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_1051" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_1052" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1046" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_1052" use="optional" order="17" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://haymaker.com/role/ShareBasedCompensationSummaryOfStockOptionActivityDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1062" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1057" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1062" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1057" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaap_PlanNameAxis_1059" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1057" xlink:to="loc_us-gaap_PlanNameAxis_1059" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_1060" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_1059" xlink:to="loc_us-gaap_PlanNameDomain_1060" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_1060_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_1059" xlink:to="loc_us-gaap_PlanNameDomain_1060_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="btmd-20221231.xsd#btmd_TwoThousandTwentyTwoEquityIncentivePlanMember" xlink:label="loc_btmd_TwoThousandTwentyTwoEquityIncentivePlanMember_1056" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_1060" xlink:to="loc_btmd_TwoThousandTwentyTwoEquityIncentivePlanMember_1056" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_1064" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1062" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_1064" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_1061" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1062" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_1061" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_1063" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1062" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_1063" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_1065" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1062" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_1065" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_1069" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1062" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_1069" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_1067" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1062" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_1067" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_1068" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1062" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_1068" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_1070" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1062" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_1070" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_1071" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1062" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_1071" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_1072" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1062" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_1072" use="optional" order="15" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://haymaker.com/role/ShareBasedCompensationSummaryOfWeightedAverageAssumptionsUsedToEstimateFairValueOfStockOptionsGrantedDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1081" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1076" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1081" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1076" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaap_PlanNameAxis_1078" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1076" xlink:to="loc_us-gaap_PlanNameAxis_1078" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_1079" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_1078" xlink:to="loc_us-gaap_PlanNameDomain_1079" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_1079_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_1078" xlink:to="loc_us-gaap_PlanNameDomain_1079_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="btmd-20221231.xsd#btmd_TwoThousandTwentyTwoEquityIncentivePlanMember" xlink:label="loc_btmd_TwoThousandTwentyTwoEquityIncentivePlanMember_1075" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_1079" xlink:to="loc_btmd_TwoThousandTwentyTwoEquityIncentivePlanMember_1075" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_1077" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1081" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_1077" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_1080" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1081" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_1080" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_1082" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1081" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_1082" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_1083" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1081" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_1083" use="optional" order="9" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://haymaker.com/role/IncomeTaxesAdditionalInformationDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowanceLineItems" xlink:label="loc_us-gaap_ValuationAllowanceLineItems_1127" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowanceTable" xlink:label="loc_us-gaap_ValuationAllowanceTable_1122" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ValuationAllowanceLineItems_1127" xlink:to="loc_us-gaap_ValuationAllowanceTable_1122" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_1124" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ValuationAllowanceTable_1122" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_1124" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_1125" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_1124" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_1125" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_1125_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_1124" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_1125_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCountryMember" xlink:label="loc_us-gaap_ForeignCountryMember_1121" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_1125" xlink:to="loc_us-gaap_ForeignCountryMember_1121" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="loc_us-gaap_OperatingLossCarryforwards_1123" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ValuationAllowanceLineItems_1127" xlink:to="loc_us-gaap_OperatingLossCarryforwards_1123" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="btmd-20221231.xsd#btmd_OperatingLossCarryforwardsExpirationYear" xlink:label="loc_btmd_OperatingLossCarryforwardsExpirationYear_1126" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ValuationAllowanceLineItems_1127" xlink:to="loc_btmd_OperatingLossCarryforwardsExpirationYear_1126" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_1128" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ValuationAllowanceLineItems_1127" xlink:to="loc_us-gaap_UnrecognizedTaxBenefits_1128" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExaminationDescription" xlink:label="loc_us-gaap_IncomeTaxExaminationDescription_1129" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ValuationAllowanceLineItems_1127" xlink:to="loc_us-gaap_IncomeTaxExaminationDescription_1129" use="optional" order="9" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://haymaker.com/role/NetLossPerCommonShareScheduleOfComputationOfNetLossPerCommonShareDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasicLineItems" xlink:label="loc_us-gaap_EarningsPerShareBasicLineItems_1177" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable_1167" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EarningsPerShareBasicLineItems_1177" xlink:to="loc_us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable_1167" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_1170" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable_1167" xlink:to="loc_us-gaap_AwardTypeAxis_1170" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1172" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_1170" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1172" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1172_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_1170" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1172_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAbstract" xlink:label="loc_us-gaap_NetIncomeLossAbstract_1169" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareBasicLineItems_1177" xlink:to="loc_us-gaap_NetIncomeLossAbstract_1169" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_1173" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetIncomeLossAbstract_1169" xlink:to="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_1173" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_1179" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetIncomeLossAbstract_1169" xlink:to="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_1179" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_1176" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareBasicLineItems_1177" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_1176" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_1168" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_1176" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_1168" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_1175" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_1176" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_1175" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_1181" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareBasicLineItems_1177" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_1181" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic" xlink:label="loc_us-gaap_EarningsPerShareBasic_1174" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_1181" xlink:to="loc_us-gaap_EarningsPerShareBasic_1174" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="loc_us-gaap_EarningsPerShareDiluted_1180" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_1181" xlink:to="loc_us-gaap_EarningsPerShareDiluted_1180" use="optional" order="13" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://haymaker.com/role/NetLossPerCommonShareScheduleOfComputationOfDilutedWeightedAverageSharesOutstandingDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_1202" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_1190" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_1202" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_1190" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_1185" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_1202" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_1185" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_1197" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_1185" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_1197" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_1191" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_1197" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_1191" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_1191_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_1197" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_1191_default" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="btmd-20221231.xsd#btmd_PublicWarrantsMember" xlink:label="loc_btmd_PublicWarrantsMember_1188" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_1191" xlink:to="loc_btmd_PublicWarrantsMember_1188" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="btmd-20221231.xsd#btmd_PrivatePlacementWarrantsMember" xlink:label="loc_btmd_PrivatePlacementWarrantsMember_1195" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_1191" xlink:to="loc_btmd_PrivatePlacementWarrantsMember_1195" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_1200" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_1185" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_1200" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_1187" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_1200" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_1187" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_1187_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_1200" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_1187_default" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_1199" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_1187" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_1199" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_1201" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_1187" xlink:to="loc_us-gaap_EmployeeStockOptionMember_1201" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_1193" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_1185" xlink:to="loc_us-gaap_StatementClassOfStockAxis_1193" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_1189" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_1193" xlink:to="loc_us-gaap_ClassOfStockDomain_1189" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_1189_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_1193" xlink:to="loc_us-gaap_ClassOfStockDomain_1189_default" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="btmd-20221231.xsd#btmd_EarnoutVotingSharesMember" xlink:label="loc_btmd_EarnoutVotingSharesMember_1194" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_1189" xlink:to="loc_btmd_EarnoutVotingSharesMember_1194" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="btmd-20221231.xsd#btmd_SponsorEarnOutSharesMember" xlink:label="loc_btmd_SponsorEarnOutSharesMember_1198" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_1189" xlink:to="loc_btmd_SponsorEarnOutSharesMember_1198" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="btmd-20221231.xsd#btmd_ClassVCommonStockMember" xlink:label="loc_btmd_ClassVCommonStockMember_1186" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_1189" xlink:to="loc_btmd_ClassVCommonStockMember_1186" use="optional" order="18" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://haymaker.com/role/CommitmentsAndContingenciesAdditionalInformationDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesLineItems" xlink:label="loc_us-gaap_LossContingenciesLineItems_1211" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyNameOfPlaintiff" xlink:label="loc_us-gaap_LossContingencyNameOfPlaintiff_1210" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_1211" xlink:to="loc_us-gaap_LossContingencyNameOfPlaintiff_1210" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyLawsuitFilingDate" xlink:label="loc_us-gaap_LossContingencyLawsuitFilingDate_1207" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_1211" xlink:to="loc_us-gaap_LossContingencyLawsuitFilingDate_1207" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesTable" xlink:label="loc_us-gaap_LossContingenciesTable_1208" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LossContingenciesLineItems_1211" xlink:to="loc_us-gaap_LossContingenciesTable_1208" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1209" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_1208" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1209" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_1206" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1209" xlink:to="loc_us-gaap_RelatedPartyDomain_1206" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_1206_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1209" xlink:to="loc_us-gaap_RelatedPartyDomain_1206_default" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyDamagesSoughtValue" xlink:label="loc_us-gaap_LossContingencyDamagesSoughtValue_1213" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_1211" xlink:to="loc_us-gaap_LossContingencyDamagesSoughtValue_1213" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyNameOfDefendant" xlink:label="loc_us-gaap_LossContingencyNameOfDefendant_1212" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_1211" xlink:to="loc_us-gaap_LossContingencyNameOfDefendant_1212" use="optional" order="8" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://haymaker.com/role/RelatedPartyTransactionsAdditionalInformationDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_1229" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_1220" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_1229" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_1220" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1222" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_1220" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1222" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_1217" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1222" xlink:to="loc_us-gaap_RelatedPartyDomain_1217" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_1217_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1222" xlink:to="loc_us-gaap_RelatedPartyDomain_1217_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="btmd-20221231.xsd#btmd_FirmMember" xlink:label="loc_btmd_FirmMember_1218" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_1217" xlink:to="loc_btmd_FirmMember_1218" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="btmd-20221231.xsd#btmd_EmployeeMember" xlink:label="loc_btmd_EmployeeMember_1223" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_1217" xlink:to="loc_btmd_EmployeeMember_1223" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="btmd-20221231.xsd#btmd_SpouseOfFounderChairmanAndBeneficialOwnerMember" xlink:label="loc_btmd_SpouseOfFounderChairmanAndBeneficialOwnerMember_1227" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_1217" xlink:to="loc_btmd_SpouseOfFounderChairmanAndBeneficialOwnerMember_1227" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="btmd-20221231.xsd#btmd_VendorMember" xlink:label="loc_btmd_VendorMember_1230" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_1217" xlink:to="loc_btmd_VendorMember_1230" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_DirectorMember" xlink:label="loc_srt_DirectorMember_1232" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_1217" xlink:to="loc_srt_DirectorMember_1232" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="btmd-20221231.xsd#btmd_ConsultantMember" xlink:label="loc_btmd_ConsultantMember_1234" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_1217" xlink:to="loc_btmd_ConsultantMember_1234" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_1226" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_1220" xlink:to="loc_us-gaap_TypeOfArrangementAxis_1226" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1216" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_1226" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1216" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1216_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_1226" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1216_default" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="btmd-20221231.xsd#btmd_FounderAdvisoryAgreementMember" xlink:label="loc_btmd_FounderAdvisoryAgreementMember_1219" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1216" xlink:to="loc_btmd_FounderAdvisoryAgreementMember_1219" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="btmd-20221231.xsd#btmd_NewIndependentContractorAgreementMember" xlink:label="loc_btmd_NewIndependentContractorAgreementMember_1224" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1216" xlink:to="loc_btmd_NewIndependentContractorAgreementMember_1224" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfessionalFees" xlink:label="loc_us-gaap_ProfessionalFees_1221" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_1229" xlink:to="loc_us-gaap_ProfessionalFees_1221" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DueToRelatedPartiesCurrentAndNoncurrent" xlink:label="loc_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent_1225" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_1229" xlink:to="loc_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent_1225" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_1228" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_1229" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_1228" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredRevenueRevenueRecognized1" xlink:label="loc_us-gaap_DeferredRevenueRevenueRecognized1_1231" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_1229" xlink:to="loc_us-gaap_DeferredRevenueRevenueRecognized1_1231" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DueFromCustomerAcceptances" xlink:label="loc_us-gaap_DueFromCustomerAcceptances_1233" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_1229" xlink:to="loc_us-gaap_DueFromCustomerAcceptances_1233" use="optional" order="20" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DueToEmployeesCurrentAndNoncurrent" xlink:label="loc_us-gaap_DueToEmployeesCurrentAndNoncurrent_1235" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_1229" xlink:to="loc_us-gaap_DueToEmployeesCurrentAndNoncurrent_1235" use="optional" order="21" />
<loc xlink:type="locator" xlink:href="btmd-20221231.xsd#btmd_InventoryPurchases" xlink:label="loc_btmd_InventoryPurchases_1236" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_1229" xlink:to="loc_btmd_InventoryPurchases_1236" use="optional" order="22" />
<loc xlink:type="locator" xlink:href="btmd-20221231.xsd#btmd_AgreementTerm" xlink:label="loc_btmd_AgreementTerm_1237" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_1229" xlink:to="loc_btmd_AgreementTerm_1237" use="optional" order="23" />
<loc xlink:type="locator" xlink:href="btmd-20221231.xsd#btmd_AnnualAdviosryFeesPayable" xlink:label="loc_btmd_AnnualAdviosryFeesPayable_1238" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_1229" xlink:to="loc_btmd_AnnualAdviosryFeesPayable_1238" use="optional" order="24" />
</definitionLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>6
<FILENAME>btmd-20221231_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<!--Generated by DFIN XBRL Instance Document - http://www.dfinsolutions.com/ - Version R3.0 - on 06-April-2023 [03:21:32] {AM}-->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" />
<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" />
<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" />
<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" />
<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" />
<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" />
<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel" />
<labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract" xlink:label="loc_dei_CoverAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_CoverAbstract" xml:lang="en-US">Cover [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentInformationTable" xlink:label="loc_dei_DocumentInformationTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_DocumentInformationTable" xml:lang="en-US">Document Information [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentInformationTable" xlink:to="lab_dei_DocumentInformationTable" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xml:lang="en-US">Equity Components [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis" xlink:to="lab_us-gaap_StatementEquityComponentsAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EquityComponentDomain" xml:lang="en-US">Equity Component [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain" xlink:to="lab_us-gaap_EquityComponentDomain" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StatementClassOfStockAxis" xml:lang="en-US">Class of Stock [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementClassOfStockAxis" xlink:to="lab_us-gaap_StatementClassOfStockAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ClassOfStockDomain" xml:lang="en-US">Class of Stock [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockDomain" xlink:to="lab_us-gaap_ClassOfStockDomain" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentInformationLineItems" xlink:label="loc_dei_DocumentInformationLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_DocumentInformationLineItems" xml:lang="en-US">Document Information [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentInformationLineItems" xlink:to="lab_dei_DocumentInformationLineItems" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType" xlink:label="loc_dei_DocumentType" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_DocumentType" xml:lang="en-US">Document Type</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey" xlink:label="loc_dei_EntityCentralIndexKey" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityCentralIndexKey" xml:lang="en-US">Entity Central Index Key</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory" xlink:label="loc_dei_EntityFilerCategory" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityFilerCategory" xml:lang="en-US">Entity Filer Category</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory" xlink:to="lab_dei_EntityFilerCategory" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness" xlink:label="loc_dei_EntitySmallBusiness" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntitySmallBusiness" xml:lang="en-US">Entity Small Business</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness" xlink:to="lab_dei_EntitySmallBusiness" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_dei_EntityEmergingGrowthCompany" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityEmergingGrowthCompany" xml:lang="en-US">Entity Emerging Growth Company</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityExTransitionPeriod" xlink:label="loc_dei_EntityExTransitionPeriod" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityExTransitionPeriod" xml:lang="en-US">Entity Ex Transition Period</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityExTransitionPeriod" xlink:to="lab_dei_EntityExTransitionPeriod" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_dei_EntityIncorporationStateCountryCode" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xml:lang="en-US">Entity Incorporation, State or Country Code</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_dei_EntityTaxIdentificationNumber" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityTaxIdentificationNumber" xml:lang="en-US">Entity Tax Identification Number</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_dei_EntityAddressAddressLine1" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityAddressAddressLine1" xml:lang="en-US">Entity Address, Address Line One</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_dei_EntityAddressCityOrTown" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityAddressCityOrTown" xml:lang="en-US">Entity Address, City or Town</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_dei_EntityAddressStateOrProvince" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityAddressStateOrProvince" xml:lang="en-US">Entity Address, State or Province</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_dei_EntityAddressPostalZipCode" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityAddressPostalZipCode" xml:lang="en-US">Entity Address, Postal Zip Code</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode" xlink:label="loc_dei_CityAreaCode" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_CityAreaCode" xml:lang="en-US">City Area Code</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber" xlink:label="loc_dei_LocalPhoneNumber" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_LocalPhoneNumber" xml:lang="en-US">Local Phone Number</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag" xlink:label="loc_dei_AmendmentFlag" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_AmendmentFlag" xml:lang="en-US">Amendment Flag</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName" xlink:label="loc_dei_EntityRegistrantName" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityRegistrantName" xml:lang="en-US">Entity Registrant Name</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityPrimarySicNumber" xlink:label="loc_dei_EntityPrimarySicNumber" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityPrimarySicNumber" xml:lang="en-US">Entity Primary SIC Number</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityPrimarySicNumber" xlink:to="lab_dei_EntityPrimarySicNumber" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_ContactPersonnelName" xlink:label="loc_dei_ContactPersonnelName" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_ContactPersonnelName" xml:lang="en-US">Contact Personnel Name</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_ContactPersonnelName" xlink:to="lab_dei_ContactPersonnelName" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressesAddressTypeAxis" xlink:label="loc_dei_EntityAddressesAddressTypeAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityAddressesAddressTypeAxis" xml:lang="en-US">Entity Addresses, Address Type [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressesAddressTypeAxis" xlink:to="lab_dei_EntityAddressesAddressTypeAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AddressTypeDomain" xlink:label="loc_dei_AddressTypeDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_AddressTypeDomain" xml:lang="en-US">Address Type [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AddressTypeDomain" xlink:to="lab_dei_AddressTypeDomain" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_BusinessContactMember" xlink:label="loc_dei_BusinessContactMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_BusinessContactMember" xml:lang="en-US">Business Contact [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_BusinessContactMember" xlink:to="lab_dei_BusinessContactMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xml:lang="en-US">Statement of Financial Position [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StatementTable" xml:lang="en-US">Statement [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable" xlink:to="lab_us-gaap_StatementTable" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonClassAMember" xlink:label="loc_us-gaap_CommonClassAMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommonClassAMember" xml:lang="en-US">Common Class A</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CommonClassAMember" xml:lang="en-US">Class A Common Stock</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonClassAMember" xlink:to="lab_us-gaap_CommonClassAMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonClassBMember" xlink:label="loc_us-gaap_CommonClassBMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommonClassBMember" xml:lang="en-US">Common Class B [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CommonClassBMember" xml:lang="en-US">Class B Common Stock</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonClassBMember" xlink:to="lab_us-gaap_CommonClassBMember" />
<loc xlink:type="locator" xlink:href="btmd-20221231.xsd#btmd_CommonClassVMember" xlink:label="loc_btmd_CommonClassVMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_btmd_CommonClassVMember" xml:lang="en-US">Common Class V [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_btmd_CommonClassVMember" xml:lang="en-US">Class V Common Stock</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_btmd_CommonClassVMember" xlink:to="lab_btmd_CommonClassVMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_btmd_CommonClassVMember" xml:lang="en-US">Common class V.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StatementLineItems" xml:lang="en-US">Statement [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="lab_us-gaap_StatementLineItems" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaap_AssetsAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AssetsAbstract" xml:lang="en-US">Assets [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AssetsAbstract" xml:lang="en-US">Assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="lab_us-gaap_AssetsAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaap_AssetsCurrentAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xml:lang="en-US">Assets, Current [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xml:lang="en-US">Current assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract" xlink:to="lab_us-gaap_AssetsCurrentAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Cash" xlink:label="loc_us-gaap_Cash" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_Cash" xml:lang="en-US">Cash</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Cash" xlink:to="lab_us-gaap_Cash" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNet" xlink:label="loc_us-gaap_InventoryNet" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_InventoryNet" xml:lang="en-US">Inventory, Net</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_InventoryNet" xml:lang="en-US">Inventory, net</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_InventoryNet" xml:lang="en-US">Net Inventory</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryNet" xlink:to="lab_us-gaap_InventoryNet" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xml:lang="en-US">Prepaid Expense and Other Assets, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xml:lang="en-US">Other current assets</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xml:lang="en-US">Total other current assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AssetsCurrent" xml:lang="en-US">Assets, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_AssetsCurrent" xml:lang="en-US">Total current assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="lab_us-gaap_AssetsCurrent" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xml:lang="en-US">Accounts Receivable, after Allowance for Credit Loss, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xml:lang="en-US">Accounts receivable, net</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableNetCurrent" xlink:to="lab_us-gaap_AccountsReceivableNetCurrent" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xml:lang="en-US">Operating Lease, Right-of-Use Asset</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xml:lang="en-US">Operating lease right-of-use assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAsset" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxAssetsNet" xlink:label="loc_us-gaap_DeferredIncomeTaxAssetsNet" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredIncomeTaxAssetsNet" xml:lang="en-US">Deferred Income Tax Assets, Net</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DeferredIncomeTaxAssetsNet" xml:lang="en-US">Deferred tax asset</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxAssetsNet" xlink:to="lab_us-gaap_DeferredIncomeTaxAssetsNet" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_Assets" xml:lang="en-US">Assets</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_Assets" xml:lang="en-US">Total assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets" xlink:to="lab_us-gaap_Assets" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xml:lang="en-US">Property, Plant and Equipment, Net</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xml:lang="en-US">Property and equipment, net</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xml:lang="en-US">Property and equipment, net</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalizedComputerSoftwareNet" xlink:label="loc_us-gaap_CapitalizedComputerSoftwareNet" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CapitalizedComputerSoftwareNet" xml:lang="en-US">Capitalized Computer Software, Net</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CapitalizedComputerSoftwareNet" xml:lang="en-US">Capitalized software, net</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_CapitalizedComputerSoftwareNet" xml:lang="en-US">Capitalized software, net</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CapitalizedComputerSoftwareNet" xlink:to="lab_us-gaap_CapitalizedComputerSoftwareNet" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xml:lang="en-US">Liabilities and Equity [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xml:lang="en-US">Liabilities and Stockholders' Equity (Deficit)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xml:lang="en-US">Liabilities, Current [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xml:lang="en-US">Current liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaap_AccountsPayableCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccountsPayableCurrent" xml:lang="en-US">Accounts Payable, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AccountsPayableCurrent" xml:lang="en-US">Accounts payable</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrent" xlink:to="lab_us-gaap_AccountsPayableCurrent" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityCurrent" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xml:lang="en-US">Contract with Customer, Liability, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xml:lang="en-US">Deferred revenue, current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xml:lang="en-US">Contract with customers liability current</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityCurrent" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xml:lang="en-US">Operating Lease, Liability, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xml:lang="en-US">Operating lease liabilities, current</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityCurrent" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LiabilitiesCurrent" xml:lang="en-US">Liabilities, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_LiabilitiesCurrent" xml:lang="en-US">Total current liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="lab_us-gaap_LiabilitiesCurrent" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xml:lang="en-US">Accrued Liabilities, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xml:lang="en-US">Accrued expenses</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xml:lang="en-US">Accrued expenses</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_AccruedLiabilitiesCurrent" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtCurrent" xlink:label="loc_us-gaap_LongTermDebtCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LongTermDebtCurrent" xml:lang="en-US">Long-Term Debt, Current Maturities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LongTermDebtCurrent" xml:lang="en-US">Term loan, current</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtCurrent" xlink:to="lab_us-gaap_LongTermDebtCurrent" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xml:lang="en-US">Operating Lease, Liability, Noncurrent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xml:lang="en-US">Operating lease liabilities, net of current portion</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantsAndRightsOutstanding" xlink:label="loc_us-gaap_WarrantsAndRightsOutstanding" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_WarrantsAndRightsOutstanding" xml:lang="en-US">Warrants and Rights Outstanding</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_WarrantsAndRightsOutstanding" xml:lang="en-US">Warrant liability</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WarrantsAndRightsOutstanding" xlink:to="lab_us-gaap_WarrantsAndRightsOutstanding" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeLiabilitiesNoncurrent" xlink:label="loc_us-gaap_DerivativeLiabilitiesNoncurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DerivativeLiabilitiesNoncurrent" xml:lang="en-US">Derivative Liability, Noncurrent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DerivativeLiabilitiesNoncurrent" xml:lang="en-US">Earnout liability</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeLiabilitiesNoncurrent" xlink:to="lab_us-gaap_DerivativeLiabilitiesNoncurrent" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaap_Liabilities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_Liabilities" xml:lang="en-US">Liabilities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_Liabilities" xml:lang="en-US">Total liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities" xlink:to="lab_us-gaap_Liabilities" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtNoncurrent" xlink:label="loc_us-gaap_LongTermDebtNoncurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LongTermDebtNoncurrent" xml:lang="en-US">Long-Term Debt, Excluding Current Maturities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LongTermDebtNoncurrent" xml:lang="en-US">Term loan, net of current portion</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_LongTermDebtNoncurrent" xml:lang="en-US">Term loan, net of current portion</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtNoncurrent" xlink:to="lab_us-gaap_LongTermDebtNoncurrent" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent" xml:lang="en-US">Contract with Customer, Liability, Noncurrent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent" xml:lang="en-US">Deferred revenue, net of current portion</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent" xml:lang="en-US">Contract with customers liability non current</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaap_CommitmentsAndContingencies" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xml:lang="en-US">Commitments and Contingencies</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xml:lang="en-US">Commitments and contingencies (See Note 18)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingencies" xlink:to="lab_us-gaap_CommitmentsAndContingencies" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xml:lang="en-US">Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xml:lang="en-US">Stockholders' Equity (Deficit)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:to="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaap_PreferredStockValue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PreferredStockValue" xml:lang="en-US">Preferred Stock, Value, Issued</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PreferredStockValue" xml:lang="en-US">Preferred stock, $0.0001 par value, 10,000,000 shares authorized; no shares issued or outstanding</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockValue" xlink:to="lab_us-gaap_PreferredStockValue" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommonStockValue" xml:lang="en-US">Common Stock, Value, Issued</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CommonStockValue" xml:lang="en-US">Common stock value</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue" xlink:to="lab_us-gaap_CommonStockValue" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Net of Tax</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xml:lang="en-US">Accumulated other comprehensive loss</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockholdersEquity" xml:lang="en-US">Stockholders' Equity Attributable to Parent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_StockholdersEquity" xml:lang="en-US">biote Corp.'s stockholders' equity (deficit)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="lab_us-gaap_StockholdersEquity" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MinorityInterest" xlink:label="loc_us-gaap_MinorityInterest" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_MinorityInterest" xml:lang="en-US">Stockholders' Equity Attributable to Noncontrolling Interest</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_MinorityInterest" xml:lang="en-US">Noncontrolling interest</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MinorityInterest" xlink:to="lab_us-gaap_MinorityInterest" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaap_AdditionalPaidInCapital" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xml:lang="en-US">Additional Paid in Capital</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xml:lang="en-US">Additional paid-in capital</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapital" xlink:to="lab_us-gaap_AdditionalPaidInCapital" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xml:lang="en-US">Retained earnings (Accumulated deficit)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xml:lang="en-US">Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xml:lang="en-US">Total stockholders' equity (deficit)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xml:lang="en-US">Beginning balance</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xml:lang="en-US">Ending balance</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xml:lang="en-US">Liabilities and Equity</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xml:lang="en-US">Total liabilities and stockholders' equity (deficit)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xml:lang="en-US">Preferred Stock, Shares Authorized</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xml:lang="en-US">Preferred stock, shares authorized</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesAuthorized" xlink:to="lab_us-gaap_PreferredStockSharesAuthorized" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaap_PreferredStockSharesIssued" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xml:lang="en-US">Preferred Stock, Shares Issued</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xml:lang="en-US">Preferred stock shares issued</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesIssued" xlink:to="lab_us-gaap_PreferredStockSharesIssued" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xml:lang="en-US">Preferred Stock, Shares Outstanding</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xml:lang="en-US">Preferred stock, shares outstanding</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesOutstanding" xlink:to="lab_us-gaap_PreferredStockSharesOutstanding" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorizedUnlimited" xlink:label="loc_us-gaap_CommonStockSharesAuthorizedUnlimited" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommonStockSharesAuthorizedUnlimited" xml:lang="en-US">Common Stock, Shares Authorized, Unlimited [Fixed List]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CommonStockSharesAuthorizedUnlimited" xml:lang="en-US">Common stock, shares authorized, unlimited</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorizedUnlimited" xlink:to="lab_us-gaap_CommonStockSharesAuthorizedUnlimited" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockNoParValue" xlink:label="loc_us-gaap_CommonStockNoParValue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommonStockNoParValue" xml:lang="en-US">Common Stock, No Par Value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CommonStockNoParValue" xml:lang="en-US">Common stock, no par value</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockNoParValue" xlink:to="lab_us-gaap_CommonStockNoParValue" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xml:lang="en-US">Common stock, par value</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaap_CommonStockSharesAuthorized" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xml:lang="en-US">Common Stock, Shares Authorized</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xml:lang="en-US">Common stock, shares authorized</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized" xlink:to="lab_us-gaap_CommonStockSharesAuthorized" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xml:lang="en-US">Preferred Stock, Par or Stated Value Per Share</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xml:lang="en-US">Preferred stock, par or stated value per share</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_PreferredStockParOrStatedValuePerShare" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaap_CommonStockSharesIssued" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommonStockSharesIssued" xml:lang="en-US">Common Stock, Shares, Issued</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CommonStockSharesIssued" xml:lang="en-US">Common stock, shares issued</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued" xlink:to="lab_us-gaap_CommonStockSharesIssued" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xml:lang="en-US">Common Stock, Shares, Outstanding</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xml:lang="en-US">Common stock, shares outstanding</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding" xlink:to="lab_us-gaap_CommonStockSharesOutstanding" />
<loc xlink:type="locator" xlink:href="btmd-20221231.xsd#btmd_ClassAMember" xlink:label="loc_btmd_ClassAMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_btmd_ClassAMember" xml:lang="en-US">Class A [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_btmd_ClassAMember" xml:lang="en-US">Class A</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_btmd_ClassAMember" xlink:to="lab_btmd_ClassAMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_btmd_ClassAMember" xml:lang="en-US">Class A.</label>
<loc xlink:type="locator" xlink:href="btmd-20221231.xsd#btmd_ClassAaUnitsMember" xlink:label="loc_btmd_ClassAaUnitsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_btmd_ClassAaUnitsMember" xml:lang="en-US">Class AA Units [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_btmd_ClassAaUnitsMember" xml:lang="en-US">Class AA Units</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_btmd_ClassAaUnitsMember" xlink:to="lab_btmd_ClassAaUnitsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_btmd_ClassAaUnitsMember" xml:lang="en-US">Class AA units.</label>
<loc xlink:type="locator" xlink:href="btmd-20221231.xsd#btmd_ClassAaaUnitsMember" xlink:label="loc_btmd_ClassAaaUnitsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_btmd_ClassAaaUnitsMember" xml:lang="en-US">Class AAA Units [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_btmd_ClassAaaUnitsMember" xml:lang="en-US">Class AAA Units</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_btmd_ClassAaaUnitsMember" xlink:to="lab_btmd_ClassAaaUnitsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_btmd_ClassAaaUnitsMember" xml:lang="en-US">Class AAA Units [Member]</label>
<loc xlink:type="locator" xlink:href="btmd-20221231.xsd#btmd_ClassAaaaUnitsMember" xlink:label="loc_btmd_ClassAaaaUnitsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_btmd_ClassAaaaUnitsMember" xml:lang="en-US">Class AAAA Units [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_btmd_ClassAaaaUnitsMember" xml:lang="en-US">Class AAAA Units</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_btmd_ClassAaaaUnitsMember" xlink:to="lab_btmd_ClassAaaaUnitsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_btmd_ClassAaaaUnitsMember" xml:lang="en-US">Class AAAA units.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_us-gaap_IncomeStatementAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeStatementAbstract" xml:lang="en-US">Income Statement [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract" xlink:to="lab_us-gaap_IncomeStatementAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srt_ProductOrServiceAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_ProductOrServiceAxis" xml:lang="en-US">Product and Service [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductOrServiceAxis" xlink:to="lab_srt_ProductOrServiceAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_ProductsAndServicesDomain" xml:lang="en-US">Product and Service [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductsAndServicesDomain" xlink:to="lab_srt_ProductsAndServicesDomain" />
<loc xlink:type="locator" xlink:href="btmd-20221231.xsd#btmd_ProductRevenueMember" xlink:label="loc_btmd_ProductRevenueMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_btmd_ProductRevenueMember" xml:lang="en-US">Product Revenue [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_btmd_ProductRevenueMember" xml:lang="en-US">Product Revenue</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_btmd_ProductRevenueMember" xlink:to="lab_btmd_ProductRevenueMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_btmd_ProductRevenueMember" xml:lang="en-US">Product revenue.</label>
<loc xlink:type="locator" xlink:href="btmd-20221231.xsd#btmd_ServiceRevenueMember" xlink:label="loc_btmd_ServiceRevenueMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_btmd_ServiceRevenueMember" xml:lang="en-US">Service Revenue [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_btmd_ServiceRevenueMember" xml:lang="en-US">Service Revenue</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_btmd_ServiceRevenueMember" xlink:to="lab_btmd_ServiceRevenueMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_btmd_ServiceRevenueMember" xml:lang="en-US">Service revenue.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenuesAbstract" xlink:label="loc_us-gaap_RevenuesAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RevenuesAbstract" xml:lang="en-US">Revenues [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_RevenuesAbstract" xml:lang="en-US">Revenue</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenuesAbstract" xlink:to="lab_us-gaap_RevenuesAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xml:lang="en-US">Revenue from Contract with Customer, Excluding Assessed Tax</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xml:lang="en-US">Total revenue</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xml:lang="en-US">Selling, General and Administrative Expense</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xml:lang="en-US">Selling, general, and administrative</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_SellingGeneralAndAdministrativeExpense" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingIncomeLoss" xml:lang="en-US">Operating Income (Loss)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_OperatingIncomeLoss" xml:lang="en-US">Income (loss) from operations</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="lab_us-gaap_OperatingIncomeLoss" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xml:lang="en-US">Nonoperating Income (Expense) [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xml:lang="en-US">Other income (expense) net :</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="lab_us-gaap_NonoperatingIncomeExpenseAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:label="loc_us-gaap_InterestIncomeExpenseNonoperatingNet" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_InterestIncomeExpenseNonoperatingNet" xml:lang="en-US">Interest Income (Expense), Nonoperating, Net</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_InterestIncomeExpenseNonoperatingNet" xml:lang="en-US">Interest expense</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:to="lab_us-gaap_InterestIncomeExpenseNonoperatingNet" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt" xml:lang="en-US">Gain (Loss) on Extinguishment of Debt</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt" xml:lang="en-US">Loss from extinguishment of debt</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt" xml:lang="en-US">Loss from extinguishment of debt</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:to="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncome" xlink:label="loc_us-gaap_OtherNonoperatingIncome" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OtherNonoperatingIncome" xml:lang="en-US">Other Nonoperating Income</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OtherNonoperatingIncome" xml:lang="en-US">Other income</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingIncome" xlink:to="lab_us-gaap_OtherNonoperatingIncome" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaap_NonoperatingIncomeExpense" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NonoperatingIncomeExpense" xml:lang="en-US">Nonoperating Income (Expense)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_NonoperatingIncomeExpense" xml:lang="en-US">Total other income (expense), net</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpense" xlink:to="lab_us-gaap_NonoperatingIncomeExpense" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="loc_us-gaap_FairValueAdjustmentOfWarrants" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueAdjustmentOfWarrants" xml:lang="en-US">Fair Value Adjustment of Warrants</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_FairValueAdjustmentOfWarrants" xml:lang="en-US">Gain from change in fair value of warrant liability</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FairValueAdjustmentOfWarrants" xml:lang="en-US">Gain from change in fair value of warrant liability</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAdjustmentOfWarrants" xlink:to="lab_us-gaap_FairValueAdjustmentOfWarrants" />
<loc xlink:type="locator" xlink:href="btmd-20221231.xsd#btmd_GainLossFromChangeInFairValueOfEarnoutLiability" xlink:label="loc_btmd_GainLossFromChangeInFairValueOfEarnoutLiability" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_btmd_GainLossFromChangeInFairValueOfEarnoutLiability" xml:lang="en-US">Gain Loss from Change in Fair Value of Earnout Liability</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_btmd_GainLossFromChangeInFairValueOfEarnoutLiability" xml:lang="en-US">Gain from change in fair value of earnout liability</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_btmd_GainLossFromChangeInFairValueOfEarnoutLiability" xlink:to="lab_btmd_GainLossFromChangeInFairValueOfEarnoutLiability" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_btmd_GainLossFromChangeInFairValueOfEarnoutLiability" xml:lang="en-US">Gain loss from change in fair value of earnout liability.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xml:lang="en-US">Income before provision for income taxes</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xml:lang="en-US">Income tax expense (benefit)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xml:lang="en-US">Income tax expense</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xml:lang="en-US">Total income tax provision (benefit)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaap_ProfitLoss" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ProfitLoss" xml:lang="en-US">Net Income (Loss), Including Portion Attributable to Noncontrolling Interest</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_ProfitLoss" xml:lang="en-US">Net income</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ProfitLoss" xml:lang="en-US">Net income (loss)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ProfitLoss" xml:lang="en-US">Net income</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProfitLoss" xlink:to="lab_us-gaap_ProfitLoss" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xml:lang="en-US">Less: Net income (loss) attributable to noncontrolling interest</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xml:lang="en-US">Less: Net income attributable to noncontrolling interest</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortizationAbstract" xlink:label="loc_us-gaap_CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortizationAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortizationAbstract" xml:lang="en-US">Cost of Goods and Service, Excluding Depreciation, Depletion, and Amortization [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortizationAbstract" xml:lang="en-US">Cost of revenue (excluding depreciation and amortization included in selling, general, and administrative, below)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortizationAbstract" xlink:to="lab_us-gaap_CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortizationAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization" xlink:label="loc_us-gaap_CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization" xml:lang="en-US">Cost of Goods and Service, Excluding Depreciation, Depletion, and Amortization</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization" xml:lang="en-US">Cost of revenue</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization" xlink:to="lab_us-gaap_CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SalesCommissionsAndFees" xlink:label="loc_us-gaap_SalesCommissionsAndFees" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SalesCommissionsAndFees" xml:lang="en-US">Sales Commissions and Fees</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SalesCommissionsAndFees" xml:lang="en-US">Commissions</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_SalesCommissionsAndFees" xml:lang="en-US">Sales commission</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SalesCommissionsAndFees" xlink:to="lab_us-gaap_SalesCommissionsAndFees" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketingExpense" xlink:label="loc_us-gaap_MarketingExpense" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_MarketingExpense" xml:lang="en-US">Marketing Expense</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_MarketingExpense" xml:lang="en-US">Marketing</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MarketingExpense" xlink:to="lab_us-gaap_MarketingExpense" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetIncomeLoss" xml:lang="en-US">Net Income (Loss) Attributable to Parent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_NetIncomeLoss" xml:lang="en-US">Net income (loss) attributable to biote Corp. stockholders</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="lab_us-gaap_NetIncomeLoss" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossTaxPortionAttributableToParentAbstract" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossTaxPortionAttributableToParentAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossTaxPortionAttributableToParentAbstract" xml:lang="en-US">Other Comprehensive Income (Loss), Tax, Portion Attributable to Parent, Parenthetical Disclosure [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossTaxPortionAttributableToParentAbstract" xml:lang="en-US">Other comprehensive income (loss):</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossTaxPortionAttributableToParentAbstract" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossTaxPortionAttributableToParentAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xml:lang="en-US">Other comprehensive income (loss)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" xml:lang="en-US">Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Gain (Loss) Arising During Period, Net of Tax</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" xml:lang="en-US">Foreign currency translation adjustments</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xml:lang="en-US">Comprehensive income</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTax" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaap_EarningsPerShareAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xml:lang="en-US">Earnings Per Share [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xml:lang="en-US">Net income (loss) per common share</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareAbstract" xlink:to="lab_us-gaap_EarningsPerShareAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic" xlink:label="loc_us-gaap_EarningsPerShareBasic" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EarningsPerShareBasic" xml:lang="en-US">Earnings Per Share, Basic</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_EarningsPerShareBasic" xml:lang="en-US">Basic</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasic" xlink:to="lab_us-gaap_EarningsPerShareBasic" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="loc_us-gaap_EarningsPerShareDiluted" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xml:lang="en-US">Earnings Per Share, Diluted</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xml:lang="en-US">Diluted</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDiluted" xlink:to="lab_us-gaap_EarningsPerShareDiluted" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xml:lang="en-US">Weighted average common shares outstanding</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xml:lang="en-US">Denominator:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xml:lang="en-US">Basic</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xml:lang="en-US">Weighted average shares outstanding (basic)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xml:lang="en-US">Diluted</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xml:lang="en-US">Weighted average shares outstanding (diluted)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RestatementAxis" xlink:label="loc_srt_RestatementAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_RestatementAxis" xml:lang="en-US">Revision of Prior Period [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RestatementAxis" xlink:to="lab_srt_RestatementAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RestatementDomain" xlink:label="loc_srt_RestatementDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_RestatementDomain" xml:lang="en-US">Revision of Prior Period [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RestatementDomain" xlink:to="lab_srt_RestatementDomain" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MemberUnitsMember" xlink:label="loc_us-gaap_MemberUnitsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_MemberUnitsMember" xml:lang="en-US">Member Units [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_MemberUnitsMember" xml:lang="en-US">Members' Equity</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MemberUnitsMember" xlink:to="lab_us-gaap_MemberUnitsMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommonStockMember" xml:lang="en-US">Common Stock</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember" xlink:to="lab_us-gaap_CommonStockMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaap_RetainedEarningsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RetainedEarningsMember" xml:lang="en-US">Retained Earnings / (Accumulated Deficit)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember" xlink:to="lab_us-gaap_RetainedEarningsMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ParentMember" xlink:label="loc_us-gaap_ParentMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ParentMember" xml:lang="en-US">Parent [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ParentMember" xml:lang="en-US">Total Stockholders' Equity (Deficit) Attributable to biote Corp.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ParentMember" xlink:to="lab_us-gaap_ParentMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncontrollingInterestMember" xlink:label="loc_us-gaap_NoncontrollingInterestMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NoncontrollingInterestMember" xml:lang="en-US">Noncontrolling Interest [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_NoncontrollingInterestMember" xml:lang="en-US">Non Controlling Interest</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncontrollingInterestMember" xlink:to="lab_us-gaap_NoncontrollingInterestMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PartnersCapitalAccountUnits" xlink:label="loc_us-gaap_PartnersCapitalAccountUnits" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PartnersCapitalAccountUnits" xml:lang="en-US">Partners' Capital Account, Units</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_us-gaap_PartnersCapitalAccountUnits" xml:lang="en-US">Beginning balance, units</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_PartnersCapitalAccountUnits" xml:lang="en-US">Ending balance, units</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PartnersCapitalAccountUnits" xlink:to="lab_us-gaap_PartnersCapitalAccountUnits" />
<loc xlink:type="locator" xlink:href="btmd-20221231.xsd#btmd_StockholdersEquityAttributableToNonControllingInterestBusinessCombination" xlink:label="loc_btmd_StockholdersEquityAttributableToNonControllingInterestBusinessCombination" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_btmd_StockholdersEquityAttributableToNonControllingInterestBusinessCombination" xml:lang="en-US">Stockholders Equity Attributable To Non-controlling Interest, Business Combination</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_btmd_StockholdersEquityAttributableToNonControllingInterestBusinessCombination" xml:lang="en-US">Business Combination: Noncontrolling interest on May 26, 2022</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_btmd_StockholdersEquityAttributableToNonControllingInterestBusinessCombination" xlink:to="lab_btmd_StockholdersEquityAttributableToNonControllingInterestBusinessCombination" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_btmd_StockholdersEquityAttributableToNonControllingInterestBusinessCombination" xml:lang="en-US">Stockholders equity attributable to non-controlling interest, business combination.</label>
<loc xlink:type="locator" xlink:href="btmd-20221231.xsd#btmd_StockholdersEquityBussinessCombinationCapitalizedTransactionCosts" xlink:label="loc_btmd_StockholdersEquityBussinessCombinationCapitalizedTransactionCosts" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_btmd_StockholdersEquityBussinessCombinationCapitalizedTransactionCosts" xml:lang="en-US">Stockholders Equity Bussiness Combination Capitalized Transaction Costs</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_btmd_StockholdersEquityBussinessCombinationCapitalizedTransactionCosts" xml:lang="en-US">Business Combination: Capitalized transaction costs</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_btmd_StockholdersEquityBussinessCombinationCapitalizedTransactionCosts" xlink:to="lab_btmd_StockholdersEquityBussinessCombinationCapitalizedTransactionCosts" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_btmd_StockholdersEquityBussinessCombinationCapitalizedTransactionCosts" xml:lang="en-US">Stockholders equity bussiness combination capitalized transaction costs.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xml:lang="en-US">APIC, Share-Based Payment Arrangement, Increase for Cost Recognition</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xml:lang="en-US">Share-based compensation</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" />
<loc xlink:type="locator" xlink:href="btmd-20221231.xsd#btmd_StockIssuedDuringPeriodValueSettlementOfEquityRights" xlink:label="loc_btmd_StockIssuedDuringPeriodValueSettlementOfEquityRights" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_btmd_StockIssuedDuringPeriodValueSettlementOfEquityRights" xml:lang="en-US">Stock Issued During Period Value Settlement Of Equity Rights</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_btmd_StockIssuedDuringPeriodValueSettlementOfEquityRights" xml:lang="en-US">Settlement of phantom equity rights</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_btmd_StockIssuedDuringPeriodValueSettlementOfEquityRights" xlink:to="lab_btmd_StockIssuedDuringPeriodValueSettlementOfEquityRights" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_btmd_StockIssuedDuringPeriodValueSettlementOfEquityRights" xml:lang="en-US">Stock issued during period value settlement of equity rights.</label>
<loc xlink:type="locator" xlink:href="btmd-20221231.xsd#btmd_StockIssuedDuringPeriodValueVestingOfRestrictedStockUnit" xlink:label="loc_btmd_StockIssuedDuringPeriodValueVestingOfRestrictedStockUnit" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_btmd_StockIssuedDuringPeriodValueVestingOfRestrictedStockUnit" xml:lang="en-US">Stock Issued During Period Value Vesting Of Restricted Stock Unit</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_btmd_StockIssuedDuringPeriodValueVestingOfRestrictedStockUnit" xml:lang="en-US">Vesting of RSUs</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_btmd_StockIssuedDuringPeriodValueVestingOfRestrictedStockUnit" xlink:to="lab_btmd_StockIssuedDuringPeriodValueVestingOfRestrictedStockUnit" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_btmd_StockIssuedDuringPeriodValueVestingOfRestrictedStockUnit" xml:lang="en-US">Stock issued during period value vesting of restricted stock unit.</label>
<loc xlink:type="locator" xlink:href="btmd-20221231.xsd#btmd_StockIssuedDuringPeriodSharesVestingOfRestrictedStockUnit" xlink:label="loc_btmd_StockIssuedDuringPeriodSharesVestingOfRestrictedStockUnit" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_btmd_StockIssuedDuringPeriodSharesVestingOfRestrictedStockUnit" xml:lang="en-US">Stock Issued During Period Shares Vesting of Restricted Stock Unit</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_btmd_StockIssuedDuringPeriodSharesVestingOfRestrictedStockUnit" xml:lang="en-US">Vesting of RSUs, shares</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_btmd_StockIssuedDuringPeriodSharesVestingOfRestrictedStockUnit" xlink:to="lab_btmd_StockIssuedDuringPeriodSharesVestingOfRestrictedStockUnit" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_btmd_StockIssuedDuringPeriodSharesVestingOfRestrictedStockUnit" xml:lang="en-US">Stock issued during period shares vesting of restricted stock unit,</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xml:lang="en-US">Stock Issued During Period, Value, New Issues</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xml:lang="en-US">Issuance of shares under SEPA</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xml:lang="en-US">Stock Issued During Period, Shares, New Issues</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xml:lang="en-US">Issuance of shares under SEPA, shares</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xml:lang="en-US">Stock issued during period, shares, new issues</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaap_SharesOutstanding" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SharesOutstanding" xml:lang="en-US">Shares, Outstanding</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_SharesOutstanding" xml:lang="en-US">Ending balance, shares</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesOutstanding" xlink:to="lab_us-gaap_SharesOutstanding" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DividendsCommonStock" xlink:label="loc_us-gaap_DividendsCommonStock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DividendsCommonStock" xml:lang="en-US">Dividends, Common Stock</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_DividendsCommonStock" xml:lang="en-US">Distributions</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DividendsCommonStock" xlink:to="lab_us-gaap_DividendsCommonStock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xml:lang="en-US">Other comprehensive income (loss)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" />
<loc xlink:type="locator" xlink:href="btmd-20221231.xsd#btmd_PartnersCapitalAccountReverseRecapitalizationUnits" xlink:label="loc_btmd_PartnersCapitalAccountReverseRecapitalizationUnits" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_btmd_PartnersCapitalAccountReverseRecapitalizationUnits" xml:lang="en-US">Partners Capital Account Reverse Recapitalization Units</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_btmd_PartnersCapitalAccountReverseRecapitalizationUnits" xml:lang="en-US">Business Combination: Reverse recapitalization on May 26, 2022, units</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_btmd_PartnersCapitalAccountReverseRecapitalizationUnits" xlink:to="lab_btmd_PartnersCapitalAccountReverseRecapitalizationUnits" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_btmd_PartnersCapitalAccountReverseRecapitalizationUnits" xml:lang="en-US">Partners capital account reverse recapitalization units.</label>
<loc xlink:type="locator" xlink:href="btmd-20221231.xsd#btmd_StockholdersEquityIncludingPortionAttributableToNonControllingInterestReverseRecapitalization" xlink:label="loc_btmd_StockholdersEquityIncludingPortionAttributableToNonControllingInterestReverseRecapitalization" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_btmd_StockholdersEquityIncludingPortionAttributableToNonControllingInterestReverseRecapitalization" xml:lang="en-US">Stockholders Equity Including Portion Attributable To Non Controlling Interest Reverse Recapitalization</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_btmd_StockholdersEquityIncludingPortionAttributableToNonControllingInterestReverseRecapitalization" xml:lang="en-US">Business Combination: Reverse recapitalization on May 26, 2022</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_btmd_StockholdersEquityIncludingPortionAttributableToNonControllingInterestReverseRecapitalization" xlink:to="lab_btmd_StockholdersEquityIncludingPortionAttributableToNonControllingInterestReverseRecapitalization" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_btmd_StockholdersEquityIncludingPortionAttributableToNonControllingInterestReverseRecapitalization" xml:lang="en-US">Stockholders equity including portion attributable to non controlling interest reverse recapitalization.</label>
<loc xlink:type="locator" xlink:href="btmd-20221231.xsd#btmd_StockholdersEquityIncludingPortionAttributableToNonControllingInterestSharesReverseRecapitalization" xlink:label="loc_btmd_StockholdersEquityIncludingPortionAttributableToNonControllingInterestSharesReverseRecapitalization" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_btmd_StockholdersEquityIncludingPortionAttributableToNonControllingInterestSharesReverseRecapitalization" xml:lang="en-US">Stockholders Equity Including Portion Attributable To Non Controlling Interest Shares Reverse Recapitalization</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_btmd_StockholdersEquityIncludingPortionAttributableToNonControllingInterestSharesReverseRecapitalization" xml:lang="en-US">Business Combination: Reverse recapitalization on May 26, 2022, shares</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_btmd_StockholdersEquityIncludingPortionAttributableToNonControllingInterestSharesReverseRecapitalization" xlink:to="lab_btmd_StockholdersEquityIncludingPortionAttributableToNonControllingInterestSharesReverseRecapitalization" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_btmd_StockholdersEquityIncludingPortionAttributableToNonControllingInterestSharesReverseRecapitalization" xml:lang="en-US">Stockholders equity including portion attributable to non controlling interest shares reverse recapitalization.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xml:lang="en-US">Statement of Cash Flows [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xml:lang="en-US">Investing Activities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForSoftware" xlink:label="loc_us-gaap_PaymentsForSoftware" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PaymentsForSoftware" xml:lang="en-US">Payments for Software</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_PaymentsForSoftware" xml:lang="en-US">Purchases of capitalized software</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForSoftware" xlink:to="lab_us-gaap_PaymentsForSoftware" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xml:lang="en-US">Purchases of property and equipment</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xml:lang="en-US">Net cash used in investing activities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xml:lang="en-US">Financing Activities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" />
<loc xlink:type="locator" xlink:href="btmd-20221231.xsd#btmd_PrincipalRepaymentsOnTermLoan" xlink:label="loc_btmd_PrincipalRepaymentsOnTermLoan" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_btmd_PrincipalRepaymentsOnTermLoan" xml:lang="en-US">Principal Repayments on Term Loan</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_btmd_PrincipalRepaymentsOnTermLoan" xml:lang="en-US">Principal repayments on term loan</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_btmd_PrincipalRepaymentsOnTermLoan" xlink:to="lab_btmd_PrincipalRepaymentsOnTermLoan" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_btmd_PrincipalRepaymentsOnTermLoan" xml:lang="en-US">Principal repayments on term loan</label>
<loc xlink:type="locator" xlink:href="btmd-20221231.xsd#btmd_BorrowingsOnTermLoan" xlink:label="loc_btmd_BorrowingsOnTermLoan" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_btmd_BorrowingsOnTermLoan" xml:lang="en-US">Borrowings on Term Loan</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_btmd_BorrowingsOnTermLoan" xml:lang="en-US">Borrowings on term loan</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_btmd_BorrowingsOnTermLoan" xlink:to="lab_btmd_BorrowingsOnTermLoan" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_btmd_BorrowingsOnTermLoan" xml:lang="en-US">Borrowings on term loan</label>
<loc xlink:type="locator" xlink:href="btmd-20221231.xsd#btmd_ProceedsFromBusinessCombination" xlink:label="loc_btmd_ProceedsFromBusinessCombination" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_btmd_ProceedsFromBusinessCombination" xml:lang="en-US">Proceeds from Business Combination</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_btmd_ProceedsFromBusinessCombination" xml:lang="en-US">Proceeds from the Business Combination</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_btmd_ProceedsFromBusinessCombination" xlink:to="lab_btmd_ProceedsFromBusinessCombination" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_btmd_ProceedsFromBusinessCombination" xml:lang="en-US">Proceeds from business combination.</label>
<loc xlink:type="locator" xlink:href="btmd-20221231.xsd#btmd_PaymentsOfSettlementOfPhantomEquityRight" xlink:label="loc_btmd_PaymentsOfSettlementOfPhantomEquityRight" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_btmd_PaymentsOfSettlementOfPhantomEquityRight" xml:lang="en-US">Payments of Settlement of Phantom Equity Right</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_btmd_PaymentsOfSettlementOfPhantomEquityRight" xml:lang="en-US">Settlement of phantom equity rights</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_btmd_PaymentsOfSettlementOfPhantomEquityRight" xlink:to="lab_btmd_PaymentsOfSettlementOfPhantomEquityRight" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_btmd_PaymentsOfSettlementOfPhantomEquityRight" xml:lang="en-US">Payments of settlement of phantom equity right.</label>
<loc xlink:type="locator" xlink:href="btmd-20221231.xsd#btmd_PaymentsOfSettlementOfRestrictedStockUnits" xlink:label="loc_btmd_PaymentsOfSettlementOfRestrictedStockUnits" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_btmd_PaymentsOfSettlementOfRestrictedStockUnits" xml:lang="en-US">Payments Of Settlement Of Restricted Stock Units</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_btmd_PaymentsOfSettlementOfRestrictedStockUnits" xml:lang="en-US">Settlement of RSUs</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_btmd_PaymentsOfSettlementOfRestrictedStockUnits" xlink:to="lab_btmd_PaymentsOfSettlementOfRestrictedStockUnits" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_btmd_PaymentsOfSettlementOfRestrictedStockUnits" xml:lang="en-US">Payments of settlement of restricted stock units</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfDividends" xlink:label="loc_us-gaap_PaymentsOfDividends" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PaymentsOfDividends" xml:lang="en-US">Payments of Dividends</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_PaymentsOfDividends" xml:lang="en-US">Distributions</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsOfDividends" xlink:to="lab_us-gaap_PaymentsOfDividends" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PaymentsOfStockIssuanceCosts" xml:lang="en-US">Payments of Stock Issuance Costs</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_PaymentsOfStockIssuanceCosts" xml:lang="en-US">Capitalized transaction costs</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsOfStockIssuanceCosts" xlink:to="lab_us-gaap_PaymentsOfStockIssuanceCosts" />
<loc xlink:type="locator" xlink:href="btmd-20221231.xsd#btmd_ProceedsFromIssuanceOfSharesUnderSepa" xlink:label="loc_btmd_ProceedsFromIssuanceOfSharesUnderSepa" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_btmd_ProceedsFromIssuanceOfSharesUnderSepa" xml:lang="en-US">Proceeds from Issuance of Shares under SEPA</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_btmd_ProceedsFromIssuanceOfSharesUnderSepa" xml:lang="en-US">Proceeds from issuance of shares under SEPA</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_btmd_ProceedsFromIssuanceOfSharesUnderSepa" xlink:to="lab_btmd_ProceedsFromIssuanceOfSharesUnderSepa" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_btmd_ProceedsFromIssuanceOfSharesUnderSepa" xml:lang="en-US">Proceeds from issuance of shares under SEPA.</label>
<loc xlink:type="locator" xlink:href="btmd-20221231.xsd#btmd_PaymentsToSEPATransactionCosts" xlink:label="loc_btmd_PaymentsToSEPATransactionCosts" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_btmd_PaymentsToSEPATransactionCosts" xml:lang="en-US">Payments to S E P A Transaction Costs</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_btmd_PaymentsToSEPATransactionCosts" xml:lang="en-US">SEPA transaction costs</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_btmd_PaymentsToSEPATransactionCosts" xlink:to="lab_btmd_PaymentsToSEPATransactionCosts" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_btmd_PaymentsToSEPATransactionCosts" xml:lang="en-US">Payments to SEPA transaction costs.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xml:lang="en-US">Net cash provided by (used in) financing activities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfDebtExtinguishmentCosts" xlink:label="loc_us-gaap_PaymentsOfDebtExtinguishmentCosts" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PaymentsOfDebtExtinguishmentCosts" xml:lang="en-US">Payment for Debt Extinguishment or Debt Prepayment Cost</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_PaymentsOfDebtExtinguishmentCosts" xml:lang="en-US">Extinguishment of Bank of America term loan</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsOfDebtExtinguishmentCosts" xlink:to="lab_us-gaap_PaymentsOfDebtExtinguishmentCosts" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfDebtIssuanceCosts" xlink:label="loc_us-gaap_PaymentsOfDebtIssuanceCosts" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PaymentsOfDebtIssuanceCosts" xml:lang="en-US">Payments of Debt Issuance Costs</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_PaymentsOfDebtIssuanceCosts" xml:lang="en-US">Debt issuance costs</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsOfDebtIssuanceCosts" xlink:to="lab_us-gaap_PaymentsOfDebtIssuanceCosts" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xml:lang="en-US">Operating Activities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xml:lang="en-US">Adjustments to reconcile net income to net cash (used in) provided by operating activites:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProvisionForDoubtfulAccounts" xlink:label="loc_us-gaap_ProvisionForDoubtfulAccounts" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ProvisionForDoubtfulAccounts" xml:lang="en-US">Accounts Receivable, Credit Loss Expense (Reversal)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ProvisionForDoubtfulAccounts" xml:lang="en-US">Bad debt expense (recoveries)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:label="lab_us-gaap_ProvisionForDoubtfulAccounts" xml:lang="en-US">Provisions charged to operating results</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProvisionForDoubtfulAccounts" xlink:to="lab_us-gaap_ProvisionForDoubtfulAccounts" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xml:lang="en-US">Depreciation, Depletion and Amortization</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xml:lang="en-US">Depreciation and amortization</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:to="lab_us-gaap_DepreciationDepletionAndAmortization" />
<loc xlink:type="locator" xlink:href="btmd-20221231.xsd#btmd_NonCashSponsorShareTransfers" xlink:label="loc_btmd_NonCashSponsorShareTransfers" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_btmd_NonCashSponsorShareTransfers" xml:lang="en-US">Non Cash Sponsor Share Transfers</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_btmd_NonCashSponsorShareTransfers" xml:lang="en-US">Non-cash sponsor share transfers</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_btmd_NonCashSponsorShareTransfers" xlink:to="lab_btmd_NonCashSponsorShareTransfers" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_btmd_NonCashSponsorShareTransfers" xml:lang="en-US">Non-cash sponsor share transfers.</label>
<loc xlink:type="locator" xlink:href="btmd-20221231.xsd#btmd_NonCashFeesUnderSepa" xlink:label="loc_btmd_NonCashFeesUnderSepa" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_btmd_NonCashFeesUnderSepa" xml:lang="en-US">Non Cash Fees under SEPA</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_btmd_NonCashFeesUnderSepa" xml:lang="en-US">Non-cash fees under SEPA</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_btmd_NonCashFeesUnderSepa" xlink:to="lab_btmd_NonCashFeesUnderSepa" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_btmd_NonCashFeesUnderSepa" xml:lang="en-US">Non-cash fees under SEPA.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensation" xml:lang="en-US">Share-Based Payment Arrangement, Noncash Expense</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensation" xml:lang="en-US">Share-based compensation expense</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation" xlink:to="lab_us-gaap_ShareBasedCompensation" />
<loc xlink:type="locator" xlink:href="btmd-20221231.xsd#btmd_FairValueAdjustmentOfEarnoutLiability" xlink:label="loc_btmd_FairValueAdjustmentOfEarnoutLiability" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_btmd_FairValueAdjustmentOfEarnoutLiability" xml:lang="en-US">Fair Value Adjustment Of Earnout Liability</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_btmd_FairValueAdjustmentOfEarnoutLiability" xml:lang="en-US">Gain from change in fair value of earnout liability</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_btmd_FairValueAdjustmentOfEarnoutLiability" xlink:to="lab_btmd_FairValueAdjustmentOfEarnoutLiability" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_btmd_FairValueAdjustmentOfEarnoutLiability" xml:lang="en-US">Fair Value Adjustment Of Earnout Liability</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxesAndTaxCredits" xlink:label="loc_us-gaap_DeferredIncomeTaxesAndTaxCredits" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredIncomeTaxesAndTaxCredits" xml:lang="en-US">Deferred Income Taxes and Tax Credits</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DeferredIncomeTaxesAndTaxCredits" xml:lang="en-US">Deferred income taxes</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxesAndTaxCredits" xlink:to="lab_us-gaap_DeferredIncomeTaxesAndTaxCredits" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfFinancingCosts" xlink:label="loc_us-gaap_AmortizationOfFinancingCosts" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AmortizationOfFinancingCosts" xml:lang="en-US">Amortization of Debt Issuance Costs</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AmortizationOfFinancingCosts" xml:lang="en-US">Amortization of debt issuance costs</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_AmortizationOfFinancingCosts" xml:lang="en-US">Amortization expense related to debt issuance costs</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfFinancingCosts" xlink:to="lab_us-gaap_AmortizationOfFinancingCosts" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryWriteDown" xlink:label="loc_us-gaap_InventoryWriteDown" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_InventoryWriteDown" xml:lang="en-US">Inventory Write-down</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_InventoryWriteDown" xml:lang="en-US">Provision for obsolete inventory</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryWriteDown" xlink:to="lab_us-gaap_InventoryWriteDown" />
<loc xlink:type="locator" xlink:href="btmd-20221231.xsd#btmd_NonCashLeaseExpense" xlink:label="loc_btmd_NonCashLeaseExpense" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_btmd_NonCashLeaseExpense" xml:lang="en-US">Non-Cash Lease Expense</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_btmd_NonCashLeaseExpense" xml:lang="en-US">Non-cash lease expense</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_btmd_NonCashLeaseExpense" xlink:to="lab_btmd_NonCashLeaseExpense" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_btmd_NonCashLeaseExpense" xml:lang="en-US">Non-Cash Lease Expense</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xml:lang="en-US">Changes in operating assets and liabilities:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xml:lang="en-US">Increase (Decrease) in Accounts Receivable</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xml:lang="en-US">Accounts receivable</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories" xml:lang="en-US">Increase (Decrease) in Inventories</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories" xml:lang="en-US">Inventory</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInInventories" xlink:to="lab_us-gaap_IncreaseDecreaseInInventories" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:label="loc_us-gaap_IncreaseDecreaseInDeferredRevenue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncreaseDecreaseInDeferredRevenue" xml:lang="en-US">Increase (Decrease) in Deferred Revenue</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IncreaseDecreaseInDeferredRevenue" xml:lang="en-US">Deferred revenue</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:to="lab_us-gaap_IncreaseDecreaseInDeferredRevenue" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xml:lang="en-US">Increase (Decrease) in Accrued Liabilities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xml:lang="en-US">Accrued expenses</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xml:lang="en-US">Increase (Decrease) in Operating Lease Liability</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xml:lang="en-US">Operating lease liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherCurrentAssets" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherCurrentAssets" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherCurrentAssets" xml:lang="en-US">Increase (Decrease) in Other Current Assets</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherCurrentAssets" xml:lang="en-US">Other current assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherCurrentAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherCurrentAssets" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xml:lang="en-US">Increase (Decrease) in Accounts Payable</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xml:lang="en-US">Accounts payable</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayable" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xml:lang="en-US">Net cash (used in) provided by operating activities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xml:lang="en-US">Cash and cash equivalents at beginning of period</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xml:lang="en-US">Cash and cash equivalents at end of period</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xml:lang="en-US">Supplemental Cash Flow Information [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xml:lang="en-US">Supplemental Disclosure of Cash Flow Information</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="lab_us-gaap_SupplementalCashFlowInformationAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxesPaid" xlink:label="loc_us-gaap_IncomeTaxesPaid" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeTaxesPaid" xml:lang="en-US">Income Taxes Paid</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IncomeTaxesPaid" xml:lang="en-US">Cash paid for income taxes</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxesPaid" xlink:to="lab_us-gaap_IncomeTaxesPaid" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestPaidNet" xlink:label="loc_us-gaap_InterestPaidNet" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_InterestPaidNet" xml:lang="en-US">Interest Paid, Excluding Capitalized Interest, Operating Activities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_InterestPaidNet" xml:lang="en-US">Cash paid for interest</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestPaidNet" xlink:to="lab_us-gaap_InterestPaidNet" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xml:lang="en-US">Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xml:lang="en-US">Non-cash investing and financing activities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" />
<loc xlink:type="locator" xlink:href="btmd-20221231.xsd#btmd_NonCashSEPATransactionCosts" xlink:label="loc_btmd_NonCashSEPATransactionCosts" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_btmd_NonCashSEPATransactionCosts" xml:lang="en-US">Non-cash S E P A Transaction Costs</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_btmd_NonCashSEPATransactionCosts" xml:lang="en-US">Non-cash SEPA transaction costs</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_btmd_NonCashSEPATransactionCosts" xlink:to="lab_btmd_NonCashSEPATransactionCosts" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_btmd_NonCashSEPATransactionCosts" xml:lang="en-US">Non-cash SEPA transaction costs.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:label="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xml:lang="en-US">Capital Expenditures Incurred but Not yet Paid</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xml:lang="en-US">Capital expenditures and capitalized software included in accounts payable</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:to="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xml:lang="en-US">Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xml:lang="en-US">Effect of exchange rate changes on cash and cash equivalents</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:to="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xml:lang="en-US">Net increase in cash and cash equivalents</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:label="loc_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xml:lang="en-US">Business Description and Basis of Presentation [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xml:lang="en-US">Description of Business and Basis of Presentation</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:to="lab_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xml:lang="en-US">Accounting Policies [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingPoliciesAbstract" xlink:to="lab_us-gaap_AccountingPoliciesAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xml:lang="en-US">Significant Accounting Policies [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xml:lang="en-US">Summary of Significant Accounting Policies</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="lab_us-gaap_SignificantAccountingPoliciesTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationsAbstract" xlink:label="loc_us-gaap_BusinessCombinationsAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_BusinessCombinationsAbstract" xml:lang="en-US">Business Combinations [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationsAbstract" xlink:to="lab_us-gaap_BusinessCombinationsAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationDisclosureTextBlock" xlink:label="loc_us-gaap_BusinessCombinationDisclosureTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_BusinessCombinationDisclosureTextBlock" xml:lang="en-US">Business Combination Disclosure [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_BusinessCombinationDisclosureTextBlock" xml:lang="en-US">Business Combination</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:to="lab_us-gaap_BusinessCombinationDisclosureTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerAbstract" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerAbstract" xml:lang="en-US">Revenue from Contract with Customer [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerTextBlock" xml:lang="en-US">Revenue from Contract with Customer [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerTextBlock" xml:lang="en-US">Revenue Recognition</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryDisclosureAbstract" xlink:label="loc_us-gaap_InventoryDisclosureAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_InventoryDisclosureAbstract" xml:lang="en-US">Inventory Disclosure [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryDisclosureAbstract" xlink:to="lab_us-gaap_InventoryDisclosureAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryDisclosureTextBlock" xlink:label="loc_us-gaap_InventoryDisclosureTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_InventoryDisclosureTextBlock" xml:lang="en-US">Inventory Disclosure [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_InventoryDisclosureTextBlock" xml:lang="en-US">Inventory, Net</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryDisclosureTextBlock" xlink:to="lab_us-gaap_InventoryDisclosureTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAbstract" xml:lang="en-US">Property, Plant and Equipment [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xml:lang="en-US">Property, Plant and Equipment Disclosure [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xml:lang="en-US">Property and Equipment, Net</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentAbstract" xlink:label="loc_us-gaap_ResearchAndDevelopmentAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ResearchAndDevelopmentAbstract" xml:lang="en-US">Research and Development [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentAbstract" xlink:to="lab_us-gaap_ResearchAndDevelopmentAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock" xlink:label="loc_us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock" xml:lang="en-US">Research, Development, and Computer Software Disclosure [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock" xml:lang="en-US">Capitalized Software, Net</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock" xlink:to="lab_us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PayablesAndAccrualsAbstract" xml:lang="en-US">Payables and Accruals [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract" xlink:to="lab_us-gaap_PayablesAndAccrualsAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:label="loc_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xml:lang="en-US">Accounts Payable, Accrued Liabilities, and Other Liabilities Disclosure, Current [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xml:lang="en-US">Accrued Expenses</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:to="lab_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaap_DebtDisclosureAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtDisclosureAbstract" xml:lang="en-US">Debt Disclosure [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureAbstract" xlink:to="lab_us-gaap_DebtDisclosureAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="loc_us-gaap_DebtDisclosureTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtDisclosureTextBlock" xml:lang="en-US">Debt Disclosure [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DebtDisclosureTextBlock" xml:lang="en-US">Long-Term Debt</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureTextBlock" xlink:to="lab_us-gaap_DebtDisclosureTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantsAndRightsNoteDisclosureAbstract" xlink:label="loc_us-gaap_WarrantsAndRightsNoteDisclosureAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_WarrantsAndRightsNoteDisclosureAbstract" xml:lang="en-US">Warrants and Rights Note Disclosure [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WarrantsAndRightsNoteDisclosureAbstract" xlink:to="lab_us-gaap_WarrantsAndRightsNoteDisclosureAbstract" />
<loc xlink:type="locator" xlink:href="btmd-20221231.xsd#btmd_WarrantLiabilityTextBlock" xlink:label="loc_btmd_WarrantLiabilityTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_btmd_WarrantLiabilityTextBlock" xml:lang="en-US">Warrant Liability [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_btmd_WarrantLiabilityTextBlock" xml:lang="en-US">Warrant Liability</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_btmd_WarrantLiabilityTextBlock" xlink:to="lab_btmd_WarrantLiabilityTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_btmd_WarrantLiabilityTextBlock" xml:lang="en-US">Warrant liability.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
<loc xlink:type="locator" xlink:href="btmd-20221231.xsd#btmd_EarnoutLiabilityTextBlock" xlink:label="loc_btmd_EarnoutLiabilityTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_btmd_EarnoutLiabilityTextBlock" xml:lang="en-US">Earnout Liability [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_btmd_EarnoutLiabilityTextBlock" xml:lang="en-US">Earnout Liability</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_btmd_EarnoutLiabilityTextBlock" xlink:to="lab_btmd_EarnoutLiabilityTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_btmd_EarnoutLiabilityTextBlock" xml:lang="en-US">Earnout liability.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xml:lang="en-US">Fair Value Disclosures [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract" xlink:to="lab_us-gaap_FairValueDisclosuresAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xml:lang="en-US">Fair Value Disclosures [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xml:lang="en-US">Fair value measurements</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:to="lab_us-gaap_FairValueDisclosuresTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncontrollingInterestAbstract" xlink:label="loc_us-gaap_NoncontrollingInterestAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NoncontrollingInterestAbstract" xml:lang="en-US">Noncontrolling Interest [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncontrollingInterestAbstract" xlink:to="lab_us-gaap_NoncontrollingInterestAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MinorityInterestDisclosureTextBlock" xlink:label="loc_us-gaap_MinorityInterestDisclosureTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_MinorityInterestDisclosureTextBlock" xml:lang="en-US">Noncontrolling Interest Disclosure [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_MinorityInterestDisclosureTextBlock" xml:lang="en-US">Noncontrolling Interest</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MinorityInterestDisclosureTextBlock" xlink:to="lab_us-gaap_MinorityInterestDisclosureTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xml:lang="en-US">Share-Based Payment Arrangement [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xml:lang="en-US">Share-Based Payment Arrangement [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xml:lang="en-US">Share-Based Compensation</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract" xlink:label="loc_us-gaap_LeasesAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LeasesAbstract" xml:lang="en-US">Leases [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeasesAbstract" xlink:to="lab_us-gaap_LeasesAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeasesTextBlock" xlink:label="loc_us-gaap_LesseeOperatingLeasesTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LesseeOperatingLeasesTextBlock" xml:lang="en-US">Lessee, Operating Leases [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LesseeOperatingLeasesTextBlock" xml:lang="en-US">Leases</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeasesTextBlock" xlink:to="lab_us-gaap_LesseeOperatingLeasesTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xml:lang="en-US">Income Tax Disclosure [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:to="lab_us-gaap_IncomeTaxDisclosureAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xml:lang="en-US">Income Tax Disclosure [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xml:lang="en-US">Income Taxes</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="lab_us-gaap_IncomeTaxDisclosureTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="loc_us-gaap_EarningsPerShareTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xml:lang="en-US">Earnings Per Share [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xml:lang="en-US">Net Loss Per Common Share</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareTextBlock" xlink:to="lab_us-gaap_EarningsPerShareTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xml:lang="en-US">Commitments and Contingencies</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RelatedPartyTransactionsAbstract" xml:lang="en-US">Related Party Transactions [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract" xlink:to="lab_us-gaap_RelatedPartyTransactionsAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xml:lang="en-US">Related Party Transactions Disclosure [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xml:lang="en-US">Related-Party Transactions</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:to="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaap_SubsequentEventsAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SubsequentEventsAbstract" xml:lang="en-US">Subsequent Events [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsAbstract" xlink:to="lab_us-gaap_SubsequentEventsAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="loc_us-gaap_SubsequentEventsTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SubsequentEventsTextBlock" xml:lang="en-US">Subsequent Events [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SubsequentEventsTextBlock" xml:lang="en-US">Subsequent Events</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsTextBlock" xlink:to="lab_us-gaap_SubsequentEventsTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UseOfEstimates" xlink:label="loc_us-gaap_UseOfEstimates" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_UseOfEstimates" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_UseOfEstimates" xml:lang="en-US">Use of Estimates</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UseOfEstimates" xlink:to="lab_us-gaap_UseOfEstimates" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:label="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xml:lang="en-US">Fair Value Measurement, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xml:lang="en-US">Fair Value Measurements</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:to="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:label="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock" xml:lang="en-US">Segment Reporting, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock" xml:lang="en-US">Segment Information</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:to="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xml:lang="en-US">Cash and Cash Equivalents, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xml:lang="en-US">Cash</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy" xlink:label="loc_us-gaap_ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy" xml:lang="en-US">Receivables, Trade and Other Accounts Receivable, Allowance for Doubtful Accounts, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy" xml:lang="en-US">Accounts Receivable and Allowance for Doubtful Accounts</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy" xlink:to="lab_us-gaap_ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryPolicyTextBlock" xlink:label="loc_us-gaap_InventoryPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_InventoryPolicyTextBlock" xml:lang="en-US">Inventory, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_InventoryPolicyTextBlock" xml:lang="en-US">Inventory</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryPolicyTextBlock" xlink:to="lab_us-gaap_InventoryPolicyTextBlock" />
<loc xlink:type="locator" xlink:href="btmd-20221231.xsd#btmd_OtherCurrentAssetsPolicyTextBlock" xlink:label="loc_btmd_OtherCurrentAssetsPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_btmd_OtherCurrentAssetsPolicyTextBlock" xml:lang="en-US">Other Current Assets [Policy Text Block\</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_btmd_OtherCurrentAssetsPolicyTextBlock" xml:lang="en-US">Other Current Assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_btmd_OtherCurrentAssetsPolicyTextBlock" xlink:to="lab_btmd_OtherCurrentAssetsPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_btmd_OtherCurrentAssetsPolicyTextBlock" xml:lang="en-US">Other current assets policy.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xml:lang="en-US">Property, Plant and Equipment, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xml:lang="en-US">Property and Equipment, Net</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InternalUseSoftwarePolicy" xlink:label="loc_us-gaap_InternalUseSoftwarePolicy" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_InternalUseSoftwarePolicy" xml:lang="en-US">Internal Use Software, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_InternalUseSoftwarePolicy" xml:lang="en-US">Capitalized Software, Net</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InternalUseSoftwarePolicy" xlink:to="lab_us-gaap_InternalUseSoftwarePolicy" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:label="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xml:lang="en-US">Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xml:lang="en-US">Impairment of Long-Lived Assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:to="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeasesPolicyTextBlock" xlink:label="loc_us-gaap_LesseeLeasesPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LesseeLeasesPolicyTextBlock" xml:lang="en-US">Lessee, Leases [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LesseeLeasesPolicyTextBlock" xml:lang="en-US">Leases</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeasesPolicyTextBlock" xlink:to="lab_us-gaap_LesseeLeasesPolicyTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock" xml:lang="en-US">Income Tax, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock" xml:lang="en-US">Income Taxes</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxPolicyTextBlock" xlink:to="lab_us-gaap_IncomeTaxPolicyTextBlock" />
<loc xlink:type="locator" xlink:href="btmd-20221231.xsd#btmd_DebtIssuanceCostsPolicyTextBlock" xlink:label="loc_btmd_DebtIssuanceCostsPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_btmd_DebtIssuanceCostsPolicyTextBlock" xml:lang="en-US">Debt Issuance Costs [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_btmd_DebtIssuanceCostsPolicyTextBlock" xml:lang="en-US">Debt Issuance Costs</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_btmd_DebtIssuanceCostsPolicyTextBlock" xlink:to="lab_btmd_DebtIssuanceCostsPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_btmd_DebtIssuanceCostsPolicyTextBlock" xml:lang="en-US">Debt issuance costs.</label>
<loc xlink:type="locator" xlink:href="btmd-20221231.xsd#btmd_WarrantLiabilitiesPolicyTextBlock" xlink:label="loc_btmd_WarrantLiabilitiesPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_btmd_WarrantLiabilitiesPolicyTextBlock" xml:lang="en-US">Warrant Liabilities [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_btmd_WarrantLiabilitiesPolicyTextBlock" xml:lang="en-US">Warrant Liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_btmd_WarrantLiabilitiesPolicyTextBlock" xlink:to="lab_btmd_WarrantLiabilitiesPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_btmd_WarrantLiabilitiesPolicyTextBlock" xml:lang="en-US">Warrant liabilities.</label>
<loc xlink:type="locator" xlink:href="btmd-20221231.xsd#btmd_EarnoutLiabilityPolicyTextBlock" xlink:label="loc_btmd_EarnoutLiabilityPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_btmd_EarnoutLiabilityPolicyTextBlock" xml:lang="en-US">Earnout Liability [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_btmd_EarnoutLiabilityPolicyTextBlock" xml:lang="en-US">Earnout Liability</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_btmd_EarnoutLiabilityPolicyTextBlock" xlink:to="lab_btmd_EarnoutLiabilityPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_btmd_EarnoutLiabilityPolicyTextBlock" xml:lang="en-US">Earnout liability.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityPolicyTextBlock" xlink:label="loc_us-gaap_StockholdersEquityPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockholdersEquityPolicyTextBlock" xml:lang="en-US">Stockholders' Equity, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_StockholdersEquityPolicyTextBlock" xml:lang="en-US">Stockholders' Equity (Deficit)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityPolicyTextBlock" xlink:to="lab_us-gaap_StockholdersEquityPolicyTextBlock" />
<loc xlink:type="locator" xlink:href="btmd-20221231.xsd#btmd_StandbyEquityPurchaseAgreementPolicyTextBlock" xlink:label="loc_btmd_StandbyEquityPurchaseAgreementPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_btmd_StandbyEquityPurchaseAgreementPolicyTextBlock" xml:lang="en-US">Standby Equity Purchase Agreement [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_btmd_StandbyEquityPurchaseAgreementPolicyTextBlock" xml:lang="en-US">Standby Equity Purchase Agreement</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_btmd_StandbyEquityPurchaseAgreementPolicyTextBlock" xlink:to="lab_btmd_StandbyEquityPurchaseAgreementPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_btmd_StandbyEquityPurchaseAgreementPolicyTextBlock" xml:lang="en-US">Standby equity purchase agreement [Policy Text Block]</label>
<loc xlink:type="locator" xlink:href="btmd-20221231.xsd#btmd_NoncontrollingInterestPolicyTextBlock" xlink:label="loc_btmd_NoncontrollingInterestPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_btmd_NoncontrollingInterestPolicyTextBlock" xml:lang="en-US">Noncontrolling Interest [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_btmd_NoncontrollingInterestPolicyTextBlock" xml:lang="en-US">Noncontrolling Interest</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_btmd_NoncontrollingInterestPolicyTextBlock" xlink:to="lab_btmd_NoncontrollingInterestPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_btmd_NoncontrollingInterestPolicyTextBlock" xml:lang="en-US">Noncontrolling interest.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRecognitionPolicyTextBlock" xlink:label="loc_us-gaap_RevenueRecognitionPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RevenueRecognitionPolicyTextBlock" xml:lang="en-US">Revenue [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_RevenueRecognitionPolicyTextBlock" xml:lang="en-US">Revenue Recognition</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueRecognitionPolicyTextBlock" xlink:to="lab_us-gaap_RevenueRecognitionPolicyTextBlock" />
<loc xlink:type="locator" xlink:href="btmd-20221231.xsd#btmd_CostOfRevenuePolicyTextBlock" xlink:label="loc_btmd_CostOfRevenuePolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_btmd_CostOfRevenuePolicyTextBlock" xml:lang="en-US">Cost of Revenue [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_btmd_CostOfRevenuePolicyTextBlock" xml:lang="en-US">Cost of Revenue</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_btmd_CostOfRevenuePolicyTextBlock" xlink:to="lab_btmd_CostOfRevenuePolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_btmd_CostOfRevenuePolicyTextBlock" xml:lang="en-US">Cost of revenue.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketRiskBenefitPolicyTextBlock" xlink:label="loc_us-gaap_MarketRiskBenefitPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_MarketRiskBenefitPolicyTextBlock" xml:lang="en-US">Market Risk Benefit [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_MarketRiskBenefitPolicyTextBlock" xml:lang="en-US">Marketing</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MarketRiskBenefitPolicyTextBlock" xlink:to="lab_us-gaap_MarketRiskBenefitPolicyTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock" xml:lang="en-US">Selling, General and Administrative Expenses, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock" xml:lang="en-US">Selling, General, and Administrative</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock" xlink:to="lab_us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PensionAndOtherPostretirementPlansPolicy" xlink:label="loc_us-gaap_PensionAndOtherPostretirementPlansPolicy" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PensionAndOtherPostretirementPlansPolicy" xml:lang="en-US">Pension and Other Postretirement Plans, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PensionAndOtherPostretirementPlansPolicy" xml:lang="en-US">Employee Retirement Plans</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PensionAndOtherPostretirementPlansPolicy" xlink:to="lab_us-gaap_PensionAndOtherPostretirementPlansPolicy" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xml:lang="en-US">Share-Based Payment Arrangement [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xml:lang="en-US">Share-Based Compensation</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommissionsPolicy" xlink:label="loc_us-gaap_CommissionsPolicy" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommissionsPolicy" xml:lang="en-US">Commissions, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CommissionsPolicy" xml:lang="en-US">Commissions</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommissionsPolicy" xlink:to="lab_us-gaap_CommissionsPolicy" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="loc_us-gaap_ConcentrationRiskCreditRisk" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ConcentrationRiskCreditRisk" xml:lang="en-US">Concentration Risk, Credit Risk, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ConcentrationRiskCreditRisk" xml:lang="en-US">Concentrations</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskCreditRisk" xlink:to="lab_us-gaap_ConcentrationRiskCreditRisk" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xml:lang="en-US">Recently Adopted and Recent Accounting Pronouncements Not Yet Adopted</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableAllowanceForCreditLossTableTextBlock" xlink:label="loc_us-gaap_AccountsReceivableAllowanceForCreditLossTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccountsReceivableAllowanceForCreditLossTableTextBlock" xml:lang="en-US">Accounts Receivable, Allowance for Credit Loss [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AccountsReceivableAllowanceForCreditLossTableTextBlock" xml:lang="en-US">Summary of Rollforward of the Allowance for Doubtful Accounts</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableAllowanceForCreditLossTableTextBlock" xlink:to="lab_us-gaap_AccountsReceivableAllowanceForCreditLossTableTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock" xml:lang="en-US">Schedule of Other Current Assets [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock" xml:lang="en-US">Summary of Total Other Current Assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock" />
<loc xlink:type="locator" xlink:href="btmd-20221231.xsd#btmd_DisclosureInTabularFormOfEstimatedUsefulLivesOfPropertyPlantAndEquipmentTableTextBlock" xlink:label="loc_btmd_DisclosureInTabularFormOfEstimatedUsefulLivesOfPropertyPlantAndEquipmentTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_btmd_DisclosureInTabularFormOfEstimatedUsefulLivesOfPropertyPlantAndEquipmentTableTextBlock" xml:lang="en-US">Disclosure In Tabular Form Of Estimated Useful Lives Of Property Plant And Equipment [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_btmd_DisclosureInTabularFormOfEstimatedUsefulLivesOfPropertyPlantAndEquipmentTableTextBlock" xml:lang="en-US">Summary of Estimated Useful Lives of Property and Equipment</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_btmd_DisclosureInTabularFormOfEstimatedUsefulLivesOfPropertyPlantAndEquipmentTableTextBlock" xlink:to="lab_btmd_DisclosureInTabularFormOfEstimatedUsefulLivesOfPropertyPlantAndEquipmentTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_btmd_DisclosureInTabularFormOfEstimatedUsefulLivesOfPropertyPlantAndEquipmentTableTextBlock" xml:lang="en-US">Disclosure in tabular form of estimated useful lives of property plant and equipment.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCapitalUnitsTextBlock" xlink:label="loc_us-gaap_ScheduleOfCapitalUnitsTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfCapitalUnitsTextBlock" xml:lang="en-US">Schedule of Capital Units [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfCapitalUnitsTextBlock" xml:lang="en-US">Summary of Members' Equity Units Issued and Outstanding</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCapitalUnitsTextBlock" xlink:to="lab_us-gaap_ScheduleOfCapitalUnitsTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfStockByClassTextBlock" xlink:label="loc_us-gaap_ScheduleOfStockByClassTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfStockByClassTextBlock" xml:lang="en-US">Schedule of Stock by Class [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfStockByClassTextBlock" xml:lang="en-US">Summary of Common Stock Issued and Outstanding</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfStockByClassTextBlock" xlink:to="lab_us-gaap_ScheduleOfStockByClassTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:label="loc_us-gaap_DisaggregationOfRevenueTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DisaggregationOfRevenueTableTextBlock" xml:lang="en-US">Disaggregation of Revenue [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DisaggregationOfRevenueTableTextBlock" xml:lang="en-US">Schedule of Revenues Recognized</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:to="lab_us-gaap_DisaggregationOfRevenueTableTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:label="loc_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xml:lang="en-US">Contract with Customer, Contract Asset, Contract Liability, and Receivable [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xml:lang="en-US">Summary of Significant Changes in Contract Liability Balances</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:to="lab_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" />
<loc xlink:type="locator" xlink:href="btmd-20221231.xsd#btmd_SummaryOfConsiderationAllocatedToPerformanceObligationsTableTextBlock" xlink:label="loc_btmd_SummaryOfConsiderationAllocatedToPerformanceObligationsTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_btmd_SummaryOfConsiderationAllocatedToPerformanceObligationsTableTextBlock" xml:lang="en-US">Summary of Consideration Allocated to Performance Obligations [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_btmd_SummaryOfConsiderationAllocatedToPerformanceObligationsTableTextBlock" xml:lang="en-US">Summary of Consideration Allocated to Performance Obligations</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_btmd_SummaryOfConsiderationAllocatedToPerformanceObligationsTableTextBlock" xlink:to="lab_btmd_SummaryOfConsiderationAllocatedToPerformanceObligationsTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_btmd_SummaryOfConsiderationAllocatedToPerformanceObligationsTableTextBlock" xml:lang="en-US">Summary of consideration allocated to performance obligations.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xml:lang="en-US">Schedule of Inventory, Current [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xml:lang="en-US">Schedule of Inventory, Net</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xml:lang="en-US">Property, Plant and Equipment [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xml:lang="en-US">Schedule of Property and Equipment, Net</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" />
<loc xlink:type="locator" xlink:href="btmd-20221231.xsd#btmd_SummaryOfCapitalizedSoftwareNetTableTextBlock" xlink:label="loc_btmd_SummaryOfCapitalizedSoftwareNetTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_btmd_SummaryOfCapitalizedSoftwareNetTableTextBlock" xml:lang="en-US">Summary of Capitalized Software, Net</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_btmd_SummaryOfCapitalizedSoftwareNetTableTextBlock" xlink:to="lab_btmd_SummaryOfCapitalizedSoftwareNetTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_btmd_SummaryOfCapitalizedSoftwareNetTableTextBlock" xml:lang="en-US">Summary of capitalized software net.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xml:lang="en-US">Schedule of Accrued Liabilities [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xml:lang="en-US">Schedule of Accrued Expenses</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDebtTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfDebtTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfDebtTableTextBlock" xml:lang="en-US">Schedule of Debt [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfDebtTableTextBlock" xml:lang="en-US">Schedule of Outstanding Debt</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDebtTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfDebtTableTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xml:lang="en-US">Schedule of Maturities of Long-Term Debt [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xml:lang="en-US">Schedule of Future Maturities of Long-term Debt</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock" xml:lang="en-US">Schedule of Fair Value Hierarchy for Financial Assets and Liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xml:lang="en-US">Fair Value Measurement Inputs and Valuation Techniques [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xml:lang="en-US">Summary of Significant Inputs to Monte Carlo Simulation for Fair Value of Private Placement Warrants and Earnout Liability</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" />
<loc xlink:type="locator" xlink:href="btmd-20221231.xsd#btmd_ScheduleOfChangesInTheFairValueOfWarrantLiabilitiesTableTextBlock" xlink:label="loc_btmd_ScheduleOfChangesInTheFairValueOfWarrantLiabilitiesTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_btmd_ScheduleOfChangesInTheFairValueOfWarrantLiabilitiesTableTextBlock" xml:lang="en-US">Schedule Of Changes In The Fair Value Of Warrant Liabilities Table Text Block</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_btmd_ScheduleOfChangesInTheFairValueOfWarrantLiabilitiesTableTextBlock" xml:lang="en-US">Summary of Changes in the Fair Value of Company's Level 3 Financial Instruments</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_btmd_ScheduleOfChangesInTheFairValueOfWarrantLiabilitiesTableTextBlock" xlink:to="lab_btmd_ScheduleOfChangesInTheFairValueOfWarrantLiabilitiesTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_btmd_ScheduleOfChangesInTheFairValueOfWarrantLiabilitiesTableTextBlock" xml:lang="en-US">Schedule of changes in the fair value of warrant liabilities.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xml:lang="en-US">Share-Based Payment Arrangement, Restricted Stock Unit, Activity [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xml:lang="en-US">Summary of Restricted Stock Unit Activity</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xml:lang="en-US">Share-Based Payment Arrangement, Option, Activity [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xml:lang="en-US">Summary of Stock Option Activity</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xml:lang="en-US">Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xml:lang="en-US">Summary of Weighted-Average Assumptions used to Estimate Fair Value of Stock Options Granted</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" />
<loc xlink:type="locator" xlink:href="btmd-20221231.xsd#btmd_SummaryOfLeaseCostsRecognizedUnderAsc842AndSupplementalCashFlowInformationForLeasesTableTextBlock" xlink:label="loc_btmd_SummaryOfLeaseCostsRecognizedUnderAsc842AndSupplementalCashFlowInformationForLeasesTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_btmd_SummaryOfLeaseCostsRecognizedUnderAsc842AndSupplementalCashFlowInformationForLeasesTableTextBlock" xml:lang="en-US">Summary of Lease Costs Recognized under ASC 842 and Supplemental Cash Flow Information for Leases [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_btmd_SummaryOfLeaseCostsRecognizedUnderAsc842AndSupplementalCashFlowInformationForLeasesTableTextBlock" xml:lang="en-US">Summary of Operating Lease Costs Recognized under ASC 842 and Supplemental Cash Flow Information for Leases</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_btmd_SummaryOfLeaseCostsRecognizedUnderAsc842AndSupplementalCashFlowInformationForLeasesTableTextBlock" xlink:to="lab_btmd_SummaryOfLeaseCostsRecognizedUnderAsc842AndSupplementalCashFlowInformationForLeasesTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_btmd_SummaryOfLeaseCostsRecognizedUnderAsc842AndSupplementalCashFlowInformationForLeasesTableTextBlock" xml:lang="en-US">Summary of lease costs recognized under ASC 842 and supplemental cash flow information for leases.</label>
<loc xlink:type="locator" xlink:href="btmd-20221231.xsd#btmd_SummaryBalanceSheetClassificationOfOperatingLeasesAndWeightedAverageRemainingLeaseTermAndDiscountRateTableTextBlock" xlink:label="loc_btmd_SummaryBalanceSheetClassificationOfOperatingLeasesAndWeightedAverageRemainingLeaseTermAndDiscountRateTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_btmd_SummaryBalanceSheetClassificationOfOperatingLeasesAndWeightedAverageRemainingLeaseTermAndDiscountRateTableTextBlock" xml:lang="en-US">Summary Balance Sheet Classification of Operating Leases and Weighted Average Remaining Lease Term and Discount Rate [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_btmd_SummaryBalanceSheetClassificationOfOperatingLeasesAndWeightedAverageRemainingLeaseTermAndDiscountRateTableTextBlock" xml:lang="en-US">Summary Balance Sheet Classification of Operating Leases and Weighted Average Remaining Lease Term and Discount Rate</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_btmd_SummaryBalanceSheetClassificationOfOperatingLeasesAndWeightedAverageRemainingLeaseTermAndDiscountRateTableTextBlock" xlink:to="lab_btmd_SummaryBalanceSheetClassificationOfOperatingLeasesAndWeightedAverageRemainingLeaseTermAndDiscountRateTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_btmd_SummaryBalanceSheetClassificationOfOperatingLeasesAndWeightedAverageRemainingLeaseTermAndDiscountRateTableTextBlock" xml:lang="en-US">Summary balance sheet classification of operating leases and weighted average remaining lease term and discount rate.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xml:lang="en-US">Lessee, Operating Lease, Liability, Maturity [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xml:lang="en-US">Summary of Payments by Date for Operating Lease</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xml:lang="en-US">Schedule of Income before Income Tax, Domestic and Foreign [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xml:lang="en-US">Schedule of Income (Loss) Before Provision for Income Taxes</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xml:lang="en-US">Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xml:lang="en-US">Schedule of Income Tax Provision</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xml:lang="en-US">Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xml:lang="en-US">Schedule of Reconciliation of the Federal Income Tax Rate to the Company Effective Tax Rate</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xml:lang="en-US">Schedule of Deferred Tax Assets and Liabilities [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xml:lang="en-US">Schedule of Deferred Tax Assets and Liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xml:lang="en-US">Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xml:lang="en-US">Schedule of Computation of Net Loss Per Common Share</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xml:lang="en-US">Schedule of Computation of Diluted Weighted Average Shares Outstanding</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfProductInformationTable" xlink:label="loc_us-gaap_ScheduleOfProductInformationTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfProductInformationTable" xml:lang="en-US">Schedule of Product Information [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfProductInformationTable" xlink:to="lab_us-gaap_ScheduleOfProductInformationTable" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalUnitsByClassAxis" xlink:label="loc_us-gaap_CapitalUnitsByClassAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CapitalUnitsByClassAxis" xml:lang="en-US">Capital Units by Class [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CapitalUnitsByClassAxis" xlink:to="lab_us-gaap_CapitalUnitsByClassAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalUnitClassDomain" xlink:label="loc_us-gaap_CapitalUnitClassDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CapitalUnitClassDomain" xml:lang="en-US">Capital Unit, Class [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CapitalUnitClassDomain" xlink:to="lab_us-gaap_CapitalUnitClassDomain" />
<loc xlink:type="locator" xlink:href="btmd-20221231.xsd#btmd_ClassAVotingUnitsMember" xlink:label="loc_btmd_ClassAVotingUnitsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_btmd_ClassAVotingUnitsMember" xml:lang="en-US">Class A Voting Units [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_btmd_ClassAVotingUnitsMember" xml:lang="en-US">Class A (Voting)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_btmd_ClassAVotingUnitsMember" xlink:to="lab_btmd_ClassAVotingUnitsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_btmd_ClassAVotingUnitsMember" xml:lang="en-US">Class A Voting Units.</label>
<loc xlink:type="locator" xlink:href="btmd-20221231.xsd#btmd_InventoryMember" xlink:label="loc_btmd_InventoryMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_btmd_InventoryMember" xml:lang="en-US">Inventory [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_btmd_InventoryMember" xml:lang="en-US">Inventory</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_btmd_InventoryMember" xlink:to="lab_btmd_InventoryMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_btmd_InventoryMember" xml:lang="en-US">Inventory.</label>
<loc xlink:type="locator" xlink:href="btmd-20221231.xsd#btmd_NatureOfCustomerAxis" xlink:label="loc_btmd_NatureOfCustomerAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_btmd_NatureOfCustomerAxis" xml:lang="en-US">Nature Of Customer [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_btmd_NatureOfCustomerAxis" xlink:to="lab_btmd_NatureOfCustomerAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_btmd_NatureOfCustomerAxis" xml:lang="en-US">Nature of customer.</label>
<loc xlink:type="locator" xlink:href="btmd-20221231.xsd#btmd_NatureOfCustomerDomain" xlink:label="loc_btmd_NatureOfCustomerDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_btmd_NatureOfCustomerDomain" xml:lang="en-US">Nature Of Customer [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_btmd_NatureOfCustomerDomain" xlink:to="lab_btmd_NatureOfCustomerDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_btmd_NatureOfCustomerDomain" xml:lang="en-US">Nature of customer.</label>
<loc xlink:type="locator" xlink:href="btmd-20221231.xsd#btmd_BioteMethodCustomerMember" xlink:label="loc_btmd_BioteMethodCustomerMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_btmd_BioteMethodCustomerMember" xml:lang="en-US">Biote Method Customer [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_btmd_BioteMethodCustomerMember" xml:lang="en-US">Biote Method Customer</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_btmd_BioteMethodCustomerMember" xlink:to="lab_btmd_BioteMethodCustomerMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_btmd_BioteMethodCustomerMember" xml:lang="en-US">Biote method customer.</label>
<loc xlink:type="locator" xlink:href="btmd-20221231.xsd#btmd_SourceOfRevenueAxis" xlink:label="loc_btmd_SourceOfRevenueAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_btmd_SourceOfRevenueAxis" xml:lang="en-US">Source Of Revenue [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_btmd_SourceOfRevenueAxis" xlink:to="lab_btmd_SourceOfRevenueAxis" />
<loc xlink:type="locator" xlink:href="btmd-20221231.xsd#btmd_SourceOfRevenueDomain" xlink:label="loc_btmd_SourceOfRevenueDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_btmd_SourceOfRevenueDomain" xml:lang="en-US">Source Of Revenue [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_btmd_SourceOfRevenueDomain" xlink:to="lab_btmd_SourceOfRevenueDomain" />
<loc xlink:type="locator" xlink:href="btmd-20221231.xsd#btmd_SourceOfServiceRevenueAxis" xlink:label="loc_btmd_SourceOfServiceRevenueAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_btmd_SourceOfServiceRevenueAxis" xml:lang="en-US">Source Of Service Revenue [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_btmd_SourceOfServiceRevenueAxis" xlink:to="lab_btmd_SourceOfServiceRevenueAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_btmd_SourceOfServiceRevenueAxis" xml:lang="en-US">Source of service revenue.</label>
<loc xlink:type="locator" xlink:href="btmd-20221231.xsd#btmd_SourceOfServiceRevenueDomain" xlink:label="loc_btmd_SourceOfServiceRevenueDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_btmd_SourceOfServiceRevenueDomain" xml:lang="en-US">Source Of Service Revenue [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_btmd_SourceOfServiceRevenueDomain" xlink:to="lab_btmd_SourceOfServiceRevenueDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_btmd_SourceOfServiceRevenueDomain" xml:lang="en-US">Source of service revenue.</label>
<loc xlink:type="locator" xlink:href="btmd-20221231.xsd#btmd_TrainingMember" xlink:label="loc_btmd_TrainingMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_btmd_TrainingMember" xml:lang="en-US">Training [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_btmd_TrainingMember" xml:lang="en-US">Training</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_btmd_TrainingMember" xlink:to="lab_btmd_TrainingMember" />
<loc xlink:type="locator" xlink:href="btmd-20221231.xsd#btmd_ContractTermServicesMember" xlink:label="loc_btmd_ContractTermServicesMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_btmd_ContractTermServicesMember" xml:lang="en-US">Contract Term Services [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_btmd_ContractTermServicesMember" xml:lang="en-US">Contract Term Services</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_btmd_ContractTermServicesMember" xlink:to="lab_btmd_ContractTermServicesMember" />
<loc xlink:type="locator" xlink:href="btmd-20221231.xsd#btmd_PalletProceduresMember" xlink:label="loc_btmd_PalletProceduresMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_btmd_PalletProceduresMember" xml:lang="en-US">Pallet Procedures [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_btmd_PalletProceduresMember" xml:lang="en-US">Pallet Procedures</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_btmd_PalletProceduresMember" xlink:to="lab_btmd_PalletProceduresMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ConcentrationRiskByTypeAxis" xml:lang="en-US">Concentration Risk Type [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis" xlink:to="lab_us-gaap_ConcentrationRiskByTypeAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ConcentrationRiskTypeDomain" xml:lang="en-US">Concentration Risk Type [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain" xlink:to="lab_us-gaap_ConcentrationRiskTypeDomain" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditAvailabilityConcentrationRiskMember" xlink:label="loc_us-gaap_CreditAvailabilityConcentrationRiskMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CreditAvailabilityConcentrationRiskMember" xml:lang="en-US">Credit Availability Concentration Risk [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CreditAvailabilityConcentrationRiskMember" xml:lang="en-US">Outstanding Debt and Available Line of Credit</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CreditAvailabilityConcentrationRiskMember" xlink:to="lab_us-gaap_CreditAvailabilityConcentrationRiskMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplierConcentrationRiskMember" xlink:label="loc_us-gaap_SupplierConcentrationRiskMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SupplierConcentrationRiskMember" xml:lang="en-US">Supplier Concentration Risk [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SupplierConcentrationRiskMember" xml:lang="en-US">Vendor Concentration</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplierConcentrationRiskMember" xlink:to="lab_us-gaap_SupplierConcentrationRiskMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xml:lang="en-US">Concentration Risk Benchmark [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xml:lang="en-US">Concentration Risk Benchmark [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="lab_us-gaap_ConcentrationRiskBenchmarkDomain" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesTotalMember" xlink:label="loc_us-gaap_LiabilitiesTotalMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LiabilitiesTotalMember" xml:lang="en-US">Liabilities, Total [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LiabilitiesTotalMember" xml:lang="en-US">Liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesTotalMember" xlink:to="lab_us-gaap_LiabilitiesTotalMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsTotalMember" xlink:label="loc_us-gaap_AssetsTotalMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AssetsTotalMember" xml:lang="en-US">Assets, Total [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AssetsTotalMember" xml:lang="en-US">Assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsTotalMember" xlink:to="lab_us-gaap_AssetsTotalMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanNameAxis" xlink:label="loc_us-gaap_RetirementPlanNameAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RetirementPlanNameAxis" xml:lang="en-US">Retirement Plan Name [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetirementPlanNameAxis" xlink:to="lab_us-gaap_RetirementPlanNameAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanNameDomain" xlink:label="loc_us-gaap_RetirementPlanNameDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RetirementPlanNameDomain" xml:lang="en-US">Retirement Plan Name [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetirementPlanNameDomain" xlink:to="lab_us-gaap_RetirementPlanNameDomain" />
<loc xlink:type="locator" xlink:href="btmd-20221231.xsd#btmd_FourZeroOneKPlanMember" xlink:label="loc_btmd_FourZeroOneKPlanMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_btmd_FourZeroOneKPlanMember" xml:lang="en-US">Four Zero One K Plan [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_btmd_FourZeroOneKPlanMember" xml:lang="en-US">401(k) Plan</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_btmd_FourZeroOneKPlanMember" xlink:to="lab_btmd_FourZeroOneKPlanMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_btmd_FourZeroOneKPlanMember" xml:lang="en-US">401 (k) Plan.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xml:lang="en-US">Accounting Standards Update [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:to="lab_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="loc_us-gaap_TypeOfAdoptionMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_TypeOfAdoptionMember" xml:lang="en-US">Accounting Standards Update [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TypeOfAdoptionMember" xlink:to="lab_us-gaap_TypeOfAdoptionMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingStandardsUpdate201912Member" xlink:label="loc_us-gaap_AccountingStandardsUpdate201912Member" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccountingStandardsUpdate201912Member" xml:lang="en-US">Accounting Standards Update 2019-12 [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AccountingStandardsUpdate201912Member" xml:lang="en-US">ASU 2019-12</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingStandardsUpdate201912Member" xlink:to="lab_us-gaap_AccountingStandardsUpdate201912Member" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_TypeOfArrangementAxis" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TypeOfArrangementAxis" xlink:to="lab_us-gaap_TypeOfArrangementAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
<loc xlink:type="locator" xlink:href="btmd-20221231.xsd#btmd_StandbyEquityPurchaseAgreementMember" xlink:label="loc_btmd_StandbyEquityPurchaseAgreementMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_btmd_StandbyEquityPurchaseAgreementMember" xml:lang="en-US">Standby Equity Purchase Agreement [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_btmd_StandbyEquityPurchaseAgreementMember" xml:lang="en-US">Standby Equity Purchase Agreement</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_btmd_StandbyEquityPurchaseAgreementMember" xlink:to="lab_btmd_StandbyEquityPurchaseAgreementMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_btmd_StandbyEquityPurchaseAgreementMember" xml:lang="en-US">Standby Equity Purchase Agreement.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityAxis" xlink:label="loc_us-gaap_CreditFacilityAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CreditFacilityAxis" xml:lang="en-US">Credit Facility [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CreditFacilityAxis" xlink:to="lab_us-gaap_CreditFacilityAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityDomain" xlink:label="loc_us-gaap_CreditFacilityDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CreditFacilityDomain" xml:lang="en-US">Credit Facility [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CreditFacilityDomain" xlink:to="lab_us-gaap_CreditFacilityDomain" />
<loc xlink:type="locator" xlink:href="btmd-20221231.xsd#btmd_YorkvilleAdvisorsGlobalLpMember" xlink:label="loc_btmd_YorkvilleAdvisorsGlobalLpMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_btmd_YorkvilleAdvisorsGlobalLpMember" xml:lang="en-US">Yorkville Advisors Global, LP [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_btmd_YorkvilleAdvisorsGlobalLpMember" xml:lang="en-US">Yorkville</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_btmd_YorkvilleAdvisorsGlobalLpMember" xlink:to="lab_btmd_YorkvilleAdvisorsGlobalLpMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_btmd_YorkvilleAdvisorsGlobalLpMember" xml:lang="en-US">Yorkville Advisors Global, LP.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xml:lang="en-US">Long-Lived Tangible Asset [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xml:lang="en-US">Long-Lived Tangible Asset [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_RangeAxis" xml:lang="en-US">Statistical Measurement [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis" xlink:to="lab_srt_RangeAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_RangeMember" xml:lang="en-US">Statistical Measurement [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeMember" xlink:to="lab_srt_RangeMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_MinimumMember" xml:lang="en-US">Minimum [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_srt_MinimumMember" xml:lang="en-US">Minimum</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MinimumMember" xlink:to="lab_srt_MinimumMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_MaximumMember" xml:lang="en-US">Maximum [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_srt_MaximumMember" xml:lang="en-US">Maximum</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MaximumMember" xlink:to="lab_srt_MaximumMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProductInformationLineItems" xlink:label="loc_us-gaap_ProductInformationLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ProductInformationLineItems" xml:lang="en-US">Product Information [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProductInformationLineItems" xlink:to="lab_us-gaap_ProductInformationLineItems" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="loc_us-gaap_NumberOfOperatingSegments" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NumberOfOperatingSegments" xml:lang="en-US">Number of Operating Segments</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_NumberOfOperatingSegments" xml:lang="en-US">Number of operating segment</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfOperatingSegments" xlink:to="lab_us-gaap_NumberOfOperatingSegments" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NumberOfReportableSegments" xlink:label="loc_us-gaap_NumberOfReportableSegments" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NumberOfReportableSegments" xml:lang="en-US">Number of Reportable Segments</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_NumberOfReportableSegments" xml:lang="en-US">Number of reportable segment</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfReportableSegments" xlink:to="lab_us-gaap_NumberOfReportableSegments" />
<loc xlink:type="locator" xlink:href="btmd-20221231.xsd#btmd_CapitalizedSoftwareEstimatedUsefulLives" xlink:label="loc_btmd_CapitalizedSoftwareEstimatedUsefulLives" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_btmd_CapitalizedSoftwareEstimatedUsefulLives" xml:lang="en-US">Capitalized Software Estimated Useful Lives</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_btmd_CapitalizedSoftwareEstimatedUsefulLives" xml:lang="en-US">Capitalized software estimated useful lives</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_btmd_CapitalizedSoftwareEstimatedUsefulLives" xlink:to="lab_btmd_CapitalizedSoftwareEstimatedUsefulLives" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_btmd_CapitalizedSoftwareEstimatedUsefulLives" xml:lang="en-US">Capitalized software estimated useful lives.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:label="loc_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xml:lang="en-US">Impairment, Long-Lived Asset, Held-for-Use</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xml:lang="en-US">Impairment charge of long-lived assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:to="lab_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" />
<loc xlink:type="locator" xlink:href="btmd-20221231.xsd#btmd_CommonUnitsVotingRightsPercentage" xlink:label="loc_btmd_CommonUnitsVotingRightsPercentage" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_btmd_CommonUnitsVotingRightsPercentage" xml:lang="en-US">Common Units Voting Rights Percentage</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_btmd_CommonUnitsVotingRightsPercentage" xml:lang="en-US">Common units voting rights percentage</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_btmd_CommonUnitsVotingRightsPercentage" xlink:to="lab_btmd_CommonUnitsVotingRightsPercentage" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_btmd_CommonUnitsVotingRightsPercentage" xml:lang="en-US">Common Units Voting Rights Percentage</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LimitedPartnersCapitalAccountDistributionAmount" xlink:label="loc_us-gaap_LimitedPartnersCapitalAccountDistributionAmount" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LimitedPartnersCapitalAccountDistributionAmount" xml:lang="en-US">Limited Partners' Capital Account, Distribution Amount</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LimitedPartnersCapitalAccountDistributionAmount" xml:lang="en-US">Operating distribution to members of holdings and taxing authorities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LimitedPartnersCapitalAccountDistributionAmount" xlink:to="lab_us-gaap_LimitedPartnersCapitalAccountDistributionAmount" />
<loc xlink:type="locator" xlink:href="btmd-20221231.xsd#btmd_PercentageOfCommonStockPurchasePrice" xlink:label="loc_btmd_PercentageOfCommonStockPurchasePrice" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_btmd_PercentageOfCommonStockPurchasePrice" xml:lang="en-US">Percentage of Common Stock Purchase Price</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_btmd_PercentageOfCommonStockPurchasePrice" xml:lang="en-US">Percentage of common stock purchase price</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_btmd_PercentageOfCommonStockPurchasePrice" xlink:to="lab_btmd_PercentageOfCommonStockPurchasePrice" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_btmd_PercentageOfCommonStockPurchasePrice" xml:lang="en-US">Percentage of common stock purchase price.</label>
<loc xlink:type="locator" xlink:href="btmd-20221231.xsd#btmd_TerminationPeriodOfPurchaseAgreement" xlink:label="loc_btmd_TerminationPeriodOfPurchaseAgreement" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_btmd_TerminationPeriodOfPurchaseAgreement" xml:lang="en-US">Termination Period of Purchase Agreement</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_btmd_TerminationPeriodOfPurchaseAgreement" xml:lang="en-US">Termination period of purchase agreement</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_btmd_TerminationPeriodOfPurchaseAgreement" xlink:to="lab_btmd_TerminationPeriodOfPurchaseAgreement" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_btmd_TerminationPeriodOfPurchaseAgreement" xml:lang="en-US">Termination period of purchase agreement.</label>
<loc xlink:type="locator" xlink:href="btmd-20221231.xsd#btmd_ConsecutiveTradingDays" xlink:label="loc_btmd_ConsecutiveTradingDays" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_btmd_ConsecutiveTradingDays" xml:lang="en-US">Consecutive Trading Days</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_btmd_ConsecutiveTradingDays" xml:lang="en-US">Consecutive trading days</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_btmd_ConsecutiveTradingDays" xlink:to="lab_btmd_ConsecutiveTradingDays" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_btmd_ConsecutiveTradingDays" xml:lang="en-US">Consecutive trading days.</label>
<loc xlink:type="locator" xlink:href="btmd-20221231.xsd#btmd_MandatoryMinimumAmountForIndividualAdvance" xlink:label="loc_btmd_MandatoryMinimumAmountForIndividualAdvance" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_btmd_MandatoryMinimumAmountForIndividualAdvance" xml:lang="en-US">Mandatory Minimum Amount for Individual Advance</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_btmd_MandatoryMinimumAmountForIndividualAdvance" xml:lang="en-US">Mandatory minimum amount for individual advance</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_btmd_MandatoryMinimumAmountForIndividualAdvance" xlink:to="lab_btmd_MandatoryMinimumAmountForIndividualAdvance" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_btmd_MandatoryMinimumAmountForIndividualAdvance" xml:lang="en-US">Mandatory minimum amount for individual advance.</label>
<loc xlink:type="locator" xlink:href="btmd-20221231.xsd#btmd_MaximumValueOfDailyVolumeTradedThresholdPercentage" xlink:label="loc_btmd_MaximumValueOfDailyVolumeTradedThresholdPercentage" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_btmd_MaximumValueOfDailyVolumeTradedThresholdPercentage" xml:lang="en-US">Maximum Value of Daily Volume Traded Threshold Percentage</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_btmd_MaximumValueOfDailyVolumeTradedThresholdPercentage" xml:lang="en-US">Maximum value of daily volume traded threshold percentage</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_btmd_MaximumValueOfDailyVolumeTradedThresholdPercentage" xlink:to="lab_btmd_MaximumValueOfDailyVolumeTradedThresholdPercentage" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_btmd_MaximumValueOfDailyVolumeTradedThresholdPercentage" xml:lang="en-US">Maximum value of daily volume traded threshold percentage.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xml:lang="en-US">Sale of Stock, Number of Shares Issued in Transaction</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xml:lang="en-US">Shares sold</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:to="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" />
<loc xlink:type="locator" xlink:href="btmd-20221231.xsd#btmd_ProceedsFromSettlementOfSEPA" xlink:label="loc_btmd_ProceedsFromSettlementOfSEPA" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_btmd_ProceedsFromSettlementOfSEPA" xml:lang="en-US">Proceeds from Settlement of S E P A</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_btmd_ProceedsFromSettlementOfSEPA" xml:lang="en-US">Proceeds from settlement of SEPA</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_btmd_ProceedsFromSettlementOfSEPA" xlink:to="lab_btmd_ProceedsFromSettlementOfSEPA" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_btmd_ProceedsFromSettlementOfSEPA" xml:lang="en-US">Proceeds from settlement of SEPA.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRemainingPerformanceObligation" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligation" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligation" xml:lang="en-US">Revenue, Remaining Performance Obligation, Amount</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligation" xml:lang="en-US">Revenue remaining performance obligation</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligation" xlink:to="lab_us-gaap_RevenueRemainingPerformanceObligation" />
<loc xlink:type="locator" xlink:href="btmd-20221231.xsd#btmd_ExpectedReturnsAndRefundsToCustomers" xlink:label="loc_btmd_ExpectedReturnsAndRefundsToCustomers" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_btmd_ExpectedReturnsAndRefundsToCustomers" xml:lang="en-US">Expected Returns And Refunds To Customers</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_btmd_ExpectedReturnsAndRefundsToCustomers" xml:lang="en-US">Expected returns and refunds to customers</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_btmd_ExpectedReturnsAndRefundsToCustomers" xlink:to="lab_btmd_ExpectedReturnsAndRefundsToCustomers" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_btmd_ExpectedReturnsAndRefundsToCustomers" xml:lang="en-US">Expected returns and refunds to customers.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xml:lang="en-US">Share-based compensation</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xml:lang="en-US">Compensation expense</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xml:lang="en-US">Compensation paid</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpense" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ConcentrationRiskPercentage1" xml:lang="en-US">Concentration Risk, Percentage</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ConcentrationRiskPercentage1" xml:lang="en-US">Concentration risk percentage</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskPercentage1" xlink:to="lab_us-gaap_ConcentrationRiskPercentage1" />
<loc xlink:type="locator" xlink:href="btmd-20221231.xsd#btmd_NumberOfInventoryVendors" xlink:label="loc_btmd_NumberOfInventoryVendors" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_btmd_NumberOfInventoryVendors" xml:lang="en-US">Number of Inventory Vendors</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_btmd_NumberOfInventoryVendors" xml:lang="en-US">Number of vendors</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_btmd_NumberOfInventoryVendors" xlink:to="lab_btmd_NumberOfInventoryVendors" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_btmd_NumberOfInventoryVendors" xml:lang="en-US">Number of Inventory Vendors</label>
<loc xlink:type="locator" xlink:href="btmd-20221231.xsd#btmd_NumberOfCustomersAccountedForTenPercentOrMoreAggregateRevenue" xlink:label="loc_btmd_NumberOfCustomersAccountedForTenPercentOrMoreAggregateRevenue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_btmd_NumberOfCustomersAccountedForTenPercentOrMoreAggregateRevenue" xml:lang="en-US">Number of Customers Accounted For Ten Percent or More Aggregate Revenue</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_btmd_NumberOfCustomersAccountedForTenPercentOrMoreAggregateRevenue" xml:lang="en-US">Number of customers accounted for 10% of total revenue</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_btmd_NumberOfCustomersAccountedForTenPercentOrMoreAggregateRevenue" xlink:to="lab_btmd_NumberOfCustomersAccountedForTenPercentOrMoreAggregateRevenue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_btmd_NumberOfCustomersAccountedForTenPercentOrMoreAggregateRevenue" xml:lang="en-US">Number of customers accounted for ten percent or more aggregate revenue.</label>
<loc xlink:type="locator" xlink:href="btmd-20221231.xsd#btmd_NumberOfCustomersAccountedForTenPercentOrMoreAccountsReceivable" xlink:label="loc_btmd_NumberOfCustomersAccountedForTenPercentOrMoreAccountsReceivable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_btmd_NumberOfCustomersAccountedForTenPercentOrMoreAccountsReceivable" xml:lang="en-US">Number of Customers Accounted For Ten Percent or More Accounts Receivable</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_btmd_NumberOfCustomersAccountedForTenPercentOrMoreAccountsReceivable" xml:lang="en-US">Number of customers accounted for 10% of accounts receivable</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_btmd_NumberOfCustomersAccountedForTenPercentOrMoreAccountsReceivable" xlink:to="lab_btmd_NumberOfCustomersAccountedForTenPercentOrMoreAccountsReceivable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_btmd_NumberOfCustomersAccountedForTenPercentOrMoreAccountsReceivable" xml:lang="en-US">Number of customers accounted for ten percent or more accounts receivable.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" xlink:label="loc_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" xml:lang="en-US">Defined Contribution Plan, Employer Matching Contribution, Percent of Match</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" xml:lang="en-US">Employer Safe Harbor non-elective contribution percentage</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" xlink:to="lab_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:label="loc_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xml:lang="en-US">Defined Contribution Plan, Employer Discretionary Contribution Amount</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xml:lang="en-US">Employer Safe Harbor contribution amount</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:to="lab_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalizedContractCostAmortization" xlink:label="loc_us-gaap_CapitalizedContractCostAmortization" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CapitalizedContractCostAmortization" xml:lang="en-US">Capitalized Contract Cost, Amortization</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CapitalizedContractCostAmortization" xml:lang="en-US">Incremental costs to fulfill contract with customers</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CapitalizedContractCostAmortization" xlink:to="lab_us-gaap_CapitalizedContractCostAmortization" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate" xlink:label="loc_us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate" xml:lang="en-US">Change in Accounting Principle, Accounting Standards Update, Adoption Date</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate" xlink:to="lab_us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted" xlink:label="loc_us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted" xml:lang="en-US">Change in Accounting Principle, Accounting Standards Update, Adopted [true false]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted" xlink:to="lab_us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect" xlink:label="loc_us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect" xml:lang="en-US">Change in Accounting Principle, Accounting Standards Update, Immaterial Effect [true false]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect" xlink:to="lab_us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xml:lang="en-US">Accounts Receivable, Allowance for Credit Loss, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xml:lang="en-US">Beginning balance</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xml:lang="en-US">Ending balance</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:to="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" />
<loc xlink:type="locator" xlink:href="btmd-20221231.xsd#btmd_ProvisonForDoubfulDebtAcoountsWriteOffAndRecoveries" xlink:label="loc_btmd_ProvisonForDoubfulDebtAcoountsWriteOffAndRecoveries" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_btmd_ProvisonForDoubfulDebtAcoountsWriteOffAndRecoveries" xml:lang="en-US">Provison For Doubful Debt Acoounts Write Off And Recoveries</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_btmd_ProvisonForDoubfulDebtAcoountsWriteOffAndRecoveries" xml:lang="en-US">Account write-off and recoveries</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_btmd_ProvisonForDoubfulDebtAcoountsWriteOffAndRecoveries" xlink:to="lab_btmd_ProvisonForDoubfulDebtAcoountsWriteOffAndRecoveries" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_btmd_ProvisonForDoubfulDebtAcoountsWriteOffAndRecoveries" xml:lang="en-US">Provision for doubtful debt accounts write off and recoveries.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xml:lang="en-US">Prepaid Expense and Other Assets, Current [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:to="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="loc_us-gaap_PrepaidExpenseCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PrepaidExpenseCurrent" xml:lang="en-US">Prepaid Expense, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PrepaidExpenseCurrent" xml:lang="en-US">Prepaid expenses</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseCurrent" xlink:to="lab_us-gaap_PrepaidExpenseCurrent" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdvancesOnInventoryPurchases" xlink:label="loc_us-gaap_AdvancesOnInventoryPurchases" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AdvancesOnInventoryPurchases" xml:lang="en-US">Advances on Inventory Purchases</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AdvancesOnInventoryPurchases" xml:lang="en-US">Advances</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdvancesOnInventoryPurchases" xlink:to="lab_us-gaap_AdvancesOnInventoryPurchases" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredOfferingCosts" xlink:label="loc_us-gaap_DeferredOfferingCosts" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredOfferingCosts" xml:lang="en-US">Deferred Offering Costs</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DeferredOfferingCosts" xml:lang="en-US">Capitalized transaction costs</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredOfferingCosts" xlink:to="lab_us-gaap_DeferredOfferingCosts" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xml:lang="en-US">Property, Plant and Equipment [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" />
<loc xlink:type="locator" xlink:href="btmd-20221231.xsd#btmd_TrocarsMember" xlink:label="loc_btmd_TrocarsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_btmd_TrocarsMember" xml:lang="en-US">Trocars [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_btmd_TrocarsMember" xml:lang="en-US">Trocars</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_btmd_TrocarsMember" xlink:to="lab_btmd_TrocarsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_btmd_TrocarsMember" xml:lang="en-US">Trocars.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="loc_us-gaap_LeaseholdImprovementsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LeaseholdImprovementsMember" xml:lang="en-US">Leasehold Improvements [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LeaseholdImprovementsMember" xml:lang="en-US">Leasehold Improvements</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseholdImprovementsMember" xlink:to="lab_us-gaap_LeaseholdImprovementsMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OfficeEquipmentMember" xlink:label="loc_us-gaap_OfficeEquipmentMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OfficeEquipmentMember" xml:lang="en-US">Office Equipment [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OfficeEquipmentMember" xml:lang="en-US">Office Equipment</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OfficeEquipmentMember" xlink:to="lab_us-gaap_OfficeEquipmentMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SoftwareDevelopmentMember" xlink:label="loc_us-gaap_SoftwareDevelopmentMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SoftwareDevelopmentMember" xml:lang="en-US">Software Development [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_SoftwareDevelopmentMember" xml:lang="en-US">Computer software</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SoftwareDevelopmentMember" xlink:to="lab_us-gaap_SoftwareDevelopmentMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="loc_us-gaap_FurnitureAndFixturesMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FurnitureAndFixturesMember" xml:lang="en-US">Furniture and Fixtures [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FurnitureAndFixturesMember" xml:lang="en-US">Furniture and Fixtures</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FurnitureAndFixturesMember" xlink:to="lab_us-gaap_FurnitureAndFixturesMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComputerEquipmentMember" xlink:label="loc_us-gaap_ComputerEquipmentMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ComputerEquipmentMember" xml:lang="en-US">Computer Equipment [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ComputerEquipmentMember" xml:lang="en-US">Computer Equipment</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComputerEquipmentMember" xlink:to="lab_us-gaap_ComputerEquipmentMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xml:lang="en-US">Property, Plant and Equipment [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentLineItems" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xml:lang="en-US">Property, Plant and Equipment, Useful Life</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xml:lang="en-US">Estimated Useful Life (in years)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" xml:lang="en-US">Property, Plant and Equipment, Estimated Useful Lives</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" xml:lang="en-US">Estimated Useful Life</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaap_EquityAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EquityAbstract" xml:lang="en-US">Equity [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityAbstract" xlink:to="lab_us-gaap_EquityAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCapitalUnitsTable" xlink:label="loc_us-gaap_ScheduleOfCapitalUnitsTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfCapitalUnitsTable" xml:lang="en-US">Schedule of Capital Units [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCapitalUnitsTable" xlink:to="lab_us-gaap_ScheduleOfCapitalUnitsTable" />
<loc xlink:type="locator" xlink:href="btmd-20221231.xsd#btmd_ClassAaNonVotingUnitsMember" xlink:label="loc_btmd_ClassAaNonVotingUnitsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_btmd_ClassAaNonVotingUnitsMember" xml:lang="en-US">Class AA Non-Voting Units [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_btmd_ClassAaNonVotingUnitsMember" xml:lang="en-US">Class AA (Non-voting)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_btmd_ClassAaNonVotingUnitsMember" xlink:to="lab_btmd_ClassAaNonVotingUnitsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_btmd_ClassAaNonVotingUnitsMember" xml:lang="en-US">Class AA Non-Voting Units.</label>
<loc xlink:type="locator" xlink:href="btmd-20221231.xsd#btmd_ClassAaaNonVotingUnitsMember" xlink:label="loc_btmd_ClassAaaNonVotingUnitsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_btmd_ClassAaaNonVotingUnitsMember" xml:lang="en-US">Class AAA Non-Voting Units [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_btmd_ClassAaaNonVotingUnitsMember" xml:lang="en-US">Class AAA (Non-voting)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_btmd_ClassAaaNonVotingUnitsMember" xlink:to="lab_btmd_ClassAaaNonVotingUnitsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_btmd_ClassAaaNonVotingUnitsMember" xml:lang="en-US">Class AAA Non-Voting Units.</label>
<loc xlink:type="locator" xlink:href="btmd-20221231.xsd#btmd_ClassAaaaNonVotingIncentiveUnitsMember" xlink:label="loc_btmd_ClassAaaaNonVotingIncentiveUnitsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_btmd_ClassAaaaNonVotingIncentiveUnitsMember" xml:lang="en-US">Class AAAA Non Voting Incentive Units [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_btmd_ClassAaaaNonVotingIncentiveUnitsMember" xml:lang="en-US">Class AAAA (Non-voting incentive units)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_btmd_ClassAaaaNonVotingIncentiveUnitsMember" xlink:to="lab_btmd_ClassAaaaNonVotingIncentiveUnitsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_btmd_ClassAaaaNonVotingIncentiveUnitsMember" xml:lang="en-US">Class AAAA Non Voting Incentive Units.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalUnitLineItems" xlink:label="loc_us-gaap_CapitalUnitLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CapitalUnitLineItems" xml:lang="en-US">Capital Unit [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CapitalUnitLineItems" xlink:to="lab_us-gaap_CapitalUnitLineItems" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonUnitIssued" xlink:label="loc_us-gaap_CommonUnitIssued" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommonUnitIssued" xml:lang="en-US">Common Unit, Issued</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CommonUnitIssued" xml:lang="en-US">Common units, issued</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonUnitIssued" xlink:to="lab_us-gaap_CommonUnitIssued" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonUnitOutstanding" xlink:label="loc_us-gaap_CommonUnitOutstanding" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommonUnitOutstanding" xml:lang="en-US">Common Unit, Outstanding</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CommonUnitOutstanding" xml:lang="en-US">Common units, outstanding</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonUnitOutstanding" xlink:to="lab_us-gaap_CommonUnitOutstanding" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable" xml:lang="en-US">Schedule of Stock by Class [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable" xlink:to="lab_us-gaap_ScheduleOfStockByClassTable" />
<loc xlink:type="locator" xlink:href="btmd-20221231.xsd#btmd_ClassVCommonStockMember" xlink:label="loc_btmd_ClassVCommonStockMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_btmd_ClassVCommonStockMember" xml:lang="en-US">Class V Common Stock [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_btmd_ClassVCommonStockMember" xml:lang="en-US">Class V Voting Stock</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_btmd_ClassVCommonStockMember" xlink:to="lab_btmd_ClassVCommonStockMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_btmd_ClassVCommonStockMember" xml:lang="en-US">Class V Common Stock.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockLineItems" xlink:label="loc_us-gaap_ClassOfStockLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ClassOfStockLineItems" xml:lang="en-US">Class of Stock [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockLineItems" xlink:to="lab_us-gaap_ClassOfStockLineItems" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xml:lang="en-US">Schedule of Business Acquisitions, by Acquisition [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" />
<loc xlink:type="locator" xlink:href="btmd-20221231.xsd#btmd_MemberEarnOutUnitsMember" xlink:label="loc_btmd_MemberEarnOutUnitsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_btmd_MemberEarnOutUnitsMember" xml:lang="en-US">Member Earn Out Units [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_btmd_MemberEarnOutUnitsMember" xml:lang="en-US">Member Earn Out Units</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_btmd_MemberEarnOutUnitsMember" xlink:to="lab_btmd_MemberEarnOutUnitsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_btmd_MemberEarnOutUnitsMember" xml:lang="en-US">Member earn out units.</label>
<loc xlink:type="locator" xlink:href="btmd-20221231.xsd#btmd_EarnoutVotingSharesMember" xlink:label="loc_btmd_EarnoutVotingSharesMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_btmd_EarnoutVotingSharesMember" xml:lang="en-US">Earnout Voting Shares [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_btmd_EarnoutVotingSharesMember" xml:lang="en-US">Earnout Voting Shares</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_btmd_EarnoutVotingSharesMember" xlink:to="lab_btmd_EarnoutVotingSharesMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_btmd_EarnoutVotingSharesMember" xml:lang="en-US">Earnout voting shares.</label>
<loc xlink:type="locator" xlink:href="btmd-20221231.xsd#btmd_SponsorEarnOutSharesMember" xlink:label="loc_btmd_SponsorEarnOutSharesMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_btmd_SponsorEarnOutSharesMember" xml:lang="en-US">Sponsor Earn Out Shares [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_btmd_SponsorEarnOutSharesMember" xml:lang="en-US">Sponsor Earn Out Shares</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_btmd_SponsorEarnOutSharesMember" xlink:to="lab_btmd_SponsorEarnOutSharesMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_btmd_SponsorEarnOutSharesMember" xml:lang="en-US">Sponsor earn out shares.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtInstrumentAxis" xml:lang="en-US">Debt Instrument [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentAxis" xlink:to="lab_us-gaap_DebtInstrumentAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xml:lang="en-US">Debt Instrument, Name [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentNameDomain" xlink:to="lab_us-gaap_DebtInstrumentNameDomain" />
<loc xlink:type="locator" xlink:href="btmd-20221231.xsd#btmd_DebtCommitmentLetterMember" xlink:label="loc_btmd_DebtCommitmentLetterMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_btmd_DebtCommitmentLetterMember" xml:lang="en-US">Debt Commitment Letter [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_btmd_DebtCommitmentLetterMember" xml:lang="en-US">Debt Commitment Letter</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_btmd_DebtCommitmentLetterMember" xlink:to="lab_btmd_DebtCommitmentLetterMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_btmd_DebtCommitmentLetterMember" xml:lang="en-US">Debt commitment letter.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidatedEntitiesAxis" xlink:label="loc_srt_ConsolidatedEntitiesAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_ConsolidatedEntitiesAxis" xml:lang="en-US">Consolidated Entities [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ConsolidatedEntitiesAxis" xlink:to="lab_srt_ConsolidatedEntitiesAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidatedEntitiesDomain" xlink:label="loc_srt_ConsolidatedEntitiesDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_ConsolidatedEntitiesDomain" xml:lang="en-US">Consolidated Entities [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ConsolidatedEntitiesDomain" xlink:to="lab_srt_ConsolidatedEntitiesDomain" />
<loc xlink:type="locator" xlink:href="btmd-20221231.xsd#btmd_HaymakeriiiMember" xlink:label="loc_btmd_HaymakeriiiMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_btmd_HaymakeriiiMember" xml:lang="en-US">HaymakerIii [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_btmd_HaymakeriiiMember" xml:lang="en-US">Haymaker III</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_btmd_HaymakeriiiMember" xlink:to="lab_btmd_HaymakeriiiMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_btmd_HaymakeriiiMember" xml:lang="en-US">HaymakerIii.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_BusinessAcquisitionAxis" xml:lang="en-US">Business Acquisition [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionAxis" xlink:to="lab_us-gaap_BusinessAcquisitionAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xml:lang="en-US">Business Acquisition, Acquiree [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="lab_us-gaap_BusinessAcquisitionAcquireeDomain" />
<loc xlink:type="locator" xlink:href="btmd-20221231.xsd#btmd_HaymakerAcquisitionCorpIiiMember" xlink:label="loc_btmd_HaymakerAcquisitionCorpIiiMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_btmd_HaymakerAcquisitionCorpIiiMember" xml:lang="en-US">Haymaker Acquisition Corp. III [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_btmd_HaymakerAcquisitionCorpIiiMember" xml:lang="en-US">Haymaker</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_btmd_HaymakerAcquisitionCorpIiiMember" xlink:to="lab_btmd_HaymakerAcquisitionCorpIiiMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_btmd_HaymakerAcquisitionCorpIiiMember" xml:lang="en-US">Haymaker acquisition corp. III.</label>
<loc xlink:type="locator" xlink:href="btmd-20221231.xsd#btmd_BusinessCombinationMember" xlink:label="loc_btmd_BusinessCombinationMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_btmd_BusinessCombinationMember" xml:lang="en-US">Business Combination [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_btmd_BusinessCombinationMember" xml:lang="en-US">Business Combination</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_btmd_BusinessCombinationMember" xlink:to="lab_btmd_BusinessCombinationMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_btmd_BusinessCombinationMember" xml:lang="en-US">Business combination.</label>
<loc xlink:type="locator" xlink:href="btmd-20221231.xsd#btmd_BioteManagementLlcMember" xlink:label="loc_btmd_BioteManagementLlcMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_btmd_BioteManagementLlcMember" xml:lang="en-US">Biote Management LLC [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_btmd_BioteManagementLlcMember" xml:lang="en-US">Biote Units</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_btmd_BioteManagementLlcMember" xlink:to="lab_btmd_BioteManagementLlcMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_btmd_BioteManagementLlcMember" xml:lang="en-US">Biote management, LLC.</label>
<loc xlink:type="locator" xlink:href="btmd-20221231.xsd#btmd_OtherBusinessCombinationMember" xlink:label="loc_btmd_OtherBusinessCombinationMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_btmd_OtherBusinessCombinationMember" xml:lang="en-US">Other Business Combination [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_btmd_OtherBusinessCombinationMember" xml:lang="en-US">Other Business Combination</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_btmd_OtherBusinessCombinationMember" xlink:to="lab_btmd_OtherBusinessCombinationMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_btmd_OtherBusinessCombinationMember" xml:lang="en-US">Other business combination.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAxis" xlink:label="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAxis" xml:lang="en-US">Business Combination, Separately Recognized Transactions [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAxis" xlink:to="lab_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsDomain" xlink:label="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsDomain" xml:lang="en-US">Business Combination, Separately Recognized Transactions [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsDomain" xlink:to="lab_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsDomain" />
<loc xlink:type="locator" xlink:href="btmd-20221231.xsd#btmd_SeniorSecuredRevolvingCreditFacilityMember" xlink:label="loc_btmd_SeniorSecuredRevolvingCreditFacilityMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_btmd_SeniorSecuredRevolvingCreditFacilityMember" xml:lang="en-US">Senior Secured Revolving Credit Facility [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_btmd_SeniorSecuredRevolvingCreditFacilityMember" xml:lang="en-US">Senior Secured Revolving Credit Facility</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_btmd_SeniorSecuredRevolvingCreditFacilityMember" xlink:to="lab_btmd_SeniorSecuredRevolvingCreditFacilityMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_btmd_SeniorSecuredRevolvingCreditFacilityMember" xml:lang="en-US">Senior secured revolving credit facility.</label>
<loc xlink:type="locator" xlink:href="btmd-20221231.xsd#btmd_SeniorSecuredTermLoanAFacilityMember" xlink:label="loc_btmd_SeniorSecuredTermLoanAFacilityMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_btmd_SeniorSecuredTermLoanAFacilityMember" xml:lang="en-US">Senior Secured Term Loan A Facility [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_btmd_SeniorSecuredTermLoanAFacilityMember" xml:lang="en-US">Senior Secured Term Loan A Facility</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_btmd_SeniorSecuredTermLoanAFacilityMember" xlink:to="lab_btmd_SeniorSecuredTermLoanAFacilityMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_btmd_SeniorSecuredTermLoanAFacilityMember" xml:lang="en-US">Senior secured term loan a facility.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_BusinessAcquisitionLineItems" xml:lang="en-US">Business Acquisition [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems" xlink:to="lab_us-gaap_BusinessAcquisitionLineItems" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationConsiderationTransferred1" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferred1" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_BusinessCombinationConsiderationTransferred1" xml:lang="en-US">Business Combination, Consideration Transferred</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_BusinessCombinationConsiderationTransferred1" xml:lang="en-US">Business combination consideration transferred</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationConsiderationTransferred1" xlink:to="lab_us-gaap_BusinessCombinationConsiderationTransferred1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" xlink:label="loc_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" xml:lang="en-US">Business Acquisition, Equity Interest Issued or Issuable, Number of Shares</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" xml:lang="en-US">Business combination number of share issued</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" xlink:to="lab_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable" xml:lang="en-US">Business Combination, Consideration Transferred, Equity Interests Issued and Issuable</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable" xml:lang="en-US">Business combination, consideration through equity value</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable" xlink:to="lab_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionSharePrice" xlink:label="loc_us-gaap_BusinessAcquisitionSharePrice" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_BusinessAcquisitionSharePrice" xml:lang="en-US">Business Acquisition, Share Price</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_BusinessAcquisitionSharePrice" xml:lang="en-US">Business acquisition, share price</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionSharePrice" xlink:to="lab_us-gaap_BusinessAcquisitionSharePrice" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromPreviousAcquisition" xlink:label="loc_us-gaap_ProceedsFromPreviousAcquisition" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ProceedsFromPreviousAcquisition" xml:lang="en-US">Proceeds from Previous Acquisition</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ProceedsFromPreviousAcquisition" xml:lang="en-US">Received aggregate proceeds amount</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromPreviousAcquisition" xlink:to="lab_us-gaap_ProceedsFromPreviousAcquisition" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xml:lang="en-US">Line of Credit Facility, Maximum Borrowing Capacity</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xml:lang="en-US">Line of credit facility, maximum borrowing capacity</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:to="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount" xml:lang="en-US">Debt Instrument, Face Amount</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount" xml:lang="en-US">Debt face amount</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount" xml:lang="en-US">Term loan face amount</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentFaceAmount" xlink:to="lab_us-gaap_DebtInstrumentFaceAmount" />
<loc xlink:type="locator" xlink:href="btmd-20221231.xsd#btmd_CommonStockTransfersThresholdTradingDays" xlink:label="loc_btmd_CommonStockTransfersThresholdTradingDays" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_btmd_CommonStockTransfersThresholdTradingDays" xml:lang="en-US">Common Stock Transfers Threshold Trading Days</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_btmd_CommonStockTransfersThresholdTradingDays" xml:lang="en-US">Common stock transfers threshold trading days</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_btmd_CommonStockTransfersThresholdTradingDays" xlink:to="lab_btmd_CommonStockTransfersThresholdTradingDays" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_btmd_CommonStockTransfersThresholdTradingDays" xml:lang="en-US">Common stock transfers threshold trading days.</label>
<loc xlink:type="locator" xlink:href="btmd-20221231.xsd#btmd_IncomeTaxPercentageOfFederalStateAndLocalIncomeTaxSavings" xlink:label="loc_btmd_IncomeTaxPercentageOfFederalStateAndLocalIncomeTaxSavings" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_btmd_IncomeTaxPercentageOfFederalStateAndLocalIncomeTaxSavings" xml:lang="en-US">Income Tax Percentage Of Federal State And Local Income Tax Savings</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_btmd_IncomeTaxPercentageOfFederalStateAndLocalIncomeTaxSavings" xml:lang="en-US">Income tax percentage of federal state and local income tax savings</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_btmd_IncomeTaxPercentageOfFederalStateAndLocalIncomeTaxSavings" xlink:to="lab_btmd_IncomeTaxPercentageOfFederalStateAndLocalIncomeTaxSavings" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_btmd_IncomeTaxPercentageOfFederalStateAndLocalIncomeTaxSavings" xml:lang="en-US">Income tax percentage of federal state and local income tax savings.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionDescriptionOfAcquiredEntity" xlink:label="loc_us-gaap_BusinessAcquisitionDescriptionOfAcquiredEntity" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_BusinessAcquisitionDescriptionOfAcquiredEntity" xml:lang="en-US">Business Acquisition, Description of Acquired Entity</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_BusinessAcquisitionDescriptionOfAcquiredEntity" xml:lang="en-US">Business acquisition, description of acquired entity</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionDescriptionOfAcquiredEntity" xlink:to="lab_us-gaap_BusinessAcquisitionDescriptionOfAcquiredEntity" />
<loc xlink:type="locator" xlink:href="btmd-20221231.xsd#btmd_TaxReceivableAgreementLiability" xlink:label="loc_btmd_TaxReceivableAgreementLiability" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_btmd_TaxReceivableAgreementLiability" xml:lang="en-US">Tax Receivable Agreement Liability</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_btmd_TaxReceivableAgreementLiability" xml:lang="en-US">Liability recorded related to tax receivable agreement</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_btmd_TaxReceivableAgreementLiability" xlink:to="lab_btmd_TaxReceivableAgreementLiability" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_btmd_TaxReceivableAgreementLiability" xml:lang="en-US">Tax receivable agreement liability.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireBusinessesGross" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesGross" xml:lang="en-US">Payments to Acquire Businesses, Gross</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesGross" xml:lang="en-US">Business combination, consideration in cash</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireBusinessesGross" xlink:to="lab_us-gaap_PaymentsToAcquireBusinessesGross" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueTable" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DisaggregationOfRevenueTable" xml:lang="en-US">Disaggregation of Revenue [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable" xlink:to="lab_us-gaap_DisaggregationOfRevenueTable" />
<loc xlink:type="locator" xlink:href="btmd-20221231.xsd#btmd_PelletProceduresProductRevenueMember" xlink:label="loc_btmd_PelletProceduresProductRevenueMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_btmd_PelletProceduresProductRevenueMember" xml:lang="en-US">Pellet Procedures Product Revenue [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_btmd_PelletProceduresProductRevenueMember" xml:lang="en-US">Pellet Procedures Product Revenue</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_btmd_PelletProceduresProductRevenueMember" xlink:to="lab_btmd_PelletProceduresProductRevenueMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_btmd_PelletProceduresProductRevenueMember" xml:lang="en-US">Pellet procedures product revenue.</label>
<loc xlink:type="locator" xlink:href="btmd-20221231.xsd#btmd_DietarySupplementsMember" xlink:label="loc_btmd_DietarySupplementsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_btmd_DietarySupplementsMember" xml:lang="en-US">Dietary Supplements [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_btmd_DietarySupplementsMember" xml:lang="en-US">Dietary Supplements</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_btmd_DietarySupplementsMember" xlink:to="lab_btmd_DietarySupplementsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_btmd_DietarySupplementsMember" xml:lang="en-US">Dietary supplements.</label>
<loc xlink:type="locator" xlink:href="btmd-20221231.xsd#btmd_DisposableTrocarsProductRevenueMember" xlink:label="loc_btmd_DisposableTrocarsProductRevenueMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_btmd_DisposableTrocarsProductRevenueMember" xml:lang="en-US">Disposable Trocars Product Revenue [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_btmd_DisposableTrocarsProductRevenueMember" xml:lang="en-US">Disposable Trocars Product Revenue</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_btmd_DisposableTrocarsProductRevenueMember" xlink:to="lab_btmd_DisposableTrocarsProductRevenueMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_btmd_DisposableTrocarsProductRevenueMember" xml:lang="en-US">Disposable trocars product revenue.</label>
<loc xlink:type="locator" xlink:href="btmd-20221231.xsd#btmd_ShippingFeesProductRevenueMember" xlink:label="loc_btmd_ShippingFeesProductRevenueMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_btmd_ShippingFeesProductRevenueMember" xml:lang="en-US">Shipping Fees Product Revenue [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_btmd_ShippingFeesProductRevenueMember" xml:lang="en-US">Shipping Fees Product Revenue</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_btmd_ShippingFeesProductRevenueMember" xlink:to="lab_btmd_ShippingFeesProductRevenueMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_btmd_ShippingFeesProductRevenueMember" xml:lang="en-US">Shipping fees product revenue.</label>
<loc xlink:type="locator" xlink:href="btmd-20221231.xsd#btmd_TrainingServiceRevenueMember" xlink:label="loc_btmd_TrainingServiceRevenueMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_btmd_TrainingServiceRevenueMember" xml:lang="en-US">Training Service Revenue [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_btmd_TrainingServiceRevenueMember" xml:lang="en-US">Training Service Revenue</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_btmd_TrainingServiceRevenueMember" xlink:to="lab_btmd_TrainingServiceRevenueMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_btmd_TrainingServiceRevenueMember" xml:lang="en-US">Training service revenue.</label>
<loc xlink:type="locator" xlink:href="btmd-20221231.xsd#btmd_ContractTermServicesRevenueMember" xlink:label="loc_btmd_ContractTermServicesRevenueMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_btmd_ContractTermServicesRevenueMember" xml:lang="en-US">Contract-Term Services Revenue [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_btmd_ContractTermServicesRevenueMember" xml:lang="en-US">Contract-Term Services Revenue</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_btmd_ContractTermServicesRevenueMember" xlink:to="lab_btmd_ContractTermServicesRevenueMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_btmd_ContractTermServicesRevenueMember" xml:lang="en-US">Contract-term services revenue.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueLineItems" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DisaggregationOfRevenueLineItems" xml:lang="en-US">Disaggregation of Revenue [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems" xlink:to="lab_us-gaap_DisaggregationOfRevenueLineItems" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis" xlink:label="loc_srt_StatementGeographicalAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_StatementGeographicalAxis" xml:lang="en-US">Geographical [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_StatementGeographicalAxis" xlink:to="lab_srt_StatementGeographicalAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srt_SegmentGeographicalDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_SegmentGeographicalDomain" xml:lang="en-US">Geographical [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_SegmentGeographicalDomain" xlink:to="lab_srt_SegmentGeographicalDomain" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_US" xlink:label="loc_country_US" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_country_US" xml:lang="en-US">UNITED STATES</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_country_US" xml:lang="en-US">United States</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_US" xlink:to="lab_country_US" />
<loc xlink:type="locator" xlink:href="btmd-20221231.xsd#btmd_AllOtherCountryMember" xlink:label="loc_btmd_AllOtherCountryMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_btmd_AllOtherCountryMember" xml:lang="en-US">All Other Country [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_btmd_AllOtherCountryMember" xml:lang="en-US">All Other</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_btmd_AllOtherCountryMember" xlink:to="lab_btmd_AllOtherCountryMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_btmd_AllOtherCountryMember" xml:lang="en-US">All other country.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerDurationAxis" xlink:label="loc_us-gaap_ContractWithCustomerDurationAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ContractWithCustomerDurationAxis" xml:lang="en-US">Contract with Customer, Duration [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerDurationAxis" xlink:to="lab_us-gaap_ContractWithCustomerDurationAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerDurationDomain" xlink:label="loc_us-gaap_ContractWithCustomerDurationDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ContractWithCustomerDurationDomain" xml:lang="en-US">Contract with Customer, Duration [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerDurationDomain" xlink:to="lab_us-gaap_ContractWithCustomerDurationDomain" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermContractWithCustomerMember" xlink:label="loc_us-gaap_ShortTermContractWithCustomerMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShortTermContractWithCustomerMember" xml:lang="en-US">Short-Term Contract with Customer [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShortTermContractWithCustomerMember" xml:lang="en-US">Deferred Revenue</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShortTermContractWithCustomerMember" xlink:to="lab_us-gaap_ShortTermContractWithCustomerMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermContractWithCustomerMember" xlink:label="loc_us-gaap_LongTermContractWithCustomerMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LongTermContractWithCustomerMember" xml:lang="en-US">Long-Term Contract with Customer [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LongTermContractWithCustomerMember" xml:lang="en-US">Deferred Revenue, Long-term</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermContractWithCustomerMember" xlink:to="lab_us-gaap_LongTermContractWithCustomerMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xml:lang="en-US">Contract with Customer, Liability, Revenue Recognized</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xml:lang="en-US">Revenue recognized that was included in the contract liability balance at the beginning of the period</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" />
<loc xlink:type="locator" xlink:href="btmd-20221231.xsd#btmd_ContractWithCustomerLiabilityIncreasesDueToCashReceivedExcludingAmountsRecognizedAsRevenue" xlink:label="loc_btmd_ContractWithCustomerLiabilityIncreasesDueToCashReceivedExcludingAmountsRecognizedAsRevenue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_btmd_ContractWithCustomerLiabilityIncreasesDueToCashReceivedExcludingAmountsRecognizedAsRevenue" xml:lang="en-US">Contract with Customer Liability, Increases Due to Cash Received, Excluding Amounts Recognized as Revenue</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_btmd_ContractWithCustomerLiabilityIncreasesDueToCashReceivedExcludingAmountsRecognizedAsRevenue" xml:lang="en-US">Increases due to cash received, excluding amounts recognized as revenue during the period</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_btmd_ContractWithCustomerLiabilityIncreasesDueToCashReceivedExcludingAmountsRecognizedAsRevenue" xlink:to="lab_btmd_ContractWithCustomerLiabilityIncreasesDueToCashReceivedExcludingAmountsRecognizedAsRevenue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_btmd_ContractWithCustomerLiabilityIncreasesDueToCashReceivedExcludingAmountsRecognizedAsRevenue" xml:lang="en-US">Contract with customer liability, increases due to cash received, excluding amounts recognized as revenue.</label>
<loc xlink:type="locator" xlink:href="btmd-20221231.xsd#btmd_ContractWithCustomerLiabilityTransfersBetweenCurrentAndNonCurrentLiabilitiesDueToExpectedRevenueRecognitionPeriod" xlink:label="loc_btmd_ContractWithCustomerLiabilityTransfersBetweenCurrentAndNonCurrentLiabilitiesDueToExpectedRevenueRecognitionPeriod" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_btmd_ContractWithCustomerLiabilityTransfersBetweenCurrentAndNonCurrentLiabilitiesDueToExpectedRevenueRecognitionPeriod" xml:lang="en-US">Contract with Customer Liability, Transfers between Current and Non-Current Liabilities Due to Expected Revenue Recognition Period</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_btmd_ContractWithCustomerLiabilityTransfersBetweenCurrentAndNonCurrentLiabilitiesDueToExpectedRevenueRecognitionPeriod" xml:lang="en-US">Transfers between current and non-current liabilities due to the expected revenue recognition period</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_btmd_ContractWithCustomerLiabilityTransfersBetweenCurrentAndNonCurrentLiabilitiesDueToExpectedRevenueRecognitionPeriod" xlink:to="lab_btmd_ContractWithCustomerLiabilityTransfersBetweenCurrentAndNonCurrentLiabilitiesDueToExpectedRevenueRecognitionPeriod" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_btmd_ContractWithCustomerLiabilityTransfersBetweenCurrentAndNonCurrentLiabilitiesDueToExpectedRevenueRecognitionPeriod" xml:lang="en-US">Contract with customer liability, transfers between current and non-current liabilities due to expected revenue recognition period.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xml:lang="en-US">Increase (Decrease) in Contract with Customer, Liability</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xml:lang="en-US">Total increase(decrease) in contract liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:to="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" />
<loc xlink:type="locator" xlink:href="btmd-20221231.xsd#btmd_UnsatisfiedTrainingObligationsMember" xlink:label="loc_btmd_UnsatisfiedTrainingObligationsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_btmd_UnsatisfiedTrainingObligationsMember" xml:lang="en-US">Unsatisfied Training Obligations [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_btmd_UnsatisfiedTrainingObligationsMember" xml:lang="en-US">Unsatisfied Training Obligations</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_btmd_UnsatisfiedTrainingObligationsMember" xlink:to="lab_btmd_UnsatisfiedTrainingObligationsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_btmd_UnsatisfiedTrainingObligationsMember" xml:lang="en-US">Unsatisfied training obligations.</label>
<loc xlink:type="locator" xlink:href="btmd-20221231.xsd#btmd_UnsatisfiedContractTermServicesMember" xlink:label="loc_btmd_UnsatisfiedContractTermServicesMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_btmd_UnsatisfiedContractTermServicesMember" xml:lang="en-US">Unsatisfied Contract-Term Services [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_btmd_UnsatisfiedContractTermServicesMember" xml:lang="en-US">Unsatisfied Contract-term Services</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_btmd_UnsatisfiedContractTermServicesMember" xlink:to="lab_btmd_UnsatisfiedContractTermServicesMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_btmd_UnsatisfiedContractTermServicesMember" xml:lang="en-US">Unsatisfied contract-term services.</label>
<loc xlink:type="locator" xlink:href="btmd-20221231.xsd#btmd_UnsatisfiedPelletProceduresMember" xlink:label="loc_btmd_UnsatisfiedPelletProceduresMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_btmd_UnsatisfiedPelletProceduresMember" xml:lang="en-US">Unsatisfied Pellet Procedures [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_btmd_UnsatisfiedPelletProceduresMember" xml:lang="en-US">Unsatisfied Pellet Procedures</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_btmd_UnsatisfiedPelletProceduresMember" xlink:to="lab_btmd_UnsatisfiedPelletProceduresMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_btmd_UnsatisfiedPelletProceduresMember" xml:lang="en-US">Unsatisfied pellet procedures.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiability" xlink:label="loc_us-gaap_ContractWithCustomerLiability" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ContractWithCustomerLiability" xml:lang="en-US">Contract with Customer, Liability</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_ContractWithCustomerLiability" xml:lang="en-US">Total Deferred Revenue</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiability" xlink:to="lab_us-gaap_ContractWithCustomerLiability" />
<loc xlink:type="locator" xlink:href="btmd-20221231.xsd#btmd_ReductionOfRevenue" xlink:label="loc_btmd_ReductionOfRevenue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_btmd_ReductionOfRevenue" xml:lang="en-US">Reduction of Revenue</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_btmd_ReductionOfRevenue" xml:lang="en-US">Reduction of revenue</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_btmd_ReductionOfRevenue" xlink:to="lab_btmd_ReductionOfRevenue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_btmd_ReductionOfRevenue" xml:lang="en-US">Reduction of revenue.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryCurrentTable" xlink:label="loc_us-gaap_InventoryCurrentTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_InventoryCurrentTable" xml:lang="en-US">Inventory, Current [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryCurrentTable" xlink:to="lab_us-gaap_InventoryCurrentTable" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryLineItems" xlink:label="loc_us-gaap_InventoryLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_InventoryLineItems" xml:lang="en-US">Inventory [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryLineItems" xlink:to="lab_us-gaap_InventoryLineItems" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryAdjustments" xlink:label="loc_us-gaap_InventoryAdjustments" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_InventoryAdjustments" xml:lang="en-US">Inventory Adjustments</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_InventoryAdjustments" xml:lang="en-US">Obsolete and expired allowance</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryAdjustments" xlink:to="lab_us-gaap_InventoryAdjustments" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryGross" xlink:label="loc_us-gaap_InventoryGross" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_InventoryGross" xml:lang="en-US">Inventory, Gross</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_InventoryGross" xml:lang="en-US">Inventory, gross</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryGross" xlink:to="lab_us-gaap_InventoryGross" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProductMember" xlink:label="loc_us-gaap_ProductMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ProductMember" xml:lang="en-US">Product [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ProductMember" xml:lang="en-US">Product</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProductMember" xlink:to="lab_us-gaap_ProductMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PublicUtilitiesInventoryAxis" xlink:label="loc_us-gaap_PublicUtilitiesInventoryAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PublicUtilitiesInventoryAxis" xml:lang="en-US">Inventory [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PublicUtilitiesInventoryAxis" xlink:to="lab_us-gaap_PublicUtilitiesInventoryAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PublicUtilitiesInventoryTypeDomain" xlink:label="loc_us-gaap_PublicUtilitiesInventoryTypeDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PublicUtilitiesInventoryTypeDomain" xml:lang="en-US">Inventory [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PublicUtilitiesInventoryTypeDomain" xlink:to="lab_us-gaap_PublicUtilitiesInventoryTypeDomain" />
<loc xlink:type="locator" xlink:href="btmd-20221231.xsd#btmd_PelletsMember" xlink:label="loc_btmd_PelletsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_btmd_PelletsMember" xml:lang="en-US">Pellets [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_btmd_PelletsMember" xml:lang="en-US">Pellets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_btmd_PelletsMember" xlink:to="lab_btmd_PelletsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_btmd_PelletsMember" xml:lang="en-US">Pellets.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" xlink:label="loc_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" xml:lang="en-US">Software and Software Development Costs [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" xml:lang="en-US">Computer Software</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" xlink:to="lab_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConstructionInProgressMember" xlink:label="loc_us-gaap_ConstructionInProgressMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ConstructionInProgressMember" xml:lang="en-US">Construction in Progress [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ConstructionInProgressMember" xml:lang="en-US">Construction in Progress</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConstructionInProgressMember" xlink:to="lab_us-gaap_ConstructionInProgressMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xml:lang="en-US">Property, Plant and Equipment, Gross</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xml:lang="en-US">Property and equipment, gross</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentGross" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentGross" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xml:lang="en-US">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xml:lang="en-US">Less: Accumulated depreciation</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Depreciation" xlink:label="loc_us-gaap_Depreciation" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_Depreciation" xml:lang="en-US">Depreciation</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_Depreciation" xml:lang="en-US">Depreciation expense</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Depreciation" xlink:to="lab_us-gaap_Depreciation" />
<loc xlink:type="locator" xlink:href="btmd-20221231.xsd#btmd_CapitalizedSoftwareWebsiteCosts" xlink:label="loc_btmd_CapitalizedSoftwareWebsiteCosts" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_btmd_CapitalizedSoftwareWebsiteCosts" xml:lang="en-US">Capitalized Software, Website Costs</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_btmd_CapitalizedSoftwareWebsiteCosts" xml:lang="en-US">Website costs</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_btmd_CapitalizedSoftwareWebsiteCosts" xlink:to="lab_btmd_CapitalizedSoftwareWebsiteCosts" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_btmd_CapitalizedSoftwareWebsiteCosts" xml:lang="en-US">Capitalized software, website costs</label>
<loc xlink:type="locator" xlink:href="btmd-20221231.xsd#btmd_CapitalizedSoftwareDevelopmentInProcess" xlink:label="loc_btmd_CapitalizedSoftwareDevelopmentInProcess" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_btmd_CapitalizedSoftwareDevelopmentInProcess" xml:lang="en-US">Capitalized Software, Development in Process</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_btmd_CapitalizedSoftwareDevelopmentInProcess" xml:lang="en-US">Development in Process</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_btmd_CapitalizedSoftwareDevelopmentInProcess" xlink:to="lab_btmd_CapitalizedSoftwareDevelopmentInProcess" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_btmd_CapitalizedSoftwareDevelopmentInProcess" xml:lang="en-US">Capitalized software, development in process.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalizedComputerSoftwareAccumulatedAmortization" xlink:label="loc_us-gaap_CapitalizedComputerSoftwareAccumulatedAmortization" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CapitalizedComputerSoftwareAccumulatedAmortization" xml:lang="en-US">Capitalized Computer Software, Accumulated Amortization</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_CapitalizedComputerSoftwareAccumulatedAmortization" xml:lang="en-US">Less: Accumulated amortization</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CapitalizedComputerSoftwareAccumulatedAmortization" xlink:to="lab_us-gaap_CapitalizedComputerSoftwareAccumulatedAmortization" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalizedComputerSoftwareAmortization1" xlink:label="loc_us-gaap_CapitalizedComputerSoftwareAmortization1" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CapitalizedComputerSoftwareAmortization1" xml:lang="en-US">Capitalized Computer Software, Amortization</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CapitalizedComputerSoftwareAmortization1" xml:lang="en-US">Amortization expense</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CapitalizedComputerSoftwareAmortization1" xlink:to="lab_us-gaap_CapitalizedComputerSoftwareAmortization1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccruedProfessionalFeesCurrent" xml:lang="en-US">Accrued Professional Fees, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AccruedProfessionalFeesCurrent" xml:lang="en-US">Accrued professional fees</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedProfessionalFeesCurrent" xlink:to="lab_us-gaap_AccruedProfessionalFeesCurrent" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xml:lang="en-US">Employee-related Liabilities, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xml:lang="en-US">Accrued employee related costs</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" />
<loc xlink:type="locator" xlink:href="btmd-20221231.xsd#btmd_AccruedMerchantFeesCurrent" xlink:label="loc_btmd_AccruedMerchantFeesCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_btmd_AccruedMerchantFeesCurrent" xml:lang="en-US">Accrued Merchant Fees Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_btmd_AccruedMerchantFeesCurrent" xml:lang="en-US">Accrued merchant fees</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_btmd_AccruedMerchantFeesCurrent" xlink:to="lab_btmd_AccruedMerchantFeesCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_btmd_AccruedMerchantFeesCurrent" xml:lang="en-US">Accrued merchant fees current.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestPayableCurrent" xlink:label="loc_us-gaap_InterestPayableCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_InterestPayableCurrent" xml:lang="en-US">Interest Payable, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_InterestPayableCurrent" xml:lang="en-US">Accrued interest</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestPayableCurrent" xlink:to="lab_us-gaap_InterestPayableCurrent" />
<loc xlink:type="locator" xlink:href="btmd-20221231.xsd#btmd_LegalAccrualCurrent" xlink:label="loc_btmd_LegalAccrualCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_btmd_LegalAccrualCurrent" xml:lang="en-US">Legal Accrual Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_btmd_LegalAccrualCurrent" xml:lang="en-US">Legal accrual</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_btmd_LegalAccrualCurrent" xlink:to="lab_btmd_LegalAccrualCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_btmd_LegalAccrualCurrent" xml:lang="en-US">Legal accrual current</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xml:lang="en-US">Other Accrued Liabilities, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xml:lang="en-US">Other</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_OtherAccruedLiabilitiesCurrent" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTable" xlink:label="loc_us-gaap_DebtInstrumentTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtInstrumentTable" xml:lang="en-US">Schedule of Long-Term Debt Instruments [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentTable" xlink:to="lab_us-gaap_DebtInstrumentTable" />
<loc xlink:type="locator" xlink:href="btmd-20221231.xsd#btmd_BankOfAmericaTermLoanMember" xlink:label="loc_btmd_BankOfAmericaTermLoanMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_btmd_BankOfAmericaTermLoanMember" xml:lang="en-US">Bank of America Term Loan [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_btmd_BankOfAmericaTermLoanMember" xml:lang="en-US">Bank of America Term Loan</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_btmd_BankOfAmericaTermLoanMember" xlink:to="lab_btmd_BankOfAmericaTermLoanMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_btmd_BankOfAmericaTermLoanMember" xml:lang="en-US">Bank of America term loan.</label>
<loc xlink:type="locator" xlink:href="btmd-20221231.xsd#btmd_TruistTermLoanMember" xlink:label="loc_btmd_TruistTermLoanMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_btmd_TruistTermLoanMember" xml:lang="en-US">Truist Term Loan [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_btmd_TruistTermLoanMember" xml:lang="en-US">Truist Term Loan</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_btmd_TruistTermLoanMember" xlink:to="lab_btmd_TruistTermLoanMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_btmd_TruistTermLoanMember" xml:lang="en-US">Truist term loan.</label>
<loc xlink:type="locator" xlink:href="btmd-20221231.xsd#btmd_BankOfAmericaTermLoanAndTruistTermLoanMember" xlink:label="loc_btmd_BankOfAmericaTermLoanAndTruistTermLoanMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_btmd_BankOfAmericaTermLoanAndTruistTermLoanMember" xml:lang="en-US">Bank of America Term Loan and Truist Term Loan [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_btmd_BankOfAmericaTermLoanAndTruistTermLoanMember" xml:lang="en-US">Bank of America Term Loan and Truist Term Loan</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_btmd_BankOfAmericaTermLoanAndTruistTermLoanMember" xlink:to="lab_btmd_BankOfAmericaTermLoanAndTruistTermLoanMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_btmd_BankOfAmericaTermLoanAndTruistTermLoanMember" xml:lang="en-US">Bank of America term loan and Truist term loan.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevolvingCreditFacilityMember" xlink:label="loc_us-gaap_RevolvingCreditFacilityMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RevolvingCreditFacilityMember" xml:lang="en-US">Revolving Credit Facility [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_RevolvingCreditFacilityMember" xml:lang="en-US">Revolving Credit Facility</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevolvingCreditFacilityMember" xlink:to="lab_us-gaap_RevolvingCreditFacilityMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditMember" xlink:label="loc_us-gaap_LineOfCreditMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LineOfCreditMember" xml:lang="en-US">Line of Credit [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LineOfCreditMember" xml:lang="en-US">Line of Credit</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditMember" xlink:to="lab_us-gaap_LineOfCreditMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableRateAxis" xlink:label="loc_us-gaap_VariableRateAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_VariableRateAxis" xml:lang="en-US">Variable Rate [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableRateAxis" xlink:to="lab_us-gaap_VariableRateAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableRateDomain" xlink:label="loc_us-gaap_VariableRateDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_VariableRateDomain" xml:lang="en-US">Variable Rate [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableRateDomain" xlink:to="lab_us-gaap_VariableRateDomain" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BaseRateMember" xlink:label="loc_us-gaap_BaseRateMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_BaseRateMember" xml:lang="en-US">Base Rate [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_BaseRateMember" xml:lang="en-US">Base Rate</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BaseRateMember" xlink:to="lab_us-gaap_BaseRateMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember" xlink:label="loc_us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember" xml:lang="en-US">Secured Overnight Financing Rate (SOFR) Overnight Index Swap Rate [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember" xml:lang="en-US">SOFR Rate</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember" xlink:to="lab_us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentRedemptionPeriodAxis" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPeriodAxis" xml:lang="en-US">Debt Instrument, Redemption, Period [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis" xlink:to="lab_us-gaap_DebtInstrumentRedemptionPeriodAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPeriodDomain" xml:lang="en-US">Debt Instrument, Redemption, Period [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:to="lab_us-gaap_DebtInstrumentRedemptionPeriodDomain" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentRedemptionPeriodTwoMember" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodTwoMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPeriodTwoMember" xml:lang="en-US">Debt Instrument, Redemption, Period Two [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPeriodTwoMember" xml:lang="en-US">Leverage Ratio with Respect to June 30, 2023 through March 31, 2024</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodTwoMember" xlink:to="lab_us-gaap_DebtInstrumentRedemptionPeriodTwoMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentRedemptionPeriodOneMember" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodOneMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPeriodOneMember" xml:lang="en-US">Debt Instrument, Redemption, Period One [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPeriodOneMember" xml:lang="en-US">Leverage Ratio with Respect to September 30, 2022 through March 31, 2023</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodOneMember" xlink:to="lab_us-gaap_DebtInstrumentRedemptionPeriodOneMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentRedemptionPeriodThreeMember" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodThreeMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPeriodThreeMember" xml:lang="en-US">Debt Instrument, Redemption, Period Three [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPeriodThreeMember" xml:lang="en-US">Leverage Ratio, Thereafter</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodThreeMember" xlink:to="lab_us-gaap_DebtInstrumentRedemptionPeriodThreeMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="loc_us-gaap_DebtInstrumentLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtInstrumentLineItems" xml:lang="en-US">Debt Instrument [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentLineItems" xlink:to="lab_us-gaap_DebtInstrumentLineItems" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateTerms" xlink:label="loc_us-gaap_DebtInstrumentInterestRateTerms" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtInstrumentInterestRateTerms" xml:lang="en-US">Debt Instrument, Interest Rate Terms</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DebtInstrumentInterestRateTerms" xml:lang="en-US">Debt instrument interest rate, terms</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentInterestRateTerms" xlink:to="lab_us-gaap_DebtInstrumentInterestRateTerms" />
<loc xlink:type="locator" xlink:href="btmd-20221231.xsd#btmd_LineOfCreditFacilityMaturityMonthAndYear" xlink:label="loc_btmd_LineOfCreditFacilityMaturityMonthAndYear" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_btmd_LineOfCreditFacilityMaturityMonthAndYear" xml:lang="en-US">Line of credit facility maturity month and year</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_btmd_LineOfCreditFacilityMaturityMonthAndYear" xlink:to="lab_btmd_LineOfCreditFacilityMaturityMonthAndYear" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_btmd_LineOfCreditFacilityMaturityMonthAndYear" xml:lang="en-US">Line of credit facility maturity month and year.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturityDate" xlink:label="loc_us-gaap_LongTermDebtMaturityDate" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LongTermDebtMaturityDate" xml:lang="en-US">Long-Term Debt, Maturity Date</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LongTermDebtMaturityDate" xml:lang="en-US">Term loan maturity date</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturityDate" xlink:to="lab_us-gaap_LongTermDebtMaturityDate" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCredit" xlink:label="loc_us-gaap_LineOfCredit" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LineOfCredit" xml:lang="en-US">Long-Term Line of Credit</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LineOfCredit" xml:lang="en-US">Line of credit drawn</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCredit" xlink:to="lab_us-gaap_LineOfCredit" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromLinesOfCredit" xlink:label="loc_us-gaap_ProceedsFromLinesOfCredit" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ProceedsFromLinesOfCredit" xml:lang="en-US">Proceeds from Lines of Credit</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ProceedsFromLinesOfCredit" xml:lang="en-US">Proceeds from line of credit</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromLinesOfCredit" xlink:to="lab_us-gaap_ProceedsFromLinesOfCredit" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentCovenantDescription" xlink:label="loc_us-gaap_DebtInstrumentCovenantDescription" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtInstrumentCovenantDescription" xml:lang="en-US">Debt Instrument, Covenant Description</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DebtInstrumentCovenantDescription" xml:lang="en-US">Covenant description</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentCovenantDescription" xlink:to="lab_us-gaap_DebtInstrumentCovenantDescription" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentCovenantCompliance" xlink:label="loc_us-gaap_DebtInstrumentCovenantCompliance" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtInstrumentCovenantCompliance" xml:lang="en-US">Debt Instrument, Covenant Compliance</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DebtInstrumentCovenantCompliance" xml:lang="en-US">Covenant compliance</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentCovenantCompliance" xlink:to="lab_us-gaap_DebtInstrumentCovenantCompliance" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RatioOfIndebtednessToNetCapital1" xlink:label="loc_us-gaap_RatioOfIndebtednessToNetCapital1" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RatioOfIndebtednessToNetCapital1" xml:lang="en-US">Ratio of Indebtedness to Net Capital</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_RatioOfIndebtednessToNetCapital1" xml:lang="en-US">Net leverage ratio</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RatioOfIndebtednessToNetCapital1" xlink:to="lab_us-gaap_RatioOfIndebtednessToNetCapital1" />
<loc xlink:type="locator" xlink:href="btmd-20221231.xsd#btmd_FixedChargeCoverageRatio" xlink:label="loc_btmd_FixedChargeCoverageRatio" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_btmd_FixedChargeCoverageRatio" xml:lang="en-US">Fixed Charge Coverage Ratio</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_btmd_FixedChargeCoverageRatio" xml:lang="en-US">Fixed charge coverage ratio</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_btmd_FixedChargeCoverageRatio" xlink:to="lab_btmd_FixedChargeCoverageRatio" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_btmd_FixedChargeCoverageRatio" xml:lang="en-US">fixed charge coverage ratio.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpenseDebt" xlink:label="loc_us-gaap_InterestExpenseDebt" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_InterestExpenseDebt" xml:lang="en-US">Interest Expense, Debt</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_InterestExpenseDebt" xml:lang="en-US">Interest expense</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpenseDebt" xlink:to="lab_us-gaap_InterestExpenseDebt" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtRelatedCommitmentFeesAndDebtIssuanceCosts" xlink:label="loc_us-gaap_DebtRelatedCommitmentFeesAndDebtIssuanceCosts" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtRelatedCommitmentFeesAndDebtIssuanceCosts" xml:lang="en-US">Debt Related Commitment Fees and Debt Issuance Costs</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DebtRelatedCommitmentFeesAndDebtIssuanceCosts" xml:lang="en-US">Company incurred lender's fees and related attorney's fees</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtRelatedCommitmentFeesAndDebtIssuanceCosts" xlink:to="lab_us-gaap_DebtRelatedCommitmentFeesAndDebtIssuanceCosts" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:label="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage" xml:lang="en-US">Debt Instrument, Interest Rate, Effective Percentage</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage" xml:lang="en-US">Interest rate</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:to="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentPeriodicPaymentPrincipal" xlink:label="loc_us-gaap_DebtInstrumentPeriodicPaymentPrincipal" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtInstrumentPeriodicPaymentPrincipal" xml:lang="en-US">Debt Instrument, Periodic Payment, Principal</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DebtInstrumentPeriodicPaymentPrincipal" xml:lang="en-US">Periodic payments</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentPeriodicPaymentPrincipal" xlink:to="lab_us-gaap_DebtInstrumentPeriodicPaymentPrincipal" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFrequencyOfPeriodicPayment" xlink:label="loc_us-gaap_DebtInstrumentFrequencyOfPeriodicPayment" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtInstrumentFrequencyOfPeriodicPayment" xml:lang="en-US">Debt Instrument, Frequency of Periodic Payment</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DebtInstrumentFrequencyOfPeriodicPayment" xml:lang="en-US">Frequency of periodic payments</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentFrequencyOfPeriodicPayment" xlink:to="lab_us-gaap_DebtInstrumentFrequencyOfPeriodicPayment" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebt" xlink:label="loc_us-gaap_LongTermDebt" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LongTermDebt" xml:lang="en-US">Long-Term Debt</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LongTermDebt" xml:lang="en-US">Outstanding principal amount of term loan</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_LongTermDebt" xml:lang="en-US">Long-term debt</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebt" xlink:to="lab_us-gaap_LongTermDebt" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xml:lang="en-US">Debt Instrument, Basis Spread on Variable Rate</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xml:lang="en-US">Debt instrument, applicable margin rate</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:to="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentCarryingAmount" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtInstrumentCarryingAmount" xml:lang="en-US">Long-Term Debt, Gross</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_DebtInstrumentCarryingAmount" xml:lang="en-US">Term loan</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentCarryingAmount" xlink:to="lab_us-gaap_DebtInstrumentCarryingAmount" />
<loc xlink:type="locator" xlink:href="btmd-20221231.xsd#btmd_TeamLoanCurrentPortionBeforeUnamortizedDebtIssuanceCosts" xlink:label="loc_btmd_TeamLoanCurrentPortionBeforeUnamortizedDebtIssuanceCosts" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_btmd_TeamLoanCurrentPortionBeforeUnamortizedDebtIssuanceCosts" xml:lang="en-US">Team Loan Current Portion before Unamortized Debt Issuance Costs</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_btmd_TeamLoanCurrentPortionBeforeUnamortizedDebtIssuanceCosts" xml:lang="en-US">Less: Current portion</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_btmd_TeamLoanCurrentPortionBeforeUnamortizedDebtIssuanceCosts" xlink:to="lab_btmd_TeamLoanCurrentPortionBeforeUnamortizedDebtIssuanceCosts" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_btmd_TeamLoanCurrentPortionBeforeUnamortizedDebtIssuanceCosts" xml:lang="en-US">Team loan current portion before unamortized debt issuance costs</label>
<loc xlink:type="locator" xlink:href="btmd-20221231.xsd#btmd_TeamLoanNonCurrentPortionBeforeUnamortizedDebtIssuanceCosts" xlink:label="loc_btmd_TeamLoanNonCurrentPortionBeforeUnamortizedDebtIssuanceCosts" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_btmd_TeamLoanNonCurrentPortionBeforeUnamortizedDebtIssuanceCosts" xml:lang="en-US">Team Loan non-current Portion before Unamortized Debt Issuance Costs</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_btmd_TeamLoanNonCurrentPortionBeforeUnamortizedDebtIssuanceCosts" xml:lang="en-US">Team loan non-current portion gross</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_btmd_TeamLoanNonCurrentPortionBeforeUnamortizedDebtIssuanceCosts" xlink:to="lab_btmd_TeamLoanNonCurrentPortionBeforeUnamortizedDebtIssuanceCosts" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_btmd_TeamLoanNonCurrentPortionBeforeUnamortizedDebtIssuanceCosts" xml:lang="en-US">Team loan non-current portion before unamortized debt issuance costs.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredFinanceCostsNet" xlink:label="loc_us-gaap_DeferredFinanceCostsNet" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredFinanceCostsNet" xml:lang="en-US">Debt Issuance Costs, Net</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_DeferredFinanceCostsNet" xml:lang="en-US">Less: unamortized deferred financing costs</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredFinanceCostsNet" xlink:to="lab_us-gaap_DeferredFinanceCostsNet" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xml:lang="en-US">Long-Term Debt, Maturity, Year One</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xml:lang="en-US">2023</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xml:lang="en-US">Long-Term Debt, Maturity, Year Two</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xml:lang="en-US">2024</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xml:lang="en-US">Long-Term Debt, Maturity, Year Three</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xml:lang="en-US">2025</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xml:lang="en-US">Long-Term Debt, Maturity, Year Four</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xml:lang="en-US">2026</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" xml:lang="en-US">Long-Term Debt, Maturity, Year Five</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" xml:lang="en-US">2027</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="loc_us-gaap_ClassOfWarrantOrRightTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ClassOfWarrantOrRightTable" xml:lang="en-US">Class of Warrant or Right [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable" xlink:to="lab_us-gaap_ClassOfWarrantOrRightTable" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ClassOfWarrantOrRightAxis" xml:lang="en-US">Class of Warrant or Right [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis" xlink:to="lab_us-gaap_ClassOfWarrantOrRightAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ClassOfWarrantOrRightDomain" xml:lang="en-US">Class of Warrant or Right [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain" xlink:to="lab_us-gaap_ClassOfWarrantOrRightDomain" />
<loc xlink:type="locator" xlink:href="btmd-20221231.xsd#btmd_RedeemableWarrantsMember" xlink:label="loc_btmd_RedeemableWarrantsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_btmd_RedeemableWarrantsMember" xml:lang="en-US">Redeemable Warrants [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_btmd_RedeemableWarrantsMember" xml:lang="en-US">Redeemable Warrants</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_btmd_RedeemableWarrantsMember" xlink:to="lab_btmd_RedeemableWarrantsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_btmd_RedeemableWarrantsMember" xml:lang="en-US">Redeemable warrants.</label>
<loc xlink:type="locator" xlink:href="btmd-20221231.xsd#btmd_PrivatePlacementWarrantsMember" xlink:label="loc_btmd_PrivatePlacementWarrantsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_btmd_PrivatePlacementWarrantsMember" xml:lang="en-US">Private Placement Warrants Member</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_btmd_PrivatePlacementWarrantsMember" xml:lang="en-US">Private Placement Warrants</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_btmd_PrivatePlacementWarrantsMember" xlink:to="lab_btmd_PrivatePlacementWarrantsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_btmd_PrivatePlacementWarrantsMember" xml:lang="en-US">Private placement warrants member.</label>
<loc xlink:type="locator" xlink:href="btmd-20221231.xsd#btmd_PublicWarrantsMember" xlink:label="loc_btmd_PublicWarrantsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_btmd_PublicWarrantsMember" xml:lang="en-US">Public Warrants Member</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_btmd_PublicWarrantsMember" xml:lang="en-US">Public Warrants</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_btmd_PublicWarrantsMember" xlink:to="lab_btmd_PublicWarrantsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_btmd_PublicWarrantsMember" xml:lang="en-US">Public warrants member.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="loc_us-gaap_MeasurementInputTypeAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_MeasurementInputTypeAxis" xml:lang="en-US">Measurement Input Type [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputTypeAxis" xlink:to="lab_us-gaap_MeasurementInputTypeAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="loc_us-gaap_MeasurementInputTypeDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_MeasurementInputTypeDomain" xml:lang="en-US">Measurement Input Type [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputTypeDomain" xlink:to="lab_us-gaap_MeasurementInputTypeDomain" />
<loc xlink:type="locator" xlink:href="btmd-20221231.xsd#btmd_SharePriceEqualOrExceedsTenRupeesPerDollarMember" xlink:label="loc_btmd_SharePriceEqualOrExceedsTenRupeesPerDollarMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_btmd_SharePriceEqualOrExceedsTenRupeesPerDollarMember" xml:lang="en-US">Share Price Equal Or Exceeds Ten Rupees Per Dollar [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_btmd_SharePriceEqualOrExceedsTenRupeesPerDollarMember" xml:lang="en-US">Share Price Equal Or Exceeds 10.00 Rupees Per Dollar</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_btmd_SharePriceEqualOrExceedsTenRupeesPerDollarMember" xlink:to="lab_btmd_SharePriceEqualOrExceedsTenRupeesPerDollarMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_btmd_SharePriceEqualOrExceedsTenRupeesPerDollarMember" xml:lang="en-US">Share price equal or exceeds ten rupees per dollar.</label>
<loc xlink:type="locator" xlink:href="btmd-20221231.xsd#btmd_SharePriceEqualOrExceedsEighteenRupeesPerDollarMember" xlink:label="loc_btmd_SharePriceEqualOrExceedsEighteenRupeesPerDollarMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_btmd_SharePriceEqualOrExceedsEighteenRupeesPerDollarMember" xml:lang="en-US">Share Price Equal Or Exceeds Eighteen Rupees Per Dollar [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_btmd_SharePriceEqualOrExceedsEighteenRupeesPerDollarMember" xml:lang="en-US">Share price equal or exceeds 18.00 Rs per dollar</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_btmd_SharePriceEqualOrExceedsEighteenRupeesPerDollarMember" xlink:to="lab_btmd_SharePriceEqualOrExceedsEighteenRupeesPerDollarMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_btmd_SharePriceEqualOrExceedsEighteenRupeesPerDollarMember" xml:lang="en-US">Share price equal or exceeds eighteen rupees per dollar.</label>
<loc xlink:type="locator" xlink:href="btmd-20221231.xsd#btmd_SharePriceEqualOrLessNinePointTwoRupeesPerDollarMember" xlink:label="loc_btmd_SharePriceEqualOrLessNinePointTwoRupeesPerDollarMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_btmd_SharePriceEqualOrLessNinePointTwoRupeesPerDollarMember" xml:lang="en-US">Share Price Equal Or Less Nine Point Two Rupees Per Dollar [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_btmd_SharePriceEqualOrLessNinePointTwoRupeesPerDollarMember" xml:lang="en-US">Share Price Equal or Less 9.2 Rs per dollar</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_btmd_SharePriceEqualOrLessNinePointTwoRupeesPerDollarMember" xlink:to="lab_btmd_SharePriceEqualOrLessNinePointTwoRupeesPerDollarMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_btmd_SharePriceEqualOrLessNinePointTwoRupeesPerDollarMember" xml:lang="en-US">Share price equal or less nine point two rupees per dollar.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xml:lang="en-US">Related Party [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RelatedPartyDomain" xml:lang="en-US">Related Party [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyDomain" xlink:to="lab_us-gaap_RelatedPartyDomain" />
<loc xlink:type="locator" xlink:href="btmd-20221231.xsd#btmd_SponseMember" xlink:label="loc_btmd_SponseMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_btmd_SponseMember" xml:lang="en-US">Sponse [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_btmd_SponseMember" xml:lang="en-US">Sponsor</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_btmd_SponseMember" xlink:to="lab_btmd_SponseMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_btmd_SponseMember" xml:lang="en-US">Sponsor</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementScenarioAxis" xlink:label="loc_srt_StatementScenarioAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_StatementScenarioAxis" xml:lang="en-US">Scenario [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_StatementScenarioAxis" xlink:to="lab_srt_StatementScenarioAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="loc_srt_ScenarioUnspecifiedDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_ScenarioUnspecifiedDomain" xml:lang="en-US">Scenario [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ScenarioUnspecifiedDomain" xlink:to="lab_srt_ScenarioUnspecifiedDomain" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="loc_us-gaap_ClassOfWarrantOrRightLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ClassOfWarrantOrRightLineItems" xml:lang="en-US">Class of Warrant or Right [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="lab_us-gaap_ClassOfWarrantOrRightLineItems" />
<loc xlink:type="locator" xlink:href="btmd-20221231.xsd#btmd_ClassOfWarrantOrRightRedemptionThresholdConsecutiveTradingDays" xlink:label="loc_btmd_ClassOfWarrantOrRightRedemptionThresholdConsecutiveTradingDays" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_btmd_ClassOfWarrantOrRightRedemptionThresholdConsecutiveTradingDays" xml:lang="en-US">Class Of Warrant Or Right Redemption Threshold Consecutive Trading Days</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_btmd_ClassOfWarrantOrRightRedemptionThresholdConsecutiveTradingDays" xml:lang="en-US">Class of warrant or right redemption threshold consecutive trading days</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_btmd_ClassOfWarrantOrRightRedemptionThresholdConsecutiveTradingDays" xlink:to="lab_btmd_ClassOfWarrantOrRightRedemptionThresholdConsecutiveTradingDays" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_btmd_ClassOfWarrantOrRightRedemptionThresholdConsecutiveTradingDays" xml:lang="en-US">Class of warrant or right redemption threshold consecutive trading days.</label>
<loc xlink:type="locator" xlink:href="btmd-20221231.xsd#btmd_ClassOfWarrantOrRightThresholdPeriodForExerciseFromDateOfClosingPublicOffering" xlink:label="loc_btmd_ClassOfWarrantOrRightThresholdPeriodForExerciseFromDateOfClosingPublicOffering" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_btmd_ClassOfWarrantOrRightThresholdPeriodForExerciseFromDateOfClosingPublicOffering" xml:lang="en-US">Class Of Warrant Or Right Threshold Period For Exercise From Date Of Closing Public Offering</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_btmd_ClassOfWarrantOrRightThresholdPeriodForExerciseFromDateOfClosingPublicOffering" xml:lang="en-US">Class of warrant or right, threshold period for exercise from date of closing public offering</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_btmd_ClassOfWarrantOrRightThresholdPeriodForExerciseFromDateOfClosingPublicOffering" xlink:to="lab_btmd_ClassOfWarrantOrRightThresholdPeriodForExerciseFromDateOfClosingPublicOffering" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_btmd_ClassOfWarrantOrRightThresholdPeriodForExerciseFromDateOfClosingPublicOffering" xml:lang="en-US">Class of warrant or right threshold period for exercise from date of closing public offering.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xml:lang="en-US">Class of Warrant or Right, Number of Securities Called by Warrants or Rights</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xml:lang="en-US">Number of securities called by warrants or rights</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:to="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xml:lang="en-US">Class of Warrant or Right, Exercise Price of Warrants or Rights</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xml:lang="en-US">Exercise price of warrants or rights outstanding</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantsAndRightsOutstandingMaturityDate" xlink:label="loc_us-gaap_WarrantsAndRightsOutstandingMaturityDate" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_WarrantsAndRightsOutstandingMaturityDate" xml:lang="en-US">Warrants and Rights Outstanding, Maturity Date</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_WarrantsAndRightsOutstandingMaturityDate" xml:lang="en-US">Warrants and rights expire date</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WarrantsAndRightsOutstandingMaturityDate" xlink:to="lab_us-gaap_WarrantsAndRightsOutstandingMaturityDate" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="loc_us-gaap_WarrantsAndRightsOutstandingTerm" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_WarrantsAndRightsOutstandingTerm" xml:lang="en-US">Warrants and Rights Outstanding, Term</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_WarrantsAndRightsOutstandingTerm" xml:lang="en-US">Warrants and rights outstanding term</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WarrantsAndRightsOutstandingTerm" xlink:to="lab_us-gaap_WarrantsAndRightsOutstandingTerm" />
<loc xlink:type="locator" xlink:href="btmd-20221231.xsd#btmd_ClassOfWarrantsOrRightsTransfersRestrictionOnNumberOfDaysFromTheDateOfBusinessCombination" xlink:label="loc_btmd_ClassOfWarrantsOrRightsTransfersRestrictionOnNumberOfDaysFromTheDateOfBusinessCombination" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_btmd_ClassOfWarrantsOrRightsTransfersRestrictionOnNumberOfDaysFromTheDateOfBusinessCombination" xml:lang="en-US">Class Of Warrants Or Rights Transfers Restriction On Number Of Days From The Date Of Business Combination</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_btmd_ClassOfWarrantsOrRightsTransfersRestrictionOnNumberOfDaysFromTheDateOfBusinessCombination" xml:lang="en-US">Class of warrants or rights transfers restriction on number of days from the date of business combination</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_btmd_ClassOfWarrantsOrRightsTransfersRestrictionOnNumberOfDaysFromTheDateOfBusinessCombination" xlink:to="lab_btmd_ClassOfWarrantsOrRightsTransfersRestrictionOnNumberOfDaysFromTheDateOfBusinessCombination" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_btmd_ClassOfWarrantsOrRightsTransfersRestrictionOnNumberOfDaysFromTheDateOfBusinessCombination" xml:lang="en-US">Class of warrants or rights transfers restriction on number of days from the date of business combination.</label>
<loc xlink:type="locator" xlink:href="btmd-20221231.xsd#btmd_NumberOfDaysFollowingItsInitialBusinessCombinationUntilTheExpirationOfTheWarrants" xlink:label="loc_btmd_NumberOfDaysFollowingItsInitialBusinessCombinationUntilTheExpirationOfTheWarrants" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_btmd_NumberOfDaysFollowingItsInitialBusinessCombinationUntilTheExpirationOfTheWarrants" xml:lang="en-US">Number Of Days Following Its Initial Business Combination Until The Expiration Of The Warrants</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_btmd_NumberOfDaysFollowingItsInitialBusinessCombinationUntilTheExpirationOfTheWarrants" xml:lang="en-US">Number of days following its initial business combination until the expiration of the warrants</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_btmd_NumberOfDaysFollowingItsInitialBusinessCombinationUntilTheExpirationOfTheWarrants" xlink:to="lab_btmd_NumberOfDaysFollowingItsInitialBusinessCombinationUntilTheExpirationOfTheWarrants" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_btmd_NumberOfDaysFollowingItsInitialBusinessCombinationUntilTheExpirationOfTheWarrants" xml:lang="en-US">Number of days following its initial business combination until the expiration of the warrants.</label>
<loc xlink:type="locator" xlink:href="btmd-20221231.xsd#btmd_ClassOfWarrantsRedemptionPricePerUnit" xlink:label="loc_btmd_ClassOfWarrantsRedemptionPricePerUnit" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_btmd_ClassOfWarrantsRedemptionPricePerUnit" xml:lang="en-US">Class Of Warrants Redemption Price Per Unit</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_btmd_ClassOfWarrantsRedemptionPricePerUnit" xml:lang="en-US">Class of warrants redemption price per unit</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_btmd_ClassOfWarrantsRedemptionPricePerUnit" xlink:to="lab_btmd_ClassOfWarrantsRedemptionPricePerUnit" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_btmd_ClassOfWarrantsRedemptionPricePerUnit" xml:lang="en-US">Class of warrants redemption price per unit.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaap_SharePrice" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SharePrice" xml:lang="en-US">Share Price</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SharePrice" xml:lang="en-US">Share Price</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharePrice" xlink:to="lab_us-gaap_SharePrice" />
<loc xlink:type="locator" xlink:href="btmd-20221231.xsd#btmd_NumberOfConsecutiveTradingDaysForDeterminingSharePrice" xlink:label="loc_btmd_NumberOfConsecutiveTradingDaysForDeterminingSharePrice" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_btmd_NumberOfConsecutiveTradingDaysForDeterminingSharePrice" xml:lang="en-US">Number Of Consecutive Trading Days For Determining Share Price</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_btmd_NumberOfConsecutiveTradingDaysForDeterminingSharePrice" xml:lang="en-US">Number of consecutive trading days for determining the share price</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_btmd_NumberOfConsecutiveTradingDaysForDeterminingSharePrice" xlink:to="lab_btmd_NumberOfConsecutiveTradingDaysForDeterminingSharePrice" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_btmd_NumberOfConsecutiveTradingDaysForDeterminingSharePrice" xml:lang="en-US">Number of consecutive trading days for determining share price.</label>
<loc xlink:type="locator" xlink:href="btmd-20221231.xsd#btmd_ShareRedemptionTriggerPrice" xlink:label="loc_btmd_ShareRedemptionTriggerPrice" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_btmd_ShareRedemptionTriggerPrice" xml:lang="en-US">Share Redemption Trigger Price</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_btmd_ShareRedemptionTriggerPrice" xml:lang="en-US">Share redemption trigger price</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_btmd_ShareRedemptionTriggerPrice" xlink:to="lab_btmd_ShareRedemptionTriggerPrice" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_btmd_ShareRedemptionTriggerPrice" xml:lang="en-US">Share redemption trigger price.</label>
<loc xlink:type="locator" xlink:href="btmd-20221231.xsd#btmd_PrivatePlacementWarrantsRedemptionDescription" xlink:label="loc_btmd_PrivatePlacementWarrantsRedemptionDescription" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_btmd_PrivatePlacementWarrantsRedemptionDescription" xml:lang="en-US">Private Placement Warrants Redemption Description</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_btmd_PrivatePlacementWarrantsRedemptionDescription" xml:lang="en-US">Private placement warrants redemption description</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_btmd_PrivatePlacementWarrantsRedemptionDescription" xlink:to="lab_btmd_PrivatePlacementWarrantsRedemptionDescription" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_btmd_PrivatePlacementWarrantsRedemptionDescription" xml:lang="en-US">Private placement warrants redemption description.</label>
<loc xlink:type="locator" xlink:href="btmd-20221231.xsd#btmd_MinimumGrossProceedsRequiredFromIssuanceOfEquity" xlink:label="loc_btmd_MinimumGrossProceedsRequiredFromIssuanceOfEquity" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_btmd_MinimumGrossProceedsRequiredFromIssuanceOfEquity" xml:lang="en-US">Minimum Gross Proceeds Required From Issuance Of Equity</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_btmd_MinimumGrossProceedsRequiredFromIssuanceOfEquity" xml:lang="en-US">Minimum gross proceeds required from issuance of equity</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_btmd_MinimumGrossProceedsRequiredFromIssuanceOfEquity" xlink:to="lab_btmd_MinimumGrossProceedsRequiredFromIssuanceOfEquity" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_btmd_MinimumGrossProceedsRequiredFromIssuanceOfEquity" xml:lang="en-US">Minimum gross proceeds required from issuance of equity.</label>
<loc xlink:type="locator" xlink:href="btmd-20221231.xsd#btmd_ClassOfWarrantOrRightMinimumNoticePeriodForRedemption" xlink:label="loc_btmd_ClassOfWarrantOrRightMinimumNoticePeriodForRedemption" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_btmd_ClassOfWarrantOrRightMinimumNoticePeriodForRedemption" xml:lang="en-US">Class Of Warrant Or Right Minimum Notice Period For Redemption</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_btmd_ClassOfWarrantOrRightMinimumNoticePeriodForRedemption" xml:lang="en-US">Class of warrant or right minimum notice period For Redemption</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_btmd_ClassOfWarrantOrRightMinimumNoticePeriodForRedemption" xlink:to="lab_btmd_ClassOfWarrantOrRightMinimumNoticePeriodForRedemption" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_btmd_ClassOfWarrantOrRightMinimumNoticePeriodForRedemption" xml:lang="en-US">Class of warrant or right minimum notice period for redemption.</label>
<loc xlink:type="locator" xlink:href="btmd-20221231.xsd#btmd_ClassOfWarrantOrRightExercisePriceAdjustmentPercentageHigherOfMarketValue" xlink:label="loc_btmd_ClassOfWarrantOrRightExercisePriceAdjustmentPercentageHigherOfMarketValue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_btmd_ClassOfWarrantOrRightExercisePriceAdjustmentPercentageHigherOfMarketValue" xml:lang="en-US">Class Of Warrant Or Right Exercise Price Adjustment Percentage Higher Of Market Value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_btmd_ClassOfWarrantOrRightExercisePriceAdjustmentPercentageHigherOfMarketValue" xml:lang="en-US">Class of warrant or right exercise price adjustment percentage higher of market value</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_btmd_ClassOfWarrantOrRightExercisePriceAdjustmentPercentageHigherOfMarketValue" xlink:to="lab_btmd_ClassOfWarrantOrRightExercisePriceAdjustmentPercentageHigherOfMarketValue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_btmd_ClassOfWarrantOrRightExercisePriceAdjustmentPercentageHigherOfMarketValue" xml:lang="en-US">Class of warrant or right exercise price adjustment percentage higher of market value.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="loc_us-gaap_SharesIssuedPricePerShare" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SharesIssuedPricePerShare" xml:lang="en-US">Shares Issued, Price Per Share</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SharesIssuedPricePerShare" xml:lang="en-US">Shares issued, price per share</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesIssuedPricePerShare" xlink:to="lab_us-gaap_SharesIssuedPricePerShare" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueIssuedForServices" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xml:lang="en-US">Stock Issued During Period, Value, Issued for Services</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xml:lang="en-US">Stock issued during period value issued for services</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueIssuedForServices" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ClassOfWarrantOrRightOutstanding" xml:lang="en-US">Class of Warrant or Right, Outstanding</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ClassOfWarrantOrRightOutstanding" xml:lang="en-US">Number of warrants or rights outstanding</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightOutstanding" xlink:to="lab_us-gaap_ClassOfWarrantOrRightOutstanding" />
<loc xlink:type="locator" xlink:href="btmd-20221231.xsd#btmd_PublicWarrantsRedeemed" xlink:label="loc_btmd_PublicWarrantsRedeemed" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_btmd_PublicWarrantsRedeemed" xml:lang="en-US">Public Warrants Redeemed</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_btmd_PublicWarrantsRedeemed" xml:lang="en-US">Public warrants redeemed</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_btmd_PublicWarrantsRedeemed" xlink:to="lab_btmd_PublicWarrantsRedeemed" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_btmd_PublicWarrantsRedeemed" xml:lang="en-US">Public warrants redeemed.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesTable" xlink:label="loc_us-gaap_LossContingenciesTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LossContingenciesTable" xml:lang="en-US">Loss Contingencies [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingenciesTable" xlink:to="lab_us-gaap_LossContingenciesTable" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VestingAxis" xlink:label="loc_us-gaap_VestingAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_VestingAxis" xml:lang="en-US">Vesting [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VestingAxis" xlink:to="lab_us-gaap_VestingAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VestingDomain" xlink:label="loc_us-gaap_VestingDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_VestingDomain" xml:lang="en-US">Vesting [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VestingDomain" xlink:to="lab_us-gaap_VestingDomain" />
<loc xlink:type="locator" xlink:href="btmd-20221231.xsd#btmd_SharePriceEqualsOrExceedsTwelvePointFivePerShareMember" xlink:label="loc_btmd_SharePriceEqualsOrExceedsTwelvePointFivePerShareMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_btmd_SharePriceEqualsOrExceedsTwelvePointFivePerShareMember" xml:lang="en-US">Share Price Equals Or Exceeds Twelve Point Five Per Share [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_btmd_SharePriceEqualsOrExceedsTwelvePointFivePerShareMember" xml:lang="en-US">Share Price Equals or Exceeds 12.50 Per Share [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_btmd_SharePriceEqualsOrExceedsTwelvePointFivePerShareMember" xlink:to="lab_btmd_SharePriceEqualsOrExceedsTwelvePointFivePerShareMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_btmd_SharePriceEqualsOrExceedsTwelvePointFivePerShareMember" xml:lang="en-US">Share price equals or exceeds twelve point five per share.</label>
<loc xlink:type="locator" xlink:href="btmd-20221231.xsd#btmd_SharePriceEqualsOrExceedsFifteenPerShareMember" xlink:label="loc_btmd_SharePriceEqualsOrExceedsFifteenPerShareMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_btmd_SharePriceEqualsOrExceedsFifteenPerShareMember" xml:lang="en-US">Share Price Equals Or Exceeds Fifteen Per Share [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_btmd_SharePriceEqualsOrExceedsFifteenPerShareMember" xml:lang="en-US">Share Price Equals or Exceeds 15.00 Per Share [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_btmd_SharePriceEqualsOrExceedsFifteenPerShareMember" xlink:to="lab_btmd_SharePriceEqualsOrExceedsFifteenPerShareMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_btmd_SharePriceEqualsOrExceedsFifteenPerShareMember" xml:lang="en-US">Share price equals or exceeds fifteen per share.</label>
<loc xlink:type="locator" xlink:href="btmd-20221231.xsd#btmd_SharePriceEqualsOrExceedsSeventeenPointFivePerShareMember" xlink:label="loc_btmd_SharePriceEqualsOrExceedsSeventeenPointFivePerShareMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_btmd_SharePriceEqualsOrExceedsSeventeenPointFivePerShareMember" xml:lang="en-US">Share Price Equals Or Exceeds Seventeen Point Five Per Share [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_btmd_SharePriceEqualsOrExceedsSeventeenPointFivePerShareMember" xml:lang="en-US">Share Price Equals or Exceeds 17.50 Per Share [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_btmd_SharePriceEqualsOrExceedsSeventeenPointFivePerShareMember" xlink:to="lab_btmd_SharePriceEqualsOrExceedsSeventeenPointFivePerShareMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_btmd_SharePriceEqualsOrExceedsSeventeenPointFivePerShareMember" xml:lang="en-US">Share price equals or exceeds seventeen point five per share.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesLineItems" xlink:label="loc_us-gaap_LossContingenciesLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LossContingenciesLineItems" xml:lang="en-US">Loss Contingencies [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingenciesLineItems" xlink:to="lab_us-gaap_LossContingenciesLineItems" />
<loc xlink:type="locator" xlink:href="btmd-20221231.xsd#btmd_NumberOfEarnoutSecuritiesShareholderEntitledToVestIfCertainSharePriceTargetsAchieved" xlink:label="loc_btmd_NumberOfEarnoutSecuritiesShareholderEntitledToVestIfCertainSharePriceTargetsAchieved" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_btmd_NumberOfEarnoutSecuritiesShareholderEntitledToVestIfCertainSharePriceTargetsAchieved" xml:lang="en-US">Number of Earnout Securities Shareholder Entitled to Vest if Certain Share Price Targets Achieved</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_btmd_NumberOfEarnoutSecuritiesShareholderEntitledToVestIfCertainSharePriceTargetsAchieved" xml:lang="en-US">Number of earnout securities shareholder entitled to vest if certain share price targets achieved</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_btmd_NumberOfEarnoutSecuritiesShareholderEntitledToVestIfCertainSharePriceTargetsAchieved" xlink:to="lab_btmd_NumberOfEarnoutSecuritiesShareholderEntitledToVestIfCertainSharePriceTargetsAchieved" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_btmd_NumberOfEarnoutSecuritiesShareholderEntitledToVestIfCertainSharePriceTargetsAchieved" xml:lang="en-US">Number of earnout securities shareholder entitled to vest if certain share price targets achieved.</label>
<loc xlink:type="locator" xlink:href="btmd-20221231.xsd#btmd_EarnoutDeadlineDate" xlink:label="loc_btmd_EarnoutDeadlineDate" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_btmd_EarnoutDeadlineDate" xml:lang="en-US">Earnout Deadline Date</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_btmd_EarnoutDeadlineDate" xml:lang="en-US">Earnout deadline date</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_btmd_EarnoutDeadlineDate" xlink:to="lab_btmd_EarnoutDeadlineDate" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_btmd_EarnoutDeadlineDate" xml:lang="en-US">Earnout deadline date.</label>
<loc xlink:type="locator" xlink:href="btmd-20221231.xsd#btmd_NumberOfConsecutiveTradingDaysForDeterminingTheSharePrice" xlink:label="loc_btmd_NumberOfConsecutiveTradingDaysForDeterminingTheSharePrice" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_btmd_NumberOfConsecutiveTradingDaysForDeterminingTheSharePrice" xml:lang="en-US">Number Of Consecutive Trading Days For Determining The Share Price</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_btmd_NumberOfConsecutiveTradingDaysForDeterminingTheSharePrice" xml:lang="en-US">Number of consecutive trading days for determining the share price</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_btmd_NumberOfConsecutiveTradingDaysForDeterminingTheSharePrice" xlink:to="lab_btmd_NumberOfConsecutiveTradingDaysForDeterminingTheSharePrice" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_btmd_NumberOfConsecutiveTradingDaysForDeterminingTheSharePrice" xml:lang="en-US">Number of consecutive trading days for determining the share price.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="loc_us-gaap_FinancialInstrumentAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xml:lang="en-US">Financial Instrument [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancialInstrumentAxis" xlink:to="lab_us-gaap_FinancialInstrumentAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xml:lang="en-US">Financial Instruments [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" />
<loc xlink:type="locator" xlink:href="btmd-20221231.xsd#btmd_EarnoutLiabilityMember" xlink:label="loc_btmd_EarnoutLiabilityMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_btmd_EarnoutLiabilityMember" xml:lang="en-US">Earnout Liability Member</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_btmd_EarnoutLiabilityMember" xml:lang="en-US">Earnout Liability</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_btmd_EarnoutLiabilityMember" xlink:to="lab_btmd_EarnoutLiabilityMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_btmd_EarnoutLiabilityMember" xml:lang="en-US">Earnout liability member.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="loc_us-gaap_FairValueInputsLevel1Member" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xml:lang="en-US">Level 1</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel1Member" xlink:to="lab_us-gaap_FairValueInputsLevel1Member" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaap_FairValueInputsLevel3Member" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xml:lang="en-US">Level 3</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel3Member" xlink:to="lab_us-gaap_FairValueInputsLevel3Member" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xml:lang="en-US">Schedule Of Changes In The Fair Value Of Warrant Liabilities [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialLiabilitiesFairValueDisclosure" xlink:label="loc_us-gaap_FinancialLiabilitiesFairValueDisclosure" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FinancialLiabilitiesFairValueDisclosure" xml:lang="en-US">Financial Liabilities Fair Value Disclosure</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FinancialLiabilitiesFairValueDisclosure" xml:lang="en-US">Liability</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_us-gaap_FinancialLiabilitiesFairValueDisclosure" xml:lang="en-US">Fair value as of May 26, 2022 (initial measurement)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_FinancialLiabilitiesFairValueDisclosure" xml:lang="en-US">Fair value as of December 31, 2022</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancialLiabilitiesFairValueDisclosure" xlink:to="lab_us-gaap_FinancialLiabilitiesFairValueDisclosure" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xml:lang="en-US">Fair Value Measurement Inputs and Valuation Techniques [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputSharePriceMember" xlink:label="loc_us-gaap_MeasurementInputSharePriceMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_MeasurementInputSharePriceMember" xml:lang="en-US">Measurement Input, Share Price [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_MeasurementInputSharePriceMember" xml:lang="en-US">Stock Price</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputSharePriceMember" xlink:to="lab_us-gaap_MeasurementInputSharePriceMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputExercisePriceMember" xlink:label="loc_us-gaap_MeasurementInputExercisePriceMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_MeasurementInputExercisePriceMember" xml:lang="en-US">Measurement Input, Exercise Price [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_MeasurementInputExercisePriceMember" xml:lang="en-US">Exercise Price</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputExercisePriceMember" xlink:to="lab_us-gaap_MeasurementInputExercisePriceMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:label="loc_us-gaap_MeasurementInputRiskFreeInterestRateMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_MeasurementInputRiskFreeInterestRateMember" xml:lang="en-US">Measurement Input, Risk Free Interest Rate [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_MeasurementInputRiskFreeInterestRateMember" xml:lang="en-US">Risk-free Rate</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:to="lab_us-gaap_MeasurementInputRiskFreeInterestRateMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputOptionVolatilityMember" xlink:label="loc_us-gaap_MeasurementInputOptionVolatilityMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_MeasurementInputOptionVolatilityMember" xml:lang="en-US">Measurement Input, Option Volatility [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_MeasurementInputOptionVolatilityMember" xml:lang="en-US">Volatility</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputOptionVolatilityMember" xlink:to="lab_us-gaap_MeasurementInputOptionVolatilityMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputExpectedTermMember" xlink:label="loc_us-gaap_MeasurementInputExpectedTermMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_MeasurementInputExpectedTermMember" xml:lang="en-US">Measurement Input, Expected Term [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_MeasurementInputExpectedTermMember" xml:lang="en-US">Term (in years)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputExpectedTermMember" xlink:to="lab_us-gaap_MeasurementInputExpectedTermMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xml:lang="en-US">Fair Value Measurement Inputs and Valuation Techniques [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="loc_us-gaap_SaleOfStockPricePerShare" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SaleOfStockPricePerShare" xml:lang="en-US">Sale of Stock, Price Per Share</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SaleOfStockPricePerShare" xml:lang="en-US">Sale of stock price per share</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockPricePerShare" xlink:to="lab_us-gaap_SaleOfStockPricePerShare" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:label="loc_us-gaap_WarrantsAndRightsOutstandingMeasurementInput" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xml:lang="en-US">Warrants and Rights Outstanding, Measurement Input</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xml:lang="en-US">Warrants and rights outstanding measurement input</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:to="lab_us-gaap_WarrantsAndRightsOutstandingMeasurementInput" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueOptionChangesInFairValueGainLoss1" xlink:label="loc_us-gaap_FairValueOptionChangesInFairValueGainLoss1" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueOptionChangesInFairValueGainLoss1" xml:lang="en-US">Fair Value, Option, Changes in Fair Value, Gain (Loss)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_FairValueOptionChangesInFairValueGainLoss1" xml:lang="en-US">Gain from change in fair value</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueOptionChangesInFairValueGainLoss1" xlink:to="lab_us-gaap_FairValueOptionChangesInFairValueGainLoss1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MinorityInterestTable" xlink:label="loc_us-gaap_MinorityInterestTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_MinorityInterestTable" xml:lang="en-US">Noncontrolling Interest [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MinorityInterestTable" xlink:to="lab_us-gaap_MinorityInterestTable" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_OwnershipAxis" xlink:label="loc_srt_OwnershipAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_OwnershipAxis" xml:lang="en-US">Ownership [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_OwnershipAxis" xlink:to="lab_srt_OwnershipAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_OwnershipDomain" xlink:label="loc_srt_OwnershipDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_OwnershipDomain" xml:lang="en-US">Ownership [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_OwnershipDomain" xlink:to="lab_srt_OwnershipDomain" />
<loc xlink:type="locator" xlink:href="btmd-20221231.xsd#btmd_MinorityInterestHoldersMember" xlink:label="loc_btmd_MinorityInterestHoldersMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_btmd_MinorityInterestHoldersMember" xml:lang="en-US">Minority Interest Holders [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_btmd_MinorityInterestHoldersMember" xml:lang="en-US">Minority Interest Holders</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_btmd_MinorityInterestHoldersMember" xlink:to="lab_btmd_MinorityInterestHoldersMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_btmd_MinorityInterestHoldersMember" xml:lang="en-US">Minority interest holders.</label>
<loc xlink:type="locator" xlink:href="btmd-20221231.xsd#btmd_BioteCorporationMember" xlink:label="loc_btmd_BioteCorporationMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_btmd_BioteCorporationMember" xml:lang="en-US">Biote Corporation [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_btmd_BioteCorporationMember" xml:lang="en-US">Biote</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_btmd_BioteCorporationMember" xlink:to="lab_btmd_BioteCorporationMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_btmd_BioteCorporationMember" xml:lang="en-US">Biote Corp.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MinorityInterestLineItems" xlink:label="loc_us-gaap_MinorityInterestLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_MinorityInterestLineItems" xml:lang="en-US">Noncontrolling Interest [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MinorityInterestLineItems" xlink:to="lab_us-gaap_MinorityInterestLineItems" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners" xlink:label="loc_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners" xml:lang="en-US">Noncontrolling Interest, Ownership Percentage by Noncontrolling Owners</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners" xml:lang="en-US">Minority interest, retained percentage by minority interest holders</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners" xlink:to="lab_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MinorityInterestOwnershipPercentageByParent" xlink:label="loc_us-gaap_MinorityInterestOwnershipPercentageByParent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_MinorityInterestOwnershipPercentageByParent" xml:lang="en-US">Noncontrolling Interest, Ownership Percentage by Parent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_MinorityInterestOwnershipPercentageByParent" xml:lang="en-US">Minority interest, ownership percentage</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MinorityInterestOwnershipPercentageByParent" xlink:to="lab_us-gaap_MinorityInterestOwnershipPercentageByParent" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockVotingRights" xlink:label="loc_us-gaap_CommonStockVotingRights" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommonStockVotingRights" xml:lang="en-US">Common Stock, Voting Rights</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockVotingRights" xlink:to="lab_us-gaap_CommonStockVotingRights" />
<loc xlink:type="locator" xlink:href="btmd-20221231.xsd#btmd_CommonStockNumberOfVotesEntitledPerShare" xlink:label="loc_btmd_CommonStockNumberOfVotesEntitledPerShare" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_btmd_CommonStockNumberOfVotesEntitledPerShare" xml:lang="en-US">Common Stock, Number of Votes Entitled Per Share</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_btmd_CommonStockNumberOfVotesEntitledPerShare" xml:lang="en-US">Common stock, number of votes per share</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_btmd_CommonStockNumberOfVotesEntitledPerShare" xlink:to="lab_btmd_CommonStockNumberOfVotesEntitledPerShare" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_btmd_CommonStockNumberOfVotesEntitledPerShare" xml:lang="en-US">Common stock, number of votes entitled per share.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xml:lang="en-US">Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaap_PlanNameAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PlanNameAxis" xml:lang="en-US">Plan Name [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameAxis" xlink:to="lab_us-gaap_PlanNameAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PlanNameDomain" xml:lang="en-US">Plan Name [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameDomain" xlink:to="lab_us-gaap_PlanNameDomain" />
<loc xlink:type="locator" xlink:href="btmd-20221231.xsd#btmd_TwoThousandTwentyTwoEquityIncentivePlanMember" xlink:label="loc_btmd_TwoThousandTwentyTwoEquityIncentivePlanMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_btmd_TwoThousandTwentyTwoEquityIncentivePlanMember" xml:lang="en-US">Two Thousand Twenty Two Equity Incentive Plan [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_btmd_TwoThousandTwentyTwoEquityIncentivePlanMember" xml:lang="en-US">2022 Equity Incentive Plan</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_btmd_TwoThousandTwentyTwoEquityIncentivePlanMember" xlink:to="lab_btmd_TwoThousandTwentyTwoEquityIncentivePlanMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_btmd_TwoThousandTwentyTwoEquityIncentivePlanMember" xml:lang="en-US">Two thousand twenty two equity incentive plan.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AwardTypeAxis" xml:lang="en-US">Award Type [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="lab_us-gaap_AwardTypeAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xml:lang="en-US">Award Type [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
<loc xlink:type="locator" xlink:href="btmd-20221231.xsd#btmd_IncentiveUnitsMember" xlink:label="loc_btmd_IncentiveUnitsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_btmd_IncentiveUnitsMember" xml:lang="en-US">Incentive Units [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_btmd_IncentiveUnitsMember" xml:lang="en-US">Incentive Units</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_btmd_IncentiveUnitsMember" xlink:to="lab_btmd_IncentiveUnitsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_btmd_IncentiveUnitsMember" xml:lang="en-US">Incentive units.</label>
<loc xlink:type="locator" xlink:href="btmd-20221231.xsd#btmd_PhantomEquityRightsMember" xlink:label="loc_btmd_PhantomEquityRightsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_btmd_PhantomEquityRightsMember" xml:lang="en-US">Phantom Equity Rights [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_btmd_PhantomEquityRightsMember" xml:lang="en-US">Phantom Equity Rights</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_btmd_PhantomEquityRightsMember" xlink:to="lab_btmd_PhantomEquityRightsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_btmd_PhantomEquityRightsMember" xml:lang="en-US">Phantom equity rights.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xml:lang="en-US">Restricted Stock Units (RSUs) [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xml:lang="en-US">RSUs</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:to="lab_us-gaap_RestrictedStockUnitsRSUMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xml:lang="en-US">Share-Based Payment Arrangement, Option [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xml:lang="en-US">Stock Options</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockOptionMember" xlink:to="lab_us-gaap_EmployeeStockOptionMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
<loc xlink:type="locator" xlink:href="btmd-20221231.xsd#btmd_ShareBasedCompensationArrangementVestingOfIncentiveUnits" xlink:label="loc_btmd_ShareBasedCompensationArrangementVestingOfIncentiveUnits" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_btmd_ShareBasedCompensationArrangementVestingOfIncentiveUnits" xml:lang="en-US">Share Based Compensation Arrangement Vesting Of Incentive Units</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_btmd_ShareBasedCompensationArrangementVestingOfIncentiveUnits" xml:lang="en-US">Vesting of incentive units, shares</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_btmd_ShareBasedCompensationArrangementVestingOfIncentiveUnits" xlink:to="lab_btmd_ShareBasedCompensationArrangementVestingOfIncentiveUnits" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_btmd_ShareBasedCompensationArrangementVestingOfIncentiveUnits" xml:lang="en-US">Share Based Compensation arrangement vesting of incentive units.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SettlementLiabilitiesCurrent" xlink:label="loc_us-gaap_SettlementLiabilitiesCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SettlementLiabilitiesCurrent" xml:lang="en-US">Settlement Liabilities, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SettlementLiabilitiesCurrent" xml:lang="en-US">Settlement of phantom equity rights</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SettlementLiabilitiesCurrent" xlink:to="lab_us-gaap_SettlementLiabilitiesCurrent" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConversionOfStockSharesConverted1" xlink:label="loc_us-gaap_ConversionOfStockSharesConverted1" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ConversionOfStockSharesConverted1" xml:lang="en-US">Conversion of Stock, Shares Converted</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ConversionOfStockSharesConverted1" xml:lang="en-US">Phantom equity rights replaced with restricted stock units</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConversionOfStockSharesConverted1" xlink:to="lab_us-gaap_ConversionOfStockSharesConverted1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xml:lang="en-US">Unrecognized compensation expense</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xml:lang="en-US">Unrecognized compensation expense, expected to be recognized, weighted-average remaining vesting period</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xml:lang="en-US">Awards vesting period</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xml:lang="en-US">Shares, RSUs Outstanding, Beginning balance</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xml:lang="en-US">Shares, RSUs Outstanding, Ending balance</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xml:lang="en-US">Shares, Granted</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xml:lang="en-US">Shares, Forfeited</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xml:lang="en-US">Shares, Vested</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xml:lang="en-US">Weighted-Average Grant-Date Fair Value, RSUs Outstanding, Beginning balance</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xml:lang="en-US">Weighted-Average Grant-Date Fair Value, RSUs Outstanding, Ending balance</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xml:lang="en-US">Weighted-Average Grant-Date Fair Value, Granted</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xml:lang="en-US">Weighted-Average Grant-Date Fair Value, Forfeited</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xml:lang="en-US">Weighted-Average Grant-Date Fair Value, Vested</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xml:lang="en-US">Stock Options, Granted</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xml:lang="en-US">Stock Options, Forfeited</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xml:lang="en-US">Stock Options Outstanding, Ending Balance</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xml:lang="en-US">Stock Options, Exercisable</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xml:lang="en-US">Weighted-Average Exercise Price, Granted</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xml:lang="en-US">Weighted-Average Exercise Price, Forfeited</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xml:lang="en-US">Weighted-Average Exercise Price Outstanding, Ending Balance</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xml:lang="en-US">Weighted-Average Exercise Price, Exercisable</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xml:lang="en-US">Weighted-Average Remaining Contractual Term (Years)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xml:lang="en-US">Weighted-Average Remaining Contractual Term (Years), Exercisable</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions and Methodology [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xml:lang="en-US">Expected term (in years)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Weighted Average Volatility Rate</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" xml:lang="en-US">Volatility</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xml:lang="en-US">Risk-free rate</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xml:lang="en-US">Dividend yield</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseExpirationDate1" xlink:label="loc_us-gaap_LeaseExpirationDate1" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LeaseExpirationDate1" xml:lang="en-US">Lease Expiration Date</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LeaseExpirationDate1" xml:lang="en-US">Extend lease term date</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseExpirationDate1" xlink:to="lab_us-gaap_LeaseExpirationDate1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseOptionToExtend" xlink:label="loc_us-gaap_LesseeOperatingLeaseOptionToExtend" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LesseeOperatingLeaseOptionToExtend" xml:lang="en-US">Lessee, Operating Lease, Option to Extend</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LesseeOperatingLeaseOptionToExtend" xml:lang="en-US">Operating lease option to Extend</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseOptionToExtend" xlink:to="lab_us-gaap_LesseeOperatingLeaseOptionToExtend" />
<loc xlink:type="locator" xlink:href="btmd-20221231.xsd#btmd_AreaOfOfficeSpace" xlink:label="loc_btmd_AreaOfOfficeSpace" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_btmd_AreaOfOfficeSpace" xml:lang="en-US">Area of Office Space</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_btmd_AreaOfOfficeSpace" xml:lang="en-US">Area of office space</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_btmd_AreaOfOfficeSpace" xlink:to="lab_btmd_AreaOfOfficeSpace" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_btmd_AreaOfOfficeSpace" xml:lang="en-US">Area of Office Space</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseCost" xlink:label="loc_us-gaap_OperatingLeaseCost" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingLeaseCost" xml:lang="en-US">Operating Lease, Cost</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OperatingLeaseCost" xml:lang="en-US">Fixed lease expense</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseCost" xlink:to="lab_us-gaap_OperatingLeaseCost" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseCost" xlink:label="loc_us-gaap_LeaseCost" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LeaseCost" xml:lang="en-US">Lease, Cost</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_LeaseCost" xml:lang="en-US">Total lease cost</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseCost" xlink:to="lab_us-gaap_LeaseCost" />
<loc xlink:type="locator" xlink:href="btmd-20221231.xsd#btmd_OtherInformationAbstract" xlink:label="loc_btmd_OtherInformationAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_btmd_OtherInformationAbstract" xml:lang="en-US">Other Information [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_btmd_OtherInformationAbstract" xml:lang="en-US">Other information:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_btmd_OtherInformationAbstract" xlink:to="lab_btmd_OtherInformationAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_btmd_OtherInformationAbstract" xml:lang="en-US">Other information.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeasePayments" xlink:label="loc_us-gaap_OperatingLeasePayments" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingLeasePayments" xml:lang="en-US">Operating Lease, Payments</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OperatingLeasePayments" xml:lang="en-US">Cash paid for amounts included in the measurement of lease liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasePayments" xlink:to="lab_us-gaap_OperatingLeasePayments" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xml:lang="en-US">Right-of-Use Asset Obtained in Exchange for Operating Lease Liability</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xml:lang="en-US">Right-of-use assets obtained in exchange for new operating lease liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:to="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" />
<loc xlink:type="locator" xlink:href="btmd-20221231.xsd#btmd_AssetsLesseeAbstract" xlink:label="loc_btmd_AssetsLesseeAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_btmd_AssetsLesseeAbstract" xml:lang="en-US">Assets Lessee [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_btmd_AssetsLesseeAbstract" xml:lang="en-US">Lease Assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_btmd_AssetsLesseeAbstract" xlink:to="lab_btmd_AssetsLesseeAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_btmd_AssetsLesseeAbstract" xml:lang="en-US">Assets lessee.</label>
<loc xlink:type="locator" xlink:href="btmd-20221231.xsd#btmd_LeaseAssets" xlink:label="loc_btmd_LeaseAssets" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_btmd_LeaseAssets" xml:lang="en-US">Lease Assets</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_btmd_LeaseAssets" xml:lang="en-US">Total lease assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_btmd_LeaseAssets" xlink:to="lab_btmd_LeaseAssets" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_btmd_LeaseAssets" xml:lang="en-US">Lease assets.</label>
<loc xlink:type="locator" xlink:href="btmd-20221231.xsd#btmd_LiabilitiesLesseeAbstract" xlink:label="loc_btmd_LiabilitiesLesseeAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_btmd_LiabilitiesLesseeAbstract" xml:lang="en-US">Liabilities Lessee [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_btmd_LiabilitiesLesseeAbstract" xml:lang="en-US">Lease Liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_btmd_LiabilitiesLesseeAbstract" xlink:to="lab_btmd_LiabilitiesLesseeAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_btmd_LiabilitiesLesseeAbstract" xml:lang="en-US">Liabilities lessee.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability" xlink:label="loc_us-gaap_OperatingLeaseLiability" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingLeaseLiability" xml:lang="en-US">Operating Lease, Liability</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_OperatingLeaseLiability" xml:lang="en-US">Total lease liabilities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_OperatingLeaseLiability" xml:lang="en-US">Present value of lease liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiability" xlink:to="lab_us-gaap_OperatingLeaseLiability" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xml:lang="en-US">Operating Lease, Weighted Average Remaining Lease Term</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xml:lang="en-US">Weighted-average remaining lease term --- operating leases (years)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xml:lang="en-US">Operating Lease, Weighted Average Discount Rate, Percent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xml:lang="en-US">Weighted-average discount rate --- operating leases</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:label="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year One</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xml:lang="en-US">2023</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Two</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xml:lang="en-US">2024</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Three</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xml:lang="en-US">2025</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Four</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xml:lang="en-US">2026</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Five</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xml:lang="en-US">2027</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, after Year Five</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xml:lang="en-US">Thereafter</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xml:lang="en-US">Total lease payments</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xml:lang="en-US">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xml:lang="en-US">Less: Interest</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowanceTable" xlink:label="loc_us-gaap_ValuationAllowanceTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ValuationAllowanceTable" xml:lang="en-US">Valuation Allowance [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowanceTable" xlink:to="lab_us-gaap_ValuationAllowanceTable" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeTaxAuthorityAxis" xml:lang="en-US">Income Tax Authority [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis" xlink:to="lab_us-gaap_IncomeTaxAuthorityAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeTaxAuthorityDomain" xml:lang="en-US">Income Tax Authority [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain" xlink:to="lab_us-gaap_IncomeTaxAuthorityDomain" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCountryMember" xlink:label="loc_us-gaap_ForeignCountryMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ForeignCountryMember" xml:lang="en-US">Foreign Tax Authority [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ForeignCountryMember" xml:lang="en-US">Foreign</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCountryMember" xlink:to="lab_us-gaap_ForeignCountryMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowanceLineItems" xlink:label="loc_us-gaap_ValuationAllowanceLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ValuationAllowanceLineItems" xml:lang="en-US">Valuation Allowance [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowanceLineItems" xlink:to="lab_us-gaap_ValuationAllowanceLineItems" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="loc_us-gaap_OperatingLossCarryforwards" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingLossCarryforwards" xml:lang="en-US">Operating Loss Carryforwards</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OperatingLossCarryforwards" xml:lang="en-US">Net operating losses</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLossCarryforwards" xlink:to="lab_us-gaap_OperatingLossCarryforwards" />
<loc xlink:type="locator" xlink:href="btmd-20221231.xsd#btmd_OperatingLossCarryforwardsExpirationYear" xlink:label="loc_btmd_OperatingLossCarryforwardsExpirationYear" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_btmd_OperatingLossCarryforwardsExpirationYear" xml:lang="en-US">Operating Loss Carryforwards, Expiration Year</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_btmd_OperatingLossCarryforwardsExpirationYear" xml:lang="en-US">Net operating losses, expiration year</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_btmd_OperatingLossCarryforwardsExpirationYear" xlink:to="lab_btmd_OperatingLossCarryforwardsExpirationYear" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_btmd_OperatingLossCarryforwardsExpirationYear" xml:lang="en-US">Operating loss carryforwards, expiration year.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits" xml:lang="en-US">Unrecognized Tax Benefits</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits" xml:lang="en-US">Uncertain tax positions</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefits" xlink:to="lab_us-gaap_UnrecognizedTaxBenefits" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExaminationDescription" xlink:label="loc_us-gaap_IncomeTaxExaminationDescription" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeTaxExaminationDescription" xml:lang="en-US">Income Tax Examination, Description</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IncomeTaxExaminationDescription" xml:lang="en-US">Income tax examination description</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExaminationDescription" xlink:to="lab_us-gaap_IncomeTaxExaminationDescription" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Domestic</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xml:lang="en-US">Domestic</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Foreign</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xml:lang="en-US">Foreign</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xml:lang="en-US">Current Income Tax Expense (Benefit), Continuing Operations [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xml:lang="en-US">Current income tax provision (benefit):</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="lab_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentFederalTaxExpenseBenefit" xlink:label="loc_us-gaap_CurrentFederalTaxExpenseBenefit" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CurrentFederalTaxExpenseBenefit" xml:lang="en-US">Current Federal Tax Expense (Benefit)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CurrentFederalTaxExpenseBenefit" xml:lang="en-US">Federal</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:to="lab_us-gaap_CurrentFederalTaxExpenseBenefit" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:label="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xml:lang="en-US">Current State and Local Tax Expense (Benefit)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xml:lang="en-US">State and Local</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:to="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentForeignTaxExpenseBenefit" xlink:label="loc_us-gaap_CurrentForeignTaxExpenseBenefit" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CurrentForeignTaxExpenseBenefit" xml:lang="en-US">Current Foreign Tax Expense (Benefit)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CurrentForeignTaxExpenseBenefit" xml:lang="en-US">Foreign</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentForeignTaxExpenseBenefit" xlink:to="lab_us-gaap_CurrentForeignTaxExpenseBenefit" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CurrentIncomeTaxExpenseBenefit" xml:lang="en-US">Current Income Tax Expense (Benefit)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_CurrentIncomeTaxExpenseBenefit" xml:lang="en-US">Total current expense (benefit):</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_CurrentIncomeTaxExpenseBenefit" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xml:lang="en-US">Deferred Income Tax Expense (Benefit), Continuing Operations [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xml:lang="en-US">Deferred income tax provision (benefit):</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="lab_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xml:lang="en-US">Deferred Federal Income Tax Expense (Benefit)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xml:lang="en-US">Federal</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xml:lang="en-US">Deferred State and Local Income Tax Expense (Benefit)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xml:lang="en-US">State and Local</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xml:lang="en-US">Deferred Income Tax Expense (Benefit)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xml:lang="en-US">Total deferred expense (benefit):</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xml:lang="en-US">Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xml:lang="en-US">Statutory federal income tax rate</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xml:lang="en-US">Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xml:lang="en-US">State taxes, net of federal tax benefit</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxExemptIncome" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxExemptIncome" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxExemptIncome" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Tax Exempt Income, Percent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxExemptIncome" xml:lang="en-US">Nontaxable partnership income</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxExemptIncome" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxExemptIncome" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Percent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xml:lang="en-US">Foreign rate differential</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xml:lang="en-US">Change in valuation allowance</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Percent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xml:lang="en-US">Income tax provision</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsNetAbstract" xlink:label="loc_us-gaap_DeferredTaxAssetsNetAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredTaxAssetsNetAbstract" xml:lang="en-US">Deferred Tax Assets, Net [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DeferredTaxAssetsNetAbstract" xml:lang="en-US">Deferred tax assets:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="lab_us-gaap_DeferredTaxAssetsNetAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsInvestments" xlink:label="loc_us-gaap_DeferredTaxAssetsInvestments" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredTaxAssetsInvestments" xml:lang="en-US">Deferred Tax Assets, Investments</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DeferredTaxAssetsInvestments" xml:lang="en-US">Outside basis difference in partnership</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsInvestments" xlink:to="lab_us-gaap_DeferredTaxAssetsInvestments" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xml:lang="en-US">Deferred Tax Assets, Operating Loss Carryforwards</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xml:lang="en-US">Net operating loss carryforwards</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:label="loc_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xml:lang="en-US">Deferred Tax Assets, Goodwill and Intangible Assets</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xml:lang="en-US">Intangibles</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:to="lab_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="loc_us-gaap_DeferredTaxAssetsGross" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredTaxAssetsGross" xml:lang="en-US">Deferred Tax Assets, Gross</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_DeferredTaxAssetsGross" xml:lang="en-US">Total deferred tax assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsGross" xlink:to="lab_us-gaap_DeferredTaxAssetsGross" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xml:lang="en-US">Deferred Tax Assets, Valuation Allowance</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xml:lang="en-US">Valuation allowance</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="lab_us-gaap_DeferredTaxAssetsValuationAllowance" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="loc_us-gaap_DeferredTaxAssetsNet" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredTaxAssetsNet" xml:lang="en-US">Deferred Tax Assets, Net of Valuation Allowance</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_DeferredTaxAssetsNet" xml:lang="en-US">Deferred tax assets, net of allowance</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsNet" xlink:to="lab_us-gaap_DeferredTaxAssetsNet" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable" xml:lang="en-US">Schedule of Earnings Per Share, Basic, by Common Class, Including Two Class Method [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable" xlink:to="lab_us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasicLineItems" xlink:label="loc_us-gaap_EarningsPerShareBasicLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EarningsPerShareBasicLineItems" xml:lang="en-US">Earnings Per Share, Basic, by Common Class, Including Two Class Method [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasicLineItems" xlink:to="lab_us-gaap_EarningsPerShareBasicLineItems" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAbstract" xlink:label="loc_us-gaap_NetIncomeLossAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetIncomeLossAbstract" xml:lang="en-US">Net Income (Loss) Attributable to Parent [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_NetIncomeLossAbstract" xml:lang="en-US">Numerator:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAbstract" xlink:to="lab_us-gaap_NetIncomeLossAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xml:lang="en-US">Net Income (Loss) Available to Common Stockholders, Basic</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xml:lang="en-US">Net loss attributable to biote Corp. stockholders (basic)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xml:lang="en-US">Net Income (Loss) Available to Common Stockholders, Diluted</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xml:lang="en-US">Net loss attributable to biote Corp. stockholders (diluted)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:to="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xml:lang="en-US">Weighted Average Number of Shares Outstanding Reconciliation [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xml:lang="en-US">Net loss per common share</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xml:lang="en-US">Antidilutive Securities [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xml:lang="en-US">Antidilutive Securities, Name [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="lab_us-gaap_AntidilutiveSecuritiesNameDomain" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xml:lang="en-US">Potentially antidilutive common units outstanding</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyNameOfPlaintiff" xlink:label="loc_us-gaap_LossContingencyNameOfPlaintiff" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LossContingencyNameOfPlaintiff" xml:lang="en-US">Loss contingency, name of plaintiff</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyNameOfPlaintiff" xlink:to="lab_us-gaap_LossContingencyNameOfPlaintiff" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyLawsuitFilingDate" xlink:label="loc_us-gaap_LossContingencyLawsuitFilingDate" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LossContingencyLawsuitFilingDate" xml:lang="en-US">Loss contingency, lawsuit filing date</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyLawsuitFilingDate" xlink:to="lab_us-gaap_LossContingencyLawsuitFilingDate" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyDamagesSoughtValue" xlink:label="loc_us-gaap_LossContingencyDamagesSoughtValue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LossContingencyDamagesSoughtValue" xml:lang="en-US">Loss Contingency, Damages Sought, Value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LossContingencyDamagesSoughtValue" xml:lang="en-US">Seeks monetary relief, exceeding amount</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyDamagesSoughtValue" xlink:to="lab_us-gaap_LossContingencyDamagesSoughtValue" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyNameOfDefendant" xlink:label="loc_us-gaap_LossContingencyNameOfDefendant" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LossContingencyNameOfDefendant" xml:lang="en-US">Loss contingency, name of defendant</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyNameOfDefendant" xlink:to="lab_us-gaap_LossContingencyNameOfDefendant" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xml:lang="en-US">Schedule of Related Party Transactions, by Related Party [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" />
<loc xlink:type="locator" xlink:href="btmd-20221231.xsd#btmd_FirmMember" xlink:label="loc_btmd_FirmMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_btmd_FirmMember" xml:lang="en-US">Firm [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_btmd_FirmMember" xml:lang="en-US">Firm</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_btmd_FirmMember" xlink:to="lab_btmd_FirmMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_btmd_FirmMember" xml:lang="en-US">Firm.</label>
<loc xlink:type="locator" xlink:href="btmd-20221231.xsd#btmd_EmployeeMember" xlink:label="loc_btmd_EmployeeMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_btmd_EmployeeMember" xml:lang="en-US">Employee [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_btmd_EmployeeMember" xml:lang="en-US">Employee</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_btmd_EmployeeMember" xlink:to="lab_btmd_EmployeeMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_btmd_EmployeeMember" xml:lang="en-US">Employee.</label>
<loc xlink:type="locator" xlink:href="btmd-20221231.xsd#btmd_SpouseOfFounderChairmanAndBeneficialOwnerMember" xlink:label="loc_btmd_SpouseOfFounderChairmanAndBeneficialOwnerMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_btmd_SpouseOfFounderChairmanAndBeneficialOwnerMember" xml:lang="en-US">Spouse of Founder, Chairman, and Beneficial Owner</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_btmd_SpouseOfFounderChairmanAndBeneficialOwnerMember" xlink:to="lab_btmd_SpouseOfFounderChairmanAndBeneficialOwnerMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_btmd_SpouseOfFounderChairmanAndBeneficialOwnerMember" xml:lang="en-US">Spouse of founder, chairman, and beneficial owner.</label>
<loc xlink:type="locator" xlink:href="btmd-20221231.xsd#btmd_VendorMember" xlink:label="loc_btmd_VendorMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_btmd_VendorMember" xml:lang="en-US">Vendor</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_btmd_VendorMember" xlink:to="lab_btmd_VendorMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_btmd_VendorMember" xml:lang="en-US">Vendor.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_DirectorMember" xlink:label="loc_srt_DirectorMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_DirectorMember" xml:lang="en-US">Director [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_srt_DirectorMember" xml:lang="en-US">Founder Advisor</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_DirectorMember" xlink:to="lab_srt_DirectorMember" />
<loc xlink:type="locator" xlink:href="btmd-20221231.xsd#btmd_ConsultantMember" xlink:label="loc_btmd_ConsultantMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_btmd_ConsultantMember" xml:lang="en-US">Consultant [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_btmd_ConsultantMember" xml:lang="en-US">Lani D.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_btmd_ConsultantMember" xlink:to="lab_btmd_ConsultantMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_btmd_ConsultantMember" xml:lang="en-US">Consultant.</label>
<loc xlink:type="locator" xlink:href="btmd-20221231.xsd#btmd_FounderAdvisoryAgreementMember" xlink:label="loc_btmd_FounderAdvisoryAgreementMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_btmd_FounderAdvisoryAgreementMember" xml:lang="en-US">Founder Advisory Agreement [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_btmd_FounderAdvisoryAgreementMember" xml:lang="en-US">Founder Advisory Agreement</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_btmd_FounderAdvisoryAgreementMember" xlink:to="lab_btmd_FounderAdvisoryAgreementMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_btmd_FounderAdvisoryAgreementMember" xml:lang="en-US">Founder advisory agreement.</label>
<loc xlink:type="locator" xlink:href="btmd-20221231.xsd#btmd_NewIndependentContractorAgreementMember" xlink:label="loc_btmd_NewIndependentContractorAgreementMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_btmd_NewIndependentContractorAgreementMember" xml:lang="en-US">New Independent Contractor Agreement [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_btmd_NewIndependentContractorAgreementMember" xml:lang="en-US">New Independent Contractor Agreement</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_btmd_NewIndependentContractorAgreementMember" xlink:to="lab_btmd_NewIndependentContractorAgreementMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_btmd_NewIndependentContractorAgreementMember" xml:lang="en-US">New independent contractor agreement.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RelatedPartyTransactionLineItems" xml:lang="en-US">Related Party Transaction [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems" xlink:to="lab_us-gaap_RelatedPartyTransactionLineItems" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfessionalFees" xlink:label="loc_us-gaap_ProfessionalFees" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ProfessionalFees" xml:lang="en-US">Professional Fees</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ProfessionalFees" xml:lang="en-US">Fees paid</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProfessionalFees" xlink:to="lab_us-gaap_ProfessionalFees" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DueToRelatedPartiesCurrentAndNoncurrent" xlink:label="loc_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent" xml:lang="en-US">Due to Related Parties</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent" xml:lang="en-US">Amount due</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent" xlink:to="lab_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredRevenueRevenueRecognized1" xlink:label="loc_us-gaap_DeferredRevenueRevenueRecognized1" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredRevenueRevenueRecognized1" xml:lang="en-US">Revenue recognized</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredRevenueRevenueRecognized1" xlink:to="lab_us-gaap_DeferredRevenueRevenueRecognized1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DueFromCustomerAcceptances" xlink:label="loc_us-gaap_DueFromCustomerAcceptances" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DueFromCustomerAcceptances" xml:lang="en-US">Due from customer</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DueFromCustomerAcceptances" xlink:to="lab_us-gaap_DueFromCustomerAcceptances" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DueToEmployeesCurrentAndNoncurrent" xlink:label="loc_us-gaap_DueToEmployeesCurrentAndNoncurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DueToEmployeesCurrentAndNoncurrent" xml:lang="en-US">Due to employees</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DueToEmployeesCurrentAndNoncurrent" xlink:to="lab_us-gaap_DueToEmployeesCurrentAndNoncurrent" />
<loc xlink:type="locator" xlink:href="btmd-20221231.xsd#btmd_InventoryPurchases" xlink:label="loc_btmd_InventoryPurchases" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_btmd_InventoryPurchases" xml:lang="en-US">Inventory purchases</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_btmd_InventoryPurchases" xlink:to="lab_btmd_InventoryPurchases" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_btmd_InventoryPurchases" xml:lang="en-US">Inventory purchases.</label>
<loc xlink:type="locator" xlink:href="btmd-20221231.xsd#btmd_AgreementTerm" xlink:label="loc_btmd_AgreementTerm" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_btmd_AgreementTerm" xml:lang="en-US">Agreement Term</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_btmd_AgreementTerm" xml:lang="en-US">Agreement term</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_btmd_AgreementTerm" xlink:to="lab_btmd_AgreementTerm" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_btmd_AgreementTerm" xml:lang="en-US">Agreement term.</label>
<loc xlink:type="locator" xlink:href="btmd-20221231.xsd#btmd_AnnualAdviosryFeesPayable" xlink:label="loc_btmd_AnnualAdviosryFeesPayable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_btmd_AnnualAdviosryFeesPayable" xml:lang="en-US">Annual Adviosry Fees Payable</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_btmd_AnnualAdviosryFeesPayable" xml:lang="en-US">Annual fees per year</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_btmd_AnnualAdviosryFeesPayable" xlink:to="lab_btmd_AnnualAdviosryFeesPayable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_btmd_AnnualAdviosryFeesPayable" xml:lang="en-US">Annual adviosry fees payable.</label>
</labelLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>7
<FILENAME>btmd-20221231_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<!--Generated by DFIN XBRL Instance Document - http://www.dfinsolutions.com/ - Version R3.0 - on 06-April-2023 [03:21:32] {AM}-->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
<roleRef xlink:type="simple" xlink:href="btmd-20221231.xsd#Cover" roleURI="http://haymaker.com/role/Cover" />
<roleRef xlink:type="simple" xlink:href="btmd-20221231.xsd#ConsolidatedBalanceSheets" roleURI="http://haymaker.com/role/ConsolidatedBalanceSheets" />
<roleRef xlink:type="simple" xlink:href="btmd-20221231.xsd#ConsolidatedBalanceSheetsParenthetical" roleURI="http://haymaker.com/role/ConsolidatedBalanceSheetsParenthetical" />
<roleRef xlink:type="simple" xlink:href="btmd-20221231.xsd#ConsolidatedStatementsOfIncomeAndComprehensiveIncome" roleURI="http://haymaker.com/role/ConsolidatedStatementsOfIncomeAndComprehensiveIncome" />
<roleRef xlink:type="simple" xlink:href="btmd-20221231.xsd#ConsolidatedStatementsOfStockholdersEquityDeficit" roleURI="http://haymaker.com/role/ConsolidatedStatementsOfStockholdersEquityDeficit" />
<roleRef xlink:type="simple" xlink:href="btmd-20221231.xsd#ConsolidatedStatementsOfCashFlows" roleURI="http://haymaker.com/role/ConsolidatedStatementsOfCashFlows" />
<roleRef xlink:type="simple" xlink:href="btmd-20221231.xsd#DescriptionOfBusinessAndBasisOfPresentation" roleURI="http://haymaker.com/role/DescriptionOfBusinessAndBasisOfPresentation" />
<roleRef xlink:type="simple" xlink:href="btmd-20221231.xsd#SummaryOfSignificantAccountingPolicies" roleURI="http://haymaker.com/role/SummaryOfSignificantAccountingPolicies" />
<roleRef xlink:type="simple" xlink:href="btmd-20221231.xsd#BusinessCombination" roleURI="http://haymaker.com/role/BusinessCombination" />
<roleRef xlink:type="simple" xlink:href="btmd-20221231.xsd#RevenueRecognition" roleURI="http://haymaker.com/role/RevenueRecognition" />
<roleRef xlink:type="simple" xlink:href="btmd-20221231.xsd#InventoryNet" roleURI="http://haymaker.com/role/InventoryNet" />
<roleRef xlink:type="simple" xlink:href="btmd-20221231.xsd#PropertyAndEquipmentNet" roleURI="http://haymaker.com/role/PropertyAndEquipmentNet" />
<roleRef xlink:type="simple" xlink:href="btmd-20221231.xsd#CapitalizedSoftwareNet" roleURI="http://haymaker.com/role/CapitalizedSoftwareNet" />
<roleRef xlink:type="simple" xlink:href="btmd-20221231.xsd#AccruedExpenses" roleURI="http://haymaker.com/role/AccruedExpenses" />
<roleRef xlink:type="simple" xlink:href="btmd-20221231.xsd#LongTermDebt" roleURI="http://haymaker.com/role/LongTermDebt" />
<roleRef xlink:type="simple" xlink:href="btmd-20221231.xsd#WarrantLiability" roleURI="http://haymaker.com/role/WarrantLiability" />
<roleRef xlink:type="simple" xlink:href="btmd-20221231.xsd#EarnoutLiability" roleURI="http://haymaker.com/role/EarnoutLiability" />
<roleRef xlink:type="simple" xlink:href="btmd-20221231.xsd#FairValueMeasurements" roleURI="http://haymaker.com/role/FairValueMeasurements" />
<roleRef xlink:type="simple" xlink:href="btmd-20221231.xsd#NoncontrollingInterest" roleURI="http://haymaker.com/role/NoncontrollingInterest" />
<roleRef xlink:type="simple" xlink:href="btmd-20221231.xsd#ShareBasedCompensation" roleURI="http://haymaker.com/role/ShareBasedCompensation" />
<roleRef xlink:type="simple" xlink:href="btmd-20221231.xsd#Leases" roleURI="http://haymaker.com/role/Leases" />
<roleRef xlink:type="simple" xlink:href="btmd-20221231.xsd#IncomeTaxes" roleURI="http://haymaker.com/role/IncomeTaxes" />
<roleRef xlink:type="simple" xlink:href="btmd-20221231.xsd#NetLossPerCommonShare" roleURI="http://haymaker.com/role/NetLossPerCommonShare" />
<roleRef xlink:type="simple" xlink:href="btmd-20221231.xsd#CommitmentsAndContingencies" roleURI="http://haymaker.com/role/CommitmentsAndContingencies" />
<roleRef xlink:type="simple" xlink:href="btmd-20221231.xsd#RelatedPartyTransactions" roleURI="http://haymaker.com/role/RelatedPartyTransactions" />
<roleRef xlink:type="simple" xlink:href="btmd-20221231.xsd#SubsequentEvents" roleURI="http://haymaker.com/role/SubsequentEvents" />
<roleRef xlink:type="simple" xlink:href="btmd-20221231.xsd#SummaryOfSignificantAccountingPoliciesPolicies" roleURI="http://haymaker.com/role/SummaryOfSignificantAccountingPoliciesPolicies" />
<roleRef xlink:type="simple" xlink:href="btmd-20221231.xsd#SummaryOfSignificantAccountingPoliciesTables" roleURI="http://haymaker.com/role/SummaryOfSignificantAccountingPoliciesTables" />
<roleRef xlink:type="simple" xlink:href="btmd-20221231.xsd#RevenueRecognitionTables" roleURI="http://haymaker.com/role/RevenueRecognitionTables" />
<roleRef xlink:type="simple" xlink:href="btmd-20221231.xsd#InventoryNetTables" roleURI="http://haymaker.com/role/InventoryNetTables" />
<roleRef xlink:type="simple" xlink:href="btmd-20221231.xsd#PropertyAndEquipmentNetTables" roleURI="http://haymaker.com/role/PropertyAndEquipmentNetTables" />
<roleRef xlink:type="simple" xlink:href="btmd-20221231.xsd#CapitalizedSoftwareNetTables" roleURI="http://haymaker.com/role/CapitalizedSoftwareNetTables" />
<roleRef xlink:type="simple" xlink:href="btmd-20221231.xsd#AccruedExpensesTables" roleURI="http://haymaker.com/role/AccruedExpensesTables" />
<roleRef xlink:type="simple" xlink:href="btmd-20221231.xsd#LongTermDebtTables" roleURI="http://haymaker.com/role/LongTermDebtTables" />
<roleRef xlink:type="simple" xlink:href="btmd-20221231.xsd#FairValueMeasurementsTables" roleURI="http://haymaker.com/role/FairValueMeasurementsTables" />
<roleRef xlink:type="simple" xlink:href="btmd-20221231.xsd#ShareBasedCompensationTables" roleURI="http://haymaker.com/role/ShareBasedCompensationTables" />
<roleRef xlink:type="simple" xlink:href="btmd-20221231.xsd#LeasesTables" roleURI="http://haymaker.com/role/LeasesTables" />
<roleRef xlink:type="simple" xlink:href="btmd-20221231.xsd#IncomeTaxesTables" roleURI="http://haymaker.com/role/IncomeTaxesTables" />
<roleRef xlink:type="simple" xlink:href="btmd-20221231.xsd#NetLossPerCommonShareTables" roleURI="http://haymaker.com/role/NetLossPerCommonShareTables" />
<roleRef xlink:type="simple" xlink:href="btmd-20221231.xsd#SummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" roleURI="http://haymaker.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" />
<roleRef xlink:type="simple" xlink:href="btmd-20221231.xsd#SummaryOfSignificantAccountingPoliciesSummaryOfRollforwardOfTheAllowanceForDoubtfulAccountsDetails" roleURI="http://haymaker.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfRollforwardOfTheAllowanceForDoubtfulAccountsDetails" />
<roleRef xlink:type="simple" xlink:href="btmd-20221231.xsd#SummaryOfSignificantAccountingPoliciesSummaryOfTotalOtherCurrentAssetsDetails" roleURI="http://haymaker.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfTotalOtherCurrentAssetsDetails" />
<roleRef xlink:type="simple" xlink:href="btmd-20221231.xsd#SummaryOfSignificantAccountingPoliciesSummaryOfEstimatedUsefulLivesOfPropertyAndEquipmentDetails" roleURI="http://haymaker.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfEstimatedUsefulLivesOfPropertyAndEquipmentDetails" />
<roleRef xlink:type="simple" xlink:href="btmd-20221231.xsd#SummaryOfSignificantAccountingPoliciesSummaryOfMembersEquityUnitsIssuedAndOutstandingDetails" roleURI="http://haymaker.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfMembersEquityUnitsIssuedAndOutstandingDetails" />
<roleRef xlink:type="simple" xlink:href="btmd-20221231.xsd#SummaryOfSignificantAccountingPoliciesSummaryOfCommonStockIssuedAndOutstandingDetails" roleURI="http://haymaker.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfCommonStockIssuedAndOutstandingDetails" />
<roleRef xlink:type="simple" xlink:href="btmd-20221231.xsd#BusinessCombinationAdditionalInformationDetails" roleURI="http://haymaker.com/role/BusinessCombinationAdditionalInformationDetails" />
<roleRef xlink:type="simple" xlink:href="btmd-20221231.xsd#RevenueRecognitionScheduleOfRevenuesRecognizedForEachRevenueStreamDetails" roleURI="http://haymaker.com/role/RevenueRecognitionScheduleOfRevenuesRecognizedForEachRevenueStreamDetails" />
<roleRef xlink:type="simple" xlink:href="btmd-20221231.xsd#RevenueRecognitionScheduleOfRevenuesRecognizedByGeographicRegionDetails" roleURI="http://haymaker.com/role/RevenueRecognitionScheduleOfRevenuesRecognizedByGeographicRegionDetails" />
<roleRef xlink:type="simple" xlink:href="btmd-20221231.xsd#RevenueRecognitionSummaryOfSignificantChangesInContractLiabilityBalancesDetails" roleURI="http://haymaker.com/role/RevenueRecognitionSummaryOfSignificantChangesInContractLiabilityBalancesDetails" />
<roleRef xlink:type="simple" xlink:href="btmd-20221231.xsd#RevenueRecognitionSummaryOfConsiderationAllocatedToPerformanceObligationsDetails" roleURI="http://haymaker.com/role/RevenueRecognitionSummaryOfConsiderationAllocatedToPerformanceObligationsDetails" />
<roleRef xlink:type="simple" xlink:href="btmd-20221231.xsd#RevenueRecognitionAdditionalInformationDetails" roleURI="http://haymaker.com/role/RevenueRecognitionAdditionalInformationDetails" />
<roleRef xlink:type="simple" xlink:href="btmd-20221231.xsd#InventoryNetScheduleOfInventoryNetDetails" roleURI="http://haymaker.com/role/InventoryNetScheduleOfInventoryNetDetails" />
<roleRef xlink:type="simple" xlink:href="btmd-20221231.xsd#PropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetails" roleURI="http://haymaker.com/role/PropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetails" />
<roleRef xlink:type="simple" xlink:href="btmd-20221231.xsd#PropertyAndEquipmentNetAdditionalInformationDetails" roleURI="http://haymaker.com/role/PropertyAndEquipmentNetAdditionalInformationDetails" />
<roleRef xlink:type="simple" xlink:href="btmd-20221231.xsd#CapitalizedSoftwareNetSummaryOfCapitalizedSoftwareNetDetails" roleURI="http://haymaker.com/role/CapitalizedSoftwareNetSummaryOfCapitalizedSoftwareNetDetails" />
<roleRef xlink:type="simple" xlink:href="btmd-20221231.xsd#CapitalizedSoftwareNetAdditionalInformationDetails" roleURI="http://haymaker.com/role/CapitalizedSoftwareNetAdditionalInformationDetails" />
<roleRef xlink:type="simple" xlink:href="btmd-20221231.xsd#AccruedExpensesScheduleOfAccruedExpensesDetails" roleURI="http://haymaker.com/role/AccruedExpensesScheduleOfAccruedExpensesDetails" />
<roleRef xlink:type="simple" xlink:href="btmd-20221231.xsd#LongTermDebtAdditionalInformationDetails" roleURI="http://haymaker.com/role/LongTermDebtAdditionalInformationDetails" />
<roleRef xlink:type="simple" xlink:href="btmd-20221231.xsd#LongTermDebtScheduleOfOutstandingDebtDetails" roleURI="http://haymaker.com/role/LongTermDebtScheduleOfOutstandingDebtDetails" />
<roleRef xlink:type="simple" xlink:href="btmd-20221231.xsd#LongTermDebtScheduleOfFutureMaturitiesOfLongTermDebtDetails" roleURI="http://haymaker.com/role/LongTermDebtScheduleOfFutureMaturitiesOfLongTermDebtDetails" />
<roleRef xlink:type="simple" xlink:href="btmd-20221231.xsd#WarrantLiabilityAdditionalInformationDetails" roleURI="http://haymaker.com/role/WarrantLiabilityAdditionalInformationDetails" />
<roleRef xlink:type="simple" xlink:href="btmd-20221231.xsd#EarnoutLiabilityAdditionalInformationDetails" roleURI="http://haymaker.com/role/EarnoutLiabilityAdditionalInformationDetails" />
<roleRef xlink:type="simple" xlink:href="btmd-20221231.xsd#FairValueMeasurementsScheduleOfFairValueHierarchyForFinancialAssetsAndLiabilitiesDetails" roleURI="http://haymaker.com/role/FairValueMeasurementsScheduleOfFairValueHierarchyForFinancialAssetsAndLiabilitiesDetails" />
<roleRef xlink:type="simple" xlink:href="btmd-20221231.xsd#FairValueMeasurementsSummaryOfSignificantInputsToMonteCarloSimulationForFairValueOfPrivatePlacementWarrantsDetails" roleURI="http://haymaker.com/role/FairValueMeasurementsSummaryOfSignificantInputsToMonteCarloSimulationForFairValueOfPrivatePlacementWarrantsDetails" />
<roleRef xlink:type="simple" xlink:href="btmd-20221231.xsd#FairValueMeasurementsSummaryOfSignificantInputsToMonteCarloSimulationForFairValueOfEarnoutLiabilityDetails" roleURI="http://haymaker.com/role/FairValueMeasurementsSummaryOfSignificantInputsToMonteCarloSimulationForFairValueOfEarnoutLiabilityDetails" />
<roleRef xlink:type="simple" xlink:href="btmd-20221231.xsd#FairValueMeasurementsSummaryOfChangesInTheFairValueOfCompanysLevel3FinancialInstrumentsDetails" roleURI="http://haymaker.com/role/FairValueMeasurementsSummaryOfChangesInTheFairValueOfCompanysLevel3FinancialInstrumentsDetails" />
<roleRef xlink:type="simple" xlink:href="btmd-20221231.xsd#NoncontrollingInterestAdditionalInformationDetails" roleURI="http://haymaker.com/role/NoncontrollingInterestAdditionalInformationDetails" />
<roleRef xlink:type="simple" xlink:href="btmd-20221231.xsd#ShareBasedCompensationAdditionalInformationDetails" roleURI="http://haymaker.com/role/ShareBasedCompensationAdditionalInformationDetails" />
<roleRef xlink:type="simple" xlink:href="btmd-20221231.xsd#ShareBasedCompensationSummaryOfRestrictedStockUnitActivityDetails" roleURI="http://haymaker.com/role/ShareBasedCompensationSummaryOfRestrictedStockUnitActivityDetails" />
<roleRef xlink:type="simple" xlink:href="btmd-20221231.xsd#ShareBasedCompensationSummaryOfStockOptionActivityDetails" roleURI="http://haymaker.com/role/ShareBasedCompensationSummaryOfStockOptionActivityDetails" />
<roleRef xlink:type="simple" xlink:href="btmd-20221231.xsd#ShareBasedCompensationSummaryOfWeightedAverageAssumptionsUsedToEstimateFairValueOfStockOptionsGrantedDetails" roleURI="http://haymaker.com/role/ShareBasedCompensationSummaryOfWeightedAverageAssumptionsUsedToEstimateFairValueOfStockOptionsGrantedDetails" />
<roleRef xlink:type="simple" xlink:href="btmd-20221231.xsd#LeasesAdditionalInformationDetails" roleURI="http://haymaker.com/role/LeasesAdditionalInformationDetails" />
<roleRef xlink:type="simple" xlink:href="btmd-20221231.xsd#LeasesSummaryOfOperatingLeaseCostsRecognizedUnderAsc842AndSupplementalCashFlowInformationForLeasesDetails" roleURI="http://haymaker.com/role/LeasesSummaryOfOperatingLeaseCostsRecognizedUnderAsc842AndSupplementalCashFlowInformationForLeasesDetails" />
<roleRef xlink:type="simple" xlink:href="btmd-20221231.xsd#LeasesSummaryBalanceSheetClassificationOfOperatingLeasesAndWeightedAverageRemainingLeaseTermAndDiscountRateDetails" roleURI="http://haymaker.com/role/LeasesSummaryBalanceSheetClassificationOfOperatingLeasesAndWeightedAverageRemainingLeaseTermAndDiscountRateDetails" />
<roleRef xlink:type="simple" xlink:href="btmd-20221231.xsd#LeasesSummaryOfPaymentsByDateForOperatingLeaseDetails" roleURI="http://haymaker.com/role/LeasesSummaryOfPaymentsByDateForOperatingLeaseDetails" />
<roleRef xlink:type="simple" xlink:href="btmd-20221231.xsd#IncomeTaxesAdditionalInformationDetails" roleURI="http://haymaker.com/role/IncomeTaxesAdditionalInformationDetails" />
<roleRef xlink:type="simple" xlink:href="btmd-20221231.xsd#IncomeTaxesScheduleOfIncomeLossBeforeProvisionForIncomeTaxesDetails" roleURI="http://haymaker.com/role/IncomeTaxesScheduleOfIncomeLossBeforeProvisionForIncomeTaxesDetails" />
<roleRef xlink:type="simple" xlink:href="btmd-20221231.xsd#IncomeTaxesScheduleOfIncomeTaxProvisionDetails" roleURI="http://haymaker.com/role/IncomeTaxesScheduleOfIncomeTaxProvisionDetails" />
<roleRef xlink:type="simple" xlink:href="btmd-20221231.xsd#IncomeTaxesScheduleOfReconciliationOfTheFederalIncomeTaxRateToTheCompanyEffectiveTaxRateDetails" roleURI="http://haymaker.com/role/IncomeTaxesScheduleOfReconciliationOfTheFederalIncomeTaxRateToTheCompanyEffectiveTaxRateDetails" />
<roleRef xlink:type="simple" xlink:href="btmd-20221231.xsd#IncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails" roleURI="http://haymaker.com/role/IncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails" />
<roleRef xlink:type="simple" xlink:href="btmd-20221231.xsd#NetLossPerCommonShareScheduleOfComputationOfNetLossPerCommonShareDetails" roleURI="http://haymaker.com/role/NetLossPerCommonShareScheduleOfComputationOfNetLossPerCommonShareDetails" />
<roleRef xlink:type="simple" xlink:href="btmd-20221231.xsd#NetLossPerCommonShareScheduleOfComputationOfDilutedWeightedAverageSharesOutstandingDetails" roleURI="http://haymaker.com/role/NetLossPerCommonShareScheduleOfComputationOfDilutedWeightedAverageSharesOutstandingDetails" />
<roleRef xlink:type="simple" xlink:href="btmd-20221231.xsd#CommitmentsAndContingenciesAdditionalInformationDetails" roleURI="http://haymaker.com/role/CommitmentsAndContingenciesAdditionalInformationDetails" />
<roleRef xlink:type="simple" xlink:href="btmd-20221231.xsd#RelatedPartyTransactionsAdditionalInformationDetails" roleURI="http://haymaker.com/role/RelatedPartyTransactionsAdditionalInformationDetails" />
<presentationLink xlink:type="extended" xlink:role="http://haymaker.com/role/Cover">
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract" xlink:label="loc_dei_CoverAbstract_101" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentInformationTable" xlink:label="loc_dei_DocumentInformationTable_149" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_101" xlink:to="loc_dei_DocumentInformationTable_149" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_107" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationTable_149" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_107" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_103" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_107" xlink:to="loc_us-gaap_EquityComponentDomain_103" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_110" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationTable_149" xlink:to="loc_us-gaap_StatementClassOfStockAxis_110" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_105" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_110" xlink:to="loc_us-gaap_ClassOfStockDomain_105" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressesAddressTypeAxis" xlink:label="loc_dei_EntityAddressesAddressTypeAxis_1242" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationTable_149" xlink:to="loc_dei_EntityAddressesAddressTypeAxis_1242" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AddressTypeDomain" xlink:label="loc_dei_AddressTypeDomain_1243" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityAddressesAddressTypeAxis_1242" xlink:to="loc_dei_AddressTypeDomain_1243" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_BusinessContactMember" xlink:label="loc_dei_BusinessContactMember_1244" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_AddressTypeDomain_1243" xlink:to="loc_dei_BusinessContactMember_1244" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentInformationLineItems" xlink:label="loc_dei_DocumentInformationLineItems_112" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationTable_149" xlink:to="loc_dei_DocumentInformationLineItems_112" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType" xlink:label="loc_dei_DocumentType_104" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_112" xlink:to="loc_dei_DocumentType_104" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag" xlink:label="loc_dei_AmendmentFlag_111" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_112" xlink:to="loc_dei_AmendmentFlag_111" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName" xlink:label="loc_dei_EntityRegistrantName_117" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_112" xlink:to="loc_dei_EntityRegistrantName_117" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey" xlink:label="loc_dei_EntityCentralIndexKey_118" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_112" xlink:to="loc_dei_EntityCentralIndexKey_118" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory" xlink:label="loc_dei_EntityFilerCategory_122" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_112" xlink:to="loc_dei_EntityFilerCategory_122" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness" xlink:label="loc_dei_EntitySmallBusiness_123" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_112" xlink:to="loc_dei_EntitySmallBusiness_123" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_dei_EntityEmergingGrowthCompany_126" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_112" xlink:to="loc_dei_EntityEmergingGrowthCompany_126" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityExTransitionPeriod" xlink:label="loc_dei_EntityExTransitionPeriod_127" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_112" xlink:to="loc_dei_EntityExTransitionPeriod_127" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_dei_EntityIncorporationStateCountryCode_133" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_112" xlink:to="loc_dei_EntityIncorporationStateCountryCode_133" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_dei_EntityTaxIdentificationNumber_134" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_112" xlink:to="loc_dei_EntityTaxIdentificationNumber_134" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_dei_EntityAddressAddressLine1_135" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_112" xlink:to="loc_dei_EntityAddressAddressLine1_135" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_dei_EntityAddressCityOrTown_137" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_112" xlink:to="loc_dei_EntityAddressCityOrTown_137" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_dei_EntityAddressStateOrProvince_138" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_112" xlink:to="loc_dei_EntityAddressStateOrProvince_138" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_dei_EntityAddressPostalZipCode_139" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_112" xlink:to="loc_dei_EntityAddressPostalZipCode_139" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode" xlink:label="loc_dei_CityAreaCode_140" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_112" xlink:to="loc_dei_CityAreaCode_140" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber" xlink:label="loc_dei_LocalPhoneNumber_141" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_112" xlink:to="loc_dei_LocalPhoneNumber_141" use="optional" order="25" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityPrimarySicNumber" xlink:label="loc_dei_EntityPrimarySicNumber_1240" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_112" xlink:to="loc_dei_EntityPrimarySicNumber_1240" use="optional" order="26" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_ContactPersonnelName" xlink:label="loc_dei_ContactPersonnelName_1241" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_112" xlink:to="loc_dei_ContactPersonnelName_1241" use="optional" order="27" preferredLabel="http://www.xbrl.org/2003/role/label" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://haymaker.com/role/ConsolidatedBalanceSheets">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_151" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_153" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_151" xlink:to="loc_us-gaap_StatementTable_153" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_152" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_153" xlink:to="loc_us-gaap_StatementClassOfStockAxis_152" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_155" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_152" xlink:to="loc_us-gaap_ClassOfStockDomain_155" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonClassAMember" xlink:label="loc_us-gaap_CommonClassAMember_154" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_155" xlink:to="loc_us-gaap_CommonClassAMember_154" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonClassBMember" xlink:label="loc_us-gaap_CommonClassBMember_163" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_155" xlink:to="loc_us-gaap_CommonClassBMember_163" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="btmd-20221231.xsd#btmd_CommonClassVMember" xlink:label="loc_btmd_CommonClassVMember_170" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_155" xlink:to="loc_btmd_CommonClassVMember_170" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_162" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_153" xlink:to="loc_us-gaap_StatementLineItems_162" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaap_AssetsAbstract_156" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_162" xlink:to="loc_us-gaap_AssetsAbstract_156" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaap_AssetsCurrentAbstract_158" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_156" xlink:to="loc_us-gaap_AssetsCurrentAbstract_158" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Cash" xlink:label="loc_us-gaap_Cash_160" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_158" xlink:to="loc_us-gaap_Cash_160" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_168" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_158" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_168" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNet" xlink:label="loc_us-gaap_InventoryNet_174" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_158" xlink:to="loc_us-gaap_InventoryNet_174" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_179" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_158" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_179" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent_184" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_158" xlink:to="loc_us-gaap_AssetsCurrent_184" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_166" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_156" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_166" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalizedComputerSoftwareNet" xlink:label="loc_us-gaap_CapitalizedComputerSoftwareNet_172" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_156" xlink:to="loc_us-gaap_CapitalizedComputerSoftwareNet_172" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_177" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_156" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_177" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxAssetsNet" xlink:label="loc_us-gaap_DeferredIncomeTaxAssetsNet_182" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_156" xlink:to="loc_us-gaap_DeferredIncomeTaxAssetsNet_182" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets_187" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_156" xlink:to="loc_us-gaap_Assets_187" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_164" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_162" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_164" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_159" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_164" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_159" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaap_AccountsPayableCurrent_161" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_159" xlink:to="loc_us-gaap_AccountsPayableCurrent_161" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_169" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_159" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_169" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtCurrent" xlink:label="loc_us-gaap_LongTermDebtCurrent_175" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_159" xlink:to="loc_us-gaap_LongTermDebtCurrent_175" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityCurrent" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_180" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_159" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_180" use="optional" order="25" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_185" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_159" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_185" use="optional" order="26" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent_189" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_159" xlink:to="loc_us-gaap_LiabilitiesCurrent_189" use="optional" order="27" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtNoncurrent" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_167" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_164" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_167" use="optional" order="28" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_173" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_164" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_173" use="optional" order="29" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_178" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_164" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_178" use="optional" order="30" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantsAndRightsOutstanding" xlink:label="loc_us-gaap_WarrantsAndRightsOutstanding_183" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_164" xlink:to="loc_us-gaap_WarrantsAndRightsOutstanding_183" use="optional" order="31" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeLiabilitiesNoncurrent" xlink:label="loc_us-gaap_DerivativeLiabilitiesNoncurrent_188" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_164" xlink:to="loc_us-gaap_DerivativeLiabilitiesNoncurrent_188" use="optional" order="32" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaap_Liabilities_191" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_164" xlink:to="loc_us-gaap_Liabilities_191" use="optional" order="33" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaap_CommitmentsAndContingencies_193" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_164" xlink:to="loc_us-gaap_CommitmentsAndContingencies_193" use="optional" order="34" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_194" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_164" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_194" use="optional" order="35" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaap_PreferredStockValue_157" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_194" xlink:to="loc_us-gaap_PreferredStockValue_157" use="optional" order="36" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue_165" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_194" xlink:to="loc_us-gaap_CommonStockValue_165" use="optional" order="37" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaap_AdditionalPaidInCapital_171" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_194" xlink:to="loc_us-gaap_AdditionalPaidInCapital_171" use="optional" order="38" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_176" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_194" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_176" use="optional" order="39" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_181" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_194" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_181" use="optional" order="40" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_186" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_194" xlink:to="loc_us-gaap_StockholdersEquity_186" use="optional" order="41" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MinorityInterest" xlink:label="loc_us-gaap_MinorityInterest_190" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_194" xlink:to="loc_us-gaap_MinorityInterest_190" use="optional" order="42" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_192" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_194" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_192" use="optional" order="43" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_195" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_164" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_195" use="optional" order="44" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://haymaker.com/role/ConsolidatedBalanceSheetsParenthetical">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_197" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_199" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_197" xlink:to="loc_us-gaap_StatementTable_199" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_198" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_199" xlink:to="loc_us-gaap_StatementClassOfStockAxis_198" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_201" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_198" xlink:to="loc_us-gaap_ClassOfStockDomain_201" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonClassAMember" xlink:label="loc_us-gaap_CommonClassAMember_200" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_201" xlink:to="loc_us-gaap_CommonClassAMember_200" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonClassBMember" xlink:label="loc_us-gaap_CommonClassBMember_204" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_201" xlink:to="loc_us-gaap_CommonClassBMember_204" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="btmd-20221231.xsd#btmd_CommonClassVMember" xlink:label="loc_btmd_CommonClassVMember_206" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_201" xlink:to="loc_btmd_CommonClassVMember_206" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="btmd-20221231.xsd#btmd_ClassAMember" xlink:label="loc_btmd_ClassAMember_208" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_201" xlink:to="loc_btmd_ClassAMember_208" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="btmd-20221231.xsd#btmd_ClassAaUnitsMember" xlink:label="loc_btmd_ClassAaUnitsMember_210" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_201" xlink:to="loc_btmd_ClassAaUnitsMember_210" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="btmd-20221231.xsd#btmd_ClassAaaUnitsMember" xlink:label="loc_btmd_ClassAaaUnitsMember_212" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_201" xlink:to="loc_btmd_ClassAaaUnitsMember_212" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="btmd-20221231.xsd#btmd_ClassAaaaUnitsMember" xlink:label="loc_btmd_ClassAaaaUnitsMember_214" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_201" xlink:to="loc_btmd_ClassAaaaUnitsMember_214" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_203" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_199" xlink:to="loc_us-gaap_StatementLineItems_203" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_202" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_203" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_202" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_205" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_203" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_205" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaap_PreferredStockSharesIssued_207" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_203" xlink:to="loc_us-gaap_PreferredStockSharesIssued_207" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_209" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_203" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_209" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorizedUnlimited" xlink:label="loc_us-gaap_CommonStockSharesAuthorizedUnlimited_211" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_203" xlink:to="loc_us-gaap_CommonStockSharesAuthorizedUnlimited_211" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockNoParValue" xlink:label="loc_us-gaap_CommonStockNoParValue_213" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_203" xlink:to="loc_us-gaap_CommonStockNoParValue_213" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_215" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_203" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_215" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_216" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_203" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_216" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaap_CommonStockSharesIssued_217" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_203" xlink:to="loc_us-gaap_CommonStockSharesIssued_217" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_218" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_203" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_218" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://haymaker.com/role/ConsolidatedStatementsOfIncomeAndComprehensiveIncome">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_us-gaap_IncomeStatementAbstract_220" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_225" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_220" xlink:to="loc_us-gaap_StatementTable_225" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srt_ProductOrServiceAxis_222" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_225" xlink:to="loc_srt_ProductOrServiceAxis_222" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_223" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_222" xlink:to="loc_srt_ProductsAndServicesDomain_223" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="btmd-20221231.xsd#btmd_ProductRevenueMember" xlink:label="loc_btmd_ProductRevenueMember_230" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_223" xlink:to="loc_btmd_ProductRevenueMember_230" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="btmd-20221231.xsd#btmd_ServiceRevenueMember" xlink:label="loc_btmd_ServiceRevenueMember_237" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_223" xlink:to="loc_btmd_ServiceRevenueMember_237" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_233" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_225" xlink:to="loc_us-gaap_StatementLineItems_233" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenuesAbstract" xlink:label="loc_us-gaap_RevenuesAbstract_226" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_233" xlink:to="loc_us-gaap_RevenuesAbstract_226" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_228" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesAbstract_226" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_228" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortizationAbstract" xlink:label="loc_us-gaap_CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortizationAbstract_235" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_233" xlink:to="loc_us-gaap_CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortizationAbstract_235" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization" xlink:label="loc_us-gaap_CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization_227" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortizationAbstract_235" xlink:to="loc_us-gaap_CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization_227" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SalesCommissionsAndFees" xlink:label="loc_us-gaap_SalesCommissionsAndFees_239" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_233" xlink:to="loc_us-gaap_SalesCommissionsAndFees_239" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketingExpense" xlink:label="loc_us-gaap_MarketingExpense_241" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_233" xlink:to="loc_us-gaap_MarketingExpense_241" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_243" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_233" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_243" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss_245" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_233" xlink:to="loc_us-gaap_OperatingIncomeLoss_245" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract_247" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_233" xlink:to="loc_us-gaap_NonoperatingIncomeExpenseAbstract_247" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:label="loc_us-gaap_InterestIncomeExpenseNonoperatingNet_229" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_247" xlink:to="loc_us-gaap_InterestIncomeExpenseNonoperatingNet_229" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="loc_us-gaap_FairValueAdjustmentOfWarrants_236" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_247" xlink:to="loc_us-gaap_FairValueAdjustmentOfWarrants_236" use="optional" order="17" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="btmd-20221231.xsd#btmd_GainLossFromChangeInFairValueOfEarnoutLiability" xlink:label="loc_btmd_GainLossFromChangeInFairValueOfEarnoutLiability_240" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_247" xlink:to="loc_btmd_GainLossFromChangeInFairValueOfEarnoutLiability_240" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_242" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_247" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_242" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncome" xlink:label="loc_us-gaap_OtherNonoperatingIncome_244" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_247" xlink:to="loc_us-gaap_OtherNonoperatingIncome_244" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_246" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_247" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_246" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_248" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_233" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_248" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_249" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_233" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_249" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaap_ProfitLoss_250" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_233" xlink:to="loc_us-gaap_ProfitLoss_250" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_251" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_233" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_251" use="optional" order="25" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_252" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_233" xlink:to="loc_us-gaap_NetIncomeLoss_252" use="optional" order="26" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossTaxPortionAttributableToParentAbstract" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossTaxPortionAttributableToParentAbstract_253" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_233" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossTaxPortionAttributableToParentAbstract_253" use="optional" order="27" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax_231" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossTaxPortionAttributableToParentAbstract_253" xlink:to="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax_231" use="optional" order="28" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_238" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossTaxPortionAttributableToParentAbstract_253" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_238" use="optional" order="29" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_254" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_233" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_254" use="optional" order="30" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaap_EarningsPerShareAbstract_255" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_233" xlink:to="loc_us-gaap_EarningsPerShareAbstract_255" use="optional" order="31" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic" xlink:label="loc_us-gaap_EarningsPerShareBasic_221" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_255" xlink:to="loc_us-gaap_EarningsPerShareBasic_221" use="optional" order="32" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="loc_us-gaap_EarningsPerShareDiluted_232" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_255" xlink:to="loc_us-gaap_EarningsPerShareDiluted_232" use="optional" order="33" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_256" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_233" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_256" use="optional" order="34" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_224" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_256" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_224" use="optional" order="35" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_234" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_256" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_234" use="optional" order="36" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://haymaker.com/role/ConsolidatedStatementsOfStockholdersEquityDeficit">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_258" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_261" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_258" xlink:to="loc_us-gaap_StatementTable_261" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_259" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_261" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_259" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_263" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_259" xlink:to="loc_us-gaap_EquityComponentDomain_263" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MemberUnitsMember" xlink:label="loc_us-gaap_MemberUnitsMember_267" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_263" xlink:to="loc_us-gaap_MemberUnitsMember_267" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_272" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_263" xlink:to="loc_us-gaap_CommonStockMember_272" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaap_RetainedEarningsMember_275" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_263" xlink:to="loc_us-gaap_RetainedEarningsMember_275" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_278" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_263" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_278" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ParentMember" xlink:label="loc_us-gaap_ParentMember_280" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_263" xlink:to="loc_us-gaap_ParentMember_280" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncontrollingInterestMember" xlink:label="loc_us-gaap_NoncontrollingInterestMember_282" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_263" xlink:to="loc_us-gaap_NoncontrollingInterestMember_282" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_268" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_261" xlink:to="loc_us-gaap_StatementClassOfStockAxis_268" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_265" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_268" xlink:to="loc_us-gaap_ClassOfStockDomain_265" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonClassAMember" xlink:label="loc_us-gaap_CommonClassAMember_262" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_265" xlink:to="loc_us-gaap_CommonClassAMember_262" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="btmd-20221231.xsd#btmd_CommonClassVMember" xlink:label="loc_btmd_CommonClassVMember_269" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_265" xlink:to="loc_btmd_CommonClassVMember_269" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RestatementAxis" xlink:label="loc_srt_RestatementAxis_273" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_261" xlink:to="loc_srt_RestatementAxis_273" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RestatementDomain" xlink:label="loc_srt_RestatementDomain_260" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RestatementAxis_273" xlink:to="loc_srt_RestatementDomain_260" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_276" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_261" xlink:to="loc_us-gaap_StatementLineItems_276" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PartnersCapitalAccountUnits" xlink:label="loc_us-gaap_PartnersCapitalAccountUnits_266" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_276" xlink:to="loc_us-gaap_PartnersCapitalAccountUnits_266" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_271" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_276" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_271" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DividendsCommonStock" xlink:label="loc_us-gaap_DividendsCommonStock_277" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_276" xlink:to="loc_us-gaap_DividendsCommonStock_277" use="optional" order="19" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaap_ProfitLoss_281" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_276" xlink:to="loc_us-gaap_ProfitLoss_281" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_283" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_276" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_283" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="btmd-20221231.xsd#btmd_PartnersCapitalAccountReverseRecapitalizationUnits" xlink:label="loc_btmd_PartnersCapitalAccountReverseRecapitalizationUnits_284" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_276" xlink:to="loc_btmd_PartnersCapitalAccountReverseRecapitalizationUnits_284" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="btmd-20221231.xsd#btmd_StockholdersEquityIncludingPortionAttributableToNonControllingInterestReverseRecapitalization" xlink:label="loc_btmd_StockholdersEquityIncludingPortionAttributableToNonControllingInterestReverseRecapitalization_285" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_276" xlink:to="loc_btmd_StockholdersEquityIncludingPortionAttributableToNonControllingInterestReverseRecapitalization_285" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="btmd-20221231.xsd#btmd_StockholdersEquityIncludingPortionAttributableToNonControllingInterestSharesReverseRecapitalization" xlink:label="loc_btmd_StockholdersEquityIncludingPortionAttributableToNonControllingInterestSharesReverseRecapitalization_286" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_276" xlink:to="loc_btmd_StockholdersEquityIncludingPortionAttributableToNonControllingInterestSharesReverseRecapitalization_286" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="btmd-20221231.xsd#btmd_StockholdersEquityAttributableToNonControllingInterestBusinessCombination" xlink:label="loc_btmd_StockholdersEquityAttributableToNonControllingInterestBusinessCombination_287" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_276" xlink:to="loc_btmd_StockholdersEquityAttributableToNonControllingInterestBusinessCombination_287" use="optional" order="25" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="btmd-20221231.xsd#btmd_StockholdersEquityBussinessCombinationCapitalizedTransactionCosts" xlink:label="loc_btmd_StockholdersEquityBussinessCombinationCapitalizedTransactionCosts_288" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_276" xlink:to="loc_btmd_StockholdersEquityBussinessCombinationCapitalizedTransactionCosts_288" use="optional" order="26" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_290" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_276" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_290" use="optional" order="27" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="btmd-20221231.xsd#btmd_StockIssuedDuringPeriodValueSettlementOfEquityRights" xlink:label="loc_btmd_StockIssuedDuringPeriodValueSettlementOfEquityRights_291" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_276" xlink:to="loc_btmd_StockIssuedDuringPeriodValueSettlementOfEquityRights_291" use="optional" order="28" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="btmd-20221231.xsd#btmd_StockIssuedDuringPeriodValueVestingOfRestrictedStockUnit" xlink:label="loc_btmd_StockIssuedDuringPeriodValueVestingOfRestrictedStockUnit_292" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_276" xlink:to="loc_btmd_StockIssuedDuringPeriodValueVestingOfRestrictedStockUnit_292" use="optional" order="29" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="btmd-20221231.xsd#btmd_StockIssuedDuringPeriodSharesVestingOfRestrictedStockUnit" xlink:label="loc_btmd_StockIssuedDuringPeriodSharesVestingOfRestrictedStockUnit_293" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_276" xlink:to="loc_btmd_StockIssuedDuringPeriodSharesVestingOfRestrictedStockUnit_293" use="optional" order="30" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_294" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_276" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_294" use="optional" order="31" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_295" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_276" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_295" use="optional" order="32" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PartnersCapitalAccountUnits" xlink:label="loc_us-gaap_PartnersCapitalAccountUnits_296" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_276" xlink:to="loc_us-gaap_PartnersCapitalAccountUnits_296" use="optional" order="33" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_297" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_276" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_297" use="optional" order="34" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaap_SharesOutstanding_298" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_276" xlink:to="loc_us-gaap_SharesOutstanding_298" use="optional" order="35" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://haymaker.com/role/ConsolidatedStatementsOfCashFlows">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_300" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_302" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_300" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_302" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaap_ProfitLoss_304" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_302" xlink:to="loc_us-gaap_ProfitLoss_304" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_312" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_302" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_312" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_306" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_312" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_306" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProvisionForDoubtfulAccounts" xlink:label="loc_us-gaap_ProvisionForDoubtfulAccounts_314" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_312" xlink:to="loc_us-gaap_ProvisionForDoubtfulAccounts_314" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfFinancingCosts" xlink:label="loc_us-gaap_AmortizationOfFinancingCosts_321" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_312" xlink:to="loc_us-gaap_AmortizationOfFinancingCosts_321" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryWriteDown" xlink:label="loc_us-gaap_InventoryWriteDown_325" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_312" xlink:to="loc_us-gaap_InventoryWriteDown_325" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="btmd-20221231.xsd#btmd_NonCashLeaseExpense" xlink:label="loc_btmd_NonCashLeaseExpense_329" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_312" xlink:to="loc_btmd_NonCashLeaseExpense_329" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="btmd-20221231.xsd#btmd_NonCashSponsorShareTransfers" xlink:label="loc_btmd_NonCashSponsorShareTransfers_333" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_312" xlink:to="loc_btmd_NonCashSponsorShareTransfers_333" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="btmd-20221231.xsd#btmd_NonCashFeesUnderSepa" xlink:label="loc_btmd_NonCashFeesUnderSepa_337" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_312" xlink:to="loc_btmd_NonCashFeesUnderSepa_337" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation_341" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_312" xlink:to="loc_us-gaap_ShareBasedCompensation_341" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="loc_us-gaap_FairValueAdjustmentOfWarrants_344" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_312" xlink:to="loc_us-gaap_FairValueAdjustmentOfWarrants_344" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="btmd-20221231.xsd#btmd_FairValueAdjustmentOfEarnoutLiability" xlink:label="loc_btmd_FairValueAdjustmentOfEarnoutLiability_346" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_312" xlink:to="loc_btmd_FairValueAdjustmentOfEarnoutLiability_346" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_348" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_312" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_348" use="optional" order="14" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxesAndTaxCredits" xlink:label="loc_us-gaap_DeferredIncomeTaxesAndTaxCredits_350" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_312" xlink:to="loc_us-gaap_DeferredIncomeTaxesAndTaxCredits_350" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_351" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_312" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_351" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_308" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_351" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_308" use="optional" order="17" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_316" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_351" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_316" use="optional" order="18" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherCurrentAssets" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherCurrentAssets_322" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_351" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherCurrentAssets_322" use="optional" order="19" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_326" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_351" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_326" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:label="loc_us-gaap_IncreaseDecreaseInDeferredRevenue_330" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_351" xlink:to="loc_us-gaap_IncreaseDecreaseInDeferredRevenue_330" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_334" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_351" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_334" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_338" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_351" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_338" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_319" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_302" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_319" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_310" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_300" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_310" use="optional" order="25" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_305" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_310" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_305" use="optional" order="26" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForSoftware" xlink:label="loc_us-gaap_PaymentsForSoftware_313" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_310" xlink:to="loc_us-gaap_PaymentsForSoftware_313" use="optional" order="27" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_320" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_310" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_320" use="optional" order="28" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_318" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_300" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_318" use="optional" order="29" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="btmd-20221231.xsd#btmd_ProceedsFromBusinessCombination" xlink:label="loc_btmd_ProceedsFromBusinessCombination_301" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_318" xlink:to="loc_btmd_ProceedsFromBusinessCombination_301" use="optional" order="30" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="btmd-20221231.xsd#btmd_PrincipalRepaymentsOnTermLoan" xlink:label="loc_btmd_PrincipalRepaymentsOnTermLoan_309" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_318" xlink:to="loc_btmd_PrincipalRepaymentsOnTermLoan_309" use="optional" order="31" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="btmd-20221231.xsd#btmd_BorrowingsOnTermLoan" xlink:label="loc_btmd_BorrowingsOnTermLoan_317" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_318" xlink:to="loc_btmd_BorrowingsOnTermLoan_317" use="optional" order="32" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfDebtExtinguishmentCosts" xlink:label="loc_us-gaap_PaymentsOfDebtExtinguishmentCosts_323" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_318" xlink:to="loc_us-gaap_PaymentsOfDebtExtinguishmentCosts_323" use="optional" order="33" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfDebtIssuanceCosts" xlink:label="loc_us-gaap_PaymentsOfDebtIssuanceCosts_327" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_318" xlink:to="loc_us-gaap_PaymentsOfDebtIssuanceCosts_327" use="optional" order="34" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="btmd-20221231.xsd#btmd_PaymentsOfSettlementOfPhantomEquityRight" xlink:label="loc_btmd_PaymentsOfSettlementOfPhantomEquityRight_331" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_318" xlink:to="loc_btmd_PaymentsOfSettlementOfPhantomEquityRight_331" use="optional" order="35" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="btmd-20221231.xsd#btmd_PaymentsOfSettlementOfRestrictedStockUnits" xlink:label="loc_btmd_PaymentsOfSettlementOfRestrictedStockUnits_335" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_318" xlink:to="loc_btmd_PaymentsOfSettlementOfRestrictedStockUnits_335" use="optional" order="36" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfDividends" xlink:label="loc_us-gaap_PaymentsOfDividends_339" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_318" xlink:to="loc_us-gaap_PaymentsOfDividends_339" use="optional" order="37" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts_342" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_318" xlink:to="loc_us-gaap_PaymentsOfStockIssuanceCosts_342" use="optional" order="38" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="btmd-20221231.xsd#btmd_ProceedsFromIssuanceOfSharesUnderSepa" xlink:label="loc_btmd_ProceedsFromIssuanceOfSharesUnderSepa_345" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_318" xlink:to="loc_btmd_ProceedsFromIssuanceOfSharesUnderSepa_345" use="optional" order="39" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="btmd-20221231.xsd#btmd_PaymentsToSEPATransactionCosts" xlink:label="loc_btmd_PaymentsToSEPATransactionCosts_347" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_318" xlink:to="loc_btmd_PaymentsToSEPATransactionCosts_347" use="optional" order="40" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_349" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_318" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_349" use="optional" order="41" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_324" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_300" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_324" use="optional" order="42" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_328" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_300" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_328" use="optional" order="43" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_332" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_300" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_332" use="optional" order="44" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_336" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_300" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_336" use="optional" order="45" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract_340" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_300" xlink:to="loc_us-gaap_SupplementalCashFlowInformationAbstract_340" use="optional" order="46" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestPaidNet" xlink:label="loc_us-gaap_InterestPaidNet_303" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_340" xlink:to="loc_us-gaap_InterestPaidNet_303" use="optional" order="47" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxesPaid" xlink:label="loc_us-gaap_IncomeTaxesPaid_311" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_340" xlink:to="loc_us-gaap_IncomeTaxesPaid_311" use="optional" order="48" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_343" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_300" xlink:to="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_343" use="optional" order="49" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:label="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_307" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_343" xlink:to="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_307" use="optional" order="50" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="btmd-20221231.xsd#btmd_NonCashSEPATransactionCosts" xlink:label="loc_btmd_NonCashSEPATransactionCosts_315" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_343" xlink:to="loc_btmd_NonCashSEPATransactionCosts_315" use="optional" order="51" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://haymaker.com/role/DescriptionOfBusinessAndBasisOfPresentation">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_353" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:label="loc_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_354" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_353" xlink:to="loc_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_354" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://haymaker.com/role/SummaryOfSignificantAccountingPolicies">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_356" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock_357" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_356" xlink:to="loc_us-gaap_SignificantAccountingPoliciesTextBlock_357" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://haymaker.com/role/BusinessCombination">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationsAbstract" xlink:label="loc_us-gaap_BusinessCombinationsAbstract_359" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationDisclosureTextBlock" xlink:label="loc_us-gaap_BusinessCombinationDisclosureTextBlock_360" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_359" xlink:to="loc_us-gaap_BusinessCombinationDisclosureTextBlock_360" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://haymaker.com/role/RevenueRecognition">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerAbstract" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_362" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerTextBlock_363" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_362" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerTextBlock_363" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://haymaker.com/role/InventoryNet">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryDisclosureAbstract" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_365" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryDisclosureTextBlock" xlink:label="loc_us-gaap_InventoryDisclosureTextBlock_366" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_365" xlink:to="loc_us-gaap_InventoryDisclosureTextBlock_366" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://haymaker.com/role/PropertyAndEquipmentNet">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_368" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_369" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_368" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_369" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://haymaker.com/role/CapitalizedSoftwareNet">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentAbstract" xlink:label="loc_us-gaap_ResearchAndDevelopmentAbstract_371" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock" xlink:label="loc_us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock_372" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentAbstract_371" xlink:to="loc_us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock_372" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://haymaker.com/role/AccruedExpenses">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_374" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:label="loc_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_375" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_374" xlink:to="loc_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_375" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://haymaker.com/role/LongTermDebt">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaap_DebtDisclosureAbstract_377" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="loc_us-gaap_DebtDisclosureTextBlock_378" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_377" xlink:to="loc_us-gaap_DebtDisclosureTextBlock_378" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://haymaker.com/role/WarrantLiability">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantsAndRightsNoteDisclosureAbstract" xlink:label="loc_us-gaap_WarrantsAndRightsNoteDisclosureAbstract_380" />
<loc xlink:type="locator" xlink:href="btmd-20221231.xsd#btmd_WarrantLiabilityTextBlock" xlink:label="loc_btmd_WarrantLiabilityTextBlock_381" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WarrantsAndRightsNoteDisclosureAbstract_380" xlink:to="loc_btmd_WarrantLiabilityTextBlock_381" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://haymaker.com/role/EarnoutLiability">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_383" />
<loc xlink:type="locator" xlink:href="btmd-20221231.xsd#btmd_EarnoutLiabilityTextBlock" xlink:label="loc_btmd_EarnoutLiabilityTextBlock_384" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_383" xlink:to="loc_btmd_EarnoutLiabilityTextBlock_384" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://haymaker.com/role/FairValueMeasurements">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_386" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock_387" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_386" xlink:to="loc_us-gaap_FairValueDisclosuresTextBlock_387" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://haymaker.com/role/NoncontrollingInterest">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncontrollingInterestAbstract" xlink:label="loc_us-gaap_NoncontrollingInterestAbstract_389" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MinorityInterestDisclosureTextBlock" xlink:label="loc_us-gaap_MinorityInterestDisclosureTextBlock_390" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncontrollingInterestAbstract_389" xlink:to="loc_us-gaap_MinorityInterestDisclosureTextBlock_390" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://haymaker.com/role/ShareBasedCompensation">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_392" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_393" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_392" xlink:to="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_393" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://haymaker.com/role/Leases">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract" xlink:label="loc_us-gaap_LeasesAbstract_395" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeasesTextBlock" xlink:label="loc_us-gaap_LesseeOperatingLeasesTextBlock_396" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_395" xlink:to="loc_us-gaap_LesseeOperatingLeasesTextBlock_396" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://haymaker.com/role/IncomeTaxes">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_398" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock_399" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_398" xlink:to="loc_us-gaap_IncomeTaxDisclosureTextBlock_399" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://haymaker.com/role/NetLossPerCommonShare">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaap_EarningsPerShareAbstract_401" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="loc_us-gaap_EarningsPerShareTextBlock_402" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_401" xlink:to="loc_us-gaap_EarningsPerShareTextBlock_402" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://haymaker.com/role/CommitmentsAndContingencies">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_404" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_405" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_404" xlink:to="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_405" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://haymaker.com/role/RelatedPartyTransactions">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_407" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_408" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_407" xlink:to="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_408" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://haymaker.com/role/SubsequentEvents">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaap_SubsequentEventsAbstract_410" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="loc_us-gaap_SubsequentEventsTextBlock_411" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventsAbstract_410" xlink:to="loc_us-gaap_SubsequentEventsTextBlock_411" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://haymaker.com/role/SummaryOfSignificantAccountingPoliciesPolicies">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_413" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UseOfEstimates" xlink:label="loc_us-gaap_UseOfEstimates_414" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_413" xlink:to="loc_us-gaap_UseOfEstimates_414" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:label="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_415" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_413" xlink:to="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_415" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:label="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock_416" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_413" xlink:to="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock_416" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_417" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_413" xlink:to="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_417" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy" xlink:label="loc_us-gaap_ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy_418" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_413" xlink:to="loc_us-gaap_ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy_418" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryPolicyTextBlock" xlink:label="loc_us-gaap_InventoryPolicyTextBlock_419" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_413" xlink:to="loc_us-gaap_InventoryPolicyTextBlock_419" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="btmd-20221231.xsd#btmd_OtherCurrentAssetsPolicyTextBlock" xlink:label="loc_btmd_OtherCurrentAssetsPolicyTextBlock_420" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_413" xlink:to="loc_btmd_OtherCurrentAssetsPolicyTextBlock_420" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_421" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_413" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_421" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InternalUseSoftwarePolicy" xlink:label="loc_us-gaap_InternalUseSoftwarePolicy_422" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_413" xlink:to="loc_us-gaap_InternalUseSoftwarePolicy_422" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:label="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_423" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_413" xlink:to="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_423" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeasesPolicyTextBlock" xlink:label="loc_us-gaap_LesseeLeasesPolicyTextBlock_424" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_413" xlink:to="loc_us-gaap_LesseeLeasesPolicyTextBlock_424" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock_425" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_413" xlink:to="loc_us-gaap_IncomeTaxPolicyTextBlock_425" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="btmd-20221231.xsd#btmd_DebtIssuanceCostsPolicyTextBlock" xlink:label="loc_btmd_DebtIssuanceCostsPolicyTextBlock_426" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_413" xlink:to="loc_btmd_DebtIssuanceCostsPolicyTextBlock_426" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="btmd-20221231.xsd#btmd_WarrantLiabilitiesPolicyTextBlock" xlink:label="loc_btmd_WarrantLiabilitiesPolicyTextBlock_427" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_413" xlink:to="loc_btmd_WarrantLiabilitiesPolicyTextBlock_427" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="btmd-20221231.xsd#btmd_EarnoutLiabilityPolicyTextBlock" xlink:label="loc_btmd_EarnoutLiabilityPolicyTextBlock_428" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_413" xlink:to="loc_btmd_EarnoutLiabilityPolicyTextBlock_428" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityPolicyTextBlock" xlink:label="loc_us-gaap_StockholdersEquityPolicyTextBlock_429" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_413" xlink:to="loc_us-gaap_StockholdersEquityPolicyTextBlock_429" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="btmd-20221231.xsd#btmd_StandbyEquityPurchaseAgreementPolicyTextBlock" xlink:label="loc_btmd_StandbyEquityPurchaseAgreementPolicyTextBlock_430" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_413" xlink:to="loc_btmd_StandbyEquityPurchaseAgreementPolicyTextBlock_430" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="btmd-20221231.xsd#btmd_NoncontrollingInterestPolicyTextBlock" xlink:label="loc_btmd_NoncontrollingInterestPolicyTextBlock_431" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_413" xlink:to="loc_btmd_NoncontrollingInterestPolicyTextBlock_431" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRecognitionPolicyTextBlock" xlink:label="loc_us-gaap_RevenueRecognitionPolicyTextBlock_432" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_413" xlink:to="loc_us-gaap_RevenueRecognitionPolicyTextBlock_432" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="btmd-20221231.xsd#btmd_CostOfRevenuePolicyTextBlock" xlink:label="loc_btmd_CostOfRevenuePolicyTextBlock_433" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_413" xlink:to="loc_btmd_CostOfRevenuePolicyTextBlock_433" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketRiskBenefitPolicyTextBlock" xlink:label="loc_us-gaap_MarketRiskBenefitPolicyTextBlock_434" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_413" xlink:to="loc_us-gaap_MarketRiskBenefitPolicyTextBlock_434" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock_435" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_413" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock_435" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PensionAndOtherPostretirementPlansPolicy" xlink:label="loc_us-gaap_PensionAndOtherPostretirementPlansPolicy_436" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_413" xlink:to="loc_us-gaap_PensionAndOtherPostretirementPlansPolicy_436" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_437" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_413" xlink:to="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_437" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommissionsPolicy" xlink:label="loc_us-gaap_CommissionsPolicy_438" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_413" xlink:to="loc_us-gaap_CommissionsPolicy_438" use="optional" order="25" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="loc_us-gaap_ConcentrationRiskCreditRisk_439" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_413" xlink:to="loc_us-gaap_ConcentrationRiskCreditRisk_439" use="optional" order="26" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_440" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_413" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_440" use="optional" order="27" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://haymaker.com/role/SummaryOfSignificantAccountingPoliciesTables">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_442" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableAllowanceForCreditLossTableTextBlock" xlink:label="loc_us-gaap_AccountsReceivableAllowanceForCreditLossTableTextBlock_443" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_442" xlink:to="loc_us-gaap_AccountsReceivableAllowanceForCreditLossTableTextBlock_443" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock_444" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_442" xlink:to="loc_us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock_444" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="btmd-20221231.xsd#btmd_DisclosureInTabularFormOfEstimatedUsefulLivesOfPropertyPlantAndEquipmentTableTextBlock" xlink:label="loc_btmd_DisclosureInTabularFormOfEstimatedUsefulLivesOfPropertyPlantAndEquipmentTableTextBlock_445" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_442" xlink:to="loc_btmd_DisclosureInTabularFormOfEstimatedUsefulLivesOfPropertyPlantAndEquipmentTableTextBlock_445" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCapitalUnitsTextBlock" xlink:label="loc_us-gaap_ScheduleOfCapitalUnitsTextBlock_446" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_442" xlink:to="loc_us-gaap_ScheduleOfCapitalUnitsTextBlock_446" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfStockByClassTextBlock" xlink:label="loc_us-gaap_ScheduleOfStockByClassTextBlock_447" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_442" xlink:to="loc_us-gaap_ScheduleOfStockByClassTextBlock_447" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://haymaker.com/role/RevenueRecognitionTables">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerAbstract" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_449" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:label="loc_us-gaap_DisaggregationOfRevenueTableTextBlock_450" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_449" xlink:to="loc_us-gaap_DisaggregationOfRevenueTableTextBlock_450" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:label="loc_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_451" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_449" xlink:to="loc_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_451" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="btmd-20221231.xsd#btmd_SummaryOfConsiderationAllocatedToPerformanceObligationsTableTextBlock" xlink:label="loc_btmd_SummaryOfConsiderationAllocatedToPerformanceObligationsTableTextBlock_452" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_449" xlink:to="loc_btmd_SummaryOfConsiderationAllocatedToPerformanceObligationsTableTextBlock_452" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://haymaker.com/role/InventoryNetTables">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryDisclosureAbstract" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_454" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_455" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_454" xlink:to="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_455" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://haymaker.com/role/PropertyAndEquipmentNetTables">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_457" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_458" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_457" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_458" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://haymaker.com/role/CapitalizedSoftwareNetTables">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentAbstract" xlink:label="loc_us-gaap_ResearchAndDevelopmentAbstract_460" />
<loc xlink:type="locator" xlink:href="btmd-20221231.xsd#btmd_SummaryOfCapitalizedSoftwareNetTableTextBlock" xlink:label="loc_btmd_SummaryOfCapitalizedSoftwareNetTableTextBlock_461" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentAbstract_460" xlink:to="loc_btmd_SummaryOfCapitalizedSoftwareNetTableTextBlock_461" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://haymaker.com/role/AccruedExpensesTables">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_463" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_464" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_463" xlink:to="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_464" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://haymaker.com/role/LongTermDebtTables">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaap_DebtDisclosureAbstract_466" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDebtTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfDebtTableTextBlock_467" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_466" xlink:to="loc_us-gaap_ScheduleOfDebtTableTextBlock_467" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_468" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_466" xlink:to="loc_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_468" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://haymaker.com/role/FairValueMeasurementsTables">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_470" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock_471" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_470" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock_471" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_472" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_470" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_472" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="btmd-20221231.xsd#btmd_ScheduleOfChangesInTheFairValueOfWarrantLiabilitiesTableTextBlock" xlink:label="loc_btmd_ScheduleOfChangesInTheFairValueOfWarrantLiabilitiesTableTextBlock_473" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_470" xlink:to="loc_btmd_ScheduleOfChangesInTheFairValueOfWarrantLiabilitiesTableTextBlock_473" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://haymaker.com/role/ShareBasedCompensationTables">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_475" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_476" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_475" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_476" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_477" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_475" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_477" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_478" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_475" xlink:to="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_478" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://haymaker.com/role/LeasesTables">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract" xlink:label="loc_us-gaap_LeasesAbstract_480" />
<loc xlink:type="locator" xlink:href="btmd-20221231.xsd#btmd_SummaryOfLeaseCostsRecognizedUnderAsc842AndSupplementalCashFlowInformationForLeasesTableTextBlock" xlink:label="loc_btmd_SummaryOfLeaseCostsRecognizedUnderAsc842AndSupplementalCashFlowInformationForLeasesTableTextBlock_481" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_480" xlink:to="loc_btmd_SummaryOfLeaseCostsRecognizedUnderAsc842AndSupplementalCashFlowInformationForLeasesTableTextBlock_481" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="btmd-20221231.xsd#btmd_SummaryBalanceSheetClassificationOfOperatingLeasesAndWeightedAverageRemainingLeaseTermAndDiscountRateTableTextBlock" xlink:label="loc_btmd_SummaryBalanceSheetClassificationOfOperatingLeasesAndWeightedAverageRemainingLeaseTermAndDiscountRateTableTextBlock_482" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_480" xlink:to="loc_btmd_SummaryBalanceSheetClassificationOfOperatingLeasesAndWeightedAverageRemainingLeaseTermAndDiscountRateTableTextBlock_482" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_483" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_480" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_483" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://haymaker.com/role/IncomeTaxesTables">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_485" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_486" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_485" xlink:to="loc_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_486" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_487" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_485" xlink:to="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_487" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_488" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_485" xlink:to="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_488" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_489" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_485" xlink:to="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_489" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://haymaker.com/role/NetLossPerCommonShareTables">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaap_EarningsPerShareAbstract_491" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_492" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_491" xlink:to="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_492" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_493" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_491" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_493" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://haymaker.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_503" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfProductInformationTable" xlink:label="loc_us-gaap_ScheduleOfProductInformationTable_527" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_503" xlink:to="loc_us-gaap_ScheduleOfProductInformationTable_527" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalUnitsByClassAxis" xlink:label="loc_us-gaap_CapitalUnitsByClassAxis_512" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfProductInformationTable_527" xlink:to="loc_us-gaap_CapitalUnitsByClassAxis_512" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalUnitClassDomain" xlink:label="loc_us-gaap_CapitalUnitClassDomain_507" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CapitalUnitsByClassAxis_512" xlink:to="loc_us-gaap_CapitalUnitClassDomain_507" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="btmd-20221231.xsd#btmd_ClassAVotingUnitsMember" xlink:label="loc_btmd_ClassAVotingUnitsMember_534" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CapitalUnitClassDomain_507" xlink:to="loc_btmd_ClassAVotingUnitsMember_534" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srt_ProductOrServiceAxis_536" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfProductInformationTable_527" xlink:to="loc_srt_ProductOrServiceAxis_536" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_505" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_536" xlink:to="loc_srt_ProductsAndServicesDomain_505" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="btmd-20221231.xsd#btmd_InventoryMember" xlink:label="loc_btmd_InventoryMember_530" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_505" xlink:to="loc_btmd_InventoryMember_530" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="btmd-20221231.xsd#btmd_NatureOfCustomerAxis" xlink:label="loc_btmd_NatureOfCustomerAxis_543" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfProductInformationTable_527" xlink:to="loc_btmd_NatureOfCustomerAxis_543" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="btmd-20221231.xsd#btmd_NatureOfCustomerDomain" xlink:label="loc_btmd_NatureOfCustomerDomain_504" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_btmd_NatureOfCustomerAxis_543" xlink:to="loc_btmd_NatureOfCustomerDomain_504" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="btmd-20221231.xsd#btmd_BioteMethodCustomerMember" xlink:label="loc_btmd_BioteMethodCustomerMember_514" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_btmd_NatureOfCustomerDomain_504" xlink:to="loc_btmd_BioteMethodCustomerMember_514" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="btmd-20221231.xsd#btmd_SourceOfRevenueAxis" xlink:label="loc_btmd_SourceOfRevenueAxis_545" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfProductInformationTable_527" xlink:to="loc_btmd_SourceOfRevenueAxis_545" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="btmd-20221231.xsd#btmd_SourceOfRevenueDomain" xlink:label="loc_btmd_SourceOfRevenueDomain_509" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_btmd_SourceOfRevenueAxis_545" xlink:to="loc_btmd_SourceOfRevenueDomain_509" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="btmd-20221231.xsd#btmd_ServiceRevenueMember" xlink:label="loc_btmd_ServiceRevenueMember_513" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_btmd_SourceOfRevenueDomain_509" xlink:to="loc_btmd_ServiceRevenueMember_513" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="btmd-20221231.xsd#btmd_ProductRevenueMember" xlink:label="loc_btmd_ProductRevenueMember_537" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_btmd_SourceOfRevenueDomain_509" xlink:to="loc_btmd_ProductRevenueMember_537" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="btmd-20221231.xsd#btmd_SourceOfServiceRevenueAxis" xlink:label="loc_btmd_SourceOfServiceRevenueAxis_547" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfProductInformationTable_527" xlink:to="loc_btmd_SourceOfServiceRevenueAxis_547" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="btmd-20221231.xsd#btmd_SourceOfServiceRevenueDomain" xlink:label="loc_btmd_SourceOfServiceRevenueDomain_515" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_btmd_SourceOfServiceRevenueAxis_547" xlink:to="loc_btmd_SourceOfServiceRevenueDomain_515" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="btmd-20221231.xsd#btmd_TrainingMember" xlink:label="loc_btmd_TrainingMember_510" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_btmd_SourceOfServiceRevenueDomain_515" xlink:to="loc_btmd_TrainingMember_510" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="btmd-20221231.xsd#btmd_ContractTermServicesMember" xlink:label="loc_btmd_ContractTermServicesMember_535" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_btmd_SourceOfServiceRevenueDomain_515" xlink:to="loc_btmd_ContractTermServicesMember_535" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="btmd-20221231.xsd#btmd_PalletProceduresMember" xlink:label="loc_btmd_PalletProceduresMember_542" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_btmd_SourceOfServiceRevenueDomain_515" xlink:to="loc_btmd_PalletProceduresMember_542" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_549" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfProductInformationTable_527" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_549" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_506" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_549" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_506" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditAvailabilityConcentrationRiskMember" xlink:label="loc_us-gaap_CreditAvailabilityConcentrationRiskMember_532" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_506" xlink:to="loc_us-gaap_CreditAvailabilityConcentrationRiskMember_532" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplierConcentrationRiskMember" xlink:label="loc_us-gaap_SupplierConcentrationRiskMember_541" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_506" xlink:to="loc_us-gaap_SupplierConcentrationRiskMember_541" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_551" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfProductInformationTable_527" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_551" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_529" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_551" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_529" use="optional" order="25" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesTotalMember" xlink:label="loc_us-gaap_LiabilitiesTotalMember_520" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_529" xlink:to="loc_us-gaap_LiabilitiesTotalMember_520" use="optional" order="26" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsTotalMember" xlink:label="loc_us-gaap_AssetsTotalMember_539" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_529" xlink:to="loc_us-gaap_AssetsTotalMember_539" use="optional" order="27" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanNameAxis" xlink:label="loc_us-gaap_RetirementPlanNameAxis_553" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfProductInformationTable_527" xlink:to="loc_us-gaap_RetirementPlanNameAxis_553" use="optional" order="28" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanNameDomain" xlink:label="loc_us-gaap_RetirementPlanNameDomain_531" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanNameAxis_553" xlink:to="loc_us-gaap_RetirementPlanNameDomain_531" use="optional" order="29" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="btmd-20221231.xsd#btmd_FourZeroOneKPlanMember" xlink:label="loc_btmd_FourZeroOneKPlanMember_526" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanNameDomain_531" xlink:to="loc_btmd_FourZeroOneKPlanMember_526" use="optional" order="30" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_555" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfProductInformationTable_527" xlink:to="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_555" use="optional" order="31" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="loc_us-gaap_TypeOfAdoptionMember_525" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_555" xlink:to="loc_us-gaap_TypeOfAdoptionMember_525" use="optional" order="32" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingStandardsUpdate201912Member" xlink:label="loc_us-gaap_AccountingStandardsUpdate201912Member_521" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfAdoptionMember_525" xlink:to="loc_us-gaap_AccountingStandardsUpdate201912Member_521" use="optional" order="33" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_557" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfProductInformationTable_527" xlink:to="loc_us-gaap_TypeOfArrangementAxis_557" use="optional" order="34" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_508" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_557" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_508" use="optional" order="35" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="btmd-20221231.xsd#btmd_StandbyEquityPurchaseAgreementMember" xlink:label="loc_btmd_StandbyEquityPurchaseAgreementMember_522" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_508" xlink:to="loc_btmd_StandbyEquityPurchaseAgreementMember_522" use="optional" order="36" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityAxis" xlink:label="loc_us-gaap_CreditFacilityAxis_559" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfProductInformationTable_527" xlink:to="loc_us-gaap_CreditFacilityAxis_559" use="optional" order="37" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityDomain" xlink:label="loc_us-gaap_CreditFacilityDomain_519" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityAxis_559" xlink:to="loc_us-gaap_CreditFacilityDomain_519" use="optional" order="38" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="btmd-20221231.xsd#btmd_YorkvilleAdvisorsGlobalLpMember" xlink:label="loc_btmd_YorkvilleAdvisorsGlobalLpMember_518" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityDomain_519" xlink:to="loc_btmd_YorkvilleAdvisorsGlobalLpMember_518" use="optional" order="39" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_561" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfProductInformationTable_527" xlink:to="loc_us-gaap_StatementClassOfStockAxis_561" use="optional" order="40" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_523" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_561" xlink:to="loc_us-gaap_ClassOfStockDomain_523" use="optional" order="41" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonClassAMember" xlink:label="loc_us-gaap_CommonClassAMember_517" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_523" xlink:to="loc_us-gaap_CommonClassAMember_517" use="optional" order="42" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_563" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfProductInformationTable_527" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_563" use="optional" order="43" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_528" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_563" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_528" use="optional" order="44" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_565" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfProductInformationTable_527" xlink:to="loc_srt_RangeAxis_565" use="optional" order="45" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_511" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_565" xlink:to="loc_srt_RangeMember_511" use="optional" order="46" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_516" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_511" xlink:to="loc_srt_MinimumMember_516" use="optional" order="47" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_538" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_511" xlink:to="loc_srt_MaximumMember_538" use="optional" order="48" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProductInformationLineItems" xlink:label="loc_us-gaap_ProductInformationLineItems_567" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfProductInformationTable_527" xlink:to="loc_us-gaap_ProductInformationLineItems_567" use="optional" order="49" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="loc_us-gaap_NumberOfOperatingSegments_524" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductInformationLineItems_567" xlink:to="loc_us-gaap_NumberOfOperatingSegments_524" use="optional" order="50" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NumberOfReportableSegments" xlink:label="loc_us-gaap_NumberOfReportableSegments_540" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductInformationLineItems_567" xlink:to="loc_us-gaap_NumberOfReportableSegments_540" use="optional" order="51" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="btmd-20221231.xsd#btmd_CapitalizedSoftwareEstimatedUsefulLives" xlink:label="loc_btmd_CapitalizedSoftwareEstimatedUsefulLives_544" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductInformationLineItems_567" xlink:to="loc_btmd_CapitalizedSoftwareEstimatedUsefulLives_544" use="optional" order="52" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:label="loc_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_546" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductInformationLineItems_567" xlink:to="loc_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_546" use="optional" order="53" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="btmd-20221231.xsd#btmd_CommonUnitsVotingRightsPercentage" xlink:label="loc_btmd_CommonUnitsVotingRightsPercentage_550" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductInformationLineItems_567" xlink:to="loc_btmd_CommonUnitsVotingRightsPercentage_550" use="optional" order="54" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LimitedPartnersCapitalAccountDistributionAmount" xlink:label="loc_us-gaap_LimitedPartnersCapitalAccountDistributionAmount_552" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductInformationLineItems_567" xlink:to="loc_us-gaap_LimitedPartnersCapitalAccountDistributionAmount_552" use="optional" order="55" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="btmd-20221231.xsd#btmd_PercentageOfCommonStockPurchasePrice" xlink:label="loc_btmd_PercentageOfCommonStockPurchasePrice_554" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductInformationLineItems_567" xlink:to="loc_btmd_PercentageOfCommonStockPurchasePrice_554" use="optional" order="56" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="btmd-20221231.xsd#btmd_TerminationPeriodOfPurchaseAgreement" xlink:label="loc_btmd_TerminationPeriodOfPurchaseAgreement_556" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductInformationLineItems_567" xlink:to="loc_btmd_TerminationPeriodOfPurchaseAgreement_556" use="optional" order="57" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="btmd-20221231.xsd#btmd_ConsecutiveTradingDays" xlink:label="loc_btmd_ConsecutiveTradingDays_558" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductInformationLineItems_567" xlink:to="loc_btmd_ConsecutiveTradingDays_558" use="optional" order="58" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="btmd-20221231.xsd#btmd_MandatoryMinimumAmountForIndividualAdvance" xlink:label="loc_btmd_MandatoryMinimumAmountForIndividualAdvance_560" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductInformationLineItems_567" xlink:to="loc_btmd_MandatoryMinimumAmountForIndividualAdvance_560" use="optional" order="59" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="btmd-20221231.xsd#btmd_MaximumValueOfDailyVolumeTradedThresholdPercentage" xlink:label="loc_btmd_MaximumValueOfDailyVolumeTradedThresholdPercentage_562" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductInformationLineItems_567" xlink:to="loc_btmd_MaximumValueOfDailyVolumeTradedThresholdPercentage_562" use="optional" order="60" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaap_CommonStockSharesIssued_564" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductInformationLineItems_567" xlink:to="loc_us-gaap_CommonStockSharesIssued_564" use="optional" order="61" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_568" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductInformationLineItems_567" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_568" use="optional" order="62" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="btmd-20221231.xsd#btmd_ProceedsFromSettlementOfSEPA" xlink:label="loc_btmd_ProceedsFromSettlementOfSEPA_569" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductInformationLineItems_567" xlink:to="loc_btmd_ProceedsFromSettlementOfSEPA_569" use="optional" order="63" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRemainingPerformanceObligation" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligation_570" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductInformationLineItems_567" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligation_570" use="optional" order="64" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityCurrent" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_571" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductInformationLineItems_567" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_571" use="optional" order="65" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_572" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductInformationLineItems_567" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_572" use="optional" order="66" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="btmd-20221231.xsd#btmd_ExpectedReturnsAndRefundsToCustomers" xlink:label="loc_btmd_ExpectedReturnsAndRefundsToCustomers_573" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductInformationLineItems_567" xlink:to="loc_btmd_ExpectedReturnsAndRefundsToCustomers_573" use="optional" order="67" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_574" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductInformationLineItems_567" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_574" use="optional" order="68" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_575" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductInformationLineItems_567" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_575" use="optional" order="69" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="btmd-20221231.xsd#btmd_NumberOfInventoryVendors" xlink:label="loc_btmd_NumberOfInventoryVendors_576" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductInformationLineItems_567" xlink:to="loc_btmd_NumberOfInventoryVendors_576" use="optional" order="70" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="btmd-20221231.xsd#btmd_NumberOfCustomersAccountedForTenPercentOrMoreAggregateRevenue" xlink:label="loc_btmd_NumberOfCustomersAccountedForTenPercentOrMoreAggregateRevenue_577" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductInformationLineItems_567" xlink:to="loc_btmd_NumberOfCustomersAccountedForTenPercentOrMoreAggregateRevenue_577" use="optional" order="71" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="btmd-20221231.xsd#btmd_NumberOfCustomersAccountedForTenPercentOrMoreAccountsReceivable" xlink:label="loc_btmd_NumberOfCustomersAccountedForTenPercentOrMoreAccountsReceivable_578" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductInformationLineItems_567" xlink:to="loc_btmd_NumberOfCustomersAccountedForTenPercentOrMoreAccountsReceivable_578" use="optional" order="72" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" xlink:label="loc_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch_579" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductInformationLineItems_567" xlink:to="loc_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch_579" use="optional" order="73" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:label="loc_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount_580" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductInformationLineItems_567" xlink:to="loc_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount_580" use="optional" order="74" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SalesCommissionsAndFees" xlink:label="loc_us-gaap_SalesCommissionsAndFees_581" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductInformationLineItems_567" xlink:to="loc_us-gaap_SalesCommissionsAndFees_581" use="optional" order="75" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalizedContractCostAmortization" xlink:label="loc_us-gaap_CapitalizedContractCostAmortization_582" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductInformationLineItems_567" xlink:to="loc_us-gaap_CapitalizedContractCostAmortization_582" use="optional" order="76" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate" xlink:label="loc_us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate_583" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductInformationLineItems_567" xlink:to="loc_us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate_583" use="optional" order="77" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted" xlink:label="loc_us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted_584" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductInformationLineItems_567" xlink:to="loc_us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted_584" use="optional" order="78" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect" xlink:label="loc_us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect_585" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductInformationLineItems_567" xlink:to="loc_us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect_585" use="optional" order="79" preferredLabel="http://www.xbrl.org/2003/role/label" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://haymaker.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfRollforwardOfTheAllowanceForDoubtfulAccountsDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_587" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_588" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_587" xlink:to="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_588" use="optional" order="1" preferredLabel="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProvisionForDoubtfulAccounts" xlink:label="loc_us-gaap_ProvisionForDoubtfulAccounts_589" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_587" xlink:to="loc_us-gaap_ProvisionForDoubtfulAccounts_589" use="optional" order="2" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" />
<loc xlink:type="locator" xlink:href="btmd-20221231.xsd#btmd_ProvisonForDoubfulDebtAcoountsWriteOffAndRecoveries" xlink:label="loc_btmd_ProvisonForDoubfulDebtAcoountsWriteOffAndRecoveries_590" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_587" xlink:to="loc_btmd_ProvisonForDoubfulDebtAcoountsWriteOffAndRecoveries_590" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_591" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_587" xlink:to="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_591" use="optional" order="4" preferredLabel="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://haymaker.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfTotalOtherCurrentAssetsDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract_593" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="loc_us-gaap_PrepaidExpenseCurrent_594" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract_593" xlink:to="loc_us-gaap_PrepaidExpenseCurrent_594" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdvancesOnInventoryPurchases" xlink:label="loc_us-gaap_AdvancesOnInventoryPurchases_595" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract_593" xlink:to="loc_us-gaap_AdvancesOnInventoryPurchases_595" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredOfferingCosts" xlink:label="loc_us-gaap_DeferredOfferingCosts_596" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract_593" xlink:to="loc_us-gaap_DeferredOfferingCosts_596" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_597" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract_593" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_597" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://haymaker.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfEstimatedUsefulLivesOfPropertyAndEquipmentDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_599" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_603" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_599" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_603" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_604" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_603" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_604" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_605" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_604" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_605" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="btmd-20221231.xsd#btmd_TrocarsMember" xlink:label="loc_btmd_TrocarsMember_606" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_605" xlink:to="loc_btmd_TrocarsMember_606" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_610" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_605" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_610" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OfficeEquipmentMember" xlink:label="loc_us-gaap_OfficeEquipmentMember_612" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_605" xlink:to="loc_us-gaap_OfficeEquipmentMember_612" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SoftwareDevelopmentMember" xlink:label="loc_us-gaap_SoftwareDevelopmentMember_613" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_605" xlink:to="loc_us-gaap_SoftwareDevelopmentMember_613" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_614" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_605" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_614" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComputerEquipmentMember" xlink:label="loc_us-gaap_ComputerEquipmentMember_615" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_605" xlink:to="loc_us-gaap_ComputerEquipmentMember_615" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_609" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_603" xlink:to="loc_srt_RangeAxis_609" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_601" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_609" xlink:to="loc_srt_RangeMember_601" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_602" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_601" xlink:to="loc_srt_MinimumMember_602" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_608" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_601" xlink:to="loc_srt_MaximumMember_608" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_611" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_603" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentLineItems_611" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_600" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_611" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_600" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives_607" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_611" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives_607" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://haymaker.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfMembersEquityUnitsIssuedAndOutstandingDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaap_EquityAbstract_617" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCapitalUnitsTable" xlink:label="loc_us-gaap_ScheduleOfCapitalUnitsTable_619" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_617" xlink:to="loc_us-gaap_ScheduleOfCapitalUnitsTable_619" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalUnitsByClassAxis" xlink:label="loc_us-gaap_CapitalUnitsByClassAxis_620" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCapitalUnitsTable_619" xlink:to="loc_us-gaap_CapitalUnitsByClassAxis_620" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalUnitClassDomain" xlink:label="loc_us-gaap_CapitalUnitClassDomain_618" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CapitalUnitsByClassAxis_620" xlink:to="loc_us-gaap_CapitalUnitClassDomain_618" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="btmd-20221231.xsd#btmd_ClassAVotingUnitsMember" xlink:label="loc_btmd_ClassAVotingUnitsMember_622" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CapitalUnitClassDomain_618" xlink:to="loc_btmd_ClassAVotingUnitsMember_622" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="btmd-20221231.xsd#btmd_ClassAaNonVotingUnitsMember" xlink:label="loc_btmd_ClassAaNonVotingUnitsMember_625" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CapitalUnitClassDomain_618" xlink:to="loc_btmd_ClassAaNonVotingUnitsMember_625" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="btmd-20221231.xsd#btmd_ClassAaaNonVotingUnitsMember" xlink:label="loc_btmd_ClassAaaNonVotingUnitsMember_626" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CapitalUnitClassDomain_618" xlink:to="loc_btmd_ClassAaaNonVotingUnitsMember_626" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="btmd-20221231.xsd#btmd_ClassAaaaNonVotingIncentiveUnitsMember" xlink:label="loc_btmd_ClassAaaaNonVotingIncentiveUnitsMember_627" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CapitalUnitClassDomain_618" xlink:to="loc_btmd_ClassAaaaNonVotingIncentiveUnitsMember_627" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalUnitLineItems" xlink:label="loc_us-gaap_CapitalUnitLineItems_623" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCapitalUnitsTable_619" xlink:to="loc_us-gaap_CapitalUnitLineItems_623" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonUnitIssued" xlink:label="loc_us-gaap_CommonUnitIssued_621" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CapitalUnitLineItems_623" xlink:to="loc_us-gaap_CommonUnitIssued_621" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonUnitOutstanding" xlink:label="loc_us-gaap_CommonUnitOutstanding_624" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CapitalUnitLineItems_623" xlink:to="loc_us-gaap_CommonUnitOutstanding_624" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://haymaker.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfCommonStockIssuedAndOutstandingDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaap_EquityAbstract_629" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_631" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_629" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_631" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_632" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_631" xlink:to="loc_us-gaap_StatementClassOfStockAxis_632" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_633" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_632" xlink:to="loc_us-gaap_ClassOfStockDomain_633" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonClassAMember" xlink:label="loc_us-gaap_CommonClassAMember_630" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_633" xlink:to="loc_us-gaap_CommonClassAMember_630" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonClassBMember" xlink:label="loc_us-gaap_CommonClassBMember_635" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_633" xlink:to="loc_us-gaap_CommonClassBMember_635" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="btmd-20221231.xsd#btmd_ClassVCommonStockMember" xlink:label="loc_btmd_ClassVCommonStockMember_638" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_633" xlink:to="loc_btmd_ClassVCommonStockMember_638" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockLineItems" xlink:label="loc_us-gaap_ClassOfStockLineItems_636" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_631" xlink:to="loc_us-gaap_ClassOfStockLineItems_636" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaap_CommonStockSharesIssued_634" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_636" xlink:to="loc_us-gaap_CommonStockSharesIssued_634" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_637" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_636" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_637" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://haymaker.com/role/BusinessCombinationAdditionalInformationDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationsAbstract" xlink:label="loc_us-gaap_BusinessCombinationsAbstract_640" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_646" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_640" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_646" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_648" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_646" xlink:to="loc_us-gaap_StatementClassOfStockAxis_648" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_650" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_648" xlink:to="loc_us-gaap_ClassOfStockDomain_650" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonClassAMember" xlink:label="loc_us-gaap_CommonClassAMember_643" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_650" xlink:to="loc_us-gaap_CommonClassAMember_643" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonClassBMember" xlink:label="loc_us-gaap_CommonClassBMember_657" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_650" xlink:to="loc_us-gaap_CommonClassBMember_657" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="btmd-20221231.xsd#btmd_ClassVCommonStockMember" xlink:label="loc_btmd_ClassVCommonStockMember_663" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_650" xlink:to="loc_btmd_ClassVCommonStockMember_663" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="btmd-20221231.xsd#btmd_MemberEarnOutUnitsMember" xlink:label="loc_btmd_MemberEarnOutUnitsMember_668" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_650" xlink:to="loc_btmd_MemberEarnOutUnitsMember_668" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="btmd-20221231.xsd#btmd_EarnoutVotingSharesMember" xlink:label="loc_btmd_EarnoutVotingSharesMember_673" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_650" xlink:to="loc_btmd_EarnoutVotingSharesMember_673" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="btmd-20221231.xsd#btmd_SponsorEarnOutSharesMember" xlink:label="loc_btmd_SponsorEarnOutSharesMember_678" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_650" xlink:to="loc_btmd_SponsorEarnOutSharesMember_678" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_659" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_646" xlink:to="loc_us-gaap_DebtInstrumentAxis_659" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_652" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_659" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_652" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="btmd-20221231.xsd#btmd_DebtCommitmentLetterMember" xlink:label="loc_btmd_DebtCommitmentLetterMember_654" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_652" xlink:to="loc_btmd_DebtCommitmentLetterMember_654" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidatedEntitiesAxis" xlink:label="loc_srt_ConsolidatedEntitiesAxis_664" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_646" xlink:to="loc_srt_ConsolidatedEntitiesAxis_664" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidatedEntitiesDomain" xlink:label="loc_srt_ConsolidatedEntitiesDomain_653" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidatedEntitiesAxis_664" xlink:to="loc_srt_ConsolidatedEntitiesDomain_653" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="btmd-20221231.xsd#btmd_HaymakeriiiMember" xlink:label="loc_btmd_HaymakeriiiMember_647" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidatedEntitiesDomain_653" xlink:to="loc_btmd_HaymakeriiiMember_647" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_669" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_646" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_669" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_641" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_669" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_641" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="btmd-20221231.xsd#btmd_HaymakerAcquisitionCorpIiiMember" xlink:label="loc_btmd_HaymakerAcquisitionCorpIiiMember_642" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_641" xlink:to="loc_btmd_HaymakerAcquisitionCorpIiiMember_642" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="btmd-20221231.xsd#btmd_BioteManagementLlcMember" xlink:label="loc_btmd_BioteManagementLlcMember_656" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_641" xlink:to="loc_btmd_BioteManagementLlcMember_656" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="btmd-20221231.xsd#btmd_BusinessCombinationMember" xlink:label="loc_btmd_BusinessCombinationMember_672" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_641" xlink:to="loc_btmd_BusinessCombinationMember_672" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="btmd-20221231.xsd#btmd_OtherBusinessCombinationMember" xlink:label="loc_btmd_OtherBusinessCombinationMember_677" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_641" xlink:to="loc_btmd_OtherBusinessCombinationMember_677" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAxis" xlink:label="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAxis_674" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_646" xlink:to="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAxis_674" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsDomain" xlink:label="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsDomain_655" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAxis_674" xlink:to="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsDomain_655" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityAxis" xlink:label="loc_us-gaap_CreditFacilityAxis_679" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_646" xlink:to="loc_us-gaap_CreditFacilityAxis_679" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityDomain" xlink:label="loc_us-gaap_CreditFacilityDomain_645" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityAxis_679" xlink:to="loc_us-gaap_CreditFacilityDomain_645" use="optional" order="25" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="btmd-20221231.xsd#btmd_SeniorSecuredRevolvingCreditFacilityMember" xlink:label="loc_btmd_SeniorSecuredRevolvingCreditFacilityMember_644" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityDomain_645" xlink:to="loc_btmd_SeniorSecuredRevolvingCreditFacilityMember_644" use="optional" order="26" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="btmd-20221231.xsd#btmd_SeniorSecuredTermLoanAFacilityMember" xlink:label="loc_btmd_SeniorSecuredTermLoanAFacilityMember_658" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityDomain_645" xlink:to="loc_btmd_SeniorSecuredTermLoanAFacilityMember_658" use="optional" order="27" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_682" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_646" xlink:to="loc_us-gaap_BusinessAcquisitionLineItems_682" use="optional" order="28" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationConsiderationTransferred1" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferred1_651" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_682" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferred1_651" use="optional" order="29" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionSharePrice" xlink:label="loc_us-gaap_BusinessAcquisitionSharePrice_661" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_682" xlink:to="loc_us-gaap_BusinessAcquisitionSharePrice_661" use="optional" order="30" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" xlink:label="loc_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_666" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_682" xlink:to="loc_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_666" use="optional" order="31" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable_671" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_682" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable_671" use="optional" order="32" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="btmd-20221231.xsd#btmd_IncomeTaxPercentageOfFederalStateAndLocalIncomeTaxSavings" xlink:label="loc_btmd_IncomeTaxPercentageOfFederalStateAndLocalIncomeTaxSavings_676" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_682" xlink:to="loc_btmd_IncomeTaxPercentageOfFederalStateAndLocalIncomeTaxSavings_676" use="optional" order="33" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionDescriptionOfAcquiredEntity" xlink:label="loc_us-gaap_BusinessAcquisitionDescriptionOfAcquiredEntity_681" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_682" xlink:to="loc_us-gaap_BusinessAcquisitionDescriptionOfAcquiredEntity_681" use="optional" order="34" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="btmd-20221231.xsd#btmd_TaxReceivableAgreementLiability" xlink:label="loc_btmd_TaxReceivableAgreementLiability_683" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_682" xlink:to="loc_btmd_TaxReceivableAgreementLiability_683" use="optional" order="35" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireBusinessesGross" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross_684" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_682" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesGross_684" use="optional" order="36" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromPreviousAcquisition" xlink:label="loc_us-gaap_ProceedsFromPreviousAcquisition_685" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_682" xlink:to="loc_us-gaap_ProceedsFromPreviousAcquisition_685" use="optional" order="37" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_686" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_682" xlink:to="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_686" use="optional" order="38" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_687" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_682" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_687" use="optional" order="39" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="btmd-20221231.xsd#btmd_CommonStockTransfersThresholdTradingDays" xlink:label="loc_btmd_CommonStockTransfersThresholdTradingDays_688" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_682" xlink:to="loc_btmd_CommonStockTransfersThresholdTradingDays_688" use="optional" order="40" preferredLabel="http://www.xbrl.org/2003/role/label" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://haymaker.com/role/RevenueRecognitionScheduleOfRevenuesRecognizedForEachRevenueStreamDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerAbstract" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_690" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueTable" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_693" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_690" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_693" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srt_ProductOrServiceAxis_692" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_693" xlink:to="loc_srt_ProductOrServiceAxis_692" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_691" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_692" xlink:to="loc_srt_ProductsAndServicesDomain_691" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="btmd-20221231.xsd#btmd_PelletProceduresProductRevenueMember" xlink:label="loc_btmd_PelletProceduresProductRevenueMember_695" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_691" xlink:to="loc_btmd_PelletProceduresProductRevenueMember_695" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="btmd-20221231.xsd#btmd_DietarySupplementsMember" xlink:label="loc_btmd_DietarySupplementsMember_698" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_691" xlink:to="loc_btmd_DietarySupplementsMember_698" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="btmd-20221231.xsd#btmd_DisposableTrocarsProductRevenueMember" xlink:label="loc_btmd_DisposableTrocarsProductRevenueMember_699" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_691" xlink:to="loc_btmd_DisposableTrocarsProductRevenueMember_699" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="btmd-20221231.xsd#btmd_ShippingFeesProductRevenueMember" xlink:label="loc_btmd_ShippingFeesProductRevenueMember_700" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_691" xlink:to="loc_btmd_ShippingFeesProductRevenueMember_700" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="btmd-20221231.xsd#btmd_ProductRevenueMember" xlink:label="loc_btmd_ProductRevenueMember_701" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_691" xlink:to="loc_btmd_ProductRevenueMember_701" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="btmd-20221231.xsd#btmd_TrainingServiceRevenueMember" xlink:label="loc_btmd_TrainingServiceRevenueMember_702" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_691" xlink:to="loc_btmd_TrainingServiceRevenueMember_702" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="btmd-20221231.xsd#btmd_ContractTermServicesRevenueMember" xlink:label="loc_btmd_ContractTermServicesRevenueMember_703" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_691" xlink:to="loc_btmd_ContractTermServicesRevenueMember_703" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="btmd-20221231.xsd#btmd_ServiceRevenueMember" xlink:label="loc_btmd_ServiceRevenueMember_704" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_691" xlink:to="loc_btmd_ServiceRevenueMember_704" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueLineItems" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_696" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_693" xlink:to="loc_us-gaap_DisaggregationOfRevenueLineItems_696" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_694" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_696" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_694" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://haymaker.com/role/RevenueRecognitionScheduleOfRevenuesRecognizedByGeographicRegionDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerAbstract" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_706" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueTable" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_711" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_706" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_711" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srt_ProductOrServiceAxis_709" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_711" xlink:to="loc_srt_ProductOrServiceAxis_709" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_707" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_709" xlink:to="loc_srt_ProductsAndServicesDomain_707" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="btmd-20221231.xsd#btmd_ProductRevenueMember" xlink:label="loc_btmd_ProductRevenueMember_713" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_707" xlink:to="loc_btmd_ProductRevenueMember_713" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="btmd-20221231.xsd#btmd_ServiceRevenueMember" xlink:label="loc_btmd_ServiceRevenueMember_716" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_707" xlink:to="loc_btmd_ServiceRevenueMember_716" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis" xlink:label="loc_srt_StatementGeographicalAxis_715" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_711" xlink:to="loc_srt_StatementGeographicalAxis_715" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srt_SegmentGeographicalDomain_710" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_715" xlink:to="loc_srt_SegmentGeographicalDomain_710" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_US" xlink:label="loc_country_US_708" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_710" xlink:to="loc_country_US_708" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="btmd-20221231.xsd#btmd_AllOtherCountryMember" xlink:label="loc_btmd_AllOtherCountryMember_714" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_710" xlink:to="loc_btmd_AllOtherCountryMember_714" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueLineItems" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_717" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_711" xlink:to="loc_us-gaap_DisaggregationOfRevenueLineItems_717" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_712" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_717" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_712" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://haymaker.com/role/RevenueRecognitionSummaryOfSignificantChangesInContractLiabilityBalancesDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerAbstract" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_719" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueTable" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_722" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_719" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_722" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerDurationAxis" xlink:label="loc_us-gaap_ContractWithCustomerDurationAxis_720" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_722" xlink:to="loc_us-gaap_ContractWithCustomerDurationAxis_720" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerDurationDomain" xlink:label="loc_us-gaap_ContractWithCustomerDurationDomain_721" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ContractWithCustomerDurationAxis_720" xlink:to="loc_us-gaap_ContractWithCustomerDurationDomain_721" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermContractWithCustomerMember" xlink:label="loc_us-gaap_ShortTermContractWithCustomerMember_724" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ContractWithCustomerDurationDomain_721" xlink:to="loc_us-gaap_ShortTermContractWithCustomerMember_724" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermContractWithCustomerMember" xlink:label="loc_us-gaap_LongTermContractWithCustomerMember_727" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ContractWithCustomerDurationDomain_721" xlink:to="loc_us-gaap_LongTermContractWithCustomerMember_727" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueLineItems" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_725" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_722" xlink:to="loc_us-gaap_DisaggregationOfRevenueLineItems_725" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_723" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_725" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_723" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="btmd-20221231.xsd#btmd_ContractWithCustomerLiabilityIncreasesDueToCashReceivedExcludingAmountsRecognizedAsRevenue" xlink:label="loc_btmd_ContractWithCustomerLiabilityIncreasesDueToCashReceivedExcludingAmountsRecognizedAsRevenue_726" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_725" xlink:to="loc_btmd_ContractWithCustomerLiabilityIncreasesDueToCashReceivedExcludingAmountsRecognizedAsRevenue_726" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="btmd-20221231.xsd#btmd_ContractWithCustomerLiabilityTransfersBetweenCurrentAndNonCurrentLiabilitiesDueToExpectedRevenueRecognitionPeriod" xlink:label="loc_btmd_ContractWithCustomerLiabilityTransfersBetweenCurrentAndNonCurrentLiabilitiesDueToExpectedRevenueRecognitionPeriod_728" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_725" xlink:to="loc_btmd_ContractWithCustomerLiabilityTransfersBetweenCurrentAndNonCurrentLiabilitiesDueToExpectedRevenueRecognitionPeriod_728" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_729" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_725" xlink:to="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_729" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://haymaker.com/role/RevenueRecognitionSummaryOfConsiderationAllocatedToPerformanceObligationsDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerAbstract" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_731" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueTable" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_734" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_731" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_734" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srt_ProductOrServiceAxis_733" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_734" xlink:to="loc_srt_ProductOrServiceAxis_733" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_732" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_733" xlink:to="loc_srt_ProductsAndServicesDomain_732" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="btmd-20221231.xsd#btmd_UnsatisfiedTrainingObligationsMember" xlink:label="loc_btmd_UnsatisfiedTrainingObligationsMember_736" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_732" xlink:to="loc_btmd_UnsatisfiedTrainingObligationsMember_736" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="btmd-20221231.xsd#btmd_UnsatisfiedContractTermServicesMember" xlink:label="loc_btmd_UnsatisfiedContractTermServicesMember_739" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_732" xlink:to="loc_btmd_UnsatisfiedContractTermServicesMember_739" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="btmd-20221231.xsd#btmd_UnsatisfiedPelletProceduresMember" xlink:label="loc_btmd_UnsatisfiedPelletProceduresMember_741" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_732" xlink:to="loc_btmd_UnsatisfiedPelletProceduresMember_741" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueLineItems" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_737" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_734" xlink:to="loc_us-gaap_DisaggregationOfRevenueLineItems_737" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityCurrent" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_735" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_737" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_735" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_738" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_737" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_738" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiability" xlink:label="loc_us-gaap_ContractWithCustomerLiability_740" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_737" xlink:to="loc_us-gaap_ContractWithCustomerLiability_740" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://haymaker.com/role/RevenueRecognitionAdditionalInformationDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerAbstract" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_743" />
<loc xlink:type="locator" xlink:href="btmd-20221231.xsd#btmd_ReductionOfRevenue" xlink:label="loc_btmd_ReductionOfRevenue_744" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_743" xlink:to="loc_btmd_ReductionOfRevenue_744" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://haymaker.com/role/InventoryNetScheduleOfInventoryNetDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryDisclosureAbstract" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_746" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryCurrentTable" xlink:label="loc_us-gaap_InventoryCurrentTable_751" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_746" xlink:to="loc_us-gaap_InventoryCurrentTable_751" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srt_ProductOrServiceAxis_748" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryCurrentTable_751" xlink:to="loc_srt_ProductOrServiceAxis_748" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_749" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_748" xlink:to="loc_srt_ProductsAndServicesDomain_749" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProductMember" xlink:label="loc_us-gaap_ProductMember_752" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_749" xlink:to="loc_us-gaap_ProductMember_752" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PublicUtilitiesInventoryAxis" xlink:label="loc_us-gaap_PublicUtilitiesInventoryAxis_755" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryCurrentTable_751" xlink:to="loc_us-gaap_PublicUtilitiesInventoryAxis_755" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PublicUtilitiesInventoryTypeDomain" xlink:label="loc_us-gaap_PublicUtilitiesInventoryTypeDomain_753" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PublicUtilitiesInventoryAxis_755" xlink:to="loc_us-gaap_PublicUtilitiesInventoryTypeDomain_753" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="btmd-20221231.xsd#btmd_PelletsMember" xlink:label="loc_btmd_PelletsMember_750" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PublicUtilitiesInventoryTypeDomain_753" xlink:to="loc_btmd_PelletsMember_750" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="btmd-20221231.xsd#btmd_DietarySupplementsMember" xlink:label="loc_btmd_DietarySupplementsMember_756" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PublicUtilitiesInventoryTypeDomain_753" xlink:to="loc_btmd_DietarySupplementsMember_756" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryLineItems" xlink:label="loc_us-gaap_InventoryLineItems_758" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryCurrentTable_751" xlink:to="loc_us-gaap_InventoryLineItems_758" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryGross" xlink:label="loc_us-gaap_InventoryGross_747" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryLineItems_758" xlink:to="loc_us-gaap_InventoryGross_747" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryAdjustments" xlink:label="loc_us-gaap_InventoryAdjustments_754" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryLineItems_758" xlink:to="loc_us-gaap_InventoryAdjustments_754" use="optional" order="11" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNet" xlink:label="loc_us-gaap_InventoryNet_757" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryLineItems_758" xlink:to="loc_us-gaap_InventoryNet_757" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://haymaker.com/role/PropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_760" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_763" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_760" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_763" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_762" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_763" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_762" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_764" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_762" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_764" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="btmd-20221231.xsd#btmd_TrocarsMember" xlink:label="loc_btmd_TrocarsMember_765" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_764" xlink:to="loc_btmd_TrocarsMember_765" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_768" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_764" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_768" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OfficeEquipmentMember" xlink:label="loc_us-gaap_OfficeEquipmentMember_770" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_764" xlink:to="loc_us-gaap_OfficeEquipmentMember_770" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" xlink:label="loc_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_771" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_764" xlink:to="loc_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_771" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_772" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_764" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_772" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComputerEquipmentMember" xlink:label="loc_us-gaap_ComputerEquipmentMember_773" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_764" xlink:to="loc_us-gaap_ComputerEquipmentMember_773" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConstructionInProgressMember" xlink:label="loc_us-gaap_ConstructionInProgressMember_774" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_764" xlink:to="loc_us-gaap_ConstructionInProgressMember_774" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_767" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_763" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentLineItems_767" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_761" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_767" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_761" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_766" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_767" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_766" use="optional" order="13" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_769" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_767" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_769" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://haymaker.com/role/PropertyAndEquipmentNetAdditionalInformationDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_776" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Depreciation" xlink:label="loc_us-gaap_Depreciation_777" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_776" xlink:to="loc_us-gaap_Depreciation_777" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://haymaker.com/role/CapitalizedSoftwareNetSummaryOfCapitalizedSoftwareNetDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentAbstract" xlink:label="loc_us-gaap_ResearchAndDevelopmentAbstract_779" />
<loc xlink:type="locator" xlink:href="btmd-20221231.xsd#btmd_CapitalizedSoftwareWebsiteCosts" xlink:label="loc_btmd_CapitalizedSoftwareWebsiteCosts_780" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentAbstract_779" xlink:to="loc_btmd_CapitalizedSoftwareWebsiteCosts_780" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="btmd-20221231.xsd#btmd_CapitalizedSoftwareDevelopmentInProcess" xlink:label="loc_btmd_CapitalizedSoftwareDevelopmentInProcess_781" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentAbstract_779" xlink:to="loc_btmd_CapitalizedSoftwareDevelopmentInProcess_781" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalizedComputerSoftwareAccumulatedAmortization" xlink:label="loc_us-gaap_CapitalizedComputerSoftwareAccumulatedAmortization_782" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentAbstract_779" xlink:to="loc_us-gaap_CapitalizedComputerSoftwareAccumulatedAmortization_782" use="optional" order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalizedComputerSoftwareNet" xlink:label="loc_us-gaap_CapitalizedComputerSoftwareNet_783" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentAbstract_779" xlink:to="loc_us-gaap_CapitalizedComputerSoftwareNet_783" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://haymaker.com/role/CapitalizedSoftwareNetAdditionalInformationDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentAbstract" xlink:label="loc_us-gaap_ResearchAndDevelopmentAbstract_785" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalizedComputerSoftwareAmortization1" xlink:label="loc_us-gaap_CapitalizedComputerSoftwareAmortization1_786" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentAbstract_785" xlink:to="loc_us-gaap_CapitalizedComputerSoftwareAmortization1_786" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://haymaker.com/role/AccruedExpensesScheduleOfAccruedExpensesDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_788" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrent_789" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_788" xlink:to="loc_us-gaap_AccruedProfessionalFeesCurrent_789" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_790" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_788" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_790" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="btmd-20221231.xsd#btmd_AccruedMerchantFeesCurrent" xlink:label="loc_btmd_AccruedMerchantFeesCurrent_791" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_788" xlink:to="loc_btmd_AccruedMerchantFeesCurrent_791" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestPayableCurrent" xlink:label="loc_us-gaap_InterestPayableCurrent_792" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_788" xlink:to="loc_us-gaap_InterestPayableCurrent_792" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="btmd-20221231.xsd#btmd_LegalAccrualCurrent" xlink:label="loc_btmd_LegalAccrualCurrent_793" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_788" xlink:to="loc_btmd_LegalAccrualCurrent_793" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_794" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_788" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_794" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_795" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_788" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_795" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://haymaker.com/role/LongTermDebtAdditionalInformationDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaap_DebtDisclosureAbstract_797" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTable" xlink:label="loc_us-gaap_DebtInstrumentTable_808" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_797" xlink:to="loc_us-gaap_DebtInstrumentTable_808" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityAxis" xlink:label="loc_us-gaap_CreditFacilityAxis_798" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_808" xlink:to="loc_us-gaap_CreditFacilityAxis_798" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityDomain" xlink:label="loc_us-gaap_CreditFacilityDomain_804" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityAxis_798" xlink:to="loc_us-gaap_CreditFacilityDomain_804" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditMember" xlink:label="loc_us-gaap_LineOfCreditMember_803" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityDomain_804" xlink:to="loc_us-gaap_LineOfCreditMember_803" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevolvingCreditFacilityMember" xlink:label="loc_us-gaap_RevolvingCreditFacilityMember_814" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityDomain_804" xlink:to="loc_us-gaap_RevolvingCreditFacilityMember_814" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_811" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_808" xlink:to="loc_us-gaap_DebtInstrumentAxis_811" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_806" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_811" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_806" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="btmd-20221231.xsd#btmd_BankOfAmericaTermLoanMember" xlink:label="loc_btmd_BankOfAmericaTermLoanMember_809" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_806" xlink:to="loc_btmd_BankOfAmericaTermLoanMember_809" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="btmd-20221231.xsd#btmd_TruistTermLoanMember" xlink:label="loc_btmd_TruistTermLoanMember_816" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_806" xlink:to="loc_btmd_TruistTermLoanMember_816" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="btmd-20221231.xsd#btmd_BankOfAmericaTermLoanAndTruistTermLoanMember" xlink:label="loc_btmd_BankOfAmericaTermLoanAndTruistTermLoanMember_820" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_806" xlink:to="loc_btmd_BankOfAmericaTermLoanAndTruistTermLoanMember_820" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableRateAxis" xlink:label="loc_us-gaap_VariableRateAxis_818" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_808" xlink:to="loc_us-gaap_VariableRateAxis_818" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableRateDomain" xlink:label="loc_us-gaap_VariableRateDomain_799" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateAxis_818" xlink:to="loc_us-gaap_VariableRateDomain_799" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember" xlink:label="loc_us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember_805" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateDomain_799" xlink:to="loc_us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember_805" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BaseRateMember" xlink:label="loc_us-gaap_BaseRateMember_815" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateDomain_799" xlink:to="loc_us-gaap_BaseRateMember_815" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentRedemptionPeriodAxis" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis_822" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_808" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis_822" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_807" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis_822" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_807" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentRedemptionPeriodOneMember" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodOneMember_800" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_807" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodOneMember_800" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentRedemptionPeriodTwoMember" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodTwoMember_812" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_807" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodTwoMember_812" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentRedemptionPeriodThreeMember" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodThreeMember_819" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_807" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodThreeMember_819" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_824" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_808" xlink:to="loc_srt_RangeAxis_824" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_801" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_824" xlink:to="loc_srt_RangeMember_801" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_802" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_801" xlink:to="loc_srt_MinimumMember_802" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_813" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_801" xlink:to="loc_srt_MaximumMember_813" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="loc_us-gaap_DebtInstrumentLineItems_826" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_808" xlink:to="loc_us-gaap_DebtInstrumentLineItems_826" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_810" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_826" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_810" use="optional" order="25" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateTerms" xlink:label="loc_us-gaap_DebtInstrumentInterestRateTerms_817" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_826" xlink:to="loc_us-gaap_DebtInstrumentInterestRateTerms_817" use="optional" order="26" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:label="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_821" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_826" xlink:to="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_821" use="optional" order="27" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentPeriodicPaymentPrincipal" xlink:label="loc_us-gaap_DebtInstrumentPeriodicPaymentPrincipal_823" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_826" xlink:to="loc_us-gaap_DebtInstrumentPeriodicPaymentPrincipal_823" use="optional" order="28" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFrequencyOfPeriodicPayment" xlink:label="loc_us-gaap_DebtInstrumentFrequencyOfPeriodicPayment_825" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_826" xlink:to="loc_us-gaap_DebtInstrumentFrequencyOfPeriodicPayment_825" use="optional" order="29" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebt" xlink:label="loc_us-gaap_LongTermDebt_827" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_826" xlink:to="loc_us-gaap_LongTermDebt_827" use="optional" order="30" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_828" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_826" xlink:to="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_828" use="optional" order="31" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="btmd-20221231.xsd#btmd_LineOfCreditFacilityMaturityMonthAndYear" xlink:label="loc_btmd_LineOfCreditFacilityMaturityMonthAndYear_829" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_826" xlink:to="loc_btmd_LineOfCreditFacilityMaturityMonthAndYear_829" use="optional" order="32" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturityDate" xlink:label="loc_us-gaap_LongTermDebtMaturityDate_831" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_826" xlink:to="loc_us-gaap_LongTermDebtMaturityDate_831" use="optional" order="33" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCredit" xlink:label="loc_us-gaap_LineOfCredit_832" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_826" xlink:to="loc_us-gaap_LineOfCredit_832" use="optional" order="34" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromLinesOfCredit" xlink:label="loc_us-gaap_ProceedsFromLinesOfCredit_833" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_826" xlink:to="loc_us-gaap_ProceedsFromLinesOfCredit_833" use="optional" order="35" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentCovenantDescription" xlink:label="loc_us-gaap_DebtInstrumentCovenantDescription_834" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_826" xlink:to="loc_us-gaap_DebtInstrumentCovenantDescription_834" use="optional" order="36" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentCovenantCompliance" xlink:label="loc_us-gaap_DebtInstrumentCovenantCompliance_835" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_826" xlink:to="loc_us-gaap_DebtInstrumentCovenantCompliance_835" use="optional" order="37" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RatioOfIndebtednessToNetCapital1" xlink:label="loc_us-gaap_RatioOfIndebtednessToNetCapital1_836" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_826" xlink:to="loc_us-gaap_RatioOfIndebtednessToNetCapital1_836" use="optional" order="38" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="btmd-20221231.xsd#btmd_FixedChargeCoverageRatio" xlink:label="loc_btmd_FixedChargeCoverageRatio_837" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_826" xlink:to="loc_btmd_FixedChargeCoverageRatio_837" use="optional" order="39" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpenseDebt" xlink:label="loc_us-gaap_InterestExpenseDebt_838" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_826" xlink:to="loc_us-gaap_InterestExpenseDebt_838" use="optional" order="40" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtRelatedCommitmentFeesAndDebtIssuanceCosts" xlink:label="loc_us-gaap_DebtRelatedCommitmentFeesAndDebtIssuanceCosts_839" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_826" xlink:to="loc_us-gaap_DebtRelatedCommitmentFeesAndDebtIssuanceCosts_839" use="optional" order="41" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfFinancingCosts" xlink:label="loc_us-gaap_AmortizationOfFinancingCosts_840" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_826" xlink:to="loc_us-gaap_AmortizationOfFinancingCosts_840" use="optional" order="42" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_841" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_826" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_841" use="optional" order="43" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_842" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_826" xlink:to="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_842" use="optional" order="44" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://haymaker.com/role/LongTermDebtScheduleOfOutstandingDebtDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaap_DebtDisclosureAbstract_844" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentCarryingAmount" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_845" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_844" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_845" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="btmd-20221231.xsd#btmd_TeamLoanCurrentPortionBeforeUnamortizedDebtIssuanceCosts" xlink:label="loc_btmd_TeamLoanCurrentPortionBeforeUnamortizedDebtIssuanceCosts_846" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_844" xlink:to="loc_btmd_TeamLoanCurrentPortionBeforeUnamortizedDebtIssuanceCosts_846" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="btmd-20221231.xsd#btmd_TeamLoanNonCurrentPortionBeforeUnamortizedDebtIssuanceCosts" xlink:label="loc_btmd_TeamLoanNonCurrentPortionBeforeUnamortizedDebtIssuanceCosts_847" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_844" xlink:to="loc_btmd_TeamLoanNonCurrentPortionBeforeUnamortizedDebtIssuanceCosts_847" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredFinanceCostsNet" xlink:label="loc_us-gaap_DeferredFinanceCostsNet_848" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_844" xlink:to="loc_us-gaap_DeferredFinanceCostsNet_848" use="optional" order="4" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtNoncurrent" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_849" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_844" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_849" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://haymaker.com/role/LongTermDebtScheduleOfFutureMaturitiesOfLongTermDebtDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaap_DebtDisclosureAbstract_851" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_853" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_851" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_853" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_854" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_851" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_854" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_855" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_851" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_855" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_856" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_851" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_856" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_857" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_851" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_857" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebt" xlink:label="loc_us-gaap_LongTermDebt_858" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_851" xlink:to="loc_us-gaap_LongTermDebt_858" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://haymaker.com/role/WarrantLiabilityAdditionalInformationDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantsAndRightsNoteDisclosureAbstract" xlink:label="loc_us-gaap_WarrantsAndRightsNoteDisclosureAbstract_860" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="loc_us-gaap_ClassOfWarrantOrRightTable_873" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WarrantsAndRightsNoteDisclosureAbstract_860" xlink:to="loc_us-gaap_ClassOfWarrantOrRightTable_873" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_862" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_873" xlink:to="loc_us-gaap_StatementClassOfStockAxis_862" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_870" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_862" xlink:to="loc_us-gaap_ClassOfStockDomain_870" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonClassAMember" xlink:label="loc_us-gaap_CommonClassAMember_865" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_870" xlink:to="loc_us-gaap_CommonClassAMember_865" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_876" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_873" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_876" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_875" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_876" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_875" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="btmd-20221231.xsd#btmd_RedeemableWarrantsMember" xlink:label="loc_btmd_RedeemableWarrantsMember_868" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_875" xlink:to="loc_btmd_RedeemableWarrantsMember_868" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="btmd-20221231.xsd#btmd_PrivatePlacementWarrantsMember" xlink:label="loc_btmd_PrivatePlacementWarrantsMember_878" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_875" xlink:to="loc_btmd_PrivatePlacementWarrantsMember_878" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="btmd-20221231.xsd#btmd_PublicWarrantsMember" xlink:label="loc_btmd_PublicWarrantsMember_882" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_875" xlink:to="loc_btmd_PublicWarrantsMember_882" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidatedEntitiesAxis" xlink:label="loc_srt_ConsolidatedEntitiesAxis_880" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_873" xlink:to="loc_srt_ConsolidatedEntitiesAxis_880" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidatedEntitiesDomain" xlink:label="loc_srt_ConsolidatedEntitiesDomain_874" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidatedEntitiesAxis_880" xlink:to="loc_srt_ConsolidatedEntitiesDomain_874" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="btmd-20221231.xsd#btmd_HaymakeriiiMember" xlink:label="loc_btmd_HaymakeriiiMember_869" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidatedEntitiesDomain_874" xlink:to="loc_btmd_HaymakeriiiMember_869" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="loc_us-gaap_MeasurementInputTypeAxis_884" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_873" xlink:to="loc_us-gaap_MeasurementInputTypeAxis_884" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_872" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_884" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_872" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="btmd-20221231.xsd#btmd_SharePriceEqualOrExceedsTenRupeesPerDollarMember" xlink:label="loc_btmd_SharePriceEqualOrExceedsTenRupeesPerDollarMember_871" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_872" xlink:to="loc_btmd_SharePriceEqualOrExceedsTenRupeesPerDollarMember_871" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="btmd-20221231.xsd#btmd_SharePriceEqualOrExceedsEighteenRupeesPerDollarMember" xlink:label="loc_btmd_SharePriceEqualOrExceedsEighteenRupeesPerDollarMember_879" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_872" xlink:to="loc_btmd_SharePriceEqualOrExceedsEighteenRupeesPerDollarMember_879" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="btmd-20221231.xsd#btmd_SharePriceEqualOrLessNinePointTwoRupeesPerDollarMember" xlink:label="loc_btmd_SharePriceEqualOrLessNinePointTwoRupeesPerDollarMember_883" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_872" xlink:to="loc_btmd_SharePriceEqualOrLessNinePointTwoRupeesPerDollarMember_883" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_886" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_873" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_886" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_861" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_886" xlink:to="loc_us-gaap_RelatedPartyDomain_861" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="btmd-20221231.xsd#btmd_SponseMember" xlink:label="loc_btmd_SponseMember_866" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_861" xlink:to="loc_btmd_SponseMember_866" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementScenarioAxis" xlink:label="loc_srt_StatementScenarioAxis_888" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_873" xlink:to="loc_srt_StatementScenarioAxis_888" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="loc_srt_ScenarioUnspecifiedDomain_867" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementScenarioAxis_888" xlink:to="loc_srt_ScenarioUnspecifiedDomain_867" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="loc_us-gaap_ClassOfWarrantOrRightLineItems_890" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_873" xlink:to="loc_us-gaap_ClassOfWarrantOrRightLineItems_890" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="btmd-20221231.xsd#btmd_ClassOfWarrantOrRightRedemptionThresholdConsecutiveTradingDays" xlink:label="loc_btmd_ClassOfWarrantOrRightRedemptionThresholdConsecutiveTradingDays_864" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_890" xlink:to="loc_btmd_ClassOfWarrantOrRightRedemptionThresholdConsecutiveTradingDays_864" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="btmd-20221231.xsd#btmd_ClassOfWarrantOrRightThresholdPeriodForExerciseFromDateOfClosingPublicOffering" xlink:label="loc_btmd_ClassOfWarrantOrRightThresholdPeriodForExerciseFromDateOfClosingPublicOffering_877" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_890" xlink:to="loc_btmd_ClassOfWarrantOrRightThresholdPeriodForExerciseFromDateOfClosingPublicOffering_877" use="optional" order="25" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_881" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_890" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_881" use="optional" order="26" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_885" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_890" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_885" use="optional" order="27" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantsAndRightsOutstandingMaturityDate" xlink:label="loc_us-gaap_WarrantsAndRightsOutstandingMaturityDate_887" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_890" xlink:to="loc_us-gaap_WarrantsAndRightsOutstandingMaturityDate_887" use="optional" order="28" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="loc_us-gaap_WarrantsAndRightsOutstandingTerm_889" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_890" xlink:to="loc_us-gaap_WarrantsAndRightsOutstandingTerm_889" use="optional" order="29" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="btmd-20221231.xsd#btmd_ClassOfWarrantsOrRightsTransfersRestrictionOnNumberOfDaysFromTheDateOfBusinessCombination" xlink:label="loc_btmd_ClassOfWarrantsOrRightsTransfersRestrictionOnNumberOfDaysFromTheDateOfBusinessCombination_891" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_890" xlink:to="loc_btmd_ClassOfWarrantsOrRightsTransfersRestrictionOnNumberOfDaysFromTheDateOfBusinessCombination_891" use="optional" order="30" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="btmd-20221231.xsd#btmd_NumberOfDaysFollowingItsInitialBusinessCombinationUntilTheExpirationOfTheWarrants" xlink:label="loc_btmd_NumberOfDaysFollowingItsInitialBusinessCombinationUntilTheExpirationOfTheWarrants_892" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_890" xlink:to="loc_btmd_NumberOfDaysFollowingItsInitialBusinessCombinationUntilTheExpirationOfTheWarrants_892" use="optional" order="31" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="btmd-20221231.xsd#btmd_ClassOfWarrantsRedemptionPricePerUnit" xlink:label="loc_btmd_ClassOfWarrantsRedemptionPricePerUnit_893" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_890" xlink:to="loc_btmd_ClassOfWarrantsRedemptionPricePerUnit_893" use="optional" order="32" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaap_SharePrice_895" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_890" xlink:to="loc_us-gaap_SharePrice_895" use="optional" order="33" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="btmd-20221231.xsd#btmd_NumberOfConsecutiveTradingDaysForDeterminingSharePrice" xlink:label="loc_btmd_NumberOfConsecutiveTradingDaysForDeterminingSharePrice_896" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_890" xlink:to="loc_btmd_NumberOfConsecutiveTradingDaysForDeterminingSharePrice_896" use="optional" order="34" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="btmd-20221231.xsd#btmd_ShareRedemptionTriggerPrice" xlink:label="loc_btmd_ShareRedemptionTriggerPrice_898" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_890" xlink:to="loc_btmd_ShareRedemptionTriggerPrice_898" use="optional" order="35" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="btmd-20221231.xsd#btmd_PrivatePlacementWarrantsRedemptionDescription" xlink:label="loc_btmd_PrivatePlacementWarrantsRedemptionDescription_899" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_890" xlink:to="loc_btmd_PrivatePlacementWarrantsRedemptionDescription_899" use="optional" order="36" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="btmd-20221231.xsd#btmd_MinimumGrossProceedsRequiredFromIssuanceOfEquity" xlink:label="loc_btmd_MinimumGrossProceedsRequiredFromIssuanceOfEquity_900" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_890" xlink:to="loc_btmd_MinimumGrossProceedsRequiredFromIssuanceOfEquity_900" use="optional" order="37" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="btmd-20221231.xsd#btmd_ClassOfWarrantOrRightMinimumNoticePeriodForRedemption" xlink:label="loc_btmd_ClassOfWarrantOrRightMinimumNoticePeriodForRedemption_901" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_890" xlink:to="loc_btmd_ClassOfWarrantOrRightMinimumNoticePeriodForRedemption_901" use="optional" order="38" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="btmd-20221231.xsd#btmd_ClassOfWarrantOrRightExercisePriceAdjustmentPercentageHigherOfMarketValue" xlink:label="loc_btmd_ClassOfWarrantOrRightExercisePriceAdjustmentPercentageHigherOfMarketValue_902" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_890" xlink:to="loc_btmd_ClassOfWarrantOrRightExercisePriceAdjustmentPercentageHigherOfMarketValue_902" use="optional" order="39" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_903" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_890" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_903" use="optional" order="40" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="loc_us-gaap_SharesIssuedPricePerShare_904" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_890" xlink:to="loc_us-gaap_SharesIssuedPricePerShare_904" use="optional" order="41" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueIssuedForServices_905" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_890" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueIssuedForServices_905" use="optional" order="42" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding_906" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_890" xlink:to="loc_us-gaap_ClassOfWarrantOrRightOutstanding_906" use="optional" order="43" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="btmd-20221231.xsd#btmd_PublicWarrantsRedeemed" xlink:label="loc_btmd_PublicWarrantsRedeemed_907" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_890" xlink:to="loc_btmd_PublicWarrantsRedeemed_907" use="optional" order="44" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://haymaker.com/role/EarnoutLiabilityAdditionalInformationDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_909" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesTable" xlink:label="loc_us-gaap_LossContingenciesTable_918" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_909" xlink:to="loc_us-gaap_LossContingenciesTable_918" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_919" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_918" xlink:to="loc_us-gaap_StatementClassOfStockAxis_919" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_916" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_919" xlink:to="loc_us-gaap_ClassOfStockDomain_916" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonClassAMember" xlink:label="loc_us-gaap_CommonClassAMember_914" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_916" xlink:to="loc_us-gaap_CommonClassAMember_914" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VestingAxis" xlink:label="loc_us-gaap_VestingAxis_922" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_918" xlink:to="loc_us-gaap_VestingAxis_922" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VestingDomain" xlink:label="loc_us-gaap_VestingDomain_915" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VestingAxis_922" xlink:to="loc_us-gaap_VestingDomain_915" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="btmd-20221231.xsd#btmd_SharePriceEqualsOrExceedsTwelvePointFivePerShareMember" xlink:label="loc_btmd_SharePriceEqualsOrExceedsTwelvePointFivePerShareMember_920" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VestingDomain_915" xlink:to="loc_btmd_SharePriceEqualsOrExceedsTwelvePointFivePerShareMember_920" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="btmd-20221231.xsd#btmd_SharePriceEqualsOrExceedsFifteenPerShareMember" xlink:label="loc_btmd_SharePriceEqualsOrExceedsFifteenPerShareMember_923" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VestingDomain_915" xlink:to="loc_btmd_SharePriceEqualsOrExceedsFifteenPerShareMember_923" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="btmd-20221231.xsd#btmd_SharePriceEqualsOrExceedsSeventeenPointFivePerShareMember" xlink:label="loc_btmd_SharePriceEqualsOrExceedsSeventeenPointFivePerShareMember_926" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VestingDomain_915" xlink:to="loc_btmd_SharePriceEqualsOrExceedsSeventeenPointFivePerShareMember_926" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_925" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_918" xlink:to="loc_srt_RangeAxis_925" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_912" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_925" xlink:to="loc_srt_RangeMember_912" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_913" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_912" xlink:to="loc_srt_MaximumMember_913" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_928" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_918" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_928" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_910" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_928" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_910" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="btmd-20221231.xsd#btmd_BusinessCombinationMember" xlink:label="loc_btmd_BusinessCombinationMember_911" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_910" xlink:to="loc_btmd_BusinessCombinationMember_911" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesLineItems" xlink:label="loc_us-gaap_LossContingenciesLineItems_930" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_918" xlink:to="loc_us-gaap_LossContingenciesLineItems_930" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="btmd-20221231.xsd#btmd_NumberOfEarnoutSecuritiesShareholderEntitledToVestIfCertainSharePriceTargetsAchieved" xlink:label="loc_btmd_NumberOfEarnoutSecuritiesShareholderEntitledToVestIfCertainSharePriceTargetsAchieved_921" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_930" xlink:to="loc_btmd_NumberOfEarnoutSecuritiesShareholderEntitledToVestIfCertainSharePriceTargetsAchieved_921" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="btmd-20221231.xsd#btmd_EarnoutDeadlineDate" xlink:label="loc_btmd_EarnoutDeadlineDate_924" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_930" xlink:to="loc_btmd_EarnoutDeadlineDate_924" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaap_SharePrice_927" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_930" xlink:to="loc_us-gaap_SharePrice_927" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="btmd-20221231.xsd#btmd_CommonStockTransfersThresholdTradingDays" xlink:label="loc_btmd_CommonStockTransfersThresholdTradingDays_929" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_930" xlink:to="loc_btmd_CommonStockTransfersThresholdTradingDays_929" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="btmd-20221231.xsd#btmd_NumberOfConsecutiveTradingDaysForDeterminingTheSharePrice" xlink:label="loc_btmd_NumberOfConsecutiveTradingDaysForDeterminingTheSharePrice_931" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_930" xlink:to="loc_btmd_NumberOfConsecutiveTradingDaysForDeterminingTheSharePrice_931" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://haymaker.com/role/FairValueMeasurementsScheduleOfFairValueHierarchyForFinancialAssetsAndLiabilitiesDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_933" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_934" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_933" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_934" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="loc_us-gaap_FinancialInstrumentAxis_938" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_934" xlink:to="loc_us-gaap_FinancialInstrumentAxis_938" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_939" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_938" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_939" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="btmd-20221231.xsd#btmd_PublicWarrantsMember" xlink:label="loc_btmd_PublicWarrantsMember_935" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_939" xlink:to="loc_btmd_PublicWarrantsMember_935" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="btmd-20221231.xsd#btmd_PrivatePlacementWarrantsMember" xlink:label="loc_btmd_PrivatePlacementWarrantsMember_941" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_939" xlink:to="loc_btmd_PrivatePlacementWarrantsMember_941" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="btmd-20221231.xsd#btmd_EarnoutLiabilityMember" xlink:label="loc_btmd_EarnoutLiabilityMember_944" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_939" xlink:to="loc_btmd_EarnoutLiabilityMember_944" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_942" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_934" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_942" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_936" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_942" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_936" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_940" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_936" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_940" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_946" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_936" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_946" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_945" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_934" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_945" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialLiabilitiesFairValueDisclosure" xlink:label="loc_us-gaap_FinancialLiabilitiesFairValueDisclosure_937" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_945" xlink:to="loc_us-gaap_FinancialLiabilitiesFairValueDisclosure_937" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://haymaker.com/role/FairValueMeasurementsSummaryOfSignificantInputsToMonteCarloSimulationForFairValueOfPrivatePlacementWarrantsDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_948" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_949" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_948" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_949" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="loc_us-gaap_FinancialInstrumentAxis_950" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_949" xlink:to="loc_us-gaap_FinancialInstrumentAxis_950" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_955" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_950" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_955" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="btmd-20221231.xsd#btmd_PrivatePlacementWarrantsMember" xlink:label="loc_btmd_PrivatePlacementWarrantsMember_952" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_955" xlink:to="loc_btmd_PrivatePlacementWarrantsMember_952" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="loc_us-gaap_MeasurementInputTypeAxis_956" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_949" xlink:to="loc_us-gaap_MeasurementInputTypeAxis_956" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_954" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_956" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_954" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputSharePriceMember" xlink:label="loc_us-gaap_MeasurementInputSharePriceMember_953" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_954" xlink:to="loc_us-gaap_MeasurementInputSharePriceMember_953" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputExercisePriceMember" xlink:label="loc_us-gaap_MeasurementInputExercisePriceMember_958" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_954" xlink:to="loc_us-gaap_MeasurementInputExercisePriceMember_958" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:label="loc_us-gaap_MeasurementInputRiskFreeInterestRateMember_961" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_954" xlink:to="loc_us-gaap_MeasurementInputRiskFreeInterestRateMember_961" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputOptionVolatilityMember" xlink:label="loc_us-gaap_MeasurementInputOptionVolatilityMember_962" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_954" xlink:to="loc_us-gaap_MeasurementInputOptionVolatilityMember_962" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputExpectedTermMember" xlink:label="loc_us-gaap_MeasurementInputExpectedTermMember_963" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_954" xlink:to="loc_us-gaap_MeasurementInputExpectedTermMember_963" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_959" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_949" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_959" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_951" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_959" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_951" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="loc_us-gaap_WarrantsAndRightsOutstandingTerm_957" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_959" xlink:to="loc_us-gaap_WarrantsAndRightsOutstandingTerm_957" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:label="loc_us-gaap_WarrantsAndRightsOutstandingMeasurementInput_960" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_959" xlink:to="loc_us-gaap_WarrantsAndRightsOutstandingMeasurementInput_960" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://haymaker.com/role/FairValueMeasurementsSummaryOfSignificantInputsToMonteCarloSimulationForFairValueOfEarnoutLiabilityDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_965" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_966" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_965" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_966" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="loc_us-gaap_FinancialInstrumentAxis_967" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_966" xlink:to="loc_us-gaap_FinancialInstrumentAxis_967" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_972" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_967" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_972" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="btmd-20221231.xsd#btmd_EarnoutLiabilityMember" xlink:label="loc_btmd_EarnoutLiabilityMember_969" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_972" xlink:to="loc_btmd_EarnoutLiabilityMember_969" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="loc_us-gaap_MeasurementInputTypeAxis_973" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_966" xlink:to="loc_us-gaap_MeasurementInputTypeAxis_973" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_971" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_973" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_971" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputSharePriceMember" xlink:label="loc_us-gaap_MeasurementInputSharePriceMember_970" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_971" xlink:to="loc_us-gaap_MeasurementInputSharePriceMember_970" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:label="loc_us-gaap_MeasurementInputRiskFreeInterestRateMember_975" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_971" xlink:to="loc_us-gaap_MeasurementInputRiskFreeInterestRateMember_975" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputOptionVolatilityMember" xlink:label="loc_us-gaap_MeasurementInputOptionVolatilityMember_978" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_971" xlink:to="loc_us-gaap_MeasurementInputOptionVolatilityMember_978" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputExpectedTermMember" xlink:label="loc_us-gaap_MeasurementInputExpectedTermMember_979" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_971" xlink:to="loc_us-gaap_MeasurementInputExpectedTermMember_979" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_976" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_966" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_976" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_968" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_976" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_968" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:label="loc_us-gaap_WarrantsAndRightsOutstandingMeasurementInput_974" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_976" xlink:to="loc_us-gaap_WarrantsAndRightsOutstandingMeasurementInput_974" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="loc_us-gaap_WarrantsAndRightsOutstandingTerm_977" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_976" xlink:to="loc_us-gaap_WarrantsAndRightsOutstandingTerm_977" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://haymaker.com/role/FairValueMeasurementsSummaryOfChangesInTheFairValueOfCompanysLevel3FinancialInstrumentsDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_981" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_982" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_981" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_982" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="loc_us-gaap_FinancialInstrumentAxis_985" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_982" xlink:to="loc_us-gaap_FinancialInstrumentAxis_985" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_986" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_985" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_986" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="btmd-20221231.xsd#btmd_PrivatePlacementWarrantsMember" xlink:label="loc_btmd_PrivatePlacementWarrantsMember_983" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_986" xlink:to="loc_btmd_PrivatePlacementWarrantsMember_983" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="btmd-20221231.xsd#btmd_EarnoutLiabilityMember" xlink:label="loc_btmd_EarnoutLiabilityMember_987" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_986" xlink:to="loc_btmd_EarnoutLiabilityMember_987" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_989" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_982" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_989" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialLiabilitiesFairValueDisclosure" xlink:label="loc_us-gaap_FinancialLiabilitiesFairValueDisclosure_984" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_989" xlink:to="loc_us-gaap_FinancialLiabilitiesFairValueDisclosure_984" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueOptionChangesInFairValueGainLoss1" xlink:label="loc_us-gaap_FairValueOptionChangesInFairValueGainLoss1_988" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_989" xlink:to="loc_us-gaap_FairValueOptionChangesInFairValueGainLoss1_988" use="optional" order="8" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialLiabilitiesFairValueDisclosure" xlink:label="loc_us-gaap_FinancialLiabilitiesFairValueDisclosure_990" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_989" xlink:to="loc_us-gaap_FinancialLiabilitiesFairValueDisclosure_990" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://haymaker.com/role/NoncontrollingInterestAdditionalInformationDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncontrollingInterestAbstract" xlink:label="loc_us-gaap_NoncontrollingInterestAbstract_992" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MinorityInterestTable" xlink:label="loc_us-gaap_MinorityInterestTable_998" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncontrollingInterestAbstract_992" xlink:to="loc_us-gaap_MinorityInterestTable_998" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_OwnershipAxis" xlink:label="loc_srt_OwnershipAxis_997" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MinorityInterestTable_998" xlink:to="loc_srt_OwnershipAxis_997" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_OwnershipDomain" xlink:label="loc_srt_OwnershipDomain_999" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_OwnershipAxis_997" xlink:to="loc_srt_OwnershipDomain_999" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="btmd-20221231.xsd#btmd_MinorityInterestHoldersMember" xlink:label="loc_btmd_MinorityInterestHoldersMember_996" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_OwnershipDomain_999" xlink:to="loc_btmd_MinorityInterestHoldersMember_996" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="btmd-20221231.xsd#btmd_BioteCorporationMember" xlink:label="loc_btmd_BioteCorporationMember_1001" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_OwnershipDomain_999" xlink:to="loc_btmd_BioteCorporationMember_1001" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_1002" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MinorityInterestTable_998" xlink:to="loc_us-gaap_StatementClassOfStockAxis_1002" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_995" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_1002" xlink:to="loc_us-gaap_ClassOfStockDomain_995" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="btmd-20221231.xsd#btmd_CommonClassVMember" xlink:label="loc_btmd_CommonClassVMember_994" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_995" xlink:to="loc_btmd_CommonClassVMember_994" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MinorityInterestLineItems" xlink:label="loc_us-gaap_MinorityInterestLineItems_1004" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MinorityInterestTable_998" xlink:to="loc_us-gaap_MinorityInterestLineItems_1004" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners" xlink:label="loc_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners_993" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MinorityInterestLineItems_1004" xlink:to="loc_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners_993" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MinorityInterestOwnershipPercentageByParent" xlink:label="loc_us-gaap_MinorityInterestOwnershipPercentageByParent_1000" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MinorityInterestLineItems_1004" xlink:to="loc_us-gaap_MinorityInterestOwnershipPercentageByParent_1000" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_1003" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MinorityInterestLineItems_1004" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_1003" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockVotingRights" xlink:label="loc_us-gaap_CommonStockVotingRights_1005" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MinorityInterestLineItems_1004" xlink:to="loc_us-gaap_CommonStockVotingRights_1005" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="btmd-20221231.xsd#btmd_CommonStockNumberOfVotesEntitledPerShare" xlink:label="loc_btmd_CommonStockNumberOfVotesEntitledPerShare_1006" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MinorityInterestLineItems_1004" xlink:to="loc_btmd_CommonStockNumberOfVotesEntitledPerShare_1006" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://haymaker.com/role/ShareBasedCompensationAdditionalInformationDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_1008" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1010" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_1008" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1010" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_1018" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1010" xlink:to="loc_us-gaap_StatementClassOfStockAxis_1018" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_1014" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_1018" xlink:to="loc_us-gaap_ClassOfStockDomain_1014" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="btmd-20221231.xsd#btmd_CommonClassVMember" xlink:label="loc_btmd_CommonClassVMember_1013" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_1014" xlink:to="loc_btmd_CommonClassVMember_1013" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaap_PlanNameAxis_1023" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1010" xlink:to="loc_us-gaap_PlanNameAxis_1023" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_1019" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_1023" xlink:to="loc_us-gaap_PlanNameDomain_1019" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="btmd-20221231.xsd#btmd_TwoThousandTwentyTwoEquityIncentivePlanMember" xlink:label="loc_btmd_TwoThousandTwentyTwoEquityIncentivePlanMember_1009" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_1019" xlink:to="loc_btmd_TwoThousandTwentyTwoEquityIncentivePlanMember_1009" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_1026" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1010" xlink:to="loc_us-gaap_AwardTypeAxis_1026" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1016" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_1026" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1016" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="btmd-20221231.xsd#btmd_IncentiveUnitsMember" xlink:label="loc_btmd_IncentiveUnitsMember_1015" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1016" xlink:to="loc_btmd_IncentiveUnitsMember_1015" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="btmd-20221231.xsd#btmd_PhantomEquityRightsMember" xlink:label="loc_btmd_PhantomEquityRightsMember_1021" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1016" xlink:to="loc_btmd_PhantomEquityRightsMember_1021" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_1024" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1016" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_1024" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_1027" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1016" xlink:to="loc_us-gaap_EmployeeStockOptionMember_1027" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_1029" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1010" xlink:to="loc_srt_RangeAxis_1029" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_1011" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_1029" xlink:to="loc_srt_RangeMember_1011" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_1012" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_1011" xlink:to="loc_srt_MinimumMember_1012" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_1020" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_1011" xlink:to="loc_srt_MaximumMember_1020" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1031" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1010" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1031" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="btmd-20221231.xsd#btmd_ShareBasedCompensationArrangementVestingOfIncentiveUnits" xlink:label="loc_btmd_ShareBasedCompensationArrangementVestingOfIncentiveUnits_1017" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1031" xlink:to="loc_btmd_ShareBasedCompensationArrangementVestingOfIncentiveUnits_1017" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_1022" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1031" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_1022" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SettlementLiabilitiesCurrent" xlink:label="loc_us-gaap_SettlementLiabilitiesCurrent_1025" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1031" xlink:to="loc_us-gaap_SettlementLiabilitiesCurrent_1025" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConversionOfStockSharesConverted1" xlink:label="loc_us-gaap_ConversionOfStockSharesConverted1_1028" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1031" xlink:to="loc_us-gaap_ConversionOfStockSharesConverted1_1028" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_1030" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1031" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_1030" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_1032" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1031" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_1032" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_1033" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1031" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_1033" use="optional" order="25" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://haymaker.com/role/ShareBasedCompensationSummaryOfRestrictedStockUnitActivityDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_1035" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1037" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_1035" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1037" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_1041" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1037" xlink:to="loc_us-gaap_AwardTypeAxis_1041" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1039" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_1041" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1039" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_1038" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1039" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_1038" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaap_PlanNameAxis_1044" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1037" xlink:to="loc_us-gaap_PlanNameAxis_1044" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_1042" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_1044" xlink:to="loc_us-gaap_PlanNameDomain_1042" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="btmd-20221231.xsd#btmd_TwoThousandTwentyTwoEquityIncentivePlanMember" xlink:label="loc_btmd_TwoThousandTwentyTwoEquityIncentivePlanMember_1036" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_1042" xlink:to="loc_btmd_TwoThousandTwentyTwoEquityIncentivePlanMember_1036" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1046" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1037" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1046" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_1040" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1046" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_1040" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_1043" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1046" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_1043" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_1045" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1046" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_1045" use="optional" order="11" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_1047" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1046" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_1047" use="optional" order="12" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_1048" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1046" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_1048" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_1049" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1046" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_1049" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_1050" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1046" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_1050" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_1051" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1046" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_1051" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_1052" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1046" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_1052" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_1053" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1046" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_1053" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://haymaker.com/role/ShareBasedCompensationSummaryOfStockOptionActivityDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_1055" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1057" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_1055" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1057" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaap_PlanNameAxis_1059" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1057" xlink:to="loc_us-gaap_PlanNameAxis_1059" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_1060" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_1059" xlink:to="loc_us-gaap_PlanNameDomain_1060" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="btmd-20221231.xsd#btmd_TwoThousandTwentyTwoEquityIncentivePlanMember" xlink:label="loc_btmd_TwoThousandTwentyTwoEquityIncentivePlanMember_1056" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_1060" xlink:to="loc_btmd_TwoThousandTwentyTwoEquityIncentivePlanMember_1056" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1062" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1057" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1062" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_1061" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1062" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_1061" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_1063" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1062" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_1063" use="optional" order="7" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_1064" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1062" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_1064" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_1065" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1062" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_1065" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_1067" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1062" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_1067" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_1068" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1062" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_1068" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_1069" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1062" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_1069" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_1070" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1062" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_1070" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_1071" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1062" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_1071" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_1072" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1062" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_1072" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://haymaker.com/role/ShareBasedCompensationSummaryOfWeightedAverageAssumptionsUsedToEstimateFairValueOfStockOptionsGrantedDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_1074" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1076" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_1074" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1076" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaap_PlanNameAxis_1078" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1076" xlink:to="loc_us-gaap_PlanNameAxis_1078" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_1079" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_1078" xlink:to="loc_us-gaap_PlanNameDomain_1079" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="btmd-20221231.xsd#btmd_TwoThousandTwentyTwoEquityIncentivePlanMember" xlink:label="loc_btmd_TwoThousandTwentyTwoEquityIncentivePlanMember_1075" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_1079" xlink:to="loc_btmd_TwoThousandTwentyTwoEquityIncentivePlanMember_1075" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1081" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1076" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1081" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_1077" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1081" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_1077" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_1080" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1081" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_1080" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_1082" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1081" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_1082" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_1083" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1081" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_1083" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://haymaker.com/role/LeasesAdditionalInformationDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract" xlink:label="loc_us-gaap_LeasesAbstract_1085" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseExpirationDate1" xlink:label="loc_us-gaap_LeaseExpirationDate1_1086" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_1085" xlink:to="loc_us-gaap_LeaseExpirationDate1_1086" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseOptionToExtend" xlink:label="loc_us-gaap_LesseeOperatingLeaseOptionToExtend_1087" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_1085" xlink:to="loc_us-gaap_LesseeOperatingLeaseOptionToExtend_1087" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="btmd-20221231.xsd#btmd_AreaOfOfficeSpace" xlink:label="loc_btmd_AreaOfOfficeSpace_1089" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_1085" xlink:to="loc_btmd_AreaOfOfficeSpace_1089" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://haymaker.com/role/LeasesSummaryOfOperatingLeaseCostsRecognizedUnderAsc842AndSupplementalCashFlowInformationForLeasesDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract" xlink:label="loc_us-gaap_LeasesAbstract_1091" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseCost" xlink:label="loc_us-gaap_OperatingLeaseCost_1092" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_1091" xlink:to="loc_us-gaap_OperatingLeaseCost_1092" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseCost" xlink:label="loc_us-gaap_LeaseCost_1094" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_1091" xlink:to="loc_us-gaap_LeaseCost_1094" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="btmd-20221231.xsd#btmd_OtherInformationAbstract" xlink:label="loc_btmd_OtherInformationAbstract_1096" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_1091" xlink:to="loc_btmd_OtherInformationAbstract_1096" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeasePayments" xlink:label="loc_us-gaap_OperatingLeasePayments_1093" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_btmd_OtherInformationAbstract_1096" xlink:to="loc_us-gaap_OperatingLeasePayments_1093" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_1095" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_btmd_OtherInformationAbstract_1096" xlink:to="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_1095" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://haymaker.com/role/LeasesSummaryBalanceSheetClassificationOfOperatingLeasesAndWeightedAverageRemainingLeaseTermAndDiscountRateDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract" xlink:label="loc_us-gaap_LeasesAbstract_1098" />
<loc xlink:type="locator" xlink:href="btmd-20221231.xsd#btmd_AssetsLesseeAbstract" xlink:label="loc_btmd_AssetsLesseeAbstract_1100" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_1098" xlink:to="loc_btmd_AssetsLesseeAbstract_1100" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_1099" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_btmd_AssetsLesseeAbstract_1100" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_1099" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="btmd-20221231.xsd#btmd_LeaseAssets" xlink:label="loc_btmd_LeaseAssets_1102" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_btmd_AssetsLesseeAbstract_1100" xlink:to="loc_btmd_LeaseAssets_1102" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="btmd-20221231.xsd#btmd_LiabilitiesLesseeAbstract" xlink:label="loc_btmd_LiabilitiesLesseeAbstract_1103" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_1098" xlink:to="loc_btmd_LiabilitiesLesseeAbstract_1103" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_1101" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_btmd_LiabilitiesLesseeAbstract_1103" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_1101" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_1104" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_btmd_LiabilitiesLesseeAbstract_1103" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_1104" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability" xlink:label="loc_us-gaap_OperatingLeaseLiability_1106" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_btmd_LiabilitiesLesseeAbstract_1103" xlink:to="loc_us-gaap_OperatingLeaseLiability_1106" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_1105" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_1098" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_1105" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_1107" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_1098" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_1107" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://haymaker.com/role/LeasesSummaryOfPaymentsByDateForOperatingLeaseDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:label="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_1109" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_1110" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_1109" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_1110" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_1111" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_1109" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_1111" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_1112" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_1109" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_1112" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_1113" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_1109" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_1113" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_1114" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_1109" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_1114" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_1115" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_1109" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_1115" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_1116" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_1109" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_1116" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_1117" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_1109" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_1117" use="optional" order="8" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability" xlink:label="loc_us-gaap_OperatingLeaseLiability_1118" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_1109" xlink:to="loc_us-gaap_OperatingLeaseLiability_1118" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://haymaker.com/role/IncomeTaxesAdditionalInformationDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_1120" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowanceTable" xlink:label="loc_us-gaap_ValuationAllowanceTable_1122" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_1120" xlink:to="loc_us-gaap_ValuationAllowanceTable_1122" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_1124" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationAllowanceTable_1122" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_1124" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_1125" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_1124" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_1125" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCountryMember" xlink:label="loc_us-gaap_ForeignCountryMember_1121" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_1125" xlink:to="loc_us-gaap_ForeignCountryMember_1121" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowanceLineItems" xlink:label="loc_us-gaap_ValuationAllowanceLineItems_1127" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationAllowanceTable_1122" xlink:to="loc_us-gaap_ValuationAllowanceLineItems_1127" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="loc_us-gaap_OperatingLossCarryforwards_1123" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationAllowanceLineItems_1127" xlink:to="loc_us-gaap_OperatingLossCarryforwards_1123" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="btmd-20221231.xsd#btmd_OperatingLossCarryforwardsExpirationYear" xlink:label="loc_btmd_OperatingLossCarryforwardsExpirationYear_1126" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationAllowanceLineItems_1127" xlink:to="loc_btmd_OperatingLossCarryforwardsExpirationYear_1126" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_1128" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationAllowanceLineItems_1127" xlink:to="loc_us-gaap_UnrecognizedTaxBenefits_1128" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExaminationDescription" xlink:label="loc_us-gaap_IncomeTaxExaminationDescription_1129" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationAllowanceLineItems_1127" xlink:to="loc_us-gaap_IncomeTaxExaminationDescription_1129" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://haymaker.com/role/IncomeTaxesScheduleOfIncomeLossBeforeProvisionForIncomeTaxesDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_1131" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_1132" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_1131" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_1132" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_1133" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_1131" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_1133" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_1134" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_1131" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_1134" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://haymaker.com/role/IncomeTaxesScheduleOfIncomeTaxProvisionDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_1136" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_1137" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_1136" xlink:to="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_1137" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentFederalTaxExpenseBenefit" xlink:label="loc_us-gaap_CurrentFederalTaxExpenseBenefit_1138" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_1137" xlink:to="loc_us-gaap_CurrentFederalTaxExpenseBenefit_1138" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:label="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_1141" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_1137" xlink:to="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_1141" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentForeignTaxExpenseBenefit" xlink:label="loc_us-gaap_CurrentForeignTaxExpenseBenefit_1143" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_1137" xlink:to="loc_us-gaap_CurrentForeignTaxExpenseBenefit_1143" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_1145" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_1137" xlink:to="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_1145" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_1140" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_1136" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_1140" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_1139" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_1140" xlink:to="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_1139" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_1142" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_1140" xlink:to="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_1142" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_1146" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_1140" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_1146" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_1147" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_1140" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_1147" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://haymaker.com/role/IncomeTaxesScheduleOfReconciliationOfTheFederalIncomeTaxRateToTheCompanyEffectiveTaxRateDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_1149" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_1150" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_1149" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_1150" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_1151" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_1149" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_1151" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxExemptIncome" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxExemptIncome_1152" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_1149" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxExemptIncome_1152" use="optional" order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_1153" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_1149" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_1153" use="optional" order="4" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_1154" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_1149" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_1154" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_1155" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_1149" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_1155" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://haymaker.com/role/IncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_1157" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsNetAbstract" xlink:label="loc_us-gaap_DeferredTaxAssetsNetAbstract_1158" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_1157" xlink:to="loc_us-gaap_DeferredTaxAssetsNetAbstract_1158" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsInvestments" xlink:label="loc_us-gaap_DeferredTaxAssetsInvestments_1159" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_1158" xlink:to="loc_us-gaap_DeferredTaxAssetsInvestments_1159" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_1160" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_1158" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_1160" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:label="loc_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_1161" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_1158" xlink:to="loc_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_1161" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_1162" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_1158" xlink:to="loc_us-gaap_DeferredTaxAssetsGross_1162" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_1163" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_1158" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_1163" use="optional" order="6" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="loc_us-gaap_DeferredTaxAssetsNet_1164" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_1158" xlink:to="loc_us-gaap_DeferredTaxAssetsNet_1164" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://haymaker.com/role/NetLossPerCommonShareScheduleOfComputationOfNetLossPerCommonShareDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaap_EarningsPerShareAbstract_1166" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable_1167" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_1166" xlink:to="loc_us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable_1167" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_1170" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable_1167" xlink:to="loc_us-gaap_AwardTypeAxis_1170" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1172" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_1170" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1172" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasicLineItems" xlink:label="loc_us-gaap_EarningsPerShareBasicLineItems_1177" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable_1167" xlink:to="loc_us-gaap_EarningsPerShareBasicLineItems_1177" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAbstract" xlink:label="loc_us-gaap_NetIncomeLossAbstract_1169" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicLineItems_1177" xlink:to="loc_us-gaap_NetIncomeLossAbstract_1169" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_1173" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetIncomeLossAbstract_1169" xlink:to="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_1173" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_1179" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetIncomeLossAbstract_1169" xlink:to="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_1179" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_1176" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicLineItems_1177" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_1176" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_1168" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_1176" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_1168" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_1175" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_1176" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_1175" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_1181" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicLineItems_1177" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_1181" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic" xlink:label="loc_us-gaap_EarningsPerShareBasic_1174" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_1181" xlink:to="loc_us-gaap_EarningsPerShareBasic_1174" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="loc_us-gaap_EarningsPerShareDiluted_1180" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_1181" xlink:to="loc_us-gaap_EarningsPerShareDiluted_1180" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://haymaker.com/role/NetLossPerCommonShareScheduleOfComputationOfDilutedWeightedAverageSharesOutstandingDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaap_EarningsPerShareAbstract_1184" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_1185" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_1184" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_1185" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_1193" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_1185" xlink:to="loc_us-gaap_StatementClassOfStockAxis_1193" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_1189" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_1193" xlink:to="loc_us-gaap_ClassOfStockDomain_1189" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="btmd-20221231.xsd#btmd_ClassVCommonStockMember" xlink:label="loc_btmd_ClassVCommonStockMember_1186" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_1189" xlink:to="loc_btmd_ClassVCommonStockMember_1186" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="btmd-20221231.xsd#btmd_EarnoutVotingSharesMember" xlink:label="loc_btmd_EarnoutVotingSharesMember_1194" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_1189" xlink:to="loc_btmd_EarnoutVotingSharesMember_1194" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="btmd-20221231.xsd#btmd_SponsorEarnOutSharesMember" xlink:label="loc_btmd_SponsorEarnOutSharesMember_1198" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_1189" xlink:to="loc_btmd_SponsorEarnOutSharesMember_1198" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_1197" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_1185" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_1197" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_1191" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_1197" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_1191" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="btmd-20221231.xsd#btmd_PublicWarrantsMember" xlink:label="loc_btmd_PublicWarrantsMember_1188" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_1191" xlink:to="loc_btmd_PublicWarrantsMember_1188" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="btmd-20221231.xsd#btmd_PrivatePlacementWarrantsMember" xlink:label="loc_btmd_PrivatePlacementWarrantsMember_1195" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_1191" xlink:to="loc_btmd_PrivatePlacementWarrantsMember_1195" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_1200" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_1185" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_1200" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_1187" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_1200" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_1187" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_1199" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_1187" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_1199" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_1201" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_1187" xlink:to="loc_us-gaap_EmployeeStockOptionMember_1201" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_1202" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_1185" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_1202" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_1190" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_1202" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_1190" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://haymaker.com/role/CommitmentsAndContingenciesAdditionalInformationDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_1205" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesTable" xlink:label="loc_us-gaap_LossContingenciesTable_1208" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_1205" xlink:to="loc_us-gaap_LossContingenciesTable_1208" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1209" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_1208" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1209" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_1206" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1209" xlink:to="loc_us-gaap_RelatedPartyDomain_1206" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesLineItems" xlink:label="loc_us-gaap_LossContingenciesLineItems_1211" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_1208" xlink:to="loc_us-gaap_LossContingenciesLineItems_1211" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyLawsuitFilingDate" xlink:label="loc_us-gaap_LossContingencyLawsuitFilingDate_1207" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_1211" xlink:to="loc_us-gaap_LossContingencyLawsuitFilingDate_1207" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyNameOfPlaintiff" xlink:label="loc_us-gaap_LossContingencyNameOfPlaintiff_1210" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_1211" xlink:to="loc_us-gaap_LossContingencyNameOfPlaintiff_1210" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyNameOfDefendant" xlink:label="loc_us-gaap_LossContingencyNameOfDefendant_1212" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_1211" xlink:to="loc_us-gaap_LossContingencyNameOfDefendant_1212" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyDamagesSoughtValue" xlink:label="loc_us-gaap_LossContingencyDamagesSoughtValue_1213" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_1211" xlink:to="loc_us-gaap_LossContingencyDamagesSoughtValue_1213" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://haymaker.com/role/RelatedPartyTransactionsAdditionalInformationDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_1215" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_1220" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_1215" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_1220" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1222" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_1220" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1222" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_1217" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1222" xlink:to="loc_us-gaap_RelatedPartyDomain_1217" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="btmd-20221231.xsd#btmd_FirmMember" xlink:label="loc_btmd_FirmMember_1218" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_1217" xlink:to="loc_btmd_FirmMember_1218" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="btmd-20221231.xsd#btmd_EmployeeMember" xlink:label="loc_btmd_EmployeeMember_1223" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_1217" xlink:to="loc_btmd_EmployeeMember_1223" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="btmd-20221231.xsd#btmd_SpouseOfFounderChairmanAndBeneficialOwnerMember" xlink:label="loc_btmd_SpouseOfFounderChairmanAndBeneficialOwnerMember_1227" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_1217" xlink:to="loc_btmd_SpouseOfFounderChairmanAndBeneficialOwnerMember_1227" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="btmd-20221231.xsd#btmd_VendorMember" xlink:label="loc_btmd_VendorMember_1230" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_1217" xlink:to="loc_btmd_VendorMember_1230" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_DirectorMember" xlink:label="loc_srt_DirectorMember_1232" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_1217" xlink:to="loc_srt_DirectorMember_1232" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="btmd-20221231.xsd#btmd_ConsultantMember" xlink:label="loc_btmd_ConsultantMember_1234" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_1217" xlink:to="loc_btmd_ConsultantMember_1234" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_1226" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_1220" xlink:to="loc_us-gaap_TypeOfArrangementAxis_1226" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1216" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_1226" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1216" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="btmd-20221231.xsd#btmd_FounderAdvisoryAgreementMember" xlink:label="loc_btmd_FounderAdvisoryAgreementMember_1219" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1216" xlink:to="loc_btmd_FounderAdvisoryAgreementMember_1219" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="btmd-20221231.xsd#btmd_NewIndependentContractorAgreementMember" xlink:label="loc_btmd_NewIndependentContractorAgreementMember_1224" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1216" xlink:to="loc_btmd_NewIndependentContractorAgreementMember_1224" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_1229" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_1220" xlink:to="loc_us-gaap_RelatedPartyTransactionLineItems_1229" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfessionalFees" xlink:label="loc_us-gaap_ProfessionalFees_1221" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_1229" xlink:to="loc_us-gaap_ProfessionalFees_1221" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DueToRelatedPartiesCurrentAndNoncurrent" xlink:label="loc_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent_1225" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_1229" xlink:to="loc_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent_1225" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_1228" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_1229" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_1228" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredRevenueRevenueRecognized1" xlink:label="loc_us-gaap_DeferredRevenueRevenueRecognized1_1231" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_1229" xlink:to="loc_us-gaap_DeferredRevenueRevenueRecognized1_1231" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DueFromCustomerAcceptances" xlink:label="loc_us-gaap_DueFromCustomerAcceptances_1233" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_1229" xlink:to="loc_us-gaap_DueFromCustomerAcceptances_1233" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DueToEmployeesCurrentAndNoncurrent" xlink:label="loc_us-gaap_DueToEmployeesCurrentAndNoncurrent_1235" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_1229" xlink:to="loc_us-gaap_DueToEmployeesCurrentAndNoncurrent_1235" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="btmd-20221231.xsd#btmd_InventoryPurchases" xlink:label="loc_btmd_InventoryPurchases_1236" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_1229" xlink:to="loc_btmd_InventoryPurchases_1236" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="btmd-20221231.xsd#btmd_AgreementTerm" xlink:label="loc_btmd_AgreementTerm_1237" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_1229" xlink:to="loc_btmd_AgreementTerm_1237" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="btmd-20221231.xsd#btmd_AnnualAdviosryFeesPayable" xlink:label="loc_btmd_AnnualAdviosryFeesPayable_1238" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_1229" xlink:to="loc_btmd_AnnualAdviosryFeesPayable_1238" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>g479690g00z01.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g479690g00z01.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[1F"4&AO=&]S:&]P(#,N,  X0DE-! 0
M    &6:^90(X0DE-! 0      %L< 5H  QLE1QP"   "   < E  "')R,SDQ
M,S,V' (% #I-:6-R;W-O9G0@5V]R9" M($)I;W1E("T@075G=7-T(#(P,C(@
M4RTQ("T@4$]3($%-7TYO,BYD;V-X #A"24T$)0      $+&4[>\FO%33+Z<R
M7\2QVM4X0DE-!#H      .4    0     0      "W!R:6YT3W5T<'5T
M!0    !0<W138F]O; $     26YT965N=6T     26YT90    !#;')M
M#W!R:6YT4VEX=&5E;D)I=&)O;VP     "W!R:6YT97).86UE5$585     $
M      ]P<FEN=%!R;V]F4V5T=7!/8FIC    # !0 '( ;P!O &8 ( !3 &4
M= !U '        IP<F]O9E-E='5P     0    !";'1N96YU;0    QB=6EL
M=&EN4')O;V8    )<')O;V9#35E+ #A"24T$.P     "+0   !     !
M   2<')I;G1/=71P=71/<'1I;VYS    %P    !#<'1N8F]O;       0VQB
M<F)O;VP      %)G<TUB;V]L      !#<FY#8F]O;       0VYT0V)O;VP
M     $QB;'-B;V]L      !.9W1V8F]O;       16UL1&)O;VP      $EN
M=')B;V]L      !"8VMG3V)J8P    $       !21T)#     P    !29" @
M9&]U8D!OX            $=R;B!D;W5B0&_@            0FP@(&1O=6)
M;^            !"<F1456YT1B-2;'0               !";&0@56YT1B-2
M;'0               !2<VQT56YT1B-0>&Q 8 KSH         IV96-T;W)$
M871A8F]O; $     4&=0<V5N=6T     4&=0<P    !09U!#     $QE9G15
M;G1&(U)L=                %1O<"!5;G1&(U)L=                %-C
M;"!5;G1&(U!R8T!9            $&-R;W!7:&5N4')I;G1I;F=B;V]L
M  YC<F]P4F5C=$)O='1O;6QO;F<         #&-R;W!296-T3&5F=&QO;F<
M        #6-R;W!296-T4FEG:'1L;VYG          MC<F]P4F5C=%1O<&QO
M;F<      #A"24T#[0      $ .__C4  @ ! [_^-0 "  $X0DE-!"8
M  X             /X   #A"24T$#0      !    '@X0DE-!!D       0
M   >.$))30/S       )           ! #A"24TG$       "@ !
M  $X0DE- _4      $@ +V9F  $ ;&9F  8       $ +V9F  $ H9F:  8
M      $ ,@    $ 6@    8       $ -0    $ +0    8       $X0DE-
M _@      '   /____________________________\#Z     #_________
M____________________ ^@     _____________________________P/H
M     /____________________________\#Z   .$))300(       0
M 0   D    )      #A"24T$'@      !      X0DE-!!H      S4    &
M              !4    O          !                          $
M             +P   !4                      $
M        $     $       !N=6QL     @    9B;W5N9'-/8FIC     0
M     %)C=#$    $     %1O<"!L;VYG          !,969T;&]N9P
M    0G1O;6QO;F<   !4     %)G:'1L;VYG    O     9S;&EC97-6;$QS
M     4]B:F,    !       %<VQI8V4    2    !W-L:6-E241L;VYG
M      =G<F]U<$E$;&]N9P         &;W)I9VEN96YU;0    Q%4VQI8V5/
M<FEG:6X    -875T;T=E;F5R871E9     !4>7!E96YU;0    I%4VQI8V54
M>7!E     $EM9R     &8F]U;F1S3V)J8P    $       !28W0Q    !
M  !4;W @;&]N9P          3&5F=&QO;F<          $)T;VUL;VYG
M5     !29VAT;&]N9P   +P    #=7)L5$585     $       !N=6QL5$58
M5     $       !-<V=E5$585     $       9A;'1486=415A4     0
M    #F-E;&Q497AT27-(5$U,8F]O; $    (8V5L;%1E>'1415A4     0
M    "6AO<GI!;&EG;F5N=6T    /15-L:6-E2&]R>D%L:6=N    !V1E9F%U
M;'0    )=F5R=$%L:6=N96YU;0    ]%4VQI8V5697)T06QI9VX    '9&5F
M875L=     MB9T-O;&]R5'EP965N=6T    115-L:6-E0D=#;VQO<E1Y<&4
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M$0P,# P,$1$,# P,# P1# P,# P,# P,# P,# P,# P,# P,# P,# P,#/_
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MU6D@.#9].QCFAWO]VSW+1P
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M'A7(U%5R\(GY5?\ S_\ ?Y)[7UT8,09DNYW;SANI-+H]E>M.FF.ZI9"D9:7
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M\-9$CXI,27Z'\+<V9S2DS/4-.*;X9T/4^7AQM3[I2)0MQ04M"4(5"XGU*2!
M 5+CEF3.!?GU$)".$FYFU_G,@&0!SSQP_P#3L;4,B?E^?[N,JJI5;C-=1GT^
MTS-(&P7\;M;,K39?:16KR5\&HA1X-0"2B(*7*G2QC5Q8$KE1XRZD8?4QD=*L
ME16FIKFUW4RIGTMM)(@ D@K($D1> 1/,[JAL%,(W6/60D&3/3D0!8_CBGKN@
MTUKB7</W1!N8I(LDNKUEDD<951B'JL@2#D=1)\F_\HIM98PI R>:,8TSV/>(
MC/)+$\/G!5:%RYML#8:%YA+B+K%02M.TCI<0>.)MATR\*>R\! NELI2>2(3
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..))_.WM;#)UG_ .8__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>9
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140468225394256">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">S-1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">biote Corp.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001819253<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityExTransitionPeriod', window );">Entity Ex Transition Period</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">85-1791125<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">1875 W. Walnut Hill Ln #100<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Irving<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">TX<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">75038<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">844<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">604-1246<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityPrimarySicNumber', window );">Entity Primary SIC Number</a></td>
<td class="text">2833<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressesAddressTypeAxis=dei_BusinessContactMember', window );">Business Contact [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">1875 W. Walnut Hill Ln #100<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Irving<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">TX<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">75038<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">312<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">212-8079<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_ContactPersonnelName', window );">Contact Personnel Name</a></td>
<td class="text">Teresa S. Weber<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_ContactPersonnelName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of contact personnel</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_ContactPersonnelName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityExTransitionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 7A<br> -Section B<br> -Subsection 2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityExTransitionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPrimarySicNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Primary Standard Industrial Classification (SIC) Number for the Entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityPrimarySicNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:sicNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressesAddressTypeAxis=dei_BusinessContactMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressesAddressTypeAxis=dei_BusinessContactMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140468224711824">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED BALANCE SHEETS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Cash', window );">Cash</a></td>
<td class="nump">$ 79,231<span></span>
</td>
<td class="nump">$ 26,766<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable, net</a></td>
<td class="nump">6,948<span></span>
</td>
<td class="nump">5,231<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventory, net</a></td>
<td class="nump">11,183<span></span>
</td>
<td class="nump">9,615<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Other current assets</a></td>
<td class="nump">3,816<span></span>
</td>
<td class="nump">5,473<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">101,178<span></span>
</td>
<td class="nump">47,085<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">1,504<span></span>
</td>
<td class="nump">2,335<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalizedComputerSoftwareNet', window );">Capitalized software, net</a></td>
<td class="nump">5,073<span></span>
</td>
<td class="nump">4,554<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets</a></td>
<td class="nump">2,052<span></span>
</td>
<td class="nump">356<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxAssetsNet', window );">Deferred tax asset</a></td>
<td class="nump">1,838<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">111,645<span></span>
</td>
<td class="nump">54,330<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">4,112<span></span>
</td>
<td class="nump">4,349<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses</a></td>
<td class="nump">6,274<span></span>
</td>
<td class="nump">6,011<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtCurrent', window );">Term loan, current</a></td>
<td class="nump">6,250<span></span>
</td>
<td class="nump">5,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Deferred revenue, current</a></td>
<td class="nump">1,965<span></span>
</td>
<td class="nump">1,705<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease liabilities, current</a></td>
<td class="nump">165<span></span>
</td>
<td class="nump">248<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">18,766<span></span>
</td>
<td class="nump">17,313<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Term loan, net of current portion</a></td>
<td class="nump">112,086<span></span>
</td>
<td class="nump">31,963<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityNoncurrent', window );">Deferred revenue, net of current portion</a></td>
<td class="nump">926<span></span>
</td>
<td class="nump">802<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liabilities, net of current portion</a></td>
<td class="nump">1,927<span></span>
</td>
<td class="nump">127<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstanding', window );">Warrant liability</a></td>
<td class="nump">4,104<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesNoncurrent', window );">Earnout liability</a></td>
<td class="nump">32,110<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">169,919<span></span>
</td>
<td class="nump">50,205<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies (See Note 18)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract', window );"><strong>Stockholders' Equity (Deficit)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock, $0.0001 par value, 10,000,000 shares authorized; no shares issued or outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Retained earnings (Accumulated deficit)</a></td>
<td class="num">(44,460)<span></span>
</td>
<td class="nump">4,165<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive loss</a></td>
<td class="num">(5)<span></span>
</td>
<td class="num">(40)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">biote Corp.'s stockholders' equity (deficit)</a></td>
<td class="num">(44,459)<span></span>
</td>
<td class="nump">4,125<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MinorityInterest', window );">Noncontrolling interest</a></td>
<td class="num">(13,815)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Total stockholders' equity (deficit)</a></td>
<td class="num">(58,274)<span></span>
</td>
<td class="nump">4,125<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders' equity (deficit)</a></td>
<td class="nump">111,645<span></span>
</td>
<td class="nump">54,330<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember', window );">Class A Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract', window );"><strong>Stockholders' Equity (Deficit)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock value</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassBMember', window );">Class B Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract', window );"><strong>Stockholders' Equity (Deficit)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=btmd_CommonClassVMember', window );">Class V Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract', window );"><strong>Stockholders' Equity (Deficit)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock value</a></td>
<td class="nump">$ 5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4428-111522<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4531-111522<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669686-108580<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e681-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalizedComputerSoftwareNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The carrying amount of capitalized computer software costs net of accumulated amortization as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalizedComputerSoftwareNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Cash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 210<br> -Section 45<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=118262064&amp;loc=SL116631418-115840<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 210<br> -Section 45<br> -Paragraph 21<br> -URI https://asc.fasb.org/extlink&amp;oid=118262064&amp;loc=SL116631419-115840<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Cash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130532-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130532-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130531-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, with jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e31931-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e31917-109318<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled after one year or the normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6904-107765<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt, classified as current. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding unamortized premium (discount) and debt issuance cost, of long-term debt classified as noncurrent. Excludes lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which is directly or indirectly attributable to that ownership interest in subsidiary equity which is not attributable to the parent (that is, noncontrolling interest, previously referred to as minority interest).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(24))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.31)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI https://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21930-107793<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21914-107793<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442411-227067<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126987489&amp;loc=SL124442142-165695<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126987489&amp;loc=SL124442142-165695<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4568740-111683<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21711-107793<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983759&amp;loc=SL121830611-158277<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 848<br> -SubTopic 10<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)(3)(iii)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=125980421&amp;loc=SL125981372-237846<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983759&amp;loc=SL121830611-158277<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128097895&amp;loc=SL121327923-165333<br><br>Reference 22: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4590271-111686<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 25: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4568447-111683<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128097895&amp;loc=SL121327923-165333<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=128097895&amp;loc=SL121327923-165333<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of outstanding derivative securities that permit the holder the right to purchase securities (usually equity) from the issuer at a specified price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassBMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassBMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=btmd_CommonClassVMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=btmd_CommonClassVMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140468222166368">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONSOLIDATED BALANCE SHEETS (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par or stated value per share</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="nump">10,000,000<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock shares issued</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorizedUnlimited', window );">Common stock, shares authorized, unlimited</a></td>
<td class="text">Unlimited<span></span>
</td>
<td class="text">Unlimited<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="nump">69,808,711<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="nump">58,221,211<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember', window );">Class A Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="nump">600,000,000<span></span>
</td>
<td class="nump">600,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="nump">11,242,887<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="nump">9,655,387<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassBMember', window );">Class B Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="nump">8,000,000<span></span>
</td>
<td class="nump">8,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=btmd_CommonClassVMember', window );">Class V Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="nump">100,000,000<span></span>
</td>
<td class="nump">100,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="nump">58,565,824<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="nump">48,565,824<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=btmd_ClassAMember', window );">Class A</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockNoParValue', window );">Common stock, no par value</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,013,197<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">982,800<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=btmd_ClassAaUnitsMember', window );">Class AA Units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockNoParValue', window );">Common stock, no par value</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,013,197<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">982,800<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=btmd_ClassAaaUnitsMember', window );">Class AAA Units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockNoParValue', window );">Common stock, no par value</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,013,197<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">982,800<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=btmd_ClassAaaaUnitsMember', window );">Class AAAA Units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockNoParValue', window );">Common stock, no par value</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,013,197<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">982,800<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockNoParValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount per share of no-par value common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockNoParValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorizedUnlimited">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the number of common shares permitted to be issued by an entity's charter and bylaws is unlimited. The acceptable value is "Unlimited".</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorizedUnlimited</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>us-types:authorizedUnlimitedItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassBMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassBMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=btmd_CommonClassVMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=btmd_CommonClassVMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=btmd_ClassAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=btmd_ClassAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=btmd_ClassAaUnitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=btmd_ClassAaUnitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=btmd_ClassAaaUnitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=btmd_ClassAaaUnitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=btmd_ClassAaaaUnitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=btmd_ClassAaaaUnitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140468222091104">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF INCOME AND COMPREHENSIVE INCOME - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenue</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">$ 164,957<span></span>
</td>
<td class="nump">$ 139,396<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortizationAbstract', window );"><strong>Cost of revenue (excluding depreciation and amortization included in selling, general, and administrative, below)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization', window );">Cost of revenue</a></td>
<td class="nump">54,575<span></span>
</td>
<td class="nump">48,817<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SalesCommissionsAndFees', window );">Commissions</a></td>
<td class="nump">974<span></span>
</td>
<td class="nump">2,056<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketingExpense', window );">Marketing</a></td>
<td class="nump">4,628<span></span>
</td>
<td class="nump">4,908<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Selling, general, and administrative</a></td>
<td class="nump">165,502<span></span>
</td>
<td class="nump">49,054<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Income (loss) from operations</a></td>
<td class="num">(60,722)<span></span>
</td>
<td class="nump">34,561<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>Other income (expense) net :</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestIncomeExpenseNonoperatingNet', window );">Interest expense</a></td>
<td class="num">(5,091)<span></span>
</td>
<td class="num">(1,673)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Gain from change in fair value of warrant liability</a></td>
<td class="nump">5,127<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_btmd_GainLossFromChangeInFairValueOfEarnoutLiability', window );">Gain from change in fair value of earnout liability</a></td>
<td class="nump">61,770<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Loss from extinguishment of debt</a></td>
<td class="num">(445)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncome', window );">Other income</a></td>
<td class="nump">1,073<span></span>
</td>
<td class="nump">17<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Total other income (expense), net</a></td>
<td class="nump">62,434<span></span>
</td>
<td class="num">(1,656)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Income before provision for income taxes</a></td>
<td class="nump">1,712<span></span>
</td>
<td class="nump">32,905<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax expense</a></td>
<td class="nump">388<span></span>
</td>
<td class="nump">286<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income</a></td>
<td class="nump">1,324<span></span>
</td>
<td class="nump">32,619<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest', window );">Less: Net income attributable to noncontrolling interest</a></td>
<td class="nump">2,293<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss) attributable to biote Corp. stockholders</a></td>
<td class="num">(969)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossTaxPortionAttributableToParentAbstract', window );"><strong>Other comprehensive income (loss):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax', window );">Foreign currency translation adjustments</a></td>
<td class="num">(1)<span></span>
</td>
<td class="num">(17)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Other comprehensive income (loss)</a></td>
<td class="num">(1)<span></span>
</td>
<td class="num">(17)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive income</a></td>
<td class="nump">$ 1,323<span></span>
</td>
<td class="nump">32,602<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Net income (loss) per common share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic</a></td>
<td class="num">$ (0.12)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Diluted</a></td>
<td class="num">$ (0.12)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract', window );"><strong>Weighted average common shares outstanding</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Basic</a></td>
<td class="nump">8,059,371<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Diluted</a></td>
<td class="nump">8,059,371<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=btmd_ProductRevenueMember', window );">Product Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenue</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">$ 163,133<span></span>
</td>
<td class="nump">137,598<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortizationAbstract', window );"><strong>Cost of revenue (excluding depreciation and amortization included in selling, general, and administrative, below)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization', window );">Cost of revenue</a></td>
<td class="nump">51,990<span></span>
</td>
<td class="nump">46,298<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=btmd_ServiceRevenueMember', window );">Service Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenue</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">1,824<span></span>
</td>
<td class="nump">1,798<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortizationAbstract', window );"><strong>Cost of revenue (excluding depreciation and amortization included in selling, general, and administrative, below)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization', window );">Cost of revenue</a></td>
<td class="nump">$ 2,585<span></span>
</td>
<td class="nump">$ 2,519<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_btmd_GainLossFromChangeInFairValueOfEarnoutLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gain loss from change in fair value of earnout liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">btmd_GainLossFromChangeInFairValueOfEarnoutLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>btmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e557-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cost of product sold and service rendered, excluding depreciation, depletion, and amortization.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(2)(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(2)(d))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortizationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortizationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAdjustmentOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (income) related to adjustment to fair value of warrant liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section 25<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=109262497&amp;loc=d3e20148-110875<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAdjustmentOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126972273&amp;loc=d3e12355-112629<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126972273&amp;loc=d3e12317-112629<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 20<br> -Section 25<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126941158&amp;loc=d3e41242-110953<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestIncomeExpenseNonoperatingNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net amount of nonoperating interest income (expense).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestIncomeExpenseNonoperatingNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketingExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expenditures for planning and executing the conception, pricing, promotion, and distribution of ideas, goods, and services. Costs of public relations and corporate promotions are typically considered to be marketing costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketingExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of Net Income (Loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax, before reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 35<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=123602790&amp;loc=d3e30304-110892<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=126980362&amp;loc=d3e28129-110885<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32022-110900<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (a-c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669646-108580<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e637-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of other comprehensive income (loss) attributable to parent entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569643-111683<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569616-111683<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossTaxPortionAttributableToParentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossTaxPortionAttributableToParentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(7)(d))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3000-108585<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569616-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 23: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 29: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI https://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenuesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenuesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SalesCommissionsAndFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Primarily represents commissions incurred in the period based upon the sale by commissioned employees or third parties of the entity's goods or services, and fees for sales assistance or product enhancements performed by third parties (such as a distributor or value added reseller).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SalesCommissionsAndFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=btmd_ProductRevenueMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=btmd_ProductRevenueMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=btmd_ServiceRevenueMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=btmd_ServiceRevenueMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140468224897024">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (DEFICIT) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Class A Common Stock</div></th>
<th class="th"><div>Class V Common Stock</div></th>
<th class="th"><div>Members' Equity</div></th>
<th class="th">
<div>Common Stock </div>
<div>Class A Common Stock</div>
</th>
<th class="th">
<div>Common Stock </div>
<div>Class V Common Stock</div>
</th>
<th class="th"><div>Retained Earnings / (Accumulated Deficit)</div></th>
<th class="th"><div>Accumulated Other Comprehensive Income (Loss)</div></th>
<th class="th"><div>Total Stockholders' Equity (Deficit) Attributable to biote Corp.</div></th>
<th class="th"><div>Non Controlling Interest</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PartnersCapitalAccountUnits', window );">Beginning balance, units at Dec. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">982,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning balance at Dec. 31, 2020</a></td>
<td class="num">$ (17,075)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (17,052)<span></span>
</td>
<td class="num">$ (23)<span></span>
</td>
<td class="num">$ (17,075)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DividendsCommonStock', window );">Distributions</a></td>
<td class="num">(11,402)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(11,402)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(11,402)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income (loss)</a></td>
<td class="nump">32,619<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">32,619<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">32,619<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest', window );">Other comprehensive income (loss)</a></td>
<td class="num">(17)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(17)<span></span>
</td>
<td class="num">(17)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PartnersCapitalAccountUnits', window );">Ending balance, units at Dec. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">982,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance at Dec. 31, 2021</a></td>
<td class="nump">4,125<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,165<span></span>
</td>
<td class="num">(40)<span></span>
</td>
<td class="nump">4,125<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income (loss)</a></td>
<td class="nump">9,143<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,143<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,143<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest', window );">Other comprehensive income (loss)</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PartnersCapitalAccountUnits', window );">Beginning balance, units at Dec. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">982,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning balance at Dec. 31, 2021</a></td>
<td class="nump">4,125<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,165<span></span>
</td>
<td class="num">(40)<span></span>
</td>
<td class="nump">4,125<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DividendsCommonStock', window );">Distributions</a></td>
<td class="num">(12,886)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(9,575)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(9,575)<span></span>
</td>
<td class="num">$ (3,311)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income (loss)</a></td>
<td class="nump">1,324<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_btmd_StockholdersEquityBussinessCombinationCapitalizedTransactionCosts', window );">Business Combination: Capitalized transaction costs</a></td>
<td class="num">(12,282)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(12,282)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(12,282)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Share-based compensation</a></td>
<td class="nump">82,180<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">82,180<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">82,180<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_btmd_StockIssuedDuringPeriodValueSettlementOfEquityRights', window );">Settlement of phantom equity rights</a></td>
<td class="num">(7,250)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(7,250)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(7,250)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_btmd_StockIssuedDuringPeriodValueVestingOfRestrictedStockUnit', window );">Vesting of RSUs</a></td>
<td class="num">(424)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(424)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(424)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_btmd_StockIssuedDuringPeriodSharesVestingOfRestrictedStockUnit', window );">Vesting of RSUs, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,950,557<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of shares under SEPA</a></td>
<td class="nump">561<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">561<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">561<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of shares under SEPA, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">48,565,824<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">130,559<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance at Dec. 31, 2022</a></td>
<td class="num">(58,274)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">$ 5<span></span>
</td>
<td class="num">(44,460)<span></span>
</td>
<td class="num">(5)<span></span>
</td>
<td class="num">(44,459)<span></span>
</td>
<td class="num">(13,815)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance, shares at Dec. 31, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,655,387<span></span>
</td>
<td class="nump">48,565,824<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_btmd_PartnersCapitalAccountReverseRecapitalizationUnits', window );">Business Combination: Reverse recapitalization on May 26, 2022, units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(982,800)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_btmd_StockholdersEquityIncludingPortionAttributableToNonControllingInterestReverseRecapitalization', window );">Business Combination: Reverse recapitalization on May 26, 2022</a></td>
<td class="num">(113,622)<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">$ 5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(113,628)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(113,622)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_btmd_StockholdersEquityIncludingPortionAttributableToNonControllingInterestSharesReverseRecapitalization', window );">Business Combination: Reverse recapitalization on May 26, 2022, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,574,271<span></span>
</td>
<td class="nump">48,565,824<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_btmd_StockholdersEquityAttributableToNonControllingInterestBusinessCombination', window );">Business Combination: Noncontrolling interest on May 26, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,619<span></span>
</td>
<td class="nump">34<span></span>
</td>
<td class="nump">3,653<span></span>
</td>
<td class="num">(3,653)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income (loss)</a></td>
<td class="num">(7,819)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(969)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(969)<span></span>
</td>
<td class="num">(6,850)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest', window );">Other comprehensive income (loss)</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance at Dec. 31, 2022</a></td>
<td class="num">$ (58,274)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">$ 5<span></span>
</td>
<td class="num">$ (44,460)<span></span>
</td>
<td class="num">$ (5)<span></span>
</td>
<td class="num">$ (44,459)<span></span>
</td>
<td class="num">$ (13,815)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance, shares at Dec. 31, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,655,387<span></span>
</td>
<td class="nump">48,565,824<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_btmd_PartnersCapitalAccountReverseRecapitalizationUnits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Partners capital account reverse recapitalization units.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">btmd_PartnersCapitalAccountReverseRecapitalizationUnits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>btmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_btmd_StockIssuedDuringPeriodSharesVestingOfRestrictedStockUnit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock issued during period shares vesting of restricted stock unit,</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">btmd_StockIssuedDuringPeriodSharesVestingOfRestrictedStockUnit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>btmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_btmd_StockIssuedDuringPeriodValueSettlementOfEquityRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock issued during period value settlement of equity rights.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">btmd_StockIssuedDuringPeriodValueSettlementOfEquityRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>btmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_btmd_StockIssuedDuringPeriodValueVestingOfRestrictedStockUnit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock issued during period value vesting of restricted stock unit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">btmd_StockIssuedDuringPeriodValueVestingOfRestrictedStockUnit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>btmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_btmd_StockholdersEquityAttributableToNonControllingInterestBusinessCombination">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stockholders equity attributable to non-controlling interest, business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">btmd_StockholdersEquityAttributableToNonControllingInterestBusinessCombination</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>btmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_btmd_StockholdersEquityBussinessCombinationCapitalizedTransactionCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stockholders equity bussiness combination capitalized transaction costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">btmd_StockholdersEquityBussinessCombinationCapitalizedTransactionCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>btmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_btmd_StockholdersEquityIncludingPortionAttributableToNonControllingInterestReverseRecapitalization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stockholders equity including portion attributable to non controlling interest reverse recapitalization.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">btmd_StockholdersEquityIncludingPortionAttributableToNonControllingInterestReverseRecapitalization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>btmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_btmd_StockholdersEquityIncludingPortionAttributableToNonControllingInterestSharesReverseRecapitalization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stockholders equity including portion attributable to non controlling interest shares reverse recapitalization.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">btmd_StockholdersEquityIncludingPortionAttributableToNonControllingInterestSharesReverseRecapitalization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>btmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=126964447&amp;loc=d3e11149-113907<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=126964447&amp;loc=d3e11178-113907<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126961718&amp;loc=d3e4534-113899<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569616-111683<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(24))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DividendsCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of paid and unpaid common stock dividends declared with the form of settlement in cash, stock and payment-in-kind (PIK).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 405<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=6957935&amp;loc=d3e64057-112817<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DividendsCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PartnersCapitalAccountUnits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of each class of partnership units outstanding at the balance sheet date. Units represent shares of ownership of the general, limited, and preferred partners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04.16(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120401414&amp;loc=d3e603758-122996<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04.16(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=120401414&amp;loc=d3e603758-122996<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 5<br> -Subparagraph (SAB TOPIC 4.F)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187171-122770<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PartnersCapitalAccountUnits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3000-108585<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569616-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 23: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 29: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21930-107793<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21914-107793<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442411-227067<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126987489&amp;loc=SL124442142-165695<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126987489&amp;loc=SL124442142-165695<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4568740-111683<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21711-107793<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983759&amp;loc=SL121830611-158277<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 848<br> -SubTopic 10<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)(3)(iii)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=125980421&amp;loc=SL125981372-237846<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983759&amp;loc=SL121830611-158277<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128097895&amp;loc=SL121327923-165333<br><br>Reference 22: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4590271-111686<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 25: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4568447-111683<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128097895&amp;loc=SL121327923-165333<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=128097895&amp;loc=SL121327923-165333<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140468221023024">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Operating Activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income</a></td>
<td class="nump">$ 1,324<span></span>
</td>
<td class="nump">$ 32,619<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net income to net cash (used in) provided by operating activites:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">2,199<span></span>
</td>
<td class="nump">1,400<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProvisionForDoubtfulAccounts', window );">Bad debt expense (recoveries)</a></td>
<td class="num">(155)<span></span>
</td>
<td class="nump">240<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCosts', window );">Amortization of debt issuance costs</a></td>
<td class="nump">589<span></span>
</td>
<td class="nump">222<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryWriteDown', window );">Provision for obsolete inventory</a></td>
<td class="nump">140<span></span>
</td>
<td class="nump">471<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_btmd_NonCashLeaseExpense', window );">Non-cash lease expense</a></td>
<td class="nump">240<span></span>
</td>
<td class="nump">226<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_btmd_NonCashSponsorShareTransfers', window );">Non-cash sponsor share transfers</a></td>
<td class="nump">7,216<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_btmd_NonCashFeesUnderSepa', window );">Non-cash fees under SEPA</a></td>
<td class="nump">119<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Share-based compensation expense</a></td>
<td class="nump">82,180<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Gain from change in fair value of warrant liability</a></td>
<td class="num">(5,127)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_btmd_FairValueAdjustmentOfEarnoutLiability', window );">Gain from change in fair value of earnout liability</a></td>
<td class="num">(61,770)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Loss from extinguishment of debt</a></td>
<td class="nump">445<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxesAndTaxCredits', window );">Deferred income taxes</a></td>
<td class="num">(743)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Accounts receivable</a></td>
<td class="num">(1,562)<span></span>
</td>
<td class="num">(752)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInventories', window );">Inventory</a></td>
<td class="num">(1,708)<span></span>
</td>
<td class="num">(5,762)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherCurrentAssets', window );">Other current assets</a></td>
<td class="num">(2,284)<span></span>
</td>
<td class="nump">34<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="nump">416<span></span>
</td>
<td class="nump">1,605<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInDeferredRevenue', window );">Deferred revenue</a></td>
<td class="nump">384<span></span>
</td>
<td class="num">(373)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilities', window );">Accrued expenses</a></td>
<td class="num">(30,841)<span></span>
</td>
<td class="nump">4,029<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability', window );">Operating lease liabilities</a></td>
<td class="num">(219)<span></span>
</td>
<td class="num">(239)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash (used in) provided by operating activities</a></td>
<td class="num">(9,157)<span></span>
</td>
<td class="nump">33,720<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Investing Activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property and equipment</a></td>
<td class="num">(333)<span></span>
</td>
<td class="num">(1,448)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForSoftware', window );">Purchases of capitalized software</a></td>
<td class="num">(1,505)<span></span>
</td>
<td class="num">(2,359)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash used in investing activities</a></td>
<td class="num">(1,838)<span></span>
</td>
<td class="num">(3,807)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Financing Activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_btmd_ProceedsFromBusinessCombination', window );">Proceeds from the Business Combination</a></td>
<td class="nump">12,282<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_btmd_PrincipalRepaymentsOnTermLoan', window );">Principal repayments on term loan</a></td>
<td class="num">(4,375)<span></span>
</td>
<td class="num">(5,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_btmd_BorrowingsOnTermLoan', window );">Borrowings on term loan</a></td>
<td class="nump">125,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfDebtExtinguishmentCosts', window );">Extinguishment of Bank of America term loan</a></td>
<td class="num">(36,250)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfDebtIssuanceCosts', window );">Debt issuance costs</a></td>
<td class="num">(4,036)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_btmd_PaymentsOfSettlementOfPhantomEquityRight', window );">Settlement of phantom equity rights</a></td>
<td class="num">(7,250)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_btmd_PaymentsOfSettlementOfRestrictedStockUnits', window );">Settlement of RSUs</a></td>
<td class="num">(424)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfDividends', window );">Distributions</a></td>
<td class="num">(12,886)<span></span>
</td>
<td class="num">(11,402)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Capitalized transaction costs</a></td>
<td class="num">(8,341)<span></span>
</td>
<td class="num">(3,941)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_btmd_ProceedsFromIssuanceOfSharesUnderSepa', window );">Proceeds from issuance of shares under SEPA</a></td>
<td class="nump">442<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_btmd_PaymentsToSEPATransactionCosts', window );">SEPA transaction costs</a></td>
<td class="num">(702)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by (used in) financing activities</a></td>
<td class="nump">63,460<span></span>
</td>
<td class="num">(20,343)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations', window );">Effect of exchange rate changes on cash and cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(12)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net increase in cash and cash equivalents</a></td>
<td class="nump">52,465<span></span>
</td>
<td class="nump">9,558<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations', window );">Cash and cash equivalents at beginning of period</a></td>
<td class="nump">26,766<span></span>
</td>
<td class="nump">17,208<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations', window );">Cash and cash equivalents at end of period</a></td>
<td class="nump">79,231<span></span>
</td>
<td class="nump">26,766<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplemental Disclosure of Cash Flow Information</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Cash paid for interest</a></td>
<td class="nump">4,426<span></span>
</td>
<td class="nump">1,462<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxesPaid', window );">Cash paid for income taxes</a></td>
<td class="nump">282<span></span>
</td>
<td class="nump">171<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract', window );"><strong>Non-cash investing and financing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid', window );">Capital expenditures and capitalized software included in accounts payable</a></td>
<td class="nump">49<span></span>
</td>
<td class="nump">$ 282<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_btmd_NonCashSEPATransactionCosts', window );">Non-cash SEPA transaction costs</a></td>
<td class="nump">$ 119<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_btmd_BorrowingsOnTermLoan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Borrowings on term loan</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">btmd_BorrowingsOnTermLoan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>btmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_btmd_FairValueAdjustmentOfEarnoutLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair Value Adjustment Of Earnout Liability</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">btmd_FairValueAdjustmentOfEarnoutLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>btmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_btmd_NonCashFeesUnderSepa">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Non-cash fees under SEPA.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">btmd_NonCashFeesUnderSepa</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>btmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_btmd_NonCashLeaseExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Non-Cash Lease Expense</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">btmd_NonCashLeaseExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>btmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_btmd_NonCashSEPATransactionCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Non-cash SEPA transaction costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">btmd_NonCashSEPATransactionCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>btmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_btmd_NonCashSponsorShareTransfers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Non-cash sponsor share transfers.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">btmd_NonCashSponsorShareTransfers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>btmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_btmd_PaymentsOfSettlementOfPhantomEquityRight">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Payments of settlement of phantom equity right.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">btmd_PaymentsOfSettlementOfPhantomEquityRight</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>btmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_btmd_PaymentsOfSettlementOfRestrictedStockUnits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Payments of settlement of restricted stock units</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">btmd_PaymentsOfSettlementOfRestrictedStockUnits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>btmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_btmd_PaymentsToSEPATransactionCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Payments to SEPA transaction costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">btmd_PaymentsToSEPATransactionCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>btmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_btmd_PrincipalRepaymentsOnTermLoan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Principal repayments on term loan</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">btmd_PrincipalRepaymentsOnTermLoan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>btmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_btmd_ProceedsFromBusinessCombination">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Proceeds from business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">btmd_ProceedsFromBusinessCombination</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>btmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_btmd_ProceedsFromIssuanceOfSharesUnderSepa">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Proceeds from issuance of shares under SEPA.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">btmd_ProceedsFromIssuanceOfSharesUnderSepa</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>btmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfFinancingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495355-112611<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfFinancingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Future cash outflow to pay for purchases of fixed assets that have occurred.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4332-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4313-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalExpendituresIncurredButNotYetPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxesAndTaxCredits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income tax expense (benefit) and income tax credits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxesAndTaxCredits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAdjustmentOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (income) related to adjustment to fair value of warrant liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section 25<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=109262497&amp;loc=d3e20148-110875<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAdjustmentOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126972273&amp;loc=d3e12355-112629<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126972273&amp;loc=d3e12317-112629<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxesPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4297-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxesPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInDeferredRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInDeferredRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInInventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInInventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherCurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in current assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherCurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4297-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3367-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryWriteDown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of loss from reductions in inventory due to subsequent measurement adjustments, including, but not limited to, physical deterioration, obsolescence, or changes in price levels.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=116847112&amp;loc=d3e4542-108314<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryWriteDown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForSoftware">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the development, modification or acquisition of software programs or applications for internal use (that is, not to be sold, leased or otherwise marketed to others) that qualify for capitalization.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForSoftware</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfDebtExtinguishmentCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for cost from early extinguishment and prepayment of debt. Includes, but is not limited to, third-party cost, premium paid, and other fee paid to lender directly for debt extinguishment or debt prepayment. Excludes accrued interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfDebtExtinguishmentCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfDebtIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfDebtIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfDividends">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash outflow in the form of capital distributions and dividends to common shareholders, preferred shareholders and noncontrolling interests.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfDividends</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for cost incurred directly with the issuance of an equity security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3000-108585<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569616-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 23: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 29: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProvisionForDoubtfulAccounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (reversal of expense) for expected credit loss on accounts receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124255953&amp;loc=SL82919249-210447<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProvisionForDoubtfulAccounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140468230239904">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Description of Business and Basis of Presentation<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock', window );">Description of Business and Basis of Presentation</a></td>
<td class="text">
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">1.</div></div></td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: left; line-height: normal;"><div style="font-weight:bold;display:inline;">DESCRIPTION OF BUSINESS AND BASIS OF PRESENTATION </div></div></td></tr></table><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Description of Business</div></div>&#8212;biote Corp. (inclusive of its consolidated subsidiaries, the &#8220;Company&#8221; or &#8220;Biote&#8221;) is a Delaware incorporated company headquartered in Irving, Texas. The Company was founded in 2012 and trains physicians and nurse practitioners in hormone optimization using <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">bio-identical</div> hormone replacement pellet therapy in men and women experiencing hormonal imbalance. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Basis of Presentation</div></div>&#8212;The consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (&#8220;U.S. GAAP&#8221;). The consolidated financial statements include the accounts of Biote and its subsidiaries. All intercompany balances and transactions have been eliminated in consolidation. The Company recognizes noncontrolling interest related to its less-than-wholly-owned subsidiary as equity in the consolidated financial statements separate from the parent entity&#8217;s equity. The net income attributable to noncontrolling interest is included in net income in the consolidated statements of income and comprehensive income. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div></div></div>&#8212;As of December&#160;31, 2022 and December&#160;31, 2021, the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> pandemic and the related disruptions caused to the global economy did not have a material impact on the Company&#8217;s business. However, the duration and intensity of the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> pandemic and any resulting disruption to the Company&#8217;s operations remains somewhat uncertain, and the Company will continue to assess the impact of the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> pandemic on its financial position. Further, global economic conditions have been worsening, with disruptions to, and volatility in, the credit and financial markets in the U.S. and worldwide resulting from the effects of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> and otherwise. If these conditions persist and deepen, the Company could experience an inability to access additional capital or its liquidity could otherwise be impacted. If the Company is unable to raise capital when needed or on attractive terms, it would be forced to delay, reduce or eliminate its research and development programs and/or other efforts. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Business Combination</div></div>&#8212;On May&#160;26, 2022 (the &#8220;Closing Date&#8221;), BioTE Holdings, LLC (&#8220;Holdings,&#8221; inclusive of its direct and indirect subsidiaries, the &#8220;BioTE Companies,&#8221; and as to its members, the &#8220;Members&#8221;) completed a series of transactions (the &#8220;Business Combination&#8221;) with Haymaker Acquisition Corp. III (&#8220;Haymaker&#8221;), Haymaker Sponsor III LLC (the &#8220;Sponsor&#8221;), BioTE Management, LLC, Dr.&#160;Gary&#160;S. Donovitz, in his individual capacity, and Teresa S. Weber, in her capacity as the Members&#8217; representative (in such capacity, the &#8220;Members&#8217; Representative&#8221;) pursuant to the business combination agreement (the &#8220;Business Combination Agreement&#8221;) dated December&#160;13, 2021 (the &#8220;Closing&#8221;), which is discussed in more detail in Note 3. As a result of the Business Combination, Haymaker was renamed &#8220;biote Corp.&#8221; </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Business Combination was accounted for as a common control transaction, in accordance with U.S. GAAP. Under this method of accounting, Haymaker&#8217;s acquisition of the BioTE Companies was accounted for at their historical carrying values, and the BioTE Companies were deemed the predecessor entity. This method of accounting is similar to a reverse recapitalization whereby the Business Combination was treated as the equivalent of the BioTE Companies issuing stock for the net assets of Haymaker, accompanied by a recapitalization. The net assets of Haymaker are stated at historical cost, with no goodwill or other intangible assets recorded. Operations prior to the Business Combination are those of the BioTE Companies. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Following the Closing of the Business Combination, the Company is organized in an <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">&#8220;Up-C&#8221;</div> structure in which the business of the Company is operated by Holdings and its subsidiaries, and Biote&#8217;s only material direct asset consists of equity interests in Holdings. The consolidated financial statements of Holdings and its subsidiaries have been determined to be the predecessor for accounting and reporting purposes for the period prior to the Business Combination. </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the business description and basis of presentation concepts. Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI https://asc.fasb.org/topic&amp;trid=2122369<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -URI https://asc.fasb.org/topic&amp;trid=2122149<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -URI https://asc.fasb.org/topic&amp;trid=2134479<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140468230376624">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Summary of Significant Accounting Policies</a></td>
<td class="text">
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2.</div></div></td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: left; line-height: normal;"><div style="font-weight:bold;display:inline;">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES </div></div></td></tr></table><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Use of Estimates&#8212;</div></div>The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. The Company regularly evaluates estimates and assumptions related to assets, liabilities, costs, expenses, contingent liabilities, share-based compensation and research and development costs. The Company bases its estimates and assumptions on historical experience and on various other factors that it believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results could differ from those estimates. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In the opinion of the Company, the accompanying consolidated financial statements contain all adjustments, consisting of only normal recurring adjustments, necessary for a fair presentation of its financial position and its results of operations, changes in stockholders&#8217; equity (deficit) and cash flows. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Fair Value Measurements</div></div>&#8212;The guidance in FASB ASC 820, <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Fair Value Measurements and Disclosures </div></div>(&#8220;ASC 820&#8221;), defines fair value and establishes a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements) and the lowest priority to unobservable inputs (Level 3 measurements). The three levels of the fair value hierarchy are described below: </div><div style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Level</div></div><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"/><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">&#160;1</div></div>&#8212;Inputs are quoted prices (unadjusted) in active markets for identical assets or liabilities that the reporting entity has the ability to access at the measurement date. </div><div style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Level 2</div></div>&#8212;Valuations based on quoted prices in markets that are not active or for which all significant inputs are observable, either directly or indirectly. </div><div style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Level</div></div><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"/><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">&#160;3</div></div>&#8212;Prices or valuations that require inputs that are both significant to the fair value measurement and unobservable. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">See Note 12 for further detail. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Segment Information</div></div>&#8212;Operating segments are defined as components of an enterprise about which separate financial information is available that is evaluated regularly by the chief operating decision maker in deciding how to allocate resources and in assessing performance. The Company&#8217;s chief operating decision maker is the chief executive officer. The Company has one business activity and there are no segment managers who are held accountable for operations, operating results, and plans for levels or components below the consolidated unit level. Accordingly, the Company has one operating segment and, therefore, one reportable segment. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Cash</div></div>&#8212;As of December&#160;31, 2022 and 2021, cash consists primarily of checking and savings deposits. The Company maintains deposits primarily with two financial institutions, which may at times exceed amounts covered by insurance provided by the U.S. Federal Deposit Insurance Corporation (&#8220;FDIC&#8221;). The Company has not experienced any losses related to amounts in excess of FDIC limits. The Company does not hold any cash equivalents, which would consist of highly liquid investments with original maturities of three months or less at the time of purchase. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Accounts Receivable and Allowance for Doubtful Accounts</div></div>&#8212;Accounts receivable are recorded net of allowances for doubtful accounts. Accounts receivable consist primarily of invoiced amounts to clinics that are not yet paid. On a periodic basis, management evaluates its accounts receivable and determines whether to provide an allowance or if any accounts should be written off based on past history of write-offs, collections, and current credit conditions. The Company maintains an allowance for doubtful accounts to provide for uncollectible amounts based on historical collection experience and an analysis of the aging of receivables. Management provides for probable uncollectible amounts through a charge to earnings and a credit to a valuation allowance based on its assessment of the current status of individual accounts. Balances still outstanding after </div><div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"/><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">management has exhausted all reasonable collection efforts are written off through a charge to the valuation allowance and a credit to accounts receivable. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Bad debt expense is classified in selling, general, and administrative expense within the consolidated statements of income and comprehensive income. The Company generally does not require any security or collateral to support its receivables. A rollforward of the allowance for doubtful accounts is as follows (in thousands): </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:68%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:86%"/>
<td style="vertical-align:bottom;width:6%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">As of December&#160;31, 2020</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(1,157</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Provisions charged to operating results</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(240</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Account <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">write-off</div> and recoveries</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(9</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">As of December&#160;31, 2021</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(1,406</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">As of December&#160;31, 2021</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(1,406</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Provisions charged to operating results</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">155</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Account <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">write-off</div> and recoveries</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">277</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">As of December&#160;31, 2022</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(974</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Inventory</div></div>&#8212;Inventory is carried at the lower of cost or net realizable value using the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">first-in,</div> <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">first-out</div> (FIFO) method. Inventory consists of bioidentical hormone pellets and dietary supplements. Bioidentical hormone pellets contain bioidentical testosterone or estrogen used to achieve hormone balance. Dietary supplements are high-grade vitamins used to enhance pellet therapy. The Company reviews its inventory balances and writes down its inventory for estimated obsolescence or excess inventory equal to the difference between the cost of inventory and the estimated net realizable value based upon assumptions about future demand and market conditions. Inventory write-downs are recorded within cost of products. Management recorded a reserve for obsolescence of inventory related to inventory which has expired. See Note 5 for further details. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Other Current Assets</div></div>&#8212;As of December&#160;31, 2022 and December&#160;31, 2021, the Company&#8217;s total other current assets consist of the following: </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:66%"/>
<td style="vertical-align:bottom;width:11%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:11%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,<br/> 2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,<br/> 2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Prepaid expenses</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2,939</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">847</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Advances</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">877</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">685</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Capitalized transaction costs</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3,941</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total other current assets</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3,816</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">5,473</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Prepaid expenses include software and technology licensing agreements, insurance premiums and other advance payments for services to be received over the next 12 months. Advances are comprised of deposit payments to vendors for inventory purchase orders to be received in the next 12 months. The capitalized transaction costs as of December&#160;31, 2021 relate to costs incurred that were directly related to the Business Combination as described in Note 1. </div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"/><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Property and Equipment, Net</div></div>&#8212;Property and equipment are stated at cost less accumulated depreciation. Depreciation is calculated using the straight-line method and is recorded in Selling, general, and administrative expense over the estimated useful lives of the assets. The estimated useful lives of property and equipment are as follows: </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:48%"/>
<td style="vertical-align:bottom;width:3%"/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Estimated&#160;Useful Life (in years)</div></div></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Trocars</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;text-align:center;">5</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Leasehold improvements</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;text-align:center;">Shorter of lease term or useful life of the<br/> improvement</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Office equipment</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;text-align:center;">5</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Computer software</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;text-align:center;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">3-5</div></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Furniture and fixtures</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;text-align:center;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">5-7</div></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Computer equipment</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;text-align:center;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">3-5</div></td></tr></table><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">See Note 6 for further details. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Capitalized Software, Net</div></div>&#8212;Capitalization of costs related to internally developed software begins when the preliminary project stage is completed and it is probable that the project will be completed and used for its intended function. Once an application has reached the development stage, internal and external costs, if direct and incremental, are capitalized until the software is substantially complete and ready for its intended use. Capitalization ceases upon completion of all substantial testing. The Company also capitalizes costs related to specific upgrades and enhancements when it is probable the expenditures will result in additional features and functionality. Maintenance costs are expensed as incurred. Internal use software is amortized on a straight-line basis over its estimated useful life, generally <span style="-sec-ix-hidden:hidden73945767">three</span> to <span style="-sec-ix-hidden:hidden73945768">eight</span> years. Capitalized software is included within capitalized software, net on the consolidated balance sheet. See Note 7 for further details. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Impairment of Long-Lived Assets</div></div>&#8212;Long-lived assets, such as property and equipment and capitalized software, are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of the asset may not be recoverable. The carrying amount of a long-lived asset is not recoverable if it exceeds the sum of the undiscounted future cash flows expected to result from the use and eventual disposition of the asset. The amount of impairment loss, if any, is measured as the difference between the carrying value of the asset and its estimated fair value. Fair value is determined through various valuation techniques, including discounted cash flow models, quoted market values, and third-party independent appraisals, as considered necessary. No impairment charges have been recorded during the years ended December&#160;31, 2022 and 2021. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Leases</div></div>&#8212;At the inception of an arrangement, the Company determines whether the arrangement is or contains a lease based on the unique facts and circumstances present in the arrangement including the use of an identified asset(s) and the Company&#8217;s control over the use of that identified asset. The Company elected, as allowed under Financial Accounting Standards Board (&#8220;FASB&#8221;) Accounting Standard Update (&#8220;ASU&#8221;) <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2016-02,</div> <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Leases </div></div>(&#8220;ASC&#160;842&#8221;), to not recognize leases with a lease term of one year or less on its balance sheet. Leases with a term greater than one year are recognized on the balance sheet as <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">right-of-use</div></div> (&#8220;ROU&#8221;) assets and current and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-current</div> lease liabilities, as applicable. As of December&#160;31, 2022 and December&#160;31, 2021, the Company does not have any financing leases. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Lease liabilities and their corresponding ROU assets are initially recorded based on the present value of lease payments over the expected remaining lease term. Certain adjustments to the ROU asset may be required for items such as incentives, prepaid lease payments, or initial direct costs. When an option to extend the lease exists, a determination is made whether that option is reasonably certain of exercise based on economic factors present at the measurement date and as circumstances may change. Lease cost for operating leases is recognized on a straight-line basis over the lease term as an operating expense. Variable lease costs are expensed as incurred as an operating expense. </div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"/><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As the rates implicit in the Company&#8217;s leases have not historically been readily determinable, the Company utilizes the appropriate incremental borrowing rate, which is the rate the Company would incur to borrow on a collateralized basis over a similar term an amount equal to the lease payments in a similar economic environment over the lease term. To estimate our incremental borrowing rate, a credit rating applicable to the Company is estimated using a synthetic credit rating analysis since the Company does not currently have a rating agency-based credit rating. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In accordance with ASC 842, contracts containing a lease should be split into three categories: lease components, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-lease</div> components, and activities or costs that do not transfer a distinct good or service <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">(&#8220;non-components&#8221;).</div> The fixed and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">in-substance</div> fixed contract consideration (including any consideration related to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-components)</div> must be allocated, based on the respective relative fair values, to the lease components and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-lease</div> components. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Entities may elect not to separate lease and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-lease</div> components. Accordingly, entities making this election would account for each lease component and related <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-lease</div> component together as a single lease component. The Company has elected to account for lease and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-lease</div> components together as a single lease component for all underlying assets and allocate all of the contract consideration to the lease component only. See Note 15 for further details. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Income Taxes</div></div>&#8212;The Company accounts for income taxes under the asset and liability method pursuant to ASC&#160;740, Income Taxes. Under this method, the Company recognizes deferred tax assets and liabilities for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating loss and tax credit carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We recognize deferred tax assets to the extent that we believe that these assets are more likely than not to be realized. In making such a determination, we consider all available positive and negative evidence, including future reversals of existing taxable temporary differences, projected future taxable income, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">tax-planning</div> strategies, and results of recent operations. If we determine that we would be able to realize our deferred tax assets in the future in excess of their net recorded amount, we would make an adjustment to the deferred tax asset valuation allowance, which would reduce the provision for income taxes. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We record uncertain tax positions in accordance with ASC 740 on the basis of a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">two-step</div> process in which (1)&#160;we determine whether it is more likely than not that the tax positions will be sustained on the basis of the technical merits of the position and (2)&#160;for those tax positions that meet the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">more-likely-than-not</div> recognition threshold, we recognize the largest amount of tax benefit that is more than 50&#160;percent likely to be realized upon ultimate settlement with the related tax authority. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We recognize interest and penalties related to unrecognized tax benefits on the income tax expense line in the accompanying consolidated statements of income and comprehensive income. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Debt Issuance Costs</div></div>&#8212;Costs incurred in connection with the issuance of the Company&#8217;s long-term debt have been recorded as a direct reduction of the debt and amortized over the life of the associated debt as a component of interest expense using the straight-line method, which is not materially different compared to the effective interest m<div style="display:inline;">ethod.</div> </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Warrant Liabilities</div></div>&#8212;The Company accounts for warrants as either equity-classified or liability-classified instruments based on an assessment of the warrant&#8217;s specific terms and applicable authoritative guidance in ASC&#160;480, <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Distinguishing Liabilities from Equity</div></div> (&#8220;ASC 480&#8221;) and ASC 815, <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Derivatives and Hedging</div></div> (&#8220;ASC&#160;815&#8221;). The assessment considers whether the warrants are freestanding financial instruments pursuant to ASC&#160;480, <div style="display:inline;">meet</div> </div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"/><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">the definition of a liability pursuant to ASC 480, and whether the warrants meet all of the requirements for equity classification under ASC 815, including whether the warrants are indexed to the Company&#8217;s own common stock, among other conditions for equity classification. This assessment, which requires the use of professional judgment, is conducted at the time of warrant issuance and as of each subsequent quarterly period end date while the warrants are outstanding. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For issued or modified warrants that meet all of the criteria for equity classification, the warrants are required to be recorded as a component of additional <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">paid-in</div> capital at the time of issuance. For issued or modified warrants that do not meet all the criteria for equity classification, the warrants are required to be recorded as a liability at their initial fair value on the date of issuance, and remeasured each balance sheet date thereafter. The Company&#8217;s warrants did not meet the criteria for equity classification and are recorded as liabilities. Changes in the estimated fair value of the warrants are recognized as a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-cash</div> gain or loss in the statements of income and comprehensive income. See Note 10 for further detail. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Earnout Liability</div></div>&#8212;In connection with the Business Combination, the Members and the Sponsor received shares that will vest upon the achievement of certain share price targets. The earnout shares are classified as a liability in the Company&#8217;s consolidated balance sheet because it does not qualify as being indexed to the Company&#8217;s own stock. The earnout liability was initially measured at fair value at the Closing Date and subsequently remeasured at the end of each reporting period. The change in fair value of the earnout liability is recorded in the consolidated statement of income and comprehensive income. See Note 11 for further detail. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Stockholders&#8217; Equity (Deficit)</div></div>&#8212;Prior to consummation of the Business Combination, the Company&#8217;s capital structure included voting units (Class A), <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-voting</div> units (Class AA and AAA), and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-voting</div> incentive units (Class AAAA), with no limit to the number of units that may be issued. Class&#160;A units had 100% of the voting rights, and there is no par value assigned to any of the classes of units. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to the Business Combination Agreement and immediately prior to the Business Combination&#8217;s consummation, the Company effectuated a recapitalization whereby all Class&#160;A, Class&#160;AA, Class&#160;AAA and Class&#160;AAAA units held by Holdings&#8217; Members were converted (whether by direct exchange, merger or otherwise) into Class&#160;A <div style="display:inline;">Common Units.</div> </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of December&#160;31, 2021, the following members&#8217; equity units were issued and outstanding: </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:68%"/>
<td style="vertical-align:bottom;width:5%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:5%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31, 2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.5pt;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; font-size: 8pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Members&#8217; Equity</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Issued</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Outstanding</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Class&#160;A (Voting)</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">16,721</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">16,721</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Class&#160;AA <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">(Non-voting)</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">903,079</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">903,079</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Class&#160;AAA <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">(Non-voting)</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">60,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">60,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Class&#160;AAAA <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">(Non-voting</div> incentive units)</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">33,397</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,013,197</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">982,800</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of December&#160;31, 2022, the following shares of common stock were issued and outstanding: </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:11pt;width:76%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:64%"/>
<td style="vertical-align:bottom;width:3%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:3%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31, 2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.5pt;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; font-size: 8pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Stockholders&#8217; Equity</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Issued</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Outstanding</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt;background-color:#cceeff">
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Class&#160;A common stock</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;">11,242,887</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;">9,655,387</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Class&#160;B common stock</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt;background-color:#cceeff">
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Class&#160;V voting stock</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;">58,565,824</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;">48,565,824</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;">69,808,711</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;">58,221,211</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"/><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company made operating distributions to Members of Holdings and taxing authorities on the Members&#8217; behalf totaling $12,886 and $11,402 during the years ended December&#160;31, 2022 and 2021, <div style="display:inline;">respectively.</div> </div><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;">Standby Equity Purchase Agreement </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On July&#160;27, 2022, the Company entered into a Standby Equity Purchase Agreement (the &#8220;SEPA&#8221;) with YA II PN, Ltd. (&#8220;Yorkville&#8221;). Yorkville is a fund managed by Yorkville Advisors Global, LP, headquartered in Mountainside, New Jersey. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company has the right, but not the obligation, from time to time at the Company&#8217;s discretion until the first day of the month following the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">36-month</div> anniversary of the date of the SEPA (unless earlier terminated), to direct Yorkville to purchase a specified amount of shares of Class&#160;A common stock (each such sale, an &#8220;Advance&#8221;) by delivering written notice to Yorkville (each, an &#8220;Advance Notice&#8221;). The shares of Class&#160;A common stock purchased pursuant to an Advance will be purchased at a price equal to 97.0% of the lowest daily VWAP of the Class&#160;A common stock during the <span style="-sec-ix-hidden:hidden73945778">three</span> consecutive trading days commencing on the date of delivery of a given Advance Notice. &#8220;VWAP&#8221; means, for any trading day, the daily volume weighted average price of the Company&#8217;s common stock for such date as reported by Bloomberg L.P. during regular trading hours. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">While there is no mandatory minimum amount for any individual Advance, it may not exceed the greater of (i)&#160;an amount equal to thirty percent (30%) of the daily volume traded on the trading day immediately preceding an Advance Notice, or (ii) 1,000,000 shares of Class&#160;A common stock. No more than 5,000,000 shares of Class&#160;A common stock, including the Commitment Shares (as defined below) may be sold pursuant to the SEPA. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Yorkville&#8217;s obligation to continue to purchase shares of Class&#160;A common stock pursuant to the SEPA is subject to a number of conditions. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As consideration for Yorkville&#8217;s commitment to purchase Class&#160;A common stock at the Company&#8217;s direction upon the terms and subject to the conditions set forth in the SEPA, upon execution of the SEPA, the Company issued 25,000 shares of Class&#160;A common stock to Yorkville (the &#8220;Commitment Shares&#8221;). During the year ended December&#160;31, 2022, the Company sold 105,559 shares to Yorkville under the SEPA for cash proceeds of $442. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Noncontrolling Interest</div></div>&#8212;Pursuant to the Business Combination, as described in Note 3, the Company is organized in an <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">&#8220;Up-C&#8221;</div> structure with the Company owning only a portion of its consolidated subsidiaries. The portion of the consolidated subsidiaries not owned by the Company and any related activity is presented as noncontrolling interest in the consolidated financial statements. The noncontrolling interests, together with their corresponding shares of Class&#160;V voting stock, can be exchanged for Class&#160;A common stock in Biote or, at the election of the Company, cash. Because redemptions for cash is solely within the control of the Company, noncontrolling interest is presented in permanent equity. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Revenue Recognition</div></div>&#8212;The Company accounts for revenue in accordance with FASB, Accounting Standards <div style="display:inline;">Update</div> (&#8220;ASU&#8221;) <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">No.&#160;2014-09,</div> <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Revenue from Contracts with Customers</div></div>, as amended, (Topic 606). Revenue is measured based on the consideration specified in a contract with a customer. The Company recognizes revenue when it satisfies a performance obligation by transferring control of a product or service to a customer. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Taxes assessed by a governmental authority that are both imposed on and concurrent with a specific revenue-producing transaction, that are collected by the Company from a customer, are excluded from revenue. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Shipping and handling costs associated with outbound freight after control of a product has transferred to a customer are accounted for as fulfillment costs and are included in cost of products in the statements of income and comprehensive income. Shipping and handling costs billed to customers are considered part of the transaction price and are recognized as revenue with the underlying product sales for dietary supplements and trocars. </div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"/><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following is a description of the principal contract activities, disaggregated by the contract type, from which the Company generates its revenue. </div><div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">The Biote Method </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company generates revenues through standard service agreements with customers who participate in the Biote Method. The Biote Method is a bioidentical hormone replacement therapy which has been developed as a treatment designed to alleviate hormone imbalances. Under this agreement, the Company provides a bundle of goods and services to customers, including initial training to medical practitioners, bioidentical hormone pellets and software tools used for inventory management and dosing, and ongoing practice development and marketing support services, which includes a license to use the Company&#8217;s trademarks and trade names in the customer&#8217;s marketing materials. The initial contract term is three years, and customers have the option to renew for additional <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">one-year</div> periods. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For the bundled goods and services, the Company accounts for individual products and services separately if they are distinct, i.e., if a product or service is separately identifiable from other items in the bundled package and if a customer can benefit from it on its own or with other resources that are readily available to the customer. The Company has identified three distinct obligations in its standard service agreement: initial training, pellet procedures (including sales of bioidentical hormone pellets, use of inventory management software to monitor pellet inventory, and use of the Company&#8217;s blood dosing website to determine the appropriate pellets to use in each procedure), contract-term services (including ongoing practice development and marketing support, options to receive reusable trocars, and the right to use the reusable trocars through the term of the contract, if the option is exercised). The third obligation includes a combined lease/nonlease component for which the Company has adopted the practical expedient within ASC 842 which allows lessors to combine lease and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-lease</div> components that have the same pattern of transfer to the customer-lessee and account for the combined component under the guidance relevant to the predominant portion of the component. By applying this expedient, the Company applies Topic 606 to the combined component. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The consideration in the contract is allocated between separate products and services in the bundle based on the stand-alone selling prices of each good and service. The stand-alone selling prices are determined based on the prices at which the Company separately sells the initial training and the pellet procedures. Judgment is required to determine the standalone selling price for each distinct performance obligation. For items that are not sold separately and for which the Company has not established a standalone selling price, the Company allocates consideration based on the residual approach. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company recognizes revenue for initial training over time as the customer completes the training. Training sessions generally occur over the course of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2-3</div> consecutive days at or near the time of contract inception. The Customer is charged an initial fixed-rate fee for this training. Customers pay in full for the initial training at the time of contract inception. The standalone selling price of these services is based on the lowest price offered by the Company for the services. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company recognizes revenue for pellet procedures at the point in time the procedures are performed by the practitioner, which is when control of the pellets transfers to the customer. Consideration for these services is in the form of a management fee assessed for each procedure performed, which includes a volume-based tiered pricing schedule. The standalone selling price for these services requires judgment and is estimated based on the Company&#8217;s historical experience with prices offered to similar customers throughout the initial term of the contract. Billings in excess of the standalone selling price constitute a premium charged to customers early in a relationship and are deferred and recognized when or as the remaining goods and services are transferred to the customer. Fees are billed and paid on a semimonthly basis. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company recognizes revenue for contract-term services on a straight-line basis over the initial term of the contract, which aligns with the Company&#8217;s satisfaction of the performance obligation. The Company allocates the residual consideration to this performance obligation, which is consistent with the allocation objective. </div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"/><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Dietary Supplements </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Dietary supplements are supplements that customer practitioners resell to patients that aid the patients with maintaining hormone balances. The Company recognizes revenue for these, net of any discounts given, when control transfers to the customer, which is generally the point of shipment from the Company&#8217;s distributor. Products are billed at standalone selling price for the dietary supplements and invoiced at shipment. </div><div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Disposable Trocars </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Disposable Trocars are manual surgical instruments intended for use by Biote-certified practitioners. These tools are used to implant the bioidentical hormone pellets into the customers&#8217; patients. The Company recognizes revenue at the time control transfers, which is generally the point of shipment from the distributor. Products are billed at the standalone selling price for the trocars and invoiced at shipment. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Revenue disaggregated by the nature of the product or service and by geography is included within Note 4: Revenue Recognition. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of the years ended December&#160;31, 2022 and 2021, the Company had allocated $104 and $67 respectively, of consideration to the unsatisfied initial training obligations, and $1,655 and $1,393, respectively, of consideration to the unsatisfied contract-term service obligations provided to the Biote Method customers. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Consideration allocated to initial training due to deposits paid upfront is presented within deferred revenue on the consolidated balance sheets and is expected to be recognized as revenue within one year, as the training is complete. Consideration allocated to contract-term services is presented within deferred revenue and deferred revenue, long-term for the amounts expected to be recognized within one year and longer than one year, respectively. As of the years ended December&#160;31, 2022 and 2021 the amount of consideration allocated to contract-term services presented within deferred revenue was $1,028 and $849, respectively, and the amount presented within deferred revenue, long-term was $627 and $544, respectively. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Consideration allocated to the premiums within the management fee for pellet procedures is presented within deferred revenue current and deferred revenue, long-term for amounts expected to be recognized within one year and longer than one year, respectively. As of the years ended December&#160;31, 2022 and 2021 the amount of these premiums within deferred revenue was $833 and $789, respectively, and the amount within deferred revenue, long-term was $299 and $258, respectively. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company has also elected the practical expedient in ASC 606 to not disclose consideration allocated to contracts with an original term of one year or less, which includes contracts for <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">point-in-time</div></div> sales of dietary supplements, disposable trocars, and pellet procedures. Pellet procedures are included in the Company&#8217;s Biote Method service agreement, which has a three-year stated term, but as revenues are recognized at a point in time, there are no minimum purchase volumes, and the contract allows for cancellation with ninety days&#8217; notice from the customer, there are no pellet procedure obligations that are satisfied over a period greater than one year. </div><div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Contract Assets and Liabilities </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Customer receivables are made up of consideration to which the Company has an unconditional right to payment, regardless of whether the Company has satisfied the performance obligations in the contract. All customer receivables are presented within accounts receivable, net of allowance for doubtful accounts in the consolidated balance sheets. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Contract assets are the Company&#8217;s right to consideration for goods or services that the entity has transferred to the customer when that right is conditioned on something other than the passage of time. The Company does not have any contract assets for the years ended December&#160;31, 2022 and 2021. </div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"/><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Contract liabilities are the Company&#8217;s obligation to transfer goods or services to a customer for which the Company has received consideration or has an unconditional right to receive consideration. The Company&#8217;s contract liabilities include deposits for initial training and contract-term services paid in advance which have not been recognized as revenue during the period. Contract liabilities are presented within deferred revenue and deferred revenue, long-term in the consolidated balance sheets. Contract liabilities are classified as current liabilities for the amount of revenue that the Company expects to recognize within one year of the reporting date. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Changes in contract liabilities between each period are attributable to fees paid by new customers, revenue recognized for completed trainings, and revenue recognized for the Company&#8217;s over-time satisfaction of contract-term services. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company does not have a history of material returns or refunds, and generally does not offer warranties or guarantees for any products or services. Expected returns and refunds are recorded as a reduction of revenue and are $0 and $0 for the years ended December&#160;31, 2022 and 2021, respectively. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A reconciliation of the beginning and ending contract liabilities is included within Note 4: Revenue Recognition. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Cost of Revenue</div></div>&#8212;Cost of services primarily consist of the costs incurred to deliver trainings to Biote Method customers. Cost of products includes the cost of pellets purchased from compounding pharmacies and sold to customers of the Biote Method, the cost of trocars and dietary supplements purchased from manufacturing facilities or third-party <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">co-packers,</div> and the shipping and handling costs incurred to deliver these products to the customers. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Marketing</div></div>&#8212;<div style="display:inline;">Mark</div>eting expense includes advertising costs, marketing events, and program costs. These costs are expensed as incurred. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Selling, General, and Administrative</div></div>&#8212;Selling, general, and administrative expense consists primarily of software licensing and maintenance and the cost of employees who engage in corporate functions, such as finance and accounting, information technology, human resources, legal, and executive management. Selling, general, and administrative expense also includes rent occupancy costs, office expenses, recruiting expenses, entertainment allocations, depreciation and amortization, other general overhead costs, insurance premiums, professional service fees, research and development, and costs related to regulatory and litigation m<div style="display:inline;">atters.</div> </div><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">Employee Retirement Plans&#8212; </div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Defined Contribution Retirement Plans </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Effective January&#160;1, 2021, the Company offers participation in the BioTE Medical, LLC (&#8221;BioTE Medical&#8221;) 401(k) Plan (the &#8220;401(k) Plan&#8221;), a defined contribution plan providing retirement benefits to eligible employees. Eligible employees may contribute a portion of their annual compensation to the 401(k) Plan, subject to the maximum annual amounts as set periodically by the IRS. The Company makes a safe harbor, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-elective</div> contribution to the 401(k) Plan equal to 3% of each participant&#8217;s eligible employee compensation. Safe harbor contributions vest immediately for each participant. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">During the years ended December&#160;31, 2022 and 2021, the Company made $915 and $335, respectively, in safe harbor contributions under the 401(k) Plan, which are presented within Selling, general and administrative expense in the consolidated statements of income and comprehensive income. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Share-Based Compensation</div></div>&#8212;Holdings previously granted Class&#160;AAAA units (&#8220;incentive units&#8221;) and phantom equity rights (collectively, the &#8220;equity awards&#8221;) to certain key members of management. The equity awards were entitled to share in the distributions of Holdings from a change in control or qualifying liquidity event. The equity awards are accounted for under ASC 718, <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Compensation&#8212;Stock Compensation</div></div>, and classified in <div style="display:inline;">equity.</div> </div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"/><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company has elected to recognize forfeitures at the time they occur. The fair value of the equity awards was determined using a Monte-Carlo simulation as of the grant date. The awards begin to vest on the date of a change in control or qualifying event. The Business Combination constituted such a qualifying event triggering the performance condition in the awards. No compensation cost was recognized historically until the Closing of the Business Combination as a qualifying event was not previously deemed probable to occur. See Note 14 for further <div style="display:inline;">details.</div></div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Commissions</div></div>&#8212;Commissions consist primarily of fees paid to a third-party sales force, internal sales force, and partner clinics which participate in the Company&#8217;s new clinic mentor program. Commissions paid to the Company&#8217;s internal and third-party sales forces relate to market support and development activities undertaken to drive channel sales through existing customers and are not considered incremental costs to obtain a customer contract. For the years ended December&#160;31, 2022 and 2021 expenses incurred for these commission programs were $124 and $317, respectively. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Commissions paid to clinics under the Company&#8217;s mentorship program represent amounts paid to existing clinics which provide services to help new customers complete onboarding and other startup activities and are only incurred after contract initiation. These costs are expensed as incurred, consistent with other contract fulfillment costs. For the years ended December&#160;31, 2022 and 2021 commissions paid under this program were $1,098 and $1,738, respectively. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Concentrations</div></div>&#8212;Financial instruments that potentially subject the Company to concentrations of credit risk consist primarily of cash, accounts receivable, credit agreements, and inventory purchases. The Company&#8217;s cash balances exceed those that are federally insured. To date, the Company has not recognized any losses caused by uninsured balances. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of December&#160;31, 2022 and December&#160;31, 2021, 100% of the Company&#8217;s outstanding debt and available line of credit was from one lender. A failure of the counterparty to perform could result in the loss of access to the available borrowing capacity under the line of credit. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Inventory purchases from three vendors totaled approximately 87% and 94% for the years ended December&#160;31, 2022 and 2021, respectively. Due to the nature of the markets and availability of alternative suppliers, the Company does not believe the loss of any one vendor would have a material adverse impact on the Company&#8217;s financial position, results of operations or cash flows for any significant period of time. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Significant customers are those which represent more than 10% of the Company&#8217;s total revenue or gross accounts receivable balance. The Company did not have any customers that accounted for 10% or more of total revenues for the years ended December&#160;31, 2022 and 2021. The Company did not have any customers that accounted for more than 10% of the outstanding gross accounts receivable as of December&#160;31, 2022 or December&#160;31, 2021. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Recently Adopted Accounting Pronouncements</div></div>&#8212;In December 2019, the FASB issued ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2019-12,</div> <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Income Taxes (Topic 740)&#8212;Simplifying the Accounting for Income Taxes</div></div>, which simplifies the accounting for income taxes by removing certain exceptions to the general principles of ASC 740, <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Income Taxes</div></div>. The amendments also improve consistent application of and simplify U.S. GAAP for other areas of ASC 740 by clarifying and amending existing guidance. ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2019-12</div> is effective for fiscal years beginning after December&#160;15, 2021, and for interim periods beginning after December&#160;15, 2022. The Company has adopted the standard as of January 1, 2022, and there was no material impact to the financial statements. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Recent Accounting Pronouncements Not Yet Adopted</div></div>&#8212;In June 2016, the FASB issued ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2016-13,</div> <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Measurement of Credit Losses on Financial Instruments</div></div> (&#8220;ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2016-13&#8221;).</div> The main objective of the update is to provide financial statement users with more decision-useful information about the expected credit losses on financial instruments and other commitments to extend credit held by companies at each reporting date. For trade </div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"/><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">and other receivables, held to maturity debt securities, and other instruments, companies will be required to use a new forward-looking &#8220;expected losses&#8221; model that generally will result in the recognition of allowances for losses earlier than under current accounting guidance. Further, the FASB issued ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2019-04,</div> ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2019-05</div> and ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2019-11</div> to provide additional guidance on the credit losses standard. The standard will be adopted using the modified retrospective approach. ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2016-13</div> is effective for annual and interim periods beginning after December&#160;15, 2022, with early adoption permitted. The Company is evaluating the potential impact of adopting ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2016-13</div> on its consolidated financial statements and related disclosures. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In August 2020, the FASB issued ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2020-06,</div><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;"> Debt&#8212;Debt with Conversion and Other Options <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">(Subtopic&#160;470-20)</div> and Derivatives and Hedging&#8212;Contracts in Entity&#8217;s Own Equity (Subtopic <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">815-40):</div> Accounting for Convertible Instruments and Contracts in an Entity&#8217;s Own Equity</div></div> (&#8220;ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2020-06&#8221;).</div> <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">ASU&#160;2020-06</div> changes how entities account for convertible instruments and contracts in an entity&#8217;s own equity and simplifies the accounting for convertible instruments by removing certain separation models for convertible instruments. ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2020-06</div> also modifies the guidance on diluted earnings per share calculations. The amendments are effective for fiscal years beginning after December&#160;15, 2023, including interim periods within those fiscal years. The Company is currently evaluating the impact of this standard on its consolidated financial statements and related disclosures. </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126899994&amp;loc=d3e18726-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI https://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140468311404000">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Business Combination<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationsAbstract', window );"><strong>Business Combinations [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationDisclosureTextBlock', window );">Business Combination</a></td>
<td class="text">
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">3.</div></div></td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: left; line-height: normal;"><div style="font-weight:bold;display:inline;">BUSINESS COMBINATION </div></div></td></tr></table><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">At the Closing, (i)&#160;Holdings transferred to the Company 9,161,771 Class&#160;A common units of Holdings (&#8220;Holdings Units&#8221;), which was equal to the number of shares of Haymaker&#8217;s Class&#160;A common stock, par value $0.0001 per share (&#8220;Class&#160;A common stock&#8221;), issued and outstanding as of immediately prior to the Closing (after giving effect to redemptions by Haymaker&#8217;s public stockholders of 30,525,729 shares of Class&#160;A common stock prior to the Closing and the conversion of Haymaker&#8217;s Class&#160;B common stock, par value $0.0001 per share (&#8220;Class&#160;B common stock&#8221;) into shares of Class&#160;A common stock and (ii)&#160;Haymaker issued 58,565,824 shares of newly authorized Class&#160;V voting stock, par value $0.0001 per share (&#8220;Class&#160;V voting stock&#8221;), which number of shares of Class&#160;V voting stock was equal to the number of Holdings Units retained by the Members immediately following the Closing (the &#8220;Retained Holdings Units&#8221;), and which shares of Class&#160;V voting stock were distributed to the Members, resulting in the Company being organized in an <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">&#8220;Up-C&#8221;</div> structure. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Also at Closing, (x)&#160;in exchange for the Closing Holdings Units, Haymaker transferred cash in an amount equal to (i)&#160;the cash in the trust account and any cash held by Haymaker outside of the trust account, less (ii)&#160;the amounts required by the redemptions of Class&#160;A common stock by the public stockholders, which was equal to $305.5&#160;million and (y)&#160;the BioTE Companies received aggregate proceeds of $125&#160;million from the Debt Financing (as defined below) (the aggregate amounts described in (x)&#160;and (y) of $137.3&#160;million, the &#8220;Closing Date Cash&#8221;) in accordance with and in the priority set forth in the Business Combination Agreement and as described further in the Proxy Statement. There was no cash consideration paid to Members at Closing. </div><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">Recapitalization </div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Immediately prior to the Closing, Holdings (i)&#160;effectuated a recapitalization, pursuant to which all its Class&#160;A units, Class&#160;AA units, Class&#160;AAA units and Class&#160;AAAA units held by the Members were converted or exchanged (whether by direct exchange, merger or otherwise) into a number of equity interests in the Company designated as &#8220;Class&#160;A Common Units&#8221; in the amounts determined in accordance with Holdings&#8217; Second Amended and Restated Operating Agreement (the &#8220;Holdings A&amp;R OA&#8221;), which was entered into prior to the Closing, the result of which was that the Members hold a single class of Holdings Units as of immediately prior to the Closing and (ii)&#160;converted into a Delaware limited liability company. </div><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">Consideration </div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">At the Closing and in consideration for the acquisition of Holdings Units, Haymaker and the BioTE Companies, pursuant to the Business Combination Agreement and the Trust Agreement (as defined in the Business Combination Agreement), disbursed the Closing Date Cash to Holdings. </div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"/><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">Earnout </div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On the Closing Date (a)&#160;the Members on a pro rata basis subjected (i) 10,000,000 Retained Holdings Units held by them (the &#8220;Member Earnout Units&#8221;) and (ii) 10,000,000 shares of Class&#160;V voting stock distributed to them by the BioTE Companies (the &#8220;Earnout Voting Shares&#8221;), (b) the Sponsor subjected 1,587,500 shares of Class&#160;A common stock held by it after giving effect to the Class&#160;B common stock Conversion (the &#8220;Sponsor Earnout Shares&#8221;), and (c)&#160;Haymaker subjected a number of Holdings Units equal to the number of Sponsor Earnout Shares (the &#8220;Sponsor Earnout Units,&#8221; and, together with the Sponsor Earnout Shares, the Earnout Voting Shares and the Member Earnout Units, the &#8220;Earnout Securities&#8221;), to certain restrictions and potential forfeiture pending the achievement (if any) of certain earnout targets or milestones pursuant to the terms of the Business Combination Agreement or the occurrence of a Change of Control (as defined in the Business Combination Agreement). </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Beginning on the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">six-month</div> anniversary of the Closing, each Retained Biote Unit held by the Members may be redeemed, together with one share of Class&#160;V voting stock and subject to certain conditions, in exchange for either one share of Class&#160;A common stock or in certain circumstances, at the election of the Company in its capacity as the sole manager of Holdings, the cash equivalent of the market value of one share of Class&#160;A common stock, pursuant to the terms and conditions of the Holdings A&amp;R OA (such exchange rights, as further described in the Holdings A&amp;R OA, the &#8220;Exchange Rights&#8221;). See Note 11 for further detail. </div><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">Other Agreements&#8212;Business Combination </div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Business Combination Agreement contemplated the execution of various additional agreements and instruments, including, among others, the following: </div><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;">Tax Receivable Agreement </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">At Closing, Biote entered into a tax receivable agreement (the &#8220;TRA&#8221;) with Holdings, the Members and the Members&#8217; Representative, which provides for, among other things, payment by the Company to the Members of 85% of the U.S. federal, state and local income tax savings realized by the Company as a result of the increases in tax basis and certain other tax benefits related to any transactions contemplated under the Business Combination Agreement and any redemption of Retained Holdings Units in exchange for Class&#160;A common stock or cash (as more fully described in the TRA). These payments are an obligation of Biote and not of the BioTE Companies. Biote&#8217;s only material asset following the Business Combination is its ownership interest in Holdings and, accordingly, the Company will depend on distributions from Holdings to make any payments required to be made by the Company under the TRA. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The term of the TRA will continue until all such tax benefits have been utilized or expired unless the Company exercises its right to terminate the TRA for an amount representing the present value of anticipated future tax benefits under the TRA or certain other acceleration events occur. The actual increase in the Company&#8217;s allocable share of tax basis in the BioTE Companies&#8217; assets, as well as the amount and timing of any payments under the TRA, will vary depending upon a number of factors, including the timing of redemptions of shares of Retained Holdings Units, the market price of shares of the Class&#160;A common stock at the time of the exchange, the extent to which such exchanges are taxable and the amount and timing of the Company&#8217;s income. Any payments the Company makes under the TRA will generally reduce the amount of overall cash flow that might have otherwise been available to the Company. To the extent that the Company is unable to make timely payments under the TRA for any reason, the unpaid amounts will be deferred and will accrue interest until paid; however, nonpayment for a specified period and/or under certain circumstances may constitute a material breach of a material obligation under the TRA and therefore accelerate payments due under the TRA. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="-sec-ix-hidden:hidden73945879">The TRA provides that, in the event that (i)&#160;the Company exercises its early termination rights under the TRA, (ii)&#160;certain changes of control occur (as described in the TRA), (iii) the Company, in certain circumstances, fails</span> </div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"/><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">to make a payment required to be made pursuant to the TRA by the applicable final payment date, which <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-payment</div> continues for 30 days following such final payment date or (iv)&#160;the Company materially breaches any of its material obligations under the TRA, which breach continues without cure for 30 days following receipt by the Company of written notice thereof (unless, in the case of clauses (iii)&#160;and (iv), certain liquidity exceptions apply) the Company&#8217;s obligations under the TRA will accelerate and the Company will be required to make a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">lump-sum</div> cash payment to the applicable parties to the TRA equal to the present value of all forecasted future payments that would have otherwise been made under the TRA, which <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">lump-sum</div> payment would be based on certain assumptions, including those relating to our future taxable income. As of December&#160;31, 2022 and December&#160;31, 2021, there have been no exchanges, and therefore, no liability is recorded related to the TRA. </div><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;">Second Amended and Restated Operating Agreement of Holdings </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">At the Closing, the Company, Holdings and the Members entered into the Holdings A&amp;R OA, which, among other things, (i)&#160;provided for a recapitalization of the ownership structure of Holdings, whereby following the execution of the Holdings A&amp;R OA, the ownership structure of Holdings consists solely of the Holdings Units, (ii)&#160;designated the Company as the sole manager of Holdings (iii)&#160;provides that on the Exchange Date (as defined in the Holdings A&amp;R OA) (unless otherwise waived by the Company, or, with respect to the Initial Shares (as defined therein), following the registration under the Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;), of such shares), each Retained Biote Unit held by the Members may be redeemed in exchange, subject to certain conditions, for either one share of Class&#160;A common stock or, at the election of the Company in its capacity as the sole manager of Holdings, the cash equivalent of the market value of one share of Class&#160;A common stock (the &#8220;Exchange Rights&#8221;), and (iv)&#160;otherwise amended and restated the rights and preferences of the Holdings Units, in each case, as more fully described in the Holdings A&amp;R OA. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In connection with the execution of the Business Combination Agreement, certain of Haymaker&#8217;s officers and directors, Haymaker, the Sponsor, Holdings and the Members&#8217; Representative entered into a letter agreement (the &#8220;Sponsor Letter&#8221;), pursuant to which, among other things, the Sponsor agreed to (i)&#160;vote, at any duly called meeting of stockholders of the Company, in favor of the Business Combination Agreement and the transactions contemplated thereby, (ii)&#160;subject to certain exceptions, not to effect any sale or distribution of any of its shares of Class&#160;B common stock or private placement warrants and (iii)&#160;waive any and all anti-dilution rights described in Haymaker&#8217;s amended and restated certificate of incorporation or otherwise with respect to the shares of Class&#160;B common stock held by the Sponsor that may be implicated by the Business Combination such that the Class&#160;B common stock Conversion will occur as discussed therein. </div><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;">Investor Rights Agreement </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">At the Closing, the Company, the Members, the Sponsor, the Members&#8217; Representative and certain other parties entered into an Investor Rights Agreement (the &#8220;IRA&#8221;). Pursuant to the terms of the IRA, among other things, (i)&#160;that certain Registration Rights Agreement, by and between Haymaker and certain security holders, dated March&#160;1, 2021, entered into in connection with Haymaker&#8217;s initial public offering, was terminated, (ii)&#160;the Company provided certain registration rights for the shares of Class&#160;A common stock held (or underlying certain securities held) by the Members, the Sponsor, and certain other parties, (iii)&#160;the Members agreed not to, subject to certain exceptions, transfer, sell, assign or otherwise dispose of the shares of Class&#160;A common stock, Class&#160;V voting stock and the Holdings Units held by such Members, as applicable, for six months following the Closing, and the Member Earnout Units (as defined therein) until the date such securities have been earned in accordance with the Business Combination Agreement and (iv)&#160;the Sponsor agreed not to, subject to certain exceptions, transfer, sell, assign or otherwise dispose of its (a)&#160;shares of Class&#160;A common stock (other than the Sponsor Earnout Shares, as defined therein) for six months following the Closing, (b)&#160;Sponsor Earnout Shares until the date such securities have been earned in accordance with the Business Combination Agreement and (c)&#160;warrants issued to the Sponsor pursuant to that certain Private Placement Warrants Purchase Agreement, dated March&#160;1, 2021, by and between the Company and the Sponsor, and the underlying shares of Class&#160;A common stock, for </div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"/><div/><div><div style="background-color:white;display: inline;"/></div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">30&#160;days following the Closing Date (such <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">lock-up</div> period superseding the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">lock-up</div> period set forth in the Insider Letter (as defined in the IRA)), in each case, as more fully described in the IRA). </div><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;">Indemnification Agreements </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In connection with the Closing, the Company entered into indemnification agreements (each, an &#8220;Indemnification Agreement&#8221;) with its directors and executive officers. Each Indemnification Agreement provides for indemnification and advancements by the Company of certain expenses and costs if the basis of the indemnitee&#8217;s involvement in a matter was by reason of the fact that the indemnitee is or was a director, officer, employee, or agent of the Company or any of its subsidiaries or was serving at the Company&#8217;s request in an official capacity for another entity, in each case to the fullest extent permitted by the laws of the State of Delaware. </div><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;">Credit Agreements </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On the Closing Date, certain direct and indirect subsidiaries of Biote entered into that certain Credit Agreement, dated as of May&#160;26, 2022 (the &#8220;Credit Agreement&#8221;; any capitalized terms used but not defined herein have the meanings assigned to such terms in the Credit Agreement), by and among, inter alios, Holdings, BioTE Medical, LLC, (&#8220;BioTE Medical&#8221;), BioTe IP, LLC, (&#8220;BioTe IP&#8221; and, together with Holdings and BioTE Medical, collectively, the &#8220;Loan Parties&#8221;), certain lenders party thereto from time to time (the &#8220;Lenders&#8221;), and Truist Bank, as administrative agent for the Lenders (&#8220;Administrative Agent&#8221;). The Credit Agreement provides for (i)&#160;a $50,000 senior secured revolving credit facility (the &#8220;Revolving Loans&#8221;) and (ii)&#160;a $125,000 senior secured term loan A credit facility, which was borrowed in full on the Closing Date (the &#8220;Term Loan&#8221; and, together with the Revolving Loans, collectively, the &#8220;Loans&#8221;, such transactions together the &#8220;Debt Financing&#8221;). BioTE Medical used the proceeds of the Debt Financing to refinance and replace an existing credit facility pursuant to a credit agreement, dated as of May&#160;17, 2019, with Bank of America, N.A and for general corporate purposes. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Loans are also subject to customary events of default. Events of default under the Credit Agreement include (subject to grace periods in certain instances): (i) the failure by any Loan Party to timely make payments due under the Credit Agreement; (ii)&#160;material misrepresentations or misstatements in any representation or warranty by any Loan Party when made; (iii)&#160;failure by any Loan Party to comply with the covenants under the Credit Agreement and other related agreements; (iv)&#160;certain defaults under a specified amount of other indebtedness of Holdings or its subsidiaries; (v)&#160;insolvency or bankruptcy-related events with respect to Holdings or any of its subsidiaries; (vi)&#160;certain undischarged, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-appealable</div> judgments above a specified threshold against Holdings or any of its subsidiaries; (vii)&#160;certain ERISA-related events reasonably expected to result in liability above a specified threshold to Holdings and its subsidiaries taken as a whole; (viii)&#160;any loan documents or a material part of the liens under the loan documents ceasing to be, or being asserted by Holdings or its subsidiaries not to be, in full force and effect; (ix)&#160;any loan party or subsidiary denying that it has further obligations under any Loan Document; (x)&#160;any obligations under the loan documents ceasing to constitute senior indebtedness; and (x)&#160;the occurrence of a change of control. If an event of default has occurred and continues beyond any applicable cure period, Administrative Agent may (i)&#160;accelerate all outstanding obligations under the Credit Agreement or (ii)&#160;terminate the commitments, amongst other remedies. Additionally, BioTE Medical may not borrow under the Loans while an event of default is continuing. See Note 9 for further detail. </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -URI https://asc.fasb.org/topic&amp;trid=2303972<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=128092470&amp;loc=d3e4946-128472<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140468311404000">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue Recognition<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue from Contract with Customer [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerTextBlock', window );">Revenue Recognition</a></td>
<td class="text">
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">4.</div></div></td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: left; line-height: normal;"><div style="font-weight:bold;display:inline;">REVENUE RECOGNITION </div></div></td></tr></table><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Revenue recognized for each revenue stream is as follows: </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:84%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:39%"/>
<td style="vertical-align:bottom;width:4%"/>
<td style="width:33%"/>
<td style="vertical-align:bottom;width:4%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:4%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td rowspan="2" style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.5pt;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; font-size: 8pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Financial Statement Caption</div></div></td>
<td rowspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td rowspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 8pt; font-family: &quot;Times New Roman&quot;; text-align: center; line-height: normal;"><div style="font-weight:bold;display:inline;">Revenue Stream</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Year Ended</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Product revenue:</div></div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">Pellet procedures</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">128,952</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">109,465</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">Dietary supplements</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">32,412</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">27,241</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">Disposable trocars</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,698</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">860</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">Shipping fees</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">71</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">32</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;">Total product revenue</div></div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">163,133</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">137,598</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Service revenue:</div></div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">Training</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">973</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">859</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">Contract-term services</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">851</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">939</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;">Total service revenue</div></div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,824</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,798</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;">Total revenue</div></div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">164,957</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">139,396</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Revenue recognized by geographic region is as follows: </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:84%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:39%"/>
<td style="vertical-align:bottom;width:4%"/>
<td style="width:33%"/>
<td style="vertical-align:bottom;width:4%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:4%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td rowspan="2" style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.5pt;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; font-size: 8pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Financial Statement Caption</div></div></td>
<td rowspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td rowspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 8pt; font-family: &quot;Times New Roman&quot;; text-align: center; line-height: normal;"><div style="font-weight:bold;display:inline;">Country</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">For the Year Ended<br/> December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Product revenue:</div></div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">United States</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">162,742</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">137,349</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">All other</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">391</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">249</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;">Total product revenue</div></div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">163,133</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">137,598</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Service revenue:</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">United States</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,781</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,798</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">All other</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">43</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;">Total service revenue</div></div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,824</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,798</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;">Total revenue</div></div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">164,957</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">139,396</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Significant changes in contract liability balances are as follows: </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:92%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:60%"/>
<td style="vertical-align:bottom;width:5%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:5%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:5%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:5%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="14" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Year Ended December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.5pt;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; font-size: 8pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Description of change</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Deferred<br/> Revenue</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Deferred<br/> Revenue,</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Long-term</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Deferred<br/> Revenue</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Deferred<br/> Revenue,</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Long-term</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Revenue recognized that was included in the contract liability balance at the beginning of the period</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(1,710</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(2,048</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Increases due to cash received, excluding amounts recognized as revenue during the period</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,342</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">760</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,022</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">652</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Transfers between current and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-current</div> liabilities due to the expected revenue recognition period</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">460</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(460</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">697</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(697</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total increase (decrease) in contract liabilities</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">92</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">300</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(329</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(45</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Consideration allocated to initial training due to deposits paid upfront is presented within deferred revenue on the consolidated balance sheets and is expected to be recognized as revenue within one year as the training is performed. Consideration allocated to contract-term services is presented within deferred revenue and deferred </div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"/><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">revenue, long-term for the amounts expected to be recognized within one year and longer than one year, respectively. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Consideration allocated to the premiums within the management fee for pellet procedures is presented within deferred revenue current and deferred revenue, long-term for amounts expected to be recognized within one year and longer than one year, respectively. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Consideration allocated to performance obligations are as follows: </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:68%"/>
<td style="vertical-align:bottom;width:10%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:10%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,<br/> 2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,<br/> 2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Unsatisfied training obligations&#8212;Current</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">104</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">67</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Unsatisfied contract-term services&#8212;Current</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,028</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">849</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Unsatisfied contract-term services&#8212;Long-term</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">627</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">544</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Total allocated to unsatisfied contract-term services</div></div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,655</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,393</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Unsatisfied pellet procedures&#8212;Current</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">833</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">789</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Unsatisfied pellet procedures&#8212;Long-term</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">299</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">258</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Total allocated to unsatisfied pellet procedures</div></div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,132</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,047</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Total deferred revenue&#8212;Current</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,965</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,705</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Total deferred revenue&#8212;Long-term</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">926</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">802</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company does not have a history of material returns or refunds and generally does not offer warranties or guarantees for any products or services. Expected returns and refunds are recorded as a reduction of revenue and are $0 and $0 for the years ended December&#160;31, 2022 and 2021, respectively. </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -URI https://asc.fasb.org/topic&amp;trid=49130388<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130551-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130556-203045<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130554-203045<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130550-203045<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130554-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130554-203045<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130554-203045<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130558-203045<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130554-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140468353424016">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Inventory, Net<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryDisclosureTextBlock', window );">Inventory, Net</a></td>
<td class="text">
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">5.</div></div></td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: left; line-height: normal;"><div style="font-weight:bold;display:inline;">INVENTORY, NET </div></div></td></tr></table><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Inventory, net consists of the following: </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:66%"/>
<td style="vertical-align:bottom;width:10%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:10%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,<br/> 2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,<br/> 2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Product inventory&#8212;Pellets</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">6,213</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">6,318</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Less: Obsolete and expired pellet allowance</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(1,298</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(1,356</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Pellet inventory, net</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">4,915</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">4,962</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Product inventory&#8212;Dietary supplements</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">6,283</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">4,849</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Less: Obsolete and expired dietary supplement allowance</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(15</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(196</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Dietary supplement inventory, net</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">6,268</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">4,653</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Inventory, net</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">11,183</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">9,615</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -URI https://asc.fasb.org/topic&amp;trid=2126998<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140468311323040">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment, Net<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock', window );">Property and Equipment, Net</a></td>
<td class="text">
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">6.</div></div></td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: left; line-height: normal;"><div style="font-weight:bold;display:inline;">PROPERTY AND EQUIPMENT, NET </div></div></td></tr></table><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Property and equipment, net consists of the following: </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:66%"/>
<td style="vertical-align:bottom;width:11%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:11%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,<br/> 2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,<br/> 2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Trocars</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">4,645</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">4,448</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Leasehold improvements</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,028</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">254</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Office equipment</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">238</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">223</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Computer software</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">140</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">135</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Furniture and fixtures</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">161</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">119</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Computer equipment</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">102</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">97</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Construction in process</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">705</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Property and equipment</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">6,314</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">5,981</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Less: Accumulated depreciation</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(4,810</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(3,646</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Property and equipment, net</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,504</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2,335</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Total depreciation expense related to property and equipment was $1,164 and $713 for the years ended December&#160;31, 2022 and 2021. Total depreciation expense was included in Selling, general and administrative expense in the consolidated statements of income and comprehensive income. The Company has not acquired any property and equipment under finance leases. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company&#8217;s property and equipment are all held within the United States. </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=126982197&amp;loc=d3e99893-112916<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -URI https://asc.fasb.org/topic&amp;trid=2155823<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126982197&amp;loc=SL120174063-112916<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126982197&amp;loc=d3e99779-112916<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140468230246592">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Capitalized Software, Net<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentAbstract', window );"><strong>Research and Development [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock', window );">Capitalized Software, Net</a></td>
<td class="text">
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">7.</div></div></td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: left; line-height: normal;"><div style="font-weight:bold;display:inline;">CAPITALIZED SOFTWARE, NET </div></div></td></tr></table><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Capitalized software, net consists of the following: </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:66%"/>
<td style="vertical-align:bottom;width:11%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:11%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,<br/> 2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,<br/> 2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Website costs</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">4,142</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3,571</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Development in process</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3,277</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2,294</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Less: Accumulated amortization</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(2,346</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(1,311</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Capitalized software, net</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">5,073</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">4,554</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Total amortization expense for capitalized software was $1,035 and $687 for the years ended December&#160;31, 2022 and 2021, respectively. Total amortization expense was included in Selling, general and administrative expense in the consolidated statements of income and comprehensive income. </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for research, development, and computer software activities, including contracts and arrangements to be performed for others and with federal government. Includes costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility and in-process research and development acquired in a business combination consummated during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 730<br> -URI https://asc.fasb.org/subtopic&amp;trid=2197926<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140468230282848">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued Expenses<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock', window );">Accrued Expenses</a></td>
<td class="text">
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">8.</div></div></td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: left; line-height: normal;"><div style="font-weight:bold;display:inline;">ACCRUED EXPENSES </div></div></td></tr></table><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Accrued expenses consist of the following: </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:66%"/>
<td style="vertical-align:bottom;width:11%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:11%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,<br/> 2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,<br/> 2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Accrued professional fees</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">354</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,192</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Accrued employee-related costs</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">4,221</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2,213</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Accrued merchant fees</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">184</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Accrued interest</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">27</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Legal accrual</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,302</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Other</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,699</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,093</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Accrued expenses</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">6,274</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">6,011</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for accounts payable, accrued expenses, and other liabilities that are classified as current at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140468230210048">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Long-Term Debt<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">Long-Term Debt</a></td>
<td class="text">
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">9.</div></div></td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: left; line-height: normal;"><div style="font-weight:bold;display:inline;">LONG-TERM DEBT </div></div></td></tr></table><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Bank of America Term Loan </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In May 2019, the Company entered into a credit arrangement (the &#8220;Bank of America Credit Agreement&#8221;) with a financial institution for a term loan for $50,000 (the &#8220;Bank of America Term Loan&#8221;), which bore an interest rate quoted as LIBOR + 300 Basis Points (BPS). As of December&#160;31, 2022 and December&#160;31, 2021, the outstanding principal on the Bank of America Term Loan was $0 and $37,500, respectively. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Bank of America Credit Agreement also included a line of credit arrangement, under which the Company could borrow up to $10,000. The line was set to expire in <div style="display:inline;"><span style="-sec-ix-hidden:hidden73946021">May of 2024</span></div> and was secured by all assets of the Company. The Company did not draw on the line of credit during the years ended December&#160;31, 2022 and 2021. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In connection with obtaining the Bank of America Credit Agreement in May of 2019, the Company incurred lender&#8217;s fees and related attorney&#8217;s fees of $1,108. The Company capitalized these costs and was amortizing these to interest expense over the maturity of the Bank of America Term Loan. The balance on the Bank of America Term Loan is presented in the consolidated balance sheet net of the related debt issuance costs. Amortization expense related to the debt issuance costs on the Bank of America Credit Agreement was $91 and $222 for the years ended December&#160;31, 2022 and 2021, respectively. At June&#160;30, 2022, the remaining unamortized Bank of America debt issuance costs of $445 were written off as a loss from extinguishment of debt in the Company&#8217;s consolidated statements of income and comprehensive income upon extinguishment of the Bank of America Credit Agreement. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In connection with the Business Combination, the Company entered into a new loan agreement as described below. A portion of the funds obtained from the new agreement were used to repay the Bank of America Term Loan in full. </div><div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Truist Term Loan </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On the Closing Date, the Company entered into a new loan agreement with Truist Bank (the &#8220;Credit Agreement&#8221; and with respect to the term loan within, the &#8220;Term Loan&#8221;) for $125,000. Interest on borrowings under the Credit Agreement is based on either, at the Company&#8217;s election, the Standard Overnight Financing Rate plus an applicable margin of 2.5% or 2.75% or the Base Rate plus an applicable margin of 1.5% or 1.75%. At December&#160;31, 2022, the interest rate charged to the Company was approximately 6.92%. The Term Loam requires principal payments of approximately $1,563 in quarterly installments on the last day of each calendar quarter, commencing on September&#160;30, 2022, with repayment of the outstanding amount of the note due on maturity, which occurs on May 26, 2027. As of December&#160;31, 2022, the outstanding principal on the Term Loan was $121,875. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to the Credit Agreement, BioTE Medical may borrow under the &#8220;Revolving Loans&#8221; from time to time up to the total commitment of $50,000. The Company has not drawn on the line of credit during the year ended December&#160;31, 2022. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Credit Agreement is secured by substantially all of the assets of the Company and is subject to, among other provisions, customary covenants regarding indebtedness, liens, negative pledges, restricted payments, certain prepayments of indebtedness, investments, fundamental changes, disposition of assets, sale and lease-back transactions, transactions with affiliates, amendments of or waivers with respect to restricted debt and permitted activities of the Company. <span style="-sec-ix-hidden:hidden73946027">In addition, the Credit Agreement is subject to (i)&#160;a maximum total net leverage ratio and (ii)&#160;a minimum fixed charge coverage ratio. The Company must maintain a total net leverage ratio of less than or equal to (i) 4.25:1.00, with respect to the fiscal quarter ending September&#160;30, 2022 through and including the fiscal quarter ending March&#160;31, 2023, (ii) 4.00:1.00, with respect to the fiscal quarter ending June&#160;30, 2023 through and including March&#160;31, 2024, and (iii) 3.75:1.00 thereafter. Beginning with the third fiscal quarter of 2022, the Company must not permit the Consolidated Fixed Charge Coverage Ratio to be less than 1.25:1.00.</span> </div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"> </div><div/><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Both financial covenants are tested quarterly. The Company was in compliance with all required covenants associated with the Credit Agreement as of December 31, 2022. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In connection with obtaining the Credit Agreement in May of 2022, the Company incurred lender&#8217;s fees and related attorney&#8217;s fees of approximately $4,036. The Company capitalized these costs and is amortizing these to interest expense over the term of the Term Loan. The balance on the Term Loan is presented in the consolidated balance sheet net of the related debt issuance costs. Amortization expense related to the debt issuance costs on the Credit Agreement was $498 for the year ended December&#160;31, 2022. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The total amortization of debt issuance costs, inclusive of those related to both the Bank of America Credit Agreement and the Credit Agreement, was $589 and $222 for the years ended December&#160;31, 2022 and 2021, respectively. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The outstanding debt as of December&#160;31, 2022 and 2021 is classified in the consolidated balance sheets as follows: </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:65%"/>
<td style="vertical-align:bottom;width:9%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:9%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,<br/> 2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,<br/> 2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Term loan</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">121,875</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">37,500</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Less: Current portion</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(6,250</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(5,000</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">115,625</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">32,500</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Less: Unamortized debt issuance costs</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(3,539</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(537</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Term loan, net of current portion</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">112,086</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">31,963</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Future maturities of long-term debt, excluding debt issuance costs, are as follows: </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:68%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:83%"/>
<td style="vertical-align:bottom;width:7%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">2023</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">6,250</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">2024</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">6,250</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">2025</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">6,250</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">2026</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">6,250</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">2027</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">96,875</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">121,875</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -URI https://asc.fasb.org/topic&amp;trid=2208564<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(c))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140468230237008">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Warrant Liability<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsNoteDisclosureAbstract', window );"><strong>Warrants and Rights Note Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_btmd_WarrantLiabilityTextBlock', window );">Warrant Liability</a></td>
<td class="text">
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">10.</div></div></td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: left; line-height: normal;"><div style="font-weight:bold;display:inline;">WARRANT LIABILITY </div></div></td></tr></table><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In connection with its initial public offering, Haymaker issued Public Warrants as part of the units sold through the offering (&#8220;Public Warrant&#8221;) as well as private placement warrants (&#8220;Private Placement Warrant&#8221;) to its Sponsor, the terms of which are further described below. </div><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">Public Warrants </div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Each whole Public Warrant is exercisable to purchase one share of Class&#160;A common stock, and only whole warrants are exercisable. The Public Warrants became exercisable on June&#160;25, 2022, 30 days after the completion of the Business Combination. Each whole Public Warrant entitles the holder to purchase one share of Class&#160;A common stock at an exercise price of $11.50. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to the warrant agreement, a warrant holder may exercise its warrants only for a whole number of shares of Class&#160;A common stock. This means that only a whole warrant may be exercised at any given time by a warrant holder. No fractional warrants were issued upon separation of the units and only whole warrants were traded, requiring a purchase of at least four units to receive or trade a whole warrant. The warrants will expire on May 26, 2027, five years after the completion of the Business Combination, or earlier upon redemption or liquidation. </div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"/><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If the shares issuable upon exercise of the warrants are not registered under the Securities Act within 60 business days following the Business Combination, the Company will be required to permit holders to exercise their warrants on a cashless basis. However, no warrant will be exercisable for cash or on a cashless basis, and the Company will not be obligated to issue any shares to holders seeking to exercise their warrants, unless the issuance of the shares upon such exercise is registered or qualified under the securities laws of the state of the exercising holder, unless an exemption is available. In the event that the conditions in the immediately preceding sentence are not satisfied with respect to a warrant, the holder of such warrant will not be entitled to exercise such warrant and such warrant may have no value and expire worthless. In no event will the Company be required to net cash settle any warrant. In the event that a registration statement is not effective for the exercised warrants, the purchaser of a unit containing such warrant will have paid the full purchase price for the unit solely for the share of Class&#160;A common stock underlying such unit. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company has agreed that as soon as practicable, but in no event later than 15 business days, after the closing of the Business Combination, the Company will use its reasonable best efforts to file with the SEC a registration statement for the registration, under the Securities Act, of the shares of Class&#160;A common stock issuable upon exercise of the warrants. The Company will use its reasonable best efforts to cause the same to become effective within 60 business days following the Business Combination and to maintain the effectiveness of such registration statement, and a current prospectus relating thereto, until the expiration of the warrants in accordance with the provisions of the warrant agreement. Notwithstanding the above, if the Company&#8217;s Class&#160;A common stock is at the time of any exercise of a warrant not listed on a national securities exchange such that it satisfies the definition of a &#8220;covered security&#8221; under Section&#160;18(b)(1) of the Securities Act, the Company may, at its option, require holders of Public Warrants who exercise their warrants to do so on a &#8220;cashless basis&#8221; in accordance with Section&#160;3(a)(9) of the Securities Act and, in the event the Company so elects, the Company will not be required to file or maintain in effect a registration statement, but the Company will be required to use its best efforts to register or qualify the shares under applicable blue sky laws to the extent an exemption is not available. </div><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;">Redemption of warrants when the price per Class&#160;A share equals or exceeds $18.00 </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Once the warrants become exercisable, the Company may call the warrants for redemption: </div><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left;">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-align: left; line-height: normal;">in whole and not in part; </div></td></tr></table><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left;">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-align: left; line-height: normal;">at a price of $0.01 per warrant; </div></td></tr></table><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left;">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-align: left; line-height: normal;">upon not less than 30 days&#8217; prior written notice of redemption (which we refer to as the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="display:inline;">30</div>-day</div> redemption period) to each warrant holder; and </div></td></tr></table><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left;">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-align: left; line-height: normal;">if, and only if, the last reported sale price of the Class&#160;A common stock equals or exceeds $18.00 per share (as adjusted for stock splits, stock capitalizations, reorganizations, recapitalizations and the like) for any 20 trading days within a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="display:inline;">30</div>-trading</div> day period ending on the third trading day prior to the date on which we send the notice of redemption to the warrant holders. </div></td></tr></table><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;">Redemption of warrants when the price per Class&#160;A share equals or exceeds $10.00 </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Once the warrants become exercisable, the Company may call the warrants for redemption: </div><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left;">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-align: left; line-height: normal;">in whole and not in part; </div></td></tr></table><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left;">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-align: left; line-height: normal;">at $0.10 per warrant upon a minimum of 30 days&#8217; prior written notice of redemption provided that holders will be able to exercise their warrants on a cashless basis prior to redemption and receive that number of shares of our Class&#160;A common stock to be determined based on the redemption date and the &#8220;fair market value&#8221; of shares of our Class&#160;A common stock except as otherwise described below; </div></td></tr></table><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left;">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-align: left; line-height: normal;">if, and only if, the closing price of shares of our Class&#160;A common stock equals or exceeds $10.00 per share (as adjusted for stock splits, stock dividends, reorganizations, recapitalizations and the like) for </div></td></tr></table><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"> </div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:9%">&#160;</td>
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt; line-height: normal;">any 20 trading days within the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">30-trading</div> day period ending on the third trading day prior to the date on which we send the notice of redemption to the warrant holders; and </div></td></tr></table><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left;">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-align: left; line-height: normal;">if the closing price of our Class A common stock for any 20 trading days within a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">30-trading</div> day period ending on the third trading day prior to the date on which we send the notice of redemption to the warrant holders is less than $18.00 per share (as adjusted for stock splits, stock dividends, reorganizations, recapitalizations and the like), the Private Placement Warrants must also be concurrently called for redemption on the same terms as the outstanding Public Warrants. </div></td></tr></table><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, if (x)&#160;the Company issues additional shares of Class&#160;A common stock or equity-linked securities for capital raising purposes in connection with the Closing of the Business Combination at an issue price or effective issue price of less than $9.20 per share of Class&#160;A common stock (with such issue price or effective issue price to be determined in good faith by the Company&#8217;s board of directors and, in the case of any such issuance to the Sponsor or its affiliates, without taking into account any founder shares held by the Sponsor or such affiliates, as applicable, prior to such issuance) (the &#8220;Newly Issued Price&#8221;), (y) the aggregate gross proceeds from such issuances represent more than 60% of the total equity proceeds, inclusive of interest earned on equity held in trust, available for the funding of the Business Combination on the date of the consummation of the Business Combination (net of redemptions), and (z)&#160;the volume weighted average trading price of the Company&#8217;s common stock during the 20 trading day period starting on the trading day prior to the day on which the Business Combination is consummated (such price, the &#8220;Market Value&#8221;) is below $9.20 per share, the exercise price of the warrants will be adjusted (to the nearest cent) to be equal to 115% of the higher of the Market Value and the Newly Issued Price, and the $18.00 per share redemption trigger price described above will be adjusted (to the nearest cent) to be equal to 180% of the higher of the Market Value and the Newly Issued Price. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company&#8217;s Public Warrants are treated as liabilities and recorded at fair value in the Warrant liability line of the consolidated balance sheet. Any changes in fair value are recorded in the changes in fair value of warrants line of the consolidated statements of income and comprehensive income. Please see Note 12 for further detail. No Public Warrants have been redeemed as of December&#160;31, 2022 or December&#160;31, 2021. </div><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">Private Placement Warrants </div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Sponsor purchased an aggregate of 5,333,333 Private Placement Warrants at a price of $1.50 per whole warrant in a private placement that occurred simultaneously with the closing of Haymaker&#8217;s initial public offering. Subsequently, the Sponsor purchased an additional 233,333 Private Placement Warrants for an aggregate purchase price of $350,000 in conjunction with the partial exercise of the underwriters&#8217; overallotment option. Each whole Private Placement Warrant was exercisable for one share of the Company&#8217;s Class&#160;A common stock at a price of $11.50 per share. The Private Placement Warrants were <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-redeemable</div> and exercisable on a cashless basis so long as they are held by the Sponsor or its permitted transferees. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Private Placement Warrants (including the Class&#160;A common stock issuable upon exercise of the Private Placement Warrants) were not transferable, assignable or saleable until 30 days after the completion of the Business Combination and they are not redeemable so long as they are held by the Sponsor or its permitted transferees. Otherwise, the Private Placement Warrants had terms and provisions that were identical to those of the Public Warrants, including as to exercise price, exercisability and exercise period. If the Private Placement Warrants are held by holders other than the Sponsor or its permitted transferees, the Private Placement Warrants will be redeemable by the Company and exercisable by the holders on the same basis as the Public Warrants. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If holders of the Private Placement Warrants elect to exercise them on a cashless basis, they would pay the exercise price by surrendering their warrants for that number of shares of Class&#160;A common stock equal to the quotient obtained by dividing (x)&#160;the product of the number of shares of Class&#160;A common stock underlying the warrants, multiplied by the difference between the exercise price of the warrants and the &#8220;fair market value&#8221; (defined below) by (y)&#160;the fair market value. The &#8220;fair market value&#8221; shall mean the average reported last sale price of the Class&#160;A common stock for the 10 trading days ending on the third trading day prior to the date on which the notice of warrant exercise is sent to the warrant agent. </div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"> </div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On December&#160;31, 2022, there were 7,937,466 Public Warrants and 5,566,666 Private Placement Warrants outstanding. The Company accounts for the Public Warrants and Private Placement Warrants in accordance with the guidance contained in ASC <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">815-40.</div> Such guidance provides that because the warrants do not meet the criteria for equity treatment thereunder, each warrant must be recorded as a liability. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The warrant liabilities are subject to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">re-measurement</div> at each balance sheet date. With each such <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">re-measurement,</div> the warrant liabilities are adjusted to current fair value, with the change in fair value recognized in the Company&#8217;s consolidated statements of income and comprehensive income. The Company reassesses the classification at each balance sheet date. If the classification changes as a result of events during the period, the warrants will be reclassified as of the date of the event that causes the reclassification. No such events requiring a change in classification of the warrants have occurred through December&#160;31, 2022. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company&#8217;s Private Placement Warrants are treated as liabilities and recorded at fair value in the Warrant liability line of the balance sheet. Any changes in fair value are recorded in the changes in fair value of warrants line of the consolidated statement of income and comprehensive income. Please see Note 12 for further detail. </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_btmd_WarrantLiabilityTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Warrant liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">btmd_WarrantLiabilityTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>btmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsNoteDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsNoteDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140468225074256">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Earnout Liability<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_btmd_EarnoutLiabilityTextBlock', window );">Earnout Liability</a></td>
<td class="text">
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">11.</div></div></td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: left; line-height: normal;"><div style="font-weight:bold;display:inline;">EARNOUT LIABILITY </div></div></td></tr></table><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Certain of the Company&#8217;s equity holders are entitled to vest in up to 11,587,500 Earnout Securities if certain share price targets (the &#8220;Triggering Events&#8221;) are achieved by <span style="-sec-ix-hidden:hidden73946098">May&#160;26, 2027</span> (the &#8220;Earnout Deadline&#8221;). The Triggering Events each entitle the eligible equity holders to a certain number of shares per Triggering Event. The Triggering Events are as follows: </div><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:5%;vertical-align:top;text-align:left;">(i)</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: left; line-height: normal;">the first time, prior to the Earnout Deadline, that the volume-weighted average share price of Biote&#8217;s Class&#160;A common stock (&#8220;VWAP&#8221;) equals or exceeds $12.50 per share (the &#8220;Price Target 1&#8221;) for twenty (20)&#160;trading days of any thirty (30)&#160;consecutive trading day period following the Closing, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">one-third</div> (1/3) of the Earnout Securities shall be vested and no longer subject to forfeiture and other transfer restrictions (the &#8220;Earnout Restrictions&#8221;); </div></td></tr></table><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:5%;vertical-align:top;text-align:left;">(ii)</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: left; line-height: normal;">the first time, prior to the Earnout Deadline, that the VWAP equals or exceeds $15.00 per share (the &#8220;Price Target 2&#8221;) for twenty (20)&#160;trading days of any thirty (30)&#160;consecutive trading day period following the Closing, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">one-third</div> (1/3) of the Earnout Securities shall be vested and no longer subject to the Earnout Restrictions; </div></td></tr></table><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:5%;vertical-align:top;text-align:left;">(iii)</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: left; line-height: normal;">the first time, prior to the Earnout Deadline, that the VWAP equals or exceeds $17.50 per share (the &#8220;Price Target 3&#8221;) for twenty (20)&#160;trading days of any thirty (30)&#160;consecutive trading day period following the Closing, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">one-third</div> (1/3) of the Earnout Securities shall be vested and no longer subject to the Earnout Restrictions; and </div></td></tr></table><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:5%;vertical-align:top;text-align:left;">(iv)</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: left; line-height: normal;">if the Company completes a change of control prior to the Earnout Deadline, then all remaining unvested Earnout Securities shall vest and no longer be subject to the Earnout Restrictions. </div></td></tr></table><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company&#8217;s Earnout liability is recorded at fair value in the consolidated balance sheet. Any changes in fair value are recorded in the changes in earnout liability line of the consolidated statement of income and comprehensive income. Please see Note 12 for further detail. </div><div style="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&#160;</div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_btmd_EarnoutLiabilityTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Earnout liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">btmd_EarnoutLiabilityTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>btmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140468230275552">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Fair value measurements</a></td>
<td class="text">
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">12.</div></div></td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: left; line-height: normal;"><div style="font-weight:bold;display:inline;">FAIR VALUE MEASUREMENTS </div></div></td></tr></table><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">To the extent that valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair value requires more judgment. Accordingly, the degree of judgment exercised by the Company in determining fair value is greatest for instruments categorized in Level&#160;3. A financial instrument&#8217;s level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement. </div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"> </div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Fair value is a market-based measure considered from the perspective of a market participant rather than an entity-specific measure. Therefore, even when market assumptions are not readily available, the Company&#8217;s own assumptions are set to reflect those that market participants would use in pricing the asset or liability at the measurement date. The Company uses prices and inputs that are current as of the measurement date, including during periods of market dislocation. In periods of market dislocation, the observability of prices and inputs may be reduced for many instruments. This condition could cause an instrument to be reclassified from Level&#160;1 to Level&#160;2 or Level&#160;2 to Level&#160;3. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company&#8217;s financial instruments consist of accounts receivable, accounts payable, accrued expenses, and short- and long-term debt. The carrying value of accounts receivable, accounts payable, accrued expenses and short-term debt are considered a reasonable estimate of their fair value, due to the short-term maturity of these instruments. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company&#8217;s debt instruments are carried at amortized cost in its consolidated balance sheets, which may differ from their respective fair values. The fair values of the Company&#8217;s term loan and revolving line of credit generally approximate their carrying values. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company&#8217;s Warrant liability and Earnout liability are recorded at fair value on a recurring basis. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following table presents the Company&#8217;s fair value hierarchy for financial assets and liabilities: </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:92%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:60%"/>
<td style="vertical-align:bottom;width:6%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:6%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:6%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:6%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="14" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Fair&#160;Value&#160;Measurements&#160;as&#160;of&#160;December&#160;31,&#160;2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;Level&#160;1&#160;&#160;</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;Level&#160;2&#160;&#160;</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;Level&#160;3&#160;&#160;</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;Total&#160;&#160;</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Liabilities:</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Public Warrants</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2,381</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2,381</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Private Placement Warrants</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,723</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,723</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Earnout liability</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">32,110</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">32,110</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:12pt">&#160;</td>
<td colspan="16" style="height:12pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="14" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Fair Value Measurements as of May&#160;26, 2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Level&#160;1</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Level&#160;2</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Level&#160;3</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Total</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Liabilities:</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Public Warrants</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">5,397</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">5,397</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Private Placement Warrants</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3,834</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3,834</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Earnout liability</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">93,880</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">93,880</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr></table><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">There were no movements between levels during the year ended December&#160;31, 2022. These instruments were not outstanding on the Company&#8217;s books for the year ended December&#160;31, 2021. </div><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">Level&#160;3 Disclosures </div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Private Placement Warrants </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As described in Note 10, the Company&#8217;s Private Placement Warrants were initially issued by Haymaker and were thus acquired by the Company through the consummation of the Business Combination. Accordingly, the initial measurement date of the Private Placement Warrants for the Company was the Closing Date. The Private Placement Warrants were valued using a Monte Carlo simulation. Calculating the fair value of the Private Placement Warrants requires the input of subjective assumptions. Other reasonable assumptions could provide differing results. The carrying amount of the liability may fluctuate significantly, and actual amounts at settlement may be materially different from the liability&#8217;s estimated value. </div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"> </div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following table provides the significant inputs to the Monte Carlo simulation for the fair value of the Private Placement Warrants as of December&#160;31, 2022 and the Closing Date: </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:71%"/>
<td style="vertical-align:bottom;width:10%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:9%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">As of</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">May&#160;26,</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Stock price</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3.73</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">9.02</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Exercise price</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">11.50</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">11.50</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Risk-free rate</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">4.0</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2.7</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Volatility</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">42.2</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">13.4</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Term (in years)</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">4.4</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">5.0</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr></table><div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Earnout Liability </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Earnout liability was valued using a Monte Carlo simulation in order to project the future path of the Company&#8217;s stock price over the earnout period. The carrying amount of the liability may fluctuate significantly, and actual amounts paid may be materially different from the liability&#8217;s estimated value. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following table provides the significant inputs to the Monte Carlo simulation for the fair value of the Earnout liability as of December&#160;31, 2022 and the Closing Date, the date of initial measurement: </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:71%"/>
<td style="vertical-align:bottom;width:12%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:11%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">As of</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,<br/> 2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">May&#160;26,<br/> 2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Stock price</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3.73</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">9.02</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Risk-free rate</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">4.1</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2.7</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Volatility</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">70.0</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">60.0</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Term (in years)</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">4.4</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">5.0</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr></table><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following table presents the changes in fair value of the Company&#8217;s Level&#160;3 financial instruments that are measured at fair value as of December&#160;31, 2022 and the Closing Date, the date of initial measurement: </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:84%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:65%"/>
<td style="vertical-align:bottom;width:5%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:5%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:5%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Private<br/> Placement</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Warrants</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Earnout<br/> Liability</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Total</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Fair value as of May&#160;26, 2022 (initial measurement)</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3,834</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">93,880</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">97,714</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Gain from change in fair value</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(2,111</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(61,770</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(63,881</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Fair value as of December&#160;31, 2022</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,723</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">32,110</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">33,833</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140468230264960">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Noncontrolling Interest<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NoncontrollingInterestAbstract', window );"><strong>Noncontrolling Interest [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MinorityInterestDisclosureTextBlock', window );">Noncontrolling Interest</a></td>
<td class="text">
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">13.</div></div></td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: left; line-height: normal;"><div style="font-weight:bold;display:inline;">NONCONTROLLING INTEREST </div></div></td></tr></table><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In connection with the Closing of the Business Combination on the Closing Date, certain Members of Holdings (the &#8220;Minority Interest Holders&#8221;) retained an approximately 86.5% membership interest in Holdings and Biote received an approximately 13.5% ownership interest in Holdings. As a result of share issuances subsequent to the Closing of the Business Combination, Biote&#8217;s ownership of Holdings, was approximately 16.6% as of December&#160;31, 2022. The Minority Interest Holders may from time to time, after the Closing Date, exchange with Biote, such holders&#8217; units in Holdings for an equal number of shares of Biote&#8217;s Class&#160;A common stock. As a result, Biote&#8217;s ownership interest in Holdings will continue to increase. The Minority Interest Holders&#8217; ownership interests are accounted for as noncontrolling interests in the Company&#8217;s consolidated financial statements. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Because the Business Combination was accounted for similar to a reverse recapitalization, the noncontrolling interest was initially recorded based on the Minority Interest Holders&#8217; ownership interest in the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-combination</div> carrying value of Holdings&#8217; equity, including net income (loss) for the periods prior to the Closing Date included in accumulated deficit as of the Closing Date. Subsequent to the Business Combination, the Minority Interest Holders&#8217; interest in the net income (loss) of Holdings after the Closing Date is allocated to noncontrolling interest. </div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"> </div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In connection with the Business Combination, Biote issued the Minority Interest Holders an aggregate of 48,565,824 shares of Class&#160;V voting stock. The Class&#160;V voting stock provides no economic rights in Biote to the holder thereof; however, each holder of Class V voting stock is entitled to vote with the holders of Class A common stock of Biote, with each share of Class V voting stock entitling the holder to one vote per share of Class V voting stock at the time of such vote (subject to customary conversion rate adjustments for stock splits, stock dividends and reclassifications). </div><div style="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&#160;</div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterestDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for noncontrolling interest in consolidated subsidiaries, which could include the name of the subsidiary, the ownership percentage held by the parent, the ownership percentage held by the noncontrolling owners, the amount of the noncontrolling interest, the location of this amount on the balance sheet (when not reported separately), an explanation of the increase or decrease in the amount of the noncontrolling interest, the noncontrolling interest share of the net Income or Loss of the subsidiary, the location of this amount on the income statement (when not reported separately), the nature of the noncontrolling interest such as background information and terms, the amount of the noncontrolling interest represented by preferred stock, a description of the preferred stock, and the dividend requirements of the preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -URI https://asc.fasb.org/topic&amp;trid=2197479<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterestDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncontrollingInterestAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncontrollingInterestAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140468225994448">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Compensation<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Share-Based Compensation</a></td>
<td class="text">
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">14.</div></div></td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: left; line-height: normal;"><div style="font-weight:bold;display:inline;">SHARE-BASED COMPENSATION </div></div></td></tr></table><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">At the Closing of the Business Combination, Holdings&#8217; share-based compensation awards (as such terms are defined below) were converted into equity in Biote. Share information below has been converted from historical disclosure based on the equivalent shares received in the Business Combination. </div><div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Incentive Units </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Holdings previously issued incentive units, which entitled the holder to participate in the net transaction proceeds from a change in control or qualifying liquidity event. Incentive units equivalent to 987,275 shares of Class&#160;V voting stock were vested as of December&#160;31, 2021, and the Closing of the Business Combination triggered the vesting of the remaining incentive units equivalent to 6,356,178 shares of Class&#160;V voting stock. No compensation cost was recognized historically until the Closing of the Business Combination, and $50,026 of share-based compensation expense was recognized at Closing related to the incentive units. As of December&#160;31, 2022, there are no incentive units outstanding. </div><div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Restricted Stock Units (Including Phantom Equity Rights) </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Holdings also previously authorized the grant of phantom equity rights, which entitled the holder to participate in the net transaction proceeds from a change in control or qualifying liquidity event. For current employees as of the Closing Date, these awards vest quarterly over a period of <span style="-sec-ix-hidden:hidden73946171">one</span> or two years after a change in control or qualifying liquidity event, and each holder is entitled to receive a stated percentage of the net transaction proceeds in excess of certain thresholds in accordance with the terms of their respective award agreement. Awards related to former employees vest at the time of a change in control or qualifying liquidity event, and each holder is entitled to receive a stated percentage of the net transaction proceeds in excess of certain thresholds or a maximum amount in accordance with the terms of their respective award agreement. The Closing of the Business Combination met the performance condition in the phantom equity rights. No compensation cost was recognized historically until the Closing of the Business Combination. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The phantom equity rights are equity-classified awards. The grant date fair value of the phantom equity rights was determined using a Monte-Carlo simulation. The significant assumptions used in valuation include the constant risk-free rate, constant volatility factor and the Geometric Brownian Motion. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">At the Closing of the Business Combination, Holdings&#8217; phantom equity rights related to former employees vested, and we recognized share-based compensation expense of $4,339 related to these awards with an offsetting increase to equity based on the awards&#8217; grant-date fair value. At Closing, the Company exercised its option to settle the awards for cash in the amount of $7,250. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">At the Closing of the Business Combination, Holdings&#8217; phantom equity rights related to current employees were replaced with 3,887,750 restricted stock units (&#8220;RSUs&#8221;) of Biote. The RSUs will continue to vest according to their original terms, quarterly over a period of <span style="-sec-ix-hidden:hidden73946172">one</span> or two years after the Closing of the Business Combination. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Since the Closing of the Business Combination, the Company continues to grant RSUs to certain employees under the <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">2022 Equity Incentive Plan</div></div> adopted on May&#160;26, 2022. New RSUs issued are valued at the Company&#8217;s </div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"> </div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">stock price on the date of grant. The following table summarizes RSU activity during the year ended December&#160;31, 2022: </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:68%"/>
<td style="vertical-align:bottom;width:7%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:7%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Shares</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Weighted-<br/> Average</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Grant-Date</div><br/> Fair Value</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">RSUs outstanding at December&#160;31, 2021</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3,887,750</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">8.85</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Granted</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">85,040</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">4.00</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Forfeited</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(296,250</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">8.71</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Vested</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(2,053,700</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">8.24</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">RSUs outstanding at December&#160;31, 2022</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,622,840</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">9.41</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr></table><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company recognized share-based compensation expense of $26,647 during the year ended December&#160;31, 2022, related to RSUs, which included a cumulative <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">catch-up</div> of unrecognized share-based compensation expense for service provided from the grant date to the Closing of the Business Combination. As of December&#160;31, 2022, there was $3,688 of unrecognized share-based compensation expense related to unvested RSUs. This expense is expected to be recognized over a weighted-average remaining vesting period of 1.0 year. </div><div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Stock Options </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Subsequent to the Closing of the Business Combination, the Company began to grant stock options to certain employees, directors, and consultants under the <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">2022 Equity Incentive Plan</div></div> adopted on May&#160;26, 2022. The following table summarizes stock option activity during the year ended December&#160;31, 2022: </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:84%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:57%"/>
<td style="vertical-align:bottom;width:8%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:8%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:8%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Shares</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Weighted-<br/> Average</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Exercise&#160;Price</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Weighted-<br/> Average</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Remaining</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Contractual<br/> Term</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(Years)</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Options outstanding at December&#160;31, 2021</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Granted</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">5,165,328</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3.86</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Forfeited</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(122,700</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3.73</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Options outstanding at December&#160;31, 2022</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">5,042,628</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3.86</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">9.5</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Options exercisable December&#160;31, 2022</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">131,461</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3.99</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2.1</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr></table><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company recognized share-based compensation expense of $1,168 during the year ended December&#160;31, 2022 related to stock options. As of December&#160;31, 2022, there was $10,156 of unrecognized share-based compensation expense related to unvested stock options. This expense is expected to be recognized over a weighted-average remaining vesting period of 3.4 years. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The weighted-average assumptions used to estimate the fair value of stock options granted during the year ended December&#160;31, 2022 were as follows: </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:68%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:90%"/>
<td style="vertical-align:bottom;width:6%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Expected term (in years)</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">6.0</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Volatility</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">60.0</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Risk-free rate</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3.5</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Dividend yield</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">0.0</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI https://asc.fasb.org/topic&amp;trid=2228938<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140468230240736">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeasesTextBlock', window );">Leases</a></td>
<td class="text">
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">15.</div></div></td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: left; line-height: normal;"><div style="font-weight:bold;display:inline;">LEASES </div></div></td></tr></table><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On July&#160;1, 2014, BioTE Medical entered into a contract to lease office space in the Las Colinas Business Center in Irving, TX. Subsequent to execution of the contract, the Company revised the lease to include additional space </div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"> </div><div/><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">and extend the lease term through <span style="-sec-ix-hidden:hidden73946198">June&#160;30, 2023</span>. On November 1, 2022, the Company executed an extension of lease office space to extend through November 30, 2028. This extension included an additional 3,700 square feet of space that would be available for use in December of 2023, which would be included in monthly rent payments at this date accordingly. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company recognizes operating lease costs on a straight-line basis over the lease term within Selling, general and administrative expense in the consolidated statement of income and comprehensive income. The following table contains a summary of the operating lease costs recognized under ASC 842 and supplemental cash flow information for leases for the years ended December&#160;31, 2022 and 2021: </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:80%"/>
<td style="vertical-align:bottom;width:5%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:5%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Year Ended</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Fixed lease expense</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">278</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">244</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total lease cost</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">278</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">244</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Other information:</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Cash paid for amounts included in the measurement of lease liabilities</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">257</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">257</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Right-of-use</div></div> assets obtained in exchange for new operating lease liabilities</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,936</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr></table><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following table summarizes the balance sheet classification of the Company&#8217;s operating leases, amounts of ROU assets and lease liabilities, the weighted average remaining lease term, and the weighted average discount rate for the Company&#8217;s operating leases: </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:66%"/>
<td style="vertical-align:bottom;width:14%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:13%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,<br/> 2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,<br/> 2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Lease assets</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Operating lease <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">right-of-use</div></div> assets</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2,052</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">356</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total lease assets</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2,052</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">356</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Lease liabilities</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Current:</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Operating lease liabilities</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">165</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">248</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-current:</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Operating lease liabilities</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,927</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">127</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total lease liabilities</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2,092</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">375</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Weighted-average remaining lease term&#8212;operating leases (years)</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">5.92</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1.50</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Weighted-average discount rate&#8212;operating leases</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">8.48</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3.75</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr></table><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"> </div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following table summarizes the payments by date for the Company&#8217;s operating lease, which is then reconciled to our total lease obligation, as of December&#160;31, 2022: </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:68%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:87%"/>
<td style="vertical-align:bottom;width:6%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">2023</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">337</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">2024</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">448</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">2025</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">464</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">2026</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">480</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">2027</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">497</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Thereafter</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">470</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total lease payments</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2,696</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Less: Interest</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(604</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Present value of lease liabilities</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2,092</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeasesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -URI https://asc.fasb.org/subtopic&amp;trid=77888251<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeasesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140468230249024">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
<td class="text">
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">16.</div></div></td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: left; line-height: normal;"><div style="font-weight:bold;display:inline;">INCOME TAXES </div></div></td></tr></table><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Income (loss) before provision for income taxes consisted of the following (in thousands): </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:76%"/>
<td style="vertical-align:bottom;width:5%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:5%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Year Ended</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Domestic</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2,221</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">33,191</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Foreign</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(509</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(286</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Income before provision for income taxes</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,712</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">32,905</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The income tax provision for the year ended December&#160;31, 2022 and 2021 consists of the following: </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:80%"/>
<td style="vertical-align:bottom;width:6%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:6%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Year Ended</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Current income tax provision (benefit):</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Federal</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">749</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">State and Local</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">377</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">286</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Foreign</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">5</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total current expense (benefit):</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,131</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">286</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Deferred income tax provision (benefit):</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Federal</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(714</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">State and Local</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(29</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Foreign</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total deferred expense (benefit):</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(743</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total income tax provision (benefit)</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">388</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">286</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"> </div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A reconciliation of the federal income tax rate to the Company&#8217;s effective tax rate for the year ended December&#160;31, 2022 and 2021 is as follows: </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:79%"/>
<td style="vertical-align:bottom;width:5%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:4%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Year Ended</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Statutory federal income tax rate</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">21.00</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">21.00</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">State taxes, net of federal benefit</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">18.20</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">0.87</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Nontaxable partnership income</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">-41.39</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">-21.00</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Foreign rate differential</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">-2.71</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">0.00</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Change in valuation allowance</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">27.55</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">0.00</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">22.65</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">0.87</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company&#8217;s significant rate reconciliation items are driven primarily by state taxes, permanent differences associated with Holdings&#8217; flowthrough income and the recognition of a valuation allowance. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company&#8217;s net deferred tax assets (liabilities) as of December&#160;31, 2022 and 2021 is as follows: </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:80%"/>
<td style="vertical-align:bottom;width:5%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:5%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Year Ended</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Deferred tax assets:</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Outside basis difference in partnership</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,173</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Net operating loss carryforwards</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">164</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Intangibles</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">978</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total deferred tax assets</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2,315</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Valuation allowance</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(477</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Deferred tax assets, net of allowance</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,838</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of December&#160;31, 2022, the Company had a foreign net operating losses of $0.5&#160;million, which begin to expire in 2032. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In assessing the realization of deferred tax assets, management considers whether it is more likely than not that some portion or all of the deferred tax assets will not be realized. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income during the periods in which temporary differences representing future deductible amounts become deductible. Management considers the scheduled reversal of deferred tax assets, projected future taxable income and tax planning strategies in making this assessment. After consideration of all the information available, management has recorded a valuation allowance against the foreign net operating losses and the portion of outside basis difference related to Holdings&#8217; permanent book/tax differences. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The calculation of our tax liabilities involves dealing with uncertainties in the application of complex tax laws and regulations for both federal taxes and the many states in which we operate or do business in. ASC 740 states that a tax benefit from an uncertain tax position may be recognized when it is more likely than not that the position will be sustained upon examination, including resolutions of any related appeals or litigation processes, on the basis of the technical merits. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We record uncertain tax positions as liabilities in accordance with ASC 740 and adjust these liabilities when our judgment changes as a result of the evaluation of new information not previously available. Because of the complexity of some of these uncertainties, the ultimate resolution may result in a payment that is materially </div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"> </div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">different from our current estimate of the unrecognized tax benefit liabilities. These differences will be reflected as increases or decreases to income tax expense in the period in which new information is available. As of December&#160;31, 2022 and 2021 we have not recorded any uncertain tax positions in our financial statements. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company files tax returns as prescribed by the tax laws of the jurisdictions in which it operates. In the normal course of business, the Company is subject to examination by federal and state jurisdictions, where applicable. There are currently no pending tax examinations. The Company&#8217;s tax years are still open under statute from December 31, 2019, to the present. The resolution of tax matters is not expected to have a material effect on the Company&#8217;s consolidated financial statements. </div><div style="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&#160;</div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32857-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330215-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32809-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.5.Q1)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32705-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 270<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6424409&amp;loc=d3e44925-109338<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -URI https://asc.fasb.org/topic&amp;trid=2144680<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6424122&amp;loc=d3e41874-109331<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140468230330048">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Common Share<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Net Loss Per Common Share</a></td>
<td class="text">
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">17.</div></div></td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: left; line-height: normal;"><div style="font-weight:bold;display:inline;">NET LOSS PER COMMON SHARE </div></div></td></tr></table><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The computation of basic and diluted net loss per common share is based on net loss attributable to Biote stockholders divided by the basic and diluted weighted average number of shares of Class&#160;A common stock outstanding, each for the period subsequent to the consummation of the Business Combination. The following table sets forth the computation of net loss per common share: </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:68%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:80%"/>
<td style="vertical-align:bottom;width:14%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Year Ended</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,<br/> 2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Net loss per common share</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Numerator:</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Net loss attributable to biote Corp. stockholders (basic and diluted)</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(969</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Denominator:</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Weighted average shares outstanding (basic and diluted)</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">8,059,371</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Net loss per common share</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Basic</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(0.12</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Diluted</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(0.12</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr></table><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On the Closing Date, the Company completed the Business Combination which materially impacted the number of shares outstanding, and the Company was organized in an <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Up-C</div> structure. Net loss per common share information for the year ended December&#160;31, 2022 has been presented on a prospective basis and reflects only the net loss attributable to holders of Biote&#8217;s Class&#160;A common stock, as well as both basic and diluted weighted average Class&#160;A common stock outstanding, for the period from the Closing Date through December&#160;31, 2022. Net loss per common share information prior to the Closing Date is not presented since the ownership structure of Holdings is not a common unit of ownership of the Company, and the resulting values would not be meaningful to the users of the consolidated financial statements. Net loss per common share is not separately presented for Class&#160;V voting stock since it has no economic rights to the income or loss of the Company. Class&#160;V voting stock is considered in the calculation of dilutive net loss per common share on an <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">if-converted</div> basis as these shares, together with the related Holdings Units, have Exchange Rights into Class&#160;A common stock that could result in additional Class&#160;A common stock being issued. All other potentially dilutive securities are determined based on the treasury stock method. See Note 1 for more information regarding the Business Combination. </div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"> </div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company excluded the following potential shares, presented based on amounts outstanding at each period end, from the computation of diluted weighted average shares outstanding for the periods indicated because including them would have had an antidilutive effect: </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:68%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:80%"/>
<td style="vertical-align:bottom;width:5%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Year Ended</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,<br/> 2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">RSUs</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,622,840</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Stock Options</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">5,042,628</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Class&#160;V Voting Stock</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">48,565,824</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Public Warrants</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">7,937,466</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Private Placement Warrants</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">5,566,666</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Earnout Voting Shares</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">10,000,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Sponsor Earnout Shares</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,587,500</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">80,322,924</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=109243012&amp;loc=SL65017193-207537<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -URI https://asc.fasb.org/topic&amp;trid=2144383<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140468230275552">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text">
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">18.</div></div></td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: left; line-height: normal;"><div style="font-weight:bold;display:inline;">COMMITMENTS AND CONTINGENCIES </div></div></td></tr></table><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Litigation Risk </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">From time to time, the Company may become involved in various legal actions arising in the ordinary course of business. Management is of the opinion that the ultimate liability, if any, from these actions will not have a material effect on its financial condition or results of operations. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company is currently involved in litigation described below with one of the Company&#8217;s stockholders, Dr.&#160;Gary&#160;S. Donovitz (&#8220;Donovitz&#8221;) (the &#8220;Donovitz Litigation&#8221;). The outcome of the Donovitz Litigation, regardless of the merits, is inherently uncertain. At this point in time, the Company cannot predict the length of the Donovitz Litigation or the ultimate liability, if any, which may arise therefrom. In addition, litigation and related matters are costly and may divert the attention of the Company&#8217;s management and other resources that would otherwise be engaged in other activities. However, the Donovitz Litigation is not expected to have a material adverse effect on the consolidated results of operations or financial position of the Company. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On June 23, 2022, Donovitz sued Haymaker Sponsor, LLC, the Company&#8217;s outside legal counsel, and certain Company executive officers and directors in the District Court of Dallas County, Texas. Donovitz alleges that the defendants made a variety of false promises regarding Donovitz&#8217;s future role in the Company, the protection of Donovitz&#8217;s interests, and the continuance of Donovitz&#8217;s seminars and training programs subsequent to the completion of the Business Combination. Otherwise, Donovitz claims he would not have agreed to the arrangements that led to the completion of the Business Combination and related transactions. Donovitz generally alleges fraud, negligent misrepresentation, a breach of the covenant of good faith and fair dealing, and breaches of fiduciary duties against the defendants (the &#8220;Donovitz Claims&#8221;). Donovitz seeks monetary relief exceeding $1.0&#160;million, including, but not limited to, actual damages, damages to be determined at trial, punitive damages, attorneys&#8217; fees, and equitable relief such as profit disgorgement, fee forfeiture, recession, and constructive trust. While not a direct party to the lawsuit, the Company believes that the allegations contained in the complaint are without merit and intends to participate in the defense of the litigation. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On July&#160;11, 2022, the Company sued Donovitz in the Delaware Court of Chancery, pursuing injunctive relief to prevent Donovitz from proceeding with the litigation over the Donovitz Claims in Texas. The Company seeks to enforce (a)&#160;the Company&#8217;s certificate of incorporation, which mandates that stockholders must bring certain actions, including some or all of the Donovitz Claims, exclusively in Delaware, and (b)&#160;the Business Combination Agreement, by which Donovitz consented to the exclusive jurisdiction of the Delaware Court of Chancery and agreed that Delaware law governs any related claims, including some or all of the Donovitz Claims. Pending a ruling from the Delaware Court of Chancery, Donovitz agreed to stay all answer dates in that </div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"> </div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">lawsuit in Texas. Then, on March&#160;23, 2023, Donovitz filed an amended answer and counterclaims alleging what appear to be the same as the Donovitz Claims originally filed in Texas. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On August&#160;2, 2022, the Company sued Donovitz, Lani Hammonds Donovitz, and Lani D. Consulting in the District Court of Dallas County, Texas, seeking injunctive relief to enforce <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-disparagement</div> obligations of that certain founder advisory agreement with Donovitz and the independent contractor agreement with Lani Hammonds Donovitz, both of which were entered into by the subject parties in connection with the Business Combination. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On August&#160;23, 2022, the defendants filed an answer, which included affirmative defenses to the Company&#8217;s claims and certain counterclaims and third-party claims against certain executive officers of the Company. The affirmative defenses included repudiation, fraud, breach of contract, unclean hands, and laches. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The counterclaims and third-party claims included claims for fraud, breach of fiduciary duty, breach of contract, and defamation, as well as other related claims. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company successfully obtained a temporary restraining order to enforce the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-disparagement</div> obligations of Donovitz and Lani Hammonds Donovitz. The parties subsequently entered into an agreed order that the temporary restraining order will stay in effect until the entry of a final judgment. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A jury trial was scheduled to commence on January&#160;3, 2023, to address the Company&#8217;s request for a permanent injunction, as well as adjudicate the affirmative defenses, with all remaining claims, counterclaims and third-party claims to be tried at a later date. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">After the filing of this lawsuit, the Company amended its claim in the Delaware Court of Chancery to also seek an injunction to prevent Donovitz from proceeding with certain of the affirmative defenses, counterclaims, and third-party claims filed by the defendants on August&#160;23, 2022. On November&#160;4, 2022, the Delaware Court of Chancery denied that request for injunctive relief, permitting the Texas lawsuit filed by the Company and all affirmative defenses and claims asserted therein to proceed in Texas. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Subsequently, the parties agreed that the trial on the Company&#8217;s claim for breach of contract, including its request for a permanent injunction, will be consolidated with a trial on the previously filed counterclaims and third-party claims. Prior to that agreement being reached, Donovitz and Lani Hammonds Donovitz filed an amended pleading which did not include any of their previously asserted affirmative defenses or assert any new affirmative defenses. It was also agreed that if Donovitz and or Lani Hammonds Donovitz seek leave to add any affirmative defenses before the final trial, at most they would be allowed to assert laches, unclean hands or mistake, and only if they can convince the trial court that any or all of those affirmative defenses would have qualified as claims that could have been non suited at the time they filed their amended pleading asserting no affirmative defenses. A jury trial is scheduled to commence on September&#160;11, 2023. The temporary restraining order entered against Gary Donovitz and Lani Hammonds Donovitz remains in effect until the entry of a final judgment. </div><div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Tax Distributions </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">To the extent the Company has funds legally available, the board of directors will approve distributions to each stockholder on a quarterly basis, in an amount per share that, when added to all other distributions made to such stockholder with respect to the previous calendar year, equals the estimated federal and state income tax liabilities applicable to such stockholder as the result of its, his or her ownership of the units and the associated net taxable income allocated with respect to such units for the previous calendar year. </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI https://asc.fasb.org/topic&amp;trid=2144648<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 440<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6491277&amp;loc=d3e6429-115629<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI https://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140468230275552">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related-Party Transactions<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related Party Transactions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock', window );">Related-Party Transactions</a></td>
<td class="text">
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">19.</div></div></td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: left; line-height: normal;"><div style="font-weight:bold;display:inline;">RELATED-PARTY TRANSACTIONS </div></div></td></tr></table><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company utilizes a professional services firm to perform accounting and tax services for the Company. Trusts whose beneficiaries are the children of a partner of the firm hold shares of our Class&#160;V voting stock. Fees </div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"> </div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">paid to the firm were $31 and $456 during the years ended December&#160;31, 2022 and 2021, respectively. Amounts due to the firm as of December&#160;31, 2022 and December&#160;31, 2021 were $0 and $0, respectively. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A former employee of the Company is the beneficiary of a trust which holds shares of our Class&#160;V voting stock, as well as being the child of the Company&#8217;s founder who beneficially owns shares of our Class&#160;V voting stock. Compensation paid to the former employee was $100 and $201 for the years ended December&#160;31, 2022 and 2021, respectively. Amounts due to the former employee were $0 and $0 as of December&#160;31, 2022 and December&#160;31, 2021, respectively. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition to their previous employment by the Company, the above referenced former employee also owns a clinic which was a customer of the Company. Revenues recognized from sales to this customer were $458 and $744 for the years ended December&#160;31, 2022 and 2021, respectively. Amounts due from this customer were $0 and $57 as of December&#160;31, 2022 and December&#160;31, 2021, respectively. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A former employee of the Company is the spouse of the Company&#8217;s founder who beneficially owns shares of our Class&#160;V voting stock. Compensation paid to the former employee was $158 and $285 for the years ended December&#160;31, 2022 and 2021, respectively. Amounts due to the former employee were $0 and $0 as of December&#160;31, 2022 and December&#160;31, 2021, respectively. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company purchases dietary supplements inventories from a vendor in which the Company&#8217;s founder holds a minority interest. Inventory purchases from this vendor were $1,304 and $888 for the years ended December&#160;31, 2022 and 2021, respectively. Amounts due to the vendor were $151 and $0 as of December&#160;31, 2022 and December&#160;31, 2021, respectively. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On May&#160;18, 2022, BioTE Medical and Dr.&#160;Gary&#160;S. Donovitz entered into a founder advisory agreement, effective as of, and contingent upon, the Closing. Pursuant to the founder advisory agreement, Dr.&#160;Gary&#160;S. Donovitz transitioned from an officer and manager of BioTE Medical into the role of Founder Advisor and Senior Advisor (as defined in the founder advisory agreement) as of the Closing. Pursuant to the founder advisory agreement, Dr.&#160;Gary&#160;S. Donovitz provides strategic advisory services to BioTE Medical for a period of four years from the Closing, unless terminated earlier pursuant to the terms of the founder advisory agreement, and will receive an annual fee equal to $300 per year, continued coverage under BioTE Medical&#8217;s employee benefits and reimbursement for reasonable and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-approved</div> business expenses. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On May&#160;18, 2022, BioTE Medical entered into an independent contractor agreement with Lani D. Consulting, a company affiliated with Lani Hammonds Donovitz, the wife of Dr.&#160;Gary&#160;S. Donovitz (the &#8220;New Independent Contractor Agreement&#8221;). Immediately upon the Closing, the New Independent Contractor Agreement replaced the independent contractor agreement dated as of May&#160;3, 2021, between Lani D. Consulting and BioTE Medical. Pursuant to the New Independent Contractor Agreement, Lani D. Consulting provides certain services to BioTE Medical for a period of four years from the Closing, unless terminated earlier pursuant to the terms of the New Independent Contractor Agreement, and will receive an annual fee equal to $250 per year and reimbursement for reasonable and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-approved</div> business expenses. BioTE Medical terminated Ms.&#160;Donovitz for cause, effective September&#160;9, 2022. </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -URI https://asc.fasb.org/topic&amp;trid=2122745<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39691-107864<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140468230154880">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">Subsequent Events</a></td>
<td class="text">
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">20.</div></div></td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: left; line-height: normal;"><div style="font-weight:bold;display:inline;">SUBSEQUENT EVENTS </div></div></td></tr></table><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company evaluated subsequent events from December&#160;31, 2022, the date of these consolidated financial statements, through March&#160;29, 2023, which represents the date the consolidated financial statements were issued, for events requiring adjustment to or disclosure in these consolidated financial statements. There are no material events that require adjustment to or disclosure in these consolidated financial statements. </div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -URI https://asc.fasb.org/topic&amp;trid=2122774<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6842918&amp;loc=SL6314017-165662<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140468312510656">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Use of Estimates&#8212;</div></div>The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. The Company regularly evaluates estimates and assumptions related to assets, liabilities, costs, expenses, contingent liabilities, share-based compensation and research and development costs. The Company bases its estimates and assumptions on historical experience and on various other factors that it believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results could differ from those estimates. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In the opinion of the Company, the accompanying consolidated financial statements contain all adjustments, consisting of only normal recurring adjustments, necessary for a fair presentation of its financial position and its results of operations, changes in stockholders&#8217; equity (deficit) and cash flows. </div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock', window );">Fair Value Measurements</a></td>
<td class="text"><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Fair Value Measurements</div></div>&#8212;The guidance in FASB ASC 820, <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Fair Value Measurements and Disclosures </div></div>(&#8220;ASC 820&#8221;), defines fair value and establishes a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements) and the lowest priority to unobservable inputs (Level 3 measurements). The three levels of the fair value hierarchy are described below: </div><div style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Level</div></div><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"/><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">&#160;1</div></div>&#8212;Inputs are quoted prices (unadjusted) in active markets for identical assets or liabilities that the reporting entity has the ability to access at the measurement date. </div><div style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Level 2</div></div>&#8212;Valuations based on quoted prices in markets that are not active or for which all significant inputs are observable, either directly or indirectly. </div><div style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Level</div></div><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"/><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">&#160;3</div></div>&#8212;Prices or valuations that require inputs that are both significant to the fair value measurement and unobservable. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">See Note 12 for further detail. </div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingPolicyPolicyTextBlock', window );">Segment Information</a></td>
<td class="text"><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Segment Information</div></div>&#8212;Operating segments are defined as components of an enterprise about which separate financial information is available that is evaluated regularly by the chief operating decision maker in deciding how to allocate resources and in assessing performance. The Company&#8217;s chief operating decision maker is the chief executive officer. The Company has one business activity and there are no segment managers who are held accountable for operations, operating results, and plans for levels or components below the consolidated unit level. Accordingly, the Company has one operating segment and, therefore, one reportable segment. </div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash</a></td>
<td class="text"><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Cash</div></div>&#8212;As of December&#160;31, 2022 and 2021, cash consists primarily of checking and savings deposits. The Company maintains deposits primarily with two financial institutions, which may at times exceed amounts covered by insurance provided by the U.S. Federal Deposit Insurance Corporation (&#8220;FDIC&#8221;). The Company has not experienced any losses related to amounts in excess of FDIC limits. The Company does not hold any cash equivalents, which would consist of highly liquid investments with original maturities of three months or less at the time of purchase. </div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy', window );">Accounts Receivable and Allowance for Doubtful Accounts</a></td>
<td class="text"><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Accounts Receivable and Allowance for Doubtful Accounts</div></div>&#8212;Accounts receivable are recorded net of allowances for doubtful accounts. Accounts receivable consist primarily of invoiced amounts to clinics that are not yet paid. On a periodic basis, management evaluates its accounts receivable and determines whether to provide an allowance or if any accounts should be written off based on past history of write-offs, collections, and current credit conditions. The Company maintains an allowance for doubtful accounts to provide for uncollectible amounts based on historical collection experience and an analysis of the aging of receivables. Management provides for probable uncollectible amounts through a charge to earnings and a credit to a valuation allowance based on its assessment of the current status of individual accounts. Balances still outstanding after </div><div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"/><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">management has exhausted all reasonable collection efforts are written off through a charge to the valuation allowance and a credit to accounts receivable. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Bad debt expense is classified in selling, general, and administrative expense within the consolidated statements of income and comprehensive income. The Company generally does not require any security or collateral to support its receivables. A rollforward of the allowance for doubtful accounts is as follows (in thousands): </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:68%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:86%"/>
<td style="vertical-align:bottom;width:6%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">As of December&#160;31, 2020</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(1,157</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Provisions charged to operating results</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(240</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Account <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">write-off</div> and recoveries</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(9</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">As of December&#160;31, 2021</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(1,406</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">As of December&#160;31, 2021</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(1,406</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Provisions charged to operating results</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">155</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Account <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">write-off</div> and recoveries</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">277</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">As of December&#160;31, 2022</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(974</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryPolicyTextBlock', window );">Inventory</a></td>
<td class="text"><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Inventory</div></div>&#8212;Inventory is carried at the lower of cost or net realizable value using the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">first-in,</div> <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">first-out</div> (FIFO) method. Inventory consists of bioidentical hormone pellets and dietary supplements. Bioidentical hormone pellets contain bioidentical testosterone or estrogen used to achieve hormone balance. Dietary supplements are high-grade vitamins used to enhance pellet therapy. The Company reviews its inventory balances and writes down its inventory for estimated obsolescence or excess inventory equal to the difference between the cost of inventory and the estimated net realizable value based upon assumptions about future demand and market conditions. Inventory write-downs are recorded within cost of products. Management recorded a reserve for obsolescence of inventory related to inventory which has expired. See Note 5 for further details. </div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_btmd_OtherCurrentAssetsPolicyTextBlock', window );">Other Current Assets</a></td>
<td class="text"><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Other Current Assets</div></div>&#8212;As of December&#160;31, 2022 and December&#160;31, 2021, the Company&#8217;s total other current assets consist of the following: </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:66%"/>
<td style="vertical-align:bottom;width:11%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:11%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,<br/> 2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,<br/> 2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Prepaid expenses</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2,939</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">847</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Advances</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">877</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">685</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Capitalized transaction costs</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3,941</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total other current assets</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3,816</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">5,473</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Prepaid expenses include software and technology licensing agreements, insurance premiums and other advance payments for services to be received over the next 12 months. Advances are comprised of deposit payments to vendors for inventory purchase orders to be received in the next 12 months. The capitalized transaction costs as of December&#160;31, 2021 relate to costs incurred that were directly related to the Business Combination as described in Note 1. </div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property and Equipment, Net</a></td>
<td class="text"><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Property and Equipment, Net</div></div>&#8212;Property and equipment are stated at cost less accumulated depreciation. Depreciation is calculated using the straight-line method and is recorded in Selling, general, and administrative expense over the estimated useful lives of the assets. The estimated useful lives of property and equipment are as follows: </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:48%"/>
<td style="vertical-align:bottom;width:3%"/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Estimated&#160;Useful Life (in years)</div></div></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Trocars</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;text-align:center;">5</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Leasehold improvements</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;text-align:center;">Shorter of lease term or useful life of the<br/> improvement</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Office equipment</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;text-align:center;">5</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Computer software</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;text-align:center;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">3-5</div></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Furniture and fixtures</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;text-align:center;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">5-7</div></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Computer equipment</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;text-align:center;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">3-5</div></td></tr></table><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">See Note 6 for further details. </div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InternalUseSoftwarePolicy', window );">Capitalized Software, Net</a></td>
<td class="text"><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Capitalized Software, Net</div></div>&#8212;Capitalization of costs related to internally developed software begins when the preliminary project stage is completed and it is probable that the project will be completed and used for its intended function. Once an application has reached the development stage, internal and external costs, if direct and incremental, are capitalized until the software is substantially complete and ready for its intended use. Capitalization ceases upon completion of all substantial testing. The Company also capitalizes costs related to specific upgrades and enhancements when it is probable the expenditures will result in additional features and functionality. Maintenance costs are expensed as incurred. Internal use software is amortized on a straight-line basis over its estimated useful life, generally <span style="-sec-ix-hidden:hidden73945767">three</span> to <span style="-sec-ix-hidden:hidden73945768">eight</span> years. Capitalized software is included within capitalized software, net on the consolidated balance sheet. See Note 7 for further details. </div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock', window );">Impairment of Long-Lived Assets</a></td>
<td class="text"><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Impairment of Long-Lived Assets</div></div>&#8212;Long-lived assets, such as property and equipment and capitalized software, are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of the asset may not be recoverable. The carrying amount of a long-lived asset is not recoverable if it exceeds the sum of the undiscounted future cash flows expected to result from the use and eventual disposition of the asset. The amount of impairment loss, if any, is measured as the difference between the carrying value of the asset and its estimated fair value. Fair value is determined through various valuation techniques, including discounted cash flow models, quoted market values, and third-party independent appraisals, as considered necessary. No impairment charges have been recorded during the years ended December&#160;31, 2022 and 2021. </div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeasesPolicyTextBlock', window );">Leases</a></td>
<td class="text"><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Leases</div></div>&#8212;At the inception of an arrangement, the Company determines whether the arrangement is or contains a lease based on the unique facts and circumstances present in the arrangement including the use of an identified asset(s) and the Company&#8217;s control over the use of that identified asset. The Company elected, as allowed under Financial Accounting Standards Board (&#8220;FASB&#8221;) Accounting Standard Update (&#8220;ASU&#8221;) <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2016-02,</div> <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Leases </div></div>(&#8220;ASC&#160;842&#8221;), to not recognize leases with a lease term of one year or less on its balance sheet. Leases with a term greater than one year are recognized on the balance sheet as <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">right-of-use</div></div> (&#8220;ROU&#8221;) assets and current and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-current</div> lease liabilities, as applicable. As of December&#160;31, 2022 and December&#160;31, 2021, the Company does not have any financing leases. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Lease liabilities and their corresponding ROU assets are initially recorded based on the present value of lease payments over the expected remaining lease term. Certain adjustments to the ROU asset may be required for items such as incentives, prepaid lease payments, or initial direct costs. When an option to extend the lease exists, a determination is made whether that option is reasonably certain of exercise based on economic factors present at the measurement date and as circumstances may change. Lease cost for operating leases is recognized on a straight-line basis over the lease term as an operating expense. Variable lease costs are expensed as incurred as an operating expense. </div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"/><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As the rates implicit in the Company&#8217;s leases have not historically been readily determinable, the Company utilizes the appropriate incremental borrowing rate, which is the rate the Company would incur to borrow on a collateralized basis over a similar term an amount equal to the lease payments in a similar economic environment over the lease term. To estimate our incremental borrowing rate, a credit rating applicable to the Company is estimated using a synthetic credit rating analysis since the Company does not currently have a rating agency-based credit rating. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In accordance with ASC 842, contracts containing a lease should be split into three categories: lease components, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-lease</div> components, and activities or costs that do not transfer a distinct good or service <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">(&#8220;non-components&#8221;).</div> The fixed and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">in-substance</div> fixed contract consideration (including any consideration related to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-components)</div> must be allocated, based on the respective relative fair values, to the lease components and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-lease</div> components. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Entities may elect not to separate lease and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-lease</div> components. Accordingly, entities making this election would account for each lease component and related <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-lease</div> component together as a single lease component. The Company has elected to account for lease and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-lease</div> components together as a single lease component for all underlying assets and allocate all of the contract consideration to the lease component only. See Note 15 for further details. </div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
<td class="text"><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Income Taxes</div></div>&#8212;The Company accounts for income taxes under the asset and liability method pursuant to ASC&#160;740, Income Taxes. Under this method, the Company recognizes deferred tax assets and liabilities for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating loss and tax credit carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We recognize deferred tax assets to the extent that we believe that these assets are more likely than not to be realized. In making such a determination, we consider all available positive and negative evidence, including future reversals of existing taxable temporary differences, projected future taxable income, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">tax-planning</div> strategies, and results of recent operations. If we determine that we would be able to realize our deferred tax assets in the future in excess of their net recorded amount, we would make an adjustment to the deferred tax asset valuation allowance, which would reduce the provision for income taxes. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We record uncertain tax positions in accordance with ASC 740 on the basis of a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">two-step</div> process in which (1)&#160;we determine whether it is more likely than not that the tax positions will be sustained on the basis of the technical merits of the position and (2)&#160;for those tax positions that meet the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">more-likely-than-not</div> recognition threshold, we recognize the largest amount of tax benefit that is more than 50&#160;percent likely to be realized upon ultimate settlement with the related tax authority. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We recognize interest and penalties related to unrecognized tax benefits on the income tax expense line in the accompanying consolidated statements of income and comprehensive income. </div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_btmd_DebtIssuanceCostsPolicyTextBlock', window );">Debt Issuance Costs</a></td>
<td class="text"><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Debt Issuance Costs</div></div>&#8212;Costs incurred in connection with the issuance of the Company&#8217;s long-term debt have been recorded as a direct reduction of the debt and amortized over the life of the associated debt as a component of interest expense using the straight-line method, which is not materially different compared to the effective interest m<div style="display:inline;">ethod.</div> </div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_btmd_WarrantLiabilitiesPolicyTextBlock', window );">Warrant Liabilities</a></td>
<td class="text"><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Warrant Liabilities</div></div>&#8212;The Company accounts for warrants as either equity-classified or liability-classified instruments based on an assessment of the warrant&#8217;s specific terms and applicable authoritative guidance in ASC&#160;480, <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Distinguishing Liabilities from Equity</div></div> (&#8220;ASC 480&#8221;) and ASC 815, <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Derivatives and Hedging</div></div> (&#8220;ASC&#160;815&#8221;). The assessment considers whether the warrants are freestanding financial instruments pursuant to ASC&#160;480, <div style="display:inline;">meet</div> </div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"/><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">the definition of a liability pursuant to ASC 480, and whether the warrants meet all of the requirements for equity classification under ASC 815, including whether the warrants are indexed to the Company&#8217;s own common stock, among other conditions for equity classification. This assessment, which requires the use of professional judgment, is conducted at the time of warrant issuance and as of each subsequent quarterly period end date while the warrants are outstanding. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For issued or modified warrants that meet all of the criteria for equity classification, the warrants are required to be recorded as a component of additional <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">paid-in</div> capital at the time of issuance. For issued or modified warrants that do not meet all the criteria for equity classification, the warrants are required to be recorded as a liability at their initial fair value on the date of issuance, and remeasured each balance sheet date thereafter. The Company&#8217;s warrants did not meet the criteria for equity classification and are recorded as liabilities. Changes in the estimated fair value of the warrants are recognized as a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-cash</div> gain or loss in the statements of income and comprehensive income. See Note 10 for further detail. </div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_btmd_EarnoutLiabilityPolicyTextBlock', window );">Earnout Liability</a></td>
<td class="text"><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Earnout Liability</div></div>&#8212;In connection with the Business Combination, the Members and the Sponsor received shares that will vest upon the achievement of certain share price targets. The earnout shares are classified as a liability in the Company&#8217;s consolidated balance sheet because it does not qualify as being indexed to the Company&#8217;s own stock. The earnout liability was initially measured at fair value at the Closing Date and subsequently remeasured at the end of each reporting period. The change in fair value of the earnout liability is recorded in the consolidated statement of income and comprehensive income. See Note 11 for further detail. </div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityPolicyTextBlock', window );">Stockholders' Equity (Deficit)</a></td>
<td class="text"><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Stockholders&#8217; Equity (Deficit)</div></div>&#8212;Prior to consummation of the Business Combination, the Company&#8217;s capital structure included voting units (Class A), <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-voting</div> units (Class AA and AAA), and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-voting</div> incentive units (Class AAAA), with no limit to the number of units that may be issued. Class&#160;A units had 100% of the voting rights, and there is no par value assigned to any of the classes of units. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to the Business Combination Agreement and immediately prior to the Business Combination&#8217;s consummation, the Company effectuated a recapitalization whereby all Class&#160;A, Class&#160;AA, Class&#160;AAA and Class&#160;AAAA units held by Holdings&#8217; Members were converted (whether by direct exchange, merger or otherwise) into Class&#160;A <div style="display:inline;">Common Units.</div> </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of December&#160;31, 2021, the following members&#8217; equity units were issued and outstanding: </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:68%"/>
<td style="vertical-align:bottom;width:5%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:5%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31, 2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.5pt;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; font-size: 8pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Members&#8217; Equity</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Issued</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Outstanding</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Class&#160;A (Voting)</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">16,721</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">16,721</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Class&#160;AA <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">(Non-voting)</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">903,079</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">903,079</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Class&#160;AAA <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">(Non-voting)</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">60,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">60,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Class&#160;AAAA <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">(Non-voting</div> incentive units)</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">33,397</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,013,197</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">982,800</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of December&#160;31, 2022, the following shares of common stock were issued and outstanding: </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:11pt;width:76%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:64%"/>
<td style="vertical-align:bottom;width:3%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:3%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31, 2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.5pt;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; font-size: 8pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Stockholders&#8217; Equity</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Issued</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Outstanding</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt;background-color:#cceeff">
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Class&#160;A common stock</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;">11,242,887</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;">9,655,387</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Class&#160;B common stock</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt;background-color:#cceeff">
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Class&#160;V voting stock</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;">58,565,824</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;">48,565,824</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;">69,808,711</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;">58,221,211</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"/><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company made operating distributions to Members of Holdings and taxing authorities on the Members&#8217; behalf totaling $12,886 and $11,402 during the years ended December&#160;31, 2022 and 2021, <div style="display:inline;">respectively.</div> </div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_btmd_StandbyEquityPurchaseAgreementPolicyTextBlock', window );">Standby Equity Purchase Agreement</a></td>
<td class="text"><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;">Standby Equity Purchase Agreement </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On July&#160;27, 2022, the Company entered into a Standby Equity Purchase Agreement (the &#8220;SEPA&#8221;) with YA II PN, Ltd. (&#8220;Yorkville&#8221;). Yorkville is a fund managed by Yorkville Advisors Global, LP, headquartered in Mountainside, New Jersey. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company has the right, but not the obligation, from time to time at the Company&#8217;s discretion until the first day of the month following the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">36-month</div> anniversary of the date of the SEPA (unless earlier terminated), to direct Yorkville to purchase a specified amount of shares of Class&#160;A common stock (each such sale, an &#8220;Advance&#8221;) by delivering written notice to Yorkville (each, an &#8220;Advance Notice&#8221;). The shares of Class&#160;A common stock purchased pursuant to an Advance will be purchased at a price equal to 97.0% of the lowest daily VWAP of the Class&#160;A common stock during the <span style="-sec-ix-hidden:hidden73945778">three</span> consecutive trading days commencing on the date of delivery of a given Advance Notice. &#8220;VWAP&#8221; means, for any trading day, the daily volume weighted average price of the Company&#8217;s common stock for such date as reported by Bloomberg L.P. during regular trading hours. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">While there is no mandatory minimum amount for any individual Advance, it may not exceed the greater of (i)&#160;an amount equal to thirty percent (30%) of the daily volume traded on the trading day immediately preceding an Advance Notice, or (ii) 1,000,000 shares of Class&#160;A common stock. No more than 5,000,000 shares of Class&#160;A common stock, including the Commitment Shares (as defined below) may be sold pursuant to the SEPA. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Yorkville&#8217;s obligation to continue to purchase shares of Class&#160;A common stock pursuant to the SEPA is subject to a number of conditions. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As consideration for Yorkville&#8217;s commitment to purchase Class&#160;A common stock at the Company&#8217;s direction upon the terms and subject to the conditions set forth in the SEPA, upon execution of the SEPA, the Company issued 25,000 shares of Class&#160;A common stock to Yorkville (the &#8220;Commitment Shares&#8221;). During the year ended December&#160;31, 2022, the Company sold 105,559 shares to Yorkville under the SEPA for cash proceeds of $442. </div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_btmd_NoncontrollingInterestPolicyTextBlock', window );">Noncontrolling Interest</a></td>
<td class="text"><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Noncontrolling Interest</div></div>&#8212;Pursuant to the Business Combination, as described in Note 3, the Company is organized in an <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">&#8220;Up-C&#8221;</div> structure with the Company owning only a portion of its consolidated subsidiaries. The portion of the consolidated subsidiaries not owned by the Company and any related activity is presented as noncontrolling interest in the consolidated financial statements. The noncontrolling interests, together with their corresponding shares of Class&#160;V voting stock, can be exchanged for Class&#160;A common stock in Biote or, at the election of the Company, cash. Because redemptions for cash is solely within the control of the Company, noncontrolling interest is presented in permanent equity. </div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRecognitionPolicyTextBlock', window );">Revenue Recognition</a></td>
<td class="text"><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Revenue Recognition</div></div>&#8212;The Company accounts for revenue in accordance with FASB, Accounting Standards <div style="display:inline;">Update</div> (&#8220;ASU&#8221;) <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">No.&#160;2014-09,</div> <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Revenue from Contracts with Customers</div></div>, as amended, (Topic 606). Revenue is measured based on the consideration specified in a contract with a customer. The Company recognizes revenue when it satisfies a performance obligation by transferring control of a product or service to a customer. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Taxes assessed by a governmental authority that are both imposed on and concurrent with a specific revenue-producing transaction, that are collected by the Company from a customer, are excluded from revenue. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Shipping and handling costs associated with outbound freight after control of a product has transferred to a customer are accounted for as fulfillment costs and are included in cost of products in the statements of income and comprehensive income. Shipping and handling costs billed to customers are considered part of the transaction price and are recognized as revenue with the underlying product sales for dietary supplements and trocars. </div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"/><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following is a description of the principal contract activities, disaggregated by the contract type, from which the Company generates its revenue. </div><div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">The Biote Method </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company generates revenues through standard service agreements with customers who participate in the Biote Method. The Biote Method is a bioidentical hormone replacement therapy which has been developed as a treatment designed to alleviate hormone imbalances. Under this agreement, the Company provides a bundle of goods and services to customers, including initial training to medical practitioners, bioidentical hormone pellets and software tools used for inventory management and dosing, and ongoing practice development and marketing support services, which includes a license to use the Company&#8217;s trademarks and trade names in the customer&#8217;s marketing materials. The initial contract term is three years, and customers have the option to renew for additional <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">one-year</div> periods. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For the bundled goods and services, the Company accounts for individual products and services separately if they are distinct, i.e., if a product or service is separately identifiable from other items in the bundled package and if a customer can benefit from it on its own or with other resources that are readily available to the customer. The Company has identified three distinct obligations in its standard service agreement: initial training, pellet procedures (including sales of bioidentical hormone pellets, use of inventory management software to monitor pellet inventory, and use of the Company&#8217;s blood dosing website to determine the appropriate pellets to use in each procedure), contract-term services (including ongoing practice development and marketing support, options to receive reusable trocars, and the right to use the reusable trocars through the term of the contract, if the option is exercised). The third obligation includes a combined lease/nonlease component for which the Company has adopted the practical expedient within ASC 842 which allows lessors to combine lease and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-lease</div> components that have the same pattern of transfer to the customer-lessee and account for the combined component under the guidance relevant to the predominant portion of the component. By applying this expedient, the Company applies Topic 606 to the combined component. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The consideration in the contract is allocated between separate products and services in the bundle based on the stand-alone selling prices of each good and service. The stand-alone selling prices are determined based on the prices at which the Company separately sells the initial training and the pellet procedures. Judgment is required to determine the standalone selling price for each distinct performance obligation. For items that are not sold separately and for which the Company has not established a standalone selling price, the Company allocates consideration based on the residual approach. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company recognizes revenue for initial training over time as the customer completes the training. Training sessions generally occur over the course of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2-3</div> consecutive days at or near the time of contract inception. The Customer is charged an initial fixed-rate fee for this training. Customers pay in full for the initial training at the time of contract inception. The standalone selling price of these services is based on the lowest price offered by the Company for the services. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company recognizes revenue for pellet procedures at the point in time the procedures are performed by the practitioner, which is when control of the pellets transfers to the customer. Consideration for these services is in the form of a management fee assessed for each procedure performed, which includes a volume-based tiered pricing schedule. The standalone selling price for these services requires judgment and is estimated based on the Company&#8217;s historical experience with prices offered to similar customers throughout the initial term of the contract. Billings in excess of the standalone selling price constitute a premium charged to customers early in a relationship and are deferred and recognized when or as the remaining goods and services are transferred to the customer. Fees are billed and paid on a semimonthly basis. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company recognizes revenue for contract-term services on a straight-line basis over the initial term of the contract, which aligns with the Company&#8217;s satisfaction of the performance obligation. The Company allocates the residual consideration to this performance obligation, which is consistent with the allocation objective. </div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"/><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Dietary Supplements </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Dietary supplements are supplements that customer practitioners resell to patients that aid the patients with maintaining hormone balances. The Company recognizes revenue for these, net of any discounts given, when control transfers to the customer, which is generally the point of shipment from the Company&#8217;s distributor. Products are billed at standalone selling price for the dietary supplements and invoiced at shipment. </div><div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Disposable Trocars </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Disposable Trocars are manual surgical instruments intended for use by Biote-certified practitioners. These tools are used to implant the bioidentical hormone pellets into the customers&#8217; patients. The Company recognizes revenue at the time control transfers, which is generally the point of shipment from the distributor. Products are billed at the standalone selling price for the trocars and invoiced at shipment. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Revenue disaggregated by the nature of the product or service and by geography is included within Note 4: Revenue Recognition. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of the years ended December&#160;31, 2022 and 2021, the Company had allocated $104 and $67 respectively, of consideration to the unsatisfied initial training obligations, and $1,655 and $1,393, respectively, of consideration to the unsatisfied contract-term service obligations provided to the Biote Method customers. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Consideration allocated to initial training due to deposits paid upfront is presented within deferred revenue on the consolidated balance sheets and is expected to be recognized as revenue within one year, as the training is complete. Consideration allocated to contract-term services is presented within deferred revenue and deferred revenue, long-term for the amounts expected to be recognized within one year and longer than one year, respectively. As of the years ended December&#160;31, 2022 and 2021 the amount of consideration allocated to contract-term services presented within deferred revenue was $1,028 and $849, respectively, and the amount presented within deferred revenue, long-term was $627 and $544, respectively. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Consideration allocated to the premiums within the management fee for pellet procedures is presented within deferred revenue current and deferred revenue, long-term for amounts expected to be recognized within one year and longer than one year, respectively. As of the years ended December&#160;31, 2022 and 2021 the amount of these premiums within deferred revenue was $833 and $789, respectively, and the amount within deferred revenue, long-term was $299 and $258, respectively. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company has also elected the practical expedient in ASC 606 to not disclose consideration allocated to contracts with an original term of one year or less, which includes contracts for <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">point-in-time</div></div> sales of dietary supplements, disposable trocars, and pellet procedures. Pellet procedures are included in the Company&#8217;s Biote Method service agreement, which has a three-year stated term, but as revenues are recognized at a point in time, there are no minimum purchase volumes, and the contract allows for cancellation with ninety days&#8217; notice from the customer, there are no pellet procedure obligations that are satisfied over a period greater than one year. </div><div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Contract Assets and Liabilities </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Customer receivables are made up of consideration to which the Company has an unconditional right to payment, regardless of whether the Company has satisfied the performance obligations in the contract. All customer receivables are presented within accounts receivable, net of allowance for doubtful accounts in the consolidated balance sheets. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Contract assets are the Company&#8217;s right to consideration for goods or services that the entity has transferred to the customer when that right is conditioned on something other than the passage of time. The Company does not have any contract assets for the years ended December&#160;31, 2022 and 2021. </div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"/><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Contract liabilities are the Company&#8217;s obligation to transfer goods or services to a customer for which the Company has received consideration or has an unconditional right to receive consideration. The Company&#8217;s contract liabilities include deposits for initial training and contract-term services paid in advance which have not been recognized as revenue during the period. Contract liabilities are presented within deferred revenue and deferred revenue, long-term in the consolidated balance sheets. Contract liabilities are classified as current liabilities for the amount of revenue that the Company expects to recognize within one year of the reporting date. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Changes in contract liabilities between each period are attributable to fees paid by new customers, revenue recognized for completed trainings, and revenue recognized for the Company&#8217;s over-time satisfaction of contract-term services. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company does not have a history of material returns or refunds, and generally does not offer warranties or guarantees for any products or services. Expected returns and refunds are recorded as a reduction of revenue and are $0 and $0 for the years ended December&#160;31, 2022 and 2021, respectively. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A reconciliation of the beginning and ending contract liabilities is included within Note 4: Revenue Recognition. </div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_btmd_CostOfRevenuePolicyTextBlock', window );">Cost of Revenue</a></td>
<td class="text"><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Cost of Revenue</div></div>&#8212;Cost of services primarily consist of the costs incurred to deliver trainings to Biote Method customers. Cost of products includes the cost of pellets purchased from compounding pharmacies and sold to customers of the Biote Method, the cost of trocars and dietary supplements purchased from manufacturing facilities or third-party <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">co-packers,</div> and the shipping and handling costs incurred to deliver these products to the customers. </div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketRiskBenefitPolicyTextBlock', window );">Marketing</a></td>
<td class="text"><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Marketing</div></div>&#8212;<div style="display:inline;">Mark</div>eting expense includes advertising costs, marketing events, and program costs. These costs are expensed as incurred. </div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock', window );">Selling, General, and Administrative</a></td>
<td class="text"><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Selling, General, and Administrative</div></div>&#8212;Selling, general, and administrative expense consists primarily of software licensing and maintenance and the cost of employees who engage in corporate functions, such as finance and accounting, information technology, human resources, legal, and executive management. Selling, general, and administrative expense also includes rent occupancy costs, office expenses, recruiting expenses, entertainment allocations, depreciation and amortization, other general overhead costs, insurance premiums, professional service fees, research and development, and costs related to regulatory and litigation m<div style="display:inline;">atters.</div> </div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PensionAndOtherPostretirementPlansPolicy', window );">Employee Retirement Plans</a></td>
<td class="text"><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">Employee Retirement Plans&#8212; </div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Defined Contribution Retirement Plans </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Effective January&#160;1, 2021, the Company offers participation in the BioTE Medical, LLC (&#8221;BioTE Medical&#8221;) 401(k) Plan (the &#8220;401(k) Plan&#8221;), a defined contribution plan providing retirement benefits to eligible employees. Eligible employees may contribute a portion of their annual compensation to the 401(k) Plan, subject to the maximum annual amounts as set periodically by the IRS. The Company makes a safe harbor, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-elective</div> contribution to the 401(k) Plan equal to 3% of each participant&#8217;s eligible employee compensation. Safe harbor contributions vest immediately for each participant. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">During the years ended December&#160;31, 2022 and 2021, the Company made $915 and $335, respectively, in safe harbor contributions under the 401(k) Plan, which are presented within Selling, general and administrative expense in the consolidated statements of income and comprehensive income. </div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Share-Based Compensation</a></td>
<td class="text"><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Share-Based Compensation</div></div>&#8212;Holdings previously granted Class&#160;AAAA units (&#8220;incentive units&#8221;) and phantom equity rights (collectively, the &#8220;equity awards&#8221;) to certain key members of management. The equity awards were entitled to share in the distributions of Holdings from a change in control or qualifying liquidity event. The equity awards are accounted for under ASC 718, <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Compensation&#8212;Stock Compensation</div></div>, and classified in <div style="display:inline;">equity.</div> </div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"/><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company has elected to recognize forfeitures at the time they occur. The fair value of the equity awards was determined using a Monte-Carlo simulation as of the grant date. The awards begin to vest on the date of a change in control or qualifying event. The Business Combination constituted such a qualifying event triggering the performance condition in the awards. No compensation cost was recognized historically until the Closing of the Business Combination as a qualifying event was not previously deemed probable to occur. See Note 14 for further <div style="display:inline;">details.</div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommissionsPolicy', window );">Commissions</a></td>
<td class="text"><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Commissions</div></div>&#8212;Commissions consist primarily of fees paid to a third-party sales force, internal sales force, and partner clinics which participate in the Company&#8217;s new clinic mentor program. Commissions paid to the Company&#8217;s internal and third-party sales forces relate to market support and development activities undertaken to drive channel sales through existing customers and are not considered incremental costs to obtain a customer contract. For the years ended December&#160;31, 2022 and 2021 expenses incurred for these commission programs were $124 and $317, respectively. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Commissions paid to clinics under the Company&#8217;s mentorship program represent amounts paid to existing clinics which provide services to help new customers complete onboarding and other startup activities and are only incurred after contract initiation. These costs are expensed as incurred, consistent with other contract fulfillment costs. For the years ended December&#160;31, 2022 and 2021 commissions paid under this program were $1,098 and $1,738, respectively. </div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Concentrations</a></td>
<td class="text"><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Concentrations</div></div>&#8212;Financial instruments that potentially subject the Company to concentrations of credit risk consist primarily of cash, accounts receivable, credit agreements, and inventory purchases. The Company&#8217;s cash balances exceed those that are federally insured. To date, the Company has not recognized any losses caused by uninsured balances. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of December&#160;31, 2022 and December&#160;31, 2021, 100% of the Company&#8217;s outstanding debt and available line of credit was from one lender. A failure of the counterparty to perform could result in the loss of access to the available borrowing capacity under the line of credit. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Inventory purchases from three vendors totaled approximately 87% and 94% for the years ended December&#160;31, 2022 and 2021, respectively. Due to the nature of the markets and availability of alternative suppliers, the Company does not believe the loss of any one vendor would have a material adverse impact on the Company&#8217;s financial position, results of operations or cash flows for any significant period of time. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Significant customers are those which represent more than 10% of the Company&#8217;s total revenue or gross accounts receivable balance. The Company did not have any customers that accounted for 10% or more of total revenues for the years ended December&#160;31, 2022 and 2021. The Company did not have any customers that accounted for more than 10% of the outstanding gross accounts receivable as of December&#160;31, 2022 or December&#160;31, 2021. </div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recently Adopted and Recent Accounting Pronouncements Not Yet Adopted</a></td>
<td class="text"><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Recently Adopted Accounting Pronouncements</div></div>&#8212;In December 2019, the FASB issued ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2019-12,</div> <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Income Taxes (Topic 740)&#8212;Simplifying the Accounting for Income Taxes</div></div>, which simplifies the accounting for income taxes by removing certain exceptions to the general principles of ASC 740, <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Income Taxes</div></div>. The amendments also improve consistent application of and simplify U.S. GAAP for other areas of ASC 740 by clarifying and amending existing guidance. ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2019-12</div> is effective for fiscal years beginning after December&#160;15, 2021, and for interim periods beginning after December&#160;15, 2022. The Company has adopted the standard as of January 1, 2022, and there was no material impact to the financial statements. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Recent Accounting Pronouncements Not Yet Adopted</div></div>&#8212;In June 2016, the FASB issued ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2016-13,</div> <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Measurement of Credit Losses on Financial Instruments</div></div> (&#8220;ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2016-13&#8221;).</div> The main objective of the update is to provide financial statement users with more decision-useful information about the expected credit losses on financial instruments and other commitments to extend credit held by companies at each reporting date. For trade </div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"/><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">and other receivables, held to maturity debt securities, and other instruments, companies will be required to use a new forward-looking &#8220;expected losses&#8221; model that generally will result in the recognition of allowances for losses earlier than under current accounting guidance. Further, the FASB issued ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2019-04,</div> ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2019-05</div> and ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2019-11</div> to provide additional guidance on the credit losses standard. The standard will be adopted using the modified retrospective approach. ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2016-13</div> is effective for annual and interim periods beginning after December&#160;15, 2022, with early adoption permitted. The Company is evaluating the potential impact of adopting ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2016-13</div> on its consolidated financial statements and related disclosures. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In August 2020, the FASB issued ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2020-06,</div><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;"> Debt&#8212;Debt with Conversion and Other Options <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">(Subtopic&#160;470-20)</div> and Derivatives and Hedging&#8212;Contracts in Entity&#8217;s Own Equity (Subtopic <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">815-40):</div> Accounting for Convertible Instruments and Contracts in an Entity&#8217;s Own Equity</div></div> (&#8220;ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2020-06&#8221;).</div> <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">ASU&#160;2020-06</div> changes how entities account for convertible instruments and contracts in an entity&#8217;s own equity and simplifies the accounting for convertible instruments by removing certain separation models for convertible instruments. ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2020-06</div> also modifies the guidance on diluted earnings per share calculations. The amendments are effective for fiscal years beginning after December&#160;15, 2023, including interim periods within those fiscal years. The Company is currently evaluating the impact of this standard on its consolidated financial statements and related disclosures. </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_btmd_CostOfRevenuePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cost of revenue.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">btmd_CostOfRevenuePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>btmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_btmd_DebtIssuanceCostsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">btmd_DebtIssuanceCostsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>btmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_btmd_EarnoutLiabilityPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Earnout liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">btmd_EarnoutLiabilityPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>btmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_btmd_NoncontrollingInterestPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">btmd_NoncontrollingInterestPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>btmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_btmd_OtherCurrentAssetsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Other current assets policy.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">btmd_OtherCurrentAssetsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>btmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_btmd_StandbyEquityPurchaseAgreementPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Standby equity purchase agreement [Policy Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">btmd_StandbyEquityPurchaseAgreementPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>btmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_btmd_WarrantLiabilitiesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Warrant liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">btmd_WarrantLiabilitiesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>btmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4273-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommissionsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for fees earned by the broker dealer, acting as an agent in the buying and selling of securities and administrative efforts on behalf of customers and may include the timing of commission revenue recognition and presentation in the financial statements. Commissions earned are usually related to the broker dealer's customers' trading volume and the dollar amounts of the trades.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 20<br> -Section 25<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126941158&amp;loc=d3e41261-110953<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 20<br> -Section 25<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126941158&amp;loc=d3e41256-110953<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommissionsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126941378&amp;loc=d3e61044-112788<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 05<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=109226317&amp;loc=d3e202-110218<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.CC)<br> -URI https://asc.fasb.org/extlink&amp;oid=27011434&amp;loc=d3e125687-122742<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e32247-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32847-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32840-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL116659661-227067<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e32280-109318<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32809-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InternalUseSoftwarePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs incurred when both (1) the software is acquired, internally developed, or modified solely to meet the entity's internal needs, and (2) during the software's development or modification, no substantive plan exists or is being developed to market the software externally.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 40<br> -Section 30<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=118172244&amp;loc=d3e17916-109280<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 50<br> -Section 25<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=16397303&amp;loc=d3e19379-109286<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InternalUseSoftwarePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=116847112&amp;loc=d3e4556-108314<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -URI https://asc.fasb.org/topic&amp;trid=2126998<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 330<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6471895&amp;loc=d3e55923-109411<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=116847112&amp;loc=d3e4492-108314<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 270<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126900757&amp;loc=d3e543-108305<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126899994&amp;loc=d3e18823-107790<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6361739&amp;loc=d3e7789-107766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeasesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for leasing arrangement entered into by lessee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918666-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeasesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketRiskBenefitPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for contract or contract feature in long-duration contract issued by insurance entity that both protects contract holder from other-than-nominal capital market risk and exposes insurance entity to other-than-nominal capital market risk. Includes, but is not limited to, input, judgment, assumption and method used in measuring market risk benefit, and change in input, judgment, and assumption.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 50<br> -Paragraph 7C<br> -URI https://asc.fasb.org/extlink&amp;oid=124506351&amp;loc=SL117782774-158439<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketRiskBenefitPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PensionAndOtherPostretirementPlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for pension and other postretirement benefit plans. This accounting policy may address (1) the types of plans sponsored by the entity, and the benefits provided by each plan (2) groups that participate in (or are covered by) each plan (3) how plan assets, liabilities and expenses are measured, including the use of any actuaries and (4) significant assumptions used by the entity to value plan assets and liabilities and how such assumptions are derived.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 60<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=66047640&amp;loc=d3e39622-114963<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 80<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=65877416&amp;loc=d3e29149-114947<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 70<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=49170846&amp;loc=d3e28014-114942<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6412939&amp;loc=d3e15145-114933<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PensionAndOtherPostretirementPlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126982197&amp;loc=d3e99779-112916<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=126982197&amp;loc=d3e99893-112916<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for determining the allowance for doubtful accounts for trade and other accounts receivable balances, and when impairments, charge-offs or recoveries are recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=123577603&amp;loc=d3e5144-111524<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRecognitionPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126899994&amp;loc=d3e18823-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126899994&amp;loc=d3e18823-107790<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRecognitionPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for segment reporting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8864-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8864-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8864-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8864-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8864-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8864-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for inclusion of significant items in the selling, general and administrative (or similar) expense report caption.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 720<br> -SubTopic 35<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6420018&amp;loc=d3e36677-107848<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI https://asc.fasb.org/topic&amp;trid=2228938<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2.Q6)<br> -URI https://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for its capital stock transactions, including dividends and accumulated other comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21459-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6191-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6161-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6143-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6061-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6132-108592<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140468225793440">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableAllowanceForCreditLossTableTextBlock', window );">Summary of Rollforward of the Allowance for Doubtful Accounts</a></td>
<td class="text">A rollforward of the allowance for doubtful accounts is as follows (in thousands): <div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:68%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:86%"/>
<td style="vertical-align:bottom;width:6%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">As of December&#160;31, 2020</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(1,157</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Provisions charged to operating results</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(240</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Account <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">write-off</div> and recoveries</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(9</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">As of December&#160;31, 2021</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(1,406</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">As of December&#160;31, 2021</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(1,406</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Provisions charged to operating results</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">155</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Account <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">write-off</div> and recoveries</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">277</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">As of December&#160;31, 2022</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(974</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock', window );">Summary of Total Other Current Assets</a></td>
<td class="text">As of December&#160;31, 2022 and December&#160;31, 2021, the Company&#8217;s total other current assets consist of the following: <div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:66%"/>
<td style="vertical-align:bottom;width:11%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:11%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,<br/> 2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,<br/> 2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Prepaid expenses</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2,939</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">847</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Advances</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">877</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">685</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Capitalized transaction costs</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3,941</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total other current assets</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3,816</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">5,473</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_btmd_DisclosureInTabularFormOfEstimatedUsefulLivesOfPropertyPlantAndEquipmentTableTextBlock', window );">Summary of Estimated Useful Lives of Property and Equipment</a></td>
<td class="text">The estimated useful lives of property and equipment are as follows: <div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:48%"/>
<td style="vertical-align:bottom;width:3%"/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Estimated&#160;Useful Life (in years)</div></div></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Trocars</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;text-align:center;">5</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Leasehold improvements</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;text-align:center;">Shorter of lease term or useful life of the<br/> improvement</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Office equipment</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;text-align:center;">5</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Computer software</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;text-align:center;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">3-5</div></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Furniture and fixtures</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;text-align:center;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">5-7</div></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Computer equipment</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;text-align:center;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">3-5</div></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfCapitalUnitsTextBlock', window );">Summary of Members' Equity Units Issued and Outstanding</a></td>
<td class="text"><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of December&#160;31, 2021, the following members&#8217; equity units were issued and outstanding: </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:68%"/>
<td style="vertical-align:bottom;width:5%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:5%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31, 2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.5pt;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; font-size: 8pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Members&#8217; Equity</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Issued</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Outstanding</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Class&#160;A (Voting)</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">16,721</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">16,721</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Class&#160;AA <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">(Non-voting)</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">903,079</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">903,079</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Class&#160;AAA <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">(Non-voting)</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">60,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">60,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Class&#160;AAAA <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">(Non-voting</div> incentive units)</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">33,397</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,013,197</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">982,800</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfStockByClassTextBlock', window );">Summary of Common Stock Issued and Outstanding</a></td>
<td class="text"><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of December&#160;31, 2022, the following shares of common stock were issued and outstanding: </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:11pt;width:76%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:64%"/>
<td style="vertical-align:bottom;width:3%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:3%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31, 2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.5pt;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; font-size: 8pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Stockholders&#8217; Equity</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Issued</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Outstanding</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt;background-color:#cceeff">
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Class&#160;A common stock</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;">11,242,887</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;">9,655,387</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Class&#160;B common stock</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt;background-color:#cceeff">
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Class&#160;V voting stock</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;">58,565,824</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;">48,565,824</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;">69,808,711</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;">58,221,211</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_btmd_DisclosureInTabularFormOfEstimatedUsefulLivesOfPropertyPlantAndEquipmentTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure in tabular form of estimated useful lives of property plant and equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">btmd_DisclosureInTabularFormOfEstimatedUsefulLivesOfPropertyPlantAndEquipmentTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>btmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableAllowanceForCreditLossTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allowance for credit loss on accounts receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 50<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=124255953&amp;loc=SL82919249-210447<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableAllowanceForCreditLossTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCapitalUnitsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's capital units or capital shares, including the value of capital units or capital shares, units authorized, units outstanding and other information necessary to a fair presentation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04.16)<br> -URI https://asc.fasb.org/extlink&amp;oid=120401414&amp;loc=d3e603758-122996<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCapitalUnitsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the carrying amounts of other current assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfStockByClassTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's stock, including par or stated value per share, number and dollar amount of share subscriptions, shares authorized, shares issued, shares outstanding, number and dollar amount of shares held in an employee trust, dividend per share, total dividends, share conversion features, par value plus additional paid in capital, the value of treasury stock and other information necessary to a fair presentation, and EPS information. Stock by class includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. Includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity. If more than one issue is outstanding, state the title of each issue and the corresponding dollar amount; dollar amount of any shares subscribed but unissued and the deduction of subscriptions receivable there from; number of shares authorized, issued, and outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=65888546&amp;loc=d3e21300-112643<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21553-112644<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=122040564&amp;loc=d3e177068-122764<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21538-112644<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21521-112644<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21488-112644<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21506-112644<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21484-112644<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfStockByClassTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140468225005216">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue Recognition (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue from Contract with Customer [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueTableTextBlock', window );">Schedule of Revenues Recognized</a></td>
<td class="text"><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Revenue recognized for each revenue stream is as follows: </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:84%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:39%"/>
<td style="vertical-align:bottom;width:4%"/>
<td style="width:33%"/>
<td style="vertical-align:bottom;width:4%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:4%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td rowspan="2" style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.5pt;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; font-size: 8pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Financial Statement Caption</div></div></td>
<td rowspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td rowspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 8pt; font-family: &quot;Times New Roman&quot;; text-align: center; line-height: normal;"><div style="font-weight:bold;display:inline;">Revenue Stream</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Year Ended</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Product revenue:</div></div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">Pellet procedures</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">128,952</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">109,465</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">Dietary supplements</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">32,412</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">27,241</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">Disposable trocars</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,698</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">860</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">Shipping fees</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">71</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">32</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;">Total product revenue</div></div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">163,133</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">137,598</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Service revenue:</div></div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">Training</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">973</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">859</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">Contract-term services</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">851</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">939</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;">Total service revenue</div></div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,824</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,798</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;">Total revenue</div></div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">164,957</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">139,396</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Revenue recognized by geographic region is as follows: </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:84%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:39%"/>
<td style="vertical-align:bottom;width:4%"/>
<td style="width:33%"/>
<td style="vertical-align:bottom;width:4%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:4%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td rowspan="2" style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.5pt;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; font-size: 8pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Financial Statement Caption</div></div></td>
<td rowspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td rowspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 8pt; font-family: &quot;Times New Roman&quot;; text-align: center; line-height: normal;"><div style="font-weight:bold;display:inline;">Country</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">For the Year Ended<br/> December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Product revenue:</div></div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">United States</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">162,742</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">137,349</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">All other</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">391</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">249</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;">Total product revenue</div></div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">163,133</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">137,598</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Service revenue:</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">United States</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,781</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,798</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">All other</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">43</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;">Total service revenue</div></div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,824</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,798</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;">Total revenue</div></div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">164,957</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">139,396</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock', window );">Summary of Significant Changes in Contract Liability Balances</a></td>
<td class="text"><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Significant changes in contract liability balances are as follows: </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:92%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:60%"/>
<td style="vertical-align:bottom;width:5%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:5%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:5%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:5%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="14" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Year Ended December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.5pt;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; font-size: 8pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Description of change</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Deferred<br/> Revenue</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Deferred<br/> Revenue,</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Long-term</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Deferred<br/> Revenue</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Deferred<br/> Revenue,</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Long-term</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Revenue recognized that was included in the contract liability balance at the beginning of the period</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(1,710</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(2,048</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Increases due to cash received, excluding amounts recognized as revenue during the period</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,342</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">760</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,022</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">652</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Transfers between current and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-current</div> liabilities due to the expected revenue recognition period</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">460</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(460</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">697</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(697</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total increase (decrease) in contract liabilities</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">92</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">300</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(329</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(45</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_btmd_SummaryOfConsiderationAllocatedToPerformanceObligationsTableTextBlock', window );">Summary of Consideration Allocated to Performance Obligations</a></td>
<td class="text"><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Consideration allocated to performance obligations are as follows: </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:68%"/>
<td style="vertical-align:bottom;width:10%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:10%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,<br/> 2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,<br/> 2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Unsatisfied training obligations&#8212;Current</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">104</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">67</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Unsatisfied contract-term services&#8212;Current</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,028</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">849</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Unsatisfied contract-term services&#8212;Long-term</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">627</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">544</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Total allocated to unsatisfied contract-term services</div></div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,655</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,393</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Unsatisfied pellet procedures&#8212;Current</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">833</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">789</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Unsatisfied pellet procedures&#8212;Long-term</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">299</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">258</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Total allocated to unsatisfied pellet procedures</div></div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,132</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,047</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Total deferred revenue&#8212;Current</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,965</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,705</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Total deferred revenue&#8212;Long-term</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">926</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">802</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_btmd_SummaryOfConsiderationAllocatedToPerformanceObligationsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Summary of consideration allocated to performance obligations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">btmd_SummaryOfConsiderationAllocatedToPerformanceObligationsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>btmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of receivable, contract asset, and contract liability from contract with customer. Includes, but is not limited to, change in contract asset and contract liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130551-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130545-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140468230240736">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Inventory, Net (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock', window );">Schedule of Inventory, Net</a></td>
<td class="text"><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Inventory, net consists of the following: </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:66%"/>
<td style="vertical-align:bottom;width:10%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:10%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,<br/> 2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,<br/> 2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Product inventory&#8212;Pellets</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">6,213</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">6,318</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Less: Obsolete and expired pellet allowance</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(1,298</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(1,356</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Pellet inventory, net</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">4,915</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">4,962</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Product inventory&#8212;Dietary supplements</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">6,283</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">4,849</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Less: Obsolete and expired dietary supplement allowance</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(15</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(196</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Dietary supplement inventory, net</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">6,268</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">4,653</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Inventory, net</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">11,183</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">9,615</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(c))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6361739&amp;loc=d3e7789-107766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfInventoryCurrentTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140468230392848">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment, Net (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Schedule of Property and Equipment, Net</a></td>
<td class="text"><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Property and equipment, net consists of the following: </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:66%"/>
<td style="vertical-align:bottom;width:11%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:11%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,<br/> 2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,<br/> 2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Trocars</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">4,645</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">4,448</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Leasehold improvements</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,028</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">254</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Office equipment</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">238</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">223</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Computer software</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">140</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">135</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Furniture and fixtures</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">161</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">119</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Computer equipment</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">102</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">97</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Construction in process</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">705</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Property and equipment</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">6,314</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">5,981</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Less: Accumulated depreciation</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(4,810</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(3,646</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Property and equipment, net</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,504</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2,335</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140468230211280">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Capitalized Software, Net (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentAbstract', window );"><strong>Research and Development [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_btmd_SummaryOfCapitalizedSoftwareNetTableTextBlock', window );">Summary of Capitalized Software, Net</a></td>
<td class="text"><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Capitalized software, net consists of the following: </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:66%"/>
<td style="vertical-align:bottom;width:11%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:11%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,<br/> 2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,<br/> 2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Website costs</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">4,142</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3,571</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Development in process</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3,277</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2,294</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Less: Accumulated amortization</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(2,346</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(1,311</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Capitalized software, net</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">5,073</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">4,554</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_btmd_SummaryOfCapitalizedSoftwareNetTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Summary of capitalized software net.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">btmd_SummaryOfCapitalizedSoftwareNetTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>btmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140468231545536">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued Expenses (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock', window );">Schedule of Accrued Expenses</a></td>
<td class="text"><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Accrued expenses consist of the following: </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:66%"/>
<td style="vertical-align:bottom;width:11%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:11%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,<br/> 2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,<br/> 2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Accrued professional fees</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">354</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,192</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Accrued employee-related costs</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">4,221</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2,213</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Accrued merchant fees</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">184</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Accrued interest</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">27</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Legal accrual</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,302</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Other</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,699</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,093</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Accrued expenses</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">6,274</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">6,011</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140468231490928">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Long-Term Debt (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDebtTableTextBlock', window );">Schedule of Outstanding Debt</a></td>
<td class="text"><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The outstanding debt as of December&#160;31, 2022 and 2021 is classified in the consolidated balance sheets as follows: </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:65%"/>
<td style="vertical-align:bottom;width:9%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:9%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,<br/> 2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,<br/> 2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Term loan</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">121,875</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">37,500</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Less: Current portion</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(6,250</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(5,000</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">115,625</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">32,500</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Less: Unamortized debt issuance costs</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(3,539</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(537</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Term loan, net of current portion</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">112,086</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">31,963</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock', window );">Schedule of Future Maturities of Long-term Debt</a></td>
<td class="text"><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Future maturities of long-term debt, excluding debt issuance costs, are as follows: </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:68%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:83%"/>
<td style="vertical-align:bottom;width:7%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">2023</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">6,250</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">2024</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">6,250</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">2025</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">6,250</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">2026</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">6,250</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">2027</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">96,875</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">121,875</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDebtTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of information pertaining to short-term and long-debt instruments or arrangements, including but not limited to identification of terms, features, collateral requirements and other information necessary to a fair presentation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDebtTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of maturity and sinking fund requirement for long-term debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123465755&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140468224679696">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock', window );">Schedule of Fair Value Hierarchy for Financial Assets and Liabilities</a></td>
<td class="text"><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following table presents the Company&#8217;s fair value hierarchy for financial assets and liabilities: </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:92%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:60%"/>
<td style="vertical-align:bottom;width:6%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:6%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:6%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:6%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="14" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Fair&#160;Value&#160;Measurements&#160;as&#160;of&#160;December&#160;31,&#160;2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;Level&#160;1&#160;&#160;</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;Level&#160;2&#160;&#160;</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;Level&#160;3&#160;&#160;</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;Total&#160;&#160;</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Liabilities:</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Public Warrants</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2,381</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2,381</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Private Placement Warrants</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,723</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,723</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Earnout liability</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">32,110</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">32,110</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:12pt">&#160;</td>
<td colspan="16" style="height:12pt">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="14" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Fair Value Measurements as of May&#160;26, 2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Level&#160;1</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Level&#160;2</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Level&#160;3</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Total</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Liabilities:</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Public Warrants</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">5,397</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">5,397</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Private Placement Warrants</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3,834</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3,834</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Earnout liability</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">93,880</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">93,880</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock', window );">Summary of Significant Inputs to Monte Carlo Simulation for Fair Value of Private Placement Warrants and Earnout Liability</a></td>
<td class="text"><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following table provides the significant inputs to the Monte Carlo simulation for the fair value of the Private Placement Warrants as of December&#160;31, 2022 and the Closing Date: </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:71%"/>
<td style="vertical-align:bottom;width:10%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:9%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">As of</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">May&#160;26,</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Stock price</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3.73</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">9.02</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Exercise price</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">11.50</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">11.50</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Risk-free rate</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">4.0</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2.7</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Volatility</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">42.2</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">13.4</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Term (in years)</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">4.4</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">5.0</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr></table><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following table provides the significant inputs to the Monte Carlo simulation for the fair value of the Earnout liability as of December&#160;31, 2022 and the Closing Date, the date of initial measurement: </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:71%"/>
<td style="vertical-align:bottom;width:12%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:11%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">As of</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,<br/> 2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">May&#160;26,<br/> 2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Stock price</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3.73</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">9.02</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Risk-free rate</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">4.1</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2.7</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Volatility</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">70.0</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">60.0</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Term (in years)</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">4.4</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">5.0</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_btmd_ScheduleOfChangesInTheFairValueOfWarrantLiabilitiesTableTextBlock', window );">Summary of Changes in the Fair Value of Company's Level 3 Financial Instruments</a></td>
<td class="text"><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following table presents the changes in fair value of the Company&#8217;s Level&#160;3 financial instruments that are measured at fair value as of December&#160;31, 2022 and the Closing Date, the date of initial measurement: </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:84%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:65%"/>
<td style="vertical-align:bottom;width:5%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:5%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:5%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Private<br/> Placement</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Warrants</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Earnout<br/> Liability</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Total</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Fair value as of May&#160;26, 2022 (initial measurement)</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3,834</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">93,880</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">97,714</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Gain from change in fair value</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(2,111</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(61,770</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(63,881</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Fair value as of December&#160;31, 2022</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,723</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">32,110</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">33,833</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_btmd_ScheduleOfChangesInTheFairValueOfWarrantLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule of changes in the fair value of warrant liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">btmd_ScheduleOfChangesInTheFairValueOfWarrantLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>btmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3). Where the quoted price in an active market for the identical liability is not available, the Level 1 input is the quoted price of an identical liability when traded as an asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140468230351488">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Compensation (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock', window );">Summary of Restricted Stock Unit Activity</a></td>
<td class="text">The following table summarizes RSU activity during the year ended December&#160;31, 2022: <div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:68%"/>
<td style="vertical-align:bottom;width:7%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:7%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Shares</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Weighted-<br/> Average</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Grant-Date</div><br/> Fair Value</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">RSUs outstanding at December&#160;31, 2021</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3,887,750</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">8.85</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Granted</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">85,040</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">4.00</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Forfeited</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(296,250</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">8.71</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Vested</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(2,053,700</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">8.24</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">RSUs outstanding at December&#160;31, 2022</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,622,840</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">9.41</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Summary of Stock Option Activity</a></td>
<td class="text">The following table summarizes stock option activity during the year ended December&#160;31, 2022: <div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:84%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:57%"/>
<td style="vertical-align:bottom;width:8%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:8%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:8%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Shares</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Weighted-<br/> Average</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Exercise&#160;Price</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Weighted-<br/> Average</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Remaining</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Contractual<br/> Term</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(Years)</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Options outstanding at December&#160;31, 2021</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Granted</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">5,165,328</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3.86</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Forfeited</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(122,700</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3.73</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Options outstanding at December&#160;31, 2022</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">5,042,628</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3.86</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">9.5</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Options exercisable December&#160;31, 2022</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">131,461</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3.99</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2.1</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Summary of Weighted-Average Assumptions used to Estimate Fair Value of Stock Options Granted</a></td>
<td class="text"><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The weighted-average assumptions used to estimate the fair value of stock options granted during the year ended December&#160;31, 2022 were as follows: </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:68%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:90%"/>
<td style="vertical-align:bottom;width:6%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Expected term (in years)</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">6.0</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Volatility</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">60.0</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Risk-free rate</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3.5</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Dividend yield</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">0.0</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the number and weighted-average grant date fair value for restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock units that were granted, vested, or forfeited during the year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140468230223600">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_btmd_SummaryOfLeaseCostsRecognizedUnderAsc842AndSupplementalCashFlowInformationForLeasesTableTextBlock', window );">Summary of Operating Lease Costs Recognized under ASC 842 and Supplemental Cash Flow Information for Leases</a></td>
<td class="text">The following table contains a summary of the operating lease costs recognized under ASC 842 and supplemental cash flow information for leases for the years ended December&#160;31, 2022 and 2021: <div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:80%"/>
<td style="vertical-align:bottom;width:5%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:5%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Year Ended</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Fixed lease expense</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">278</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">244</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total lease cost</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">278</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">244</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Other information:</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Cash paid for amounts included in the measurement of lease liabilities</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">257</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">257</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Right-of-use</div></div> assets obtained in exchange for new operating lease liabilities</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,936</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_btmd_SummaryBalanceSheetClassificationOfOperatingLeasesAndWeightedAverageRemainingLeaseTermAndDiscountRateTableTextBlock', window );">Summary Balance Sheet Classification of Operating Leases and Weighted Average Remaining Lease Term and Discount Rate</a></td>
<td class="text"><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following table summarizes the balance sheet classification of the Company&#8217;s operating leases, amounts of ROU assets and lease liabilities, the weighted average remaining lease term, and the weighted average discount rate for the Company&#8217;s operating leases: </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:66%"/>
<td style="vertical-align:bottom;width:14%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:13%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,<br/> 2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,<br/> 2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Lease assets</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Operating lease <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">right-of-use</div></div> assets</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2,052</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">356</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total lease assets</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2,052</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">356</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Lease liabilities</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Current:</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Operating lease liabilities</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">165</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">248</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-current:</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Operating lease liabilities</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,927</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">127</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total lease liabilities</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2,092</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">375</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Weighted-average remaining lease term&#8212;operating leases (years)</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">5.92</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1.50</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Weighted-average discount rate&#8212;operating leases</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">8.48</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3.75</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Summary of Payments by Date for Operating Lease</a></td>
<td class="text"><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following table summarizes the payments by date for the Company&#8217;s operating lease, which is then reconciled to our total lease obligation, as of December&#160;31, 2022: </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:68%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:87%"/>
<td style="vertical-align:bottom;width:6%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">2023</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">337</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">2024</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">448</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">2025</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">464</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">2026</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">480</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">2027</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">497</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Thereafter</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">470</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total lease payments</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2,696</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Less: Interest</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(604</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Present value of lease liabilities</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2,092</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_btmd_SummaryBalanceSheetClassificationOfOperatingLeasesAndWeightedAverageRemainingLeaseTermAndDiscountRateTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Summary balance sheet classification of operating leases and weighted average remaining lease term and discount rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">btmd_SummaryBalanceSheetClassificationOfOperatingLeasesAndWeightedAverageRemainingLeaseTermAndDiscountRateTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>btmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_btmd_SummaryOfLeaseCostsRecognizedUnderAsc842AndSupplementalCashFlowInformationForLeasesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Summary of lease costs recognized under ASC 842 and supplemental cash flow information for leases.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">btmd_SummaryOfLeaseCostsRecognizedUnderAsc842AndSupplementalCashFlowInformationForLeasesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>btmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140468231149424">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock', window );">Schedule of Income (Loss) Before Provision for Income Taxes</a></td>
<td class="text"><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Income (loss) before provision for income taxes consisted of the following (in thousands): </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:76%"/>
<td style="vertical-align:bottom;width:5%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:5%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Year Ended</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Domestic</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2,221</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">33,191</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Foreign</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(509</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(286</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Income before provision for income taxes</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,712</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">32,905</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock', window );">Schedule of Income Tax Provision</a></td>
<td class="text"><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The income tax provision for the year ended December&#160;31, 2022 and 2021 consists of the following: </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:80%"/>
<td style="vertical-align:bottom;width:6%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:6%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Year Ended</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Current income tax provision (benefit):</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Federal</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">749</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">State and Local</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">377</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">286</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Foreign</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">5</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total current expense (benefit):</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,131</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">286</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Deferred income tax provision (benefit):</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Federal</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(714</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">State and Local</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(29</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Foreign</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total deferred expense (benefit):</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(743</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total income tax provision (benefit)</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">388</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">286</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Schedule of Reconciliation of the Federal Income Tax Rate to the Company Effective Tax Rate</a></td>
<td class="text"><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A reconciliation of the federal income tax rate to the Company&#8217;s effective tax rate for the year ended December&#160;31, 2022 and 2021 is as follows: </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:79%"/>
<td style="vertical-align:bottom;width:5%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:4%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Year Ended</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Statutory federal income tax rate</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">21.00</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">21.00</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">State taxes, net of federal benefit</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">18.20</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">0.87</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Nontaxable partnership income</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">-41.39</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">-21.00</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Foreign rate differential</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">-2.71</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">0.00</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Change in valuation allowance</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">27.55</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">0.00</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">22.65</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">0.87</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Schedule of Deferred Tax Assets and Liabilities</a></td>
<td class="text"><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company&#8217;s net deferred tax assets (liabilities) as of December&#160;31, 2022 and 2021 is as follows: </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:80%"/>
<td style="vertical-align:bottom;width:5%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:5%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Year Ended</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Deferred tax assets:</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Outside basis difference in partnership</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,173</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Net operating loss carryforwards</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">164</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Intangibles</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">978</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total deferred tax assets</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2,315</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Valuation allowance</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(477</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Deferred tax assets, net of allowance</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,838</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of income before income tax between domestic and foreign jurisdictions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140468231152800">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Common Share (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Schedule of Computation of Net Loss Per Common Share</a></td>
<td class="text">The following table sets forth the computation of net loss per common share: <div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:68%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:80%"/>
<td style="vertical-align:bottom;width:14%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Year Ended</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,<br/> 2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Net loss per common share</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Numerator:</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Net loss attributable to biote Corp. stockholders (basic and diluted)</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(969</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Denominator:</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Weighted average shares outstanding (basic and diluted)</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">8,059,371</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Net loss per common share</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Basic</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(0.12</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Diluted</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(0.12</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Schedule of Computation of Diluted Weighted Average Shares Outstanding</a></td>
<td class="text"><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company excluded the following potential shares, presented based on amounts outstanding at each period end, from the computation of diluted weighted average shares outstanding for the periods indicated because including them would have had an antidilutive effect: </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:68%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:80%"/>
<td style="vertical-align:bottom;width:5%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Year Ended</div></div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,<br/> 2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">RSUs</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,622,840</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Stock Options</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">5,042,628</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Class&#160;V Voting Stock</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">48,565,824</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Public Warrants</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">7,937,466</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Private Placement Warrants</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">5,566,666</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Earnout Voting Shares</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">10,000,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Sponsor Earnout Shares</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,587,500</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">80,322,924</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140468221256352">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Additional Information (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Jul. 27, 2022 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($) </div>
<div>SEGMENT </div>
<div>CUSTOMER </div>
<div>vendor </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($) </div>
<div>CUSTOMER </div>
<div>vendor </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProductInformationLineItems', window );"><strong>Product Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Number of operating segment | SEGMENT</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfReportableSegments', window );">Number of reportable segment | SEGMENT</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse', window );">Impairment charge of long-lived assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LimitedPartnersCapitalAccountDistributionAmount', window );">Operating distribution to members of holdings and taxing authorities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12,886<span></span>
</td>
<td class="nump">11,402<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_btmd_ConsecutiveTradingDays', window );">Consecutive trading days</a></td>
<td class="text">3 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_btmd_MaximumValueOfDailyVolumeTradedThresholdPercentage', window );">Maximum value of daily volume traded threshold percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">69,808,711<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Contract with customers liability current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,965<span></span>
</td>
<td class="nump">1,705<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityNoncurrent', window );">Contract with customers liability non current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">926<span></span>
</td>
<td class="nump">802<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_btmd_ExpectedReturnsAndRefundsToCustomers', window );">Expected returns and refunds to customers</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_btmd_NumberOfInventoryVendors', window );">Number of vendors | vendor</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_btmd_NumberOfCustomersAccountedForTenPercentOrMoreAggregateRevenue', window );">Number of customers accounted for 10% of total revenue | CUSTOMER</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_btmd_NumberOfCustomersAccountedForTenPercentOrMoreAccountsReceivable', window );">Number of customers accounted for 10% of accounts receivable | CUSTOMER</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SalesCommissionsAndFees', window );">Sales commission</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 974<span></span>
</td>
<td class="nump">$ 2,056<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalizedContractCostAmortization', window );">Incremental costs to fulfill contract with customers</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,098<span></span>
</td>
<td class="nump">$ 1,738<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProductInformationLineItems', window );"><strong>Product Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_btmd_CapitalizedSoftwareEstimatedUsefulLives', window );">Capitalized software estimated useful lives</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProductInformationLineItems', window );"><strong>Product Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_btmd_CapitalizedSoftwareEstimatedUsefulLives', window );">Capitalized software estimated useful lives</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">8 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember', window );">Class A Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProductInformationLineItems', window );"><strong>Product Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,242,887<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=btmd_StandbyEquityPurchaseAgreementMember', window );">Standby Equity Purchase Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProductInformationLineItems', window );"><strong>Product Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_btmd_PercentageOfCommonStockPurchasePrice', window );">Percentage of common stock purchase price</a></td>
<td class="nump">97.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_btmd_TerminationPeriodOfPurchaseAgreement', window );">Termination period of purchase agreement</a></td>
<td class="text">36 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_btmd_MandatoryMinimumAmountForIndividualAdvance', window );">Mandatory minimum amount for individual advance</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_btmd_MaximumValueOfDailyVolumeTradedThresholdPercentage', window );">Maximum value of daily volume traded threshold percentage</a></td>
<td class="nump">30.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Shares sold | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">105,559<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_btmd_ProceedsFromSettlementOfSEPA', window );">Proceeds from settlement of SEPA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 442<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=btmd_StandbyEquityPurchaseAgreementMember', window );">Standby Equity Purchase Agreement | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProductInformationLineItems', window );"><strong>Product Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued | shares</a></td>
<td class="nump">5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=btmd_StandbyEquityPurchaseAgreementMember', window );">Standby Equity Purchase Agreement | Class A Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProductInformationLineItems', window );"><strong>Product Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued | shares</a></td>
<td class="nump">1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=btmd_StandbyEquityPurchaseAgreementMember', window );">Standby Equity Purchase Agreement | Yorkville</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProductInformationLineItems', window );"><strong>Product Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued | shares</a></td>
<td class="nump">25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201912Member', window );">ASU 2019-12</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProductInformationLineItems', window );"><strong>Product Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate', window );">Change in Accounting Principle, Accounting Standards Update, Adoption Date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Jan.  01,  2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted', window );">Change in Accounting Principle, Accounting Standards Update, Adopted [true false]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect', window );">Change in Accounting Principle, Accounting Standards Update, Immaterial Effect [true false]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanNameAxis=btmd_FourZeroOneKPlanMember', window );">401(k) Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProductInformationLineItems', window );"><strong>Product Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 915<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch', window );">Employer Safe Harbor non-elective contribution percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount', window );">Employer Safe Harbor contribution amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 335<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CreditAvailabilityConcentrationRiskMember', window );">Outstanding Debt and Available Line of Credit | Liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProductInformationLineItems', window );"><strong>Product Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_btmd_NatureOfCustomerAxis=btmd_BioteMethodCustomerMember', window );">Biote Method Customer</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProductInformationLineItems', window );"><strong>Product Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SalesCommissionsAndFees', window );">Sales commission</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 124<span></span>
</td>
<td class="nump">317<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_btmd_NatureOfCustomerAxis=btmd_BioteMethodCustomerMember', window );">Biote Method Customer | Service Revenue | Training</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProductInformationLineItems', window );"><strong>Product Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligation', window );">Revenue remaining performance obligation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">104<span></span>
</td>
<td class="nump">67<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_btmd_NatureOfCustomerAxis=btmd_BioteMethodCustomerMember', window );">Biote Method Customer | Service Revenue | Contract Term Services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProductInformationLineItems', window );"><strong>Product Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligation', window );">Revenue remaining performance obligation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,655<span></span>
</td>
<td class="nump">1,393<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Contract with customers liability current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,028<span></span>
</td>
<td class="nump">849<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityNoncurrent', window );">Contract with customers liability non current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">627<span></span>
</td>
<td class="nump">544<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_btmd_NatureOfCustomerAxis=btmd_BioteMethodCustomerMember', window );">Biote Method Customer | Product Revenue | Pallet Procedures</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProductInformationLineItems', window );"><strong>Product Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Contract with customers liability current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">833<span></span>
</td>
<td class="nump">789<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityNoncurrent', window );">Contract with customers liability non current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 299<span></span>
</td>
<td class="nump">$ 258<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=btmd_InventoryMember', window );">Inventory | Vendor Concentration | Assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProductInformationLineItems', window );"><strong>Product Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">87.00%<span></span>
</td>
<td class="nump">94.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalUnitsByClassAxis=btmd_ClassAVotingUnitsMember', window );">Class A (Voting)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProductInformationLineItems', window );"><strong>Product Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_btmd_CommonUnitsVotingRightsPercentage', window );">Common units voting rights percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_btmd_CapitalizedSoftwareEstimatedUsefulLives">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Capitalized software estimated useful lives.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">btmd_CapitalizedSoftwareEstimatedUsefulLives</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>btmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_btmd_CommonUnitsVotingRightsPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Common Units Voting Rights Percentage</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">btmd_CommonUnitsVotingRightsPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>btmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_btmd_ConsecutiveTradingDays">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Consecutive trading days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">btmd_ConsecutiveTradingDays</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>btmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_btmd_ExpectedReturnsAndRefundsToCustomers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected returns and refunds to customers.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">btmd_ExpectedReturnsAndRefundsToCustomers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>btmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_btmd_MandatoryMinimumAmountForIndividualAdvance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Mandatory minimum amount for individual advance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">btmd_MandatoryMinimumAmountForIndividualAdvance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>btmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_btmd_MaximumValueOfDailyVolumeTradedThresholdPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum value of daily volume traded threshold percentage.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">btmd_MaximumValueOfDailyVolumeTradedThresholdPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>btmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_btmd_NumberOfCustomersAccountedForTenPercentOrMoreAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of customers accounted for ten percent or more accounts receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">btmd_NumberOfCustomersAccountedForTenPercentOrMoreAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>btmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_btmd_NumberOfCustomersAccountedForTenPercentOrMoreAggregateRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of customers accounted for ten percent or more aggregate revenue.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">btmd_NumberOfCustomersAccountedForTenPercentOrMoreAggregateRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>btmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_btmd_NumberOfInventoryVendors">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of Inventory Vendors</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">btmd_NumberOfInventoryVendors</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>btmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_btmd_PercentageOfCommonStockPurchasePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of common stock purchase price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">btmd_PercentageOfCommonStockPurchasePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>btmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_btmd_ProceedsFromSettlementOfSEPA">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Proceeds from settlement of SEPA.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">btmd_ProceedsFromSettlementOfSEPA</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>btmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_btmd_TerminationPeriodOfPurchaseAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Termination period of purchase agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">btmd_TerminationPeriodOfPurchaseAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>btmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalizedContractCostAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for asset recognized from cost incurred to obtain or fulfill contract with customer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 40<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126905575&amp;loc=SL49131252-203054<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalizedContractCostAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates (true false) whether accounting standards update was adopted.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 10<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128293352&amp;loc=SL126838806-209984<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 20<br> -Section 65<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=121483254&amp;loc=SL120254523-199619<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 10<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=128293352&amp;loc=SL126838806-209984<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 10<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=128293352&amp;loc=SL126838806-209984<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 20<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126986314&amp;loc=SL124402458-218513<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983759&amp;loc=SL121830611-158277<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=120154821&amp;loc=SL120154904-197079<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=120154821&amp;loc=SL120154904-197079<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983955&amp;loc=SL122642865-165497<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983955&amp;loc=SL122642865-165497<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983955&amp;loc=SL120254526-165497<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126983955&amp;loc=SL120254526-165497<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL120254519-210437<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128293352&amp;loc=SL120154346-209984<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 848<br> -SubTopic 10<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=125980421&amp;loc=SL122150809-237846<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 20<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126986314&amp;loc=SL124402458-218513<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 65<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=128092918&amp;loc=SL128093175-196984<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 65<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128092918&amp;loc=SL128093175-196984<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL126732908-238011<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983955&amp;loc=SL121967933-165497<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL120320025-210437<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126987489&amp;loc=SL124442142-165695<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 848<br> -SubTopic 10<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=125980421&amp;loc=SL125981372-237846<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983955&amp;loc=SL121967933-165497<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL120320025-210437<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126987489&amp;loc=SL124442142-165695<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 832<br> -SubTopic 10<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128342835&amp;loc=SL128342857-244232<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Date accounting standards update was adopted, in YYYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 20<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126986314&amp;loc=SL124402458-218513<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983955&amp;loc=SL122642865-165497<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 832<br> -SubTopic 10<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128342835&amp;loc=SL128342857-244232<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983955&amp;loc=SL120254526-165497<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 20<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126986314&amp;loc=SL124402458-218513<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 65<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128092918&amp;loc=SL128093175-196984<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL120320025-210437<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126987489&amp;loc=SL124442142-165695<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126987489&amp;loc=SL124442142-165695<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL120320025-210437<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=120154821&amp;loc=SL120154904-197079<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983955&amp;loc=SL122642865-165497<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983955&amp;loc=SL121967933-165497<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 848<br> -SubTopic 10<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=125980421&amp;loc=SL122150809-237846<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 10<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=128293352&amp;loc=SL126838806-209984<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 10<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=128293352&amp;loc=SL126838806-209984<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 65<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=128092918&amp;loc=SL128093175-196984<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL126732908-238011<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128293352&amp;loc=SL120154346-209984<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983759&amp;loc=SL121830611-158277<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 65<br> -Paragraph 3<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=128092918&amp;loc=SL128093175-196984<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 848<br> -SubTopic 10<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=125980421&amp;loc=SL125981372-237846<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 20<br> -Section 65<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=121483254&amp;loc=SL120254523-199619<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=120154821&amp;loc=SL120154904-197079<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983955&amp;loc=SL121967933-165497<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL120254519-210437<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126983955&amp;loc=SL120254526-165497<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 10<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128293352&amp;loc=SL126838806-209984<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates (true false) whether effect from applying amendment to accounting standards is immaterial.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=122038215&amp;loc=d3e31010-122693<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 20<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126986314&amp;loc=SL124402458-218513<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (e)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983759&amp;loc=SL121830611-158277<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskPercentage1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6351-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13531-108611<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13537-108611<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6404-108592<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskPercentage1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130532-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130532-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130531-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of discretionary contributions made by an employer to a defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage employer matches of the employee's percentage contribution matched.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of write-downs for impairments recognized during the period for long lived assets held for use (including those held for disposal by means other than sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2921-110230<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126905981&amp;loc=d3e2420-110228<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfLongLivedAssetsHeldForUse</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LimitedPartnersCapitalAccountDistributionAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The total amount of distributions to limited partners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 5<br> -Subparagraph (SAB TOPIC 4.F)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187171-122770<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LimitedPartnersCapitalAccountDistributionAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8672-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfReportableSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8672-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfReportableSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProductInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProductInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRemainingPerformanceObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of transaction price allocated to performance obligation that has not been recognized as revenue.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130556-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRemainingPerformanceObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SalesCommissionsAndFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Primarily represents commissions incurred in the period based upon the sale by commissioned employees or third parties of the entity's goods or services, and fees for sales assistance or product enhancements performed by third parties (such as a distributor or value added reseller).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SalesCommissionsAndFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=btmd_StandbyEquityPurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=btmd_StandbyEquityPurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=btmd_YorkvilleAdvisorsGlobalLpMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=btmd_YorkvilleAdvisorsGlobalLpMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201912Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201912Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanNameAxis=btmd_FourZeroOneKPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanNameAxis=btmd_FourZeroOneKPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CreditAvailabilityConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CreditAvailabilityConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_LiabilitiesTotalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_LiabilitiesTotalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_btmd_NatureOfCustomerAxis=btmd_BioteMethodCustomerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">btmd_NatureOfCustomerAxis=btmd_BioteMethodCustomerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_btmd_SourceOfRevenueAxis=btmd_ServiceRevenueMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">btmd_SourceOfRevenueAxis=btmd_ServiceRevenueMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_btmd_SourceOfServiceRevenueAxis=btmd_TrainingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">btmd_SourceOfServiceRevenueAxis=btmd_TrainingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_btmd_SourceOfServiceRevenueAxis=btmd_ContractTermServicesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">btmd_SourceOfServiceRevenueAxis=btmd_ContractTermServicesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_btmd_SourceOfRevenueAxis=btmd_ProductRevenueMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">btmd_SourceOfRevenueAxis=btmd_ProductRevenueMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_btmd_SourceOfServiceRevenueAxis=btmd_PalletProceduresMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">btmd_SourceOfServiceRevenueAxis=btmd_PalletProceduresMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=btmd_InventoryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=btmd_InventoryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_SupplierConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=us-gaap_SupplierConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AssetsTotalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AssetsTotalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalUnitsByClassAxis=btmd_ClassAVotingUnitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalUnitsByClassAxis=btmd_ClassAVotingUnitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140468221027184">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Summary of Rollforward of the Allowance for Doubtful Accounts (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent', window );">Beginning balance</a></td>
<td class="num">$ (1,406)<span></span>
</td>
<td class="num">$ (1,157)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProvisionForDoubtfulAccounts', window );">Provisions charged to operating results</a></td>
<td class="nump">155<span></span>
</td>
<td class="num">(240)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_btmd_ProvisonForDoubfulDebtAcoountsWriteOffAndRecoveries', window );">Account write-off and recoveries</a></td>
<td class="nump">277<span></span>
</td>
<td class="num">(9)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent', window );">Ending balance</a></td>
<td class="num">$ (974)<span></span>
</td>
<td class="num">$ (1,406)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_btmd_ProvisonForDoubfulDebtAcoountsWriteOffAndRecoveries">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Provision for doubtful debt accounts write off and recoveries.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">btmd_ProvisonForDoubfulDebtAcoountsWriteOffAndRecoveries</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>btmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of allowance for credit loss on accounts receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=123577603&amp;loc=d3e5074-111524<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124255206&amp;loc=SL82895884-210446<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProvisionForDoubtfulAccounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (reversal of expense) for expected credit loss on accounts receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124255953&amp;loc=SL82919249-210447<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProvisionForDoubtfulAccounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140468231145840">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Summary of Total Other Current Assets (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract', window );"><strong>Prepaid Expense and Other Assets, Current [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseCurrent', window );">Prepaid expenses</a></td>
<td class="nump">$ 2,939<span></span>
</td>
<td class="nump">$ 847<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdvancesOnInventoryPurchases', window );">Advances</a></td>
<td class="nump">877<span></span>
</td>
<td class="nump">685<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredOfferingCosts', window );">Capitalized transaction costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,941<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Total other current assets</a></td>
<td class="nump">$ 3,816<span></span>
</td>
<td class="nump">$ 5,473<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdvancesOnInventoryPurchases">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value of capitalized payments made in advance for inventory that is expected to be received within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdvancesOnInventoryPurchases</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredOfferingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Specific incremental costs directly attributable to a proposed or actual offering of securities which are deferred at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.A)<br> -URI https://asc.fasb.org/extlink&amp;oid=122040515&amp;loc=d3e105025-122735<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredOfferingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6387103&amp;loc=d3e6435-108320<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 05<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126905020&amp;loc=d3e5879-108316<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140468225042960">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Summary of Estimated Useful Lives of Property and Equipment (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=btmd_TrocarsMember', window );">Trocars</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated Useful Life (in years)</a></td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold Improvements</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives', window );">Estimated Useful Life</a></td>
<td class="text">Shorter of lease term or useful life of the improvement<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember', window );">Office Equipment</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated Useful Life (in years)</a></td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareDevelopmentMember', window );">Computer software | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated Useful Life (in years)</a></td>
<td class="text">3 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareDevelopmentMember', window );">Computer software | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated Useful Life (in years)</a></td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture and Fixtures | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated Useful Life (in years)</a></td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture and Fixtures | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated Useful Life (in years)</a></td>
<td class="text">7 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember', window );">Computer Equipment | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated Useful Life (in years)</a></td>
<td class="text">3 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember', window );">Computer Equipment | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated Useful Life (in years)</a></td>
<td class="text">5 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Describes the periods of time over which an entity anticipates to receive utility from its property, plant and equipment (that is, the periods of time over which an entity allocates the initial cost of its property, plant and equipment).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 35<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126905813&amp;loc=d3e1205-110223<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=btmd_TrocarsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=btmd_TrocarsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareDevelopmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareDevelopmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140468225090560">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Summary of Members' Equity Units Issued and Outstanding (Details)<br></strong></div></th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalUnitLineItems', window );"><strong>Capital Unit [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonUnitIssued', window );">Common units, issued</a></td>
<td class="nump">1,013,197<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonUnitOutstanding', window );">Common units, outstanding</a></td>
<td class="nump">982,800<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalUnitsByClassAxis=btmd_ClassAVotingUnitsMember', window );">Class A (Voting)</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalUnitLineItems', window );"><strong>Capital Unit [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonUnitIssued', window );">Common units, issued</a></td>
<td class="nump">16,721<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonUnitOutstanding', window );">Common units, outstanding</a></td>
<td class="nump">16,721<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalUnitsByClassAxis=btmd_ClassAaNonVotingUnitsMember', window );">Class AA (Non-voting)</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalUnitLineItems', window );"><strong>Capital Unit [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonUnitIssued', window );">Common units, issued</a></td>
<td class="nump">903,079<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonUnitOutstanding', window );">Common units, outstanding</a></td>
<td class="nump">903,079<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalUnitsByClassAxis=btmd_ClassAaaNonVotingUnitsMember', window );">Class AAA (Non-voting)</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalUnitLineItems', window );"><strong>Capital Unit [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonUnitIssued', window );">Common units, issued</a></td>
<td class="nump">60,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonUnitOutstanding', window );">Common units, outstanding</a></td>
<td class="nump">60,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalUnitsByClassAxis=btmd_ClassAaaaNonVotingIncentiveUnitsMember', window );">Class AAAA (Non-voting incentive units)</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalUnitLineItems', window );"><strong>Capital Unit [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonUnitIssued', window );">Common units, issued</a></td>
<td class="nump">33,397<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonUnitOutstanding', window );">Common units, outstanding</a></td>
<td class="nump">3,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalUnitLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalUnitLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonUnitIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of common units issued of limited liability company (LLC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonUnitIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonUnitOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of common units of ownership outstanding of a limited liability company (LLC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonUnitOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalUnitsByClassAxis=btmd_ClassAVotingUnitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalUnitsByClassAxis=btmd_ClassAVotingUnitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalUnitsByClassAxis=btmd_ClassAaNonVotingUnitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalUnitsByClassAxis=btmd_ClassAaNonVotingUnitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalUnitsByClassAxis=btmd_ClassAaaNonVotingUnitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalUnitsByClassAxis=btmd_ClassAaaNonVotingUnitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalUnitsByClassAxis=btmd_ClassAaaaNonVotingIncentiveUnitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalUnitsByClassAxis=btmd_ClassAaaaNonVotingIncentiveUnitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140468222439488">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Summary of Common Stock Issued and Outstanding (Details) - shares<br></strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="nump">69,808,711<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="nump">58,221,211<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember', window );">Class A Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="nump">11,242,887<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="nump">9,655,387<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassBMember', window );">Class B Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=btmd_ClassVCommonStockMember', window );">Class V Voting Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="nump">58,565,824<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="nump">48,565,824<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassBMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassBMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=btmd_ClassVCommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=btmd_ClassVCommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140468226495232">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Business Combination - Additional Information (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 13, 2021</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>May 26, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=btmd_BioteManagementLlcMember', window );">Biote Units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferred1', window );">Business combination consideration transferred</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesGross', window );">Business combination, consideration in cash</a></td>
<td class="nump">$ 137,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromPreviousAcquisition', window );">Received aggregate proceeds amount</a></td>
<td class="nump">$ 125,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidatedEntitiesAxis=btmd_HaymakeriiiMember', window );">Haymaker III | Other Business Combination</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_btmd_IncomeTaxPercentageOfFederalStateAndLocalIncomeTaxSavings', window );">Income tax percentage of federal state and local income tax savings</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">85.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionDescriptionOfAcquiredEntity', window );">Business acquisition, description of acquired entity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">The TRA provides that, in the event that (i) the Company exercises its early termination rights under the TRA, (ii) certain changes of control occur (as described in the TRA), (iii) the Company, in certain circumstances, fails to make a payment required to be made pursuant to the TRA by the applicable final payment date, which non-payment continues for 30 days following such final payment date or (iv) the Company materially breaches any of its material obligations under the TRA, which breach continues without cure for 30 days following receipt by the Company of written notice thereof (unless, in the case of clauses (iii) and (iv), certain liquidity exceptions apply) the Company&#8217;s obligations under the TRA will accelerate and the Company will be required to make a lump-sum cash payment to the applicable parties to the TRA equal to the present value of all forecasted future payments that would have otherwise been made under the TRA, which lump-sum payment would be based on certain assumptions, including those relating to our future taxable income. <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_btmd_TaxReceivableAgreementLiability', window );">Liability recorded related to tax receivable agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=btmd_DebtCommitmentLetterMember', window );">Debt Commitment Letter | Haymaker III | Senior Secured Revolving Credit Facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Line of credit facility, maximum borrowing capacity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=btmd_DebtCommitmentLetterMember', window );">Debt Commitment Letter | Haymaker III | Senior Secured Term Loan A Facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt face amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 125,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember', window );">Class A Common Stock | Haymaker</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionSharePrice', window );">Business acquisition, share price</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued', window );">Business combination number of share issued</a></td>
<td class="nump">30,525,729<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember', window );">Class A Common Stock | Biote Units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferred1', window );">Business combination consideration transferred</a></td>
<td class="nump">$ 9,161,771<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesGross', window );">Business combination, consideration in cash</a></td>
<td class="nump">$ 305,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember', window );">Class A Common Stock | Haymaker III | Other Business Combination</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_btmd_CommonStockTransfersThresholdTradingDays', window );">Common Stock Transfers Threshold Trading Days</a></td>
<td class="text">30 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassBMember', window );">Class B Common Stock | Haymaker</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionSharePrice', window );">Business acquisition, share price</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=btmd_ClassVCommonStockMember', window );">Class V Voting Stock | Haymaker</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionSharePrice', window );">Business acquisition, share price</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued', window );">Business combination number of share issued</a></td>
<td class="nump">58,565,824<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=btmd_MemberEarnOutUnitsMember', window );">Member Earn Out Units | Haymaker III | Business Combination</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued', window );">Business combination number of share issued</a></td>
<td class="nump">10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=btmd_EarnoutVotingSharesMember', window );">Earnout Voting Shares | Haymaker III | Business Combination</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable', window );">Business combination, consideration through equity value</a></td>
<td class="nump">$ 10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=btmd_SponsorEarnOutSharesMember', window );">Sponsor Earn Out Shares | Haymaker III | Business Combination</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued', window );">Business combination number of share issued</a></td>
<td class="nump">1,587,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_btmd_CommonStockTransfersThresholdTradingDays">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Common stock transfers threshold trading days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">btmd_CommonStockTransfersThresholdTradingDays</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>btmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_btmd_IncomeTaxPercentageOfFederalStateAndLocalIncomeTaxSavings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Income tax percentage of federal state and local income tax savings.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">btmd_IncomeTaxPercentageOfFederalStateAndLocalIncomeTaxSavings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>btmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_btmd_TaxReceivableAgreementLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tax receivable agreement liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">btmd_TaxReceivableAgreementLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>btmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionDescriptionOfAcquiredEntity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>With respect to a business combination completed during the period, this element provides a description of the business, other than the name, which may include the industry, size, products and other important information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1392-128463<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionDescriptionOfAcquiredEntity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of equity interests issued or issuable to acquire entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126975305&amp;loc=d3e6927-128479<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionSharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks paid or offered to be paid in a business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionSharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationConsiderationTransferred1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 30<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126966197&amp;loc=d3e6613-128477<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126975305&amp;loc=d3e6927-128479<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 30<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126966197&amp;loc=d3e6578-128477<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationConsiderationTransferred1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity interests of the acquirer, including instruments or interests issued or issuable in consideration for the business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 30<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126966197&amp;loc=d3e6613-128477<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 30<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126966197&amp;loc=d3e6578-128477<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28551-108399<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429444&amp;loc=SL124452920-239629<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(b),22(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireBusinessesGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126975305&amp;loc=d3e6927-128479<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireBusinessesGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromPreviousAcquisition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash inflow representing an adjustment to the purchase price of a previous acquisition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromPreviousAcquisition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=btmd_BioteManagementLlcMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=btmd_BioteManagementLlcMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidatedEntitiesAxis=btmd_HaymakeriiiMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidatedEntitiesAxis=btmd_HaymakeriiiMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=btmd_OtherBusinessCombinationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=btmd_OtherBusinessCombinationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=btmd_DebtCommitmentLetterMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=btmd_DebtCommitmentLetterMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=btmd_SeniorSecuredRevolvingCreditFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=btmd_SeniorSecuredRevolvingCreditFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=btmd_SeniorSecuredTermLoanAFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=btmd_SeniorSecuredTermLoanAFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=btmd_HaymakerAcquisitionCorpIiiMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=btmd_HaymakerAcquisitionCorpIiiMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassBMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassBMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=btmd_ClassVCommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=btmd_ClassVCommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=btmd_MemberEarnOutUnitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=btmd_MemberEarnOutUnitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=btmd_BusinessCombinationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=btmd_BusinessCombinationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=btmd_EarnoutVotingSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=btmd_EarnoutVotingSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=btmd_SponsorEarnOutSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=btmd_SponsorEarnOutSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140468222468928">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue Recognition - Schedule of Revenues Recognized for Each Revenue Stream (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">$ 164,957<span></span>
</td>
<td class="nump">$ 139,396<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=btmd_PelletProceduresProductRevenueMember', window );">Pellet Procedures Product Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">128,952<span></span>
</td>
<td class="nump">109,465<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=btmd_DietarySupplementsMember', window );">Dietary Supplements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">32,412<span></span>
</td>
<td class="nump">27,241<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=btmd_DisposableTrocarsProductRevenueMember', window );">Disposable Trocars Product Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">1,698<span></span>
</td>
<td class="nump">860<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=btmd_ShippingFeesProductRevenueMember', window );">Shipping Fees Product Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">71<span></span>
</td>
<td class="nump">32<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=btmd_ProductRevenueMember', window );">Product Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">163,133<span></span>
</td>
<td class="nump">137,598<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=btmd_TrainingServiceRevenueMember', window );">Training Service Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">973<span></span>
</td>
<td class="nump">859<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=btmd_ContractTermServicesRevenueMember', window );">Contract-Term Services Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">851<span></span>
</td>
<td class="nump">939<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=btmd_ServiceRevenueMember', window );">Service Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">$ 1,824<span></span>
</td>
<td class="nump">$ 1,798<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI https://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=btmd_PelletProceduresProductRevenueMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=btmd_PelletProceduresProductRevenueMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=btmd_DietarySupplementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=btmd_DietarySupplementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=btmd_DisposableTrocarsProductRevenueMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=btmd_DisposableTrocarsProductRevenueMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=btmd_ShippingFeesProductRevenueMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=btmd_ShippingFeesProductRevenueMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=btmd_ProductRevenueMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=btmd_ProductRevenueMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=btmd_TrainingServiceRevenueMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=btmd_TrainingServiceRevenueMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=btmd_ContractTermServicesRevenueMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=btmd_ContractTermServicesRevenueMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=btmd_ServiceRevenueMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=btmd_ServiceRevenueMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140468226471936">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue Recognition - Schedule of Revenues Recognized by Geographic Region (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">$ 164,957<span></span>
</td>
<td class="nump">$ 139,396<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=btmd_ProductRevenueMember', window );">Product Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">163,133<span></span>
</td>
<td class="nump">137,598<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=btmd_ProductRevenueMember', window );">Product Revenue | United States</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">162,742<span></span>
</td>
<td class="nump">137,349<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=btmd_ProductRevenueMember', window );">Product Revenue | All Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">391<span></span>
</td>
<td class="nump">249<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=btmd_ServiceRevenueMember', window );">Service Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">1,824<span></span>
</td>
<td class="nump">1,798<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=btmd_ServiceRevenueMember', window );">Service Revenue | United States</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">1,781<span></span>
</td>
<td class="nump">$ 1,798<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=btmd_ServiceRevenueMember', window );">Service Revenue | All Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">$ 43<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI https://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=btmd_ProductRevenueMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=btmd_ProductRevenueMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=btmd_AllOtherCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=btmd_AllOtherCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=btmd_ServiceRevenueMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=btmd_ServiceRevenueMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140468221106288">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue Recognition - Summary of Significant Changes in Contract Liability Balances (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerDurationAxis=us-gaap_ShortTermContractWithCustomerMember', window );">Deferred Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized', window );">Revenue recognized that was included in the contract liability balance at the beginning of the period</a></td>
<td class="num">$ (1,710)<span></span>
</td>
<td class="num">$ (2,048)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_btmd_ContractWithCustomerLiabilityIncreasesDueToCashReceivedExcludingAmountsRecognizedAsRevenue', window );">Increases due to cash received, excluding amounts recognized as revenue during the period</a></td>
<td class="nump">1,342<span></span>
</td>
<td class="nump">1,022<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_btmd_ContractWithCustomerLiabilityTransfersBetweenCurrentAndNonCurrentLiabilitiesDueToExpectedRevenueRecognitionPeriod', window );">Transfers between current and non-current liabilities due to the expected revenue recognition period</a></td>
<td class="nump">460<span></span>
</td>
<td class="nump">697<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability', window );">Total increase(decrease) in contract liabilities</a></td>
<td class="nump">92<span></span>
</td>
<td class="num">(329)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerDurationAxis=us-gaap_LongTermContractWithCustomerMember', window );">Deferred Revenue, Long-term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_btmd_ContractWithCustomerLiabilityIncreasesDueToCashReceivedExcludingAmountsRecognizedAsRevenue', window );">Increases due to cash received, excluding amounts recognized as revenue during the period</a></td>
<td class="nump">760<span></span>
</td>
<td class="nump">652<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_btmd_ContractWithCustomerLiabilityTransfersBetweenCurrentAndNonCurrentLiabilitiesDueToExpectedRevenueRecognitionPeriod', window );">Transfers between current and non-current liabilities due to the expected revenue recognition period</a></td>
<td class="num">(460)<span></span>
</td>
<td class="num">(697)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability', window );">Total increase(decrease) in contract liabilities</a></td>
<td class="nump">$ 300<span></span>
</td>
<td class="num">$ (45)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_btmd_ContractWithCustomerLiabilityIncreasesDueToCashReceivedExcludingAmountsRecognizedAsRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contract with customer liability, increases due to cash received, excluding amounts recognized as revenue.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">btmd_ContractWithCustomerLiabilityIncreasesDueToCashReceivedExcludingAmountsRecognizedAsRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>btmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_btmd_ContractWithCustomerLiabilityTransfersBetweenCurrentAndNonCurrentLiabilitiesDueToExpectedRevenueRecognitionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contract with customer liability, transfers between current and non-current liabilities due to expected revenue recognition period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">btmd_ContractWithCustomerLiabilityTransfersBetweenCurrentAndNonCurrentLiabilitiesDueToExpectedRevenueRecognitionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>btmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityRevenueRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 310<br> -Section 45<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126938201&amp;loc=d3e55415-109406<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerDurationAxis=us-gaap_ShortTermContractWithCustomerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerDurationAxis=us-gaap_ShortTermContractWithCustomerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerDurationAxis=us-gaap_LongTermContractWithCustomerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerDurationAxis=us-gaap_LongTermContractWithCustomerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140468221008608">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Revenue Recognition - Summary of Consideration Allocated to Performance Obligations (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Contract with customers liability current</a></td>
<td class="nump">$ 1,965<span></span>
</td>
<td class="nump">$ 1,705<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityNoncurrent', window );">Deferred revenue, net of current portion</a></td>
<td class="nump">926<span></span>
</td>
<td class="nump">802<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=btmd_UnsatisfiedTrainingObligationsMember', window );">Unsatisfied Training Obligations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Contract with customers liability current</a></td>
<td class="nump">104<span></span>
</td>
<td class="nump">67<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=btmd_UnsatisfiedContractTermServicesMember', window );">Unsatisfied Contract-term Services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Contract with customers liability current</a></td>
<td class="nump">1,028<span></span>
</td>
<td class="nump">849<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityNoncurrent', window );">Deferred revenue, net of current portion</a></td>
<td class="nump">627<span></span>
</td>
<td class="nump">544<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Total Deferred Revenue</a></td>
<td class="nump">1,655<span></span>
</td>
<td class="nump">1,393<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=btmd_UnsatisfiedPelletProceduresMember', window );">Unsatisfied Pellet Procedures</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Contract with customers liability current</a></td>
<td class="nump">833<span></span>
</td>
<td class="nump">789<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityNoncurrent', window );">Deferred revenue, net of current portion</a></td>
<td class="nump">299<span></span>
</td>
<td class="nump">258<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Total Deferred Revenue</a></td>
<td class="nump">$ 1,132<span></span>
</td>
<td class="nump">$ 1,047<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130549-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130532-203044<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130532-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130532-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130531-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=btmd_UnsatisfiedTrainingObligationsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=btmd_UnsatisfiedTrainingObligationsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=btmd_UnsatisfiedContractTermServicesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=btmd_UnsatisfiedContractTermServicesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=btmd_UnsatisfiedPelletProceduresMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=btmd_UnsatisfiedPelletProceduresMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140468228443872">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue Recognition - Additional Information (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue from Contract with Customer [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_btmd_ReductionOfRevenue', window );">Reduction of revenue</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_btmd_ReductionOfRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Reduction of revenue.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">btmd_ReductionOfRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>btmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140468225718896">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Inventory, Net - Schedule of Inventory, Net (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryLineItems', window );"><strong>Inventory [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Net Inventory</a></td>
<td class="nump">$ 11,183<span></span>
</td>
<td class="nump">$ 9,615<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Product | Pellets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryLineItems', window );"><strong>Inventory [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryGross', window );">Inventory, gross</a></td>
<td class="nump">6,213<span></span>
</td>
<td class="nump">6,318<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryAdjustments', window );">Obsolete and expired allowance</a></td>
<td class="num">(1,298)<span></span>
</td>
<td class="num">(1,356)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Net Inventory</a></td>
<td class="nump">4,915<span></span>
</td>
<td class="nump">4,962<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Product | Dietary Supplements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryLineItems', window );"><strong>Inventory [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryGross', window );">Inventory, gross</a></td>
<td class="nump">6,283<span></span>
</td>
<td class="nump">4,849<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryAdjustments', window );">Obsolete and expired allowance</a></td>
<td class="num">(15)<span></span>
</td>
<td class="num">(196)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Net Inventory</a></td>
<td class="nump">$ 6,268<span></span>
</td>
<td class="nump">$ 4,653<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of inventory reserves for last-in first-out (LIFO) and other inventory valuation methods.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=116847112&amp;loc=d3e4492-108314<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross amount, as of the balance sheet date, of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PublicUtilitiesInventoryAxis=btmd_PelletsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PublicUtilitiesInventoryAxis=btmd_PelletsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PublicUtilitiesInventoryAxis=btmd_DietarySupplementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PublicUtilitiesInventoryAxis=btmd_DietarySupplementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140468220213520">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Property and Equipment, Net - Schedule of Property and Equipment, Net (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">$ 6,314<span></span>
</td>
<td class="nump">$ 5,981<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Less: Accumulated depreciation</a></td>
<td class="num">(4,810)<span></span>
</td>
<td class="num">(3,646)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">1,504<span></span>
</td>
<td class="nump">2,335<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=btmd_TrocarsMember', window );">Trocars</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">4,645<span></span>
</td>
<td class="nump">4,448<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold Improvements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">1,028<span></span>
</td>
<td class="nump">254<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember', window );">Office Equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">238<span></span>
</td>
<td class="nump">223<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareAndSoftwareDevelopmentCostsMember', window );">Computer Software</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">140<span></span>
</td>
<td class="nump">135<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture and Fixtures</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">161<span></span>
</td>
<td class="nump">119<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember', window );">Computer Equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">$ 102<span></span>
</td>
<td class="nump">97<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember', window );">Construction in Progress</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 705<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=btmd_TrocarsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=btmd_TrocarsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareAndSoftwareDevelopmentCostsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareAndSoftwareDevelopmentCostsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140468231152800">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment, Net - Additional Information (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation expense</a></td>
<td class="nump">$ 1,164<span></span>
</td>
<td class="nump">$ 713<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140468231258464">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Capitalized Software, Net - Summary of Capitalized Software, Net (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentAbstract', window );"><strong>Research and Development [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_btmd_CapitalizedSoftwareWebsiteCosts', window );">Website costs</a></td>
<td class="nump">$ 4,142<span></span>
</td>
<td class="nump">$ 3,571<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_btmd_CapitalizedSoftwareDevelopmentInProcess', window );">Development in Process</a></td>
<td class="nump">3,277<span></span>
</td>
<td class="nump">2,294<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalizedComputerSoftwareAccumulatedAmortization', window );">Less: Accumulated amortization</a></td>
<td class="num">(2,346)<span></span>
</td>
<td class="num">(1,311)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalizedComputerSoftwareNet', window );">Capitalized software, net</a></td>
<td class="nump">$ 5,073<span></span>
</td>
<td class="nump">$ 4,554<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_btmd_CapitalizedSoftwareDevelopmentInProcess">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Capitalized software, development in process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">btmd_CapitalizedSoftwareDevelopmentInProcess</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>btmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_btmd_CapitalizedSoftwareWebsiteCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Capitalized software, website costs</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">btmd_CapitalizedSoftwareWebsiteCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>btmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalizedComputerSoftwareAccumulatedAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For each balance sheet presented, the amount of accumulated amortization for capitalized computer software costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalizedComputerSoftwareAccumulatedAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalizedComputerSoftwareNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The carrying amount of capitalized computer software costs net of accumulated amortization as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalizedComputerSoftwareNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140468231091264">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Capitalized Software, Net - Additional Information (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentAbstract', window );"><strong>Research and Development [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalizedComputerSoftwareAmortization1', window );">Amortization expense</a></td>
<td class="nump">$ 1,035<span></span>
</td>
<td class="nump">$ 687<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalizedComputerSoftwareAmortization1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for amortization of capitalized computer software costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128487-111756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalizedComputerSoftwareAmortization1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140468225771120">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Accrued Expenses - Schedule of Accrued Expenses (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedProfessionalFeesCurrent', window );">Accrued professional fees</a></td>
<td class="nump">$ 354<span></span>
</td>
<td class="nump">$ 1,192<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Accrued employee related costs</a></td>
<td class="nump">4,221<span></span>
</td>
<td class="nump">2,213<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_btmd_AccruedMerchantFeesCurrent', window );">Accrued merchant fees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">184<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestPayableCurrent', window );">Accrued interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">27<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_btmd_LegalAccrualCurrent', window );">Legal accrual</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,302<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Other</a></td>
<td class="nump">1,699<span></span>
</td>
<td class="nump">1,093<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses</a></td>
<td class="nump">$ 6,274<span></span>
</td>
<td class="nump">$ 6,011<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_btmd_AccruedMerchantFeesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued merchant fees current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">btmd_AccruedMerchantFeesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>btmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_btmd_LegalAccrualCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Legal accrual current</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">btmd_LegalAccrualCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>btmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedProfessionalFeesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedProfessionalFeesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of [accrued] interest payable on all forms of debt, including trade payables, that has been incurred and is unpaid. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140468220512080">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Long-Term Debt - Additional Information (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>May 26, 2022</div></th>
<th class="th"><div>May 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Outstanding principal amount of term loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 121,875,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCosts', window );">Amortization expense related to debt issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">589,000<span></span>
</td>
<td class="nump">$ 222,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Loss from extinguishment of debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (445,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_LineOfCreditMember', window );">Line of Credit | Bank of America Term Loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Term loan face amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateTerms', window );">Debt instrument interest rate, terms</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">LIBOR + 300 Basis Points (BPS)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Outstanding principal amount of term loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">37,500,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Line of credit facility, maximum borrowing capacity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_btmd_LineOfCreditFacilityMaturityMonthAndYear', window );">Line of credit facility maturity month and year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2024-05<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCredit', window );">Line of credit drawn</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpenseDebt', window );">Interest expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,108,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCosts', window );">Amortization expense related to debt issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">91,000<span></span>
</td>
<td class="nump">222,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Loss from extinguishment of debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (445,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_LineOfCreditMember', window );">Line of Credit | Truist Term Loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Term loan face amount</a></td>
<td class="nump">$ 125,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.92%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentPeriodicPaymentPrincipal', window );">Periodic payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,563,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFrequencyOfPeriodicPayment', window );">Frequency of periodic payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">quarterly<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Outstanding principal amount of term loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 121,875,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturityDate', window );">Term loan maturity date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">May 26,  2027<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromLinesOfCredit', window );">Proceeds from line of credit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCovenantDescription', window );">Covenant description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">In addition, the Credit Agreement is subject to (i) a maximum total net leverage ratio and (ii) a minimum fixed charge coverage ratio. The Company must maintain a total net leverage ratio of less than or equal to (i) 4.25:1.00, with respect to the fiscal quarter ending September 30, 2022 through and including the fiscal quarter ending March 31, 2023, (ii) 4.00:1.00, with respect to the fiscal quarter ending June 30, 2023 through and including March 31, 2024, and (iii) 3.75:1.00 thereafter. Beginning with the third fiscal quarter of 2022, the Company must not permit the Consolidated Fixed Charge Coverage Ratio to be less than 1.25:1.00. Both financial covenants are tested quarterly.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCovenantCompliance', window );">Covenant compliance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">The Company was in compliance with all required covenants associated with the Credit Agreement as of December 31, 2022.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtRelatedCommitmentFeesAndDebtIssuanceCosts', window );">Company incurred lender's fees and related attorney's fees</a></td>
<td class="nump">$ 4,036,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCosts', window );">Amortization expense related to debt issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 498,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_LineOfCreditMember', window );">Line of Credit | Truist Term Loan | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_btmd_FixedChargeCoverageRatio', window );">Fixed charge coverage ratio</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_LineOfCreditMember', window );">Line of Credit | Truist Term Loan | Leverage Ratio with Respect to September 30, 2022 through March 31, 2023 | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RatioOfIndebtednessToNetCapital1', window );">Net leverage ratio</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_LineOfCreditMember', window );">Line of Credit | Truist Term Loan | Leverage Ratio with Respect to June 30, 2023 through March 31, 2024 | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RatioOfIndebtednessToNetCapital1', window );">Net leverage ratio</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_LineOfCreditMember', window );">Line of Credit | Truist Term Loan | Leverage Ratio, Thereafter | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RatioOfIndebtednessToNetCapital1', window );">Net leverage ratio</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.75<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_LineOfCreditMember', window );">Line of Credit | Truist Term Loan | SOFR Rate | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Debt instrument, applicable margin rate</a></td>
<td class="nump">2.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_LineOfCreditMember', window );">Line of Credit | Truist Term Loan | SOFR Rate | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Debt instrument, applicable margin rate</a></td>
<td class="nump">2.75%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_LineOfCreditMember', window );">Line of Credit | Truist Term Loan | Base Rate | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Debt instrument, applicable margin rate</a></td>
<td class="nump">1.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_LineOfCreditMember', window );">Line of Credit | Truist Term Loan | Base Rate | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Debt instrument, applicable margin rate</a></td>
<td class="nump">1.75%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_LineOfCreditMember', window );">Line of Credit | Bank of America Term Loan and Truist Term Loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCosts', window );">Amortization expense related to debt issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 589,000<span></span>
</td>
<td class="nump">$ 222,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember', window );">Revolving Credit Facility | Truist Term Loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Line of credit facility, maximum borrowing capacity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_btmd_FixedChargeCoverageRatio">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>fixed charge coverage ratio.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">btmd_FixedChargeCoverageRatio</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>btmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_btmd_LineOfCreditFacilityMaturityMonthAndYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line of credit facility maturity month and year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">btmd_LineOfCreditFacilityMaturityMonthAndYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>btmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearMonthItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfFinancingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495355-112611<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfFinancingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage points added to the reference rate to compute the variable rate on the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentBasisSpreadOnVariableRate1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentCovenantCompliance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>States whether the entity was in compliance with the debt covenants throughout the reporting period, and describes facts and circumstances of any compliance failure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 470<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=123599511&amp;loc=d3e64711-112823<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentCovenantCompliance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentCovenantDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of minimum financial levels (for example, tangible net worth and working capital) and achievement of certain financial ratios (for example, working capital ratio and debt service coverage ratio), and adherence to certain clauses which generally require or restrict certain actions (for example, entering into a debt arrangement with equal or greater seniority, and selling or discontinuing a certain business segment or material subsidiary) to be in compliance with the covenant clauses of the debt agreement. May also include a discussion of the adverse consequences that would result if the entity violates or fails to satisfy the covenants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 470<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=123599511&amp;loc=d3e64711-112823<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentCovenantDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28551-108399<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429444&amp;loc=SL124452920-239629<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFrequencyOfPeriodicPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of the frequency of periodic payments (monthly, quarterly, annual).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 470<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123599511&amp;loc=d3e64711-112823<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFrequencyOfPeriodicPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6036836-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28551-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429444&amp;loc=SL124452920-239629<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateEffectivePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateTerms">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of the interest rate as being fixed or variable, and, if variable, identification of the index or rate on which the interest rate is based and the number of points or percentage added to that index or rate to set the rate, and other pertinent information, such as frequency of rate resets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateTerms</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentPeriodicPaymentPrincipal">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the required periodic payments applied to principal.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentPeriodicPaymentPrincipal</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtRelatedCommitmentFeesAndDebtIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the charge against earnings during the period for commitment fees and debt issuance expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtRelatedCommitmentFeesAndDebtIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126972273&amp;loc=d3e12355-112629<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126972273&amp;loc=d3e12317-112629<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense for debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6036836-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69F<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495745-112612<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69E<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495743-112612<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495355-112611<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The carrying value as of the balance sheet date of the current and noncurrent portions of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(b),22(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031897-161870<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495340-112611<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturityDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maturity date of long-term debt, in YYYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturityDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromLinesOfCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from contractual arrangement with the lender, including but not limited to, letter of credit, standby letter of credit and revolving credit arrangements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(f))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromLinesOfCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RatioOfIndebtednessToNetCapital1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indebtedness divided by net capital.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RatioOfIndebtednessToNetCapital1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=us-gaap_LineOfCreditMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=us-gaap_LineOfCreditMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=btmd_BankOfAmericaTermLoanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=btmd_BankOfAmericaTermLoanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=btmd_TruistTermLoanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=btmd_TruistTermLoanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentRedemptionPeriodAxis=us-gaap_DebtInstrumentRedemptionPeriodOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentRedemptionPeriodAxis=us-gaap_DebtInstrumentRedemptionPeriodOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentRedemptionPeriodAxis=us-gaap_DebtInstrumentRedemptionPeriodTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentRedemptionPeriodAxis=us-gaap_DebtInstrumentRedemptionPeriodTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentRedemptionPeriodAxis=us-gaap_DebtInstrumentRedemptionPeriodThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentRedemptionPeriodAxis=us-gaap_DebtInstrumentRedemptionPeriodThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableRateAxis=us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableRateAxis=us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableRateAxis=us-gaap_BaseRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableRateAxis=us-gaap_BaseRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=btmd_BankOfAmericaTermLoanAndTruistTermLoanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=btmd_BankOfAmericaTermLoanAndTruistTermLoanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140468225774832">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Long-Term Debt - Schedule of Outstanding Debt (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Term loan</a></td>
<td class="nump">$ 121,875<span></span>
</td>
<td class="nump">$ 37,500<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_btmd_TeamLoanCurrentPortionBeforeUnamortizedDebtIssuanceCosts', window );">Less: Current portion</a></td>
<td class="num">(6,250)<span></span>
</td>
<td class="num">(5,000)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_btmd_TeamLoanNonCurrentPortionBeforeUnamortizedDebtIssuanceCosts', window );">Team loan non-current portion gross</a></td>
<td class="nump">115,625<span></span>
</td>
<td class="nump">32,500<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredFinanceCostsNet', window );">Less: unamortized deferred financing costs</a></td>
<td class="num">(3,539)<span></span>
</td>
<td class="num">(537)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Term loan, net of current portion</a></td>
<td class="nump">$ 112,086<span></span>
</td>
<td class="nump">$ 31,963<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_btmd_TeamLoanCurrentPortionBeforeUnamortizedDebtIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Team loan current portion before unamortized debt issuance costs</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">btmd_TeamLoanCurrentPortionBeforeUnamortizedDebtIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>btmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_btmd_TeamLoanNonCurrentPortionBeforeUnamortizedDebtIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Team loan non-current portion before unamortized debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">btmd_TeamLoanNonCurrentPortionBeforeUnamortizedDebtIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>btmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentCarryingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031897-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentCarryingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFinanceCostsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495340-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFinanceCostsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding unamortized premium (discount) and debt issuance cost, of long-term debt classified as noncurrent. Excludes lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140468226369920">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Long-Term Debt - Schedule of Future Maturities of Long-term Debt (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths', window );">2023</a></td>
<td class="nump">$ 6,250<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo', window );">2024</a></td>
<td class="nump">6,250<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree', window );">2025</a></td>
<td class="nump">6,250<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour', window );">2026</a></td>
<td class="nump">6,250<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive', window );">2027</a></td>
<td class="nump">96,875<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-term debt</a></td>
<td class="nump">$ 121,875<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031897-161870<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495340-112611<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123465755&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123465755&amp;loc=d3e1835-112601<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123465755&amp;loc=d3e1835-112601<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123465755&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123465755&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140468220278048">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Warrant Liability - Additional Information (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_btmd_PrivatePlacementWarrantsRedemptionDescription', window );">Private placement warrants redemption description</a></td>
<td class="text">if the closing price of our Class A common stock for any 20 trading days within a 30-trading day period ending on the third trading day prior to the date on which we send the notice of redemption to the warrant holders is less than $18.00 per share (as adjusted for stock splits, stock dividends, reorganizations, recapitalizations and the like), the Private Placement Warrants must also be concurrently called for redemption on the same terms as the outstanding Public Warrants.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidatedEntitiesAxis=btmd_HaymakeriiiMember', window );">Haymaker III</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price of warrants or rights outstanding</a></td>
<td class="nump">$ 11.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMaturityDate', window );">Warrants and rights expire date</a></td>
<td class="text">May 26,  2027<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Warrants and rights outstanding term</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_btmd_NumberOfDaysFollowingItsInitialBusinessCombinationUntilTheExpirationOfTheWarrants', window );">Number of days following its initial business combination until the expiration of the warrants</a></td>
<td class="text">60 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_btmd_ClassOfWarrantsRedemptionPricePerUnit', window );">Class of warrants redemption price per unit</a></td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_btmd_NumberOfConsecutiveTradingDaysForDeterminingSharePrice', window );">Number of consecutive trading days for determining the share price</a></td>
<td class="text">30 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_btmd_PublicWarrantsRedeemed', window );">Public warrants redeemed</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=btmd_PrivatePlacementWarrantsMember', window );">Private Placement Warrants | Haymaker III</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Stock issued during period, shares, new issues</a></td>
<td class="nump">233,333<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Shares issued, price per share</a></td>
<td class="nump">$ 1.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices', window );">Stock issued during period value issued for services</a></td>
<td class="nump">$ 350,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=btmd_PrivatePlacementWarrantsMember', window );">Private Placement Warrants | Haymaker III | Sponsor</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Stock issued during period, shares, new issues</a></td>
<td class="nump">5,333,333<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Number of warrants or rights outstanding</a></td>
<td class="nump">5,566,666<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=btmd_PublicWarrantsMember', window );">Public Warrants Member | Haymaker III</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Number of warrants or rights outstanding</a></td>
<td class="nump">7,937,466<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember', window );">Common Class A | Share Price Equal Or Exceeds 10.00 Rupees Per Dollar</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_btmd_ClassOfWarrantOrRightThresholdPeriodForExerciseFromDateOfClosingPublicOffering', window );">Class of warrant or right, threshold period for exercise from date of closing public offering</a></td>
<td class="text">30 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_btmd_ClassOfWarrantsRedemptionPricePerUnit', window );">Class of warrants redemption price per unit</a></td>
<td class="nump">$ 0.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Share Price</a></td>
<td class="nump">$ 10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_btmd_ClassOfWarrantOrRightMinimumNoticePeriodForRedemption', window );">Class of warrant or right minimum notice period For Redemption</a></td>
<td class="text">20 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember', window );">Common Class A | Share price equal or exceeds 18.00 Rs per dollar</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Share Price</a></td>
<td class="nump">$ 18<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_btmd_NumberOfConsecutiveTradingDaysForDeterminingSharePrice', window );">Number of consecutive trading days for determining the share price</a></td>
<td class="text">20 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember', window );">Common Class A | Haymaker III</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_btmd_ClassOfWarrantOrRightThresholdPeriodForExerciseFromDateOfClosingPublicOffering', window );">Class of warrant or right, threshold period for exercise from date of closing public offering</a></td>
<td class="text">15 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_btmd_ClassOfWarrantsOrRightsTransfersRestrictionOnNumberOfDaysFromTheDateOfBusinessCombination', window );">Class of warrants or rights transfers restriction on number of days from the date of business combination</a></td>
<td class="text">60 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember', window );">Common Class A | Haymaker III | Sponsor</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_btmd_ClassOfWarrantOrRightThresholdPeriodForExerciseFromDateOfClosingPublicOffering', window );">Class of warrant or right, threshold period for exercise from date of closing public offering</a></td>
<td class="text">30 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember', window );">Common Class A | Haymaker III | Share price equal or exceeds 18.00 Rs per dollar</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_btmd_ShareRedemptionTriggerPrice', window );">Share redemption trigger price</a></td>
<td class="nump">$ 18<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_btmd_ClassOfWarrantOrRightExercisePriceAdjustmentPercentageHigherOfMarketValue', window );">Class of warrant or right exercise price adjustment percentage higher of market value</a></td>
<td class="nump">180.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember', window );">Common Class A | Haymaker III | Share Price Equal or Less 9.2 Rs per dollar</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price of warrants or rights outstanding</a></td>
<td class="nump">$ 9.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_btmd_ShareRedemptionTriggerPrice', window );">Share redemption trigger price</a></td>
<td class="nump">$ 9.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_btmd_MinimumGrossProceedsRequiredFromIssuanceOfEquity', window );">Minimum gross proceeds required from issuance of equity</a></td>
<td class="nump">60.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_btmd_ClassOfWarrantOrRightMinimumNoticePeriodForRedemption', window );">Class of warrant or right minimum notice period For Redemption</a></td>
<td class="text">20 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_btmd_ClassOfWarrantOrRightExercisePriceAdjustmentPercentageHigherOfMarketValue', window );">Class of warrant or right exercise price adjustment percentage higher of market value</a></td>
<td class="nump">115.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember', window );">Common Class A | Redeemable Warrants | Haymaker III</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_btmd_ClassOfWarrantOrRightRedemptionThresholdConsecutiveTradingDays', window );">Class of warrant or right redemption threshold consecutive trading days</a></td>
<td class="text">30 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of securities called by warrants or rights</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember', window );">Common Class A | Private Placement Warrants | Haymaker III</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Shares issued, price per share</a></td>
<td class="nump">$ 11.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_btmd_ClassOfWarrantOrRightExercisePriceAdjustmentPercentageHigherOfMarketValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Class of warrant or right exercise price adjustment percentage higher of market value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">btmd_ClassOfWarrantOrRightExercisePriceAdjustmentPercentageHigherOfMarketValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>btmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_btmd_ClassOfWarrantOrRightMinimumNoticePeriodForRedemption">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Class of warrant or right minimum notice period for redemption.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">btmd_ClassOfWarrantOrRightMinimumNoticePeriodForRedemption</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>btmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_btmd_ClassOfWarrantOrRightRedemptionThresholdConsecutiveTradingDays">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Class of warrant or right redemption threshold consecutive trading days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">btmd_ClassOfWarrantOrRightRedemptionThresholdConsecutiveTradingDays</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>btmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_btmd_ClassOfWarrantOrRightThresholdPeriodForExerciseFromDateOfClosingPublicOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Class of warrant or right threshold period for exercise from date of closing public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">btmd_ClassOfWarrantOrRightThresholdPeriodForExerciseFromDateOfClosingPublicOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>btmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_btmd_ClassOfWarrantsOrRightsTransfersRestrictionOnNumberOfDaysFromTheDateOfBusinessCombination">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Class of warrants or rights transfers restriction on number of days from the date of business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">btmd_ClassOfWarrantsOrRightsTransfersRestrictionOnNumberOfDaysFromTheDateOfBusinessCombination</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>btmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_btmd_ClassOfWarrantsRedemptionPricePerUnit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Class of warrants redemption price per unit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">btmd_ClassOfWarrantsRedemptionPricePerUnit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>btmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_btmd_MinimumGrossProceedsRequiredFromIssuanceOfEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Minimum gross proceeds required from issuance of equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">btmd_MinimumGrossProceedsRequiredFromIssuanceOfEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>btmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_btmd_NumberOfConsecutiveTradingDaysForDeterminingSharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of consecutive trading days for determining share price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">btmd_NumberOfConsecutiveTradingDaysForDeterminingSharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>btmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_btmd_NumberOfDaysFollowingItsInitialBusinessCombinationUntilTheExpirationOfTheWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of days following its initial business combination until the expiration of the warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">btmd_NumberOfDaysFollowingItsInitialBusinessCombinationUntilTheExpirationOfTheWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>btmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_btmd_PrivatePlacementWarrantsRedemptionDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Private placement warrants redemption description.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">btmd_PrivatePlacementWarrantsRedemptionDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>btmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_btmd_PublicWarrantsRedeemed">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Public warrants redeemed.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">btmd_PublicWarrantsRedeemed</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>btmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_btmd_ShareRedemptionTriggerPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share redemption trigger price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">btmd_ShareRedemptionTriggerPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>btmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssuedPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or per unit amount of equity securities issued.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssuedPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueIssuedForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstandingMaturityDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expiration date of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in YYYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstandingMaturityDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstandingTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstandingTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidatedEntitiesAxis=btmd_HaymakeriiiMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidatedEntitiesAxis=btmd_HaymakeriiiMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=btmd_PrivatePlacementWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=btmd_PrivatePlacementWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=btmd_SponseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=btmd_SponseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=btmd_PublicWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=btmd_PublicWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=btmd_SharePriceEqualOrExceedsTenRupeesPerDollarMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=btmd_SharePriceEqualOrExceedsTenRupeesPerDollarMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=btmd_SharePriceEqualOrExceedsEighteenRupeesPerDollarMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=btmd_SharePriceEqualOrExceedsEighteenRupeesPerDollarMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=btmd_SharePriceEqualOrLessNinePointTwoRupeesPerDollarMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=btmd_SharePriceEqualOrLessNinePointTwoRupeesPerDollarMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=btmd_RedeemableWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=btmd_RedeemableWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R62.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140468220441056">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Earnout Liability - Additional Information (Details) - Business Combination<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2022 </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_btmd_EarnoutDeadlineDate', window );">Earnout deadline date</a></td>
<td class="text">May 26,  2027<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_btmd_NumberOfEarnoutSecuritiesShareholderEntitledToVestIfCertainSharePriceTargetsAchieved', window );">Number of earnout securities shareholder entitled to vest if certain share price targets achieved | shares</a></td>
<td class="nump">11,587,500<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_VestingAxis=btmd_SharePriceEqualsOrExceedsFifteenPerShareMember', window );">Share Price Equals or Exceeds 15.00 Per Share [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Share Price</a></td>
<td class="nump">$ 15<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_btmd_CommonStockTransfersThresholdTradingDays', window );">Common stock transfers threshold trading days</a></td>
<td class="text">20 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_btmd_NumberOfConsecutiveTradingDaysForDeterminingTheSharePrice', window );">Number of consecutive trading days for determining the share price</a></td>
<td class="text">30 days<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_VestingAxis=btmd_SharePriceEqualsOrExceedsSeventeenPointFivePerShareMember', window );">Share Price Equals or Exceeds 17.50 Per Share [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Share Price</a></td>
<td class="nump">$ 17.5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_btmd_CommonStockTransfersThresholdTradingDays', window );">Common stock transfers threshold trading days</a></td>
<td class="text">20 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_btmd_NumberOfConsecutiveTradingDaysForDeterminingTheSharePrice', window );">Number of consecutive trading days for determining the share price</a></td>
<td class="text">30 days<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember', window );">Class A Common Stock | Share Price Equals or Exceeds 12.50 Per Share [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Share Price</a></td>
<td class="nump">$ 12.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_btmd_CommonStockTransfersThresholdTradingDays', window );">Common stock transfers threshold trading days</a></td>
<td class="text">20 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_btmd_NumberOfConsecutiveTradingDaysForDeterminingTheSharePrice', window );">Number of consecutive trading days for determining the share price</a></td>
<td class="text">30 days<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_btmd_CommonStockTransfersThresholdTradingDays">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Common stock transfers threshold trading days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">btmd_CommonStockTransfersThresholdTradingDays</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>btmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_btmd_EarnoutDeadlineDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Earnout deadline date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">btmd_EarnoutDeadlineDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>btmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_btmd_NumberOfConsecutiveTradingDaysForDeterminingTheSharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of consecutive trading days for determining the share price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">btmd_NumberOfConsecutiveTradingDaysForDeterminingTheSharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>btmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_btmd_NumberOfEarnoutSecuritiesShareholderEntitledToVestIfCertainSharePriceTargetsAchieved">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of earnout securities shareholder entitled to vest if certain share price targets achieved.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">btmd_NumberOfEarnoutSecuritiesShareholderEntitledToVestIfCertainSharePriceTargetsAchieved</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>btmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingenciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingenciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=btmd_BusinessCombinationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=btmd_BusinessCombinationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=btmd_SharePriceEqualsOrExceedsFifteenPerShareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=btmd_SharePriceEqualsOrExceedsFifteenPerShareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=btmd_SharePriceEqualsOrExceedsSeventeenPointFivePerShareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=btmd_SharePriceEqualsOrExceedsSeventeenPointFivePerShareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=btmd_SharePriceEqualsOrExceedsTwelvePointFivePerShareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=btmd_SharePriceEqualsOrExceedsTwelvePointFivePerShareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R63.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140468224776704">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements - Schedule of Fair Value Hierarchy for Financial Assets and Liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>May 26, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Schedule Of Changes In The Fair Value Of Warrant Liabilities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialLiabilitiesFairValueDisclosure', window );">Liability</a></td>
<td class="nump">$ 33,833<span></span>
</td>
<td class="nump">$ 97,714<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=btmd_PublicWarrantsMember', window );">Public Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Schedule Of Changes In The Fair Value Of Warrant Liabilities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialLiabilitiesFairValueDisclosure', window );">Liability</a></td>
<td class="nump">2,381<span></span>
</td>
<td class="nump">5,397<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=btmd_PublicWarrantsMember', window );">Public Warrants | Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Schedule Of Changes In The Fair Value Of Warrant Liabilities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialLiabilitiesFairValueDisclosure', window );">Liability</a></td>
<td class="nump">2,381<span></span>
</td>
<td class="nump">5,397<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=btmd_PrivatePlacementWarrantsMember', window );">Private Placement Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Schedule Of Changes In The Fair Value Of Warrant Liabilities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialLiabilitiesFairValueDisclosure', window );">Liability</a></td>
<td class="nump">1,723<span></span>
</td>
<td class="nump">3,834<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=btmd_PrivatePlacementWarrantsMember', window );">Private Placement Warrants | Level 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Schedule Of Changes In The Fair Value Of Warrant Liabilities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialLiabilitiesFairValueDisclosure', window );">Liability</a></td>
<td class="nump">1,723<span></span>
</td>
<td class="nump">3,834<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=btmd_EarnoutLiabilityMember', window );">Earnout Liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Schedule Of Changes In The Fair Value Of Warrant Liabilities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialLiabilitiesFairValueDisclosure', window );">Liability</a></td>
<td class="nump">32,110<span></span>
</td>
<td class="nump">93,880<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=btmd_EarnoutLiabilityMember', window );">Earnout Liability | Level 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Schedule Of Changes In The Fair Value Of Warrant Liabilities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialLiabilitiesFairValueDisclosure', window );">Liability</a></td>
<td class="nump">$ 32,110<span></span>
</td>
<td class="nump">$ 93,880<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialLiabilitiesFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial obligations, including, but not limited to, debt instruments, derivative liabilities, federal funds purchased and sold under agreements to repurchase, securities loaned or sold under agreements to repurchase, financial instruments sold not yet purchased, guarantees, line of credit, loans and notes payable, servicing liability, and trading liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialLiabilitiesFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=btmd_PublicWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=btmd_PublicWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=btmd_PrivatePlacementWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=btmd_PrivatePlacementWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=btmd_EarnoutLiabilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=btmd_EarnoutLiabilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R64.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140468220221792">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements - Summary of Significant Inputs to Monte Carlo Simulation for Fair Value of Private Placement Warrants (Details) - Private Placement Warrants<br></strong></div></th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>May 26, 2022 </div>
<div>$ / shares</div>
</th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=btmd_PrivatePlacementWarrantsMember', window );">Stock Price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Sale of Stock, Price Per Share</a></td>
<td class="nump">$ 3.73<span></span>
</td>
<td class="nump">$ 9.02<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=btmd_PrivatePlacementWarrantsMember', window );">Exercise Price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants and rights outstanding measurement input</a></td>
<td class="nump">11.5<span></span>
</td>
<td class="nump">11.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=btmd_PrivatePlacementWarrantsMember', window );">Risk-free Rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants and rights outstanding measurement input</a></td>
<td class="nump">0.04<span></span>
</td>
<td class="nump">0.027<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=btmd_PrivatePlacementWarrantsMember', window );">Volatility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants and rights outstanding measurement input</a></td>
<td class="nump">0.422<span></span>
</td>
<td class="nump">0.134<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=btmd_PrivatePlacementWarrantsMember', window );">Term (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Warrants and rights outstanding term</a></td>
<td class="text">4 years 4 months 24 days<span></span>
</td>
<td class="text">5 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of input used to measure outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstandingMeasurementInput</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstandingTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstandingTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=btmd_PrivatePlacementWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=btmd_PrivatePlacementWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputSharePriceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputSharePriceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExercisePriceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExercisePriceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputOptionVolatilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputOptionVolatilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R65.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140468231220240">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements - Summary of Significant Inputs to Monte Carlo Simulation for Fair Value of Earnout Liability (Details) - Earnout Liability<br></strong></div></th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>May 26, 2022 </div>
<div>$ / shares</div>
</th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=btmd_EarnoutLiabilityMember', window );">Stock Price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Sale of stock price per share</a></td>
<td class="nump">$ 3.73<span></span>
</td>
<td class="nump">$ 9.02<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=btmd_EarnoutLiabilityMember', window );">Risk-free Rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants and rights outstanding measurement input</a></td>
<td class="nump">0.041<span></span>
</td>
<td class="nump">0.027<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=btmd_EarnoutLiabilityMember', window );">Volatility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants and rights outstanding measurement input</a></td>
<td class="nump">0.70<span></span>
</td>
<td class="nump">0.60<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=btmd_EarnoutLiabilityMember', window );">Term (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Warrants and rights outstanding term</a></td>
<td class="text">4 years 4 months 24 days<span></span>
</td>
<td class="text">5 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of input used to measure outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstandingMeasurementInput</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstandingTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstandingTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=btmd_EarnoutLiabilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=btmd_EarnoutLiabilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputSharePriceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputSharePriceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputOptionVolatilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputOptionVolatilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R66.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140468222199520">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements - Summary of Changes in the Fair Value of Company's Level 3 Financial Instruments (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">7 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Schedule Of Changes In The Fair Value Of Warrant Liabilities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialLiabilitiesFairValueDisclosure', window );">Fair value as of May 26, 2022 (initial measurement)</a></td>
<td class="nump">$ 97,714<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueOptionChangesInFairValueGainLoss1', window );">Gain from change in fair value</a></td>
<td class="num">(63,881)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialLiabilitiesFairValueDisclosure', window );">Fair value as of December 31, 2022</a></td>
<td class="nump">33,833<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=btmd_PrivatePlacementWarrantsMember', window );">Private Placement Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Schedule Of Changes In The Fair Value Of Warrant Liabilities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialLiabilitiesFairValueDisclosure', window );">Fair value as of May 26, 2022 (initial measurement)</a></td>
<td class="nump">3,834<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueOptionChangesInFairValueGainLoss1', window );">Gain from change in fair value</a></td>
<td class="num">(2,111)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialLiabilitiesFairValueDisclosure', window );">Fair value as of December 31, 2022</a></td>
<td class="nump">1,723<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=btmd_EarnoutLiabilityMember', window );">Earnout Liability</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Schedule Of Changes In The Fair Value Of Warrant Liabilities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialLiabilitiesFairValueDisclosure', window );">Fair value as of May 26, 2022 (initial measurement)</a></td>
<td class="nump">93,880<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueOptionChangesInFairValueGainLoss1', window );">Gain from change in fair value</a></td>
<td class="num">(61,770)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialLiabilitiesFairValueDisclosure', window );">Fair value as of December 31, 2022</a></td>
<td class="nump">$ 32,110<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueOptionChangesInFairValueGainLoss1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For each line item in the statement of financial position, the amounts of gains and losses from fair value changes included in earnings.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14172-108612<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueOptionChangesInFairValueGainLoss1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialLiabilitiesFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial obligations, including, but not limited to, debt instruments, derivative liabilities, federal funds purchased and sold under agreements to repurchase, securities loaned or sold under agreements to repurchase, financial instruments sold not yet purchased, guarantees, line of credit, loans and notes payable, servicing liability, and trading liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialLiabilitiesFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=btmd_PrivatePlacementWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=btmd_PrivatePlacementWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=btmd_EarnoutLiabilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=btmd_EarnoutLiabilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R67.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140468231594080">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Noncontrolling Interest - Additional Information (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>VOTE </div>
<div>shares</div>
</th>
<th class="th"><div>May 26, 2022</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=btmd_CommonClassVMember', window );">Class V Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MinorityInterestLineItems', window );"><strong>Noncontrolling Interest [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of shares under SEPA, shares | shares</a></td>
<td class="nump">48,565,824<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockVotingRights', window );">Common Stock, Voting Rights</a></td>
<td class="text">each holder of Class V voting stock is entitled to vote with the holders of Class A common stock of Biote, with each share of Class V voting stock entitling the holder to one vote per share of Class V voting stock at the time of such vote (subject to customary conversion rate adjustments for stock splits, stock dividends and reclassifications).<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_btmd_CommonStockNumberOfVotesEntitledPerShare', window );">Common stock, number of votes per share | VOTE</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_OwnershipAxis=btmd_MinorityInterestHoldersMember', window );">Minority Interest Holders</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MinorityInterestLineItems', window );"><strong>Noncontrolling Interest [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners', window );">Minority interest, retained percentage by minority interest holders</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">86.50%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_OwnershipAxis=btmd_BioteCorporationMember', window );">Biote</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MinorityInterestLineItems', window );"><strong>Noncontrolling Interest [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MinorityInterestOwnershipPercentageByParent', window );">Minority interest, ownership percentage</a></td>
<td class="nump">16.60%<span></span>
</td>
<td class="nump">13.50%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_btmd_CommonStockNumberOfVotesEntitledPerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Common stock, number of votes entitled per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">btmd_CommonStockNumberOfVotesEntitledPerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>btmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockVotingRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of voting rights of common stock. Includes eligibility to vote and votes per share owned. Include also, if any, unusual voting rights.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockVotingRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterestLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterestLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The equity interest of noncontrolling shareholders, partners or other equity holders in consolidated entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterestOwnershipPercentageByParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The parent entity's interest in net assets of the subsidiary, expressed as a percentage.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterestOwnershipPercentageByParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=btmd_CommonClassVMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=btmd_CommonClassVMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_OwnershipAxis=btmd_MinorityInterestHoldersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_OwnershipAxis=btmd_MinorityInterestHoldersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_OwnershipAxis=btmd_BioteCorporationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_OwnershipAxis=btmd_BioteCorporationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R68.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140468220861696">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Compensation - Additional Information (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="1">2 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>May 26, 2022</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>May 26, 2022</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=btmd_IncentiveUnitsMember', window );">Incentive Units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Compensation expense</a></td>
<td class="nump">$ 50,026<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=btmd_PhantomEquityRightsMember', window );">Phantom Equity Rights</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Compensation expense</a></td>
<td class="nump">4,339<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SettlementLiabilitiesCurrent', window );">Settlement of phantom equity rights</a></td>
<td class="nump">$ 7,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConversionOfStockSharesConverted1', window );">Phantom equity rights replaced with restricted stock units</a></td>
<td class="nump">3,887,750<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=btmd_PhantomEquityRightsMember', window );">Phantom Equity Rights | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Awards vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=btmd_PhantomEquityRightsMember', window );">Phantom Equity Rights | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Awards vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=btmd_TwoThousandTwentyTwoEquityIncentivePlanMember', window );">2022 Equity Incentive Plan | RSUs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 26,647<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Unrecognized compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,688<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Unrecognized compensation expense, expected to be recognized, weighted-average remaining vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=btmd_TwoThousandTwentyTwoEquityIncentivePlanMember', window );">2022 Equity Incentive Plan | Stock Options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,168<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Unrecognized compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,156<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Unrecognized compensation expense, expected to be recognized, weighted-average remaining vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years 4 months 24 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=btmd_CommonClassVMember', window );">Class V Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_btmd_ShareBasedCompensationArrangementVestingOfIncentiveUnits', window );">Vesting of incentive units, shares</a></td>
<td class="nump">6,356,178<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">987,275<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_btmd_ShareBasedCompensationArrangementVestingOfIncentiveUnits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share Based Compensation arrangement vesting of incentive units.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">btmd_ShareBasedCompensationArrangementVestingOfIncentiveUnits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>btmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockSharesConverted1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4313-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4304-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4332-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConversionOfStockSharesConverted1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost not yet recognized for nonvested award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SettlementLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amounts payable for money transfers, money orders, and consumer payment service arrangements. Settlement liabilities include amounts payable to intermediaries for global payment transfers.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SettlementLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=btmd_IncentiveUnitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=btmd_IncentiveUnitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=btmd_PhantomEquityRightsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=btmd_PhantomEquityRightsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=btmd_TwoThousandTwentyTwoEquityIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=btmd_TwoThousandTwentyTwoEquityIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=btmd_CommonClassVMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=btmd_CommonClassVMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R69.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140468220172960">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Compensation - Summary of Restricted Stock Unit Activity (Details) - RSUs - 2022 Equity Incentive Plan<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2022 </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Shares, RSUs Outstanding, Beginning balance | shares</a></td>
<td class="nump">3,887,750<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Shares, Granted | shares</a></td>
<td class="nump">85,040<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Shares, Forfeited | shares</a></td>
<td class="num">(296,250)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Shares, Vested | shares</a></td>
<td class="num">(2,053,700)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Shares, RSUs Outstanding, Ending balance | shares</a></td>
<td class="nump">1,622,840<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Weighted-Average Grant-Date Fair Value, RSUs Outstanding, Beginning balance | $ / shares</a></td>
<td class="nump">$ 8.85<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted-Average Grant-Date Fair Value, Granted | $ / shares</a></td>
<td class="nump">4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue', window );">Weighted-Average Grant-Date Fair Value, Forfeited | $ / shares</a></td>
<td class="nump">8.71<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue', window );">Weighted-Average Grant-Date Fair Value, Vested | $ / shares</a></td>
<td class="nump">8.24<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Weighted-Average Grant-Date Fair Value, RSUs Outstanding, Ending balance | $ / shares</a></td>
<td class="nump">$ 9.41<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=btmd_TwoThousandTwentyTwoEquityIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=btmd_TwoThousandTwentyTwoEquityIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R70.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140468225094128">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Compensation - Summary of Stock Option Activity (Details) - 2022 Equity Incentive Plan<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2022 </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Stock Options, Granted | shares</a></td>
<td class="nump">5,165,328<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod', window );">Stock Options, Forfeited | shares</a></td>
<td class="num">(122,700)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Stock Options Outstanding, Ending Balance | shares</a></td>
<td class="nump">5,042,628<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Stock Options, Exercisable | shares</a></td>
<td class="nump">131,461<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Weighted-Average Exercise Price, Granted | $ / shares</a></td>
<td class="nump">$ 3.86<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice', window );">Weighted-Average Exercise Price, Forfeited | $ / shares</a></td>
<td class="nump">3.73<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted-Average Exercise Price Outstanding, Ending Balance | $ / shares</a></td>
<td class="nump">3.86<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Weighted-Average Exercise Price, Exercisable | $ / shares</a></td>
<td class="nump">$ 3.99<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted-Average Remaining Contractual Term (Years)</a></td>
<td class="text">9 years 6 months<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Weighted-Average Remaining Contractual Term (Years), Exercisable</a></td>
<td class="text">2 years 1 month 6 days<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price of options that were either forfeited or expired.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=btmd_TwoThousandTwentyTwoEquityIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=btmd_TwoThousandTwentyTwoEquityIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R71.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140468222431168">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Compensation - Summary of Weighted-Average Assumptions used to Estimate Fair Value of Stock Options Granted (Details) - 2022 Equity Incentive Plan<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (in years)</a></td>
<td class="text">6 years<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate', window );">Volatility</a></td>
<td class="nump">60.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free rate</a></td>
<td class="nump">3.50%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Rate of weighted-average expected volatility for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=btmd_TwoThousandTwentyTwoEquityIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=btmd_TwoThousandTwentyTwoEquityIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R72.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140468224709040">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases - Additional Information (Details) - ft&#178;<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jul. 01, 2014</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Nov. 01, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseExpirationDate1', window );">Extend lease term date</a></td>
<td class="text">Jun. 30,  2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseOptionToExtend', window );">Operating lease option to Extend</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">On November 1, 2022, the Company executed an extension of lease office space to extend through November 30, 2028.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_btmd_AreaOfOfficeSpace', window );">Area of office space</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,700<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_btmd_AreaOfOfficeSpace">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area of Office Space</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">btmd_AreaOfOfficeSpace</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>btmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseExpirationDate1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Date which lease or group of leases is set to expire, in YYYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseExpirationDate1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseOptionToExtend">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of terms and conditions of option to extend lessee's operating lease. Includes, but is not limited to, information about option recognized as part of right-of-use asset and lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseOptionToExtend</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>R73.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140468231472112">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases - Summary of Operating Lease Costs Recognized under ASC 842 and Supplemental Cash Flow Information for Leases (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseCost', window );">Fixed lease expense</a></td>
<td class="nump">$ 278<span></span>
</td>
<td class="nump">$ 244<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCost', window );">Total lease cost</a></td>
<td class="nump">278<span></span>
</td>
<td class="nump">244<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_btmd_OtherInformationAbstract', window );"><strong>Other information:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeasePayments', window );">Cash paid for amounts included in the measurement of lease liabilities</a></td>
<td class="nump">257<span></span>
</td>
<td class="nump">$ 257<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability', window );">Right-of-use assets obtained in exchange for new operating lease liabilities</a></td>
<td class="nump">$ 1,936<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_btmd_OtherInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Other information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">btmd_OtherInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>btmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lease cost recognized by lessee for lease contract.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918643-209977<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>R74.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140468231163840">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases - Summary Balance Sheet Classification of Operating Leases and Weighted Average Remaining Lease Term and Discount Rate (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_btmd_AssetsLesseeAbstract', window );"><strong>Lease Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets</a></td>
<td class="nump">$ 2,052<span></span>
</td>
<td class="nump">$ 356<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_btmd_LeaseAssets', window );">Total lease assets</a></td>
<td class="nump">2,052<span></span>
</td>
<td class="nump">356<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_btmd_LiabilitiesLesseeAbstract', window );"><strong>Lease Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease liabilities, current</a></td>
<td class="nump">165<span></span>
</td>
<td class="nump">248<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liabilities, net of current portion</a></td>
<td class="nump">1,927<span></span>
</td>
<td class="nump">127<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Total lease liabilities</a></td>
<td class="nump">$ 2,092<span></span>
</td>
<td class="nump">$ 375<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Weighted-average remaining lease term --- operating leases (years)</a></td>
<td class="text">5 years 11 months 1 day<span></span>
</td>
<td class="text">1 year 6 months<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Weighted-average discount rate --- operating leases</a></td>
<td class="nump">8.48%<span></span>
</td>
<td class="nump">3.75%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_btmd_AssetsLesseeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Assets lessee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">btmd_AssetsLesseeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>btmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_btmd_LeaseAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lease assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">btmd_LeaseAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>btmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_btmd_LiabilitiesLesseeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Liabilities lessee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">btmd_LiabilitiesLesseeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>btmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>R75.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140468225097840">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases - Summary of Payments by Date for Operating Lease (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract', window );"><strong>Lessee, Operating Lease, Liability, to be Paid [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2023</a></td>
<td class="nump">$ 337<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2024</a></td>
<td class="nump">448<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">2025</a></td>
<td class="nump">464<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour', window );">2026</a></td>
<td class="nump">480<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive', window );">2027</a></td>
<td class="nump">497<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive', window );">Thereafter</a></td>
<td class="nump">470<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total lease payments</a></td>
<td class="nump">2,696<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less: Interest</a></td>
<td class="num">(604)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Present value of lease liabilities</a></td>
<td class="nump">$ 2,092<span></span>
</td>
<td class="nump">$ 375<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>R76.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140468221002496">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Additional Information (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowanceLineItems', window );"><strong>Valuation Allowance [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Uncertain tax positions</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExaminationDescription', window );">Income tax examination description</a></td>
<td class="text">There are currently no pending tax examinations. The Company&#8217;s tax years are still open under statute from December 31, 2019, to the present.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignCountryMember', window );">Foreign</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowanceLineItems', window );"><strong>Valuation Allowance [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating losses</a></td>
<td class="nump">$ 500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_btmd_OperatingLossCarryforwardsExpirationYear', window );">Net operating losses, expiration year</a></td>
<td class="text">2032<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_btmd_OperatingLossCarryforwardsExpirationYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Operating loss carryforwards, expiration year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">btmd_OperatingLossCarryforwardsExpirationYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>btmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExaminationDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A brief description of status of the tax examination, significant findings to date, and the entity's position with respect to the findings.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (d)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32718-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExaminationDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10B<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=SL37586934-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowanceLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowanceLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>85
<FILENAME>R77.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140468231464528">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Schedule of Income (Loss) Before Provision for Income Taxes (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic', window );">Domestic</a></td>
<td class="nump">$ 2,221<span></span>
</td>
<td class="nump">$ 33,191<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign', window );">Foreign</a></td>
<td class="num">(509)<span></span>
</td>
<td class="num">(286)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Income before provision for income taxes</a></td>
<td class="nump">$ 1,712<span></span>
</td>
<td class="nump">$ 32,905<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of earnings or loss from continuing operations before income taxes that is attributable to domestic operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.3)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 20<br> -Section 25<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126941158&amp;loc=d3e41242-110953<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of earnings or loss from continuing operations before income taxes that is attributable to foreign operations, which is defined as Income or Loss generated from operations located outside the entity's country of domicile.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.3)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>86
<FILENAME>R78.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140468220570224">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Schedule of Income Tax Provision (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract', window );"><strong>Current income tax provision (benefit):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentFederalTaxExpenseBenefit', window );">Federal</a></td>
<td class="nump">$ 749<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentStateAndLocalTaxExpenseBenefit', window );">State and Local</a></td>
<td class="nump">377<span></span>
</td>
<td class="nump">$ 286<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentForeignTaxExpenseBenefit', window );">Foreign</a></td>
<td class="nump">5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentIncomeTaxExpenseBenefit', window );">Total current expense (benefit):</a></td>
<td class="nump">1,131<span></span>
</td>
<td class="nump">286<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract', window );"><strong>Deferred income tax provision (benefit):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredFederalIncomeTaxExpenseBenefit', window );">Federal</a></td>
<td class="num">(714)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit', window );">State and Local</a></td>
<td class="num">(29)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefit', window );">Total deferred expense (benefit):</a></td>
<td class="num">(743)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Total income tax provision (benefit)</a></td>
<td class="nump">$ 388<span></span>
</td>
<td class="nump">$ 286<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentFederalTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current national tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentFederalTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentForeignTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentForeignTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.2)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentStateAndLocalTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentStateAndLocalTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFederalIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred national tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFederalIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.1)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.2)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>87
<FILENAME>R79.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140468224894240">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Schedule of Reconciliation of the Federal Income Tax Rate to the Company Effective Tax Rate (Details)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Statutory federal income tax rate</a></td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes', window );">State taxes, net of federal tax benefit</a></td>
<td class="nump">18.20%<span></span>
</td>
<td class="nump">0.87%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxExemptIncome', window );">Nontaxable partnership income</a></td>
<td class="nump">41.39%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential', window );">Foreign rate differential</a></td>
<td class="nump">2.71%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Change in valuation allowance</a></td>
<td class="nump">27.55%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Income tax provision</a></td>
<td class="nump">22.65%<span></span>
</td>
<td class="nump">0.87%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to statutory income tax expense (benefit) outside of the country of domicile.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxExemptIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to income (loss) exempt from income taxes.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationTaxExemptIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>88
<FILENAME>R80.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140468312502096">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Income Taxes - Deferred Tax Assets and Liabilities (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNetAbstract', window );"><strong>Deferred tax assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsInvestments', window );">Outside basis difference in partnership</a></td>
<td class="nump">$ 1,173<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">164<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets', window );">Intangibles</a></td>
<td class="nump">978<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGross', window );">Total deferred tax assets</a></td>
<td class="nump">2,315<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Valuation allowance</a></td>
<td class="num">(477)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNet', window );">Deferred tax assets, net of allowance</a></td>
<td class="nump">$ 1,838<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from intangible assets including goodwill.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from investments (excludes investments in subsidiaries and equity method investments).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>89
<FILENAME>R81.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140468231591648">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Common Share - Schedule of Computation of Net Loss Per Common Share (Details)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAbstract', window );"><strong>Numerator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic', window );">Net loss attributable to biote Corp. stockholders (basic) | $</a></td>
<td class="nump">$ 969<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted', window );">Net loss attributable to biote Corp. stockholders (diluted) | $</a></td>
<td class="nump">$ 969<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract', window );"><strong>Denominator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average shares outstanding (basic) | shares</a></td>
<td class="nump">8,059,371<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted average shares outstanding (diluted) | shares</a></td>
<td class="nump">8,059,371<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract', window );"><strong>Net loss per common share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic | $ / shares</a></td>
<td class="num">$ (0.12)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Diluted | $ / shares</a></td>
<td class="num">$ (0.12)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1377-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities, and addition from assumption of issuance of common shares for dilutive potential common shares; of income (loss) available to common shareholders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 40<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1930-109256<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 40<br> -Subparagraph (b)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1930-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 40<br> -Subparagraph (b)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1930-109256<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1505-109256<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 40<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1930-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>90
<FILENAME>R82.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140468220257536">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Common Share - Schedule of Computation of Diluted Weighted Average Shares Outstanding (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2022 </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Potentially antidilutive common units outstanding</a></td>
<td class="nump">80,322,924<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">RSUs</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Potentially antidilutive common units outstanding</a></td>
<td class="nump">1,622,840<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember', window );">Stock Options</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Potentially antidilutive common units outstanding</a></td>
<td class="nump">5,042,628<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=btmd_PublicWarrantsMember', window );">Public Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Potentially antidilutive common units outstanding</a></td>
<td class="nump">7,937,466<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=btmd_PrivatePlacementWarrantsMember', window );">Private Placement Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Potentially antidilutive common units outstanding</a></td>
<td class="nump">5,566,666<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=btmd_ClassVCommonStockMember', window );">Class V Voting Stock</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Potentially antidilutive common units outstanding</a></td>
<td class="nump">48,565,824<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=btmd_EarnoutVotingSharesMember', window );">Earnout Voting Shares</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Potentially antidilutive common units outstanding</a></td>
<td class="nump">10,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=btmd_SponsorEarnOutSharesMember', window );">Sponsor Earn Out Shares</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Potentially antidilutive common units outstanding</a></td>
<td class="nump">1,587,500<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=btmd_PublicWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=btmd_PublicWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=btmd_PrivatePlacementWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=btmd_PrivatePlacementWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=btmd_ClassVCommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=btmd_ClassVCommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=btmd_EarnoutVotingSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=btmd_EarnoutVotingSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=btmd_SponsorEarnOutSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=btmd_SponsorEarnOutSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>91
<FILENAME>R83.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140468228488528">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies - Additional Information (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 23, 2022</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyLawsuitFilingDate', window );">Loss contingency, lawsuit filing date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">June 23, 2022<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyNameOfPlaintiff', window );">Loss contingency, name of plaintiff</a></td>
<td class="text">Donovitz<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyNameOfDefendant', window );">Loss contingency, name of defendant</a></td>
<td class="text">Haymaker Sponsor, LLC<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyDamagesSoughtValue', window );">Seeks monetary relief, exceeding amount</a></td>
<td class="nump">$ 1.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingenciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingenciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyDamagesSoughtValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The value (monetary amount) of the award the plaintiff seeks in the legal matter.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14435-108349<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14557-108349<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyDamagesSoughtValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyLawsuitFilingDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>States the date the complaint was formally filed in a court of law, in arbitration or mediation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14557-108349<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14435-108349<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyLawsuitFilingDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyNameOfDefendant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Identifies the named defendant in a lawsuit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14557-108349<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14435-108349<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyNameOfDefendant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyNameOfPlaintiff">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Identifies the plaintiff in the lawsuit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14557-108349<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14435-108349<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyNameOfPlaintiff</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>92
<FILENAME>R84.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140468225405184">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related-Party Transactions - Additional Information (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>May 18, 2022</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=btmd_FirmMember', window );">Firm</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfessionalFees', window );">Fees paid</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 31<span></span>
</td>
<td class="nump">$ 456<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent', window );">Amount due</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=btmd_EmployeeMember', window );">Employee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent', window );">Amount due</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Compensation paid</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100<span></span>
</td>
<td class="nump">201<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredRevenueRevenueRecognized1', window );">Revenue recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">458<span></span>
</td>
<td class="nump">744<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DueFromCustomerAcceptances', window );">Due from customer</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">57<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=btmd_SpouseOfFounderChairmanAndBeneficialOwnerMember', window );">Spouse of Founder, Chairman, and Beneficial Owner</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Compensation paid</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">158<span></span>
</td>
<td class="nump">285<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DueToEmployeesCurrentAndNoncurrent', window );">Due to employees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=btmd_VendorMember', window );">Vendor</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent', window );">Amount due</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">151<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_btmd_InventoryPurchases', window );">Inventory purchases</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,304<span></span>
</td>
<td class="nump">$ 888<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_DirectorMember', window );">Founder Advisor | Founder Advisory Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_btmd_AgreementTerm', window );">Agreement term</a></td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_btmd_AnnualAdviosryFeesPayable', window );">Annual fees per year</a></td>
<td class="nump">$ 300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=btmd_ConsultantMember', window );">Lani D. | New Independent Contractor Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_btmd_AgreementTerm', window );">Agreement term</a></td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_btmd_AnnualAdviosryFeesPayable', window );">Annual fees per year</a></td>
<td class="nump">$ 250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_btmd_AgreementTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Agreement term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">btmd_AgreementTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>btmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_btmd_AnnualAdviosryFeesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Annual adviosry fees payable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">btmd_AnnualAdviosryFeesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>btmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_btmd_InventoryPurchases">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Inventory purchases.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">btmd_InventoryPurchases</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>btmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenueRevenueRecognized1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized that was previously reported as deferred or unearned revenue.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRevenueRevenueRecognized1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DueFromCustomerAcceptances">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amounts receivable from customers on short-term negotiable time drafts drawn on and accepted by the institution (also known as banker's acceptance transactions) that are outstanding on the reporting date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.9)<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DueFromCustomerAcceptances</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DueToEmployeesCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amounts due to employees, not to include stockholders or officers.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.17)<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.15)<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DueToEmployeesCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of obligations due all related parties.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(C))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.17)<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.15(3),(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DueToRelatedPartiesCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfessionalFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A fee charged for services from professionals such as doctors, lawyers and accountants. The term is often expanded to include other professions, for example, pharmacists charging to maintain a medicinal profile of a client or customer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07.2(a),(b),(c),(d))<br> -URI https://asc.fasb.org/extlink&amp;oid=120401555&amp;loc=SL114874292-224272<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 220<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (k)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433917&amp;loc=SL114874205-224268<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfessionalFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=btmd_FirmMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=btmd_FirmMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=btmd_EmployeeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=btmd_EmployeeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=btmd_SpouseOfFounderChairmanAndBeneficialOwnerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=btmd_SpouseOfFounderChairmanAndBeneficialOwnerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=btmd_VendorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=btmd_VendorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_DirectorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_DirectorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=btmd_FounderAdvisoryAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=btmd_FounderAdvisoryAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=btmd_ConsultantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=btmd_ConsultantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=btmd_NewIndependentContractorAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=btmd_NewIndependentContractorAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>93
<FILENAME>d479690dposam_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:btmd="http://haymaker.com/20221231"
  xmlns:country="http://xbrl.sec.gov/country/2022"
  xmlns:dei="http://xbrl.sec.gov/dei/2022"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2022"
  xmlns:us-gaap="http://fasb.org/us-gaap/2022"
  xmlns:utr="http://www.xbrl.org/2009/utr"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="btmd-20221231.xsd" xlink:type="simple"/>
    <context id="PAsOn12_31_2022">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819253</identifier>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819253</identifier>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819253</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819253</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P07_01_2014To07_01_2014">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819253</identifier>
        </entity>
        <period>
            <startDate>2014-07-01</startDate>
            <endDate>2014-07-01</endDate>
        </period>
    </context>
    <context id="P06_23_2022To06_23_2022">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819253</identifier>
        </entity>
        <period>
            <startDate>2022-06-23</startDate>
            <endDate>2022-06-23</endDate>
        </period>
    </context>
    <context id="P05_27_2022To12_31_2022">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819253</identifier>
        </entity>
        <period>
            <startDate>2022-05-27</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="PAsOn11_01_2022">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819253</identifier>
        </entity>
        <period>
            <instant>2022-11-01</instant>
        </period>
    </context>
    <context id="P01_01_2022To05_26_2022">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819253</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-05-26</endDate>
        </period>
    </context>
    <context id="PAsOn05_26_2022">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819253</identifier>
        </entity>
        <period>
            <instant>2022-05-26</instant>
        </period>
    </context>
    <context id="P07_27_2022To07_27_2022">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819253</identifier>
        </entity>
        <period>
            <startDate>2022-07-27</startDate>
            <endDate>2022-07-27</endDate>
        </period>
    </context>
    <context id="PAsOn12_31_2020">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819253</identifier>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_ClassAVotingUnitsMemberusgaapCapitalUnitsByClassAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CapitalUnitsByClassAxis">btmd:ClassAVotingUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_ClassAaNonVotingUnitsMemberusgaapCapitalUnitsByClassAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CapitalUnitsByClassAxis">btmd:ClassAaNonVotingUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_ClassAaaNonVotingUnitsMemberusgaapCapitalUnitsByClassAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CapitalUnitsByClassAxis">btmd:ClassAaaNonVotingUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_ClassAaaaNonVotingIncentiveUnitsMemberusgaapCapitalUnitsByClassAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CapitalUnitsByClassAxis">btmd:ClassAaaaNonVotingIncentiveUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_UnsatisfiedTrainingObligationsMembersrtProductOrServiceAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">btmd:UnsatisfiedTrainingObligationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_UnsatisfiedContractTermServicesMembersrtProductOrServiceAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">btmd:UnsatisfiedContractTermServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_UnsatisfiedPelletProceduresMembersrtProductOrServiceAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">btmd:UnsatisfiedPelletProceduresMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_PelletsMemberusgaapPublicUtilitiesInventoryAxis_ProductMembersrtProductOrServiceAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PublicUtilitiesInventoryAxis">btmd:PelletsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_DietarySupplementsMemberusgaapPublicUtilitiesInventoryAxis_ProductMembersrtProductOrServiceAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PublicUtilitiesInventoryAxis">btmd:DietarySupplementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_TrocarsMemberusgaapPropertyPlantAndEquipmentByTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">btmd:TrocarsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_LeaseholdImprovementsMemberusgaapPropertyPlantAndEquipmentByTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_OfficeEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_SoftwareAndSoftwareDevelopmentCostsMemberusgaapPropertyPlantAndEquipmentByTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareAndSoftwareDevelopmentCostsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_FurnitureAndFixturesMemberusgaapPropertyPlantAndEquipmentByTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_ComputerEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_ConstructionInProgressMemberusgaapPropertyPlantAndEquipmentByTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_FirmMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">btmd:FirmMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_EmployeeMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">btmd:EmployeeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_VendorMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">btmd:VendorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_CommonClassBMemberusgaapStatementClassOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_SpouseOfFounderChairmanAndBeneficialOwnerMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">btmd:SpouseOfFounderChairmanAndBeneficialOwnerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_BankOfAmericaTermLoanMemberusgaapDebtInstrumentAxis_LineOfCreditMemberusgaapCreditFacilityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">btmd:BankOfAmericaTermLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_ClassAMemberusgaapStatementClassOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">btmd:ClassAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_ClassAaUnitsMemberusgaapStatementClassOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">btmd:ClassAaUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_ClassAaaUnitsMemberusgaapStatementClassOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">btmd:ClassAaaUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_ClassAaaaUnitsMemberusgaapStatementClassOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">btmd:ClassAaaaUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_CommonClassAMemberusgaapStatementClassOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_CommonClassVMemberusgaapStatementClassOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">btmd:CommonClassVMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_HaymakeriiiMembersrtConsolidatedEntitiesAxis_OtherBusinessCombinationMemberusgaapBusinessAcquisitionAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">btmd:HaymakeriiiMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">btmd:OtherBusinessCombinationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_BioteMethodCustomerMemberbtmdNatureOfCustomerAxis_ServiceRevenueMemberbtmdSourceOfRevenueAxis_TrainingMemberbtmdSourceOfServiceRevenueAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="btmd:NatureOfCustomerAxis">btmd:BioteMethodCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="btmd:SourceOfRevenueAxis">btmd:ServiceRevenueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="btmd:SourceOfServiceRevenueAxis">btmd:TrainingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_BioteMethodCustomerMemberbtmdNatureOfCustomerAxis_ContractTermServicesMemberbtmdSourceOfServiceRevenueAxis_ServiceRevenueMemberbtmdSourceOfRevenueAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="btmd:NatureOfCustomerAxis">btmd:BioteMethodCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="btmd:SourceOfRevenueAxis">btmd:ServiceRevenueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="btmd:SourceOfServiceRevenueAxis">btmd:ContractTermServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_BioteMethodCustomerMemberbtmdNatureOfCustomerAxis_PalletProceduresMemberbtmdSourceOfServiceRevenueAxis_ProductRevenueMemberbtmdSourceOfRevenueAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="btmd:NatureOfCustomerAxis">btmd:BioteMethodCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="btmd:SourceOfRevenueAxis">btmd:ProductRevenueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="btmd:SourceOfServiceRevenueAxis">btmd:PalletProceduresMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_HaymakeriiiMembersrtConsolidatedEntitiesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">btmd:HaymakeriiiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_UnsatisfiedTrainingObligationsMembersrtProductOrServiceAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">btmd:UnsatisfiedTrainingObligationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_UnsatisfiedContractTermServicesMembersrtProductOrServiceAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">btmd:UnsatisfiedContractTermServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_UnsatisfiedPelletProceduresMembersrtProductOrServiceAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">btmd:UnsatisfiedPelletProceduresMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_PelletsMemberusgaapPublicUtilitiesInventoryAxis_ProductMembersrtProductOrServiceAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PublicUtilitiesInventoryAxis">btmd:PelletsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_DietarySupplementsMemberusgaapPublicUtilitiesInventoryAxis_ProductMembersrtProductOrServiceAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PublicUtilitiesInventoryAxis">btmd:DietarySupplementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_TrocarsMemberusgaapPropertyPlantAndEquipmentByTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">btmd:TrocarsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_LeaseholdImprovementsMemberusgaapPropertyPlantAndEquipmentByTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_OfficeEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_SoftwareAndSoftwareDevelopmentCostsMemberusgaapPropertyPlantAndEquipmentByTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareAndSoftwareDevelopmentCostsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_FurnitureAndFixturesMemberusgaapPropertyPlantAndEquipmentByTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_ComputerEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_CommonClassAMemberusgaapStatementClassOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_CommonClassBMemberusgaapStatementClassOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_ClassVCommonStockMemberusgaapStatementClassOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">btmd:ClassVCommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_PublicWarrantsMemberusgaapFinancialInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">btmd:PublicWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_PublicWarrantsMemberusgaapFinancialInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">btmd:PublicWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_PrivatePlacementWarrantsMemberusgaapFinancialInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">btmd:PrivatePlacementWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_PrivatePlacementWarrantsMemberusgaapFinancialInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">btmd:PrivatePlacementWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_EarnoutLiabilityMemberusgaapFinancialInstrumentAxis_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">btmd:EarnoutLiabilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_EarnoutLiabilityMemberusgaapFinancialInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">btmd:EarnoutLiabilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_MeasurementInputSharePriceMemberusgaapMeasurementInputTypeAxis_PrivatePlacementWarrantsMemberusgaapFinancialInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">btmd:PrivatePlacementWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputSharePriceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_EarnoutLiabilityMemberusgaapFinancialInstrumentAxis_MeasurementInputSharePriceMemberusgaapMeasurementInputTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">btmd:EarnoutLiabilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputSharePriceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_ForeignCountryMemberusgaapIncomeTaxAuthorityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_FirmMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">btmd:FirmMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_EmployeeMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">btmd:EmployeeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_VendorMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">btmd:VendorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_BioteCorporationMembersrtOwnershipAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">btmd:BioteCorporationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_EarnoutLiabilityMemberusgaapFinancialInstrumentAxis_MeasurementInputRiskFreeInterestRateMemberusgaapMeasurementInputTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">btmd:EarnoutLiabilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_EarnoutLiabilityMemberusgaapFinancialInstrumentAxis_MeasurementInputOptionVolatilityMemberusgaapMeasurementInputTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">btmd:EarnoutLiabilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputOptionVolatilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_MeasurementInputExpectedTermMemberusgaapMeasurementInputTypeAxis_PrivatePlacementWarrantsMemberusgaapFinancialInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">btmd:PrivatePlacementWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_CommonClassVMemberusgaapStatementClassOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">btmd:CommonClassVMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_LineOfCreditMemberusgaapCreditFacilityAxis_TruistTermLoanMemberusgaapDebtInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">btmd:TruistTermLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_CommonClassAMemberusgaapStatementClassOfStockAxis_HaymakeriiiMembersrtConsolidatedEntitiesAxis_RedeemableWarrantsMemberusgaapClassOfWarrantOrRightAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">btmd:HaymakeriiiMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">btmd:RedeemableWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_MeasurementInputExercisePriceMemberusgaapMeasurementInputTypeAxis_PrivatePlacementWarrantsMemberusgaapFinancialInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">btmd:PrivatePlacementWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExercisePriceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_MeasurementInputRiskFreeInterestRateMemberusgaapMeasurementInputTypeAxis_PrivatePlacementWarrantsMemberusgaapFinancialInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">btmd:PrivatePlacementWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_MeasurementInputOptionVolatilityMemberusgaapMeasurementInputTypeAxis_PrivatePlacementWarrantsMemberusgaapFinancialInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">btmd:PrivatePlacementWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputOptionVolatilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_EarnoutLiabilityMemberusgaapFinancialInstrumentAxis_MeasurementInputExpectedTermMemberusgaapMeasurementInputTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">btmd:EarnoutLiabilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_BusinessCombinationMemberusgaapBusinessAcquisitionAxis_CommonClassAMemberusgaapStatementClassOfStockAxis_SharePriceEqualsOrExceedsTwelvePointFivePerShareMemberusgaapVestingAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">btmd:BusinessCombinationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">btmd:SharePriceEqualsOrExceedsTwelvePointFivePerShareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_BusinessCombinationMemberusgaapBusinessAcquisitionAxis_SharePriceEqualsOrExceedsFifteenPerShareMemberusgaapVestingAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">btmd:BusinessCombinationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">btmd:SharePriceEqualsOrExceedsFifteenPerShareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_BusinessCombinationMemberusgaapBusinessAcquisitionAxis_SharePriceEqualsOrExceedsSeventeenPointFivePerShareMemberusgaapVestingAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">btmd:BusinessCombinationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">btmd:SharePriceEqualsOrExceedsSeventeenPointFivePerShareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_HaymakeriiiMembersrtConsolidatedEntitiesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">btmd:HaymakeriiiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_CommonClassAMemberusgaapStatementClassOfStockAxis_HaymakeriiiMembersrtConsolidatedEntitiesAxis_SharePriceEqualOrLessNinePointTwoRupeesPerDollarMemberusgaapMeasurementInputTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">btmd:HaymakeriiiMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">btmd:SharePriceEqualOrLessNinePointTwoRupeesPerDollarMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis_TwoThousandTwentyTwoEquityIncentivePlanMemberusgaapPlanNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">btmd:TwoThousandTwentyTwoEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_EmployeeStockOptionMemberusgaapAwardTypeAxis_TwoThousandTwentyTwoEquityIncentivePlanMemberusgaapPlanNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">btmd:TwoThousandTwentyTwoEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_TwoThousandTwentyTwoEquityIncentivePlanMemberusgaapPlanNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">btmd:TwoThousandTwentyTwoEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_SpouseOfFounderChairmanAndBeneficialOwnerMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">btmd:SpouseOfFounderChairmanAndBeneficialOwnerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_BankOfAmericaTermLoanMemberusgaapDebtInstrumentAxis_LineOfCreditMemberusgaapCreditFacilityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">btmd:BankOfAmericaTermLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_ClassAVotingUnitsMemberusgaapCapitalUnitsByClassAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CapitalUnitsByClassAxis">btmd:ClassAVotingUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_ClassAMemberusgaapStatementClassOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">btmd:ClassAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_ClassAaUnitsMemberusgaapStatementClassOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">btmd:ClassAaUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_ClassAaaUnitsMemberusgaapStatementClassOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">btmd:ClassAaaUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_ClassAaaaUnitsMemberusgaapStatementClassOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">btmd:ClassAaaaUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_HaymakeriiiMembersrtConsolidatedEntitiesAxis_OtherBusinessCombinationMemberusgaapBusinessAcquisitionAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">btmd:HaymakeriiiMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">btmd:OtherBusinessCombinationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_RevolvingCreditFacilityMemberusgaapCreditFacilityAxis_TruistTermLoanMemberusgaapDebtInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">btmd:TruistTermLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_CommonClassAMemberusgaapStatementClassOfStockAxis_SharePriceEqualOrExceedsTenRupeesPerDollarMemberusgaapMeasurementInputTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">btmd:SharePriceEqualOrExceedsTenRupeesPerDollarMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_CommonClassAMemberusgaapStatementClassOfStockAxis_SharePriceEqualOrExceedsEighteenRupeesPerDollarMemberusgaapMeasurementInputTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">btmd:SharePriceEqualOrExceedsEighteenRupeesPerDollarMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_CommonClassAMemberusgaapStatementClassOfStockAxis_HaymakeriiiMembersrtConsolidatedEntitiesAxis_SharePriceEqualOrExceedsEighteenRupeesPerDollarMemberusgaapMeasurementInputTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">btmd:HaymakeriiiMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">btmd:SharePriceEqualOrExceedsEighteenRupeesPerDollarMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_DebtInstrumentRedemptionPeriodOneMemberusgaapDebtInstrumentRedemptionPeriodAxis_LineOfCreditMemberusgaapCreditFacilityAxis_MaximumMembersrtRangeAxis_TruistTermLoanMemberusgaapDebtInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">btmd:TruistTermLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_DebtInstrumentRedemptionPeriodTwoMemberusgaapDebtInstrumentRedemptionPeriodAxis_LineOfCreditMemberusgaapCreditFacilityAxis_MaximumMembersrtRangeAxis_TruistTermLoanMemberusgaapDebtInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">btmd:TruistTermLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_DebtInstrumentRedemptionPeriodThreeMemberusgaapDebtInstrumentRedemptionPeriodAxis_LineOfCreditMemberusgaapCreditFacilityAxis_MaximumMembersrtRangeAxis_TruistTermLoanMemberusgaapDebtInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">btmd:TruistTermLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_LineOfCreditMemberusgaapCreditFacilityAxis_MinimumMembersrtRangeAxis_TruistTermLoanMemberusgaapDebtInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">btmd:TruistTermLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_BioteMethodCustomerMemberbtmdNatureOfCustomerAxis_ServiceRevenueMemberbtmdSourceOfRevenueAxis_TrainingMemberbtmdSourceOfServiceRevenueAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="btmd:NatureOfCustomerAxis">btmd:BioteMethodCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="btmd:SourceOfRevenueAxis">btmd:ServiceRevenueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="btmd:SourceOfServiceRevenueAxis">btmd:TrainingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_BioteMethodCustomerMemberbtmdNatureOfCustomerAxis_ContractTermServicesMemberbtmdSourceOfServiceRevenueAxis_ServiceRevenueMemberbtmdSourceOfRevenueAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="btmd:NatureOfCustomerAxis">btmd:BioteMethodCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="btmd:SourceOfRevenueAxis">btmd:ServiceRevenueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="btmd:SourceOfServiceRevenueAxis">btmd:ContractTermServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_BioteMethodCustomerMemberbtmdNatureOfCustomerAxis_PalletProceduresMemberbtmdSourceOfServiceRevenueAxis_ProductRevenueMemberbtmdSourceOfRevenueAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="btmd:NatureOfCustomerAxis">btmd:BioteMethodCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="btmd:SourceOfRevenueAxis">btmd:ProductRevenueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="btmd:SourceOfServiceRevenueAxis">btmd:PalletProceduresMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_HaymakeriiiMembersrtConsolidatedEntitiesAxis_PrivatePlacementWarrantsMemberusgaapClassOfWarrantOrRightAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">btmd:HaymakeriiiMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">btmd:PrivatePlacementWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_CommonClassAMemberusgaapStatementClassOfStockAxis_HaymakeriiiMembersrtConsolidatedEntitiesAxis_PrivatePlacementWarrantsMemberusgaapClassOfWarrantOrRightAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">btmd:HaymakeriiiMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">btmd:PrivatePlacementWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_HaymakeriiiMembersrtConsolidatedEntitiesAxis_PublicWarrantsMemberusgaapClassOfWarrantOrRightAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">btmd:HaymakeriiiMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">btmd:PublicWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_HaymakeriiiMembersrtConsolidatedEntitiesAxis_PrivatePlacementWarrantsMemberusgaapClassOfWarrantOrRightAxis_SponseMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">btmd:HaymakeriiiMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">btmd:PrivatePlacementWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">btmd:SponseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_AccountingStandardsUpdate201912MemberusgaapAdjustmentsForNewAccountingPronouncementsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201912Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_ProductRevenueMembersrtProductOrServiceAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">btmd:ProductRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_ServiceRevenueMembersrtProductOrServiceAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">btmd:ServiceRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_PelletProceduresProductRevenueMembersrtProductOrServiceAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">btmd:PelletProceduresProductRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_DietarySupplementsMembersrtProductOrServiceAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">btmd:DietarySupplementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_DisposableTrocarsProductRevenueMembersrtProductOrServiceAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">btmd:DisposableTrocarsProductRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_ShippingFeesProductRevenueMembersrtProductOrServiceAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">btmd:ShippingFeesProductRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_TrainingServiceRevenueMembersrtProductOrServiceAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">btmd:TrainingServiceRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_ContractTermServicesRevenueMembersrtProductOrServiceAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">btmd:ContractTermServicesRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_ProductRevenueMembersrtProductOrServiceAxis_USsrtStatementGeographicalAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">btmd:ProductRevenueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_AllOtherCountryMembersrtStatementGeographicalAxis_ProductRevenueMembersrtProductOrServiceAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">btmd:ProductRevenueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">btmd:AllOtherCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_ServiceRevenueMembersrtProductOrServiceAxis_USsrtStatementGeographicalAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">btmd:ServiceRevenueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_ShortTermContractWithCustomerMemberusgaapContractWithCustomerDurationAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ContractWithCustomerDurationAxis">us-gaap:ShortTermContractWithCustomerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_CommonClassVMemberusgaapStatementClassOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">btmd:CommonClassVMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_FirmMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">btmd:FirmMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_LongTermContractWithCustomerMemberusgaapContractWithCustomerDurationAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ContractWithCustomerDurationAxis">us-gaap:LongTermContractWithCustomerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_EmployeeMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">btmd:EmployeeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_SpouseOfFounderChairmanAndBeneficialOwnerMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">btmd:SpouseOfFounderChairmanAndBeneficialOwnerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_RetainedEarningsMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_ParentMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_VendorMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">btmd:VendorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_BankOfAmericaTermLoanMemberusgaapDebtInstrumentAxis_LineOfCreditMemberusgaapCreditFacilityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">btmd:BankOfAmericaTermLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_BankOfAmericaTermLoanAndTruistTermLoanMemberusgaapDebtInstrumentAxis_LineOfCreditMemberusgaapCreditFacilityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">btmd:BankOfAmericaTermLoanAndTruistTermLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_AssetsTotalMemberusgaapConcentrationRiskByBenchmarkAxis_InventoryMembersrtProductOrServiceAxis_SupplierConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">btmd:InventoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AssetsTotalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:SupplierConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_FourZeroOneKPlanMemberusgaapRetirementPlanNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanNameAxis">btmd:FourZeroOneKPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_BioteMethodCustomerMemberbtmdNatureOfCustomerAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="btmd:NatureOfCustomerAxis">btmd:BioteMethodCustomerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_ProductRevenueMembersrtProductOrServiceAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">btmd:ProductRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_ServiceRevenueMembersrtProductOrServiceAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">btmd:ServiceRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_TrocarsMemberusgaapPropertyPlantAndEquipmentByTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">btmd:TrocarsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_OfficeEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_MinimumMembersrtRangeAxis_SoftwareDevelopmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_MaximumMembersrtRangeAxis_SoftwareDevelopmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_FurnitureAndFixturesMemberusgaapPropertyPlantAndEquipmentByTypeAxis_MinimumMembersrtRangeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_FurnitureAndFixturesMemberusgaapPropertyPlantAndEquipmentByTypeAxis_MaximumMembersrtRangeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_ComputerEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis_MinimumMembersrtRangeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_ComputerEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis_MaximumMembersrtRangeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_PelletProceduresProductRevenueMembersrtProductOrServiceAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">btmd:PelletProceduresProductRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_DietarySupplementsMembersrtProductOrServiceAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">btmd:DietarySupplementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_DisposableTrocarsProductRevenueMembersrtProductOrServiceAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">btmd:DisposableTrocarsProductRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_ShippingFeesProductRevenueMembersrtProductOrServiceAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">btmd:ShippingFeesProductRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_TrainingServiceRevenueMembersrtProductOrServiceAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">btmd:TrainingServiceRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_ContractTermServicesRevenueMembersrtProductOrServiceAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">btmd:ContractTermServicesRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_ProductRevenueMembersrtProductOrServiceAxis_USsrtStatementGeographicalAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">btmd:ProductRevenueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_AllOtherCountryMembersrtStatementGeographicalAxis_ProductRevenueMembersrtProductOrServiceAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">btmd:ProductRevenueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">btmd:AllOtherCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_ServiceRevenueMembersrtProductOrServiceAxis_USsrtStatementGeographicalAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">btmd:ServiceRevenueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_AllOtherCountryMembersrtStatementGeographicalAxis_ServiceRevenueMembersrtProductOrServiceAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">btmd:ServiceRevenueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">btmd:AllOtherCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_ShortTermContractWithCustomerMemberusgaapContractWithCustomerDurationAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ContractWithCustomerDurationAxis">us-gaap:ShortTermContractWithCustomerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_BioteManagementLlcMemberusgaapBusinessAcquisitionAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">btmd:BioteManagementLlcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_CommonClassAMemberusgaapStatementClassOfStockAxis_HaymakeriiiMembersrtConsolidatedEntitiesAxis_RedeemableWarrantsMemberusgaapClassOfWarrantOrRightAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">btmd:HaymakeriiiMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">btmd:RedeemableWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_TwoThousandTwentyTwoEquityIncentivePlanMemberusgaapPlanNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">btmd:TwoThousandTwentyTwoEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_RestrictedStockUnitsRSUMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_EmployeeStockOptionMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_ClassVCommonStockMemberusgaapStatementClassOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">btmd:ClassVCommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_PublicWarrantsMemberusgaapClassOfWarrantOrRightAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">btmd:PublicWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_PrivatePlacementWarrantsMemberusgaapClassOfWarrantOrRightAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">btmd:PrivatePlacementWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_EarnoutVotingSharesMemberusgaapStatementClassOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">btmd:EarnoutVotingSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_SponsorEarnOutSharesMemberusgaapStatementClassOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">btmd:SponsorEarnOutSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_FirmMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">btmd:FirmMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_ForeignCountryMemberusgaapIncomeTaxAuthorityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis_TwoThousandTwentyTwoEquityIncentivePlanMemberusgaapPlanNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">btmd:TwoThousandTwentyTwoEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_EmployeeStockOptionMemberusgaapAwardTypeAxis_TwoThousandTwentyTwoEquityIncentivePlanMemberusgaapPlanNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">btmd:TwoThousandTwentyTwoEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_BusinessCombinationMemberusgaapBusinessAcquisitionAxis_MaximumMembersrtRangeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">btmd:BusinessCombinationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_CommonClassAMemberusgaapStatementClassOfStockAxis_HaymakeriiiMembersrtConsolidatedEntitiesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">btmd:HaymakeriiiMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_CommonClassAMemberusgaapStatementClassOfStockAxis_HaymakeriiiMembersrtConsolidatedEntitiesAxis_SponseMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">btmd:HaymakeriiiMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">btmd:SponseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_CommonClassAMemberusgaapStatementClassOfStockAxis_SharePriceEqualOrExceedsTenRupeesPerDollarMemberusgaapMeasurementInputTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">btmd:SharePriceEqualOrExceedsTenRupeesPerDollarMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_BankOfAmericaTermLoanMemberusgaapDebtInstrumentAxis_LineOfCreditMemberusgaapCreditFacilityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">btmd:BankOfAmericaTermLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_LongTermContractWithCustomerMemberusgaapContractWithCustomerDurationAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ContractWithCustomerDurationAxis">us-gaap:LongTermContractWithCustomerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_LeaseholdImprovementsMemberusgaapPropertyPlantAndEquipmentByTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_MinimumMembersrtRangeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_MaximumMembersrtRangeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_BusinessCombinationMemberusgaapBusinessAcquisitionAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">btmd:BusinessCombinationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_CommonClassVMemberusgaapStatementClassOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">btmd:CommonClassVMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_EmployeeMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">btmd:EmployeeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_SpouseOfFounderChairmanAndBeneficialOwnerMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">btmd:SpouseOfFounderChairmanAndBeneficialOwnerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_LineOfCreditMemberusgaapCreditFacilityAxis_TruistTermLoanMemberusgaapDebtInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">btmd:TruistTermLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_RetainedEarningsMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_ParentMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_NoncontrollingInterestMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_HaymakeriiiMembersrtConsolidatedEntitiesAxis_OtherBusinessCombinationMemberusgaapBusinessAcquisitionAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">btmd:HaymakeriiiMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">btmd:OtherBusinessCombinationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_BusinessCombinationMemberusgaapBusinessAcquisitionAxis_CommonClassAMemberusgaapStatementClassOfStockAxis_SharePriceEqualsOrExceedsTwelvePointFivePerShareMemberusgaapVestingAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">btmd:BusinessCombinationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">btmd:SharePriceEqualsOrExceedsTwelvePointFivePerShareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_BusinessCombinationMemberusgaapBusinessAcquisitionAxis_SharePriceEqualsOrExceedsFifteenPerShareMemberusgaapVestingAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">btmd:BusinessCombinationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">btmd:SharePriceEqualsOrExceedsFifteenPerShareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_BusinessCombinationMemberusgaapBusinessAcquisitionAxis_SharePriceEqualsOrExceedsSeventeenPointFivePerShareMemberusgaapVestingAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">btmd:BusinessCombinationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">btmd:SharePriceEqualsOrExceedsSeventeenPointFivePerShareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_MaximumMembersrtRangeAxis_PhantomEquityRightsMemberusgaapAwardTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">btmd:PhantomEquityRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_MinimumMembersrtRangeAxis_PhantomEquityRightsMemberusgaapAwardTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">btmd:PhantomEquityRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_VendorMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">btmd:VendorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_HaymakeriiiMembersrtConsolidatedEntitiesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">btmd:HaymakeriiiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_CommonClassAMemberusgaapStatementClassOfStockAxis_SharePriceEqualOrExceedsEighteenRupeesPerDollarMemberusgaapMeasurementInputTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">btmd:SharePriceEqualOrExceedsEighteenRupeesPerDollarMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_StandbyEquityPurchaseAgreementMemberusgaapTypeOfArrangementAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">btmd:StandbyEquityPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_CommonClassAMemberusgaapStatementClassOfStockAxis_HaymakeriiiMembersrtConsolidatedEntitiesAxis_SharePriceEqualOrLessNinePointTwoRupeesPerDollarMemberusgaapMeasurementInputTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">btmd:HaymakeriiiMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">btmd:SharePriceEqualOrLessNinePointTwoRupeesPerDollarMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_CommonClassAMemberusgaapStatementClassOfStockAxis_CommonStockMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_HaymakeriiiMembersrtConsolidatedEntitiesAxis_PrivatePlacementWarrantsMemberusgaapClassOfWarrantOrRightAxis_SponseMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">btmd:HaymakeriiiMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">btmd:PrivatePlacementWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">btmd:SponseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_HaymakeriiiMembersrtConsolidatedEntitiesAxis_PrivatePlacementWarrantsMemberusgaapClassOfWarrantOrRightAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">btmd:HaymakeriiiMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">btmd:PrivatePlacementWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_BankOfAmericaTermLoanAndTruistTermLoanMemberusgaapDebtInstrumentAxis_LineOfCreditMemberusgaapCreditFacilityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">btmd:BankOfAmericaTermLoanAndTruistTermLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_FourZeroOneKPlanMemberusgaapRetirementPlanNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanNameAxis">btmd:FourZeroOneKPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_CreditAvailabilityConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis_LiabilitiesTotalMemberusgaapConcentrationRiskByBenchmarkAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:LiabilitiesTotalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CreditAvailabilityConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_AssetsTotalMemberusgaapConcentrationRiskByBenchmarkAxis_InventoryMembersrtProductOrServiceAxis_SupplierConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">btmd:InventoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AssetsTotalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:SupplierConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_BusinessContactMemberdeiEntityAddressesAddressTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:EntityAddressesAddressTypeAxis">dei:BusinessContactMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_BioteMethodCustomerMemberbtmdNatureOfCustomerAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="btmd:NatureOfCustomerAxis">btmd:BioteMethodCustomerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To05_26_2022_RetainedEarningsMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-05-26</endDate>
        </period>
    </context>
    <context id="P01_01_2022To05_26_2022_ParentMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-05-26</endDate>
        </period>
    </context>
    <context id="P01_01_2022To05_26_2022_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-05-26</endDate>
        </period>
    </context>
    <context id="PAsOn05_26_2022_LineOfCreditMemberusgaapCreditFacilityAxis_TruistTermLoanMemberusgaapDebtInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">btmd:TruistTermLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-05-26</instant>
        </period>
    </context>
    <context id="PAsOn05_26_2022_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_PublicWarrantsMemberusgaapFinancialInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">btmd:PublicWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-05-26</instant>
        </period>
    </context>
    <context id="PAsOn05_26_2022_PublicWarrantsMemberusgaapFinancialInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">btmd:PublicWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-05-26</instant>
        </period>
    </context>
    <context id="PAsOn05_26_2022_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_PrivatePlacementWarrantsMemberusgaapFinancialInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">btmd:PrivatePlacementWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-05-26</instant>
        </period>
    </context>
    <context id="PAsOn05_26_2022_PrivatePlacementWarrantsMemberusgaapFinancialInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">btmd:PrivatePlacementWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-05-26</instant>
        </period>
    </context>
    <context id="PAsOn05_26_2022_EarnoutLiabilityMemberusgaapFinancialInstrumentAxis_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">btmd:EarnoutLiabilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-05-26</instant>
        </period>
    </context>
    <context id="PAsOn05_26_2022_EarnoutLiabilityMemberusgaapFinancialInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">btmd:EarnoutLiabilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-05-26</instant>
        </period>
    </context>
    <context id="PAsOn05_26_2022_MeasurementInputSharePriceMemberusgaapMeasurementInputTypeAxis_PrivatePlacementWarrantsMemberusgaapFinancialInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">btmd:PrivatePlacementWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputSharePriceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-05-26</instant>
        </period>
    </context>
    <context id="PAsOn05_26_2022_EarnoutLiabilityMemberusgaapFinancialInstrumentAxis_MeasurementInputSharePriceMemberusgaapMeasurementInputTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">btmd:EarnoutLiabilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputSharePriceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-05-26</instant>
        </period>
    </context>
    <context id="PAsOn05_26_2022_MinorityInterestHoldersMembersrtOwnershipAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">btmd:MinorityInterestHoldersMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-05-26</instant>
        </period>
    </context>
    <context id="PAsOn05_26_2022_BioteCorporationMembersrtOwnershipAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">btmd:BioteCorporationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-05-26</instant>
        </period>
    </context>
    <context id="PAsOn05_26_2022_EarnoutLiabilityMemberusgaapFinancialInstrumentAxis_MeasurementInputRiskFreeInterestRateMemberusgaapMeasurementInputTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">btmd:EarnoutLiabilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-05-26</instant>
        </period>
    </context>
    <context id="PAsOn05_26_2022_EarnoutLiabilityMemberusgaapFinancialInstrumentAxis_MeasurementInputOptionVolatilityMemberusgaapMeasurementInputTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">btmd:EarnoutLiabilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputOptionVolatilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-05-26</instant>
        </period>
    </context>
    <context id="PAsOn05_26_2022_MeasurementInputExpectedTermMemberusgaapMeasurementInputTypeAxis_PrivatePlacementWarrantsMemberusgaapFinancialInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">btmd:PrivatePlacementWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-05-26</instant>
        </period>
    </context>
    <context id="PAsOn05_26_2022_MeasurementInputExercisePriceMemberusgaapMeasurementInputTypeAxis_PrivatePlacementWarrantsMemberusgaapFinancialInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">btmd:PrivatePlacementWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExercisePriceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-05-26</instant>
        </period>
    </context>
    <context id="PAsOn05_26_2022_MeasurementInputRiskFreeInterestRateMemberusgaapMeasurementInputTypeAxis_PrivatePlacementWarrantsMemberusgaapFinancialInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">btmd:PrivatePlacementWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-05-26</instant>
        </period>
    </context>
    <context id="PAsOn05_26_2022_MeasurementInputOptionVolatilityMemberusgaapMeasurementInputTypeAxis_PrivatePlacementWarrantsMemberusgaapFinancialInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">btmd:PrivatePlacementWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputOptionVolatilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-05-26</instant>
        </period>
    </context>
    <context id="PAsOn05_26_2022_EarnoutLiabilityMemberusgaapFinancialInstrumentAxis_MeasurementInputExpectedTermMemberusgaapMeasurementInputTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">btmd:EarnoutLiabilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-05-26</instant>
        </period>
    </context>
    <context id="PAsOn05_26_2022_PhantomEquityRightsMemberusgaapAwardTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">btmd:PhantomEquityRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-05-26</instant>
        </period>
    </context>
    <context id="PAsOn05_26_2022_MemberUnitsMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:MemberUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-05-26</instant>
        </period>
    </context>
    <context id="PAsOn05_26_2022_CommonClassAMemberusgaapStatementClassOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-05-26</instant>
        </period>
    </context>
    <context id="PAsOn05_26_2022_CommonClassVMemberusgaapStatementClassOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">btmd:CommonClassVMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-05-26</instant>
        </period>
    </context>
    <context id="PAsOn05_26_2022_RetainedEarningsMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-05-26</instant>
        </period>
    </context>
    <context id="PAsOn05_26_2022_ParentMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-05-26</instant>
        </period>
    </context>
    <context id="PAsOn05_26_2022_DebtCommitmentLetterMemberusgaapDebtInstrumentAxis_HaymakeriiiMembersrtConsolidatedEntitiesAxis_SeniorSecuredRevolvingCreditFacilityMemberusgaapCreditFacilityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">btmd:HaymakeriiiMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">btmd:SeniorSecuredRevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">btmd:DebtCommitmentLetterMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-05-26</instant>
        </period>
    </context>
    <context id="PAsOn05_26_2022_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-05-26</instant>
        </period>
    </context>
    <context id="PAsOn05_26_2022_NoncontrollingInterestMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-05-26</instant>
        </period>
    </context>
    <context id="PAsOn05_26_2022_DebtCommitmentLetterMemberusgaapDebtInstrumentAxis_HaymakeriiiMembersrtConsolidatedEntitiesAxis_SeniorSecuredTermLoanAFacilityMemberusgaapCreditFacilityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">btmd:HaymakeriiiMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">btmd:SeniorSecuredTermLoanAFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">btmd:DebtCommitmentLetterMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-05-26</instant>
        </period>
    </context>
    <context id="P05_27_2022To12_31_2022_PrivatePlacementWarrantsMemberusgaapFinancialInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">btmd:PrivatePlacementWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-05-27</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P05_27_2022To12_31_2022_EarnoutLiabilityMemberusgaapFinancialInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">btmd:EarnoutLiabilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-05-27</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P05_27_2022To12_31_2022_RetainedEarningsMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-05-27</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P05_27_2022To12_31_2022_ParentMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-05-27</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P05_27_2022To12_31_2022_NoncontrollingInterestMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-05-27</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P07_27_2022To07_27_2022_StandbyEquityPurchaseAgreementMemberusgaapTypeOfArrangementAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">btmd:StandbyEquityPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-27</startDate>
            <endDate>2022-07-27</endDate>
        </period>
    </context>
    <context id="PAsOn07_27_2022_StandbyEquityPurchaseAgreementMemberusgaapTypeOfArrangementAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">btmd:StandbyEquityPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-07-27</instant>
        </period>
    </context>
    <context id="PAsOn07_27_2022_CommonClassAMemberusgaapStatementClassOfStockAxis_StandbyEquityPurchaseAgreementMemberusgaapTypeOfArrangementAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">btmd:StandbyEquityPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-07-27</instant>
        </period>
    </context>
    <context id="PAsOn07_27_2022_MaximumMembersrtRangeAxis_StandbyEquityPurchaseAgreementMemberusgaapTypeOfArrangementAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">btmd:StandbyEquityPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-07-27</instant>
        </period>
    </context>
    <context id="PAsOn07_27_2022_StandbyEquityPurchaseAgreementMemberusgaapTypeOfArrangementAxis_YorkvilleAdvisorsGlobalLpMemberusgaapCreditFacilityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">btmd:YorkvilleAdvisorsGlobalLpMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">btmd:StandbyEquityPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-07-27</instant>
        </period>
    </context>
    <context id="P12_13_2021To12_13_2021_BioteManagementLlcMemberusgaapBusinessAcquisitionAxis_CommonClassAMemberusgaapStatementClassOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">btmd:BioteManagementLlcMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-12-13</startDate>
            <endDate>2021-12-13</endDate>
        </period>
    </context>
    <context id="P12_13_2021To12_13_2021_CommonClassAMemberusgaapStatementClassOfStockAxis_HaymakerAcquisitionCorpIiiMemberusgaapBusinessAcquisitionAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">btmd:HaymakerAcquisitionCorpIiiMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-12-13</startDate>
            <endDate>2021-12-13</endDate>
        </period>
    </context>
    <context id="P12_13_2021To12_13_2021_ClassVCommonStockMemberusgaapStatementClassOfStockAxis_HaymakerAcquisitionCorpIiiMemberusgaapBusinessAcquisitionAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">btmd:HaymakerAcquisitionCorpIiiMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">btmd:ClassVCommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-12-13</startDate>
            <endDate>2021-12-13</endDate>
        </period>
    </context>
    <context id="P12_13_2021To12_13_2021_BusinessCombinationMemberusgaapBusinessAcquisitionAxis_HaymakeriiiMembersrtConsolidatedEntitiesAxis_MemberEarnOutUnitsMemberusgaapStatementClassOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">btmd:HaymakeriiiMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">btmd:BusinessCombinationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">btmd:MemberEarnOutUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-12-13</startDate>
            <endDate>2021-12-13</endDate>
        </period>
    </context>
    <context id="P12_13_2021To12_13_2021_BusinessCombinationMemberusgaapBusinessAcquisitionAxis_HaymakeriiiMembersrtConsolidatedEntitiesAxis_SponsorEarnOutSharesMemberusgaapStatementClassOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">btmd:HaymakeriiiMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">btmd:BusinessCombinationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">btmd:SponsorEarnOutSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-12-13</startDate>
            <endDate>2021-12-13</endDate>
        </period>
    </context>
    <context id="P12_13_2021To12_13_2021_BusinessCombinationMemberusgaapBusinessAcquisitionAxis_EarnoutVotingSharesMemberusgaapStatementClassOfStockAxis_HaymakeriiiMembersrtConsolidatedEntitiesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">btmd:HaymakeriiiMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">btmd:BusinessCombinationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">btmd:EarnoutVotingSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-12-13</startDate>
            <endDate>2021-12-13</endDate>
        </period>
    </context>
    <context id="P12_13_2021To12_13_2021_BioteManagementLlcMemberusgaapBusinessAcquisitionAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">btmd:BioteManagementLlcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-12-13</startDate>
            <endDate>2021-12-13</endDate>
        </period>
    </context>
    <context id="P12_13_2021To12_13_2021_CommonClassAMemberusgaapStatementClassOfStockAxis_HaymakeriiiMembersrtConsolidatedEntitiesAxis_OtherBusinessCombinationMemberusgaapBusinessAcquisitionAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">btmd:HaymakeriiiMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">btmd:OtherBusinessCombinationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-12-13</startDate>
            <endDate>2021-12-13</endDate>
        </period>
    </context>
    <context id="PAsOn12_13_2021_CommonClassAMemberusgaapStatementClassOfStockAxis_HaymakerAcquisitionCorpIiiMemberusgaapBusinessAcquisitionAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">btmd:HaymakerAcquisitionCorpIiiMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-13</instant>
        </period>
    </context>
    <context id="PAsOn12_13_2021_CommonClassBMemberusgaapStatementClassOfStockAxis_HaymakerAcquisitionCorpIiiMemberusgaapBusinessAcquisitionAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">btmd:HaymakerAcquisitionCorpIiiMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-13</instant>
        </period>
    </context>
    <context id="PAsOn12_13_2021_ClassVCommonStockMemberusgaapStatementClassOfStockAxis_HaymakerAcquisitionCorpIiiMemberusgaapBusinessAcquisitionAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">btmd:HaymakerAcquisitionCorpIiiMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">btmd:ClassVCommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-13</instant>
        </period>
    </context>
    <context id="PAsOn05_31_2019_BankOfAmericaTermLoanMemberusgaapDebtInstrumentAxis_LineOfCreditMemberusgaapCreditFacilityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">btmd:BankOfAmericaTermLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-05-31</instant>
        </period>
    </context>
    <context id="P05_01_2019To05_31_2019_BankOfAmericaTermLoanMemberusgaapDebtInstrumentAxis_LineOfCreditMemberusgaapCreditFacilityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">btmd:BankOfAmericaTermLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-05-01</startDate>
            <endDate>2019-05-31</endDate>
        </period>
    </context>
    <context id="P05_26_2022To05_26_2022_CommonClassVMemberusgaapStatementClassOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">btmd:CommonClassVMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-05-26</startDate>
            <endDate>2022-05-26</endDate>
        </period>
    </context>
    <context id="P05_26_2022To05_26_2022_IncentiveUnitsMemberusgaapAwardTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">btmd:IncentiveUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-05-26</startDate>
            <endDate>2022-05-26</endDate>
        </period>
    </context>
    <context id="P05_26_2022To05_26_2022_PhantomEquityRightsMemberusgaapAwardTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">btmd:PhantomEquityRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-05-26</startDate>
            <endDate>2022-05-26</endDate>
        </period>
    </context>
    <context id="P05_26_2022To05_26_2022_LineOfCreditMemberusgaapCreditFacilityAxis_TruistTermLoanMemberusgaapDebtInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">btmd:TruistTermLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-05-26</startDate>
            <endDate>2022-05-26</endDate>
        </period>
    </context>
    <context id="P05_26_2022To05_26_2022_LineOfCreditMemberusgaapCreditFacilityAxis_MinimumMembersrtRangeAxis_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMemberusgaapVariableRateAxis_TruistTermLoanMemberusgaapDebtInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">btmd:TruistTermLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-05-26</startDate>
            <endDate>2022-05-26</endDate>
        </period>
    </context>
    <context id="P05_26_2022To05_26_2022_LineOfCreditMemberusgaapCreditFacilityAxis_MaximumMembersrtRangeAxis_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMemberusgaapVariableRateAxis_TruistTermLoanMemberusgaapDebtInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">btmd:TruistTermLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-05-26</startDate>
            <endDate>2022-05-26</endDate>
        </period>
    </context>
    <context id="P05_26_2022To05_26_2022_BaseRateMemberusgaapVariableRateAxis_LineOfCreditMemberusgaapCreditFacilityAxis_MinimumMembersrtRangeAxis_TruistTermLoanMemberusgaapDebtInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">btmd:TruistTermLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:BaseRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-05-26</startDate>
            <endDate>2022-05-26</endDate>
        </period>
    </context>
    <context id="P05_26_2022To05_26_2022_BaseRateMemberusgaapVariableRateAxis_LineOfCreditMemberusgaapCreditFacilityAxis_MaximumMembersrtRangeAxis_TruistTermLoanMemberusgaapDebtInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">btmd:TruistTermLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:BaseRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-05-26</startDate>
            <endDate>2022-05-26</endDate>
        </period>
    </context>
    <context id="PAsOn05_18_2022_DirectorMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_FounderAdvisoryAgreementMemberusgaapTypeOfArrangementAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:DirectorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">btmd:FounderAdvisoryAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-05-18</instant>
        </period>
    </context>
    <context id="PAsOn05_18_2022_ConsultantMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_NewIndependentContractorAgreementMemberusgaapTypeOfArrangementAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">btmd:ConsultantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">btmd:NewIndependentContractorAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-05-18</instant>
        </period>
    </context>
    <context id="P05_18_2022To05_18_2022_DirectorMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_FounderAdvisoryAgreementMemberusgaapTypeOfArrangementAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:DirectorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">btmd:FounderAdvisoryAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-05-18</startDate>
            <endDate>2022-05-18</endDate>
        </period>
    </context>
    <context id="P05_18_2022To05_18_2022_ConsultantMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_NewIndependentContractorAgreementMemberusgaapTypeOfArrangementAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">btmd:ConsultantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">btmd:NewIndependentContractorAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-05-18</startDate>
            <endDate>2022-05-18</endDate>
        </period>
    </context>
    <context id="P03_26_2022To05_26_2022_IncentiveUnitsMemberusgaapAwardTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">btmd:IncentiveUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-03-26</startDate>
            <endDate>2022-05-26</endDate>
        </period>
    </context>
    <context id="P03_26_2022To05_26_2022_PhantomEquityRightsMemberusgaapAwardTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">btmd:PhantomEquityRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-03-26</startDate>
            <endDate>2022-05-26</endDate>
        </period>
    </context>
    <context id="P05_31_2022To06_30_2022_MaximumMembersrtRangeAxis_PhantomEquityRightsMemberusgaapAwardTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">btmd:PhantomEquityRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-05-31</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="P06_01_2022To06_30_2022_MinimumMembersrtRangeAxis_PhantomEquityRightsMemberusgaapAwardTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">btmd:PhantomEquityRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-06-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="PAsOn12_31_2021_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis_TwoThousandTwentyTwoEquityIncentivePlanMemberusgaapPlanNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">btmd:TwoThousandTwentyTwoEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_MemberUnitsMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:MemberUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_RetainedEarningsMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_ParentMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_MemberUnitsMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:MemberUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_RetainedEarningsMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_ParentMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_CommonClassAMemberusgaapStatementClassOfStockAxis_CommonStockMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_CommonClassVMemberusgaapStatementClassOfStockAxis_CommonStockMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">btmd:CommonClassVMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_RetainedEarningsMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_ParentMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_NoncontrollingInterestMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819253</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <unit id="Unit_USD">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="Unit_shares">
        <measure>shares</measure>
    </unit>
    <unit id="Unit_Year">
        <measure>utr:Year</measure>
    </unit>
    <unit id="Unit_Day">
        <measure>utr:Day</measure>
    </unit>
    <unit id="Unit_pure">
        <measure>pure</measure>
    </unit>
    <unit id="Unit_Month">
        <measure>utr:Month</measure>
    </unit>
    <unit id="Unit_USD_per_Share">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="Unit_SEGMENT">
        <measure>btmd:SEGMENT</measure>
    </unit>
    <unit id="Unit_sqft">
        <measure>utr:sqft</measure>
    </unit>
    <unit id="Unit_VOTE">
        <measure>btmd:VOTE</measure>
    </unit>
    <unit id="Unit_vendor">
        <measure>btmd:vendor</measure>
    </unit>
    <unit id="Unit_CUSTOMER">
        <measure>btmd:CUSTOMER</measure>
    </unit>
    <dei:DocumentType contextRef="P01_01_2022To12_31_2022" id="hidden73945327">S-1</dei:DocumentType>
    <dei:AmendmentFlag contextRef="P01_01_2022To12_31_2022">false</dei:AmendmentFlag>
    <dei:EntityCentralIndexKey contextRef="P01_01_2022To12_31_2022">0001819253</dei:EntityCentralIndexKey>
    <dei:EntityAddressStateOrProvince contextRef="P01_01_2022To12_31_2022" id="hidden73945344">TX</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressStateOrProvince
      contextRef="P01_01_2022To12_31_2022_BusinessContactMemberdeiEntityAddressesAddressTypeAxis"
      id="hidden73945345">TX</dei:EntityAddressStateOrProvince>
    <dei:EntityRegistrantName contextRef="P01_01_2022To12_31_2022">biote Corp.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="P01_01_2022To12_31_2022">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityPrimarySicNumber contextRef="P01_01_2022To12_31_2022">2833</dei:EntityPrimarySicNumber>
    <dei:EntityTaxIdentificationNumber contextRef="P01_01_2022To12_31_2022">85-1791125</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="P01_01_2022To12_31_2022">1875 W. Walnut Hill Ln #100</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown contextRef="P01_01_2022To12_31_2022">Irving</dei:EntityAddressCityOrTown>
    <dei:EntityAddressPostalZipCode contextRef="P01_01_2022To12_31_2022">75038</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="P01_01_2022To12_31_2022">844</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="P01_01_2022To12_31_2022">604-1246</dei:LocalPhoneNumber>
    <dei:ContactPersonnelName contextRef="P01_01_2022To12_31_2022_BusinessContactMemberdeiEntityAddressesAddressTypeAxis">Teresa S. Weber</dei:ContactPersonnelName>
    <dei:EntityAddressAddressLine1 contextRef="P01_01_2022To12_31_2022_BusinessContactMemberdeiEntityAddressesAddressTypeAxis">1875 W. Walnut Hill Ln #100</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown contextRef="P01_01_2022To12_31_2022_BusinessContactMemberdeiEntityAddressesAddressTypeAxis">Irving</dei:EntityAddressCityOrTown>
    <dei:EntityAddressPostalZipCode contextRef="P01_01_2022To12_31_2022_BusinessContactMemberdeiEntityAddressesAddressTypeAxis">75038</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="P01_01_2022To12_31_2022_BusinessContactMemberdeiEntityAddressesAddressTypeAxis">312</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="P01_01_2022To12_31_2022_BusinessContactMemberdeiEntityAddressesAddressTypeAxis">212-8079</dei:LocalPhoneNumber>
    <dei:EntityFilerCategory contextRef="P01_01_2022To12_31_2022">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness contextRef="P01_01_2022To12_31_2022">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany contextRef="P01_01_2022To12_31_2022">true</dei:EntityEmergingGrowthCompany>
    <dei:EntityExTransitionPeriod contextRef="P01_01_2022To12_31_2022">false</dei:EntityExTransitionPeriod>
    <us-gaap:LeaseExpirationDate1 contextRef="P07_01_2014To07_01_2014" id="hidden73946198">2023-06-30</us-gaap:LeaseExpirationDate1>
    <btmd:CapitalizedSoftwareEstimatedUsefulLives
      contextRef="P01_01_2022To12_31_2022_MinimumMembersrtRangeAxis"
      id="hidden73945767">P3Y</btmd:CapitalizedSoftwareEstimatedUsefulLives>
    <btmd:CapitalizedSoftwareEstimatedUsefulLives
      contextRef="P01_01_2022To12_31_2022_MaximumMembersrtRangeAxis"
      id="hidden73945768">P8Y</btmd:CapitalizedSoftwareEstimatedUsefulLives>
    <btmd:EarnoutDeadlineDate
      contextRef="P01_01_2022To12_31_2022_BusinessCombinationMemberusgaapBusinessAcquisitionAxis"
      id="hidden73946098">2027-05-26</btmd:EarnoutDeadlineDate>
    <us-gaap:CommonStockSharesAuthorizedUnlimited contextRef="P01_01_2022To12_31_2022" id="hidden73945433">Unlimited</us-gaap:CommonStockSharesAuthorizedUnlimited>
    <us-gaap:CommonStockSharesAuthorizedUnlimited contextRef="P01_01_2021To12_31_2021" id="hidden73945434">Unlimited</us-gaap:CommonStockSharesAuthorizedUnlimited>
    <us-gaap:BusinessAcquisitionDescriptionOfAcquiredEntity
      contextRef="P01_01_2022To12_31_2022_HaymakeriiiMembersrtConsolidatedEntitiesAxis_OtherBusinessCombinationMemberusgaapBusinessAcquisitionAxis"
      id="hidden73945879">The TRA provides that, in the event that (i) the Company exercises its early termination rights under the TRA, (ii) certain changes of control occur (as described in the TRA), (iii) the Company, in certain circumstances, fails to make a payment required to be made pursuant to the TRA by the applicable final payment date, which non-payment continues for 30 days following such final payment date or (iv) the Company materially breaches any of its material obligations under the TRA, which breach continues without cure for 30 days following receipt by the Company of written notice thereof (unless, in the case of clauses (iii) and (iv), certain liquidity exceptions apply) the Company&#x2019;s obligations under the TRA will accelerate and the Company will be required to make a lump-sum cash payment to the applicable parties to the TRA equal to the present value of all forecasted future payments that would have otherwise been made under the TRA, which lump-sum payment would be based on certain assumptions, including those relating to our future taxable income. </us-gaap:BusinessAcquisitionDescriptionOfAcquiredEntity>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="P01_01_2022To12_31_2022_MinimumMembersrtRangeAxis_PhantomEquityRightsMemberusgaapAwardTypeAxis"
      id="hidden73946171">P1Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="P06_01_2022To06_30_2022_MinimumMembersrtRangeAxis_PhantomEquityRightsMemberusgaapAwardTypeAxis"
      id="hidden73946172">P1Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <btmd:LineOfCreditFacilityMaturityMonthAndYear
      contextRef="P01_01_2022To12_31_2022_BankOfAmericaTermLoanMemberusgaapDebtInstrumentAxis_LineOfCreditMemberusgaapCreditFacilityAxis"
      id="hidden73946021">2024-05</btmd:LineOfCreditFacilityMaturityMonthAndYear>
    <btmd:ConsecutiveTradingDays contextRef="P07_27_2022To07_27_2022" id="hidden73945778">P3D</btmd:ConsecutiveTradingDays>
    <us-gaap:DebtInstrumentCovenantDescription
      contextRef="P01_01_2022To12_31_2022_LineOfCreditMemberusgaapCreditFacilityAxis_TruistTermLoanMemberusgaapDebtInstrumentAxis"
      id="hidden73946027">In addition, the Credit Agreement is subject to (i) a maximum total net leverage ratio and (ii) a minimum fixed charge coverage ratio. The Company must maintain a total net leverage ratio of less than or equal to (i) 4.25:1.00, with respect to the fiscal quarter ending September 30, 2022 through and including the fiscal quarter ending March 31, 2023, (ii) 4.00:1.00, with respect to the fiscal quarter ending June 30, 2023 through and including March 31, 2024, and (iii) 3.75:1.00 thereafter. Beginning with the third fiscal quarter of 2022, the Company must not permit the Consolidated Fixed Charge Coverage Ratio to be less than 1.25:1.00. Both financial covenants are tested quarterly.</us-gaap:DebtInstrumentCovenantDescription>
    <us-gaap:Cash
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">79231000</us-gaap:Cash>
    <us-gaap:Cash
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">26766000</us-gaap:Cash>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">6948000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">5231000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:InventoryNet
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">11183000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">9615000</us-gaap:InventoryNet>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">3816000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">5473000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">101178000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">47085000</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">1504000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">2335000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:CapitalizedComputerSoftwareNet
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">5073000</us-gaap:CapitalizedComputerSoftwareNet>
    <us-gaap:CapitalizedComputerSoftwareNet
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">4554000</us-gaap:CapitalizedComputerSoftwareNet>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">2052000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">356000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:DeferredIncomeTaxAssetsNet
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">1838000</us-gaap:DeferredIncomeTaxAssetsNet>
    <us-gaap:Assets
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">111645000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">54330000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">4112000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">4349000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">6274000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">6011000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:LongTermDebtCurrent
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">6250000</us-gaap:LongTermDebtCurrent>
    <us-gaap:LongTermDebtCurrent
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">5000000</us-gaap:LongTermDebtCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">1965000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">1705000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">165000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">248000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">18766000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">17313000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">112086000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">31963000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">926000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">802000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">1927000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">127000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:WarrantsAndRightsOutstanding
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">4104000</us-gaap:WarrantsAndRightsOutstanding>
    <us-gaap:DerivativeLiabilitiesNoncurrent
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">32110000</us-gaap:DerivativeLiabilitiesNoncurrent>
    <us-gaap:Liabilities
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">169919000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">50205000</us-gaap:Liabilities>
    <us-gaap:CommitmentsAndContingencies
      contextRef="PAsOn12_31_2022"
      unitRef="Unit_USD"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="PAsOn12_31_2021"
      unitRef="Unit_USD"
      xsi:nil="true"/>
    <us-gaap:CommonStockNoParValue
      contextRef="PAsOn12_31_2022_ClassAaUnitsMemberusgaapStatementClassOfStockAxis"
      decimals="INF"
      unitRef="Unit_USD_per_Share">0</us-gaap:CommonStockNoParValue>
    <us-gaap:CommonStockNoParValue
      contextRef="PAsOn12_31_2022_ClassAaaUnitsMemberusgaapStatementClassOfStockAxis"
      decimals="INF"
      unitRef="Unit_USD_per_Share">0</us-gaap:CommonStockNoParValue>
    <us-gaap:CommonStockNoParValue
      contextRef="PAsOn12_31_2022_ClassAaaaUnitsMemberusgaapStatementClassOfStockAxis"
      decimals="INF"
      unitRef="Unit_USD_per_Share">0</us-gaap:CommonStockNoParValue>
    <us-gaap:CommonStockNoParValue
      contextRef="PAsOn12_31_2022_ClassAMemberusgaapStatementClassOfStockAxis"
      decimals="INF"
      unitRef="Unit_USD_per_Share">0</us-gaap:CommonStockNoParValue>
    <us-gaap:CommonStockSharesIssued
      contextRef="PAsOn12_31_2022_ClassAaUnitsMemberusgaapStatementClassOfStockAxis"
      decimals="INF"
      unitRef="Unit_shares">0</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesIssued
      contextRef="PAsOn12_31_2022_ClassAaaUnitsMemberusgaapStatementClassOfStockAxis"
      decimals="INF"
      unitRef="Unit_shares">0</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesIssued
      contextRef="PAsOn12_31_2022_ClassAaaaUnitsMemberusgaapStatementClassOfStockAxis"
      decimals="INF"
      unitRef="Unit_shares">0</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesIssued
      contextRef="PAsOn12_31_2022_ClassAMemberusgaapStatementClassOfStockAxis"
      decimals="INF"
      unitRef="Unit_shares">0</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesIssued
      contextRef="PAsOn12_31_2021_ClassAaUnitsMemberusgaapStatementClassOfStockAxis"
      decimals="INF"
      unitRef="Unit_shares">1013197</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesIssued
      contextRef="PAsOn12_31_2021_ClassAaaUnitsMemberusgaapStatementClassOfStockAxis"
      decimals="INF"
      unitRef="Unit_shares">1013197</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesIssued
      contextRef="PAsOn12_31_2021_ClassAaaaUnitsMemberusgaapStatementClassOfStockAxis"
      decimals="INF"
      unitRef="Unit_shares">1013197</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesIssued
      contextRef="PAsOn12_31_2021_ClassAMemberusgaapStatementClassOfStockAxis"
      decimals="INF"
      unitRef="Unit_shares">1013197</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="PAsOn12_31_2022_ClassAaUnitsMemberusgaapStatementClassOfStockAxis"
      decimals="INF"
      unitRef="Unit_shares">0</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="PAsOn12_31_2022_ClassAaaUnitsMemberusgaapStatementClassOfStockAxis"
      decimals="INF"
      unitRef="Unit_shares">0</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="PAsOn12_31_2022_ClassAaaaUnitsMemberusgaapStatementClassOfStockAxis"
      decimals="INF"
      unitRef="Unit_shares">0</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="PAsOn12_31_2022_ClassAMemberusgaapStatementClassOfStockAxis"
      decimals="INF"
      unitRef="Unit_shares">0</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="PAsOn12_31_2021_ClassAaUnitsMemberusgaapStatementClassOfStockAxis"
      decimals="INF"
      unitRef="Unit_shares">982800</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="PAsOn12_31_2021_ClassAaaUnitsMemberusgaapStatementClassOfStockAxis"
      decimals="INF"
      unitRef="Unit_shares">982800</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="PAsOn12_31_2021_ClassAaaaUnitsMemberusgaapStatementClassOfStockAxis"
      decimals="INF"
      unitRef="Unit_shares">982800</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="PAsOn12_31_2021_ClassAMemberusgaapStatementClassOfStockAxis"
      decimals="INF"
      unitRef="Unit_shares">982800</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="PAsOn12_31_2021"
      decimals="INF"
      unitRef="Unit_USD_per_Share">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="PAsOn12_31_2022"
      decimals="INF"
      unitRef="Unit_USD_per_Share">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="PAsOn12_31_2021"
      decimals="INF"
      unitRef="Unit_shares">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="PAsOn12_31_2022"
      decimals="INF"
      unitRef="Unit_shares">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued
      contextRef="PAsOn12_31_2021"
      decimals="INF"
      unitRef="Unit_shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="PAsOn12_31_2022"
      decimals="INF"
      unitRef="Unit_shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="PAsOn12_31_2021"
      decimals="INF"
      unitRef="Unit_shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesIssued
      contextRef="PAsOn12_31_2022"
      decimals="INF"
      unitRef="Unit_shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockValue
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockValue
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:PreferredStockValue>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="PAsOn12_31_2021_CommonClassAMemberusgaapStatementClassOfStockAxis"
      decimals="INF"
      unitRef="Unit_USD_per_Share">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="PAsOn12_31_2022_CommonClassAMemberusgaapStatementClassOfStockAxis"
      decimals="INF"
      unitRef="Unit_USD_per_Share">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="PAsOn12_31_2021_CommonClassAMemberusgaapStatementClassOfStockAxis"
      decimals="INF"
      unitRef="Unit_shares">600000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="PAsOn12_31_2022_CommonClassAMemberusgaapStatementClassOfStockAxis"
      decimals="INF"
      unitRef="Unit_shares">600000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="PAsOn12_31_2022_CommonClassAMemberusgaapStatementClassOfStockAxis"
      decimals="INF"
      unitRef="Unit_shares">11242887</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesIssued
      contextRef="PAsOn12_31_2021_CommonClassAMemberusgaapStatementClassOfStockAxis"
      decimals="INF"
      unitRef="Unit_shares">0</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="PAsOn12_31_2022_CommonClassAMemberusgaapStatementClassOfStockAxis"
      decimals="INF"
      unitRef="Unit_shares">9655387</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="PAsOn12_31_2021_CommonClassAMemberusgaapStatementClassOfStockAxis"
      decimals="INF"
      unitRef="Unit_shares">0</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue
      contextRef="PAsOn12_31_2022_CommonClassAMemberusgaapStatementClassOfStockAxis"
      decimals="-3"
      unitRef="Unit_USD">1000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="PAsOn12_31_2021_CommonClassBMemberusgaapStatementClassOfStockAxis"
      decimals="INF"
      unitRef="Unit_USD_per_Share">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="PAsOn12_31_2022_CommonClassBMemberusgaapStatementClassOfStockAxis"
      decimals="INF"
      unitRef="Unit_USD_per_Share">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="PAsOn12_31_2021_CommonClassBMemberusgaapStatementClassOfStockAxis"
      decimals="INF"
      unitRef="Unit_shares">8000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="PAsOn12_31_2022_CommonClassBMemberusgaapStatementClassOfStockAxis"
      decimals="INF"
      unitRef="Unit_shares">8000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="PAsOn12_31_2021_CommonClassBMemberusgaapStatementClassOfStockAxis"
      decimals="INF"
      unitRef="Unit_shares">0</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="PAsOn12_31_2022_CommonClassBMemberusgaapStatementClassOfStockAxis"
      decimals="INF"
      unitRef="Unit_shares">0</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="PAsOn12_31_2021_CommonClassBMemberusgaapStatementClassOfStockAxis"
      decimals="INF"
      unitRef="Unit_shares">0</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="PAsOn12_31_2022_CommonClassBMemberusgaapStatementClassOfStockAxis"
      decimals="INF"
      unitRef="Unit_shares">0</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockValue
      contextRef="PAsOn12_31_2022_CommonClassBMemberusgaapStatementClassOfStockAxis"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="PAsOn12_31_2021_CommonClassBMemberusgaapStatementClassOfStockAxis"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:CommonStockValue>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="PAsOn12_31_2021_CommonClassVMemberusgaapStatementClassOfStockAxis"
      decimals="INF"
      unitRef="Unit_USD_per_Share">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="PAsOn12_31_2022_CommonClassVMemberusgaapStatementClassOfStockAxis"
      decimals="INF"
      unitRef="Unit_USD_per_Share">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="PAsOn12_31_2021_CommonClassVMemberusgaapStatementClassOfStockAxis"
      decimals="INF"
      unitRef="Unit_shares">100000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="PAsOn12_31_2022_CommonClassVMemberusgaapStatementClassOfStockAxis"
      decimals="INF"
      unitRef="Unit_shares">100000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="PAsOn12_31_2022_CommonClassVMemberusgaapStatementClassOfStockAxis"
      decimals="INF"
      unitRef="Unit_shares">58565824</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesIssued
      contextRef="PAsOn12_31_2021_CommonClassVMemberusgaapStatementClassOfStockAxis"
      decimals="INF"
      unitRef="Unit_shares">0</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="PAsOn12_31_2022_CommonClassVMemberusgaapStatementClassOfStockAxis"
      decimals="INF"
      unitRef="Unit_shares">48565824</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="PAsOn12_31_2021_CommonClassVMemberusgaapStatementClassOfStockAxis"
      decimals="INF"
      unitRef="Unit_shares">0</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue
      contextRef="PAsOn12_31_2022_CommonClassVMemberusgaapStatementClassOfStockAxis"
      decimals="-3"
      unitRef="Unit_USD">5000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:AdditionalPaidInCapital>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">-44460000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">4165000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">-5000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">-40000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">-44459000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">4125000</us-gaap:StockholdersEquity>
    <us-gaap:CommonStockNoParValue
      contextRef="PAsOn12_31_2021_ClassAaUnitsMemberusgaapStatementClassOfStockAxis"
      decimals="INF"
      unitRef="Unit_USD_per_Share">0</us-gaap:CommonStockNoParValue>
    <us-gaap:CommonStockNoParValue
      contextRef="PAsOn12_31_2021_ClassAaaUnitsMemberusgaapStatementClassOfStockAxis"
      decimals="INF"
      unitRef="Unit_USD_per_Share">0</us-gaap:CommonStockNoParValue>
    <us-gaap:CommonStockNoParValue
      contextRef="PAsOn12_31_2021_ClassAaaaUnitsMemberusgaapStatementClassOfStockAxis"
      decimals="INF"
      unitRef="Unit_USD_per_Share">0</us-gaap:CommonStockNoParValue>
    <us-gaap:CommonStockNoParValue
      contextRef="PAsOn12_31_2021_ClassAMemberusgaapStatementClassOfStockAxis"
      decimals="INF"
      unitRef="Unit_USD_per_Share">0</us-gaap:CommonStockNoParValue>
    <us-gaap:MinorityInterest
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">-13815000</us-gaap:MinorityInterest>
    <us-gaap:MinorityInterest
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:MinorityInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">-58274000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">4125000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">111645000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">54330000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P01_01_2022To12_31_2022_ProductRevenueMembersrtProductOrServiceAxis"
      decimals="-3"
      unitRef="Unit_USD">163133000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P01_01_2021To12_31_2021_ProductRevenueMembersrtProductOrServiceAxis"
      decimals="-3"
      unitRef="Unit_USD">137598000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P01_01_2022To12_31_2022_ServiceRevenueMembersrtProductOrServiceAxis"
      decimals="-3"
      unitRef="Unit_USD">1824000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P01_01_2021To12_31_2021_ServiceRevenueMembersrtProductOrServiceAxis"
      decimals="-3"
      unitRef="Unit_USD">1798000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">164957000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">139396000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization
      contextRef="P01_01_2022To12_31_2022_ProductRevenueMembersrtProductOrServiceAxis"
      decimals="-3"
      unitRef="Unit_USD">51990000</us-gaap:CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization>
    <us-gaap:CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization
      contextRef="P01_01_2021To12_31_2021_ProductRevenueMembersrtProductOrServiceAxis"
      decimals="-3"
      unitRef="Unit_USD">46298000</us-gaap:CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization>
    <us-gaap:CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization
      contextRef="P01_01_2022To12_31_2022_ServiceRevenueMembersrtProductOrServiceAxis"
      decimals="-3"
      unitRef="Unit_USD">2585000</us-gaap:CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization>
    <us-gaap:CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization
      contextRef="P01_01_2021To12_31_2021_ServiceRevenueMembersrtProductOrServiceAxis"
      decimals="-3"
      unitRef="Unit_USD">2519000</us-gaap:CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization>
    <us-gaap:CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">54575000</us-gaap:CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization>
    <us-gaap:CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">48817000</us-gaap:CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization>
    <us-gaap:SalesCommissionsAndFees
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">974000</us-gaap:SalesCommissionsAndFees>
    <us-gaap:SalesCommissionsAndFees
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">2056000</us-gaap:SalesCommissionsAndFees>
    <us-gaap:MarketingExpense
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">4628000</us-gaap:MarketingExpense>
    <us-gaap:MarketingExpense
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">4908000</us-gaap:MarketingExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">165502000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">49054000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:OperatingIncomeLoss
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">-60722000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">34561000</us-gaap:OperatingIncomeLoss>
    <us-gaap:InterestIncomeExpenseNonoperatingNet
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">-5091000</us-gaap:InterestIncomeExpenseNonoperatingNet>
    <us-gaap:InterestIncomeExpenseNonoperatingNet
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">-1673000</us-gaap:InterestIncomeExpenseNonoperatingNet>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">-5127000</us-gaap:FairValueAdjustmentOfWarrants>
    <btmd:GainLossFromChangeInFairValueOfEarnoutLiability
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">61770000</btmd:GainLossFromChangeInFairValueOfEarnoutLiability>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">-445000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:OtherNonoperatingIncome
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">1073000</us-gaap:OtherNonoperatingIncome>
    <us-gaap:OtherNonoperatingIncome
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">17000</us-gaap:OtherNonoperatingIncome>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">62434000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">-1656000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">1712000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">32905000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">388000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">286000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:ProfitLoss
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">1324000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">32619000</us-gaap:ProfitLoss>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">2293000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLoss
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">-969000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">-1000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">-17000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">-1000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">-17000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">1323000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">32602000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:EarningsPerShareBasic
      contextRef="P01_01_2022To12_31_2022"
      decimals="2"
      unitRef="Unit_USD_per_Share">-0.12</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="P01_01_2022To12_31_2022"
      decimals="2"
      unitRef="Unit_USD_per_Share">-0.12</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="P01_01_2022To12_31_2022"
      decimals="0"
      unitRef="Unit_shares">8059371</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="P01_01_2022To12_31_2022"
      decimals="0"
      unitRef="Unit_shares">8059371</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:PartnersCapitalAccountUnits
      contextRef="PAsOn12_31_2020_MemberUnitsMemberusgaapStatementEquityComponentsAxis"
      decimals="INF"
      unitRef="Unit_shares">982800</us-gaap:PartnersCapitalAccountUnits>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="PAsOn12_31_2020_RetainedEarningsMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">-17052000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="PAsOn12_31_2020_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">-23000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="PAsOn12_31_2020_ParentMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">-17075000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">-17075000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:DividendsCommonStock
      contextRef="P01_01_2021To12_31_2021_RetainedEarningsMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">11402000</us-gaap:DividendsCommonStock>
    <us-gaap:DividendsCommonStock
      contextRef="P01_01_2021To12_31_2021_ParentMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">11402000</us-gaap:DividendsCommonStock>
    <us-gaap:DividendsCommonStock
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">11402000</us-gaap:DividendsCommonStock>
    <us-gaap:ProfitLoss
      contextRef="P01_01_2021To12_31_2021_RetainedEarningsMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">32619000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="P01_01_2021To12_31_2021_ParentMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">32619000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">32619000</us-gaap:ProfitLoss>
    <us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
      contextRef="P01_01_2021To12_31_2021_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">-17000</us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
      contextRef="P01_01_2021To12_31_2021_ParentMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">-17000</us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">-17000</us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:PartnersCapitalAccountUnits
      contextRef="PAsOn12_31_2021_MemberUnitsMemberusgaapStatementEquityComponentsAxis"
      decimals="INF"
      unitRef="Unit_shares">982800</us-gaap:PartnersCapitalAccountUnits>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="PAsOn12_31_2021_RetainedEarningsMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">4165000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="PAsOn12_31_2021_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">-40000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="PAsOn12_31_2021_ParentMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">4125000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">4125000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:PartnersCapitalAccountUnits
      contextRef="PAsOn12_31_2021_MemberUnitsMemberusgaapStatementEquityComponentsAxis"
      decimals="INF"
      unitRef="Unit_shares">982800</us-gaap:PartnersCapitalAccountUnits>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="PAsOn12_31_2021_RetainedEarningsMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">4165000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="PAsOn12_31_2021_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">-40000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="PAsOn12_31_2021_ParentMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">4125000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">4125000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:DividendsCommonStock
      contextRef="P01_01_2022To12_31_2022_RetainedEarningsMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">9575000</us-gaap:DividendsCommonStock>
    <us-gaap:DividendsCommonStock
      contextRef="P01_01_2022To12_31_2022_ParentMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">9575000</us-gaap:DividendsCommonStock>
    <us-gaap:DividendsCommonStock
      contextRef="P01_01_2022To12_31_2022_NoncontrollingInterestMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">3311000</us-gaap:DividendsCommonStock>
    <us-gaap:DividendsCommonStock
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">12886000</us-gaap:DividendsCommonStock>
    <us-gaap:ProfitLoss
      contextRef="P01_01_2022To05_26_2022_RetainedEarningsMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">9143000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="P01_01_2022To05_26_2022_ParentMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">9143000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="P01_01_2022To05_26_2022"
      decimals="-3"
      unitRef="Unit_USD">9143000</us-gaap:ProfitLoss>
    <us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
      contextRef="P01_01_2022To05_26_2022_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">1000</us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
      contextRef="P01_01_2022To05_26_2022_ParentMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">1000</us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
      contextRef="P01_01_2022To05_26_2022"
      decimals="-3"
      unitRef="Unit_USD">1000</us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest>
    <btmd:PartnersCapitalAccountReverseRecapitalizationUnits
      contextRef="PAsOn05_26_2022_MemberUnitsMemberusgaapStatementEquityComponentsAxis"
      decimals="0"
      unitRef="Unit_shares">-982800</btmd:PartnersCapitalAccountReverseRecapitalizationUnits>
    <btmd:StockholdersEquityIncludingPortionAttributableToNonControllingInterestSharesReverseRecapitalization
      contextRef="PAsOn05_26_2022_CommonClassAMemberusgaapStatementClassOfStockAxis"
      decimals="0"
      unitRef="Unit_shares">7574271</btmd:StockholdersEquityIncludingPortionAttributableToNonControllingInterestSharesReverseRecapitalization>
    <btmd:StockholdersEquityIncludingPortionAttributableToNonControllingInterestReverseRecapitalization
      contextRef="PAsOn05_26_2022_CommonClassAMemberusgaapStatementClassOfStockAxis"
      decimals="-3"
      unitRef="Unit_USD">1000</btmd:StockholdersEquityIncludingPortionAttributableToNonControllingInterestReverseRecapitalization>
    <btmd:StockholdersEquityIncludingPortionAttributableToNonControllingInterestSharesReverseRecapitalization
      contextRef="PAsOn05_26_2022_CommonClassVMemberusgaapStatementClassOfStockAxis"
      decimals="0"
      unitRef="Unit_shares">48565824</btmd:StockholdersEquityIncludingPortionAttributableToNonControllingInterestSharesReverseRecapitalization>
    <btmd:StockholdersEquityIncludingPortionAttributableToNonControllingInterestReverseRecapitalization
      contextRef="PAsOn05_26_2022_CommonClassVMemberusgaapStatementClassOfStockAxis"
      decimals="-3"
      unitRef="Unit_USD">5000</btmd:StockholdersEquityIncludingPortionAttributableToNonControllingInterestReverseRecapitalization>
    <btmd:StockholdersEquityIncludingPortionAttributableToNonControllingInterestReverseRecapitalization
      contextRef="PAsOn05_26_2022_RetainedEarningsMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">-113628000</btmd:StockholdersEquityIncludingPortionAttributableToNonControllingInterestReverseRecapitalization>
    <btmd:StockholdersEquityIncludingPortionAttributableToNonControllingInterestReverseRecapitalization
      contextRef="PAsOn05_26_2022_ParentMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">-113622000</btmd:StockholdersEquityIncludingPortionAttributableToNonControllingInterestReverseRecapitalization>
    <btmd:StockholdersEquityIncludingPortionAttributableToNonControllingInterestReverseRecapitalization
      contextRef="PAsOn05_26_2022"
      decimals="-3"
      unitRef="Unit_USD">-113622000</btmd:StockholdersEquityIncludingPortionAttributableToNonControllingInterestReverseRecapitalization>
    <btmd:StockholdersEquityAttributableToNonControllingInterestBusinessCombination
      contextRef="PAsOn05_26_2022_RetainedEarningsMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">3619000</btmd:StockholdersEquityAttributableToNonControllingInterestBusinessCombination>
    <btmd:StockholdersEquityAttributableToNonControllingInterestBusinessCombination
      contextRef="PAsOn05_26_2022_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">34000</btmd:StockholdersEquityAttributableToNonControllingInterestBusinessCombination>
    <btmd:StockholdersEquityAttributableToNonControllingInterestBusinessCombination
      contextRef="PAsOn05_26_2022_ParentMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">3653000</btmd:StockholdersEquityAttributableToNonControllingInterestBusinessCombination>
    <btmd:StockholdersEquityAttributableToNonControllingInterestBusinessCombination
      contextRef="PAsOn05_26_2022_NoncontrollingInterestMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">-3653000</btmd:StockholdersEquityAttributableToNonControllingInterestBusinessCombination>
    <btmd:StockholdersEquityBussinessCombinationCapitalizedTransactionCosts
      contextRef="P01_01_2022To12_31_2022_RetainedEarningsMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">-12282000</btmd:StockholdersEquityBussinessCombinationCapitalizedTransactionCosts>
    <btmd:StockholdersEquityBussinessCombinationCapitalizedTransactionCosts
      contextRef="P01_01_2022To12_31_2022_ParentMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">-12282000</btmd:StockholdersEquityBussinessCombinationCapitalizedTransactionCosts>
    <btmd:StockholdersEquityBussinessCombinationCapitalizedTransactionCosts
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">-12282000</btmd:StockholdersEquityBussinessCombinationCapitalizedTransactionCosts>
    <us-gaap:ProfitLoss
      contextRef="P05_27_2022To12_31_2022_RetainedEarningsMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">-969000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="P05_27_2022To12_31_2022_ParentMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">-969000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="P05_27_2022To12_31_2022_NoncontrollingInterestMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">-6850000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="P05_27_2022To12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">-7819000</us-gaap:ProfitLoss>
    <us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
      contextRef="P05_27_2022To12_31_2022_NoncontrollingInterestMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">-1000</us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
      contextRef="P05_27_2022To12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">1000</us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="P01_01_2022To12_31_2022_RetainedEarningsMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">82180000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="P01_01_2022To12_31_2022_ParentMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">82180000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">82180000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <btmd:StockIssuedDuringPeriodValueSettlementOfEquityRights
      contextRef="P01_01_2022To12_31_2022_RetainedEarningsMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">-7250000</btmd:StockIssuedDuringPeriodValueSettlementOfEquityRights>
    <btmd:StockIssuedDuringPeriodValueSettlementOfEquityRights
      contextRef="P01_01_2022To12_31_2022_ParentMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">-7250000</btmd:StockIssuedDuringPeriodValueSettlementOfEquityRights>
    <btmd:StockIssuedDuringPeriodValueSettlementOfEquityRights
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">-7250000</btmd:StockIssuedDuringPeriodValueSettlementOfEquityRights>
    <btmd:StockIssuedDuringPeriodSharesVestingOfRestrictedStockUnit
      contextRef="P01_01_2022To12_31_2022_CommonClassAMemberusgaapStatementClassOfStockAxis_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="INF"
      unitRef="Unit_shares">1950557</btmd:StockIssuedDuringPeriodSharesVestingOfRestrictedStockUnit>
    <btmd:StockIssuedDuringPeriodValueVestingOfRestrictedStockUnit
      contextRef="P01_01_2022To12_31_2022_RetainedEarningsMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">-424000</btmd:StockIssuedDuringPeriodValueVestingOfRestrictedStockUnit>
    <btmd:StockIssuedDuringPeriodValueVestingOfRestrictedStockUnit
      contextRef="P01_01_2022To12_31_2022_ParentMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">-424000</btmd:StockIssuedDuringPeriodValueVestingOfRestrictedStockUnit>
    <btmd:StockIssuedDuringPeriodValueVestingOfRestrictedStockUnit
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">-424000</btmd:StockIssuedDuringPeriodValueVestingOfRestrictedStockUnit>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="P01_01_2022To12_31_2022_CommonClassAMemberusgaapStatementClassOfStockAxis_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="INF"
      unitRef="Unit_shares">130559</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="P01_01_2022To12_31_2022_RetainedEarningsMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">561000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="P01_01_2022To12_31_2022_ParentMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">561000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">561000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:SharesOutstanding
      contextRef="PAsOn12_31_2022_CommonClassAMemberusgaapStatementClassOfStockAxis_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="INF"
      unitRef="Unit_shares">9655387</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="PAsOn12_31_2022_CommonClassAMemberusgaapStatementClassOfStockAxis_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">1000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesOutstanding
      contextRef="PAsOn12_31_2022_CommonClassVMemberusgaapStatementClassOfStockAxis_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="INF"
      unitRef="Unit_shares">48565824</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="PAsOn12_31_2022_CommonClassVMemberusgaapStatementClassOfStockAxis_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">5000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="PAsOn12_31_2022_RetainedEarningsMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">-44460000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="PAsOn12_31_2022_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">-5000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="PAsOn12_31_2022_ParentMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">-44459000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="PAsOn12_31_2022_NoncontrollingInterestMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">-13815000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">-58274000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ProfitLoss
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">1324000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">32619000</us-gaap:ProfitLoss>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">2199000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">1400000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:ProvisionForDoubtfulAccounts
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">-155000</us-gaap:ProvisionForDoubtfulAccounts>
    <us-gaap:ProvisionForDoubtfulAccounts
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">240000</us-gaap:ProvisionForDoubtfulAccounts>
    <us-gaap:AmortizationOfFinancingCosts
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">589000</us-gaap:AmortizationOfFinancingCosts>
    <us-gaap:AmortizationOfFinancingCosts
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">222000</us-gaap:AmortizationOfFinancingCosts>
    <us-gaap:InventoryWriteDown
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">140000</us-gaap:InventoryWriteDown>
    <us-gaap:InventoryWriteDown
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">471000</us-gaap:InventoryWriteDown>
    <btmd:NonCashLeaseExpense
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">240000</btmd:NonCashLeaseExpense>
    <btmd:NonCashLeaseExpense
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">226000</btmd:NonCashLeaseExpense>
    <btmd:NonCashSponsorShareTransfers
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">7216000</btmd:NonCashSponsorShareTransfers>
    <btmd:NonCashFeesUnderSepa
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">119000</btmd:NonCashFeesUnderSepa>
    <us-gaap:ShareBasedCompensation
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">82180000</us-gaap:ShareBasedCompensation>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">-5127000</us-gaap:FairValueAdjustmentOfWarrants>
    <btmd:FairValueAdjustmentOfEarnoutLiability
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">-61770000</btmd:FairValueAdjustmentOfEarnoutLiability>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">-445000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:DeferredIncomeTaxesAndTaxCredits
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">-743000</us-gaap:DeferredIncomeTaxesAndTaxCredits>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">1562000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">752000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">1708000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">5762000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInOtherCurrentAssets
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">2284000</us-gaap:IncreaseDecreaseInOtherCurrentAssets>
    <us-gaap:IncreaseDecreaseInOtherCurrentAssets
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">-34000</us-gaap:IncreaseDecreaseInOtherCurrentAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">416000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">1605000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInDeferredRevenue
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">384000</us-gaap:IncreaseDecreaseInDeferredRevenue>
    <us-gaap:IncreaseDecreaseInDeferredRevenue
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">-373000</us-gaap:IncreaseDecreaseInDeferredRevenue>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">-30841000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">4029000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">-219000</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">-239000</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">-9157000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">33720000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">333000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">1448000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsForSoftware
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">1505000</us-gaap:PaymentsForSoftware>
    <us-gaap:PaymentsForSoftware
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">2359000</us-gaap:PaymentsForSoftware>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">-1838000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">-3807000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <btmd:ProceedsFromBusinessCombination
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">12282000</btmd:ProceedsFromBusinessCombination>
    <btmd:PrincipalRepaymentsOnTermLoan
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">4375000</btmd:PrincipalRepaymentsOnTermLoan>
    <btmd:PrincipalRepaymentsOnTermLoan
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">5000000</btmd:PrincipalRepaymentsOnTermLoan>
    <btmd:BorrowingsOnTermLoan
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">125000000</btmd:BorrowingsOnTermLoan>
    <us-gaap:PaymentsOfDebtExtinguishmentCosts
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">36250000</us-gaap:PaymentsOfDebtExtinguishmentCosts>
    <us-gaap:PaymentsOfDebtIssuanceCosts
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">4036000</us-gaap:PaymentsOfDebtIssuanceCosts>
    <btmd:PaymentsOfSettlementOfPhantomEquityRight
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">7250000</btmd:PaymentsOfSettlementOfPhantomEquityRight>
    <btmd:PaymentsOfSettlementOfRestrictedStockUnits
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">424000</btmd:PaymentsOfSettlementOfRestrictedStockUnits>
    <us-gaap:PaymentsOfDividends
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">12886000</us-gaap:PaymentsOfDividends>
    <us-gaap:PaymentsOfDividends
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">11402000</us-gaap:PaymentsOfDividends>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">8341000</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">3941000</us-gaap:PaymentsOfStockIssuanceCosts>
    <btmd:ProceedsFromIssuanceOfSharesUnderSepa
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">442000</btmd:ProceedsFromIssuanceOfSharesUnderSepa>
    <btmd:PaymentsToSEPATransactionCosts
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">702000</btmd:PaymentsToSEPATransactionCosts>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">63460000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">-20343000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">-12000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">52465000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">9558000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">26766000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">17208000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">79231000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">26766000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:InterestPaidNet
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">4426000</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">1462000</us-gaap:InterestPaidNet>
    <us-gaap:IncomeTaxesPaid
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">282000</us-gaap:IncomeTaxesPaid>
    <us-gaap:IncomeTaxesPaid
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">171000</us-gaap:IncomeTaxesPaid>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">49000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">282000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <btmd:NonCashSEPATransactionCosts
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">119000</btmd:NonCashSEPATransactionCosts>
    <us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock contextRef="P01_01_2022To12_31_2022">
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%"&gt;
&lt;tr style="page-break-inside:avoid"&gt;
&lt;td style="width:4%;vertical-align:top;text-align:left;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;1.&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:top;text-align:left;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; text-align: left; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;DESCRIPTION OF BUSINESS AND BASIS OF PRESENTATION &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Description of Business&lt;/div&gt;&lt;/div&gt;&#x2014;biote Corp. (inclusive of its consolidated subsidiaries, the &#x201c;Company&#x201d; or &#x201c;Biote&#x201d;) is a Delaware incorporated company headquartered in Irving, Texas. The Company was founded in 2012 and trains physicians and nurse practitioners in hormone optimization using &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;bio-identical&lt;/div&gt; hormone replacement pellet therapy in men and women experiencing hormonal imbalance. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Basis of Presentation&lt;/div&gt;&lt;/div&gt;&#x2014;The consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (&#x201c;U.S. GAAP&#x201d;). The consolidated financial statements include the accounts of Biote and its subsidiaries. All intercompany balances and transactions have been eliminated in consolidation. The Company recognizes noncontrolling interest related to its less-than-wholly-owned subsidiary as equity in the consolidated financial statements separate from the parent entity&#x2019;s equity. The net income attributable to noncontrolling interest is included in net income in the consolidated statements of income and comprehensive income. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;COVID-19&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&#x2014;As of December&#160;31, 2022 and December&#160;31, 2021, the &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;COVID-19&lt;/div&gt; pandemic and the related disruptions caused to the global economy did not have a material impact on the Company&#x2019;s business. However, the duration and intensity of the &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;COVID-19&lt;/div&gt; pandemic and any resulting disruption to the Company&#x2019;s operations remains somewhat uncertain, and the Company will continue to assess the impact of the &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;COVID-19&lt;/div&gt; pandemic on its financial position. Further, global economic conditions have been worsening, with disruptions to, and volatility in, the credit and financial markets in the U.S. and worldwide resulting from the effects of &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;COVID-19&lt;/div&gt; and otherwise. If these conditions persist and deepen, the Company could experience an inability to access additional capital or its liquidity could otherwise be impacted. If the Company is unable to raise capital when needed or on attractive terms, it would be forced to delay, reduce or eliminate its research and development programs and/or other efforts. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Business Combination&lt;/div&gt;&lt;/div&gt;&#x2014;On May&#160;26, 2022 (the &#x201c;Closing Date&#x201d;), BioTE Holdings, LLC (&#x201c;Holdings,&#x201d; inclusive of its direct and indirect subsidiaries, the &#x201c;BioTE Companies,&#x201d; and as to its members, the &#x201c;Members&#x201d;) completed a series of transactions (the &#x201c;Business Combination&#x201d;) with Haymaker Acquisition Corp. III (&#x201c;Haymaker&#x201d;), Haymaker Sponsor III LLC (the &#x201c;Sponsor&#x201d;), BioTE Management, LLC, Dr.&#160;Gary&#160;S. Donovitz, in his individual capacity, and Teresa S. Weber, in her capacity as the Members&#x2019; representative (in such capacity, the &#x201c;Members&#x2019; Representative&#x201d;) pursuant to the business combination agreement (the &#x201c;Business Combination Agreement&#x201d;) dated December&#160;13, 2021 (the &#x201c;Closing&#x201d;), which is discussed in more detail in Note 3. As a result of the Business Combination, Haymaker was renamed &#x201c;biote Corp.&#x201d; &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;The Business Combination was accounted for as a common control transaction, in accordance with U.S. GAAP. Under this method of accounting, Haymaker&#x2019;s acquisition of the BioTE Companies was accounted for at their historical carrying values, and the BioTE Companies were deemed the predecessor entity. This method of accounting is similar to a reverse recapitalization whereby the Business Combination was treated as the equivalent of the BioTE Companies issuing stock for the net assets of Haymaker, accompanied by a recapitalization. The net assets of Haymaker are stated at historical cost, with no goodwill or other intangible assets recorded. Operations prior to the Business Combination are those of the BioTE Companies. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;Following the Closing of the Business Combination, the Company is organized in an &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x201c;Up-C&#x201d;&lt;/div&gt; structure in which the business of the Company is operated by Holdings and its subsidiaries, and Biote&#x2019;s only material direct asset consists of equity interests in Holdings. The consolidated financial statements of Holdings and its subsidiaries have been determined to be the predecessor for accounting and reporting purposes for the period prior to the Business Combination. &lt;/div&gt;</us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock>
    <us-gaap:SignificantAccountingPoliciesTextBlock contextRef="P01_01_2022To12_31_2022">
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%"&gt;
&lt;tr style="page-break-inside:avoid"&gt;
&lt;td style="width:4%;vertical-align:top;text-align:left;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2.&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:top;text-align:left;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; text-align: left; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Use of Estimates&#x2014;&lt;/div&gt;&lt;/div&gt;The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. The Company regularly evaluates estimates and assumptions related to assets, liabilities, costs, expenses, contingent liabilities, share-based compensation and research and development costs. The Company bases its estimates and assumptions on historical experience and on various other factors that it believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results could differ from those estimates. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;In the opinion of the Company, the accompanying consolidated financial statements contain all adjustments, consisting of only normal recurring adjustments, necessary for a fair presentation of its financial position and its results of operations, changes in stockholders&#x2019; equity (deficit) and cash flows. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Fair Value Measurements&lt;/div&gt;&lt;/div&gt;&#x2014;The guidance in FASB ASC 820, &lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Fair Value Measurements and Disclosures &lt;/div&gt;&lt;/div&gt;(&#x201c;ASC 820&#x201d;), defines fair value and establishes a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements) and the lowest priority to unobservable inputs (Level 3 measurements). The three levels of the fair value hierarchy are described below: &lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Level&lt;/div&gt;&lt;/div&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;&#160;1&lt;/div&gt;&lt;/div&gt;&#x2014;Inputs are quoted prices (unadjusted) in active markets for identical assets or liabilities that the reporting entity has the ability to access at the measurement date. &lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Level 2&lt;/div&gt;&lt;/div&gt;&#x2014;Valuations based on quoted prices in markets that are not active or for which all significant inputs are observable, either directly or indirectly. &lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Level&lt;/div&gt;&lt;/div&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;&#160;3&lt;/div&gt;&lt;/div&gt;&#x2014;Prices or valuations that require inputs that are both significant to the fair value measurement and unobservable. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;See Note 12 for further detail. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Segment Information&lt;/div&gt;&lt;/div&gt;&#x2014;Operating segments are defined as components of an enterprise about which separate financial information is available that is evaluated regularly by the chief operating decision maker in deciding how to allocate resources and in assessing performance. The Company&#x2019;s chief operating decision maker is the chief executive officer. The Company has one business activity and there are no segment managers who are held accountable for operations, operating results, and plans for levels or components below the consolidated unit level. Accordingly, the Company has one operating segment and, therefore, one reportable segment. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Cash&lt;/div&gt;&lt;/div&gt;&#x2014;As of December&#160;31, 2022 and 2021, cash consists primarily of checking and savings deposits. The Company maintains deposits primarily with two financial institutions, which may at times exceed amounts covered by insurance provided by the U.S. Federal Deposit Insurance Corporation (&#x201c;FDIC&#x201d;). The Company has not experienced any losses related to amounts in excess of FDIC limits. The Company does not hold any cash equivalents, which would consist of highly liquid investments with original maturities of three months or less at the time of purchase. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Accounts Receivable and Allowance for Doubtful Accounts&lt;/div&gt;&lt;/div&gt;&#x2014;Accounts receivable are recorded net of allowances for doubtful accounts. Accounts receivable consist primarily of invoiced amounts to clinics that are not yet paid. On a periodic basis, management evaluates its accounts receivable and determines whether to provide an allowance or if any accounts should be written off based on past history of write-offs, collections, and current credit conditions. The Company maintains an allowance for doubtful accounts to provide for uncollectible amounts based on historical collection experience and an analysis of the aging of receivables. Management provides for probable uncollectible amounts through a charge to earnings and a credit to a valuation allowance based on its assessment of the current status of individual accounts. Balances still outstanding after &lt;/div&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;"&gt;&#160;&lt;/div&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"/&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;management has exhausted all reasonable collection efforts are written off through a charge to the valuation allowance and a credit to accounts receivable. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;Bad debt expense is classified in selling, general, and administrative expense within the consolidated statements of income and comprehensive income. The Company generally does not require any security or collateral to support its receivables. A rollforward of the allowance for doubtful accounts is as follows (in thousands): &lt;/div&gt;&lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:68%;border:0;margin:0 auto"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width:86%"/&gt;
&lt;td style="vertical-align:bottom;width:6%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;As of December&#160;31, 2020&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(1,157&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Provisions charged to operating results&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(240&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Account &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;write-off&lt;/div&gt; and recoveries&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(9&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;As of December&#160;31, 2021&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(1,406&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;As of December&#160;31, 2021&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(1,406&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Provisions charged to operating results&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;155&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Account &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;write-off&lt;/div&gt; and recoveries&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;277&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;As of December&#160;31, 2022&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(974&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Inventory&lt;/div&gt;&lt;/div&gt;&#x2014;Inventory is carried at the lower of cost or net realizable value using the &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;first-in,&lt;/div&gt; &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;first-out&lt;/div&gt; (FIFO) method. Inventory consists of bioidentical hormone pellets and dietary supplements. Bioidentical hormone pellets contain bioidentical testosterone or estrogen used to achieve hormone balance. Dietary supplements are high-grade vitamins used to enhance pellet therapy. The Company reviews its inventory balances and writes down its inventory for estimated obsolescence or excess inventory equal to the difference between the cost of inventory and the estimated net realizable value based upon assumptions about future demand and market conditions. Inventory write-downs are recorded within cost of products. Management recorded a reserve for obsolescence of inventory related to inventory which has expired. See Note 5 for further details. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Other Current Assets&lt;/div&gt;&lt;/div&gt;&#x2014;As of December&#160;31, 2022 and December&#160;31, 2021, the Company&#x2019;s total other current assets consist of the following: &lt;/div&gt;&lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width:66%"/&gt;
&lt;td style="vertical-align:bottom;width:11%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:11%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;br/&gt; 2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;br/&gt; 2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Prepaid expenses&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2,939&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;847&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Advances&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;877&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;685&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Capitalized transaction costs&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3,941&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Total other current assets&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3,816&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;5,473&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;Prepaid expenses include software and technology licensing agreements, insurance premiums and other advance payments for services to be received over the next 12 months. Advances are comprised of deposit payments to vendors for inventory purchase orders to be received in the next 12 months. The capitalized transaction costs as of December&#160;31, 2021 relate to costs incurred that were directly related to the Business Combination as described in Note 1. &lt;/div&gt;&lt;div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"&gt;&#160;&lt;/div&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"/&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Property and Equipment, Net&lt;/div&gt;&lt;/div&gt;&#x2014;Property and equipment are stated at cost less accumulated depreciation. Depreciation is calculated using the straight-line method and is recorded in Selling, general, and administrative expense over the estimated useful lives of the assets. The estimated useful lives of property and equipment are as follows: &lt;/div&gt;&lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width:48%"/&gt;
&lt;td style="vertical-align:bottom;width:3%"/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Estimated&#160;Useful Life (in years)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Trocars&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:center;"&gt;5&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Leasehold improvements&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:center;"&gt;Shorter of lease term or useful life of the&lt;br/&gt; improvement&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Office equipment&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:center;"&gt;5&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Computer software&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;3-5&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Furniture and fixtures&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;5-7&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Computer equipment&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;3-5&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;See Note 6 for further details. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Capitalized Software, Net&lt;/div&gt;&lt;/div&gt;&#x2014;Capitalization of costs related to internally developed software begins when the preliminary project stage is completed and it is probable that the project will be completed and used for its intended function. Once an application has reached the development stage, internal and external costs, if direct and incremental, are capitalized until the software is substantially complete and ready for its intended use. Capitalization ceases upon completion of all substantial testing. The Company also capitalizes costs related to specific upgrades and enhancements when it is probable the expenditures will result in additional features and functionality. Maintenance costs are expensed as incurred. Internal use software is amortized on a straight-line basis over its estimated useful life, generally &lt;span style="-sec-ix-hidden:hidden73945767"&gt;three&lt;/span&gt; to &lt;span style="-sec-ix-hidden:hidden73945768"&gt;eight&lt;/span&gt; years. Capitalized software is included within capitalized software, net on the consolidated balance sheet. See Note 7 for further details. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Impairment of Long-Lived Assets&lt;/div&gt;&lt;/div&gt;&#x2014;Long-lived assets, such as property and equipment and capitalized software, are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of the asset may not be recoverable. The carrying amount of a long-lived asset is not recoverable if it exceeds the sum of the undiscounted future cash flows expected to result from the use and eventual disposition of the asset. The amount of impairment loss, if any, is measured as the difference between the carrying value of the asset and its estimated fair value. Fair value is determined through various valuation techniques, including discounted cash flow models, quoted market values, and third-party independent appraisals, as considered necessary. No impairment charges have been recorded during the years ended December&#160;31, 2022 and 2021. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Leases&lt;/div&gt;&lt;/div&gt;&#x2014;At the inception of an arrangement, the Company determines whether the arrangement is or contains a lease based on the unique facts and circumstances present in the arrangement including the use of an identified asset(s) and the Company&#x2019;s control over the use of that identified asset. The Company elected, as allowed under Financial Accounting Standards Board (&#x201c;FASB&#x201d;) Accounting Standard Update (&#x201c;ASU&#x201d;) &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2016-02,&lt;/div&gt; &lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Leases &lt;/div&gt;&lt;/div&gt;(&#x201c;ASC&#160;842&#x201d;), to not recognize leases with a lease term of one year or less on its balance sheet. Leases with a term greater than one year are recognized on the balance sheet as &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;right-of-use&lt;/div&gt;&lt;/div&gt; (&#x201c;ROU&#x201d;) assets and current and &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-current&lt;/div&gt; lease liabilities, as applicable. As of December&#160;31, 2022 and December&#160;31, 2021, the Company does not have any financing leases. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;Lease liabilities and their corresponding ROU assets are initially recorded based on the present value of lease payments over the expected remaining lease term. Certain adjustments to the ROU asset may be required for items such as incentives, prepaid lease payments, or initial direct costs. When an option to extend the lease exists, a determination is made whether that option is reasonably certain of exercise based on economic factors present at the measurement date and as circumstances may change. Lease cost for operating leases is recognized on a straight-line basis over the lease term as an operating expense. Variable lease costs are expensed as incurred as an operating expense. &lt;/div&gt;&lt;div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"&gt;&#160;&lt;/div&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"/&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;As the rates implicit in the Company&#x2019;s leases have not historically been readily determinable, the Company utilizes the appropriate incremental borrowing rate, which is the rate the Company would incur to borrow on a collateralized basis over a similar term an amount equal to the lease payments in a similar economic environment over the lease term. To estimate our incremental borrowing rate, a credit rating applicable to the Company is estimated using a synthetic credit rating analysis since the Company does not currently have a rating agency-based credit rating. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;In accordance with ASC 842, contracts containing a lease should be split into three categories: lease components, &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-lease&lt;/div&gt; components, and activities or costs that do not transfer a distinct good or service &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(&#x201c;non-components&#x201d;).&lt;/div&gt; The fixed and &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;in-substance&lt;/div&gt; fixed contract consideration (including any consideration related to &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-components)&lt;/div&gt; must be allocated, based on the respective relative fair values, to the lease components and &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-lease&lt;/div&gt; components. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;Entities may elect not to separate lease and &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-lease&lt;/div&gt; components. Accordingly, entities making this election would account for each lease component and related &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-lease&lt;/div&gt; component together as a single lease component. The Company has elected to account for lease and &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-lease&lt;/div&gt; components together as a single lease component for all underlying assets and allocate all of the contract consideration to the lease component only. See Note 15 for further details. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Income Taxes&lt;/div&gt;&lt;/div&gt;&#x2014;The Company accounts for income taxes under the asset and liability method pursuant to ASC&#160;740, Income Taxes. Under this method, the Company recognizes deferred tax assets and liabilities for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating loss and tax credit carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;We recognize deferred tax assets to the extent that we believe that these assets are more likely than not to be realized. In making such a determination, we consider all available positive and negative evidence, including future reversals of existing taxable temporary differences, projected future taxable income, &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;tax-planning&lt;/div&gt; strategies, and results of recent operations. If we determine that we would be able to realize our deferred tax assets in the future in excess of their net recorded amount, we would make an adjustment to the deferred tax asset valuation allowance, which would reduce the provision for income taxes. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;We record uncertain tax positions in accordance with ASC 740 on the basis of a &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;two-step&lt;/div&gt; process in which (1)&#160;we determine whether it is more likely than not that the tax positions will be sustained on the basis of the technical merits of the position and (2)&#160;for those tax positions that meet the &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;more-likely-than-not&lt;/div&gt; recognition threshold, we recognize the largest amount of tax benefit that is more than 50&#160;percent likely to be realized upon ultimate settlement with the related tax authority. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;We recognize interest and penalties related to unrecognized tax benefits on the income tax expense line in the accompanying consolidated statements of income and comprehensive income. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Debt Issuance Costs&lt;/div&gt;&lt;/div&gt;&#x2014;Costs incurred in connection with the issuance of the Company&#x2019;s long-term debt have been recorded as a direct reduction of the debt and amortized over the life of the associated debt as a component of interest expense using the straight-line method, which is not materially different compared to the effective interest m&lt;div style="display:inline;"&gt;ethod.&lt;/div&gt; &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Warrant Liabilities&lt;/div&gt;&lt;/div&gt;&#x2014;The Company accounts for warrants as either equity-classified or liability-classified instruments based on an assessment of the warrant&#x2019;s specific terms and applicable authoritative guidance in ASC&#160;480, &lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Distinguishing Liabilities from Equity&lt;/div&gt;&lt;/div&gt; (&#x201c;ASC 480&#x201d;) and ASC 815, &lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Derivatives and Hedging&lt;/div&gt;&lt;/div&gt; (&#x201c;ASC&#160;815&#x201d;). The assessment considers whether the warrants are freestanding financial instruments pursuant to ASC&#160;480, &lt;div style="display:inline;"&gt;meet&lt;/div&gt; &lt;/div&gt;&lt;div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"&gt;&#160;&lt;/div&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"/&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;the definition of a liability pursuant to ASC 480, and whether the warrants meet all of the requirements for equity classification under ASC 815, including whether the warrants are indexed to the Company&#x2019;s own common stock, among other conditions for equity classification. This assessment, which requires the use of professional judgment, is conducted at the time of warrant issuance and as of each subsequent quarterly period end date while the warrants are outstanding. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;For issued or modified warrants that meet all of the criteria for equity classification, the warrants are required to be recorded as a component of additional &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;paid-in&lt;/div&gt; capital at the time of issuance. For issued or modified warrants that do not meet all the criteria for equity classification, the warrants are required to be recorded as a liability at their initial fair value on the date of issuance, and remeasured each balance sheet date thereafter. The Company&#x2019;s warrants did not meet the criteria for equity classification and are recorded as liabilities. Changes in the estimated fair value of the warrants are recognized as a &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-cash&lt;/div&gt; gain or loss in the statements of income and comprehensive income. See Note 10 for further detail. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Earnout Liability&lt;/div&gt;&lt;/div&gt;&#x2014;In connection with the Business Combination, the Members and the Sponsor received shares that will vest upon the achievement of certain share price targets. The earnout shares are classified as a liability in the Company&#x2019;s consolidated balance sheet because it does not qualify as being indexed to the Company&#x2019;s own stock. The earnout liability was initially measured at fair value at the Closing Date and subsequently remeasured at the end of each reporting period. The change in fair value of the earnout liability is recorded in the consolidated statement of income and comprehensive income. See Note 11 for further detail. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Stockholders&#x2019; Equity (Deficit)&lt;/div&gt;&lt;/div&gt;&#x2014;Prior to consummation of the Business Combination, the Company&#x2019;s capital structure included voting units (Class A), &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-voting&lt;/div&gt; units (Class AA and AAA), and &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-voting&lt;/div&gt; incentive units (Class AAAA), with no limit to the number of units that may be issued. Class&#160;A units had 100% of the voting rights, and there is no par value assigned to any of the classes of units. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;Pursuant to the Business Combination Agreement and immediately prior to the Business Combination&#x2019;s consummation, the Company effectuated a recapitalization whereby all Class&#160;A, Class&#160;AA, Class&#160;AAA and Class&#160;AAAA units held by Holdings&#x2019; Members were converted (whether by direct exchange, merger or otherwise) into Class&#160;A &lt;div style="display:inline;"&gt;Common Units.&lt;/div&gt; &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;As of December&#160;31, 2021, the following members&#x2019; equity units were issued and outstanding: &lt;/div&gt;&lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width:68%"/&gt;
&lt;td style="vertical-align:bottom;width:5%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:5%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31, 2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.5pt;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; font-size: 8pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Members&#x2019; Equity&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Issued&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Outstanding&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Class&#160;A (Voting)&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;16,721&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;16,721&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Class&#160;AA &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(Non-voting)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;903,079&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;903,079&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Class&#160;AAA &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(Non-voting)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;60,000&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;60,000&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Class&#160;AAAA &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(Non-voting&lt;/div&gt; incentive units)&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;33,397&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3,000&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Total&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,013,197&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;982,800&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;As of December&#160;31, 2022, the following shares of common stock were issued and outstanding: &lt;/div&gt;&lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:11pt;width:76%;border:0;margin:0 auto"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width:64%"/&gt;
&lt;td style="vertical-align:bottom;width:3%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:3%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31, 2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.5pt;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; font-size: 8pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Stockholders&#x2019; Equity&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Issued&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Outstanding&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Class&#160;A common stock&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right;"&gt;11,242,887&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right;"&gt;9,655,387&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Class&#160;B common stock&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Class&#160;V voting stock&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right;"&gt;58,565,824&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right;"&gt;48,565,824&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Total&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right;"&gt;69,808,711&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right;"&gt;58,221,211&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"&gt;&#160;&lt;/div&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"/&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;The Company made operating distributions to Members of Holdings and taxing authorities on the Members&#x2019; behalf totaling $12,886 and $11,402 during the years ended December&#160;31, 2022 and 2021, &lt;div style="display:inline;"&gt;respectively.&lt;/div&gt; &lt;/div&gt;&lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Standby Equity Purchase Agreement &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;On July&#160;27, 2022, the Company entered into a Standby Equity Purchase Agreement (the &#x201c;SEPA&#x201d;) with YA II PN, Ltd. (&#x201c;Yorkville&#x201d;). Yorkville is a fund managed by Yorkville Advisors Global, LP, headquartered in Mountainside, New Jersey. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;The Company has the right, but not the obligation, from time to time at the Company&#x2019;s discretion until the first day of the month following the &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;36-month&lt;/div&gt; anniversary of the date of the SEPA (unless earlier terminated), to direct Yorkville to purchase a specified amount of shares of Class&#160;A common stock (each such sale, an &#x201c;Advance&#x201d;) by delivering written notice to Yorkville (each, an &#x201c;Advance Notice&#x201d;). The shares of Class&#160;A common stock purchased pursuant to an Advance will be purchased at a price equal to 97.0% of the lowest daily VWAP of the Class&#160;A common stock during the &lt;span style="-sec-ix-hidden:hidden73945778"&gt;three&lt;/span&gt; consecutive trading days commencing on the date of delivery of a given Advance Notice. &#x201c;VWAP&#x201d; means, for any trading day, the daily volume weighted average price of the Company&#x2019;s common stock for such date as reported by Bloomberg L.P. during regular trading hours. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;While there is no mandatory minimum amount for any individual Advance, it may not exceed the greater of (i)&#160;an amount equal to thirty percent (30%) of the daily volume traded on the trading day immediately preceding an Advance Notice, or (ii) 1,000,000 shares of Class&#160;A common stock. No more than 5,000,000 shares of Class&#160;A common stock, including the Commitment Shares (as defined below) may be sold pursuant to the SEPA. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;Yorkville&#x2019;s obligation to continue to purchase shares of Class&#160;A common stock pursuant to the SEPA is subject to a number of conditions. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;As consideration for Yorkville&#x2019;s commitment to purchase Class&#160;A common stock at the Company&#x2019;s direction upon the terms and subject to the conditions set forth in the SEPA, upon execution of the SEPA, the Company issued 25,000 shares of Class&#160;A common stock to Yorkville (the &#x201c;Commitment Shares&#x201d;). During the year ended December&#160;31, 2022, the Company sold 105,559 shares to Yorkville under the SEPA for cash proceeds of $442. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Noncontrolling Interest&lt;/div&gt;&lt;/div&gt;&#x2014;Pursuant to the Business Combination, as described in Note 3, the Company is organized in an &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x201c;Up-C&#x201d;&lt;/div&gt; structure with the Company owning only a portion of its consolidated subsidiaries. The portion of the consolidated subsidiaries not owned by the Company and any related activity is presented as noncontrolling interest in the consolidated financial statements. The noncontrolling interests, together with their corresponding shares of Class&#160;V voting stock, can be exchanged for Class&#160;A common stock in Biote or, at the election of the Company, cash. Because redemptions for cash is solely within the control of the Company, noncontrolling interest is presented in permanent equity. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Revenue Recognition&lt;/div&gt;&lt;/div&gt;&#x2014;The Company accounts for revenue in accordance with FASB, Accounting Standards &lt;div style="display:inline;"&gt;Update&lt;/div&gt; (&#x201c;ASU&#x201d;) &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;No.&#160;2014-09,&lt;/div&gt; &lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Revenue from Contracts with Customers&lt;/div&gt;&lt;/div&gt;, as amended, (Topic 606). Revenue is measured based on the consideration specified in a contract with a customer. The Company recognizes revenue when it satisfies a performance obligation by transferring control of a product or service to a customer. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;Taxes assessed by a governmental authority that are both imposed on and concurrent with a specific revenue-producing transaction, that are collected by the Company from a customer, are excluded from revenue. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;Shipping and handling costs associated with outbound freight after control of a product has transferred to a customer are accounted for as fulfillment costs and are included in cost of products in the statements of income and comprehensive income. Shipping and handling costs billed to customers are considered part of the transaction price and are recognized as revenue with the underlying product sales for dietary supplements and trocars. &lt;/div&gt;&lt;div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"&gt;&#160;&lt;/div&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"/&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;The following is a description of the principal contract activities, disaggregated by the contract type, from which the Company generates its revenue. &lt;/div&gt;&lt;div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;The Biote Method &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;The Company generates revenues through standard service agreements with customers who participate in the Biote Method. The Biote Method is a bioidentical hormone replacement therapy which has been developed as a treatment designed to alleviate hormone imbalances. Under this agreement, the Company provides a bundle of goods and services to customers, including initial training to medical practitioners, bioidentical hormone pellets and software tools used for inventory management and dosing, and ongoing practice development and marketing support services, which includes a license to use the Company&#x2019;s trademarks and trade names in the customer&#x2019;s marketing materials. The initial contract term is three years, and customers have the option to renew for additional &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;one-year&lt;/div&gt; periods. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;For the bundled goods and services, the Company accounts for individual products and services separately if they are distinct, i.e., if a product or service is separately identifiable from other items in the bundled package and if a customer can benefit from it on its own or with other resources that are readily available to the customer. The Company has identified three distinct obligations in its standard service agreement: initial training, pellet procedures (including sales of bioidentical hormone pellets, use of inventory management software to monitor pellet inventory, and use of the Company&#x2019;s blood dosing website to determine the appropriate pellets to use in each procedure), contract-term services (including ongoing practice development and marketing support, options to receive reusable trocars, and the right to use the reusable trocars through the term of the contract, if the option is exercised). The third obligation includes a combined lease/nonlease component for which the Company has adopted the practical expedient within ASC 842 which allows lessors to combine lease and &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-lease&lt;/div&gt; components that have the same pattern of transfer to the customer-lessee and account for the combined component under the guidance relevant to the predominant portion of the component. By applying this expedient, the Company applies Topic 606 to the combined component. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;The consideration in the contract is allocated between separate products and services in the bundle based on the stand-alone selling prices of each good and service. The stand-alone selling prices are determined based on the prices at which the Company separately sells the initial training and the pellet procedures. Judgment is required to determine the standalone selling price for each distinct performance obligation. For items that are not sold separately and for which the Company has not established a standalone selling price, the Company allocates consideration based on the residual approach. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;The Company recognizes revenue for initial training over time as the customer completes the training. Training sessions generally occur over the course of &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2-3&lt;/div&gt; consecutive days at or near the time of contract inception. The Customer is charged an initial fixed-rate fee for this training. Customers pay in full for the initial training at the time of contract inception. The standalone selling price of these services is based on the lowest price offered by the Company for the services. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;The Company recognizes revenue for pellet procedures at the point in time the procedures are performed by the practitioner, which is when control of the pellets transfers to the customer. Consideration for these services is in the form of a management fee assessed for each procedure performed, which includes a volume-based tiered pricing schedule. The standalone selling price for these services requires judgment and is estimated based on the Company&#x2019;s historical experience with prices offered to similar customers throughout the initial term of the contract. Billings in excess of the standalone selling price constitute a premium charged to customers early in a relationship and are deferred and recognized when or as the remaining goods and services are transferred to the customer. Fees are billed and paid on a semimonthly basis. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;The Company recognizes revenue for contract-term services on a straight-line basis over the initial term of the contract, which aligns with the Company&#x2019;s satisfaction of the performance obligation. The Company allocates the residual consideration to this performance obligation, which is consistent with the allocation objective. &lt;/div&gt;&lt;div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"&gt;&#160;&lt;/div&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"/&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Dietary Supplements &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;Dietary supplements are supplements that customer practitioners resell to patients that aid the patients with maintaining hormone balances. The Company recognizes revenue for these, net of any discounts given, when control transfers to the customer, which is generally the point of shipment from the Company&#x2019;s distributor. Products are billed at standalone selling price for the dietary supplements and invoiced at shipment. &lt;/div&gt;&lt;div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Disposable Trocars &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;Disposable Trocars are manual surgical instruments intended for use by Biote-certified practitioners. These tools are used to implant the bioidentical hormone pellets into the customers&#x2019; patients. The Company recognizes revenue at the time control transfers, which is generally the point of shipment from the distributor. Products are billed at the standalone selling price for the trocars and invoiced at shipment. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;Revenue disaggregated by the nature of the product or service and by geography is included within Note 4: Revenue Recognition. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;As of the years ended December&#160;31, 2022 and 2021, the Company had allocated $104 and $67 respectively, of consideration to the unsatisfied initial training obligations, and $1,655 and $1,393, respectively, of consideration to the unsatisfied contract-term service obligations provided to the Biote Method customers. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;Consideration allocated to initial training due to deposits paid upfront is presented within deferred revenue on the consolidated balance sheets and is expected to be recognized as revenue within one year, as the training is complete. Consideration allocated to contract-term services is presented within deferred revenue and deferred revenue, long-term for the amounts expected to be recognized within one year and longer than one year, respectively. As of the years ended December&#160;31, 2022 and 2021 the amount of consideration allocated to contract-term services presented within deferred revenue was $1,028 and $849, respectively, and the amount presented within deferred revenue, long-term was $627 and $544, respectively. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;The Consideration allocated to the premiums within the management fee for pellet procedures is presented within deferred revenue current and deferred revenue, long-term for amounts expected to be recognized within one year and longer than one year, respectively. As of the years ended December&#160;31, 2022 and 2021 the amount of these premiums within deferred revenue was $833 and $789, respectively, and the amount within deferred revenue, long-term was $299 and $258, respectively. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;The Company has also elected the practical expedient in ASC 606 to not disclose consideration allocated to contracts with an original term of one year or less, which includes contracts for &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;point-in-time&lt;/div&gt;&lt;/div&gt; sales of dietary supplements, disposable trocars, and pellet procedures. Pellet procedures are included in the Company&#x2019;s Biote Method service agreement, which has a three-year stated term, but as revenues are recognized at a point in time, there are no minimum purchase volumes, and the contract allows for cancellation with ninety days&#x2019; notice from the customer, there are no pellet procedure obligations that are satisfied over a period greater than one year. &lt;/div&gt;&lt;div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Contract Assets and Liabilities &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;Customer receivables are made up of consideration to which the Company has an unconditional right to payment, regardless of whether the Company has satisfied the performance obligations in the contract. All customer receivables are presented within accounts receivable, net of allowance for doubtful accounts in the consolidated balance sheets. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;Contract assets are the Company&#x2019;s right to consideration for goods or services that the entity has transferred to the customer when that right is conditioned on something other than the passage of time. The Company does not have any contract assets for the years ended December&#160;31, 2022 and 2021. &lt;/div&gt;&lt;div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"&gt;&#160;&lt;/div&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"/&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;Contract liabilities are the Company&#x2019;s obligation to transfer goods or services to a customer for which the Company has received consideration or has an unconditional right to receive consideration. The Company&#x2019;s contract liabilities include deposits for initial training and contract-term services paid in advance which have not been recognized as revenue during the period. Contract liabilities are presented within deferred revenue and deferred revenue, long-term in the consolidated balance sheets. Contract liabilities are classified as current liabilities for the amount of revenue that the Company expects to recognize within one year of the reporting date. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;Changes in contract liabilities between each period are attributable to fees paid by new customers, revenue recognized for completed trainings, and revenue recognized for the Company&#x2019;s over-time satisfaction of contract-term services. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;The Company does not have a history of material returns or refunds, and generally does not offer warranties or guarantees for any products or services. Expected returns and refunds are recorded as a reduction of revenue and are $0 and $0 for the years ended December&#160;31, 2022 and 2021, respectively. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;A reconciliation of the beginning and ending contract liabilities is included within Note 4: Revenue Recognition. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Cost of Revenue&lt;/div&gt;&lt;/div&gt;&#x2014;Cost of services primarily consist of the costs incurred to deliver trainings to Biote Method customers. Cost of products includes the cost of pellets purchased from compounding pharmacies and sold to customers of the Biote Method, the cost of trocars and dietary supplements purchased from manufacturing facilities or third-party &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;co-packers,&lt;/div&gt; and the shipping and handling costs incurred to deliver these products to the customers. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Marketing&lt;/div&gt;&lt;/div&gt;&#x2014;&lt;div style="display:inline;"&gt;Mark&lt;/div&gt;eting expense includes advertising costs, marketing events, and program costs. These costs are expensed as incurred. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Selling, General, and Administrative&lt;/div&gt;&lt;/div&gt;&#x2014;Selling, general, and administrative expense consists primarily of software licensing and maintenance and the cost of employees who engage in corporate functions, such as finance and accounting, information technology, human resources, legal, and executive management. Selling, general, and administrative expense also includes rent occupancy costs, office expenses, recruiting expenses, entertainment allocations, depreciation and amortization, other general overhead costs, insurance premiums, professional service fees, research and development, and costs related to regulatory and litigation m&lt;div style="display:inline;"&gt;atters.&lt;/div&gt; &lt;/div&gt;&lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Employee Retirement Plans&#x2014; &lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Defined Contribution Retirement Plans &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;Effective January&#160;1, 2021, the Company offers participation in the BioTE Medical, LLC (&#x201d;BioTE Medical&#x201d;) 401(k) Plan (the &#x201c;401(k) Plan&#x201d;), a defined contribution plan providing retirement benefits to eligible employees. Eligible employees may contribute a portion of their annual compensation to the 401(k) Plan, subject to the maximum annual amounts as set periodically by the IRS. The Company makes a safe harbor, &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-elective&lt;/div&gt; contribution to the 401(k) Plan equal to 3% of each participant&#x2019;s eligible employee compensation. Safe harbor contributions vest immediately for each participant. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;During the years ended December&#160;31, 2022 and 2021, the Company made $915 and $335, respectively, in safe harbor contributions under the 401(k) Plan, which are presented within Selling, general and administrative expense in the consolidated statements of income and comprehensive income. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Share-Based Compensation&lt;/div&gt;&lt;/div&gt;&#x2014;Holdings previously granted Class&#160;AAAA units (&#x201c;incentive units&#x201d;) and phantom equity rights (collectively, the &#x201c;equity awards&#x201d;) to certain key members of management. The equity awards were entitled to share in the distributions of Holdings from a change in control or qualifying liquidity event. The equity awards are accounted for under ASC 718, &lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Compensation&#x2014;Stock Compensation&lt;/div&gt;&lt;/div&gt;, and classified in &lt;div style="display:inline;"&gt;equity.&lt;/div&gt; &lt;/div&gt;&lt;div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"&gt;&#160;&lt;/div&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"/&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;The Company has elected to recognize forfeitures at the time they occur. The fair value of the equity awards was determined using a Monte-Carlo simulation as of the grant date. The awards begin to vest on the date of a change in control or qualifying event. The Business Combination constituted such a qualifying event triggering the performance condition in the awards. No compensation cost was recognized historically until the Closing of the Business Combination as a qualifying event was not previously deemed probable to occur. See Note 14 for further &lt;div style="display:inline;"&gt;details.&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Commissions&lt;/div&gt;&lt;/div&gt;&#x2014;Commissions consist primarily of fees paid to a third-party sales force, internal sales force, and partner clinics which participate in the Company&#x2019;s new clinic mentor program. Commissions paid to the Company&#x2019;s internal and third-party sales forces relate to market support and development activities undertaken to drive channel sales through existing customers and are not considered incremental costs to obtain a customer contract. For the years ended December&#160;31, 2022 and 2021 expenses incurred for these commission programs were $124 and $317, respectively. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;Commissions paid to clinics under the Company&#x2019;s mentorship program represent amounts paid to existing clinics which provide services to help new customers complete onboarding and other startup activities and are only incurred after contract initiation. These costs are expensed as incurred, consistent with other contract fulfillment costs. For the years ended December&#160;31, 2022 and 2021 commissions paid under this program were $1,098 and $1,738, respectively. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Concentrations&lt;/div&gt;&lt;/div&gt;&#x2014;Financial instruments that potentially subject the Company to concentrations of credit risk consist primarily of cash, accounts receivable, credit agreements, and inventory purchases. The Company&#x2019;s cash balances exceed those that are federally insured. To date, the Company has not recognized any losses caused by uninsured balances. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;As of December&#160;31, 2022 and December&#160;31, 2021, 100% of the Company&#x2019;s outstanding debt and available line of credit was from one lender. A failure of the counterparty to perform could result in the loss of access to the available borrowing capacity under the line of credit. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;Inventory purchases from three vendors totaled approximately 87% and 94% for the years ended December&#160;31, 2022 and 2021, respectively. Due to the nature of the markets and availability of alternative suppliers, the Company does not believe the loss of any one vendor would have a material adverse impact on the Company&#x2019;s financial position, results of operations or cash flows for any significant period of time. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;Significant customers are those which represent more than 10% of the Company&#x2019;s total revenue or gross accounts receivable balance. The Company did not have any customers that accounted for 10% or more of total revenues for the years ended December&#160;31, 2022 and 2021. The Company did not have any customers that accounted for more than 10% of the outstanding gross accounts receivable as of December&#160;31, 2022 or December&#160;31, 2021. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Recently Adopted Accounting Pronouncements&lt;/div&gt;&lt;/div&gt;&#x2014;In December 2019, the FASB issued ASU &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2019-12,&lt;/div&gt; &lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Income Taxes (Topic 740)&#x2014;Simplifying the Accounting for Income Taxes&lt;/div&gt;&lt;/div&gt;, which simplifies the accounting for income taxes by removing certain exceptions to the general principles of ASC 740, &lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Income Taxes&lt;/div&gt;&lt;/div&gt;. The amendments also improve consistent application of and simplify U.S. GAAP for other areas of ASC 740 by clarifying and amending existing guidance. ASU &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2019-12&lt;/div&gt; is effective for fiscal years beginning after December&#160;15, 2021, and for interim periods beginning after December&#160;15, 2022. The Company has adopted the standard as of January 1, 2022, and there was no material impact to the financial statements. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Recent Accounting Pronouncements Not Yet Adopted&lt;/div&gt;&lt;/div&gt;&#x2014;In June 2016, the FASB issued ASU &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2016-13,&lt;/div&gt; &lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Measurement of Credit Losses on Financial Instruments&lt;/div&gt;&lt;/div&gt; (&#x201c;ASU &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2016-13&#x201d;).&lt;/div&gt; The main objective of the update is to provide financial statement users with more decision-useful information about the expected credit losses on financial instruments and other commitments to extend credit held by companies at each reporting date. For trade &lt;/div&gt;&lt;div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"&gt;&#160;&lt;/div&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"/&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;and other receivables, held to maturity debt securities, and other instruments, companies will be required to use a new forward-looking &#x201c;expected losses&#x201d; model that generally will result in the recognition of allowances for losses earlier than under current accounting guidance. Further, the FASB issued ASU &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2019-04,&lt;/div&gt; ASU &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2019-05&lt;/div&gt; and ASU &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2019-11&lt;/div&gt; to provide additional guidance on the credit losses standard. The standard will be adopted using the modified retrospective approach. ASU &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2016-13&lt;/div&gt; is effective for annual and interim periods beginning after December&#160;15, 2022, with early adoption permitted. The Company is evaluating the potential impact of adopting ASU &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2016-13&lt;/div&gt; on its consolidated financial statements and related disclosures. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;In August 2020, the FASB issued ASU &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2020-06,&lt;/div&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt; Debt&#x2014;Debt with Conversion and Other Options &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(Subtopic&#160;470-20)&lt;/div&gt; and Derivatives and Hedging&#x2014;Contracts in Entity&#x2019;s Own Equity (Subtopic &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;815-40):&lt;/div&gt; Accounting for Convertible Instruments and Contracts in an Entity&#x2019;s Own Equity&lt;/div&gt;&lt;/div&gt; (&#x201c;ASU &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2020-06&#x201d;).&lt;/div&gt; &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;ASU&#160;2020-06&lt;/div&gt; changes how entities account for convertible instruments and contracts in an entity&#x2019;s own equity and simplifies the accounting for convertible instruments by removing certain separation models for convertible instruments. ASU &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2020-06&lt;/div&gt; also modifies the guidance on diluted earnings per share calculations. The amendments are effective for fiscal years beginning after December&#160;15, 2023, including interim periods within those fiscal years. The Company is currently evaluating the impact of this standard on its consolidated financial statements and related disclosures. &lt;/div&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:UseOfEstimates contextRef="P01_01_2022To12_31_2022">&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Use of Estimates&#x2014;&lt;/div&gt;&lt;/div&gt;The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. The Company regularly evaluates estimates and assumptions related to assets, liabilities, costs, expenses, contingent liabilities, share-based compensation and research and development costs. The Company bases its estimates and assumptions on historical experience and on various other factors that it believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results could differ from those estimates. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;In the opinion of the Company, the accompanying consolidated financial statements contain all adjustments, consisting of only normal recurring adjustments, necessary for a fair presentation of its financial position and its results of operations, changes in stockholders&#x2019; equity (deficit) and cash flows. &lt;/div&gt;</us-gaap:UseOfEstimates>
    <us-gaap:FairValueMeasurementPolicyPolicyTextBlock contextRef="P01_01_2022To12_31_2022">&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Fair Value Measurements&lt;/div&gt;&lt;/div&gt;&#x2014;The guidance in FASB ASC 820, &lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Fair Value Measurements and Disclosures &lt;/div&gt;&lt;/div&gt;(&#x201c;ASC 820&#x201d;), defines fair value and establishes a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements) and the lowest priority to unobservable inputs (Level 3 measurements). The three levels of the fair value hierarchy are described below: &lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Level&lt;/div&gt;&lt;/div&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;&#160;1&lt;/div&gt;&lt;/div&gt;&#x2014;Inputs are quoted prices (unadjusted) in active markets for identical assets or liabilities that the reporting entity has the ability to access at the measurement date. &lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Level 2&lt;/div&gt;&lt;/div&gt;&#x2014;Valuations based on quoted prices in markets that are not active or for which all significant inputs are observable, either directly or indirectly. &lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Level&lt;/div&gt;&lt;/div&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;&#160;3&lt;/div&gt;&lt;/div&gt;&#x2014;Prices or valuations that require inputs that are both significant to the fair value measurement and unobservable. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;See Note 12 for further detail. &lt;/div&gt;</us-gaap:FairValueMeasurementPolicyPolicyTextBlock>
    <us-gaap:SegmentReportingPolicyPolicyTextBlock contextRef="P01_01_2022To12_31_2022">&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Segment Information&lt;/div&gt;&lt;/div&gt;&#x2014;Operating segments are defined as components of an enterprise about which separate financial information is available that is evaluated regularly by the chief operating decision maker in deciding how to allocate resources and in assessing performance. The Company&#x2019;s chief operating decision maker is the chief executive officer. The Company has one business activity and there are no segment managers who are held accountable for operations, operating results, and plans for levels or components below the consolidated unit level. Accordingly, the Company has one operating segment and, therefore, one reportable segment. &lt;/div&gt;</us-gaap:SegmentReportingPolicyPolicyTextBlock>
    <us-gaap:NumberOfOperatingSegments
      contextRef="P01_01_2022To12_31_2022"
      decimals="0"
      unitRef="Unit_SEGMENT">1</us-gaap:NumberOfOperatingSegments>
    <us-gaap:NumberOfReportableSegments
      contextRef="P01_01_2022To12_31_2022"
      decimals="0"
      unitRef="Unit_SEGMENT">1</us-gaap:NumberOfReportableSegments>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock contextRef="P01_01_2022To12_31_2022">&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Cash&lt;/div&gt;&lt;/div&gt;&#x2014;As of December&#160;31, 2022 and 2021, cash consists primarily of checking and savings deposits. The Company maintains deposits primarily with two financial institutions, which may at times exceed amounts covered by insurance provided by the U.S. Federal Deposit Insurance Corporation (&#x201c;FDIC&#x201d;). The Company has not experienced any losses related to amounts in excess of FDIC limits. The Company does not hold any cash equivalents, which would consist of highly liquid investments with original maturities of three months or less at the time of purchase. &lt;/div&gt;</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <us-gaap:ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy contextRef="P01_01_2022To12_31_2022">&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Accounts Receivable and Allowance for Doubtful Accounts&lt;/div&gt;&lt;/div&gt;&#x2014;Accounts receivable are recorded net of allowances for doubtful accounts. Accounts receivable consist primarily of invoiced amounts to clinics that are not yet paid. On a periodic basis, management evaluates its accounts receivable and determines whether to provide an allowance or if any accounts should be written off based on past history of write-offs, collections, and current credit conditions. The Company maintains an allowance for doubtful accounts to provide for uncollectible amounts based on historical collection experience and an analysis of the aging of receivables. Management provides for probable uncollectible amounts through a charge to earnings and a credit to a valuation allowance based on its assessment of the current status of individual accounts. Balances still outstanding after &lt;/div&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; font-size: 8pt;"&gt;&#160;&lt;/div&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"/&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;management has exhausted all reasonable collection efforts are written off through a charge to the valuation allowance and a credit to accounts receivable. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;Bad debt expense is classified in selling, general, and administrative expense within the consolidated statements of income and comprehensive income. The Company generally does not require any security or collateral to support its receivables. A rollforward of the allowance for doubtful accounts is as follows (in thousands): &lt;/div&gt;&lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:68%;border:0;margin:0 auto"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width:86%"/&gt;
&lt;td style="vertical-align:bottom;width:6%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;As of December&#160;31, 2020&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(1,157&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Provisions charged to operating results&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(240&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Account &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;write-off&lt;/div&gt; and recoveries&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(9&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;As of December&#160;31, 2021&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(1,406&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;As of December&#160;31, 2021&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(1,406&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Provisions charged to operating results&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;155&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Account &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;write-off&lt;/div&gt; and recoveries&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;277&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;As of December&#160;31, 2022&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(974&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy>
    <us-gaap:AccountsReceivableAllowanceForCreditLossTableTextBlock contextRef="P01_01_2022To12_31_2022">A rollforward of the allowance for doubtful accounts is as follows (in thousands): &lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:68%;border:0;margin:0 auto"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width:86%"/&gt;
&lt;td style="vertical-align:bottom;width:6%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;As of December&#160;31, 2020&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(1,157&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Provisions charged to operating results&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(240&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Account &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;write-off&lt;/div&gt; and recoveries&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(9&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;As of December&#160;31, 2021&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(1,406&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;As of December&#160;31, 2021&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(1,406&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Provisions charged to operating results&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;155&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Account &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;write-off&lt;/div&gt; and recoveries&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;277&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;As of December&#160;31, 2022&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(974&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:AccountsReceivableAllowanceForCreditLossTableTextBlock>
    <us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">1157000</us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent>
    <us-gaap:ProvisionForDoubtfulAccounts
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">240000</us-gaap:ProvisionForDoubtfulAccounts>
    <btmd:ProvisonForDoubfulDebtAcoountsWriteOffAndRecoveries
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">-9000</btmd:ProvisonForDoubfulDebtAcoountsWriteOffAndRecoveries>
    <us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">1406000</us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent>
    <us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">1406000</us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent>
    <us-gaap:ProvisionForDoubtfulAccounts
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">-155000</us-gaap:ProvisionForDoubtfulAccounts>
    <btmd:ProvisonForDoubfulDebtAcoountsWriteOffAndRecoveries
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">277000</btmd:ProvisonForDoubfulDebtAcoountsWriteOffAndRecoveries>
    <us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">974000</us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent>
    <us-gaap:InventoryPolicyTextBlock contextRef="P01_01_2022To12_31_2022">&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Inventory&lt;/div&gt;&lt;/div&gt;&#x2014;Inventory is carried at the lower of cost or net realizable value using the &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;first-in,&lt;/div&gt; &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;first-out&lt;/div&gt; (FIFO) method. Inventory consists of bioidentical hormone pellets and dietary supplements. Bioidentical hormone pellets contain bioidentical testosterone or estrogen used to achieve hormone balance. Dietary supplements are high-grade vitamins used to enhance pellet therapy. The Company reviews its inventory balances and writes down its inventory for estimated obsolescence or excess inventory equal to the difference between the cost of inventory and the estimated net realizable value based upon assumptions about future demand and market conditions. Inventory write-downs are recorded within cost of products. Management recorded a reserve for obsolescence of inventory related to inventory which has expired. See Note 5 for further details. &lt;/div&gt;</us-gaap:InventoryPolicyTextBlock>
    <btmd:OtherCurrentAssetsPolicyTextBlock contextRef="P01_01_2022To12_31_2022">&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Other Current Assets&lt;/div&gt;&lt;/div&gt;&#x2014;As of December&#160;31, 2022 and December&#160;31, 2021, the Company&#x2019;s total other current assets consist of the following: &lt;/div&gt;&lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width:66%"/&gt;
&lt;td style="vertical-align:bottom;width:11%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:11%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;br/&gt; 2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;br/&gt; 2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Prepaid expenses&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2,939&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;847&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Advances&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;877&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;685&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Capitalized transaction costs&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3,941&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Total other current assets&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3,816&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;5,473&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;Prepaid expenses include software and technology licensing agreements, insurance premiums and other advance payments for services to be received over the next 12 months. Advances are comprised of deposit payments to vendors for inventory purchase orders to be received in the next 12 months. The capitalized transaction costs as of December&#160;31, 2021 relate to costs incurred that were directly related to the Business Combination as described in Note 1. &lt;/div&gt;</btmd:OtherCurrentAssetsPolicyTextBlock>
    <us-gaap:ScheduleOfOtherCurrentAssetsTableTextBlock contextRef="P01_01_2022To12_31_2022">As of December&#160;31, 2022 and December&#160;31, 2021, the Company&#x2019;s total other current assets consist of the following: &lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width:66%"/&gt;
&lt;td style="vertical-align:bottom;width:11%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:11%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;br/&gt; 2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;br/&gt; 2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Prepaid expenses&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2,939&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;847&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Advances&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;877&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;685&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Capitalized transaction costs&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3,941&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Total other current assets&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3,816&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;5,473&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfOtherCurrentAssetsTableTextBlock>
    <us-gaap:PrepaidExpenseCurrent
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">2939000</us-gaap:PrepaidExpenseCurrent>
    <us-gaap:PrepaidExpenseCurrent
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">847000</us-gaap:PrepaidExpenseCurrent>
    <us-gaap:AdvancesOnInventoryPurchases
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">877000</us-gaap:AdvancesOnInventoryPurchases>
    <us-gaap:AdvancesOnInventoryPurchases
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">685000</us-gaap:AdvancesOnInventoryPurchases>
    <us-gaap:DeferredOfferingCosts
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">3941000</us-gaap:DeferredOfferingCosts>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">3816000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">5473000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock contextRef="P01_01_2022To12_31_2022">&lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Property and Equipment, Net&lt;/div&gt;&lt;/div&gt;&#x2014;Property and equipment are stated at cost less accumulated depreciation. Depreciation is calculated using the straight-line method and is recorded in Selling, general, and administrative expense over the estimated useful lives of the assets. The estimated useful lives of property and equipment are as follows: &lt;/div&gt;&lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width:48%"/&gt;
&lt;td style="vertical-align:bottom;width:3%"/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Estimated&#160;Useful Life (in years)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Trocars&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:center;"&gt;5&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Leasehold improvements&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:center;"&gt;Shorter of lease term or useful life of the&lt;br/&gt; improvement&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Office equipment&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:center;"&gt;5&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Computer software&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;3-5&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Furniture and fixtures&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;5-7&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Computer equipment&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;3-5&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;See Note 6 for further details. &lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
    <btmd:DisclosureInTabularFormOfEstimatedUsefulLivesOfPropertyPlantAndEquipmentTableTextBlock contextRef="P01_01_2022To12_31_2022">The estimated useful lives of property and equipment are as follows: &lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width:48%"/&gt;
&lt;td style="vertical-align:bottom;width:3%"/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Estimated&#160;Useful Life (in years)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Trocars&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:center;"&gt;5&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Leasehold improvements&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:center;"&gt;Shorter of lease term or useful life of the&lt;br/&gt; improvement&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Office equipment&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:center;"&gt;5&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Computer software&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;3-5&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Furniture and fixtures&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;5-7&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Computer equipment&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;3-5&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</btmd:DisclosureInTabularFormOfEstimatedUsefulLivesOfPropertyPlantAndEquipmentTableTextBlock>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="P01_01_2022To12_31_2022_TrocarsMemberusgaapPropertyPlantAndEquipmentByTypeAxis">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentEstimatedUsefulLives contextRef="P01_01_2022To12_31_2022_LeaseholdImprovementsMemberusgaapPropertyPlantAndEquipmentByTypeAxis">Shorter of lease term or useful life of the improvement</us-gaap:PropertyPlantAndEquipmentEstimatedUsefulLives>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="P01_01_2022To12_31_2022_OfficeEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="P01_01_2022To12_31_2022_MinimumMembersrtRangeAxis_SoftwareDevelopmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="P01_01_2022To12_31_2022_MaximumMembersrtRangeAxis_SoftwareDevelopmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="P01_01_2022To12_31_2022_FurnitureAndFixturesMemberusgaapPropertyPlantAndEquipmentByTypeAxis_MinimumMembersrtRangeAxis">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="P01_01_2022To12_31_2022_FurnitureAndFixturesMemberusgaapPropertyPlantAndEquipmentByTypeAxis_MaximumMembersrtRangeAxis">P7Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="P01_01_2022To12_31_2022_ComputerEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis_MinimumMembersrtRangeAxis">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="P01_01_2022To12_31_2022_ComputerEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis_MaximumMembersrtRangeAxis">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:InternalUseSoftwarePolicy contextRef="P01_01_2022To12_31_2022">&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Capitalized Software, Net&lt;/div&gt;&lt;/div&gt;&#x2014;Capitalization of costs related to internally developed software begins when the preliminary project stage is completed and it is probable that the project will be completed and used for its intended function. Once an application has reached the development stage, internal and external costs, if direct and incremental, are capitalized until the software is substantially complete and ready for its intended use. Capitalization ceases upon completion of all substantial testing. The Company also capitalizes costs related to specific upgrades and enhancements when it is probable the expenditures will result in additional features and functionality. Maintenance costs are expensed as incurred. Internal use software is amortized on a straight-line basis over its estimated useful life, generally &lt;span style="-sec-ix-hidden:hidden73945767"&gt;three&lt;/span&gt; to &lt;span style="-sec-ix-hidden:hidden73945768"&gt;eight&lt;/span&gt; years. Capitalized software is included within capitalized software, net on the consolidated balance sheet. See Note 7 for further details. &lt;/div&gt;</us-gaap:InternalUseSoftwarePolicy>
    <us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock contextRef="P01_01_2022To12_31_2022">&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Impairment of Long-Lived Assets&lt;/div&gt;&lt;/div&gt;&#x2014;Long-lived assets, such as property and equipment and capitalized software, are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of the asset may not be recoverable. The carrying amount of a long-lived asset is not recoverable if it exceeds the sum of the undiscounted future cash flows expected to result from the use and eventual disposition of the asset. The amount of impairment loss, if any, is measured as the difference between the carrying value of the asset and its estimated fair value. Fair value is determined through various valuation techniques, including discounted cash flow models, quoted market values, and third-party independent appraisals, as considered necessary. No impairment charges have been recorded during the years ended December&#160;31, 2022 and 2021. &lt;/div&gt;</us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock>
    <us-gaap:ImpairmentOfLongLivedAssetsHeldForUse
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:ImpairmentOfLongLivedAssetsHeldForUse>
    <us-gaap:ImpairmentOfLongLivedAssetsHeldForUse
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:ImpairmentOfLongLivedAssetsHeldForUse>
    <us-gaap:LesseeLeasesPolicyTextBlock contextRef="P01_01_2022To12_31_2022">&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Leases&lt;/div&gt;&lt;/div&gt;&#x2014;At the inception of an arrangement, the Company determines whether the arrangement is or contains a lease based on the unique facts and circumstances present in the arrangement including the use of an identified asset(s) and the Company&#x2019;s control over the use of that identified asset. The Company elected, as allowed under Financial Accounting Standards Board (&#x201c;FASB&#x201d;) Accounting Standard Update (&#x201c;ASU&#x201d;) &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2016-02,&lt;/div&gt; &lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Leases &lt;/div&gt;&lt;/div&gt;(&#x201c;ASC&#160;842&#x201d;), to not recognize leases with a lease term of one year or less on its balance sheet. Leases with a term greater than one year are recognized on the balance sheet as &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;right-of-use&lt;/div&gt;&lt;/div&gt; (&#x201c;ROU&#x201d;) assets and current and &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-current&lt;/div&gt; lease liabilities, as applicable. As of December&#160;31, 2022 and December&#160;31, 2021, the Company does not have any financing leases. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;Lease liabilities and their corresponding ROU assets are initially recorded based on the present value of lease payments over the expected remaining lease term. Certain adjustments to the ROU asset may be required for items such as incentives, prepaid lease payments, or initial direct costs. When an option to extend the lease exists, a determination is made whether that option is reasonably certain of exercise based on economic factors present at the measurement date and as circumstances may change. Lease cost for operating leases is recognized on a straight-line basis over the lease term as an operating expense. Variable lease costs are expensed as incurred as an operating expense. &lt;/div&gt;&lt;div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"&gt;&#160;&lt;/div&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"/&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;As the rates implicit in the Company&#x2019;s leases have not historically been readily determinable, the Company utilizes the appropriate incremental borrowing rate, which is the rate the Company would incur to borrow on a collateralized basis over a similar term an amount equal to the lease payments in a similar economic environment over the lease term. To estimate our incremental borrowing rate, a credit rating applicable to the Company is estimated using a synthetic credit rating analysis since the Company does not currently have a rating agency-based credit rating. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;In accordance with ASC 842, contracts containing a lease should be split into three categories: lease components, &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-lease&lt;/div&gt; components, and activities or costs that do not transfer a distinct good or service &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(&#x201c;non-components&#x201d;).&lt;/div&gt; The fixed and &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;in-substance&lt;/div&gt; fixed contract consideration (including any consideration related to &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-components)&lt;/div&gt; must be allocated, based on the respective relative fair values, to the lease components and &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-lease&lt;/div&gt; components. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;Entities may elect not to separate lease and &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-lease&lt;/div&gt; components. Accordingly, entities making this election would account for each lease component and related &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-lease&lt;/div&gt; component together as a single lease component. The Company has elected to account for lease and &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-lease&lt;/div&gt; components together as a single lease component for all underlying assets and allocate all of the contract consideration to the lease component only. See Note 15 for further details. &lt;/div&gt;</us-gaap:LesseeLeasesPolicyTextBlock>
    <us-gaap:IncomeTaxPolicyTextBlock contextRef="P01_01_2022To12_31_2022">&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Income Taxes&lt;/div&gt;&lt;/div&gt;&#x2014;The Company accounts for income taxes under the asset and liability method pursuant to ASC&#160;740, Income Taxes. Under this method, the Company recognizes deferred tax assets and liabilities for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating loss and tax credit carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;We recognize deferred tax assets to the extent that we believe that these assets are more likely than not to be realized. In making such a determination, we consider all available positive and negative evidence, including future reversals of existing taxable temporary differences, projected future taxable income, &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;tax-planning&lt;/div&gt; strategies, and results of recent operations. If we determine that we would be able to realize our deferred tax assets in the future in excess of their net recorded amount, we would make an adjustment to the deferred tax asset valuation allowance, which would reduce the provision for income taxes. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;We record uncertain tax positions in accordance with ASC 740 on the basis of a &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;two-step&lt;/div&gt; process in which (1)&#160;we determine whether it is more likely than not that the tax positions will be sustained on the basis of the technical merits of the position and (2)&#160;for those tax positions that meet the &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;more-likely-than-not&lt;/div&gt; recognition threshold, we recognize the largest amount of tax benefit that is more than 50&#160;percent likely to be realized upon ultimate settlement with the related tax authority. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;We recognize interest and penalties related to unrecognized tax benefits on the income tax expense line in the accompanying consolidated statements of income and comprehensive income. &lt;/div&gt;</us-gaap:IncomeTaxPolicyTextBlock>
    <btmd:DebtIssuanceCostsPolicyTextBlock contextRef="P01_01_2022To12_31_2022">&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Debt Issuance Costs&lt;/div&gt;&lt;/div&gt;&#x2014;Costs incurred in connection with the issuance of the Company&#x2019;s long-term debt have been recorded as a direct reduction of the debt and amortized over the life of the associated debt as a component of interest expense using the straight-line method, which is not materially different compared to the effective interest m&lt;div style="display:inline;"&gt;ethod.&lt;/div&gt; &lt;/div&gt;</btmd:DebtIssuanceCostsPolicyTextBlock>
    <btmd:WarrantLiabilitiesPolicyTextBlock contextRef="P01_01_2022To12_31_2022">&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Warrant Liabilities&lt;/div&gt;&lt;/div&gt;&#x2014;The Company accounts for warrants as either equity-classified or liability-classified instruments based on an assessment of the warrant&#x2019;s specific terms and applicable authoritative guidance in ASC&#160;480, &lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Distinguishing Liabilities from Equity&lt;/div&gt;&lt;/div&gt; (&#x201c;ASC 480&#x201d;) and ASC 815, &lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Derivatives and Hedging&lt;/div&gt;&lt;/div&gt; (&#x201c;ASC&#160;815&#x201d;). The assessment considers whether the warrants are freestanding financial instruments pursuant to ASC&#160;480, &lt;div style="display:inline;"&gt;meet&lt;/div&gt; &lt;/div&gt;&lt;div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"&gt;&#160;&lt;/div&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"/&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;the definition of a liability pursuant to ASC 480, and whether the warrants meet all of the requirements for equity classification under ASC 815, including whether the warrants are indexed to the Company&#x2019;s own common stock, among other conditions for equity classification. This assessment, which requires the use of professional judgment, is conducted at the time of warrant issuance and as of each subsequent quarterly period end date while the warrants are outstanding. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;For issued or modified warrants that meet all of the criteria for equity classification, the warrants are required to be recorded as a component of additional &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;paid-in&lt;/div&gt; capital at the time of issuance. For issued or modified warrants that do not meet all the criteria for equity classification, the warrants are required to be recorded as a liability at their initial fair value on the date of issuance, and remeasured each balance sheet date thereafter. The Company&#x2019;s warrants did not meet the criteria for equity classification and are recorded as liabilities. Changes in the estimated fair value of the warrants are recognized as a &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-cash&lt;/div&gt; gain or loss in the statements of income and comprehensive income. See Note 10 for further detail. &lt;/div&gt;</btmd:WarrantLiabilitiesPolicyTextBlock>
    <btmd:EarnoutLiabilityPolicyTextBlock contextRef="P01_01_2022To12_31_2022">&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Earnout Liability&lt;/div&gt;&lt;/div&gt;&#x2014;In connection with the Business Combination, the Members and the Sponsor received shares that will vest upon the achievement of certain share price targets. The earnout shares are classified as a liability in the Company&#x2019;s consolidated balance sheet because it does not qualify as being indexed to the Company&#x2019;s own stock. The earnout liability was initially measured at fair value at the Closing Date and subsequently remeasured at the end of each reporting period. The change in fair value of the earnout liability is recorded in the consolidated statement of income and comprehensive income. See Note 11 for further detail. &lt;/div&gt;</btmd:EarnoutLiabilityPolicyTextBlock>
    <us-gaap:StockholdersEquityPolicyTextBlock contextRef="P01_01_2022To12_31_2022">&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Stockholders&#x2019; Equity (Deficit)&lt;/div&gt;&lt;/div&gt;&#x2014;Prior to consummation of the Business Combination, the Company&#x2019;s capital structure included voting units (Class A), &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-voting&lt;/div&gt; units (Class AA and AAA), and &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-voting&lt;/div&gt; incentive units (Class AAAA), with no limit to the number of units that may be issued. Class&#160;A units had 100% of the voting rights, and there is no par value assigned to any of the classes of units. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;Pursuant to the Business Combination Agreement and immediately prior to the Business Combination&#x2019;s consummation, the Company effectuated a recapitalization whereby all Class&#160;A, Class&#160;AA, Class&#160;AAA and Class&#160;AAAA units held by Holdings&#x2019; Members were converted (whether by direct exchange, merger or otherwise) into Class&#160;A &lt;div style="display:inline;"&gt;Common Units.&lt;/div&gt; &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;As of December&#160;31, 2021, the following members&#x2019; equity units were issued and outstanding: &lt;/div&gt;&lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width:68%"/&gt;
&lt;td style="vertical-align:bottom;width:5%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:5%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31, 2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.5pt;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; font-size: 8pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Members&#x2019; Equity&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Issued&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Outstanding&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Class&#160;A (Voting)&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;16,721&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;16,721&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Class&#160;AA &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(Non-voting)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;903,079&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;903,079&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Class&#160;AAA &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(Non-voting)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;60,000&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;60,000&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Class&#160;AAAA &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(Non-voting&lt;/div&gt; incentive units)&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;33,397&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3,000&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Total&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,013,197&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;982,800&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;As of December&#160;31, 2022, the following shares of common stock were issued and outstanding: &lt;/div&gt;&lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:11pt;width:76%;border:0;margin:0 auto"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width:64%"/&gt;
&lt;td style="vertical-align:bottom;width:3%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:3%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31, 2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.5pt;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; font-size: 8pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Stockholders&#x2019; Equity&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Issued&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Outstanding&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Class&#160;A common stock&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right;"&gt;11,242,887&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right;"&gt;9,655,387&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Class&#160;B common stock&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Class&#160;V voting stock&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right;"&gt;58,565,824&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right;"&gt;48,565,824&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Total&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right;"&gt;69,808,711&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right;"&gt;58,221,211&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"&gt;&#160;&lt;/div&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"/&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;The Company made operating distributions to Members of Holdings and taxing authorities on the Members&#x2019; behalf totaling $12,886 and $11,402 during the years ended December&#160;31, 2022 and 2021, &lt;div style="display:inline;"&gt;respectively.&lt;/div&gt; &lt;/div&gt;</us-gaap:StockholdersEquityPolicyTextBlock>
    <btmd:CommonUnitsVotingRightsPercentage
      contextRef="PAsOn12_31_2022_ClassAVotingUnitsMemberusgaapCapitalUnitsByClassAxis"
      decimals="2"
      unitRef="Unit_pure">1</btmd:CommonUnitsVotingRightsPercentage>
    <us-gaap:ScheduleOfCapitalUnitsTextBlock contextRef="P01_01_2022To12_31_2022">&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;As of December&#160;31, 2021, the following members&#x2019; equity units were issued and outstanding: &lt;/div&gt;&lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width:68%"/&gt;
&lt;td style="vertical-align:bottom;width:5%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:5%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31, 2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.5pt;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; font-size: 8pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Members&#x2019; Equity&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Issued&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Outstanding&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Class&#160;A (Voting)&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;16,721&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;16,721&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Class&#160;AA &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(Non-voting)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;903,079&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;903,079&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Class&#160;AAA &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(Non-voting)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;60,000&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;60,000&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Class&#160;AAAA &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(Non-voting&lt;/div&gt; incentive units)&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;33,397&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3,000&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Total&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,013,197&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;982,800&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfCapitalUnitsTextBlock>
    <us-gaap:CommonUnitIssued
      contextRef="PAsOn12_31_2021_ClassAVotingUnitsMemberusgaapCapitalUnitsByClassAxis"
      decimals="INF"
      unitRef="Unit_shares">16721</us-gaap:CommonUnitIssued>
    <us-gaap:CommonUnitOutstanding
      contextRef="PAsOn12_31_2021_ClassAVotingUnitsMemberusgaapCapitalUnitsByClassAxis"
      decimals="INF"
      unitRef="Unit_shares">16721</us-gaap:CommonUnitOutstanding>
    <us-gaap:CommonUnitIssued
      contextRef="PAsOn12_31_2021_ClassAaNonVotingUnitsMemberusgaapCapitalUnitsByClassAxis"
      decimals="INF"
      unitRef="Unit_shares">903079</us-gaap:CommonUnitIssued>
    <us-gaap:CommonUnitOutstanding
      contextRef="PAsOn12_31_2021_ClassAaNonVotingUnitsMemberusgaapCapitalUnitsByClassAxis"
      decimals="INF"
      unitRef="Unit_shares">903079</us-gaap:CommonUnitOutstanding>
    <us-gaap:CommonUnitIssued
      contextRef="PAsOn12_31_2021_ClassAaaNonVotingUnitsMemberusgaapCapitalUnitsByClassAxis"
      decimals="INF"
      unitRef="Unit_shares">60000</us-gaap:CommonUnitIssued>
    <us-gaap:CommonUnitOutstanding
      contextRef="PAsOn12_31_2021_ClassAaaNonVotingUnitsMemberusgaapCapitalUnitsByClassAxis"
      decimals="INF"
      unitRef="Unit_shares">60000</us-gaap:CommonUnitOutstanding>
    <us-gaap:CommonUnitIssued
      contextRef="PAsOn12_31_2021_ClassAaaaNonVotingIncentiveUnitsMemberusgaapCapitalUnitsByClassAxis"
      decimals="INF"
      unitRef="Unit_shares">33397</us-gaap:CommonUnitIssued>
    <us-gaap:CommonUnitOutstanding
      contextRef="PAsOn12_31_2021_ClassAaaaNonVotingIncentiveUnitsMemberusgaapCapitalUnitsByClassAxis"
      decimals="INF"
      unitRef="Unit_shares">3000</us-gaap:CommonUnitOutstanding>
    <us-gaap:CommonUnitIssued
      contextRef="PAsOn12_31_2021"
      decimals="INF"
      unitRef="Unit_shares">1013197</us-gaap:CommonUnitIssued>
    <us-gaap:CommonUnitOutstanding
      contextRef="PAsOn12_31_2021"
      decimals="INF"
      unitRef="Unit_shares">982800</us-gaap:CommonUnitOutstanding>
    <us-gaap:ScheduleOfStockByClassTextBlock contextRef="P01_01_2022To12_31_2022">&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;As of December&#160;31, 2022, the following shares of common stock were issued and outstanding: &lt;/div&gt;&lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:11pt;width:76%;border:0;margin:0 auto"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width:64%"/&gt;
&lt;td style="vertical-align:bottom;width:3%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:3%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31, 2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.5pt;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; font-size: 8pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Stockholders&#x2019; Equity&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Issued&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Outstanding&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Class&#160;A common stock&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right;"&gt;11,242,887&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right;"&gt;9,655,387&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Class&#160;B common stock&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Class&#160;V voting stock&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right;"&gt;58,565,824&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right;"&gt;48,565,824&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Total&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right;"&gt;69,808,711&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right;"&gt;58,221,211&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfStockByClassTextBlock>
    <us-gaap:CommonStockSharesIssued
      contextRef="PAsOn12_31_2022_CommonClassAMemberusgaapStatementClassOfStockAxis"
      decimals="INF"
      unitRef="Unit_shares">11242887</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="PAsOn12_31_2022_CommonClassAMemberusgaapStatementClassOfStockAxis"
      decimals="INF"
      unitRef="Unit_shares">9655387</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="PAsOn12_31_2022_CommonClassBMemberusgaapStatementClassOfStockAxis"
      decimals="INF"
      unitRef="Unit_shares">0</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="PAsOn12_31_2022_CommonClassBMemberusgaapStatementClassOfStockAxis"
      decimals="INF"
      unitRef="Unit_shares">0</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="PAsOn12_31_2022_ClassVCommonStockMemberusgaapStatementClassOfStockAxis"
      decimals="INF"
      unitRef="Unit_shares">58565824</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="PAsOn12_31_2022_ClassVCommonStockMemberusgaapStatementClassOfStockAxis"
      decimals="INF"
      unitRef="Unit_shares">48565824</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="PAsOn12_31_2022"
      decimals="INF"
      unitRef="Unit_shares">69808711</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="PAsOn12_31_2022"
      decimals="INF"
      unitRef="Unit_shares">58221211</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:LimitedPartnersCapitalAccountDistributionAmount
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">12886000</us-gaap:LimitedPartnersCapitalAccountDistributionAmount>
    <us-gaap:LimitedPartnersCapitalAccountDistributionAmount
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">11402000</us-gaap:LimitedPartnersCapitalAccountDistributionAmount>
    <btmd:StandbyEquityPurchaseAgreementPolicyTextBlock contextRef="P01_01_2022To12_31_2022">&lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Standby Equity Purchase Agreement &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;On July&#160;27, 2022, the Company entered into a Standby Equity Purchase Agreement (the &#x201c;SEPA&#x201d;) with YA II PN, Ltd. (&#x201c;Yorkville&#x201d;). Yorkville is a fund managed by Yorkville Advisors Global, LP, headquartered in Mountainside, New Jersey. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;The Company has the right, but not the obligation, from time to time at the Company&#x2019;s discretion until the first day of the month following the &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;36-month&lt;/div&gt; anniversary of the date of the SEPA (unless earlier terminated), to direct Yorkville to purchase a specified amount of shares of Class&#160;A common stock (each such sale, an &#x201c;Advance&#x201d;) by delivering written notice to Yorkville (each, an &#x201c;Advance Notice&#x201d;). The shares of Class&#160;A common stock purchased pursuant to an Advance will be purchased at a price equal to 97.0% of the lowest daily VWAP of the Class&#160;A common stock during the &lt;span style="-sec-ix-hidden:hidden73945778"&gt;three&lt;/span&gt; consecutive trading days commencing on the date of delivery of a given Advance Notice. &#x201c;VWAP&#x201d; means, for any trading day, the daily volume weighted average price of the Company&#x2019;s common stock for such date as reported by Bloomberg L.P. during regular trading hours. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;While there is no mandatory minimum amount for any individual Advance, it may not exceed the greater of (i)&#160;an amount equal to thirty percent (30%) of the daily volume traded on the trading day immediately preceding an Advance Notice, or (ii) 1,000,000 shares of Class&#160;A common stock. No more than 5,000,000 shares of Class&#160;A common stock, including the Commitment Shares (as defined below) may be sold pursuant to the SEPA. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;Yorkville&#x2019;s obligation to continue to purchase shares of Class&#160;A common stock pursuant to the SEPA is subject to a number of conditions. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;As consideration for Yorkville&#x2019;s commitment to purchase Class&#160;A common stock at the Company&#x2019;s direction upon the terms and subject to the conditions set forth in the SEPA, upon execution of the SEPA, the Company issued 25,000 shares of Class&#160;A common stock to Yorkville (the &#x201c;Commitment Shares&#x201d;). During the year ended December&#160;31, 2022, the Company sold 105,559 shares to Yorkville under the SEPA for cash proceeds of $442. &lt;/div&gt;</btmd:StandbyEquityPurchaseAgreementPolicyTextBlock>
    <btmd:TerminationPeriodOfPurchaseAgreement contextRef="P07_27_2022To07_27_2022_StandbyEquityPurchaseAgreementMemberusgaapTypeOfArrangementAxis">P36M</btmd:TerminationPeriodOfPurchaseAgreement>
    <btmd:PercentageOfCommonStockPurchasePrice
      contextRef="P07_27_2022To07_27_2022_StandbyEquityPurchaseAgreementMemberusgaapTypeOfArrangementAxis"
      decimals="INF"
      unitRef="Unit_pure">0.97</btmd:PercentageOfCommonStockPurchasePrice>
    <btmd:MandatoryMinimumAmountForIndividualAdvance
      contextRef="PAsOn07_27_2022_StandbyEquityPurchaseAgreementMemberusgaapTypeOfArrangementAxis"
      decimals="-3"
      unitRef="Unit_USD">0</btmd:MandatoryMinimumAmountForIndividualAdvance>
    <btmd:MaximumValueOfDailyVolumeTradedThresholdPercentage
      contextRef="P07_27_2022To07_27_2022_StandbyEquityPurchaseAgreementMemberusgaapTypeOfArrangementAxis"
      decimals="2"
      unitRef="Unit_pure">0.30</btmd:MaximumValueOfDailyVolumeTradedThresholdPercentage>
    <us-gaap:CommonStockSharesIssued
      contextRef="PAsOn07_27_2022_CommonClassAMemberusgaapStatementClassOfStockAxis_StandbyEquityPurchaseAgreementMemberusgaapTypeOfArrangementAxis"
      decimals="INF"
      unitRef="Unit_shares">1000000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesIssued
      contextRef="PAsOn07_27_2022_MaximumMembersrtRangeAxis_StandbyEquityPurchaseAgreementMemberusgaapTypeOfArrangementAxis"
      decimals="INF"
      unitRef="Unit_shares">5000000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesIssued
      contextRef="PAsOn07_27_2022_StandbyEquityPurchaseAgreementMemberusgaapTypeOfArrangementAxis_YorkvilleAdvisorsGlobalLpMemberusgaapCreditFacilityAxis"
      decimals="INF"
      unitRef="Unit_shares">25000</us-gaap:CommonStockSharesIssued>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="P01_01_2022To12_31_2022_StandbyEquityPurchaseAgreementMemberusgaapTypeOfArrangementAxis"
      decimals="INF"
      unitRef="Unit_shares">105559</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <btmd:ProceedsFromSettlementOfSEPA
      contextRef="P01_01_2022To12_31_2022_StandbyEquityPurchaseAgreementMemberusgaapTypeOfArrangementAxis"
      decimals="-3"
      unitRef="Unit_USD">442000</btmd:ProceedsFromSettlementOfSEPA>
    <btmd:NoncontrollingInterestPolicyTextBlock contextRef="P01_01_2022To12_31_2022">&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Noncontrolling Interest&lt;/div&gt;&lt;/div&gt;&#x2014;Pursuant to the Business Combination, as described in Note 3, the Company is organized in an &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x201c;Up-C&#x201d;&lt;/div&gt; structure with the Company owning only a portion of its consolidated subsidiaries. The portion of the consolidated subsidiaries not owned by the Company and any related activity is presented as noncontrolling interest in the consolidated financial statements. The noncontrolling interests, together with their corresponding shares of Class&#160;V voting stock, can be exchanged for Class&#160;A common stock in Biote or, at the election of the Company, cash. Because redemptions for cash is solely within the control of the Company, noncontrolling interest is presented in permanent equity. &lt;/div&gt;</btmd:NoncontrollingInterestPolicyTextBlock>
    <us-gaap:RevenueRecognitionPolicyTextBlock contextRef="P01_01_2022To12_31_2022">&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Revenue Recognition&lt;/div&gt;&lt;/div&gt;&#x2014;The Company accounts for revenue in accordance with FASB, Accounting Standards &lt;div style="display:inline;"&gt;Update&lt;/div&gt; (&#x201c;ASU&#x201d;) &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;No.&#160;2014-09,&lt;/div&gt; &lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Revenue from Contracts with Customers&lt;/div&gt;&lt;/div&gt;, as amended, (Topic 606). Revenue is measured based on the consideration specified in a contract with a customer. The Company recognizes revenue when it satisfies a performance obligation by transferring control of a product or service to a customer. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;Taxes assessed by a governmental authority that are both imposed on and concurrent with a specific revenue-producing transaction, that are collected by the Company from a customer, are excluded from revenue. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;Shipping and handling costs associated with outbound freight after control of a product has transferred to a customer are accounted for as fulfillment costs and are included in cost of products in the statements of income and comprehensive income. Shipping and handling costs billed to customers are considered part of the transaction price and are recognized as revenue with the underlying product sales for dietary supplements and trocars. &lt;/div&gt;&lt;div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"&gt;&#160;&lt;/div&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"/&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;The following is a description of the principal contract activities, disaggregated by the contract type, from which the Company generates its revenue. &lt;/div&gt;&lt;div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;The Biote Method &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;The Company generates revenues through standard service agreements with customers who participate in the Biote Method. The Biote Method is a bioidentical hormone replacement therapy which has been developed as a treatment designed to alleviate hormone imbalances. Under this agreement, the Company provides a bundle of goods and services to customers, including initial training to medical practitioners, bioidentical hormone pellets and software tools used for inventory management and dosing, and ongoing practice development and marketing support services, which includes a license to use the Company&#x2019;s trademarks and trade names in the customer&#x2019;s marketing materials. The initial contract term is three years, and customers have the option to renew for additional &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;one-year&lt;/div&gt; periods. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;For the bundled goods and services, the Company accounts for individual products and services separately if they are distinct, i.e., if a product or service is separately identifiable from other items in the bundled package and if a customer can benefit from it on its own or with other resources that are readily available to the customer. The Company has identified three distinct obligations in its standard service agreement: initial training, pellet procedures (including sales of bioidentical hormone pellets, use of inventory management software to monitor pellet inventory, and use of the Company&#x2019;s blood dosing website to determine the appropriate pellets to use in each procedure), contract-term services (including ongoing practice development and marketing support, options to receive reusable trocars, and the right to use the reusable trocars through the term of the contract, if the option is exercised). The third obligation includes a combined lease/nonlease component for which the Company has adopted the practical expedient within ASC 842 which allows lessors to combine lease and &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-lease&lt;/div&gt; components that have the same pattern of transfer to the customer-lessee and account for the combined component under the guidance relevant to the predominant portion of the component. By applying this expedient, the Company applies Topic 606 to the combined component. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;The consideration in the contract is allocated between separate products and services in the bundle based on the stand-alone selling prices of each good and service. The stand-alone selling prices are determined based on the prices at which the Company separately sells the initial training and the pellet procedures. Judgment is required to determine the standalone selling price for each distinct performance obligation. For items that are not sold separately and for which the Company has not established a standalone selling price, the Company allocates consideration based on the residual approach. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;The Company recognizes revenue for initial training over time as the customer completes the training. Training sessions generally occur over the course of &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2-3&lt;/div&gt; consecutive days at or near the time of contract inception. The Customer is charged an initial fixed-rate fee for this training. Customers pay in full for the initial training at the time of contract inception. The standalone selling price of these services is based on the lowest price offered by the Company for the services. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;The Company recognizes revenue for pellet procedures at the point in time the procedures are performed by the practitioner, which is when control of the pellets transfers to the customer. Consideration for these services is in the form of a management fee assessed for each procedure performed, which includes a volume-based tiered pricing schedule. The standalone selling price for these services requires judgment and is estimated based on the Company&#x2019;s historical experience with prices offered to similar customers throughout the initial term of the contract. Billings in excess of the standalone selling price constitute a premium charged to customers early in a relationship and are deferred and recognized when or as the remaining goods and services are transferred to the customer. Fees are billed and paid on a semimonthly basis. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;The Company recognizes revenue for contract-term services on a straight-line basis over the initial term of the contract, which aligns with the Company&#x2019;s satisfaction of the performance obligation. The Company allocates the residual consideration to this performance obligation, which is consistent with the allocation objective. &lt;/div&gt;&lt;div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"&gt;&#160;&lt;/div&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"/&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Dietary Supplements &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;Dietary supplements are supplements that customer practitioners resell to patients that aid the patients with maintaining hormone balances. The Company recognizes revenue for these, net of any discounts given, when control transfers to the customer, which is generally the point of shipment from the Company&#x2019;s distributor. Products are billed at standalone selling price for the dietary supplements and invoiced at shipment. &lt;/div&gt;&lt;div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Disposable Trocars &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;Disposable Trocars are manual surgical instruments intended for use by Biote-certified practitioners. These tools are used to implant the bioidentical hormone pellets into the customers&#x2019; patients. The Company recognizes revenue at the time control transfers, which is generally the point of shipment from the distributor. Products are billed at the standalone selling price for the trocars and invoiced at shipment. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;Revenue disaggregated by the nature of the product or service and by geography is included within Note 4: Revenue Recognition. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;As of the years ended December&#160;31, 2022 and 2021, the Company had allocated $104 and $67 respectively, of consideration to the unsatisfied initial training obligations, and $1,655 and $1,393, respectively, of consideration to the unsatisfied contract-term service obligations provided to the Biote Method customers. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;Consideration allocated to initial training due to deposits paid upfront is presented within deferred revenue on the consolidated balance sheets and is expected to be recognized as revenue within one year, as the training is complete. Consideration allocated to contract-term services is presented within deferred revenue and deferred revenue, long-term for the amounts expected to be recognized within one year and longer than one year, respectively. As of the years ended December&#160;31, 2022 and 2021 the amount of consideration allocated to contract-term services presented within deferred revenue was $1,028 and $849, respectively, and the amount presented within deferred revenue, long-term was $627 and $544, respectively. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;The Consideration allocated to the premiums within the management fee for pellet procedures is presented within deferred revenue current and deferred revenue, long-term for amounts expected to be recognized within one year and longer than one year, respectively. As of the years ended December&#160;31, 2022 and 2021 the amount of these premiums within deferred revenue was $833 and $789, respectively, and the amount within deferred revenue, long-term was $299 and $258, respectively. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;The Company has also elected the practical expedient in ASC 606 to not disclose consideration allocated to contracts with an original term of one year or less, which includes contracts for &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;point-in-time&lt;/div&gt;&lt;/div&gt; sales of dietary supplements, disposable trocars, and pellet procedures. Pellet procedures are included in the Company&#x2019;s Biote Method service agreement, which has a three-year stated term, but as revenues are recognized at a point in time, there are no minimum purchase volumes, and the contract allows for cancellation with ninety days&#x2019; notice from the customer, there are no pellet procedure obligations that are satisfied over a period greater than one year. &lt;/div&gt;&lt;div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Contract Assets and Liabilities &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;Customer receivables are made up of consideration to which the Company has an unconditional right to payment, regardless of whether the Company has satisfied the performance obligations in the contract. All customer receivables are presented within accounts receivable, net of allowance for doubtful accounts in the consolidated balance sheets. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;Contract assets are the Company&#x2019;s right to consideration for goods or services that the entity has transferred to the customer when that right is conditioned on something other than the passage of time. The Company does not have any contract assets for the years ended December&#160;31, 2022 and 2021. &lt;/div&gt;&lt;div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"&gt;&#160;&lt;/div&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"/&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;Contract liabilities are the Company&#x2019;s obligation to transfer goods or services to a customer for which the Company has received consideration or has an unconditional right to receive consideration. The Company&#x2019;s contract liabilities include deposits for initial training and contract-term services paid in advance which have not been recognized as revenue during the period. Contract liabilities are presented within deferred revenue and deferred revenue, long-term in the consolidated balance sheets. Contract liabilities are classified as current liabilities for the amount of revenue that the Company expects to recognize within one year of the reporting date. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;Changes in contract liabilities between each period are attributable to fees paid by new customers, revenue recognized for completed trainings, and revenue recognized for the Company&#x2019;s over-time satisfaction of contract-term services. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;The Company does not have a history of material returns or refunds, and generally does not offer warranties or guarantees for any products or services. Expected returns and refunds are recorded as a reduction of revenue and are $0 and $0 for the years ended December&#160;31, 2022 and 2021, respectively. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;A reconciliation of the beginning and ending contract liabilities is included within Note 4: Revenue Recognition. &lt;/div&gt;</us-gaap:RevenueRecognitionPolicyTextBlock>
    <us-gaap:RevenueRemainingPerformanceObligation
      contextRef="PAsOn12_31_2022_BioteMethodCustomerMemberbtmdNatureOfCustomerAxis_ServiceRevenueMemberbtmdSourceOfRevenueAxis_TrainingMemberbtmdSourceOfServiceRevenueAxis"
      decimals="-3"
      unitRef="Unit_USD">104000</us-gaap:RevenueRemainingPerformanceObligation>
    <us-gaap:RevenueRemainingPerformanceObligation
      contextRef="PAsOn12_31_2021_BioteMethodCustomerMemberbtmdNatureOfCustomerAxis_ServiceRevenueMemberbtmdSourceOfRevenueAxis_TrainingMemberbtmdSourceOfServiceRevenueAxis"
      decimals="-3"
      unitRef="Unit_USD">67000</us-gaap:RevenueRemainingPerformanceObligation>
    <us-gaap:RevenueRemainingPerformanceObligation
      contextRef="PAsOn12_31_2022_BioteMethodCustomerMemberbtmdNatureOfCustomerAxis_ContractTermServicesMemberbtmdSourceOfServiceRevenueAxis_ServiceRevenueMemberbtmdSourceOfRevenueAxis"
      decimals="-3"
      unitRef="Unit_USD">1655000</us-gaap:RevenueRemainingPerformanceObligation>
    <us-gaap:RevenueRemainingPerformanceObligation
      contextRef="PAsOn12_31_2021_BioteMethodCustomerMemberbtmdNatureOfCustomerAxis_ContractTermServicesMemberbtmdSourceOfServiceRevenueAxis_ServiceRevenueMemberbtmdSourceOfRevenueAxis"
      decimals="-3"
      unitRef="Unit_USD">1393000</us-gaap:RevenueRemainingPerformanceObligation>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="PAsOn12_31_2022_BioteMethodCustomerMemberbtmdNatureOfCustomerAxis_ContractTermServicesMemberbtmdSourceOfServiceRevenueAxis_ServiceRevenueMemberbtmdSourceOfRevenueAxis"
      decimals="-3"
      unitRef="Unit_USD">1028000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="PAsOn12_31_2021_BioteMethodCustomerMemberbtmdNatureOfCustomerAxis_ContractTermServicesMemberbtmdSourceOfServiceRevenueAxis_ServiceRevenueMemberbtmdSourceOfRevenueAxis"
      decimals="-3"
      unitRef="Unit_USD">849000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent
      contextRef="PAsOn12_31_2022_BioteMethodCustomerMemberbtmdNatureOfCustomerAxis_ContractTermServicesMemberbtmdSourceOfServiceRevenueAxis_ServiceRevenueMemberbtmdSourceOfRevenueAxis"
      decimals="-3"
      unitRef="Unit_USD">627000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent
      contextRef="PAsOn12_31_2021_BioteMethodCustomerMemberbtmdNatureOfCustomerAxis_ContractTermServicesMemberbtmdSourceOfServiceRevenueAxis_ServiceRevenueMemberbtmdSourceOfRevenueAxis"
      decimals="-3"
      unitRef="Unit_USD">544000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="PAsOn12_31_2022_BioteMethodCustomerMemberbtmdNatureOfCustomerAxis_PalletProceduresMemberbtmdSourceOfServiceRevenueAxis_ProductRevenueMemberbtmdSourceOfRevenueAxis"
      decimals="-3"
      unitRef="Unit_USD">833000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="PAsOn12_31_2021_BioteMethodCustomerMemberbtmdNatureOfCustomerAxis_PalletProceduresMemberbtmdSourceOfServiceRevenueAxis_ProductRevenueMemberbtmdSourceOfRevenueAxis"
      decimals="-3"
      unitRef="Unit_USD">789000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent
      contextRef="PAsOn12_31_2022_BioteMethodCustomerMemberbtmdNatureOfCustomerAxis_PalletProceduresMemberbtmdSourceOfServiceRevenueAxis_ProductRevenueMemberbtmdSourceOfRevenueAxis"
      decimals="-3"
      unitRef="Unit_USD">299000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent
      contextRef="PAsOn12_31_2021_BioteMethodCustomerMemberbtmdNatureOfCustomerAxis_PalletProceduresMemberbtmdSourceOfServiceRevenueAxis_ProductRevenueMemberbtmdSourceOfRevenueAxis"
      decimals="-3"
      unitRef="Unit_USD">258000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <btmd:ExpectedReturnsAndRefundsToCustomers
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">0</btmd:ExpectedReturnsAndRefundsToCustomers>
    <btmd:ExpectedReturnsAndRefundsToCustomers
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">0</btmd:ExpectedReturnsAndRefundsToCustomers>
    <btmd:CostOfRevenuePolicyTextBlock contextRef="P01_01_2022To12_31_2022">&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Cost of Revenue&lt;/div&gt;&lt;/div&gt;&#x2014;Cost of services primarily consist of the costs incurred to deliver trainings to Biote Method customers. Cost of products includes the cost of pellets purchased from compounding pharmacies and sold to customers of the Biote Method, the cost of trocars and dietary supplements purchased from manufacturing facilities or third-party &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;co-packers,&lt;/div&gt; and the shipping and handling costs incurred to deliver these products to the customers. &lt;/div&gt;</btmd:CostOfRevenuePolicyTextBlock>
    <us-gaap:MarketRiskBenefitPolicyTextBlock contextRef="P01_01_2022To12_31_2022">&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Marketing&lt;/div&gt;&lt;/div&gt;&#x2014;&lt;div style="display:inline;"&gt;Mark&lt;/div&gt;eting expense includes advertising costs, marketing events, and program costs. These costs are expensed as incurred. &lt;/div&gt;</us-gaap:MarketRiskBenefitPolicyTextBlock>
    <us-gaap:SellingGeneralAndAdministrativeExpensesPolicyTextBlock contextRef="P01_01_2022To12_31_2022">&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Selling, General, and Administrative&lt;/div&gt;&lt;/div&gt;&#x2014;Selling, general, and administrative expense consists primarily of software licensing and maintenance and the cost of employees who engage in corporate functions, such as finance and accounting, information technology, human resources, legal, and executive management. Selling, general, and administrative expense also includes rent occupancy costs, office expenses, recruiting expenses, entertainment allocations, depreciation and amortization, other general overhead costs, insurance premiums, professional service fees, research and development, and costs related to regulatory and litigation m&lt;div style="display:inline;"&gt;atters.&lt;/div&gt; &lt;/div&gt;</us-gaap:SellingGeneralAndAdministrativeExpensesPolicyTextBlock>
    <us-gaap:PensionAndOtherPostretirementPlansPolicy contextRef="P01_01_2022To12_31_2022">&lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Employee Retirement Plans&#x2014; &lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Defined Contribution Retirement Plans &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;Effective January&#160;1, 2021, the Company offers participation in the BioTE Medical, LLC (&#x201d;BioTE Medical&#x201d;) 401(k) Plan (the &#x201c;401(k) Plan&#x201d;), a defined contribution plan providing retirement benefits to eligible employees. Eligible employees may contribute a portion of their annual compensation to the 401(k) Plan, subject to the maximum annual amounts as set periodically by the IRS. The Company makes a safe harbor, &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-elective&lt;/div&gt; contribution to the 401(k) Plan equal to 3% of each participant&#x2019;s eligible employee compensation. Safe harbor contributions vest immediately for each participant. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;During the years ended December&#160;31, 2022 and 2021, the Company made $915 and $335, respectively, in safe harbor contributions under the 401(k) Plan, which are presented within Selling, general and administrative expense in the consolidated statements of income and comprehensive income. &lt;/div&gt;</us-gaap:PensionAndOtherPostretirementPlansPolicy>
    <us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch
      contextRef="P01_01_2022To12_31_2022_FourZeroOneKPlanMemberusgaapRetirementPlanNameAxis"
      decimals="2"
      unitRef="Unit_pure">0.03</us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="P01_01_2022To12_31_2022_FourZeroOneKPlanMemberusgaapRetirementPlanNameAxis"
      decimals="-3"
      unitRef="Unit_USD">915000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount
      contextRef="P01_01_2021To12_31_2021_FourZeroOneKPlanMemberusgaapRetirementPlanNameAxis"
      decimals="-3"
      unitRef="Unit_USD">335000</us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount>
    <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy contextRef="P01_01_2022To12_31_2022">&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Share-Based Compensation&lt;/div&gt;&lt;/div&gt;&#x2014;Holdings previously granted Class&#160;AAAA units (&#x201c;incentive units&#x201d;) and phantom equity rights (collectively, the &#x201c;equity awards&#x201d;) to certain key members of management. The equity awards were entitled to share in the distributions of Holdings from a change in control or qualifying liquidity event. The equity awards are accounted for under ASC 718, &lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Compensation&#x2014;Stock Compensation&lt;/div&gt;&lt;/div&gt;, and classified in &lt;div style="display:inline;"&gt;equity.&lt;/div&gt; &lt;/div&gt;&lt;div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"&gt;&#160;&lt;/div&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"/&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;The Company has elected to recognize forfeitures at the time they occur. The fair value of the equity awards was determined using a Monte-Carlo simulation as of the grant date. The awards begin to vest on the date of a change in control or qualifying event. The Business Combination constituted such a qualifying event triggering the performance condition in the awards. No compensation cost was recognized historically until the Closing of the Business Combination as a qualifying event was not previously deemed probable to occur. See Note 14 for further &lt;div style="display:inline;"&gt;details.&lt;/div&gt;&lt;/div&gt;</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
    <btmd:MaximumValueOfDailyVolumeTradedThresholdPercentage
      contextRef="P01_01_2022To12_31_2022"
      decimals="0"
      unitRef="Unit_pure">0</btmd:MaximumValueOfDailyVolumeTradedThresholdPercentage>
    <us-gaap:CommissionsPolicy contextRef="P01_01_2022To12_31_2022">&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Commissions&lt;/div&gt;&lt;/div&gt;&#x2014;Commissions consist primarily of fees paid to a third-party sales force, internal sales force, and partner clinics which participate in the Company&#x2019;s new clinic mentor program. Commissions paid to the Company&#x2019;s internal and third-party sales forces relate to market support and development activities undertaken to drive channel sales through existing customers and are not considered incremental costs to obtain a customer contract. For the years ended December&#160;31, 2022 and 2021 expenses incurred for these commission programs were $124 and $317, respectively. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;Commissions paid to clinics under the Company&#x2019;s mentorship program represent amounts paid to existing clinics which provide services to help new customers complete onboarding and other startup activities and are only incurred after contract initiation. These costs are expensed as incurred, consistent with other contract fulfillment costs. For the years ended December&#160;31, 2022 and 2021 commissions paid under this program were $1,098 and $1,738, respectively. &lt;/div&gt;</us-gaap:CommissionsPolicy>
    <us-gaap:SalesCommissionsAndFees
      contextRef="P01_01_2022To12_31_2022_BioteMethodCustomerMemberbtmdNatureOfCustomerAxis"
      decimals="-3"
      unitRef="Unit_USD">124000</us-gaap:SalesCommissionsAndFees>
    <us-gaap:SalesCommissionsAndFees
      contextRef="P01_01_2021To12_31_2021_BioteMethodCustomerMemberbtmdNatureOfCustomerAxis"
      decimals="-3"
      unitRef="Unit_USD">317000</us-gaap:SalesCommissionsAndFees>
    <us-gaap:CapitalizedContractCostAmortization
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">1098000</us-gaap:CapitalizedContractCostAmortization>
    <us-gaap:CapitalizedContractCostAmortization
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">1738000</us-gaap:CapitalizedContractCostAmortization>
    <us-gaap:ConcentrationRiskCreditRisk contextRef="P01_01_2022To12_31_2022">&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Concentrations&lt;/div&gt;&lt;/div&gt;&#x2014;Financial instruments that potentially subject the Company to concentrations of credit risk consist primarily of cash, accounts receivable, credit agreements, and inventory purchases. The Company&#x2019;s cash balances exceed those that are federally insured. To date, the Company has not recognized any losses caused by uninsured balances. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;As of December&#160;31, 2022 and December&#160;31, 2021, 100% of the Company&#x2019;s outstanding debt and available line of credit was from one lender. A failure of the counterparty to perform could result in the loss of access to the available borrowing capacity under the line of credit. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;Inventory purchases from three vendors totaled approximately 87% and 94% for the years ended December&#160;31, 2022 and 2021, respectively. Due to the nature of the markets and availability of alternative suppliers, the Company does not believe the loss of any one vendor would have a material adverse impact on the Company&#x2019;s financial position, results of operations or cash flows for any significant period of time. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;Significant customers are those which represent more than 10% of the Company&#x2019;s total revenue or gross accounts receivable balance. The Company did not have any customers that accounted for 10% or more of total revenues for the years ended December&#160;31, 2022 and 2021. The Company did not have any customers that accounted for more than 10% of the outstanding gross accounts receivable as of December&#160;31, 2022 or December&#160;31, 2021. &lt;/div&gt;</us-gaap:ConcentrationRiskCreditRisk>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="P01_01_2022To12_31_2022_CreditAvailabilityConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis_LiabilitiesTotalMemberusgaapConcentrationRiskByBenchmarkAxis"
      decimals="2"
      unitRef="Unit_pure">1</us-gaap:ConcentrationRiskPercentage1>
    <btmd:NumberOfInventoryVendors
      contextRef="P01_01_2021To12_31_2021"
      decimals="0"
      unitRef="Unit_vendor">3</btmd:NumberOfInventoryVendors>
    <btmd:NumberOfInventoryVendors
      contextRef="P01_01_2022To12_31_2022"
      decimals="0"
      unitRef="Unit_vendor">3</btmd:NumberOfInventoryVendors>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="P01_01_2022To12_31_2022_AssetsTotalMemberusgaapConcentrationRiskByBenchmarkAxis_InventoryMembersrtProductOrServiceAxis_SupplierConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis"
      decimals="2"
      unitRef="Unit_pure">0.87</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="P01_01_2021To12_31_2021_AssetsTotalMemberusgaapConcentrationRiskByBenchmarkAxis_InventoryMembersrtProductOrServiceAxis_SupplierConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis"
      decimals="2"
      unitRef="Unit_pure">0.94</us-gaap:ConcentrationRiskPercentage1>
    <btmd:NumberOfCustomersAccountedForTenPercentOrMoreAggregateRevenue
      contextRef="P01_01_2021To12_31_2021"
      decimals="0"
      unitRef="Unit_CUSTOMER">0</btmd:NumberOfCustomersAccountedForTenPercentOrMoreAggregateRevenue>
    <btmd:NumberOfCustomersAccountedForTenPercentOrMoreAggregateRevenue
      contextRef="P01_01_2022To12_31_2022"
      decimals="0"
      unitRef="Unit_CUSTOMER">0</btmd:NumberOfCustomersAccountedForTenPercentOrMoreAggregateRevenue>
    <btmd:NumberOfCustomersAccountedForTenPercentOrMoreAccountsReceivable
      contextRef="PAsOn12_31_2021"
      decimals="0"
      unitRef="Unit_CUSTOMER">0</btmd:NumberOfCustomersAccountedForTenPercentOrMoreAccountsReceivable>
    <btmd:NumberOfCustomersAccountedForTenPercentOrMoreAccountsReceivable
      contextRef="PAsOn12_31_2022"
      decimals="0"
      unitRef="Unit_CUSTOMER">0</btmd:NumberOfCustomersAccountedForTenPercentOrMoreAccountsReceivable>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="P01_01_2022To12_31_2022">&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Recently Adopted Accounting Pronouncements&lt;/div&gt;&lt;/div&gt;&#x2014;In December 2019, the FASB issued ASU &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2019-12,&lt;/div&gt; &lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Income Taxes (Topic 740)&#x2014;Simplifying the Accounting for Income Taxes&lt;/div&gt;&lt;/div&gt;, which simplifies the accounting for income taxes by removing certain exceptions to the general principles of ASC 740, &lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Income Taxes&lt;/div&gt;&lt;/div&gt;. The amendments also improve consistent application of and simplify U.S. GAAP for other areas of ASC 740 by clarifying and amending existing guidance. ASU &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2019-12&lt;/div&gt; is effective for fiscal years beginning after December&#160;15, 2021, and for interim periods beginning after December&#160;15, 2022. The Company has adopted the standard as of January 1, 2022, and there was no material impact to the financial statements. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Recent Accounting Pronouncements Not Yet Adopted&lt;/div&gt;&lt;/div&gt;&#x2014;In June 2016, the FASB issued ASU &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2016-13,&lt;/div&gt; &lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Measurement of Credit Losses on Financial Instruments&lt;/div&gt;&lt;/div&gt; (&#x201c;ASU &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2016-13&#x201d;).&lt;/div&gt; The main objective of the update is to provide financial statement users with more decision-useful information about the expected credit losses on financial instruments and other commitments to extend credit held by companies at each reporting date. For trade &lt;/div&gt;&lt;div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"&gt;&#160;&lt;/div&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"/&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;and other receivables, held to maturity debt securities, and other instruments, companies will be required to use a new forward-looking &#x201c;expected losses&#x201d; model that generally will result in the recognition of allowances for losses earlier than under current accounting guidance. Further, the FASB issued ASU &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2019-04,&lt;/div&gt; ASU &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2019-05&lt;/div&gt; and ASU &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2019-11&lt;/div&gt; to provide additional guidance on the credit losses standard. The standard will be adopted using the modified retrospective approach. ASU &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2016-13&lt;/div&gt; is effective for annual and interim periods beginning after December&#160;15, 2022, with early adoption permitted. The Company is evaluating the potential impact of adopting ASU &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2016-13&lt;/div&gt; on its consolidated financial statements and related disclosures. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;In August 2020, the FASB issued ASU &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2020-06,&lt;/div&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt; Debt&#x2014;Debt with Conversion and Other Options &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(Subtopic&#160;470-20)&lt;/div&gt; and Derivatives and Hedging&#x2014;Contracts in Entity&#x2019;s Own Equity (Subtopic &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;815-40):&lt;/div&gt; Accounting for Convertible Instruments and Contracts in an Entity&#x2019;s Own Equity&lt;/div&gt;&lt;/div&gt; (&#x201c;ASU &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2020-06&#x201d;).&lt;/div&gt; &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;ASU&#160;2020-06&lt;/div&gt; changes how entities account for convertible instruments and contracts in an entity&#x2019;s own equity and simplifies the accounting for convertible instruments by removing certain separation models for convertible instruments. ASU &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2020-06&lt;/div&gt; also modifies the guidance on diluted earnings per share calculations. The amendments are effective for fiscal years beginning after December&#160;15, 2023, including interim periods within those fiscal years. The Company is currently evaluating the impact of this standard on its consolidated financial statements and related disclosures. &lt;/div&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted contextRef="PAsOn12_31_2022_AccountingStandardsUpdate201912MemberusgaapAdjustmentsForNewAccountingPronouncementsAxis">true</us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted>
    <us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate contextRef="PAsOn12_31_2022_AccountingStandardsUpdate201912MemberusgaapAdjustmentsForNewAccountingPronouncementsAxis">2022-01-01</us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate>
    <us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect contextRef="PAsOn12_31_2022_AccountingStandardsUpdate201912MemberusgaapAdjustmentsForNewAccountingPronouncementsAxis">true</us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect>
    <us-gaap:BusinessCombinationDisclosureTextBlock contextRef="P01_01_2022To12_31_2022">
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%"&gt;
&lt;tr style="page-break-inside:avoid"&gt;
&lt;td style="width:4%;vertical-align:top;text-align:left;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;3.&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:top;text-align:left;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; text-align: left; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;BUSINESS COMBINATION &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;At the Closing, (i)&#160;Holdings transferred to the Company 9,161,771 Class&#160;A common units of Holdings (&#x201c;Holdings Units&#x201d;), which was equal to the number of shares of Haymaker&#x2019;s Class&#160;A common stock, par value $0.0001 per share (&#x201c;Class&#160;A common stock&#x201d;), issued and outstanding as of immediately prior to the Closing (after giving effect to redemptions by Haymaker&#x2019;s public stockholders of 30,525,729 shares of Class&#160;A common stock prior to the Closing and the conversion of Haymaker&#x2019;s Class&#160;B common stock, par value $0.0001 per share (&#x201c;Class&#160;B common stock&#x201d;) into shares of Class&#160;A common stock and (ii)&#160;Haymaker issued 58,565,824 shares of newly authorized Class&#160;V voting stock, par value $0.0001 per share (&#x201c;Class&#160;V voting stock&#x201d;), which number of shares of Class&#160;V voting stock was equal to the number of Holdings Units retained by the Members immediately following the Closing (the &#x201c;Retained Holdings Units&#x201d;), and which shares of Class&#160;V voting stock were distributed to the Members, resulting in the Company being organized in an &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x201c;Up-C&#x201d;&lt;/div&gt; structure. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;Also at Closing, (x)&#160;in exchange for the Closing Holdings Units, Haymaker transferred cash in an amount equal to (i)&#160;the cash in the trust account and any cash held by Haymaker outside of the trust account, less (ii)&#160;the amounts required by the redemptions of Class&#160;A common stock by the public stockholders, which was equal to $305.5&#160;million and (y)&#160;the BioTE Companies received aggregate proceeds of $125&#160;million from the Debt Financing (as defined below) (the aggregate amounts described in (x)&#160;and (y) of $137.3&#160;million, the &#x201c;Closing Date Cash&#x201d;) in accordance with and in the priority set forth in the Business Combination Agreement and as described further in the Proxy Statement. There was no cash consideration paid to Members at Closing. &lt;/div&gt;&lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Recapitalization &lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;Immediately prior to the Closing, Holdings (i)&#160;effectuated a recapitalization, pursuant to which all its Class&#160;A units, Class&#160;AA units, Class&#160;AAA units and Class&#160;AAAA units held by the Members were converted or exchanged (whether by direct exchange, merger or otherwise) into a number of equity interests in the Company designated as &#x201c;Class&#160;A Common Units&#x201d; in the amounts determined in accordance with Holdings&#x2019; Second Amended and Restated Operating Agreement (the &#x201c;Holdings A&amp;amp;R OA&#x201d;), which was entered into prior to the Closing, the result of which was that the Members hold a single class of Holdings Units as of immediately prior to the Closing and (ii)&#160;converted into a Delaware limited liability company. &lt;/div&gt;&lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Consideration &lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;At the Closing and in consideration for the acquisition of Holdings Units, Haymaker and the BioTE Companies, pursuant to the Business Combination Agreement and the Trust Agreement (as defined in the Business Combination Agreement), disbursed the Closing Date Cash to Holdings. &lt;/div&gt;&lt;div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"&gt;&#160;&lt;/div&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"/&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Earnout &lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;On the Closing Date (a)&#160;the Members on a pro rata basis subjected (i) 10,000,000 Retained Holdings Units held by them (the &#x201c;Member Earnout Units&#x201d;) and (ii) 10,000,000 shares of Class&#160;V voting stock distributed to them by the BioTE Companies (the &#x201c;Earnout Voting Shares&#x201d;), (b) the Sponsor subjected 1,587,500 shares of Class&#160;A common stock held by it after giving effect to the Class&#160;B common stock Conversion (the &#x201c;Sponsor Earnout Shares&#x201d;), and (c)&#160;Haymaker subjected a number of Holdings Units equal to the number of Sponsor Earnout Shares (the &#x201c;Sponsor Earnout Units,&#x201d; and, together with the Sponsor Earnout Shares, the Earnout Voting Shares and the Member Earnout Units, the &#x201c;Earnout Securities&#x201d;), to certain restrictions and potential forfeiture pending the achievement (if any) of certain earnout targets or milestones pursuant to the terms of the Business Combination Agreement or the occurrence of a Change of Control (as defined in the Business Combination Agreement). &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;Beginning on the &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;six-month&lt;/div&gt; anniversary of the Closing, each Retained Biote Unit held by the Members may be redeemed, together with one share of Class&#160;V voting stock and subject to certain conditions, in exchange for either one share of Class&#160;A common stock or in certain circumstances, at the election of the Company in its capacity as the sole manager of Holdings, the cash equivalent of the market value of one share of Class&#160;A common stock, pursuant to the terms and conditions of the Holdings A&amp;amp;R OA (such exchange rights, as further described in the Holdings A&amp;amp;R OA, the &#x201c;Exchange Rights&#x201d;). See Note 11 for further detail. &lt;/div&gt;&lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Other Agreements&#x2014;Business Combination &lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;The Business Combination Agreement contemplated the execution of various additional agreements and instruments, including, among others, the following: &lt;/div&gt;&lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Tax Receivable Agreement &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;At Closing, Biote entered into a tax receivable agreement (the &#x201c;TRA&#x201d;) with Holdings, the Members and the Members&#x2019; Representative, which provides for, among other things, payment by the Company to the Members of 85% of the U.S. federal, state and local income tax savings realized by the Company as a result of the increases in tax basis and certain other tax benefits related to any transactions contemplated under the Business Combination Agreement and any redemption of Retained Holdings Units in exchange for Class&#160;A common stock or cash (as more fully described in the TRA). These payments are an obligation of Biote and not of the BioTE Companies. Biote&#x2019;s only material asset following the Business Combination is its ownership interest in Holdings and, accordingly, the Company will depend on distributions from Holdings to make any payments required to be made by the Company under the TRA. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;The term of the TRA will continue until all such tax benefits have been utilized or expired unless the Company exercises its right to terminate the TRA for an amount representing the present value of anticipated future tax benefits under the TRA or certain other acceleration events occur. The actual increase in the Company&#x2019;s allocable share of tax basis in the BioTE Companies&#x2019; assets, as well as the amount and timing of any payments under the TRA, will vary depending upon a number of factors, including the timing of redemptions of shares of Retained Holdings Units, the market price of shares of the Class&#160;A common stock at the time of the exchange, the extent to which such exchanges are taxable and the amount and timing of the Company&#x2019;s income. Any payments the Company makes under the TRA will generally reduce the amount of overall cash flow that might have otherwise been available to the Company. To the extent that the Company is unable to make timely payments under the TRA for any reason, the unpaid amounts will be deferred and will accrue interest until paid; however, nonpayment for a specified period and/or under certain circumstances may constitute a material breach of a material obligation under the TRA and therefore accelerate payments due under the TRA. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;&lt;span style="-sec-ix-hidden:hidden73945879"&gt;The TRA provides that, in the event that (i)&#160;the Company exercises its early termination rights under the TRA, (ii)&#160;certain changes of control occur (as described in the TRA), (iii) the Company, in certain circumstances, fails&lt;/span&gt; &lt;/div&gt;&lt;div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"&gt;&#160;&lt;/div&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"/&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;to make a payment required to be made pursuant to the TRA by the applicable final payment date, which &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-payment&lt;/div&gt; continues for 30 days following such final payment date or (iv)&#160;the Company materially breaches any of its material obligations under the TRA, which breach continues without cure for 30 days following receipt by the Company of written notice thereof (unless, in the case of clauses (iii)&#160;and (iv), certain liquidity exceptions apply) the Company&#x2019;s obligations under the TRA will accelerate and the Company will be required to make a &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;lump-sum&lt;/div&gt; cash payment to the applicable parties to the TRA equal to the present value of all forecasted future payments that would have otherwise been made under the TRA, which &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;lump-sum&lt;/div&gt; payment would be based on certain assumptions, including those relating to our future taxable income. As of December&#160;31, 2022 and December&#160;31, 2021, there have been no exchanges, and therefore, no liability is recorded related to the TRA. &lt;/div&gt;&lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Second Amended and Restated Operating Agreement of Holdings &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;At the Closing, the Company, Holdings and the Members entered into the Holdings A&amp;amp;R OA, which, among other things, (i)&#160;provided for a recapitalization of the ownership structure of Holdings, whereby following the execution of the Holdings A&amp;amp;R OA, the ownership structure of Holdings consists solely of the Holdings Units, (ii)&#160;designated the Company as the sole manager of Holdings (iii)&#160;provides that on the Exchange Date (as defined in the Holdings A&amp;amp;R OA) (unless otherwise waived by the Company, or, with respect to the Initial Shares (as defined therein), following the registration under the Securities Act of 1933, as amended (the &#x201c;Securities Act&#x201d;), of such shares), each Retained Biote Unit held by the Members may be redeemed in exchange, subject to certain conditions, for either one share of Class&#160;A common stock or, at the election of the Company in its capacity as the sole manager of Holdings, the cash equivalent of the market value of one share of Class&#160;A common stock (the &#x201c;Exchange Rights&#x201d;), and (iv)&#160;otherwise amended and restated the rights and preferences of the Holdings Units, in each case, as more fully described in the Holdings A&amp;amp;R OA. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;In connection with the execution of the Business Combination Agreement, certain of Haymaker&#x2019;s officers and directors, Haymaker, the Sponsor, Holdings and the Members&#x2019; Representative entered into a letter agreement (the &#x201c;Sponsor Letter&#x201d;), pursuant to which, among other things, the Sponsor agreed to (i)&#160;vote, at any duly called meeting of stockholders of the Company, in favor of the Business Combination Agreement and the transactions contemplated thereby, (ii)&#160;subject to certain exceptions, not to effect any sale or distribution of any of its shares of Class&#160;B common stock or private placement warrants and (iii)&#160;waive any and all anti-dilution rights described in Haymaker&#x2019;s amended and restated certificate of incorporation or otherwise with respect to the shares of Class&#160;B common stock held by the Sponsor that may be implicated by the Business Combination such that the Class&#160;B common stock Conversion will occur as discussed therein. &lt;/div&gt;&lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Investor Rights Agreement &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;At the Closing, the Company, the Members, the Sponsor, the Members&#x2019; Representative and certain other parties entered into an Investor Rights Agreement (the &#x201c;IRA&#x201d;). Pursuant to the terms of the IRA, among other things, (i)&#160;that certain Registration Rights Agreement, by and between Haymaker and certain security holders, dated March&#160;1, 2021, entered into in connection with Haymaker&#x2019;s initial public offering, was terminated, (ii)&#160;the Company provided certain registration rights for the shares of Class&#160;A common stock held (or underlying certain securities held) by the Members, the Sponsor, and certain other parties, (iii)&#160;the Members agreed not to, subject to certain exceptions, transfer, sell, assign or otherwise dispose of the shares of Class&#160;A common stock, Class&#160;V voting stock and the Holdings Units held by such Members, as applicable, for six months following the Closing, and the Member Earnout Units (as defined therein) until the date such securities have been earned in accordance with the Business Combination Agreement and (iv)&#160;the Sponsor agreed not to, subject to certain exceptions, transfer, sell, assign or otherwise dispose of its (a)&#160;shares of Class&#160;A common stock (other than the Sponsor Earnout Shares, as defined therein) for six months following the Closing, (b)&#160;Sponsor Earnout Shares until the date such securities have been earned in accordance with the Business Combination Agreement and (c)&#160;warrants issued to the Sponsor pursuant to that certain Private Placement Warrants Purchase Agreement, dated March&#160;1, 2021, by and between the Company and the Sponsor, and the underlying shares of Class&#160;A common stock, for &lt;/div&gt;&lt;div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"&gt;&#160;&lt;/div&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"/&gt;&lt;div/&gt;&lt;div&gt;&lt;div style="background-color:white;display: inline;"/&gt;&lt;/div&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;30&#160;days following the Closing Date (such &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;lock-up&lt;/div&gt; period superseding the &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;lock-up&lt;/div&gt; period set forth in the Insider Letter (as defined in the IRA)), in each case, as more fully described in the IRA). &lt;/div&gt;&lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Indemnification Agreements &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;In connection with the Closing, the Company entered into indemnification agreements (each, an &#x201c;Indemnification Agreement&#x201d;) with its directors and executive officers. Each Indemnification Agreement provides for indemnification and advancements by the Company of certain expenses and costs if the basis of the indemnitee&#x2019;s involvement in a matter was by reason of the fact that the indemnitee is or was a director, officer, employee, or agent of the Company or any of its subsidiaries or was serving at the Company&#x2019;s request in an official capacity for another entity, in each case to the fullest extent permitted by the laws of the State of Delaware. &lt;/div&gt;&lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Credit Agreements &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;On the Closing Date, certain direct and indirect subsidiaries of Biote entered into that certain Credit Agreement, dated as of May&#160;26, 2022 (the &#x201c;Credit Agreement&#x201d;; any capitalized terms used but not defined herein have the meanings assigned to such terms in the Credit Agreement), by and among, inter alios, Holdings, BioTE Medical, LLC, (&#x201c;BioTE Medical&#x201d;), BioTe IP, LLC, (&#x201c;BioTe IP&#x201d; and, together with Holdings and BioTE Medical, collectively, the &#x201c;Loan Parties&#x201d;), certain lenders party thereto from time to time (the &#x201c;Lenders&#x201d;), and Truist Bank, as administrative agent for the Lenders (&#x201c;Administrative Agent&#x201d;). The Credit Agreement provides for (i)&#160;a $50,000 senior secured revolving credit facility (the &#x201c;Revolving Loans&#x201d;) and (ii)&#160;a $125,000 senior secured term loan A credit facility, which was borrowed in full on the Closing Date (the &#x201c;Term Loan&#x201d; and, together with the Revolving Loans, collectively, the &#x201c;Loans&#x201d;, such transactions together the &#x201c;Debt Financing&#x201d;). BioTE Medical used the proceeds of the Debt Financing to refinance and replace an existing credit facility pursuant to a credit agreement, dated as of May&#160;17, 2019, with Bank of America, N.A and for general corporate purposes. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;The Loans are also subject to customary events of default. Events of default under the Credit Agreement include (subject to grace periods in certain instances): (i) the failure by any Loan Party to timely make payments due under the Credit Agreement; (ii)&#160;material misrepresentations or misstatements in any representation or warranty by any Loan Party when made; (iii)&#160;failure by any Loan Party to comply with the covenants under the Credit Agreement and other related agreements; (iv)&#160;certain defaults under a specified amount of other indebtedness of Holdings or its subsidiaries; (v)&#160;insolvency or bankruptcy-related events with respect to Holdings or any of its subsidiaries; (vi)&#160;certain undischarged, &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-appealable&lt;/div&gt; judgments above a specified threshold against Holdings or any of its subsidiaries; (vii)&#160;certain ERISA-related events reasonably expected to result in liability above a specified threshold to Holdings and its subsidiaries taken as a whole; (viii)&#160;any loan documents or a material part of the liens under the loan documents ceasing to be, or being asserted by Holdings or its subsidiaries not to be, in full force and effect; (ix)&#160;any loan party or subsidiary denying that it has further obligations under any Loan Document; (x)&#160;any obligations under the loan documents ceasing to constitute senior indebtedness; and (x)&#160;the occurrence of a change of control. If an event of default has occurred and continues beyond any applicable cure period, Administrative Agent may (i)&#160;accelerate all outstanding obligations under the Credit Agreement or (ii)&#160;terminate the commitments, amongst other remedies. Additionally, BioTE Medical may not borrow under the Loans while an event of default is continuing. See Note 9 for further detail. &lt;/div&gt;</us-gaap:BusinessCombinationDisclosureTextBlock>
    <us-gaap:BusinessCombinationConsiderationTransferred1
      contextRef="P12_13_2021To12_13_2021_BioteManagementLlcMemberusgaapBusinessAcquisitionAxis_CommonClassAMemberusgaapStatementClassOfStockAxis"
      decimals="0"
      unitRef="Unit_USD">9161771</us-gaap:BusinessCombinationConsiderationTransferred1>
    <us-gaap:BusinessAcquisitionSharePrice
      contextRef="PAsOn12_13_2021_CommonClassAMemberusgaapStatementClassOfStockAxis_HaymakerAcquisitionCorpIiiMemberusgaapBusinessAcquisitionAxis"
      decimals="INF"
      unitRef="Unit_USD_per_Share">0.0001</us-gaap:BusinessAcquisitionSharePrice>
    <us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued
      contextRef="P12_13_2021To12_13_2021_CommonClassAMemberusgaapStatementClassOfStockAxis_HaymakerAcquisitionCorpIiiMemberusgaapBusinessAcquisitionAxis"
      decimals="INF"
      unitRef="Unit_shares">30525729</us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued>
    <us-gaap:BusinessAcquisitionSharePrice
      contextRef="PAsOn12_13_2021_CommonClassBMemberusgaapStatementClassOfStockAxis_HaymakerAcquisitionCorpIiiMemberusgaapBusinessAcquisitionAxis"
      decimals="INF"
      unitRef="Unit_USD_per_Share">0.0001</us-gaap:BusinessAcquisitionSharePrice>
    <us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued
      contextRef="P12_13_2021To12_13_2021_ClassVCommonStockMemberusgaapStatementClassOfStockAxis_HaymakerAcquisitionCorpIiiMemberusgaapBusinessAcquisitionAxis"
      decimals="INF"
      unitRef="Unit_shares">58565824</us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued>
    <us-gaap:BusinessAcquisitionSharePrice
      contextRef="PAsOn12_13_2021_ClassVCommonStockMemberusgaapStatementClassOfStockAxis_HaymakerAcquisitionCorpIiiMemberusgaapBusinessAcquisitionAxis"
      decimals="INF"
      unitRef="Unit_USD_per_Share">0.0001</us-gaap:BusinessAcquisitionSharePrice>
    <us-gaap:PaymentsToAcquireBusinessesGross
      contextRef="P12_13_2021To12_13_2021_BioteManagementLlcMemberusgaapBusinessAcquisitionAxis_CommonClassAMemberusgaapStatementClassOfStockAxis"
      decimals="-5"
      unitRef="Unit_USD">305500000</us-gaap:PaymentsToAcquireBusinessesGross>
    <us-gaap:ProceedsFromPreviousAcquisition
      contextRef="P12_13_2021To12_13_2021_BioteManagementLlcMemberusgaapBusinessAcquisitionAxis"
      decimals="-6"
      unitRef="Unit_USD">125000000</us-gaap:ProceedsFromPreviousAcquisition>
    <us-gaap:PaymentsToAcquireBusinessesGross
      contextRef="P12_13_2021To12_13_2021_BioteManagementLlcMemberusgaapBusinessAcquisitionAxis"
      decimals="-5"
      unitRef="Unit_USD">137300000</us-gaap:PaymentsToAcquireBusinessesGross>
    <us-gaap:BusinessCombinationConsiderationTransferred1
      contextRef="P01_01_2022To12_31_2022_BioteManagementLlcMemberusgaapBusinessAcquisitionAxis"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:BusinessCombinationConsiderationTransferred1>
    <us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued
      contextRef="P12_13_2021To12_13_2021_BusinessCombinationMemberusgaapBusinessAcquisitionAxis_HaymakeriiiMembersrtConsolidatedEntitiesAxis_MemberEarnOutUnitsMemberusgaapStatementClassOfStockAxis"
      decimals="0"
      unitRef="Unit_shares">10000000</us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued>
    <us-gaap:BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable
      contextRef="P12_13_2021To12_13_2021_BusinessCombinationMemberusgaapBusinessAcquisitionAxis_EarnoutVotingSharesMemberusgaapStatementClassOfStockAxis_HaymakeriiiMembersrtConsolidatedEntitiesAxis"
      decimals="0"
      unitRef="Unit_USD">10000000</us-gaap:BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable>
    <us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued
      contextRef="P12_13_2021To12_13_2021_BusinessCombinationMemberusgaapBusinessAcquisitionAxis_HaymakeriiiMembersrtConsolidatedEntitiesAxis_SponsorEarnOutSharesMemberusgaapStatementClassOfStockAxis"
      decimals="0"
      unitRef="Unit_shares">1587500</us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued>
    <btmd:IncomeTaxPercentageOfFederalStateAndLocalIncomeTaxSavings
      contextRef="P01_01_2022To12_31_2022_HaymakeriiiMembersrtConsolidatedEntitiesAxis_OtherBusinessCombinationMemberusgaapBusinessAcquisitionAxis"
      decimals="2"
      unitRef="Unit_pure">0.85</btmd:IncomeTaxPercentageOfFederalStateAndLocalIncomeTaxSavings>
    <btmd:TaxReceivableAgreementLiability
      contextRef="PAsOn12_31_2021_HaymakeriiiMembersrtConsolidatedEntitiesAxis_OtherBusinessCombinationMemberusgaapBusinessAcquisitionAxis"
      decimals="-3"
      unitRef="Unit_USD">0</btmd:TaxReceivableAgreementLiability>
    <btmd:TaxReceivableAgreementLiability
      contextRef="PAsOn12_31_2022_HaymakeriiiMembersrtConsolidatedEntitiesAxis_OtherBusinessCombinationMemberusgaapBusinessAcquisitionAxis"
      decimals="-3"
      unitRef="Unit_USD">0</btmd:TaxReceivableAgreementLiability>
    <btmd:CommonStockTransfersThresholdTradingDays contextRef="P12_13_2021To12_13_2021_CommonClassAMemberusgaapStatementClassOfStockAxis_HaymakeriiiMembersrtConsolidatedEntitiesAxis_OtherBusinessCombinationMemberusgaapBusinessAcquisitionAxis">P30D</btmd:CommonStockTransfersThresholdTradingDays>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="PAsOn05_26_2022_DebtCommitmentLetterMemberusgaapDebtInstrumentAxis_HaymakeriiiMembersrtConsolidatedEntitiesAxis_SeniorSecuredRevolvingCreditFacilityMemberusgaapCreditFacilityAxis"
      decimals="0"
      unitRef="Unit_USD">50000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="PAsOn05_26_2022_DebtCommitmentLetterMemberusgaapDebtInstrumentAxis_HaymakeriiiMembersrtConsolidatedEntitiesAxis_SeniorSecuredTermLoanAFacilityMemberusgaapCreditFacilityAxis"
      decimals="0"
      unitRef="Unit_USD">125000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:RevenueFromContractWithCustomerTextBlock contextRef="P01_01_2022To12_31_2022">
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%"&gt;
&lt;tr style="page-break-inside:avoid"&gt;
&lt;td style="width:4%;vertical-align:top;text-align:left;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;4.&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:top;text-align:left;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; text-align: left; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;REVENUE RECOGNITION &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;Revenue recognized for each revenue stream is as follows: &lt;/div&gt;&lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:84%;border:0;margin:0 auto"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width:39%"/&gt;
&lt;td style="vertical-align:bottom;width:4%"/&gt;
&lt;td style="width:33%"/&gt;
&lt;td style="vertical-align:bottom;width:4%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:4%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td rowspan="2" style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.5pt;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; font-size: 8pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Financial Statement Caption&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td rowspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td rowspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 8pt; font-family: &amp;quot;Times New Roman&amp;quot;; text-align: center; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Revenue Stream&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Year Ended&lt;/div&gt;&lt;/div&gt;&lt;br/&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Product revenue:&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;white-space:nowrap"&gt;Pellet procedures&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;128,952&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;109,465&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;white-space:nowrap"&gt;Dietary supplements&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;32,412&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;27,241&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;white-space:nowrap"&gt;Disposable trocars&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,698&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;860&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;white-space:nowrap"&gt;Shipping fees&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;71&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;32&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total product revenue&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;163,133&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;137,598&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Service revenue:&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;white-space:nowrap"&gt;Training&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;973&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;859&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;white-space:nowrap"&gt;Contract-term services&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;851&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;939&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total service revenue&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,824&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,798&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total revenue&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;164,957&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;139,396&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;Revenue recognized by geographic region is as follows: &lt;/div&gt;&lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:84%;border:0;margin:0 auto"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width:39%"/&gt;
&lt;td style="vertical-align:bottom;width:4%"/&gt;
&lt;td style="width:33%"/&gt;
&lt;td style="vertical-align:bottom;width:4%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:4%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td rowspan="2" style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.5pt;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; font-size: 8pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Financial Statement Caption&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td rowspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td rowspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 8pt; font-family: &amp;quot;Times New Roman&amp;quot;; text-align: center; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Country&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;For the Year Ended&lt;br/&gt; December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Product revenue:&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;white-space:nowrap"&gt;United States&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;162,742&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;137,349&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;white-space:nowrap"&gt;All other&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;391&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;249&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total product revenue&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;163,133&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;137,598&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Service revenue:&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;white-space:nowrap"&gt;United States&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,781&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,798&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;white-space:nowrap"&gt;All other&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;43&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total service revenue&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,824&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,798&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total revenue&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;164,957&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;139,396&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;Significant changes in contract liability balances are as follows: &lt;/div&gt;&lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:92%;border:0;margin:0 auto"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width:60%"/&gt;
&lt;td style="vertical-align:bottom;width:5%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:5%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:5%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:5%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="14" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Year Ended December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.5pt;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; font-size: 8pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Description of change&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Deferred&lt;br/&gt; Revenue&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Deferred&lt;br/&gt; Revenue,&lt;/div&gt;&lt;/div&gt;&lt;br/&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Long-term&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Deferred&lt;br/&gt; Revenue&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Deferred&lt;br/&gt; Revenue,&lt;/div&gt;&lt;/div&gt;&lt;br/&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Long-term&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Revenue recognized that was included in the contract liability balance at the beginning of the period&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(1,710&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(2,048&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Increases due to cash received, excluding amounts recognized as revenue during the period&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,342&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;760&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,022&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;652&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Transfers between current and &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-current&lt;/div&gt; liabilities due to the expected revenue recognition period&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;460&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(460&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;697&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(697&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Total increase (decrease) in contract liabilities&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;92&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;300&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(329&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(45&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;Consideration allocated to initial training due to deposits paid upfront is presented within deferred revenue on the consolidated balance sheets and is expected to be recognized as revenue within one year as the training is performed. Consideration allocated to contract-term services is presented within deferred revenue and deferred &lt;/div&gt;&lt;div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"&gt;&#160;&lt;/div&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"/&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;revenue, long-term for the amounts expected to be recognized within one year and longer than one year, respectively. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;Consideration allocated to the premiums within the management fee for pellet procedures is presented within deferred revenue current and deferred revenue, long-term for amounts expected to be recognized within one year and longer than one year, respectively. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;Consideration allocated to performance obligations are as follows: &lt;/div&gt;&lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width:68%"/&gt;
&lt;td style="vertical-align:bottom;width:10%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:10%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;br/&gt; 2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;br/&gt; 2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Unsatisfied training obligations&#x2014;Current&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;104&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;67&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Unsatisfied contract-term services&#x2014;Current&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,028&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;849&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Unsatisfied contract-term services&#x2014;Long-term&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;627&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;544&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Total allocated to unsatisfied contract-term services&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,655&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,393&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Unsatisfied pellet procedures&#x2014;Current&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;833&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;789&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Unsatisfied pellet procedures&#x2014;Long-term&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;299&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;258&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Total allocated to unsatisfied pellet procedures&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,132&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,047&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Total deferred revenue&#x2014;Current&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,965&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,705&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Total deferred revenue&#x2014;Long-term&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;926&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;802&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;The Company does not have a history of material returns or refunds and generally does not offer warranties or guarantees for any products or services. Expected returns and refunds are recorded as a reduction of revenue and are $0 and $0 for the years ended December&#160;31, 2022 and 2021, respectively. &lt;/div&gt;</us-gaap:RevenueFromContractWithCustomerTextBlock>
    <us-gaap:DisaggregationOfRevenueTableTextBlock contextRef="P01_01_2022To12_31_2022">&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;Revenue recognized for each revenue stream is as follows: &lt;/div&gt;&lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:84%;border:0;margin:0 auto"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width:39%"/&gt;
&lt;td style="vertical-align:bottom;width:4%"/&gt;
&lt;td style="width:33%"/&gt;
&lt;td style="vertical-align:bottom;width:4%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:4%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td rowspan="2" style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.5pt;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; font-size: 8pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Financial Statement Caption&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td rowspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td rowspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 8pt; font-family: &amp;quot;Times New Roman&amp;quot;; text-align: center; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Revenue Stream&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Year Ended&lt;/div&gt;&lt;/div&gt;&lt;br/&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Product revenue:&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;white-space:nowrap"&gt;Pellet procedures&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;128,952&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;109,465&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;white-space:nowrap"&gt;Dietary supplements&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;32,412&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;27,241&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;white-space:nowrap"&gt;Disposable trocars&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,698&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;860&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;white-space:nowrap"&gt;Shipping fees&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;71&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;32&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total product revenue&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;163,133&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;137,598&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Service revenue:&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;white-space:nowrap"&gt;Training&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;973&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;859&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;white-space:nowrap"&gt;Contract-term services&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;851&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;939&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total service revenue&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,824&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,798&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total revenue&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;164,957&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;139,396&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;Revenue recognized by geographic region is as follows: &lt;/div&gt;&lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:84%;border:0;margin:0 auto"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width:39%"/&gt;
&lt;td style="vertical-align:bottom;width:4%"/&gt;
&lt;td style="width:33%"/&gt;
&lt;td style="vertical-align:bottom;width:4%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:4%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td rowspan="2" style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.5pt;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; font-size: 8pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Financial Statement Caption&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td rowspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td rowspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 8pt; font-family: &amp;quot;Times New Roman&amp;quot;; text-align: center; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Country&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;For the Year Ended&lt;br/&gt; December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Product revenue:&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;white-space:nowrap"&gt;United States&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;162,742&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;137,349&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;white-space:nowrap"&gt;All other&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;391&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;249&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total product revenue&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;163,133&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;137,598&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Service revenue:&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;white-space:nowrap"&gt;United States&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,781&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,798&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;white-space:nowrap"&gt;All other&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;43&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total service revenue&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,824&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,798&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total revenue&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;164,957&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;139,396&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:DisaggregationOfRevenueTableTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P01_01_2022To12_31_2022_PelletProceduresProductRevenueMembersrtProductOrServiceAxis"
      decimals="-3"
      unitRef="Unit_USD">128952000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P01_01_2021To12_31_2021_PelletProceduresProductRevenueMembersrtProductOrServiceAxis"
      decimals="-3"
      unitRef="Unit_USD">109465000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P01_01_2022To12_31_2022_DietarySupplementsMembersrtProductOrServiceAxis"
      decimals="-3"
      unitRef="Unit_USD">32412000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P01_01_2021To12_31_2021_DietarySupplementsMembersrtProductOrServiceAxis"
      decimals="-3"
      unitRef="Unit_USD">27241000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P01_01_2022To12_31_2022_DisposableTrocarsProductRevenueMembersrtProductOrServiceAxis"
      decimals="-3"
      unitRef="Unit_USD">1698000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P01_01_2021To12_31_2021_DisposableTrocarsProductRevenueMembersrtProductOrServiceAxis"
      decimals="-3"
      unitRef="Unit_USD">860000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P01_01_2022To12_31_2022_ShippingFeesProductRevenueMembersrtProductOrServiceAxis"
      decimals="-3"
      unitRef="Unit_USD">71000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P01_01_2021To12_31_2021_ShippingFeesProductRevenueMembersrtProductOrServiceAxis"
      decimals="-3"
      unitRef="Unit_USD">32000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P01_01_2022To12_31_2022_ProductRevenueMembersrtProductOrServiceAxis"
      decimals="-3"
      unitRef="Unit_USD">163133000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P01_01_2021To12_31_2021_ProductRevenueMembersrtProductOrServiceAxis"
      decimals="-3"
      unitRef="Unit_USD">137598000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P01_01_2022To12_31_2022_TrainingServiceRevenueMembersrtProductOrServiceAxis"
      decimals="-3"
      unitRef="Unit_USD">973000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P01_01_2021To12_31_2021_TrainingServiceRevenueMembersrtProductOrServiceAxis"
      decimals="-3"
      unitRef="Unit_USD">859000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P01_01_2022To12_31_2022_ContractTermServicesRevenueMembersrtProductOrServiceAxis"
      decimals="-3"
      unitRef="Unit_USD">851000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P01_01_2021To12_31_2021_ContractTermServicesRevenueMembersrtProductOrServiceAxis"
      decimals="-3"
      unitRef="Unit_USD">939000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P01_01_2022To12_31_2022_ServiceRevenueMembersrtProductOrServiceAxis"
      decimals="-3"
      unitRef="Unit_USD">1824000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P01_01_2021To12_31_2021_ServiceRevenueMembersrtProductOrServiceAxis"
      decimals="-3"
      unitRef="Unit_USD">1798000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">164957000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">139396000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P01_01_2022To12_31_2022_ProductRevenueMembersrtProductOrServiceAxis_USsrtStatementGeographicalAxis"
      decimals="-3"
      unitRef="Unit_USD">162742000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P01_01_2021To12_31_2021_ProductRevenueMembersrtProductOrServiceAxis_USsrtStatementGeographicalAxis"
      decimals="-3"
      unitRef="Unit_USD">137349000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P01_01_2022To12_31_2022_AllOtherCountryMembersrtStatementGeographicalAxis_ProductRevenueMembersrtProductOrServiceAxis"
      decimals="-3"
      unitRef="Unit_USD">391000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P01_01_2021To12_31_2021_AllOtherCountryMembersrtStatementGeographicalAxis_ProductRevenueMembersrtProductOrServiceAxis"
      decimals="-3"
      unitRef="Unit_USD">249000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P01_01_2022To12_31_2022_ProductRevenueMembersrtProductOrServiceAxis"
      decimals="-3"
      unitRef="Unit_USD">163133000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P01_01_2021To12_31_2021_ProductRevenueMembersrtProductOrServiceAxis"
      decimals="-3"
      unitRef="Unit_USD">137598000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P01_01_2022To12_31_2022_ServiceRevenueMembersrtProductOrServiceAxis_USsrtStatementGeographicalAxis"
      decimals="-3"
      unitRef="Unit_USD">1781000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P01_01_2021To12_31_2021_ServiceRevenueMembersrtProductOrServiceAxis_USsrtStatementGeographicalAxis"
      decimals="-3"
      unitRef="Unit_USD">1798000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P01_01_2022To12_31_2022_AllOtherCountryMembersrtStatementGeographicalAxis_ServiceRevenueMembersrtProductOrServiceAxis"
      decimals="-3"
      unitRef="Unit_USD">43000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P01_01_2022To12_31_2022_ServiceRevenueMembersrtProductOrServiceAxis"
      decimals="-3"
      unitRef="Unit_USD">1824000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P01_01_2021To12_31_2021_ServiceRevenueMembersrtProductOrServiceAxis"
      decimals="-3"
      unitRef="Unit_USD">1798000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">164957000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">139396000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock contextRef="P01_01_2022To12_31_2022">&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;Significant changes in contract liability balances are as follows: &lt;/div&gt;&lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:92%;border:0;margin:0 auto"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width:60%"/&gt;
&lt;td style="vertical-align:bottom;width:5%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:5%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:5%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:5%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="14" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Year Ended December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.5pt;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; font-size: 8pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Description of change&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Deferred&lt;br/&gt; Revenue&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Deferred&lt;br/&gt; Revenue,&lt;/div&gt;&lt;/div&gt;&lt;br/&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Long-term&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Deferred&lt;br/&gt; Revenue&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Deferred&lt;br/&gt; Revenue,&lt;/div&gt;&lt;/div&gt;&lt;br/&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Long-term&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Revenue recognized that was included in the contract liability balance at the beginning of the period&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(1,710&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(2,048&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Increases due to cash received, excluding amounts recognized as revenue during the period&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,342&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;760&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,022&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;652&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Transfers between current and &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-current&lt;/div&gt; liabilities due to the expected revenue recognition period&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;460&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(460&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;697&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(697&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Total increase (decrease) in contract liabilities&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;92&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;300&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(329&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(45&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock>
    <us-gaap:ContractWithCustomerLiabilityRevenueRecognized
      contextRef="P01_01_2022To12_31_2022_ShortTermContractWithCustomerMemberusgaapContractWithCustomerDurationAxis"
      decimals="-3"
      unitRef="Unit_USD">-1710000</us-gaap:ContractWithCustomerLiabilityRevenueRecognized>
    <us-gaap:ContractWithCustomerLiabilityRevenueRecognized
      contextRef="P01_01_2021To12_31_2021_ShortTermContractWithCustomerMemberusgaapContractWithCustomerDurationAxis"
      decimals="-3"
      unitRef="Unit_USD">-2048000</us-gaap:ContractWithCustomerLiabilityRevenueRecognized>
    <btmd:ContractWithCustomerLiabilityIncreasesDueToCashReceivedExcludingAmountsRecognizedAsRevenue
      contextRef="P01_01_2022To12_31_2022_ShortTermContractWithCustomerMemberusgaapContractWithCustomerDurationAxis"
      decimals="-3"
      unitRef="Unit_USD">1342000</btmd:ContractWithCustomerLiabilityIncreasesDueToCashReceivedExcludingAmountsRecognizedAsRevenue>
    <btmd:ContractWithCustomerLiabilityIncreasesDueToCashReceivedExcludingAmountsRecognizedAsRevenue
      contextRef="P01_01_2022To12_31_2022_LongTermContractWithCustomerMemberusgaapContractWithCustomerDurationAxis"
      decimals="-3"
      unitRef="Unit_USD">760000</btmd:ContractWithCustomerLiabilityIncreasesDueToCashReceivedExcludingAmountsRecognizedAsRevenue>
    <btmd:ContractWithCustomerLiabilityIncreasesDueToCashReceivedExcludingAmountsRecognizedAsRevenue
      contextRef="P01_01_2021To12_31_2021_ShortTermContractWithCustomerMemberusgaapContractWithCustomerDurationAxis"
      decimals="-3"
      unitRef="Unit_USD">1022000</btmd:ContractWithCustomerLiabilityIncreasesDueToCashReceivedExcludingAmountsRecognizedAsRevenue>
    <btmd:ContractWithCustomerLiabilityIncreasesDueToCashReceivedExcludingAmountsRecognizedAsRevenue
      contextRef="P01_01_2021To12_31_2021_LongTermContractWithCustomerMemberusgaapContractWithCustomerDurationAxis"
      decimals="-3"
      unitRef="Unit_USD">652000</btmd:ContractWithCustomerLiabilityIncreasesDueToCashReceivedExcludingAmountsRecognizedAsRevenue>
    <btmd:ContractWithCustomerLiabilityTransfersBetweenCurrentAndNonCurrentLiabilitiesDueToExpectedRevenueRecognitionPeriod
      contextRef="P01_01_2022To12_31_2022_ShortTermContractWithCustomerMemberusgaapContractWithCustomerDurationAxis"
      decimals="-3"
      unitRef="Unit_USD">460000</btmd:ContractWithCustomerLiabilityTransfersBetweenCurrentAndNonCurrentLiabilitiesDueToExpectedRevenueRecognitionPeriod>
    <btmd:ContractWithCustomerLiabilityTransfersBetweenCurrentAndNonCurrentLiabilitiesDueToExpectedRevenueRecognitionPeriod
      contextRef="P01_01_2022To12_31_2022_LongTermContractWithCustomerMemberusgaapContractWithCustomerDurationAxis"
      decimals="-3"
      unitRef="Unit_USD">-460000</btmd:ContractWithCustomerLiabilityTransfersBetweenCurrentAndNonCurrentLiabilitiesDueToExpectedRevenueRecognitionPeriod>
    <btmd:ContractWithCustomerLiabilityTransfersBetweenCurrentAndNonCurrentLiabilitiesDueToExpectedRevenueRecognitionPeriod
      contextRef="P01_01_2021To12_31_2021_ShortTermContractWithCustomerMemberusgaapContractWithCustomerDurationAxis"
      decimals="-3"
      unitRef="Unit_USD">697000</btmd:ContractWithCustomerLiabilityTransfersBetweenCurrentAndNonCurrentLiabilitiesDueToExpectedRevenueRecognitionPeriod>
    <btmd:ContractWithCustomerLiabilityTransfersBetweenCurrentAndNonCurrentLiabilitiesDueToExpectedRevenueRecognitionPeriod
      contextRef="P01_01_2021To12_31_2021_LongTermContractWithCustomerMemberusgaapContractWithCustomerDurationAxis"
      decimals="-3"
      unitRef="Unit_USD">-697000</btmd:ContractWithCustomerLiabilityTransfersBetweenCurrentAndNonCurrentLiabilitiesDueToExpectedRevenueRecognitionPeriod>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability
      contextRef="P01_01_2022To12_31_2022_ShortTermContractWithCustomerMemberusgaapContractWithCustomerDurationAxis"
      decimals="-3"
      unitRef="Unit_USD">92000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability
      contextRef="P01_01_2022To12_31_2022_LongTermContractWithCustomerMemberusgaapContractWithCustomerDurationAxis"
      decimals="-3"
      unitRef="Unit_USD">300000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability
      contextRef="P01_01_2021To12_31_2021_ShortTermContractWithCustomerMemberusgaapContractWithCustomerDurationAxis"
      decimals="-3"
      unitRef="Unit_USD">-329000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability
      contextRef="P01_01_2021To12_31_2021_LongTermContractWithCustomerMemberusgaapContractWithCustomerDurationAxis"
      decimals="-3"
      unitRef="Unit_USD">-45000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <btmd:SummaryOfConsiderationAllocatedToPerformanceObligationsTableTextBlock contextRef="P01_01_2022To12_31_2022">&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;Consideration allocated to performance obligations are as follows: &lt;/div&gt;&lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width:68%"/&gt;
&lt;td style="vertical-align:bottom;width:10%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:10%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;br/&gt; 2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;br/&gt; 2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Unsatisfied training obligations&#x2014;Current&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;104&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;67&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Unsatisfied contract-term services&#x2014;Current&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,028&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;849&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Unsatisfied contract-term services&#x2014;Long-term&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;627&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;544&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Total allocated to unsatisfied contract-term services&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,655&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,393&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Unsatisfied pellet procedures&#x2014;Current&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;833&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;789&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Unsatisfied pellet procedures&#x2014;Long-term&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;299&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;258&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Total allocated to unsatisfied pellet procedures&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,132&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,047&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Total deferred revenue&#x2014;Current&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,965&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,705&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Total deferred revenue&#x2014;Long-term&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;926&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;802&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</btmd:SummaryOfConsiderationAllocatedToPerformanceObligationsTableTextBlock>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="PAsOn12_31_2022_UnsatisfiedTrainingObligationsMembersrtProductOrServiceAxis"
      decimals="-3"
      unitRef="Unit_USD">104000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="PAsOn12_31_2021_UnsatisfiedTrainingObligationsMembersrtProductOrServiceAxis"
      decimals="-3"
      unitRef="Unit_USD">67000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="PAsOn12_31_2022_UnsatisfiedContractTermServicesMembersrtProductOrServiceAxis"
      decimals="-3"
      unitRef="Unit_USD">1028000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="PAsOn12_31_2021_UnsatisfiedContractTermServicesMembersrtProductOrServiceAxis"
      decimals="-3"
      unitRef="Unit_USD">849000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent
      contextRef="PAsOn12_31_2022_UnsatisfiedContractTermServicesMembersrtProductOrServiceAxis"
      decimals="-3"
      unitRef="Unit_USD">627000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent
      contextRef="PAsOn12_31_2021_UnsatisfiedContractTermServicesMembersrtProductOrServiceAxis"
      decimals="-3"
      unitRef="Unit_USD">544000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <us-gaap:ContractWithCustomerLiability
      contextRef="PAsOn12_31_2022_UnsatisfiedContractTermServicesMembersrtProductOrServiceAxis"
      decimals="-3"
      unitRef="Unit_USD">1655000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerLiability
      contextRef="PAsOn12_31_2021_UnsatisfiedContractTermServicesMembersrtProductOrServiceAxis"
      decimals="-3"
      unitRef="Unit_USD">1393000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="PAsOn12_31_2022_UnsatisfiedPelletProceduresMembersrtProductOrServiceAxis"
      decimals="-3"
      unitRef="Unit_USD">833000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="PAsOn12_31_2021_UnsatisfiedPelletProceduresMembersrtProductOrServiceAxis"
      decimals="-3"
      unitRef="Unit_USD">789000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent
      contextRef="PAsOn12_31_2022_UnsatisfiedPelletProceduresMembersrtProductOrServiceAxis"
      decimals="-3"
      unitRef="Unit_USD">299000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent
      contextRef="PAsOn12_31_2021_UnsatisfiedPelletProceduresMembersrtProductOrServiceAxis"
      decimals="-3"
      unitRef="Unit_USD">258000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <us-gaap:ContractWithCustomerLiability
      contextRef="PAsOn12_31_2022_UnsatisfiedPelletProceduresMembersrtProductOrServiceAxis"
      decimals="-3"
      unitRef="Unit_USD">1132000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerLiability
      contextRef="PAsOn12_31_2021_UnsatisfiedPelletProceduresMembersrtProductOrServiceAxis"
      decimals="-3"
      unitRef="Unit_USD">1047000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">1965000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">1705000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">926000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">802000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <btmd:ReductionOfRevenue
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">0</btmd:ReductionOfRevenue>
    <btmd:ReductionOfRevenue
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">0</btmd:ReductionOfRevenue>
    <us-gaap:InventoryDisclosureTextBlock contextRef="P01_01_2022To12_31_2022">
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%"&gt;
&lt;tr style="page-break-inside:avoid"&gt;
&lt;td style="width:4%;vertical-align:top;text-align:left;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;5.&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:top;text-align:left;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; text-align: left; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;INVENTORY, NET &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;Inventory, net consists of the following: &lt;/div&gt;&lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width:66%"/&gt;
&lt;td style="vertical-align:bottom;width:10%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:10%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;br/&gt; 2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;br/&gt; 2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Product inventory&#x2014;Pellets&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;6,213&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;6,318&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Less: Obsolete and expired pellet allowance&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(1,298&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(1,356&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Pellet inventory, net&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;4,915&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;4,962&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Product inventory&#x2014;Dietary supplements&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;6,283&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;4,849&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Less: Obsolete and expired dietary supplement allowance&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(15&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(196&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Dietary supplement inventory, net&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;6,268&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;4,653&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Inventory, net&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;11,183&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;9,615&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:InventoryDisclosureTextBlock>
    <us-gaap:ScheduleOfInventoryCurrentTableTextBlock contextRef="P01_01_2022To12_31_2022">&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;Inventory, net consists of the following: &lt;/div&gt;&lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width:66%"/&gt;
&lt;td style="vertical-align:bottom;width:10%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:10%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;br/&gt; 2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;br/&gt; 2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Product inventory&#x2014;Pellets&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;6,213&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;6,318&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Less: Obsolete and expired pellet allowance&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(1,298&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(1,356&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Pellet inventory, net&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;4,915&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;4,962&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Product inventory&#x2014;Dietary supplements&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;6,283&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;4,849&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Less: Obsolete and expired dietary supplement allowance&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(15&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(196&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Dietary supplement inventory, net&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;6,268&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;4,653&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Inventory, net&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;11,183&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;9,615&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfInventoryCurrentTableTextBlock>
    <us-gaap:InventoryGross
      contextRef="PAsOn12_31_2022_PelletsMemberusgaapPublicUtilitiesInventoryAxis_ProductMembersrtProductOrServiceAxis"
      decimals="-3"
      unitRef="Unit_USD">6213000</us-gaap:InventoryGross>
    <us-gaap:InventoryGross
      contextRef="PAsOn12_31_2021_PelletsMemberusgaapPublicUtilitiesInventoryAxis_ProductMembersrtProductOrServiceAxis"
      decimals="-3"
      unitRef="Unit_USD">6318000</us-gaap:InventoryGross>
    <us-gaap:InventoryAdjustments
      contextRef="PAsOn12_31_2022_PelletsMemberusgaapPublicUtilitiesInventoryAxis_ProductMembersrtProductOrServiceAxis"
      decimals="-3"
      unitRef="Unit_USD">1298000</us-gaap:InventoryAdjustments>
    <us-gaap:InventoryAdjustments
      contextRef="PAsOn12_31_2021_PelletsMemberusgaapPublicUtilitiesInventoryAxis_ProductMembersrtProductOrServiceAxis"
      decimals="-3"
      unitRef="Unit_USD">1356000</us-gaap:InventoryAdjustments>
    <us-gaap:InventoryNet
      contextRef="PAsOn12_31_2022_PelletsMemberusgaapPublicUtilitiesInventoryAxis_ProductMembersrtProductOrServiceAxis"
      decimals="-3"
      unitRef="Unit_USD">4915000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet
      contextRef="PAsOn12_31_2021_PelletsMemberusgaapPublicUtilitiesInventoryAxis_ProductMembersrtProductOrServiceAxis"
      decimals="-3"
      unitRef="Unit_USD">4962000</us-gaap:InventoryNet>
    <us-gaap:InventoryGross
      contextRef="PAsOn12_31_2022_DietarySupplementsMemberusgaapPublicUtilitiesInventoryAxis_ProductMembersrtProductOrServiceAxis"
      decimals="-3"
      unitRef="Unit_USD">6283000</us-gaap:InventoryGross>
    <us-gaap:InventoryGross
      contextRef="PAsOn12_31_2021_DietarySupplementsMemberusgaapPublicUtilitiesInventoryAxis_ProductMembersrtProductOrServiceAxis"
      decimals="-3"
      unitRef="Unit_USD">4849000</us-gaap:InventoryGross>
    <us-gaap:InventoryAdjustments
      contextRef="PAsOn12_31_2022_DietarySupplementsMemberusgaapPublicUtilitiesInventoryAxis_ProductMembersrtProductOrServiceAxis"
      decimals="-3"
      unitRef="Unit_USD">15000</us-gaap:InventoryAdjustments>
    <us-gaap:InventoryAdjustments
      contextRef="PAsOn12_31_2021_DietarySupplementsMemberusgaapPublicUtilitiesInventoryAxis_ProductMembersrtProductOrServiceAxis"
      decimals="-3"
      unitRef="Unit_USD">196000</us-gaap:InventoryAdjustments>
    <us-gaap:InventoryNet
      contextRef="PAsOn12_31_2022_DietarySupplementsMemberusgaapPublicUtilitiesInventoryAxis_ProductMembersrtProductOrServiceAxis"
      decimals="-3"
      unitRef="Unit_USD">6268000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet
      contextRef="PAsOn12_31_2021_DietarySupplementsMemberusgaapPublicUtilitiesInventoryAxis_ProductMembersrtProductOrServiceAxis"
      decimals="-3"
      unitRef="Unit_USD">4653000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">11183000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">9615000</us-gaap:InventoryNet>
    <us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock contextRef="P01_01_2022To12_31_2022">
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%"&gt;
&lt;tr style="page-break-inside:avoid"&gt;
&lt;td style="width:4%;vertical-align:top;text-align:left;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;6.&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:top;text-align:left;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; text-align: left; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;PROPERTY AND EQUIPMENT, NET &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;Property and equipment, net consists of the following: &lt;/div&gt;&lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width:66%"/&gt;
&lt;td style="vertical-align:bottom;width:11%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:11%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;br/&gt; 2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;br/&gt; 2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Trocars&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;4,645&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;4,448&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Leasehold improvements&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,028&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;254&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Office equipment&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;238&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;223&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Computer software&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;140&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;135&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Furniture and fixtures&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;161&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;119&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Computer equipment&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;102&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;97&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Construction in process&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;705&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Property and equipment&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;6,314&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;5,981&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Less: Accumulated depreciation&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(4,810&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(3,646&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Property and equipment, net&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,504&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2,335&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;Total depreciation expense related to property and equipment was $1,164 and $713 for the years ended December&#160;31, 2022 and 2021. Total depreciation expense was included in Selling, general and administrative expense in the consolidated statements of income and comprehensive income. The Company has not acquired any property and equipment under finance leases. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;The Company&#x2019;s property and equipment are all held within the United States. &lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
    <us-gaap:PropertyPlantAndEquipmentTextBlock contextRef="P01_01_2022To12_31_2022">&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;Property and equipment, net consists of the following: &lt;/div&gt;&lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width:66%"/&gt;
&lt;td style="vertical-align:bottom;width:11%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:11%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;br/&gt; 2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;br/&gt; 2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Trocars&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;4,645&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;4,448&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Leasehold improvements&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,028&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;254&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Office equipment&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;238&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;223&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Computer software&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;140&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;135&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Furniture and fixtures&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;161&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;119&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Computer equipment&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;102&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;97&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Construction in process&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;705&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Property and equipment&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;6,314&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;5,981&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Less: Accumulated depreciation&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(4,810&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(3,646&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Property and equipment, net&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,504&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2,335&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="PAsOn12_31_2022_TrocarsMemberusgaapPropertyPlantAndEquipmentByTypeAxis"
      decimals="-3"
      unitRef="Unit_USD">4645000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="PAsOn12_31_2021_TrocarsMemberusgaapPropertyPlantAndEquipmentByTypeAxis"
      decimals="-3"
      unitRef="Unit_USD">4448000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="PAsOn12_31_2022_LeaseholdImprovementsMemberusgaapPropertyPlantAndEquipmentByTypeAxis"
      decimals="-3"
      unitRef="Unit_USD">1028000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="PAsOn12_31_2021_LeaseholdImprovementsMemberusgaapPropertyPlantAndEquipmentByTypeAxis"
      decimals="-3"
      unitRef="Unit_USD">254000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="PAsOn12_31_2022_OfficeEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis"
      decimals="-3"
      unitRef="Unit_USD">238000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="PAsOn12_31_2021_OfficeEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis"
      decimals="-3"
      unitRef="Unit_USD">223000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="PAsOn12_31_2022_SoftwareAndSoftwareDevelopmentCostsMemberusgaapPropertyPlantAndEquipmentByTypeAxis"
      decimals="-3"
      unitRef="Unit_USD">140000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="PAsOn12_31_2021_SoftwareAndSoftwareDevelopmentCostsMemberusgaapPropertyPlantAndEquipmentByTypeAxis"
      decimals="-3"
      unitRef="Unit_USD">135000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="PAsOn12_31_2022_FurnitureAndFixturesMemberusgaapPropertyPlantAndEquipmentByTypeAxis"
      decimals="-3"
      unitRef="Unit_USD">161000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="PAsOn12_31_2021_FurnitureAndFixturesMemberusgaapPropertyPlantAndEquipmentByTypeAxis"
      decimals="-3"
      unitRef="Unit_USD">119000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="PAsOn12_31_2022_ComputerEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis"
      decimals="-3"
      unitRef="Unit_USD">102000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="PAsOn12_31_2021_ComputerEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis"
      decimals="-3"
      unitRef="Unit_USD">97000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="PAsOn12_31_2021_ConstructionInProgressMemberusgaapPropertyPlantAndEquipmentByTypeAxis"
      decimals="-3"
      unitRef="Unit_USD">705000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">6314000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">5981000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">4810000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">3646000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">1504000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">2335000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:Depreciation
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">1164000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">713000</us-gaap:Depreciation>
    <us-gaap:ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock contextRef="P01_01_2022To12_31_2022">
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%"&gt;
&lt;tr style="page-break-inside:avoid"&gt;
&lt;td style="width:4%;vertical-align:top;text-align:left;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;7.&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:top;text-align:left;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; text-align: left; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;CAPITALIZED SOFTWARE, NET &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;Capitalized software, net consists of the following: &lt;/div&gt;&lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width:66%"/&gt;
&lt;td style="vertical-align:bottom;width:11%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:11%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;br/&gt; 2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;br/&gt; 2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Website costs&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;4,142&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3,571&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Development in process&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3,277&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2,294&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Less: Accumulated amortization&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(2,346&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(1,311&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Capitalized software, net&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;5,073&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;4,554&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;Total amortization expense for capitalized software was $1,035 and $687 for the years ended December&#160;31, 2022 and 2021, respectively. Total amortization expense was included in Selling, general and administrative expense in the consolidated statements of income and comprehensive income. &lt;/div&gt;</us-gaap:ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock>
    <btmd:SummaryOfCapitalizedSoftwareNetTableTextBlock contextRef="P01_01_2022To12_31_2022">&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;Capitalized software, net consists of the following: &lt;/div&gt;&lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width:66%"/&gt;
&lt;td style="vertical-align:bottom;width:11%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:11%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;br/&gt; 2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;br/&gt; 2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Website costs&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;4,142&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3,571&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Development in process&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3,277&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2,294&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Less: Accumulated amortization&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(2,346&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(1,311&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Capitalized software, net&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;5,073&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;4,554&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</btmd:SummaryOfCapitalizedSoftwareNetTableTextBlock>
    <btmd:CapitalizedSoftwareWebsiteCosts
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">4142000</btmd:CapitalizedSoftwareWebsiteCosts>
    <btmd:CapitalizedSoftwareWebsiteCosts
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">3571000</btmd:CapitalizedSoftwareWebsiteCosts>
    <btmd:CapitalizedSoftwareDevelopmentInProcess
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">3277000</btmd:CapitalizedSoftwareDevelopmentInProcess>
    <btmd:CapitalizedSoftwareDevelopmentInProcess
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">2294000</btmd:CapitalizedSoftwareDevelopmentInProcess>
    <us-gaap:CapitalizedComputerSoftwareAccumulatedAmortization
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">2346000</us-gaap:CapitalizedComputerSoftwareAccumulatedAmortization>
    <us-gaap:CapitalizedComputerSoftwareAccumulatedAmortization
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">1311000</us-gaap:CapitalizedComputerSoftwareAccumulatedAmortization>
    <us-gaap:CapitalizedComputerSoftwareNet
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">5073000</us-gaap:CapitalizedComputerSoftwareNet>
    <us-gaap:CapitalizedComputerSoftwareNet
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">4554000</us-gaap:CapitalizedComputerSoftwareNet>
    <us-gaap:CapitalizedComputerSoftwareAmortization1
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">1035000</us-gaap:CapitalizedComputerSoftwareAmortization1>
    <us-gaap:CapitalizedComputerSoftwareAmortization1
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">687000</us-gaap:CapitalizedComputerSoftwareAmortization1>
    <us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock contextRef="P01_01_2022To12_31_2022">
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%"&gt;
&lt;tr style="page-break-inside:avoid"&gt;
&lt;td style="width:4%;vertical-align:top;text-align:left;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;8.&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:top;text-align:left;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; text-align: left; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;ACCRUED EXPENSES &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;Accrued expenses consist of the following: &lt;/div&gt;&lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width:66%"/&gt;
&lt;td style="vertical-align:bottom;width:11%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:11%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;br/&gt; 2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;br/&gt; 2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Accrued professional fees&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;354&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,192&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Accrued employee-related costs&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;4,221&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2,213&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Accrued merchant fees&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;184&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Accrued interest&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;27&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Legal accrual&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,302&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Other&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,699&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,093&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Accrued expenses&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;6,274&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;6,011&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock>
    <us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock contextRef="P01_01_2022To12_31_2022">&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;Accrued expenses consist of the following: &lt;/div&gt;&lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width:66%"/&gt;
&lt;td style="vertical-align:bottom;width:11%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:11%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;br/&gt; 2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;br/&gt; 2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Accrued professional fees&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;354&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,192&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Accrued employee-related costs&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;4,221&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2,213&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Accrued merchant fees&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;184&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Accrued interest&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;27&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Legal accrual&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,302&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Other&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,699&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,093&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Accrued expenses&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;6,274&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;6,011&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">354000</us-gaap:AccruedProfessionalFeesCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">1192000</us-gaap:AccruedProfessionalFeesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">4221000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">2213000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <btmd:AccruedMerchantFeesCurrent
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">184000</btmd:AccruedMerchantFeesCurrent>
    <us-gaap:InterestPayableCurrent
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">27000</us-gaap:InterestPayableCurrent>
    <btmd:LegalAccrualCurrent
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">1302000</btmd:LegalAccrualCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">1699000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">1093000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">6274000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">6011000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:DebtDisclosureTextBlock contextRef="P01_01_2022To12_31_2022">
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%"&gt;
&lt;tr style="page-break-inside:avoid"&gt;
&lt;td style="width:4%;vertical-align:top;text-align:left;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;9.&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:top;text-align:left;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; text-align: left; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;LONG-TERM DEBT &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Bank of America Term Loan &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;In May 2019, the Company entered into a credit arrangement (the &#x201c;Bank of America Credit Agreement&#x201d;) with a financial institution for a term loan for $50,000 (the &#x201c;Bank of America Term Loan&#x201d;), which bore an interest rate quoted as LIBOR + 300 Basis Points (BPS). As of December&#160;31, 2022 and December&#160;31, 2021, the outstanding principal on the Bank of America Term Loan was $0 and $37,500, respectively. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;The Bank of America Credit Agreement also included a line of credit arrangement, under which the Company could borrow up to $10,000. The line was set to expire in &lt;div style="display:inline;"&gt;&lt;span style="-sec-ix-hidden:hidden73946021"&gt;May of 2024&lt;/span&gt;&lt;/div&gt; and was secured by all assets of the Company. The Company did not draw on the line of credit during the years ended December&#160;31, 2022 and 2021. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;In connection with obtaining the Bank of America Credit Agreement in May of 2019, the Company incurred lender&#x2019;s fees and related attorney&#x2019;s fees of $1,108. The Company capitalized these costs and was amortizing these to interest expense over the maturity of the Bank of America Term Loan. The balance on the Bank of America Term Loan is presented in the consolidated balance sheet net of the related debt issuance costs. Amortization expense related to the debt issuance costs on the Bank of America Credit Agreement was $91 and $222 for the years ended December&#160;31, 2022 and 2021, respectively. At June&#160;30, 2022, the remaining unamortized Bank of America debt issuance costs of $445 were written off as a loss from extinguishment of debt in the Company&#x2019;s consolidated statements of income and comprehensive income upon extinguishment of the Bank of America Credit Agreement. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;In connection with the Business Combination, the Company entered into a new loan agreement as described below. A portion of the funds obtained from the new agreement were used to repay the Bank of America Term Loan in full. &lt;/div&gt;&lt;div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Truist Term Loan &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;On the Closing Date, the Company entered into a new loan agreement with Truist Bank (the &#x201c;Credit Agreement&#x201d; and with respect to the term loan within, the &#x201c;Term Loan&#x201d;) for $125,000. Interest on borrowings under the Credit Agreement is based on either, at the Company&#x2019;s election, the Standard Overnight Financing Rate plus an applicable margin of 2.5% or 2.75% or the Base Rate plus an applicable margin of 1.5% or 1.75%. At December&#160;31, 2022, the interest rate charged to the Company was approximately 6.92%. The Term Loam requires principal payments of approximately $1,563 in quarterly installments on the last day of each calendar quarter, commencing on September&#160;30, 2022, with repayment of the outstanding amount of the note due on maturity, which occurs on May 26, 2027. As of December&#160;31, 2022, the outstanding principal on the Term Loan was $121,875. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;Pursuant to the Credit Agreement, BioTE Medical may borrow under the &#x201c;Revolving Loans&#x201d; from time to time up to the total commitment of $50,000. The Company has not drawn on the line of credit during the year ended December&#160;31, 2022. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;The Credit Agreement is secured by substantially all of the assets of the Company and is subject to, among other provisions, customary covenants regarding indebtedness, liens, negative pledges, restricted payments, certain prepayments of indebtedness, investments, fundamental changes, disposition of assets, sale and lease-back transactions, transactions with affiliates, amendments of or waivers with respect to restricted debt and permitted activities of the Company. &lt;span style="-sec-ix-hidden:hidden73946027"&gt;In addition, the Credit Agreement is subject to (i)&#160;a maximum total net leverage ratio and (ii)&#160;a minimum fixed charge coverage ratio. The Company must maintain a total net leverage ratio of less than or equal to (i) 4.25:1.00, with respect to the fiscal quarter ending September&#160;30, 2022 through and including the fiscal quarter ending March&#160;31, 2023, (ii) 4.00:1.00, with respect to the fiscal quarter ending June&#160;30, 2023 through and including March&#160;31, 2024, and (iii) 3.75:1.00 thereafter. Beginning with the third fiscal quarter of 2022, the Company must not permit the Consolidated Fixed Charge Coverage Ratio to be less than 1.25:1.00.&lt;/span&gt; &lt;/div&gt;&lt;div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"&gt;&#160;&lt;/div&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"&gt; &lt;/div&gt;&lt;div/&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;Both financial covenants are tested quarterly. The Company was in compliance with all required covenants associated with the Credit Agreement as of December 31, 2022. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;In connection with obtaining the Credit Agreement in May of 2022, the Company incurred lender&#x2019;s fees and related attorney&#x2019;s fees of approximately $4,036. The Company capitalized these costs and is amortizing these to interest expense over the term of the Term Loan. The balance on the Term Loan is presented in the consolidated balance sheet net of the related debt issuance costs. Amortization expense related to the debt issuance costs on the Credit Agreement was $498 for the year ended December&#160;31, 2022. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;The total amortization of debt issuance costs, inclusive of those related to both the Bank of America Credit Agreement and the Credit Agreement, was $589 and $222 for the years ended December&#160;31, 2022 and 2021, respectively. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;The outstanding debt as of December&#160;31, 2022 and 2021 is classified in the consolidated balance sheets as follows: &lt;/div&gt;&lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width:65%"/&gt;
&lt;td style="vertical-align:bottom;width:9%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:9%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;br/&gt; 2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;br/&gt; 2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Term loan&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;121,875&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;37,500&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Less: Current portion&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(6,250&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(5,000&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;115,625&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;32,500&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Less: Unamortized debt issuance costs&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(3,539&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(537&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Term loan, net of current portion&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;112,086&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;31,963&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;Future maturities of long-term debt, excluding debt issuance costs, are as follows: &lt;/div&gt;&lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:68%;border:0;margin:0 auto"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width:83%"/&gt;
&lt;td style="vertical-align:bottom;width:7%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;2023&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;6,250&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;2024&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;6,250&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;2025&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;6,250&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;2026&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;6,250&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;2027&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;96,875&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;121,875&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:DebtDisclosureTextBlock>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="PAsOn05_31_2019_BankOfAmericaTermLoanMemberusgaapDebtInstrumentAxis_LineOfCreditMemberusgaapCreditFacilityAxis"
      decimals="-3"
      unitRef="Unit_USD">50000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateTerms contextRef="P01_01_2022To12_31_2022_BankOfAmericaTermLoanMemberusgaapDebtInstrumentAxis_LineOfCreditMemberusgaapCreditFacilityAxis">LIBOR + 300 Basis Points (BPS)</us-gaap:DebtInstrumentInterestRateTerms>
    <us-gaap:LongTermDebt
      contextRef="PAsOn12_31_2022_BankOfAmericaTermLoanMemberusgaapDebtInstrumentAxis_LineOfCreditMemberusgaapCreditFacilityAxis"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="PAsOn12_31_2021_BankOfAmericaTermLoanMemberusgaapDebtInstrumentAxis_LineOfCreditMemberusgaapCreditFacilityAxis"
      decimals="-3"
      unitRef="Unit_USD">37500000</us-gaap:LongTermDebt>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="PAsOn12_31_2022_BankOfAmericaTermLoanMemberusgaapDebtInstrumentAxis_LineOfCreditMemberusgaapCreditFacilityAxis"
      decimals="INF"
      unitRef="Unit_USD">10000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:LineOfCredit
      contextRef="PAsOn12_31_2021_BankOfAmericaTermLoanMemberusgaapDebtInstrumentAxis_LineOfCreditMemberusgaapCreditFacilityAxis"
      decimals="INF"
      unitRef="Unit_USD">0</us-gaap:LineOfCredit>
    <us-gaap:LineOfCredit
      contextRef="PAsOn12_31_2022_BankOfAmericaTermLoanMemberusgaapDebtInstrumentAxis_LineOfCreditMemberusgaapCreditFacilityAxis"
      decimals="INF"
      unitRef="Unit_USD">0</us-gaap:LineOfCredit>
    <us-gaap:InterestExpenseDebt
      contextRef="P05_01_2019To05_31_2019_BankOfAmericaTermLoanMemberusgaapDebtInstrumentAxis_LineOfCreditMemberusgaapCreditFacilityAxis"
      decimals="-3"
      unitRef="Unit_USD">1108000</us-gaap:InterestExpenseDebt>
    <us-gaap:AmortizationOfFinancingCosts
      contextRef="P01_01_2022To12_31_2022_BankOfAmericaTermLoanMemberusgaapDebtInstrumentAxis_LineOfCreditMemberusgaapCreditFacilityAxis"
      decimals="-3"
      unitRef="Unit_USD">91000</us-gaap:AmortizationOfFinancingCosts>
    <us-gaap:AmortizationOfFinancingCosts
      contextRef="P01_01_2021To12_31_2021_BankOfAmericaTermLoanMemberusgaapDebtInstrumentAxis_LineOfCreditMemberusgaapCreditFacilityAxis"
      decimals="-3"
      unitRef="Unit_USD">222000</us-gaap:AmortizationOfFinancingCosts>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="P01_01_2022To12_31_2022_BankOfAmericaTermLoanMemberusgaapDebtInstrumentAxis_LineOfCreditMemberusgaapCreditFacilityAxis"
      decimals="-3"
      unitRef="Unit_USD">-445000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="PAsOn05_26_2022_LineOfCreditMemberusgaapCreditFacilityAxis_TruistTermLoanMemberusgaapDebtInstrumentAxis"
      decimals="-3"
      unitRef="Unit_USD">125000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="P05_26_2022To05_26_2022_LineOfCreditMemberusgaapCreditFacilityAxis_MinimumMembersrtRangeAxis_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMemberusgaapVariableRateAxis_TruistTermLoanMemberusgaapDebtInstrumentAxis"
      decimals="3"
      unitRef="Unit_pure">0.025</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="P05_26_2022To05_26_2022_LineOfCreditMemberusgaapCreditFacilityAxis_MaximumMembersrtRangeAxis_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMemberusgaapVariableRateAxis_TruistTermLoanMemberusgaapDebtInstrumentAxis"
      decimals="4"
      unitRef="Unit_pure">0.0275</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="P05_26_2022To05_26_2022_BaseRateMemberusgaapVariableRateAxis_LineOfCreditMemberusgaapCreditFacilityAxis_MinimumMembersrtRangeAxis_TruistTermLoanMemberusgaapDebtInstrumentAxis"
      decimals="3"
      unitRef="Unit_pure">0.015</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="P05_26_2022To05_26_2022_BaseRateMemberusgaapVariableRateAxis_LineOfCreditMemberusgaapCreditFacilityAxis_MaximumMembersrtRangeAxis_TruistTermLoanMemberusgaapDebtInstrumentAxis"
      decimals="4"
      unitRef="Unit_pure">0.0175</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="PAsOn12_31_2022_LineOfCreditMemberusgaapCreditFacilityAxis_TruistTermLoanMemberusgaapDebtInstrumentAxis"
      decimals="INF"
      unitRef="Unit_pure">0.0692</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:DebtInstrumentPeriodicPaymentPrincipal
      contextRef="P01_01_2022To12_31_2022_LineOfCreditMemberusgaapCreditFacilityAxis_TruistTermLoanMemberusgaapDebtInstrumentAxis"
      decimals="-3"
      unitRef="Unit_USD">1563000</us-gaap:DebtInstrumentPeriodicPaymentPrincipal>
    <us-gaap:DebtInstrumentFrequencyOfPeriodicPayment contextRef="P01_01_2022To12_31_2022_LineOfCreditMemberusgaapCreditFacilityAxis_TruistTermLoanMemberusgaapDebtInstrumentAxis">quarterly</us-gaap:DebtInstrumentFrequencyOfPeriodicPayment>
    <us-gaap:LongTermDebtMaturityDate contextRef="PAsOn12_31_2022_LineOfCreditMemberusgaapCreditFacilityAxis_TruistTermLoanMemberusgaapDebtInstrumentAxis">2027-05-26</us-gaap:LongTermDebtMaturityDate>
    <us-gaap:LongTermDebt
      contextRef="PAsOn12_31_2022_LineOfCreditMemberusgaapCreditFacilityAxis_TruistTermLoanMemberusgaapDebtInstrumentAxis"
      decimals="-3"
      unitRef="Unit_USD">121875000</us-gaap:LongTermDebt>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="PAsOn12_31_2022_RevolvingCreditFacilityMemberusgaapCreditFacilityAxis_TruistTermLoanMemberusgaapDebtInstrumentAxis"
      decimals="INF"
      unitRef="Unit_USD">50000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:ProceedsFromLinesOfCredit
      contextRef="P01_01_2022To12_31_2022_LineOfCreditMemberusgaapCreditFacilityAxis_TruistTermLoanMemberusgaapDebtInstrumentAxis"
      decimals="INF"
      unitRef="Unit_USD">0</us-gaap:ProceedsFromLinesOfCredit>
    <us-gaap:RatioOfIndebtednessToNetCapital1
      contextRef="PAsOn12_31_2022_DebtInstrumentRedemptionPeriodOneMemberusgaapDebtInstrumentRedemptionPeriodAxis_LineOfCreditMemberusgaapCreditFacilityAxis_MaximumMembersrtRangeAxis_TruistTermLoanMemberusgaapDebtInstrumentAxis"
      decimals="2"
      unitRef="Unit_pure">4.25</us-gaap:RatioOfIndebtednessToNetCapital1>
    <us-gaap:RatioOfIndebtednessToNetCapital1
      contextRef="PAsOn12_31_2022_DebtInstrumentRedemptionPeriodTwoMemberusgaapDebtInstrumentRedemptionPeriodAxis_LineOfCreditMemberusgaapCreditFacilityAxis_MaximumMembersrtRangeAxis_TruistTermLoanMemberusgaapDebtInstrumentAxis"
      decimals="2"
      unitRef="Unit_pure">4</us-gaap:RatioOfIndebtednessToNetCapital1>
    <us-gaap:RatioOfIndebtednessToNetCapital1
      contextRef="PAsOn12_31_2022_DebtInstrumentRedemptionPeriodThreeMemberusgaapDebtInstrumentRedemptionPeriodAxis_LineOfCreditMemberusgaapCreditFacilityAxis_MaximumMembersrtRangeAxis_TruistTermLoanMemberusgaapDebtInstrumentAxis"
      decimals="2"
      unitRef="Unit_pure">3.75</us-gaap:RatioOfIndebtednessToNetCapital1>
    <btmd:FixedChargeCoverageRatio
      contextRef="PAsOn12_31_2022_LineOfCreditMemberusgaapCreditFacilityAxis_MinimumMembersrtRangeAxis_TruistTermLoanMemberusgaapDebtInstrumentAxis"
      decimals="2"
      unitRef="Unit_pure">1.25</btmd:FixedChargeCoverageRatio>
    <us-gaap:DebtInstrumentCovenantCompliance contextRef="P01_01_2022To12_31_2022_LineOfCreditMemberusgaapCreditFacilityAxis_TruistTermLoanMemberusgaapDebtInstrumentAxis">The Company was in compliance with all required covenants associated with the Credit Agreement as of December 31, 2022.</us-gaap:DebtInstrumentCovenantCompliance>
    <us-gaap:DebtRelatedCommitmentFeesAndDebtIssuanceCosts
      contextRef="P05_26_2022To05_26_2022_LineOfCreditMemberusgaapCreditFacilityAxis_TruistTermLoanMemberusgaapDebtInstrumentAxis"
      decimals="-3"
      unitRef="Unit_USD">4036000</us-gaap:DebtRelatedCommitmentFeesAndDebtIssuanceCosts>
    <us-gaap:AmortizationOfFinancingCosts
      contextRef="P01_01_2022To12_31_2022_LineOfCreditMemberusgaapCreditFacilityAxis_TruistTermLoanMemberusgaapDebtInstrumentAxis"
      decimals="-3"
      unitRef="Unit_USD">498000</us-gaap:AmortizationOfFinancingCosts>
    <us-gaap:AmortizationOfFinancingCosts
      contextRef="P01_01_2022To12_31_2022_BankOfAmericaTermLoanAndTruistTermLoanMemberusgaapDebtInstrumentAxis_LineOfCreditMemberusgaapCreditFacilityAxis"
      decimals="-3"
      unitRef="Unit_USD">589000</us-gaap:AmortizationOfFinancingCosts>
    <us-gaap:AmortizationOfFinancingCosts
      contextRef="P01_01_2021To12_31_2021_BankOfAmericaTermLoanAndTruistTermLoanMemberusgaapDebtInstrumentAxis_LineOfCreditMemberusgaapCreditFacilityAxis"
      decimals="-3"
      unitRef="Unit_USD">222000</us-gaap:AmortizationOfFinancingCosts>
    <us-gaap:ScheduleOfDebtTableTextBlock contextRef="P01_01_2022To12_31_2022">&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;The outstanding debt as of December&#160;31, 2022 and 2021 is classified in the consolidated balance sheets as follows: &lt;/div&gt;&lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width:65%"/&gt;
&lt;td style="vertical-align:bottom;width:9%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:9%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;br/&gt; 2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;br/&gt; 2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Term loan&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;121,875&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;37,500&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Less: Current portion&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(6,250&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(5,000&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;115,625&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;32,500&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Less: Unamortized debt issuance costs&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(3,539&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(537&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Term loan, net of current portion&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;112,086&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;31,963&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfDebtTableTextBlock>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">121875000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">37500000</us-gaap:DebtInstrumentCarryingAmount>
    <btmd:TeamLoanCurrentPortionBeforeUnamortizedDebtIssuanceCosts
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">-6250000</btmd:TeamLoanCurrentPortionBeforeUnamortizedDebtIssuanceCosts>
    <btmd:TeamLoanCurrentPortionBeforeUnamortizedDebtIssuanceCosts
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">-5000000</btmd:TeamLoanCurrentPortionBeforeUnamortizedDebtIssuanceCosts>
    <btmd:TeamLoanNonCurrentPortionBeforeUnamortizedDebtIssuanceCosts
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">115625000</btmd:TeamLoanNonCurrentPortionBeforeUnamortizedDebtIssuanceCosts>
    <btmd:TeamLoanNonCurrentPortionBeforeUnamortizedDebtIssuanceCosts
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">32500000</btmd:TeamLoanNonCurrentPortionBeforeUnamortizedDebtIssuanceCosts>
    <us-gaap:DeferredFinanceCostsNet
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">3539000</us-gaap:DeferredFinanceCostsNet>
    <us-gaap:DeferredFinanceCostsNet
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">537000</us-gaap:DeferredFinanceCostsNet>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">112086000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">31963000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock contextRef="P01_01_2022To12_31_2022">&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;Future maturities of long-term debt, excluding debt issuance costs, are as follows: &lt;/div&gt;&lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:68%;border:0;margin:0 auto"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width:83%"/&gt;
&lt;td style="vertical-align:bottom;width:7%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;2023&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;6,250&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;2024&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;6,250&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;2025&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;6,250&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;2026&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;6,250&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;2027&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;96,875&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;121,875&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">6250000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">6250000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">6250000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">6250000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">96875000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive>
    <us-gaap:LongTermDebt
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">121875000</us-gaap:LongTermDebt>
    <btmd:WarrantLiabilityTextBlock contextRef="P01_01_2022To12_31_2022">
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%"&gt;
&lt;tr style="page-break-inside:avoid"&gt;
&lt;td style="width:4%;vertical-align:top;text-align:left;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;10.&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:top;text-align:left;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; text-align: left; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;WARRANT LIABILITY &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;In connection with its initial public offering, Haymaker issued Public Warrants as part of the units sold through the offering (&#x201c;Public Warrant&#x201d;) as well as private placement warrants (&#x201c;Private Placement Warrant&#x201d;) to its Sponsor, the terms of which are further described below. &lt;/div&gt;&lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Public Warrants &lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;Each whole Public Warrant is exercisable to purchase one share of Class&#160;A common stock, and only whole warrants are exercisable. The Public Warrants became exercisable on June&#160;25, 2022, 30 days after the completion of the Business Combination. Each whole Public Warrant entitles the holder to purchase one share of Class&#160;A common stock at an exercise price of $11.50. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;Pursuant to the warrant agreement, a warrant holder may exercise its warrants only for a whole number of shares of Class&#160;A common stock. This means that only a whole warrant may be exercised at any given time by a warrant holder. No fractional warrants were issued upon separation of the units and only whole warrants were traded, requiring a purchase of at least four units to receive or trade a whole warrant. The warrants will expire on May 26, 2027, five years after the completion of the Business Combination, or earlier upon redemption or liquidation. &lt;/div&gt;&lt;div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"&gt;&#160;&lt;/div&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"/&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;If the shares issuable upon exercise of the warrants are not registered under the Securities Act within 60 business days following the Business Combination, the Company will be required to permit holders to exercise their warrants on a cashless basis. However, no warrant will be exercisable for cash or on a cashless basis, and the Company will not be obligated to issue any shares to holders seeking to exercise their warrants, unless the issuance of the shares upon such exercise is registered or qualified under the securities laws of the state of the exercising holder, unless an exemption is available. In the event that the conditions in the immediately preceding sentence are not satisfied with respect to a warrant, the holder of such warrant will not be entitled to exercise such warrant and such warrant may have no value and expire worthless. In no event will the Company be required to net cash settle any warrant. In the event that a registration statement is not effective for the exercised warrants, the purchaser of a unit containing such warrant will have paid the full purchase price for the unit solely for the share of Class&#160;A common stock underlying such unit. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;The Company has agreed that as soon as practicable, but in no event later than 15 business days, after the closing of the Business Combination, the Company will use its reasonable best efforts to file with the SEC a registration statement for the registration, under the Securities Act, of the shares of Class&#160;A common stock issuable upon exercise of the warrants. The Company will use its reasonable best efforts to cause the same to become effective within 60 business days following the Business Combination and to maintain the effectiveness of such registration statement, and a current prospectus relating thereto, until the expiration of the warrants in accordance with the provisions of the warrant agreement. Notwithstanding the above, if the Company&#x2019;s Class&#160;A common stock is at the time of any exercise of a warrant not listed on a national securities exchange such that it satisfies the definition of a &#x201c;covered security&#x201d; under Section&#160;18(b)(1) of the Securities Act, the Company may, at its option, require holders of Public Warrants who exercise their warrants to do so on a &#x201c;cashless basis&#x201d; in accordance with Section&#160;3(a)(9) of the Securities Act and, in the event the Company so elects, the Company will not be required to file or maintain in effect a registration statement, but the Company will be required to use its best efforts to register or qualify the shares under applicable blue sky laws to the extent an exemption is not available. &lt;/div&gt;&lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Redemption of warrants when the price per Class&#160;A share equals or exceeds $18.00 &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;Once the warrants become exercisable, the Company may call the warrants for redemption: &lt;/div&gt;&lt;div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%"&gt;
&lt;tr style="page-break-inside:avoid"&gt;
&lt;td style="width:5%"&gt;&#160;&lt;/td&gt;
&lt;td style="width:3%;vertical-align:top;text-align:left;"&gt;&#x2022;&lt;/td&gt;
&lt;td style="width:1%;vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:top;text-align:left;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; text-align: left; line-height: normal;"&gt;in whole and not in part; &lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%"&gt;
&lt;tr style="page-break-inside:avoid"&gt;
&lt;td style="width:5%"&gt;&#160;&lt;/td&gt;
&lt;td style="width:3%;vertical-align:top;text-align:left;"&gt;&#x2022;&lt;/td&gt;
&lt;td style="width:1%;vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:top;text-align:left;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; text-align: left; line-height: normal;"&gt;at a price of $0.01 per warrant; &lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%"&gt;
&lt;tr style="page-break-inside:avoid"&gt;
&lt;td style="width:5%"&gt;&#160;&lt;/td&gt;
&lt;td style="width:3%;vertical-align:top;text-align:left;"&gt;&#x2022;&lt;/td&gt;
&lt;td style="width:1%;vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:top;text-align:left;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; text-align: left; line-height: normal;"&gt;upon not less than 30 days&#x2019; prior written notice of redemption (which we refer to as the &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="display:inline;"&gt;30&lt;/div&gt;-day&lt;/div&gt; redemption period) to each warrant holder; and &lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%"&gt;
&lt;tr style="page-break-inside:avoid"&gt;
&lt;td style="width:5%"&gt;&#160;&lt;/td&gt;
&lt;td style="width:3%;vertical-align:top;text-align:left;"&gt;&#x2022;&lt;/td&gt;
&lt;td style="width:1%;vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:top;text-align:left;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; text-align: left; line-height: normal;"&gt;if, and only if, the last reported sale price of the Class&#160;A common stock equals or exceeds $18.00 per share (as adjusted for stock splits, stock capitalizations, reorganizations, recapitalizations and the like) for any 20 trading days within a &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="display:inline;"&gt;30&lt;/div&gt;-trading&lt;/div&gt; day period ending on the third trading day prior to the date on which we send the notice of redemption to the warrant holders. &lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Redemption of warrants when the price per Class&#160;A share equals or exceeds $10.00 &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;Once the warrants become exercisable, the Company may call the warrants for redemption: &lt;/div&gt;&lt;div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%"&gt;
&lt;tr style="page-break-inside:avoid"&gt;
&lt;td style="width:5%"&gt;&#160;&lt;/td&gt;
&lt;td style="width:3%;vertical-align:top;text-align:left;"&gt;&#x2022;&lt;/td&gt;
&lt;td style="width:1%;vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:top;text-align:left;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; text-align: left; line-height: normal;"&gt;in whole and not in part; &lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%"&gt;
&lt;tr style="page-break-inside:avoid"&gt;
&lt;td style="width:5%"&gt;&#160;&lt;/td&gt;
&lt;td style="width:3%;vertical-align:top;text-align:left;"&gt;&#x2022;&lt;/td&gt;
&lt;td style="width:1%;vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:top;text-align:left;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; text-align: left; line-height: normal;"&gt;at $0.10 per warrant upon a minimum of 30 days&#x2019; prior written notice of redemption provided that holders will be able to exercise their warrants on a cashless basis prior to redemption and receive that number of shares of our Class&#160;A common stock to be determined based on the redemption date and the &#x201c;fair market value&#x201d; of shares of our Class&#160;A common stock except as otherwise described below; &lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%"&gt;
&lt;tr style="page-break-inside:avoid"&gt;
&lt;td style="width:5%"&gt;&#160;&lt;/td&gt;
&lt;td style="width:3%;vertical-align:top;text-align:left;"&gt;&#x2022;&lt;/td&gt;
&lt;td style="width:1%;vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:top;text-align:left;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; text-align: left; line-height: normal;"&gt;if, and only if, the closing price of shares of our Class&#160;A common stock equals or exceeds $10.00 per share (as adjusted for stock splits, stock dividends, reorganizations, recapitalizations and the like) for &lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"&gt;&#160;&lt;/div&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"&gt; &lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%"&gt;
&lt;tr style="page-break-inside:avoid"&gt;
&lt;td style="width:9%"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; line-height: normal;"&gt;any 20 trading days within the &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;30-trading&lt;/div&gt; day period ending on the third trading day prior to the date on which we send the notice of redemption to the warrant holders; and &lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%"&gt;
&lt;tr style="page-break-inside:avoid"&gt;
&lt;td style="width:5%"&gt;&#160;&lt;/td&gt;
&lt;td style="width:3%;vertical-align:top;text-align:left;"&gt;&#x2022;&lt;/td&gt;
&lt;td style="width:1%;vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:top;text-align:left;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; text-align: left; line-height: normal;"&gt;if the closing price of our Class A common stock for any 20 trading days within a &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;30-trading&lt;/div&gt; day period ending on the third trading day prior to the date on which we send the notice of redemption to the warrant holders is less than $18.00 per share (as adjusted for stock splits, stock dividends, reorganizations, recapitalizations and the like), the Private Placement Warrants must also be concurrently called for redemption on the same terms as the outstanding Public Warrants. &lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;In addition, if (x)&#160;the Company issues additional shares of Class&#160;A common stock or equity-linked securities for capital raising purposes in connection with the Closing of the Business Combination at an issue price or effective issue price of less than $9.20 per share of Class&#160;A common stock (with such issue price or effective issue price to be determined in good faith by the Company&#x2019;s board of directors and, in the case of any such issuance to the Sponsor or its affiliates, without taking into account any founder shares held by the Sponsor or such affiliates, as applicable, prior to such issuance) (the &#x201c;Newly Issued Price&#x201d;), (y) the aggregate gross proceeds from such issuances represent more than 60% of the total equity proceeds, inclusive of interest earned on equity held in trust, available for the funding of the Business Combination on the date of the consummation of the Business Combination (net of redemptions), and (z)&#160;the volume weighted average trading price of the Company&#x2019;s common stock during the 20 trading day period starting on the trading day prior to the day on which the Business Combination is consummated (such price, the &#x201c;Market Value&#x201d;) is below $9.20 per share, the exercise price of the warrants will be adjusted (to the nearest cent) to be equal to 115% of the higher of the Market Value and the Newly Issued Price, and the $18.00 per share redemption trigger price described above will be adjusted (to the nearest cent) to be equal to 180% of the higher of the Market Value and the Newly Issued Price. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;The Company&#x2019;s Public Warrants are treated as liabilities and recorded at fair value in the Warrant liability line of the consolidated balance sheet. Any changes in fair value are recorded in the changes in fair value of warrants line of the consolidated statements of income and comprehensive income. Please see Note 12 for further detail. No Public Warrants have been redeemed as of December&#160;31, 2022 or December&#160;31, 2021. &lt;/div&gt;&lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Private Placement Warrants &lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;The Sponsor purchased an aggregate of 5,333,333 Private Placement Warrants at a price of $1.50 per whole warrant in a private placement that occurred simultaneously with the closing of Haymaker&#x2019;s initial public offering. Subsequently, the Sponsor purchased an additional 233,333 Private Placement Warrants for an aggregate purchase price of $350,000 in conjunction with the partial exercise of the underwriters&#x2019; overallotment option. Each whole Private Placement Warrant was exercisable for one share of the Company&#x2019;s Class&#160;A common stock at a price of $11.50 per share. The Private Placement Warrants were &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-redeemable&lt;/div&gt; and exercisable on a cashless basis so long as they are held by the Sponsor or its permitted transferees. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;The Private Placement Warrants (including the Class&#160;A common stock issuable upon exercise of the Private Placement Warrants) were not transferable, assignable or saleable until 30 days after the completion of the Business Combination and they are not redeemable so long as they are held by the Sponsor or its permitted transferees. Otherwise, the Private Placement Warrants had terms and provisions that were identical to those of the Public Warrants, including as to exercise price, exercisability and exercise period. If the Private Placement Warrants are held by holders other than the Sponsor or its permitted transferees, the Private Placement Warrants will be redeemable by the Company and exercisable by the holders on the same basis as the Public Warrants. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;If holders of the Private Placement Warrants elect to exercise them on a cashless basis, they would pay the exercise price by surrendering their warrants for that number of shares of Class&#160;A common stock equal to the quotient obtained by dividing (x)&#160;the product of the number of shares of Class&#160;A common stock underlying the warrants, multiplied by the difference between the exercise price of the warrants and the &#x201c;fair market value&#x201d; (defined below) by (y)&#160;the fair market value. The &#x201c;fair market value&#x201d; shall mean the average reported last sale price of the Class&#160;A common stock for the 10 trading days ending on the third trading day prior to the date on which the notice of warrant exercise is sent to the warrant agent. &lt;/div&gt;&lt;div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"&gt;&#160;&lt;/div&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"&gt; &lt;/div&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;On December&#160;31, 2022, there were 7,937,466 Public Warrants and 5,566,666 Private Placement Warrants outstanding. The Company accounts for the Public Warrants and Private Placement Warrants in accordance with the guidance contained in ASC &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;815-40.&lt;/div&gt; Such guidance provides that because the warrants do not meet the criteria for equity treatment thereunder, each warrant must be recorded as a liability. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;The warrant liabilities are subject to &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;re-measurement&lt;/div&gt; at each balance sheet date. With each such &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;re-measurement,&lt;/div&gt; the warrant liabilities are adjusted to current fair value, with the change in fair value recognized in the Company&#x2019;s consolidated statements of income and comprehensive income. The Company reassesses the classification at each balance sheet date. If the classification changes as a result of events during the period, the warrants will be reclassified as of the date of the event that causes the reclassification. No such events requiring a change in classification of the warrants have occurred through December&#160;31, 2022. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;The Company&#x2019;s Private Placement Warrants are treated as liabilities and recorded at fair value in the Warrant liability line of the balance sheet. Any changes in fair value are recorded in the changes in fair value of warrants line of the consolidated statement of income and comprehensive income. Please see Note 12 for further detail. &lt;/div&gt;</btmd:WarrantLiabilityTextBlock>
    <btmd:ClassOfWarrantOrRightRedemptionThresholdConsecutiveTradingDays contextRef="P01_01_2022To12_31_2022_CommonClassAMemberusgaapStatementClassOfStockAxis_HaymakeriiiMembersrtConsolidatedEntitiesAxis_RedeemableWarrantsMemberusgaapClassOfWarrantOrRightAxis">P30D</btmd:ClassOfWarrantOrRightRedemptionThresholdConsecutiveTradingDays>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="PAsOn12_31_2022_CommonClassAMemberusgaapStatementClassOfStockAxis_HaymakeriiiMembersrtConsolidatedEntitiesAxis_RedeemableWarrantsMemberusgaapClassOfWarrantOrRightAxis"
      decimals="0"
      unitRef="Unit_shares">1</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="PAsOn12_31_2022_HaymakeriiiMembersrtConsolidatedEntitiesAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">11.5</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:WarrantsAndRightsOutstandingMaturityDate contextRef="PAsOn12_31_2022_HaymakeriiiMembersrtConsolidatedEntitiesAxis">2027-05-26</us-gaap:WarrantsAndRightsOutstandingMaturityDate>
    <us-gaap:WarrantsAndRightsOutstandingTerm contextRef="PAsOn12_31_2022_HaymakeriiiMembersrtConsolidatedEntitiesAxis">P5Y</us-gaap:WarrantsAndRightsOutstandingTerm>
    <btmd:ClassOfWarrantsOrRightsTransfersRestrictionOnNumberOfDaysFromTheDateOfBusinessCombination contextRef="P01_01_2022To12_31_2022_CommonClassAMemberusgaapStatementClassOfStockAxis_HaymakeriiiMembersrtConsolidatedEntitiesAxis">P60D</btmd:ClassOfWarrantsOrRightsTransfersRestrictionOnNumberOfDaysFromTheDateOfBusinessCombination>
    <btmd:ClassOfWarrantOrRightThresholdPeriodForExerciseFromDateOfClosingPublicOffering contextRef="P01_01_2022To12_31_2022_CommonClassAMemberusgaapStatementClassOfStockAxis_HaymakeriiiMembersrtConsolidatedEntitiesAxis">P15D</btmd:ClassOfWarrantOrRightThresholdPeriodForExerciseFromDateOfClosingPublicOffering>
    <btmd:NumberOfDaysFollowingItsInitialBusinessCombinationUntilTheExpirationOfTheWarrants contextRef="P01_01_2022To12_31_2022_HaymakeriiiMembersrtConsolidatedEntitiesAxis">P60D</btmd:NumberOfDaysFollowingItsInitialBusinessCombinationUntilTheExpirationOfTheWarrants>
    <us-gaap:SharePrice
      contextRef="PAsOn12_31_2022_CommonClassAMemberusgaapStatementClassOfStockAxis_SharePriceEqualOrExceedsEighteenRupeesPerDollarMemberusgaapMeasurementInputTypeAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">18</us-gaap:SharePrice>
    <btmd:ClassOfWarrantsRedemptionPricePerUnit
      contextRef="PAsOn12_31_2022_HaymakeriiiMembersrtConsolidatedEntitiesAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">0.01</btmd:ClassOfWarrantsRedemptionPricePerUnit>
    <btmd:NumberOfConsecutiveTradingDaysForDeterminingSharePrice contextRef="P01_01_2022To12_31_2022_HaymakeriiiMembersrtConsolidatedEntitiesAxis">P30D</btmd:NumberOfConsecutiveTradingDaysForDeterminingSharePrice>
    <us-gaap:SharePrice
      contextRef="PAsOn12_31_2022_CommonClassAMemberusgaapStatementClassOfStockAxis_SharePriceEqualOrExceedsEighteenRupeesPerDollarMemberusgaapMeasurementInputTypeAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">18</us-gaap:SharePrice>
    <btmd:NumberOfConsecutiveTradingDaysForDeterminingSharePrice contextRef="P01_01_2022To12_31_2022_CommonClassAMemberusgaapStatementClassOfStockAxis_SharePriceEqualOrExceedsEighteenRupeesPerDollarMemberusgaapMeasurementInputTypeAxis">P20D</btmd:NumberOfConsecutiveTradingDaysForDeterminingSharePrice>
    <us-gaap:SharePrice
      contextRef="PAsOn12_31_2022_CommonClassAMemberusgaapStatementClassOfStockAxis_SharePriceEqualOrExceedsTenRupeesPerDollarMemberusgaapMeasurementInputTypeAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">10</us-gaap:SharePrice>
    <btmd:ClassOfWarrantsRedemptionPricePerUnit
      contextRef="PAsOn12_31_2022_CommonClassAMemberusgaapStatementClassOfStockAxis_SharePriceEqualOrExceedsTenRupeesPerDollarMemberusgaapMeasurementInputTypeAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">0.1</btmd:ClassOfWarrantsRedemptionPricePerUnit>
    <btmd:ClassOfWarrantOrRightThresholdPeriodForExerciseFromDateOfClosingPublicOffering contextRef="P01_01_2022To12_31_2022_CommonClassAMemberusgaapStatementClassOfStockAxis_SharePriceEqualOrExceedsTenRupeesPerDollarMemberusgaapMeasurementInputTypeAxis">P30D</btmd:ClassOfWarrantOrRightThresholdPeriodForExerciseFromDateOfClosingPublicOffering>
    <us-gaap:SharePrice
      contextRef="PAsOn12_31_2022_CommonClassAMemberusgaapStatementClassOfStockAxis_SharePriceEqualOrExceedsTenRupeesPerDollarMemberusgaapMeasurementInputTypeAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">10</us-gaap:SharePrice>
    <btmd:ClassOfWarrantOrRightMinimumNoticePeriodForRedemption contextRef="P01_01_2022To12_31_2022_CommonClassAMemberusgaapStatementClassOfStockAxis_SharePriceEqualOrExceedsTenRupeesPerDollarMemberusgaapMeasurementInputTypeAxis">P20D</btmd:ClassOfWarrantOrRightMinimumNoticePeriodForRedemption>
    <btmd:PrivatePlacementWarrantsRedemptionDescription contextRef="P01_01_2022To12_31_2022">if the closing price of our Class A common stock for any 20 trading days within a 30-trading day period ending on the third trading day prior to the date on which we send the notice of redemption to the warrant holders is less than $18.00 per share (as adjusted for stock splits, stock dividends, reorganizations, recapitalizations and the like), the Private Placement Warrants must also be concurrently called for redemption on the same terms as the outstanding Public Warrants.</btmd:PrivatePlacementWarrantsRedemptionDescription>
    <btmd:ShareRedemptionTriggerPrice
      contextRef="PAsOn12_31_2022_CommonClassAMemberusgaapStatementClassOfStockAxis_HaymakeriiiMembersrtConsolidatedEntitiesAxis_SharePriceEqualOrLessNinePointTwoRupeesPerDollarMemberusgaapMeasurementInputTypeAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">9.2</btmd:ShareRedemptionTriggerPrice>
    <btmd:MinimumGrossProceedsRequiredFromIssuanceOfEquity
      contextRef="PAsOn12_31_2022_CommonClassAMemberusgaapStatementClassOfStockAxis_HaymakeriiiMembersrtConsolidatedEntitiesAxis_SharePriceEqualOrLessNinePointTwoRupeesPerDollarMemberusgaapMeasurementInputTypeAxis"
      decimals="2"
      unitRef="Unit_pure">0.60</btmd:MinimumGrossProceedsRequiredFromIssuanceOfEquity>
    <btmd:ClassOfWarrantOrRightMinimumNoticePeriodForRedemption contextRef="P01_01_2022To12_31_2022_CommonClassAMemberusgaapStatementClassOfStockAxis_HaymakeriiiMembersrtConsolidatedEntitiesAxis_SharePriceEqualOrLessNinePointTwoRupeesPerDollarMemberusgaapMeasurementInputTypeAxis">P20D</btmd:ClassOfWarrantOrRightMinimumNoticePeriodForRedemption>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="PAsOn12_31_2022_CommonClassAMemberusgaapStatementClassOfStockAxis_HaymakeriiiMembersrtConsolidatedEntitiesAxis_SharePriceEqualOrLessNinePointTwoRupeesPerDollarMemberusgaapMeasurementInputTypeAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">9.2</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <btmd:ClassOfWarrantOrRightExercisePriceAdjustmentPercentageHigherOfMarketValue
      contextRef="PAsOn12_31_2022_CommonClassAMemberusgaapStatementClassOfStockAxis_HaymakeriiiMembersrtConsolidatedEntitiesAxis_SharePriceEqualOrLessNinePointTwoRupeesPerDollarMemberusgaapMeasurementInputTypeAxis"
      decimals="2"
      unitRef="Unit_pure">1.15</btmd:ClassOfWarrantOrRightExercisePriceAdjustmentPercentageHigherOfMarketValue>
    <btmd:ShareRedemptionTriggerPrice
      contextRef="PAsOn12_31_2022_CommonClassAMemberusgaapStatementClassOfStockAxis_HaymakeriiiMembersrtConsolidatedEntitiesAxis_SharePriceEqualOrExceedsEighteenRupeesPerDollarMemberusgaapMeasurementInputTypeAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">18</btmd:ShareRedemptionTriggerPrice>
    <btmd:ClassOfWarrantOrRightExercisePriceAdjustmentPercentageHigherOfMarketValue
      contextRef="PAsOn12_31_2022_CommonClassAMemberusgaapStatementClassOfStockAxis_HaymakeriiiMembersrtConsolidatedEntitiesAxis_SharePriceEqualOrExceedsEighteenRupeesPerDollarMemberusgaapMeasurementInputTypeAxis"
      decimals="2"
      unitRef="Unit_pure">1.80</btmd:ClassOfWarrantOrRightExercisePriceAdjustmentPercentageHigherOfMarketValue>
    <btmd:PublicWarrantsRedeemed
      contextRef="PAsOn12_31_2021_HaymakeriiiMembersrtConsolidatedEntitiesAxis"
      decimals="-3"
      unitRef="Unit_USD">0</btmd:PublicWarrantsRedeemed>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="P01_01_2022To12_31_2022_HaymakeriiiMembersrtConsolidatedEntitiesAxis_PrivatePlacementWarrantsMemberusgaapClassOfWarrantOrRightAxis_SponseMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis"
      decimals="0"
      unitRef="Unit_shares">5333333</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="PAsOn12_31_2022_HaymakeriiiMembersrtConsolidatedEntitiesAxis_PrivatePlacementWarrantsMemberusgaapClassOfWarrantOrRightAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">1.5</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="P01_01_2022To12_31_2022_HaymakeriiiMembersrtConsolidatedEntitiesAxis_PrivatePlacementWarrantsMemberusgaapClassOfWarrantOrRightAxis"
      decimals="0"
      unitRef="Unit_shares">233333</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="P01_01_2022To12_31_2022_HaymakeriiiMembersrtConsolidatedEntitiesAxis_PrivatePlacementWarrantsMemberusgaapClassOfWarrantOrRightAxis"
      decimals="0"
      unitRef="Unit_USD">350000</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="PAsOn12_31_2022_CommonClassAMemberusgaapStatementClassOfStockAxis_HaymakeriiiMembersrtConsolidatedEntitiesAxis_PrivatePlacementWarrantsMemberusgaapClassOfWarrantOrRightAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">11.5</us-gaap:SharesIssuedPricePerShare>
    <btmd:ClassOfWarrantOrRightThresholdPeriodForExerciseFromDateOfClosingPublicOffering contextRef="P01_01_2022To12_31_2022_CommonClassAMemberusgaapStatementClassOfStockAxis_HaymakeriiiMembersrtConsolidatedEntitiesAxis_SponseMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis">P30D</btmd:ClassOfWarrantOrRightThresholdPeriodForExerciseFromDateOfClosingPublicOffering>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="PAsOn12_31_2022_HaymakeriiiMembersrtConsolidatedEntitiesAxis_PublicWarrantsMemberusgaapClassOfWarrantOrRightAxis"
      decimals="0"
      unitRef="Unit_shares">7937466</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="PAsOn12_31_2022_HaymakeriiiMembersrtConsolidatedEntitiesAxis_PrivatePlacementWarrantsMemberusgaapClassOfWarrantOrRightAxis_SponseMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis"
      decimals="0"
      unitRef="Unit_shares">5566666</us-gaap:ClassOfWarrantOrRightOutstanding>
    <btmd:EarnoutLiabilityTextBlock contextRef="P01_01_2022To12_31_2022">
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%"&gt;
&lt;tr style="page-break-inside:avoid"&gt;
&lt;td style="width:4%;vertical-align:top;text-align:left;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;11.&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:top;text-align:left;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; text-align: left; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;EARNOUT LIABILITY &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;Certain of the Company&#x2019;s equity holders are entitled to vest in up to 11,587,500 Earnout Securities if certain share price targets (the &#x201c;Triggering Events&#x201d;) are achieved by &lt;span style="-sec-ix-hidden:hidden73946098"&gt;May&#160;26, 2027&lt;/span&gt; (the &#x201c;Earnout Deadline&#x201d;). The Triggering Events each entitle the eligible equity holders to a certain number of shares per Triggering Event. The Triggering Events are as follows: &lt;/div&gt;&lt;div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%"&gt;
&lt;tr style="page-break-inside:avoid"&gt;
&lt;td style="width:4%"&gt;&#160;&lt;/td&gt;
&lt;td style="width:5%;vertical-align:top;text-align:left;"&gt;(i)&lt;/td&gt;
&lt;td style="vertical-align:top;text-align:left;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; text-align: left; line-height: normal;"&gt;the first time, prior to the Earnout Deadline, that the volume-weighted average share price of Biote&#x2019;s Class&#160;A common stock (&#x201c;VWAP&#x201d;) equals or exceeds $12.50 per share (the &#x201c;Price Target 1&#x201d;) for twenty (20)&#160;trading days of any thirty (30)&#160;consecutive trading day period following the Closing, &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;one-third&lt;/div&gt; (1/3) of the Earnout Securities shall be vested and no longer subject to forfeiture and other transfer restrictions (the &#x201c;Earnout Restrictions&#x201d;); &lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%"&gt;
&lt;tr style="page-break-inside:avoid"&gt;
&lt;td style="width:4%"&gt;&#160;&lt;/td&gt;
&lt;td style="width:5%;vertical-align:top;text-align:left;"&gt;(ii)&lt;/td&gt;
&lt;td style="vertical-align:top;text-align:left;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; text-align: left; line-height: normal;"&gt;the first time, prior to the Earnout Deadline, that the VWAP equals or exceeds $15.00 per share (the &#x201c;Price Target 2&#x201d;) for twenty (20)&#160;trading days of any thirty (30)&#160;consecutive trading day period following the Closing, &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;one-third&lt;/div&gt; (1/3) of the Earnout Securities shall be vested and no longer subject to the Earnout Restrictions; &lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%"&gt;
&lt;tr style="page-break-inside:avoid"&gt;
&lt;td style="width:4%"&gt;&#160;&lt;/td&gt;
&lt;td style="width:5%;vertical-align:top;text-align:left;"&gt;(iii)&lt;/td&gt;
&lt;td style="vertical-align:top;text-align:left;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; text-align: left; line-height: normal;"&gt;the first time, prior to the Earnout Deadline, that the VWAP equals or exceeds $17.50 per share (the &#x201c;Price Target 3&#x201d;) for twenty (20)&#160;trading days of any thirty (30)&#160;consecutive trading day period following the Closing, &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;one-third&lt;/div&gt; (1/3) of the Earnout Securities shall be vested and no longer subject to the Earnout Restrictions; and &lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%"&gt;
&lt;tr style="page-break-inside:avoid"&gt;
&lt;td style="width:4%"&gt;&#160;&lt;/td&gt;
&lt;td style="width:5%;vertical-align:top;text-align:left;"&gt;(iv)&lt;/td&gt;
&lt;td style="vertical-align:top;text-align:left;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; text-align: left; line-height: normal;"&gt;if the Company completes a change of control prior to the Earnout Deadline, then all remaining unvested Earnout Securities shall vest and no longer be subject to the Earnout Restrictions. &lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;The Company&#x2019;s Earnout liability is recorded at fair value in the consolidated balance sheet. Any changes in fair value are recorded in the changes in earnout liability line of the consolidated statement of income and comprehensive income. Please see Note 12 for further detail. &lt;/div&gt;&lt;div style="font-size:18pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;</btmd:EarnoutLiabilityTextBlock>
    <btmd:NumberOfEarnoutSecuritiesShareholderEntitledToVestIfCertainSharePriceTargetsAchieved
      contextRef="P01_01_2022To12_31_2022_BusinessCombinationMemberusgaapBusinessAcquisitionAxis_MaximumMembersrtRangeAxis"
      decimals="INF"
      unitRef="Unit_shares">11587500</btmd:NumberOfEarnoutSecuritiesShareholderEntitledToVestIfCertainSharePriceTargetsAchieved>
    <us-gaap:SharePrice
      contextRef="PAsOn12_31_2022_BusinessCombinationMemberusgaapBusinessAcquisitionAxis_CommonClassAMemberusgaapStatementClassOfStockAxis_SharePriceEqualsOrExceedsTwelvePointFivePerShareMemberusgaapVestingAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">12.5</us-gaap:SharePrice>
    <btmd:CommonStockTransfersThresholdTradingDays contextRef="P01_01_2022To12_31_2022_BusinessCombinationMemberusgaapBusinessAcquisitionAxis_CommonClassAMemberusgaapStatementClassOfStockAxis_SharePriceEqualsOrExceedsTwelvePointFivePerShareMemberusgaapVestingAxis">P20D</btmd:CommonStockTransfersThresholdTradingDays>
    <btmd:NumberOfConsecutiveTradingDaysForDeterminingTheSharePrice contextRef="P01_01_2022To12_31_2022_BusinessCombinationMemberusgaapBusinessAcquisitionAxis_CommonClassAMemberusgaapStatementClassOfStockAxis_SharePriceEqualsOrExceedsTwelvePointFivePerShareMemberusgaapVestingAxis">P30D</btmd:NumberOfConsecutiveTradingDaysForDeterminingTheSharePrice>
    <us-gaap:SharePrice
      contextRef="PAsOn12_31_2022_BusinessCombinationMemberusgaapBusinessAcquisitionAxis_SharePriceEqualsOrExceedsFifteenPerShareMemberusgaapVestingAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">15</us-gaap:SharePrice>
    <btmd:CommonStockTransfersThresholdTradingDays contextRef="P01_01_2022To12_31_2022_BusinessCombinationMemberusgaapBusinessAcquisitionAxis_SharePriceEqualsOrExceedsFifteenPerShareMemberusgaapVestingAxis">P20D</btmd:CommonStockTransfersThresholdTradingDays>
    <btmd:NumberOfConsecutiveTradingDaysForDeterminingTheSharePrice contextRef="P01_01_2022To12_31_2022_BusinessCombinationMemberusgaapBusinessAcquisitionAxis_SharePriceEqualsOrExceedsFifteenPerShareMemberusgaapVestingAxis">P30D</btmd:NumberOfConsecutiveTradingDaysForDeterminingTheSharePrice>
    <us-gaap:SharePrice
      contextRef="PAsOn12_31_2022_BusinessCombinationMemberusgaapBusinessAcquisitionAxis_SharePriceEqualsOrExceedsSeventeenPointFivePerShareMemberusgaapVestingAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">17.5</us-gaap:SharePrice>
    <btmd:CommonStockTransfersThresholdTradingDays contextRef="P01_01_2022To12_31_2022_BusinessCombinationMemberusgaapBusinessAcquisitionAxis_SharePriceEqualsOrExceedsSeventeenPointFivePerShareMemberusgaapVestingAxis">P20D</btmd:CommonStockTransfersThresholdTradingDays>
    <btmd:NumberOfConsecutiveTradingDaysForDeterminingTheSharePrice contextRef="P01_01_2022To12_31_2022_BusinessCombinationMemberusgaapBusinessAcquisitionAxis_SharePriceEqualsOrExceedsSeventeenPointFivePerShareMemberusgaapVestingAxis">P30D</btmd:NumberOfConsecutiveTradingDaysForDeterminingTheSharePrice>
    <us-gaap:FairValueDisclosuresTextBlock contextRef="P01_01_2022To12_31_2022">
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%"&gt;
&lt;tr style="page-break-inside:avoid"&gt;
&lt;td style="width:4%;vertical-align:top;text-align:left;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;12.&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:top;text-align:left;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; text-align: left; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;FAIR VALUE MEASUREMENTS &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;To the extent that valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair value requires more judgment. Accordingly, the degree of judgment exercised by the Company in determining fair value is greatest for instruments categorized in Level&#160;3. A financial instrument&#x2019;s level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement. &lt;/div&gt;&lt;div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"&gt;&#160;&lt;/div&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"&gt; &lt;/div&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;Fair value is a market-based measure considered from the perspective of a market participant rather than an entity-specific measure. Therefore, even when market assumptions are not readily available, the Company&#x2019;s own assumptions are set to reflect those that market participants would use in pricing the asset or liability at the measurement date. The Company uses prices and inputs that are current as of the measurement date, including during periods of market dislocation. In periods of market dislocation, the observability of prices and inputs may be reduced for many instruments. This condition could cause an instrument to be reclassified from Level&#160;1 to Level&#160;2 or Level&#160;2 to Level&#160;3. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;The Company&#x2019;s financial instruments consist of accounts receivable, accounts payable, accrued expenses, and short- and long-term debt. The carrying value of accounts receivable, accounts payable, accrued expenses and short-term debt are considered a reasonable estimate of their fair value, due to the short-term maturity of these instruments. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;The Company&#x2019;s debt instruments are carried at amortized cost in its consolidated balance sheets, which may differ from their respective fair values. The fair values of the Company&#x2019;s term loan and revolving line of credit generally approximate their carrying values. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;The Company&#x2019;s Warrant liability and Earnout liability are recorded at fair value on a recurring basis. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;The following table presents the Company&#x2019;s fair value hierarchy for financial assets and liabilities: &lt;/div&gt;&lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:92%;border:0;margin:0 auto"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width:60%"/&gt;
&lt;td style="vertical-align:bottom;width:6%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:6%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:6%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:6%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="14" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Fair&#160;Value&#160;Measurements&#160;as&#160;of&#160;December&#160;31,&#160;2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&#160;Level&#160;1&#160;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&#160;Level&#160;2&#160;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&#160;Level&#160;3&#160;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&#160;Total&#160;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Liabilities:&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Public Warrants&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2,381&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2,381&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Private Placement Warrants&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,723&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,723&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Earnout liability&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;32,110&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;32,110&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:12pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="16" style="height:12pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="14" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Fair Value Measurements as of May&#160;26, 2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Level&#160;1&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Level&#160;2&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Level&#160;3&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Total&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Liabilities:&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Public Warrants&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;5,397&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;5,397&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Private Placement Warrants&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3,834&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3,834&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Earnout liability&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;93,880&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;93,880&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;There were no movements between levels during the year ended December&#160;31, 2022. These instruments were not outstanding on the Company&#x2019;s books for the year ended December&#160;31, 2021. &lt;/div&gt;&lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Level&#160;3 Disclosures &lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Private Placement Warrants &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;As described in Note 10, the Company&#x2019;s Private Placement Warrants were initially issued by Haymaker and were thus acquired by the Company through the consummation of the Business Combination. Accordingly, the initial measurement date of the Private Placement Warrants for the Company was the Closing Date. The Private Placement Warrants were valued using a Monte Carlo simulation. Calculating the fair value of the Private Placement Warrants requires the input of subjective assumptions. Other reasonable assumptions could provide differing results. The carrying amount of the liability may fluctuate significantly, and actual amounts at settlement may be materially different from the liability&#x2019;s estimated value. &lt;/div&gt;&lt;div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"&gt;&#160;&lt;/div&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"&gt; &lt;/div&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;The following table provides the significant inputs to the Monte Carlo simulation for the fair value of the Private Placement Warrants as of December&#160;31, 2022 and the Closing Date: &lt;/div&gt;&lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width:71%"/&gt;
&lt;td style="vertical-align:bottom;width:10%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:9%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;As of&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;br/&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;May&#160;26,&lt;/div&gt;&lt;/div&gt;&lt;br/&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Stock price&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3.73&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;9.02&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Exercise price&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;11.50&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;11.50&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Risk-free rate&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;4.0&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2.7&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Volatility&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;42.2&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;13.4&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Term (in years)&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;4.4&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;5.0&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Earnout Liability &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;The Earnout liability was valued using a Monte Carlo simulation in order to project the future path of the Company&#x2019;s stock price over the earnout period. The carrying amount of the liability may fluctuate significantly, and actual amounts paid may be materially different from the liability&#x2019;s estimated value. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;The following table provides the significant inputs to the Monte Carlo simulation for the fair value of the Earnout liability as of December&#160;31, 2022 and the Closing Date, the date of initial measurement: &lt;/div&gt;&lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width:71%"/&gt;
&lt;td style="vertical-align:bottom;width:12%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:11%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;As of&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;br/&gt; 2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;May&#160;26,&lt;br/&gt; 2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Stock price&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3.73&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;9.02&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Risk-free rate&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;4.1&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2.7&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Volatility&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;70.0&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;60.0&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Term (in years)&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;4.4&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;5.0&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;The following table presents the changes in fair value of the Company&#x2019;s Level&#160;3 financial instruments that are measured at fair value as of December&#160;31, 2022 and the Closing Date, the date of initial measurement: &lt;/div&gt;&lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:84%;border:0;margin:0 auto"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width:65%"/&gt;
&lt;td style="vertical-align:bottom;width:5%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:5%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:5%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Private&lt;br/&gt; Placement&lt;/div&gt;&lt;/div&gt;&lt;br/&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Warrants&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Earnout&lt;br/&gt; Liability&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Total&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Fair value as of May&#160;26, 2022 (initial measurement)&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3,834&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;93,880&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;97,714&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Gain from change in fair value&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(2,111&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(61,770&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(63,881&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Fair value as of December&#160;31, 2022&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,723&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;32,110&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;33,833&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock contextRef="P01_01_2022To12_31_2022">&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;The following table presents the Company&#x2019;s fair value hierarchy for financial assets and liabilities: &lt;/div&gt;&lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:92%;border:0;margin:0 auto"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width:60%"/&gt;
&lt;td style="vertical-align:bottom;width:6%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:6%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:6%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:6%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="14" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Fair&#160;Value&#160;Measurements&#160;as&#160;of&#160;December&#160;31,&#160;2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&#160;Level&#160;1&#160;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&#160;Level&#160;2&#160;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&#160;Level&#160;3&#160;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&#160;Total&#160;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Liabilities:&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Public Warrants&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2,381&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2,381&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Private Placement Warrants&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,723&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,723&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Earnout liability&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;32,110&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;32,110&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td style="height:12pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="16" style="height:12pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="14" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Fair Value Measurements as of May&#160;26, 2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Level&#160;1&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Level&#160;2&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Level&#160;3&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Total&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Liabilities:&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Public Warrants&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;5,397&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;5,397&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Private Placement Warrants&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3,834&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3,834&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Earnout liability&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;93,880&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;93,880&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock>
    <us-gaap:FinancialLiabilitiesFairValueDisclosure
      contextRef="PAsOn12_31_2022_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_PublicWarrantsMemberusgaapFinancialInstrumentAxis"
      decimals="-3"
      unitRef="Unit_USD">2381000</us-gaap:FinancialLiabilitiesFairValueDisclosure>
    <us-gaap:FinancialLiabilitiesFairValueDisclosure
      contextRef="PAsOn12_31_2022_PublicWarrantsMemberusgaapFinancialInstrumentAxis"
      decimals="-3"
      unitRef="Unit_USD">2381000</us-gaap:FinancialLiabilitiesFairValueDisclosure>
    <us-gaap:FinancialLiabilitiesFairValueDisclosure
      contextRef="PAsOn12_31_2022_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_PrivatePlacementWarrantsMemberusgaapFinancialInstrumentAxis"
      decimals="-3"
      unitRef="Unit_USD">1723000</us-gaap:FinancialLiabilitiesFairValueDisclosure>
    <us-gaap:FinancialLiabilitiesFairValueDisclosure
      contextRef="PAsOn12_31_2022_PrivatePlacementWarrantsMemberusgaapFinancialInstrumentAxis"
      decimals="-3"
      unitRef="Unit_USD">1723000</us-gaap:FinancialLiabilitiesFairValueDisclosure>
    <us-gaap:FinancialLiabilitiesFairValueDisclosure
      contextRef="PAsOn12_31_2022_EarnoutLiabilityMemberusgaapFinancialInstrumentAxis_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis"
      decimals="-3"
      unitRef="Unit_USD">32110000</us-gaap:FinancialLiabilitiesFairValueDisclosure>
    <us-gaap:FinancialLiabilitiesFairValueDisclosure
      contextRef="PAsOn12_31_2022_EarnoutLiabilityMemberusgaapFinancialInstrumentAxis"
      decimals="-3"
      unitRef="Unit_USD">32110000</us-gaap:FinancialLiabilitiesFairValueDisclosure>
    <us-gaap:FinancialLiabilitiesFairValueDisclosure
      contextRef="PAsOn05_26_2022_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_PublicWarrantsMemberusgaapFinancialInstrumentAxis"
      decimals="-3"
      unitRef="Unit_USD">5397000</us-gaap:FinancialLiabilitiesFairValueDisclosure>
    <us-gaap:FinancialLiabilitiesFairValueDisclosure
      contextRef="PAsOn05_26_2022_PublicWarrantsMemberusgaapFinancialInstrumentAxis"
      decimals="-3"
      unitRef="Unit_USD">5397000</us-gaap:FinancialLiabilitiesFairValueDisclosure>
    <us-gaap:FinancialLiabilitiesFairValueDisclosure
      contextRef="PAsOn05_26_2022_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_PrivatePlacementWarrantsMemberusgaapFinancialInstrumentAxis"
      decimals="-3"
      unitRef="Unit_USD">3834000</us-gaap:FinancialLiabilitiesFairValueDisclosure>
    <us-gaap:FinancialLiabilitiesFairValueDisclosure
      contextRef="PAsOn05_26_2022_PrivatePlacementWarrantsMemberusgaapFinancialInstrumentAxis"
      decimals="-3"
      unitRef="Unit_USD">3834000</us-gaap:FinancialLiabilitiesFairValueDisclosure>
    <us-gaap:FinancialLiabilitiesFairValueDisclosure
      contextRef="PAsOn05_26_2022_EarnoutLiabilityMemberusgaapFinancialInstrumentAxis_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis"
      decimals="-3"
      unitRef="Unit_USD">93880000</us-gaap:FinancialLiabilitiesFairValueDisclosure>
    <us-gaap:FinancialLiabilitiesFairValueDisclosure
      contextRef="PAsOn05_26_2022_EarnoutLiabilityMemberusgaapFinancialInstrumentAxis"
      decimals="-3"
      unitRef="Unit_USD">93880000</us-gaap:FinancialLiabilitiesFairValueDisclosure>
    <us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock contextRef="P01_01_2022To12_31_2022">&lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;The following table provides the significant inputs to the Monte Carlo simulation for the fair value of the Private Placement Warrants as of December&#160;31, 2022 and the Closing Date: &lt;/div&gt;&lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width:71%"/&gt;
&lt;td style="vertical-align:bottom;width:10%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:9%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;As of&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;br/&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;May&#160;26,&lt;/div&gt;&lt;/div&gt;&lt;br/&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Stock price&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3.73&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;9.02&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Exercise price&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;11.50&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;11.50&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Risk-free rate&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;4.0&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2.7&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Volatility&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;42.2&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;13.4&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Term (in years)&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;4.4&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;5.0&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;The following table provides the significant inputs to the Monte Carlo simulation for the fair value of the Earnout liability as of December&#160;31, 2022 and the Closing Date, the date of initial measurement: &lt;/div&gt;&lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width:71%"/&gt;
&lt;td style="vertical-align:bottom;width:12%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:11%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;As of&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;br/&gt; 2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;May&#160;26,&lt;br/&gt; 2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Stock price&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3.73&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;9.02&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Risk-free rate&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;4.1&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2.7&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Volatility&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;70.0&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;60.0&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Term (in years)&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;4.4&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;5.0&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="PAsOn12_31_2022_MeasurementInputSharePriceMemberusgaapMeasurementInputTypeAxis_PrivatePlacementWarrantsMemberusgaapFinancialInstrumentAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">3.73</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="PAsOn05_26_2022_MeasurementInputSharePriceMemberusgaapMeasurementInputTypeAxis_PrivatePlacementWarrantsMemberusgaapFinancialInstrumentAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">9.02</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="PAsOn12_31_2022_MeasurementInputExercisePriceMemberusgaapMeasurementInputTypeAxis_PrivatePlacementWarrantsMemberusgaapFinancialInstrumentAxis"
      decimals="2"
      unitRef="Unit_pure">11.5</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="PAsOn05_26_2022_MeasurementInputExercisePriceMemberusgaapMeasurementInputTypeAxis_PrivatePlacementWarrantsMemberusgaapFinancialInstrumentAxis"
      decimals="2"
      unitRef="Unit_pure">11.5</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="PAsOn12_31_2022_MeasurementInputRiskFreeInterestRateMemberusgaapMeasurementInputTypeAxis_PrivatePlacementWarrantsMemberusgaapFinancialInstrumentAxis"
      decimals="3"
      unitRef="Unit_pure">0.04</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="PAsOn05_26_2022_MeasurementInputRiskFreeInterestRateMemberusgaapMeasurementInputTypeAxis_PrivatePlacementWarrantsMemberusgaapFinancialInstrumentAxis"
      decimals="3"
      unitRef="Unit_pure">0.027</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="PAsOn12_31_2022_MeasurementInputOptionVolatilityMemberusgaapMeasurementInputTypeAxis_PrivatePlacementWarrantsMemberusgaapFinancialInstrumentAxis"
      decimals="3"
      unitRef="Unit_pure">0.422</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="PAsOn05_26_2022_MeasurementInputOptionVolatilityMemberusgaapMeasurementInputTypeAxis_PrivatePlacementWarrantsMemberusgaapFinancialInstrumentAxis"
      decimals="3"
      unitRef="Unit_pure">0.134</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingTerm contextRef="PAsOn12_31_2022_MeasurementInputExpectedTermMemberusgaapMeasurementInputTypeAxis_PrivatePlacementWarrantsMemberusgaapFinancialInstrumentAxis">P4Y4M24D</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:WarrantsAndRightsOutstandingTerm contextRef="PAsOn05_26_2022_MeasurementInputExpectedTermMemberusgaapMeasurementInputTypeAxis_PrivatePlacementWarrantsMemberusgaapFinancialInstrumentAxis">P5Y</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="PAsOn12_31_2022_EarnoutLiabilityMemberusgaapFinancialInstrumentAxis_MeasurementInputSharePriceMemberusgaapMeasurementInputTypeAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">3.73</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="PAsOn05_26_2022_EarnoutLiabilityMemberusgaapFinancialInstrumentAxis_MeasurementInputSharePriceMemberusgaapMeasurementInputTypeAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">9.02</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="PAsOn12_31_2022_EarnoutLiabilityMemberusgaapFinancialInstrumentAxis_MeasurementInputRiskFreeInterestRateMemberusgaapMeasurementInputTypeAxis"
      decimals="3"
      unitRef="Unit_pure">0.041</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="PAsOn05_26_2022_EarnoutLiabilityMemberusgaapFinancialInstrumentAxis_MeasurementInputRiskFreeInterestRateMemberusgaapMeasurementInputTypeAxis"
      decimals="3"
      unitRef="Unit_pure">0.027</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="PAsOn12_31_2022_EarnoutLiabilityMemberusgaapFinancialInstrumentAxis_MeasurementInputOptionVolatilityMemberusgaapMeasurementInputTypeAxis"
      decimals="3"
      unitRef="Unit_pure">0.70</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="PAsOn05_26_2022_EarnoutLiabilityMemberusgaapFinancialInstrumentAxis_MeasurementInputOptionVolatilityMemberusgaapMeasurementInputTypeAxis"
      decimals="3"
      unitRef="Unit_pure">0.60</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingTerm contextRef="PAsOn12_31_2022_EarnoutLiabilityMemberusgaapFinancialInstrumentAxis_MeasurementInputExpectedTermMemberusgaapMeasurementInputTypeAxis">P4Y4M24D</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:WarrantsAndRightsOutstandingTerm contextRef="PAsOn05_26_2022_EarnoutLiabilityMemberusgaapFinancialInstrumentAxis_MeasurementInputExpectedTermMemberusgaapMeasurementInputTypeAxis">P5Y</us-gaap:WarrantsAndRightsOutstandingTerm>
    <btmd:ScheduleOfChangesInTheFairValueOfWarrantLiabilitiesTableTextBlock contextRef="P01_01_2022To12_31_2022">&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;The following table presents the changes in fair value of the Company&#x2019;s Level&#160;3 financial instruments that are measured at fair value as of December&#160;31, 2022 and the Closing Date, the date of initial measurement: &lt;/div&gt;&lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:84%;border:0;margin:0 auto"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width:65%"/&gt;
&lt;td style="vertical-align:bottom;width:5%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:5%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:5%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Private&lt;br/&gt; Placement&lt;/div&gt;&lt;/div&gt;&lt;br/&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Warrants&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Earnout&lt;br/&gt; Liability&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Total&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Fair value as of May&#160;26, 2022 (initial measurement)&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3,834&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;93,880&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;97,714&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Gain from change in fair value&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(2,111&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(61,770&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(63,881&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Fair value as of December&#160;31, 2022&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,723&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;32,110&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;33,833&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</btmd:ScheduleOfChangesInTheFairValueOfWarrantLiabilitiesTableTextBlock>
    <us-gaap:FinancialLiabilitiesFairValueDisclosure
      contextRef="PAsOn05_26_2022_PrivatePlacementWarrantsMemberusgaapFinancialInstrumentAxis"
      decimals="-3"
      unitRef="Unit_USD">3834000</us-gaap:FinancialLiabilitiesFairValueDisclosure>
    <us-gaap:FinancialLiabilitiesFairValueDisclosure
      contextRef="PAsOn05_26_2022_EarnoutLiabilityMemberusgaapFinancialInstrumentAxis"
      decimals="-3"
      unitRef="Unit_USD">93880000</us-gaap:FinancialLiabilitiesFairValueDisclosure>
    <us-gaap:FinancialLiabilitiesFairValueDisclosure
      contextRef="PAsOn05_26_2022"
      decimals="-3"
      unitRef="Unit_USD">97714000</us-gaap:FinancialLiabilitiesFairValueDisclosure>
    <us-gaap:FairValueOptionChangesInFairValueGainLoss1
      contextRef="P05_27_2022To12_31_2022_PrivatePlacementWarrantsMemberusgaapFinancialInstrumentAxis"
      decimals="-3"
      unitRef="Unit_USD">2111000</us-gaap:FairValueOptionChangesInFairValueGainLoss1>
    <us-gaap:FairValueOptionChangesInFairValueGainLoss1
      contextRef="P05_27_2022To12_31_2022_EarnoutLiabilityMemberusgaapFinancialInstrumentAxis"
      decimals="-3"
      unitRef="Unit_USD">61770000</us-gaap:FairValueOptionChangesInFairValueGainLoss1>
    <us-gaap:FairValueOptionChangesInFairValueGainLoss1
      contextRef="P05_27_2022To12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">63881000</us-gaap:FairValueOptionChangesInFairValueGainLoss1>
    <us-gaap:FinancialLiabilitiesFairValueDisclosure
      contextRef="PAsOn12_31_2022_PrivatePlacementWarrantsMemberusgaapFinancialInstrumentAxis"
      decimals="-3"
      unitRef="Unit_USD">1723000</us-gaap:FinancialLiabilitiesFairValueDisclosure>
    <us-gaap:FinancialLiabilitiesFairValueDisclosure
      contextRef="PAsOn12_31_2022_EarnoutLiabilityMemberusgaapFinancialInstrumentAxis"
      decimals="-3"
      unitRef="Unit_USD">32110000</us-gaap:FinancialLiabilitiesFairValueDisclosure>
    <us-gaap:FinancialLiabilitiesFairValueDisclosure
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">33833000</us-gaap:FinancialLiabilitiesFairValueDisclosure>
    <us-gaap:MinorityInterestDisclosureTextBlock contextRef="P01_01_2022To12_31_2022">
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%"&gt;
&lt;tr style="page-break-inside:avoid"&gt;
&lt;td style="width:4%;vertical-align:top;text-align:left;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;13.&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:top;text-align:left;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; text-align: left; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;NONCONTROLLING INTEREST &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;In connection with the Closing of the Business Combination on the Closing Date, certain Members of Holdings (the &#x201c;Minority Interest Holders&#x201d;) retained an approximately 86.5% membership interest in Holdings and Biote received an approximately 13.5% ownership interest in Holdings. As a result of share issuances subsequent to the Closing of the Business Combination, Biote&#x2019;s ownership of Holdings, was approximately 16.6% as of December&#160;31, 2022. The Minority Interest Holders may from time to time, after the Closing Date, exchange with Biote, such holders&#x2019; units in Holdings for an equal number of shares of Biote&#x2019;s Class&#160;A common stock. As a result, Biote&#x2019;s ownership interest in Holdings will continue to increase. The Minority Interest Holders&#x2019; ownership interests are accounted for as noncontrolling interests in the Company&#x2019;s consolidated financial statements. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;Because the Business Combination was accounted for similar to a reverse recapitalization, the noncontrolling interest was initially recorded based on the Minority Interest Holders&#x2019; ownership interest in the &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;pre-combination&lt;/div&gt; carrying value of Holdings&#x2019; equity, including net income (loss) for the periods prior to the Closing Date included in accumulated deficit as of the Closing Date. Subsequent to the Business Combination, the Minority Interest Holders&#x2019; interest in the net income (loss) of Holdings after the Closing Date is allocated to noncontrolling interest. &lt;/div&gt;&lt;div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"&gt;&#160;&lt;/div&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"&gt; &lt;/div&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;In connection with the Business Combination, Biote issued the Minority Interest Holders an aggregate of 48,565,824 shares of Class&#160;V voting stock. The Class&#160;V voting stock provides no economic rights in Biote to the holder thereof; however, each holder of Class V voting stock is entitled to vote with the holders of Class A common stock of Biote, with each share of Class V voting stock entitling the holder to one vote per share of Class V voting stock at the time of such vote (subject to customary conversion rate adjustments for stock splits, stock dividends and reclassifications). &lt;/div&gt;&lt;div style="font-size:18pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;</us-gaap:MinorityInterestDisclosureTextBlock>
    <us-gaap:MinorityInterestOwnershipPercentageByNoncontrollingOwners
      contextRef="PAsOn05_26_2022_MinorityInterestHoldersMembersrtOwnershipAxis"
      decimals="3"
      unitRef="Unit_pure">0.865</us-gaap:MinorityInterestOwnershipPercentageByNoncontrollingOwners>
    <us-gaap:MinorityInterestOwnershipPercentageByParent
      contextRef="PAsOn05_26_2022_BioteCorporationMembersrtOwnershipAxis"
      decimals="3"
      unitRef="Unit_pure">0.135</us-gaap:MinorityInterestOwnershipPercentageByParent>
    <us-gaap:MinorityInterestOwnershipPercentageByParent
      contextRef="PAsOn12_31_2022_BioteCorporationMembersrtOwnershipAxis"
      decimals="3"
      unitRef="Unit_pure">0.166</us-gaap:MinorityInterestOwnershipPercentageByParent>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="P01_01_2022To12_31_2022_CommonClassVMemberusgaapStatementClassOfStockAxis"
      decimals="INF"
      unitRef="Unit_shares">48565824</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:CommonStockVotingRights contextRef="P01_01_2022To12_31_2022_CommonClassVMemberusgaapStatementClassOfStockAxis">each holder of Class V voting stock is entitled to vote with the holders of Class A common stock of Biote, with each share of Class V voting stock entitling the holder to one vote per share of Class V voting stock at the time of such vote (subject to customary conversion rate adjustments for stock splits, stock dividends and reclassifications).</us-gaap:CommonStockVotingRights>
    <btmd:CommonStockNumberOfVotesEntitledPerShare
      contextRef="P01_01_2022To12_31_2022_CommonClassVMemberusgaapStatementClassOfStockAxis"
      decimals="0"
      unitRef="Unit_VOTE">1</btmd:CommonStockNumberOfVotesEntitledPerShare>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock contextRef="P01_01_2022To12_31_2022">
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%"&gt;
&lt;tr style="page-break-inside:avoid"&gt;
&lt;td style="width:4%;vertical-align:top;text-align:left;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;14.&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:top;text-align:left;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; text-align: left; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;SHARE-BASED COMPENSATION &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;At the Closing of the Business Combination, Holdings&#x2019; share-based compensation awards (as such terms are defined below) were converted into equity in Biote. Share information below has been converted from historical disclosure based on the equivalent shares received in the Business Combination. &lt;/div&gt;&lt;div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Incentive Units &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;Holdings previously issued incentive units, which entitled the holder to participate in the net transaction proceeds from a change in control or qualifying liquidity event. Incentive units equivalent to 987,275 shares of Class&#160;V voting stock were vested as of December&#160;31, 2021, and the Closing of the Business Combination triggered the vesting of the remaining incentive units equivalent to 6,356,178 shares of Class&#160;V voting stock. No compensation cost was recognized historically until the Closing of the Business Combination, and $50,026 of share-based compensation expense was recognized at Closing related to the incentive units. As of December&#160;31, 2022, there are no incentive units outstanding. &lt;/div&gt;&lt;div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Restricted Stock Units (Including Phantom Equity Rights) &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;Holdings also previously authorized the grant of phantom equity rights, which entitled the holder to participate in the net transaction proceeds from a change in control or qualifying liquidity event. For current employees as of the Closing Date, these awards vest quarterly over a period of &lt;span style="-sec-ix-hidden:hidden73946171"&gt;one&lt;/span&gt; or two years after a change in control or qualifying liquidity event, and each holder is entitled to receive a stated percentage of the net transaction proceeds in excess of certain thresholds in accordance with the terms of their respective award agreement. Awards related to former employees vest at the time of a change in control or qualifying liquidity event, and each holder is entitled to receive a stated percentage of the net transaction proceeds in excess of certain thresholds or a maximum amount in accordance with the terms of their respective award agreement. The Closing of the Business Combination met the performance condition in the phantom equity rights. No compensation cost was recognized historically until the Closing of the Business Combination. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;The phantom equity rights are equity-classified awards. The grant date fair value of the phantom equity rights was determined using a Monte-Carlo simulation. The significant assumptions used in valuation include the constant risk-free rate, constant volatility factor and the Geometric Brownian Motion. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;At the Closing of the Business Combination, Holdings&#x2019; phantom equity rights related to former employees vested, and we recognized share-based compensation expense of $4,339 related to these awards with an offsetting increase to equity based on the awards&#x2019; grant-date fair value. At Closing, the Company exercised its option to settle the awards for cash in the amount of $7,250. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;At the Closing of the Business Combination, Holdings&#x2019; phantom equity rights related to current employees were replaced with 3,887,750 restricted stock units (&#x201c;RSUs&#x201d;) of Biote. The RSUs will continue to vest according to their original terms, quarterly over a period of &lt;span style="-sec-ix-hidden:hidden73946172"&gt;one&lt;/span&gt; or two years after the Closing of the Business Combination. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;Since the Closing of the Business Combination, the Company continues to grant RSUs to certain employees under the &lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;2022 Equity Incentive Plan&lt;/div&gt;&lt;/div&gt; adopted on May&#160;26, 2022. New RSUs issued are valued at the Company&#x2019;s &lt;/div&gt;&lt;div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"&gt;&#160;&lt;/div&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"&gt; &lt;/div&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;stock price on the date of grant. The following table summarizes RSU activity during the year ended December&#160;31, 2022: &lt;/div&gt;&lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width:68%"/&gt;
&lt;td style="vertical-align:bottom;width:7%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:7%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Shares&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Weighted-&lt;br/&gt; Average&lt;/div&gt;&lt;/div&gt;&lt;br/&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Grant-Date&lt;/div&gt;&lt;br/&gt; Fair Value&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;RSUs outstanding at December&#160;31, 2021&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3,887,750&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;8.85&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Granted&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;85,040&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;4.00&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Forfeited&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(296,250&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;8.71&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Vested&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(2,053,700&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;8.24&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;RSUs outstanding at December&#160;31, 2022&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,622,840&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;9.41&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;The Company recognized share-based compensation expense of $26,647 during the year ended December&#160;31, 2022, related to RSUs, which included a cumulative &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;catch-up&lt;/div&gt; of unrecognized share-based compensation expense for service provided from the grant date to the Closing of the Business Combination. As of December&#160;31, 2022, there was $3,688 of unrecognized share-based compensation expense related to unvested RSUs. This expense is expected to be recognized over a weighted-average remaining vesting period of 1.0 year. &lt;/div&gt;&lt;div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Stock Options &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;Subsequent to the Closing of the Business Combination, the Company began to grant stock options to certain employees, directors, and consultants under the &lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;2022 Equity Incentive Plan&lt;/div&gt;&lt;/div&gt; adopted on May&#160;26, 2022. The following table summarizes stock option activity during the year ended December&#160;31, 2022: &lt;/div&gt;&lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:84%;border:0;margin:0 auto"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width:57%"/&gt;
&lt;td style="vertical-align:bottom;width:8%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:8%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:8%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Shares&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Weighted-&lt;br/&gt; Average&lt;/div&gt;&lt;/div&gt;&lt;br/&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Exercise&#160;Price&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Weighted-&lt;br/&gt; Average&lt;/div&gt;&lt;/div&gt;&lt;br/&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Remaining&lt;/div&gt;&lt;/div&gt;&lt;br/&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Contractual&lt;br/&gt; Term&lt;/div&gt;&lt;/div&gt;&lt;br/&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(Years)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Options outstanding at December&#160;31, 2021&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Granted&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;5,165,328&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3.86&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Forfeited&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(122,700&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3.73&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Options outstanding at December&#160;31, 2022&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;5,042,628&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3.86&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;9.5&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Options exercisable December&#160;31, 2022&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;131,461&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3.99&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2.1&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;The Company recognized share-based compensation expense of $1,168 during the year ended December&#160;31, 2022 related to stock options. As of December&#160;31, 2022, there was $10,156 of unrecognized share-based compensation expense related to unvested stock options. This expense is expected to be recognized over a weighted-average remaining vesting period of 3.4 years. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;The weighted-average assumptions used to estimate the fair value of stock options granted during the year ended December&#160;31, 2022 were as follows: &lt;/div&gt;&lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:68%;border:0;margin:0 auto"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width:90%"/&gt;
&lt;td style="vertical-align:bottom;width:6%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Expected term (in years)&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;6.0&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Volatility&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;60.0&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Risk-free rate&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3.5&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Dividend yield&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;0.0&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <btmd:ShareBasedCompensationArrangementVestingOfIncentiveUnits
      contextRef="P01_01_2021To12_31_2021_CommonClassVMemberusgaapStatementClassOfStockAxis"
      decimals="0"
      unitRef="Unit_shares">987275</btmd:ShareBasedCompensationArrangementVestingOfIncentiveUnits>
    <btmd:ShareBasedCompensationArrangementVestingOfIncentiveUnits
      contextRef="P05_26_2022To05_26_2022_CommonClassVMemberusgaapStatementClassOfStockAxis"
      decimals="0"
      unitRef="Unit_shares">6356178</btmd:ShareBasedCompensationArrangementVestingOfIncentiveUnits>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="P03_26_2022To05_26_2022_IncentiveUnitsMemberusgaapAwardTypeAxis"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="P05_26_2022To05_26_2022_IncentiveUnitsMemberusgaapAwardTypeAxis"
      decimals="-3"
      unitRef="Unit_USD">50026000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="P01_01_2022To12_31_2022_MaximumMembersrtRangeAxis_PhantomEquityRightsMemberusgaapAwardTypeAxis">P2Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="P03_26_2022To05_26_2022_PhantomEquityRightsMemberusgaapAwardTypeAxis"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="P05_26_2022To05_26_2022_PhantomEquityRightsMemberusgaapAwardTypeAxis"
      decimals="-3"
      unitRef="Unit_USD">4339000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:SettlementLiabilitiesCurrent
      contextRef="PAsOn05_26_2022_PhantomEquityRightsMemberusgaapAwardTypeAxis"
      decimals="-3"
      unitRef="Unit_USD">7250000</us-gaap:SettlementLiabilitiesCurrent>
    <us-gaap:ConversionOfStockSharesConverted1
      contextRef="P05_26_2022To05_26_2022_PhantomEquityRightsMemberusgaapAwardTypeAxis"
      decimals="0"
      unitRef="Unit_shares">3887750</us-gaap:ConversionOfStockSharesConverted1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="P05_31_2022To06_30_2022_MaximumMembersrtRangeAxis_PhantomEquityRightsMemberusgaapAwardTypeAxis">P2Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock contextRef="P01_01_2022To12_31_2022">The following table summarizes RSU activity during the year ended December&#160;31, 2022: &lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width:68%"/&gt;
&lt;td style="vertical-align:bottom;width:7%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:7%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Shares&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Weighted-&lt;br/&gt; Average&lt;/div&gt;&lt;/div&gt;&lt;br/&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Grant-Date&lt;/div&gt;&lt;br/&gt; Fair Value&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;RSUs outstanding at December&#160;31, 2021&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3,887,750&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;8.85&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Granted&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;85,040&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;4.00&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Forfeited&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(296,250&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;8.71&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Vested&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(2,053,700&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;8.24&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;RSUs outstanding at December&#160;31, 2022&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,622,840&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;9.41&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="PAsOn12_31_2021_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis_TwoThousandTwentyTwoEquityIncentivePlanMemberusgaapPlanNameAxis"
      decimals="INF"
      unitRef="Unit_shares">3887750</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="PAsOn12_31_2021_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis_TwoThousandTwentyTwoEquityIncentivePlanMemberusgaapPlanNameAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">8.85</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="P01_01_2022To12_31_2022_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis_TwoThousandTwentyTwoEquityIncentivePlanMemberusgaapPlanNameAxis"
      decimals="INF"
      unitRef="Unit_shares">85040</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="P01_01_2022To12_31_2022_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis_TwoThousandTwentyTwoEquityIncentivePlanMemberusgaapPlanNameAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">4</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="P01_01_2022To12_31_2022_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis_TwoThousandTwentyTwoEquityIncentivePlanMemberusgaapPlanNameAxis"
      decimals="INF"
      unitRef="Unit_shares">296250</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="P01_01_2022To12_31_2022_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis_TwoThousandTwentyTwoEquityIncentivePlanMemberusgaapPlanNameAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">8.71</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="P01_01_2022To12_31_2022_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis_TwoThousandTwentyTwoEquityIncentivePlanMemberusgaapPlanNameAxis"
      decimals="INF"
      unitRef="Unit_shares">2053700</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="P01_01_2022To12_31_2022_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis_TwoThousandTwentyTwoEquityIncentivePlanMemberusgaapPlanNameAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">8.24</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="PAsOn12_31_2022_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis_TwoThousandTwentyTwoEquityIncentivePlanMemberusgaapPlanNameAxis"
      decimals="INF"
      unitRef="Unit_shares">1622840</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="PAsOn12_31_2022_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis_TwoThousandTwentyTwoEquityIncentivePlanMemberusgaapPlanNameAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">9.41</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="P01_01_2022To12_31_2022_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis_TwoThousandTwentyTwoEquityIncentivePlanMemberusgaapPlanNameAxis"
      decimals="-3"
      unitRef="Unit_USD">26647000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="PAsOn12_31_2022_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis_TwoThousandTwentyTwoEquityIncentivePlanMemberusgaapPlanNameAxis"
      decimals="-3"
      unitRef="Unit_USD">3688000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 contextRef="P01_01_2022To12_31_2022_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis_TwoThousandTwentyTwoEquityIncentivePlanMemberusgaapPlanNameAxis">P1Y</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock contextRef="P01_01_2022To12_31_2022">The following table summarizes stock option activity during the year ended December&#160;31, 2022: &lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:84%;border:0;margin:0 auto"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width:57%"/&gt;
&lt;td style="vertical-align:bottom;width:8%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:8%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:8%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Shares&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Weighted-&lt;br/&gt; Average&lt;/div&gt;&lt;/div&gt;&lt;br/&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Exercise&#160;Price&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Weighted-&lt;br/&gt; Average&lt;/div&gt;&lt;/div&gt;&lt;br/&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Remaining&lt;/div&gt;&lt;/div&gt;&lt;br/&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Contractual&lt;br/&gt; Term&lt;/div&gt;&lt;/div&gt;&lt;br/&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(Years)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Options outstanding at December&#160;31, 2021&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Granted&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;5,165,328&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3.86&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Forfeited&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(122,700&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3.73&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Options outstanding at December&#160;31, 2022&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;5,042,628&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3.86&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;9.5&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Options exercisable December&#160;31, 2022&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;131,461&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3.99&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2.1&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="P01_01_2022To12_31_2022_TwoThousandTwentyTwoEquityIncentivePlanMemberusgaapPlanNameAxis"
      decimals="INF"
      unitRef="Unit_shares">5165328</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="P01_01_2022To12_31_2022_TwoThousandTwentyTwoEquityIncentivePlanMemberusgaapPlanNameAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">3.86</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
      contextRef="P01_01_2022To12_31_2022_TwoThousandTwentyTwoEquityIncentivePlanMemberusgaapPlanNameAxis"
      decimals="INF"
      unitRef="Unit_shares">122700</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="P01_01_2022To12_31_2022_TwoThousandTwentyTwoEquityIncentivePlanMemberusgaapPlanNameAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">3.73</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="PAsOn12_31_2022_TwoThousandTwentyTwoEquityIncentivePlanMemberusgaapPlanNameAxis"
      decimals="INF"
      unitRef="Unit_shares">5042628</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="PAsOn12_31_2022_TwoThousandTwentyTwoEquityIncentivePlanMemberusgaapPlanNameAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">3.86</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="P01_01_2022To12_31_2022_TwoThousandTwentyTwoEquityIncentivePlanMemberusgaapPlanNameAxis">P9Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="PAsOn12_31_2022_TwoThousandTwentyTwoEquityIncentivePlanMemberusgaapPlanNameAxis"
      decimals="INF"
      unitRef="Unit_shares">131461</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="PAsOn12_31_2022_TwoThousandTwentyTwoEquityIncentivePlanMemberusgaapPlanNameAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">3.99</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1 contextRef="P01_01_2022To12_31_2022_TwoThousandTwentyTwoEquityIncentivePlanMemberusgaapPlanNameAxis">P2Y1M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="P01_01_2022To12_31_2022_EmployeeStockOptionMemberusgaapAwardTypeAxis_TwoThousandTwentyTwoEquityIncentivePlanMemberusgaapPlanNameAxis"
      decimals="-3"
      unitRef="Unit_USD">1168000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="PAsOn12_31_2022_EmployeeStockOptionMemberusgaapAwardTypeAxis_TwoThousandTwentyTwoEquityIncentivePlanMemberusgaapPlanNameAxis"
      decimals="-3"
      unitRef="Unit_USD">10156000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 contextRef="P01_01_2022To12_31_2022_EmployeeStockOptionMemberusgaapAwardTypeAxis_TwoThousandTwentyTwoEquityIncentivePlanMemberusgaapPlanNameAxis">P3Y4M24D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock contextRef="P01_01_2022To12_31_2022">&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;The weighted-average assumptions used to estimate the fair value of stock options granted during the year ended December&#160;31, 2022 were as follows: &lt;/div&gt;&lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:68%;border:0;margin:0 auto"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width:90%"/&gt;
&lt;td style="vertical-align:bottom;width:6%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Expected term (in years)&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;6.0&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Volatility&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;60.0&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Risk-free rate&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3.5&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Dividend yield&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;0.0&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="P01_01_2022To12_31_2022_TwoThousandTwentyTwoEquityIncentivePlanMemberusgaapPlanNameAxis">P6Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate
      contextRef="P01_01_2022To12_31_2022_TwoThousandTwentyTwoEquityIncentivePlanMemberusgaapPlanNameAxis"
      decimals="3"
      unitRef="Unit_pure">0.60</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="P01_01_2022To12_31_2022_TwoThousandTwentyTwoEquityIncentivePlanMemberusgaapPlanNameAxis"
      decimals="3"
      unitRef="Unit_pure">0.035</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="P01_01_2022To12_31_2022_TwoThousandTwentyTwoEquityIncentivePlanMemberusgaapPlanNameAxis"
      decimals="3"
      unitRef="Unit_pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:LesseeOperatingLeasesTextBlock contextRef="P01_01_2022To12_31_2022">
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%"&gt;
&lt;tr style="page-break-inside:avoid"&gt;
&lt;td style="width:4%;vertical-align:top;text-align:left;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;15.&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:top;text-align:left;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; text-align: left; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;LEASES &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;On July&#160;1, 2014, BioTE Medical entered into a contract to lease office space in the Las Colinas Business Center in Irving, TX. Subsequent to execution of the contract, the Company revised the lease to include additional space &lt;/div&gt;&lt;div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"&gt;&#160;&lt;/div&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"&gt; &lt;/div&gt;&lt;div/&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;and extend the lease term through &lt;span style="-sec-ix-hidden:hidden73946198"&gt;June&#160;30, 2023&lt;/span&gt;. On November 1, 2022, the Company executed an extension of lease office space to extend through November 30, 2028. This extension included an additional 3,700 square feet of space that would be available for use in December of 2023, which would be included in monthly rent payments at this date accordingly. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;The Company recognizes operating lease costs on a straight-line basis over the lease term within Selling, general and administrative expense in the consolidated statement of income and comprehensive income. The following table contains a summary of the operating lease costs recognized under ASC 842 and supplemental cash flow information for leases for the years ended December&#160;31, 2022 and 2021: &lt;/div&gt;&lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width:80%"/&gt;
&lt;td style="vertical-align:bottom;width:5%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:5%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Year Ended&lt;/div&gt;&lt;/div&gt;&lt;br/&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Fixed lease expense&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;278&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;244&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Total lease cost&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;278&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;244&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Other information:&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Cash paid for amounts included in the measurement of lease liabilities&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;257&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;257&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Right-of-use&lt;/div&gt;&lt;/div&gt; assets obtained in exchange for new operating lease liabilities&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,936&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;The following table summarizes the balance sheet classification of the Company&#x2019;s operating leases, amounts of ROU assets and lease liabilities, the weighted average remaining lease term, and the weighted average discount rate for the Company&#x2019;s operating leases: &lt;/div&gt;&lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width:66%"/&gt;
&lt;td style="vertical-align:bottom;width:14%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:13%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;br/&gt; 2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;br/&gt; 2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Lease assets&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Operating lease &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;right-of-use&lt;/div&gt;&lt;/div&gt; assets&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2,052&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;356&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Total lease assets&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2,052&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;356&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Lease liabilities&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Current:&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Operating lease liabilities&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;165&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;248&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Non-current:&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Operating lease liabilities&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,927&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;127&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Total lease liabilities&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2,092&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;375&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Weighted-average remaining lease term&#x2014;operating leases (years)&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;5.92&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1.50&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Weighted-average discount rate&#x2014;operating leases&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;8.48&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3.75&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"&gt;&#160;&lt;/div&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"&gt; &lt;/div&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;The following table summarizes the payments by date for the Company&#x2019;s operating lease, which is then reconciled to our total lease obligation, as of December&#160;31, 2022: &lt;/div&gt;&lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:68%;border:0;margin:0 auto"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width:87%"/&gt;
&lt;td style="vertical-align:bottom;width:6%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;2023&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;337&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;2024&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;448&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;2025&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;464&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;2026&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;480&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;2027&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;497&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Thereafter&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;470&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Total lease payments&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2,696&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Less: Interest&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(604&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Present value of lease liabilities&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2,092&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:LesseeOperatingLeasesTextBlock>
    <us-gaap:LesseeOperatingLeaseOptionToExtend contextRef="P01_01_2022To12_31_2022">On November 1, 2022, the Company executed an extension of lease office space to extend through November 30, 2028.</us-gaap:LesseeOperatingLeaseOptionToExtend>
    <btmd:AreaOfOfficeSpace
      contextRef="PAsOn11_01_2022"
      decimals="INF"
      unitRef="Unit_sqft">3700</btmd:AreaOfOfficeSpace>
    <btmd:SummaryOfLeaseCostsRecognizedUnderAsc842AndSupplementalCashFlowInformationForLeasesTableTextBlock contextRef="P01_01_2022To12_31_2022">The following table contains a summary of the operating lease costs recognized under ASC 842 and supplemental cash flow information for leases for the years ended December&#160;31, 2022 and 2021: &lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width:80%"/&gt;
&lt;td style="vertical-align:bottom;width:5%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:5%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Year Ended&lt;/div&gt;&lt;/div&gt;&lt;br/&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Fixed lease expense&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;278&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;244&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Total lease cost&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;278&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;244&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Other information:&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Cash paid for amounts included in the measurement of lease liabilities&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;257&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;257&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Right-of-use&lt;/div&gt;&lt;/div&gt; assets obtained in exchange for new operating lease liabilities&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,936&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</btmd:SummaryOfLeaseCostsRecognizedUnderAsc842AndSupplementalCashFlowInformationForLeasesTableTextBlock>
    <us-gaap:OperatingLeaseCost
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">278000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">244000</us-gaap:OperatingLeaseCost>
    <us-gaap:LeaseCost
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">278000</us-gaap:LeaseCost>
    <us-gaap:LeaseCost
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">244000</us-gaap:LeaseCost>
    <us-gaap:OperatingLeasePayments
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">257000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeasePayments
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">257000</us-gaap:OperatingLeasePayments>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">1936000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <btmd:SummaryBalanceSheetClassificationOfOperatingLeasesAndWeightedAverageRemainingLeaseTermAndDiscountRateTableTextBlock contextRef="P01_01_2022To12_31_2022">&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;The following table summarizes the balance sheet classification of the Company&#x2019;s operating leases, amounts of ROU assets and lease liabilities, the weighted average remaining lease term, and the weighted average discount rate for the Company&#x2019;s operating leases: &lt;/div&gt;&lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width:66%"/&gt;
&lt;td style="vertical-align:bottom;width:14%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:13%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;br/&gt; 2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;br/&gt; 2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Lease assets&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Operating lease &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;right-of-use&lt;/div&gt;&lt;/div&gt; assets&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2,052&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;356&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Total lease assets&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2,052&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;356&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Lease liabilities&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Current:&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Operating lease liabilities&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;165&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;248&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Non-current:&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Operating lease liabilities&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,927&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;127&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Total lease liabilities&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2,092&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;375&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Weighted-average remaining lease term&#x2014;operating leases (years)&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;5.92&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1.50&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Weighted-average discount rate&#x2014;operating leases&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;8.48&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3.75&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</btmd:SummaryBalanceSheetClassificationOfOperatingLeasesAndWeightedAverageRemainingLeaseTermAndDiscountRateTableTextBlock>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">2052000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">356000</us-gaap:OperatingLeaseRightOfUseAsset>
    <btmd:LeaseAssets
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">2052000</btmd:LeaseAssets>
    <btmd:LeaseAssets
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">356000</btmd:LeaseAssets>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">165000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">248000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">1927000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">127000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiability
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">2092000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseLiability
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">375000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1 contextRef="PAsOn12_31_2022">P5Y11M1D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1 contextRef="PAsOn12_31_2021">P1Y6M</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="PAsOn12_31_2022"
      decimals="4"
      unitRef="Unit_pure">0.0848</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="PAsOn12_31_2021"
      decimals="4"
      unitRef="Unit_pure">0.0375</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock contextRef="P01_01_2022To12_31_2022">&lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;The following table summarizes the payments by date for the Company&#x2019;s operating lease, which is then reconciled to our total lease obligation, as of December&#160;31, 2022: &lt;/div&gt;&lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:68%;border:0;margin:0 auto"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width:87%"/&gt;
&lt;td style="vertical-align:bottom;width:6%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;2023&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;337&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;2024&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;448&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;2025&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;464&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;2026&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;480&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;2027&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;497&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Thereafter&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;470&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Total lease payments&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2,696&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Less: Interest&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(604&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Present value of lease liabilities&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2,092&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">337000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">448000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">464000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">480000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">497000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">470000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">2696000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">604000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">2092000</us-gaap:OperatingLeaseLiability>
    <us-gaap:IncomeTaxDisclosureTextBlock contextRef="P01_01_2022To12_31_2022">
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%"&gt;
&lt;tr style="page-break-inside:avoid"&gt;
&lt;td style="width:4%;vertical-align:top;text-align:left;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;16.&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:top;text-align:left;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; text-align: left; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;INCOME TAXES &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;Income (loss) before provision for income taxes consisted of the following (in thousands): &lt;/div&gt;&lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width:76%"/&gt;
&lt;td style="vertical-align:bottom;width:5%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:5%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Year Ended&lt;/div&gt;&lt;/div&gt;&lt;br/&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Domestic&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2,221&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;33,191&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Foreign&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(509&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(286&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Income before provision for income taxes&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,712&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;32,905&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;The income tax provision for the year ended December&#160;31, 2022 and 2021 consists of the following: &lt;/div&gt;&lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width:80%"/&gt;
&lt;td style="vertical-align:bottom;width:6%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:6%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Year Ended&lt;/div&gt;&lt;/div&gt;&lt;br/&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Current income tax provision (benefit):&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Federal&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;749&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;State and Local&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;377&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;286&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Foreign&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;5&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Total current expense (benefit):&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,131&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;286&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Deferred income tax provision (benefit):&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Federal&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(714&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;State and Local&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(29&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Foreign&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Total deferred expense (benefit):&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(743&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Total income tax provision (benefit)&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;388&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;286&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"&gt;&#160;&lt;/div&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"&gt; &lt;/div&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;A reconciliation of the federal income tax rate to the Company&#x2019;s effective tax rate for the year ended December&#160;31, 2022 and 2021 is as follows: &lt;/div&gt;&lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width:79%"/&gt;
&lt;td style="vertical-align:bottom;width:5%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:4%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Year Ended&lt;/div&gt;&lt;/div&gt;&lt;br/&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Statutory federal income tax rate&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;21.00&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;21.00&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;State taxes, net of federal benefit&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;18.20&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;0.87&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Nontaxable partnership income&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;-41.39&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;-21.00&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Foreign rate differential&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;-2.71&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;0.00&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Change in valuation allowance&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;27.55&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;0.00&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;22.65&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;0.87&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;The Company&#x2019;s significant rate reconciliation items are driven primarily by state taxes, permanent differences associated with Holdings&#x2019; flowthrough income and the recognition of a valuation allowance. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;The Company&#x2019;s net deferred tax assets (liabilities) as of December&#160;31, 2022 and 2021 is as follows: &lt;/div&gt;&lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width:80%"/&gt;
&lt;td style="vertical-align:bottom;width:5%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:5%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Year Ended&lt;/div&gt;&lt;/div&gt;&lt;br/&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Deferred tax assets:&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Outside basis difference in partnership&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,173&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Net operating loss carryforwards&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;164&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Intangibles&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;978&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Total deferred tax assets&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2,315&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Valuation allowance&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(477&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Deferred tax assets, net of allowance&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,838&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;As of December&#160;31, 2022, the Company had a foreign net operating losses of $0.5&#160;million, which begin to expire in 2032. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;In assessing the realization of deferred tax assets, management considers whether it is more likely than not that some portion or all of the deferred tax assets will not be realized. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income during the periods in which temporary differences representing future deductible amounts become deductible. Management considers the scheduled reversal of deferred tax assets, projected future taxable income and tax planning strategies in making this assessment. After consideration of all the information available, management has recorded a valuation allowance against the foreign net operating losses and the portion of outside basis difference related to Holdings&#x2019; permanent book/tax differences. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;The calculation of our tax liabilities involves dealing with uncertainties in the application of complex tax laws and regulations for both federal taxes and the many states in which we operate or do business in. ASC 740 states that a tax benefit from an uncertain tax position may be recognized when it is more likely than not that the position will be sustained upon examination, including resolutions of any related appeals or litigation processes, on the basis of the technical merits. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;We record uncertain tax positions as liabilities in accordance with ASC 740 and adjust these liabilities when our judgment changes as a result of the evaluation of new information not previously available. Because of the complexity of some of these uncertainties, the ultimate resolution may result in a payment that is materially &lt;/div&gt;&lt;div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"&gt;&#160;&lt;/div&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"&gt; &lt;/div&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;different from our current estimate of the unrecognized tax benefit liabilities. These differences will be reflected as increases or decreases to income tax expense in the period in which new information is available. As of December&#160;31, 2022 and 2021 we have not recorded any uncertain tax positions in our financial statements. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;The Company files tax returns as prescribed by the tax laws of the jurisdictions in which it operates. In the normal course of business, the Company is subject to examination by federal and state jurisdictions, where applicable. There are currently no pending tax examinations. The Company&#x2019;s tax years are still open under statute from December 31, 2019, to the present. The resolution of tax matters is not expected to have a material effect on the Company&#x2019;s consolidated financial statements. &lt;/div&gt;&lt;div style="font-size:18pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock contextRef="P01_01_2022To12_31_2022">&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;Income (loss) before provision for income taxes consisted of the following (in thousands): &lt;/div&gt;&lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width:76%"/&gt;
&lt;td style="vertical-align:bottom;width:5%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:5%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Year Ended&lt;/div&gt;&lt;/div&gt;&lt;br/&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Domestic&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2,221&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;33,191&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Foreign&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(509&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(286&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Income before provision for income taxes&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,712&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;32,905&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">2221000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">33191000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">-509000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">-286000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">1712000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">32905000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock contextRef="P01_01_2022To12_31_2022">&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;The income tax provision for the year ended December&#160;31, 2022 and 2021 consists of the following: &lt;/div&gt;&lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width:80%"/&gt;
&lt;td style="vertical-align:bottom;width:6%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:6%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Year Ended&lt;/div&gt;&lt;/div&gt;&lt;br/&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Current income tax provision (benefit):&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Federal&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;749&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;State and Local&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;377&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;286&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Foreign&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;5&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Total current expense (benefit):&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,131&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;286&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Deferred income tax provision (benefit):&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Federal&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(714&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;State and Local&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(29&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Foreign&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Total deferred expense (benefit):&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(743&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Total income tax provision (benefit)&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;388&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;286&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock>
    <us-gaap:CurrentFederalTaxExpenseBenefit
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">749000</us-gaap:CurrentFederalTaxExpenseBenefit>
    <us-gaap:CurrentStateAndLocalTaxExpenseBenefit
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">377000</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
    <us-gaap:CurrentStateAndLocalTaxExpenseBenefit
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">286000</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
    <us-gaap:CurrentForeignTaxExpenseBenefit
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">5000</us-gaap:CurrentForeignTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">1131000</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">286000</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:DeferredFederalIncomeTaxExpenseBenefit
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">-714000</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">-29000</us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">-743000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">388000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">286000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock contextRef="P01_01_2022To12_31_2022">&lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;A reconciliation of the federal income tax rate to the Company&#x2019;s effective tax rate for the year ended December&#160;31, 2022 and 2021 is as follows: &lt;/div&gt;&lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width:79%"/&gt;
&lt;td style="vertical-align:bottom;width:5%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:4%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Year Ended&lt;/div&gt;&lt;/div&gt;&lt;br/&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Statutory federal income tax rate&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;21.00&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;21.00&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;State taxes, net of federal benefit&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;18.20&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;0.87&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Nontaxable partnership income&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;-41.39&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;-21.00&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Foreign rate differential&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;-2.71&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;0.00&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Change in valuation allowance&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;27.55&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;0.00&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;22.65&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;0.87&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="P01_01_2022To12_31_2022"
      decimals="4"
      unitRef="Unit_pure">0.21</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="P01_01_2021To12_31_2021"
      decimals="4"
      unitRef="Unit_pure">0.21</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="P01_01_2022To12_31_2022"
      decimals="4"
      unitRef="Unit_pure">0.182</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="P01_01_2021To12_31_2021"
      decimals="4"
      unitRef="Unit_pure">0.0087</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxExemptIncome
      contextRef="P01_01_2022To12_31_2022"
      decimals="4"
      unitRef="Unit_pure">-0.4139</us-gaap:EffectiveIncomeTaxRateReconciliationTaxExemptIncome>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxExemptIncome
      contextRef="P01_01_2021To12_31_2021"
      decimals="4"
      unitRef="Unit_pure">-0.21</us-gaap:EffectiveIncomeTaxRateReconciliationTaxExemptIncome>
    <us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential
      contextRef="P01_01_2022To12_31_2022"
      decimals="4"
      unitRef="Unit_pure">-0.0271</us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential>
    <us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential
      contextRef="P01_01_2021To12_31_2021"
      decimals="4"
      unitRef="Unit_pure">0</us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="P01_01_2022To12_31_2022"
      decimals="4"
      unitRef="Unit_pure">0.2755</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="P01_01_2021To12_31_2021"
      decimals="4"
      unitRef="Unit_pure">0</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="P01_01_2022To12_31_2022"
      decimals="4"
      unitRef="Unit_pure">0.2265</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="P01_01_2021To12_31_2021"
      decimals="4"
      unitRef="Unit_pure">0.0087</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock contextRef="P01_01_2022To12_31_2022">&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;The Company&#x2019;s net deferred tax assets (liabilities) as of December&#160;31, 2022 and 2021 is as follows: &lt;/div&gt;&lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width:80%"/&gt;
&lt;td style="vertical-align:bottom;width:5%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="vertical-align:bottom;width:5%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Year Ended&lt;/div&gt;&lt;/div&gt;&lt;br/&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Deferred tax assets:&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Outside basis difference in partnership&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,173&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Net operating loss carryforwards&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;164&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Intangibles&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;978&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Total deferred tax assets&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2,315&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Valuation allowance&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(477&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Deferred tax assets, net of allowance&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,838&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
    <us-gaap:DeferredTaxAssetsInvestments
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">1173000</us-gaap:DeferredTaxAssetsInvestments>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">164000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">978000</us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">2315000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">477000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">1838000</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:OperatingLossCarryforwards
      contextRef="PAsOn12_31_2022_ForeignCountryMemberusgaapIncomeTaxAuthorityAxis"
      decimals="-5"
      unitRef="Unit_USD">500000</us-gaap:OperatingLossCarryforwards>
    <btmd:OperatingLossCarryforwardsExpirationYear contextRef="P01_01_2022To12_31_2022_ForeignCountryMemberusgaapIncomeTaxAuthorityAxis">2032</btmd:OperatingLossCarryforwardsExpirationYear>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:IncomeTaxExaminationDescription contextRef="P01_01_2022To12_31_2022">There are currently no pending tax examinations. The Company&#x2019;s tax years are still open under statute from December 31, 2019, to the present.</us-gaap:IncomeTaxExaminationDescription>
    <us-gaap:EarningsPerShareTextBlock contextRef="P01_01_2022To12_31_2022">
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%"&gt;
&lt;tr style="page-break-inside:avoid"&gt;
&lt;td style="width:4%;vertical-align:top;text-align:left;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;17.&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:top;text-align:left;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; text-align: left; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;NET LOSS PER COMMON SHARE &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;The computation of basic and diluted net loss per common share is based on net loss attributable to Biote stockholders divided by the basic and diluted weighted average number of shares of Class&#160;A common stock outstanding, each for the period subsequent to the consummation of the Business Combination. The following table sets forth the computation of net loss per common share: &lt;/div&gt;&lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:68%;border:0;margin:0 auto"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width:80%"/&gt;
&lt;td style="vertical-align:bottom;width:14%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Year Ended&lt;/div&gt;&lt;/div&gt;&lt;br/&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;br/&gt; 2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Net loss per common share&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Numerator:&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Net loss attributable to biote Corp. stockholders (basic and diluted)&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(969&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Denominator:&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Weighted average shares outstanding (basic and diluted)&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;8,059,371&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Net loss per common share&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Basic&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(0.12&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Diluted&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(0.12&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;On the Closing Date, the Company completed the Business Combination which materially impacted the number of shares outstanding, and the Company was organized in an &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Up-C&lt;/div&gt; structure. Net loss per common share information for the year ended December&#160;31, 2022 has been presented on a prospective basis and reflects only the net loss attributable to holders of Biote&#x2019;s Class&#160;A common stock, as well as both basic and diluted weighted average Class&#160;A common stock outstanding, for the period from the Closing Date through December&#160;31, 2022. Net loss per common share information prior to the Closing Date is not presented since the ownership structure of Holdings is not a common unit of ownership of the Company, and the resulting values would not be meaningful to the users of the consolidated financial statements. Net loss per common share is not separately presented for Class&#160;V voting stock since it has no economic rights to the income or loss of the Company. Class&#160;V voting stock is considered in the calculation of dilutive net loss per common share on an &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;if-converted&lt;/div&gt; basis as these shares, together with the related Holdings Units, have Exchange Rights into Class&#160;A common stock that could result in additional Class&#160;A common stock being issued. All other potentially dilutive securities are determined based on the treasury stock method. See Note 1 for more information regarding the Business Combination. &lt;/div&gt;&lt;div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"&gt;&#160;&lt;/div&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"&gt; &lt;/div&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;The Company excluded the following potential shares, presented based on amounts outstanding at each period end, from the computation of diluted weighted average shares outstanding for the periods indicated because including them would have had an antidilutive effect: &lt;/div&gt;&lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:68%;border:0;margin:0 auto"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width:80%"/&gt;
&lt;td style="vertical-align:bottom;width:5%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Year Ended&lt;/div&gt;&lt;/div&gt;&lt;br/&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;br/&gt; 2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;RSUs&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,622,840&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Stock Options&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;5,042,628&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Class&#160;V Voting Stock&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;48,565,824&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Public Warrants&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;7,937,466&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Private Placement Warrants&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;5,566,666&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Earnout Voting Shares&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;10,000,000&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Sponsor Earnout Shares&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,587,500&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;80,322,924&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock contextRef="P01_01_2022To12_31_2022">The following table sets forth the computation of net loss per common share: &lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:68%;border:0;margin:0 auto"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width:80%"/&gt;
&lt;td style="vertical-align:bottom;width:14%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Year Ended&lt;/div&gt;&lt;/div&gt;&lt;br/&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;br/&gt; 2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Net loss per common share&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Numerator:&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Net loss attributable to biote Corp. stockholders (basic and diluted)&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(969&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Denominator:&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Weighted average shares outstanding (basic and diluted)&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;8,059,371&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Net loss per common share&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Basic&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(0.12&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Diluted&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(0.12&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">969000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">969000</us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="P01_01_2022To12_31_2022"
      decimals="INF"
      unitRef="Unit_shares">8059371</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="P01_01_2022To12_31_2022"
      decimals="INF"
      unitRef="Unit_shares">8059371</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:EarningsPerShareBasic
      contextRef="P01_01_2022To12_31_2022"
      decimals="2"
      unitRef="Unit_USD_per_Share">-0.12</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="P01_01_2022To12_31_2022"
      decimals="2"
      unitRef="Unit_USD_per_Share">-0.12</us-gaap:EarningsPerShareDiluted>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock contextRef="P01_01_2022To12_31_2022">&lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;The Company excluded the following potential shares, presented based on amounts outstanding at each period end, from the computation of diluted weighted average shares outstanding for the periods indicated because including them would have had an antidilutive effect: &lt;/div&gt;&lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:68%;border:0;margin:0 auto"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width:80%"/&gt;
&lt;td style="vertical-align:bottom;width:5%"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Year Ended&lt;/div&gt;&lt;/div&gt;&lt;br/&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;br/&gt; 2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;RSUs&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,622,840&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Stock Options&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;5,042,628&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Class&#160;V Voting Stock&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;48,565,824&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Public Warrants&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;7,937,466&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Private Placement Warrants&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;5,566,666&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Earnout Voting Shares&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;10,000,000&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Sponsor Earnout Shares&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,587,500&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;80,322,924&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="P01_01_2022To12_31_2022_RestrictedStockUnitsRSUMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"
      decimals="0"
      unitRef="Unit_shares">1622840</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="P01_01_2022To12_31_2022_EmployeeStockOptionMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"
      decimals="INF"
      unitRef="Unit_shares">5042628</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="P01_01_2022To12_31_2022_ClassVCommonStockMemberusgaapStatementClassOfStockAxis"
      decimals="0"
      unitRef="Unit_shares">48565824</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="P01_01_2022To12_31_2022_PublicWarrantsMemberusgaapClassOfWarrantOrRightAxis"
      decimals="0"
      unitRef="Unit_shares">7937466</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="P01_01_2022To12_31_2022_PrivatePlacementWarrantsMemberusgaapClassOfWarrantOrRightAxis"
      decimals="0"
      unitRef="Unit_shares">5566666</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="P01_01_2022To12_31_2022_EarnoutVotingSharesMemberusgaapStatementClassOfStockAxis"
      decimals="INF"
      unitRef="Unit_shares">10000000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="P01_01_2022To12_31_2022_SponsorEarnOutSharesMemberusgaapStatementClassOfStockAxis"
      decimals="INF"
      unitRef="Unit_shares">1587500</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="P01_01_2022To12_31_2022"
      decimals="0"
      unitRef="Unit_shares">80322924</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="P01_01_2022To12_31_2022">
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%"&gt;
&lt;tr style="page-break-inside:avoid"&gt;
&lt;td style="width:4%;vertical-align:top;text-align:left;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;18.&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:top;text-align:left;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; text-align: left; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;COMMITMENTS AND CONTINGENCIES &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Litigation Risk &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;From time to time, the Company may become involved in various legal actions arising in the ordinary course of business. Management is of the opinion that the ultimate liability, if any, from these actions will not have a material effect on its financial condition or results of operations. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;The Company is currently involved in litigation described below with one of the Company&#x2019;s stockholders, Dr.&#160;Gary&#160;S. Donovitz (&#x201c;Donovitz&#x201d;) (the &#x201c;Donovitz Litigation&#x201d;). The outcome of the Donovitz Litigation, regardless of the merits, is inherently uncertain. At this point in time, the Company cannot predict the length of the Donovitz Litigation or the ultimate liability, if any, which may arise therefrom. In addition, litigation and related matters are costly and may divert the attention of the Company&#x2019;s management and other resources that would otherwise be engaged in other activities. However, the Donovitz Litigation is not expected to have a material adverse effect on the consolidated results of operations or financial position of the Company. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;On June 23, 2022, Donovitz sued Haymaker Sponsor, LLC, the Company&#x2019;s outside legal counsel, and certain Company executive officers and directors in the District Court of Dallas County, Texas. Donovitz alleges that the defendants made a variety of false promises regarding Donovitz&#x2019;s future role in the Company, the protection of Donovitz&#x2019;s interests, and the continuance of Donovitz&#x2019;s seminars and training programs subsequent to the completion of the Business Combination. Otherwise, Donovitz claims he would not have agreed to the arrangements that led to the completion of the Business Combination and related transactions. Donovitz generally alleges fraud, negligent misrepresentation, a breach of the covenant of good faith and fair dealing, and breaches of fiduciary duties against the defendants (the &#x201c;Donovitz Claims&#x201d;). Donovitz seeks monetary relief exceeding $1.0&#160;million, including, but not limited to, actual damages, damages to be determined at trial, punitive damages, attorneys&#x2019; fees, and equitable relief such as profit disgorgement, fee forfeiture, recession, and constructive trust. While not a direct party to the lawsuit, the Company believes that the allegations contained in the complaint are without merit and intends to participate in the defense of the litigation. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;On July&#160;11, 2022, the Company sued Donovitz in the Delaware Court of Chancery, pursuing injunctive relief to prevent Donovitz from proceeding with the litigation over the Donovitz Claims in Texas. The Company seeks to enforce (a)&#160;the Company&#x2019;s certificate of incorporation, which mandates that stockholders must bring certain actions, including some or all of the Donovitz Claims, exclusively in Delaware, and (b)&#160;the Business Combination Agreement, by which Donovitz consented to the exclusive jurisdiction of the Delaware Court of Chancery and agreed that Delaware law governs any related claims, including some or all of the Donovitz Claims. Pending a ruling from the Delaware Court of Chancery, Donovitz agreed to stay all answer dates in that &lt;/div&gt;&lt;div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"&gt;&#160;&lt;/div&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"&gt; &lt;/div&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;lawsuit in Texas. Then, on March&#160;23, 2023, Donovitz filed an amended answer and counterclaims alleging what appear to be the same as the Donovitz Claims originally filed in Texas. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;On August&#160;2, 2022, the Company sued Donovitz, Lani Hammonds Donovitz, and Lani D. Consulting in the District Court of Dallas County, Texas, seeking injunctive relief to enforce &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-disparagement&lt;/div&gt; obligations of that certain founder advisory agreement with Donovitz and the independent contractor agreement with Lani Hammonds Donovitz, both of which were entered into by the subject parties in connection with the Business Combination. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;On August&#160;23, 2022, the defendants filed an answer, which included affirmative defenses to the Company&#x2019;s claims and certain counterclaims and third-party claims against certain executive officers of the Company. The affirmative defenses included repudiation, fraud, breach of contract, unclean hands, and laches. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;The counterclaims and third-party claims included claims for fraud, breach of fiduciary duty, breach of contract, and defamation, as well as other related claims. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;The Company successfully obtained a temporary restraining order to enforce the &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-disparagement&lt;/div&gt; obligations of Donovitz and Lani Hammonds Donovitz. The parties subsequently entered into an agreed order that the temporary restraining order will stay in effect until the entry of a final judgment. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;A jury trial was scheduled to commence on January&#160;3, 2023, to address the Company&#x2019;s request for a permanent injunction, as well as adjudicate the affirmative defenses, with all remaining claims, counterclaims and third-party claims to be tried at a later date. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;After the filing of this lawsuit, the Company amended its claim in the Delaware Court of Chancery to also seek an injunction to prevent Donovitz from proceeding with certain of the affirmative defenses, counterclaims, and third-party claims filed by the defendants on August&#160;23, 2022. On November&#160;4, 2022, the Delaware Court of Chancery denied that request for injunctive relief, permitting the Texas lawsuit filed by the Company and all affirmative defenses and claims asserted therein to proceed in Texas. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;Subsequently, the parties agreed that the trial on the Company&#x2019;s claim for breach of contract, including its request for a permanent injunction, will be consolidated with a trial on the previously filed counterclaims and third-party claims. Prior to that agreement being reached, Donovitz and Lani Hammonds Donovitz filed an amended pleading which did not include any of their previously asserted affirmative defenses or assert any new affirmative defenses. It was also agreed that if Donovitz and or Lani Hammonds Donovitz seek leave to add any affirmative defenses before the final trial, at most they would be allowed to assert laches, unclean hands or mistake, and only if they can convince the trial court that any or all of those affirmative defenses would have qualified as claims that could have been non suited at the time they filed their amended pleading asserting no affirmative defenses. A jury trial is scheduled to commence on September&#160;11, 2023. The temporary restraining order entered against Gary Donovitz and Lani Hammonds Donovitz remains in effect until the entry of a final judgment. &lt;/div&gt;&lt;div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Tax Distributions &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;To the extent the Company has funds legally available, the board of directors will approve distributions to each stockholder on a quarterly basis, in an amount per share that, when added to all other distributions made to such stockholder with respect to the previous calendar year, equals the estimated federal and state income tax liabilities applicable to such stockholder as the result of its, his or her ownership of the units and the associated net taxable income allocated with respect to such units for the previous calendar year. &lt;/div&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:LossContingencyLawsuitFilingDate contextRef="P01_01_2022To12_31_2022">June 23, 2022</us-gaap:LossContingencyLawsuitFilingDate>
    <us-gaap:LossContingencyNameOfPlaintiff contextRef="P06_23_2022To06_23_2022">Donovitz</us-gaap:LossContingencyNameOfPlaintiff>
    <us-gaap:LossContingencyNameOfDefendant contextRef="P06_23_2022To06_23_2022">Haymaker Sponsor, LLC</us-gaap:LossContingencyNameOfDefendant>
    <us-gaap:LossContingencyDamagesSoughtValue
      contextRef="P06_23_2022To06_23_2022"
      decimals="-5"
      unitRef="Unit_USD">1000000</us-gaap:LossContingencyDamagesSoughtValue>
    <us-gaap:RelatedPartyTransactionsDisclosureTextBlock contextRef="P01_01_2022To12_31_2022">
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%"&gt;
&lt;tr style="page-break-inside:avoid"&gt;
&lt;td style="width:4%;vertical-align:top;text-align:left;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;19.&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:top;text-align:left;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; text-align: left; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;RELATED-PARTY TRANSACTIONS &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;The Company utilizes a professional services firm to perform accounting and tax services for the Company. Trusts whose beneficiaries are the children of a partner of the firm hold shares of our Class&#160;V voting stock. Fees &lt;/div&gt;&lt;div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"&gt;&#160;&lt;/div&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"&gt; &lt;/div&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;paid to the firm were $31 and $456 during the years ended December&#160;31, 2022 and 2021, respectively. Amounts due to the firm as of December&#160;31, 2022 and December&#160;31, 2021 were $0 and $0, respectively. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;A former employee of the Company is the beneficiary of a trust which holds shares of our Class&#160;V voting stock, as well as being the child of the Company&#x2019;s founder who beneficially owns shares of our Class&#160;V voting stock. Compensation paid to the former employee was $100 and $201 for the years ended December&#160;31, 2022 and 2021, respectively. Amounts due to the former employee were $0 and $0 as of December&#160;31, 2022 and December&#160;31, 2021, respectively. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;In addition to their previous employment by the Company, the above referenced former employee also owns a clinic which was a customer of the Company. Revenues recognized from sales to this customer were $458 and $744 for the years ended December&#160;31, 2022 and 2021, respectively. Amounts due from this customer were $0 and $57 as of December&#160;31, 2022 and December&#160;31, 2021, respectively. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;A former employee of the Company is the spouse of the Company&#x2019;s founder who beneficially owns shares of our Class&#160;V voting stock. Compensation paid to the former employee was $158 and $285 for the years ended December&#160;31, 2022 and 2021, respectively. Amounts due to the former employee were $0 and $0 as of December&#160;31, 2022 and December&#160;31, 2021, respectively. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;The Company purchases dietary supplements inventories from a vendor in which the Company&#x2019;s founder holds a minority interest. Inventory purchases from this vendor were $1,304 and $888 for the years ended December&#160;31, 2022 and 2021, respectively. Amounts due to the vendor were $151 and $0 as of December&#160;31, 2022 and December&#160;31, 2021, respectively. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;On May&#160;18, 2022, BioTE Medical and Dr.&#160;Gary&#160;S. Donovitz entered into a founder advisory agreement, effective as of, and contingent upon, the Closing. Pursuant to the founder advisory agreement, Dr.&#160;Gary&#160;S. Donovitz transitioned from an officer and manager of BioTE Medical into the role of Founder Advisor and Senior Advisor (as defined in the founder advisory agreement) as of the Closing. Pursuant to the founder advisory agreement, Dr.&#160;Gary&#160;S. Donovitz provides strategic advisory services to BioTE Medical for a period of four years from the Closing, unless terminated earlier pursuant to the terms of the founder advisory agreement, and will receive an annual fee equal to $300 per year, continued coverage under BioTE Medical&#x2019;s employee benefits and reimbursement for reasonable and &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;pre-approved&lt;/div&gt; business expenses. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;On May&#160;18, 2022, BioTE Medical entered into an independent contractor agreement with Lani D. Consulting, a company affiliated with Lani Hammonds Donovitz, the wife of Dr.&#160;Gary&#160;S. Donovitz (the &#x201c;New Independent Contractor Agreement&#x201d;). Immediately upon the Closing, the New Independent Contractor Agreement replaced the independent contractor agreement dated as of May&#160;3, 2021, between Lani D. Consulting and BioTE Medical. Pursuant to the New Independent Contractor Agreement, Lani D. Consulting provides certain services to BioTE Medical for a period of four years from the Closing, unless terminated earlier pursuant to the terms of the New Independent Contractor Agreement, and will receive an annual fee equal to $250 per year and reimbursement for reasonable and &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;pre-approved&lt;/div&gt; business expenses. BioTE Medical terminated Ms.&#160;Donovitz for cause, effective September&#160;9, 2022. &lt;/div&gt;</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
    <us-gaap:ProfessionalFees
      contextRef="P01_01_2022To12_31_2022_FirmMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis"
      decimals="-3"
      unitRef="Unit_USD">31000</us-gaap:ProfessionalFees>
    <us-gaap:ProfessionalFees
      contextRef="P01_01_2021To12_31_2021_FirmMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis"
      decimals="-3"
      unitRef="Unit_USD">456000</us-gaap:ProfessionalFees>
    <us-gaap:DueToRelatedPartiesCurrentAndNoncurrent
      contextRef="PAsOn12_31_2022_FirmMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:DueToRelatedPartiesCurrentAndNoncurrent>
    <us-gaap:DueToRelatedPartiesCurrentAndNoncurrent
      contextRef="PAsOn12_31_2021_FirmMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:DueToRelatedPartiesCurrentAndNoncurrent>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="P01_01_2022To12_31_2022_EmployeeMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis"
      decimals="-3"
      unitRef="Unit_USD">100000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="P01_01_2021To12_31_2021_EmployeeMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis"
      decimals="-3"
      unitRef="Unit_USD">201000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:DueToRelatedPartiesCurrentAndNoncurrent
      contextRef="PAsOn12_31_2022_EmployeeMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:DueToRelatedPartiesCurrentAndNoncurrent>
    <us-gaap:DueToRelatedPartiesCurrentAndNoncurrent
      contextRef="PAsOn12_31_2021_EmployeeMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:DueToRelatedPartiesCurrentAndNoncurrent>
    <us-gaap:DeferredRevenueRevenueRecognized1
      contextRef="P01_01_2022To12_31_2022_EmployeeMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis"
      decimals="-3"
      unitRef="Unit_USD">458000</us-gaap:DeferredRevenueRevenueRecognized1>
    <us-gaap:DeferredRevenueRevenueRecognized1
      contextRef="P01_01_2021To12_31_2021_EmployeeMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis"
      decimals="-3"
      unitRef="Unit_USD">744000</us-gaap:DeferredRevenueRevenueRecognized1>
    <us-gaap:DueFromCustomerAcceptances
      contextRef="PAsOn12_31_2022_EmployeeMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:DueFromCustomerAcceptances>
    <us-gaap:DueFromCustomerAcceptances
      contextRef="PAsOn12_31_2021_EmployeeMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis"
      decimals="-3"
      unitRef="Unit_USD">57000</us-gaap:DueFromCustomerAcceptances>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="P01_01_2022To12_31_2022_SpouseOfFounderChairmanAndBeneficialOwnerMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis"
      decimals="-3"
      unitRef="Unit_USD">158000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="P01_01_2021To12_31_2021_SpouseOfFounderChairmanAndBeneficialOwnerMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis"
      decimals="-3"
      unitRef="Unit_USD">285000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:DueToEmployeesCurrentAndNoncurrent
      contextRef="PAsOn12_31_2022_SpouseOfFounderChairmanAndBeneficialOwnerMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:DueToEmployeesCurrentAndNoncurrent>
    <us-gaap:DueToEmployeesCurrentAndNoncurrent
      contextRef="PAsOn12_31_2021_SpouseOfFounderChairmanAndBeneficialOwnerMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:DueToEmployeesCurrentAndNoncurrent>
    <btmd:InventoryPurchases
      contextRef="P01_01_2022To12_31_2022_VendorMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis"
      decimals="-3"
      unitRef="Unit_USD">1304000</btmd:InventoryPurchases>
    <btmd:InventoryPurchases
      contextRef="P01_01_2021To12_31_2021_VendorMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis"
      decimals="-3"
      unitRef="Unit_USD">888000</btmd:InventoryPurchases>
    <us-gaap:DueToRelatedPartiesCurrentAndNoncurrent
      contextRef="PAsOn12_31_2022_VendorMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis"
      decimals="-3"
      unitRef="Unit_USD">151000</us-gaap:DueToRelatedPartiesCurrentAndNoncurrent>
    <us-gaap:DueToRelatedPartiesCurrentAndNoncurrent
      contextRef="PAsOn12_31_2021_VendorMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:DueToRelatedPartiesCurrentAndNoncurrent>
    <btmd:AgreementTerm contextRef="P05_18_2022To05_18_2022_DirectorMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_FounderAdvisoryAgreementMemberusgaapTypeOfArrangementAxis">P4Y</btmd:AgreementTerm>
    <btmd:AnnualAdviosryFeesPayable
      contextRef="PAsOn05_18_2022_DirectorMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_FounderAdvisoryAgreementMemberusgaapTypeOfArrangementAxis"
      decimals="-3"
      unitRef="Unit_USD">300000</btmd:AnnualAdviosryFeesPayable>
    <btmd:AgreementTerm contextRef="P05_18_2022To05_18_2022_ConsultantMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_NewIndependentContractorAgreementMemberusgaapTypeOfArrangementAxis">P4Y</btmd:AgreementTerm>
    <btmd:AnnualAdviosryFeesPayable
      contextRef="PAsOn05_18_2022_ConsultantMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_NewIndependentContractorAgreementMemberusgaapTypeOfArrangementAxis"
      decimals="-3"
      unitRef="Unit_USD">250000</btmd:AnnualAdviosryFeesPayable>
    <us-gaap:SubsequentEventsTextBlock contextRef="P01_01_2022To12_31_2022">
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%"&gt;
&lt;tr style="page-break-inside:avoid"&gt;
&lt;td style="width:4%;vertical-align:top;text-align:left;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;20.&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:top;text-align:left;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; text-align: left; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;SUBSEQUENT EVENTS &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;The Company evaluated subsequent events from December&#160;31, 2022, the date of these consolidated financial statements, through March&#160;29, 2023, which represents the date the consolidated financial statements were issued, for events requiring adjustment to or disclosure in these consolidated financial statements. There are no material events that require adjustment to or disclosure in these consolidated financial statements. &lt;/div&gt;&lt;div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"&gt;&#160;&lt;/div&gt;</us-gaap:SubsequentEventsTextBlock>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>94
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M]$^!%C 4(.P(<LU0Q1L17I V/2/,9PS1:Q<-:V=Z[5-Z*MQ"[[%D*O.^Z_K
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MXCT$]LTI]"#L-Y^O:>;WO4'+) X*C0.GQGNN4,CE"U 9#=#?JVBIX"1;G_;
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MNR$?QV;+SY]6GS^\OY]_?;@'B_F'^:?E UB]>WCXN@*_/@84)VR'6;@.HM_
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MXO>:%HO4Q0XC^WR=]YDP1N)\<X>##:99 7__A1!VVLE.4/VKP.P_4$L#!!0
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M#-3OCXS)UYOB!:O#2,/_ 5!+ P04    " #]HH56OH']":T)   <80  &
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M.AZJ:QJ W^<5_$;WA18(-QZ_^%]02P,$%     @ _:*%5OH&<Q8^$@  JSD
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MV%_C"_#]4@&Q<!]P@?#[S$__!E!+ P04    " #]HH56DY'7.4,&  "!$
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MN3-$&_IT"4&Y1LBR[F)*"U)?VF'QC.L+8D;R-KA,O$))5(2DBL_(>$58]O"
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M-.Z/!@'H5E!;PZK&B]A269)$/ZWH'X3:.=#^2BG[9+@#NK_:[ ]02P,$%
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MM2.?J"I+R764ME7)$/_C@0N"5\+Q)'T->@5>BF^EA)NESR0(@S-&E%B)*HH
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M99!G+#I5U'_)7?X$)YV>][-0EB970+UX^L',NA/EK2^8T/T9*$68+N;"D!7
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M)0.H"[&<NX^CNR[/N!!FS'X._5/VB.2040K_K0%RE0Q5*0S=Y6Z!US:YJQ@
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MJ?'4ZX3/@@X*6C:@]9DA\IL!.VC:U>%?4$L#!!0    ( /VBA58^!:V:7@@
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M 3R?:4Q*U0\ZH/EGP/E_ %!+ P04    " #]HH56;3"H^Y@$  "4"P  &0
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M#)4UH.]K23U7O]@ S7UO]A]02P,$%     @ _:*%5@K$FA"$"P  J1X  !D
M  !X;"]W;W)K<VAE971S+W-H965T,C0N>&ULG5EM;QLW$OXKA'HH4D"5;3EM
M@R8QX-AIDZ))@SIW_7"X#]Q=KL282RHD5XKNU]\S0^Z+[)7CWA=;VB6'\_+,
M,S/4BYWSMV&M5!1?&F/#R]DZQLW/)R>A7*M&AH7;*(LWM?.-C/CJ5R=AXY6L
M>%-C3I:GIS^>-%+;V<4+?O;!7[QP;33:J@]>A+9II-^_4L;M7L[.9MV#/_5J
M'>G!R<6+C5RI&Q7_N?G@\>VDEU+I1MF@G15>U2]GEV<_OWI*ZWG!O[3:A=%G
M0984SMW2E[?5R]DI*:2,*B-)D/BW55?*&!($-3YGF;/^2-HX_MQ)_X5MARV%
M#.K*F;]T%=<O9\]FHE*U;$W\T^W>J&S/#R2O=";P7[%+:W]8SD39ANB:O!D:
M--JF__)+]L-HP[/3(QN6><.2]4X'L9;7,LJ+%][MA*?5D$8?V%3>#>6TI:#<
M1(^W&OOBQ95K&AWAY1B$M)6X<C9JNU*VU"J\.(DX@A:>E%G<JR1N>43<V5*\
M@X1U$*]MI:I# 2?0K5=PV2GX:OF@Q&M5+L3YV5PL3Y?+!^2=]P:?L[SS_\=@
M<:U#:5QHO1+_OBQ"]$#-?Z;<D YY.GT(9=+/82-+]7*&5 G*;]7LXMMOSGX\
M??Z "4][$YX^)/WOQ^Q!<=/*GCU;B*L_WKU[^_'=Z_<?;\3E^VM\?__Q[?M?
M7[^_>OOZ1ORNHUY)3JT_=;@5OWC7B(B$%='Q_[F(:P7EFHVT>V!V+PI5.KS7
M=NO,5E7X(+;2:]<&8=1*&LY19V&5UP$6T0*2X7RE+2A#E*[U =]K4;18H$)8
MB'?2@CW(&T('>L4[-MJ29G$M(S] DFKDL!)&RT(;'?=SH6NX#_]KUGP-TWL%
M=MH885T4:[G%4T%;O8:&JJ[!)P*B-;Q?0RUX'<]+9RO-SG >9!5P'BL#]O3L
M)&CZ<>0.J%JVWD-KLS]PB!G<6JE0>EW@>4'D":7B&B>KSL@LZ]MOGBW/?GH>
M!,BBO%T[4RD?YN+:+\2OY+2;A;AVUFUU_*]X0HN7I\^[!_SU[/EWX@D)O/-R
M%.)N73("Y,Z!S'I,K)_#!ROI*X,0=<L:>#!",9BN[5IEVUM;*A]1/1;BDD*%
MMQNG*9AV D6EM!05X+3298JL479%?CFJ"T7D:Q#8K76Y9HP2]!2M1W4 +A;B
M+4I'E6(['T>',L\K X$5P0/X(-PJ("&07?2:Y%4H.CYI2HMLTF@Z@,T 9=KN
M2 L"$U!?@IP8S#O7FOQJ1YH62L !V,;H25NXU$%3!="]<3L%#>9'O0.'DTO5
MEPV #2G(WKN@EQ4DX*P!_"0,D _.Z(H], EY\OR0(AL7](3U"_&'%;^U@/7R
M/+'\?- SM)#]1NX;>0N[;C9T)&SY_?>K^:0'@<R@*Y7I!'1AT0#,V9L99CV4
MU!=5MM020)]:EQP^+*NTAXW.AXY\4!*B)[!=(0R1E+^6QLA WRUAZ*/Z@C9I
MT!EOU:H+%TE DZ!L)8FN&UF19XGU5-R3L%H:>'8#J"&:(:<-<=\X1=FVNHU4
ME[PSJM,MVY)\ 1DQ]SJDY-WMR"E@.E &DITY@B@<+>*C)K<$U1#O)L>@%H)3
MH1C.67G9X'5;!/6Y);@2Y;/ 9F/4.,BO,D^3J@6$T3M$O(/O*-2ED1I"L2=!
M?&#?E5<)EYQ$WDN;DB2[V PO'W?^0>K"+!LR[8^"B&H*%!M*Y!S.VLNVF@NK
M5D:OR&8$S"NNF#9FTI.B0&=<]FQ4NJT"_!DU*^<J1)LXG,[')P]D2%3C58I(
MVJHXAVI=M4@:L'?54A[#"?!^N(>G2=J^8D\.E#UDDU*WP"!*2"31<(%6-1*A
MA'\ILO\X6YS"+&/8&&U+TU:L7M%&CH?1:#S8W7,BF18Y5LD&Y -0Y0\4BH)T
M!-J 'BRF+" :F8M-:S5G7+\)E.B\5?N0,2=JI3) @2P=90&P9SU#"\<B[X"_
M6D<D:EAA&&$DS&F?P(A2*TU)0N4'C!E24"CY$=WH6QX!H WZZH7X:ZTAG,R2
M.>O%1GID90:3D;L %0X+4$&Z;,?9S?C(?$<))=EH;0= 2BIG5!JH@(.A4B5D
MO2@I;<5.H[-UJ3=4H?)N#G3HZ^Q0?#)G IUG9QUGCK5DVNS#WA$9$+\C-7HB
MNUI3ZOL]1<;#5NZX/J$BLYNRVTDU#Y-A0R^1.R;$H0,.=R:'*@I WQ\6G81+
M4B=3YK@A2MC$8<HBCB"D)_*[28HG'M<@;/(3; !*G=\XGS.P*^26RE*.TK@O
M$@UBCU0CK;N*D+-_A'@1N+WQ%-Q[G44R8TYY8\ N6\4=7._>!+@GQ7?'^>>2
M&"WAMMAGE0<>A"IX-9!:?X[XU*(YH<9G1'#'H\IZ=.1)?NB7XA_H"/&A5MON
M>RXLLV5_QP\+\0$(IK52^);8K.^G'T3<4"Y[>@]1,MU"I[ #>%((=>[B<SH>
MP@<1ARO>20\/YO;A?"2[UE0<)$(,;U?\D24G2FBI(N:RPUG,4*:SY&:CI,]4
M1I8$""#NF<*S\QH[N5:D\P8-D:67[8H0M_QJFJ*KD5:CV6E T*"$X3EIR^^N
M%S3K4:,U&HX>UY_,.<&.9GB7=-;9[T&LX**N$1V9<#ZV852$!B^S=[LD3"BB
M-^BOZ *%F3]16NC ?2^[<SA&#=N=0''OHGWU?2+K[G&NC]VFB>[N;MM)[#.I
M6J\XRCO2(#-+KO]#@2>RI_N!.<TP1L%^@+O*U<MP*4^'/,J _M#\O:;>^>Z1
M!VW!?EH9;F)5+9NN)\$TJRBI0C]0C+/]#@NW)=7-NB4TNR(7,RFB:HACN6D(
M?2>(N5SY,7S(O_<A=$G$M4]-@-A!#[I:K-K<MZ%$8A5UH"AI$MTHEO:9C/<8
MOCP1Z!1:/+6?B#HY2PK,'2!^O@C(&+]COZP^(9Y<.>*1X,]3+2,6\JK)=G:\
M^*A 9M) @\^MCQ3D[41F&''KF*LBDH9=6*>9=[+9Z%B+KAI8^M=+.7O,!,?I
M3CDYN.+QE;Q+HIPQTWXZ<,;\F#<2-Z#*W>$,=X]6F"W?HRHU!5ST=,PU#YA;
M*:N[^C9&PSV6FS,\=&3J)*%,BWU5.="S]S\54(+.%$LP164DA "/L1H8L73V
M-/MT5 QN^G')=!,;M7S<W ]%FIZG3''V.$.RC5/9/Y1N LUC\H.ONHH[XWQ*
M@D-%"#MT5]?7N<>D ]H#KYU/=$_IT+4^.)*T3#-/->X'NFIWKQ+>+^<8]F2"
M+5><2J>Q,7,I]S8)PYBU1NKW\9H,+/F*%_!^JW:3RQ;B;60RXVP;1U#7A\9
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MJ@W1 9:IRF(K2A2_ G1 UM8U_M!YH%29,@9Y&'24D&(A=2UH2[!"8\'5L&2
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M1R-&>A!U4PF:DP%$%5JK%3H], W_<"H^!5WKE@6MF%<@@&75P 9 #]4XP1;
M QV)2@E0CPB$=6 T[M>TFPT@T:H[MV504M>BAH& X'M9YTZURPX1<T=$CS3
M"]!N4>$P\ QHDU5K8 _FY/G1->T+++1:ST'JK94>BZ?B>)),9A?BY.A#7=UI
M=.V,I5V.0%KE"RK>:>3C]&P,PRWW$/75"&E_?(5?]RXTP67.QN</&?!0.)Z*
MR6S6 T9Z<7%@D12W>W5Q)DX&I/K*2_75H+"]+>^ 7:IZVR>G#WP4#&!MFI$N
M$_L.G/0!T";CX$*.!U?XC73[#1AG%.IK8U2_/AF>IM]"]<U]U$%U_ '(J392
MYTX"D6YI<C6]@M?+,Z!4?H=,;<3EQ84XOYP=W<B-;F2A_P?I7LO22-8X666
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M8V,-4!>B1)#>IEU9%<DJ]%3\ 4XGX 4\'U*)L#RH:\5XLK.HK^#APAP2A0X
M=^I3HT\/MNU^I4@D20O;>;0)+OU69':C@"KU5=49F)J 44!Q6:UU!@%\UJ"1
M<>B5#0&Q#H&H0#>:'6]PVW2=@65LV(PAFCAL/[6$QPT2MH)35S#'$'!9M2Q)
M1M$0"'3AB8^0Z1 V'9$Q4G_2,++<C-;0GT+07&L*7PJ_.#.3'9%;2K'!.C@-
MN)2X8HU)&%3'F)!JG"6UL8!-0QBWG96\4Q00K(!.5:TS8MVY4I@^E;G&F,$1
M#B!,XKE$VVA45;RLW(#^!T\ L0RP,M*!9>8@+=4]N<7P4P(4U\!Z.L#:F?*^
M:M&6X%[)):"'&<TA-"'41W@&$NBU+F1M\0RCU^1R ]]S(!,HX05-E]%SGH]4
M>:?KJF0MMD]#\$" R:UY%%5;#V[5AXZ64H BH E1VL+DM@T[4=[HMNS3";,%
MIT<U -7.-*4LMKAY@]+;F<?'=U:/ ?F(PM(_"[%@MAVQ '6F/<6$'<9J=4XN
M(L:AXOKV!GS@E#)LE-3T23@&D3%C5D0UT#0&-H@L1]M#@Y7!CI; 5\H\]]R]
M!M5ITW"@<?G;8V3,=/PCZ6 _@KZ<_'AR"E..3#MG@17=02?1-*]!EY&V1I&F
M+#YA T-9T&W$;3P0]4!XK.?=D+D*>;C)<"+N+4?IG^37 T;K.])O\9SB#Q6T
M$=85%+NT\JLS29;/2"\WSM<%2A5:W2G^#+\C0H()6U<UFKXO"K@'1I0.A61)
M6/J(6=;R"W(!FY*N?D]P%<K*YBB?F*^] Y>+6)\3J7>6!FIITQ]W,!2(F]BP
M!V=>M.3MU0!J;61AV ;81"]LDB5) 2/4F,K-]0(0@).0,:O^Q?;3SN+&<X(D
MP<^C32%+XF2+QQJ$KW0&!['HDKZL+GJ$X^)L["R[54@+P$5S7XU,HS:$RA&C
M<H2H'"$J.T0#60&8P=H@-D"1RX+X-PI!VC(R. C47)5J@2D9N[#-!>%/+HE$
MELAJ_L-)]D>FE(9$(F1@)\/9TU>8*7MK3$MXO$%3URL9CYY%@"-1Y:=#0(9<
M[&0XK?J'K&NL:+T+_E\OD(^>!1/AR+VM-BLD1_S3HJ[6%(E!4/9*U?J.!(,=
MSW^H?(GCUTJQ8X/E@U*[2H7TGBH%UH@6DECDT+/+,><;@ZL%_,N@&9X0Y=/F
M\*RK&)(#ME[A$IH9NV]MB7)-UF$RBT6V=Q'VBW-PW_(=P^?=D>H> _@UQ/E<
M-4G0A&,YAS,GZ&NS'!Z$"9,#E&$$M\9P+,NNAMT2.QPM%ZM .RQ@&#P&9OM?
M;;[D!S29M[PEO6%=2+#*](C=#8RQ7&==2=1)$I9!\P0KH9H%KP.C7U"?X*3I
M*A?H$Y/["1 5:A\Y5=N@:<O)#+]!?QL60?>R!@V2<Q[9/T!*>Y=N&287P?DZ
MC)]D?UD?%_CD"P<LZ&$&.TT,EC/^L0X&(<)(EVR$A\L/DU!_F S7!5[+N@0D
M>'GH35G^N3FZD(4<ZF0X$WH;U?#^YL3S^)6MWO6"^? )75%P=UI"[EU%=BYZ
M^R$2[8.)J6N7"^1"Y7H-/AZP'C(C\&(]]*R71K026.,/?.,<3 4F-FM:,A\2
M.<8E+'AQ$/]:S;?$F3?(?N(Z<6^B=]<$F_]T#?H$[=E*H1>Y%?\ [,!^/7K>
M4R[/<)8.8 -W -<_=LIFOG6!J?K*<5P" E(O,0%5LPJYA[#QA!U3NRQN"=7-
M9UR:@J>^O"'OGFL6K( )E)UJ+H-/X%G)I91KD.KG1WLS'[WO3F5YX"T__UMX
M]L@!?/P[L<&)F)PG%^G$OKB?X?=?/:N<B*OQ-!E?7+G7HX#ZSK#S<3(>C^W+
M4421:)283I/IU868TAC.:$^2\62:3.#;J\LTN83O#Q0T=A%H5A)U,0R-U?WC
M<)<>#0C1  ([*TXF20J1S>4E;"$YG\V2Z>6%'?FR.])E].VK'?2[L-CA0;/+
M9'8^2R[3,["X[JU%UOD58.@RN9A,<!A$-$DZF1S%%3K*A820/L>RH)ZW;/*
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M*<A:*]^LXM7+0EGY=+UOP2NS5@"+J!TET&,03B%6H,T0BC%E:HP;<W#'*#E
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M]VXLWRC!&\GBC6!VSV9*^"HNOR]_;!;OJ0!/1J-94!9;J-WVON.+(=SL5+1
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MPY/Q^(=#;8;1V5:^.);XP+=I4O4?HT.^G0?EG+M(J7L-,8U1#VCF(JK!\=&
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M7='_(91&@/9S(72W, [Z?UCS_P%02P,$%     @ _:*%5K/?FCQ(!0  V0T
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M- R([B9"9UC5^BY<*HL][;<U#E'0S@'O*Z7LSG !^K&<_P502P,$%     @
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M)C6U3<TL;^0?TC,S=13W9Y:E;I,;+TL#$&L-G#KG1MK9E=Z*T4<MHA?DPB+
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M[.%-+_-W?S[08F[?VF.A\>5NNS/\50)I!'!](H0N!V:#ZN=K^"]02P,$%
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M1GBD(L2#A3G:N\"BWM$I8+MHQPNX^(7@]66O3O,,W=^_&[&8?: =;T?-?U<
MB1^GB=]G([+I!Z/TL 9BTJL5NA\,^^?&96"KBI'>+2H)GG3>6"?M]O9(F=!H
MD,;.\?H:6'"J4-*N4-)S"Z7;X]D+*KHQ8:9)X(;:SAYF1L*#-H(N*X2/7"AX
MXL4._UYD&IHM/%9D)]D</]ULY>U;;KSAQH]PPY:;K;>5Y??2\CLL3PWK1N(S
MRY.B*QNQJ7]]TWMXW:([&@VJ$BY$Y?SU):1!U'N2!=UQA:W_- HB^+XW%_KY
M:J4005EZ_2"AR7MJD9PBPIO (@=G"<<4#0^NWQ+5VCTR-&1R5YGZ)NYFNW?,
MK+Z^OYG7CZ!/7*T%;4"!*W*-@B'UO*H?%O6'D5MWF2^EH:>!&V[H+8;*&M#Z
M2DK3?M@ W>MN^B=02P,$%     @ _:*%5KIA 3V6!   +0P  !D   !X;"]W
M;W)K<VAE971S+W-H965T,S<N>&ULE5?1;N(X%'W/5UQE=D>M1"&$)% *2"W=
M:D>:F5:ELZ/5:A],8L :)\[:3FGWZ^?:@90 S;(OQ(FOC\^Y/M<VH[60/]2*
M4@TO*<_4V%UIG0\['16O:$I46^0TPYZ%D"G1^"J7'95+2A([*.4=W_.B3DI8
MYDY&]MN#G(Q$H3G+Z(,$5:0ID:\WE(OUV.VZVP^/;+G2YD-G,LK)DLZH_I8_
M2'SK5"@)2VFFF,A TL78O>X.;R(3;P/^8'2M=MI@E,R%^&%>/B5CUS.$**>Q
M-@@$'\]T2CDW0$CCGPVF6TUI!NZVM^AW5CMJF1-%IX)_9XE>C=V!"PE=D(+K
M1['^G6[TA 8O%ES97UAO8CT7XD)ID6X&(X.49>63O&SR<,H ?S/ M[S+B2S+
M6Z+)9"3%&J2)1C33L%+M:"3',K,H,RVQE^$X/?E,49*"LR<RYU2=CSH:04U7
M)]X W)0 _CL 71^^B$RO%/R6)32I W20347)WU*Z\1L1;VG<AEZW!;[G^PUX
MO4IBS^+UFB7^=3U76J(+_CXFLH0(CD.8RABJG,1T[*+U%97/U)U\_-"-O*L&
M@D%%,&A"G\S*@@"Q@/N<2J)9M@3+&J9":06/-!;+C/U+$R@PR1*N9U,8!#Z0
M+(%9D>><8IUHPF%*U KNL-+@4U96K+$^MDH\=4QZ([GCTI]6%$$YSF.H:N,=
MB-$%N DH(-L*-X(T1HI*%+>B8BM*-HE2NZ)B(VIA1+$]4;Q<6M,T$[U2(A50
MXT- %]%TCK!;)UE<;'2'SI\85]JU%N;8,!/BW+$7["SITA?< ?'Y"_C]@?D-
M N=)&&)O<FJ=]\A%[G(=.G9=<L(2RY6DHL@P!2R+>6%8L,SR3Q&OD%:VR5T)
MSQF9,\XT0Z&('_;+7\?NGQ=B<5%8;MW692_"Y\</ [_K7T&#+\/*E^%)OKPA
MG&0QA9D])::<*,46+"Z7X="TRF;ZN]T/4=OU,_8N*9K8G!%OUGZB,K61MTS%
M)A_P2#0]9M!&EJ<;M'0E&D[99,\WJLJS+SY096*F(LU)]FISVK]2^TY6K6HI
M<<#C_3= $*K+!!RL7LM"KK=Y(9N\R"HOY0B->6E9A*/AR39;2(16SO\OHD.G
M5@\UUY?+43)W[O=J5=9=YK>\T,=G+XQJ-;#170_XO)\!9UI(B>8>'DQ3-WDW
M"FTI#9RO(KN(3QF$]O?[T/7[-5I[M=/R+BVW?NAL[7G1M R;6MI/)IS9C>8<
MPC;B==NA=PA76Z;W< ;M8 "_0J_=#_'14+%15;'1J2?) WDU^XB"^2O<;JVR
M5ZG'BJUY@A/J*M^9./D?'FW!>L7B%3 +D]GS(8L91^]K :) D)V5%7/.EK96
ML59L^1UL^$.SG_>@U^N;1@ !^@D;(0118!H1! //-/H07*)O<-.F9('K#D'?
MJ]FHDN2WHDOC:Z6&>,!B*,6M_RSR CAW'LSF@PO^3'A!W]V^C06/+71GYPJ7
M4KFT%U4%UD/E;:[Z6MV%K\LKX%MX>9'^0N32G,.<+G"HA^9RRS+>OFB1VPOA
M7&B\7MKF"N_S5)H [%\(H;<O9H+J'\+D)U!+ P04    " #]HH560_602ZD$
M  #V#   &0   'AL+W=O<FMS:&5E=',O<VAE970S."YX;6RM5VUOVD@0_LZO
M6+F]"B0"V 8,"2 EH=5%:GM1DNOI=+H/BSW JO:NN[L.R;^_V?4+;N.X5+HO
MV.N=EV=FGMD=%@<AOZH]@"9/2<S5TMEKG9X/ARK<0T+50*3 <6<K9$(U+N5N
MJ%()-+)*23ST1J/I,*&,.ZN%_78K5PN1Z9AQN)5$94E"Y?,5Q.*P=%RG_'#'
M=GMM/@Q7BY3NX![TG^FMQ-6PLA*Q!+AB@A,)VZ5SZ9Y?!4;>"GQA<%"U=V(B
MV0CQU2QNHJ4S,H @AE ;"Q0?CW -<6P,(8QOA4VG<FD4Z^^E]0\V=HQE0Q5<
MB_@O%NG]TIDY)((MS6)])PZ_0Q'/Q-@+1:SL+SD4LB.'A)G2(BF4$4'">/ZD
M3T4>3E'P"@7/XLX=691KJNEJ(<6!2".-ULR+#=5J(SC&35'NM<1=AGIZ=<-#
MD0!YH$^@2/>!;F)0O<50HVDC, P+,U>Y&>\5,ZY'/@FN]XJ\YQ%$WQL8(J8*
MF%<"N_):+:XA'!#?[1-OY'DM]OPJ4-_:\W\:*%DS%<9"91+(/Y<;I252X]^F
MF'.+XV:+IEW.54I#6#K8#PKD(SBK=V_<Z>BB!>^XPCMNL[ZZQ_:+LAB(V)("
M>_>C4*I'K@![$<BM%(_,]@8N2;V.3:&T.RL=Q-;!)G>0?N> Y2+:$B44V)5*
M0V30Z3V@1(SMS?B.=!G'+R)3E$>J=][Y&ZC,24&PI)!L0)JR=DQ936W=SAKM
M*LU"\I9X?<]S\>G[?7?N=K#OL*LXZ4Y&<](C76\V);U. ?;G*-\2MQ\@,]&>
MUY^/)BU5F515F?QJ50RCJEHTI;[=X@-F[XCZAW!,:I]- N%% FU?$$RR36)9
M$?6B(*=4X#J3$KANQM'= (<MTUC+#Q"!I#$F-!C/\??=FYGG>A>=>TTU6"P?
M18C[?A 0K%55OTDE^2 T[H>%/WC"NT5!S056S/5=J[R&+:!8=#*J;N".D26O
M@>IZ\]IN":U8_P P*GTW(.P&8[]F*%=HQV@8.)L9?L^F+22<5B2<GDS".\#*
MARQFU%YR1?7+E-0H>F>RH87=OA9)2ODS>;_=@KT5*XDF_K:#N<2KN0G"MH!0
MRXQ\"<%F,;A0!"HHE>2O-0!3A*J"]NH4TAM^9%K(YU>A>NY@-"*_E<^"4?9L
MZ1.. Q.&6NH6I2;N;. 9G=%@%J#*9[P4Z9.Y54E*I>8@U9ZEI:>SL3OPYRA]
M5KHH:6G]1PR38AJ%H8,S;Q"XUK 5O-Y3OC,G!WFD<99GGIK8*0\1>3"83(["
MGC>83BI0+0P,*@8&)S.PZE/#H4NE  \AVW6,;I 4FC5?2.T.'AHH8C)>-:8I
M$LV==>.CIYXA@07U_Q%E_=+G>>>/3"L6@9D(T6!9J=!6I%YI<P>Y@5\[+#\;
MXJ1(&FVN2W/CDI!*^8QT/U 9*>).QY7P#=*'[YB9RL@\F+UV3-6R82Y1WYW4
M''YI($AWC$?T\1!K"+%B^%')Q#+S9T?334P:UF;1!.3.3MQF8LBXSL?2ZFLU
MU%_FL^Q1//]'\(G*'>.*Q+!%U=$@P)M4YE-VOM BM9/M1FB<D^WK'O^8@#0"
MN+\50I<+XZ#ZJ[/Z#U!+ P04    " #]HH56#(?^$]P#  #L"   &0   'AL
M+W=O<FMS:&5E=',O<VAE970S.2YX;6R=5FUOXS8,_IY?07C#T )&[#AQ7KHD
M0-/>L &[7M#<M1B&?5!L.C8J6SY);GK_?I3D."V0!,,^Q+%D\N%#\:'I^5[(
M%Y4C:G@K>:467JYU?1,$*LFQ9*HO:JSH229DR30MY2Y0M4266J>2!U$8CH.2
M%96WG-N]M5S.1:-Y4>%:@FK*DLD?*^1BO_ &WF'CL=CEVFP$RWG-=KA!_:U>
M2UH%'4I:E%BI0E0@,5MXMX.;56SLK<%3@7OU[AY,)ELA7LSBCW3AA880<DRT
M06#T]XIWR+D!(AK?6TRO"VD<W]\?T'^SN5,N6Z;P3O#G(M7YPIMZD&+&&JX?
MQ?YW;/.Q!!/!E;W"WME.*&+2*"W*UIG695&Y?_;6GL,[AVEXQB%J'2++VP6R
M+.^99LNY%'N0QIK0S(U-U7H3N:(R1=EH24\+\M/+!ZK[GT(I6*.$.U&6=%*;
MG$F$JZ]LRU%=SP--<8QUD+28*X<9G<$<1/!95#I7\*E*,?T($!#!CF5T8+F*
M+B+>8]*'X<"'*(RB"WC#+NNAQ1N>P?O$9%54.Y>U2_?OVZW2DD3RSZF$'=SH
M-)QIG!M5LP07'G6&0OF*WO*7GP;C\-<+9$<=V=$E].6&&C%M.(+(3(7J1C,K
M:%J>K=ZI'"Y&.9W#UQPA$YPZETX+M!$$*-2*-J7.0=/CY".CBAAQPZ@F1HEC
MI RCF]Y?R*13!% ]L=R2!=6T]W#.I??0E"B9%O+F:,2TEL6V<5RT@&TA-%+N
MLNX#=4ORD@N>HE1P1<U:),"J%-*"-QK3:_@9KF;C&5SW[K$2U$T.^]FV+M%B
MKQ1NARZZ GJ'*4W^)O=3:%,_C&?^<#*XD,+*NE'<L$]M08&=\W$'+B@D[A02
M_U^%'.)U.=ZV.6Y<CE^..9[2S.6X1AXF'JM^ +XEO#&UU1\T4U-U*ETPWAZJ
M#U9=E:%BWJ8IF%=S*9I*?SQPI@%9DIL3+40*6*4^9%*4IT375@3V_Z&0I%P+
MX7 5%+2=,$L'$]8HI!V3B14\34":*@U/(2=(NA TT:6$;$B:)X!91@/FO+H?
M-]\4#/QQ%/G34=C;&(G"E]I05Q#[X2BB9]/>'6<DGR=X$MI$=F:CJ1^/8W\:
MC7KK9LM)2,],2F:.:N+/AA-_-![WUK)X)?ZPYM2\-"[UT2@F][$_)B/SPJ-3
MZ.#=N0Q"/PSMK[>IB0\=S<'P8.''TXD?D\$T](>4PRP:G1)L\&X"4<_N[)Q5
M5">JJQM&W6XWRF_=!#N:N^^ STSN"CH;CAFYAOT):5"ZV>H66M1VGFV%INEH
M;W/Z'$%I#.AY)DAS[<($Z#YPEO\"4$L#!!0    ( /VBA59&0GD9- P  /9@
M   9    >&PO=V]R:W-H965T<R]S:&5E=#0P+GAM;+5=6V_;.!K]*T1V=M$"
M;6/=[6X:(+$R.QE,IT'=SF(QV ?&HFVBNG@HRFD6_?%+2HIIRA1EM5_ZT/I"
M'HK'_,AS>.O%0\&^E!M"./J:I7GY[FS#^?;M^7FYW) ,EV^*+<G%-ZN"99B+
MMVQ]7FX9P4F=*4O/W<DD/,\PS<\N+^K/[MCE15'QE.;DCJ&RRC+,'J])6CR\
M.W/.GC[X2-<;+C\XO[S8XC59$/YY>\?$N_,]2D(SDI>TR!$CJW=G5\[;.)K*
M#'6*/RAY* ]>(UF5^Z+X(M_<)N_.)O*)2$J67$)@\<^.S$F:2B3Q''^UH&?[
M,F7&P]=/Z#_7E1>5N<<EF1?IOVG"-^_.IF<H(2M<I?QC\? +:2L42+QED9;U
MW^BA33LY0\NJY$769A9/D-&\^1=_;8DXR.#.>C*X;0:WDR'P>C)X;0:OD\$/
M>C+X;0:_9J:I2LU#C#F^O&#% V(RM4"3+VHRZ]RB^C27O_N",_$M%?GXY:+Y
MO5&Q0@NZSNF*+G'.T=5R650YI_D:W14I75)2HM?H*DFH_+5PBF[SILW)W^Y%
M3#BF:?D2_81HCCYMBJK$>5)>G'/QA+*<\V7[-//F:=R>IW%<]+[(^:9$-WE"
M$AW@7%1M7S_WJ7[7KA7QURI]@]SH%7(GKHL^+V+TXJ>7J-Q@1HS/9T>+R?(-
M\IP.VN+F7^]O?O^$YI\7GSZ\O_F(=B1/"M9?2GQZ*<Z^E%/0-8J\?1/PZN*\
MGN+N6)%42Z[]I'_^)A*A6TZR\K^&"EPWB+X94?95;\LM7I)W9Z(S*@G;D;/+
M?_S-"2?_-'$."18#@6E,^GLF?1OZY>]5=D^8C"71+S-<AT])UJ*;Y.C;4S,Q
MT6F%'4MG Q;68++;WUTZ%^>[0XZ BM,X"O8<!2=RQ,BV8!S?I^0TDJRX8TD*
M!DD"*DXC*=R3%%I)NLVVF+*:DJ4(\S61?*5%OGZ=BE$R0;@L"3?U+-=6W+$D
M-6#! 4F3#DFV%%K-HWW-(VO-/^P#)Z$E9_2^JOLC7J",R(932B8V19J()"42
MHPSB^*M,CBN^*9@8GHP][K6UU+&\1$>U=MSI-.QP$QTW,<>?N&9^IGM^IE9^
MYD5>DF4EQ1+B#"<U4_C16&<[DM>7;V[--[8_!@+3R)KMR9I9J_A>-(VLRM .
MIU4=0HF0*8]H5Z15UM G8HEO1,&R12'1])8BY(3<-;%I+6IL"VK 9I;( BI.
MX\V9*%4X&6AF62;"3LC/Y9=7K=1 M"PK0=BW?F%S;8<=RU*+=AA"X6PZF49.
MM[.&*E>GZT!$.T-1*5J3T% /E&]:V2[[JI3B>YI2_B@^8TRT+2-G5NS1G#G'
MG=,L#+I\.<>=4S0)S'V3XRH>W!_D(1>MRL:%%7\T%^Y1+6=NMYLV))KV]=*.
MTM2.56A>WGS="F<KHH417K&\&:J$I:V$+Y*CV9X;(PN@\KI%LPWCUB0Z TH+
M.Z>*X<:PE*+C:%X9JPPJ@9UC#>QUJVQ+HE=925OG5&VKFCYNG+1H"<)=(6?R
M=_DU+[CPT(P(/L3 ]&WO[8S,@.I>YUCX'C4&6Q*=&:5G';N@/9F9]L-2D+,D
M=%>[@P%^0"5OBV;EQY9$YT>I7L<N>Q<X%0/L4HRZ8I 5@M=845 -ZQR+V%GD
M=ZMZG,B=!&%/;96&=>S2\S9?,B+=C0B"95'RND=<5>F*IO(#XQAB9 12J<Y;
M-&WDG,RF74H,J2)OVD.)4JK.@%2EN92JQEJ"*D]0M!@*39_;4S+5G8!/7;F@
M$A44+89"T^E4,M8=D+%X2T5,TO^)/KDL5OQ!R'Q$2DX%M>*CJA3Z)45R"L(8
MCG;TT<S:G]5#CP0;NX48ZCET%I4(=NTBN'6=1H9 Y2TH6@R%IK.F!+,+/POM
M@NID4+08"DVG4ZEOUZZ^?S240>7XP+-.+:'\'%/5KA+TKEW0SU-<EN@*M=,A
M"SD=8J0+5*.#HL50:#J%2OF[(7Q<@TIZ4+08"DVG4QD%UVX4OG=BS@X[FE+3
MW+;KN]-IU)'+AI0]9LE5]L&UVX<%QWER_XAN_JKDE-)=Q98;7!)TM6:DMA5&
M D"] BA:#(6F\ZF\ASN##U%04P**%D.AZ:OIRI1X]KGSN_TR0CW?<1"P:/O4
M5+>,+HVK#"VVMC+P9M:)JKG]"48OF3^'Z_"4Z_#L2OX381G-FV:W)8P6B>1M
M3Q6V1?4 M!>BK-Y/8MQV &E78B@TG41E.KPATY$GF!?L46X2JA>]<"8GTNJY
M-9HG=$>3"J<()SN<]S0]=VB>>&Y_B-&4/8?C\ ZVO=BGZ$%7!]NR]+CUNO3!
M[G1Y#H?A*8?AV57[HM$>I>3&ICSL,*/W"AEVMTR"()AU= =4J3HYRCAX=N,@
MAM0E(4F)5JS(4$DX3^L^K-YG=W-W920*U$2T:(?1[/MNEZ7G\ :>\@:>?55@
M4,B)AF693;&CCR8,U"9 H>G,*IO@1>"2S@.U"*!H,12:3J=R'-[0KIOO<UTM
M[&%O%4SJ/]V1 =1/0*'I;"D_X=G7,DX)ZU-G5NQ%C6Z4H#X#"DW?:ZI\A@^_
M^.&#+GZ HL50:#J=RH;X0WMXOB_&?<-6&F.,V\L?S=9S^ U?^0W?[C=.B?'_
M%.S+CJ:I43#;\4>W1%!C H6F<ZN,B0^_%.*#+H6 HL50:#J=!YOR!Y9"OC>P
MCZV&&QC"&M+?Q%!H.E?*M_AVWW*U^(S<B3-[[;A&2D M"BA:#(6F,Z>\C ^_
MSN&#&AA0M!@*3:=3&1A_8)UC@_,UD<?)#H^B,9HOZ38EKPX_K8<BS(39_KQ-
M,)=?)L6V_@%B\=9(/*C5&:C*KSA_@]#$>87J8V-&LI_#WOC*WO@#]N:'R19=
MZ9^<502M<%H2<V,'78 9J)%\%B/1S^&,?.6,?+LS^B&B;S.Y=L\H3M'-:D5$
M7S-(.:AY&JA;+^7/X9("Y9("^VJ,/W%>?'F)[E)LW%1ISSWZ5!FH(8)"TYE3
MABAPP$>T '0+&"A:#(6FTZD<4S!T-B+;DKQL>"1?Y6OCV&2'&4WA\:+.S.F>
M!H$J4F=&^9U@X*Q$MDV+1\+0 J\(^@6S^X+)@R*OF]L!=J39$_QT%M"^$&,O
M:S1]IF6=2?<L 529.G_*X 1V@V/D3Z.L60LTT@6Z.@.*%K=HAVW7\WK.* 4'
MYX_M%N=#Q4LYMLI!-B;WO#Z9<[7#-*T/&]0=7+%"<T82*F<Q?FO/+O4<++67
M-II 4$L$A:8SK2Q1 &^) E!+!(H60Z'I="I+% QM_<IEO\<:(ADMOPQUA: N
MIT4[[ J/CLP_AXT)E(T)[*+_FA:<H/>$;XH$S=N#(T9B0*T(*%H,A:9SJ!Q*
M +\7+ "U&:!H,12:?HV#<A^AW7V<<J[+#C'ZSH;)T:#IN-US7>'QP6K/B<PC
M:Z@,0VA?03'&G[S30SPS71+T<7_>\1/#-!<#L)$.4 L!BA9#H>D$*PL1NN#!
M&8+:"5"T& I-IU/YCM#N.Y[:(R-9TQSE>%HS*P9:5-RG=%US;*05U&:T:/H:
MXE'0'B<*^V)6>8?0[AU.C]G]V7ZY7_/I>_,=-*"> A0MAD+3Z5;F(PS@(QC4
M88"BQ5!H.IT'UR39-Y#]4 3#7I5T?"C<"8/N1(LIE3?KN7<@5,X@''0&WW_]
MB!U[- ^&DR$3MWN(VI!JZL]Z:%#Z/QR\&^G';A^QXX^FXGCS5^AVS\<8$@6^
MW\.$4O&A?2Z^KU=_ZGY4KWZ'TY1P5.]73:J>E7![::-Y 17X4&CZ;65*X$?P
MF[ B4,$/BA9#H>ET*@L1/>-%2G;LT;P>[^N:>MV97T.B:-K3D45*YT?/?(V2
M'7\T$\=K".ZLN^'>E"CHN18C4A(]LDOTVUQT5/6QEF_HC^;>4WT:[!NZZKT+
MT8X]F@70/5%0:#JO2O9'/GRW!2KK0=%B*#2=3B7KHX%SXF.G9NUXH[D,#*M4
M1T=QC:EFWDS[TQ.P2I%'=D7^M*_[Q1^%W,;PTEAY4.4-BA9#H>GT'=Q^"G]N
M(X*]VQ3TW 84FDZG<@312><VJISR$NWJ%BFB<[T1[P;B$]0)M&BVI1.H ANB
MS@\NA!?*85U?K"_GH:N<-W>G[S_=7]Y_55]9W_E\[KR-FROX%4SS/P*\QVQ-
M<Z%)R$I 3M[(WH4UE^PW;WBQK:^=OR^XD"_URPW!"6$R@?A^50B/TKZ1!>S_
MJX/+_P-02P,$%     @ _:*%5C86BO+W @  \P<  !D   !X;"]W;W)K<VAE
M971S+W-H965T-#$N>&ULK57;CM,P$/T5*ZS0KD0WE[8)+&VD=@N"AY6J+0L/
MB <WF336.G:QW6;Y>\9)&GI)"P^\M+[,G)PS,YX9E5(]ZQS D)>""SUV<F/6
M=ZZKDQP*JF_E&@3>9%(5U.!6K5R]5D#3RJG@;N!YH5M0)IQX5)W-53R2&\.9
M@+DB>E,45/V: I?EV/&=W<$C6^7&'KCQ:$U7L #SM)XKW+DM2LH*$)I)011D
M8V?BW]U'UKXR^,J@U'MK8I4LI7RVF\_IV/$L(>"0&(M \6\+]\"Y!4(:/QM,
MI_VD==Q?[] _5MI1RY)JN)?\&TM-/G;>.B2%C&ZX>93E)VCT#"U>(KFN?DG9
MV'H.23;:R*)Q1@8%$_4_?6GBL.?@AV<<@L8A.'88G''H-P[]2FC-K)(UHX;&
M(R5+HJPUHME%%9O*&]4P8;.X, IO&?J9>%%GC\B,+-A*L(PE5!@R21*Y$8:)
M%9E+SA(&FO3(GO&CY+:&2JI2NS4YD G'DJ B 8(79"8W2Y-M^ Y*D^L9&,JX
MOD&DI\6,7%_=D"O"!/F2RXVF(M4CUZ D2\Q-&OK3FGYPAKX?D <I3*[)!Y%"
M>@C@8BS:@ 2[@$R#BX@S2&Y)WW]# B\(.@C=_[N[?X%.O\U/O\+KG\'K2L3W
MR5(;A0_@1U? :KQ!-YYM"G=Z31,8._CJ-:@M./'K5W[HO>\2^Y_ #J0/6NF#
M2^CQ%%9,"*M\2;FMJRZU-<2P@K =:QOW_($7CMSMOHPN*W\8M58'_(8MO^%%
M?G,EM\QV,TV2G*H5I,1(@OU5T2I?&!'L)9U%70.'>WS\X?"(\ZE-+QAXW93#
MEG)XD7)33:14S$!/9AG!9X=$$[D%A:75Q34\X1%$T1'74YO>NVZF4<LTNL@4
MG_-?,A^=YO1=-#@BUF%T4!XU-W>O?Q: F;1C!;-J8U5WCO:TG5R3JF$?G4]Q
MHM4#Z ],/0X?L$ 85@J'#"&]VP@YJ7K$U!LCUU677DJ#/;]:YCB505D#O,^D
M-+N-_4 [Y^/?4$L#!!0    ( /VBA5;&;OL=M@(  %L'   9    >&PO=V]R
M:W-H965T<R]S:&5E=#0R+GAM;*U576^;,!3]*Q:KIE;JRC=).X*4)INVAVE1
MTVX/TQX<N 2K8#/;)-U^_6Q#$6UHU$E[26RXY_B<8_L2[QF_%P6 1 ]52<7,
M*J2LKVQ;I 546%RP&JAZDS->8:FF?&N+F@/.#*@J;<]Q(KO"A%I);)ZM>!*S
M1I:$PHHCT505YK^OH63[F>5:CP]NR+:0^H&=Q#7>PAKD7;WB:F;W+!FI@ K"
M*.*0SZRY>[6(=+TI^$9@+P9CI)UL&+O7D\_9S'*T("@AE9H!J[\=+* L-9&2
M\:OCM/HE-7 X?F3_:+PK+QLL8,'*[R23Q<R:6BB#'#>EO&'[3]#Y"35?RDIA
M?M&^JW4LE#9"LJH#*P45H>T_?NAR& #<X 6 UP&\UP+\#N ;HZTR8VN))4YB
MSO:(ZVK%I@<F&X-6;@C5N[B67+TE"B>3=;M[B.5H3;:4Y"3%5*)YFK*&2D*W
M:,5*DA(0Z!T:%-\RB4OT51; T:+A'#1(") "G2Y!8E**,X6X6R_1Z<D9.D&$
MHMN"-0+33,2V5-*U #OM9%ZW,KT79"XAO4"^>XX\Q_-&X(O7P]VG<%L%UJ?F
M]:EYAL]_@6_%H<8D0Q\>U&T2@)2I+HLV@_,^DQ_SC9!<'=:?8Z;;58+Q5?0%
MOA(U3F%FJ1LJ@._ 2MZ^<2/G_5@$_XGL22!^'XA_C+T/!-I 1G>X90@-@VXN
MN\2[]"]C>S<T<5@T#29]S1-M0:\M.*IMGNTP3<<UM<AHN-QD\DS284TT#<<E
MA;VD\*BD!:Z)NC_D#V1(G0XJ<-O44B;DJ,ZC=/]Z4,(#0_YEX(X[BGI'T5%'
M;3]@Y@ZDW=G'YBZ,V8D.=MF?NM&SW ^+PF#B/Y-I#UJ?_NQ\P7Q+J$ EY KF
M7$P4GK>MO)U(5IMNN&%2]58S+-37#[@N4.]SQN3C1#?8_GN:_ 502P,$%
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MH-P$^SR5TNP'[@7M&?#R7U!+ P04    " #]HH566DJ?ET@#  !"#@  &0
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M+W=O<FMS:&5E=',O<VAE970T-BYX;6RU7%UOVS@6_2N$9S%(@;2V)#M..DF
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MYI_H,_$O#EI'QQ?N=?@BV!(:6+SQ(4*YT(Q\+;A6+97YT&ELHM)[M:0QNQE
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MAC(WP/6Y$'IS8 K8?A#M]O]02P,$%     @ _:*%5G"MEJ66!   R!H  !D
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MD5H%'7?I0]6'Q1Y@%=M+=Q=(_GUG;6,P&.M0X 6\]LS'-]_.C&<9[H3\IE8
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MP=3='5=T'A1.QK -ZC$-6J:!D>E[POD->!/'55YE6)!$[F[9D#C%ZOFAHWK
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M:/ .:+B%^)+X[COB.9YG@,].A[O[<!NST:7$ZU+BU7S^ ;XY?:)+AE[139,
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M<SE"O&@N[J:C>%7??4NN\":MFQG^ZX#0 3B?<JZ>._HZ[?Z>HG]02P,$%
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MUZ6EO[)2=90GP>2WF2PG+N^K<O[I&V4%PO19H$_H:CK-5 A)CN[*IB.J@'[
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M4@"3A#,D(!];U^YH$IGX.N [@;7<&".3R9SS9S/YDHTMQP !A509!ZP?*Y@
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M8_UUR6C(A'H [B_2--O^4!64Q_IG_P-02P,$%     @ _:*%5GRXI&G^ P
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M94JG)#3>@)[/M79O-SY!_:5D^@]02P,$%     @ _:*%5M9!QG?< P  R14
M !D   !X;"]W;W)K<VAE971S+W-H965T-C,N>&ULQ5AKC]HX%/TK5K:J6FEW
M$B<\PBP@M<R..M*,%G6V[8?5?C#A E:=F-H&.E)__-HAY#$$3ZDL\07RN.?D
MWN-#=/!PQ\57N0)0Z'O*,CGR5DJMKWU?)BM(B;SB:\CTG047*5'Z5"Q]N19
MYCDH97X8!#T_)33SQL/\VE2,AWRC&,U@*I#<I"D13^^!\=W(P][APD>Z7"ES
MP1\/UV0)CZ ^K:="G_DERYRFD$G*,R1@,?+>X>M)F /RBL\4=K)VC,PH,\Z_
MFI.[^<@+3$? (%&&@NBO+4R ,<.D^_A6D'KE,PVP?GQ@O\V'U\/,B(0)9U_H
M7*U&7NRA.2S(AJF/?/<!BH&ZAB_A3.:?:%?4!AY*-E+QM #K#E*:[;_)]T*(
M&@!W3@#" A ^!T0G %$!B/)!]YWE8]T01<9#P7=(F&K-9@YR;7*TGH9F9AD?
ME=!WJ<:I\2VA GTF; /H 8C<"-!KI"3Z SUJQ\PW#!!?H%K5!PJ"B&3UA+2'
MT"W-2)90PM [*4'C2#9']Y3,**.*@D1O;D 1RN1;S?CI\0:]>?46O4(T0_^L
M^$;J:CGTE9[#=.,G1<_O]SV')WJ^@>0*1?AW% 9AV *?V.$/Y F%O3:TK\4K
M%0Q+!<.<+CI!5^KT]P)-5B1;ZJGOS'Q0ETW?_$*$()EJR//OO69#=PI2^5^;
M$/M'=]H?;7[BUW)-$AAY^C<L06S!&[_^#?>"/]MD<4364"DJ58IL[./#T$]M
M4^ZAW1QJWCO;<13%433TM_7VCZL&_3[NE%6-OCIE7QUK7]/-C-'DL#:M9K02
MG+L&CL@:LW;+6;N7<VK7I4J.R!HJ]4J5>K_NU#VT5_-@&,7XF5&/B[K1H-_N
MTW[95?\<GZ(?Z!ZVP!!NZ])*=>Y:.")K3!V74\>7<VSL4B5'9 V5!J5*@U]W
M[.!G''M<=-JQ.*BB16#WK*!;H@!-F9[<Q KK:]9.=NYZN&)KCEY+5?ARQBV>
M[4HI1VQ-I:KTA*VQPV[> ELW)NZ'SX-!2Y6.#R>" :X2"[9'EM/V+=^^46O3
M5MJSE\<16U.$*A[AS@6-[#1:N6)K*E6%*VQ-)2\8N?M31CZNLABY"C38GFC^
M(B+3_^"1O4,KQ]EKX8BM.7$5EG#_@JYU&J]<L365J@(6MB:3%UP;'_LQQ#AX
M;MOCLD$4Q\$)WU:Q!MMSS9%O7WCO6MG.7A=';,T]A2H[A<$%=Q6<1BU7;$VE
MJJ@56@.*W<$%MON"@UO*VASLU_;9S";G Q%+FDG$8*%QP55?$XC]ON'^1/%U
MOO4VXTKQ-#]< 9F#, 7Z_H)S=3@QNWGE[NWX?U!+ P04    " #]HH560&:(
M>,$#   -$@  &0   'AL+W=O<FMS:&5E=',O<VAE970V-"YX;6S%6&&/HS80
M_2LC6E5WTEW 0)+=;1*IE^VI*W6E:'/=^U#U@Y=,@K6 <[9)-O^^MB$$MH15
M)*K]DF \\SSO^0$#DST7SS)&5/"2)IF<.K%2VQO7E5&,*94#OL5,SZRY2*G2
M0[%QY58@7=FD-'%]SQNY*669,YO8<PLQF_!<)2S#A0"9IRD5AR^8\/W4(<[Q
MQ /;Q,J<<&>3+=W@$M5?VX70([="6;$4,\EX!@+74^<W<C,G(Y-@(QX9[F7M
M& R5)\Z?S>!N-74\4Q$F&"D#0?7?#N>8) 9)U_&C!'6J-4UB_?B(_M62UV2>
MJ,0Y3[ZSE8JGSI4#*US3/%$/?/\'EH2&!B_BB;2_L"]C/0>B7"J>ELFZ@I1E
MQ3]]*86H)?C#,PE^F>"_3@C/) 1E0F")%I596K=4T=E$\#T($ZW1S('5QF9K
M-BPSV[A40L\RG:=F7RD3\$B3'.$>J<P%ZCU2$C[#LMA8X&M8LDW&UBRBF8*[
M;)OK><7AGF<*84Y%PG5$FB?4;HRV%M10=?I"L!W5H8N$1A8>OE,AJ%GFPRTJ
MRA+Y42]X/FSB*DW5%.Q&):TO!2W_#*U;C 80D$_@>[X//X,+,J8"VY#FW4CW
M] #^Z T@5ZM>2>]7TOL6.3R#O%0\>C:L(VPCV)ELKNX;N=5"31U]^4H4.W1F
MO_Q$1MZO;1Q[ FOP#"J>@44/+K+8T4@T6]G)PCS?,(HS]B-'"7__J7'@3F$J
M_VG3)^A3GY[ &OJ$E3YAMP]H8B\3ZX=/A2%@@0*6QFEMU N\*XMG[M.[63 8
M!Q-W5Z?TWZ#K@>=708U2AU6IP\Y2?W]!$3&)YUW;F7_IKO0$UJ ZJJB.WL.U
MHS[UZ0FLH<^XTF?<:87J%FZD$.9A*4&W"5+I,<LVD-9$8T:T-C6*)4A0,RDA
M@^$K)[\5U:C_JJK_JK/^!R:?/Z\%(CSHATY;<9WYEVY53V -JM<5U>OWL/)U
MG_KT!-;0AWBG)LC[_\U<KD%(S:?>P M?N?D8%C;#_'&[GTFMDR.=)!ZYZ< 2
MI@ZMU74F7[I=?:$UJ9XZ)^*_AZ-)KSU77VA-C4Y=%^EL6GKR=-!FUM#W7YNZ
M-8X$X1E3GWHCTMT<?4.1P@>6P0&ID!];:^Q$N'C7>D)K\CTU6&3X+L[NM2_K
M"ZVIT:DS(YV-S9O.5MHSK2)TPX:%QR"$5+_9QA+\$%;TT/[.V TU+*#:V+JU
M=W7SH>2>B@W+)"2XUE#>8*RU%<6WAV*@^-:^OC]QI7AJ#V.D*Q0F0,^O.5?'
M@?DB4'T!FOT+4$L#!!0    ( /VBA59O,[-N>0,  " /   9    >&PO=V]R
M:W-H965T<R]S:&5E=#8U+GAM;,5776_3,!3]*U<!(9"@^6R[C;82=$Q,8M*T
MPGA /'CI;6,ML8/MK/3?8SM9EHPT:%+07MHXOO?DGN/CY'JVX^)6)H@*?F<I
MDW,G42H_<5T9)Y@1.>(Y,CVSX2(C2@_%UI6Y0+*V25GJ!IXW<3-"F;.8V7N7
M8C'CA4HIPTL!LL@R(O8?,>6[N>,[]S>NZ#91YH:[F.5DBRM4W_)+H4=NC;*F
M&3)).0.!F[GSP3]9^J%)L!'7%'>R<0V&R@WGMV9POIX[GJD(4XR5@2#Z[PZ7
MF*8&2=?QJP)UZF>:Q.;U/?J9):_)W!")2YY^IVN5S)TC!]:X(46JKOCN,U:$
MQ@8OYJFTO["K8CT'XD(JGE7)NH*,LO*?_*Z$:"0$XP,)0940/$Z(#B2$58)5
MSBTKL[1.B2*+F> [$"9:HYD+JXW-UFPH,\NX4D+/4IVG%F>$"K@F:8%P@406
M O4:*0GO8%4N+/ -K.B6T0V-"5-PSO)"SRL.%YPIA"41*=<169$2NS#:6M!
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MW[#F-VSE=\>XD$P_[PO?1Y>:351:H5Y;\\X$=L3ZLF9]^4.*_N4Y!3@3V)$
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M0T_2@&R/SYY8)UO+)#V4^RCZDJY<N>>=7IJ1\,5,I@BN_CV*J?#]E*3R^%I
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MHAL7=<QN>5$.?F *DTR3#.8H&K3[>$^KHL(J!D:N7%7S) W62*Z[Q*H4E%V
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M:_O+-K7MB(RC2J,L&C!%4&2B_O)MH\,>@'BZ 7X#\)\!)MX+@* !!,\]C%X
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M-,FZ%]<3+4K7SN9"F^;HAKGY?8&T 69_(83>3NP![0\Q^0-02P,$%     @
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M>QZT*@]:3>C^(X3 <'I,8Y'8UHGJVEGZ7JLW,)>[U!O!+Z3>KJBW&ZE/!1:
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M(\),T-=77+?>#$R!=C\Q^0]02P,$%     @ _:*%5HM^3.CF @  P@@  !D
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M><*(H7LZ;6J]A$%=9:-!5HA-L46^#6AUDE/O@?"A/R:<320#5D9RQE<VW(7
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MO+@"P4.$@J_J$#T45D!Y(6#VP@QN:6O,""@?!,P^F,*]+)18RF]M)G(NP2P
M&.K%S$*Z<:]<?0L+2.":NXH!*0$$W!,)8-)E$Y2-1T<0#A *RF2ZW8N4#0)F
M&SS4C6I]=2]KW2]A#/:R*0>T""DS!,QF2*N55U\K.$E,G@]&N( R0\!L!C(I
M_QQ@3,H3P27G#I_[&)/R1<#LBQ,YNOAC*0'"_XD9*6D$S-)H)^NG\/J4,_K,
MSB"R]IH58U(RZ7.7J<YE[KL.Q9B47_K,?CG,WT_>;K).Q>R7=B)_$H\R2Y_9
M+&?RTSTGQJ3TTN?6RYE$\ <GQJ1DTV>6S2X?/'F3*;GTF>6"$\.3<)12^MQ3
MD',9XO% 0UFESST5(04=XH(S99>0V2XT9H0Q*;N$S':A,6.,2=DE9+8+C9E@
M3,HQ(;-C:,P!QB170YA=0V.^P9B4:T)FUYRJD(LK,5RO#VO2(>6:D-DUIU+Q
M*Y'"E==5K@3&I-P3,KN'Q&S-OT+*0N$%)C: N7]B,29EH?#WKY'\PFSU9D19
M*&*VT&G,?03A.4Y$62AB+YBU9HHH>F"(FN)(CR@+1<P6HF:,P(PQ*0M%S!:B
M,8<8D[)0Q+TH?W9BVP02QB17Y;F7Y0E,""2,25DH8K;0T?R['408D[)0Q&RA
M@UDX&HMR"/0-QJ0L%#%;Z @3]^6BPIB4A2)F"Y&8=Q@SIBP4,UOH:+6R?=\Q
M)F6AF-E"1VN7YS$I"\7,%CI7*?IQ]S$F9:&8V4($9ITE84S*0O&%ZFX-9BN1
MBRD+Q<P6HC'QLD1,[@YCMM"99>Q](&%,RD(Q]R+/N2KFCA-C4A:*F2U$8-8Q
MA#$I"\47VAS08+9"**$LE'!7Y$A,'$()9:&$V4(_2M>'F5%SJ7;5(Z$LE#!;
MZ"<F*B8M8-HAZT5[,<.8E(42[E6?0\Q;F4N3*9$V7XDQ*0LEW+O,3O3FO7S=
MC?$KO(DJH2R4,%NHM7YQ_(1B3,I"";.%#C#;Q80,UY 2<I?R[UP-.L1LCYN4
MA1)F"Q&8=5D)8U(62MAW&[0PQVJCG(.A'AK$T.,%U %EH0&SA<ZOLC5=BS$I
M"PV8+41BMI[- 66A ?>V9FK3F+C"F)2%!LP6.K]MK!E%,29EH4%CH6YSLG__
M;JTVVJCU'+["0WLF\^S>B?JEOE(O"*-ZS^BFRO,1M"W,S,KU_I^^]O^P]OX_
M4$L#!!0    ( /VBA5:3,;S]@ (  ),Q   :    >&PO7W)E;',O=V]R:V)O
M;VLN>&UL+G)E;'/-VDUNHT 0AN&K6!P@[:[JJNZ,XJQFD^TH%T!.^T>QC06,
M)KG]6,["_M L9A/QK5"#*-X%>H2 IU_UT([[[C3L]N=A\7$\G(95LQO'\X\0
MAO6N'MOAH3O7T^7(INN/[7A9]MMP;M?O[;8&62X]]/<SFN>G^YF+U\]S_9^)
MW6:S7]>?W?KWL9[&?PP.?[K^?=C5.C:+U[;?UG'5A(_#;?<0KIOX<)G<+%[>
M5DW_\A:;,'>00)#,'Z00I/,')0A*\P<9!-G\00Y!/G]0AJ \?U"!H#)_T",$
M/<X?%)<HXY(@:8(U@=81N8X$7D<$.Q*('9'L2&!V1+0C@=H1V8X$;D>$.Q+(
M'9'N2&!W1+PC@=Z">@N!WH)Z"X'>,GG8)M!;4&\AT%M0;R'06U!O(=!;4&\A
MT%M0;R'06U!O(=!;4&\AT%M1;R706U%O)=!;46\ET%LG+TL(]%;46PGT5M1;
M"?16U%L)]%;46PGT5M1;"?16U%L)]$ZH=R+0.Z'>B4#OA'HG KT3ZIT(]$Z3
ME]T$>B?4.Q'HG5#O1*!W0KT3@=X)]4X$>B?4.Q'H;:BW$>AMJ+<1Z&VHMQ'H
M;:BW$>AMJ+<1Z&V3CY4$>AOJ;01Z&^IM!'H;ZFT$>AOJ;01Z.^KM!'H[ZNT$
M>COJ[01Z.^KM!'H[ZNT$>COJ[01Z^^1G$P*]'?5V KT=]78"O1WU=@*],^J=
M"?3.J'<FT#NCWIE [XQZ9P*],^J="?3.J'<FT#NCWIE [SSY69! [XQZ9P*]
M,^J="?0NJ'<AT+N@WH5 [X)Z%P*]"^I="/0NJ'?Y3KV'\?-0AUO/UQJO_YU4
MCY=SZ^WRU^77SLG=>\4YW%<,SW\!4$L#!!0    ( /VBA5;W,"8&)P(  #(P
M   3    6T-O;G1E;G1?5'EP97-=+GAM;,W;36[;,! %X*L8V@86S7^UB+-I
MNVVSZ 58:1P+ED2"9%+G]J7D)$"+U$C@ GT;"S;)>2,.\.U\_?TQ4%H=QV%*
MVVJ?<_C(6&KW-+I4^T!36=GY.+I<OL8[%EQ[<'?$Q&9C6.NG3%->Y[E&=7/]
MF7;N?LBK+\?R<^K]M*TB#:E:?3IMG+.VE0MAZ%N7RSI[F+H_4M9/"74YN>Q)
M^SZDJ[*A8J\FS"M_#W@Z]^V!8NP[6MVZF+^ZL>QBQX&E_#A0JL^7>*5'O]OU
M+76^O1_+D3J%2*Y+>Z(\#O6IZ-7YY%QNF$Z?_.+\I<RYP++S-OJ0RL0BO3_N
M>23SZ74HA2CF_OPKOB26TA>_'\W3[JA[8W:YWI\^'I9Y)+8\+K_CWV?\4O^=
M?0B0/B1('PJD#PW2AP'IPX+TT8#T\0&D#[Y!:01%5(Y"*D<QE:.@RE%4Y2BL
M<A17.0JL'$56@2*K0)%5H,@J4&05*+(*%%D%BJP"15:!(JM D56BR"I19)4H
MLDH4626*K!)%5HDBJT215:+(*E%D52BR*A19%8JL"D56A2*K0I%5H<BJ4&15
M*+(J%%DUBJP:15:-(JM&D56CR*I19-4HLFH4636*K!I%5H,BJT&1U:#(:E!D
M-2BR&A19#8JL!D56@R*K09'5HLAJ462U*+):%%DMBJP615:+(JM%D=6BR&I1
M9&U09&U09&U09&U09&W^IZP_O#_\X_CE68^NGY[SV?)7@9M?4$L! A0#%
M  @ _:*%5@=!36*!    L0   !               ( !     &1O8U!R;W!S
M+V%P<"YX;6Q02P$"% ,4    " #]HH564\F]5^X    K @  $0
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M=#(N>&UL4$L! A0#%     @ _:*%5JM0T*HQ!0  -B   !@
M ("!$!0  'AL+W=O<FMS:&5E=',O<VAE970S+GAM;%!+ 0(4 Q0    ( /VB
MA5;^5SI8%0<  )@D   8              " @7<9  !X;"]W;W)K<VAE971S
M+W-H965T-"YX;6Q02P$"% ,4    " #]HH56OH']":T)   <80  &
M        @('"(   >&PO=V]R:W-H965T<R]S:&5E=#4N>&UL4$L! A0#%
M  @ _:*%5F>+@&4+"0  3RP  !@              ("!I2H  'AL+W=O<FMS
M:&5E=',O<VAE970V+GAM;%!+ 0(4 Q0    ( /VBA59: 'M(U0,  /((   8
M              " @>8S  !X;"]W;W)K<VAE971S+W-H965T-RYX;6Q02P$"
M% ,4    " #]HH56T8WU] \>  #]6   &               @('Q-P  >&PO
M=V]R:W-H965T<R]S:&5E=#@N>&UL4$L! A0#%     @ _:*%5OH&<Q8^$@
MJSD  !@              ("!-E8  'AL+W=O<FMS:&5E=',O<VAE970Y+GAM
M;%!+ 0(4 Q0    ( /VBA5:3D=<Y0P8  ($0   9              " @:IH
M  !X;"]W;W)K<VAE971S+W-H965T,3 N>&UL4$L! A0#%     @ _:*%5@A:
MM&C% @  .@8  !D              ("!)&\  'AL+W=O<FMS:&5E=',O<VAE
M970Q,2YX;6Q02P$"% ,4    " #]HH56T8&4>KP#   V"   &0
M    @($@<@  >&PO=V]R:W-H965T<R]S:&5E=#$R+GAM;%!+ 0(4 Q0    (
M /VBA59OC7F$)@,  .$&   9              " @1-V  !X;"]W;W)K<VAE
M971S+W-H965T,3,N>&UL4$L! A0#%     @ _:*%5@',YK2H @  QP4  !D
M             ("!<'D  'AL+W=O<FMS:&5E=',O<VAE970Q-"YX;6Q02P$"
M% ,4    " #]HH562!++DT,)  "W&0  &0              @(%/?   >&PO
M=V]R:W-H965T<R]S:&5E=#$U+GAM;%!+ 0(4 Q0    ( /VBA583*SJ',@X
M #PM   9              " @<F%  !X;"]W;W)K<VAE971S+W-H965T,38N
M>&UL4$L! A0#%     @ _:*%5B!+3#%#!   N@H  !D              ("!
M,I0  'AL+W=O<FMS:&5E=',O<VAE970Q-RYX;6Q02P$"% ,4    " #]HH56
M/@6MFEX(   8&   &0              @(&LF   >&PO=V]R:W-H965T<R]S
M:&5E=#$X+GAM;%!+ 0(4 Q0    ( /VBA59M,*C[F 0  )0+   9
M      " @4&A  !X;"]W;W)K<VAE971S+W-H965T,3DN>&UL4$L! A0#%
M  @ _:*%5GP%2-VP!P  XA0  !D              ("!$*8  'AL+W=O<FMS
M:&5E=',O<VAE970R,"YX;6Q02P$"% ,4    " #]HH565UP^*PL%  #T"P
M&0              @('WK0  >&PO=V]R:W-H965T<R]S:&5E=#(Q+GAM;%!+
M 0(4 Q0    ( /VBA59^3*(?>0@  ,$5   9              " @3FS  !X
M;"]W;W)K<VAE971S+W-H965T,C(N>&UL4$L! A0#%     @ _:*%5F?]U9-L
M!   ^PD  !D              ("!Z;L  'AL+W=O<FMS:&5E=',O<VAE970R
M,RYX;6Q02P$"% ,4    " #]HH56"L2:$(0+  "I'@  &0
M@(&,P   >&PO=V]R:W-H965T<R]S:&5E=#(T+GAM;%!+ 0(4 Q0    ( /VB
MA59;4K3F'P8  ,T2   9              " @4?,  !X;"]W;W)K<VAE971S
M+W-H965T,C4N>&UL4$L! A0#%     @ _:*%5DDZ\K2G @  808  !D
M         ("!G=(  'AL+W=O<FMS:&5E=',O<VAE970R-BYX;6Q02P$"% ,4
M    " #]HH5634_$:<\?  #V9P  &0              @(%[U0  >&PO=V]R
M:W-H965T<R]S:&5E=#(W+GAM;%!+ 0(4 Q0    ( /VBA5;NRJL<!@4  &T-
M   9              " @8'U  !X;"]W;W)K<VAE971S+W-H965T,C@N>&UL
M4$L! A0#%     @ _:*%5K/?FCQ(!0  V0T  !D              ("!OOH
M 'AL+W=O<FMS:&5E=',O<VAE970R.2YX;6Q02P$"% ,4    " #]HH56"86K
M3,<"   ]!@  &0              @($]  $ >&PO=V]R:W-H965T<R]S:&5E
M=#,P+GAM;%!+ 0(4 Q0    ( /VBA58.J$9)]@(  %L&   9
M  " @3L# 0!X;"]W;W)K<VAE971S+W-H965T,S$N>&UL4$L! A0#%     @
M_:*%5BZ/8(>8 @  H@4  !D              ("!: 8! 'AL+W=O<FMS:&5E
M=',O<VAE970S,BYX;6Q02P$"% ,4    " #]HH56%="Y%J8"  #(!0  &0
M            @($W"0$ >&PO=V]R:W-H965T<R]S:&5E=#,S+GAM;%!+ 0(4
M Q0    ( /VBA593VD1Q&0,  "0'   9              " @10, 0!X;"]W
M;W)K<VAE971S+W-H965T,S0N>&UL4$L! A0#%     @ _:*%5@XSKP.%!
MB T  !D              ("!9 \! 'AL+W=O<FMS:&5E=',O<VAE970S-2YX
M;6Q02P$"% ,4    " #]HH56HB/I&N8#  #I"0  &0              @($@
M% $ >&PO=V]R:W-H965T<R]S:&5E=#,V+GAM;%!+ 0(4 Q0    ( /VBA5:Z
M80$]E@0  "T,   9              " @3T8 0!X;"]W;W)K<VAE971S+W-H
M965T,S<N>&UL4$L! A0#%     @ _:*%5D/UD$NI!   ]@P  !D
M     ("!"AT! 'AL+W=O<FMS:&5E=',O<VAE970S."YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( /VBA58*';@_ZP,   \6   9              "
M@8,X 0!X;"]W;W)K<VAE971S+W-H965T-#,N>&UL4$L! A0#%     @ _:*%
M5EI*GY=( P  0@X  !D              ("!I3P! 'AL+W=O<FMS:&5E=',O
M<VAE970T-"YX;6Q02P$"% ,4    " #]HH56+F26%$\#  !D$   &0
M        @($D0 $ >&PO=V]R:W-H965T<R]S:&5E=#0U+GAM;%!+ 0(4 Q0
M   ( /VBA5;X;"#0_PD  !Q-   9              " @:I# 0!X;"]W;W)K
M<VAE971S+W-H965T-#8N>&UL4$L! A0#%     @ _:*%5G"MEJ66!   R!H
M !D              ("!X$T! 'AL+W=O<FMS:&5E=',O<VAE970T-RYX;6Q0
M2P$"% ,4    " #]HH56AK8;Q/\#  "O%0  &0              @(&M4@$
M>&PO=V]R:W-H965T<R]S:&5E=#0X+GAM;%!+ 0(4 Q0    ( /VBA59;I.U&
M[P,  %@.   9              " @>-6 0!X;"]W;W)K<VAE971S+W-H965T
M-#DN>&UL4$L! A0#%     @ _:*%5A>,<N/- P  ]Q   !D
M ("!"5L! 'AL+W=O<FMS:&5E=',O<VAE970U,"YX;6Q02P$"% ,4    " #]
MHH56]_=A*6,"  #'!0  &0              @($-7P$ >&PO=V]R:W-H965T
M<R]S:&5E=#4Q+GAM;%!+ 0(4 Q0    ( /VBA59\DSW]*P,  *T,   9
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M970U-BYX;6Q02P$"% ,4    " #]HH56V<SY). "  !)"0  &0
M    @(&W<0$ >&PO=V]R:W-H965T<R]S:&5E=#4W+GAM;%!+ 0(4 Q0    (
M /VBA59@E_?Z2 L  /5A   9              " @<YT 0!X;"]W;W)K<VAE
M971S+W-H965T-3@N>&UL4$L! A0#%     @ _:*%5J0,-!?0 @  S0<  !D
M             ("!38 ! 'AL+W=O<FMS:&5E=',O<VAE970U.2YX;6Q02P$"
M% ,4    " #]HH56-Z1.Z&4"  !=!@  &0              @(%4@P$ >&PO
M=V]R:W-H965T<R]S:&5E=#8P+GAM;%!+ 0(4 Q0    ( /VBA58^W/J$?0D
M .(_   9              " @?"% 0!X;"]W;W)K<VAE971S+W-H965T-C$N
M>&UL4$L! A0#%     @ _:*%5GRXI&G^ P  -1$  !D              ("!
MI(\! 'AL+W=O<FMS:&5E=',O<VAE970V,BYX;6Q02P$"% ,4    " #]HH56
MUD'&=]P#  #)%0  &0              @('9DP$ >&PO=V]R:W-H965T<R]S
M:&5E=#8S+GAM;%!+ 0(4 Q0    ( /VBA59 9HAXP0,   T2   9
M      " @>R7 0!X;"]W;W)K<VAE971S+W-H965T-C0N>&UL4$L! A0#%
M  @ _:*%5F\SLVYY P  ( \  !D              ("!Y)L! 'AL+W=O<FMS
M:&5E=',O<VAE970V-2YX;6Q02P$"% ,4    " #]HH56FD1*9W@#  #)#
M&0              @(&4GP$ >&PO=V]R:W-H965T<R]S:&5E=#8V+GAM;%!+
M 0(4 Q0    ( /VBA59/^LY@% 0  (P/   9              " @4.C 0!X
M;"]W;W)K<VAE971S+W-H965T-C<N>&UL4$L! A0#%     @ _:*%5A*TT4C7
M!@  9T$  !D              ("!CJ<! 'AL+W=O<FMS:&5E=',O<VAE970V
M."YX;6Q02P$"% ,4    " #]HH567.!J^6<#  #S"@  &0
M@(&<K@$ >&PO=V]R:W-H965T<R]S:&5E=#8Y+GAM;%!+ 0(4 Q0    ( /VB
MA59>TYNY<@,  /L*   9              " @3JR 0!X;"]W;W)K<VAE971S
M+W-H965T-S N>&UL4$L! A0#%     @ _:*%5M:,ST#* @  M@8  !D
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M=#<U+GAM;%!+ 0(4 Q0    ( /VBA580.5F=0P,  *@*   9
M  " @4K& 0!X;"]W;W)K<VAE971S+W-H965T-S8N>&UL4$L! A0#%     @
M_:*%5A%F]2^T @  ' <  !D              ("!Q,D! 'AL+W=O<FMS:&5E
M=',O<VAE970W-RYX;6Q02P$"% ,4    " #]HH566A>5_S #  #X"P  &0
M            @(&OS $ >&PO=V]R:W-H965T<R]S:&5E=#<X+GAM;%!+ 0(4
M Q0    ( /VBA584V61W. ,  &H)   9              " @1;0 0!X;"]W
M;W)K<VAE971S+W-H965T-SDN>&UL4$L! A0#%     @ _:*%5A!.)[JF @
MQ08  !D              ("!A=,! 'AL+W=O<FMS:&5E=',O<VAE970X,"YX
M;6Q02P$"% ,4    " #]HH56<$2;;A,#  !*"0  &0              @(%B
MU@$ >&PO=V]R:W-H965T<R]S:&5E=#@Q+GAM;%!+ 0(4 Q0    ( /VBA5;A
M_6\\] ,  %L4   9              " @:S9 0!X;"]W;W)K<VAE971S+W-H
M965T.#(N>&UL4$L! A0#%     @ _:*%5HM^3.CF @  P@@  !D
M     ("!U]T! 'AL+W=O<FMS:&5E=',O<VAE970X,RYX;6Q02P$"% ,4
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M+W=O<FMB;V]K+GAM;%!+ 0(4 Q0    ( /VBA5:3,;S]@ (  ),Q   :
M          "  1SQ 0!X;"]?<F5L<R]W;W)K8F]O:RYX;6PN<F5L<U!+ 0(4
M Q0    ( /VBA5;W,"8&)P(  #(P   3              "  =3S 0!;0V]N
E=&5N=%]4>7!E<UTN>&UL4$L%!@    !< %P .QD  "SV 0    $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>95
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>96
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>97
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.23.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>297</ContextCount>
  <ElementCount>426</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>121</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>12</UnitCount>
  <MyReports>
    <Report instance="d479690dposam.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>1001 - Document -  Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://haymaker.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="d479690dposam.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>1002 - Statement -  CONSOLIDATED BALANCE SHEETS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://haymaker.com/role/ConsolidatedBalanceSheets</Role>
      <ShortName>CONSOLIDATED BALANCE SHEETS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="d479690dposam.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>1003 - Statement -  CONSOLIDATED BALANCE SHEETS (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://haymaker.com/role/ConsolidatedBalanceSheetsParenthetical</Role>
      <ShortName>CONSOLIDATED BALANCE SHEETS (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="d479690dposam.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>1004 - Statement -  CONSOLIDATED STATEMENTS OF INCOME AND COMPREHENSIVE INCOME</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://haymaker.com/role/ConsolidatedStatementsOfIncomeAndComprehensiveIncome</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF INCOME AND COMPREHENSIVE INCOME</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="d479690dposam.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>1005 - Statement -  CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (DEFICIT)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://haymaker.com/role/ConsolidatedStatementsOfStockholdersEquityDeficit</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (DEFICIT)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="d479690dposam.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>1006 - Statement -  CONSOLIDATED STATEMENTS OF CASH FLOWS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://haymaker.com/role/ConsolidatedStatementsOfCashFlows</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF CASH FLOWS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="d479690dposam.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>1007 - Disclosure -  Description of Business and Basis of Presentation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://haymaker.com/role/DescriptionOfBusinessAndBasisOfPresentation</Role>
      <ShortName>Description of Business and Basis of Presentation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="d479690dposam.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>1008 - Disclosure -  Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://haymaker.com/role/SummaryOfSignificantAccountingPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="d479690dposam.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>1009 - Disclosure -  Business Combination</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://haymaker.com/role/BusinessCombination</Role>
      <ShortName>Business Combination</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="d479690dposam.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>1010 - Disclosure -  Revenue Recognition</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://haymaker.com/role/RevenueRecognition</Role>
      <ShortName>Revenue Recognition</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="d479690dposam.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>1011 - Disclosure -  Inventory, Net</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://haymaker.com/role/InventoryNet</Role>
      <ShortName>Inventory, Net</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="d479690dposam.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>1012 - Disclosure -  Property and Equipment, Net</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://haymaker.com/role/PropertyAndEquipmentNet</Role>
      <ShortName>Property and Equipment, Net</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="d479690dposam.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>1013 - Disclosure -  Capitalized Software, Net</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://haymaker.com/role/CapitalizedSoftwareNet</Role>
      <ShortName>Capitalized Software, Net</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="d479690dposam.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>1014 - Disclosure -  Accrued Expenses</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://haymaker.com/role/AccruedExpenses</Role>
      <ShortName>Accrued Expenses</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="d479690dposam.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>1015 - Disclosure -  Long-Term Debt</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://haymaker.com/role/LongTermDebt</Role>
      <ShortName>Long-Term Debt</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="d479690dposam.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>1016 - Disclosure -  Warrant Liability</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://haymaker.com/role/WarrantLiability</Role>
      <ShortName>Warrant Liability</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="d479690dposam.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>1017 - Disclosure -  Earnout Liability</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://haymaker.com/role/EarnoutLiability</Role>
      <ShortName>Earnout Liability</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="d479690dposam.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>1018 - Disclosure -  Fair Value Measurements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://haymaker.com/role/FairValueMeasurements</Role>
      <ShortName>Fair Value Measurements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="d479690dposam.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>1019 - Disclosure -  Noncontrolling Interest</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://haymaker.com/role/NoncontrollingInterest</Role>
      <ShortName>Noncontrolling Interest</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="d479690dposam.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>1020 - Disclosure -  Share-Based Compensation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://haymaker.com/role/ShareBasedCompensation</Role>
      <ShortName>Share-Based Compensation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="d479690dposam.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>1021 - Disclosure -  Leases</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://haymaker.com/role/Leases</Role>
      <ShortName>Leases</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="d479690dposam.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>1022 - Disclosure -  Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://haymaker.com/role/IncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="d479690dposam.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>1023 - Disclosure -  Net Loss Per Common Share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://haymaker.com/role/NetLossPerCommonShare</Role>
      <ShortName>Net Loss Per Common Share</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="d479690dposam.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>1024 - Disclosure -  Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://haymaker.com/role/CommitmentsAndContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>24</Position>
    </Report>
    <Report instance="d479690dposam.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>1025 - Disclosure -  Related-Party Transactions</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://haymaker.com/role/RelatedPartyTransactions</Role>
      <ShortName>Related-Party Transactions</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>25</Position>
    </Report>
    <Report instance="d479690dposam.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>1026 - Disclosure -  Subsequent Events</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://haymaker.com/role/SubsequentEvents</Role>
      <ShortName>Subsequent Events</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>26</Position>
    </Report>
    <Report instance="d479690dposam.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>1027 - Disclosure -  Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://haymaker.com/role/SummaryOfSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://haymaker.com/role/SummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="d479690dposam.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>1028 - Disclosure -  Summary of Significant Accounting Policies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://haymaker.com/role/SummaryOfSignificantAccountingPoliciesTables</Role>
      <ShortName>Summary of Significant Accounting Policies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://haymaker.com/role/SummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="d479690dposam.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>1029 - Disclosure -  Revenue Recognition (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://haymaker.com/role/RevenueRecognitionTables</Role>
      <ShortName>Revenue Recognition (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://haymaker.com/role/RevenueRecognition</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="d479690dposam.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>1030 - Disclosure -  Inventory, Net (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://haymaker.com/role/InventoryNetTables</Role>
      <ShortName>Inventory, Net (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://haymaker.com/role/InventoryNet</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="d479690dposam.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>1031 - Disclosure -  Property and Equipment, Net (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://haymaker.com/role/PropertyAndEquipmentNetTables</Role>
      <ShortName>Property and Equipment, Net (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://haymaker.com/role/PropertyAndEquipmentNet</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="d479690dposam.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>1032 - Disclosure -  Capitalized Software, Net (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://haymaker.com/role/CapitalizedSoftwareNetTables</Role>
      <ShortName>Capitalized Software, Net (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://haymaker.com/role/CapitalizedSoftwareNet</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="d479690dposam.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>1033 - Disclosure -  Accrued Expenses (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://haymaker.com/role/AccruedExpensesTables</Role>
      <ShortName>Accrued Expenses (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://haymaker.com/role/AccruedExpenses</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="d479690dposam.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>1034 - Disclosure -  Long-Term Debt (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://haymaker.com/role/LongTermDebtTables</Role>
      <ShortName>Long-Term Debt (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://haymaker.com/role/LongTermDebt</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="d479690dposam.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>1035 - Disclosure -  Fair Value Measurements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://haymaker.com/role/FairValueMeasurementsTables</Role>
      <ShortName>Fair Value Measurements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://haymaker.com/role/FairValueMeasurements</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="d479690dposam.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>1036 - Disclosure -  Share-Based Compensation (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://haymaker.com/role/ShareBasedCompensationTables</Role>
      <ShortName>Share-Based Compensation (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://haymaker.com/role/ShareBasedCompensation</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="d479690dposam.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>1037 - Disclosure -  Leases (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://haymaker.com/role/LeasesTables</Role>
      <ShortName>Leases (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://haymaker.com/role/Leases</ParentRole>
      <Position>37</Position>
    </Report>
    <Report instance="d479690dposam.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>1038 - Disclosure -  Income Taxes (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://haymaker.com/role/IncomeTaxesTables</Role>
      <ShortName>Income Taxes (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://haymaker.com/role/IncomeTaxes</ParentRole>
      <Position>38</Position>
    </Report>
    <Report instance="d479690dposam.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>1039 - Disclosure -  Net Loss Per Common Share (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://haymaker.com/role/NetLossPerCommonShareTables</Role>
      <ShortName>Net Loss Per Common Share (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://haymaker.com/role/NetLossPerCommonShare</ParentRole>
      <Position>39</Position>
    </Report>
    <Report instance="d479690dposam.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>1040 - Disclosure -  Summary of Significant Accounting Policies - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://haymaker.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="d479690dposam.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>1041 - Disclosure -  Summary of Significant Accounting Policies - Summary of Rollforward of the Allowance for Doubtful Accounts (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://haymaker.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfRollforwardOfTheAllowanceForDoubtfulAccountsDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Summary of Rollforward of the Allowance for Doubtful Accounts (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="d479690dposam.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>1042 - Disclosure -  Summary of Significant Accounting Policies - Summary of Total Other Current Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://haymaker.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfTotalOtherCurrentAssetsDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Summary of Total Other Current Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="d479690dposam.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>1043 - Disclosure -  Summary of Significant Accounting Policies - Summary of Estimated Useful Lives of Property and Equipment (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://haymaker.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfEstimatedUsefulLivesOfPropertyAndEquipmentDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Summary of Estimated Useful Lives of Property and Equipment (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="d479690dposam.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>1044 - Disclosure -  Summary of Significant Accounting Policies - Summary of Members' Equity Units Issued and Outstanding (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://haymaker.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfMembersEquityUnitsIssuedAndOutstandingDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Summary of Members' Equity Units Issued and Outstanding (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="d479690dposam.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>1045 - Disclosure -  Summary of Significant Accounting Policies - Summary of Common Stock Issued and Outstanding (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://haymaker.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfCommonStockIssuedAndOutstandingDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Summary of Common Stock Issued and Outstanding (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="d479690dposam.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>1046 - Disclosure -  Business Combination - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://haymaker.com/role/BusinessCombinationAdditionalInformationDetails</Role>
      <ShortName>Business Combination - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report instance="d479690dposam.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>1047 - Disclosure -  Revenue Recognition - Schedule of Revenues Recognized for Each Revenue Stream (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://haymaker.com/role/RevenueRecognitionScheduleOfRevenuesRecognizedForEachRevenueStreamDetails</Role>
      <ShortName>Revenue Recognition - Schedule of Revenues Recognized for Each Revenue Stream (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report instance="d479690dposam.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>1048 - Disclosure -  Revenue Recognition - Schedule of Revenues Recognized by Geographic Region (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://haymaker.com/role/RevenueRecognitionScheduleOfRevenuesRecognizedByGeographicRegionDetails</Role>
      <ShortName>Revenue Recognition - Schedule of Revenues Recognized by Geographic Region (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>48</Position>
    </Report>
    <Report instance="d479690dposam.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>1049 - Disclosure -  Revenue Recognition - Summary of Significant Changes in Contract Liability Balances (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://haymaker.com/role/RevenueRecognitionSummaryOfSignificantChangesInContractLiabilityBalancesDetails</Role>
      <ShortName>Revenue Recognition - Summary of Significant Changes in Contract Liability Balances (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>49</Position>
    </Report>
    <Report instance="d479690dposam.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>1050 - Disclosure -  Revenue Recognition - Summary of Consideration Allocated to Performance Obligations (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://haymaker.com/role/RevenueRecognitionSummaryOfConsiderationAllocatedToPerformanceObligationsDetails</Role>
      <ShortName>Revenue Recognition - Summary of Consideration Allocated to Performance Obligations (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>50</Position>
    </Report>
    <Report instance="d479690dposam.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>1051 - Disclosure -  Revenue Recognition - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://haymaker.com/role/RevenueRecognitionAdditionalInformationDetails</Role>
      <ShortName>Revenue Recognition - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>51</Position>
    </Report>
    <Report instance="d479690dposam.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>1052 - Disclosure -  Inventory, Net - Schedule of Inventory, Net (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://haymaker.com/role/InventoryNetScheduleOfInventoryNetDetails</Role>
      <ShortName>Inventory, Net - Schedule of Inventory, Net (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>52</Position>
    </Report>
    <Report instance="d479690dposam.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>1053 - Disclosure -  Property and Equipment, Net - Schedule of Property and Equipment, Net (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://haymaker.com/role/PropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetails</Role>
      <ShortName>Property and Equipment, Net - Schedule of Property and Equipment, Net (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>53</Position>
    </Report>
    <Report instance="d479690dposam.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>1054 - Disclosure -  Property and Equipment, Net - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://haymaker.com/role/PropertyAndEquipmentNetAdditionalInformationDetails</Role>
      <ShortName>Property and Equipment, Net - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>54</Position>
    </Report>
    <Report instance="d479690dposam.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>1055 - Disclosure -  Capitalized Software, Net - Summary of Capitalized Software, Net (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://haymaker.com/role/CapitalizedSoftwareNetSummaryOfCapitalizedSoftwareNetDetails</Role>
      <ShortName>Capitalized Software, Net - Summary of Capitalized Software, Net (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>55</Position>
    </Report>
    <Report instance="d479690dposam.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>1056 - Disclosure -  Capitalized Software, Net - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://haymaker.com/role/CapitalizedSoftwareNetAdditionalInformationDetails</Role>
      <ShortName>Capitalized Software, Net - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>56</Position>
    </Report>
    <Report instance="d479690dposam.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>1057 - Disclosure -  Accrued Expenses - Schedule of Accrued Expenses (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://haymaker.com/role/AccruedExpensesScheduleOfAccruedExpensesDetails</Role>
      <ShortName>Accrued Expenses - Schedule of Accrued Expenses (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>57</Position>
    </Report>
    <Report instance="d479690dposam.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>1058 - Disclosure -  Long-Term Debt - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://haymaker.com/role/LongTermDebtAdditionalInformationDetails</Role>
      <ShortName>Long-Term Debt - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>58</Position>
    </Report>
    <Report instance="d479690dposam.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>1059 - Disclosure -  Long-Term Debt - Schedule of Outstanding Debt (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://haymaker.com/role/LongTermDebtScheduleOfOutstandingDebtDetails</Role>
      <ShortName>Long-Term Debt - Schedule of Outstanding Debt (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>59</Position>
    </Report>
    <Report instance="d479690dposam.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>1060 - Disclosure -  Long-Term Debt - Schedule of Future Maturities of Long-term Debt (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://haymaker.com/role/LongTermDebtScheduleOfFutureMaturitiesOfLongTermDebtDetails</Role>
      <ShortName>Long-Term Debt - Schedule of Future Maturities of Long-term Debt (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>60</Position>
    </Report>
    <Report instance="d479690dposam.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>1061 - Disclosure -  Warrant Liability - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://haymaker.com/role/WarrantLiabilityAdditionalInformationDetails</Role>
      <ShortName>Warrant Liability - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>61</Position>
    </Report>
    <Report instance="d479690dposam.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R62.htm</HtmlFileName>
      <LongName>1062 - Disclosure -  Earnout Liability - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://haymaker.com/role/EarnoutLiabilityAdditionalInformationDetails</Role>
      <ShortName>Earnout Liability - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>62</Position>
    </Report>
    <Report instance="d479690dposam.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R63.htm</HtmlFileName>
      <LongName>1063 - Disclosure -  Fair Value Measurements - Schedule of Fair Value Hierarchy for Financial Assets and Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://haymaker.com/role/FairValueMeasurementsScheduleOfFairValueHierarchyForFinancialAssetsAndLiabilitiesDetails</Role>
      <ShortName>Fair Value Measurements - Schedule of Fair Value Hierarchy for Financial Assets and Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>63</Position>
    </Report>
    <Report instance="d479690dposam.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R64.htm</HtmlFileName>
      <LongName>1064 - Disclosure -  Fair Value Measurements - Summary of Significant Inputs to Monte Carlo Simulation for Fair Value of Private Placement Warrants (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://haymaker.com/role/FairValueMeasurementsSummaryOfSignificantInputsToMonteCarloSimulationForFairValueOfPrivatePlacementWarrantsDetails</Role>
      <ShortName>Fair Value Measurements - Summary of Significant Inputs to Monte Carlo Simulation for Fair Value of Private Placement Warrants (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>64</Position>
    </Report>
    <Report instance="d479690dposam.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R65.htm</HtmlFileName>
      <LongName>1065 - Disclosure -  Fair Value Measurements - Summary of Significant Inputs to Monte Carlo Simulation for Fair Value of Earnout Liability (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://haymaker.com/role/FairValueMeasurementsSummaryOfSignificantInputsToMonteCarloSimulationForFairValueOfEarnoutLiabilityDetails</Role>
      <ShortName>Fair Value Measurements - Summary of Significant Inputs to Monte Carlo Simulation for Fair Value of Earnout Liability (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>65</Position>
    </Report>
    <Report instance="d479690dposam.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R66.htm</HtmlFileName>
      <LongName>1066 - Disclosure -  Fair Value Measurements - Summary of Changes in the Fair Value of Company's Level 3 Financial Instruments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://haymaker.com/role/FairValueMeasurementsSummaryOfChangesInTheFairValueOfCompanysLevel3FinancialInstrumentsDetails</Role>
      <ShortName>Fair Value Measurements - Summary of Changes in the Fair Value of Company's Level 3 Financial Instruments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>66</Position>
    </Report>
    <Report instance="d479690dposam.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R67.htm</HtmlFileName>
      <LongName>1067 - Disclosure -  Noncontrolling Interest - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://haymaker.com/role/NoncontrollingInterestAdditionalInformationDetails</Role>
      <ShortName>Noncontrolling Interest - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>67</Position>
    </Report>
    <Report instance="d479690dposam.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R68.htm</HtmlFileName>
      <LongName>1068 - Disclosure -  Share-Based Compensation - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://haymaker.com/role/ShareBasedCompensationAdditionalInformationDetails</Role>
      <ShortName>Share-Based Compensation - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>68</Position>
    </Report>
    <Report instance="d479690dposam.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R69.htm</HtmlFileName>
      <LongName>1069 - Disclosure -  Share-Based Compensation - Summary of Restricted Stock Unit Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://haymaker.com/role/ShareBasedCompensationSummaryOfRestrictedStockUnitActivityDetails</Role>
      <ShortName>Share-Based Compensation - Summary of Restricted Stock Unit Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>69</Position>
    </Report>
    <Report instance="d479690dposam.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R70.htm</HtmlFileName>
      <LongName>1070 - Disclosure -  Share-Based Compensation - Summary of Stock Option Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://haymaker.com/role/ShareBasedCompensationSummaryOfStockOptionActivityDetails</Role>
      <ShortName>Share-Based Compensation - Summary of Stock Option Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>70</Position>
    </Report>
    <Report instance="d479690dposam.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R71.htm</HtmlFileName>
      <LongName>1071 - Disclosure -  Share-Based Compensation - Summary of Weighted-Average Assumptions used to Estimate Fair Value of Stock Options Granted (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://haymaker.com/role/ShareBasedCompensationSummaryOfWeightedAverageAssumptionsUsedToEstimateFairValueOfStockOptionsGrantedDetails</Role>
      <ShortName>Share-Based Compensation - Summary of Weighted-Average Assumptions used to Estimate Fair Value of Stock Options Granted (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>71</Position>
    </Report>
    <Report instance="d479690dposam.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R72.htm</HtmlFileName>
      <LongName>1072 - Disclosure -  Leases - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://haymaker.com/role/LeasesAdditionalInformationDetails</Role>
      <ShortName>Leases - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>72</Position>
    </Report>
    <Report instance="d479690dposam.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R73.htm</HtmlFileName>
      <LongName>1073 - Disclosure -  Leases - Summary of Operating Lease Costs Recognized under ASC 842 and Supplemental Cash Flow Information for Leases (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://haymaker.com/role/LeasesSummaryOfOperatingLeaseCostsRecognizedUnderAsc842AndSupplementalCashFlowInformationForLeasesDetails</Role>
      <ShortName>Leases - Summary of Operating Lease Costs Recognized under ASC 842 and Supplemental Cash Flow Information for Leases (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>73</Position>
    </Report>
    <Report instance="d479690dposam.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R74.htm</HtmlFileName>
      <LongName>1074 - Disclosure -  Leases - Summary Balance Sheet Classification of Operating Leases and Weighted Average Remaining Lease Term and Discount Rate (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://haymaker.com/role/LeasesSummaryBalanceSheetClassificationOfOperatingLeasesAndWeightedAverageRemainingLeaseTermAndDiscountRateDetails</Role>
      <ShortName>Leases - Summary Balance Sheet Classification of Operating Leases and Weighted Average Remaining Lease Term and Discount Rate (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>74</Position>
    </Report>
    <Report instance="d479690dposam.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R75.htm</HtmlFileName>
      <LongName>1075 - Disclosure -  Leases - Summary of Payments by Date for Operating Lease (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://haymaker.com/role/LeasesSummaryOfPaymentsByDateForOperatingLeaseDetails</Role>
      <ShortName>Leases - Summary of Payments by Date for Operating Lease (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>75</Position>
    </Report>
    <Report instance="d479690dposam.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R76.htm</HtmlFileName>
      <LongName>1076 - Disclosure -  Income Taxes - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://haymaker.com/role/IncomeTaxesAdditionalInformationDetails</Role>
      <ShortName>Income Taxes - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>76</Position>
    </Report>
    <Report instance="d479690dposam.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R77.htm</HtmlFileName>
      <LongName>1077 - Disclosure -  Income Taxes - Schedule of Income (Loss) Before Provision for Income Taxes (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://haymaker.com/role/IncomeTaxesScheduleOfIncomeLossBeforeProvisionForIncomeTaxesDetails</Role>
      <ShortName>Income Taxes - Schedule of Income (Loss) Before Provision for Income Taxes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>77</Position>
    </Report>
    <Report instance="d479690dposam.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R78.htm</HtmlFileName>
      <LongName>1078 - Disclosure -  Income Taxes - Schedule of Income Tax Provision (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://haymaker.com/role/IncomeTaxesScheduleOfIncomeTaxProvisionDetails</Role>
      <ShortName>Income Taxes - Schedule of Income Tax Provision (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>78</Position>
    </Report>
    <Report instance="d479690dposam.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R79.htm</HtmlFileName>
      <LongName>1079 - Disclosure -  Income Taxes - Schedule of Reconciliation of the Federal Income Tax Rate to the Company Effective Tax Rate (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://haymaker.com/role/IncomeTaxesScheduleOfReconciliationOfTheFederalIncomeTaxRateToTheCompanyEffectiveTaxRateDetails</Role>
      <ShortName>Income Taxes - Schedule of Reconciliation of the Federal Income Tax Rate to the Company Effective Tax Rate (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>79</Position>
    </Report>
    <Report instance="d479690dposam.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R80.htm</HtmlFileName>
      <LongName>1080 - Disclosure -  Income Taxes - Deferred Tax Assets and Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://haymaker.com/role/IncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails</Role>
      <ShortName>Income Taxes - Deferred Tax Assets and Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>80</Position>
    </Report>
    <Report instance="d479690dposam.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R81.htm</HtmlFileName>
      <LongName>1081 - Disclosure -  Net Loss Per Common Share - Schedule of Computation of Net Loss Per Common Share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://haymaker.com/role/NetLossPerCommonShareScheduleOfComputationOfNetLossPerCommonShareDetails</Role>
      <ShortName>Net Loss Per Common Share - Schedule of Computation of Net Loss Per Common Share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>81</Position>
    </Report>
    <Report instance="d479690dposam.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R82.htm</HtmlFileName>
      <LongName>1082 - Disclosure -  Net Loss Per Common Share - Schedule of Computation of Diluted Weighted Average Shares Outstanding (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://haymaker.com/role/NetLossPerCommonShareScheduleOfComputationOfDilutedWeightedAverageSharesOutstandingDetails</Role>
      <ShortName>Net Loss Per Common Share - Schedule of Computation of Diluted Weighted Average Shares Outstanding (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>82</Position>
    </Report>
    <Report instance="d479690dposam.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R83.htm</HtmlFileName>
      <LongName>1083 - Disclosure -  Commitments and Contingencies - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://haymaker.com/role/CommitmentsAndContingenciesAdditionalInformationDetails</Role>
      <ShortName>Commitments and Contingencies - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>83</Position>
    </Report>
    <Report instance="d479690dposam.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R84.htm</HtmlFileName>
      <LongName>1084 - Disclosure -  Related-Party Transactions - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://haymaker.com/role/RelatedPartyTransactionsAdditionalInformationDetails</Role>
      <ShortName>Related-Party Transactions - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>84</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <Logs>
    <Log type="Warning">[dq-0542-Deprecated-Concept] Concept PropertyPlantAndEquipmentEstimatedUsefulLives in us-gaap/2022 used in 1 facts was deprecated in us-gaap/2023 as of 2023 and should not be used. d479690dposam.htm 10102</Log>
    <Log type="Warning">[dq-0542-Deprecated-Concept] Concept DueToRelatedPartiesCurrentAndNoncurrent in us-gaap/2022 used in 6 facts was deprecated in us-gaap/2023 as of 2023 and should not be used. d479690dposam.htm 13431</Log>
    <Log type="Warning">[dq-0542-Deprecated-Concept] Concept DueToEmployeesCurrentAndNoncurrent in us-gaap/2022 used in 2 facts was deprecated in us-gaap/2023 as of 2023 and should not be used. d479690dposam.htm 13431</Log>
    <Log type="Warning">[ix-0514-Hidden-Fact-Eligible-For-Transform] WARN: 10 fact(s) appearing in ix:hidden were eligible for transformation: btmd:CapitalizedSoftwareEstimatedUsefulLives, btmd:ConsecutiveTradingDays, btmd:EarnoutDeadlineDate, btmd:LineOfCreditFacilityMaturityMonthAndYear, us-gaap:BusinessAcquisitionDescriptionOfAcquiredEntity, us-gaap:DebtInstrumentCovenantDescription, us-gaap:LeaseExpirationDate1, us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 -  d479690dposam.htm 6949</Log>
  </Logs>
  <InputFiles>
    <File doctype="S-1" original="d479690dposam.htm">d479690dposam.htm</File>
    <File>btmd-20221231.xsd</File>
    <File>btmd-20221231_cal.xml</File>
    <File>btmd-20221231_def.xml</File>
    <File>btmd-20221231_lab.xml</File>
    <File>btmd-20221231_pre.xml</File>
    <File>d479690dex231.htm</File>
  </InputFiles>
  <SupplementalFiles>
    <File>g479690g00z01.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="789">http://fasb.org/us-gaap/2022</BaseTaxonomy>
    <BaseTaxonomy items="24">http://xbrl.sec.gov/dei/2022</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>100
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "d479690dposam.htm": {
   "axisCustom": 3,
   "axisStandard": 32,
   "baseTaxonomies": {
    "http://fasb.org/us-gaap/2022": 789,
    "http://xbrl.sec.gov/dei/2022": 24
   },
   "contextCount": 297,
   "dts": {
    "calculationLink": {
     "local": [
      "btmd-20221231_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "btmd-20221231_def.xml"
     ]
    },
    "inline": {
     "local": [
      "d479690dposam.htm"
     ]
    },
    "labelLink": {
     "local": [
      "btmd-20221231_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "btmd-20221231_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "btmd-20221231.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd",
      "https://xbrl.fasb.org/srt/2022q3/srt-sup-2022q3.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022q3/us-gaap-sup-2022q3.xsd",
      "https://xbrl.sec.gov/country/2022/country-2022.xsd",
      "https://xbrl.sec.gov/currency/2022/currency-2022.xsd",
      "https://xbrl.sec.gov/dei/2022/dei-2022.xsd",
      "https://xbrl.sec.gov/exch/2022/exch-2022.xsd",
      "https://xbrl.sec.gov/naics/2022/naics-2022.xsd",
      "https://xbrl.sec.gov/sic/2022/sic-2022.xsd",
      "https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd"
     ]
    }
   },
   "elementCount": 709,
   "entityCount": 1,
   "hidden": {
    "http://fasb.org/us-gaap/2022": 7,
    "http://haymaker.com/20221231": 5,
    "http://xbrl.sec.gov/dei/2022": 5,
    "total": 17
   },
   "keyCustom": 86,
   "keyStandard": 340,
   "memberCustom": 69,
   "memberStandard": 45,
   "nsprefix": "btmd",
   "nsuri": "http://haymaker.com/20221231",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d479690dposam.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:EntityRegistrantName",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "1001 - Document -  Cover",
     "menuCat": "Cover",
     "order": "1",
     "role": "http://haymaker.com/role/Cover",
     "shortName": "Cover",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d479690dposam.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:EntityRegistrantName",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d479690dposam.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1010 - Disclosure -  Revenue Recognition",
     "menuCat": "Notes",
     "order": "10",
     "role": "http://haymaker.com/role/RevenueRecognition",
     "shortName": "Revenue Recognition",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d479690dposam.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d479690dposam.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1011 - Disclosure -  Inventory, Net",
     "menuCat": "Notes",
     "order": "11",
     "role": "http://haymaker.com/role/InventoryNet",
     "shortName": "Inventory, Net",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d479690dposam.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d479690dposam.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1012 - Disclosure -  Property and Equipment, Net",
     "menuCat": "Notes",
     "order": "12",
     "role": "http://haymaker.com/role/PropertyAndEquipmentNet",
     "shortName": "Property and Equipment, Net",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d479690dposam.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d479690dposam.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1013 - Disclosure -  Capitalized Software, Net",
     "menuCat": "Notes",
     "order": "13",
     "role": "http://haymaker.com/role/CapitalizedSoftwareNet",
     "shortName": "Capitalized Software, Net",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d479690dposam.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d479690dposam.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1014 - Disclosure -  Accrued Expenses",
     "menuCat": "Notes",
     "order": "14",
     "role": "http://haymaker.com/role/AccruedExpenses",
     "shortName": "Accrued Expenses",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d479690dposam.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d479690dposam.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1015 - Disclosure -  Long-Term Debt",
     "menuCat": "Notes",
     "order": "15",
     "role": "http://haymaker.com/role/LongTermDebt",
     "shortName": "Long-Term Debt",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d479690dposam.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d479690dposam.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "btmd:WarrantLiabilityTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1016 - Disclosure -  Warrant Liability",
     "menuCat": "Notes",
     "order": "16",
     "role": "http://haymaker.com/role/WarrantLiability",
     "shortName": "Warrant Liability",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d479690dposam.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "btmd:WarrantLiabilityTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d479690dposam.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "btmd:EarnoutLiabilityTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1017 - Disclosure -  Earnout Liability",
     "menuCat": "Notes",
     "order": "17",
     "role": "http://haymaker.com/role/EarnoutLiability",
     "shortName": "Earnout Liability",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d479690dposam.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "btmd:EarnoutLiabilityTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d479690dposam.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1018 - Disclosure -  Fair Value Measurements",
     "menuCat": "Notes",
     "order": "18",
     "role": "http://haymaker.com/role/FairValueMeasurements",
     "shortName": "Fair Value Measurements",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d479690dposam.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d479690dposam.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:MinorityInterestDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1019 - Disclosure -  Noncontrolling Interest",
     "menuCat": "Notes",
     "order": "19",
     "role": "http://haymaker.com/role/NoncontrollingInterest",
     "shortName": "Noncontrolling Interest",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d479690dposam.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:MinorityInterestDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d479690dposam.htm",
      "contextRef": "PAsOn12_31_2022",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:Cash",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1002 - Statement -  CONSOLIDATED BALANCE SHEETS",
     "menuCat": "Statements",
     "order": "2",
     "role": "http://haymaker.com/role/ConsolidatedBalanceSheets",
     "shortName": "CONSOLIDATED BALANCE SHEETS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d479690dposam.htm",
      "contextRef": "PAsOn12_31_2022",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:Cash",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d479690dposam.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1020 - Disclosure -  Share-Based Compensation",
     "menuCat": "Notes",
     "order": "20",
     "role": "http://haymaker.com/role/ShareBasedCompensation",
     "shortName": "Share-Based Compensation",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d479690dposam.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d479690dposam.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1021 - Disclosure -  Leases",
     "menuCat": "Notes",
     "order": "21",
     "role": "http://haymaker.com/role/Leases",
     "shortName": "Leases",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d479690dposam.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d479690dposam.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1022 - Disclosure -  Income Taxes",
     "menuCat": "Notes",
     "order": "22",
     "role": "http://haymaker.com/role/IncomeTaxes",
     "shortName": "Income Taxes",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d479690dposam.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d479690dposam.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1023 - Disclosure -  Net Loss Per Common Share",
     "menuCat": "Notes",
     "order": "23",
     "role": "http://haymaker.com/role/NetLossPerCommonShare",
     "shortName": "Net Loss Per Common Share",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d479690dposam.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d479690dposam.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1024 - Disclosure -  Commitments and Contingencies",
     "menuCat": "Notes",
     "order": "24",
     "role": "http://haymaker.com/role/CommitmentsAndContingencies",
     "shortName": "Commitments and Contingencies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d479690dposam.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d479690dposam.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1025 - Disclosure -  Related-Party Transactions",
     "menuCat": "Notes",
     "order": "25",
     "role": "http://haymaker.com/role/RelatedPartyTransactions",
     "shortName": "Related-Party Transactions",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d479690dposam.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d479690dposam.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1026 - Disclosure -  Subsequent Events",
     "menuCat": "Notes",
     "order": "26",
     "role": "http://haymaker.com/role/SubsequentEvents",
     "shortName": "Subsequent Events",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d479690dposam.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d479690dposam.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:UseOfEstimates",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1027 - Disclosure -  Summary of Significant Accounting Policies (Policies)",
     "menuCat": "Policies",
     "order": "27",
     "role": "http://haymaker.com/role/SummaryOfSignificantAccountingPoliciesPolicies",
     "shortName": "Summary of Significant Accounting Policies (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d479690dposam.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:UseOfEstimates",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d479690dposam.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsReceivableAllowanceForCreditLossTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1028 - Disclosure -  Summary of Significant Accounting Policies (Tables)",
     "menuCat": "Tables",
     "order": "28",
     "role": "http://haymaker.com/role/SummaryOfSignificantAccountingPoliciesTables",
     "shortName": "Summary of Significant Accounting Policies (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d479690dposam.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsReceivableAllowanceForCreditLossTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:RevenueFromContractWithCustomerTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d479690dposam.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisaggregationOfRevenueTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1029 - Disclosure -  Revenue Recognition (Tables)",
     "menuCat": "Tables",
     "order": "29",
     "role": "http://haymaker.com/role/RevenueRecognitionTables",
     "shortName": "Revenue Recognition (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:RevenueFromContractWithCustomerTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d479690dposam.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisaggregationOfRevenueTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:PreferredStockParOrStatedValuePerShare",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d479690dposam.htm",
      "contextRef": "PAsOn12_31_2022",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD_per_Share",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1003 - Statement -  CONSOLIDATED BALANCE SHEETS (Parenthetical)",
     "menuCat": "Statements",
     "order": "3",
     "role": "http://haymaker.com/role/ConsolidatedBalanceSheetsParenthetical",
     "shortName": "CONSOLIDATED BALANCE SHEETS (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:PreferredStockParOrStatedValuePerShare",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d479690dposam.htm",
      "contextRef": "PAsOn12_31_2022",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD_per_Share",
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:InventoryDisclosureTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d479690dposam.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1030 - Disclosure -  Inventory, Net (Tables)",
     "menuCat": "Tables",
     "order": "30",
     "role": "http://haymaker.com/role/InventoryNetTables",
     "shortName": "Inventory, Net (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:InventoryDisclosureTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d479690dposam.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d479690dposam.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1031 - Disclosure -  Property and Equipment, Net (Tables)",
     "menuCat": "Tables",
     "order": "31",
     "role": "http://haymaker.com/role/PropertyAndEquipmentNetTables",
     "shortName": "Property and Equipment, Net (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d479690dposam.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d479690dposam.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "btmd:SummaryOfCapitalizedSoftwareNetTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1032 - Disclosure -  Capitalized Software, Net (Tables)",
     "menuCat": "Tables",
     "order": "32",
     "role": "http://haymaker.com/role/CapitalizedSoftwareNetTables",
     "shortName": "Capitalized Software, Net (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d479690dposam.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "btmd:SummaryOfCapitalizedSoftwareNetTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d479690dposam.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1033 - Disclosure -  Accrued Expenses (Tables)",
     "menuCat": "Tables",
     "order": "33",
     "role": "http://haymaker.com/role/AccruedExpensesTables",
     "shortName": "Accrued Expenses (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d479690dposam.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d479690dposam.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfDebtTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1034 - Disclosure -  Long-Term Debt (Tables)",
     "menuCat": "Tables",
     "order": "34",
     "role": "http://haymaker.com/role/LongTermDebtTables",
     "shortName": "Long-Term Debt (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d479690dposam.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfDebtTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d479690dposam.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1035 - Disclosure -  Fair Value Measurements (Tables)",
     "menuCat": "Tables",
     "order": "35",
     "role": "http://haymaker.com/role/FairValueMeasurementsTables",
     "shortName": "Fair Value Measurements (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d479690dposam.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d479690dposam.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1036 - Disclosure -  Share-Based Compensation (Tables)",
     "menuCat": "Tables",
     "order": "36",
     "role": "http://haymaker.com/role/ShareBasedCompensationTables",
     "shortName": "Share-Based Compensation (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d479690dposam.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d479690dposam.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "btmd:SummaryOfLeaseCostsRecognizedUnderAsc842AndSupplementalCashFlowInformationForLeasesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1037 - Disclosure -  Leases (Tables)",
     "menuCat": "Tables",
     "order": "37",
     "role": "http://haymaker.com/role/LeasesTables",
     "shortName": "Leases (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d479690dposam.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "btmd:SummaryOfLeaseCostsRecognizedUnderAsc842AndSupplementalCashFlowInformationForLeasesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d479690dposam.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1038 - Disclosure -  Income Taxes (Tables)",
     "menuCat": "Tables",
     "order": "38",
     "role": "http://haymaker.com/role/IncomeTaxesTables",
     "shortName": "Income Taxes (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d479690dposam.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d479690dposam.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1039 - Disclosure -  Net Loss Per Common Share (Tables)",
     "menuCat": "Tables",
     "order": "39",
     "role": "http://haymaker.com/role/NetLossPerCommonShareTables",
     "shortName": "Net Loss Per Common Share (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d479690dposam.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d479690dposam.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1004 - Statement -  CONSOLIDATED STATEMENTS OF INCOME AND COMPREHENSIVE INCOME",
     "menuCat": "Statements",
     "order": "4",
     "role": "http://haymaker.com/role/ConsolidatedStatementsOfIncomeAndComprehensiveIncome",
     "shortName": "CONSOLIDATED STATEMENTS OF INCOME AND COMPREHENSIVE INCOME",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d479690dposam.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R40": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "us-gaap:SegmentReportingPolicyPolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d479690dposam.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:NumberOfOperatingSegments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_SEGMENT",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1040 - Disclosure -  Summary of Significant Accounting Policies - Additional Information (Details)",
     "menuCat": "Details",
     "order": "40",
     "role": "http://haymaker.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
     "shortName": "Summary of Significant Accounting Policies - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "us-gaap:SegmentReportingPolicyPolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d479690dposam.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:NumberOfOperatingSegments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_SEGMENT",
      "xsiNil": "false"
     }
    },
    "R41": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d479690dposam.htm",
      "contextRef": "PAsOn12_31_2021",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent",
      "reportCount": 1,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1041 - Disclosure -  Summary of Significant Accounting Policies - Summary of Rollforward of the Allowance for Doubtful Accounts (Details)",
     "menuCat": "Details",
     "order": "41",
     "role": "http://haymaker.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfRollforwardOfTheAllowanceForDoubtfulAccountsDetails",
     "shortName": "Summary of Significant Accounting Policies - Summary of Rollforward of the Allowance for Doubtful Accounts (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d479690dposam.htm",
      "contextRef": "PAsOn12_31_2020",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R42": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "btmd:OtherCurrentAssetsPolicyTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d479690dposam.htm",
      "contextRef": "PAsOn12_31_2022",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:PrepaidExpenseCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1042 - Disclosure -  Summary of Significant Accounting Policies - Summary of Total Other Current Assets (Details)",
     "menuCat": "Details",
     "order": "42",
     "role": "http://haymaker.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfTotalOtherCurrentAssetsDetails",
     "shortName": "Summary of Significant Accounting Policies - Summary of Total Other Current Assets (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "btmd:OtherCurrentAssetsPolicyTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d479690dposam.htm",
      "contextRef": "PAsOn12_31_2022",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:PrepaidExpenseCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R43": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d479690dposam.htm",
      "contextRef": "P01_01_2022To12_31_2022_TrocarsMemberusgaapPropertyPlantAndEquipmentByTypeAxis",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentUsefulLife",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1043 - Disclosure -  Summary of Significant Accounting Policies - Summary of Estimated Useful Lives of Property and Equipment (Details)",
     "menuCat": "Details",
     "order": "43",
     "role": "http://haymaker.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfEstimatedUsefulLivesOfPropertyAndEquipmentDetails",
     "shortName": "Summary of Significant Accounting Policies - Summary of Estimated Useful Lives of Property and Equipment (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d479690dposam.htm",
      "contextRef": "P01_01_2022To12_31_2022_TrocarsMemberusgaapPropertyPlantAndEquipmentByTypeAxis",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentUsefulLife",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R44": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfCapitalUnitsTextBlock",
       "us-gaap:StockholdersEquityPolicyTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d479690dposam.htm",
      "contextRef": "PAsOn12_31_2021",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:CommonUnitIssued",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1044 - Disclosure -  Summary of Significant Accounting Policies - Summary of Members' Equity Units Issued and Outstanding (Details)",
     "menuCat": "Details",
     "order": "44",
     "role": "http://haymaker.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfMembersEquityUnitsIssuedAndOutstandingDetails",
     "shortName": "Summary of Significant Accounting Policies - Summary of Members' Equity Units Issued and Outstanding (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfCapitalUnitsTextBlock",
       "us-gaap:StockholdersEquityPolicyTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d479690dposam.htm",
      "contextRef": "PAsOn12_31_2021",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:CommonUnitIssued",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_shares",
      "xsiNil": "false"
     }
    },
    "R45": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfStockByClassTextBlock",
       "us-gaap:StockholdersEquityPolicyTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d479690dposam.htm",
      "contextRef": "PAsOn12_31_2022",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:CommonStockSharesIssued",
      "reportCount": 1,
      "unitRef": "Unit_shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1045 - Disclosure -  Summary of Significant Accounting Policies - Summary of Common Stock Issued and Outstanding (Details)",
     "menuCat": "Details",
     "order": "45",
     "role": "http://haymaker.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfCommonStockIssuedAndOutstandingDetails",
     "shortName": "Summary of Significant Accounting Policies - Summary of Common Stock Issued and Outstanding (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfStockByClassTextBlock",
       "us-gaap:StockholdersEquityPolicyTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d479690dposam.htm",
      "contextRef": "PAsOn12_31_2022_ClassVCommonStockMemberusgaapStatementClassOfStockAxis",
      "decimals": "INF",
      "lang": null,
      "name": "us-gaap:CommonStockSharesIssued",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_shares",
      "xsiNil": "false"
     }
    },
    "R46": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "us-gaap:BusinessCombinationDisclosureTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d479690dposam.htm",
      "contextRef": "P01_01_2022To12_31_2022_BioteManagementLlcMemberusgaapBusinessAcquisitionAxis",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:BusinessCombinationConsiderationTransferred1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1046 - Disclosure -  Business Combination - Additional Information (Details)",
     "menuCat": "Details",
     "order": "46",
     "role": "http://haymaker.com/role/BusinessCombinationAdditionalInformationDetails",
     "shortName": "Business Combination - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "us-gaap:BusinessCombinationDisclosureTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d479690dposam.htm",
      "contextRef": "P01_01_2022To12_31_2022_BioteManagementLlcMemberusgaapBusinessAcquisitionAxis",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:BusinessCombinationConsiderationTransferred1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R47": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d479690dposam.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1047 - Disclosure -  Revenue Recognition - Schedule of Revenues Recognized for Each Revenue Stream (Details)",
     "menuCat": "Details",
     "order": "47",
     "role": "http://haymaker.com/role/RevenueRecognitionScheduleOfRevenuesRecognizedForEachRevenueStreamDetails",
     "shortName": "Revenue Recognition - Schedule of Revenues Recognized for Each Revenue Stream (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:DisaggregationOfRevenueTableTextBlock",
       "us-gaap:RevenueFromContractWithCustomerTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d479690dposam.htm",
      "contextRef": "P01_01_2022To12_31_2022_PelletProceduresProductRevenueMembersrtProductOrServiceAxis",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R48": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d479690dposam.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1048 - Disclosure -  Revenue Recognition - Schedule of Revenues Recognized by Geographic Region (Details)",
     "menuCat": "Details",
     "order": "48",
     "role": "http://haymaker.com/role/RevenueRecognitionScheduleOfRevenuesRecognizedByGeographicRegionDetails",
     "shortName": "Revenue Recognition - Schedule of Revenues Recognized by Geographic Region (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:DisaggregationOfRevenueTableTextBlock",
       "us-gaap:RevenueFromContractWithCustomerTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d479690dposam.htm",
      "contextRef": "P01_01_2022To12_31_2022_ProductRevenueMembersrtProductOrServiceAxis_USsrtStatementGeographicalAxis",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R49": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock",
       "us-gaap:RevenueFromContractWithCustomerTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d479690dposam.htm",
      "contextRef": "P01_01_2022To12_31_2022_ShortTermContractWithCustomerMemberusgaapContractWithCustomerDurationAxis",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ContractWithCustomerLiabilityRevenueRecognized",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1049 - Disclosure -  Revenue Recognition - Summary of Significant Changes in Contract Liability Balances (Details)",
     "menuCat": "Details",
     "order": "49",
     "role": "http://haymaker.com/role/RevenueRecognitionSummaryOfSignificantChangesInContractLiabilityBalancesDetails",
     "shortName": "Revenue Recognition - Summary of Significant Changes in Contract Liability Balances (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock",
       "us-gaap:RevenueFromContractWithCustomerTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d479690dposam.htm",
      "contextRef": "P01_01_2022To12_31_2022_ShortTermContractWithCustomerMemberusgaapContractWithCustomerDurationAxis",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ContractWithCustomerLiabilityRevenueRecognized",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d479690dposam.htm",
      "contextRef": "PAsOn12_31_2020_MemberUnitsMemberusgaapStatementEquityComponentsAxis",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:PartnersCapitalAccountUnits",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_shares",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1005 - Statement -  CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (DEFICIT)",
     "menuCat": "Statements",
     "order": "5",
     "role": "http://haymaker.com/role/ConsolidatedStatementsOfStockholdersEquityDeficit",
     "shortName": "CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (DEFICIT)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d479690dposam.htm",
      "contextRef": "PAsOn12_31_2020_MemberUnitsMemberusgaapStatementEquityComponentsAxis",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:PartnersCapitalAccountUnits",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_shares",
      "xsiNil": "false"
     }
    },
    "R50": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d479690dposam.htm",
      "contextRef": "PAsOn12_31_2022",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ContractWithCustomerLiabilityCurrent",
      "reportCount": 1,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1050 - Disclosure -  Revenue Recognition - Summary of Consideration Allocated to Performance Obligations (Details)",
     "menuCat": "Details",
     "order": "50",
     "role": "http://haymaker.com/role/RevenueRecognitionSummaryOfConsiderationAllocatedToPerformanceObligationsDetails",
     "shortName": "Revenue Recognition - Summary of Consideration Allocated to Performance Obligations (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "btmd:SummaryOfConsiderationAllocatedToPerformanceObligationsTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d479690dposam.htm",
      "contextRef": "PAsOn12_31_2022_UnsatisfiedTrainingObligationsMembersrtProductOrServiceAxis",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:ContractWithCustomerLiabilityCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R51": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d479690dposam.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "btmd:ReductionOfRevenue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1051 - Disclosure -  Revenue Recognition - Additional Information (Details)",
     "menuCat": "Details",
     "order": "51",
     "role": "http://haymaker.com/role/RevenueRecognitionAdditionalInformationDetails",
     "shortName": "Revenue Recognition - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d479690dposam.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "btmd:ReductionOfRevenue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R52": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d479690dposam.htm",
      "contextRef": "PAsOn12_31_2022",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:InventoryNet",
      "reportCount": 1,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1052 - Disclosure -  Inventory, Net - Schedule of Inventory, Net (Details)",
     "menuCat": "Details",
     "order": "52",
     "role": "http://haymaker.com/role/InventoryNetScheduleOfInventoryNetDetails",
     "shortName": "Inventory, Net - Schedule of Inventory, Net (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
       "us-gaap:InventoryDisclosureTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d479690dposam.htm",
      "contextRef": "PAsOn12_31_2022_PelletsMemberusgaapPublicUtilitiesInventoryAxis_ProductMembersrtProductOrServiceAxis",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:InventoryGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R53": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d479690dposam.htm",
      "contextRef": "PAsOn12_31_2022",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1053 - Disclosure -  Property and Equipment, Net - Schedule of Property and Equipment, Net (Details)",
     "menuCat": "Details",
     "order": "53",
     "role": "http://haymaker.com/role/PropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetails",
     "shortName": "Property and Equipment, Net - Schedule of Property and Equipment, Net (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d479690dposam.htm",
      "contextRef": "PAsOn12_31_2022",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R54": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d479690dposam.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:Depreciation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1054 - Disclosure -  Property and Equipment, Net - Additional Information (Details)",
     "menuCat": "Details",
     "order": "54",
     "role": "http://haymaker.com/role/PropertyAndEquipmentNetAdditionalInformationDetails",
     "shortName": "Property and Equipment, Net - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d479690dposam.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:Depreciation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R55": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "btmd:SummaryOfCapitalizedSoftwareNetTableTextBlock",
       "us-gaap:ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d479690dposam.htm",
      "contextRef": "PAsOn12_31_2022",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "btmd:CapitalizedSoftwareWebsiteCosts",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1055 - Disclosure -  Capitalized Software, Net - Summary of Capitalized Software, Net (Details)",
     "menuCat": "Details",
     "order": "55",
     "role": "http://haymaker.com/role/CapitalizedSoftwareNetSummaryOfCapitalizedSoftwareNetDetails",
     "shortName": "Capitalized Software, Net - Summary of Capitalized Software, Net (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "btmd:SummaryOfCapitalizedSoftwareNetTableTextBlock",
       "us-gaap:ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d479690dposam.htm",
      "contextRef": "PAsOn12_31_2022",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "btmd:CapitalizedSoftwareWebsiteCosts",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R56": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "us-gaap:ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d479690dposam.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:CapitalizedComputerSoftwareAmortization1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1056 - Disclosure -  Capitalized Software, Net - Additional Information (Details)",
     "menuCat": "Details",
     "order": "56",
     "role": "http://haymaker.com/role/CapitalizedSoftwareNetAdditionalInformationDetails",
     "shortName": "Capitalized Software, Net - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "us-gaap:ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d479690dposam.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:CapitalizedComputerSoftwareAmortization1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R57": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d479690dposam.htm",
      "contextRef": "PAsOn12_31_2022",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AccruedProfessionalFeesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1057 - Disclosure -  Accrued Expenses - Schedule of Accrued Expenses (Details)",
     "menuCat": "Details",
     "order": "57",
     "role": "http://haymaker.com/role/AccruedExpensesScheduleOfAccruedExpensesDetails",
     "shortName": "Accrued Expenses - Schedule of Accrued Expenses (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d479690dposam.htm",
      "contextRef": "PAsOn12_31_2022",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AccruedProfessionalFeesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R58": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d479690dposam.htm",
      "contextRef": "PAsOn12_31_2022",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:LongTermDebt",
      "reportCount": 1,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1058 - Disclosure -  Long-Term Debt - Additional Information (Details)",
     "menuCat": "Details",
     "order": "58",
     "role": "http://haymaker.com/role/LongTermDebtAdditionalInformationDetails",
     "shortName": "Long-Term Debt - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "us-gaap:DebtDisclosureTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d479690dposam.htm",
      "contextRef": "PAsOn05_31_2019_BankOfAmericaTermLoanMemberusgaapDebtInstrumentAxis_LineOfCreditMemberusgaapCreditFacilityAxis",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:DebtInstrumentFaceAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R59": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDebtTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d479690dposam.htm",
      "contextRef": "PAsOn12_31_2022",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:DebtInstrumentCarryingAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1059 - Disclosure -  Long-Term Debt - Schedule of Outstanding Debt (Details)",
     "menuCat": "Details",
     "order": "59",
     "role": "http://haymaker.com/role/LongTermDebtScheduleOfOutstandingDebtDetails",
     "shortName": "Long-Term Debt - Schedule of Outstanding Debt (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDebtTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d479690dposam.htm",
      "contextRef": "PAsOn12_31_2022",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:DebtInstrumentCarryingAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d479690dposam.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ProfitLoss",
      "reportCount": 1,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1006 - Statement -  CONSOLIDATED STATEMENTS OF CASH FLOWS",
     "menuCat": "Statements",
     "order": "6",
     "role": "http://haymaker.com/role/ConsolidatedStatementsOfCashFlows",
     "shortName": "CONSOLIDATED STATEMENTS OF CASH FLOWS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d479690dposam.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:DepreciationDepletionAndAmortization",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R60": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d479690dposam.htm",
      "contextRef": "PAsOn12_31_2022",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1060 - Disclosure -  Long-Term Debt - Schedule of Future Maturities of Long-term Debt (Details)",
     "menuCat": "Details",
     "order": "60",
     "role": "http://haymaker.com/role/LongTermDebtScheduleOfFutureMaturitiesOfLongTermDebtDetails",
     "shortName": "Long-Term Debt - Schedule of Future Maturities of Long-term Debt (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d479690dposam.htm",
      "contextRef": "PAsOn12_31_2022",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R61": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d479690dposam.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "btmd:PrivatePlacementWarrantsRedemptionDescription",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1061 - Disclosure -  Warrant Liability - Additional Information (Details)",
     "menuCat": "Details",
     "order": "61",
     "role": "http://haymaker.com/role/WarrantLiabilityAdditionalInformationDetails",
     "shortName": "Warrant Liability - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d479690dposam.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "btmd:PrivatePlacementWarrantsRedemptionDescription",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R62": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "btmd:EarnoutLiabilityTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d479690dposam.htm",
      "contextRef": "P01_01_2022To12_31_2022_BusinessCombinationMemberusgaapBusinessAcquisitionAxis_MaximumMembersrtRangeAxis",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "btmd:NumberOfEarnoutSecuritiesShareholderEntitledToVestIfCertainSharePriceTargetsAchieved",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1062 - Disclosure -  Earnout Liability - Additional Information (Details)",
     "menuCat": "Details",
     "order": "62",
     "role": "http://haymaker.com/role/EarnoutLiabilityAdditionalInformationDetails",
     "shortName": "Earnout Liability - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "btmd:EarnoutLiabilityTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d479690dposam.htm",
      "contextRef": "P01_01_2022To12_31_2022_BusinessCombinationMemberusgaapBusinessAcquisitionAxis_MaximumMembersrtRangeAxis",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "btmd:NumberOfEarnoutSecuritiesShareholderEntitledToVestIfCertainSharePriceTargetsAchieved",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_shares",
      "xsiNil": "false"
     }
    },
    "R63": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "btmd:ScheduleOfChangesInTheFairValueOfWarrantLiabilitiesTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d479690dposam.htm",
      "contextRef": "PAsOn12_31_2022",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:FinancialLiabilitiesFairValueDisclosure",
      "reportCount": 1,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1063 - Disclosure -  Fair Value Measurements - Schedule of Fair Value Hierarchy for Financial Assets and Liabilities (Details)",
     "menuCat": "Details",
     "order": "63",
     "role": "http://haymaker.com/role/FairValueMeasurementsScheduleOfFairValueHierarchyForFinancialAssetsAndLiabilitiesDetails",
     "shortName": "Fair Value Measurements - Schedule of Fair Value Hierarchy for Financial Assets and Liabilities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d479690dposam.htm",
      "contextRef": "PAsOn12_31_2022_PublicWarrantsMemberusgaapFinancialInstrumentAxis",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:FinancialLiabilitiesFairValueDisclosure",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R64": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d479690dposam.htm",
      "contextRef": "PAsOn12_31_2022_MeasurementInputSharePriceMemberusgaapMeasurementInputTypeAxis_PrivatePlacementWarrantsMemberusgaapFinancialInstrumentAxis",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "us-gaap:SaleOfStockPricePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD_per_Share",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1064 - Disclosure -  Fair Value Measurements - Summary of Significant Inputs to Monte Carlo Simulation for Fair Value of Private Placement Warrants (Details)",
     "menuCat": "Details",
     "order": "64",
     "role": "http://haymaker.com/role/FairValueMeasurementsSummaryOfSignificantInputsToMonteCarloSimulationForFairValueOfPrivatePlacementWarrantsDetails",
     "shortName": "Fair Value Measurements - Summary of Significant Inputs to Monte Carlo Simulation for Fair Value of Private Placement Warrants (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d479690dposam.htm",
      "contextRef": "PAsOn12_31_2022_MeasurementInputSharePriceMemberusgaapMeasurementInputTypeAxis_PrivatePlacementWarrantsMemberusgaapFinancialInstrumentAxis",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "us-gaap:SaleOfStockPricePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD_per_Share",
      "xsiNil": "false"
     }
    },
    "R65": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d479690dposam.htm",
      "contextRef": "PAsOn12_31_2022_EarnoutLiabilityMemberusgaapFinancialInstrumentAxis_MeasurementInputSharePriceMemberusgaapMeasurementInputTypeAxis",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "us-gaap:SaleOfStockPricePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD_per_Share",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1065 - Disclosure -  Fair Value Measurements - Summary of Significant Inputs to Monte Carlo Simulation for Fair Value of Earnout Liability (Details)",
     "menuCat": "Details",
     "order": "65",
     "role": "http://haymaker.com/role/FairValueMeasurementsSummaryOfSignificantInputsToMonteCarloSimulationForFairValueOfEarnoutLiabilityDetails",
     "shortName": "Fair Value Measurements - Summary of Significant Inputs to Monte Carlo Simulation for Fair Value of Earnout Liability (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d479690dposam.htm",
      "contextRef": "PAsOn12_31_2022_EarnoutLiabilityMemberusgaapFinancialInstrumentAxis_MeasurementInputSharePriceMemberusgaapMeasurementInputTypeAxis",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "us-gaap:SaleOfStockPricePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD_per_Share",
      "xsiNil": "false"
     }
    },
    "R66": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "btmd:ScheduleOfChangesInTheFairValueOfWarrantLiabilitiesTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d479690dposam.htm",
      "contextRef": "PAsOn05_26_2022",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:FinancialLiabilitiesFairValueDisclosure",
      "reportCount": 1,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1066 - Disclosure -  Fair Value Measurements - Summary of Changes in the Fair Value of Company's Level 3 Financial Instruments (Details)",
     "menuCat": "Details",
     "order": "66",
     "role": "http://haymaker.com/role/FairValueMeasurementsSummaryOfChangesInTheFairValueOfCompanysLevel3FinancialInstrumentsDetails",
     "shortName": "Fair Value Measurements - Summary of Changes in the Fair Value of Company's Level 3 Financial Instruments (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "btmd:ScheduleOfChangesInTheFairValueOfWarrantLiabilitiesTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d479690dposam.htm",
      "contextRef": "P05_27_2022To12_31_2022",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:FairValueOptionChangesInFairValueGainLoss1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R67": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d479690dposam.htm",
      "contextRef": "P01_01_2022To12_31_2022_CommonClassVMemberusgaapStatementClassOfStockAxis",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockIssuedDuringPeriodSharesNewIssues",
      "reportCount": 1,
      "unitRef": "Unit_shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1067 - Disclosure -  Noncontrolling Interest - Additional Information (Details)",
     "menuCat": "Details",
     "order": "67",
     "role": "http://haymaker.com/role/NoncontrollingInterestAdditionalInformationDetails",
     "shortName": "Noncontrolling Interest - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d479690dposam.htm",
      "contextRef": "P01_01_2022To12_31_2022_CommonClassVMemberusgaapStatementClassOfStockAxis",
      "decimals": null,
      "lang": "en-US",
      "name": "us-gaap:CommonStockVotingRights",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R68": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d479690dposam.htm",
      "contextRef": "P05_26_2022To05_26_2022_IncentiveUnitsMemberusgaapAwardTypeAxis",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1068 - Disclosure -  Share-Based Compensation - Additional Information (Details)",
     "menuCat": "Details",
     "order": "68",
     "role": "http://haymaker.com/role/ShareBasedCompensationAdditionalInformationDetails",
     "shortName": "Share-Based Compensation - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d479690dposam.htm",
      "contextRef": "P05_26_2022To05_26_2022_IncentiveUnitsMemberusgaapAwardTypeAxis",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R69": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d479690dposam.htm",
      "contextRef": "PAsOn12_31_2021_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis_TwoThousandTwentyTwoEquityIncentivePlanMemberusgaapPlanNameAxis",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1069 - Disclosure -  Share-Based Compensation - Summary of Restricted Stock Unit Activity (Details)",
     "menuCat": "Details",
     "order": "69",
     "role": "http://haymaker.com/role/ShareBasedCompensationSummaryOfRestrictedStockUnitActivityDetails",
     "shortName": "Share-Based Compensation - Summary of Restricted Stock Unit Activity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d479690dposam.htm",
      "contextRef": "PAsOn12_31_2021_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis_TwoThousandTwentyTwoEquityIncentivePlanMemberusgaapPlanNameAxis",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_shares",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d479690dposam.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1007 - Disclosure -  Description of Business and Basis of Presentation",
     "menuCat": "Notes",
     "order": "7",
     "role": "http://haymaker.com/role/DescriptionOfBusinessAndBasisOfPresentation",
     "shortName": "Description of Business and Basis of Presentation",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d479690dposam.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R70": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d479690dposam.htm",
      "contextRef": "P01_01_2022To12_31_2022_TwoThousandTwentyTwoEquityIncentivePlanMemberusgaapPlanNameAxis",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1070 - Disclosure -  Share-Based Compensation - Summary of Stock Option Activity (Details)",
     "menuCat": "Details",
     "order": "70",
     "role": "http://haymaker.com/role/ShareBasedCompensationSummaryOfStockOptionActivityDetails",
     "shortName": "Share-Based Compensation - Summary of Stock Option Activity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d479690dposam.htm",
      "contextRef": "P01_01_2022To12_31_2022_TwoThousandTwentyTwoEquityIncentivePlanMemberusgaapPlanNameAxis",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_shares",
      "xsiNil": "false"
     }
    },
    "R71": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d479690dposam.htm",
      "contextRef": "P01_01_2022To12_31_2022_TwoThousandTwentyTwoEquityIncentivePlanMemberusgaapPlanNameAxis",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1071 - Disclosure -  Share-Based Compensation - Summary of Weighted-Average Assumptions used to Estimate Fair Value of Stock Options Granted (Details)",
     "menuCat": "Details",
     "order": "71",
     "role": "http://haymaker.com/role/ShareBasedCompensationSummaryOfWeightedAverageAssumptionsUsedToEstimateFairValueOfStockOptionsGrantedDetails",
     "shortName": "Share-Based Compensation - Summary of Weighted-Average Assumptions used to Estimate Fair Value of Stock Options Granted (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d479690dposam.htm",
      "contextRef": "P01_01_2022To12_31_2022_TwoThousandTwentyTwoEquityIncentivePlanMemberusgaapPlanNameAxis",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R72": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d479690dposam.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseOptionToExtend",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1072 - Disclosure -  Leases - Additional Information (Details)",
     "menuCat": "Details",
     "order": "72",
     "role": "http://haymaker.com/role/LeasesAdditionalInformationDetails",
     "shortName": "Leases - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d479690dposam.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseOptionToExtend",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R73": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d479690dposam.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLeaseCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1073 - Disclosure -  Leases - Summary of Operating Lease Costs Recognized under ASC 842 and Supplemental Cash Flow Information for Leases (Details)",
     "menuCat": "Details",
     "order": "73",
     "role": "http://haymaker.com/role/LeasesSummaryOfOperatingLeaseCostsRecognizedUnderAsc842AndSupplementalCashFlowInformationForLeasesDetails",
     "shortName": "Leases - Summary of Operating Lease Costs Recognized under ASC 842 and Supplemental Cash Flow Information for Leases (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d479690dposam.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLeaseCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R74": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d479690dposam.htm",
      "contextRef": "PAsOn12_31_2022",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLeaseRightOfUseAsset",
      "reportCount": 1,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1074 - Disclosure -  Leases - Summary Balance Sheet Classification of Operating Leases and Weighted Average Remaining Lease Term and Discount Rate (Details)",
     "menuCat": "Details",
     "order": "74",
     "role": "http://haymaker.com/role/LeasesSummaryBalanceSheetClassificationOfOperatingLeasesAndWeightedAverageRemainingLeaseTermAndDiscountRateDetails",
     "shortName": "Leases - Summary Balance Sheet Classification of Operating Leases and Weighted Average Remaining Lease Term and Discount Rate (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "btmd:SummaryBalanceSheetClassificationOfOperatingLeasesAndWeightedAverageRemainingLeaseTermAndDiscountRateTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d479690dposam.htm",
      "contextRef": "PAsOn12_31_2022",
      "decimals": "-3",
      "lang": null,
      "name": "btmd:LeaseAssets",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R75": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d479690dposam.htm",
      "contextRef": "PAsOn12_31_2022",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1075 - Disclosure -  Leases - Summary of Payments by Date for Operating Lease (Details)",
     "menuCat": "Details",
     "order": "75",
     "role": "http://haymaker.com/role/LeasesSummaryOfPaymentsByDateForOperatingLeaseDetails",
     "shortName": "Leases - Summary of Payments by Date for Operating Lease (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d479690dposam.htm",
      "contextRef": "PAsOn12_31_2022",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R76": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d479690dposam.htm",
      "contextRef": "PAsOn12_31_2022",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:UnrecognizedTaxBenefits",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1076 - Disclosure -  Income Taxes - Additional Information (Details)",
     "menuCat": "Details",
     "order": "76",
     "role": "http://haymaker.com/role/IncomeTaxesAdditionalInformationDetails",
     "shortName": "Income Taxes - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d479690dposam.htm",
      "contextRef": "PAsOn12_31_2022",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:UnrecognizedTaxBenefits",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R77": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d479690dposam.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1077 - Disclosure -  Income Taxes - Schedule of Income (Loss) Before Provision for Income Taxes (Details)",
     "menuCat": "Details",
     "order": "77",
     "role": "http://haymaker.com/role/IncomeTaxesScheduleOfIncomeLossBeforeProvisionForIncomeTaxesDetails",
     "shortName": "Income Taxes - Schedule of Income (Loss) Before Provision for Income Taxes (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d479690dposam.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R78": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d479690dposam.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:CurrentFederalTaxExpenseBenefit",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1078 - Disclosure -  Income Taxes - Schedule of Income Tax Provision (Details)",
     "menuCat": "Details",
     "order": "78",
     "role": "http://haymaker.com/role/IncomeTaxesScheduleOfIncomeTaxProvisionDetails",
     "shortName": "Income Taxes - Schedule of Income Tax Provision (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d479690dposam.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:CurrentFederalTaxExpenseBenefit",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R79": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d479690dposam.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": "4",
      "first": true,
      "lang": null,
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_pure",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1079 - Disclosure -  Income Taxes - Schedule of Reconciliation of the Federal Income Tax Rate to the Company Effective Tax Rate (Details)",
     "menuCat": "Details",
     "order": "79",
     "role": "http://haymaker.com/role/IncomeTaxesScheduleOfReconciliationOfTheFederalIncomeTaxRateToTheCompanyEffectiveTaxRateDetails",
     "shortName": "Income Taxes - Schedule of Reconciliation of the Federal Income Tax Rate to the Company Effective Tax Rate (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d479690dposam.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": "4",
      "first": true,
      "lang": null,
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_pure",
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d479690dposam.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1008 - Disclosure -  Summary of Significant Accounting Policies",
     "menuCat": "Notes",
     "order": "8",
     "role": "http://haymaker.com/role/SummaryOfSignificantAccountingPolicies",
     "shortName": "Summary of Significant Accounting Policies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d479690dposam.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R80": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d479690dposam.htm",
      "contextRef": "PAsOn12_31_2022",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:DeferredTaxAssetsInvestments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1080 - Disclosure -  Income Taxes - Deferred Tax Assets and Liabilities (Details)",
     "menuCat": "Details",
     "order": "80",
     "role": "http://haymaker.com/role/IncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails",
     "shortName": "Income Taxes - Deferred Tax Assets and Liabilities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d479690dposam.htm",
      "contextRef": "PAsOn12_31_2022",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:DeferredTaxAssetsInvestments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R81": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d479690dposam.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1081 - Disclosure -  Net Loss Per Common Share - Schedule of Computation of Net Loss Per Common Share (Details)",
     "menuCat": "Details",
     "order": "81",
     "role": "http://haymaker.com/role/NetLossPerCommonShareScheduleOfComputationOfNetLossPerCommonShareDetails",
     "shortName": "Net Loss Per Common Share - Schedule of Computation of Net Loss Per Common Share (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d479690dposam.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R82": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d479690dposam.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1082 - Disclosure -  Net Loss Per Common Share - Schedule of Computation of Diluted Weighted Average Shares Outstanding (Details)",
     "menuCat": "Details",
     "order": "82",
     "role": "http://haymaker.com/role/NetLossPerCommonShareScheduleOfComputationOfDilutedWeightedAverageSharesOutstandingDetails",
     "shortName": "Net Loss Per Common Share - Schedule of Computation of Diluted Weighted Average Shares Outstanding (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d479690dposam.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_shares",
      "xsiNil": "false"
     }
    },
    "R83": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d479690dposam.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LossContingencyLawsuitFilingDate",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1083 - Disclosure -  Commitments and Contingencies - Additional Information (Details)",
     "menuCat": "Details",
     "order": "83",
     "role": "http://haymaker.com/role/CommitmentsAndContingenciesAdditionalInformationDetails",
     "shortName": "Commitments and Contingencies - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d479690dposam.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LossContingencyLawsuitFilingDate",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R84": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d479690dposam.htm",
      "contextRef": "P01_01_2022To12_31_2022_FirmMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ProfessionalFees",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1084 - Disclosure -  Related-Party Transactions - Additional Information (Details)",
     "menuCat": "Details",
     "order": "84",
     "role": "http://haymaker.com/role/RelatedPartyTransactionsAdditionalInformationDetails",
     "shortName": "Related-Party Transactions - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d479690dposam.htm",
      "contextRef": "P01_01_2022To12_31_2022_FirmMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ProfessionalFees",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d479690dposam.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1009 - Disclosure -  Business Combination",
     "menuCat": "Notes",
     "order": "9",
     "role": "http://haymaker.com/role/BusinessCombination",
     "shortName": "Business Combination",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d479690dposam.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 121,
   "tag": {
    "btmd_AccruedMerchantFeesCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://haymaker.com/role/AccruedExpensesScheduleOfAccruedExpensesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued merchant fees current.",
        "label": "Accrued Merchant Fees Current",
        "terseLabel": "Accrued merchant fees"
       }
      }
     },
     "localname": "AccruedMerchantFeesCurrent",
     "nsuri": "http://haymaker.com/20221231",
     "presentation": [
      "http://haymaker.com/role/AccruedExpensesScheduleOfAccruedExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "btmd_AgreementTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Agreement term.",
        "label": "Agreement Term",
        "terseLabel": "Agreement term"
       }
      }
     },
     "localname": "AgreementTerm",
     "nsuri": "http://haymaker.com/20221231",
     "presentation": [
      "http://haymaker.com/role/RelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "btmd_AllOtherCountryMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "All other country.",
        "label": "All Other Country [Member]",
        "terseLabel": "All Other"
       }
      }
     },
     "localname": "AllOtherCountryMember",
     "nsuri": "http://haymaker.com/20221231",
     "presentation": [
      "http://haymaker.com/role/RevenueRecognitionScheduleOfRevenuesRecognizedByGeographicRegionDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "btmd_AnnualAdviosryFeesPayable": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Annual adviosry fees payable.",
        "label": "Annual Adviosry Fees Payable",
        "terseLabel": "Annual fees per year"
       }
      }
     },
     "localname": "AnnualAdviosryFeesPayable",
     "nsuri": "http://haymaker.com/20221231",
     "presentation": [
      "http://haymaker.com/role/RelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "btmd_AreaOfOfficeSpace": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area of Office Space",
        "label": "Area of Office Space",
        "terseLabel": "Area of office space"
       }
      }
     },
     "localname": "AreaOfOfficeSpace",
     "nsuri": "http://haymaker.com/20221231",
     "presentation": [
      "http://haymaker.com/role/LeasesAdditionalInformationDetails"
     ],
     "xbrltype": "decimalItemType"
    },
    "btmd_AssetsLesseeAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Assets lessee.",
        "label": "Assets Lessee [Abstract]",
        "terseLabel": "Lease Assets"
       }
      }
     },
     "localname": "AssetsLesseeAbstract",
     "nsuri": "http://haymaker.com/20221231",
     "presentation": [
      "http://haymaker.com/role/LeasesSummaryBalanceSheetClassificationOfOperatingLeasesAndWeightedAverageRemainingLeaseTermAndDiscountRateDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "btmd_BankOfAmericaTermLoanAndTruistTermLoanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Bank of America term loan and Truist term loan.",
        "label": "Bank of America Term Loan and Truist Term Loan [Member]",
        "terseLabel": "Bank of America Term Loan and Truist Term Loan"
       }
      }
     },
     "localname": "BankOfAmericaTermLoanAndTruistTermLoanMember",
     "nsuri": "http://haymaker.com/20221231",
     "presentation": [
      "http://haymaker.com/role/LongTermDebtAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "btmd_BankOfAmericaTermLoanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Bank of America term loan.",
        "label": "Bank of America Term Loan [Member]",
        "terseLabel": "Bank of America Term Loan"
       }
      }
     },
     "localname": "BankOfAmericaTermLoanMember",
     "nsuri": "http://haymaker.com/20221231",
     "presentation": [
      "http://haymaker.com/role/LongTermDebtAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "btmd_BioteCorporationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Biote Corp.",
        "label": "Biote Corporation [Member]",
        "terseLabel": "Biote"
       }
      }
     },
     "localname": "BioteCorporationMember",
     "nsuri": "http://haymaker.com/20221231",
     "presentation": [
      "http://haymaker.com/role/NoncontrollingInterestAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "btmd_BioteManagementLlcMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Biote management, LLC.",
        "label": "Biote Management LLC [Member]",
        "terseLabel": "Biote Units"
       }
      }
     },
     "localname": "BioteManagementLlcMember",
     "nsuri": "http://haymaker.com/20221231",
     "presentation": [
      "http://haymaker.com/role/BusinessCombinationAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "btmd_BioteMethodCustomerMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Biote method customer.",
        "label": "Biote Method Customer [Member]",
        "terseLabel": "Biote Method Customer"
       }
      }
     },
     "localname": "BioteMethodCustomerMember",
     "nsuri": "http://haymaker.com/20221231",
     "presentation": [
      "http://haymaker.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "btmd_BorrowingsOnTermLoan": {
     "auth_ref": [],
     "calculation": {
      "http://haymaker.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Borrowings on term loan",
        "label": "Borrowings on Term Loan",
        "terseLabel": "Borrowings on term loan"
       }
      }
     },
     "localname": "BorrowingsOnTermLoan",
     "nsuri": "http://haymaker.com/20221231",
     "presentation": [
      "http://haymaker.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "btmd_BusinessCombinationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business combination.",
        "label": "Business Combination [Member]",
        "terseLabel": "Business Combination"
       }
      }
     },
     "localname": "BusinessCombinationMember",
     "nsuri": "http://haymaker.com/20221231",
     "presentation": [
      "http://haymaker.com/role/BusinessCombinationAdditionalInformationDetails",
      "http://haymaker.com/role/EarnoutLiabilityAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "btmd_CapitalizedSoftwareDevelopmentInProcess": {
     "auth_ref": [],
     "calculation": {
      "http://haymaker.com/role/CapitalizedSoftwareNetSummaryOfCapitalizedSoftwareNetDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_CapitalizedComputerSoftwareNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Capitalized software, development in process.",
        "label": "Capitalized Software, Development in Process",
        "terseLabel": "Development in Process"
       }
      }
     },
     "localname": "CapitalizedSoftwareDevelopmentInProcess",
     "nsuri": "http://haymaker.com/20221231",
     "presentation": [
      "http://haymaker.com/role/CapitalizedSoftwareNetSummaryOfCapitalizedSoftwareNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "btmd_CapitalizedSoftwareEstimatedUsefulLives": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Capitalized software estimated useful lives.",
        "label": "Capitalized Software Estimated Useful Lives",
        "terseLabel": "Capitalized software estimated useful lives"
       }
      }
     },
     "localname": "CapitalizedSoftwareEstimatedUsefulLives",
     "nsuri": "http://haymaker.com/20221231",
     "presentation": [
      "http://haymaker.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "btmd_CapitalizedSoftwareWebsiteCosts": {
     "auth_ref": [],
     "calculation": {
      "http://haymaker.com/role/CapitalizedSoftwareNetSummaryOfCapitalizedSoftwareNetDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_CapitalizedComputerSoftwareNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Capitalized software, website costs",
        "label": "Capitalized Software, Website Costs",
        "terseLabel": "Website costs"
       }
      }
     },
     "localname": "CapitalizedSoftwareWebsiteCosts",
     "nsuri": "http://haymaker.com/20221231",
     "presentation": [
      "http://haymaker.com/role/CapitalizedSoftwareNetSummaryOfCapitalizedSoftwareNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "btmd_ClassAMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Class A.",
        "label": "Class A [Member]",
        "terseLabel": "Class A"
       }
      }
     },
     "localname": "ClassAMember",
     "nsuri": "http://haymaker.com/20221231",
     "presentation": [
      "http://haymaker.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "domainItemType"
    },
    "btmd_ClassAVotingUnitsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Class A Voting Units.",
        "label": "Class A Voting Units [Member]",
        "terseLabel": "Class A (Voting)"
       }
      }
     },
     "localname": "ClassAVotingUnitsMember",
     "nsuri": "http://haymaker.com/20221231",
     "presentation": [
      "http://haymaker.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://haymaker.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfMembersEquityUnitsIssuedAndOutstandingDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "btmd_ClassAaNonVotingUnitsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Class AA Non-Voting Units.",
        "label": "Class AA Non-Voting Units [Member]",
        "terseLabel": "Class AA (Non-voting)"
       }
      }
     },
     "localname": "ClassAaNonVotingUnitsMember",
     "nsuri": "http://haymaker.com/20221231",
     "presentation": [
      "http://haymaker.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfMembersEquityUnitsIssuedAndOutstandingDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "btmd_ClassAaUnitsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Class AA units.",
        "label": "Class AA Units [Member]",
        "terseLabel": "Class AA Units"
       }
      }
     },
     "localname": "ClassAaUnitsMember",
     "nsuri": "http://haymaker.com/20221231",
     "presentation": [
      "http://haymaker.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "domainItemType"
    },
    "btmd_ClassAaaNonVotingUnitsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Class AAA Non-Voting Units.",
        "label": "Class AAA Non-Voting Units [Member]",
        "terseLabel": "Class AAA (Non-voting)"
       }
      }
     },
     "localname": "ClassAaaNonVotingUnitsMember",
     "nsuri": "http://haymaker.com/20221231",
     "presentation": [
      "http://haymaker.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfMembersEquityUnitsIssuedAndOutstandingDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "btmd_ClassAaaUnitsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Class AAA Units [Member]",
        "label": "Class AAA Units [Member]",
        "terseLabel": "Class AAA Units"
       }
      }
     },
     "localname": "ClassAaaUnitsMember",
     "nsuri": "http://haymaker.com/20221231",
     "presentation": [
      "http://haymaker.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "domainItemType"
    },
    "btmd_ClassAaaaNonVotingIncentiveUnitsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Class AAAA Non Voting Incentive Units.",
        "label": "Class AAAA Non Voting Incentive Units [Member]",
        "terseLabel": "Class AAAA (Non-voting incentive units)"
       }
      }
     },
     "localname": "ClassAaaaNonVotingIncentiveUnitsMember",
     "nsuri": "http://haymaker.com/20221231",
     "presentation": [
      "http://haymaker.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfMembersEquityUnitsIssuedAndOutstandingDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "btmd_ClassAaaaUnitsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Class AAAA units.",
        "label": "Class AAAA Units [Member]",
        "terseLabel": "Class AAAA Units"
       }
      }
     },
     "localname": "ClassAaaaUnitsMember",
     "nsuri": "http://haymaker.com/20221231",
     "presentation": [
      "http://haymaker.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "domainItemType"
    },
    "btmd_ClassOfWarrantOrRightExercisePriceAdjustmentPercentageHigherOfMarketValue": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Class of warrant or right exercise price adjustment percentage higher of market value.",
        "label": "Class Of Warrant Or Right Exercise Price Adjustment Percentage Higher Of Market Value",
        "terseLabel": "Class of warrant or right exercise price adjustment percentage higher of market value"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightExercisePriceAdjustmentPercentageHigherOfMarketValue",
     "nsuri": "http://haymaker.com/20221231",
     "presentation": [
      "http://haymaker.com/role/WarrantLiabilityAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "btmd_ClassOfWarrantOrRightMinimumNoticePeriodForRedemption": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Class of warrant or right minimum notice period for redemption.",
        "label": "Class Of Warrant Or Right Minimum Notice Period For Redemption",
        "terseLabel": "Class of warrant or right minimum notice period For Redemption"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightMinimumNoticePeriodForRedemption",
     "nsuri": "http://haymaker.com/20221231",
     "presentation": [
      "http://haymaker.com/role/WarrantLiabilityAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "btmd_ClassOfWarrantOrRightRedemptionThresholdConsecutiveTradingDays": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Class of warrant or right redemption threshold consecutive trading days.",
        "label": "Class Of Warrant Or Right Redemption Threshold Consecutive Trading Days",
        "terseLabel": "Class of warrant or right redemption threshold consecutive trading days"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightRedemptionThresholdConsecutiveTradingDays",
     "nsuri": "http://haymaker.com/20221231",
     "presentation": [
      "http://haymaker.com/role/WarrantLiabilityAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "btmd_ClassOfWarrantOrRightThresholdPeriodForExerciseFromDateOfClosingPublicOffering": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Class of warrant or right threshold period for exercise from date of closing public offering.",
        "label": "Class Of Warrant Or Right Threshold Period For Exercise From Date Of Closing Public Offering",
        "terseLabel": "Class of warrant or right, threshold period for exercise from date of closing public offering"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightThresholdPeriodForExerciseFromDateOfClosingPublicOffering",
     "nsuri": "http://haymaker.com/20221231",
     "presentation": [
      "http://haymaker.com/role/WarrantLiabilityAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "btmd_ClassOfWarrantsOrRightsTransfersRestrictionOnNumberOfDaysFromTheDateOfBusinessCombination": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Class of warrants or rights transfers restriction on number of days from the date of business combination.",
        "label": "Class Of Warrants Or Rights Transfers Restriction On Number Of Days From The Date Of Business Combination",
        "terseLabel": "Class of warrants or rights transfers restriction on number of days from the date of business combination"
       }
      }
     },
     "localname": "ClassOfWarrantsOrRightsTransfersRestrictionOnNumberOfDaysFromTheDateOfBusinessCombination",
     "nsuri": "http://haymaker.com/20221231",
     "presentation": [
      "http://haymaker.com/role/WarrantLiabilityAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "btmd_ClassOfWarrantsRedemptionPricePerUnit": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Class of warrants redemption price per unit.",
        "label": "Class Of Warrants Redemption Price Per Unit",
        "terseLabel": "Class of warrants redemption price per unit"
       }
      }
     },
     "localname": "ClassOfWarrantsRedemptionPricePerUnit",
     "nsuri": "http://haymaker.com/20221231",
     "presentation": [
      "http://haymaker.com/role/WarrantLiabilityAdditionalInformationDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "btmd_ClassVCommonStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Class V Common Stock.",
        "label": "Class V Common Stock [Member]",
        "terseLabel": "Class V Voting Stock"
       }
      }
     },
     "localname": "ClassVCommonStockMember",
     "nsuri": "http://haymaker.com/20221231",
     "presentation": [
      "http://haymaker.com/role/BusinessCombinationAdditionalInformationDetails",
      "http://haymaker.com/role/NetLossPerCommonShareScheduleOfComputationOfDilutedWeightedAverageSharesOutstandingDetails",
      "http://haymaker.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfCommonStockIssuedAndOutstandingDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "btmd_CommonClassVMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Common class V.",
        "label": "Common Class V [Member]",
        "terseLabel": "Class V Common Stock"
       }
      }
     },
     "localname": "CommonClassVMember",
     "nsuri": "http://haymaker.com/20221231",
     "presentation": [
      "http://haymaker.com/role/ConsolidatedBalanceSheets",
      "http://haymaker.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://haymaker.com/role/ConsolidatedStatementsOfStockholdersEquityDeficit",
      "http://haymaker.com/role/NoncontrollingInterestAdditionalInformationDetails",
      "http://haymaker.com/role/ShareBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "btmd_CommonStockNumberOfVotesEntitledPerShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Common stock, number of votes entitled per share.",
        "label": "Common Stock, Number of Votes Entitled Per Share",
        "terseLabel": "Common stock, number of votes per share"
       }
      }
     },
     "localname": "CommonStockNumberOfVotesEntitledPerShare",
     "nsuri": "http://haymaker.com/20221231",
     "presentation": [
      "http://haymaker.com/role/NoncontrollingInterestAdditionalInformationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "btmd_CommonStockTransfersThresholdTradingDays": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Common stock transfers threshold trading days.",
        "label": "Common Stock Transfers Threshold Trading Days",
        "terseLabel": "Common stock transfers threshold trading days"
       }
      }
     },
     "localname": "CommonStockTransfersThresholdTradingDays",
     "nsuri": "http://haymaker.com/20221231",
     "presentation": [
      "http://haymaker.com/role/BusinessCombinationAdditionalInformationDetails",
      "http://haymaker.com/role/EarnoutLiabilityAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "btmd_CommonUnitsVotingRightsPercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Common Units Voting Rights Percentage",
        "label": "Common Units Voting Rights Percentage",
        "terseLabel": "Common units voting rights percentage"
       }
      }
     },
     "localname": "CommonUnitsVotingRightsPercentage",
     "nsuri": "http://haymaker.com/20221231",
     "presentation": [
      "http://haymaker.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "btmd_ConsecutiveTradingDays": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Consecutive trading days.",
        "label": "Consecutive Trading Days",
        "terseLabel": "Consecutive trading days"
       }
      }
     },
     "localname": "ConsecutiveTradingDays",
     "nsuri": "http://haymaker.com/20221231",
     "presentation": [
      "http://haymaker.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "btmd_ConsultantMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Consultant.",
        "label": "Consultant [Member]",
        "terseLabel": "Lani D."
       }
      }
     },
     "localname": "ConsultantMember",
     "nsuri": "http://haymaker.com/20221231",
     "presentation": [
      "http://haymaker.com/role/RelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "btmd_ContractTermServicesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contract Term Services [Member]",
        "terseLabel": "Contract Term Services"
       }
      }
     },
     "localname": "ContractTermServicesMember",
     "nsuri": "http://haymaker.com/20221231",
     "presentation": [
      "http://haymaker.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "btmd_ContractTermServicesRevenueMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contract-term services revenue.",
        "label": "Contract-Term Services Revenue [Member]",
        "terseLabel": "Contract-Term Services Revenue"
       }
      }
     },
     "localname": "ContractTermServicesRevenueMember",
     "nsuri": "http://haymaker.com/20221231",
     "presentation": [
      "http://haymaker.com/role/RevenueRecognitionScheduleOfRevenuesRecognizedForEachRevenueStreamDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "btmd_ContractWithCustomerLiabilityIncreasesDueToCashReceivedExcludingAmountsRecognizedAsRevenue": {
     "auth_ref": [],
     "calculation": {
      "http://haymaker.com/role/RevenueRecognitionSummaryOfSignificantChangesInContractLiabilityBalancesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_IncreaseDecreaseInContractWithCustomerLiability",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contract with customer liability, increases due to cash received, excluding amounts recognized as revenue.",
        "label": "Contract with Customer Liability, Increases Due to Cash Received, Excluding Amounts Recognized as Revenue",
        "terseLabel": "Increases due to cash received, excluding amounts recognized as revenue during the period"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityIncreasesDueToCashReceivedExcludingAmountsRecognizedAsRevenue",
     "nsuri": "http://haymaker.com/20221231",
     "presentation": [
      "http://haymaker.com/role/RevenueRecognitionSummaryOfSignificantChangesInContractLiabilityBalancesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "btmd_ContractWithCustomerLiabilityTransfersBetweenCurrentAndNonCurrentLiabilitiesDueToExpectedRevenueRecognitionPeriod": {
     "auth_ref": [],
     "calculation": {
      "http://haymaker.com/role/RevenueRecognitionSummaryOfSignificantChangesInContractLiabilityBalancesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_IncreaseDecreaseInContractWithCustomerLiability",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contract with customer liability, transfers between current and non-current liabilities due to expected revenue recognition period.",
        "label": "Contract with Customer Liability, Transfers between Current and Non-Current Liabilities Due to Expected Revenue Recognition Period",
        "terseLabel": "Transfers between current and non-current liabilities due to the expected revenue recognition period"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityTransfersBetweenCurrentAndNonCurrentLiabilitiesDueToExpectedRevenueRecognitionPeriod",
     "nsuri": "http://haymaker.com/20221231",
     "presentation": [
      "http://haymaker.com/role/RevenueRecognitionSummaryOfSignificantChangesInContractLiabilityBalancesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "btmd_CostOfRevenuePolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cost of revenue.",
        "label": "Cost of Revenue [Policy Text Block]",
        "terseLabel": "Cost of Revenue"
       }
      }
     },
     "localname": "CostOfRevenuePolicyTextBlock",
     "nsuri": "http://haymaker.com/20221231",
     "presentation": [
      "http://haymaker.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "btmd_DebtCommitmentLetterMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt commitment letter.",
        "label": "Debt Commitment Letter [Member]",
        "terseLabel": "Debt Commitment Letter"
       }
      }
     },
     "localname": "DebtCommitmentLetterMember",
     "nsuri": "http://haymaker.com/20221231",
     "presentation": [
      "http://haymaker.com/role/BusinessCombinationAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "btmd_DebtIssuanceCostsPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt issuance costs.",
        "label": "Debt Issuance Costs [Policy Text Block]",
        "terseLabel": "Debt Issuance Costs"
       }
      }
     },
     "localname": "DebtIssuanceCostsPolicyTextBlock",
     "nsuri": "http://haymaker.com/20221231",
     "presentation": [
      "http://haymaker.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "btmd_DietarySupplementsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Dietary supplements.",
        "label": "Dietary Supplements [Member]",
        "terseLabel": "Dietary Supplements"
       }
      }
     },
     "localname": "DietarySupplementsMember",
     "nsuri": "http://haymaker.com/20221231",
     "presentation": [
      "http://haymaker.com/role/InventoryNetScheduleOfInventoryNetDetails",
      "http://haymaker.com/role/RevenueRecognitionScheduleOfRevenuesRecognizedForEachRevenueStreamDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "btmd_DisclosureInTabularFormOfEstimatedUsefulLivesOfPropertyPlantAndEquipmentTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure in tabular form of estimated useful lives of property plant and equipment.",
        "label": "Disclosure In Tabular Form Of Estimated Useful Lives Of Property Plant And Equipment [Table Text Block]",
        "terseLabel": "Summary of Estimated Useful Lives of Property and Equipment"
       }
      }
     },
     "localname": "DisclosureInTabularFormOfEstimatedUsefulLivesOfPropertyPlantAndEquipmentTableTextBlock",
     "nsuri": "http://haymaker.com/20221231",
     "presentation": [
      "http://haymaker.com/role/SummaryOfSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "btmd_DisposableTrocarsProductRevenueMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disposable trocars product revenue.",
        "label": "Disposable Trocars Product Revenue [Member]",
        "terseLabel": "Disposable Trocars Product Revenue"
       }
      }
     },
     "localname": "DisposableTrocarsProductRevenueMember",
     "nsuri": "http://haymaker.com/20221231",
     "presentation": [
      "http://haymaker.com/role/RevenueRecognitionScheduleOfRevenuesRecognizedForEachRevenueStreamDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "btmd_EarnoutDeadlineDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Earnout deadline date.",
        "label": "Earnout Deadline Date",
        "terseLabel": "Earnout deadline date"
       }
      }
     },
     "localname": "EarnoutDeadlineDate",
     "nsuri": "http://haymaker.com/20221231",
     "presentation": [
      "http://haymaker.com/role/EarnoutLiabilityAdditionalInformationDetails"
     ],
     "xbrltype": "dateItemType"
    },
    "btmd_EarnoutLiabilityMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Earnout liability member.",
        "label": "Earnout Liability Member",
        "terseLabel": "Earnout Liability"
       }
      }
     },
     "localname": "EarnoutLiabilityMember",
     "nsuri": "http://haymaker.com/20221231",
     "presentation": [
      "http://haymaker.com/role/FairValueMeasurementsScheduleOfFairValueHierarchyForFinancialAssetsAndLiabilitiesDetails",
      "http://haymaker.com/role/FairValueMeasurementsSummaryOfChangesInTheFairValueOfCompanysLevel3FinancialInstrumentsDetails",
      "http://haymaker.com/role/FairValueMeasurementsSummaryOfSignificantInputsToMonteCarloSimulationForFairValueOfEarnoutLiabilityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "btmd_EarnoutLiabilityPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Earnout liability.",
        "label": "Earnout Liability [Policy Text Block]",
        "terseLabel": "Earnout Liability"
       }
      }
     },
     "localname": "EarnoutLiabilityPolicyTextBlock",
     "nsuri": "http://haymaker.com/20221231",
     "presentation": [
      "http://haymaker.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "btmd_EarnoutLiabilityTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Earnout liability.",
        "label": "Earnout Liability [Text Block]",
        "terseLabel": "Earnout Liability"
       }
      }
     },
     "localname": "EarnoutLiabilityTextBlock",
     "nsuri": "http://haymaker.com/20221231",
     "presentation": [
      "http://haymaker.com/role/EarnoutLiability"
     ],
     "xbrltype": "textBlockItemType"
    },
    "btmd_EarnoutVotingSharesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Earnout voting shares.",
        "label": "Earnout Voting Shares [Member]",
        "terseLabel": "Earnout Voting Shares"
       }
      }
     },
     "localname": "EarnoutVotingSharesMember",
     "nsuri": "http://haymaker.com/20221231",
     "presentation": [
      "http://haymaker.com/role/BusinessCombinationAdditionalInformationDetails",
      "http://haymaker.com/role/NetLossPerCommonShareScheduleOfComputationOfDilutedWeightedAverageSharesOutstandingDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "btmd_EmployeeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Employee.",
        "label": "Employee [Member]",
        "terseLabel": "Employee"
       }
      }
     },
     "localname": "EmployeeMember",
     "nsuri": "http://haymaker.com/20221231",
     "presentation": [
      "http://haymaker.com/role/RelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "btmd_ExpectedReturnsAndRefundsToCustomers": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expected returns and refunds to customers.",
        "label": "Expected Returns And Refunds To Customers",
        "terseLabel": "Expected returns and refunds to customers"
       }
      }
     },
     "localname": "ExpectedReturnsAndRefundsToCustomers",
     "nsuri": "http://haymaker.com/20221231",
     "presentation": [
      "http://haymaker.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "btmd_FairValueAdjustmentOfEarnoutLiability": {
     "auth_ref": [],
     "calculation": {
      "http://haymaker.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 25.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair Value Adjustment Of Earnout Liability",
        "label": "Fair Value Adjustment Of Earnout Liability",
        "terseLabel": "Gain from change in fair value of earnout liability"
       }
      }
     },
     "localname": "FairValueAdjustmentOfEarnoutLiability",
     "nsuri": "http://haymaker.com/20221231",
     "presentation": [
      "http://haymaker.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "btmd_FirmMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Firm.",
        "label": "Firm [Member]",
        "terseLabel": "Firm"
       }
      }
     },
     "localname": "FirmMember",
     "nsuri": "http://haymaker.com/20221231",
     "presentation": [
      "http://haymaker.com/role/RelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "btmd_FixedChargeCoverageRatio": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "fixed charge coverage ratio.",
        "label": "Fixed Charge Coverage Ratio",
        "terseLabel": "Fixed charge coverage ratio"
       }
      }
     },
     "localname": "FixedChargeCoverageRatio",
     "nsuri": "http://haymaker.com/20221231",
     "presentation": [
      "http://haymaker.com/role/LongTermDebtAdditionalInformationDetails"
     ],
     "xbrltype": "pureItemType"
    },
    "btmd_FounderAdvisoryAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Founder advisory agreement.",
        "label": "Founder Advisory Agreement [Member]",
        "terseLabel": "Founder Advisory Agreement"
       }
      }
     },
     "localname": "FounderAdvisoryAgreementMember",
     "nsuri": "http://haymaker.com/20221231",
     "presentation": [
      "http://haymaker.com/role/RelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "btmd_FourZeroOneKPlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "401 (k) Plan.",
        "label": "Four Zero One K Plan [Member]",
        "terseLabel": "401(k) Plan"
       }
      }
     },
     "localname": "FourZeroOneKPlanMember",
     "nsuri": "http://haymaker.com/20221231",
     "presentation": [
      "http://haymaker.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "btmd_GainLossFromChangeInFairValueOfEarnoutLiability": {
     "auth_ref": [],
     "calculation": {
      "http://haymaker.com/role/ConsolidatedStatementsOfIncomeAndComprehensiveIncome": {
       "order": 28.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gain loss from change in fair value of earnout liability.",
        "label": "Gain Loss from Change in Fair Value of Earnout Liability",
        "terseLabel": "Gain from change in fair value of earnout liability"
       }
      }
     },
     "localname": "GainLossFromChangeInFairValueOfEarnoutLiability",
     "nsuri": "http://haymaker.com/20221231",
     "presentation": [
      "http://haymaker.com/role/ConsolidatedStatementsOfIncomeAndComprehensiveIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "btmd_HaymakerAcquisitionCorpIiiMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Haymaker acquisition corp. III.",
        "label": "Haymaker Acquisition Corp. III [Member]",
        "terseLabel": "Haymaker"
       }
      }
     },
     "localname": "HaymakerAcquisitionCorpIiiMember",
     "nsuri": "http://haymaker.com/20221231",
     "presentation": [
      "http://haymaker.com/role/BusinessCombinationAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "btmd_HaymakeriiiMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "HaymakerIii.",
        "label": "HaymakerIii [Member]",
        "terseLabel": "Haymaker III"
       }
      }
     },
     "localname": "HaymakeriiiMember",
     "nsuri": "http://haymaker.com/20221231",
     "presentation": [
      "http://haymaker.com/role/BusinessCombinationAdditionalInformationDetails",
      "http://haymaker.com/role/WarrantLiabilityAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "btmd_IncentiveUnitsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Incentive units.",
        "label": "Incentive Units [Member]",
        "terseLabel": "Incentive Units"
       }
      }
     },
     "localname": "IncentiveUnitsMember",
     "nsuri": "http://haymaker.com/20221231",
     "presentation": [
      "http://haymaker.com/role/ShareBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "btmd_IncomeTaxPercentageOfFederalStateAndLocalIncomeTaxSavings": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Income tax percentage of federal state and local income tax savings.",
        "label": "Income Tax Percentage Of Federal State And Local Income Tax Savings",
        "terseLabel": "Income tax percentage of federal state and local income tax savings"
       }
      }
     },
     "localname": "IncomeTaxPercentageOfFederalStateAndLocalIncomeTaxSavings",
     "nsuri": "http://haymaker.com/20221231",
     "presentation": [
      "http://haymaker.com/role/BusinessCombinationAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "btmd_InventoryMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Inventory.",
        "label": "Inventory [Member]",
        "terseLabel": "Inventory"
       }
      }
     },
     "localname": "InventoryMember",
     "nsuri": "http://haymaker.com/20221231",
     "presentation": [
      "http://haymaker.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "btmd_InventoryPurchases": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Inventory purchases.",
        "label": "Inventory purchases"
       }
      }
     },
     "localname": "InventoryPurchases",
     "nsuri": "http://haymaker.com/20221231",
     "presentation": [
      "http://haymaker.com/role/RelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "btmd_LeaseAssets": {
     "auth_ref": [],
     "calculation": {
      "http://haymaker.com/role/LeasesSummaryBalanceSheetClassificationOfOperatingLeasesAndWeightedAverageRemainingLeaseTermAndDiscountRateDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lease assets.",
        "label": "Lease Assets",
        "totalLabel": "Total lease assets"
       }
      }
     },
     "localname": "LeaseAssets",
     "nsuri": "http://haymaker.com/20221231",
     "presentation": [
      "http://haymaker.com/role/LeasesSummaryBalanceSheetClassificationOfOperatingLeasesAndWeightedAverageRemainingLeaseTermAndDiscountRateDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "btmd_LegalAccrualCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://haymaker.com/role/AccruedExpensesScheduleOfAccruedExpensesDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Legal accrual current",
        "label": "Legal Accrual Current",
        "terseLabel": "Legal accrual"
       }
      }
     },
     "localname": "LegalAccrualCurrent",
     "nsuri": "http://haymaker.com/20221231",
     "presentation": [
      "http://haymaker.com/role/AccruedExpensesScheduleOfAccruedExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "btmd_LiabilitiesLesseeAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Liabilities lessee.",
        "label": "Liabilities Lessee [Abstract]",
        "terseLabel": "Lease Liabilities"
       }
      }
     },
     "localname": "LiabilitiesLesseeAbstract",
     "nsuri": "http://haymaker.com/20221231",
     "presentation": [
      "http://haymaker.com/role/LeasesSummaryBalanceSheetClassificationOfOperatingLeasesAndWeightedAverageRemainingLeaseTermAndDiscountRateDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "btmd_LineOfCreditFacilityMaturityMonthAndYear": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line of credit facility maturity month and year.",
        "label": "Line of credit facility maturity month and year"
       }
      }
     },
     "localname": "LineOfCreditFacilityMaturityMonthAndYear",
     "nsuri": "http://haymaker.com/20221231",
     "presentation": [
      "http://haymaker.com/role/LongTermDebtAdditionalInformationDetails"
     ],
     "xbrltype": "gYearMonthItemType"
    },
    "btmd_MandatoryMinimumAmountForIndividualAdvance": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Mandatory minimum amount for individual advance.",
        "label": "Mandatory Minimum Amount for Individual Advance",
        "terseLabel": "Mandatory minimum amount for individual advance"
       }
      }
     },
     "localname": "MandatoryMinimumAmountForIndividualAdvance",
     "nsuri": "http://haymaker.com/20221231",
     "presentation": [
      "http://haymaker.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "btmd_MaximumValueOfDailyVolumeTradedThresholdPercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum value of daily volume traded threshold percentage.",
        "label": "Maximum Value of Daily Volume Traded Threshold Percentage",
        "terseLabel": "Maximum value of daily volume traded threshold percentage"
       }
      }
     },
     "localname": "MaximumValueOfDailyVolumeTradedThresholdPercentage",
     "nsuri": "http://haymaker.com/20221231",
     "presentation": [
      "http://haymaker.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "btmd_MemberEarnOutUnitsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Member earn out units.",
        "label": "Member Earn Out Units [Member]",
        "terseLabel": "Member Earn Out Units"
       }
      }
     },
     "localname": "MemberEarnOutUnitsMember",
     "nsuri": "http://haymaker.com/20221231",
     "presentation": [
      "http://haymaker.com/role/BusinessCombinationAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "btmd_MinimumGrossProceedsRequiredFromIssuanceOfEquity": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Minimum gross proceeds required from issuance of equity.",
        "label": "Minimum Gross Proceeds Required From Issuance Of Equity",
        "terseLabel": "Minimum gross proceeds required from issuance of equity"
       }
      }
     },
     "localname": "MinimumGrossProceedsRequiredFromIssuanceOfEquity",
     "nsuri": "http://haymaker.com/20221231",
     "presentation": [
      "http://haymaker.com/role/WarrantLiabilityAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "btmd_MinorityInterestHoldersMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Minority interest holders.",
        "label": "Minority Interest Holders [Member]",
        "terseLabel": "Minority Interest Holders"
       }
      }
     },
     "localname": "MinorityInterestHoldersMember",
     "nsuri": "http://haymaker.com/20221231",
     "presentation": [
      "http://haymaker.com/role/NoncontrollingInterestAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "btmd_NatureOfCustomerAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Nature of customer.",
        "label": "Nature Of Customer [Axis]"
       }
      }
     },
     "localname": "NatureOfCustomerAxis",
     "nsuri": "http://haymaker.com/20221231",
     "presentation": [
      "http://haymaker.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "btmd_NatureOfCustomerDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Nature of customer.",
        "label": "Nature Of Customer [Domain]"
       }
      }
     },
     "localname": "NatureOfCustomerDomain",
     "nsuri": "http://haymaker.com/20221231",
     "presentation": [
      "http://haymaker.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "btmd_NewIndependentContractorAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "New independent contractor agreement.",
        "label": "New Independent Contractor Agreement [Member]",
        "terseLabel": "New Independent Contractor Agreement"
       }
      }
     },
     "localname": "NewIndependentContractorAgreementMember",
     "nsuri": "http://haymaker.com/20221231",
     "presentation": [
      "http://haymaker.com/role/RelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "btmd_NonCashFeesUnderSepa": {
     "auth_ref": [],
     "calculation": {
      "http://haymaker.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 21.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Non-cash fees under SEPA.",
        "label": "Non Cash Fees under SEPA",
        "terseLabel": "Non-cash fees under SEPA"
       }
      }
     },
     "localname": "NonCashFeesUnderSepa",
     "nsuri": "http://haymaker.com/20221231",
     "presentation": [
      "http://haymaker.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "btmd_NonCashLeaseExpense": {
     "auth_ref": [],
     "calculation": {
      "http://haymaker.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 20.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Non-Cash Lease Expense",
        "label": "Non-Cash Lease Expense",
        "terseLabel": "Non-cash lease expense"
       }
      }
     },
     "localname": "NonCashLeaseExpense",
     "nsuri": "http://haymaker.com/20221231",
     "presentation": [
      "http://haymaker.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "btmd_NonCashSEPATransactionCosts": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Non-cash SEPA transaction costs.",
        "label": "Non-cash S E P A Transaction Costs",
        "terseLabel": "Non-cash SEPA transaction costs"
       }
      }
     },
     "localname": "NonCashSEPATransactionCosts",
     "nsuri": "http://haymaker.com/20221231",
     "presentation": [
      "http://haymaker.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "btmd_NonCashSponsorShareTransfers": {
     "auth_ref": [],
     "calculation": {
      "http://haymaker.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 22.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Non-cash sponsor share transfers.",
        "label": "Non Cash Sponsor Share Transfers",
        "terseLabel": "Non-cash sponsor share transfers"
       }
      }
     },
     "localname": "NonCashSponsorShareTransfers",
     "nsuri": "http://haymaker.com/20221231",
     "presentation": [
      "http://haymaker.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "btmd_NoncontrollingInterestPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Noncontrolling interest.",
        "label": "Noncontrolling Interest [Policy Text Block]",
        "terseLabel": "Noncontrolling Interest"
       }
      }
     },
     "localname": "NoncontrollingInterestPolicyTextBlock",
     "nsuri": "http://haymaker.com/20221231",
     "presentation": [
      "http://haymaker.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "btmd_NumberOfConsecutiveTradingDaysForDeterminingSharePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of consecutive trading days for determining share price.",
        "label": "Number Of Consecutive Trading Days For Determining Share Price",
        "terseLabel": "Number of consecutive trading days for determining the share price"
       }
      }
     },
     "localname": "NumberOfConsecutiveTradingDaysForDeterminingSharePrice",
     "nsuri": "http://haymaker.com/20221231",
     "presentation": [
      "http://haymaker.com/role/WarrantLiabilityAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "btmd_NumberOfConsecutiveTradingDaysForDeterminingTheSharePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of consecutive trading days for determining the share price.",
        "label": "Number Of Consecutive Trading Days For Determining The Share Price",
        "terseLabel": "Number of consecutive trading days for determining the share price"
       }
      }
     },
     "localname": "NumberOfConsecutiveTradingDaysForDeterminingTheSharePrice",
     "nsuri": "http://haymaker.com/20221231",
     "presentation": [
      "http://haymaker.com/role/EarnoutLiabilityAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "btmd_NumberOfCustomersAccountedForTenPercentOrMoreAccountsReceivable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of customers accounted for ten percent or more accounts receivable.",
        "label": "Number of Customers Accounted For Ten Percent or More Accounts Receivable",
        "terseLabel": "Number of customers accounted for 10% of accounts receivable"
       }
      }
     },
     "localname": "NumberOfCustomersAccountedForTenPercentOrMoreAccountsReceivable",
     "nsuri": "http://haymaker.com/20221231",
     "presentation": [
      "http://haymaker.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "btmd_NumberOfCustomersAccountedForTenPercentOrMoreAggregateRevenue": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of customers accounted for ten percent or more aggregate revenue.",
        "label": "Number of Customers Accounted For Ten Percent or More Aggregate Revenue",
        "terseLabel": "Number of customers accounted for 10% of total revenue"
       }
      }
     },
     "localname": "NumberOfCustomersAccountedForTenPercentOrMoreAggregateRevenue",
     "nsuri": "http://haymaker.com/20221231",
     "presentation": [
      "http://haymaker.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "btmd_NumberOfDaysFollowingItsInitialBusinessCombinationUntilTheExpirationOfTheWarrants": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of days following its initial business combination until the expiration of the warrants.",
        "label": "Number Of Days Following Its Initial Business Combination Until The Expiration Of The Warrants",
        "terseLabel": "Number of days following its initial business combination until the expiration of the warrants"
       }
      }
     },
     "localname": "NumberOfDaysFollowingItsInitialBusinessCombinationUntilTheExpirationOfTheWarrants",
     "nsuri": "http://haymaker.com/20221231",
     "presentation": [
      "http://haymaker.com/role/WarrantLiabilityAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "btmd_NumberOfEarnoutSecuritiesShareholderEntitledToVestIfCertainSharePriceTargetsAchieved": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of earnout securities shareholder entitled to vest if certain share price targets achieved.",
        "label": "Number of Earnout Securities Shareholder Entitled to Vest if Certain Share Price Targets Achieved",
        "terseLabel": "Number of earnout securities shareholder entitled to vest if certain share price targets achieved"
       }
      }
     },
     "localname": "NumberOfEarnoutSecuritiesShareholderEntitledToVestIfCertainSharePriceTargetsAchieved",
     "nsuri": "http://haymaker.com/20221231",
     "presentation": [
      "http://haymaker.com/role/EarnoutLiabilityAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "btmd_NumberOfInventoryVendors": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of Inventory Vendors",
        "label": "Number of Inventory Vendors",
        "terseLabel": "Number of vendors"
       }
      }
     },
     "localname": "NumberOfInventoryVendors",
     "nsuri": "http://haymaker.com/20221231",
     "presentation": [
      "http://haymaker.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "btmd_OperatingLossCarryforwardsExpirationYear": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating loss carryforwards, expiration year.",
        "label": "Operating Loss Carryforwards, Expiration Year",
        "terseLabel": "Net operating losses, expiration year"
       }
      }
     },
     "localname": "OperatingLossCarryforwardsExpirationYear",
     "nsuri": "http://haymaker.com/20221231",
     "presentation": [
      "http://haymaker.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "gYearItemType"
    },
    "btmd_OtherBusinessCombinationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other business combination.",
        "label": "Other Business Combination [Member]",
        "terseLabel": "Other Business Combination"
       }
      }
     },
     "localname": "OtherBusinessCombinationMember",
     "nsuri": "http://haymaker.com/20221231",
     "presentation": [
      "http://haymaker.com/role/BusinessCombinationAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "btmd_OtherCurrentAssetsPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other current assets policy.",
        "label": "Other Current Assets [Policy Text Block\\",
        "terseLabel": "Other Current Assets"
       }
      }
     },
     "localname": "OtherCurrentAssetsPolicyTextBlock",
     "nsuri": "http://haymaker.com/20221231",
     "presentation": [
      "http://haymaker.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "btmd_OtherInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other information.",
        "label": "Other Information [Abstract]",
        "terseLabel": "Other information:"
       }
      }
     },
     "localname": "OtherInformationAbstract",
     "nsuri": "http://haymaker.com/20221231",
     "presentation": [
      "http://haymaker.com/role/LeasesSummaryOfOperatingLeaseCostsRecognizedUnderAsc842AndSupplementalCashFlowInformationForLeasesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "btmd_PalletProceduresMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pallet Procedures [Member]",
        "terseLabel": "Pallet Procedures"
       }
      }
     },
     "localname": "PalletProceduresMember",
     "nsuri": "http://haymaker.com/20221231",
     "presentation": [
      "http://haymaker.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "btmd_PartnersCapitalAccountReverseRecapitalizationUnits": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Partners capital account reverse recapitalization units.",
        "label": "Partners Capital Account Reverse Recapitalization Units",
        "terseLabel": "Business Combination: Reverse recapitalization on May 26, 2022, units"
       }
      }
     },
     "localname": "PartnersCapitalAccountReverseRecapitalizationUnits",
     "nsuri": "http://haymaker.com/20221231",
     "presentation": [
      "http://haymaker.com/role/ConsolidatedStatementsOfStockholdersEquityDeficit"
     ],
     "xbrltype": "sharesItemType"
    },
    "btmd_PaymentsOfSettlementOfPhantomEquityRight": {
     "auth_ref": [],
     "calculation": {
      "http://haymaker.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payments of settlement of phantom equity right.",
        "label": "Payments of Settlement of Phantom Equity Right",
        "negatedLabel": "Settlement of phantom equity rights"
       }
      }
     },
     "localname": "PaymentsOfSettlementOfPhantomEquityRight",
     "nsuri": "http://haymaker.com/20221231",
     "presentation": [
      "http://haymaker.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "btmd_PaymentsOfSettlementOfRestrictedStockUnits": {
     "auth_ref": [],
     "calculation": {
      "http://haymaker.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payments of settlement of restricted stock units",
        "label": "Payments Of Settlement Of Restricted Stock Units",
        "negatedLabel": "Settlement of RSUs"
       }
      }
     },
     "localname": "PaymentsOfSettlementOfRestrictedStockUnits",
     "nsuri": "http://haymaker.com/20221231",
     "presentation": [
      "http://haymaker.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "btmd_PaymentsToSEPATransactionCosts": {
     "auth_ref": [],
     "calculation": {
      "http://haymaker.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payments to SEPA transaction costs.",
        "label": "Payments to S E P A Transaction Costs",
        "negatedLabel": "SEPA transaction costs"
       }
      }
     },
     "localname": "PaymentsToSEPATransactionCosts",
     "nsuri": "http://haymaker.com/20221231",
     "presentation": [
      "http://haymaker.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "btmd_PelletProceduresProductRevenueMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Pellet procedures product revenue.",
        "label": "Pellet Procedures Product Revenue [Member]",
        "terseLabel": "Pellet Procedures Product Revenue"
       }
      }
     },
     "localname": "PelletProceduresProductRevenueMember",
     "nsuri": "http://haymaker.com/20221231",
     "presentation": [
      "http://haymaker.com/role/RevenueRecognitionScheduleOfRevenuesRecognizedForEachRevenueStreamDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "btmd_PelletsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Pellets.",
        "label": "Pellets [Member]",
        "terseLabel": "Pellets"
       }
      }
     },
     "localname": "PelletsMember",
     "nsuri": "http://haymaker.com/20221231",
     "presentation": [
      "http://haymaker.com/role/InventoryNetScheduleOfInventoryNetDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "btmd_PercentageOfCommonStockPurchasePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of common stock purchase price.",
        "label": "Percentage of Common Stock Purchase Price",
        "terseLabel": "Percentage of common stock purchase price"
       }
      }
     },
     "localname": "PercentageOfCommonStockPurchasePrice",
     "nsuri": "http://haymaker.com/20221231",
     "presentation": [
      "http://haymaker.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "btmd_PhantomEquityRightsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Phantom equity rights.",
        "label": "Phantom Equity Rights [Member]",
        "terseLabel": "Phantom Equity Rights"
       }
      }
     },
     "localname": "PhantomEquityRightsMember",
     "nsuri": "http://haymaker.com/20221231",
     "presentation": [
      "http://haymaker.com/role/ShareBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "btmd_PrincipalRepaymentsOnTermLoan": {
     "auth_ref": [],
     "calculation": {
      "http://haymaker.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Principal repayments on term loan",
        "label": "Principal Repayments on Term Loan",
        "negatedLabel": "Principal repayments on term loan"
       }
      }
     },
     "localname": "PrincipalRepaymentsOnTermLoan",
     "nsuri": "http://haymaker.com/20221231",
     "presentation": [
      "http://haymaker.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "btmd_PrivatePlacementWarrantsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Private placement warrants member.",
        "label": "Private Placement Warrants Member",
        "verboseLabel": "Private Placement Warrants"
       }
      }
     },
     "localname": "PrivatePlacementWarrantsMember",
     "nsuri": "http://haymaker.com/20221231",
     "presentation": [
      "http://haymaker.com/role/FairValueMeasurementsScheduleOfFairValueHierarchyForFinancialAssetsAndLiabilitiesDetails",
      "http://haymaker.com/role/FairValueMeasurementsSummaryOfChangesInTheFairValueOfCompanysLevel3FinancialInstrumentsDetails",
      "http://haymaker.com/role/FairValueMeasurementsSummaryOfSignificantInputsToMonteCarloSimulationForFairValueOfPrivatePlacementWarrantsDetails",
      "http://haymaker.com/role/NetLossPerCommonShareScheduleOfComputationOfDilutedWeightedAverageSharesOutstandingDetails",
      "http://haymaker.com/role/WarrantLiabilityAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "btmd_PrivatePlacementWarrantsRedemptionDescription": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Private placement warrants redemption description.",
        "label": "Private Placement Warrants Redemption Description",
        "terseLabel": "Private placement warrants redemption description"
       }
      }
     },
     "localname": "PrivatePlacementWarrantsRedemptionDescription",
     "nsuri": "http://haymaker.com/20221231",
     "presentation": [
      "http://haymaker.com/role/WarrantLiabilityAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "btmd_ProceedsFromBusinessCombination": {
     "auth_ref": [],
     "calculation": {
      "http://haymaker.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Proceeds from business combination.",
        "label": "Proceeds from Business Combination",
        "terseLabel": "Proceeds from the Business Combination"
       }
      }
     },
     "localname": "ProceedsFromBusinessCombination",
     "nsuri": "http://haymaker.com/20221231",
     "presentation": [
      "http://haymaker.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "btmd_ProceedsFromIssuanceOfSharesUnderSepa": {
     "auth_ref": [],
     "calculation": {
      "http://haymaker.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Proceeds from issuance of shares under SEPA.",
        "label": "Proceeds from Issuance of Shares under SEPA",
        "terseLabel": "Proceeds from issuance of shares under SEPA"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfSharesUnderSepa",
     "nsuri": "http://haymaker.com/20221231",
     "presentation": [
      "http://haymaker.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "btmd_ProceedsFromSettlementOfSEPA": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Proceeds from settlement of SEPA.",
        "label": "Proceeds from Settlement of S E P A",
        "terseLabel": "Proceeds from settlement of SEPA"
       }
      }
     },
     "localname": "ProceedsFromSettlementOfSEPA",
     "nsuri": "http://haymaker.com/20221231",
     "presentation": [
      "http://haymaker.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "btmd_ProductRevenueMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Product revenue.",
        "label": "Product Revenue [Member]",
        "terseLabel": "Product Revenue"
       }
      }
     },
     "localname": "ProductRevenueMember",
     "nsuri": "http://haymaker.com/20221231",
     "presentation": [
      "http://haymaker.com/role/ConsolidatedStatementsOfIncomeAndComprehensiveIncome",
      "http://haymaker.com/role/RevenueRecognitionScheduleOfRevenuesRecognizedByGeographicRegionDetails",
      "http://haymaker.com/role/RevenueRecognitionScheduleOfRevenuesRecognizedForEachRevenueStreamDetails",
      "http://haymaker.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "btmd_ProvisonForDoubfulDebtAcoountsWriteOffAndRecoveries": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Provision for doubtful debt accounts write off and recoveries.",
        "label": "Provison For Doubful Debt Acoounts Write Off And Recoveries",
        "terseLabel": "Account write-off and recoveries"
       }
      }
     },
     "localname": "ProvisonForDoubfulDebtAcoountsWriteOffAndRecoveries",
     "nsuri": "http://haymaker.com/20221231",
     "presentation": [
      "http://haymaker.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfRollforwardOfTheAllowanceForDoubtfulAccountsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "btmd_PublicWarrantsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Public warrants member.",
        "label": "Public Warrants Member",
        "verboseLabel": "Public Warrants"
       }
      }
     },
     "localname": "PublicWarrantsMember",
     "nsuri": "http://haymaker.com/20221231",
     "presentation": [
      "http://haymaker.com/role/FairValueMeasurementsScheduleOfFairValueHierarchyForFinancialAssetsAndLiabilitiesDetails",
      "http://haymaker.com/role/NetLossPerCommonShareScheduleOfComputationOfDilutedWeightedAverageSharesOutstandingDetails",
      "http://haymaker.com/role/WarrantLiabilityAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "btmd_PublicWarrantsRedeemed": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Public warrants redeemed.",
        "label": "Public Warrants Redeemed",
        "terseLabel": "Public warrants redeemed"
       }
      }
     },
     "localname": "PublicWarrantsRedeemed",
     "nsuri": "http://haymaker.com/20221231",
     "presentation": [
      "http://haymaker.com/role/WarrantLiabilityAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "btmd_RedeemableWarrantsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Redeemable warrants.",
        "label": "Redeemable Warrants [Member]",
        "terseLabel": "Redeemable Warrants"
       }
      }
     },
     "localname": "RedeemableWarrantsMember",
     "nsuri": "http://haymaker.com/20221231",
     "presentation": [
      "http://haymaker.com/role/WarrantLiabilityAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "btmd_ReductionOfRevenue": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reduction of revenue.",
        "label": "Reduction of Revenue",
        "terseLabel": "Reduction of revenue"
       }
      }
     },
     "localname": "ReductionOfRevenue",
     "nsuri": "http://haymaker.com/20221231",
     "presentation": [
      "http://haymaker.com/role/RevenueRecognitionAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "btmd_ScheduleOfChangesInTheFairValueOfWarrantLiabilitiesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of changes in the fair value of warrant liabilities.",
        "label": "Schedule Of Changes In The Fair Value Of Warrant Liabilities Table Text Block",
        "terseLabel": "Summary of Changes in the Fair Value of Company's Level 3 Financial Instruments"
       }
      }
     },
     "localname": "ScheduleOfChangesInTheFairValueOfWarrantLiabilitiesTableTextBlock",
     "nsuri": "http://haymaker.com/20221231",
     "presentation": [
      "http://haymaker.com/role/FairValueMeasurementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "btmd_SeniorSecuredRevolvingCreditFacilityMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Senior secured revolving credit facility.",
        "label": "Senior Secured Revolving Credit Facility [Member]",
        "terseLabel": "Senior Secured Revolving Credit Facility"
       }
      }
     },
     "localname": "SeniorSecuredRevolvingCreditFacilityMember",
     "nsuri": "http://haymaker.com/20221231",
     "presentation": [
      "http://haymaker.com/role/BusinessCombinationAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "btmd_SeniorSecuredTermLoanAFacilityMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Senior secured term loan a facility.",
        "label": "Senior Secured Term Loan A Facility [Member]",
        "verboseLabel": "Senior Secured Term Loan A Facility"
       }
      }
     },
     "localname": "SeniorSecuredTermLoanAFacilityMember",
     "nsuri": "http://haymaker.com/20221231",
     "presentation": [
      "http://haymaker.com/role/BusinessCombinationAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "btmd_ServiceRevenueMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Service revenue.",
        "label": "Service Revenue [Member]",
        "terseLabel": "Service Revenue"
       }
      }
     },
     "localname": "ServiceRevenueMember",
     "nsuri": "http://haymaker.com/20221231",
     "presentation": [
      "http://haymaker.com/role/ConsolidatedStatementsOfIncomeAndComprehensiveIncome",
      "http://haymaker.com/role/RevenueRecognitionScheduleOfRevenuesRecognizedByGeographicRegionDetails",
      "http://haymaker.com/role/RevenueRecognitionScheduleOfRevenuesRecognizedForEachRevenueStreamDetails",
      "http://haymaker.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "btmd_ShareBasedCompensationArrangementVestingOfIncentiveUnits": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share Based Compensation arrangement vesting of incentive units.",
        "label": "Share Based Compensation Arrangement Vesting Of Incentive Units",
        "terseLabel": "Vesting of incentive units, shares"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementVestingOfIncentiveUnits",
     "nsuri": "http://haymaker.com/20221231",
     "presentation": [
      "http://haymaker.com/role/ShareBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "btmd_SharePriceEqualOrExceedsEighteenRupeesPerDollarMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share price equal or exceeds eighteen rupees per dollar.",
        "label": "Share Price Equal Or Exceeds Eighteen Rupees Per Dollar [Member]",
        "terseLabel": "Share price equal or exceeds 18.00 Rs per dollar"
       }
      }
     },
     "localname": "SharePriceEqualOrExceedsEighteenRupeesPerDollarMember",
     "nsuri": "http://haymaker.com/20221231",
     "presentation": [
      "http://haymaker.com/role/WarrantLiabilityAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "btmd_SharePriceEqualOrExceedsTenRupeesPerDollarMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share price equal or exceeds ten rupees per dollar.",
        "label": "Share Price Equal Or Exceeds Ten Rupees Per Dollar [Member]",
        "terseLabel": "Share Price Equal Or Exceeds 10.00 Rupees Per Dollar"
       }
      }
     },
     "localname": "SharePriceEqualOrExceedsTenRupeesPerDollarMember",
     "nsuri": "http://haymaker.com/20221231",
     "presentation": [
      "http://haymaker.com/role/WarrantLiabilityAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "btmd_SharePriceEqualOrLessNinePointTwoRupeesPerDollarMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share price equal or less nine point two rupees per dollar.",
        "label": "Share Price Equal Or Less Nine Point Two Rupees Per Dollar [Member]",
        "terseLabel": "Share Price Equal or Less 9.2 Rs per dollar"
       }
      }
     },
     "localname": "SharePriceEqualOrLessNinePointTwoRupeesPerDollarMember",
     "nsuri": "http://haymaker.com/20221231",
     "presentation": [
      "http://haymaker.com/role/WarrantLiabilityAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "btmd_SharePriceEqualsOrExceedsFifteenPerShareMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share price equals or exceeds fifteen per share.",
        "label": "Share Price Equals Or Exceeds Fifteen Per Share [Member]",
        "terseLabel": "Share Price Equals or Exceeds 15.00 Per Share [Member]"
       }
      }
     },
     "localname": "SharePriceEqualsOrExceedsFifteenPerShareMember",
     "nsuri": "http://haymaker.com/20221231",
     "presentation": [
      "http://haymaker.com/role/EarnoutLiabilityAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "btmd_SharePriceEqualsOrExceedsSeventeenPointFivePerShareMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share price equals or exceeds seventeen point five per share.",
        "label": "Share Price Equals Or Exceeds Seventeen Point Five Per Share [Member]",
        "terseLabel": "Share Price Equals or Exceeds 17.50 Per Share [Member]"
       }
      }
     },
     "localname": "SharePriceEqualsOrExceedsSeventeenPointFivePerShareMember",
     "nsuri": "http://haymaker.com/20221231",
     "presentation": [
      "http://haymaker.com/role/EarnoutLiabilityAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "btmd_SharePriceEqualsOrExceedsTwelvePointFivePerShareMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share price equals or exceeds twelve point five per share.",
        "label": "Share Price Equals Or Exceeds Twelve Point Five Per Share [Member]",
        "terseLabel": "Share Price Equals or Exceeds 12.50 Per Share [Member]"
       }
      }
     },
     "localname": "SharePriceEqualsOrExceedsTwelvePointFivePerShareMember",
     "nsuri": "http://haymaker.com/20221231",
     "presentation": [
      "http://haymaker.com/role/EarnoutLiabilityAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "btmd_ShareRedemptionTriggerPrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share redemption trigger price.",
        "label": "Share Redemption Trigger Price",
        "terseLabel": "Share redemption trigger price"
       }
      }
     },
     "localname": "ShareRedemptionTriggerPrice",
     "nsuri": "http://haymaker.com/20221231",
     "presentation": [
      "http://haymaker.com/role/WarrantLiabilityAdditionalInformationDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "btmd_ShippingFeesProductRevenueMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Shipping fees product revenue.",
        "label": "Shipping Fees Product Revenue [Member]",
        "terseLabel": "Shipping Fees Product Revenue"
       }
      }
     },
     "localname": "ShippingFeesProductRevenueMember",
     "nsuri": "http://haymaker.com/20221231",
     "presentation": [
      "http://haymaker.com/role/RevenueRecognitionScheduleOfRevenuesRecognizedForEachRevenueStreamDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "btmd_SourceOfRevenueAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Source Of Revenue [Axis]"
       }
      }
     },
     "localname": "SourceOfRevenueAxis",
     "nsuri": "http://haymaker.com/20221231",
     "presentation": [
      "http://haymaker.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "btmd_SourceOfRevenueDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Source Of Revenue [Domain]"
       }
      }
     },
     "localname": "SourceOfRevenueDomain",
     "nsuri": "http://haymaker.com/20221231",
     "presentation": [
      "http://haymaker.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "btmd_SourceOfServiceRevenueAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Source of service revenue.",
        "label": "Source Of Service Revenue [Axis]"
       }
      }
     },
     "localname": "SourceOfServiceRevenueAxis",
     "nsuri": "http://haymaker.com/20221231",
     "presentation": [
      "http://haymaker.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "btmd_SourceOfServiceRevenueDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Source of service revenue.",
        "label": "Source Of Service Revenue [Domain]"
       }
      }
     },
     "localname": "SourceOfServiceRevenueDomain",
     "nsuri": "http://haymaker.com/20221231",
     "presentation": [
      "http://haymaker.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "btmd_SponseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sponsor",
        "label": "Sponse [Member]",
        "terseLabel": "Sponsor"
       }
      }
     },
     "localname": "SponseMember",
     "nsuri": "http://haymaker.com/20221231",
     "presentation": [
      "http://haymaker.com/role/WarrantLiabilityAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "btmd_SponsorEarnOutSharesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sponsor earn out shares.",
        "label": "Sponsor Earn Out Shares [Member]",
        "terseLabel": "Sponsor Earn Out Shares"
       }
      }
     },
     "localname": "SponsorEarnOutSharesMember",
     "nsuri": "http://haymaker.com/20221231",
     "presentation": [
      "http://haymaker.com/role/BusinessCombinationAdditionalInformationDetails",
      "http://haymaker.com/role/NetLossPerCommonShareScheduleOfComputationOfDilutedWeightedAverageSharesOutstandingDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "btmd_SpouseOfFounderChairmanAndBeneficialOwnerMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Spouse of founder, chairman, and beneficial owner.",
        "label": "Spouse of Founder, Chairman, and Beneficial Owner"
       }
      }
     },
     "localname": "SpouseOfFounderChairmanAndBeneficialOwnerMember",
     "nsuri": "http://haymaker.com/20221231",
     "presentation": [
      "http://haymaker.com/role/RelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "btmd_StandbyEquityPurchaseAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Standby Equity Purchase Agreement.",
        "label": "Standby Equity Purchase Agreement [Member]",
        "terseLabel": "Standby Equity Purchase Agreement"
       }
      }
     },
     "localname": "StandbyEquityPurchaseAgreementMember",
     "nsuri": "http://haymaker.com/20221231",
     "presentation": [
      "http://haymaker.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "btmd_StandbyEquityPurchaseAgreementPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Standby equity purchase agreement [Policy Text Block]",
        "label": "Standby Equity Purchase Agreement [Policy Text Block]",
        "terseLabel": "Standby Equity Purchase Agreement"
       }
      }
     },
     "localname": "StandbyEquityPurchaseAgreementPolicyTextBlock",
     "nsuri": "http://haymaker.com/20221231",
     "presentation": [
      "http://haymaker.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "btmd_StockIssuedDuringPeriodSharesVestingOfRestrictedStockUnit": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock issued during period shares vesting of restricted stock unit,",
        "label": "Stock Issued During Period Shares Vesting of Restricted Stock Unit",
        "terseLabel": "Vesting of RSUs, shares"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesVestingOfRestrictedStockUnit",
     "nsuri": "http://haymaker.com/20221231",
     "presentation": [
      "http://haymaker.com/role/ConsolidatedStatementsOfStockholdersEquityDeficit"
     ],
     "xbrltype": "sharesItemType"
    },
    "btmd_StockIssuedDuringPeriodValueSettlementOfEquityRights": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock issued during period value settlement of equity rights.",
        "label": "Stock Issued During Period Value Settlement Of Equity Rights",
        "terseLabel": "Settlement of phantom equity rights"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueSettlementOfEquityRights",
     "nsuri": "http://haymaker.com/20221231",
     "presentation": [
      "http://haymaker.com/role/ConsolidatedStatementsOfStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "btmd_StockIssuedDuringPeriodValueVestingOfRestrictedStockUnit": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock issued during period value vesting of restricted stock unit.",
        "label": "Stock Issued During Period Value Vesting Of Restricted Stock Unit",
        "terseLabel": "Vesting of RSUs"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueVestingOfRestrictedStockUnit",
     "nsuri": "http://haymaker.com/20221231",
     "presentation": [
      "http://haymaker.com/role/ConsolidatedStatementsOfStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "btmd_StockholdersEquityAttributableToNonControllingInterestBusinessCombination": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stockholders equity attributable to non-controlling interest, business combination.",
        "label": "Stockholders Equity Attributable To Non-controlling Interest, Business Combination",
        "terseLabel": "Business Combination: Noncontrolling interest on May 26, 2022"
       }
      }
     },
     "localname": "StockholdersEquityAttributableToNonControllingInterestBusinessCombination",
     "nsuri": "http://haymaker.com/20221231",
     "presentation": [
      "http://haymaker.com/role/ConsolidatedStatementsOfStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "btmd_StockholdersEquityBussinessCombinationCapitalizedTransactionCosts": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stockholders equity bussiness combination capitalized transaction costs.",
        "label": "Stockholders Equity Bussiness Combination Capitalized Transaction Costs",
        "terseLabel": "Business Combination: Capitalized transaction costs"
       }
      }
     },
     "localname": "StockholdersEquityBussinessCombinationCapitalizedTransactionCosts",
     "nsuri": "http://haymaker.com/20221231",
     "presentation": [
      "http://haymaker.com/role/ConsolidatedStatementsOfStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "btmd_StockholdersEquityIncludingPortionAttributableToNonControllingInterestReverseRecapitalization": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stockholders equity including portion attributable to non controlling interest reverse recapitalization.",
        "label": "Stockholders Equity Including Portion Attributable To Non Controlling Interest Reverse Recapitalization",
        "terseLabel": "Business Combination: Reverse recapitalization on May 26, 2022"
       }
      }
     },
     "localname": "StockholdersEquityIncludingPortionAttributableToNonControllingInterestReverseRecapitalization",
     "nsuri": "http://haymaker.com/20221231",
     "presentation": [
      "http://haymaker.com/role/ConsolidatedStatementsOfStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "btmd_StockholdersEquityIncludingPortionAttributableToNonControllingInterestSharesReverseRecapitalization": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stockholders equity including portion attributable to non controlling interest shares reverse recapitalization.",
        "label": "Stockholders Equity Including Portion Attributable To Non Controlling Interest Shares Reverse Recapitalization",
        "terseLabel": "Business Combination: Reverse recapitalization on May 26, 2022, shares"
       }
      }
     },
     "localname": "StockholdersEquityIncludingPortionAttributableToNonControllingInterestSharesReverseRecapitalization",
     "nsuri": "http://haymaker.com/20221231",
     "presentation": [
      "http://haymaker.com/role/ConsolidatedStatementsOfStockholdersEquityDeficit"
     ],
     "xbrltype": "sharesItemType"
    },
    "btmd_SummaryBalanceSheetClassificationOfOperatingLeasesAndWeightedAverageRemainingLeaseTermAndDiscountRateTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Summary balance sheet classification of operating leases and weighted average remaining lease term and discount rate.",
        "label": "Summary Balance Sheet Classification of Operating Leases and Weighted Average Remaining Lease Term and Discount Rate [Table Text Block]",
        "terseLabel": "Summary Balance Sheet Classification of Operating Leases and Weighted Average Remaining Lease Term and Discount Rate"
       }
      }
     },
     "localname": "SummaryBalanceSheetClassificationOfOperatingLeasesAndWeightedAverageRemainingLeaseTermAndDiscountRateTableTextBlock",
     "nsuri": "http://haymaker.com/20221231",
     "presentation": [
      "http://haymaker.com/role/LeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "btmd_SummaryOfCapitalizedSoftwareNetTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Summary of capitalized software net.",
        "label": "Summary of Capitalized Software, Net"
       }
      }
     },
     "localname": "SummaryOfCapitalizedSoftwareNetTableTextBlock",
     "nsuri": "http://haymaker.com/20221231",
     "presentation": [
      "http://haymaker.com/role/CapitalizedSoftwareNetTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "btmd_SummaryOfConsiderationAllocatedToPerformanceObligationsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Summary of consideration allocated to performance obligations.",
        "label": "Summary of Consideration Allocated to Performance Obligations [Table Text Block]",
        "terseLabel": "Summary of Consideration Allocated to Performance Obligations"
       }
      }
     },
     "localname": "SummaryOfConsiderationAllocatedToPerformanceObligationsTableTextBlock",
     "nsuri": "http://haymaker.com/20221231",
     "presentation": [
      "http://haymaker.com/role/RevenueRecognitionTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "btmd_SummaryOfLeaseCostsRecognizedUnderAsc842AndSupplementalCashFlowInformationForLeasesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Summary of lease costs recognized under ASC 842 and supplemental cash flow information for leases.",
        "label": "Summary of Lease Costs Recognized under ASC 842 and Supplemental Cash Flow Information for Leases [Table Text Block]",
        "terseLabel": "Summary of Operating Lease Costs Recognized under ASC 842 and Supplemental Cash Flow Information for Leases"
       }
      }
     },
     "localname": "SummaryOfLeaseCostsRecognizedUnderAsc842AndSupplementalCashFlowInformationForLeasesTableTextBlock",
     "nsuri": "http://haymaker.com/20221231",
     "presentation": [
      "http://haymaker.com/role/LeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "btmd_TaxReceivableAgreementLiability": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tax receivable agreement liability.",
        "label": "Tax Receivable Agreement Liability",
        "terseLabel": "Liability recorded related to tax receivable agreement"
       }
      }
     },
     "localname": "TaxReceivableAgreementLiability",
     "nsuri": "http://haymaker.com/20221231",
     "presentation": [
      "http://haymaker.com/role/BusinessCombinationAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "btmd_TeamLoanCurrentPortionBeforeUnamortizedDebtIssuanceCosts": {
     "auth_ref": [],
     "calculation": {
      "http://haymaker.com/role/LongTermDebtScheduleOfOutstandingDebtDetails": {
       "order": 4.0,
       "parentTag": "btmd_TeamLoanNonCurrentPortionBeforeUnamortizedDebtIssuanceCosts",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Team loan current portion before unamortized debt issuance costs",
        "label": "Team Loan Current Portion before Unamortized Debt Issuance Costs",
        "terseLabel": "Less: Current portion"
       }
      }
     },
     "localname": "TeamLoanCurrentPortionBeforeUnamortizedDebtIssuanceCosts",
     "nsuri": "http://haymaker.com/20221231",
     "presentation": [
      "http://haymaker.com/role/LongTermDebtScheduleOfOutstandingDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "btmd_TeamLoanNonCurrentPortionBeforeUnamortizedDebtIssuanceCosts": {
     "auth_ref": [],
     "calculation": {
      "http://haymaker.com/role/LongTermDebtScheduleOfOutstandingDebtDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LongTermDebtNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Team loan non-current portion before unamortized debt issuance costs.",
        "label": "Team Loan non-current Portion before Unamortized Debt Issuance Costs",
        "totalLabel": "Team loan non-current portion gross"
       }
      }
     },
     "localname": "TeamLoanNonCurrentPortionBeforeUnamortizedDebtIssuanceCosts",
     "nsuri": "http://haymaker.com/20221231",
     "presentation": [
      "http://haymaker.com/role/LongTermDebtScheduleOfOutstandingDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "btmd_TerminationPeriodOfPurchaseAgreement": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Termination period of purchase agreement.",
        "label": "Termination Period of Purchase Agreement",
        "terseLabel": "Termination period of purchase agreement"
       }
      }
     },
     "localname": "TerminationPeriodOfPurchaseAgreement",
     "nsuri": "http://haymaker.com/20221231",
     "presentation": [
      "http://haymaker.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "btmd_TrainingMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Training [Member]",
        "terseLabel": "Training"
       }
      }
     },
     "localname": "TrainingMember",
     "nsuri": "http://haymaker.com/20221231",
     "presentation": [
      "http://haymaker.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "btmd_TrainingServiceRevenueMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Training service revenue.",
        "label": "Training Service Revenue [Member]",
        "terseLabel": "Training Service Revenue"
       }
      }
     },
     "localname": "TrainingServiceRevenueMember",
     "nsuri": "http://haymaker.com/20221231",
     "presentation": [
      "http://haymaker.com/role/RevenueRecognitionScheduleOfRevenuesRecognizedForEachRevenueStreamDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "btmd_TrocarsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trocars.",
        "label": "Trocars [Member]",
        "terseLabel": "Trocars"
       }
      }
     },
     "localname": "TrocarsMember",
     "nsuri": "http://haymaker.com/20221231",
     "presentation": [
      "http://haymaker.com/role/PropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetails",
      "http://haymaker.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfEstimatedUsefulLivesOfPropertyAndEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "btmd_TruistTermLoanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Truist term loan.",
        "label": "Truist Term Loan [Member]",
        "terseLabel": "Truist Term Loan"
       }
      }
     },
     "localname": "TruistTermLoanMember",
     "nsuri": "http://haymaker.com/20221231",
     "presentation": [
      "http://haymaker.com/role/LongTermDebtAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "btmd_TwoThousandTwentyTwoEquityIncentivePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two thousand twenty two equity incentive plan.",
        "label": "Two Thousand Twenty Two Equity Incentive Plan [Member]",
        "verboseLabel": "2022 Equity Incentive Plan"
       }
      }
     },
     "localname": "TwoThousandTwentyTwoEquityIncentivePlanMember",
     "nsuri": "http://haymaker.com/20221231",
     "presentation": [
      "http://haymaker.com/role/ShareBasedCompensationAdditionalInformationDetails",
      "http://haymaker.com/role/ShareBasedCompensationSummaryOfRestrictedStockUnitActivityDetails",
      "http://haymaker.com/role/ShareBasedCompensationSummaryOfStockOptionActivityDetails",
      "http://haymaker.com/role/ShareBasedCompensationSummaryOfWeightedAverageAssumptionsUsedToEstimateFairValueOfStockOptionsGrantedDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "btmd_UnsatisfiedContractTermServicesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unsatisfied contract-term services.",
        "label": "Unsatisfied Contract-Term Services [Member]",
        "terseLabel": "Unsatisfied Contract-term Services"
       }
      }
     },
     "localname": "UnsatisfiedContractTermServicesMember",
     "nsuri": "http://haymaker.com/20221231",
     "presentation": [
      "http://haymaker.com/role/RevenueRecognitionSummaryOfConsiderationAllocatedToPerformanceObligationsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "btmd_UnsatisfiedPelletProceduresMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unsatisfied pellet procedures.",
        "label": "Unsatisfied Pellet Procedures [Member]",
        "terseLabel": "Unsatisfied Pellet Procedures"
       }
      }
     },
     "localname": "UnsatisfiedPelletProceduresMember",
     "nsuri": "http://haymaker.com/20221231",
     "presentation": [
      "http://haymaker.com/role/RevenueRecognitionSummaryOfConsiderationAllocatedToPerformanceObligationsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "btmd_UnsatisfiedTrainingObligationsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unsatisfied training obligations.",
        "label": "Unsatisfied Training Obligations [Member]",
        "terseLabel": "Unsatisfied Training Obligations"
       }
      }
     },
     "localname": "UnsatisfiedTrainingObligationsMember",
     "nsuri": "http://haymaker.com/20221231",
     "presentation": [
      "http://haymaker.com/role/RevenueRecognitionSummaryOfConsiderationAllocatedToPerformanceObligationsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "btmd_VendorMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Vendor.",
        "label": "Vendor"
       }
      }
     },
     "localname": "VendorMember",
     "nsuri": "http://haymaker.com/20221231",
     "presentation": [
      "http://haymaker.com/role/RelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "btmd_WarrantLiabilitiesPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Warrant liabilities.",
        "label": "Warrant Liabilities [Policy Text Block]",
        "terseLabel": "Warrant Liabilities"
       }
      }
     },
     "localname": "WarrantLiabilitiesPolicyTextBlock",
     "nsuri": "http://haymaker.com/20221231",
     "presentation": [
      "http://haymaker.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "btmd_WarrantLiabilityTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Warrant liability.",
        "label": "Warrant Liability [Text Block]",
        "terseLabel": "Warrant Liability"
       }
      }
     },
     "localname": "WarrantLiabilityTextBlock",
     "nsuri": "http://haymaker.com/20221231",
     "presentation": [
      "http://haymaker.com/role/WarrantLiability"
     ],
     "xbrltype": "textBlockItemType"
    },
    "btmd_YorkvilleAdvisorsGlobalLpMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Yorkville Advisors Global, LP.",
        "label": "Yorkville Advisors Global, LP [Member]",
        "terseLabel": "Yorkville"
       }
      }
     },
     "localname": "YorkvilleAdvisorsGlobalLpMember",
     "nsuri": "http://haymaker.com/20221231",
     "presentation": [
      "http://haymaker.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "country_US": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "UNITED STATES",
        "terseLabel": "United States"
       }
      }
     },
     "localname": "US",
     "nsuri": "http://xbrl.sec.gov/country/2022",
     "presentation": [
      "http://haymaker.com/role/RevenueRecognitionScheduleOfRevenuesRecognizedByGeographicRegionDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_AddressTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "An entity may have several addresses for different purposes and this domain represents all such types.",
        "label": "Address Type [Domain]"
       }
      }
     },
     "localname": "AddressTypeDomain",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://haymaker.com/role/Cover"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://haymaker.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_BusinessContactMember": {
     "auth_ref": [
      "r760",
      "r761"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business contact for the entity",
        "label": "Business Contact [Member]"
       }
      }
     },
     "localname": "BusinessContactMember",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://haymaker.com/role/Cover"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://haymaker.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_ContactPersonnelName": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of contact personnel",
        "label": "Contact Personnel Name"
       }
      }
     },
     "localname": "ContactPersonnelName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://haymaker.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "xbrltype": "stringItemType"
    },
    "dei_DocumentInformationLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Document Information [Line Items]"
       }
      }
     },
     "localname": "DocumentInformationLineItems",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://haymaker.com/role/Cover"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_DocumentInformationTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package.",
        "label": "Document Information [Table]"
       }
      }
     },
     "localname": "DocumentInformationTable",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://haymaker.com/role/Cover"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://haymaker.com/role/Cover"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://haymaker.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://haymaker.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://haymaker.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://haymaker.com/role/Cover"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityAddressesAddressTypeAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the domain members or categories in the table and the line items or concepts that complete the table.",
        "label": "Entity Addresses, Address Type [Axis]"
       }
      }
     },
     "localname": "EntityAddressesAddressTypeAxis",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://haymaker.com/role/Cover"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r759"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://haymaker.com/role/Cover"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r759"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://haymaker.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityExTransitionPeriod": {
     "auth_ref": [
      "r762"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.",
        "label": "Entity Ex Transition Period"
       }
      }
     },
     "localname": "EntityExTransitionPeriod",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://haymaker.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r759"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://haymaker.com/role/Cover"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://haymaker.com/role/Cover"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityPrimarySicNumber": {
     "auth_ref": [
      "r761"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity.",
        "label": "Entity Primary SIC Number"
       }
      }
     },
     "localname": "EntityPrimarySicNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://haymaker.com/role/Cover"
     ],
     "xbrltype": "sicNumberItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r759"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://haymaker.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r759"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://haymaker.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r759"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://haymaker.com/role/Cover"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://haymaker.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "srt_ConsolidatedEntitiesAxis": {
     "auth_ref": [
      "r260",
      "r544",
      "r545",
      "r548",
      "r549",
      "r623",
      "r717",
      "r806",
      "r809",
      "r810"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Consolidated Entities [Axis]"
       }
      }
     },
     "localname": "ConsolidatedEntitiesAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://haymaker.com/role/BusinessCombinationAdditionalInformationDetails",
      "http://haymaker.com/role/WarrantLiabilityAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ConsolidatedEntitiesDomain": {
     "auth_ref": [
      "r260",
      "r544",
      "r545",
      "r548",
      "r549",
      "r623",
      "r717",
      "r806",
      "r809",
      "r810"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Consolidated Entities [Domain]"
       }
      }
     },
     "localname": "ConsolidatedEntitiesDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://haymaker.com/role/BusinessCombinationAdditionalInformationDetails",
      "http://haymaker.com/role/WarrantLiabilityAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_DirectorMember": {
     "auth_ref": [
      "r792"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Director [Member]",
        "terseLabel": "Founder Advisor"
       }
      }
     },
     "localname": "DirectorMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://haymaker.com/role/RelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [
      "r371",
      "r372",
      "r373",
      "r374",
      "r454",
      "r656",
      "r685",
      "r718",
      "r719",
      "r737",
      "r750",
      "r758",
      "r811",
      "r921",
      "r922",
      "r923",
      "r924",
      "r925",
      "r926"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum [Member]",
        "terseLabel": "Maximum"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://haymaker.com/role/EarnoutLiabilityAdditionalInformationDetails",
      "http://haymaker.com/role/LongTermDebtAdditionalInformationDetails",
      "http://haymaker.com/role/ShareBasedCompensationAdditionalInformationDetails",
      "http://haymaker.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://haymaker.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfEstimatedUsefulLivesOfPropertyAndEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [
      "r371",
      "r372",
      "r373",
      "r374",
      "r454",
      "r656",
      "r685",
      "r718",
      "r719",
      "r737",
      "r750",
      "r758",
      "r811",
      "r921",
      "r922",
      "r923",
      "r924",
      "r925",
      "r926"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum [Member]",
        "terseLabel": "Minimum"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://haymaker.com/role/LongTermDebtAdditionalInformationDetails",
      "http://haymaker.com/role/ShareBasedCompensationAdditionalInformationDetails",
      "http://haymaker.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://haymaker.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfEstimatedUsefulLivesOfPropertyAndEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_OwnershipAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Ownership [Axis]"
       }
      }
     },
     "localname": "OwnershipAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://haymaker.com/role/NoncontrollingInterestAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_OwnershipDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Ownership [Domain]"
       }
      }
     },
     "localname": "OwnershipDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://haymaker.com/role/NoncontrollingInterestAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ProductOrServiceAxis": {
     "auth_ref": [
      "r328",
      "r659",
      "r738",
      "r756",
      "r803",
      "r804",
      "r814",
      "r927"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Axis]"
       }
      }
     },
     "localname": "ProductOrServiceAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://haymaker.com/role/ConsolidatedStatementsOfIncomeAndComprehensiveIncome",
      "http://haymaker.com/role/InventoryNetScheduleOfInventoryNetDetails",
      "http://haymaker.com/role/RevenueRecognitionScheduleOfRevenuesRecognizedByGeographicRegionDetails",
      "http://haymaker.com/role/RevenueRecognitionScheduleOfRevenuesRecognizedForEachRevenueStreamDetails",
      "http://haymaker.com/role/RevenueRecognitionSummaryOfConsiderationAllocatedToPerformanceObligationsDetails",
      "http://haymaker.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ProductsAndServicesDomain": {
     "auth_ref": [
      "r328",
      "r659",
      "r738",
      "r756",
      "r803",
      "r804",
      "r814",
      "r927"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Domain]"
       }
      }
     },
     "localname": "ProductsAndServicesDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://haymaker.com/role/ConsolidatedStatementsOfIncomeAndComprehensiveIncome",
      "http://haymaker.com/role/InventoryNetScheduleOfInventoryNetDetails",
      "http://haymaker.com/role/RevenueRecognitionScheduleOfRevenuesRecognizedByGeographicRegionDetails",
      "http://haymaker.com/role/RevenueRecognitionScheduleOfRevenuesRecognizedForEachRevenueStreamDetails",
      "http://haymaker.com/role/RevenueRecognitionSummaryOfConsiderationAllocatedToPerformanceObligationsDetails",
      "http://haymaker.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [
      "r371",
      "r372",
      "r373",
      "r374",
      "r443",
      "r454",
      "r489",
      "r490",
      "r491",
      "r632",
      "r656",
      "r685",
      "r718",
      "r719",
      "r737",
      "r750",
      "r758",
      "r799",
      "r811",
      "r922",
      "r923",
      "r924",
      "r925",
      "r926"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://haymaker.com/role/EarnoutLiabilityAdditionalInformationDetails",
      "http://haymaker.com/role/LongTermDebtAdditionalInformationDetails",
      "http://haymaker.com/role/ShareBasedCompensationAdditionalInformationDetails",
      "http://haymaker.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://haymaker.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfEstimatedUsefulLivesOfPropertyAndEquipmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [
      "r371",
      "r372",
      "r373",
      "r374",
      "r443",
      "r454",
      "r489",
      "r490",
      "r491",
      "r632",
      "r656",
      "r685",
      "r718",
      "r719",
      "r737",
      "r750",
      "r758",
      "r799",
      "r811",
      "r922",
      "r923",
      "r924",
      "r925",
      "r926"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Domain]"
       }
      }
     },
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://haymaker.com/role/EarnoutLiabilityAdditionalInformationDetails",
      "http://haymaker.com/role/LongTermDebtAdditionalInformationDetails",
      "http://haymaker.com/role/ShareBasedCompensationAdditionalInformationDetails",
      "http://haymaker.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://haymaker.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfEstimatedUsefulLivesOfPropertyAndEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RestatementAxis": {
     "auth_ref": [
      "r215",
      "r261",
      "r262",
      "r263",
      "r265",
      "r266",
      "r269",
      "r270",
      "r271",
      "r272",
      "r274",
      "r275",
      "r276",
      "r277",
      "r278",
      "r280",
      "r298",
      "r349",
      "r350",
      "r524",
      "r556",
      "r560",
      "r561",
      "r562",
      "r597",
      "r615",
      "r616",
      "r689",
      "r690",
      "r691",
      "r692",
      "r693",
      "r694",
      "r695",
      "r696",
      "r697",
      "r698"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revision of Prior Period [Axis]"
       }
      }
     },
     "localname": "RestatementAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://haymaker.com/role/ConsolidatedStatementsOfStockholdersEquityDeficit"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RestatementDomain": {
     "auth_ref": [
      "r215",
      "r261",
      "r262",
      "r263",
      "r265",
      "r266",
      "r269",
      "r270",
      "r271",
      "r272",
      "r274",
      "r275",
      "r276",
      "r277",
      "r278",
      "r280",
      "r298",
      "r349",
      "r350",
      "r524",
      "r556",
      "r560",
      "r561",
      "r562",
      "r597",
      "r615",
      "r616",
      "r689",
      "r690",
      "r691",
      "r692",
      "r693",
      "r694",
      "r695",
      "r696",
      "r697",
      "r698"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revision of Prior Period [Domain]"
       }
      }
     },
     "localname": "RestatementDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://haymaker.com/role/ConsolidatedStatementsOfStockholdersEquityDeficit"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ScenarioUnspecifiedDomain": {
     "auth_ref": [
      "r280",
      "r459",
      "r764",
      "r788"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Scenario [Domain]"
       }
      }
     },
     "localname": "ScenarioUnspecifiedDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://haymaker.com/role/WarrantLiabilityAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_SegmentGeographicalDomain": {
     "auth_ref": [
      "r329",
      "r330",
      "r708",
      "r709",
      "r710",
      "r711",
      "r712",
      "r713",
      "r714",
      "r715",
      "r716",
      "r739",
      "r757",
      "r814"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Domain]"
       }
      }
     },
     "localname": "SegmentGeographicalDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://haymaker.com/role/RevenueRecognitionScheduleOfRevenuesRecognizedByGeographicRegionDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_StatementGeographicalAxis": {
     "auth_ref": [
      "r329",
      "r330",
      "r702",
      "r708",
      "r709",
      "r710",
      "r711",
      "r712",
      "r713",
      "r714",
      "r715",
      "r716",
      "r739",
      "r757",
      "r814"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Axis]"
       }
      }
     },
     "localname": "StatementGeographicalAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://haymaker.com/role/RevenueRecognitionScheduleOfRevenuesRecognizedByGeographicRegionDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_StatementScenarioAxis": {
     "auth_ref": [
      "r280",
      "r459",
      "r764",
      "r765",
      "r788"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Scenario [Axis]"
       }
      }
     },
     "localname": "StatementScenarioAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://haymaker.com/role/WarrantLiabilityAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]"
       }
      }
     },
     "localname": "AccountingPoliciesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountingStandardsUpdate201912Member": {
     "auth_ref": [
      "r521",
      "r522",
      "r523",
      "r524"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accounting Standards Update 2019-12 Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes.",
        "label": "Accounting Standards Update 2019-12 [Member]",
        "terseLabel": "ASU 2019-12"
       }
      }
     },
     "localname": "AccountingStandardsUpdate201912Member",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://haymaker.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for accounts payable, accrued expenses, and other liabilities that are classified as current at the end of the reporting period.",
        "label": "Accounts Payable, Accrued Liabilities, and Other Liabilities Disclosure, Current [Text Block]",
        "terseLabel": "Accrued Expenses"
       }
      }
     },
     "localname": "AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://haymaker.com/role/AccruedExpenses"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r16",
      "r755"
     ],
     "calculation": {
      "http://haymaker.com/role/ConsolidatedBalanceSheets": {
       "order": 12.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts Payable, Current",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://haymaker.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsReceivableAllowanceForCreditLossTableTextBlock": {
     "auth_ref": [
      "r797"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of allowance for credit loss on accounts receivable.",
        "label": "Accounts Receivable, Allowance for Credit Loss [Table Text Block]",
        "terseLabel": "Summary of Rollforward of the Allowance for Doubtful Accounts"
       }
      }
     },
     "localname": "AccountsReceivableAllowanceForCreditLossTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://haymaker.com/role/SummaryOfSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_AccountsReceivableNetCurrent": {
     "auth_ref": [
      "r332",
      "r333"
     ],
     "calculation": {
      "http://haymaker.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.",
        "label": "Accounts Receivable, after Allowance for Credit Loss, Current",
        "terseLabel": "Accounts receivable, net"
       }
      }
     },
     "localname": "AccountsReceivableNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://haymaker.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r20"
     ],
     "calculation": {
      "http://haymaker.com/role/AccruedExpensesScheduleOfAccruedExpensesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://haymaker.com/role/ConsolidatedBalanceSheets": {
       "order": 13.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Liabilities, Current",
        "terseLabel": "Accrued expenses",
        "totalLabel": "Accrued expenses"
       }
      }
     },
     "localname": "AccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://haymaker.com/role/AccruedExpensesScheduleOfAccruedExpensesDetails",
      "http://haymaker.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedProfessionalFeesCurrent": {
     "auth_ref": [
      "r20"
     ],
     "calculation": {
      "http://haymaker.com/role/AccruedExpensesScheduleOfAccruedExpensesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Professional Fees, Current",
        "terseLabel": "Accrued professional fees"
       }
      }
     },
     "localname": "AccruedProfessionalFeesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://haymaker.com/role/AccruedExpensesScheduleOfAccruedExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "auth_ref": [
      "r82",
      "r222"
     ],
     "calculation": {
      "http://haymaker.com/role/PropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.",
        "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment",
        "negatedLabel": "Less: Accumulated depreciation"
       }
      }
     },
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://haymaker.com/role/PropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r30",
      "r31",
      "r32",
      "r228",
      "r680",
      "r694",
      "r698"
     ],
     "calculation": {
      "http://haymaker.com/role/ConsolidatedBalanceSheets": {
       "order": 28.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.",
        "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax",
        "terseLabel": "Accumulated other comprehensive loss"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://haymaker.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "auth_ref": [
      "r29",
      "r32",
      "r152",
      "r616",
      "r689",
      "r690",
      "r771",
      "r772",
      "r773",
      "r784",
      "r785",
      "r786"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.",
        "label": "Accumulated Other Comprehensive Income (Loss)"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://haymaker.com/role/ConsolidatedStatementsOfStockholdersEquityDeficit"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdditionalPaidInCapital": {
     "auth_ref": [
      "r8",
      "r755"
     ],
     "calculation": {
      "http://haymaker.com/role/ConsolidatedBalanceSheets": {
       "order": 26.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.",
        "label": "Additional Paid in Capital",
        "terseLabel": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapital",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://haymaker.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsForNewAccountingPronouncementsAxis": {
     "auth_ref": [
      "r212",
      "r213",
      "r214",
      "r215",
      "r216",
      "r265",
      "r266",
      "r267",
      "r268",
      "r280",
      "r335",
      "r336",
      "r344",
      "r345",
      "r346",
      "r347",
      "r349",
      "r350",
      "r498",
      "r499",
      "r500",
      "r521",
      "r522",
      "r523",
      "r524",
      "r539",
      "r540",
      "r541",
      "r552",
      "r553",
      "r554",
      "r555",
      "r556",
      "r557",
      "r558",
      "r559",
      "r560",
      "r561",
      "r562",
      "r563",
      "r571",
      "r572",
      "r574",
      "r575",
      "r576",
      "r577",
      "r578",
      "r579",
      "r589",
      "r590",
      "r594",
      "r595",
      "r596",
      "r597",
      "r611",
      "r612",
      "r613",
      "r614",
      "r615",
      "r616",
      "r660",
      "r661",
      "r662",
      "r687",
      "r688",
      "r689",
      "r690",
      "r691",
      "r692",
      "r693",
      "r694",
      "r695",
      "r696",
      "r697",
      "r698"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by amendment to accounting standards.",
        "label": "Accounting Standards Update [Axis]"
       }
      }
     },
     "localname": "AdjustmentsForNewAccountingPronouncementsAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://haymaker.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "auth_ref": [
      "r125",
      "r126",
      "r461"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.",
        "label": "APIC, Share-Based Payment Arrangement, Increase for Cost Recognition",
        "terseLabel": "Share-based compensation"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://haymaker.com/role/ConsolidatedStatementsOfStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Adjustments to reconcile net income to net cash (used in) provided by operating activites:"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://haymaker.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AdvancesOnInventoryPurchases": {
     "auth_ref": [
      "r769"
     ],
     "calculation": {
      "http://haymaker.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfTotalOtherCurrentAssetsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value of capitalized payments made in advance for inventory that is expected to be received within one year or the normal operating cycle, if longer.",
        "label": "Advances on Inventory Purchases",
        "terseLabel": "Advances"
       }
      }
     },
     "localname": "AdvancesOnInventoryPurchases",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://haymaker.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfTotalOtherCurrentAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "auth_ref": [
      "r493"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.",
        "label": "Share-based compensation",
        "terseLabel": "Compensation paid",
        "verboseLabel": "Compensation expense"
       }
      }
     },
     "localname": "AllocatedShareBasedCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://haymaker.com/role/RelatedPartyTransactionsAdditionalInformationDetails",
      "http://haymaker.com/role/ShareBasedCompensationAdditionalInformationDetails",
      "http://haymaker.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent": {
     "auth_ref": [
      "r229",
      "r334",
      "r351"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of allowance for credit loss on accounts receivable, classified as current.",
        "label": "Accounts Receivable, Allowance for Credit Loss, Current",
        "negatedPeriodEndLabel": "Ending balance",
        "negatedPeriodStartLabel": "Beginning balance"
       }
      }
     },
     "localname": "AllowanceForDoubtfulAccountsReceivableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://haymaker.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfRollforwardOfTheAllowanceForDoubtfulAccountsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AmortizationOfFinancingCosts": {
     "auth_ref": [
      "r36",
      "r408",
      "r591",
      "r778"
     ],
     "calculation": {
      "http://haymaker.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 18.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization expense attributable to debt issuance costs.",
        "label": "Amortization of Debt Issuance Costs",
        "terseLabel": "Amortization of debt issuance costs",
        "verboseLabel": "Amortization expense related to debt issuance costs"
       }
      }
     },
     "localname": "AmortizationOfFinancingCosts",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://haymaker.com/role/ConsolidatedStatementsOfCashFlows",
      "http://haymaker.com/role/LongTermDebtAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "auth_ref": [
      "r295"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "terseLabel": "Potentially antidilutive common units outstanding"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://haymaker.com/role/NetLossPerCommonShareScheduleOfComputationOfDilutedWeightedAverageSharesOutstandingDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "auth_ref": [
      "r63"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of antidilutive security.",
        "label": "Antidilutive Securities [Axis]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://haymaker.com/role/NetLossPerCommonShareScheduleOfComputationOfDilutedWeightedAverageSharesOutstandingDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://haymaker.com/role/NetLossPerCommonShareScheduleOfComputationOfDilutedWeightedAverageSharesOutstandingDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "auth_ref": [
      "r63"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented.",
        "label": "Antidilutive Securities, Name [Domain]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://haymaker.com/role/NetLossPerCommonShareScheduleOfComputationOfDilutedWeightedAverageSharesOutstandingDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]"
       }
      }
     },
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://haymaker.com/role/RelatedPartyTransactionsAdditionalInformationDetails",
      "http://haymaker.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r175",
      "r193",
      "r223",
      "r256",
      "r313",
      "r322",
      "r326",
      "r340",
      "r375",
      "r376",
      "r378",
      "r379",
      "r380",
      "r381",
      "r382",
      "r384",
      "r385",
      "r544",
      "r548",
      "r570",
      "r755",
      "r807",
      "r808",
      "r919"
     ],
     "calculation": {
      "http://haymaker.com/role/ConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://haymaker.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [Abstract]",
        "terseLabel": "Assets"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://haymaker.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r218",
      "r233",
      "r256",
      "r340",
      "r375",
      "r376",
      "r378",
      "r379",
      "r380",
      "r381",
      "r382",
      "r384",
      "r385",
      "r544",
      "r548",
      "r570",
      "r755",
      "r807",
      "r808",
      "r919"
     ],
     "calculation": {
      "http://haymaker.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://haymaker.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "terseLabel": "Current assets"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://haymaker.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsTotalMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total assets, when it serves as a benchmark in a concentration of risk calculation, representing the sum of all reported assets as of the balance sheet date.",
        "label": "Assets, Total [Member]",
        "terseLabel": "Assets"
       }
      }
     },
     "localname": "AssetsTotalMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://haymaker.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AwardTypeAxis": {
     "auth_ref": [
      "r464",
      "r465",
      "r466",
      "r468",
      "r469",
      "r470",
      "r471",
      "r472",
      "r473",
      "r474",
      "r475",
      "r476",
      "r477",
      "r478",
      "r479",
      "r480",
      "r481",
      "r482",
      "r483",
      "r484",
      "r485",
      "r488",
      "r489",
      "r490",
      "r491",
      "r492"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of award under share-based payment arrangement.",
        "label": "Award Type [Axis]"
       }
      }
     },
     "localname": "AwardTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://haymaker.com/role/NetLossPerCommonShareScheduleOfComputationOfNetLossPerCommonShareDetails",
      "http://haymaker.com/role/ShareBasedCompensationAdditionalInformationDetails",
      "http://haymaker.com/role/ShareBasedCompensationSummaryOfRestrictedStockUnitActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BaseRateMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Minimum rate investor will accept.",
        "label": "Base Rate [Member]",
        "terseLabel": "Base Rate"
       }
      }
     },
     "localname": "BaseRateMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://haymaker.com/role/LongTermDebtAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BusinessAcquisitionAcquireeDomain": {
     "auth_ref": [
      "r537",
      "r748",
      "r749"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree.",
        "label": "Business Acquisition, Acquiree [Domain]"
       }
      }
     },
     "localname": "BusinessAcquisitionAcquireeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://haymaker.com/role/BusinessCombinationAdditionalInformationDetails",
      "http://haymaker.com/role/EarnoutLiabilityAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BusinessAcquisitionAxis": {
     "auth_ref": [
      "r139",
      "r140",
      "r537",
      "r748",
      "r749"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by business combination or series of individually immaterial business combinations.",
        "label": "Business Acquisition [Axis]"
       }
      }
     },
     "localname": "BusinessAcquisitionAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://haymaker.com/role/BusinessCombinationAdditionalInformationDetails",
      "http://haymaker.com/role/EarnoutLiabilityAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessAcquisitionDescriptionOfAcquiredEntity": {
     "auth_ref": [
      "r137"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "With respect to a business combination completed during the period, this element provides a description of the business, other than the name, which may include the industry, size, products and other important information.",
        "label": "Business Acquisition, Description of Acquired Entity",
        "terseLabel": "Business acquisition, description of acquired entity"
       }
      }
     },
     "localname": "BusinessAcquisitionDescriptionOfAcquiredEntity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://haymaker.com/role/BusinessCombinationAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued": {
     "auth_ref": [
      "r144"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of equity interests issued or issuable to acquire entity.",
        "label": "Business Acquisition, Equity Interest Issued or Issuable, Number of Shares",
        "verboseLabel": "Business combination number of share issued"
       }
      }
     },
     "localname": "BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://haymaker.com/role/BusinessCombinationAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_BusinessAcquisitionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Business Acquisition [Line Items]"
       }
      }
     },
     "localname": "BusinessAcquisitionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://haymaker.com/role/BusinessCombinationAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessAcquisitionSharePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Price of a single share of a number of saleable stocks paid or offered to be paid in a business combination.",
        "label": "Business Acquisition, Share Price",
        "terseLabel": "Business acquisition, share price"
       }
      }
     },
     "localname": "BusinessAcquisitionSharePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://haymaker.com/role/BusinessCombinationAdditionalInformationDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_BusinessCombinationConsiderationTransferred1": {
     "auth_ref": [
      "r141",
      "r142",
      "r143"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer.",
        "label": "Business Combination, Consideration Transferred",
        "terseLabel": "Business combination consideration transferred"
       }
      }
     },
     "localname": "BusinessCombinationConsiderationTransferred1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://haymaker.com/role/BusinessCombinationAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable": {
     "auth_ref": [
      "r141",
      "r142"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of equity interests of the acquirer, including instruments or interests issued or issuable in consideration for the business combination.",
        "label": "Business Combination, Consideration Transferred, Equity Interests Issued and Issuable",
        "terseLabel": "Business combination, consideration through equity value"
       }
      }
     },
     "localname": "BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://haymaker.com/role/BusinessCombinationAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationDisclosureTextBlock": {
     "auth_ref": [
      "r145",
      "r538"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable).",
        "label": "Business Combination Disclosure [Text Block]",
        "terseLabel": "Business Combination"
       }
      }
     },
     "localname": "BusinessCombinationDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://haymaker.com/role/BusinessCombination"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAxis": {
     "auth_ref": [
      "r138"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosures related to transactions that are recognized separately from the acquisition of assets and assumptions of liabilities in the business combination by type of transaction.",
        "label": "Business Combination, Separately Recognized Transactions [Axis]"
       }
      }
     },
     "localname": "BusinessCombinationSeparatelyRecognizedTransactionsAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://haymaker.com/role/BusinessCombinationAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsDomain": {
     "auth_ref": [
      "r138"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of transaction that is recognized separately from the acquisition of assets and assumptions of liabilities in a business combination by transaction.",
        "label": "Business Combination, Separately Recognized Transactions [Domain]"
       }
      }
     },
     "localname": "BusinessCombinationSeparatelyRecognizedTransactionsDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://haymaker.com/role/BusinessCombinationAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BusinessCombinationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Combinations [Abstract]"
       }
      }
     },
     "localname": "BusinessCombinationsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock": {
     "auth_ref": [
      "r0",
      "r61",
      "r71"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the business description and basis of presentation concepts. Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).",
        "label": "Business Description and Basis of Presentation [Text Block]",
        "terseLabel": "Description of Business and Basis of Presentation"
       }
      }
     },
     "localname": "BusinessDescriptionAndBasisOfPresentationTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://haymaker.com/role/DescriptionOfBusinessAndBasisOfPresentation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CapitalExpendituresIncurredButNotYetPaid": {
     "auth_ref": [
      "r57",
      "r58",
      "r59"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Future cash outflow to pay for purchases of fixed assets that have occurred.",
        "label": "Capital Expenditures Incurred but Not yet Paid",
        "terseLabel": "Capital expenditures and capitalized software included in accounts payable"
       }
      }
     },
     "localname": "CapitalExpendituresIncurredButNotYetPaid",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://haymaker.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CapitalUnitClassDomain": {
     "auth_ref": [
      "r204"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of the type or class of capital units or capital shares.",
        "label": "Capital Unit, Class [Domain]"
       }
      }
     },
     "localname": "CapitalUnitClassDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://haymaker.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://haymaker.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfMembersEquityUnitsIssuedAndOutstandingDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CapitalUnitLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Capital Unit [Line Items]"
       }
      }
     },
     "localname": "CapitalUnitLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://haymaker.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfMembersEquityUnitsIssuedAndOutstandingDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CapitalUnitsByClassAxis": {
     "auth_ref": [
      "r203",
      "r206"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type or class of the entity's capital units.",
        "label": "Capital Units by Class [Axis]"
       }
      }
     },
     "localname": "CapitalUnitsByClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://haymaker.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://haymaker.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfMembersEquityUnitsIssuedAndOutstandingDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CapitalizedComputerSoftwareAccumulatedAmortization": {
     "auth_ref": [
      "r929"
     ],
     "calculation": {
      "http://haymaker.com/role/CapitalizedSoftwareNetSummaryOfCapitalizedSoftwareNetDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_CapitalizedComputerSoftwareNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For each balance sheet presented, the amount of accumulated amortization for capitalized computer software costs.",
        "label": "Capitalized Computer Software, Accumulated Amortization",
        "negatedLabel": "Less: Accumulated amortization"
       }
      }
     },
     "localname": "CapitalizedComputerSoftwareAccumulatedAmortization",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://haymaker.com/role/CapitalizedSoftwareNetSummaryOfCapitalizedSoftwareNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CapitalizedComputerSoftwareAmortization1": {
     "auth_ref": [
      "r209",
      "r210"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for amortization of capitalized computer software costs.",
        "label": "Capitalized Computer Software, Amortization",
        "terseLabel": "Amortization expense"
       }
      }
     },
     "localname": "CapitalizedComputerSoftwareAmortization1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://haymaker.com/role/CapitalizedSoftwareNetAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CapitalizedComputerSoftwareNet": {
     "auth_ref": [
      "r720"
     ],
     "calculation": {
      "http://haymaker.com/role/CapitalizedSoftwareNetSummaryOfCapitalizedSoftwareNetDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://haymaker.com/role/ConsolidatedBalanceSheets": {
       "order": 7.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The carrying amount of capitalized computer software costs net of accumulated amortization as of the balance sheet date.",
        "label": "Capitalized Computer Software, Net",
        "terseLabel": "Capitalized software, net",
        "totalLabel": "Capitalized software, net"
       }
      }
     },
     "localname": "CapitalizedComputerSoftwareNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://haymaker.com/role/CapitalizedSoftwareNetSummaryOfCapitalizedSoftwareNetDetails",
      "http://haymaker.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CapitalizedContractCostAmortization": {
     "auth_ref": [
      "r367"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization expense for asset recognized from cost incurred to obtain or fulfill contract with customer.",
        "label": "Capitalized Contract Cost, Amortization",
        "terseLabel": "Incremental costs to fulfill contract with customers"
       }
      }
     },
     "localname": "CapitalizedContractCostAmortization",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://haymaker.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Cash": {
     "auth_ref": [
      "r700",
      "r701",
      "r755",
      "r766"
     ],
     "calculation": {
      "http://haymaker.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash"
       }
      }
     },
     "localname": "Cash",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://haymaker.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsPolicyTextBlock": {
     "auth_ref": [
      "r55"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.",
        "label": "Cash and Cash Equivalents, Policy [Policy Text Block]",
        "terseLabel": "Cash"
       }
      }
     },
     "localname": "CashAndCashEquivalentsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://haymaker.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations": {
     "auth_ref": [
      "r48",
      "r54",
      "r60"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations",
        "periodEndLabel": "Cash and cash equivalents at end of period",
        "periodStartLabel": "Cash and cash equivalents at beginning of period"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://haymaker.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "auth_ref": [
      "r48",
      "r164"
     ],
     "calculation": {
      "http://haymaker.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "totalLabel": "Net increase in cash and cash equivalents"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://haymaker.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]",
        "terseLabel": "Non-cash investing and financing activities"
       }
      }
     },
     "localname": "CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://haymaker.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted": {
     "auth_ref": [
      "r212",
      "r213",
      "r264",
      "r335",
      "r336",
      "r341",
      "r342",
      "r343",
      "r344",
      "r345",
      "r521",
      "r539",
      "r540",
      "r550",
      "r552",
      "r553",
      "r563",
      "r571",
      "r573",
      "r574",
      "r575",
      "r578",
      "r579",
      "r589",
      "r593",
      "r594",
      "r595",
      "r596",
      "r611",
      "r612",
      "r660",
      "r661",
      "r687",
      "r688"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates (true false) whether accounting standards update was adopted.",
        "label": "Change in Accounting Principle, Accounting Standards Update, Adopted [true false]"
       }
      }
     },
     "localname": "ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://haymaker.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "booleanItemType"
    },
    "us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate": {
     "auth_ref": [
      "r212",
      "r213",
      "r335",
      "r336",
      "r341",
      "r342",
      "r343",
      "r344",
      "r345",
      "r521",
      "r539",
      "r540",
      "r541",
      "r550",
      "r552",
      "r553",
      "r554",
      "r557",
      "r563",
      "r571",
      "r573",
      "r574",
      "r575",
      "r578",
      "r579",
      "r589",
      "r593",
      "r594",
      "r595",
      "r596",
      "r611",
      "r612",
      "r660",
      "r661",
      "r687",
      "r688",
      "r787"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Date accounting standards update was adopted, in YYYY-MM-DD format.",
        "label": "Change in Accounting Principle, Accounting Standards Update, Adoption Date"
       }
      }
     },
     "localname": "ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://haymaker.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "dateItemType"
    },
    "us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect": {
     "auth_ref": [
      "r265",
      "r279",
      "r337",
      "r348",
      "r525"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates (true false) whether effect from applying amendment to accounting standards is immaterial.",
        "label": "Change in Accounting Principle, Accounting Standards Update, Immaterial Effect [true false]"
       }
      }
     },
     "localname": "ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://haymaker.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "booleanItemType"
    },
    "us-gaap_ClassOfStockDomain": {
     "auth_ref": [
      "r225",
      "r226",
      "r227",
      "r256",
      "r284",
      "r285",
      "r292",
      "r294",
      "r302",
      "r303",
      "r340",
      "r375",
      "r378",
      "r379",
      "r380",
      "r384",
      "r385",
      "r417",
      "r418",
      "r420",
      "r421",
      "r423",
      "r570",
      "r721",
      "r763",
      "r779",
      "r789"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock.",
        "label": "Class of Stock [Domain]"
       }
      }
     },
     "localname": "ClassOfStockDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://haymaker.com/role/BusinessCombinationAdditionalInformationDetails",
      "http://haymaker.com/role/ConsolidatedBalanceSheets",
      "http://haymaker.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://haymaker.com/role/ConsolidatedStatementsOfStockholdersEquityDeficit",
      "http://haymaker.com/role/Cover",
      "http://haymaker.com/role/EarnoutLiabilityAdditionalInformationDetails",
      "http://haymaker.com/role/NetLossPerCommonShareScheduleOfComputationOfDilutedWeightedAverageSharesOutstandingDetails",
      "http://haymaker.com/role/NoncontrollingInterestAdditionalInformationDetails",
      "http://haymaker.com/role/ShareBasedCompensationAdditionalInformationDetails",
      "http://haymaker.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://haymaker.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfCommonStockIssuedAndOutstandingDetails",
      "http://haymaker.com/role/WarrantLiabilityAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ClassOfStockLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Class of Stock [Line Items]"
       }
      }
     },
     "localname": "ClassOfStockLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://haymaker.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfCommonStockIssuedAndOutstandingDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ClassOfWarrantOrRightAxis": {
     "auth_ref": [
      "r112",
      "r118"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of warrant or right issued.",
        "label": "Class of Warrant or Right [Axis]"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://haymaker.com/role/NetLossPerCommonShareScheduleOfComputationOfDilutedWeightedAverageSharesOutstandingDetails",
      "http://haymaker.com/role/WarrantLiabilityAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ClassOfWarrantOrRightDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the class or type of warrant or right outstanding. Warrants and rights represent derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months.",
        "label": "Class of Warrant or Right [Domain]"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://haymaker.com/role/NetLossPerCommonShareScheduleOfComputationOfDilutedWeightedAverageSharesOutstandingDetails",
      "http://haymaker.com/role/WarrantLiabilityAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": {
     "auth_ref": [
      "r424"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exercise price per share or per unit of warrants or rights outstanding.",
        "label": "Class of Warrant or Right, Exercise Price of Warrants or Rights",
        "terseLabel": "Exercise price of warrants or rights outstanding"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://haymaker.com/role/WarrantLiabilityAdditionalInformationDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ClassOfWarrantOrRightLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Class of Warrant or Right [Line Items]"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://haymaker.com/role/WarrantLiabilityAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": {
     "auth_ref": [
      "r424"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.",
        "label": "Class of Warrant or Right, Number of Securities Called by Warrants or Rights",
        "terseLabel": "Number of securities called by warrants or rights"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://haymaker.com/role/WarrantLiabilityAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ClassOfWarrantOrRightOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of warrants or rights outstanding.",
        "label": "Class of Warrant or Right, Outstanding",
        "terseLabel": "Number of warrants or rights outstanding"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://haymaker.com/role/WarrantLiabilityAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ClassOfWarrantOrRightTable": {
     "auth_ref": [
      "r112",
      "r118"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure for warrants or rights issued, which includes the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.",
        "label": "Class of Warrant or Right [Table]"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://haymaker.com/role/WarrantLiabilityAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommissionsPolicy": {
     "auth_ref": [
      "r173",
      "r174"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for fees earned by the broker dealer, acting as an agent in the buying and selling of securities and administrative efforts on behalf of customers and may include the timing of commission revenue recognition and presentation in the financial statements. Commissions earned are usually related to the broker dealer's customers' trading volume and the dollar amounts of the trades.",
        "label": "Commissions, Policy [Policy Text Block]",
        "terseLabel": "Commissions"
       }
      }
     },
     "localname": "CommissionsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://haymaker.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommitmentsAndContingencies": {
     "auth_ref": [
      "r24",
      "r182",
      "r199"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.",
        "label": "Commitments and Contingencies",
        "terseLabel": "Commitments and contingencies (See Note 18)"
       }
      }
     },
     "localname": "CommitmentsAndContingencies",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://haymaker.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "auth_ref": [
      "r87",
      "r368",
      "r369",
      "r704",
      "r805"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for commitments and contingencies.",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "terseLabel": "Commitments and Contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://haymaker.com/role/CommitmentsAndContingencies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommonClassAMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Classification of common stock representing ownership interest in a corporation.",
        "label": "Common Class A",
        "terseLabel": "Class A Common Stock"
       }
      }
     },
     "localname": "CommonClassAMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://haymaker.com/role/BusinessCombinationAdditionalInformationDetails",
      "http://haymaker.com/role/ConsolidatedBalanceSheets",
      "http://haymaker.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://haymaker.com/role/ConsolidatedStatementsOfStockholdersEquityDeficit",
      "http://haymaker.com/role/EarnoutLiabilityAdditionalInformationDetails",
      "http://haymaker.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://haymaker.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfCommonStockIssuedAndOutstandingDetails",
      "http://haymaker.com/role/WarrantLiabilityAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonClassBMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Classification of common stock that has different rights than Common Class A, representing ownership interest in a corporation.",
        "label": "Common Class B [Member]",
        "terseLabel": "Class B Common Stock"
       }
      }
     },
     "localname": "CommonClassBMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://haymaker.com/role/BusinessCombinationAdditionalInformationDetails",
      "http://haymaker.com/role/ConsolidatedBalanceSheets",
      "http://haymaker.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://haymaker.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfCommonStockIssuedAndOutstandingDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r784",
      "r785",
      "r911"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://haymaker.com/role/ConsolidatedStatementsOfStockholdersEquityDeficit"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockNoParValue": {
     "auth_ref": [
      "r7"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount per share of no-par value common stock.",
        "label": "Common Stock, No Par Value",
        "terseLabel": "Common stock, no par value"
       }
      }
     },
     "localname": "CommonStockNoParValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://haymaker.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r7"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common Stock, Par or Stated Value Per Share",
        "terseLabel": "Common stock, par value"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://haymaker.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r7"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common Stock, Shares Authorized",
        "terseLabel": "Common stock, shares authorized"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://haymaker.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesAuthorizedUnlimited": {
     "auth_ref": [
      "r25"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the number of common shares permitted to be issued by an entity's charter and bylaws is unlimited. The acceptable value is \"Unlimited\".",
        "label": "Common Stock, Shares Authorized, Unlimited [Fixed List]",
        "terseLabel": "Common stock, shares authorized, unlimited"
       }
      }
     },
     "localname": "CommonStockSharesAuthorizedUnlimited",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://haymaker.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "authorizedUnlimitedItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r7"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common Stock, Shares, Issued",
        "terseLabel": "Common stock, shares issued"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://haymaker.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://haymaker.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://haymaker.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfCommonStockIssuedAndOutstandingDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r7",
      "r103"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common Stock, Shares, Outstanding",
        "terseLabel": "Common stock, shares outstanding"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://haymaker.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://haymaker.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfCommonStockIssuedAndOutstandingDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r7",
      "r755"
     ],
     "calculation": {
      "http://haymaker.com/role/ConsolidatedBalanceSheets": {
       "order": 25.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common Stock, Value, Issued",
        "terseLabel": "Common stock value"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://haymaker.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommonStockVotingRights": {
     "auth_ref": [
      "r104"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of voting rights of common stock. Includes eligibility to vote and votes per share owned. Include also, if any, unusual voting rights.",
        "label": "Common Stock, Voting Rights"
       }
      }
     },
     "localname": "CommonStockVotingRights",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://haymaker.com/role/NoncontrollingInterestAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommonUnitIssued": {
     "auth_ref": [
      "r110"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of common units issued of limited liability company (LLC).",
        "label": "Common Unit, Issued",
        "terseLabel": "Common units, issued"
       }
      }
     },
     "localname": "CommonUnitIssued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://haymaker.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfMembersEquityUnitsIssuedAndOutstandingDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonUnitOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of common units of ownership outstanding of a limited liability company (LLC).",
        "label": "Common Unit, Outstanding",
        "terseLabel": "Common units, outstanding"
       }
      }
     },
     "localname": "CommonUnitOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://haymaker.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfMembersEquityUnitsIssuedAndOutstandingDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "auth_ref": [
      "r33",
      "r237",
      "r239",
      "r245",
      "r676",
      "r682"
     ],
     "calculation": {
      "http://haymaker.com/role/ConsolidatedStatementsOfIncomeAndComprehensiveIncome": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "totalLabel": "Comprehensive income"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://haymaker.com/role/ConsolidatedStatementsOfIncomeAndComprehensiveIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r148",
      "r156",
      "r237",
      "r239",
      "r244",
      "r675",
      "r681"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest",
        "terseLabel": "Other comprehensive income (loss)"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://haymaker.com/role/ConsolidatedStatementsOfStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComputerEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Long lived, depreciable assets that are used in the creation, maintenance and utilization of information systems.",
        "label": "Computer Equipment [Member]",
        "terseLabel": "Computer Equipment"
       }
      }
     },
     "localname": "ComputerEquipmentMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://haymaker.com/role/PropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetails",
      "http://haymaker.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfEstimatedUsefulLivesOfPropertyAndEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConcentrationRiskBenchmarkDomain": {
     "auth_ref": [
      "r66",
      "r67",
      "r161",
      "r162",
      "r331",
      "r703"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The denominator in a calculation of a disclosed concentration risk percentage.",
        "label": "Concentration Risk Benchmark [Domain]"
       }
      }
     },
     "localname": "ConcentrationRiskBenchmarkDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://haymaker.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConcentrationRiskByBenchmarkAxis": {
     "auth_ref": [
      "r66",
      "r67",
      "r161",
      "r162",
      "r331",
      "r699",
      "r703"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by benchmark of concentration risk.",
        "label": "Concentration Risk Benchmark [Axis]"
       }
      }
     },
     "localname": "ConcentrationRiskByBenchmarkAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://haymaker.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskByTypeAxis": {
     "auth_ref": [
      "r66",
      "r67",
      "r161",
      "r162",
      "r331",
      "r703",
      "r928"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender.",
        "label": "Concentration Risk Type [Axis]"
       }
      }
     },
     "localname": "ConcentrationRiskByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://haymaker.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskCreditRisk": {
     "auth_ref": [
      "r191",
      "r306"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for credit risk.",
        "label": "Concentration Risk, Credit Risk, Policy [Policy Text Block]",
        "terseLabel": "Concentrations"
       }
      }
     },
     "localname": "ConcentrationRiskCreditRisk",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://haymaker.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ConcentrationRiskPercentage1": {
     "auth_ref": [
      "r66",
      "r67",
      "r161",
      "r162",
      "r331"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.",
        "label": "Concentration Risk, Percentage",
        "terseLabel": "Concentration risk percentage"
       }
      }
     },
     "localname": "ConcentrationRiskPercentage1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://haymaker.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ConcentrationRiskTypeDomain": {
     "auth_ref": [
      "r66",
      "r67",
      "r161",
      "r162",
      "r331",
      "r703"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration.",
        "label": "Concentration Risk Type [Domain]"
       }
      }
     },
     "localname": "ConcentrationRiskTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://haymaker.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConstructionInProgressMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Structure or a modification to a structure under construction. Includes recently completed structures or modifications to structures that have not been placed into service.",
        "label": "Construction in Progress [Member]",
        "terseLabel": "Construction in Progress"
       }
      }
     },
     "localname": "ConstructionInProgressMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://haymaker.com/role/PropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock": {
     "auth_ref": [
      "r813"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of receivable, contract asset, and contract liability from contract with customer. Includes, but is not limited to, change in contract asset and contract liability.",
        "label": "Contract with Customer, Contract Asset, Contract Liability, and Receivable [Table Text Block]",
        "terseLabel": "Summary of Significant Changes in Contract Liability Balances"
       }
      }
     },
     "localname": "ContractWithCustomerAssetAndLiabilityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://haymaker.com/role/RevenueRecognitionTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ContractWithCustomerDurationAxis": {
     "auth_ref": [
      "r742",
      "r814"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by duration of contract with customer. Includes, but is not limited to, short-term and long-term contracts.",
        "label": "Contract with Customer, Duration [Axis]"
       }
      }
     },
     "localname": "ContractWithCustomerDurationAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://haymaker.com/role/RevenueRecognitionSummaryOfSignificantChangesInContractLiabilityBalancesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ContractWithCustomerDurationDomain": {
     "auth_ref": [
      "r742",
      "r814"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Duration of contract with customer. Includes, but is not limited to, short-term and long-term contracts.",
        "label": "Contract with Customer, Duration [Domain]"
       }
      }
     },
     "localname": "ContractWithCustomerDurationDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://haymaker.com/role/RevenueRecognitionSummaryOfSignificantChangesInContractLiabilityBalancesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ContractWithCustomerLiability": {
     "auth_ref": [
      "r426",
      "r427",
      "r439"
     ],
     "calculation": {
      "http://haymaker.com/role/RevenueRecognitionSummaryOfConsiderationAllocatedToPerformanceObligationsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.",
        "label": "Contract with Customer, Liability",
        "totalLabel": "Total Deferred Revenue"
       }
      }
     },
     "localname": "ContractWithCustomerLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://haymaker.com/role/RevenueRecognitionSummaryOfConsiderationAllocatedToPerformanceObligationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityCurrent": {
     "auth_ref": [
      "r426",
      "r427",
      "r439"
     ],
     "calculation": {
      "http://haymaker.com/role/ConsolidatedBalanceSheets": {
       "order": 15.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      },
      "http://haymaker.com/role/RevenueRecognitionSummaryOfConsiderationAllocatedToPerformanceObligationsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_ContractWithCustomerLiability",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.",
        "label": "Contract with Customer, Liability, Current",
        "terseLabel": "Contract with customers liability current",
        "verboseLabel": "Deferred revenue, current"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://haymaker.com/role/ConsolidatedBalanceSheets",
      "http://haymaker.com/role/RevenueRecognitionSummaryOfConsiderationAllocatedToPerformanceObligationsDetails",
      "http://haymaker.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityNoncurrent": {
     "auth_ref": [
      "r426",
      "r427",
      "r439"
     ],
     "calculation": {
      "http://haymaker.com/role/ConsolidatedBalanceSheets": {
       "order": 18.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      },
      "http://haymaker.com/role/RevenueRecognitionSummaryOfConsiderationAllocatedToPerformanceObligationsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_ContractWithCustomerLiability",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.",
        "label": "Contract with Customer, Liability, Noncurrent",
        "terseLabel": "Deferred revenue, net of current portion",
        "verboseLabel": "Contract with customers liability non current"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://haymaker.com/role/ConsolidatedBalanceSheets",
      "http://haymaker.com/role/RevenueRecognitionSummaryOfConsiderationAllocatedToPerformanceObligationsDetails",
      "http://haymaker.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityRevenueRecognized": {
     "auth_ref": [
      "r440"
     ],
     "calculation": {
      "http://haymaker.com/role/RevenueRecognitionSummaryOfSignificantChangesInContractLiabilityBalancesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_IncreaseDecreaseInContractWithCustomerLiability",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due.",
        "label": "Contract with Customer, Liability, Revenue Recognized",
        "terseLabel": "Revenue recognized that was included in the contract liability balance at the beginning of the period"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityRevenueRecognized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://haymaker.com/role/RevenueRecognitionSummaryOfSignificantChangesInContractLiabilityBalancesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ConversionOfStockSharesConverted1": {
     "auth_ref": [
      "r57",
      "r58",
      "r59"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.",
        "label": "Conversion of Stock, Shares Converted",
        "terseLabel": "Phantom equity rights replaced with restricted stock units"
       }
      }
     },
     "localname": "ConversionOfStockSharesConverted1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://haymaker.com/role/ShareBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization": {
     "auth_ref": [
      "r774",
      "r775"
     ],
     "calculation": {
      "http://haymaker.com/role/ConsolidatedStatementsOfIncomeAndComprehensiveIncome": {
       "order": 21.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cost of product sold and service rendered, excluding depreciation, depletion, and amortization.",
        "label": "Cost of Goods and Service, Excluding Depreciation, Depletion, and Amortization",
        "terseLabel": "Cost of revenue"
       }
      }
     },
     "localname": "CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://haymaker.com/role/ConsolidatedStatementsOfIncomeAndComprehensiveIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortizationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cost of Goods and Service, Excluding Depreciation, Depletion, and Amortization [Abstract]",
        "terseLabel": "Cost of revenue (excluding depreciation and amortization included in selling, general, and administrative, below)"
       }
      }
     },
     "localname": "CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortizationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://haymaker.com/role/ConsolidatedStatementsOfIncomeAndComprehensiveIncome"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CreditAvailabilityConcentrationRiskMember": {
     "auth_ref": [
      "r65"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reflects the percentage that borrowing or credit line availability under commitments from one or more lenders is to a selected benchmark, such as total debt, segment debt. Risk is the materially adverse effects that funds which may be needed for operations or for a specific purpose will not be available on terms that are acceptable to an entity, if at all.",
        "label": "Credit Availability Concentration Risk [Member]",
        "terseLabel": "Outstanding Debt and Available Line of Credit"
       }
      }
     },
     "localname": "CreditAvailabilityConcentrationRiskMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://haymaker.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CreditFacilityAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.",
        "label": "Credit Facility [Axis]"
       }
      }
     },
     "localname": "CreditFacilityAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://haymaker.com/role/BusinessCombinationAdditionalInformationDetails",
      "http://haymaker.com/role/LongTermDebtAdditionalInformationDetails",
      "http://haymaker.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CreditFacilityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.",
        "label": "Credit Facility [Domain]"
       }
      }
     },
     "localname": "CreditFacilityDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://haymaker.com/role/BusinessCombinationAdditionalInformationDetails",
      "http://haymaker.com/role/LongTermDebtAdditionalInformationDetails",
      "http://haymaker.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CurrentFederalTaxExpenseBenefit": {
     "auth_ref": [
      "r782",
      "r905",
      "r907"
     ],
     "calculation": {
      "http://haymaker.com/role/IncomeTaxesScheduleOfIncomeTaxProvisionDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current national tax expense (benefit) for non-US (United States of America) jurisdiction.",
        "label": "Current Federal Tax Expense (Benefit)",
        "terseLabel": "Federal"
       }
      }
     },
     "localname": "CurrentFederalTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://haymaker.com/role/IncomeTaxesScheduleOfIncomeTaxProvisionDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CurrentForeignTaxExpenseBenefit": {
     "auth_ref": [
      "r782",
      "r905"
     ],
     "calculation": {
      "http://haymaker.com/role/IncomeTaxesScheduleOfIncomeTaxProvisionDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Current Foreign Tax Expense (Benefit)",
        "terseLabel": "Foreign"
       }
      }
     },
     "localname": "CurrentForeignTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://haymaker.com/role/IncomeTaxesScheduleOfIncomeTaxProvisionDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CurrentIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r136",
      "r518",
      "r529",
      "r782"
     ],
     "calculation": {
      "http://haymaker.com/role/IncomeTaxesScheduleOfIncomeTaxProvisionDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations.",
        "label": "Current Income Tax Expense (Benefit)",
        "totalLabel": "Total current expense (benefit):"
       }
      }
     },
     "localname": "CurrentIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://haymaker.com/role/IncomeTaxesScheduleOfIncomeTaxProvisionDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Income Tax Expense (Benefit), Continuing Operations [Abstract]",
        "terseLabel": "Current income tax provision (benefit):"
       }
      }
     },
     "localname": "CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://haymaker.com/role/IncomeTaxesScheduleOfIncomeTaxProvisionDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CurrentStateAndLocalTaxExpenseBenefit": {
     "auth_ref": [
      "r782",
      "r905",
      "r907"
     ],
     "calculation": {
      "http://haymaker.com/role/IncomeTaxesScheduleOfIncomeTaxProvisionDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction.",
        "label": "Current State and Local Tax Expense (Benefit)",
        "terseLabel": "State and Local"
       }
      }
     },
     "localname": "CurrentStateAndLocalTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://haymaker.com/role/IncomeTaxesScheduleOfIncomeTaxProvisionDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Disclosure [Abstract]"
       }
      }
     },
     "localname": "DebtDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtDisclosureTextBlock": {
     "auth_ref": [
      "r96",
      "r255",
      "r391",
      "r392",
      "r393",
      "r394",
      "r395",
      "r396",
      "r397",
      "r402",
      "r409",
      "r410",
      "r412"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.",
        "label": "Debt Disclosure [Text Block]",
        "terseLabel": "Long-Term Debt"
       }
      }
     },
     "localname": "DebtDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://haymaker.com/role/LongTermDebt"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DebtInstrumentAxis": {
     "auth_ref": [
      "r2",
      "r3",
      "r4",
      "r176",
      "r177",
      "r192",
      "r260",
      "r386",
      "r387",
      "r388",
      "r389",
      "r390",
      "r392",
      "r398",
      "r399",
      "r400",
      "r401",
      "r403",
      "r404",
      "r405",
      "r406",
      "r407",
      "r408",
      "r592",
      "r732",
      "r733",
      "r734",
      "r735",
      "r736",
      "r780"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.",
        "label": "Debt Instrument [Axis]"
       }
      }
     },
     "localname": "DebtInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://haymaker.com/role/BusinessCombinationAdditionalInformationDetails",
      "http://haymaker.com/role/LongTermDebtAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentBasisSpreadOnVariableRate1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage points added to the reference rate to compute the variable rate on the debt instrument.",
        "label": "Debt Instrument, Basis Spread on Variable Rate",
        "terseLabel": "Debt instrument, applicable margin rate"
       }
      }
     },
     "localname": "DebtInstrumentBasisSpreadOnVariableRate1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://haymaker.com/role/LongTermDebtAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentCarryingAmount": {
     "auth_ref": [
      "r4",
      "r177",
      "r192",
      "r413"
     ],
     "calculation": {
      "http://haymaker.com/role/LongTermDebtScheduleOfOutstandingDebtDetails": {
       "order": 3.0,
       "parentTag": "btmd_TeamLoanNonCurrentPortionBeforeUnamortizedDebtIssuanceCosts",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.",
        "label": "Long-Term Debt, Gross",
        "verboseLabel": "Term loan"
       }
      }
     },
     "localname": "DebtInstrumentCarryingAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://haymaker.com/role/LongTermDebtScheduleOfOutstandingDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentCovenantCompliance": {
     "auth_ref": [
      "r4",
      "r188"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "States whether the entity was in compliance with the debt covenants throughout the reporting period, and describes facts and circumstances of any compliance failure.",
        "label": "Debt Instrument, Covenant Compliance",
        "terseLabel": "Covenant compliance"
       }
      }
     },
     "localname": "DebtInstrumentCovenantCompliance",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://haymaker.com/role/LongTermDebtAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentCovenantDescription": {
     "auth_ref": [
      "r4",
      "r188"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of minimum financial levels (for example, tangible net worth and working capital) and achievement of certain financial ratios (for example, working capital ratio and debt service coverage ratio), and adherence to certain clauses which generally require or restrict certain actions (for example, entering into a debt arrangement with equal or greater seniority, and selling or discontinuing a certain business segment or material subsidiary) to be in compliance with the covenant clauses of the debt agreement. May also include a discussion of the adverse consequences that would result if the entity violates or fails to satisfy the covenants.",
        "label": "Debt Instrument, Covenant Description",
        "terseLabel": "Covenant description"
       }
      }
     },
     "localname": "DebtInstrumentCovenantDescription",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://haymaker.com/role/LongTermDebtAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentFaceAmount": {
     "auth_ref": [
      "r166",
      "r168",
      "r386",
      "r592",
      "r733",
      "r734"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face (par) amount of debt instrument at time of issuance.",
        "label": "Debt Instrument, Face Amount",
        "terseLabel": "Debt face amount",
        "verboseLabel": "Term loan face amount"
       }
      }
     },
     "localname": "DebtInstrumentFaceAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://haymaker.com/role/BusinessCombinationAdditionalInformationDetails",
      "http://haymaker.com/role/LongTermDebtAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentFrequencyOfPeriodicPayment": {
     "auth_ref": [
      "r23",
      "r187"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of the frequency of periodic payments (monthly, quarterly, annual).",
        "label": "Debt Instrument, Frequency of Periodic Payment",
        "terseLabel": "Frequency of periodic payments"
       }
      }
     },
     "localname": "DebtInstrumentFrequencyOfPeriodicPayment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://haymaker.com/role/LongTermDebtAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentInterestRateEffectivePercentage": {
     "auth_ref": [
      "r22",
      "r166",
      "r415",
      "r592"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium.",
        "label": "Debt Instrument, Interest Rate, Effective Percentage",
        "terseLabel": "Interest rate"
       }
      }
     },
     "localname": "DebtInstrumentInterestRateEffectivePercentage",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://haymaker.com/role/LongTermDebtAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentInterestRateTerms": {
     "auth_ref": [
      "r22"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of the interest rate as being fixed or variable, and, if variable, identification of the index or rate on which the interest rate is based and the number of points or percentage added to that index or rate to set the rate, and other pertinent information, such as frequency of rate resets.",
        "label": "Debt Instrument, Interest Rate Terms",
        "terseLabel": "Debt instrument interest rate, terms"
       }
      }
     },
     "localname": "DebtInstrumentInterestRateTerms",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://haymaker.com/role/LongTermDebtAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Debt Instrument [Line Items]"
       }
      }
     },
     "localname": "DebtInstrumentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://haymaker.com/role/LongTermDebtAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentNameDomain": {
     "auth_ref": [
      "r23",
      "r260",
      "r386",
      "r387",
      "r388",
      "r389",
      "r390",
      "r392",
      "r398",
      "r399",
      "r400",
      "r401",
      "r403",
      "r404",
      "r405",
      "r406",
      "r407",
      "r408",
      "r592",
      "r732",
      "r733",
      "r734",
      "r735",
      "r736",
      "r780"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities.",
        "label": "Debt Instrument, Name [Domain]"
       }
      }
     },
     "localname": "DebtInstrumentNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://haymaker.com/role/BusinessCombinationAdditionalInformationDetails",
      "http://haymaker.com/role/LongTermDebtAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtInstrumentPeriodicPaymentPrincipal": {
     "auth_ref": [
      "r23"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the required periodic payments applied to principal.",
        "label": "Debt Instrument, Periodic Payment, Principal",
        "terseLabel": "Periodic payments"
       }
      }
     },
     "localname": "DebtInstrumentPeriodicPaymentPrincipal",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://haymaker.com/role/LongTermDebtAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentRedemptionPeriodAxis": {
     "auth_ref": [
      "r189"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information about timing of debt redemption features under terms of the debt agreement.",
        "label": "Debt Instrument, Redemption, Period [Axis]"
       }
      }
     },
     "localname": "DebtInstrumentRedemptionPeriodAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://haymaker.com/role/LongTermDebtAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentRedemptionPeriodDomain": {
     "auth_ref": [
      "r189"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period as defined under terms of the debt agreement for debt redemption features.",
        "label": "Debt Instrument, Redemption, Period [Domain]"
       }
      }
     },
     "localname": "DebtInstrumentRedemptionPeriodDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://haymaker.com/role/LongTermDebtAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtInstrumentRedemptionPeriodOneMember": {
     "auth_ref": [
      "r189"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period one representing most current period of debt redemption features under terms of the debt agreement.",
        "label": "Debt Instrument, Redemption, Period One [Member]",
        "terseLabel": "Leverage Ratio with Respect to September 30, 2022 through March 31, 2023"
       }
      }
     },
     "localname": "DebtInstrumentRedemptionPeriodOneMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://haymaker.com/role/LongTermDebtAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtInstrumentRedemptionPeriodThreeMember": {
     "auth_ref": [
      "r189"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period three representing third most current period of debt redemption features under terms of the debt agreement.",
        "label": "Debt Instrument, Redemption, Period Three [Member]",
        "terseLabel": "Leverage Ratio, Thereafter"
       }
      }
     },
     "localname": "DebtInstrumentRedemptionPeriodThreeMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://haymaker.com/role/LongTermDebtAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtInstrumentRedemptionPeriodTwoMember": {
     "auth_ref": [
      "r189"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period two representing second most current period of debt redemption features under terms of the debt agreement.",
        "label": "Debt Instrument, Redemption, Period Two [Member]",
        "terseLabel": "Leverage Ratio with Respect to June 30, 2023 through March 31, 2024"
       }
      }
     },
     "localname": "DebtInstrumentRedemptionPeriodTwoMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://haymaker.com/role/LongTermDebtAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtInstrumentTable": {
     "auth_ref": [
      "r23",
      "r104",
      "r107",
      "r108",
      "r109",
      "r165",
      "r166",
      "r168",
      "r190",
      "r260",
      "r386",
      "r387",
      "r388",
      "r389",
      "r390",
      "r392",
      "r398",
      "r399",
      "r400",
      "r401",
      "r403",
      "r404",
      "r405",
      "r406",
      "r407",
      "r408",
      "r411",
      "r592",
      "r732",
      "r733",
      "r734",
      "r735",
      "r736",
      "r780"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.",
        "label": "Schedule of Long-Term Debt Instruments [Table]"
       }
      }
     },
     "localname": "DebtInstrumentTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://haymaker.com/role/LongTermDebtAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtRelatedCommitmentFeesAndDebtIssuanceCosts": {
     "auth_ref": [
      "r40"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the charge against earnings during the period for commitment fees and debt issuance expenses.",
        "label": "Debt Related Commitment Fees and Debt Issuance Costs",
        "terseLabel": "Company incurred lender's fees and related attorney's fees"
       }
      }
     },
     "localname": "DebtRelatedCommitmentFeesAndDebtIssuanceCosts",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://haymaker.com/role/LongTermDebtAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredFederalIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r782",
      "r906",
      "r907"
     ],
     "calculation": {
      "http://haymaker.com/role/IncomeTaxesScheduleOfIncomeTaxProvisionDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_DeferredIncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred national tax expense (benefit) for non-US (United States of America) jurisdiction.",
        "label": "Deferred Federal Income Tax Expense (Benefit)",
        "terseLabel": "Federal"
       }
      }
     },
     "localname": "DeferredFederalIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://haymaker.com/role/IncomeTaxesScheduleOfIncomeTaxProvisionDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredFinanceCostsNet": {
     "auth_ref": [
      "r167",
      "r812"
     ],
     "calculation": {
      "http://haymaker.com/role/LongTermDebtScheduleOfOutstandingDebtDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LongTermDebtNoncurrent",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.",
        "label": "Debt Issuance Costs, Net",
        "negatedLabel": "Less: unamortized deferred financing costs"
       }
      }
     },
     "localname": "DeferredFinanceCostsNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://haymaker.com/role/LongTermDebtScheduleOfOutstandingDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxAssetsNet": {
     "auth_ref": [
      "r506",
      "r507"
     ],
     "calculation": {
      "http://haymaker.com/role/ConsolidatedBalanceSheets": {
       "order": 9.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, with jurisdictional netting.",
        "label": "Deferred Income Tax Assets, Net",
        "terseLabel": "Deferred tax asset"
       }
      }
     },
     "localname": "DeferredIncomeTaxAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://haymaker.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r52",
      "r136",
      "r519",
      "r528",
      "r529",
      "r782"
     ],
     "calculation": {
      "http://haymaker.com/role/IncomeTaxesScheduleOfIncomeTaxProvisionDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Deferred Income Tax Expense (Benefit)",
        "totalLabel": "Total deferred expense (benefit):"
       }
      }
     },
     "localname": "DeferredIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://haymaker.com/role/IncomeTaxesScheduleOfIncomeTaxProvisionDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Income Tax Expense (Benefit), Continuing Operations [Abstract]",
        "terseLabel": "Deferred income tax provision (benefit):"
       }
      }
     },
     "localname": "DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://haymaker.com/role/IncomeTaxesScheduleOfIncomeTaxProvisionDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DeferredIncomeTaxesAndTaxCredits": {
     "auth_ref": [
      "r53"
     ],
     "calculation": {
      "http://haymaker.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 27.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred income tax expense (benefit) and income tax credits.",
        "label": "Deferred Income Taxes and Tax Credits",
        "terseLabel": "Deferred income taxes"
       }
      }
     },
     "localname": "DeferredIncomeTaxesAndTaxCredits",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://haymaker.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredOfferingCosts": {
     "auth_ref": [
      "r798"
     ],
     "calculation": {
      "http://haymaker.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfTotalOtherCurrentAssetsDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Specific incremental costs directly attributable to a proposed or actual offering of securities which are deferred at the end of the reporting period.",
        "label": "Deferred Offering Costs",
        "terseLabel": "Capitalized transaction costs"
       }
      }
     },
     "localname": "DeferredOfferingCosts",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://haymaker.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfTotalOtherCurrentAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredRevenueRevenueRecognized1": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of revenue recognized that was previously reported as deferred or unearned revenue.",
        "label": "Revenue recognized"
       }
      }
     },
     "localname": "DeferredRevenueRevenueRecognized1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://haymaker.com/role/RelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r782",
      "r906",
      "r907"
     ],
     "calculation": {
      "http://haymaker.com/role/IncomeTaxesScheduleOfIncomeTaxProvisionDetails": {
       "order": 7.0,
       "parentTag": "us-gaap_DeferredIncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction.",
        "label": "Deferred State and Local Income Tax Expense (Benefit)",
        "terseLabel": "State and Local"
       }
      }
     },
     "localname": "DeferredStateAndLocalIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://haymaker.com/role/IncomeTaxesScheduleOfIncomeTaxProvisionDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets": {
     "auth_ref": [],
     "calculation": {
      "http://haymaker.com/role/IncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from intangible assets including goodwill.",
        "label": "Deferred Tax Assets, Goodwill and Intangible Assets",
        "terseLabel": "Intangibles"
       }
      }
     },
     "localname": "DeferredTaxAssetsGoodwillAndIntangibleAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://haymaker.com/role/IncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsGross": {
     "auth_ref": [
      "r514"
     ],
     "calculation": {
      "http://haymaker.com/role/IncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.",
        "label": "Deferred Tax Assets, Gross",
        "totalLabel": "Total deferred tax assets"
       }
      }
     },
     "localname": "DeferredTaxAssetsGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://haymaker.com/role/IncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsInvestments": {
     "auth_ref": [],
     "calculation": {
      "http://haymaker.com/role/IncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from investments (excludes investments in subsidiaries and equity method investments).",
        "label": "Deferred Tax Assets, Investments",
        "terseLabel": "Outside basis difference in partnership"
       }
      }
     },
     "localname": "DeferredTaxAssetsInvestments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://haymaker.com/role/IncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsNet": {
     "auth_ref": [
      "r903"
     ],
     "calculation": {
      "http://haymaker.com/role/IncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.",
        "label": "Deferred Tax Assets, Net of Valuation Allowance",
        "totalLabel": "Deferred tax assets, net of allowance"
       }
      }
     },
     "localname": "DeferredTaxAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://haymaker.com/role/IncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsNetAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Net [Abstract]",
        "terseLabel": "Deferred tax assets:"
       }
      }
     },
     "localname": "DeferredTaxAssetsNetAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://haymaker.com/role/IncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": {
     "auth_ref": [
      "r134",
      "r904"
     ],
     "calculation": {
      "http://haymaker.com/role/IncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.",
        "label": "Deferred Tax Assets, Operating Loss Carryforwards",
        "terseLabel": "Net operating loss carryforwards"
       }
      }
     },
     "localname": "DeferredTaxAssetsOperatingLossCarryforwards",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://haymaker.com/role/IncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsValuationAllowance": {
     "auth_ref": [
      "r515"
     ],
     "calculation": {
      "http://haymaker.com/role/IncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.",
        "label": "Deferred Tax Assets, Valuation Allowance",
        "negatedLabel": "Valuation allowance"
       }
      }
     },
     "localname": "DeferredTaxAssetsValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://haymaker.com/role/IncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of discretionary contributions made by an employer to a defined contribution plan.",
        "label": "Defined Contribution Plan, Employer Discretionary Contribution Amount",
        "terseLabel": "Employer Safe Harbor contribution amount"
       }
      }
     },
     "localname": "DefinedContributionPlanEmployerDiscretionaryContributionAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://haymaker.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage employer matches of the employee's percentage contribution matched.",
        "label": "Defined Contribution Plan, Employer Matching Contribution, Percent of Match",
        "terseLabel": "Employer Safe Harbor non-elective contribution percentage"
       }
      }
     },
     "localname": "DefinedContributionPlanEmployerMatchingContributionPercentOfMatch",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://haymaker.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_Depreciation": {
     "auth_ref": [
      "r52",
      "r80"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.",
        "label": "Depreciation",
        "terseLabel": "Depreciation expense"
       }
      }
     },
     "localname": "Depreciation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://haymaker.com/role/PropertyAndEquipmentNetAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DepreciationDepletionAndAmortization": {
     "auth_ref": [
      "r52",
      "r311"
     ],
     "calculation": {
      "http://haymaker.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 16.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.",
        "label": "Depreciation, Depletion and Amortization",
        "terseLabel": "Depreciation and amortization"
       }
      }
     },
     "localname": "DepreciationDepletionAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://haymaker.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeLiabilitiesNoncurrent": {
     "auth_ref": [
      "r234"
     ],
     "calculation": {
      "http://haymaker.com/role/ConsolidatedBalanceSheets": {
       "order": 21.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled after one year or the normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset.",
        "label": "Derivative Liability, Noncurrent",
        "terseLabel": "Earnout liability"
       }
      }
     },
     "localname": "DerivativeLiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://haymaker.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisaggregationOfRevenueLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Disaggregation of Revenue [Line Items]"
       }
      }
     },
     "localname": "DisaggregationOfRevenueLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://haymaker.com/role/RevenueRecognitionScheduleOfRevenuesRecognizedByGeographicRegionDetails",
      "http://haymaker.com/role/RevenueRecognitionScheduleOfRevenuesRecognizedForEachRevenueStreamDetails",
      "http://haymaker.com/role/RevenueRecognitionSummaryOfConsiderationAllocatedToPerformanceObligationsDetails",
      "http://haymaker.com/role/RevenueRecognitionSummaryOfSignificantChangesInContractLiabilityBalancesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisaggregationOfRevenueTable": {
     "auth_ref": [
      "r438",
      "r738",
      "r739",
      "r740",
      "r741",
      "r742",
      "r743",
      "r744"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.",
        "label": "Disaggregation of Revenue [Table]"
       }
      }
     },
     "localname": "DisaggregationOfRevenueTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://haymaker.com/role/RevenueRecognitionScheduleOfRevenuesRecognizedByGeographicRegionDetails",
      "http://haymaker.com/role/RevenueRecognitionScheduleOfRevenuesRecognizedForEachRevenueStreamDetails",
      "http://haymaker.com/role/RevenueRecognitionSummaryOfConsiderationAllocatedToPerformanceObligationsDetails",
      "http://haymaker.com/role/RevenueRecognitionSummaryOfSignificantChangesInContractLiabilityBalancesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisaggregationOfRevenueTableTextBlock": {
     "auth_ref": [
      "r814"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.",
        "label": "Disaggregation of Revenue [Table Text Block]",
        "terseLabel": "Schedule of Revenues Recognized"
       }
      }
     },
     "localname": "DisaggregationOfRevenueTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://haymaker.com/role/RevenueRecognitionTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "auth_ref": [
      "r463",
      "r494",
      "r495",
      "r497",
      "r502",
      "r751"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement [Text Block]",
        "terseLabel": "Share-Based Compensation"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://haymaker.com/role/ShareBasedCompensation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement [Abstract]"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DividendsCommonStock": {
     "auth_ref": [
      "r110",
      "r186"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of paid and unpaid common stock dividends declared with the form of settlement in cash, stock and payment-in-kind (PIK).",
        "label": "Dividends, Common Stock",
        "negatedLabel": "Distributions"
       }
      }
     },
     "localname": "DividendsCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://haymaker.com/role/ConsolidatedStatementsOfStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DueFromCustomerAcceptances": {
     "auth_ref": [
      "r183"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amounts receivable from customers on short-term negotiable time drafts drawn on and accepted by the institution (also known as banker's acceptance transactions) that are outstanding on the reporting date.",
        "label": "Due from customer"
       }
      }
     },
     "localname": "DueFromCustomerAcceptances",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://haymaker.com/role/RelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DueToEmployeesCurrentAndNoncurrent": {
     "auth_ref": [
      "r169",
      "r181",
      "r200"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amounts due to employees, not to include stockholders or officers.",
        "label": "Due to employees"
       }
      }
     },
     "localname": "DueToEmployeesCurrentAndNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://haymaker.com/role/RelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DueToRelatedPartiesCurrentAndNoncurrent": {
     "auth_ref": [
      "r180",
      "r200",
      "r377",
      "r378",
      "r379",
      "r383",
      "r384",
      "r385",
      "r620",
      "r783"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount as of the balance sheet date of obligations due all related parties.",
        "label": "Due to Related Parties",
        "terseLabel": "Amount due"
       }
      }
     },
     "localname": "DueToRelatedPartiesCurrentAndNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://haymaker.com/role/RelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EarningsPerShareAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share [Abstract]",
        "terseLabel": "Net income (loss) per common share"
       }
      }
     },
     "localname": "EarningsPerShareAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://haymaker.com/role/ConsolidatedStatementsOfIncomeAndComprehensiveIncome"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasic": {
     "auth_ref": [
      "r246",
      "r269",
      "r270",
      "r272",
      "r273",
      "r274",
      "r281",
      "r284",
      "r292",
      "r293",
      "r294",
      "r298",
      "r561",
      "r562",
      "r677",
      "r683",
      "r728"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.",
        "label": "Earnings Per Share, Basic",
        "terseLabel": "Basic"
       }
      }
     },
     "localname": "EarningsPerShareBasic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://haymaker.com/role/ConsolidatedStatementsOfIncomeAndComprehensiveIncome",
      "http://haymaker.com/role/NetLossPerCommonShareScheduleOfComputationOfNetLossPerCommonShareDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareBasicLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Earnings Per Share, Basic, by Common Class, Including Two Class Method [Line Items]"
       }
      }
     },
     "localname": "EarningsPerShareBasicLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://haymaker.com/role/NetLossPerCommonShareScheduleOfComputationOfNetLossPerCommonShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareDiluted": {
     "auth_ref": [
      "r246",
      "r269",
      "r270",
      "r272",
      "r273",
      "r274",
      "r284",
      "r292",
      "r293",
      "r294",
      "r298",
      "r561",
      "r562",
      "r677",
      "r683",
      "r728"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Earnings Per Share, Diluted",
        "terseLabel": "Diluted"
       }
      }
     },
     "localname": "EarningsPerShareDiluted",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://haymaker.com/role/ConsolidatedStatementsOfIncomeAndComprehensiveIncome",
      "http://haymaker.com/role/NetLossPerCommonShareScheduleOfComputationOfNetLossPerCommonShareDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "auth_ref": [
      "r295",
      "r296",
      "r297",
      "r299"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for earnings per share.",
        "label": "Earnings Per Share [Text Block]",
        "terseLabel": "Net Loss Per Common Share"
       }
      }
     },
     "localname": "EarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://haymaker.com/role/NetLossPerCommonShare"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations": {
     "auth_ref": [
      "r915"
     ],
     "calculation": {
      "http://haymaker.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 13.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations",
        "terseLabel": "Effect of exchange rate changes on cash and cash equivalents"
       }
      }
     },
     "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://haymaker.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperations": {
     "auth_ref": [
      "r509"
     ],
     "calculation": {
      "http://haymaker.com/role/IncomeTaxesScheduleOfReconciliationOfTheFederalIncomeTaxRateToTheCompanyEffectiveTaxRateDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Effective Income Tax Rate Reconciliation, Percent",
        "totalLabel": "Income tax provision"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateContinuingOperations",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://haymaker.com/role/IncomeTaxesScheduleOfReconciliationOfTheFederalIncomeTaxRateToTheCompanyEffectiveTaxRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": {
     "auth_ref": [
      "r258",
      "r509",
      "r531"
     ],
     "calculation": {
      "http://haymaker.com/role/IncomeTaxesScheduleOfReconciliationOfTheFederalIncomeTaxRateToTheCompanyEffectiveTaxRateDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss).",
        "label": "Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent",
        "verboseLabel": "Statutory federal income tax rate"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://haymaker.com/role/IncomeTaxesScheduleOfReconciliationOfTheFederalIncomeTaxRateToTheCompanyEffectiveTaxRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance": {
     "auth_ref": [
      "r902",
      "r908"
     ],
     "calculation": {
      "http://haymaker.com/role/IncomeTaxesScheduleOfReconciliationOfTheFederalIncomeTaxRateToTheCompanyEffectiveTaxRateDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.",
        "label": "Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent",
        "terseLabel": "Change in valuation allowance"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://haymaker.com/role/IncomeTaxesScheduleOfReconciliationOfTheFederalIncomeTaxRateToTheCompanyEffectiveTaxRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential": {
     "auth_ref": [
      "r902",
      "r908"
     ],
     "calculation": {
      "http://haymaker.com/role/IncomeTaxesScheduleOfReconciliationOfTheFederalIncomeTaxRateToTheCompanyEffectiveTaxRateDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to statutory income tax expense (benefit) outside of the country of domicile.",
        "label": "Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Percent",
        "negatedLabel": "Foreign rate differential"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://haymaker.com/role/IncomeTaxesScheduleOfReconciliationOfTheFederalIncomeTaxRateToTheCompanyEffectiveTaxRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes": {
     "auth_ref": [
      "r902",
      "r908"
     ],
     "calculation": {
      "http://haymaker.com/role/IncomeTaxesScheduleOfReconciliationOfTheFederalIncomeTaxRateToTheCompanyEffectiveTaxRateDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).",
        "label": "Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent",
        "terseLabel": "State taxes, net of federal tax benefit"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://haymaker.com/role/IncomeTaxesScheduleOfReconciliationOfTheFederalIncomeTaxRateToTheCompanyEffectiveTaxRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationTaxExemptIncome": {
     "auth_ref": [
      "r902",
      "r908"
     ],
     "calculation": {
      "http://haymaker.com/role/IncomeTaxesScheduleOfReconciliationOfTheFederalIncomeTaxRateToTheCompanyEffectiveTaxRateDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to income (loss) exempt from income taxes.",
        "label": "Effective Income Tax Rate Reconciliation, Tax Exempt Income, Percent",
        "negatedLabel": "Nontaxable partnership income"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationTaxExemptIncome",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://haymaker.com/role/IncomeTaxesScheduleOfReconciliationOfTheFederalIncomeTaxRateToTheCompanyEffectiveTaxRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EmployeeRelatedLiabilitiesCurrent": {
     "auth_ref": [
      "r20"
     ],
     "calculation": {
      "http://haymaker.com/role/AccruedExpensesScheduleOfAccruedExpensesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Employee-related Liabilities, Current",
        "terseLabel": "Accrued employee related costs"
       }
      }
     },
     "localname": "EmployeeRelatedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://haymaker.com/role/AccruedExpensesScheduleOfAccruedExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": {
     "auth_ref": [
      "r496"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount",
        "terseLabel": "Unrecognized compensation expense"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://haymaker.com/role/ShareBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "auth_ref": [
      "r496"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition",
        "terseLabel": "Unrecognized compensation expense, expected to be recognized, weighted-average remaining vesting period"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://haymaker.com/role/ShareBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_EmployeeStockOptionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.",
        "label": "Share-Based Payment Arrangement, Option [Member]",
        "terseLabel": "Stock Options"
       }
      }
     },
     "localname": "EmployeeStockOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://haymaker.com/role/NetLossPerCommonShareScheduleOfComputationOfDilutedWeightedAverageSharesOutstandingDetails",
      "http://haymaker.com/role/ShareBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity [Abstract]"
       }
      }
     },
     "localname": "EquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r103",
      "r214",
      "r241",
      "r242",
      "r243",
      "r261",
      "r262",
      "r263",
      "r266",
      "r275",
      "r278",
      "r301",
      "r347",
      "r425",
      "r498",
      "r499",
      "r500",
      "r523",
      "r524",
      "r560",
      "r583",
      "r584",
      "r585",
      "r586",
      "r587",
      "r588",
      "r616",
      "r689",
      "r690",
      "r691"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://haymaker.com/role/ConsolidatedStatementsOfStockholdersEquityDeficit",
      "http://haymaker.com/role/Cover"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueAdjustmentOfWarrants": {
     "auth_ref": [
      "r52",
      "r97"
     ],
     "calculation": {
      "http://haymaker.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 24.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://haymaker.com/role/ConsolidatedStatementsOfIncomeAndComprehensiveIncome": {
       "order": 27.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense (income) related to adjustment to fair value of warrant liability.",
        "label": "Fair Value Adjustment of Warrants",
        "negatedLabel": "Gain from change in fair value of warrant liability",
        "terseLabel": "Gain from change in fair value of warrant liability"
       }
      }
     },
     "localname": "FairValueAdjustmentOfWarrants",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://haymaker.com/role/ConsolidatedStatementsOfCashFlows",
      "http://haymaker.com/role/ConsolidatedStatementsOfIncomeAndComprehensiveIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Schedule Of Changes In The Fair Value Of Warrant Liabilities [Line Items]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://haymaker.com/role/FairValueMeasurementsScheduleOfFairValueHierarchyForFinancialAssetsAndLiabilitiesDetails",
      "http://haymaker.com/role/FairValueMeasurementsSummaryOfChangesInTheFairValueOfCompanysLevel3FinancialInstrumentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": {
     "auth_ref": [
      "r564",
      "r565",
      "r569"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis.",
        "label": "Fair Value, Recurring and Nonrecurring [Table]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://haymaker.com/role/FairValueMeasurementsScheduleOfFairValueHierarchyForFinancialAssetsAndLiabilitiesDetails",
      "http://haymaker.com/role/FairValueMeasurementsSummaryOfChangesInTheFairValueOfCompanysLevel3FinancialInstrumentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value Measurement Inputs and Valuation Techniques [Line Items]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://haymaker.com/role/FairValueMeasurementsSummaryOfSignificantInputsToMonteCarloSimulationForFairValueOfEarnoutLiabilityDetails",
      "http://haymaker.com/role/FairValueMeasurementsSummaryOfSignificantInputsToMonteCarloSimulationForFairValueOfPrivatePlacementWarrantsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable": {
     "auth_ref": [
      "r160"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis.",
        "label": "Fair Value Measurement Inputs and Valuation Techniques [Table]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://haymaker.com/role/FairValueMeasurementsSummaryOfSignificantInputsToMonteCarloSimulationForFairValueOfEarnoutLiabilityDetails",
      "http://haymaker.com/role/FairValueMeasurementsSummaryOfSignificantInputsToMonteCarloSimulationForFairValueOfPrivatePlacementWarrantsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock": {
     "auth_ref": [
      "r160"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis.",
        "label": "Fair Value Measurement Inputs and Valuation Techniques [Table Text Block]",
        "terseLabel": "Summary of Significant Inputs to Monte Carlo Simulation for Fair Value of Private Placement Warrants and Earnout Liability"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://haymaker.com/role/FairValueMeasurementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "auth_ref": [
      "r400",
      "r444",
      "r445",
      "r446",
      "r447",
      "r448",
      "r449",
      "r565",
      "r629",
      "r630",
      "r631",
      "r733",
      "r734",
      "r745",
      "r746",
      "r747"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.",
        "label": "Fair Value Hierarchy and NAV [Axis]"
       }
      }
     },
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://haymaker.com/role/FairValueMeasurementsScheduleOfFairValueHierarchyForFinancialAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Disclosures [Abstract]"
       }
      }
     },
     "localname": "FairValueDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "auth_ref": [
      "r568"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.",
        "label": "Fair Value Disclosures [Text Block]",
        "terseLabel": "Fair value measurements"
       }
      }
     },
     "localname": "FairValueDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://haymaker.com/role/FairValueMeasurements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "auth_ref": [
      "r400",
      "r444",
      "r449",
      "r565",
      "r629",
      "r745",
      "r746",
      "r747"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.",
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "terseLabel": "Level 1"
       }
      }
     },
     "localname": "FairValueInputsLevel1Member",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://haymaker.com/role/FairValueMeasurementsScheduleOfFairValueHierarchyForFinancialAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "auth_ref": [
      "r400",
      "r444",
      "r445",
      "r446",
      "r447",
      "r448",
      "r449",
      "r565",
      "r631",
      "r733",
      "r734",
      "r745",
      "r746",
      "r747"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Inputs, Level 3 [Member]",
        "terseLabel": "Level 3"
       }
      }
     },
     "localname": "FairValueInputsLevel3Member",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://haymaker.com/role/FairValueMeasurementsScheduleOfFairValueHierarchyForFinancialAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock": {
     "auth_ref": [
      "r158",
      "r159"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3). Where the quoted price in an active market for the identical liability is not available, the Level 1 input is the quoted price of an identical liability when traded as an asset.",
        "label": "Fair Value, Liabilities Measured on Recurring Basis [Table Text Block]",
        "terseLabel": "Schedule of Fair Value Hierarchy for Financial Assets and Liabilities"
       }
      }
     },
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://haymaker.com/role/FairValueMeasurementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueMeasurementPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.",
        "label": "Fair Value Measurement, Policy [Policy Text Block]",
        "terseLabel": "Fair Value Measurements"
       }
      }
     },
     "localname": "FairValueMeasurementPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://haymaker.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "auth_ref": [
      "r400",
      "r444",
      "r445",
      "r446",
      "r447",
      "r448",
      "r449",
      "r629",
      "r630",
      "r631",
      "r733",
      "r734",
      "r745",
      "r746",
      "r747"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.",
        "label": "Fair Value Hierarchy and NAV [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://haymaker.com/role/FairValueMeasurementsScheduleOfFairValueHierarchyForFinancialAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueOptionChangesInFairValueGainLoss1": {
     "auth_ref": [
      "r163"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For each line item in the statement of financial position, the amounts of gains and losses from fair value changes included in earnings.",
        "label": "Fair Value, Option, Changes in Fair Value, Gain (Loss)",
        "negatedLabel": "Gain from change in fair value"
       }
      }
     },
     "localname": "FairValueOptionChangesInFairValueGainLoss1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://haymaker.com/role/FairValueMeasurementsSummaryOfChangesInTheFairValueOfCompanysLevel3FinancialInstrumentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinancialInstrumentAxis": {
     "auth_ref": [
      "r338",
      "r339",
      "r352",
      "r354",
      "r355",
      "r356",
      "r357",
      "r358",
      "r359",
      "r360",
      "r411",
      "r422",
      "r551",
      "r626",
      "r627",
      "r628",
      "r629",
      "r630",
      "r631",
      "r632",
      "r633",
      "r634",
      "r635",
      "r636",
      "r637",
      "r638",
      "r639",
      "r640",
      "r641",
      "r642",
      "r643",
      "r644",
      "r645",
      "r646",
      "r647",
      "r648",
      "r649",
      "r650",
      "r651",
      "r652",
      "r653",
      "r654",
      "r655",
      "r731",
      "r793",
      "r794",
      "r795",
      "r930",
      "r931",
      "r932",
      "r933",
      "r934",
      "r935",
      "r936"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of financial instrument.",
        "label": "Financial Instrument [Axis]"
       }
      }
     },
     "localname": "FinancialInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://haymaker.com/role/FairValueMeasurementsScheduleOfFairValueHierarchyForFinancialAssetsAndLiabilitiesDetails",
      "http://haymaker.com/role/FairValueMeasurementsSummaryOfChangesInTheFairValueOfCompanysLevel3FinancialInstrumentsDetails",
      "http://haymaker.com/role/FairValueMeasurementsSummaryOfSignificantInputsToMonteCarloSimulationForFairValueOfEarnoutLiabilityDetails",
      "http://haymaker.com/role/FairValueMeasurementsSummaryOfSignificantInputsToMonteCarloSimulationForFairValueOfPrivatePlacementWarrantsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FinancialLiabilitiesFairValueDisclosure": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of financial obligations, including, but not limited to, debt instruments, derivative liabilities, federal funds purchased and sold under agreements to repurchase, securities loaned or sold under agreements to repurchase, financial instruments sold not yet purchased, guarantees, line of credit, loans and notes payable, servicing liability, and trading liabilities.",
        "label": "Financial Liabilities Fair Value Disclosure",
        "periodEndLabel": "Fair value as of December 31, 2022",
        "periodStartLabel": "Fair value as of May 26, 2022 (initial measurement)",
        "terseLabel": "Liability"
       }
      }
     },
     "localname": "FinancialLiabilitiesFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://haymaker.com/role/FairValueMeasurementsScheduleOfFairValueHierarchyForFinancialAssetsAndLiabilitiesDetails",
      "http://haymaker.com/role/FairValueMeasurementsSummaryOfChangesInTheFairValueOfCompanysLevel3FinancialInstrumentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ForeignCountryMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designated tax departments of governments entitled to levy and collect income taxes from the entity outside the entity's country of domicile.",
        "label": "Foreign Tax Authority [Member]",
        "terseLabel": "Foreign"
       }
      }
     },
     "localname": "ForeignCountryMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://haymaker.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FurnitureAndFixturesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases.",
        "label": "Furniture and Fixtures [Member]",
        "terseLabel": "Furniture and Fixtures"
       }
      }
     },
     "localname": "FurnitureAndFixturesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://haymaker.com/role/PropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetails",
      "http://haymaker.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfEstimatedUsefulLivesOfPropertyAndEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_GainsLossesOnExtinguishmentOfDebt": {
     "auth_ref": [
      "r52",
      "r94",
      "r95"
     ],
     "calculation": {
      "http://haymaker.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 26.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      },
      "http://haymaker.com/role/ConsolidatedStatementsOfIncomeAndComprehensiveIncome": {
       "order": 29.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.",
        "label": "Gain (Loss) on Extinguishment of Debt",
        "negatedLabel": "Loss from extinguishment of debt",
        "terseLabel": "Loss from extinguishment of debt"
       }
      }
     },
     "localname": "GainsLossesOnExtinguishmentOfDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://haymaker.com/role/ConsolidatedStatementsOfCashFlows",
      "http://haymaker.com/role/ConsolidatedStatementsOfIncomeAndComprehensiveIncome",
      "http://haymaker.com/role/LongTermDebtAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ImpairmentOfLongLivedAssetsHeldForUse": {
     "auth_ref": [
      "r52",
      "r79",
      "r84"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate amount of write-downs for impairments recognized during the period for long lived assets held for use (including those held for disposal by means other than sale).",
        "label": "Impairment, Long-Lived Asset, Held-for-Use",
        "terseLabel": "Impairment charge of long-lived assets"
       }
      }
     },
     "localname": "ImpairmentOfLongLivedAssetsHeldForUse",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://haymaker.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock": {
     "auth_ref": [
      "r77",
      "r85"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.",
        "label": "Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]",
        "terseLabel": "Impairment of Long-Lived Assets"
       }
      }
     },
     "localname": "ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://haymaker.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic": {
     "auth_ref": [
      "r257",
      "r530"
     ],
     "calculation": {
      "http://haymaker.com/role/IncomeTaxesScheduleOfIncomeLossBeforeProvisionForIncomeTaxesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of earnings or loss from continuing operations before income taxes that is attributable to domestic operations.",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Domestic",
        "terseLabel": "Domestic"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://haymaker.com/role/IncomeTaxesScheduleOfIncomeLossBeforeProvisionForIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
     "auth_ref": [
      "r34",
      "r172",
      "r184",
      "r202",
      "r313",
      "r321",
      "r325",
      "r327",
      "r678",
      "r730"
     ],
     "calculation": {
      "http://haymaker.com/role/ConsolidatedStatementsOfIncomeAndComprehensiveIncome": {
       "order": 18.0,
       "parentTag": "us-gaap_ProfitLoss",
       "weight": 1.0
      },
      "http://haymaker.com/role/IncomeTaxesScheduleOfIncomeLossBeforeProvisionForIncomeTaxesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest",
        "totalLabel": "Income before provision for income taxes"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://haymaker.com/role/ConsolidatedStatementsOfIncomeAndComprehensiveIncome",
      "http://haymaker.com/role/IncomeTaxesScheduleOfIncomeLossBeforeProvisionForIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign": {
     "auth_ref": [
      "r257",
      "r530"
     ],
     "calculation": {
      "http://haymaker.com/role/IncomeTaxesScheduleOfIncomeLossBeforeProvisionForIncomeTaxesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of earnings or loss from continuing operations before income taxes that is attributable to foreign operations, which is defined as Income or Loss generated from operations located outside the entity's country of domicile.",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Foreign",
        "terseLabel": "Foreign"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://haymaker.com/role/IncomeTaxesScheduleOfIncomeLossBeforeProvisionForIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxAuthorityAxis": {
     "auth_ref": [
      "r130"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by tax jurisdiction.",
        "label": "Income Tax Authority [Axis]"
       }
      }
     },
     "localname": "IncomeTaxAuthorityAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://haymaker.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxAuthorityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Agency, division or body classification that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes.",
        "label": "Income Tax Authority [Domain]"
       }
      }
     },
     "localname": "IncomeTaxAuthorityDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://haymaker.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "localname": "IncomeTaxDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "auth_ref": [
      "r258",
      "r510",
      "r512",
      "r517",
      "r526",
      "r532",
      "r534",
      "r535",
      "r536"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.",
        "label": "Income Tax Disclosure [Text Block]",
        "terseLabel": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://haymaker.com/role/IncomeTaxes"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxExaminationDescription": {
     "auth_ref": [
      "r129"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A brief description of status of the tax examination, significant findings to date, and the entity's position with respect to the findings.",
        "label": "Income Tax Examination, Description",
        "terseLabel": "Income tax examination description"
       }
      }
     },
     "localname": "IncomeTaxExaminationDescription",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://haymaker.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r259",
      "r277",
      "r278",
      "r312",
      "r508",
      "r527",
      "r533",
      "r684"
     ],
     "calculation": {
      "http://haymaker.com/role/ConsolidatedStatementsOfIncomeAndComprehensiveIncome": {
       "order": 31.0,
       "parentTag": "us-gaap_ProfitLoss",
       "weight": -1.0
      },
      "http://haymaker.com/role/IncomeTaxesScheduleOfIncomeTaxProvisionDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Income tax expense (benefit)",
        "terseLabel": "Income tax expense",
        "totalLabel": "Total income tax provision (benefit)"
       }
      }
     },
     "localname": "IncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://haymaker.com/role/ConsolidatedStatementsOfIncomeAndComprehensiveIncome",
      "http://haymaker.com/role/IncomeTaxesScheduleOfIncomeTaxProvisionDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "auth_ref": [
      "r240",
      "r504",
      "r505",
      "r512",
      "r513",
      "r516",
      "r520"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.",
        "label": "Income Tax, Policy [Policy Text Block]",
        "terseLabel": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://haymaker.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxesPaid": {
     "auth_ref": [
      "r49",
      "r56"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income.",
        "label": "Income Taxes Paid",
        "terseLabel": "Cash paid for income taxes"
       }
      }
     },
     "localname": "IncomeTaxesPaid",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://haymaker.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayable": {
     "auth_ref": [
      "r51"
     ],
     "calculation": {
      "http://haymaker.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 31.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.",
        "label": "Increase (Decrease) in Accounts Payable",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://haymaker.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivable": {
     "auth_ref": [
      "r51"
     ],
     "calculation": {
      "http://haymaker.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 28.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.",
        "label": "Increase (Decrease) in Accounts Receivable",
        "negatedLabel": "Accounts receivable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsReceivable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://haymaker.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccruedLiabilities": {
     "auth_ref": [
      "r51"
     ],
     "calculation": {
      "http://haymaker.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 33.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.",
        "label": "Increase (Decrease) in Accrued Liabilities",
        "terseLabel": "Accrued expenses"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccruedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://haymaker.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInContractWithCustomerLiability": {
     "auth_ref": [
      "r657",
      "r777"
     ],
     "calculation": {
      "http://haymaker.com/role/RevenueRecognitionSummaryOfSignificantChangesInContractLiabilityBalancesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.",
        "label": "Increase (Decrease) in Contract with Customer, Liability",
        "totalLabel": "Total increase(decrease) in contract liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInContractWithCustomerLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://haymaker.com/role/RevenueRecognitionSummaryOfSignificantChangesInContractLiabilityBalancesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInDeferredRevenue": {
     "auth_ref": [
      "r724"
     ],
     "calculation": {
      "http://haymaker.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 32.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable.",
        "label": "Increase (Decrease) in Deferred Revenue",
        "terseLabel": "Deferred revenue"
       }
      }
     },
     "localname": "IncreaseDecreaseInDeferredRevenue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://haymaker.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInInventories": {
     "auth_ref": [
      "r51"
     ],
     "calculation": {
      "http://haymaker.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 29.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.",
        "label": "Increase (Decrease) in Inventories",
        "negatedLabel": "Inventory"
       }
      }
     },
     "localname": "IncreaseDecreaseInInventories",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://haymaker.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Operating Capital [Abstract]",
        "terseLabel": "Changes in operating assets and liabilities:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://haymaker.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingLeaseLiability": {
     "auth_ref": [
      "r777",
      "r916"
     ],
     "calculation": {
      "http://haymaker.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 34.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in obligation for operating lease.",
        "label": "Increase (Decrease) in Operating Lease Liability",
        "terseLabel": "Operating lease liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://haymaker.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherCurrentAssets": {
     "auth_ref": [
      "r777"
     ],
     "calculation": {
      "http://haymaker.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 30.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in current assets classified as other.",
        "label": "Increase (Decrease) in Other Current Assets",
        "negatedLabel": "Other current assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherCurrentAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://haymaker.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestExpenseDebt": {
     "auth_ref": [
      "r40",
      "r406",
      "r416",
      "r735",
      "r736"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense for debt.",
        "label": "Interest Expense, Debt",
        "terseLabel": "Interest expense"
       }
      }
     },
     "localname": "InterestExpenseDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://haymaker.com/role/LongTermDebtAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestIncomeExpenseNonoperatingNet": {
     "auth_ref": [],
     "calculation": {
      "http://haymaker.com/role/ConsolidatedStatementsOfIncomeAndComprehensiveIncome": {
       "order": 26.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net amount of nonoperating interest income (expense).",
        "label": "Interest Income (Expense), Nonoperating, Net",
        "terseLabel": "Interest expense"
       }
      }
     },
     "localname": "InterestIncomeExpenseNonoperatingNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://haymaker.com/role/ConsolidatedStatementsOfIncomeAndComprehensiveIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestPaidNet": {
     "auth_ref": [
      "r249",
      "r252",
      "r253"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.",
        "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities",
        "terseLabel": "Cash paid for interest"
       }
      }
     },
     "localname": "InterestPaidNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://haymaker.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestPayableCurrent": {
     "auth_ref": [
      "r20"
     ],
     "calculation": {
      "http://haymaker.com/role/AccruedExpensesScheduleOfAccruedExpensesDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of [accrued] interest payable on all forms of debt, including trade payables, that has been incurred and is unpaid. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Interest Payable, Current",
        "terseLabel": "Accrued interest"
       }
      }
     },
     "localname": "InterestPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://haymaker.com/role/AccruedExpensesScheduleOfAccruedExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InternalUseSoftwarePolicy": {
     "auth_ref": [
      "r75",
      "r76"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for costs incurred when both (1) the software is acquired, internally developed, or modified solely to meet the entity's internal needs, and (2) during the software's development or modification, no substantive plan exists or is being developed to market the software externally.",
        "label": "Internal Use Software, Policy [Policy Text Block]",
        "terseLabel": "Capitalized Software, Net"
       }
      }
     },
     "localname": "InternalUseSoftwarePolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://haymaker.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InventoryAdjustments": {
     "auth_ref": [
      "r74",
      "r768"
     ],
     "calculation": {
      "http://haymaker.com/role/InventoryNetScheduleOfInventoryNetDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_InventoryNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of inventory reserves for last-in first-out (LIFO) and other inventory valuation methods.",
        "label": "Inventory Adjustments",
        "negatedLabel": "Obsolete and expired allowance"
       }
      }
     },
     "localname": "InventoryAdjustments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://haymaker.com/role/InventoryNetScheduleOfInventoryNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryCurrentTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about inventory expected to be sold or consumed within one year or operating cycle, if longer.",
        "label": "Inventory, Current [Table]"
       }
      }
     },
     "localname": "InventoryCurrentTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://haymaker.com/role/InventoryNetScheduleOfInventoryNetDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InventoryDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Inventory Disclosure [Abstract]"
       }
      }
     },
     "localname": "InventoryDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_InventoryDisclosureTextBlock": {
     "auth_ref": [
      "r364"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.",
        "label": "Inventory Disclosure [Text Block]",
        "terseLabel": "Inventory, Net"
       }
      }
     },
     "localname": "InventoryDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://haymaker.com/role/InventoryNet"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InventoryGross": {
     "auth_ref": [
      "r768"
     ],
     "calculation": {
      "http://haymaker.com/role/InventoryNetScheduleOfInventoryNetDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross amount, as of the balance sheet date, of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.",
        "label": "Inventory, Gross",
        "terseLabel": "Inventory, gross"
       }
      }
     },
     "localname": "InventoryGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://haymaker.com/role/InventoryNetScheduleOfInventoryNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Inventory [Line Items]"
       }
      }
     },
     "localname": "InventoryLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://haymaker.com/role/InventoryNetScheduleOfInventoryNetDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InventoryNet": {
     "auth_ref": [
      "r231",
      "r722",
      "r755"
     ],
     "calculation": {
      "http://haymaker.com/role/ConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      },
      "http://haymaker.com/role/InventoryNetScheduleOfInventoryNetDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.",
        "label": "Inventory, Net",
        "terseLabel": "Inventory, net",
        "totalLabel": "Net Inventory"
       }
      }
     },
     "localname": "InventoryNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://haymaker.com/role/ConsolidatedBalanceSheets",
      "http://haymaker.com/role/InventoryNetScheduleOfInventoryNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryPolicyTextBlock": {
     "auth_ref": [
      "r220",
      "r230",
      "r300",
      "r361",
      "r363",
      "r364",
      "r658",
      "r725"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost.",
        "label": "Inventory, Policy [Policy Text Block]",
        "terseLabel": "Inventory"
       }
      }
     },
     "localname": "InventoryPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://haymaker.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InventoryWriteDown": {
     "auth_ref": [
      "r362"
     ],
     "calculation": {
      "http://haymaker.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 19.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of loss from reductions in inventory due to subsequent measurement adjustments, including, but not limited to, physical deterioration, obsolescence, or changes in price levels.",
        "label": "Inventory Write-down",
        "terseLabel": "Provision for obsolete inventory"
       }
      }
     },
     "localname": "InventoryWriteDown",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://haymaker.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LeaseCost": {
     "auth_ref": [
      "r608",
      "r754"
     ],
     "calculation": {
      "http://haymaker.com/role/LeasesSummaryOfOperatingLeaseCostsRecognizedUnderAsc842AndSupplementalCashFlowInformationForLeasesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lease cost recognized by lessee for lease contract.",
        "label": "Lease, Cost",
        "totalLabel": "Total lease cost"
       }
      }
     },
     "localname": "LeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://haymaker.com/role/LeasesSummaryOfOperatingLeaseCostsRecognizedUnderAsc842AndSupplementalCashFlowInformationForLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LeaseExpirationDate1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Date which lease or group of leases is set to expire, in YYYY-MM-DD format.",
        "label": "Lease Expiration Date",
        "terseLabel": "Extend lease term date"
       }
      }
     },
     "localname": "LeaseExpirationDate1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://haymaker.com/role/LeasesAdditionalInformationDetails"
     ],
     "xbrltype": "dateItemType"
    },
    "us-gaap_LeaseholdImprovementsMember": {
     "auth_ref": [
      "r81"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additions or improvements to assets held under a lease arrangement.",
        "label": "Leasehold Improvements [Member]",
        "terseLabel": "Leasehold Improvements"
       }
      }
     },
     "localname": "LeaseholdImprovementsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://haymaker.com/role/PropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetails",
      "http://haymaker.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfEstimatedUsefulLivesOfPropertyAndEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LeasesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Leases [Abstract]"
       }
      }
     },
     "localname": "LeasesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeLeasesPolicyTextBlock": {
     "auth_ref": [
      "r601"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee.",
        "label": "Lessee, Leases [Policy Text Block]",
        "terseLabel": "Leases"
       }
      }
     },
     "localname": "LesseeLeasesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://haymaker.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "auth_ref": [
      "r917"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.",
        "label": "Lessee, Operating Lease, Liability, Maturity [Table Text Block]",
        "terseLabel": "Summary of Payments by Date for Operating Lease"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://haymaker.com/role/LeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "auth_ref": [
      "r609"
     ],
     "calculation": {
      "http://haymaker.com/role/LeasesSummaryOfPaymentsByDateForOperatingLeaseDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease.",
        "label": "Lessee, Operating Lease, Liability, to be Paid",
        "totalLabel": "Total lease payments"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://haymaker.com/role/LeasesSummaryOfPaymentsByDateForOperatingLeaseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive": {
     "auth_ref": [
      "r609"
     ],
     "calculation": {
      "http://haymaker.com/role/LeasesSummaryOfPaymentsByDateForOperatingLeaseDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, after Year Five",
        "terseLabel": "Thereafter"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://haymaker.com/role/LeasesSummaryOfPaymentsByDateForOperatingLeaseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "auth_ref": [
      "r609"
     ],
     "calculation": {
      "http://haymaker.com/role/LeasesSummaryOfPaymentsByDateForOperatingLeaseDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year One",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://haymaker.com/role/LeasesSummaryOfPaymentsByDateForOperatingLeaseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive": {
     "auth_ref": [
      "r609"
     ],
     "calculation": {
      "http://haymaker.com/role/LeasesSummaryOfPaymentsByDateForOperatingLeaseDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Five",
        "terseLabel": "2027"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFive",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://haymaker.com/role/LeasesSummaryOfPaymentsByDateForOperatingLeaseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": {
     "auth_ref": [
      "r609"
     ],
     "calculation": {
      "http://haymaker.com/role/LeasesSummaryOfPaymentsByDateForOperatingLeaseDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Four",
        "terseLabel": "2026"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://haymaker.com/role/LeasesSummaryOfPaymentsByDateForOperatingLeaseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": {
     "auth_ref": [
      "r609"
     ],
     "calculation": {
      "http://haymaker.com/role/LeasesSummaryOfPaymentsByDateForOperatingLeaseDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three",
        "terseLabel": "2025"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://haymaker.com/role/LeasesSummaryOfPaymentsByDateForOperatingLeaseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "auth_ref": [
      "r609"
     ],
     "calculation": {
      "http://haymaker.com/role/LeasesSummaryOfPaymentsByDateForOperatingLeaseDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://haymaker.com/role/LeasesSummaryOfPaymentsByDateForOperatingLeaseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "auth_ref": [
      "r609"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.",
        "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount",
        "negatedLabel": "Less: Interest"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://haymaker.com/role/LeasesSummaryOfPaymentsByDateForOperatingLeaseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseOptionToExtend": {
     "auth_ref": [
      "r602"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of terms and conditions of option to extend lessee's operating lease. Includes, but is not limited to, information about option recognized as part of right-of-use asset and lease liability.",
        "label": "Lessee, Operating Lease, Option to Extend",
        "terseLabel": "Operating lease option to Extend"
       }
      }
     },
     "localname": "LesseeOperatingLeaseOptionToExtend",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://haymaker.com/role/LeasesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeOperatingLeasesTextBlock": {
     "auth_ref": [
      "r610"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.",
        "label": "Lessee, Operating Leases [Text Block]",
        "terseLabel": "Leases"
       }
      }
     },
     "localname": "LesseeOperatingLeasesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://haymaker.com/role/Leases"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r19",
      "r256",
      "r340",
      "r375",
      "r376",
      "r378",
      "r379",
      "r380",
      "r381",
      "r382",
      "r384",
      "r385",
      "r545",
      "r548",
      "r549",
      "r570",
      "r729",
      "r807",
      "r919",
      "r920"
     ],
     "calculation": {
      "http://haymaker.com/role/ConsolidatedBalanceSheets": {
       "order": 10.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "totalLabel": "Total liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://haymaker.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r12",
      "r179",
      "r197",
      "r755",
      "r781",
      "r796",
      "r914"
     ],
     "calculation": {
      "http://haymaker.com/role/ConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "Total liabilities and stockholders' equity (deficit)"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://haymaker.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity [Abstract]",
        "terseLabel": "Liabilities and Stockholders' Equity (Deficit)"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://haymaker.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r21",
      "r219",
      "r256",
      "r340",
      "r375",
      "r376",
      "r378",
      "r379",
      "r380",
      "r381",
      "r382",
      "r384",
      "r385",
      "r545",
      "r548",
      "r549",
      "r570",
      "r755",
      "r807",
      "r919",
      "r920"
     ],
     "calculation": {
      "http://haymaker.com/role/ConsolidatedBalanceSheets": {
       "order": 11.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://haymaker.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "terseLabel": "Current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://haymaker.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesTotalMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount as of the balance sheet date of total liabilities, when it serves as a benchmark in a concentration of risk calculation. Sum of all reported liabilities as of the balance sheet date.",
        "label": "Liabilities, Total [Member]",
        "terseLabel": "Liabilities"
       }
      }
     },
     "localname": "LiabilitiesTotalMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://haymaker.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LimitedPartnersCapitalAccountDistributionAmount": {
     "auth_ref": [
      "r111"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The total amount of distributions to limited partners.",
        "label": "Limited Partners' Capital Account, Distribution Amount",
        "terseLabel": "Operating distribution to members of holdings and taxing authorities"
       }
      }
     },
     "localname": "LimitedPartnersCapitalAccountDistributionAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://haymaker.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LineOfCredit": {
     "auth_ref": [
      "r4",
      "r177",
      "r192"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The carrying value as of the balance sheet date of the current and noncurrent portions of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement.",
        "label": "Long-Term Line of Credit",
        "terseLabel": "Line of credit drawn"
       }
      }
     },
     "localname": "LineOfCredit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://haymaker.com/role/LongTermDebtAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity": {
     "auth_ref": [
      "r17"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.",
        "label": "Line of Credit Facility, Maximum Borrowing Capacity",
        "terseLabel": "Line of credit facility, maximum borrowing capacity"
       }
      }
     },
     "localname": "LineOfCreditFacilityMaximumBorrowingCapacity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://haymaker.com/role/BusinessCombinationAdditionalInformationDetails",
      "http://haymaker.com/role/LongTermDebtAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LineOfCreditMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A contractual arrangement with a lender under which borrowings can be made up to a specific amount at any point in time, and under which borrowings outstanding may be either short-term or long-term, depending upon the particulars.",
        "label": "Line of Credit [Member]",
        "terseLabel": "Line of Credit"
       }
      }
     },
     "localname": "LineOfCreditMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://haymaker.com/role/LongTermDebtAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LongTermContractWithCustomerMember": {
     "auth_ref": [
      "r742"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contract with customer in which duration is classified as long-term.",
        "label": "Long-Term Contract with Customer [Member]",
        "terseLabel": "Deferred Revenue, Long-term"
       }
      }
     },
     "localname": "LongTermContractWithCustomerMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://haymaker.com/role/RevenueRecognitionSummaryOfSignificantChangesInContractLiabilityBalancesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LongTermDebt": {
     "auth_ref": [
      "r4",
      "r177",
      "r194",
      "r399",
      "r414",
      "r733",
      "r734"
     ],
     "calculation": {
      "http://haymaker.com/role/LongTermDebtScheduleOfFutureMaturitiesOfLongTermDebtDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, excluding unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation.",
        "label": "Long-Term Debt",
        "terseLabel": "Outstanding principal amount of term loan",
        "totalLabel": "Long-term debt"
       }
      }
     },
     "localname": "LongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://haymaker.com/role/LongTermDebtAdditionalInformationDetails",
      "http://haymaker.com/role/LongTermDebtScheduleOfFutureMaturitiesOfLongTermDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtCurrent": {
     "auth_ref": [
      "r18"
     ],
     "calculation": {
      "http://haymaker.com/role/ConsolidatedBalanceSheets": {
       "order": 14.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt, classified as current. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.",
        "label": "Long-Term Debt, Current Maturities",
        "terseLabel": "Term loan, current"
       }
      }
     },
     "localname": "LongTermDebtCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://haymaker.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths": {
     "auth_ref": [
      "r93",
      "r260",
      "r404"
     ],
     "calculation": {
      "http://haymaker.com/role/LongTermDebtScheduleOfFutureMaturitiesOfLongTermDebtDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LongTermDebt",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Long-Term Debt, Maturity, Year One",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://haymaker.com/role/LongTermDebtScheduleOfFutureMaturitiesOfLongTermDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive": {
     "auth_ref": [
      "r93",
      "r260",
      "r404"
     ],
     "calculation": {
      "http://haymaker.com/role/LongTermDebtScheduleOfFutureMaturitiesOfLongTermDebtDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_LongTermDebt",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Long-Term Debt, Maturity, Year Five",
        "terseLabel": "2027"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://haymaker.com/role/LongTermDebtScheduleOfFutureMaturitiesOfLongTermDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour": {
     "auth_ref": [
      "r93",
      "r260",
      "r404"
     ],
     "calculation": {
      "http://haymaker.com/role/LongTermDebtScheduleOfFutureMaturitiesOfLongTermDebtDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_LongTermDebt",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Long-Term Debt, Maturity, Year Four",
        "terseLabel": "2026"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://haymaker.com/role/LongTermDebtScheduleOfFutureMaturitiesOfLongTermDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree": {
     "auth_ref": [
      "r93",
      "r260",
      "r404"
     ],
     "calculation": {
      "http://haymaker.com/role/LongTermDebtScheduleOfFutureMaturitiesOfLongTermDebtDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_LongTermDebt",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Long-Term Debt, Maturity, Year Three",
        "terseLabel": "2025"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://haymaker.com/role/LongTermDebtScheduleOfFutureMaturitiesOfLongTermDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo": {
     "auth_ref": [
      "r93",
      "r260",
      "r404"
     ],
     "calculation": {
      "http://haymaker.com/role/LongTermDebtScheduleOfFutureMaturitiesOfLongTermDebtDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LongTermDebt",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Long-Term Debt, Maturity, Year Two",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://haymaker.com/role/LongTermDebtScheduleOfFutureMaturitiesOfLongTermDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturityDate": {
     "auth_ref": [
      "r913"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maturity date of long-term debt, in YYYY-MM-DD format.",
        "label": "Long-Term Debt, Maturity Date",
        "terseLabel": "Term loan maturity date"
       }
      }
     },
     "localname": "LongTermDebtMaturityDate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://haymaker.com/role/LongTermDebtAdditionalInformationDetails"
     ],
     "xbrltype": "dateItemType"
    },
    "us-gaap_LongTermDebtNoncurrent": {
     "auth_ref": [
      "r224"
     ],
     "calculation": {
      "http://haymaker.com/role/ConsolidatedBalanceSheets": {
       "order": 17.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      },
      "http://haymaker.com/role/LongTermDebtScheduleOfOutstandingDebtDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, excluding unamortized premium (discount) and debt issuance cost, of long-term debt classified as noncurrent. Excludes lease obligation.",
        "label": "Long-Term Debt, Excluding Current Maturities",
        "terseLabel": "Term loan, net of current portion",
        "totalLabel": "Term loan, net of current portion"
       }
      }
     },
     "localname": "LongTermDebtNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://haymaker.com/role/ConsolidatedBalanceSheets",
      "http://haymaker.com/role/LongTermDebtScheduleOfOutstandingDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LossContingenciesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Loss Contingencies [Line Items]"
       }
      }
     },
     "localname": "LossContingenciesLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://haymaker.com/role/CommitmentsAndContingenciesAdditionalInformationDetails",
      "http://haymaker.com/role/EarnoutLiabilityAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LossContingenciesTable": {
     "auth_ref": [
      "r91",
      "r92",
      "r370",
      "r371",
      "r372",
      "r801",
      "r802"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Discloses the specific components (such as the nature, name, and date) of the loss contingency and gives an estimate of the possible loss or range of loss, or states that a reasonable estimate cannot be made. Excludes environmental contingencies, warranties and unconditional purchase obligations.",
        "label": "Loss Contingencies [Table]"
       }
      }
     },
     "localname": "LossContingenciesTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://haymaker.com/role/CommitmentsAndContingenciesAdditionalInformationDetails",
      "http://haymaker.com/role/EarnoutLiabilityAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LossContingencyDamagesSoughtValue": {
     "auth_ref": [
      "r800",
      "r801",
      "r802"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The value (monetary amount) of the award the plaintiff seeks in the legal matter.",
        "label": "Loss Contingency, Damages Sought, Value",
        "terseLabel": "Seeks monetary relief, exceeding amount"
       }
      }
     },
     "localname": "LossContingencyDamagesSoughtValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://haymaker.com/role/CommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LossContingencyLawsuitFilingDate": {
     "auth_ref": [
      "r88",
      "r89",
      "r90"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "States the date the complaint was formally filed in a court of law, in arbitration or mediation.",
        "label": "Loss contingency, lawsuit filing date"
       }
      }
     },
     "localname": "LossContingencyLawsuitFilingDate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://haymaker.com/role/CommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LossContingencyNameOfDefendant": {
     "auth_ref": [
      "r88",
      "r89",
      "r90"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identifies the named defendant in a lawsuit.",
        "label": "Loss contingency, name of defendant"
       }
      }
     },
     "localname": "LossContingencyNameOfDefendant",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://haymaker.com/role/CommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LossContingencyNameOfPlaintiff": {
     "auth_ref": [
      "r88",
      "r89",
      "r90"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identifies the plaintiff in the lawsuit.",
        "label": "Loss contingency, name of plaintiff"
       }
      }
     },
     "localname": "LossContingencyNameOfPlaintiff",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://haymaker.com/role/CommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_MarketRiskBenefitPolicyTextBlock": {
     "auth_ref": [
      "r686"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for contract or contract feature in long-duration contract issued by insurance entity that both protects contract holder from other-than-nominal capital market risk and exposes insurance entity to other-than-nominal capital market risk. Includes, but is not limited to, input, judgment, assumption and method used in measuring market risk benefit, and change in input, judgment, and assumption.",
        "label": "Market Risk Benefit [Policy Text Block]",
        "terseLabel": "Marketing"
       }
      }
     },
     "localname": "MarketRiskBenefitPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://haymaker.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_MarketingExpense": {
     "auth_ref": [
      "r38"
     ],
     "calculation": {
      "http://haymaker.com/role/ConsolidatedStatementsOfIncomeAndComprehensiveIncome": {
       "order": 23.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expenditures for planning and executing the conception, pricing, promotion, and distribution of ideas, goods, and services. Costs of public relations and corporate promotions are typically considered to be marketing costs.",
        "label": "Marketing Expense",
        "terseLabel": "Marketing"
       }
      }
     },
     "localname": "MarketingExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://haymaker.com/role/ConsolidatedStatementsOfIncomeAndComprehensiveIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MeasurementInputExercisePriceMember": {
     "auth_ref": [
      "r912"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input using agreed upon price for exchange of underlying asset.",
        "label": "Measurement Input, Exercise Price [Member]",
        "verboseLabel": "Exercise Price"
       }
      }
     },
     "localname": "MeasurementInputExercisePriceMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://haymaker.com/role/FairValueMeasurementsSummaryOfSignificantInputsToMonteCarloSimulationForFairValueOfPrivatePlacementWarrantsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MeasurementInputExpectedTermMember": {
     "auth_ref": [
      "r912"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input using period financial instrument is expected to be outstanding. Excludes maturity date.",
        "label": "Measurement Input, Expected Term [Member]",
        "terseLabel": "Term (in years)"
       }
      }
     },
     "localname": "MeasurementInputExpectedTermMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://haymaker.com/role/FairValueMeasurementsSummaryOfSignificantInputsToMonteCarloSimulationForFairValueOfEarnoutLiabilityDetails",
      "http://haymaker.com/role/FairValueMeasurementsSummaryOfSignificantInputsToMonteCarloSimulationForFairValueOfPrivatePlacementWarrantsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MeasurementInputOptionVolatilityMember": {
     "auth_ref": [
      "r912"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input using rate at which price of option increases (decreases) for given set of returns.",
        "label": "Measurement Input, Option Volatility [Member]",
        "terseLabel": "Volatility"
       }
      }
     },
     "localname": "MeasurementInputOptionVolatilityMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://haymaker.com/role/FairValueMeasurementsSummaryOfSignificantInputsToMonteCarloSimulationForFairValueOfEarnoutLiabilityDetails",
      "http://haymaker.com/role/FairValueMeasurementsSummaryOfSignificantInputsToMonteCarloSimulationForFairValueOfPrivatePlacementWarrantsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MeasurementInputRiskFreeInterestRateMember": {
     "auth_ref": [
      "r912"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input using interest rate on instrument with zero risk of financial loss.",
        "label": "Measurement Input, Risk Free Interest Rate [Member]",
        "terseLabel": "Risk-free Rate"
       }
      }
     },
     "localname": "MeasurementInputRiskFreeInterestRateMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://haymaker.com/role/FairValueMeasurementsSummaryOfSignificantInputsToMonteCarloSimulationForFairValueOfEarnoutLiabilityDetails",
      "http://haymaker.com/role/FairValueMeasurementsSummaryOfSignificantInputsToMonteCarloSimulationForFairValueOfPrivatePlacementWarrantsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MeasurementInputSharePriceMember": {
     "auth_ref": [
      "r912"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input using share price of saleable stock.",
        "label": "Measurement Input, Share Price [Member]",
        "terseLabel": "Stock Price"
       }
      }
     },
     "localname": "MeasurementInputSharePriceMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://haymaker.com/role/FairValueMeasurementsSummaryOfSignificantInputsToMonteCarloSimulationForFairValueOfEarnoutLiabilityDetails",
      "http://haymaker.com/role/FairValueMeasurementsSummaryOfSignificantInputsToMonteCarloSimulationForFairValueOfPrivatePlacementWarrantsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MeasurementInputTypeAxis": {
     "auth_ref": [
      "r566"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of measurement input used to determine value of asset and liability.",
        "label": "Measurement Input Type [Axis]"
       }
      }
     },
     "localname": "MeasurementInputTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://haymaker.com/role/FairValueMeasurementsSummaryOfSignificantInputsToMonteCarloSimulationForFairValueOfEarnoutLiabilityDetails",
      "http://haymaker.com/role/FairValueMeasurementsSummaryOfSignificantInputsToMonteCarloSimulationForFairValueOfPrivatePlacementWarrantsDetails",
      "http://haymaker.com/role/WarrantLiabilityAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_MeasurementInputTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input used to determine value of asset and liability.",
        "label": "Measurement Input Type [Domain]"
       }
      }
     },
     "localname": "MeasurementInputTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://haymaker.com/role/FairValueMeasurementsSummaryOfSignificantInputsToMonteCarloSimulationForFairValueOfEarnoutLiabilityDetails",
      "http://haymaker.com/role/FairValueMeasurementsSummaryOfSignificantInputsToMonteCarloSimulationForFairValueOfPrivatePlacementWarrantsDetails",
      "http://haymaker.com/role/WarrantLiabilityAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MemberUnitsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Ownership interest in limited liability company (LLC).",
        "label": "Member Units [Member]",
        "terseLabel": "Members' Equity"
       }
      }
     },
     "localname": "MemberUnitsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://haymaker.com/role/ConsolidatedStatementsOfStockholdersEquityDeficit"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MinorityInterest": {
     "auth_ref": [
      "r27",
      "r178",
      "r196",
      "r256",
      "r340",
      "r375",
      "r378",
      "r379",
      "r380",
      "r384",
      "r385",
      "r570"
     ],
     "calculation": {
      "http://haymaker.com/role/ConsolidatedBalanceSheets": {
       "order": 23.0,
       "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which is directly or indirectly attributable to that ownership interest in subsidiary equity which is not attributable to the parent (that is, noncontrolling interest, previously referred to as minority interest).",
        "label": "Stockholders' Equity Attributable to Noncontrolling Interest",
        "terseLabel": "Noncontrolling interest"
       }
      }
     },
     "localname": "MinorityInterest",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://haymaker.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MinorityInterestDisclosureTextBlock": {
     "auth_ref": [
      "r157"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for noncontrolling interest in consolidated subsidiaries, which could include the name of the subsidiary, the ownership percentage held by the parent, the ownership percentage held by the noncontrolling owners, the amount of the noncontrolling interest, the location of this amount on the balance sheet (when not reported separately), an explanation of the increase or decrease in the amount of the noncontrolling interest, the noncontrolling interest share of the net Income or Loss of the subsidiary, the location of this amount on the income statement (when not reported separately), the nature of the noncontrolling interest such as background information and terms, the amount of the noncontrolling interest represented by preferred stock, a description of the preferred stock, and the dividend requirements of the preferred stock.",
        "label": "Noncontrolling Interest Disclosure [Text Block]",
        "terseLabel": "Noncontrolling Interest"
       }
      }
     },
     "localname": "MinorityInterestDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://haymaker.com/role/NoncontrollingInterest"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_MinorityInterestLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Noncontrolling Interest [Line Items]"
       }
      }
     },
     "localname": "MinorityInterestLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://haymaker.com/role/NoncontrollingInterestAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The equity interest of noncontrolling shareholders, partners or other equity holders in consolidated entity.",
        "label": "Noncontrolling Interest, Ownership Percentage by Noncontrolling Owners",
        "terseLabel": "Minority interest, retained percentage by minority interest holders"
       }
      }
     },
     "localname": "MinorityInterestOwnershipPercentageByNoncontrollingOwners",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://haymaker.com/role/NoncontrollingInterestAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_MinorityInterestOwnershipPercentageByParent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The parent entity's interest in net assets of the subsidiary, expressed as a percentage.",
        "label": "Noncontrolling Interest, Ownership Percentage by Parent",
        "terseLabel": "Minority interest, ownership percentage"
       }
      }
     },
     "localname": "MinorityInterestOwnershipPercentageByParent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://haymaker.com/role/NoncontrollingInterestAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_MinorityInterestTable": {
     "auth_ref": [
      "r27",
      "r37",
      "r147",
      "r153"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of noncontrolling interest disclosure which includes the name of the subsidiary, the ownership percentage held by the parent, the ownership percentage held by the noncontrolling owners, the amount of the noncontrolling interest, the location of this amount on the balance sheet (when not reported separately), an explanation of the increase or decrease in the amount of the noncontrolling interest, the noncontrolling interest share of the net Income or Loss of the subsidiary, the location of this amount on the income statement (when not reported separately), the nature of the noncontrolling interest such as background information and terms, the amount of the noncontrolling interest represented by preferred stock, a description of the preferred stock, and the dividend requirements of the preferred stock.",
        "label": "Noncontrolling Interest [Table]"
       }
      }
     },
     "localname": "MinorityInterestTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://haymaker.com/role/NoncontrollingInterestAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r251"
     ],
     "calculation": {
      "http://haymaker.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash provided by (used in) financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://haymaker.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]",
        "terseLabel": "Financing Activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://haymaker.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r251"
     ],
     "calculation": {
      "http://haymaker.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 35.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash used in investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://haymaker.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]",
        "terseLabel": "Investing Activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://haymaker.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r48",
      "r50",
      "r53"
     ],
     "calculation": {
      "http://haymaker.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 14.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net cash (used in) provided by operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://haymaker.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Operating Activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://haymaker.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r35",
      "r53",
      "r185",
      "r201",
      "r217",
      "r235",
      "r238",
      "r243",
      "r256",
      "r265",
      "r269",
      "r270",
      "r272",
      "r273",
      "r277",
      "r278",
      "r290",
      "r313",
      "r321",
      "r325",
      "r327",
      "r340",
      "r375",
      "r376",
      "r378",
      "r379",
      "r380",
      "r381",
      "r382",
      "r384",
      "r385",
      "r562",
      "r570",
      "r730",
      "r807"
     ],
     "calculation": {
      "http://haymaker.com/role/ConsolidatedStatementsOfIncomeAndComprehensiveIncome": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Income (Loss) Attributable to Parent",
        "totalLabel": "Net income (loss) attributable to biote Corp. stockholders"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://haymaker.com/role/ConsolidatedStatementsOfIncomeAndComprehensiveIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetIncomeLossAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Income (Loss) Attributable to Parent [Abstract]",
        "terseLabel": "Numerator:"
       }
      }
     },
     "localname": "NetIncomeLossAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://haymaker.com/role/NetLossPerCommonShareScheduleOfComputationOfNetLossPerCommonShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLossAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r150",
      "r155",
      "r235",
      "r238",
      "r277",
      "r278",
      "r773"
     ],
     "calculation": {
      "http://haymaker.com/role/ConsolidatedStatementsOfIncomeAndComprehensiveIncome": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of Net Income (Loss) attributable to noncontrolling interest.",
        "label": "Less: Net income (loss) attributable to noncontrolling interest",
        "terseLabel": "Less: Net income attributable to noncontrolling interest"
       }
      }
     },
     "localname": "NetIncomeLossAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://haymaker.com/role/ConsolidatedStatementsOfIncomeAndComprehensiveIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic": {
     "auth_ref": [
      "r269",
      "r270",
      "r272",
      "r273",
      "r281",
      "r282",
      "r291",
      "r294",
      "r313",
      "r321",
      "r325",
      "r327",
      "r730"
     ],
     "calculation": {
      "http://haymaker.com/role/NetLossPerCommonShareScheduleOfComputationOfNetLossPerCommonShareDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.",
        "label": "Net Income (Loss) Available to Common Stockholders, Basic",
        "terseLabel": "Net loss attributable to biote Corp. stockholders (basic)"
       }
      }
     },
     "localname": "NetIncomeLossAvailableToCommonStockholdersBasic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://haymaker.com/role/NetLossPerCommonShareScheduleOfComputationOfNetLossPerCommonShareDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted": {
     "auth_ref": [
      "r283",
      "r286",
      "r287",
      "r288",
      "r289",
      "r291",
      "r294"
     ],
     "calculation": {
      "http://haymaker.com/role/NetLossPerCommonShareScheduleOfComputationOfNetLossPerCommonShareDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities, and addition from assumption of issuance of common shares for dilutive potential common shares; of income (loss) available to common shareholders.",
        "label": "Net Income (Loss) Available to Common Stockholders, Diluted",
        "totalLabel": "Net loss attributable to biote Corp. stockholders (diluted)"
       }
      }
     },
     "localname": "NetIncomeLossAvailableToCommonStockholdersDiluted",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://haymaker.com/role/NetLossPerCommonShareScheduleOfComputationOfNetLossPerCommonShareDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "verboseLabel": "Recently Adopted and Recent Accounting Pronouncements Not Yet Adopted"
       }
      }
     },
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://haymaker.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NoncontrollingInterestAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Noncontrolling Interest [Abstract]"
       }
      }
     },
     "localname": "NoncontrollingInterestAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_NoncontrollingInterestMember": {
     "auth_ref": [
      "r146",
      "r425",
      "r784",
      "r785",
      "r786"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This element represents that portion of equity (net assets) in a subsidiary not attributable, directly or indirectly, to the parent. A noncontrolling interest is sometimes called a minority interest.",
        "label": "Noncontrolling Interest [Member]",
        "terseLabel": "Non Controlling Interest"
       }
      }
     },
     "localname": "NoncontrollingInterestMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://haymaker.com/role/ConsolidatedStatementsOfStockholdersEquityDeficit"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NonoperatingIncomeExpense": {
     "auth_ref": [
      "r39"
     ],
     "calculation": {
      "http://haymaker.com/role/ConsolidatedStatementsOfIncomeAndComprehensiveIncome": {
       "order": 25.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).",
        "label": "Nonoperating Income (Expense)",
        "totalLabel": "Total other income (expense), net"
       }
      }
     },
     "localname": "NonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://haymaker.com/role/ConsolidatedStatementsOfIncomeAndComprehensiveIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NonoperatingIncomeExpenseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Nonoperating Income (Expense) [Abstract]",
        "terseLabel": "Other income (expense) net :"
       }
      }
     },
     "localname": "NonoperatingIncomeExpenseAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://haymaker.com/role/ConsolidatedStatementsOfIncomeAndComprehensiveIncome"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NumberOfOperatingSegments": {
     "auth_ref": [
      "r791"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.",
        "label": "Number of Operating Segments",
        "terseLabel": "Number of operating segment"
       }
      }
     },
     "localname": "NumberOfOperatingSegments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://haymaker.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_NumberOfReportableSegments": {
     "auth_ref": [
      "r791"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements.",
        "label": "Number of Reportable Segments",
        "terseLabel": "Number of reportable segment"
       }
      }
     },
     "localname": "NumberOfReportableSegments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://haymaker.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_OfficeEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tangible personal property used in an office setting. Examples include, but are not limited to, computers, copiers and fax machine.",
        "label": "Office Equipment [Member]",
        "terseLabel": "Office Equipment"
       }
      }
     },
     "localname": "OfficeEquipmentMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://haymaker.com/role/PropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetails",
      "http://haymaker.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfEstimatedUsefulLivesOfPropertyAndEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [
      "r313",
      "r321",
      "r325",
      "r327",
      "r730"
     ],
     "calculation": {
      "http://haymaker.com/role/ConsolidatedStatementsOfIncomeAndComprehensiveIncome": {
       "order": 19.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income (Loss)",
        "totalLabel": "Income (loss) from operations"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://haymaker.com/role/ConsolidatedStatementsOfIncomeAndComprehensiveIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseCost": {
     "auth_ref": [
      "r603",
      "r754"
     ],
     "calculation": {
      "http://haymaker.com/role/LeasesSummaryOfOperatingLeaseCostsRecognizedUnderAsc842AndSupplementalCashFlowInformationForLeasesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LeaseCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.",
        "label": "Operating Lease, Cost",
        "terseLabel": "Fixed lease expense"
       }
      }
     },
     "localname": "OperatingLeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://haymaker.com/role/LeasesSummaryOfOperatingLeaseCostsRecognizedUnderAsc842AndSupplementalCashFlowInformationForLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, to be Paid [Abstract]"
       }
      }
     },
     "localname": "OperatingLeaseLiabilitiesPaymentsDueAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingLeaseLiability": {
     "auth_ref": [
      "r599"
     ],
     "calculation": {
      "http://haymaker.com/role/LeasesSummaryBalanceSheetClassificationOfOperatingLeasesAndWeightedAverageRemainingLeaseTermAndDiscountRateDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.",
        "label": "Operating Lease, Liability",
        "totalLabel": "Total lease liabilities",
        "verboseLabel": "Present value of lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://haymaker.com/role/LeasesSummaryBalanceSheetClassificationOfOperatingLeasesAndWeightedAverageRemainingLeaseTermAndDiscountRateDetails",
      "http://haymaker.com/role/LeasesSummaryOfPaymentsByDateForOperatingLeaseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "auth_ref": [
      "r599"
     ],
     "calculation": {
      "http://haymaker.com/role/ConsolidatedBalanceSheets": {
       "order": 16.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      },
      "http://haymaker.com/role/LeasesSummaryBalanceSheetClassificationOfOperatingLeasesAndWeightedAverageRemainingLeaseTermAndDiscountRateDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingLeaseLiability",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.",
        "label": "Operating Lease, Liability, Current",
        "terseLabel": "Operating lease liabilities, current"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://haymaker.com/role/ConsolidatedBalanceSheets",
      "http://haymaker.com/role/LeasesSummaryBalanceSheetClassificationOfOperatingLeasesAndWeightedAverageRemainingLeaseTermAndDiscountRateDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r599"
     ],
     "calculation": {
      "http://haymaker.com/role/ConsolidatedBalanceSheets": {
       "order": 19.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      },
      "http://haymaker.com/role/LeasesSummaryBalanceSheetClassificationOfOperatingLeasesAndWeightedAverageRemainingLeaseTermAndDiscountRateDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingLeaseLiability",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.",
        "label": "Operating Lease, Liability, Noncurrent",
        "terseLabel": "Operating lease liabilities, net of current portion"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://haymaker.com/role/ConsolidatedBalanceSheets",
      "http://haymaker.com/role/LeasesSummaryBalanceSheetClassificationOfOperatingLeasesAndWeightedAverageRemainingLeaseTermAndDiscountRateDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeasePayments": {
     "auth_ref": [
      "r600",
      "r604"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.",
        "label": "Operating Lease, Payments",
        "terseLabel": "Cash paid for amounts included in the measurement of lease liabilities"
       }
      }
     },
     "localname": "OperatingLeasePayments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://haymaker.com/role/LeasesSummaryOfOperatingLeaseCostsRecognizedUnderAsc842AndSupplementalCashFlowInformationForLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "auth_ref": [
      "r598"
     ],
     "calculation": {
      "http://haymaker.com/role/ConsolidatedBalanceSheets": {
       "order": 8.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      },
      "http://haymaker.com/role/LeasesSummaryBalanceSheetClassificationOfOperatingLeasesAndWeightedAverageRemainingLeaseTermAndDiscountRateDetails": {
       "order": 3.0,
       "parentTag": "btmd_LeaseAssets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's right to use underlying asset under operating lease.",
        "label": "Operating Lease, Right-of-Use Asset",
        "terseLabel": "Operating lease right-of-use assets"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://haymaker.com/role/ConsolidatedBalanceSheets",
      "http://haymaker.com/role/LeasesSummaryBalanceSheetClassificationOfOperatingLeasesAndWeightedAverageRemainingLeaseTermAndDiscountRateDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": {
     "auth_ref": [
      "r607",
      "r754"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average discount rate for operating lease calculated at point in time.",
        "label": "Operating Lease, Weighted Average Discount Rate, Percent",
        "terseLabel": "Weighted-average discount rate --- operating leases"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageDiscountRatePercent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://haymaker.com/role/LeasesSummaryBalanceSheetClassificationOfOperatingLeasesAndWeightedAverageRemainingLeaseTermAndDiscountRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
     "auth_ref": [
      "r606",
      "r754"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Operating Lease, Weighted Average Remaining Lease Term",
        "terseLabel": "Weighted-average remaining lease term --- operating leases (years)"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://haymaker.com/role/LeasesSummaryBalanceSheetClassificationOfOperatingLeasesAndWeightedAverageRemainingLeaseTermAndDiscountRateDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_OperatingLossCarryforwards": {
     "auth_ref": [
      "r133"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.",
        "label": "Operating Loss Carryforwards",
        "terseLabel": "Net operating losses"
       }
      }
     },
     "localname": "OperatingLossCarryforwards",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://haymaker.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherAccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r20"
     ],
     "calculation": {
      "http://haymaker.com/role/AccruedExpensesScheduleOfAccruedExpensesDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.",
        "label": "Other Accrued Liabilities, Current",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "OtherAccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://haymaker.com/role/AccruedExpensesScheduleOfAccruedExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax": {
     "auth_ref": [
      "r28",
      "r30",
      "r580",
      "r581",
      "r582"
     ],
     "calculation": {
      "http://haymaker.com/role/ConsolidatedStatementsOfIncomeAndComprehensiveIncome": {
       "order": 33.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax, before reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.",
        "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Gain (Loss) Arising During Period, Net of Tax",
        "terseLabel": "Foreign currency translation adjustments"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://haymaker.com/role/ConsolidatedStatementsOfIncomeAndComprehensiveIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent": {
     "auth_ref": [
      "r148",
      "r149",
      "r151",
      "r236",
      "r239"
     ],
     "calculation": {
      "http://haymaker.com/role/ConsolidatedStatementsOfIncomeAndComprehensiveIncome": {
       "order": 32.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of other comprehensive income (loss) attributable to parent entity.",
        "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent",
        "totalLabel": "Other comprehensive income (loss)"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://haymaker.com/role/ConsolidatedStatementsOfIncomeAndComprehensiveIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossTaxPortionAttributableToParentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Comprehensive Income (Loss), Tax, Portion Attributable to Parent, Parenthetical Disclosure [Abstract]",
        "terseLabel": "Other comprehensive income (loss):"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossTaxPortionAttributableToParentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://haymaker.com/role/ConsolidatedStatementsOfIncomeAndComprehensiveIncome"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherNonoperatingIncome": {
     "auth_ref": [
      "r248"
     ],
     "calculation": {
      "http://haymaker.com/role/ConsolidatedStatementsOfIncomeAndComprehensiveIncome": {
       "order": 30.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income related to nonoperating activities, classified as other.",
        "label": "Other Nonoperating Income",
        "terseLabel": "Other income"
       }
      }
     },
     "localname": "OtherNonoperatingIncome",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://haymaker.com/role/ConsolidatedStatementsOfIncomeAndComprehensiveIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ParentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Portion of equity, or net assets, in the consolidated entity attributable, directly or indirectly, to the parent. Excludes noncontrolling interests.",
        "label": "Parent [Member]",
        "terseLabel": "Total Stockholders' Equity (Deficit) Attributable to biote Corp."
       }
      }
     },
     "localname": "ParentMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://haymaker.com/role/ConsolidatedStatementsOfStockholdersEquityDeficit"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PartnersCapitalAccountUnits": {
     "auth_ref": [
      "r111",
      "r204",
      "r205"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of each class of partnership units outstanding at the balance sheet date. Units represent shares of ownership of the general, limited, and preferred partners.",
        "label": "Partners' Capital Account, Units",
        "periodEndLabel": "Ending balance, units",
        "periodStartLabel": "Beginning balance, units"
       }
      }
     },
     "localname": "PartnersCapitalAccountUnits",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://haymaker.com/role/ConsolidatedStatementsOfStockholdersEquityDeficit"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PayablesAndAccrualsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payables and Accruals [Abstract]"
       }
      }
     },
     "localname": "PayablesAndAccrualsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_PaymentsForSoftware": {
     "auth_ref": [
      "r42"
     ],
     "calculation": {
      "http://haymaker.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 37.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the development, modification or acquisition of software programs or applications for internal use (that is, not to be sold, leased or otherwise marketed to others) that qualify for capitalization.",
        "label": "Payments for Software",
        "negatedLabel": "Purchases of capitalized software"
       }
      }
     },
     "localname": "PaymentsForSoftware",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://haymaker.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsOfDebtExtinguishmentCosts": {
     "auth_ref": [
      "r46"
     ],
     "calculation": {
      "http://haymaker.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow for cost from early extinguishment and prepayment of debt. Includes, but is not limited to, third-party cost, premium paid, and other fee paid to lender directly for debt extinguishment or debt prepayment. Excludes accrued interest.",
        "label": "Payment for Debt Extinguishment or Debt Prepayment Cost",
        "negatedLabel": "Extinguishment of Bank of America term loan"
       }
      }
     },
     "localname": "PaymentsOfDebtExtinguishmentCosts",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://haymaker.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsOfDebtIssuanceCosts": {
     "auth_ref": [
      "r45"
     ],
     "calculation": {
      "http://haymaker.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt.",
        "label": "Payments of Debt Issuance Costs",
        "negatedLabel": "Debt issuance costs"
       }
      }
     },
     "localname": "PaymentsOfDebtIssuanceCosts",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://haymaker.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsOfDividends": {
     "auth_ref": [
      "r44"
     ],
     "calculation": {
      "http://haymaker.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 11.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash outflow in the form of capital distributions and dividends to common shareholders, preferred shareholders and noncontrolling interests.",
        "label": "Payments of Dividends",
        "negatedLabel": "Distributions"
       }
      }
     },
     "localname": "PaymentsOfDividends",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://haymaker.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsOfStockIssuanceCosts": {
     "auth_ref": [
      "r47"
     ],
     "calculation": {
      "http://haymaker.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 12.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for cost incurred directly with the issuance of an equity security.",
        "label": "Payments of Stock Issuance Costs",
        "negatedLabel": "Capitalized transaction costs"
       }
      }
     },
     "localname": "PaymentsOfStockIssuanceCosts",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://haymaker.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireBusinessesGross": {
     "auth_ref": [
      "r41",
      "r542"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price.",
        "label": "Payments to Acquire Businesses, Gross",
        "terseLabel": "Business combination, consideration in cash"
       }
      }
     },
     "localname": "PaymentsToAcquireBusinessesGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://haymaker.com/role/BusinessCombinationAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "auth_ref": [
      "r42"
     ],
     "calculation": {
      "http://haymaker.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 36.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "negatedLabel": "Purchases of property and equipment"
       }
      }
     },
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://haymaker.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PensionAndOtherPostretirementPlansPolicy": {
     "auth_ref": [
      "r113",
      "r114",
      "r115",
      "r116",
      "r117"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for pension and other postretirement benefit plans. This accounting policy may address (1) the types of plans sponsored by the entity, and the benefits provided by each plan (2) groups that participate in (or are covered by) each plan (3) how plan assets, liabilities and expenses are measured, including the use of any actuaries and (4) significant assumptions used by the entity to value plan assets and liabilities and how such assumptions are derived.",
        "label": "Pension and Other Postretirement Plans, Policy [Policy Text Block]",
        "terseLabel": "Employee Retirement Plans"
       }
      }
     },
     "localname": "PensionAndOtherPostretirementPlansPolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://haymaker.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PlanNameAxis": {
     "auth_ref": [
      "r876",
      "r877",
      "r878",
      "r879",
      "r880",
      "r881",
      "r882",
      "r883",
      "r884",
      "r885",
      "r886",
      "r887",
      "r888",
      "r889",
      "r890",
      "r891",
      "r892",
      "r893",
      "r894",
      "r895",
      "r896",
      "r897",
      "r898",
      "r899",
      "r900",
      "r901"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by plan name for share-based payment arrangement.",
        "label": "Plan Name [Axis]"
       }
      }
     },
     "localname": "PlanNameAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://haymaker.com/role/ShareBasedCompensationAdditionalInformationDetails",
      "http://haymaker.com/role/ShareBasedCompensationSummaryOfRestrictedStockUnitActivityDetails",
      "http://haymaker.com/role/ShareBasedCompensationSummaryOfStockOptionActivityDetails",
      "http://haymaker.com/role/ShareBasedCompensationSummaryOfWeightedAverageAssumptionsUsedToEstimateFairValueOfStockOptionsGrantedDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PlanNameDomain": {
     "auth_ref": [
      "r876",
      "r877",
      "r878",
      "r879",
      "r880",
      "r881",
      "r882",
      "r883",
      "r884",
      "r885",
      "r886",
      "r887",
      "r888",
      "r889",
      "r890",
      "r891",
      "r892",
      "r893",
      "r894",
      "r895",
      "r896",
      "r897",
      "r898",
      "r899",
      "r900",
      "r901"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plan name for share-based payment arrangement.",
        "label": "Plan Name [Domain]"
       }
      }
     },
     "localname": "PlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://haymaker.com/role/ShareBasedCompensationAdditionalInformationDetails",
      "http://haymaker.com/role/ShareBasedCompensationSummaryOfRestrictedStockUnitActivityDetails",
      "http://haymaker.com/role/ShareBasedCompensationSummaryOfStockOptionActivityDetails",
      "http://haymaker.com/role/ShareBasedCompensationSummaryOfWeightedAverageAssumptionsUsedToEstimateFairValueOfStockOptionsGrantedDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r6",
      "r417"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.",
        "label": "Preferred Stock, Par or Stated Value Per Share",
        "terseLabel": "Preferred stock, par or stated value per share"
       }
      }
     },
     "localname": "PreferredStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://haymaker.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "auth_ref": [
      "r6"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.",
        "label": "Preferred Stock, Shares Authorized",
        "terseLabel": "Preferred stock, shares authorized"
       }
      }
     },
     "localname": "PreferredStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://haymaker.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesIssued": {
     "auth_ref": [
      "r6",
      "r417"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.",
        "label": "Preferred Stock, Shares Issued",
        "terseLabel": "Preferred stock shares issued"
       }
      }
     },
     "localname": "PreferredStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://haymaker.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "auth_ref": [
      "r6"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.",
        "label": "Preferred Stock, Shares Outstanding",
        "terseLabel": "Preferred stock, shares outstanding"
       }
      }
     },
     "localname": "PreferredStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://haymaker.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockValue": {
     "auth_ref": [
      "r6",
      "r755"
     ],
     "calculation": {
      "http://haymaker.com/role/ConsolidatedBalanceSheets": {
       "order": 29.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Preferred Stock, Value, Issued",
        "terseLabel": "Preferred stock, $0.0001 par value, 10,000,000 shares authorized; no shares issued or outstanding"
       }
      }
     },
     "localname": "PreferredStockValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://haymaker.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "auth_ref": [
      "r770"
     ],
     "calculation": {
      "http://haymaker.com/role/ConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      },
      "http://haymaker.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfTotalOtherCurrentAssetsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.",
        "label": "Prepaid Expense and Other Assets, Current",
        "terseLabel": "Other current assets",
        "totalLabel": "Total other current assets"
       }
      }
     },
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://haymaker.com/role/ConsolidatedBalanceSheets",
      "http://haymaker.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfTotalOtherCurrentAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Prepaid Expense and Other Assets, Current [Abstract]"
       }
      }
     },
     "localname": "PrepaidExpenseAndOtherAssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_PrepaidExpenseCurrent": {
     "auth_ref": [
      "r232",
      "r365",
      "r366",
      "r723"
     ],
     "calculation": {
      "http://haymaker.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfTotalOtherCurrentAssetsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.",
        "label": "Prepaid Expense, Current",
        "terseLabel": "Prepaid expenses"
       }
      }
     },
     "localname": "PrepaidExpenseCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://haymaker.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfTotalOtherCurrentAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromLinesOfCredit": {
     "auth_ref": [
      "r43",
      "r780"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from contractual arrangement with the lender, including but not limited to, letter of credit, standby letter of credit and revolving credit arrangements.",
        "label": "Proceeds from Lines of Credit",
        "terseLabel": "Proceeds from line of credit"
       }
      }
     },
     "localname": "ProceedsFromLinesOfCredit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://haymaker.com/role/LongTermDebtAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromPreviousAcquisition": {
     "auth_ref": [
      "r776"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash inflow representing an adjustment to the purchase price of a previous acquisition.",
        "label": "Proceeds from Previous Acquisition",
        "terseLabel": "Received aggregate proceeds amount"
       }
      }
     },
     "localname": "ProceedsFromPreviousAcquisition",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://haymaker.com/role/BusinessCombinationAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProductInformationLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Product Information [Line Items]"
       }
      }
     },
     "localname": "ProductInformationLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://haymaker.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ProductMember": {
     "auth_ref": [
      "r738"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Article or substance produced by nature, labor or machinery.",
        "label": "Product [Member]",
        "terseLabel": "Product"
       }
      }
     },
     "localname": "ProductMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://haymaker.com/role/InventoryNetScheduleOfInventoryNetDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ProfessionalFees": {
     "auth_ref": [
      "r207",
      "r208"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A fee charged for services from professionals such as doctors, lawyers and accountants. The term is often expanded to include other professions, for example, pharmacists charging to maintain a medicinal profile of a client or customer.",
        "label": "Professional Fees",
        "terseLabel": "Fees paid"
       }
      }
     },
     "localname": "ProfessionalFees",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://haymaker.com/role/RelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProfitLoss": {
     "auth_ref": [
      "r217",
      "r235",
      "r238",
      "r250",
      "r256",
      "r265",
      "r277",
      "r278",
      "r313",
      "r321",
      "r325",
      "r327",
      "r340",
      "r375",
      "r376",
      "r378",
      "r379",
      "r380",
      "r381",
      "r382",
      "r384",
      "r385",
      "r543",
      "r546",
      "r547",
      "r562",
      "r570",
      "r678",
      "r730",
      "r752",
      "r753",
      "r773",
      "r807"
     ],
     "calculation": {
      "http://haymaker.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 15.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://haymaker.com/role/ConsolidatedStatementsOfIncomeAndComprehensiveIncome": {
       "order": 17.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.",
        "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest",
        "terseLabel": "Net income",
        "totalLabel": "Net income",
        "verboseLabel": "Net income (loss)"
       }
      }
     },
     "localname": "ProfitLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://haymaker.com/role/ConsolidatedStatementsOfCashFlows",
      "http://haymaker.com/role/ConsolidatedStatementsOfIncomeAndComprehensiveIncome",
      "http://haymaker.com/role/ConsolidatedStatementsOfStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Abstract]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "auth_ref": [
      "r83"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.",
        "label": "Long-Lived Tangible Asset [Axis]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://haymaker.com/role/PropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetails",
      "http://haymaker.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://haymaker.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfEstimatedUsefulLivesOfPropertyAndEquipmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": {
     "auth_ref": [
      "r86",
      "r705",
      "r706",
      "r707"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.",
        "label": "Property, Plant and Equipment Disclosure [Text Block]",
        "terseLabel": "Property and Equipment, Net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://haymaker.com/role/PropertyAndEquipmentNet"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives": {
     "auth_ref": [
      "r78"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Describes the periods of time over which an entity anticipates to receive utility from its property, plant and equipment (that is, the periods of time over which an entity allocates the initial cost of its property, plant and equipment).",
        "label": "Property, Plant and Equipment, Estimated Useful Lives",
        "verboseLabel": "Estimated Useful Life"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentEstimatedUsefulLives",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://haymaker.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfEstimatedUsefulLivesOfPropertyAndEquipmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentGross": {
     "auth_ref": [
      "r81",
      "r221"
     ],
     "calculation": {
      "http://haymaker.com/role/PropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Gross",
        "terseLabel": "Property and equipment, gross"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://haymaker.com/role/PropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Property, Plant and Equipment [Line Items]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://haymaker.com/role/PropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetails",
      "http://haymaker.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfEstimatedUsefulLivesOfPropertyAndEquipmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r83",
      "r198",
      "r679",
      "r755"
     ],
     "calculation": {
      "http://haymaker.com/role/ConsolidatedBalanceSheets": {
       "order": 6.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      },
      "http://haymaker.com/role/PropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Net",
        "terseLabel": "Property and equipment, net",
        "totalLabel": "Property and equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://haymaker.com/role/ConsolidatedBalanceSheets",
      "http://haymaker.com/role/PropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": {
     "auth_ref": [
      "r83",
      "r705",
      "r706"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.",
        "label": "Property, Plant and Equipment, Policy [Policy Text Block]",
        "terseLabel": "Property and Equipment, Net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://haymaker.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "auth_ref": [
      "r83"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table Text Block]",
        "terseLabel": "Schedule of Property and Equipment, Net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://haymaker.com/role/PropertyAndEquipmentNetTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "auth_ref": [
      "r81"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.",
        "label": "Long-Lived Tangible Asset [Domain]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://haymaker.com/role/PropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetails",
      "http://haymaker.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://haymaker.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfEstimatedUsefulLivesOfPropertyAndEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentUsefulLife": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.",
        "label": "Property, Plant and Equipment, Useful Life",
        "verboseLabel": "Estimated Useful Life (in years)"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentUsefulLife",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://haymaker.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfEstimatedUsefulLivesOfPropertyAndEquipmentDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ProvisionForDoubtfulAccounts": {
     "auth_ref": [
      "r247",
      "r353"
     ],
     "calculation": {
      "http://haymaker.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 17.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense (reversal of expense) for expected credit loss on accounts receivable.",
        "label": "Accounts Receivable, Credit Loss Expense (Reversal)",
        "negatedTerseLabel": "Provisions charged to operating results",
        "verboseLabel": "Bad debt expense (recoveries)"
       }
      }
     },
     "localname": "ProvisionForDoubtfulAccounts",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://haymaker.com/role/ConsolidatedStatementsOfCashFlows",
      "http://haymaker.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfRollforwardOfTheAllowanceForDoubtfulAccountsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PublicUtilitiesInventoryAxis": {
     "auth_ref": [
      "r767"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of inventory held.",
        "label": "Inventory [Axis]"
       }
      }
     },
     "localname": "PublicUtilitiesInventoryAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://haymaker.com/role/InventoryNetScheduleOfInventoryNetDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PublicUtilitiesInventoryTypeDomain": {
     "auth_ref": [
      "r767"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tangible personal property that is held for sale in the ordinary course of business, in process of production for such sale or is to be currently consumed in the production of goods or services to be available for sale.",
        "label": "Inventory [Domain]"
       }
      }
     },
     "localname": "PublicUtilitiesInventoryTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://haymaker.com/role/InventoryNetScheduleOfInventoryNetDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RatioOfIndebtednessToNetCapital1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indebtedness divided by net capital.",
        "label": "Ratio of Indebtedness to Net Capital",
        "terseLabel": "Net leverage ratio"
       }
      }
     },
     "localname": "RatioOfIndebtednessToNetCapital1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://haymaker.com/role/LongTermDebtAdditionalInformationDetails"
     ],
     "xbrltype": "pureItemType"
    },
    "us-gaap_ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy": {
     "auth_ref": [
      "r72"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for determining the allowance for doubtful accounts for trade and other accounts receivable balances, and when impairments, charge-offs or recoveries are recognized.",
        "label": "Receivables, Trade and Other Accounts Receivable, Allowance for Doubtful Accounts, Policy [Policy Text Block]",
        "terseLabel": "Accounts Receivable and Allowance for Doubtful Accounts"
       }
      }
     },
     "localname": "ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://haymaker.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RelatedPartyDomain": {
     "auth_ref": [
      "r450",
      "r619",
      "r620"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.",
        "label": "Related Party [Domain]"
       }
      }
     },
     "localname": "RelatedPartyDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://haymaker.com/role/CommitmentsAndContingenciesAdditionalInformationDetails",
      "http://haymaker.com/role/RelatedPartyTransactionsAdditionalInformationDetails",
      "http://haymaker.com/role/WarrantLiabilityAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RelatedPartyTransactionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Related Party Transaction [Line Items]"
       }
      }
     },
     "localname": "RelatedPartyTransactionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://haymaker.com/role/RelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transactions [Abstract]"
       }
      }
     },
     "localname": "RelatedPartyTransactionsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": {
     "auth_ref": [
      "r450",
      "r619",
      "r663",
      "r664",
      "r665",
      "r666",
      "r667",
      "r668",
      "r669",
      "r670",
      "r671",
      "r672",
      "r673",
      "r674",
      "r918"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.",
        "label": "Related Party [Axis]"
       }
      }
     },
     "localname": "RelatedPartyTransactionsByRelatedPartyAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://haymaker.com/role/CommitmentsAndContingenciesAdditionalInformationDetails",
      "http://haymaker.com/role/RelatedPartyTransactionsAdditionalInformationDetails",
      "http://haymaker.com/role/WarrantLiabilityAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": {
     "auth_ref": [
      "r617",
      "r618",
      "r620",
      "r621",
      "r622"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.",
        "label": "Related Party Transactions Disclosure [Text Block]",
        "terseLabel": "Related-Party Transactions"
       }
      }
     },
     "localname": "RelatedPartyTransactionsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://haymaker.com/role/RelatedPartyTransactions"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ResearchAndDevelopmentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and Development [Abstract]"
       }
      }
     },
     "localname": "ResearchAndDevelopmentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock": {
     "auth_ref": [
      "r211"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for research, development, and computer software activities, including contracts and arrangements to be performed for others and with federal government. Includes costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility and in-process research and development acquired in a business combination consummated during the period.",
        "label": "Research, Development, and Computer Software Disclosure [Text Block]",
        "terseLabel": "Capitalized Software, Net"
       }
      }
     },
     "localname": "ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://haymaker.com/role/CapitalizedSoftwareNet"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RestrictedStockUnitsRSUMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.",
        "label": "Restricted Stock Units (RSUs) [Member]",
        "terseLabel": "RSUs"
       }
      }
     },
     "localname": "RestrictedStockUnitsRSUMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://haymaker.com/role/NetLossPerCommonShareScheduleOfComputationOfDilutedWeightedAverageSharesOutstandingDetails",
      "http://haymaker.com/role/ShareBasedCompensationAdditionalInformationDetails",
      "http://haymaker.com/role/ShareBasedCompensationSummaryOfRestrictedStockUnitActivityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r9",
      "r110",
      "r195",
      "r693",
      "r698",
      "r755"
     ],
     "calculation": {
      "http://haymaker.com/role/ConsolidatedBalanceSheets": {
       "order": 27.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings (Accumulated Deficit)",
        "terseLabel": "Retained earnings (Accumulated deficit)"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://haymaker.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r214",
      "r261",
      "r262",
      "r263",
      "r266",
      "r275",
      "r278",
      "r347",
      "r498",
      "r499",
      "r500",
      "r523",
      "r524",
      "r560",
      "r689",
      "r691"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings / (Accumulated Deficit)"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://haymaker.com/role/ConsolidatedStatementsOfStockholdersEquityDeficit"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RetirementPlanNameAxis": {
     "auth_ref": [
      "r451",
      "r452",
      "r453",
      "r454",
      "r455",
      "r456",
      "r457",
      "r458",
      "r459",
      "r750",
      "r815",
      "r816",
      "r817",
      "r818",
      "r819",
      "r820",
      "r821",
      "r822",
      "r823",
      "r824",
      "r825",
      "r826",
      "r827",
      "r828",
      "r829",
      "r830",
      "r831",
      "r832",
      "r833",
      "r834",
      "r835",
      "r836",
      "r837",
      "r838",
      "r839",
      "r840",
      "r841",
      "r842",
      "r843",
      "r844",
      "r845",
      "r846",
      "r847",
      "r848",
      "r849",
      "r850",
      "r851",
      "r852",
      "r853",
      "r854",
      "r855",
      "r856",
      "r857",
      "r858",
      "r859",
      "r860",
      "r861",
      "r862",
      "r863",
      "r864",
      "r865",
      "r866",
      "r867",
      "r868",
      "r869",
      "r870",
      "r871",
      "r872",
      "r873",
      "r874",
      "r875"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by name of plan designed to provide retirement benefits. Includes, but is not limited to, legal name of defined benefit and defined contribution plans.",
        "label": "Retirement Plan Name [Axis]"
       }
      }
     },
     "localname": "RetirementPlanNameAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://haymaker.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RetirementPlanNameDomain": {
     "auth_ref": [
      "r451",
      "r452",
      "r453",
      "r454",
      "r455",
      "r456",
      "r457",
      "r458",
      "r459",
      "r750",
      "r815",
      "r816",
      "r817",
      "r818",
      "r819",
      "r820",
      "r821",
      "r822",
      "r823",
      "r824",
      "r825",
      "r826",
      "r827",
      "r828",
      "r829",
      "r830",
      "r831",
      "r832",
      "r833",
      "r834",
      "r835",
      "r836",
      "r837",
      "r838",
      "r839",
      "r840",
      "r841",
      "r842",
      "r843",
      "r844",
      "r845",
      "r846",
      "r847",
      "r848",
      "r849",
      "r850",
      "r851",
      "r852",
      "r853",
      "r854",
      "r855",
      "r856",
      "r857",
      "r858",
      "r859",
      "r860",
      "r861",
      "r862",
      "r863",
      "r864",
      "r865",
      "r866",
      "r867",
      "r868",
      "r869",
      "r870",
      "r871",
      "r872",
      "r873",
      "r874",
      "r875"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of plan designed to provide retirement benefits. Includes, but is not limited to, legal name of defined benefit and defined contribution plans.",
        "label": "Retirement Plan Name [Domain]"
       }
      }
     },
     "localname": "RetirementPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://haymaker.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue from Contract with Customer [Abstract]"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": {
     "auth_ref": [
      "r309",
      "r310",
      "r320",
      "r323",
      "r324",
      "r328",
      "r329",
      "r331",
      "r437",
      "r438",
      "r659"
     ],
     "calculation": {
      "http://haymaker.com/role/ConsolidatedStatementsOfIncomeAndComprehensiveIncome": {
       "order": 20.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.",
        "label": "Revenue from Contract with Customer, Excluding Assessed Tax",
        "verboseLabel": "Total revenue"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerExcludingAssessedTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://haymaker.com/role/ConsolidatedStatementsOfIncomeAndComprehensiveIncome",
      "http://haymaker.com/role/RevenueRecognitionScheduleOfRevenuesRecognizedByGeographicRegionDetails",
      "http://haymaker.com/role/RevenueRecognitionScheduleOfRevenuesRecognizedForEachRevenueStreamDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerTextBlock": {
     "auth_ref": [
      "r428",
      "r429",
      "r430",
      "r431",
      "r432",
      "r433",
      "r435",
      "r436",
      "r441",
      "r442"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.",
        "label": "Revenue from Contract with Customer [Text Block]",
        "terseLabel": "Revenue Recognition"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://haymaker.com/role/RevenueRecognition"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RevenueRecognitionPolicyTextBlock": {
     "auth_ref": [
      "r726",
      "r727"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources.",
        "label": "Revenue [Policy Text Block]",
        "terseLabel": "Revenue Recognition"
       }
      }
     },
     "localname": "RevenueRecognitionPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://haymaker.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RevenueRemainingPerformanceObligation": {
     "auth_ref": [
      "r434"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of transaction price allocated to performance obligation that has not been recognized as revenue.",
        "label": "Revenue, Remaining Performance Obligation, Amount",
        "terseLabel": "Revenue remaining performance obligation"
       }
      }
     },
     "localname": "RevenueRemainingPerformanceObligation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://haymaker.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenuesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenues [Abstract]",
        "terseLabel": "Revenue"
       }
      }
     },
     "localname": "RevenuesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://haymaker.com/role/ConsolidatedStatementsOfIncomeAndComprehensiveIncome"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RevolvingCreditFacilityMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Arrangement in which loan proceeds can continuously be obtained following repayments, but the total amount borrowed cannot exceed a specified maximum amount.",
        "label": "Revolving Credit Facility [Member]",
        "terseLabel": "Revolving Credit Facility"
       }
      }
     },
     "localname": "RevolvingCreditFacilityMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://haymaker.com/role/LongTermDebtAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": {
     "auth_ref": [
      "r605",
      "r754"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability.",
        "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability",
        "terseLabel": "Right-of-use assets obtained in exchange for new operating lease liabilities"
       }
      }
     },
     "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://haymaker.com/role/LeasesSummaryOfOperatingLeaseCostsRecognizedUnderAsc842AndSupplementalCashFlowInformationForLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.",
        "label": "Sale of Stock, Number of Shares Issued in Transaction",
        "terseLabel": "Shares sold"
       }
      }
     },
     "localname": "SaleOfStockNumberOfSharesIssuedInTransaction",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://haymaker.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SaleOfStockPricePerShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.",
        "label": "Sale of Stock, Price Per Share",
        "terseLabel": "Sale of stock price per share"
       }
      }
     },
     "localname": "SaleOfStockPricePerShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://haymaker.com/role/FairValueMeasurementsSummaryOfSignificantInputsToMonteCarloSimulationForFairValueOfEarnoutLiabilityDetails",
      "http://haymaker.com/role/FairValueMeasurementsSummaryOfSignificantInputsToMonteCarloSimulationForFairValueOfPrivatePlacementWarrantsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SalesCommissionsAndFees": {
     "auth_ref": [
      "r38"
     ],
     "calculation": {
      "http://haymaker.com/role/ConsolidatedStatementsOfIncomeAndComprehensiveIncome": {
       "order": 22.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primarily represents commissions incurred in the period based upon the sale by commissioned employees or third parties of the entity's goods or services, and fees for sales assistance or product enhancements performed by third parties (such as a distributor or value added reseller).",
        "label": "Sales Commissions and Fees",
        "terseLabel": "Commissions",
        "verboseLabel": "Sales commission"
       }
      }
     },
     "localname": "SalesCommissionsAndFees",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://haymaker.com/role/ConsolidatedStatementsOfIncomeAndComprehensiveIncome",
      "http://haymaker.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of accrued liabilities.",
        "label": "Schedule of Accrued Liabilities [Table Text Block]",
        "terseLabel": "Schedule of Accrued Expenses"
       }
      }
     },
     "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://haymaker.com/role/AccruedExpensesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "auth_ref": [
      "r63"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://haymaker.com/role/NetLossPerCommonShareScheduleOfComputationOfDilutedWeightedAverageSharesOutstandingDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "auth_ref": [
      "r63"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]",
        "terseLabel": "Schedule of Computation of Diluted Weighted Average Shares Outstanding"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://haymaker.com/role/NetLossPerCommonShareTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable": {
     "auth_ref": [
      "r139",
      "r140",
      "r537"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting each material business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities.",
        "label": "Schedule of Business Acquisitions, by Acquisition [Table]"
       }
      }
     },
     "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://haymaker.com/role/BusinessCombinationAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfCapitalUnitsTable": {
     "auth_ref": [
      "r206"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This table may be used to capture the complete disclosure pertaining to an entity's capital units or capital shares, including the value of capital units or capital shares, units authorized, units outstanding and other information necessary to a fair presentation.",
        "label": "Schedule of Capital Units [Table]"
       }
      }
     },
     "localname": "ScheduleOfCapitalUnitsTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://haymaker.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfMembersEquityUnitsIssuedAndOutstandingDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfCapitalUnitsTextBlock": {
     "auth_ref": [
      "r206"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of an entity's capital units or capital shares, including the value of capital units or capital shares, units authorized, units outstanding and other information necessary to a fair presentation.",
        "label": "Schedule of Capital Units [Table Text Block]",
        "terseLabel": "Summary of Members' Equity Units Issued and Outstanding"
       }
      }
     },
     "localname": "ScheduleOfCapitalUnitsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://haymaker.com/role/SummaryOfSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock": {
     "auth_ref": [
      "r135"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.",
        "label": "Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]",
        "terseLabel": "Schedule of Income Tax Provision"
       }
      }
     },
     "localname": "ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://haymaker.com/role/IncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDebtTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of information pertaining to short-term and long-debt instruments or arrangements, including but not limited to identification of terms, features, collateral requirements and other information necessary to a fair presentation.",
        "label": "Schedule of Debt [Table Text Block]",
        "terseLabel": "Schedule of Outstanding Debt"
       }
      }
     },
     "localname": "ScheduleOfDebtTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://haymaker.com/role/LongTermDebtTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": {
     "auth_ref": [
      "r132"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.",
        "label": "Schedule of Deferred Tax Assets and Liabilities [Table Text Block]",
        "terseLabel": "Schedule of Deferred Tax Assets and Liabilities"
       }
      }
     },
     "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://haymaker.com/role/IncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": {
     "auth_ref": [
      "r790"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.",
        "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]",
        "terseLabel": "Schedule of Computation of Net Loss Per Common Share"
       }
      }
     },
     "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://haymaker.com/role/NetLossPerCommonShareTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable": {
     "auth_ref": [
      "r62",
      "r64",
      "r284",
      "r285",
      "r292"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The table contains disclosure pertaining to an entity's basic earnings per share.",
        "label": "Schedule of Earnings Per Share, Basic, by Common Class, Including Two Class Method [Table]"
       }
      }
     },
     "localname": "ScheduleOfEarningsPerShareBasicByCommonClassTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://haymaker.com/role/NetLossPerCommonShareScheduleOfComputationOfNetLossPerCommonShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": {
     "auth_ref": [
      "r128"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.",
        "label": "Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]",
        "terseLabel": "Schedule of Reconciliation of the Federal Income Tax Rate to the Company Effective Tax Rate"
       }
      }
     },
     "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://haymaker.com/role/IncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock": {
     "auth_ref": [
      "r782"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of income before income tax between domestic and foreign jurisdictions.",
        "label": "Schedule of Income before Income Tax, Domestic and Foreign [Table Text Block]",
        "terseLabel": "Schedule of Income (Loss) Before Provision for Income Taxes"
       }
      }
     },
     "localname": "ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://haymaker.com/role/IncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfInventoryCurrentTableTextBlock": {
     "auth_ref": [
      "r1",
      "r13",
      "r14",
      "r15"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.",
        "label": "Schedule of Inventory, Current [Table Text Block]",
        "terseLabel": "Schedule of Inventory, Net"
       }
      }
     },
     "localname": "ScheduleOfInventoryCurrentTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://haymaker.com/role/InventoryNetTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock": {
     "auth_ref": [
      "r93"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of maturity and sinking fund requirement for long-term debt.",
        "label": "Schedule of Maturities of Long-Term Debt [Table Text Block]",
        "terseLabel": "Schedule of Future Maturities of Long-term Debt"
       }
      }
     },
     "localname": "ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://haymaker.com/role/LongTermDebtTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the carrying amounts of other current assets.",
        "label": "Schedule of Other Current Assets [Table Text Block]",
        "terseLabel": "Summary of Total Other Current Assets"
       }
      }
     },
     "localname": "ScheduleOfOtherCurrentAssetsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://haymaker.com/role/SummaryOfSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfProductInformationTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule detailing quantitative information concerning products or product lines by product or product line.",
        "label": "Schedule of Product Information [Table]"
       }
      }
     },
     "localname": "ScheduleOfProductInformationTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://haymaker.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "auth_ref": [
      "r83"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table]"
       }
      }
     },
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://haymaker.com/role/PropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetails",
      "http://haymaker.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfEstimatedUsefulLivesOfPropertyAndEquipmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable": {
     "auth_ref": [
      "r170",
      "r171"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of quantitative and qualitative information pertaining to related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.",
        "label": "Schedule of Related Party Transactions, by Related Party [Table]"
       }
      }
     },
     "localname": "ScheduleOfRelatedPartyTransactionsByRelatedPartyTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://haymaker.com/role/RelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "auth_ref": [
      "r460",
      "r462",
      "r464",
      "r465",
      "r466",
      "r468",
      "r469",
      "r470",
      "r471",
      "r472",
      "r473",
      "r474",
      "r475",
      "r476",
      "r477",
      "r478",
      "r479",
      "r480",
      "r481",
      "r482",
      "r483",
      "r484",
      "r485",
      "r488",
      "r489",
      "r490",
      "r491",
      "r492"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about share-based payment arrangement.",
        "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://haymaker.com/role/ShareBasedCompensationAdditionalInformationDetails",
      "http://haymaker.com/role/ShareBasedCompensationSummaryOfRestrictedStockUnitActivityDetails",
      "http://haymaker.com/role/ShareBasedCompensationSummaryOfStockOptionActivityDetails",
      "http://haymaker.com/role/ShareBasedCompensationSummaryOfWeightedAverageAssumptionsUsedToEstimateFairValueOfStockOptionsGrantedDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock": {
     "auth_ref": [
      "r119"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the number and weighted-average grant date fair value for restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock units that were granted, vested, or forfeited during the year.",
        "label": "Share-Based Payment Arrangement, Restricted Stock Unit, Activity [Table Text Block]",
        "verboseLabel": "Summary of Restricted Stock Unit Activity"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://haymaker.com/role/ShareBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "auth_ref": [
      "r119",
      "r120",
      "r121"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.",
        "label": "Share-Based Payment Arrangement, Option, Activity [Table Text Block]",
        "terseLabel": "Summary of Stock Option Activity"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://haymaker.com/role/ShareBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "auth_ref": [
      "r123"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.",
        "label": "Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]",
        "terseLabel": "Summary of Weighted-Average Assumptions used to Estimate Fair Value of Stock Options Granted"
       }
      }
     },
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://haymaker.com/role/ShareBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfStockByClassTable": {
     "auth_ref": [
      "r98",
      "r100",
      "r102",
      "r104",
      "r105",
      "r106",
      "r107",
      "r108",
      "r109",
      "r110",
      "r225",
      "r226",
      "r227",
      "r302",
      "r417",
      "r418",
      "r419",
      "r420",
      "r421",
      "r422",
      "r423",
      "r737",
      "r763",
      "r779"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule detailing information related to equity by class of stock. Class of stock includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. It also includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity.",
        "label": "Schedule of Stock by Class [Table]"
       }
      }
     },
     "localname": "ScheduleOfStockByClassTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://haymaker.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfCommonStockIssuedAndOutstandingDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfStockByClassTextBlock": {
     "auth_ref": [
      "r5",
      "r6",
      "r7",
      "r99",
      "r100",
      "r102",
      "r104",
      "r105",
      "r106",
      "r107",
      "r108",
      "r109",
      "r110"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of an entity's stock, including par or stated value per share, number and dollar amount of share subscriptions, shares authorized, shares issued, shares outstanding, number and dollar amount of shares held in an employee trust, dividend per share, total dividends, share conversion features, par value plus additional paid in capital, the value of treasury stock and other information necessary to a fair presentation, and EPS information. Stock by class includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. Includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity. If more than one issue is outstanding, state the title of each issue and the corresponding dollar amount; dollar amount of any shares subscribed but unissued and the deduction of subscriptions receivable there from; number of shares authorized, issued, and outstanding.",
        "label": "Schedule of Stock by Class [Table Text Block]",
        "terseLabel": "Summary of Common Stock Issued and Outstanding"
       }
      }
     },
     "localname": "ScheduleOfStockByClassTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://haymaker.com/role/SummaryOfSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember": {
     "auth_ref": [
      "r910"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fixed rate on U.S. dollar, constant-notional interest rate swap that has its variable-rate leg referenced to Secured Overnight Financing Rate (SOFR) with no additional spread over SOFR on variable-rate leg.",
        "label": "Secured Overnight Financing Rate (SOFR) Overnight Index Swap Rate [Member]",
        "terseLabel": "SOFR Rate"
       }
      }
     },
     "localname": "SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://haymaker.com/role/LongTermDebtAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SegmentReportingPolicyPolicyTextBlock": {
     "auth_ref": [
      "r314",
      "r315",
      "r316",
      "r317",
      "r318",
      "r319",
      "r329"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for segment reporting.",
        "label": "Segment Reporting, Policy [Policy Text Block]",
        "terseLabel": "Segment Information"
       }
      }
     },
     "localname": "SegmentReportingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://haymaker.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SellingGeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r38"
     ],
     "calculation": {
      "http://haymaker.com/role/ConsolidatedStatementsOfIncomeAndComprehensiveIncome": {
       "order": 24.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.",
        "label": "Selling, General and Administrative Expense",
        "terseLabel": "Selling, general, and administrative"
       }
      }
     },
     "localname": "SellingGeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://haymaker.com/role/ConsolidatedStatementsOfIncomeAndComprehensiveIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock": {
     "auth_ref": [
      "r127"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for inclusion of significant items in the selling, general and administrative (or similar) expense report caption.",
        "label": "Selling, General and Administrative Expenses, Policy [Policy Text Block]",
        "terseLabel": "Selling, General, and Administrative"
       }
      }
     },
     "localname": "SellingGeneralAndAdministrativeExpensesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://haymaker.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SettlementLiabilitiesCurrent": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amounts payable for money transfers, money orders, and consumer payment service arrangements. Settlement liabilities include amounts payable to intermediaries for global payment transfers.",
        "label": "Settlement Liabilities, Current",
        "terseLabel": "Settlement of phantom equity rights"
       }
      }
     },
     "localname": "SettlementLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://haymaker.com/role/ShareBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r51"
     ],
     "calculation": {
      "http://haymaker.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 23.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement, Noncash Expense",
        "terseLabel": "Share-based compensation expense"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://haymaker.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": {
     "auth_ref": [
      "r751"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period",
        "terseLabel": "Awards vesting period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://haymaker.com/role/ShareBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": {
     "auth_ref": [
      "r481"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period",
        "negatedLabel": "Shares, Forfeited"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://haymaker.com/role/ShareBasedCompensationSummaryOfRestrictedStockUnitActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r481"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value",
        "verboseLabel": "Weighted-Average Grant-Date Fair Value, Forfeited"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://haymaker.com/role/ShareBasedCompensationSummaryOfRestrictedStockUnitActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "auth_ref": [
      "r479"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period",
        "verboseLabel": "Shares, Granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://haymaker.com/role/ShareBasedCompensationSummaryOfRestrictedStockUnitActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r479"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "verboseLabel": "Weighted-Average Grant-Date Fair Value, Granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://haymaker.com/role/ShareBasedCompensationSummaryOfRestrictedStockUnitActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": {
     "auth_ref": [
      "r476",
      "r477"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number",
        "periodEndLabel": "Shares, RSUs Outstanding, Ending balance",
        "periodStartLabel": "Shares, RSUs Outstanding, Beginning balance"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://haymaker.com/role/ShareBasedCompensationSummaryOfRestrictedStockUnitActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r476",
      "r477"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value",
        "periodEndLabel": "Weighted-Average Grant-Date Fair Value, RSUs Outstanding, Ending balance",
        "periodStartLabel": "Weighted-Average Grant-Date Fair Value, RSUs Outstanding, Beginning balance"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://haymaker.com/role/ShareBasedCompensationSummaryOfRestrictedStockUnitActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": {
     "auth_ref": [
      "r480"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period",
        "negatedLabel": "Shares, Vested"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://haymaker.com/role/ShareBasedCompensationSummaryOfRestrictedStockUnitActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r480"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value",
        "verboseLabel": "Weighted-Average Grant-Date Fair Value, Vested"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://haymaker.com/role/ShareBasedCompensationSummaryOfRestrictedStockUnitActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions and Methodology [Abstract]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "auth_ref": [
      "r490"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate",
        "terseLabel": "Dividend yield"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://haymaker.com/role/ShareBasedCompensationSummaryOfWeightedAverageAssumptionsUsedToEstimateFairValueOfStockOptionsGrantedDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "auth_ref": [
      "r491"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate",
        "terseLabel": "Risk-free rate"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://haymaker.com/role/ShareBasedCompensationSummaryOfWeightedAverageAssumptionsUsedToEstimateFairValueOfStockOptionsGrantedDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate": {
     "auth_ref": [
      "r489"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Rate of weighted-average expected volatility for award under share-based payment arrangement.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Weighted Average Volatility Rate",
        "terseLabel": "Volatility"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://haymaker.com/role/ShareBasedCompensationSummaryOfWeightedAverageAssumptionsUsedToEstimateFairValueOfStockOptionsGrantedDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://haymaker.com/role/ShareBasedCompensationAdditionalInformationDetails",
      "http://haymaker.com/role/ShareBasedCompensationSummaryOfRestrictedStockUnitActivityDetails",
      "http://haymaker.com/role/ShareBasedCompensationSummaryOfStockOptionActivityDetails",
      "http://haymaker.com/role/ShareBasedCompensationSummaryOfWeightedAverageAssumptionsUsedToEstimateFairValueOfStockOptionsGrantedDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "auth_ref": [
      "r470"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number",
        "terseLabel": "Stock Options, Exercisable"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://haymaker.com/role/ShareBasedCompensationSummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "auth_ref": [
      "r470"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price",
        "terseLabel": "Weighted-Average Exercise Price, Exercisable"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://haymaker.com/role/ShareBasedCompensationSummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod": {
     "auth_ref": [
      "r882"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period",
        "negatedLabel": "Stock Options, Forfeited"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://haymaker.com/role/ShareBasedCompensationSummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r882"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price of options that were either forfeited or expired.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price",
        "terseLabel": "Weighted-Average Exercise Price, Forfeited"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://haymaker.com/role/ShareBasedCompensationSummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "auth_ref": [
      "r472"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross number of share options (or share units) granted during the period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross",
        "terseLabel": "Stock Options, Granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://haymaker.com/role/ShareBasedCompensationSummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "auth_ref": [
      "r468",
      "r469"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options outstanding, including both vested and non-vested options.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number",
        "periodEndLabel": "Stock Options Outstanding, Ending Balance"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://haymaker.com/role/ShareBasedCompensationSummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r468",
      "r469"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "periodEndLabel": "Weighted-Average Exercise Price Outstanding, Ending Balance"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://haymaker.com/role/ShareBasedCompensationSummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "auth_ref": [
      "r464",
      "r465",
      "r466",
      "r468",
      "r469",
      "r470",
      "r471",
      "r472",
      "r473",
      "r474",
      "r475",
      "r476",
      "r477",
      "r478",
      "r479",
      "r480",
      "r481",
      "r482",
      "r483",
      "r484",
      "r485",
      "r488",
      "r489",
      "r490",
      "r491",
      "r492"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award under share-based payment arrangement.",
        "label": "Award Type [Domain]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://haymaker.com/role/NetLossPerCommonShareScheduleOfComputationOfNetLossPerCommonShareDetails",
      "http://haymaker.com/role/ShareBasedCompensationAdditionalInformationDetails",
      "http://haymaker.com/role/ShareBasedCompensationSummaryOfRestrictedStockUnitActivityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r472"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "terseLabel": "Weighted-Average Exercise Price, Granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://haymaker.com/role/ShareBasedCompensationSummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": {
     "auth_ref": [
      "r467",
      "r486",
      "r487",
      "r488",
      "r489",
      "r492",
      "r501",
      "r502"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.",
        "label": "Share-Based Payment Arrangement [Policy Text Block]",
        "terseLabel": "Share-Based Compensation"
       }
      }
     },
     "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://haymaker.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SharePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Price of a single share of a number of saleable stocks of a company.",
        "label": "Share Price",
        "terseLabel": "Share Price"
       }
      }
     },
     "localname": "SharePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://haymaker.com/role/EarnoutLiabilityAdditionalInformationDetails",
      "http://haymaker.com/role/WarrantLiabilityAdditionalInformationDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "auth_ref": [
      "r488"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term",
        "terseLabel": "Expected term (in years)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://haymaker.com/role/ShareBasedCompensationSummaryOfWeightedAverageAssumptionsUsedToEstimateFairValueOfStockOptionsGrantedDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r124"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term",
        "terseLabel": "Weighted-Average Remaining Contractual Term (Years), Exercisable"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://haymaker.com/role/ShareBasedCompensationSummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "auth_ref": [
      "r122"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term",
        "terseLabel": "Weighted-Average Remaining Contractual Term (Years)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://haymaker.com/role/ShareBasedCompensationSummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharesIssuedPricePerShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share or per unit amount of equity securities issued.",
        "label": "Shares Issued, Price Per Share",
        "terseLabel": "Shares issued, price per share"
       }
      }
     },
     "localname": "SharesIssuedPricePerShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://haymaker.com/role/WarrantLiabilityAdditionalInformationDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.",
        "label": "Shares, Outstanding",
        "periodEndLabel": "Ending balance, shares"
       }
      }
     },
     "localname": "SharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://haymaker.com/role/ConsolidatedStatementsOfStockholdersEquityDeficit"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShortTermContractWithCustomerMember": {
     "auth_ref": [
      "r742"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contract with customer in which duration is classified as short-term.",
        "label": "Short-Term Contract with Customer [Member]",
        "terseLabel": "Deferred Revenue"
       }
      }
     },
     "localname": "ShortTermContractWithCustomerMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://haymaker.com/role/RevenueRecognitionSummaryOfSignificantChangesInContractLiabilityBalancesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r61",
      "r254"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.",
        "label": "Significant Accounting Policies [Text Block]",
        "terseLabel": "Summary of Significant Accounting Policies"
       }
      }
     },
     "localname": "SignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://haymaker.com/role/SummaryOfSignificantAccountingPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SoftwareAndSoftwareDevelopmentCostsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Purchased software applications and internally developed software for sale, licensing or long-term internal use.",
        "label": "Software and Software Development Costs [Member]",
        "terseLabel": "Computer Software"
       }
      }
     },
     "localname": "SoftwareAndSoftwareDevelopmentCostsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://haymaker.com/role/PropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SoftwareDevelopmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Internally developed software for sale, licensing or long-term internal use.",
        "label": "Software Development [Member]",
        "verboseLabel": "Computer software"
       }
      }
     },
     "localname": "SoftwareDevelopmentMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://haymaker.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfEstimatedUsefulLivesOfPropertyAndEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_StatementClassOfStockAxis": {
     "auth_ref": [
      "r225",
      "r226",
      "r227",
      "r256",
      "r284",
      "r285",
      "r292",
      "r294",
      "r302",
      "r303",
      "r340",
      "r375",
      "r378",
      "r379",
      "r380",
      "r384",
      "r385",
      "r417",
      "r418",
      "r420",
      "r421",
      "r423",
      "r570",
      "r721",
      "r763",
      "r779",
      "r789"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by the different classes of stock of the entity.",
        "label": "Class of Stock [Axis]"
       }
      }
     },
     "localname": "StatementClassOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://haymaker.com/role/BusinessCombinationAdditionalInformationDetails",
      "http://haymaker.com/role/ConsolidatedBalanceSheets",
      "http://haymaker.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://haymaker.com/role/ConsolidatedStatementsOfStockholdersEquityDeficit",
      "http://haymaker.com/role/Cover",
      "http://haymaker.com/role/EarnoutLiabilityAdditionalInformationDetails",
      "http://haymaker.com/role/NetLossPerCommonShareScheduleOfComputationOfDilutedWeightedAverageSharesOutstandingDetails",
      "http://haymaker.com/role/NoncontrollingInterestAdditionalInformationDetails",
      "http://haymaker.com/role/ShareBasedCompensationAdditionalInformationDetails",
      "http://haymaker.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://haymaker.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfCommonStockIssuedAndOutstandingDetails",
      "http://haymaker.com/role/WarrantLiabilityAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r26",
      "r103",
      "r214",
      "r241",
      "r242",
      "r243",
      "r261",
      "r262",
      "r263",
      "r266",
      "r275",
      "r278",
      "r301",
      "r347",
      "r425",
      "r498",
      "r499",
      "r500",
      "r523",
      "r524",
      "r560",
      "r583",
      "r584",
      "r585",
      "r586",
      "r587",
      "r588",
      "r616",
      "r689",
      "r690",
      "r691"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://haymaker.com/role/ConsolidatedStatementsOfStockholdersEquityDeficit",
      "http://haymaker.com/role/Cover"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://haymaker.com/role/ConsolidatedBalanceSheets",
      "http://haymaker.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://haymaker.com/role/ConsolidatedStatementsOfIncomeAndComprehensiveIncome",
      "http://haymaker.com/role/ConsolidatedStatementsOfStockholdersEquityDeficit"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r261",
      "r262",
      "r263",
      "r301",
      "r659"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://haymaker.com/role/ConsolidatedBalanceSheets",
      "http://haymaker.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://haymaker.com/role/ConsolidatedStatementsOfIncomeAndComprehensiveIncome",
      "http://haymaker.com/role/ConsolidatedStatementsOfStockholdersEquityDeficit"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "auth_ref": [
      "r6",
      "r7",
      "r103",
      "r110"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of new stock issued during the period.",
        "label": "Stock Issued During Period, Shares, New Issues",
        "terseLabel": "Stock issued during period, shares, new issues",
        "verboseLabel": "Issuance of shares under SEPA, shares"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://haymaker.com/role/ConsolidatedStatementsOfStockholdersEquityDeficit",
      "http://haymaker.com/role/NoncontrollingInterestAdditionalInformationDetails",
      "http://haymaker.com/role/WarrantLiabilityAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueIssuedForServices": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders.",
        "label": "Stock Issued During Period, Value, Issued for Services",
        "terseLabel": "Stock issued during period value issued for services"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueIssuedForServices",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://haymaker.com/role/WarrantLiabilityAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "auth_ref": [
      "r6",
      "r7",
      "r103",
      "r110"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.",
        "label": "Stock Issued During Period, Value, New Issues",
        "verboseLabel": "Issuance of shares under SEPA"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://haymaker.com/role/ConsolidatedStatementsOfStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r7",
      "r10",
      "r11",
      "r73",
      "r755",
      "r781",
      "r796",
      "r914"
     ],
     "calculation": {
      "http://haymaker.com/role/ConsolidatedBalanceSheets": {
       "order": 24.0,
       "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders' Equity Attributable to Parent",
        "totalLabel": "biote Corp.'s stockholders' equity (deficit)"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://haymaker.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r146",
      "r147",
      "r154",
      "r214",
      "r215",
      "r242",
      "r261",
      "r262",
      "r263",
      "r266",
      "r275",
      "r347",
      "r425",
      "r498",
      "r499",
      "r500",
      "r523",
      "r524",
      "r560",
      "r583",
      "r584",
      "r588",
      "r616",
      "r690",
      "r691",
      "r781",
      "r796",
      "r914"
     ],
     "calculation": {
      "http://haymaker.com/role/ConsolidatedBalanceSheets": {
       "order": 22.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.",
        "label": "Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance",
        "totalLabel": "Total stockholders' equity (deficit)"
       }
      }
     },
     "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://haymaker.com/role/ConsolidatedBalanceSheets",
      "http://haymaker.com/role/ConsolidatedStatementsOfStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest [Abstract]",
        "terseLabel": "Stockholders' Equity (Deficit)"
       }
      }
     },
     "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://haymaker.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityPolicyTextBlock": {
     "auth_ref": [
      "r101"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for its capital stock transactions, including dividends and accumulated other comprehensive income.",
        "label": "Stockholders' Equity, Policy [Policy Text Block]",
        "terseLabel": "Stockholders' Equity (Deficit)"
       }
      }
     },
     "localname": "StockholdersEquityPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://haymaker.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SubsequentEventsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events [Abstract]"
       }
      }
     },
     "localname": "SubsequentEventsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "auth_ref": [
      "r624",
      "r625"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.",
        "label": "Subsequent Events [Text Block]",
        "terseLabel": "Subsequent Events"
       }
      }
     },
     "localname": "SubsequentEventsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://haymaker.com/role/SubsequentEvents"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplemental Cash Flow Information [Abstract]",
        "terseLabel": "Supplemental Disclosure of Cash Flow Information"
       }
      }
     },
     "localname": "SupplementalCashFlowInformationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://haymaker.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SupplierConcentrationRiskMember": {
     "auth_ref": [
      "r65"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reflects the percentage that purchases in the period from one or more significant suppliers is to cost of goods or services, as defined by the entity, such as total cost of sales or services, product line cost of sales or services, segment cost of sales or services. Risk is the materially adverse effects of loss of a material supplier or a supplier of critically needed goods or services.",
        "label": "Supplier Concentration Risk [Member]",
        "terseLabel": "Vendor Concentration"
       }
      }
     },
     "localname": "SupplierConcentrationRiskMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://haymaker.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": {
     "auth_ref": [
      "r338",
      "r339",
      "r411",
      "r422",
      "r551",
      "r626",
      "r627",
      "r628",
      "r629",
      "r630",
      "r631",
      "r632",
      "r633",
      "r634",
      "r635",
      "r636",
      "r637",
      "r638",
      "r639",
      "r640",
      "r641",
      "r642",
      "r643",
      "r644",
      "r645",
      "r646",
      "r647",
      "r648",
      "r649",
      "r650",
      "r651",
      "r652",
      "r653",
      "r654",
      "r655",
      "r793",
      "r794",
      "r795",
      "r930",
      "r931",
      "r932",
      "r933",
      "r934",
      "r935",
      "r936"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms.",
        "label": "Financial Instruments [Domain]"
       }
      }
     },
     "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://haymaker.com/role/FairValueMeasurementsScheduleOfFairValueHierarchyForFinancialAssetsAndLiabilitiesDetails",
      "http://haymaker.com/role/FairValueMeasurementsSummaryOfChangesInTheFairValueOfCompanysLevel3FinancialInstrumentsDetails",
      "http://haymaker.com/role/FairValueMeasurementsSummaryOfSignificantInputsToMonteCarloSimulationForFairValueOfEarnoutLiabilityDetails",
      "http://haymaker.com/role/FairValueMeasurementsSummaryOfSignificantInputsToMonteCarloSimulationForFairValueOfPrivatePlacementWarrantsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TypeOfAdoptionMember": {
     "auth_ref": [
      "r212",
      "r213",
      "r214",
      "r215",
      "r216",
      "r265",
      "r266",
      "r267",
      "r268",
      "r280",
      "r335",
      "r336",
      "r344",
      "r345",
      "r346",
      "r347",
      "r349",
      "r350",
      "r498",
      "r499",
      "r500",
      "r521",
      "r522",
      "r523",
      "r524",
      "r539",
      "r540",
      "r541",
      "r552",
      "r553",
      "r554",
      "r555",
      "r556",
      "r557",
      "r558",
      "r559",
      "r560",
      "r561",
      "r562",
      "r563",
      "r571",
      "r572",
      "r574",
      "r575",
      "r576",
      "r577",
      "r578",
      "r579",
      "r589",
      "r590",
      "r594",
      "r595",
      "r596",
      "r597",
      "r611",
      "r612",
      "r613",
      "r614",
      "r615",
      "r616",
      "r660",
      "r661",
      "r662",
      "r687",
      "r688",
      "r689",
      "r690",
      "r691",
      "r692",
      "r693",
      "r694",
      "r695",
      "r696",
      "r697",
      "r698"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amendment to accounting standards.",
        "label": "Accounting Standards Update [Domain]"
       }
      }
     },
     "localname": "TypeOfAdoptionMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://haymaker.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TypeOfArrangementAxis": {
     "auth_ref": [
      "r909"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]"
       }
      }
     },
     "localname": "TypeOfArrangementAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://haymaker.com/role/RelatedPartyTransactionsAdditionalInformationDetails",
      "http://haymaker.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_UnrecognizedTaxBenefits": {
     "auth_ref": [
      "r503",
      "r511"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of unrecognized tax benefits.",
        "label": "Unrecognized Tax Benefits",
        "terseLabel": "Uncertain tax positions"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefits",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://haymaker.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UseOfEstimates": {
     "auth_ref": [
      "r68",
      "r69",
      "r70",
      "r304",
      "r305",
      "r307",
      "r308"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.",
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "terseLabel": "Use of Estimates"
       }
      }
     },
     "localname": "UseOfEstimates",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://haymaker.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ValuationAllowanceLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Valuation Allowance [Line Items]"
       }
      }
     },
     "localname": "ValuationAllowanceLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://haymaker.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ValuationAllowanceTable": {
     "auth_ref": [
      "r131"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A listing of an entity's valuation allowances to reduce deferred tax assets to amounts which it is more likely than not will not be realized, including a description of the deferred tax assets for which the valuation allowance has been recorded and the amount of the valuation allowance.",
        "label": "Valuation Allowance [Table]"
       }
      }
     },
     "localname": "ValuationAllowanceTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://haymaker.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_VariableRateAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of variable rate.",
        "label": "Variable Rate [Axis]"
       }
      }
     },
     "localname": "VariableRateAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://haymaker.com/role/LongTermDebtAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_VariableRateDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Interest rate that fluctuates over time as a result of an underlying benchmark interest rate or index.",
        "label": "Variable Rate [Domain]"
       }
      }
     },
     "localname": "VariableRateDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://haymaker.com/role/LongTermDebtAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_VestingAxis": {
     "auth_ref": [
      "r876",
      "r877",
      "r878",
      "r879",
      "r880",
      "r881",
      "r882",
      "r883",
      "r884",
      "r885",
      "r886",
      "r887",
      "r888",
      "r889",
      "r890",
      "r891",
      "r892",
      "r893",
      "r894",
      "r895",
      "r896",
      "r897",
      "r898",
      "r899",
      "r900",
      "r901"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by vesting schedule of award under share-based payment arrangement.",
        "label": "Vesting [Axis]"
       }
      }
     },
     "localname": "VestingAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://haymaker.com/role/EarnoutLiabilityAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_VestingDomain": {
     "auth_ref": [
      "r876",
      "r877",
      "r878",
      "r879",
      "r880",
      "r881",
      "r882",
      "r883",
      "r884",
      "r885",
      "r886",
      "r887",
      "r888",
      "r889",
      "r890",
      "r891",
      "r892",
      "r893",
      "r894",
      "r895",
      "r896",
      "r897",
      "r898",
      "r899",
      "r900",
      "r901"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Vesting schedule of award under share-based payment arrangement.",
        "label": "Vesting [Domain]"
       }
      }
     },
     "localname": "VestingDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://haymaker.com/role/EarnoutLiabilityAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_WarrantsAndRightsNoteDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrants and Rights Note Disclosure [Abstract]"
       }
      }
     },
     "localname": "WarrantsAndRightsNoteDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_WarrantsAndRightsOutstanding": {
     "auth_ref": [],
     "calculation": {
      "http://haymaker.com/role/ConsolidatedBalanceSheets": {
       "order": 20.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of outstanding derivative securities that permit the holder the right to purchase securities (usually equity) from the issuer at a specified price.",
        "label": "Warrants and Rights Outstanding",
        "terseLabel": "Warrant liability"
       }
      }
     },
     "localname": "WarrantsAndRightsOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://haymaker.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_WarrantsAndRightsOutstandingMaturityDate": {
     "auth_ref": [
      "r913"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expiration date of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in YYYY-MM-DD format.",
        "label": "Warrants and Rights Outstanding, Maturity Date",
        "terseLabel": "Warrants and rights expire date"
       }
      }
     },
     "localname": "WarrantsAndRightsOutstandingMaturityDate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://haymaker.com/role/WarrantLiabilityAdditionalInformationDetails"
     ],
     "xbrltype": "dateItemType"
    },
    "us-gaap_WarrantsAndRightsOutstandingMeasurementInput": {
     "auth_ref": [
      "r567"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of input used to measure outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur.",
        "label": "Warrants and Rights Outstanding, Measurement Input",
        "terseLabel": "Warrants and rights outstanding measurement input"
       }
      }
     },
     "localname": "WarrantsAndRightsOutstandingMeasurementInput",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://haymaker.com/role/FairValueMeasurementsSummaryOfSignificantInputsToMonteCarloSimulationForFairValueOfEarnoutLiabilityDetails",
      "http://haymaker.com/role/FairValueMeasurementsSummaryOfSignificantInputsToMonteCarloSimulationForFairValueOfPrivatePlacementWarrantsDetails"
     ],
     "xbrltype": "decimalItemType"
    },
    "us-gaap_WarrantsAndRightsOutstandingTerm": {
     "auth_ref": [
      "r913"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Warrants and Rights Outstanding, Term",
        "terseLabel": "Warrants and rights outstanding term"
       }
      }
     },
     "localname": "WarrantsAndRightsOutstandingTerm",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://haymaker.com/role/FairValueMeasurementsSummaryOfSignificantInputsToMonteCarloSimulationForFairValueOfEarnoutLiabilityDetails",
      "http://haymaker.com/role/FairValueMeasurementsSummaryOfSignificantInputsToMonteCarloSimulationForFairValueOfPrivatePlacementWarrantsDetails",
      "http://haymaker.com/role/WarrantLiabilityAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "auth_ref": [
      "r283",
      "r294"
     ],
     "calculation": {
      "http://haymaker.com/role/NetLossPerCommonShareScheduleOfComputationOfNetLossPerCommonShareDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "totalLabel": "Weighted average shares outstanding (diluted)",
        "verboseLabel": "Diluted"
       }
      }
     },
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://haymaker.com/role/ConsolidatedStatementsOfIncomeAndComprehensiveIncome",
      "http://haymaker.com/role/NetLossPerCommonShareScheduleOfComputationOfNetLossPerCommonShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Number of Shares Outstanding, Diluted [Abstract]",
        "terseLabel": "Weighted average common shares outstanding",
        "verboseLabel": "Denominator:"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://haymaker.com/role/ConsolidatedStatementsOfIncomeAndComprehensiveIncome",
      "http://haymaker.com/role/NetLossPerCommonShareScheduleOfComputationOfNetLossPerCommonShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "auth_ref": [
      "r281",
      "r294"
     ],
     "calculation": {
      "http://haymaker.com/role/NetLossPerCommonShareScheduleOfComputationOfNetLossPerCommonShareDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "terseLabel": "Weighted average shares outstanding (basic)",
        "verboseLabel": "Basic"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://haymaker.com/role/ConsolidatedStatementsOfIncomeAndComprehensiveIncome",
      "http://haymaker.com/role/NetLossPerCommonShareScheduleOfComputationOfNetLossPerCommonShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Number of Shares Outstanding Reconciliation [Abstract]",
        "verboseLabel": "Net loss per common share"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://haymaker.com/role/NetLossPerCommonShareScheduleOfComputationOfNetLossPerCommonShareDetails"
     ],
     "xbrltype": "stringItemType"
    }
   },
   "unitCount": 12
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "205",
   "URI": "https://asc.fasb.org/topic&trid=2122149",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=65888546&loc=d3e21300-112643",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21459-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21553-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21475-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21484-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21488-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21506-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21521-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21538-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 4.F)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187171-122770",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "50",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=6784392&loc=d3e188667-122775",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=6412939&loc=d3e15145-114933",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "60",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=66047640&loc=d3e39622-114963",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "70",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=49170846&loc=d3e28014-114942",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=d3e29149-114947",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5047-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126964447&loc=d3e11149-113907",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126964447&loc=d3e11178-113907",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "35",
   "Subparagraph": "(a)",
   "Topic": "720",
   "URI": "https://asc.fasb.org/extlink&oid=6420018&loc=d3e36677-107848",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32559-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32632-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(b))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=79982066&loc=d3e1486-128463",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "30",
   "SubTopic": "30",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=126966197&loc=d3e6578-128477",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "30",
   "SubTopic": "30",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=126966197&loc=d3e6613-128477",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=126975305&loc=d3e6927-128479",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)(4)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=126975305&loc=d3e6927-128479",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "805",
   "URI": "https://asc.fasb.org/topic&trid=2303972",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4568447-111683",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4568740-111683",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4569616-111683",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4569643-111683",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(c))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(3)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c),(3)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4I",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4590271-111686",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4591551-111686",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4591552-111686",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "810",
   "URI": "https://asc.fasb.org/topic&trid=2197479",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13531-108611",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13537-108611",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14172-108612",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28541-108399",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28551-108399",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28555-108399",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(b),22(b))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "940",
   "URI": "https://asc.fasb.org/extlink&oid=126941158&loc=d3e41242-110953",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "940",
   "URI": "https://asc.fasb.org/extlink&oid=126941158&loc=d3e41256-110953",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "940",
   "URI": "https://asc.fasb.org/extlink&oid=126941158&loc=d3e41261-110953",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(13))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(16))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(22))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19,20)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.15(3),(4))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.15)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.17)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.9)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(15))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "405",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=6957935&loc=d3e64057-112817",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "470",
   "Subparagraph": "(c)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=123599511&loc=d3e64711-112823",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "470",
   "Subparagraph": "(g)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=123599511&loc=d3e64711-112823",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "470",
   "Subparagraph": "e",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=123599511&loc=d3e64711-112823",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "470",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=123599511&loc=d3e64711-112823",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126941378&loc=d3e61044-112788",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(16))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(16))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(24))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.(a),19)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(19))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.17)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(8))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "205",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=25866437&loc=d3e10246-115837",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04.16(a))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=120401414&loc=d3e603758-122996",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04.16(b))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=120401414&loc=d3e603758-122996",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04.16)",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=120401414&loc=d3e603758-122996",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "220",
   "Subparagraph": "(k)",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=124433917&loc=SL114874205-224268",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-07.2(a),(b),(c),(d))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=120401555&loc=SL114874292-224272",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "985",
   "URI": "https://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "985",
   "URI": "https://asc.fasb.org/extlink&oid=6501960&loc=d3e128487-111756",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "730",
   "Topic": "985",
   "URI": "https://asc.fasb.org/subtopic&trid=2197926",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "105",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "105",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "105",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "105",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "105",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6904-107765",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22(a)(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(13))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(14))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(18))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(22))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(4))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(b))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(7))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(9))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=51824906&loc=SL20225862-175312",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.25)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL116659661-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(22))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(24))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(25))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(5))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(7)(d))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3367-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3000-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4297-108586",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18726-107790",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(c))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(1))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-04(a))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(4)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.31)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=SL124452830-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=122038215&loc=d3e31010-122693",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a-c)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.M.Q2)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=122038215&loc=d3e31137-122693",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1448-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1377-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1505-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1252-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1278-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1930-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)(1)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1930-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1930-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1930-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1337-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e3842-109258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "260",
   "URI": "https://asc.fasb.org/topic&trid=2144383",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(20))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e637-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "270",
   "URI": "https://asc.fasb.org/extlink&oid=126900757&loc=d3e543-108305",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=6373374&loc=d3e70478-108055",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e681-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669686-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9031-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e557-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "42",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9054-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4428-111522",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4531-111522",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=123577603&loc=d3e5074-111524",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=126986314&loc=SL124402458-218513",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=126986314&loc=SL124402458-218513",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(d)(1)",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=126986314&loc=SL124402458-218513",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27232-111563",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=SL120269820-111563",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(10))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL120254519-210437",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL120320025-210437",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL120320025-210437",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r349": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(3)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r350": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(4)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r351": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255206&loc=SL82895884-210446",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r352": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919244-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r353": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r354": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r355": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919253-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r356": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919258-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r357": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919230-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r358": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922888-210455",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r359": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922895-210455",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(8))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r360": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922900-210455",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r361": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "330",
   "URI": "https://asc.fasb.org/extlink&oid=116847112&loc=d3e4492-108314",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r362": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "330",
   "URI": "https://asc.fasb.org/extlink&oid=116847112&loc=d3e4542-108314",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r363": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "330",
   "URI": "https://asc.fasb.org/extlink&oid=116847112&loc=d3e4556-108314",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r364": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "330",
   "URI": "https://asc.fasb.org/topic&trid=2126998",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r365": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Topic": "340",
   "URI": "https://asc.fasb.org/extlink&oid=126905020&loc=d3e5879-108316",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r366": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "340",
   "URI": "https://asc.fasb.org/extlink&oid=6387103&loc=d3e6435-108320",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r367": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(b)",
   "Topic": "340",
   "URI": "https://asc.fasb.org/extlink&oid=126905575&loc=SL49131252-203054",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r368": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "440",
   "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r369": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "440",
   "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.19)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r370": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r371": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r372": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r373": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r374": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r375": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r376": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r377": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r378": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r379": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r380": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r381": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r382": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r383": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(C))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r384": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r385": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r386": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r387": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r388": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r389": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r390": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(f)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r391": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r392": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r393": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(i)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r394": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r395": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r396": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r397": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r398": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r399": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(22))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.8)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r400": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r401": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r402": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r403": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r404": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r405": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r406": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r407": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r408": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r409": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r410": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r411": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r412": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r413": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466204&loc=SL6031897-161870",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r414": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466204&loc=SL6031897-161870",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r415": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466204&loc=SL6036836-161870",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r416": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466204&loc=SL6036836-161870",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r417": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r418": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r419": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r420": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r421": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r422": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r423": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r424": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21475-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r425": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r426": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126919976&loc=SL49130531-203044",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r427": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126919976&loc=SL49130532-203044",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r428": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130551-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r429": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r430": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r431": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r432": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r433": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r434": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130556-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r435": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130556-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r436": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130558-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r437": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130543-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r438": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130545-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r439": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130549-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r440": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130549-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r441": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130550-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r442": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "606",
   "URI": "https://asc.fasb.org/topic&trid=49130388",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r443": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(i)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r444": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r445": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r446": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r447": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r448": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r449": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(03)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r450": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(n)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r451": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r452": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(b)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r453": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(c)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r454": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(d)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r455": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(e)(1)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r456": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(e)(2)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r457": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(f)(1)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r458": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(f)(2)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r459": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(f)(3)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r460": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=SL116886442-113899",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r461": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=d3e4534-113899",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r462": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=d3e4549-113899",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r463": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r464": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r465": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r466": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r467": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r468": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r469": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r470": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r471": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r472": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r473": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r474": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r475": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r476": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r477": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r478": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r479": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r480": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r481": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r482": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r483": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r484": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r485": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r486": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r487": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r488": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r489": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r490": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r491": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r492": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(v)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r493": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r494": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r495": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r496": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r497": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(l)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r498": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r499": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(27))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r500": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r501": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.D.2.Q6)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r502": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "718",
   "URI": "https://asc.fasb.org/topic&trid=2228938",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r503": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=SL37586934-109318",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r504": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e32247-109318",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r505": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e32280-109318",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r506": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e31917-109318",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r507": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e31931-109318",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r508": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32672-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r509": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r510": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r511": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r512": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r513": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32840-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r514": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r515": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r516": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32847-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r517": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r518": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r519": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r520": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r521": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r522": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r523": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r524": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r525": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(3)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r526": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.5.Q1)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r527": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.7)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r528": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.1)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r529": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.2)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r530": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.3)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r531": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.4)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r532": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.C)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r533": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r534": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "270",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r535": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r536": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "740",
   "URI": "https://asc.fasb.org/topic&trid=2144680",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r537": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=128092470&loc=d3e4946-128472",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r538": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=128092470&loc=d3e4946-128472",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r539": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=128092918&loc=SL128093175-196984",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3044-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r540": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=128092918&loc=SL128093175-196984",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r541": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=128092918&loc=SL128093175-196984",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r542": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)(1)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=126975305&loc=d3e6927-128479",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r543": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4569616-111683",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r544": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r545": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r546": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r547": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r548": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r549": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4273-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r550": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=121483254&loc=SL120254523-199619",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r551": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126731327&loc=d3e90205-114008",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r552": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(a)(1)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r553": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(a)(2)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r554": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(a)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r555": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(b)(1)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r556": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(b)(2)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r557": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(c)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r558": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r559": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(2)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4297-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r560": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r561": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(4)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r562": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r563": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL126732908-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r564": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r565": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r566": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r567": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(2)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r568": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r569": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19279-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4304-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r570": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r571": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL120254526-165497",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r572": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL120254526-165497",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r573": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL120254526-165497",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r574": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL121967933-165497",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r575": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL121967933-165497",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r576": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL121967933-165497",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r577": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL121967933-165497",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r578": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL122642865-165497",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r579": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL122642865-165497",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4313-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r580": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=126980362&loc=d3e28129-110885",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r581": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "20",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=123602790&loc=d3e30304-110892",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r582": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32022-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r583": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r584": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r585": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r586": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r587": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r588": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r589": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "832",
   "URI": "https://asc.fasb.org/extlink&oid=128342835&loc=SL128342857-244232",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4332-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r590": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "832",
   "URI": "https://asc.fasb.org/extlink&oid=128342835&loc=SL128342857-244232",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r591": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28555-108399",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r592": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124429444&loc=SL124452920-239629",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r593": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128293352&loc=SL120154346-209984",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r594": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128293352&loc=SL126838806-209984",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r595": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128293352&loc=SL126838806-209984",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r596": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128293352&loc=SL126838806-209984",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r597": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128293352&loc=SL126838806-209984",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r598": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r599": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=SL98516268-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r600": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918643-209977",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r601": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918666-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r602": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(3)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918673-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r603": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r604": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(1)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r605": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(2)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r606": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(3)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r607": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(4)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r608": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r609": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918701-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "https://asc.fasb.org/topic&trid=2122369",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r610": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/subtopic&trid=77888251",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r611": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL122150809-237846",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r612": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r613": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r614": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r615": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(01)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r616": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r617": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r618": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r619": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r620": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r621": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39691-107864",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r622": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "850",
   "URI": "https://asc.fasb.org/topic&trid=2122745",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r623": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=124437977&loc=d3e55792-112764",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r624": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "855",
   "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r625": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "855",
   "URI": "https://asc.fasb.org/topic&trid=2122774",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r626": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)(i)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r627": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)(ii)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r628": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r629": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r630": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r631": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r632": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r633": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r634": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r635": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r636": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r637": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r638": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r639": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=66007379&loc=d3e113888-111728",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "52",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e4984-109258",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r640": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=109249958&loc=SL34722452-111729",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r641": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r642": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r643": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r644": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(4)(i)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r645": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r646": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r647": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r648": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(4)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r649": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(5)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r650": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(6)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r651": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(7)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r652": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(b)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r653": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r654": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r655": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r656": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "910",
   "URI": "https://asc.fasb.org/extlink&oid=126937589&loc=SL119991595-234733",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r657": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "310",
   "Subparagraph": "(b)",
   "Topic": "912",
   "URI": "https://asc.fasb.org/extlink&oid=126938201&loc=d3e55415-109406",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r658": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "330",
   "Topic": "912",
   "URI": "https://asc.fasb.org/extlink&oid=6471895&loc=d3e55923-109411",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r659": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "https://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r660": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "926",
   "URI": "https://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r661": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "926",
   "URI": "https://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r662": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "926",
   "URI": "https://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r663": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61929-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r664": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61929-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r665": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62059-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r666": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62059-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r667": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62395-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r668": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62395-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r669": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "33",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62479-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6404-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r670": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "33",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62479-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r671": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "35A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=SL6807758-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r672": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "35A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=SL6807758-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r673": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(c)(1)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61872-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r674": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(c)(2)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61872-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r675": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(24))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r676": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(26))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r677": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(27))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r678": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r679": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r680": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r681": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(20))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r682": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(22))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r683": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(23))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r684": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(9))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r685": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r686": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124506351&loc=SL117782774-158439",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r687": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r688": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(b)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r689": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r690": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r691": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r692": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(1)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r693": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r694": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(ii)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r695": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(iii)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r696": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(iv)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r697": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(1)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r698": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r699": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=123600520&loc=SL75241803-196195",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r700": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "210",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=118262064&loc=SL116631418-115840",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r701": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "210",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=118262064&loc=SL116631419-115840",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r702": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "310",
   "Subparagraph": "(SX 210.12-29(Footnote 4))",
   "Topic": "948",
   "URI": "https://asc.fasb.org/extlink&oid=120402547&loc=d3e617274-123014",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r703": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Topic": "954",
   "URI": "https://asc.fasb.org/extlink&oid=126942805&loc=d3e3115-115594",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r704": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "440",
   "Subparagraph": "(a)",
   "Topic": "954",
   "URI": "https://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r705": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Subparagraph": "(d)",
   "Topic": "958",
   "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=d3e99779-112916",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r706": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "958",
   "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=d3e99893-112916",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r707": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "958",
   "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=SL120174063-112916",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r708": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column B))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r709": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column C))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "275",
   "URI": "https://asc.fasb.org/topic&trid=2134479",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r710": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column D))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r711": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column E))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r712": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column F))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r713": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column G))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r714": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column H))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r715": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column I))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r716": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Footnote 2))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r717": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Footnote 4))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r718": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(c)",
   "Topic": "976",
   "URI": "https://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r719": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(b)",
   "Topic": "978",
   "URI": "https://asc.fasb.org/extlink&oid=126945304&loc=d3e27327-108691",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=123577603&loc=d3e5144-111524",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r720": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "985",
   "URI": "https://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r721": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "1402",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r722": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r723": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r724": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r725": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r726": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r727": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r728": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "52",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e4984-109258",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r729": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r730": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r731": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=121590138&loc=SL82922954-210456",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r732": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r733": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r734": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r735": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69E",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495743-112612",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r736": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495745-112612",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r737": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r738": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r739": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "330",
   "URI": "https://asc.fasb.org/extlink&oid=116847112&loc=d3e4492-108314",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r740": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r741": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r742": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r743": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r744": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r745": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r746": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r747": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r748": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r749": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450673-114947",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "30",
   "SubTopic": "40",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=118172244&loc=d3e17916-109280",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r750": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r751": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r752": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4591551-111686",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r753": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4591552-111686",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r754": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "53",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123414884&loc=SL77918982-209971",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r755": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r756": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117783719-158441",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r757": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(b)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117783719-158441",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r758": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117819544-158441",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r759": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "50",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=16397303&loc=d3e19379-109286",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r760": {
   "Name": "Form 20-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "220",
   "Subsection": "f",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r761": {
   "Name": "Form 40-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "240",
   "Subsection": "f",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r762": {
   "Name": "Securities Act",
   "Number": "7A",
   "Publisher": "SEC",
   "Section": "B",
   "Subsection": "2",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r763": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70229-108054",
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef"
  },
  "r764": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14615-108349",
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef"
  },
  "r765": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314020-165662",
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef"
  },
  "r766": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r767": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r768": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r769": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(8))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=109226317&loc=d3e202-110218",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r770": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(9))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r771": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r772": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r773": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r774": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(2)(a))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r775": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(2)(d))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r776": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3179-108585",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r777": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r778": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r779": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(d))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=126905813&loc=d3e1205-110223",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r780": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(f))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r781": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r782": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r783": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(k)(1))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r784": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r785": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r786": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r787": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r788": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r789": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "55",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e2626-109256",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=126905981&loc=d3e2420-110228",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r790": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r791": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8672-108599",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r792": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4647-111522",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r793": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "321",
   "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r794": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "321",
   "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r795": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "321",
   "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r796": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r797": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r798": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.A)",
   "Topic": "340",
   "URI": "https://asc.fasb.org/extlink&oid=122040515&loc=d3e105025-122735",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r799": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "410",
   "URI": "https://asc.fasb.org/extlink&oid=6393242&loc=d3e13237-110859",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r800": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r801": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r802": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r803": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r804": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r805": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "450",
   "URI": "https://asc.fasb.org/topic&trid=2127136",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r806": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r807": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r808": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r809": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r810": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r811": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r812": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r813": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130551-203045",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r814": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130545-203045",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r815": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r816": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(1)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r817": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(10)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r818": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(2)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r819": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(3)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r820": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(4)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r821": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(5)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r822": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(6)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r823": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(7)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r824": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(8)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r825": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(9)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r826": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r827": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r828": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r829": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r830": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(4)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r831": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(5)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r832": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(6)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r833": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(7)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r834": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(8)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r835": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r836": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(i)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r837": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r838": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r839": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=109226691&loc=d3e2921-110230",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r840": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r841": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r842": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r843": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(03)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r844": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r845": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(f)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r846": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r847": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r848": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)(1)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r849": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)(2)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.CC)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=27011434&loc=d3e125687-122742",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r850": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)(3)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r851": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)(4)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r852": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)(5)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r853": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)(6)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r854": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)(7)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r855": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(i)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r856": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(j)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r857": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(k)(1)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r858": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(k)(2)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r859": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(k)(3)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "360",
   "URI": "https://asc.fasb.org/topic&trid=2155823",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r860": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(k)(4)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r861": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(n)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r862": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(q)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r863": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2410-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r864": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2417-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r865": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2417-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r866": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r867": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(1)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r868": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(2)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r869": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(3)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "440",
   "URI": "https://asc.fasb.org/topic&trid=2144648",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r870": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(4)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r871": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(5)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r872": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(6)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r873": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(7)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r874": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r875": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2919-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r876": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r877": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r878": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r879": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r880": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r881": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r882": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r883": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r884": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r885": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r886": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r887": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r888": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r889": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r890": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r891": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r892": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r893": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r894": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r895": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r896": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r897": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r898": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r899": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r900": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r901": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(v)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r902": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r903": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r904": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32621-109319",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r905": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r906": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r907": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r908": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.4)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r909": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "808",
   "URI": "https://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "460",
   "URI": "https://asc.fasb.org/extlink&oid=124440162&loc=d3e12021-110248",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r910": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=124256753&loc=SL5864739-113975",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r911": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r912": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r913": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(2)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r914": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r915": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r916": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(1)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r917": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918701-209980",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r918": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r919": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "460",
   "URI": "https://asc.fasb.org/extlink&oid=124440162&loc=d3e12053-110248",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r920": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r921": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r922": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r923": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r924": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r925": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r926": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r927": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4H",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r928": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=123600520&loc=SL75241803-196195",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r929": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "985",
   "URI": "https://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123465755&loc=d3e1835-112601",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r930": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "1402",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r931": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(1)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r932": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r933": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(3)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r934": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(i)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r935": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(ii)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r936": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(iii)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "40",
   "SubTopic": "50",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126972273&loc=d3e12317-112629",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "40",
   "SubTopic": "50",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126972273&loc=d3e12355-112629",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "470",
   "URI": "https://asc.fasb.org/topic&trid=2208564",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "10",
   "Topic": "480",
   "URI": "https://asc.fasb.org/extlink&oid=109262497&loc=d3e20148-110875",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(CFRR 211.02)",
   "Topic": "480",
   "URI": "https://asc.fasb.org/extlink&oid=122040564&loc=d3e177068-122764",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Topic": "480",
   "URI": "https://asc.fasb.org/extlink&oid=122040564&loc=d3e177068-122764",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  }
 },
 "version": "2.2"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>101
<FILENAME>0001193125-23-092665-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001193125-23-092665-xbrl.zip
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MFY-U;-ENON@408O%PW+ETS5NUTVP3=3J($'((5J<AG 1SO4"$;AGJA]X5SC
MLN\FR!^]!"WGH*F-JC[C.J-BJUQE2=IESPU]Z#O;CAS=(FN5"%[=LZ33>J^[
MR9V^"X2%]P2_#&63<OKFR8=Q6!=EW?!7&<T>]PO%::!;2OU81+>Q.)=8+'#B
MO1UWUA9)BXED$.ATSH1RME:A]VB=STGZ5J$Y9NI[G"(^Y>X"+]&?_@]02P,$
M%     @ _:*%5G$<3KNN%@  6E4! !4   !B=&UD+3(P,C(Q,C,Q7V-A;"YX
M;6SM76UOXSB2_G[ _H=<]G,Z;6=NIKNQO0LG3AH!TNT@3F_OX; 8,#)E<UN6
MO)24Q'.X_WY%2K9EBV]ZL2@Y!G9[8ILO57R*9+%85?S+WU[GWLDSIB$)_,^G
MO7?O3T^P[P03XD\_G\:1>_;A]&]__=-__.4_S\Z^8!]3%.')R=/R9'AS^^WD
M'Y</=R>W?A@AW\$GP\")Y]B/3LY.9E&T^'1^_O+R\F[B$C\,O#B"#L)W3C _
MA]__GG1X\G#Q[CU\A+_>_WHV6%#BG?7?]R]._N?]Q:=^[]-%_Y\G_SOX^G]G
M9XP$C_@_GU"(3X!D/_Q\FNGD]8EZ[P(Z/>^_?W]QOBIXFI3\]!J2K=(O%ZNR
MO?-_?+T;.S,\1V<DY6-=BS4CJM?[^/'C.?\5BH;D4\CKWP4.BO@@:NDZD99@
MG\Y6Q<[85V>]_ME%[]UK.#EE8T ##S]@]X1W_RE:+O#GTY#,%QXCFW\WH]C]
M?/H4S2=L*/N]?E+[SU<!@X%,&("7R&.<CF<81^'I"6OT^\/MFO(96L[13TPY
M6NS'<T7E\_K(&D?P+Y.@<.3>@A#.\<"?7 7S!<4S[(?D&2??%J78O-T],7.%
MPMF-%[P4'FM)(Q7)',?S.:++D3LF4Y^XQ$%^-'"<(/8CF/;WT+E#<+@N]1A$
MR!M%,TRO8DJ!F$$8 O1#'"'B&;%4<X<5V7_ S]B/H;(3 #5LSHKHNYHA?XK#
M6Q_PB"ARHCN"GHA'HF4Z 8H,0.U=[F\(F/B1"5OHX=N!Y[%E#4\>@WM,W8#.
M&1FC)X],^>\UC4')/BL.PJT/!$4!77[#$=L#)K&'V0*Q^;8 =P4:JTCV/0T6
MF$9+6,.N_QV3!5L>MCJ5%"C 3.4NJJZC:$%@"2!_P H8N-$+HIAUOQ87X<\%
M^*O6?D7F8.&C,9Y<ORY@[X%5;SVH.S\4X*=PDQ59N O\Z2.F\R%^R@C%*(Z8
M!L541_9# ?J+M;<7XF_B**;X*X)_86W"L-]FRU7FQ;#YJJQA%&;VT=&"+ZG^
ME']_%811F*Z^(-G??5AP!Z'SX9<^S.)QO(#VV31&WDK1N/7YXLO6W)N )FT7
M&8CFB*ESV++J[96'PI!OSJS?71Y"(/4')M,9[%4#.$*A*?0_1\1?%6#P0IDA
M";FJ\P";6MGQ:XBJ>N7O'GABNNOE<@B= &S;E):7)=.&*RL([%3PB%ZS2VKR
MY5T0AI<81!+#5OA,PD0L,Q4*J0XU=+,_5N'+=>?U<"5L<1\,L 7&=T"#3F?*
MXPS?8*9G>NOB3/P? _B!G0>1O[QV7>Q$<"1,?ZO*<9TDU#=$0^QB.%E-X$-R
MMH(%8778(&6%U[31BFR *L:F!9P-8+SF<(J8@7ZV&7 VB'&4CK:P; 'NZNN+
M,^T@SXD]7OX.6-QB'K]&&';!R8I]UG_=]@UN10N<K7[Y82N@VZ/.N@VA7VZ=
M<E'XQ$U4<7@V16AQSN XQUX4KK[A '%PTB]^A\'8K&"KMCWTA#W>X^^2<N>6
M*!Q$$25/ .63!U/Q&\Q8=@(//.AP>NM'F.(P,N7"K*U=>1C0;:81=58=PI];
MPI W&Z8ESD.V0;+6S@@(Q*J^2X.Y<M33?H/*3,4A4!DL& 7(.ST)*"QTGT][
MIR<O7"'Y?'K6:Q1CV&5<$FE$,%NH_:ADJ14/=W\SW,V.]H;X&^"-V;"('X-\
MI,H9+%B)*I/9,JY?(XJ ;N*#7G<+HQ,6GGM[[=6J/.2E=U<8]LJ[6+HN;$G7
M6L4WVE>$I:VBV<#LV!4/X2"(8?W%%JRI57@U)LSJ_8-$LZLXC(!D>OWJ>#&S
M #&-$O['E$L%[*5:LRH6"K'>A;,4<V*X_\L6W,SN,W*_!,&$G0[&F#X3!Z\I
M'V)069WDJ 1_>YC#X4\&\X!&Y _^O0+].AKOBC#4P:M8-GZUIJZ-D8=#=G@B
M(3,-,,9N,%8M\](:78%1RH 8F]^L8?,5T9^8\93>)2A R1?M"AIYRL4P?+ W
M13#?^1-7'(_-Z,F<^"2,&(O/6 ^.:0-=@<R4'S&0'ZT!"9I<L,VE'CM%G;>F
MVBJ&0F*$>&_O6)RPLD5FEGXX]RO/MR;5[1HN=+*</[>:\"0!LF<+R!M$Z-^1
M%^/!Y%^@<S.#Z\C]@2A%?J124C3UN@6=AAD)9OVRZVS>_,^^^?T+(OYZO>%>
M4[?^FK*1>XVH'\0;]RD!..6:Z096Y7B30&?-X,,8"!D'.!SYL%\ US$)9XG$
M,:\)Q90SJ-L-* LP),'/FF6'.W#F&549[60UNH65E T)0M:,,6M]+&7H$I1H
ME^B-[8(:G3"4"^B60"*R@9SOW-Z^K0M=0>^@I(U<M3U66>MX$2B19X.Q+GXM
MV/OM>"]XO!?<V[U@[\/Q8K SUI,"%X.]C\>;P=8;06N\&>Q;LY,=KP9;?S78
MM^?*=;P;U-T-]DL;V8Z7@W5>#O8OCK>#;<&LVNU@_Y?C]6 W%=S"UX-]BT:X
MX_5@C=>#_5^/UX-=NQ[LEW9K.EX/6KX>[%LS^QRO!^NX'NQ;,^\<KP?-K@<O
M+#HN':\'Q9#8,X,D69'R]T.,N]4=T3TSY, 8;X7LW2.62$DWNZJTW+4KL\H,
M2X3#6OR=C*$;.%N1J9_DTG*6CZ"+A<A)S7[\4P+82B484!(R0V%,67(N3$DP
M,;CJ;:1WNW:'>N:>J1S6.G 2614X=UER<]ADMVOPQ@'Z9/]G*:R>D<<(>8!C
M)R4.$,=^@('>_B)3,AEA@(HF*4>2_\+GQ,Q^_>IPK9HE<$@2.JAN)QHFI-DP
M>T8OS_<!4G*Y_!YB(/:&^,AWV)44RW3!\T.H+%L%&K&[#5F1*$'DOO%P:4/V
MZSB/ R4.QA-^V+R,897"(;O8> *")/=V9M5LA^L7E.RM [B6N7JC^Z7($"!V
M@;P'O$B3*HU\EB'J+D *7)25NHV*DC5M3'PMYJO+@-+@!8@UP$)<MLL0B#EJ
M6=CZ*@-98EW9MKCPW'8J/T-]W8[B5X!#;5QZTZEBMDB^#<.8Y=LK!N5.K8,"
M<8>WFD/'9;O3FH0QCJ(D)>3(O0<U* KF3'.*E@^L.^E&95R_HU@5Y++FH/)"
MJ&W4WG$4.#^_^T0XLPJW<'C(B?FL.1+=0%-?37F@CJ6R"WF2UC'H12;ZNJ)R
MIQ$S8U$;;5[G/'L,QM?W@XQ]2+9K&=7J-#H:WO2AX?:T#L(X]B>&VL:F=$?Q
M4O*DC_RVAA-?DHNKAZ)J!X.<B+FZ \$K0YB8S$9NUHPV\BL9[-:FN2$)%T&(
MO"\TB!>KW-K<S0U/-EYN"D%I W%'PVDK8&A;&+YDH5@[X58QX L;.<IAH>%J
M6]A_MT)MBTMWB<A;:[[%%8.F.A 651V_*O%0/6O.QMGG((9!_!2YL9>^J*:9
M=XIJ'4=2S5S;HN*S\C5RUWJW[DBAKM9Q!-7,M2WP?/VXVP\* S,,7E1KJ:AP
MQ]$2L51S$+G$\O4MX$HY?^Q''A<E+]K1@9<S5',LMWK861"JUA8L+GL  [_#
MD3Y0NL:1'R^8]QSEYF9NW70QE1IZU74.  D)9_KHZ(:#<AE]ES!;>08GF*\Z
MM5M6H:.0Z=C21U$?X_CLHU<NL*^L%4*R# J),(WF,ZS<49R*L-BV$.B##N6K
M///*Q_;9>\EA]11@)J2?!2V@UROX4NSX85ZUXWCJ&=1'23<>"+ACT5Z951ZP
M@\DSBW)1'GU-JG<<53,F]4'4#4_4/-FK4[WZ0D=3[^# W.).'TIM'<4DJ(R'
MCD7)8ZR%P!15/SA,14SJ8["M0[M:5^[1LO3"NZY[<*#F.-2'<-L&=*40I%D<
M"P&:JWMP@.8X;%O8M5 &:8RS;U\7G:2YZ@<'JXA)\R!E:]OJBF5N?E>9'$JT
M<7 82SF5 &W-9T7"/%/ZPJH^3L)&CCY.A89+(B_6#%8;/_.! T-#,7 !LAXM
M[ST$NJ0_80.VF*L3KA1II(U+@V)VR%R%35B58&W/EK4B_B:@X\"-7A!5J6C"
MT@<"WQ9/$IQ$P61[3BDR9@-!ER-W3*8^<8G#9"HY!K!,*(%''&!N7>HQB)"7
M/_L-<82(UV3ZD7N*%XA,TDM\F 6<J(2:E#2E*Y=![48]TK+T%*5_FV)[F<*,
M$<D[GPG9J3>]1G6GL\DSB]$(1VN#UO(^IK!EATK51EVMJY"IN:HW_49M-RHC
M4*JH@9^@I'Q7L9*PH\W'T= 6E!HG'K 3P!;$6A1M2DF>U?#67SW2L3X272*/
MBV+SFU!>DQ>](%+NI*MIJ=&W1124;(/WQP9TX3LBQ1JRG7B]#+;Y]T2*\:S=
M\VJ)5%=2M>(\',;X,6#J;W(+AR>;MW#FJ]NYE/!!*#? [KW'+LO)W@='NQ7O
M7Z#6_H67.'K!V%\='?P)<T9,/F1LF9Q/ML\Q"TI^<TB,**7D;#^$'+;X[6?,
MS'.!V5,^6+9-./0GP:4#CT\'/'D,@ <WH'.>O>+)(],D^+1Y[:.LKM$1S4)_
M"C:K;CFU<MTZ0UM/QTJBV0,TU>#,MG!@B&99,SXX[WE97!_JO^%H[,SP)/8P
M>TYY\ZV-T]:F=^51*EO,1DC;%ZH.X-XM:%F!R(^J-%@M);AE2\^:O(WGMM'P
M;Q7O#@A;9)NK]WM>,5:W4MD+J:W%0U+ QM6!Y/Y,O:ZHJS4;OBXF1+?NZ"K:
M?FA$BXH@:%W)4,O6J8'CQ',VMGABDCBAS+UX?5UT3ACJ8[TU:^H56I (><RB
ML[H[9DOJ^H J_-G"071#!XM.C"-,,_2H-'Y-Q>IFJ?P(_<!/(0B?,LVCMIIE
M%R23X=ZV\.@8:N0E P$50_R,O8#/NUN?YP<5[F#%JA\ .F+&6G:MJF ULQB;
M/C)?HK$. 5V%S=882U._X_0..MSH]CL_-+\%Y3VB]>9#19UFE4)&!<N$AOE3
M]<AC63*,R9=6M#HYM'@(M#<E-RU3Y:_G"R]88OR ^7PM)'<&=;N%G0%#C;S'
MDQ+^%3,_)#]23R-MC6Y@H&7#V,NG*5M=\CQY&F*FGRVR"MV 1\=%O2_S2.;%
M'9XBCY.,/,V$$!;MQE#+Z=<^EV/AJ=$R"HNN8C=P,N5&^TI.0TKO7>!/V5-:
M+%O(1N,=Q5$8(9\GIX8?FM=XLV097:_**ECPPTV24R:V![6%2%K#JJRKQU[F
M?IOCH1E?OT>,^#-P&W>=])W=2^P&%'_W47+89&93_>-=U9OL '+5F6R9I893
MZ(<1C?DK<HC2Y=IM4#G[5-6L %F72.<GJ8K5>I5HS42M>Y9V9(K6C6S%,3#6
MS/>M?G#?W_6=SW98.*=UX_;+4ZL.0N?#+_V!/QG'BT7R+!KHPND+X;<^=UUD
MA-T$-&G;@NZRHEVEKFS*-*F;YX97I8\+"MO=W7:)SNG< HJ-+6M-"GH:TS.>
M81Q=>2@,>100ZV9W"K#\;S\XI7@R>(9?IO@!SQ'Q5P78=K]Z,@86<Q9<W[S$
M%\]]H<YT895J@Y.JIJ+56:+!0CUG6N^'*R'7Z(AH4/< D&NCOVV;%S^I51':
MEZ;'RQ>Q-@?X^[TC]WM*BK'\Y^K94XL%8ZT6]ASM;0GVW5%G5]DQ+I=#$$U0
M2;?9L*&:PGAAR<JQHG:H3#1GWD2#4\*4J/_&B-X$,:V!OTU3EI7B8HCN3JSB
M[+9,(RC"P"/T68=L9]IZ,^"G_+;,]&?*P<"-,.4R3)[KD("=]MZ$%.SPW+*K
M]T*R_!+4M0JPEMX$^FMNZ[W4;W;KKV?RO[%YKYORUEP-3!GX!EK\XPOVGO'7
MP(]FJB"B\DV^"5'(L]T6/X;,DQG9B%[V)7L@);D3R3X#FJE@);522M@-8'F5
M//8- []Y[3LA.$/D]6M$$0PO\>%H>0O2$#)+#XN\#CP@;;KRP5(ZF^VQUV:3
M+Q?E8PA_A!%QZAV=3:NVLZ3L6YH$&9W+#U;+3I E>('U TA5/^I:OM&C,)F/
M55M,W%O;2>(1!1\2H^; S[H -K_;Y @R\TK;+F[!D6Y-@"[T6U;!ZD12C;K,
MB6Z7@9:ME#DRDTS1NI04ZFKM FE+U+0P;3'2,M-8CMB->@\L<A\P6%1?$)T4
MPD[52I>A5/'5,E-7GM,@F+P0SX.-!O9:Y$_)DR>_O"S73)>Q53+6,GM6CGCV
M:FLRXIX7O+"K\R*8BFJW"\HBVZ*(&ZU1JK%\%NS-<8],6)1@ULFAT4AAW:2W
MX*]@^FR!Z($":_$^2F^$'4I;IJ4Q;UC%,"<_MV!T-1%4"9TM4ZKR+[>R-U1,
MHMD5U=J/A9K^EJE'Y3,IMAJ#;7I;IK4T]6!-JQ$R8J-E=VC[2Q?8SJU;3;CQ
M;593._D^4X^U$R =Z6*(?FN'0WJWG7'- "KEBOO!]G%Z;9\O8@$756HQ,BJR
MQ;!\;/R>I V'Y,QE# LDC +GYRSP8$!"MALHXY;T59OT?S%Z1;H]CT6;CGO.
M.T7_$G3OO34GI"(Y3EJ7UT0@0HK1UUD\;.8>YN=3X[Q+L@IM </P/&Z6<*EG
MTUQ2>^+"3J!3+.U/SY[7="9CB,'R)2K=$5"$M$O@L&9&.?PG@\P!J_1.D+WT
M9P<95%X@[UFY>')K)I9Z$XVU !^3]4\?(]ZS9E!Y*R]M&4!6\5VMGC6CRR%G
M:3# K71FAI[ 'M,,8C\0I<CGKJK<HA=F,D JP%)7:SM.:NHE-\_6# U#3,DS
M</Z,,ZP932EMS;8#I65 @I4U>T3>MG7KIZ\9ITG:!E%$R5,<L>/[8U XE*>N
M#MJ"?"%[8%W,2Z3&FK7D*_$#RKG1XI\O:A7)>N5]%^\\LQ+DK)E1"MTA2&\-
M#A,]$;L2_"S:7>;SP.>4,A=3E8=MOFC+L).?)G8)EZ!@S78RF$Q(0LP](I-;
M/W4%4-F*934Z@HF4?@DTULPD#RQHS<>3:T19]K5PZSE"ESA$M5F95.X(8":L
M2+"S9E')T,@=TIA;#<4S[(>@4&]B+[_A:.0^HE?UU4RQECJ":F&^)!!;,[C<
MT]3UPV@+$Y;N"%1"VB5P-._= A+"!.6>BQ#;;6>(XDT^BL2AC?<T<H5EFP\.
M!C(V$CYXAMX3)2^C+J3 #(D71YNA$ A6B;8:G"3FU%VB4)DJHG!+5B=7:81W
MYUYAMMN2?+N#TW(G[^VW>/Z$Z<A-$>)$F=IHB[;4I-E93%N.*-V$+-B.U>E8
M$MF<\;H8RRW,D[&;IPF^7"=HLI62"6A(PS<NL0\*O3Z=DJ!&DX:+Q )>G'A=
MQ1;DH)&RD[-L:'AI6WQF0NX-!C*05P(T>4VKJ)G)H@0\.4\MBP!-Z1V#OL!"
MO.Z@DS(8ZNIW%TD=9RV+%EW)7Y)0JLQLE-;L+H9RGEH6=YH+>3%&3UNS2SN@
MEIF619VN'XU,5OWRZ.D::$6JDY)@ZGAK6;#J<&V8RZS_Y9$U:Z;+^)IQ:!SO
M:N6AX)LXBBG^BN!?[L<Q<K/E[+X;;.C$:\W=>#-J#WB1YE@>N?>4^ Y9,(DH
MDK>Z6KNM>;76Q'NY!'\M.P$6XL;@P8)2S1T6YIKG">P]4%*8"=T;-24;/$"X
M52_2M"*BSH@-W7M4Y=H[/+A5KT_9>WVD,!>:)TC*M7> :!=[<,3&K05[F1I(
M]DAZ<_@XP[M'-O8BY6, /[ K1N0OKUT7.\R//?VM>05Y3<$6C:*<ZPHI+=)(
M@Y-13-8V3(.5I9F=OF*63FVK<&&F"[9N=:(6QWYW&M<R!BU3QDUX$A_5E6E7
MJC7[!N1$SGS+5'@39KCA!L\7J;V]HESD6GL#XI#CN65ZO0D/Z;7)5HDA@8KL
M3H4H/=GK:?X-R(E^$%IV1#!AZFJ&_"D4J);\O?:>WH X%1J/2L>1<T;C$PKQ
M7_\?4$L#!!0    ( /VBA59-+Q>AGUD  +E_!0 5    8G1M9"TR,#(R,3(S
M,5]D968N>&UL[7UK<^.XTM[W5.4_3":?=V=LC^WQJ6Q2\FV/ZYVQ7+9G-F]2
M*15-01+?I4@=D/18)Y7_G@:I"R6A<2$! IRS5:?.CFT [*<?7!J-1N.__8^W
M>?SNE= L2I/?WA_]^O'].Y*$Z3A*IK^]+_+)+Y_?_X___I__TW_[+[_\\CM)
M" UR,G[WLGQW?7MW_^Y_7CY^>7>79'F0A.3==1H6<Y+D[WYY-\OSQ=\^?/CQ
MX\>OXTF49&E<Y/"![-<PG7^ OW^O/OCN\>37C_ C_.OCV2^#!8WB7XX_'I^\
M^]\?3_YV?/2WD^/_\^[_#K[^OU]^82+$4?+G2Y"1=R!RDOWVOO:1MQ<:_YK2
MZ8?CCQ]//JP+OJ]*_NTMBW9*_SA9ESWZ\#^_?GD*9V0>_!*M<&QJL69X]8XN
M+BX^E'^%HEGTMZRL_R4-@[Q4HE2N=V@)]M,OZV*_L%_]<G3\R\G1KV_9>",7
ME!GGF\_4&SC]4/WQ/5,736/R2";O2DG_EB\7Y+?W631?Q QA^;L9)9/?WK_D
M\S'3^O'1<?6A_WJ50H=X_XXU\.WQ;O.E6;"<!W\26I+(_OAA5?!#V\^Q#A*-
M6=>Z#&+&P=.,D#Q3$P&M;$NLAX!"+Y^1/ J#N)6,>RT9%/@IA_]G@S$;3NY@
M/,_)(!E?I?,%)3.29-$KJ7ZK*[YZNY; /.5I^.<LC<<P@]S\HXCRY3691&&4
MMT$B:+0EC*=B/@_H$CX139,(V@R2?!"&:9'D,,,^@#!A1++!>!RQN2.([Y))
M2N?E1')-\B"*E0:!B:]T G13ZB;+HSFCX5M&)D7\!3H.\/! TP6A^1+Z%*-A
MP>@QKH8V,G2KI*]D_K+ID=^2*,_NLJP@8Q!M6.1LM6++M#T%:7Z_6^7 I#-/
MDW+D=JL5U0^W5,=ED44)R3+XW$N4E&.U[32AW61+"(_DE20%5 Y34"QKF9E:
MXR(FP\GJ;]GJC_\DX]N4W@3A;/6'IYR28*X!SN#'.H5]N?R=I%,:+&91^$BF
M>HP:^Y1YR)Q!=34+DBG)[A)8AW,:A/F7*'B)8IA<5E91U@YZNT_:4P$S.Z(Q
MVSNQ$1?';*= QL_I Z'EF ,QAB]Q-"W_;D@'#;_94@EW"0B4IW1Y3_)M3ZS_
M5@.=1F,MQ>:M^3L?10IH@&G]B980OZ3)])E0F.1>\K;KB'I;+87^(Z 4!O%F
MS+857*^]EL+?!#1)"W/"Z[774OC;(*+?@[@@7TF0%;3:*&T[Z^;/?X]@BJ'A
M; D+ZBW8%$D8!?$@RV!S"QUY+6ND-;/;^[85I7!6G;MD 0;A<_H5%AUR%= X
M?8KF15PRQ(1=M\-&??0*$_-#'(1E<ZL>VEY==J7R3Y'[H\.M E%IK"IN8^P\
MSTA-&.:>"9)E]@6LA?AD,U*8WY:6#EMSO:V]!"T5=)\F(;/TTAB*3>^ )TJR
MU@M>DU;;[H9G 267049*[QI),B,[P":M6@&RZ3&/H$@:A:5##G;4S,LP"//H
M56\(&_B(79CE=X>+4MO&X8D:MPOK#Q)-9Z#6P2LLQ5,"BV\Q+^7(OF5LM[%V
ML=7F@IJPV>]L52%C<YHP+$_KW1!SA3\';^T]O,I-M9T_2?XES3+8):[<7$S?
M6]N+*;W(RR\.)]RR.K.JL6]U"/HZB@OH(GL=K:R1-7,_VOQZZT.8^3S*RP6Z
M/.8I':(D,7%DT;CIUFZ:F#E"'@+8:C_#<,^"L!SZ;?$T:]?2(=E5D,UNX_2'
M]@DJTDA+,:])%M)H477AM1,:6(=Y/"I/7$@&GRPUHR*P5G.='$J8.V6P<6S0
M\&C @D>TF4_3J%=2U_%HR[?8PF?8?MH(%E$>Q.Q(X"F=Y#]@]5"4"*O94B 8
M![0@XYLW9M&I#:>#*@;]H[H^4.-^SB:^3./^RB8^23L.CL9^"4ONA.8N TO[
ML>8[I_;C!M2M-F+7)<UMJC0W3G;V"8U-?)O6>4L+W)J5W<:2-F#+O63D'P4
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M;@]E173K23YFQ=1KC=H!_*[CK&V<#>%0$:K72O#I$+;JH5GUXE69$*NZD0U
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M/*#%5H(I;'@SU+<C[H*T!(&,TRBTV'$: B\@FC!P7NRB--> 1]'>(VA4')O
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M(&@U\]WR&P4"7@4VY!A6 ,//>BJJGG4K*/9GGVLFSH\PON37H&N,@9J$5<5
M1U[&["I_(7 IRO?/6.=UQLT\CN&$O^E8=G_>(-( QJ_8LY@?@\5!*LVY+)+?
MHJX)I&G(T#@U$1D4O9C*;8GW49I<O.UQ7N&3/+FIGW$Y<KL:"[*B]FA8=M),
MD=)0H88,17F"&"&:S/8PICA/*"Y K)WV_=CI//Y9-EU46$CATY8=S&5JX@ZV
MXC]&MXW-X6)R<RP.@VX['(>#8"NL J(RCNECXNH.QSA]H0=^9$:T *F6S"=F
M]?P+$&Z:H[[]!D7;FLX]65:\LFH#6_IJO,1)6J/KHH*>CN9*6 XDE,2,7FW
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MDQV='/_.?F]QO7'-CWA-V[BB;L3TB!4[^F#=#Y^3#Q^M#+^Q0=U7^+7TX8?
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MN/<@/NUFJ^=YINNPZCD0OV&GA1E.@\Z&Q=;&=P#EBCB24C0^(527X& )+O[
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M!/,$'28X3Z#A!="_D57%,_GHR0LNHR?\^4!K#]QLA=K,%M&)>U<>36"&G%.
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MLU*]BC%W+^:\_!$(*_OY)4_K2EF[5M/6YS,0":?"ZPKV!\0: 16N=6>WF\%
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M+19RLN9>5VY2?N5!\J^H<2 <"] K,R?.F[B>-89==ZD!(BZTCHP.^Y75;)0
MK)PH%XV!6RV=Y.U]!AT*CN7Z[7QQ,,LGG<*%"5RG;<\3^.FA(AQ4U4G\MT-:
MI=0(JM/WP4_VL[IM5R!3O;6<NOF_[00->]G0@&#PB[#" K?Q5<<*;H.[((#@
MGO4B*G,2W5IL!:O;^PHA-!Q/P<3_@&A;NF*"W]Y=RCM8&&&"R2B.\((1JT#"
M7=^8ZILL4_F*=:WC%\H!Z91'A*R$M\',- 2^[$S'LW!MB;?M0E[6&M+0%C,/
M9FE&J(Q,S0].K&QMCLJ;4ZJ*M5[+V.[W9+(L6JNWL38=A2]STW(M1$F\<3\[
MP%O<&OR#&9T9,B.K\X07*[.;I?=NEIMI>2ND['JLK_*J+IF )V^I/E^7V-AK
MLBX)KV*FKL<:]:W0[[0=Z*)$K6(QU95*OP!8^!SM\'FQBU)=Z2XU"1@N1GP;
MT+%!M#7ZG;</""6B\O58$36_8-ZF7=-]O+1FS^!P328=_;RMH_ U;VNYEN*@
M;XUX<\AI>P7VP69M,V!&L[8GM%C-VNYJCWNU9ZSY2I-V5=8#)TU^ZATT^>&O
M9S1@R%):$R6YR.NT3G&EF*[US3W8HX%?\6BZ;XK:MH 3MXVZ6T#;Z-HK)I13
MMHD $!?*Z5J!#,#IVD[M)G2L-E7_:_2^B_[ 99JF^AE:TM#7Q"SC<3K0;9NK
M-(6<A%U815=75V SKG+<1Q/M<0?=:GYU''S_"V#) 8]A%:RD\+CD47,MU*F2
MG-T%L"@VJ'VZVC'H' PI])\E-J^3+6B!T3.5Q 9'&]22!;&$MAX@&W1)1V>%
MF7KPC;.BW%_93MQJ.M_SN$8"Y5PY=#Z4Z#LZ>X8PT\\0!GS2-T%(&@-XP8]3
M2# '1]$ 1W&+H[7.JUHW<%;L'M.<R:"W30V!+Z/4\:QTX8/&D#:XE'<P0S0"
M962!?E!B97JS-![WC5>SM+2H\:<HCYY8@NWK+#88FK*]-SM3<RPHCC9%?5MT
M?7T&:F:NK,/><#)A8VQ;/H!A9UJN6MYU;3<4(6N9%JODYSR3F:A\F9F1>R$M
M.RO4&-K,MJ(88'9H!Z21-7I$D95-SAR&QS5FOM6V&P9\W^-]5$8USMYI;=JG
MG%;V>N@+>ZG.@Q;W"+ UX2ZU3<2X07UGJ.\-#;L+:'-LYM"KMC=FCGNH:+?>
M=)O19]B(-V_2.6,^H.V[V1!8 ?>K;??=XSPMRGL<'TJ<W.&7(GNAM0O)#VE]
M&<5IEM;OAKNP#CUXNQOK(I5PYY$1HX8:=>2(TZ.V ]#+LSX$A+M=ZPS*\6U;
M&$3:W;Y=8>"J9N#*;N!B/G#;IH/5+L8/F7W Y>ZZB/*3&6Y!20OB$-22&"R%
M$B)*B4X\> %#VNDCRQ6&\1M IS9['XAS-WCG$6I-O:8CE-$1BN9;^3%.EJ\M
M7J_KR6#/DX?\VUU)N [C1;O-6%B<'PL# ;6*HM?/T@27[ <6ZO)RVA_=%DZ:
M;F#72CKY[)9'HQ[0H N8A$YKR3C8O"+_'HI8JT4$7N\9P6JQQ#,B%<JE\_S\
M5SE! :[JBN=DNRGI?VD.@<\'.F7=;/G+,6."O[4^ #M-S-.)W=VDIH1#VWF3
M91"1V;_M?H/X!UA>%>G#QV,'F_Y4,W0'>2<U>W880$K#=<W%8GY>8"NAS>12
M44[RI)5EG8G>_)4PXP +[2P,$P1/4[6NAI95:K\3?#"Q1%'Q4%&38..Y+ Y/
MSPAS';U$V0&T^-(1#&M!4&)K55 Q"_-_MV4:VW@1!1ULA#&2P"YP8"2(T<!:
MK;,8T5 ,/K?O96( 3^TBJBQF;!%2OHH)QA@GU241[+;$+VEQ&'*E,0LCI=^"
M@08I)"4"&06B(XI:FJ&AP-B&NR1W.,;I"YV.GYY*_!35U"@:X:)=<8 MB6R)
M+TGY/QMP>3$1NM=ULYV<M41OZ>ZP.RW*LGBE)S'1GORE?M?8BULW'HW'4;XI
M_MC&)BT6-SX%W*"F#]1U@MI>8$QK)3DGAV8;M&OD?.SDC!5R^C2\.:B=6N$<
MR *D<B&LX1/FZ33FIR8!2^4RXMN8RH6V1B=2A^['?ER9WU*&Y3.0KWTG!Y8?
MNJ,R#=]P&7-$C.LSYH@ 7Y+]O<^0W2[NJ@="43T7&;U?1"L5G$?OLL,\1WIO
M^>'M)5)4FN")JCMBU%&CAAQ1>H@$\HM%JYAH=2=:W8E6-Z(E$M'\I9IW1.,X
M]SP$%.V2T7L:M[5N^5SE<;'##]';+2YI1;'HB<0*EYCN F7W1%1\DB?7I+^L
M:W@?T5M'2B^QH$-?;F.)S--!XTT0:8/ZWM#-%C7](=8A(CTBUB4:$#2] GB7
M(VB@)@+M>PV0$'O;:*!B&J#;S!G30-H35'(->'-"B]$_\DIA0-_*304&@"!N
M,YWC*B[3/?WGS;9)K<"3(>DV!%P[@MUHULMHM_,\Z(..<ML+3WT%M"NPGJBC
MW>ED+&K4BHJEH@)O6%O@UV('VP*\"\(-XDCX3B<]-SIY*C%_AYI&CVQ;0A54
M&,E\A0YF_H45*?%R/0GJ:%!'!##_NXO1_0V5."[*A-U SUC*N[I@KKSLA8S:
M'L$F=DN<C:9OGR"SFJ3G@4TV#BAKB?S/M+?1.V6A>B@:;](Z'5S]4A:5[NZP
MF=3GZ919#N%XJB&A)M(0H9YJ@Q@=T F5NS0V%RG2',51]0QZ5F6)-^&PRA)L
M?K;&TZH]"&03\1U^P?D!F^I]Z<E\;I'K^1=VFD?-::C5$(10K\MF+(1M7(N!
M6!!&W>(LPS4[7DT.9/S(OY)#7#=?T;_-LJ/U%5!92B)X5D:&>CK4$/; @7N?
M>2R9P*(I%[B-0BKO6+.*JY:-S[X?GWTS/B6G7&M/]CS%=52^WQ_V^XR%;X:"
M1.KVWLH:J#D673UKB@9M02L:+.(<KIB! 2+C4@8^\&%7R,!=VU7?=CW[JO9%
M1:?B!V++4>DT?5H2^[,\.UDD$5=#AQK"D&;0XTD%:+$.H)N8KV_$6=KRXC&J
MFS$ZTCQZ_YSN]VG^=(G=(F0SG;?,!68)A+?C#0FB-"'9]-JRP.4HL(35.#^!
M3TS9Y298,!Y;?+SH]Z&,TIP6!<7E2QIC*XO5TW@['-!S+FS6-LU1TSX$(UU)
M!+A]?POPC#?]?2'';L=_IOJK1OTKF^)9D==E%-?T5F7#4F5ECQ:$_NX(FF60
M5'1B-!_8==*6*@3[7%\:P N EN":W/SSB2S+*W\+QH3E]JG:,9EKO\<Z;[BV
M2/!C)H4_=QC*X7#V<!U&MA_;P;$\A!!&YFBE_]A-,FH_O^#BJ8SVSVD<99IZ
MD)KVG@K_Z3B> F?8!+@0I%'1PUI_1BT?#P_X:?I=;25(37M?>-!PK,<#</E'
MHZI'B##IV1D1%8Z_>RI>"*<',M&]<U T/_28:'[Q5Z(]$0##/WH8[1$OTZ']
M\OGJX>(<W3^</%S<^PW[]'SE*;V!Q2P:Y#!"',$65^+P+5B(G&09RWI_QCO5
M+SX4C7TM.%2\3L>.M$,\E7_3$G)=X<PTV+)!"X714N'X.+!:'KBHMF!X:$S'
M_RJ@797\EM;/9X>J+G:X/#_PJUV&L@UF4H^K  LY5 LR]$IH4$NT02U9  47
M;$=GN@RP'1IPB!EK)=@0!P(S7;5P ] "J')@/THN8%L84\Z!V_US4;*-&1E?
MRC#"B=HCX.RD$4]M"!7?_).##RCP6";5.>;)R2#W,6>@;&HO#A#SDR:GR)]F
MVXL-L<^4.#:R" ]="%' QC)+IJFM;!"3DNX]@R:WL<::D-+&&FA@04WW3*?1
M>5_*QS' T74$'.QH9;0-?+I.-MW&>]\/C)$MEK45I.PK6=7/$1$]JNCKY^Q
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MTH%A9%%'1X*5*;FI=W73D5KR29ZXF)1;'Z!SG%HR^TF/OC (R4"]"AK6?&D
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M(@\N<;2M8>\M.^/1<:X3P0A@9M<69?^4%& F=*TI #@QF&#* !KTK@>/H'0
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M,????XWV0W^CRE3AP?E[5%IG.)W24J*TM%&:S'K0@2F-&AGNE4:K)S_WZ97
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MX-AC0(R"EGKMY.(HF[*.:\9[Z"S43WL':Q,:K?#6SR<([O B6QC7B(SI4[U
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M_>8@.-L4(N&F<BP<6OV6ULNA,+Y\6Z.B9^2XUEB.B=L+A7 2C<>PCVT.T/8
M;= >&_^+JIW"YPA]91(?#;7_:W.19;"T5"'8B*,J^#HA++X:C1Z]W>VR5_P"
M[2-^\$1"26$-AZ032SVX';DN"9JBX'=2V.L"ML+L?1PI;.X$*=?I.MNC[[Z=
M'<MMEB, G[TELD5G406'.!'*W(<)+0A02= 4!;_CPEYA(K=Y'R5R@WL"R46&
MM^L9P:2NXA4HC=QZ4*'% P-+U_9JN'0-[P0P5UD.D^?T' ]\^>DKW#]!V=H
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MB7:WKRG,Y<PP;L85=<SU&P0;I 4<:E1MD%M122LK<CU(VQ @+7G#]\B^[!#
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M3KI4<@(2/5J96SRJP4)-3XNSA*/_=8,^1_^%_N,)C4?__7]02P,$%     @
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M)AB!153#E0@K9,W24@IE79 0<42/#770A(E<X7#%I[9ZFQO$5!S95%^>DNB
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M8[TMTH@#M)4,BGBK5T:&;4>+J>[I*>N"#=-/L]Y0!0P!-TX>16WD;^/DJ<]
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MIK>C%--(('2AL<M+4H,T93HKAE[%T?$A<7R:&8<FJ,1,NI):&KURKC]P=9L
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M8W.8,OG-AT>8((WTL<NN "_$3ATS#>U>-FX;/&7:^&W)K&.UEZ<C^B9VC=9
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M##KX:3/@X(?1<M89)D\L>0U\ALRC6%& 3>QVKS6!RN%82K)G:>;4(Y"[5)9
M\ E36AXTGB@9C)P-E#D,@I@^X_3YMN;)=88:^?RX4PRP$V7;TY"P8%H4=E_,
M!/'KD_Q0FQ^0K%)ZB2<\M.SHA#JW>:T93X%'S)3Q@Y*VQLQN1]$935(:5)7(
MLE#(6H.8*@(Q-<8//MJBYB*(,_:%9;-XO.JM?&)#*X =W">"JC(74*2 @>RE
M.WK;$0OTB_/$9^LLI[*I3E 4M)4X.US]F0Z%@_#4OM-#CR+Y1"<L#!I+=#XH
ME[2:E6K_$5[:=U=@O)1FS[*G\AE.5!9F!2(S025I$2\H (26C@[Q$6Z6DX$6
M-Z*R8)P2>89J<(,#0+CIR-N@F,^V54IGY=FO ?,(L0>O^0*$H4+(:]_)8,2;
MWG(DJ@/3!Y'QH"5^;<:J:!#.R#P+STD9VR^? ;=+ 1(BOX*FD 7,B! @7-#Z
M%E8IP_D]BY7?1.$51VO '-^_ :0@2H4&(<W8S6#7FO#"D&4PO_LPU2<JPL2E
M85(A.D>L3Y8,"4*4L=.A+V_-7KP_P^=49\1X+9 *<0QFLW-B%3+DK-C8>T%P
M6+P+C0-3GQCCM< 0)S[14K*E2?(N)H1D%^(]BI<W!Z]>$"ZOINV!16=MXS9@
MJ2*."5$RB2B &4)$'9RYZ\$O90<\RMI4$Q0U88P1WV"OR;\6+H1U5VYE".;&
M"Q;YL[F7_&&^O&]5'9U0/UAE>XT7P$/H-_89]6"A7Z,S7^UWJH)8B:T[/?)T
MB1>A0XBG"FHQN<]?N2@49UZHG-_%%4 ,Q,\7ZA$E)EF&":'6V"U%-*4O7\_6
MHG:O+)@RO1NZ^JPB<!!"._)M-2;TD65!F9*;OR%T[\U5&V]Q!9CS7 RTT0&%
M$-Q^N$T+W"I77ZP*Z#KY@S\X1;JD5K$@M)*%ZMS$>?*_6!(/(_8_>'_EGDUQ
M:5!Q8G>(7.8"QZ8,"!)#WU&83O.U<OR?>9H5B09OXN2>?:_<#TKB"/[IEV\A
M*&9<HW9@0+@8!]0 *Z(E#GC*N*=@.!F,R\XK[2E1<9 E,=TU&!-3C\-#&';@
M=M1&%D^9%XV]9)Q^78R]C!U^.C@_.%2;T#KU04C$:S-.'3+*]6$AW+OB EM*
MAJ?;GQ;#0#'7"\O#J'$QM$8#$\*N QZN"IRT?(_#V_SF&?Z5>CZ'A9]0UVQI
M=/*).$>1A$]DN-=!B*@&7<P5GZE>WOD+N]G[0Y[X,R]E@VG""A2*F%.-NC""
MB$^R:M$D,.GUT2(<N^(,*\_P;CR_.+]3G6CL%88AXW2< @(((=78(49U<KU"
MI#ZI$!0?G1Q0NS@16G1(K&) :"2[9?8?<?+':Q"&;#!^#=(X27\+XQ<OO%O(
MIUY%-<!*O)KB# BF5BTT"'.NQ(/!\I$5*T5Q>7\X*1Y84$RN:)W1"?5#Y8WF
M6 4N)(.!"Y%@%3SJB7:O,,B,^KA!S@PRVR) $!X=<&&5:1/+-!OJJ*Z]PC!A
M4:=]02C!CN_%"! "70G/@IEIP1(PUD.>_2P:<]-]P95;*Q17HS8,"NKQVF0:
MUD:(Z$'[:7_:4P&M$%V-VB!?8DM+FT5#)=C%B"@!E5-+D9+FD>_P)8F$UG\'
MV;AXLB3 @!#4TYQ!1>?1M76G!"Q'1/:N0,X($=6>(E2T?TNO%A5?@BB8YW,I
M&5ME "31@;Q0VON$"'J+4$(:T*3BQ7M3\U(M,SHY(EJ,='G9[RW"2T?W\6P8
M&#M3]ET0L5O81"EL2ZP6S#$NGXHID2%\MQ^@U)CJ^YQK;>7!LR<V+4X5)$2C
M=4"&Q#DGE4R)"58@0O(6NA+<M$+WR!9QDG%E-R!YO]+HY)@XX+LARQ@DA&;:
M-R67653YXYE/\23[#@*Z3K-@SI_*_9JR21[>!:\,30*B61T$X-;(-0>'L.N*
MW^=VOO""A&OK<'(71U..;%S&N?^;A?P-,T L&<]:]4%2Q$&I-8>V 3I$#V@S
M+Y7.RB+M<9D!^9&_-LI?<.!W(+RIB%F]BJ.3$[=F:Q-8")>D>:&-;F#-@XP_
M49YD$?1@.9TM(^ZN@C1+@I>\8&O.?R,9W88M@?2( UAJCO-:.!$M,?8AV<V.
MLE;EXDU!_J 5/]=8Q> \)(&/#GJ=N@#=P15='QE":D?Q2%CB*);,@ZC "DB"
M> S;S=V@*HQ4G;H W:WUV1 90BIY\JF4^<7C2\^)-X;%Z,I[QPUN86F 1W^B
M4F,5QK$@5-&FG/K"(]2+9.FEK[1<!<#ZNXW&P6LPSF&M&+_R5]\Q^O1; *DY
M:%B9XD-H[BA ":6Y\+A^\\*</X+I!>'[MSC,YX66LO$S5$YG<3A6F\_F+8%8
MW#*=&N%$GGQPQ?-5,2&*E_#2VS3--^_-H7$O>S5 &FY94UIX$':=>972X_[\
M MO*M5?%>!M5 N%E 8D&S8#<W%K'ZX-$E*,C?QF>H=IG;)SR-R^?6):%K/3Y
M/%T_#-#=DJ0.0"6. :^U2U(B0LASY2K>,M'F(YN7"6IA62K$ V;)\"4,IIYB
M2&O5'YV<N67 U4"'Z($K#K)5WMO?@VRV>AQDE;'G_3)/$O%^VJ0ZR(DXZKSV
MRJX+#E&"COQ?[2K!?1SYS?1@TP)(RRW3OA8^1!N,'6>O+'F)[:WLUV\+YF=L
M_,BR/(GXI<9'-LFC<?H<KR"A/A>=N@">.*RYSDJOCPRAU97<5H.P:)>-"ZOT
MPDO9F+]ISL FY9"X'"+I^:9> R K-_=Q)O 053!VS=4=X?934F[<$@?R:1ZM
M!I(ACHBN/[<K0"%TT[KH5IO,]?.5WU@TCO$I'"L/$!T\\9"C05[OI'W2;M7E
M];*R/%1E/'CBF45+M1LF7^*$#:;3A,$^8_4B@HK56HV"L(B#1IM0WP RHA^T
M<6AFN,J_I8_,9\$KC[2SHR%[S8+ W/+'V0.-:(DK\6Q7; )R&A=;EV7,!K^M
M=3U?A/$[2[YX&0@^FF[]?2F62?%'B2'0N&V0L%MN0<O($=URQ7VHD,)5D/H)
M*\ E[]5"RC"K9@V/3CZ[Z7"T 1M1*5<\D?S\).6':4&: @2^$[]APK!K10V0
MAIO^1BD>A%UC%R/=EG,32K[RIEW&:08:G&3!7ZKS!HW:("='G8NZV! =<"9#
MV(Q?];N-JCE1@\@/%B%#<V"NTFA>P;]EZM&P:9"O6[Y+N\ 1Q7(A2UE=_/(8
ME?JM@D#=]'\VQHPHD0-/ ]2!?COGEZ"2P NO)Q/F2P_'+#0/(G;4NVH-/*)?
MC:X _UH5)N#Y8U? _'=;$F9O&8O&F]EC2\8S[WWN_<&2?_CQO/S84PY8DO?A
MY"F81L$D\'FZE(THXC#P Y:N2SW&80CR_0ZR&$Z>9XP?2GSG80<W<7(5YR_9
M)%_=Q4BO6.8%8?HS10+O5<<'+VEAK\B.C=!*0.M9YT=@F#0WSA]UU(-1.X"2
MV(&F8@ _#S,$B;R]JSU S\LQ$Q4.VW%YDP&FAB0C2=#P&O!=F "]1#-DU4!&
MQ"ZO>HJ@QH2\'E.3]V?+X8P\-^BJ[]#U*_8",W!<=/_W),C8<#(I3OW]&/;&
M 7[1NT93HY-S8G^4&>7-<"*I5AW9G1(M#N?$OJI.%H=S/+E5H\7A.AK?]=B:
M*Y['&V8SEBPE4=Z7[]YP>TC8P@O&RQ@6&+I%I\K>K+JFMN0,6@'*CSI>KZM]
M4X]287GH-?G>W5#$V)*-HFMJHU&_(E;<G$N'T3KP8W715?YH&%X-Q$*^L[9"
MNAID4SN-_,RQZ",8'S#Y\R/65&J+"\N#(,BCG:RP+4'GMAVF(9]F:Q0(B3SJ
MJ8597H*UJ>FU4@ANSO39WA*EIBK2$1:IBJM9BC^ [^S\O-OC^6IZ1R3U,Q*&
M9MK$Z/03\6&<2N[(^;T1/DN&6/>G)>WGQS_]1&R&FS&)NLWT@%JRRGJD"-:R
MY)]^(C?--4DTU(%=C)9,-F,=P+(L)5 XP5]KW"\$,,CM:DU9"UR> BBV;":B
MO'<,=GT\W<CM?)'$K^4SALHG:22U1J<'])&5=?C5QH;DX7&$<-@&!CY;RT1)
MM; \"((^@JX)R1)4R!TN1^A=)=^]8J\LC/4H1NN 0.B#W9K0K$"&!(HX$RE[
MDR=1D.4)W]+?!&_\7^JY&Z\$0B'W:C>B6P5-S+<K3T'P2\8Y?%M_[D9J@##Z
M:BWK\2S%)2:9]!E/:V])G7[JT]/'AOM= 13$M4'U$J?5)Z5./_7B2:E"S@@1
MU9XB5%"YF:P_*77ZB<AB%4I[GQ!!;Q%*2(_AK#\I=?JI)T]*8;SL]Q;AQ9US
M,V3FOM-[64I1&5;A/KT=;=LINX,3T06J5RMMJ,'J3&PB.Z+1J WB[:LG:(=$
M0Q78A8CH@#LW+E&DFL\;U6H'9$=^NMZ*>N!@$46QD>^M;R?LY7J9<J%D[\7C
M,65V6QY\D&<IO\;#<]AW?KI>=DCC1'V[("A"MS=0-FO8\M)O(4/]@_.]6H"
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MV"L+XP+G99QJC&[M-D!@Q%$D#=7 $"FI([^Q:MSD211D>8'V)GC+I+=1U)5
M),3&=T/R5=#<]O]?QO-%#M_6G^F1&B",ONZU]7B6XG(^TCS-DC)J]#8".4V!
M(?6@EE4#L?1U*Z5+MPJ<XX<+J'QT3OK4E4&VQ*[K5ITJ.SAMY??ND5-%=5HH
MKPABZ:M-MT.=(?$5=-;.-F@F@('OY_,\Y(=A5PQZ[ ?+^R6+D!5<1>/!/$ZR
MX*_B]ZA$)#IBZQ,@;^KPD$;:9%<.C5];I3X)1?')3T9EU4 RQ/FT6IIOUM@0
MULT]A'TY2>W)[;:63T_/.GY!MS*]2#I>+09])+;4-,4H'CG[4)R]Z7;I+0(8
MG#Q+Z,J/Q",.UKGFA'^FN ^:,B!X!DQ5W%Q:UT!E%8$\HT=4L.2E^U+ZG;VD
M0<8*1QQVNJ2H-CK[3.RJUA&>X*A)"U=;(\8RCQ7<Q9;<9\(=BDEUP$_^/+@M
M7G%\EH[\J=Q3&Z@K)]S:X[XQK*L&M,QI9=P8B)#\8213%6F*MFE\ /4.0X);
MOL>05P3A$#NQ6U&%-3);00B=;S'$IE%/=ABMV4N?3_HRJ*HSR$'-V;?:!& C
M=OCHR-Y\SMW'Z.QF!=:/).</'2Q8E+)TXVW?^0/!CMY[YWY]?L.YZ(L7ICI[
M>;P6,/6Y:]<L%R'8<!.PX0K5N&$L5>>#DU<$'-1.,I604?^I$A;I'J8QX]?S
M11B_,_;("HNL\A:#FG1EW='9.76<53W>-9&1;F^PE])+E?W"8 WQHDP^?!4U
M "7U89H9?UIX+,4@D]W-@P^S-%M*1CU*Q15 %-3A3_6&I@Q.'Y-CW\%6-%P"
M5 Q$05' 11V]5&,$HD <CSW.9BQ9SBY&"Z6\(HB&.F2IWE#4@>5V.'(=LF4"
MH;XZTL@*QA#9"BONW'FS>L#UBKWTQ67#NV*4VE%< 8@YZ_CX]R6[+0(7=>[)
M"DJ//G^BS@XMD21V HS </;*ZR5T+<AN/+](;*RXX;I?&(35 Q*%E" N,P2"
MLU=5MP$I[Z:*BH.\J!]G1UC1X;"*P=GLCK"PL>&D!*:^S+A7&- 3;QIP3L0<
M8AC<OISZR%[C\#6(IMOB4#(JK3?Z?-"KX:DF5P..V_O"[45'L6KN%P81$'O9
M#%=-#(*S[]UO [KWYNJL#E@5D!OUB^,(.SI<[N*@>MX(\:5=>-$?P\E@SI+
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M!&K5X\L%L7]-DS@QZSK@6CM/Z^@\:KX(XW?&"H## H:2<[0.'T+$>XM&?*N
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M;<B?_^;T,V8Z&#>257!WOA<7-M?L&C,J[YO'[!2;LRO*)$^;[2=02P,$%
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MLA2_C?Q.SPQ$_=X7!#:=,!&G-]TZ]MWB#MXK3Y5%*V:2G&+CVT0(BRX.S7*
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MX'A#K+;()YGE;J\ZK^VE)60AM9!8@_]!@R]MT'8<8?I(,;U/??-)+:?0;%V
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M]VB5B777C<"284?4]#BM[NW\4V%$A5J[=@ 6LC$4IF^PA74N.I0J+Y%996C
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M/@*S[45AO-XQ9T8=%O+Q/=KP!0QZ>($8/9CCI8QDX46,\]8AF]LX5X<24:*
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M9?DCN\+&F=V1CY).>D+)9X_Z&VCZ&+KOV8.*[CP#:YBBA ^PYL@G(SD*0JP
M2G4@-_4@J);,7!G7VTQ:Y@#E',?!Z@)8NC2EOESO_ 1KU1'6_7BESDS?QS*>
M?'29%[(?*JWJ:<T8LVG@8^MW0'WIVA@:H8,UDPLJ5;:#2651X5+U4ZDG&E$+
M,'GKI8O\''=PBT5?>ON*]"6])4$ -!1TS3@&A?680"VDD>8YEN,(+^K/%$OK
M](05*<]]XM%;%^)B !>[=V5?5@!-!AZR^VI<FH7NG:1^1BN@7 ]+?[01<L$Y
MTYI84MXD\',)D3AF8B9A?VDQM47X*(0[DB3W9QVL!./VNF)<M<YW4UE2_X@<
ME29U_%KY@5.6=F;3=7.K/,E/EKF1P>GAD MB1*,YPCH7TID VQ>HH"#1C59D
M5/+* "KYJ>>99#PMX3E/>2>CB5E7XHG7PGB@(:AX#SPICX"Z6 %@^/?<ES@N
M;95-U$R-?<9G+ GCR6,65R\2G8RV-(L;KNE->D;[;*G=]-A1A]7%F+N$K3'-
M0&O[1V]9V4.;2;\IE(Q_/]32582+E$5!68%ZHWI%AW-V0!BP$A%/VNEZ<3>9
M;%[/RD)&\['5.\4J0_HV1'OU9'^?%&A95;:Z.V1O4VRFCTM6JAQ^.*X<%N4J
MU8LC=^HC8SJB%/9(U)+V5Q:(+?,)BRV$_4 FU63'80@/^,D#9K[?,+#[P&Y,
M5WA1 +P\&UV<NI*\DG:;I,O*\UV+RO4D3V_ />YS*\_-(:U<HGJD$#R3IP8T
M\^'P%Z4:?]MM[F;B5K0^#EVAX=)G8 7F [7]\ 5*O:3]6%[=N2GYM/H(O 8>
M"[C5/;Z,*AYRG*=T3;A@:5-:6%P53Q@K;'"8C-F8HL<6BV_5,@U7F.ONRF:,
MC<T.HY2MMQ.JSXM(='7]AW&.:+$\JM8.BP02^4T<>-JH/TLDZ4WIVI[O>X\,
M2P2O2DY<B_K>;XFS>9(/-N/<3DQ*.JJ:TYJL%CP%I'&ZH0J&8Y^0CIRZEI\8
M<7E[LPZ0R@?2&8CX>]^+!L;OCM<&!L6>MR!)\#ZCL@KCP@[_<X\\S9(#(#&E
M$;C"+JD$Z=;ML9L@$!0"2$4'%'6N,MC^X#PXSHO/AQL\!"R.?$8LTUNRS:4.
MGA;UH!R3N2H3[BA/(M38;K* M#JYGJ& PS(4L ZA@!&BF^SG&'DD6\\5Q_:J
M*F29\7MPVTKD,[.?*)YB\6C\Z?D_TX[?[-%:74X#2T=Y>R;S>8NMU2YPAR!)
M+%+V!T5$P J17=A&DBY1F5(:(5]*]8+WX,&.4J&3MH\T0Z\=<1-K'(_DM8'"
MI?)8825$-1R5.1EQ%UW\DF]Q.S2>]9E2-0%1TFV1)TS7*B,&Z>[!=IS\*MZT
M!P]I]0PS ESC,G!,Q*5X0ITY#E)H@8^UYO9');=?8LWA,R:;UMY\/JM_P^G?
M];L_C>N;5L.X:_Q>OSN_O/[=N+BY^P/^W+FZN?DG_KO9JK<:7QO7K5<:?%HP
M[TN.)2,C'DL$=AS/^\D53/*6@!HZ!V+,'=(@1D;%DS3-I-2A&V'(41M6/! ^
M#?:BK& US=B@I<$2,<F37+V9UVBI4#'/50]/L4 Y@R?-BQ7#0$Z<VLP]O,5.
MYU\EC)Z#,%I3RE"8_?BROO"*T?,&@DK7'%MTJ=H+LUKY&AJD\:8S'V6@[8+Q
M$(]?T]*J>9DDP>*VPV"W_EL.7:M04B]8_F&0-*[$_M4^" [AR\  Z142.5A.
MP$4JF1*R=,XSJ=7.D >[!)%L[<[]RB>0SSC<\!@T-1T/S$67\L.=X<@TN9'1
M0VJF7!/3N_RX#[4*FMC!3^/")$F<;6J=S/&*47=N!YV($ZFYHL)TAN@,PJYF
M,?6>J=(TU>M13=N^B:=M9S^E1+'>0ULX@> >JWFC:0'M 7JWL'<@P!<'ZW5
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M22 ;(>&G[WVS+]OP<9,9N8=D4XYX %9@1-1CA]O@RN9/<&BB5-EHDI -1NU
M.?"X;B:5585]GVB+ONAAEB%VNGKY<&WA6D B._"?S&QMA44CQB(VC<*#R<PI
M;J\U'L"Q5I>P50U->/(IEX(;/P'0@*0LF;JKOV8BT7Q, TM844?6\(!FRP-S
M5-<L^B!?BS>IU<L&7C=\-+$-,3)0EUS[N9?9C$M855(CF]2+J07[(NDOA)JQ
M.1@:;R5_^G+7BAO2 E1AY2%WL'X$PPG_:]GWMLH4?3G&!]AK><?K[B#?SR"=
M774L^R@S>]> 8VXZ@8>2SY$$R&<!3QSCONUC? W;+[M4$I=3PT#ON1<N\PL?
M"ZHB0>6@6/A[KZK+^'VR0X)(L@R[ HT!V?\9?H^I2B60,_+UEF\&@)4@)LN#
MDL$)Z47G+O9T:#S8?B@'1@*/Y30+&@*EER5AR(<;4%6-H3!]%)SXTG/@25@7
MQ8;#?E5-N0;6)8L\9>-3+4F-V1N91VWLF))P()PKU*<J^+CHB< @25 2RL#C
MV1/R_$BG _/DY5><G0Z-I'EW"KTQ/U-C6M0A# @^DFV/L.EDCI]0W,#!(EB"
M >Z2LF'&"!7X>%PL$-\HSZ)JF48J0)=(3TVE+>)L%;H99XF*>QY\T=46A<3'
MAVG7N SQ5E61;!'F58=Z((L]KH<+/3SBU%505O9X1-K8T&P8$[3&'V(> ]!X
M,'W;BXCN^P&7)@HK,/Y^S 38!BM;Z3&V:@+ HHMR)8]_P1FU$7%A-6H$5G9$
MIU81;(I6];7!]_G@46M,Q7@EO\KEL,)_0'SC6A(<DBM %@K#.G!AN\;OK%(H
M91'0X(QLH8T-"83#.%-%ULA2E')FB;Y*GF<EDR,7+(MP]@H<8KB'F 7-<:2Y
M\^D*8%1-03W69YQP899E8<6A)"A\JM\V'2I"7?ZANY6*1##L#^"-HRP35N\-
MJ*(1(/KHP3^YYMBU_.1W^+42U^?WP%;I.F;0P^/I4G0[> 0X!#3L319;]CW/
MPFY!CR "VK;EX4&F6^]-Y0^BCGQ2'<#N>[!,/P%MU^M$/!71087NWN0QV=*#
MCXBB*12<$>+876RC; Y9,*'+/[--U$9C%QBBM -$#8($IU!S.TTSY&G4=("P
MG%.0J-%8"*MPNMG30>GN/9A@.J!R*M]5,;P@%#B;RE.M.=')$H38$Z&#HR[K
M S@>3W3X84O5_=T/?"K[\E0B%DB0X'2J@T/%W;#C(6RHB185UZ:;E ;#=-X;
M#KQ[(#A819\=;BY.K&IC(]SJ[G[Z"V]/?GG'_ G]>/%KR**Z]X#F0+C!)GSB
MB(K*8>%8^0[\\9[$8.TX_5(F']7?B\8/W'-+0-@#KNCH@%Q\M;VX9ZJ<>8_/
M^C]IU%V%3K(/5(LL(J9.["<X)(FZ"[(T&-A<PXWU7#3<F6?D351UU#G8^7#P
MBU)QX#E>.:ADJ#FHCZ+QJHX-R6;RT*,LB+4-&Q,PP:;>(5@??OB%Y_99;$SB
M.8@W0(^8:*DZ8=R*UJ\DF*I]^(7G&&:((P7C2HPBY/TT18T@":OCY_%-^]6\
M-QT4O*BM2T%XZSM2=FI[^R"&B BKN[6TT"!H58SJ08S&>VXAF9@K%6;>;<4^
M)!!0BP>ZVHE_V37^%-@Z3L.HDMQ)'3EC)R8+"BNK%U2XDI_5(6R(1MM">8+B
M.5[/\CGO#9R<G[ RR\=)[W%?B,CMBS 6**X0)+Q83< .N%PU3P,[E&!2AP%?
M@4>1+*_>,,"9FV@77GC46F*8U4;XI3@0#P?22#!ATURB2Q-Y&ZB2<@"GG';A
M)I](L)81"-A%UN*:3+6/H-/S/ <(1_7*,(& JA\,TM <*ACZAW!=&POD__"<
M;E>.8=&:X_R!-'SN<;G].0\,J!Y_"HU_ CR,.K&QKS'68Z<.%3B[XA$%MGPX
MB #Y0W8HP2H.*\8'9CAJM2"CB.(#>>)1/Q8"XQ)QWQ5@KC16MX^>)A0)L>8@
M_40\LWD46* @D<@B9">HO#<'G*##5:[* DWI_W;(XDN_KR>#+#160E;!)EH'
ML!+AN]QYM4)UWP$]ACD6K,>29Z]/ZC4W*4!JQ.Q)(!X\2C)U*%]-CC4U$LBV
MB]H@MHAZS*1]T()XQ^KP9D]>7KQB#>,O'\KX2QE_65K\Y66]C3PC'JPB6[FD
MC"M=3HZ:E\28$O<;NW/U'BNL6X\Z=A.7H%=HN"M^D3C#8A,IT;@2P:?ZM6B-
M*G*<H;&7)';#IER)HPY$G&='5D9*ZN%'1VVB3QFU1;N0%H[O4UHXZS[*WD?+
MDB2M-%)]&R4#9;.K;#D0$X%T/-!OE$JG[.=\DU/92& 8T>CR>Y4?SQR>[*/4
MQE5ANF:YJ^!%'&]1>)':*FMY-MHC!"-I5&)GK%WC1GF\!JAK*+<7$1 IPT@:
M[-?2:4/YZ_/I*KMG)2UCB:2\?"#*X<T=H1(,<]RS(6@F:K@I1;?:@CYG=[!E
M$=*%F;P77?>JH9-JL1)/#_8>7T&/_ .0V1]XJ.",]ZNWA[+?%*((& ^8GT#;
M$RTB6.M ']ZG03N4P<(1-SE##?3[\2MBZZ1+^ K!Q@2;(.C)0?61+"<?[P $
MZHK2YS965U'3(Q,X'ACBQH.F**+7AQ.;XB+L.J8QMEBH1)I/[*2)W7Z)=8_S
M2NR!0U$F=#78;,NBX:5\(5@7C^ZU>W(,P+GHD%=D +8/.0I4A\NXI8,7D3>X
MG>=Y'& ME72,AS1HC5>,6K[2NN*.BH)<8C)UQ^-9)/)%.RJ^RJ<UZ1[!QJ:F
M<6(5OB^DLW&0AC,?08\)*^WZUFT2,A"3,X]&+OV6\3<4Z)<>X"7"Z3O2A3Z%
MEY6T6&R5J/?Z3!FZ^W*(ABD'?<<R ^.3U*,K#@"QTPGE@YP72FY*9ZAS* JT
M!Z$:>B+[(0*&.CU)3HI9 ;62":INH=$LJ>ADHJ*_/&IC^DA,.X"\G8[C=7YF
M C<QM1,'C1>K&">>X+%P?H5NC)Y$CVF$D>^B\:PD!@'1$=+U))OXF1,(!51F
MZ@C(,5<D7+B_!;?@:&X5M"- :"4[3 ?8)S$M0XP 3KH#R$-:"0+*$T;?]( '
MF3(=[W"O2!G,DN$;'KGITOQ1?)!#5ZI%<$Y8<HH@+GPJOCM&N!X(-DRK#Y<Y
MB>]!) YVCF0S#9 W'M:THSS\V*"=] 7F1"JLJP,5G:QH[ ="/R/ "C$:D]?[
M8R1BD(9.W$Z29@E[[7_+B:-LLY(_G:'- ;^.[P7L+GDP?6KLB]3%N_(&&)-3
M(DKRJLD22D44VW#Z7>(*283:!L,;2(W+#E-18^ZKRNH6 0_]$SQ;*5;0NCPN
M4_]D+)TD5]HUZK)=,AO7,OU2AU <PIR\'>5+9W[5&<IXBUY 6<&L&[PO]BA(
M8,:#<K&IG**6N(%ENC.7'J)3KB!T0-T#YEQ2H1'O-R/()O<&G?% UU"ECN<"
M'?OT X\R&M7E*$8F82J/'(5^\)B3.]_DG"4\OA168[)&P!$'!!OZ/F$J!"Y$
M6Z(VF3$RV"'M8,3I%;K2IDY00C-R8#)EMBCV'L^65OB).9O*)C@[;\;9!'"8
M;.PKF_@/R<10"2^<&@:6L&U%,CW%XK%09#_%DO2F@)E2K$/9%:QXFYCDD9-C
M(]$?.@K!,C4LPWHK*L )9Q^P%,C6X@EU $KIU"?&2[P P=YQT_"]-@X/&>OD
M(CZE^%E1UL$,\OOBO+[#>=3XACC6$(5DL!!(>807N?JHO:C)2$0) [2);-7W
MF?<4J4\4^9THR],JD-IC*KG0F\!9DDP6I8BZH;BGU W6^?()8@RE(%E,2A6"
M[TC:H*H"1C$Z^CE1$F?$<O!?$0.3#SWX4XB!Y%49\9ZT\!\"<OJ!$0V44OD*
M61%BZ"FZQ61+#!)A5J@8L-W-F97]OO I Y$T4&6O8\0E5I 2N>N:?4'N$&"4
M*'6QE,%'(XD27 A&]ZY,8R3C:50F*H)1D4=< ?J%D%8?69L0Q(Q!O8]X* !I
M[O_[)V9%"A[^H^PP=B[Y\G=C$+4=):2S08 FG(^>/O7GFA(]9930^"*/P9V6
M.]62N5-?^3.7;I ,Y;Z0?;01O92]H+SXMZD=J][3N4DI>"IYKF^7C*\D34<\
M@?U!RE9*-1A-DV-&2 $Q$,8#:7*EW""8GP$ZE[0Q,MZ0CLGCA77O%X@]1+'#
MLAF]*.DCGQIB3CZJ-MAEQLG>+X ).=.!^[$Q#4RP!?X0\=0#GROH.)Y)^U5V
MDJY_QMJ"Q_;@4>4 3++,\49(DH_(M("S"6N:E*!=XXKM *74,U4#$0KW/NR1
MI<!F1)*ZQE*/!WAH2<O2-8&SDZ535'FV$O^3ZB^-\31/1J''\EJ9T(HK<T6(
M6L1&14!.R@A(&0%9CPB(9G>F7%@JE*"R!VV:[<"V*2N*^?P\DRD\P;+$+!%,
MPF0U2T;%*7MWH#K7Y&EUHPEVQ-Y,Z\$$K>=>JEL H]Y8L8W>"72@")FE/JI)
MR-1\.=%G6)&!##*WP[B"FD>;(.M+O"^>JO/7\_^6KSF=Q7G'^<FD@?)52CM7
MY2++\:X[CMFF%,&B_NJI-#X0' ]V""N1R6MD/Z$Y*6TP+9XNQQRARNFS<6-W
M!8=R$+SWV? XR?)$)Y6YH^9@($R'\USSHC=*4FF9C)PO0C&W("$%!(R>FTD]
MB"D+)/7B'50+^SS??7(^M.X/X!C1D'=&N4-.6D#'T:VQ<K-MLDN)L\I)"0HX
M(T]HGH\Q:ZID/-ND6*"#GESA;F)QQL[X)&O]]:A8)=,GQ2-90D8*$'[?#N4X
M;YY)IIB2ZE_ 5F "J!';E4TQ/1DWG\MI7L_84=(3SB!(E\^,VL;$%T0G"F7R
MRV0'MN/LX+CON-2 ?$2<E0JO[%.FCMUO1W[ Z\'L37E>6!$-F!(3#SW5C%"S
M8@J"I9^FK$E*YR4W)Y4CQ]ZZV'W 23-ZTG?L*Y$:X^M0">O)B+3.3^4F 6Z6
MVCL;?(32#M@3PI>T;ZDP:YRTDY0!(%5T@6YV,(03^^M4K$IF@2MI009#[%>J
M_WX7.Y:HIJ*V5SW:P01VRA&KU7Y).P'QQ[]7CPYW]]+!(5S@WZO[)[OI%,78
M1SZYCH)>P5-F@6D/V(?L#'<!AB%5'?35U[.)L/3M_=KNT=P_O?3*OS-96R'
M"$Y<.TNN :39L CJI-9#E78*SEQ&JCT7CDEN(%C@/R)GR" ](HCN\0PFRMY
M3A?!6VC@3NS^(^J,Y_O)V"]@^ M.644O4UV[%Z&R:UQ>7NX:7SR'JT1)/8K7
MH%JH.K$+7+T_T=R^)O.,&?'5$XKV:;\?J#G'! *6+[1WG*F.(\_I=KG5VI$J
M "J:?<N,,%XR@I1+$_I<Z,.3AV0M+PN,MN"TQ'M0.?[#4 >F-9$/R^/\;;"C
MVB8HCLR1]DB5MJFYO^RHY181V/*8FC'P1@D/P))5'B6M"U$PJ<YZ-S-)EW84
M^Y"POO>O"$2.4JT=CSM6@*I5_7!\:/P!>K/IN%%H?$$WRY5K_ V,&N/2?Z"
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MIBM:U7>\S+N6.YZ9TC:SJ^)KJ*'#RF$U>^ 59E#T[MFAG4_>U$L7WQF&3N
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MOQ'Z'#AZT2VE;=VV^%3GZ6^NBGS*#:[/'PCQO%IS^TT PJ\:?E/KS0B"&-W
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M7BNO=(!#?I V0[X:4#1RJWM$F/F*N_QPX-5(>T]O1>8LZV68R_S7NHG$'"2
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M^%Y()(<H<SV1K9=\1$[L*TDB;C7H;<W] &",80DR-N7,C96U7(.47,[/> +
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M+FX>3*%7"@S6LFC#2(!I?'H*[JNB+N7'![7].+[@O_LDJK<R?>69 :I:IK"
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M>)OL,V?:JZ;<D%OETEL@BV#&\-WOS8^5T;9D8! ]1\>!%Z6KKO+"@UEX@47
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M\+IBM>=$G45I'DWQ DT=Y%;"/"ZD!2R @G)YPG):5(LR4*[A+NC&(/7DV:3
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MV8H2C4OTGS).#^4_L'_4^>1T4=#ZRY\6:[=L5=]"0QB^E 0*N@ 6OB]S#E>
M#JY+I_<O:>QTXU]<%!^9@QJ=SNAT3@-R+^COF! 403"%"7$DRDH3>NZA9D&>
M(&S)A2/[H%AXO<:.H-QN<>:W&#(W'+YRW&919(^S6 K;4^[#%&W+W6;9(.O-
MRE@S&H?JBE6P41.*B<Z+RBB_HX-\Q[;X3%NLWXXMUH$6ZW^&>_INGWNZ8[_
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M]#]^'15I7N9K&3WD^0/L]/U%*/Z<\><P)VW!\C(6;7RN$,9'(X3QCB&,"7;
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M$O5BP5O";Q6C86 Q@&S"H_WK"<#?9A5ZPO"D"Z4K!<@!]+?^&V=AP#1F2]%
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MB;I*ABSJ2"S>!#R+48)HM9-NRY(U]DW+E1F 79W>8RLD8]..;JH24/4E'8O
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M9@R(B#M90+D$P%$DO52VO<N8V\#>JGO>KXZ<$OJ_3R">ND'98^*N8KC?-$%
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M$-#('!)SJUEV6885;*0?3<N?78W)1<3[(IXQ=IABHY>5#Q63%E;057U5J8B
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M'IDS-N\3FJ^K&_,R;4W@)55Q&4&E V5VU,[$5=T[4OM;@FD*'O"WY@'/M?F
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M_"?W.?Q/G,,7R >$:41^!C"@PE95D5@6 1^IC8KVR5>\5*U"IJ:&S[S@#ZT
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M,GB,#8Z[8I8(W3+D*;S1?CAB9G1]X=+>?>\$1Q25YR(%B'G_</I8>$M!'3N
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M,-.8PR,Z8CP=Q0X^.;%N%O4RG"EA(J$ECLPS)LFC)>1)',&9JXB&&&7[_CD
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M!34I4WZA"<YIMD4M77;R4WB09EW%O9#!(+6EL3 P%U(CQ"0PLS*+42".UY0
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MZ )Q?#HF\7#/Q4I<Y(%SS!2>SWQPL!/?.\]5+!L\0^>\A#AOBFQU"V242!<
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M?EZQ9(+?(=2ZTA!A."*0VMLOIA$-4-WM.6NY$BR(U=S<D&=$XY;02<%3_L^
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M;ZL#L\^!I/!P7]RGI<PK%-]<T2NZ@^,:H'/+9/T I0300>')PC0G2V$-1L'
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MH>U7C^_;KS+M5_<FY]_&Y' Q3JDEB'ZN@<S+W/=N=QK" D,/R1 7VL\/G *
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M)42S[5$5G2<2](Z0B#*,PJ:C&),)+RE,B!\OXX]LX0.',,&#L91E(J9RM%K
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M"\<>)LE53/F78Y /-L'[2;/&1NR[4-I?=/[J#OR%:_##?7CLZU/>U5>, 5Q
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MU2JT/,:YR;QJ9B9Q4#L;-@_:-C9:7]ZP",6R2DPUTB \-GT3W*?@,VNVOJT
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M5IG.TKI-5Y- =FR\.0NTO;SIZCG2_$)JF93$T=(G*_74':-\M,,3A4 -%.&
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MK]*4R2](O@D1[[:'_08-MS]=7*&M/ ?NZ548X98I.>0/?T-*)"%RII9#;#N
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ME-U.N1FO6BMW&[&?+;>;5Z0>;WZO8&N0?7^5-L/T7SC7>AV:ONTZ(!^GM)U
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M-!MPM2JI_TT5%H/2TG\]E 5X02&N0Y0W4>\19BYY^#T(%Q8B?#VI&>Q"(WO
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M5M8IBZ6A/9!)[7@[K'D6\*>##10CX#[](KV 0!E:)FG1H?.N8RU)5ZCT24L
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M"^8B!X>,HMN 78 64HW0T6%7Q;+[([CC -YMCMWFV+PY1'YR"S0,?02L*DK
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M:RPJUYRUFXXOK6\P/X)[7;UD, %O.W;-WK0:RM'/I&)5Z4]2&63@X=OC9N6
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M-E"B@JQU2#&7-%\Z&[8ETYF@A&4B9D[0K5.69GI'DLVOMY!:\#QN.*V0KH!
M(ZWBP\/ODR>GO[YUJK;H[N4'9_\4_%VIQDD!Q2VS@U4FNJ!I+GL-S(KE9,.'
M&!"('IF>T7.N>6:(D.;^\TD8A*021 Q&ZMBB8C!*RY9.DC$#E8$0X0HOV3*@
M9&MSP6U6UJ"+C*HBK^*9TD4K^37UI3S)FE^,FV4/C27'2WC<OOZM9363T\&_
M%BSJ8^*G9E%>@Q,'-O\.[ F?%A/7E<S) D<5'0F<@S=0^?"Z%FUP7I4T)KS1
M3,@6FXB^#T=A(:300A_N5CTV4ZV$2*O26B'MXE=G<&"804\:,2*!K-'+;6BV
MU,FVB'*,R*QJLDXRSS0-^EEY&LU%FPK2(B!S<?EQ3S[N96!;Z71;?)?"1C4P
M5G]_ $B<Q*DOF^M0E3?B(DS$PU]JEGD>Z$;UUB@.ZW#^K1SOT^HR$.^VB1M4
MBV+H]&Q$"=5TQ(4HJQJ\G]#&8FF[6]_,3Z>SHEIFMR]H'0L>=?"50AKPX-$#
MQ*LRPIZQ%Q\<0$,^K5EZS2)<,J?% @FI$<OUN<?2N$H)Y[&2LW3:2PZ.'F#?
M>:9-1[<LI0') -(G9$6*@ZL:;,Q.%K"%<498;^C)M]BQ&5>0*'\5Z.#ZD9$/
M^U[5V\!U/$"LIZN5YMKH#<=D=/0YP: ?765J @%\#!;S^ LV)?Z6&G:'7Z$C
MT/T:XO$E?B'[D?;!3.GH'/<J[<P<.A-E53J><(C*T[]1T1U 5-G.>]!KCDN3
MQUOP^T9=B1]S(9ESR V0@<:"='O3Y^YH[]2-E7GRZ*EYA N:E-^JJXPS/W*\
MJZ);R>R>"V9Z<(4UR!KXV;%Z6";Y&2XT<ZY-/KSL-E(4GOQK(?S_DM^^BZ)8
ME]<,9T*6;[D@HU9[;DSRBXTJ4Y:$R!K0RT=F0XI=QF('RRUJ#GE95I>2!#+-
ME28BB74,J6WU$-. ;O'$]DQ#3-W&GC.!;GVN,IU/)'5YF=;L"_F,+%)'Q<P+
M?<*W!=T6O:M47/FJ4%)\SJQG'UKZ2/2ZIY+<W^R0PIU$>+R7.FU(<]]8_(2F
MCPL$$I;21K5?]!)0_ F(07T^G7YL?N$49JI*%[UJADT*FT^V(/S^,N$&V9]2
M71 IG6BB@(M==(YZ<0T\9\[%DT&]R)V*AT9:O%?'%:2U+I8_KN<W>_#)]&;?
M-#;DY/OK8$!*$[89/L*YZ0?KKW'0>8V..W]1X,F6[V %>/*.,S_"^"]UN#^K
MB^2B2NNANEM*IX<DE7YB@-S/D.TTQ_8;H2J[I;A;BA^S%,ML#A-./_ZP:+):
MR($#M0Q;B.3)E%)"V"W!W1*\@25XYF6FR6E1U\GTDGGYD;-^F2V;^'QF3X2=
M]] 1J<I0Q%K^ (4*\;!V*W:W8F]@Q3[1R,3"3F24A1.=<_B29Q:]GQG'D)9%
M26>S3 HZ*\?ZVL7YC19%CW9%T8ZBZ,Y(_,<8":L8)*,%>TOSM!!.?5=AL A3
M1,FR=L4&PB^B.JL!_SQCZ=C*M)4M4-72BE9<-,6T.^IVJ_@&5O$KGWJS].EH
M(;G^K,124Y0%10X,CMRMN]VZNXEU)W**HH95C9"?8P1K6.Q*FX9^+ZEOJ66$
MQ:\ ^]"\9R47V%$*9"6T187\[KM]1-(\C%"<O)JOTC;S;-:81%P<_EP7_"#W
MS$5(NJFKCP"-6<XE)^M2H*Y^"WC0@J5]+*G+^]PE?-TNOXL:/2 )2Z!74<*J
MZN1,L0KG#JN@%7N48^;)\[+!&J8I^3O0J;=<"P2ZI9$1#WC$]%NR$;QNLQ*3
MB2:E; !A:E3=N9K!VFQIO0?!#Q$ZK<JQ_,M5>W7I7F0#EJ4WC46(82>7Y%>H
M@F!>JJ27HBJL@N4T=Q2;X:O;*A!D$%"GHF>CXTI& _&E@T<J"G@-;(06%SWQ
M8I0.X/N(>,@'%%3H,1U.7BHPD'O//W#KV9[H</-E<JX>!\+V9<4:0O;'\/J-
MR IQ6X&4.9W0E@J3B\*\(EF\X/9@4M%>6PGC7+E==MP*)L8-,)$!5T%S'88$
M02,I5=+S_I@<W,>V7@2%1%8ESWFBM3#8=1=4;'Y*#N\'(N9<QKNH5;,M=7/I
M #E0+!Y7]?*GY.A^J"?I-S^W!:)TG+$"<\IGNBO0^%EUZN7IX+T<\H8M-$79
MQ/(O#$Q$\OJGY/C^=AU^M&&L[B1*B[2"1V2F\>12SCVY3X-N[@8H@DUR*9T*
M;KVY&1PLPU45[O*@=DL;<UBQ?BZ9>-20&?;!93<NRIJBI5]*C)UVB"Z/\L/6
MR1G3K0C!=:O2ED#EH$IT'U3=?94_0J$HG$O+C)AKA;W+(OTA?'BRI9< >+-R
MI50UTWS*U5.Z <JQ*'GG0[<D%.OMEP:=5[XM-%#"$V@"7UU%F42*>^7QY)P;
MDS7)PSW(OZ<M/X2X&"JY+(4ZR!0:A:TSF#N( Z->1'A\K22C5*(=]H8+HB@9
MPTY&5LU+W*IZ)U=TMV\Y =M-(%SIEP*#Z]D>C7FYT4M9F!1J,V'X#1N"M":;
M8$]%]E&'>LW:0+O6(A T+9#^IS?#*X'>YI]DV*%O.@2:01^9&SNPR/EYZVR\
MH&_%J-0<4 <ZS+!T&.J?2GMR<.H%E6Y^9:*N-\3+AXZOW>Q::\M;)&@<^4I1
MJ\#FE1#GD<4]@7PPC&EMH!U1"4Z3HS<O#%703\*^8+(_"UYCB>F"_7+X"XM/
MTH?P+1;"VSB21L7/B^5&%7 @PBH^C!8U>MDRWB/^RX9QX(;Q2&*9U9O%F<S*
M2UD#[$RL,5.1"S*EDU]U%J$<?@F( UL7V;>F#\S'^P9<NA4+ OGYK$8B#\9.
M01U=JXOQ4@:=^1)(WGX+R@O;27M[D,_<YN';DQ]#3@0CM/Q9B#<]FKOS?@H-
MQC'2SV3Y+L$UQ<_&\S."^B)]A=[>%,T0M9RL H8Z_*G[;8KM$"@1WTH'4PUH
M+8H*-,YJKUGM[*)S6ZV?K\S@'6!ZY9AK3.6=%ZRMZ)[WC!*)KR-I2+=; O5G
M#N48> DW=ZE616;N#AOY#5#*YZWX"FG!QWR\,N=7%6*X&A,]D^ D=\')^UR%
M?=F;QT[O!,VZQHH>SQ:^,,7-/&(= ;#^991%?P.<$*^7;\4&OY#S&:<VM]'5
MRM^07J9YP9&>ER?V;PMB9E4C^1<QR4UR;UQ4C"?%BFXR&O*@1S[' M*_P>?)
M%:#0FUR ^:!_GP/WZ45A#;!N;MC1S'BX_C#6@7H('3\&EJ*<&,.>OU[/:2<7
MN=E86B7UD#6^Q6V#G9NZ@YOVL@/0]9-SM@7B"3=9[!  XPKMQ4:(,!0"%NP'
MBB6J)E,5;AZ/728%3\!&PT%+DXYV.L^]D/7MKN=3UZX9-CU;<Q&:(:)F<-\+
M'30 R?IN! +&\<(0IQA98D@/RSL1U%IBL#6 $6L'&:_@G- :>"TP1[>*77\E
M6J_H*PMM>AYBSF$'O'0LVIQ$899&VM U0+Z  >FRT,B85@FJS(LYX,JP/R,R
M:.\!=6/SR4WX?)C=DY:GC2_P:.]X.O5@NJ1@?H7[N#7WFEO[A<V17C?LR,#9
MQ0X[1>8T#?<3$2Z%L> -H$./WL.(SKP%P]<VCC#=DXWH!VEF:)A=\K3_/@.)
M1?AFPQ'C">IL6EU*][FHEN."*U>B\P*MW+1-JD:*'S,):W#IH9XKRG0@UOLT
MX%?XIKM!CW>%S\_M!OTHL_6__I^AX3>%J:A<666K:[&?/'4IF+8G.5_.M"'#
ME=W\)@A6>M!J.8*; S>%DT]D1LG'IT-QF,VR4ET<<9$6: U@IA<SE+JY;]]]
MN=Z=MJ[0E Y-LET,5Z83M+O7L]5N=Y%7$A##!K=.AE[K/E -9R\J.#[=.;1R
M"(G]"R#7?"S1'/&MIME\4@W)L +'/*5;C;EACCZ+%K7[Y#K5X:<:=/"48T2Z
MG-[FP9'O*Y^D-_.GH.&;U?<8/8,U&UB3O:]+>)R_C=<U)EAO+F/.[X0()473
MY+&RMUQ',G*>?< <&;U(SW:"O90K]"I+(I5.]X.'W^-+1X\.6QXJ!^]:W#"Z
M,B$XJ_*!8[X:544AT9N]IY4EM_Q17ZQ_0^+XY5/$)%HAC%P567O]Y)F0A*#O
M9E IUTTE,W&T;B::= I\+D]'#Z,YH,^"I (!,S>[7'%Z*KYEQ!9AF]WQP)P<
M]D^^YWZ@AN9A,!&OI&/,GF@"615;Z/3X4=/WT4G_N'4Y_KR;(,_8<P=!DH9K
MPN-60K5X)7'*1$;PDWN\H5/UQ/&5UZY#*7EC$><;M;SWE/SD_'^GT]E/K]\H
MH\E];:!"TW#*6'V\M@BG-;=^X!25#M#6[666%HL+-YQ3X-=,86G3O?.MF4C2
M^3-7NF075\/CP CH\.S\T#8IG 6S!:)!?M717J 'P>SX- 9">:['(RFM67[<
MR 7EJ:74N *QZU+8E> _N@3_C(XFI*AE05Z?F&5XTWL8,9\?]GQB04)4,@RY
M@^V&J2Z-$KG#;0<CV:WA&UC#_ARQKE<TRUJ3C9Y&D@*6;*JZ$HHS<76369TS
M?X=+8^ZPY+L5>B,K]*5U::]?F5+Y-!,Z%7JVGJU1K<Q/*Z.V%4I'Y-XE@YPY
M?HCX0D(AX3AR=FMYMY8_%RQ*'[VF^!R"]X+%SGW>&:,A/'0!:02#N4@S9,^#
M;2@869 E7@J;E6P0@21EM79Q?RW8/L_(I]Y]6@O#=SG(40&AG3Z?H/3B/7RX
M_A;1A)@;QD]X1A;A2]1&T6%&]QSVW%0C4SA(&Z0TI BHZ*]U[T8RMTQ4N^0A
MSI&_P[CP>L'K*D05DACG,BU\M]+";U\E:J0:')!/K..;B((@Z7T/']%!%M1@
M,:-);>&D\&IY*( B4WHK#.@ V_$Z,K8UMU!B3(L.3RQF:"8!C+F##,U62(,H
M4D6X6V=3*98QS2PCLY@%(J*I0T&227^XF(\Z#9\90HTPS5)^!T/A$QH7U06@
M(.&-AGE3+V;ZYJ^R@/>)XWJA=646F.0>4GG3Q31!;3JOHXFM,.1R>-\"7G 1
M7679>U[LG%'E?_639UI@QJ)N,N&UD*8*3V=MO%YL+_3T%#P;UJ% TY7" \O-
MHW0VS:K5LOG+!9*2PG&CY/@ND51<GUSY,J#8YR'YR!LC'[E]ABISEP,@92;!
M(#,L8L:>G)T;0>&LUCE'M+<P<IF1YH4V@EI:G!J92],S'$53)/XD<8CJAG-T
MS!W"2\C1O: .#'*'N:6IP/D-DL-2F/@%K0*D V,[#=: +>9XK1T%:IWQRD))
MRV$K0/3R0;"#7 4#+!!8:V:@SFCSS(U*9$A/F\.,I0BJ&9ZI=3+GJ\DDZMT"
M(*G;85SVMH>3X6(.8$UY---X2B[2NLZE*$&_J95 /9U;N\<=+.NHD"F7PL\_
M(D^7#[[[^4TZY\$[8,W7Q?-4795,10R#EC<-R 996&.8@3X(:4 >/?,J:3V:
MJZB"U*#SLB8C/6+WP&$1Y&KZU5YR]O#A4>_!@^.>(/HN_C2PU.8B\,$Q,^D[
MCFL#F[,9I?5$:PBF.7Z^!WB\HWT9H!PR?*A>5>&8'A_TC@X/^6IGC_;W>T?[
M#WL"U?BX$9YL-<*_+8JEC.Z81W<HH?NW7#L^V=6.;[EV_)HLNEOE!P]M(:GM
MHZ,!Y_H?$%>H>2,;I&=N0;:B%@124N;_6F2VSP4*G3M$D>UR=O]!7H[SS:!?
M>4N&0] BM>RS&%>.#556W!R2U0K]X*I ;%[HY&AU6G E0O :$<R_QWXOYVGI
MC$J'0F]8D^>C 8RQT<AWF8VAE$.'P5C:.B+4;&L 9:X>P6=Z"QAV%S2!F\Z8
M=SB=\>!?YS'#@ ,;8D#2RFH2.?FXR>%Q\($Z&^?LL_)"0/^! &W\)Q@=92N%
M6;]0^.\GYT"<^NL[4D)(LLBQMN8N/; :;K3U957NX2K.V*^[F!Z 6H?_C.M&
M#VJP2;MNZX'"SWZM:S0Y9P_RKI9I"_LA=+1%GJJ.0+!&';V@<_6%XD4M'=T^
M-: Q "$U8*IV!763:1UL?//OZ8>]2775<]3),=5CR)@8Q"N2@1U,2JA=<)7=
M^ +EP<(0Q_6\X"'",,+Z9_H\0XY!<T(>2^S32\.*&X#Q5O8T/:2>/# !,.D<
MA*02Y06C#TX?&8A_SH0U.J8R>JW?-0J XO-LGKX75 ]C#2;+AA^99IE.!"W-
M#987H"C1WVA>(,KU*)>AXSC)%7HE(^.D@L@_P EQ--%(];@_;Q[X1<:OAI9*
M0R&=3LNBY(&A69 %MK[&W?G$TXG>U1%2S"?<V6-P9Q\5MHG$Z00GG\+Z3X+H
M,= )83RKG.0!@_@U--#:)K>6"IHW[@KQK%'G(+*))+(8NUY+FR<^R-W1P2,)
MG%PS7Z,Z'4\%:J2W><=J-45UA9Q./;=8V^0#2S1D%.'U#-[A<PD\-%V"T@)Y
MSR6EA1 Z<GJ"M7S_&A &)Q _K:;2JG"L5$!NJN9"'CP-RL<"OOXB _UQW[GK
MRG)3&]U-J\)Q>/3]=Y*9;_^]4\'5[FE?DJ_L+O#U7$!E=>VU;ZBN;:_4_6@K
MH6XKA+G@<\4HQ^J2:EM>I:[_^&-UDC=_OFM<;"UNYU9/+[,/^2PK;N=NY[@&
M@Q5O:2*KX?(%/+279[=S0^:3 %O_[=SNMW=/3F_G3AL]Z3=UM8<W&VX4WNTW
MO=-QN-S\7G^U\(%S-9+_OE%GQ=J)Y+<OK-?P5DW"4>_!_OXMW>JV;G1P<DLW
M.CZYI0>ZM9D[O.57U+&3 Y=T=4-:3KC_D'=KQ\WC3P#7C-WT/]\=[CZ]]M/?
MD#W]U2L*G=+H;M56OJIJ"CU/IQD4D&[GEI(]O*T[R??/J\5\\M\7=?+#S[?Z
MK(>/5%_^=F[W$AW4/+_\J+=]:[GK:AY&@^V#(!7C*DWM4/AC2WNK3SN[I:US
M^#A\MSNK_S5\^ANR^N?&S22,C$X<^Y:BO=_>OI-M\]0JHSWY]SNMC7+17W[U
MW*!E\L^7CGSH%@/%N8EOMT9]FT/0";K#<?C7]K(::A5<_NU>UA\T5"2)Y5]O
MH,*33N4?SR!R-<F;6XJXHTFS5:7#"O[D""7EGV?,<W!+I];7\EZOF2IDUM!F
M3[_1N9ND]30=Z$"?HTBS.X&^FD]_0R?0&Z/A.:=_WNKI8TM<5WC!X&%=[TH_
MJSZ=1Z?*_1B^;QO#P66^T5'S+\"B>X?C7QF@F*+;BAH8@\.D>W+W>67^4"V_
M$-ZBNYRA;_T-W^ZMHP/>YBZ8KK"T=4?=0VLY@85=BZOAO;#.S> *J7Z'H!3K
MENH)Y\:(;J*8;VTKF@L4/Z'!3Y+KV"2;JO"BYRWZ18]M478")1T& V)2E07@
M8J%FNJ (M6>QYE*\:U-R4K@)-*\S;0$!.A&PHIXA#\+2?Y&S&G9Z45W2!ZP$
MUDM<]4;!P=O4/-[XFH>'^@@^'PKTU\V0UUIE!DU[V)2L0Y$SVGN5M=)7T'I)
M4-WBOZ$:9)?"_3=S?8;SWNC$A\0G)2O6UB5%*DV6UH.)\$8X'C9@#I^_!(?:
MK)JAD[_C7KTD+XJ%],"$W-N'^]KK)C+9.1 */.((-?2*U>,<H=L?J<"-L.+_
MD<]I/Y3)^:2:S?#*')0B6$'1*OR89006R0E6:->M_DB+*1.0\%BX6:S_36/)
M'^RPY)^+)?\L"WZ6-;-<N<,"'%-,@4&[K9,\7]J:2D%R\X=$S7BN^PG0/7SE
M B9Q+F#K(A,XGI($>B/0ZAU5,AH#>$^%'LM^#2B@0""-F^JY 1 ;-BZRPR,D
MV59M6ZJVF],\Y^A,Q"X60D&/AK]87L_R*^S#'A6M8&CN _U 5YX#,_I0&*CD
M0BNBS0(N99.ZL;W2"$ CB)J?5_\P2EZVY3PTQMZ=M1]>WT'PR'> :_P5W:*B
M<OZ6R5RX-/[#;UYL^D5Z]2F*&E\6;MDY[#L"7KX.";*%E3"6KF$B!B$3R;FA
MG3\BD,*73'RVRB,,OC&F-[Q@AR;Q>Z3CZ[QDA9G8NDA4&<Q)R41W8R#VP%K-
M4U.#95>+-[SW$# .1I->9%DI5U\WAG?MA]+>\<8:792IR@W1./16>&%3.M_)
M,O'N5QXMARF]TE1B<+\U!D1:R-!OP[ZN(#]]/RKKWLYHY0"VJ>XT=TM@ N#Z
M83V@50!WMZ'^N1B.A=*@<MW%.D ;F(+&WP?[/77R\Z;J$#X%''S/(@B.1$\.
M/M_PC,ZQ0H_GH,YG#G(_K!?CR!,;:,X.QJ>#L[$Q&8AXU&L.K=MOD<?;GGBK
MY%@A=))^+W,XW%+\:O5)TFWI2$1T5'M;P8VSGJ)S[ S*_V7OW9O;QJY]P?^G
MZGX'5$]WE3P%,:)DR:^35*GM[L3WVFV/Y9S4^6L*(C9)Q"# X"&9^?2SGOL!
M@*)LR:*D\-:Y'5D"-O9C[?5>OX6H*D7#M5PL0,&* NI$0,":>GMPMYZ)]-?(
MF1*]N<E7L.P]1_D]$3Q<%D9N7HKA+F7G(V:U+"8M*]8%#JV=FPPT%9R)!3#]
M&A$V!'<A6ED[2M0,^VI:&BY-ILO=4+9T8:89@5+X&HRW&" .H/]LPIG[H+(M
M40?G$HCWH"665+16=M@AD'Q"Z!7X-=#L5RS[4(3F0^OU>E +AKT4YIPSWGK+
M]=JTF>?<#Q%-MJO'"H>0@HRXSX%P^HU"Z6$)>"95?5JWDHGU,7$><%"CR/E-
MZ*A<!HY[X+7#$&U"YB-5?3!G3Z7CT^-*&K+<$7Q#2@FIG)Q@\H?6V-L=K 5L
MR/RD!/B8+:'A=\-R781X3;5O#55+31MLPE%AM:-NM+0@<_W%K+WL%5"1[L9M
M8:B%F:D#J #J97(%9<=ZY=@&I%OGW5UN2 A<;J*J6U96?$XT9D8K2XB7*EZ%
MT#\1(V[LY3R;("YY@61YCLHJT@*!\WZFOCSP)_Q]08R^K1A/3,Z/)(N\Z.T?
M<&#$#J"; KN8(RBX83S)H.^!+?2F0R'P"J338L5'Y5Z]I/8O]D/:%@%VM_<L
M]O0P)+QA/'S#/1ZC,@#C, @^V@"F0I)+4FY+;$!S@ 6T" <>W%XF%Y1%#+7@
MX;G<.5X]R"AN)J1U3'T*&21Q/F>D!&;QA/8K5. U82&@!<33-#YN#:/C^.B<
MO<J.[9<>>0HP6DL#G?*VHQ=?C3F-BB7M[GJ54G0A44?6HH,0?T<>< %$L _6
MMLE9IM\+O>7O=/MQ:;^_>7T:1X)B.S W ;1EV4=8*BE5#[+O"J45_ HH'GZ"
M:WZ.LHKN.TPU(7QIK"B$9V!?)YD 9?$3[F/GH@TXR=C6BD=L+6%M41<4,2*(
M%7J/$P([1_8/9]FR P-UD(0:B"S@0T"U&3U$C:T6YUFAE<A3YEDZ'=?@2[1Y
MW"&6+V@YXZ&+AT1]>;2-)5#&&>,.O2]A<PNM,#N=-+;O0O\:1&S3TA,VDD[O
M(,SSBQ=/HSU\4<[GS=G??CM5B.%8%00YQU,':)VTV*-9^NX)WQERYM=V9@.K
MM^C30_W)2-8%#AU1]59N%E)$RA]"[9_5>VP<NJ2*SEA[M:$.R[5]L6TV;>M8
M/\OJM QP>'&DDL#H,*,\ \FQFN32SV*]5R7V^3+[GWQ H-@WF(-NDK%K21A'
M=+?IIWE)U8>Q T.,"8PL'FQ\.<@(NA<S0V4EM38Z&FNHX[)H$: #[K^4U>+Q
M@:^E;4[PTO@/+'3&^W:)RDU;@#C"[LD;HQ"PX_NZ,QKR=N?/L&GS[#PCW>2_
MLU(EFUZ*:Y7'._4RZ#CS0-W=SW;N[CN&3K&L!OF#WL. [X#.#B*(E=RLSDW"
M"(%X?9@OH>*N=&W]%NY*PWO?1,F-$G+1-A5Y8%(SR1/5W%!]1\!(#%!9>$%W
M=8,^%@A$W[M6KLTR(7[I%<1YIF@@5:B$>DS<XC&*C\\S'HEQ2X?0+NN>_/7]
MQ\X^<HA.AV+S 10 $/+$Q;"#8G;%(CV>M)U>$W97KY((8E^1<].;<91-0?H[
MY)&$H$+[,M,U6%*\475H;)2-PP-BN&'=MR@$/_![-@<3_B[CYCA--O1(,6.)
M0@2BXY@4#U\6D=X12$ +YRDRK:SJ-3)-VZ?AO5NSR&@!]C7J@8NL6;^WL!R+
M)!2C)"-/,;F/[#.H(Y!/6%N8R[*GJ)X)J"*V9$#W09.ABD":)K6L*TOI!D>N
MUZP0(\V^/I<MI?$G<[.0%CT$R8A4O?:D_)GS6@<U-W,A'1Q(;1&5;Y[5[.::
MDM-8I7GP,.-=JJ;.Z*RV&9E<='IYND;7TX])$\BD+A&?<(7VO85Y13A<0Y\:
MZ9>^8<'LDH#S5;@Y63C,#)@R//#L&!C8RI(DM2H:'EQ<($K9&STC;H_19IA,
M#.@,=O= $45D(0E:VEV3MBM3:3B$3I!UM*O>%S0++Q-VPBM<L+(#^+R5+969
MMC4W59;)$&^W,V*OB(*3. !1:<^^WE8)F%RC79R+DLTV3L3!'!7_GO86(AUB
M%S MVP3D.H?L\3,]$/[XK 7A!ZK%X&',"' 5:;_5[[.#T>^4ZL\Q9*-9'7YW
M"V(E-8@-R-Q-75U.Z$FGY'/K)V3C>4@"Q79KX.0S<\FLK20O'J=0D5N36$-7
M7?'YL@9,/,Y,%K/2EP9Y-[UD!P<&@,W-6,? _D;H-;&Z%N@V&?:Y(J]=DQ$2
MW"+!=MY,_:4ZPRXKO/N%IWK%C&G$^V=\L6F_/<&\/$MDSA3$NR9_6_DZ!FUM
MU2+B,W!LTEG\MK_='EK=W>4D+_,UP9!%+&NC;":"(P8#*L'@Y;!^0Q\6(+H@
MT.-??GHFU*M\+X+W%^G&A!+19Y=\&7$4SZ_-KF;'>#H=SCWL/G67JW"1/IA\
MB,K66>Y1JUW9 5R4B[<R@4JV'R4^7#BRHEG6=3G)M+N1U83IUF)3;C L18^,
M*6J"4K5!"':^"&*UTVYSZ!-GN:]@I5;3)#(X-ZJ6$03.>M6NI]QW.*9LB6\:
M3'GN$ES!(4%4V&UR0<R-%D)=[J.NX QI^S'IY?$G!3+OGH5(-;M$BBG)W</]
MU/:=H83!\U%I;Q<D0'K> G'_4HK0GB,\TB62,^E%0=*=K]Z23]ZB,6D[93MY
M.*R9(7<@>>CV&3A+)G)>IJLX4E!L@P&=K%[0:4\T^"FD-_1M:M/',8$K/K_N
MLTAF]<#R23?'+1?Q,T1 HA4I>#'WE:=LT(FOL"G%BF;*@1 :VFJEFVX.ZI"*
M/:5:&V%&ZZ37T&1 %JQ@EIP'H&R?B&/\2B0P]M-V\MB-+GUBY6$7"!2.,O0\
M'$,S1X\2+HDL#FMF#Q#<5:H@ HI24W%*Y,2FR:!\D4Z83/'7#$H\R.$\PY4=
M^Q/M62U3UDV5;1%?GVL7;K4O2I.062*P.KZFC9R+ZWG-L V"[S2C@V'P.R &
MZF;N%FXW)Z:VPA-OJX5'4"J&V_+ "C$72=YR4-6C(>UJP+T+^'$2<"E_-\V2
M65%2\!&9;LSBC>Q[5CIQIX2:K:[OZW16P4:7ITB6*[4[RG(1AVXMTI?S_AH*
M;[-W72*C$L)'!'&Z/6ROM87X?;$U@B^W8F>J3?#ZB2HNX4D7@1:@=AI2T1]=
MCW%248Q*%#]-PXOH)M*,$^'^%A2*5Q79%Y16-1A@)<[50W&(!*?E= @RL=CW
M0 M6!F%E?AMXA[<0[ZPC[Q0LS:&C6H^>.AZFY5*K 5!C-%(=@%XEU'@4$QBM
M9\H*&O*$?R82H5=P$,S,<"DSKG$A^L=SI:G01V_=\<Z=Y[GMK^F2MS8<Q20*
MEPT[/.65ZG!BAE,WDP%"( ,VI6P#[M_@Y5C 7ZCU;("03"''*G5I&$/F$7R-
MHYIP-!ILH3Z@A(G(EC60G/H($N+.9BEY.=^]<^<N-,C][9VN#ZRPLK%K;A/%
M#=DQ+,=-,BAB@4.6DY8)Y95LNJ0?8#_O1!V8WS!/WZ"1:5)",YQC9;NSN*_&
MDO"F_0LD-K4O-,:-#AH-4%65N$6D"L"-HW^DI@ZLF. FU]&>&HCZSD,.=CS?
M!3ON.-BA=3-2;*+"1@I+?&U(=8L0>SU3%KF>N; 1J:2,MH'-#Q9M^IK!$$(=
MQ?*Z,'#XA$UX9NJ<48!9?:R62#Q9ORY^7F=E*1_3W!_NW(7 O14+X>\)+^.Z
MT#M&[98'F7I@)/+,E<4G3EDO.;D61_]B@*,J"^2-)9'!LL &&M"3A95=UF7@
M->.@SVBG"Y<UY'(/V0Y",8 9*QY/#!R\O;*P2\-E!^29::OKR+_0Z9(:LQ#U
ML"?2@JBSLCKQP[,G@ VG*99N<:,<:G'><A(G*&Q>?[4DFB993@LJ Z\??MS/
M6NMI D+F$L&RFP<'.:7IHU[BSW183W,:) ?,\Y7;+-%L\!G.4RW9P\<FOE,*
MV52!#]/QHNE!Y6A]31D(,!U(Q>NOK:NWRJ>S E2)?[6:!<P)2DRB/5D4RY]9
M1^UL9B= X-./DH[-()A*<TB2LV%^>.(R<@FCEY=,VCU<EXS7H/5'UFO%.7,F
M'VJ(M:74;G)F,1(\;:<SJTCAX.1YZ3JQG.-.<NXV]S=(TXIMS2DEL&N< 9T%
MFN-XP3Y 3D.13]2&4PF#A[SW<32\^<'NG%J?7O":]5755D,[IY9L3=L8?_;Z
M,A!$Q]TF)J&X]%3%0S*1D-+@!5*F)K.Q9B1G(N/TP^59=DB]24R&9H_:X<Q#
MV?G5598;*T[0P&Y)>Y,*7,KJ'MS,VAL:=S7P0Z /1MUS0R][6XIAQ& 5N.J7
M5D!AGSJPKU'H4$[2/C:0P-8H>(JN;1;*.%=/4E,K>$D>HQI8S%3FG&:\<5X2
M/*S8%O&1-RI!&.Z&G6PHFXJ9P>@\\GN@Z9P>.\\0Q@Z( ;C"JX@(D^G.8[XV
M FAZ)28X(_T=>=<K[53@:R:EYTK W'6R:=73* >$6>F8QAT$(EA_IX3](!J!
M8@YV&=LSH-\,.P>JR1?<R+7T*$15$\OC4^=GAV_;%>0^S" 'X^NQ-1SQJV&0
M^RH2DPDJI<%"WYOT'U@DB0&*171T?'!PJNH!+47IF5MV">C]^-@E39,?#69/
M^["DM?MM#ERC=,JP\R<#]Z%W6_FKM1/SN@R5X[VKRXK1DO9)-T1U(^?58*'=
MYJ;V/:$TF*V"]S4J-&"]PX1GPWGN48V5W>/K5-^C_BHO/%'ME3ANI'TDX4LG
MVKR2G10Z)0GW*4\E/4FTV;#7FCTX3[]]Z1.+]>5?11^^\Y1UHZ:!':'/O;(Q
M:[VM_G'#!92XP;KQF06_(DXMI^U_#MW0:\;NK'/P VS@XPPQA;$MK(UR;II+
M*NGS[HT^*D6 ,$I9[-5/2/.5/(KTJAETJ'G;J=:-KU<,YK1F!77^ZN5JA0FH
MK!LRPV1/2"?7<\J "Y(BXZ61#BKZ7F[GFBQ39PDTJZ5X[_Q8=;<NR?%F+[?
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M3!1-QV%+ '0$AD/HU_?XUUUV%V=*-S_)<F%V>CX=+JEOV/B\&TP-_J%Y4RB
MH0E8AK+#LJ?=X<EP<&T".^;92LE*,[Q8@;0ZH\- X1V47#DG^1AB@&!M@,6?
ML1>BD;WW,VP3*2^7+:G,X.YA/^@BD!O4J7&BN<Q^;BM\H+\9=R]?NVA'75 3
M#Z:!-7NMU^]AIR27G6[29/#4=,1<J\\REBK_2S&PL3,CR\F@?+33XGJP9M0G
MU6M7B09IRKR@CR#P-:9Y<JSZ#ODA<9C7P"EA;D66>+4!B:T'&*K!EF 9.G-+
M2E/2\!UJ@UE1HG-Y(LYGWZM, #4HS]'+ZY!0L)26K6T+*>%E=YJO$X1ZXYN
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M*1$TMI*$(.1*=^]PFX?W#N[;"+1'?\/$#O8NQ]!V"6;=2JS#0L%VK1JA?7B
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M"8&'16?2J?.LG#:7K#9M@Y>=2CZLZY+![63 H&8\@M=OSA3CN8XV5'4C)?O
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MIY UU!_=)>,G2BL1PS'*R=-)81#0GC]<B/^V6R0+O9I:>]?4Y"6UP"DN,LD
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M,8RKVAAN[=_.H@]D^#/Z":D_GU!4!?Z^OE>OJ]?R&7&"B?KW_>:<H@9B5&/
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MBYRQ0L(O=D2)Y^7G[W9PES1:I?Y7YQA>,"0- 0VB/+A6]3,_@ &<@CQ$&I%
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M"B1;7@I80N$\73R6RP=LRLD7$?YQ]*8:L7?WKY0SB#^=C2*[&YHLH;_0C(D
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M4,=7PXOG@#O,1^T AQ)J@S&>C-G.ECCN1STJIBWYZ\]%84S@ P@'PYI^;8U
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M$-?M7XB6^<E)E92Z-&NM[ (Y&6C5&:@U*6-($&M/70%F"C,%BG!X=_*->PA
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MQ;-[DO_V0U9W&!\<WQ/3ZX>L;V\<'SR_F:ONR3U?X?&-#<<G=\"Y'A2#LGC
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M-TDZ*=NB&0&K@-N*IZ.DERS*JLG^'5S&KKEUL$D?AB-'U7>9)Q/RM42UN"[
MQ,.M.#? IPNYB\J\X/;9;<E7,1+4E'T.L$U3([N4%74+YSXQ/46V1_DTUY/N
MR2]@NX#?=:<<;-8PX9X;'#^)ENTY""YFP,5J^P+4@O7^)KQS.]*RBQG\W2+Q
M:$@@'G<T9!:'"%MZ(VW8\0%?&";";I0\Q0)"S*+H/,F)_,JVJ1N@R( E%; =
M]!08!BVR'A@UJ6@<Y;/7$5KRO4QW%/5L(O6VJH9Y?&_SF9'YBR(BEZ?HL@=+
M*-!L!$Y(]Z''"&#^)9C<.E6\C=NG>P?Q]]I"_/V.$'__K1!__Q LU7<*\;>E
MJX&4-K.S):UH#2@A6E\]!%C2N[H7H*._=4G6F7F%"DLZ9WAC8K_TD3F9;%,-
M7V0%H8C^2.HT^1?=/+!"#I#.1&##']?<8EH</'[R/'R<UBO4?X5^$4?ODQ4/
M>7C"0SX$&OM-8"2W36-_7UY_J_547LNC;X!5Q,!]?$42MJ6'D$F$^.)H]*(C
M_H%=.#T;B+$"-28!.2TF0'\<Y$5 ;R'M_WQTV*5Q\I6MH3=FX->_5L.K.1EW
ME9GP7CUH7_&SG:_XCGW%F]BP7LZ #;_.0=5D(CE%1691%F*%#S+DH]&SHV]@
MR"]&!X=]ANQ?_>VS6<8TDTJB[?#/H*_-=WMSAOVX?:[V0R)L5KV352#'8^H1
MA1)_(C,[J>>JR(KAC9IE,5E%TQP=#-PV;4C1W#:E"(U\3KY:<V?O5ZDVVYKA
MTRN ^WZ/[RV1BN_HJ\PT-Y.&TS)@EI[X$Z<63K]K$',@J9F#R<ZI U<YK9 <
M:>3<AGI?LWE,J*#/7M71>YII&/O"+9-20<'J%O]/0 7]%-R?_E(69K_)%C:O
MZ9M<;+2H2]AA^+A=-[]#J_[15/Z*_G;)0O&\S-,.V0\M^(^RV/_KZ>E'7?![
M5K#J*Z;Z0XC]-/UG2S+IMU_??GYSBG9SLOFXBL[L)8F(#&E1%974RHLL-;47
ML4QR(%%ZVCL\]"'EF;D@P[VM#6:Z4;PJR5?DNR%7$7I\2Z Y^(M!73 ABC;J
MNK&T61:S$AD=RV[2.5WSR.AR;@IV\:4&[V&2P_/X#TYGH.L31WLX\ (S%=(,
MU&A4@_GFTJ7X^^AL%.$.Z'*?7$EDAS_BZ/YA<*>B[@G"U4URBO&1DWZAA.5O
M&FHI=D?@0+SS&T4P[B3))^CE[X\.]]Q\14>L]9.X37OI));<WU? #Z_CD'PE
M!^P ';K>PTLCWS66J5@>X5$/:D1%B1-*LPEO@"AE2A,>(917;X+$/?I;8"8)
M;GS6\&WY8E:6Z%OA_/A%SP&\9N]1<70?C5T,=MI24,![#&0[WX+4P!8O.(=K
MF:QP>+@Q0$)5Q\M>E;,J6>!&3B9EA><E^ZA[13>ONSA[8>42!E>U].Z@C6N0
MAY4F8)U/Y,OF]=*6!RO62RD:-*6VP?H+BI!T-FX4_:V\A+E6\;?SI"F(AP(H
M+UP#^04UGD5!J36,"0FBK98E$EA9X-;-$_2H+$!S8?+!BU8PBZ(<8MB?DOWX
M];QL\Y0(\=SXK";#"92Y&.VTX(1,[29KVH;UC.%YNTECSB6=*'%;\F1;;C2*
MSO &L28 )!I,%[-$,620Y^5E_;++KASK.=F4>7[0,8(?1S[Y\2]7E2'1(T?7
M2#E'(71XLGZ,\> 8 U_^H>GJUSR#7KHZ2!:@[=E\ U]'6KO6A47+12_L!.S9
MF:DYX5="3ARCL1\SJ?\M@T&V%=S+"])2SRE8;6-4. KST5A2$$).EY:P=+RB
MHD^S%:6161(N(( X;_E?;5899K7,,R9S_1;_%N\M_'^,%VP:X=7FI/W=7=S=
MQ<UW<3-!D_<4)2U%UXB^N[0<<XBBK+Y0TH#0;H&1?U;*=L2Z(]:[(%;T'5A]
MEE13Y.TV^RC(K,60/A)S<I%DN3HI6@EA7KL<ZH<896]=QE'<$SD9Y2_]DY:+
MNC1HSX8"@X%2F36AB\=\-=4DXW2M?[;IC"P*L#'(MV%M7L_:2,XQ+L+IR=9(
M0I$L%E0:,7H>_3R*V%/*-G2&\I?_Q$E$\DO<<F04L"VPH@JT83R=]68B"DE8
M59Y4&*G.&JS1^68-WIJN:3:=TE;!8&5%GT8#C-.J!@U<^$M6A<85V)'4CY.V
M94(*.E$4NQ#8W"'7DAB,0W8UJ_@HZ=D7 ,I\@<%Z:Q3A)H,5VU:8T8TSJLQ%
M!M2!G\!@'"CV>2;A4>2N> /H*5P9*E*K"-WX0-'.#+ .E8X1>2Z^L-'##FH]
MWP6U;AK4NG$R QN%5-%7$Z?U*14OA'/R1'MY6==/D!J[-V2/M.ZRK8&RX0G?
M:5Y?[37'JX"N[BNL4F+7WZ===&1]3Q>X5>V#3__9R2].#^%IOCRPITN$_5]4
M!SXDZ9\=_B+%XMV_#Q:6RR=/?@EJT:_^^8<-_",@A9YO1!2Z&7I+_RW@#"B"
M_OS3B572Y*;K@)W*>P1::#K%]^M0 'H1L2!R\#\8#OH-+\M_G5? ?7HWQ@;%
MO@/ZX)&=SN&=GPYRJYL<P ->]_C&A.<8WZT1W^.!7?U!2&3?@#EUKS'&[FR!
MMXLA]E 1]FZOO6$WD_FQ(+4?QP<OQO?I(FP5M?[D]MH]_J@K\P@:,/<SDQ[+
M;=H.;/=]W(E;A/C>"9\KR^$>R]TYC,<OM@%Z>A_W8AP_/;BU-F8[2;3V8KTK
MZYK3OV"HK)BU63U?2&4U%<RYLN=KN?UM>I#Z_N&QQ:/IZK-W<G@S\?:=D+SW
M<B]NV!7[AS=R>5 "[@QK0/;/*>%\"'?AL=R@YR#DGF^C/^5]W R*^1Z^^A$3
MW(F\]7&R*Y! 'LLU.P1+_O!F_/GQ7+/#^.CYK>W%3E2]RYILUL'$>2SWYFG\
M_.FM.< >^%Z,X^<G]]Y__@CDD8,R6%<EWP.>>"S7;>\X'M]03#TBB^H!JH./
MZ9;U<"@>S2T[&<?/GMW,Z-I=L^^\9AZ1/H;N0O\A'0AW.WJM'7UT6MWMI0%U
M<FH?05?"XX,;*VM;$R*WN0]/#^+#\:U%N1^_R/B/::&VV]-O$1O_:ZAUVH\'
M='F7_:O-4H390>?5:ZF3_&3JLJTF=P_;\@^$(D.(;S [=&(./XKL%1N&Q8I/
M^+,4%"$\ [90RIJ,4#:N0.3CVE +D#J5HCL%G,)QP0JB@CT"T'[VH@/.&TNU
M558'38D(_O)P" ]]_.)D=/!+'& DK0-%^M BAA&>@H][2JN&G8"5+N%/.OFK
M@ =Y\F,8\\7@[&T-8G\5SY]VL6TMJ/9M3&W,,(K/.EMU]U SN-=,7JM(*=[2
M0\7E:/2/:5Y>,ODYG)4XRK&L+ED@1'7-\-]PKM,6O< 6%D1#*5P7URU(#LJ6
M/4PHQ",IFA(+$A$40S[@H=[J+QG%''_/']C4 H +]VL!@M&+A56'M$X[_U9@
MA!41NSS/Q<L-*_&72+]8&--<N;9X"#Z P59H?F:6302$A9[?=($O331/TBLN
M+A)8[][RKL E#1N68#%CF5_@W+%7)5$ 7-*L&46_4@2:P-WK)H"#<FATG (\
M:70SNE T1$3RI*OL]<@-M[/&*C-;GKIV6<N\K1V$O<4378O03V=H.>03AR:6
MPJA44%K*GSO@2;B.;S[/V*<90LCQJ0;GLRP1?1ZK/],,\7APX5A/!]N4&]QB
M1J?^"C]<FAQAGN#ZSJ\&<?XAG.$LTRW!'Y9<V4I4=Z$UK";M;)D<V0"=>^C6
M\XIP1O0Q1_/"7EI$W&#<(Y=KM&!0NKASGA8.!(@2":F>EU6SCSA*1,BUHV0:
M"_' ^*^(HFT9BE3L&D$*R0ID=G67VVT%!XPO5@=H:>TN>_#XC%+N_FE;"<3X
M2E(,'ATV0N#;2DT8(TP_&45OIWX?!+ZKB<,^(7:-8$MEU0QB3H37)IG O^K,
M 771^2HB$Y$8EH'7QGRA NH$"^3YHTHZWFR('+"]5D<58N 6.D :7Y@-+0;A
MDVG4WJKT X2V^/^S]V;+<5O)VNC]B?C? =%;_H,\ 99KY&#UZ0B*HFRZ-7"+
MLK5]M0.L6D6BA0*J,9"J?OJ3TQJ 0DV<2:$OVB()+*PA,U>.7V99H=4C&9VJ
MPV-2FU& ":N#9".5R]?PFUBZ%5S B]=P$V67X=0 &_,PNE$*EZJ#+,I _0['
MH(I3'?PHC!#DD(F2T9YB=0U_$*AZ^T4+DD.6:(:M&!35TY-<I9O]*HP40H6
MFF.P(1-6<M1WZ;17GM>*/4(,M/-<>DU&":*7B10.TQ&!Z)N]0$Z33B7X24=/
MQ?#5A5SZN C!+("%7O!5/01U*PX$@(>/$&M-TE :J21QJ5*>[QG>4&Q>$Z85
MEAE'L%J!TZ0[$!N/"&%ZA>8<>,59;Q7S3@#T8@VE!D($T8RDRP7-P-TMLUIS
MY9BK#Y]$T(+4]\*Q_;UO,!.O-6EH# S>\OKQ$<"-=GH<7"5I%37#>Z[P 0<-
M?,"CPP<8A)(2#+9I0Q"B>=5I#;CM@/R:V,3J?VC(?H.?+I-DQ/2MFSUH.4C\
M8;[$ !_Z$T8*IG1HC"!&]H8Q4XPR6&8>Z6[DXR1'"B])5#$*#;Y?VV9A(;ZW
M[_2$Q 8/@S).]X<@'5[R>YT!:>@]DJ+S'T)5;SF2.$PW$HD6N[M+'ROIUGK_
M%O2(P(T[A0L E=Q3#6AF_ZRE4A'3^1#4_X)#>!RSU&E!,'<5:=7"O;"Q<=+:
ME_6BRY<[GS'4)T.[Z&&E QG\:_'985,V;D6G/S73AP0*#NH3N<8[3L'@8\.4
MWH9#XBS[V'N'NNS*W/JSG8[%PXQTYR,<^>SX"(?YO8B5D.2>,1I+$#D$?T^-
MOIT]0)QKL@&7M2-9O ,E$P?V\S(D13ZI.T]]B-AKBNXOOD(1S7*(%H>]R3PV
MD&!$Q.1Q<)@JUD"=4ZQZQ;*Z@>8N?.<B5<H!IM)JB-4^",&)+EE' 1'D4V=!
M>? -* E4==Q%3[J]^0PG&.B&0#3#LNJ*TRGIRB5U/DGI- )ZTYB+6C_#C2IB
MO4DK-%K+%.4M$]!DA(5#E5.4[_.R<C]243#S>2_(FT? IH$^8P%;*ML3[,83
MN-M:9X\(=K'$AP1S;E4DGCX)*9;>'K4$B^%D87N3M(1FQ?HEHI6#?,TO#0*M
M8E0Q@:DB'+;VZ\]A]LU[QX/0KSJO;0LZ>C/,%K#G(^"-'^$5]X[LT4?HA63A
M@P3.KYB@&?\?Q7B^"("+$6)I?2ANPNR'!@@ZZ-X"(&BW?1. H/Y] 02]\('O
M(UNA@32Z*TBCY[HI)^)R^WGKK;0,V6Z0G1IDIV>'[/1$U_VZSAI:L16O7N ^
MK%ST3T\2UNL6R7PW35"YCWR^.DW=58;/M,G '@.KQ+\-\N"7AP ">]PGFSG_
MD'-^KF4E=XOV1Y;P%G4,"N-M'2[B]D$VB&MRM5Y *O#6@=\9/->ZK;O<B%[/
MW^L^4SB#.R6(?M??WWNN%''W%5>=[EZK>ZLY_?00^"@OH,[""&"1OY)@]"1$
M[CW0E;_?:Q"(]&[T_/UV(W-,N?[!W97K/_.]&'1:MZ.+GUY [?0]R%A7M;4*
M;UU!PDN1N+L]O[_[3!6\NQ>XW;;?NR4^R@N2N/MX_S1H,5(5V>FV;L<G<S+W
MD2K$5G6Z_V1L^D,C[F[>X7XC0;QJ:D>FF95N(K]!2/[F:[A5WL&1DT?@9."7
M;I-2AL'RU8PD"#?R7O6[E4(PS,UQ*]+6&;'3\CXZW<0#7=:-,]JX,ZIIXJ8S
MA99V7_7YOLTH QJ_=QYP@0NF&E'ZE8L4Z:^"#^(4G"K*2:@KM2K?2LZS)%*Y
M,I59_. DP6PH:A?M2TZ9M#*F@@J]^U2.U!FLL?_3%//4X<S#9%3M%5Y77>#4
MCT@K.VJ?!]I80(=HVT#;FC)3%D&*RZM^J[/AM+YPCI"LUE0AA7&8A[5SHNSX
M'<R.GWGC(AK#A^C/' R"<R]23F1:BP"_2%6 [01ZK3 3=3S&'"A84N"]ZK9Z
MY4694A"84G43:07!Z"J@R@$^?66:-DZ"$>68Z?[LL(LCW2E<CYKI]M65HCPZ
M^'9KOU+G6#[75[U.]0A07%E<1F\8)1GW+<QR62VFWD^P;W"&WTT+![61R^J*
M\TS]N^#F@E2;2,F_>+! QZ$5B2GV(<_4SD2E%RKE1,K?8.W!-_Q)*D4QQ6VT
MH!2R4GG[X#EBJVZ!$^,!:2ZH.[B@UO(PW>B&0F$$6M-=W%$DH8STQ;QU6X(W
MPOKRF.5$J??JM$A!H&2<Y@SR'\A;ZF4P<7.J<<!?5;G5=P9/59%Q4FJ:# ,L
M)W)Y74L<ZO&=)>/\&M-81\"!4<+C,X>7]Z1=N3>>=V5+I]U4MMRVLN5^!>8[
MX\!H!.9="DS7753G)-I :%H-[M5^KZ)>W%AD.O6R84E@%DJ/,Z\^U):>EY0(
MD<8FR?Q59TXYFRMF6EW9#J,,JG>%;M) I:)F,*TP5I1$VY0;2R'SD/I(2TDH
MU]76853X#M*%C, /SFEPG(3_)2U@3*EVD'G/86N4E3U3MV]J<.E2T VMJ8.$
MW<W 7G-PA8TP;3\\+[A,%%;V@2O'Y=[: &_CGO+YL?YH"'MWR+HR;O9I JP=
MBMIZ# <P"?*'1Y[Y0E8.:/VI:0YL6U5G-I\))ZF!.F"W43.G:A71_],1G1@Q
MP!^MLY:'C;]UY0>7#3@=S>& D$5,^W,T*5&OG]JB=&4VA.N#QF-JLVX* =':
MP-ISUL6H,&?([<UG;#$X:5D+%T3#N:\Q0( A,A5EZAJK$&]3(7)OI7+.AIZS
M+0;+LON&"S0;C'P)\T<#?B@%1V#*4R-U@^8!>Y9,L)")##QN#(\;.0KML< P
M5R =$ZS.(K:4NAQ;Q25UBB2"J:(H@%N+5$-&=R!Q&J;#8H+%1%2=#]=M075"
M:%ES:3BWB#?R$+C<+HS',4WD2Z3#]7\RXX<_%N2FB<HODQ&0M)FQ7SD+7;):
ML/ *IM-H9LK+K("8:@%!Q?[E>CVN6-325N^<'IA90S/&2EYH>6?8AT[*_.IF
M4*Z9)][%_0^'6$PH9O>_L.[JJL34H.DKNI<#77@HMR=6GIF1[,D"=P4IU7;!
MS^0A,605QI=TVHC:$XM+XI'8#FXE;Z@%NK-;=AVZHA!]#'&AJ '[12S5B[A^
M=,H9>>N 'LW]K<[!-_?0'&2Q$6ZEQ^;PPQ]G_UPRKJ,U-@TSV.%S%NZKE../
M(+0]G>Q/L GK$?W7"F"1O@VJ$[*32=4XTL L"\E@ZM[KC@RHH(])^:)4H$IE
M:J4F%PM5\>0T2S$&#.FBW^G\#NGJA:^B/ZT$P(0BL[2E9JKH&"XBXB.L4=9P
M9C1;H1>11>:&M?MGA*LH!"QW4'*LAYCS.*ZPS\*'GRT?/I)1]!4K7Y,I;NH[
MLZF.4GB&QP$R,//>)/ ?;TO*5]\=GKV1LM7MNN>]/Z9(ZN;YP[,_S.,KXQ/=
M=J>_TS[0=5LK&4YO)]W.1_#W%.ZBC)6_(U ;X#)),QG,KWAE07T#>XSOP:UA
M$D5\:R#]FJD?>;OM73U]G\K:@[@(TIE4MJ/IUCEXA-L=BZ*Q:!TKY6MD.T-Z
MN2@WN"6Z+'D(+(*<(NLC?A5D-4&STE6W8[Q&LUQ-LU^\K8Z$RK$,/ _',[%'
M>=.WLFW>]D# FUY[6]VZ%UP(-P>=3-=,Z_'@]9Z\;E<J@ #&4"-0 'BR+T\&
M,.\A@:K5/6A"*>O. .EE:R!CR^[^Q^XW5:YOX4;CVA$ (@\S6.6"\4G,+QC%
M?#>)M&("QO,D1/_"10(Z'%6],Q(@P9[0XD#K% \#AYPPO!,K_!4? =M$L08L
M(0$O%T>F/XG)0F)$7!NX+S+(";X$1U#?)9 WIM)[N#KFIO1(^FWPKR0E6(&Q
MW!*\I>1Y1A_SR$*Z6>@U#:CH@"_@PA9MH?:RX)_!F$>-FD @-%7JL-D<N1%;
MR3U&QTQ6BL3RAC1+T54)XP L6;8FD: HJ&N<(V4&H+!;Z>#@$8&'<4\03!YD
M.X0>>.;^ZD[CKWY4)*;/EJ^,_!JQX)H76AC.<41#C; BR<, ?UMA2[5\'@JY
MM%YT$JN0< W5:%OKKVC]PSS/57ZM1(1:2WR1C'>N02WGY[A9LZI>VV507@+=
MK7JIQ.6:'1'J)6<O34:/L'Y-)X<KU_Y*PH($"S-B:!!!II7/IF'V37NYKDD!
M0_%FL/S(!%^XHRV$[S%BN3PY_0$-H@DW@XIA,4-%3I':6=K;B0],K@6^/LY5
MK,9A;A"@G$UO@8:+;A,8CHVBM:TAWEX'I@8$8Y%E8CFZ8M[5=\C 6&Y&/E[L
M6[)5'DG1_T00JG861 \9.4"FE[,,[+(@WD%2%=-RJD 5AG,H)/K)%R,Z.D+D
M/Z!JO.5PU]$M@E';N3L3*:><!3,*54X8SR8;)A,V1HL0*&+$7G?M/;=TO>A>
M%L=""&0'O,UV-*G\HYF11K*25$V"4)A_^7(X"*/?PZD)#W.>ATW@$?S'>@+6
MH1.R@PBZ2V+7:"I%K$*!,4X8J?#<C#&G!"N:%DGY2SG<49S$0Y'R91,7]YO=
M#!/)(@RRF!RL.)7EAVG/;6Z_6]X;!61IU)U_@Q4$<Y60E@7[ZK4YG"583F&,
M[C$!ZEU%$L[^HJ^MG+04# 7M"K58">1EHI;1P:XT+H<)C#7\YO0"9TQ>]*,C
M15G]6M\F-I0C))69*PXVY!V>\R$H<U')&C285PXJGP[RT:Z,PA&Z]\WN,'+5
MM88P<_QPR*Y\LJ4/O]7)6N@J0CKBM#!YCJ)L%49:Q$178>"-TF1J273.:!21
MB^!BY%25Y*N'U_A=28H,0^F$(T_<96"P(AN,*52'^@>JR<! 4?@?NMWH:3'!
M+HHH2"E5Y"I4UX(Q[0R.]Q[8%;"+>"K5/R-G:6<:DD^& 0^)T'*28C9D=DM1
M&P]926?)@@;J-2DE8\KF8SE#]HJH^"/O7".>DQ?P0FEI9N#=8#<*#'8P%41)
MGE75+XJ;&,''L.IC)>+'G=/;&K&,>ZO-%K.]>N0(,V7L%!&<T%[_0J":?U!7
M0%4,4<5A1C_S?BB"-Q1@MA%,, ;SY)W[(RE/%&7C"P@(Z1O;/!)-\1&0V'ZN
MC&$_C0)\0@4@9-'5K/M$.+:6F+-$W2!3\HC.*D[P4%#EPATCK5".F8'4[<D2
M%X-8P"PB1.M&G8<-,0?$CU#B*1*!?I3R<A_#6*9 !UGP);A_%K=TK&1KJC@C
MQ#ST\^/%<(6SCN _:=FQ(>K<PML9XV_<AP)HZ *O7R8DU&Y+H88RSP@?&6W3
MXO4]0=WN#"$Y=[A#P9$3&'DD18^GP[SIQFF\@,V(*<J[I,A \EU@^(6YZS=8
M*@,Q*BM4"TIV#;P/\#VU<P32,O&R< )R,Y?\%I$X-! K.N=J&!2,W6I3O4F&
M\>>O Q<(%WV4PA35C(ESI<T,\=\$3B:Y,3A35$% K,U8O.E>-6@;Y"QL2^$=
M)S*KTR;+82D=*=-^,<27)&K=&6/L WG&MW^X2G K2"'AN+,)=/VJDHE"G$[O
M30K7!RC7L(OYXR1[K"+@8PG7O3?ANL<S4>9#AT@PZ]$CZE#IB,U-^34?I) 8
M*,67^I9B)4O@9'5/'?UQFU^/H*%I2L1E\9X935K/#[,#QE&!*0-Y%<>76\10
M,D&I/8V@FZ+ND#)ZJ?59&+O!?((Z@^Z]MKD46HVY'7D?<9J)&=W9$M^E;$W2
MHS0<Y\0!3Y"&-9KW8]/P5RWU<,<&_F!WU]_=W:46"'AP4X. ;:I?R.H5*_=L
MBGZ1U-O"'R3\M!@\VP34[ILOR&$NA+]X.D^77T8/P#!EC'I_[LZH,A1LZ3/W
MQW<;?_P3RA^O<W5\&H]!+R7U6_LZSBZQ11A0\B3,;=[AH6ON/[#$7-E@3#M*
MQ%L]6^WB26#=Y^5U9[3NDEN#%-$Q&=O ]B>YFFC?56\KV-[J;V^%X3;.[3.Y
M"EBE7PV(_\^625MX\*Q>B66@_/SDA#L>08^SV=E#9U)N#$92APP=.@YI]S&.
M1%"+'V=03@F5QCB% ?>WX5WN3JECNYPJZHQJ7['%<Q$WK-+O/+Q]7HZ5[-.D
MZ9^=]H9QDTJXA.+% =WU=/>$$_)E\(T_ORWL0+2!<;XW15F0:[T\CCD*D\R_
MSIFDRGJ"8'U7Z((R_2/<[UPJ"DT@*K_D4AN*,E].*=%1UL1I_C:R(-O!G"Z[
MNWY>WH/S\6=RF8&6<\*]MDA$2Y:6F["?)F"NQ,/'D=MGH-K<**A7(4XW4[&\
MH%1O@\Y0XVBH_%+ZD"U^'>^,&0I]YVV)CICNAY*V+ MX(L?_^Z<W9YB#[I[U
M<21=)!XA/S#E(#$6)N-4L#U??NE)E8)?N4?/>)Y\E7;A(M4"Z,QVO<&UP6\[
M![T>O4XI>/"Z:_:4'[?)=_#X)!EQV$JZX^C]:I4_WFGOZ6^;'341(\[C7K@J
M:K!&[52H'#T7!SR^\#WGR5+P7<+.''@Q=675;=A#?:*[O?5FT6:,J4Q@(FGW
M) /1MTW=7JXH_<LA\\RD9&*B/A@RTGMERIV7> 4,BV#:9ERJB6FA(NU.DJF-
M:%'?$C,L!PBJO^5^5E1D<4U-7K!*@+XK%J'Y,,572%M3D9'N[!,,LV4;: LR
M[)$>VF1]WTE)7%23YJ\IB="B1 %Q+O,V#>O(+JY[@X)*LD);!N VJ.$3M%>8
MHN@%^<[I<AI3/&KUL=H&1"O.ER\X7 K5+?#*G39(W!<YI\L2IR$-C;'JYG'Z
MB%(C'0Y'+6.^>3HP-$E.NBA4K"ANA9*6Z019^V0Z[/H>J>_D&,#0DX["LYS/
M,/&<BC$1AD)GS7%2#376#N(8U0N86):95!.4 +I![JM.J]N3.KYS79,(G]0S
MLI%_YP-<2J FIAHIT.(N@LWFCE,1ZJ-$MA&:0]P9R.Y(6DBL+9<F6YQN:Z:U
MUV[7E&.Z?<*=]F.7*B(INA9B3#"&*85(R=K 04]5>+5LP;2C<E-/N',>]9/3
M4SPWJ"!KHM;87FIZ$M66:@Z&B0YU8"Q>28GR(]SG_XT=U\*<6XJB%O+?&+*0
MG]\ZM8O!.7J?/W"@DQI$/<YM#UIYDNF"*)H,9Z.)=XPJ/ *JQ2O2S'"5[H):
M;HFEQ6!6LA-2NC $-8:-N7$DT>@3)Y1*%9XT4(*!GO(V_MO9QM'<-K(54YY_
MYG3G.E=PE3Q!3_:)WJ//N$?OQ%.*FR$4\1AN;:[*Q4)TC-3JRCHY> =GR"FB
M#Z4T3[);J*X<LZC2*VX13;WJ*<Q6UY9-&Z?ESM!RM]?Y$RA2KQW:I$YPWB-=
M.?A.&'-0V>1B5Z;.N8,E9[E$P745HSL*S9YF"/*(NNCJ77F<F[7"MF5&HVA[
MJ+F)4\5K3'/GDB"]*\Q89G-U5JD$SMK0.E"Z7-U:MW"9U3?WMGK6+O)>XR)_
M0!<Y#KY2BS T7](?+JDF&'/).0E:E$7-1KY-(+)P'*4,+5/W]@GD04PYU!:^
MY3/%3+_:RF)C?AJ@#S2'VVT<$[^1A+%-H*JXN#3H03T/LY5FA\7Z:5)E*5F_
MVDN<8(U D5T?CN*^Y-<H(7-,Q1<!9WB@':!SE/C"H,:?W,$>!1U)YH2%R;RX
M*W5HU7*J1BI6=E-C#YPG:4J&9N8;-84@MDI'P2UL'2@(\W<LI0NT(4/M0OEF
MLN-JPJ$NMVA;@A$)R[.M1[GE[&H_ZN/DD1E6*>^I)$17YGK)S6<%*0>T1.G3
M2H:98XSYN.C <-]NZZ#;:_=_DD2C!1 \DAND7^JU.DM?Z#Q)E6\</6;*F.6_
M4OVYT<GI "\#!+G1(7C1ZO6!6]V_IC3;E[;%=:797RMJ51*'N>2L:TB)L3,1
M5SO#1/D)Y5ZB@B%&ALZZQB@\>U6T"/%UJB@JJ-1B.P7=S<9 *6/8X-!Q?V/6
M-PW6(]GL"+CJII&64##T1%%/QIH!,DA,0V-Q.&GV9KU*D)"H'. 2B$;I3[I+
ML9!0TM(8=EGR*1+$/ DC$8=PCEDB@NDR2"?KG,ZJROGGJGWU&^WK,1,4:@[%
M"T>PR&38WSO8/6C_;Z?SMW]\./QX^.OQA^./7VYRC]U.+G^P@$54\T((!WAQ
M@!G**$)/H=FUXL 9^D<%^=9)-G>=+0$Y4XB''7]H=X_NO9ZO;6KU70T+L=]!
M;NF*GXE%*"/G.F[&W%WIK.99M<-&CKMY/^S>WDWZ87?NJ[MT9>#R7 <'/]UC
M%SRW9>\#-%1=6UAURL)@_PYDU3\^!A-U-_U"'K']ZN&%>K2NLW>]U$>EAM.$
M8Y5;V;8ABJ?8GO8)]>?!2\A[BR6C*GTIC7<&MVMS=L>-5=:7I$=@:V<\SLG)
MB=%PFDY21*EO01'T?@^&R?GLI1!J_P40ZL.0Z<N0M-\0^.R.])7'I]ZGU=OL
MAF*VD;*5C-$<\VB\WUO>;VKV<E2"O896?R!1>QB/4OSIA1'Q[N#Y$W$C;RM:
MK3I/ ^]]R_N0I&GX<GJ?]I\_J3;R=FV7.$:7 ^\,0X7G+T?>/ENEX3)48^_8
MA! ^<0C!]QH'PU+5-X!QO7\&DU'P8DCXEAV7'YF$+=JYD' CB%?Z&&;>,0&I
M*<153^(HB1M:?EQ:_A,HEX<YA6N2$-9]_ED71_%/;VUK0_EV,)G*!'Y5,:8P
M\P]'0**9BAZ]V_7<#?/(L7A"\CU/47*<A\D%;/[EC%N=,, <(:!9X)'Z$/LW
M-?/49!HE,_48:>(K0H6KLM3F-#$)*TI;A94M Q=I#E95H)' 7,E:3(S\1?ZW
M_BSEHE$5P4B 4[T%(YMCD8Q#RHE@;$[I'(6)8R;I@Y-!X*3X:<0RQ8?W6PAY
MDU#&V;\2AE&D47T[3Y[8VI,Z!#8$?8D@\GSO)!ZV, <+L]XU;.NE"J+\<DAM
M4A@#SU3;4KJCM)_ ^0VHNYQ96JLZ*\ILCC+,7,/61QJF5U+>8LSZ(B0<K#O*
M\S")0MGG(_XCK->GO#^LHZ$?#'(^I8UQ<8=YUAN'Z<2O[&&OA;@CWB60&3*"
M]P$;LL%K3OX-+>NT2!'Y[X\8@08S#943>&_D^6/I"";@NDC:1]BQXP+K9)(T
M' 5SRP>^98"XD)-\Z9"X ]1(Z$ZC#6+FG9O,%ZE@)&C;MCW9L^-:5_/TRSR[
M)LO6:$J:45/9:QY^(6O.C2#T<5A<%%E.:;Q+N*SRD?4^ &QV%LWB(?.7MS7Z
M^?SG@'_5"A.L(S>0OXB_KH:7,:AE%S-3@TH4=J:F.:5%<=]2F)R0=.V$]>BW
MF/.7X#M6NXI,\/+@>ZD9HFE57)JEV<8.5>387>W43++TA>7S1.7",WH%3H_G
M3'G61U@9BU+!2#"!@:5<,BTM+)JRGC%E%G.*J:H"\6,G]53:BIB&?W,'T>E+
M-;"S[AI:9&%C9 >5HDNSP1@85"DJ$Z71WP0S$!_S<N=#ZTWKL&41QIP'\*S4
M]P#D]X<AEI]GWMGP,N$6"%KU>G:R8H&*[\J,54/X%:KQ;96^HX.N.=B:CSD:
MK2?*K&?TV*I.4;O&&LFUSC*(3"I?K&H=6F#4\6)5CY#)C-%,A)E\(<PY^M7[
MX!J8#V_6T]81M\I P'RJRL2:2\37C>"9JG;0=666.P5DP_DO(]9F'&!YNE$3
M<N]+&ER%0.A'070),W-WFU];:U(N![?[K;E/:W[]O?6V5>)*7+KPEM8&#HFC
M$<2L -U(ZD/K.?FQJSWJC+:/2;QS+&: OHH?+>7X]B+#R?':S"*PRO'191 B
MHG2=,9!:QAW29VK5#'Z_E+Q<4NJK7&E8!+G"?,,,3QKSFM_XE(87L+G>60$G
M@_?+^_='6L'!M@#XD3;3[HJ1WL/]]_%_OK@#.%=[@%4H433/Q*79K]/_0 2,
MIKW/*DZP!0!I2L!8]J.[FJD=,(5HQK 1!+ @29&TO_7+PG4OLH7$!J'JGZRB
MG5M\\F $XB=)D<:P[ +^ K+IV9<&#YKBE <N#7;)O,HUURL%"5S^Z54 (Q:@
M^ [)%LRT<?'Q\.SMX7__\O'X\Y_;? _ITD.R?ND.MG?R_IS T:KJ&;_\(41Q
MXMYAY><WL6D1\J+>IK4>Z7*#[6=LZY;2.#>[BQ8[H9Q!*S=/(#4S:]\Z]999
M50N4;ZWM3CK#CB!!!$;)1Y5?)^FWS/'=B*<$*QV%',EAY-!GMTVUTI]@]?+$
MWOQDM$KZ)U/7!S6BF^Y7H)^IJ_C52_,%DV_-?6;.0V2T;B31WXQ7#"888(\D
M7#[_UCN;P2\F3MNES[B<W/L*UJ3W>W(99Z!DZGEK?3*O,>OH&2S*QD^^19Q
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M6?!QT.4P*H+I6WAZP/_X6UK$?*0&M%F@<%= <J87Q3A'X54XPM&=3#"?0D'
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M]@;N TR4FS-6>-(UVJ^G%5]?M!A*X63W)+^$R7WUZJS-/CC"STX"G:LWETK
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M5X5<8A.^ADOP&K.3_%6RB,V1VPB^A[[5W@=QZ/T6X!:/LAVK5.54[S)6]ZN
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M.2\X8'0].0M7K6&Z4O3^INQ\G 8S_8[^Y/Z "]I$:J#/!E>D50K?X_)YGZW
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M\#TGP)/S#;6]YF$8M+_ZH1_R/(9& Q'-1)(RRBG/2[+=1,<Y-3K.5SW2J2X
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MPI2<"%XJ=Z:"9K:+1:K6'/,3E%DUL[P_V57OY%];A@V>K@Q[ZS:&UZUK3BH
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MU<A/_,C^X/;+MML7=XIAA&[3XA[V,*7'Q@98'?Z>*0LR(CBWXGY'Y(S._M[
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MU!O)EDZ_[Q]T]A?(%N-,>1,F7X[G_6(P'Q[/U#N8S&O7C\2WM/7&>=VNWS^
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M"E4)X^KIK*>S6Z$S\L!%IB(2:.U@C[0Q#0RSZM6L:'/%,<K8M:GFHH(>[.W
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M;]I-T(]^.7CZ9.>O/^-3O^#A;/#\TYUQM-2?+&%ZM??O!F\RG"[2XFP.9[Z
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M0N,JUEC[10X3"-+X C2M.!UA( FXV*0"HQ"X!?":BMWFPVB,)F9YJ=:@'H4
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M%,&S\2\[0=]!$AIDJI*0:^,\=OIO*6RU4Y13")#?53:]XD07\7QH2O!N\%H
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MTNTA-R5E+(E"T5ZI-0*S**#?:1(SX%BQ:6*5;)A8 -('PI8:,T0X0EBS"IG
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M&Z"=>V!!I"I[TV6L'_'(;HCRLZK_1AWYQXG,A0X,4):O-E"O@0ET/XZ'[PX
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M ,R#8J+;4^P%T5^GNB]I9\U--GW 6QG-6Z@*ZTRU8](XTC^X_NY\F3H\S:)
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M2/W/0'>3NXN-L-^1#;)XWN\\7:VM >QF&K .*TQ%[;/LID.Y1+R-?,RLZ(E
MI4>!RFG(4W5;T /3SS)<3/H]Q-6BX;@R*[E6_?)IW;IN7J7)VW$FMI*L'+>B
MH%$_$33B?] 3Q"3]9B;\9E/XS:+I&;H/ W0?%A:4ZR$YRJW99(4=XG4C]F5Y
MQCY>=.<OLJ8-WF9&P&)>K;<$##5IQ,1BT49-U$?.JPZ7N=,#PW)'/+D?LZ?#
M-'>1O^9-+Q%VG1(5LC)S;(-2>WYV+Q@)\.-_)J*+)F=6_&@M4/)V-E@52%UY
M,.$M5IP^<;%YZ03+#)^8#6_ Y'Y,69]$I?3:=]L*W4#:C\AWW05A<&YX%@>/
M% MYL?[CD'D+*(M2^CB*)]@@-=D1:+K @'<%X\TZL5)ZZEL6'P?"._IA+;&3
ME'_3R\W=49BD3]6T**P\*H^G2NP%31?B;1G"1$IQ$REI/G8CV0%GP4-,"25S
MF""K3^*RDE=D&"Z;KHR)]X.86Q0OWBB:+[@F2=)P7]^/N\?:@&$KVM',3"')
M<K'""I=*;_$/;MAT*ISM$2O<QR?"CF 7T4P0N20=:@6CI*/6_Z(N(&9 P^LB
M-"X""%8FF8"'\%!BIX]4AA']5:!!DU/N@;WXZ4 >T2@) AR^BDHV>I2O'!:4
M,ZKV<.G51@]+?%Z&C+HR+!2[!HVEX37LH:Q%L$8]">0:)N_P"VJ =R(;N+"1
M9!ZUJ%J.$Q,J9)V&+KP [>*99,]#;$#,3T4M2/BIA/SE#0<H,U?4AP$]QT[
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M$887 .,9M-';+J\<+F<6"9 K 8\8-$1/P?1DG@?[@L]6.14G^DDSW:[ZG_9
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ML]W.B%7$OXO$O[4@A")Y1?);(?E=(6&5_; TO$#)@3BE)C9!&:<BJF!#286
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M*6J6-P"?S5MH@B\3_=>P^Q](5=^ E,%UPD.2\?3&__U8:EA)0M$()(V@I,7
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M\Q0><N.],+QAQD(>XO:R#R95Z)5A;AOK6QXNQ*\)+9L^,7EN]@NINA&@'#<
MMC/WJD5BB,A6HWL5YM*6*'\[%K((+Y-6O=:+;8Z]@F?*)?\ >(^YR2@(:F/,
M.0_OO43SGC=IEV*!$FD0"7L1AG(] *E#?QNR49@.39!#[HF[JM%.A2_+;\B
M%&QN34B3U8TCDLS2V91;+'?G7\!X!%Z>PL*CM^35(AYKQ;#; ',B.H.0M@0I
MOJ_JOGOU)U;,Q2OO*V'A?251>'_DL3X6W[_ SCT&W(;@GRF\=Z9)'B&F<X3@
MQ9"^YO&XZ$&L%.M\;K@O><!W"5C1UWQZ0I82L&%N9=A@8[-,:IXW3?&B\'X:
MQ"D<'(.$\-W^D/7_EG?"GO%,U\TFH^C55*054WA]2N.5?X\M1<%N_\5)2&0/
M/(5 " \NN,?&&_D'!$DLID2Y+T+:?>>92H1Z>'$.-@3%4^+SVL,TUVMF8AD'
M')SV 6I'/GXAZH^0DV08X_KR1B8-?)J5FFA31Q%AGN4\<E"()X+=434H[IHG
M%N#"&B9Q3D/*=!A?&(-YM.+T> L)#YXG*E"#:V(  \#)\U9%:S:N*@G"CFL!
MQ5+VKQ^XW$>C" %&#,9 1D/NPL7\,(0UC=$ -04'9N]BT <@,8ML.._1-4P&
MS-I!(29N7[WH[VW,)4%<7#ONI1/T_$$PDD]QAL[D6O:TTB@-LTMP:1%4B3U#
MT)*RE<#5Y./SY(-<R8VMY+(P6XD2H]#2DBMS/6[*I67ETK$V;R5)M@F! B3K
M6/T86P/W].%@5G_*D7V#5V-[UF.M U:32#H!PJ/;$3U^2Q9=3*',,>:=B>Z)
M1!(,6C2,3'YXM9 ?:$N&AR3'=T!\&2[F#67&]@NPE<\PHC^(?/.)X<D$,3HE
M/L2.X!&Z31@)4A0&$?7>PMLJGK8?);PODJ>)S<U%0/PH^$!@R[?2\06HP^TF
M4MGD[J8OOO"M($K>1"T>!7.>Q)U(!%O8=)2\*_? R01^Z8E[L'F[ :'D!$]#
M3+<< N]1,CTS7#O,:#(DA"C/,(H!1[ (#T2()\MZ',L=E(#&.Y] E&Z%^<(1
M[9[+,CK01YC%!RZM#^\GK3< HBE!SQL4WJ"8L-[MZ_41;P E?U\@[F=^C\5!
MX$]"X J'REPH=)=(YO8$.]*%C_ZL'JR],F;9K+DR/"I7#D^<<KI6$II31UCC
M3+/;W>!LM:FS;9P[EO;N:YOLOKX8,]ML6K0<)',^F<X(W*TN1QOCN+X)CD\V
M?8,4!IF)R(.O,?,!K7SV.C3X%2#&RF,I'''UR$NJR$")&P'S]!AJGWD*:T:M
MS1HKN01!SPTTB'J^S,3!8%)_!!K4&E@\:<AC5#&MRYIX;KH8)EA08#RXO#Y&
M?AM]CQ3JIN/63U2*'WI+,NJ,?_8P$8,J75W"$:9<@U('D'K!!&,.(J<B9J8L
M=6"6.RH7A+!;</M(:F2;07I::X&-KV').A#<B^&:H?FUP@C$N"::7OB81\5+
M86NB3Y^U!1I]75V.NYHOGHDDIQATAD"3UL]V$F2YI&RV?HU29?D^/U>$)%PP
M)TYT69J3)=MJ_GJP;M]2^?[$-Y;]F$$?6YXH7."F^)OFV,[/J%T2^*J4H]?L
MX?+ \+(P2R3C+KB#E-?P:KW:.$VU]^RG;)L^5RO%&$:7#D_<HV_N\?X49*A0
MY'+FTJ9$TV]6\$@(D#D\DG<S])/*KC'&/F@13@SIERN&X<%8+PR,N3Y3 7_Y
M.9!:HG/V"[D/F.\2/))VWR$&_ M!U!D,:)RQA$SZ7(G)*O#9"O9,MV/Z<N:,
M<=EN3"=>P++QT;-P$HV\PFV,QLUI?QD/H"B7+;+$/J^67_RE;J2G.Y:RDNX0
MT?T3=]L=!9[7!G,0>/M@8RI)J"2A,A%V+5R1ZP2W]P0JWC\]:CV7J-IH[-#X
MMGU1)BI@D0DCIAVOR&JB]FFZX?6],]Q5G$(9(>M:Y[5R6!YY&>8IBKFSTQ,5
MH-B^_U_X#2Z>Q;E.2M^R;*$;^QG(W7%5C6?T= B3N2T(Q-\HS\QP78NW5)4-
M,5PJ-7*PQ,6EF@-00-BA%?'/RX;Y?)Y,NOH/+-=#1:+',C<S>($3^.(%A]<W
MUYU/HKONL18!)]XBM&<Y4?,%.3*(CPGBV?&FQ7SL.(3Y;B,YG?5\V;=DOZ/$
MTC[S?  \<VDDDHO-6ESGB=EA>Q4#"TR?6;A:.'+H<G8#O$X4B.3H":N M&?+
M![JTHUXMS![RLJW$O*/ICF//%GOAQ1Q6")O$K!MR1SR0$"_VU&,#?@3J2V5B
M=P-G!-S&1%6'J,V*'F?_"WC6(,W2H Y7]&R/^2_8.95G-/+2J^A;LI=+]**Y
M-,NK$X*)8R>ZC?%"Y4% 76E--N:U%J9HYY H!XE(@SM@>& O6:$C4B_E)B>N
M8P9]/UF5$3Y,_;N9^RQJ=Q/0B1\P/N@GV@)5I/%LV8GE8B_CL):^,:>4?K/F
M4^1B4<V8,";:U'!$"=CP:0*.)J"C<?#,D;7+.Q7TA\P,1N"HSH(ZE]36L^4V
M]<KQ/M,U\KY#TSP(-++<1[2JB55-4@\*V<7ZXYFP9R7)A#UMII@)V]P\$[9:
M73L5-HLU,_!^6ZN<7TUL5A.HCDQ@FO*^MN^PYCHSJ_4=)"K[CX-:2%'"[A8+
M5(\K%9Q@2U&&7RKTO]7>I)@(G.^\RRDI\7O/_>UKPC-?RU]1&,D>(]7,,*+N
M"MY_O\:PO#KLQ5N.<-:JBS0Z\Q4_<KY1JYI^5D\WCS#5,%-9,)9B D#K),?K
M%!5X3P;>S6=R]TM_M1@&VL6!.W847!0=6::O$;.24*WLK@\5[C*65<V62L<H
MG!"[D*/&6&(\-Q]34"+))B)/66]Q!R&S7&Y<L@$#@\;L8-P9')T+I(N<!$9=
M/SNIJFR1;6=C%'U_"@M%V%\97(=Z7EKW<>&5P/Z%.,(^C'3^? ,>=;U533=_
M?O\"'AOC+T4+H:&?G-:5A;#U-*;";U#AH1@;W"3?+<N4B.F;!>SOA:WTP P:
M^"^&RUN T20G\/N?L)MQ'SN!8;]-.=S>TQ--GMG8"L8\]X<K=H.'7+2)\<8S
MCS#_!%-;:&2%G,2'^:F8!O3,Y)CP5Q_G/O!.R,>:#-Q02@WU)+.HH>A MK".
MUL<I5,PV<? ?#<8)TV)DWV2-T#GS;M$6;?K--.-Y67@ .WDM+ P4"3K4.]?A
M\Z/)TC%Y"UT^X%V.<8DE\RR>,^[%!D7!EOF C T'.,_-=M!FKL>+T@6U6EG4
M!G5Q;\>-&R6>;-(HL;%;;4K7;NZ*#S>+UJ:TN<GN3W>Q36FQ6XB>;@+_UHJ!
MW_<N%H;Z;_<C'/EMFS@E8A+-K<PD?S"5/J3Y96=($)$2#>&CPV;\N;.?8D\S
M^33I26KJ2>G;E'3*9PGT^\$XX'H&5"=H'HO(X!AG,(2_\>SO45\\&.5T8T-1
MW/H1[E4D1O.!.5Z4O IJJ;M)4])0ZT=INH''L&'FB.9!RJ::Y%HM: ]*6:G1
M',P;&]@19P-=@R46C<<VO].ZM[AL9["0%O-(L*Q7#F@<]>(S3Q9C-FH>^N$<
M2=R'RI&<SI$\:6V<(UF?D\ZXCXF+NYT:%TH*?BXN+[1;:\"H3>\;,USOTTR2
M7+%N7M_MZ&[G\O71=?H U51COAN0UKNL%:E'!FPM[?!3G/$;N8B!AXLO7/O\
M[?%MPMJOEC<[Q\L,7"3!@Z^-6;&_K2N''2.W6V9XC.8Y66.<@I(<![X3U#?/
MG%F/#L/#W\3.OBE5?NT.'=?GM8 C7%##@3U8MA6:, ,FK#:>61R#=)YTNQ_R
MLT-S)",+<:=(>5-!R@\;?ET)U.W3'U9Z!2@.9-1X6P28=CEP/A3]#5SB<3#F
ME.RY_H-A/Q&Q_NP*>%[B<%4G97JO3]/[44['-5ZW<=PY[*VL]S2X_SIP;8LJ
MI#%,,0# P\];,Z=V4P2$,(1%K@4$-R3]Q6)D$Z;(20:D<MY%<F3)>4_S%P*E
MXO50TV_=UMQ-/I?P>Z_Y^BXFWY:B__AAW\'A*]7\EC(MPOX;S0_WWXA:&P%P
M;6,$>)&6T_O',I>E]4:\D$-"9='-6?@LOR 1C8V\9$\5#F,<;L>M4IR5)Y-C
M>NP)6^:\#$7_F0E\TQI;-O;:F;C.?UF?)MH^\:%]P YP=B:NRWS\+)R[2\D@
M? G^M1><;]MC4]^BYCR4U$*9)#ZS\;IM$-A]?H77X9,+-6,R 4+@Q\(V,*##
ML)T([YT36==\<WIX2G[1]"I^(6#H.%^9)ZCP?=M]E\(X=*7G)E-C N"F$;\F
ME"""0WI!#Z?T^A:!41Y(-"8US+?9 P4XVWP*.WV,,WF\1X]80R -YT#&WD%]
MDH"RDJV*C)'GQ/;JS:+:F["^-0 N"R;4$HGG,(DV2&)P.R)Z!G/B'M,D@\;C
MF.,MC_$B%.].<*>PL0$S^"-D* NDP7;\-^P!1*>G3"F15>2&%Z0FWO?)Q"'L
M-20P!'!*0-H8.Z! _^&#EHVINUJ:QLVO6A'8<ZX=!TR/#7/\'7L=2,9#(7MD
MO1X-+1,,C,_\/_S^L'EZ\)6FUO_^&W[C*\)R[>^V#KX2-\OOTO5*#/=Q;K/"
M]+2HE]*<YW0^"GW.C$O1F$KSAHSYL99(I^F)9" VRT5BZ;B7()H<SQAU!K>.
M_80A6E,U2IKN1!?""QD9X71$@%K<,XF>&=$S/!U !][O#Y%!%EV7XQ#3N73"
MNW-A"S,I5:/M(*LSY!7VS(>BNMC;'.P/)$*M;[G]8(P2IT\?F"AL8U(<&^>]
M498D35!/)#  >MYH2"K//42&Y,-D'^=_T=!&4V=&3N!35L-OHY2V?.J:QDR/
MB^!@+-\;P 8]Z@1*VH*<];[A#;4!C1]%*=,74E (KH'KC/E7/2ZI"0S8@<TD
MLK:D\ V/Q?<?;3L&RY'C<3T"@EC'S8]!E@<N%VO+VKE)8/ F;0D@<AT:%V,#
M>!U_\EB[#G_&UP%',Q?4,BE /@'XV7 M)_!BDW\IR=7Z7\ HGQ7%#+XY!K<0
M8-K8,=D('D-7B87=X.AUGBY:SEFN>30QD!K1)4/U0+0XF8!(!J& SXF^5R9S
MJ2T=]KL#PR%,;UE0=1 3,=."Y=]L9%X[+MB#F<[$(X/;#L8OCFMZS%Y5)O&A
M#:?2?GMFPW>.-J=:8NJ#& 'SJ08>F%+/2*% GF&J$S@>,C6*=)?&+9@E/=,0
M].]2+K= ((S1!5X:.F1UAE)U\63O75,T'&IS]$F;"VS@>#8)#4HPGEP7A3W/
MNXMULXMD"5F#9#"04(J>1XE#HZZIA:>'\INN2'F/26&7!"1J0&;U18_0I$:9
M8/-'VY<IZ8G50]DDQ3/?,>\32C/!24(>>I_"[I?3K?AP;ZXSBO+NQ#*DOZ87
M2MK11"+,)/%%0Z[)[ <9IEU;:+VB 2ZZ3N,>NW @TP"VT\X='(]]B'NH5;Y<
MM[OG]&/URZ=YSVO?)VBSA<^WN]_#QU./_=0JU>91I3:OJRPG9_PYC()M'EJ:
MOQX9)/U%I*K%:36"P@47**V3F@2'CEI;6@-/-G >IS>/;.20^O@%_4##OK H
MJ)!$*1_4X7U9IVSCV\02].4G<-9\HA>@MG 9V>&4WAR2=V(U))7TXW5I+T@Y
MTD?.X AX(0[[D 0?.A$)BKZ5Q+BR;A5^3GU3H N.Q O$;C@V1Y;1L\!QM!@W
M)(2_3V9D&DT[-=-AW,8DE8>?##A[ X]R\@I56)8*XG;ZM%*D62A@ 2Y@B]HD
M# $[(5;05P3[@,<;0DV=D+]2P(:6)8=K6$,4921+V]AE8Q#GX?F))\!1!8?#
M("__OX'GA_5'^,UP1V3PD[$//HD;!G#8V M=%U0_-J9$ SHGHB8KN2-=HU(F
M.I6,QU"<X%C["Z,2R)-<@6'OYE<,I/">W;0*>[4HEF.$^BO,\AYC]^=(E8$"
M$.M00K?A.3:0U9O6%P<%4+%7YO:MN$8#$-O.& P6U&=8=R7!*]PA8>^3_B*Q
M3KG@WI320S!Q'TO('YZU3OV/PUE20K:);/-(ZBR)=D1@(#F&[&+'5A0QEF/M
M!_@$Y$N-PI<OCL(L7F9EN=0N%5Y5%Q5>)2+L'RO$BJS--<M,X-&?U?<4LK0V
M*60YVZT2K[--SE:M%*W&JUK9:/_57:SR6LXGD?'Y]?=IOI]))"'K(K07M+EF
M40$KR=;G<7JZMND[I&3(L RLS4-6(/51#8W1[K)"1VW:T1+:BHPHLJ9 #3LN
M7G&/WF0@P3"M4>17(G4E3;' M_B-!7F"$XQR@I[R6?PJ!BO476J93AO3Q00
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M6)@'18=X$R>=?'DM0=\"M83I8SX&IGTQ((:)0XAEJ3%&%$F8DA$+DD47]RH
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MM'BRP2[-@:GG. >FN?X<F.8[Y\"L_0IZ^G3'YL"<;G2Z5N'FP+0VVO]9.>;
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M3I+G8C&\-"H>[0HK&9<Z<"OJL;#5A@9G!<:DJ\O&SH0O!@8Y0W<HLWR?'QD
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MQ.E6JHOBBJ@/_).9H&8,\G#FV>?-4?CRZ+7=/3DHXN9GMCJ#AJQX)"8H6Q?
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M2%?"&58Y)O(*Q53E@<0Y:H\$'C1(AM1++R<QX2Z]5]V")(7+7LF(7#3T'C3
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M8%T^W!W0=D#X*N6&7F8A\ KCL,AV C#>K_"-1-LILTC)J$[;ZII-$##H"A1
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M&K[!CT$ZWI3\&C^>@N*0B37EW@QZ\I"[Q:E**SGNUP!N^ W[T-))Z-0YC#H
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MV8FL_YK.&4V#:DX4D>6)LO9Q4931$I8PZ;8QZ26R\9.2KO+X!"&93(031I8
M'<RU"@7[A)Y J\,9'5A33A;/S?/[PP0'\GSK3@R!<A]LZT'X(H2G<!3''7F^
M%\4A//LD]+/P<YP*@JR@9DP4$L7P/U0LAI@K,'(PXHQ+^ ->_P@/XA#\!<P,
MGL?L",>?6(\P%3^(+:</5(5M2O##"G)+8.&A-?!\;%EB#;%8+3HHP719_B5)
M)TQ1[9,/4=4<'<PU'0ZM1S%TK6<O?I3[A60!J[O#G4HG/>6F&Q,\71B89BK<
MSZV(@([ZCT;J-*@L*EU%)U8W@%BBOH!8)PT@%F[#Q?G-U?WYUZO_??G9NKO^
M<O_/\]O+%\-A]>*1^]M=,H*53ZX'%\[8 P8*B]6U!J#,$\A=?6&QC$GK4J,&
M%*L!Q6I L;8:@JD!Q:K;B32@6/4+7?]3]")0LH'^HHV!OJS%ZTB*2HE^(C>
MZB#7%G=N'^Y$;<%6'-Q2@\A')]N6?K,[K,HPO7<S^7\Q^C>V@[+6<3/6Q,"Z
M=N=D9>4QS2FN+?C5.6O HFK'YHK)A(Z11[5#[&Y&@IEQ6?)N5F-SS!RS-7&_
MCMU=82I9<ZH+G.H2N6';[K:7J]LU"8)U"T$W"8*[> K;:CBM+4&P,L"QR_Z>
M.03.^A($C^S62=,S<7U'MT2]X- ^6B>D[BZJ!6\O-:TYAWJ<PZ93!$W+72>#
M86):OT0DSY,9.,U\,M[57GO68*LDCWJ>K,'7+FA%&87'IT7_YDLR"FTK%-%8
M]#$;<#A1^86E9+'A_,)-)M>!Y1\D,-$;9X(W%?X9)L+]ZCD];^C%GHC.??<:
M%A@:'Z6I=A=)&+ZZ[UZ3<;>*7(#3)N,.M^'\XN+VC\O/UN7_=W/Y_>[R[C5]
M)^_ZC\)-AN)Z4+PF-4^TDQ-67"M2^75->EV37M>DUVU9,E>37E>W$VG2Z^H7
MS%4B;QP& Q%%H.^#(C\0&X-37ZO_3B[^QEC[%UBZU-?7E:NR.N]=<W"K#<BV
MSU:6);FM,:.U,RXQ&@^#B1#[JK!UDXG"ZT=]NY3+O^75&[;6>KG8H=WI--T<
MUG^$RTVW*RE3KC<_>T,:VDB$_4?'CS>IG:WB<C2(XB](U)5$\4W2Q :4G]-M
MR\S=/8[@H6TOHEV"*&Z8P<MTB"M)"C) M6;%H>E$4CL>\54\8$06.84S;!C$
MFV40I"T0,9PS+:S;1])=79>J1E&8U=8=4Q)VZ/)/EX&TVF+,>;U^D+9]?+:R
MGH;-^:V!8;7.UN@$V<5LVK=6WM&<0AU.8>=,A;55W^2SGMY0Y'=C:L*QW3EI
MPKYK.;5E)EW;K267X+XYY>#ME7@TYU"/<YA>:C-?Z4UI)J]52/W,3*9ZI%?F
M*Q?S_-Y]_++?.<HE;T_#449](C<)01EW6G/J">"(H#D-GYU)]$X-]ZAYE-2)
MSN@_'^2QP-F9!0._5N1)6P>GJ.2D$[) I3DX/DD_XTFE'YO9AQ:E'\*4'.LQ
M1.;^MSCHO_M(*>:8L'V!$L''5!#G8\F.T'];OZO=R4RQH/,10]>ICE9I9F3)
M:9A?\WZ<'AQY?J&$(*/W8>*U^B3DE7(N]M2L^\^B%R\)W)D>\7P0M.<@"'&H
M.S$4).M^G'3/#H^.3T^:>I35),^>-?4HN U?K[__??_^\O:;]?GRTTS8YQ56
MA!09%_ZMUV6]FAIX/*HP[!=__LGQ_T)>=DY7WK'N13BRO@:./S^/7\HV7/G6
M-V=B=5KM,YLJ8130/S$Z#D4'EF/UX6\/X?)#QW^@VCYK#W^.49M.ZT-^.1?\
M\_.'4-"/Z6?M#^\)8A^&XZ8 GC.$\:/8BQ.R";#*T0'"@ZT8XE;@OV>V?NC%
M5]1$'5_S!?3R\Q$6])78#:TC9HOMLQ\XW>N!G"QN/>Z\V78].RQV6?_Q%0[N
M>L +,W_*G\";T7"9++<A^U'+;K6*?2*G;KVF)+7GM@5"KO^(.AA68>KD BMT
M8F'A;4>@K\B:*872#5%!Z5L8 =^7QXTKET:KWO:/7Z] %EG_E]5MM:Q/3N1%
MUDW@817JWJ>;N_=Y3?# .J?ZU"EUM*5?M?FB!$D<Q? CX [6./2 FL= S@&7
MPU9?[SDJK;\&_@,^@+LQU6NQ-71<0L)S%&C/NP_MK=F'[HE]5'*?\Z7::VJ1
M,HMI6["\("T,=T@!P >*PL"6S5Z8TYARI!\D0Q=Y3Q@\6\D8NQ/-.G;C8-0Q
M?'-^>J-D](F&@1MWX:!<CB<UOAY7W[_,'YLJY_/<>H=V'=E&)&+</O%S[(54
M>&]22%$AP:HS]>U^)/K[WL_]1\]UA?\;_P^J_,?H1ON(*@"<*VS:X>^_XG/*
MBL);RJ_N)Z@-]";4+<>)8"ZZ-X4\ZFRC(-=SK?G/N<;7N_H<<5/Q+)_!=(F$
M/\O'.>]Z:TNWA?7Z08G+-/=!;+FA\ZSD8HZ#N$F(XG/A7EEK8)"@&,,1^6P=
ML]H:]&+'\]6$9W)/CU5KNE=Y[1J8*OJW73 SD&_J+E68 4[K5#4O#DP_],4D
M^PL8<P8351K:)8=^2D0HJ,,M5H?O@RU4C=MVNW5:P3&U[#&@;F#W(]EK0',U
M"88B3Q2^CH-4.U8 )P%8YG1V,!<@UWBBV%ZECL>3Z#E#ZGLV4R/TL#D9O-V/
M&7VE *>B1HH>!4@ [ XD9Z"(Q(4C@6&BA'Y&:P3EM@SIQ>@1B .4/%@UWP)Y
MSZ'(FE.X'GQAFP^$=PEN_F8LAJ51XUDQ>#2/AON2#<K #FW-!G4ZQ63!9: :
MG<?6?R>^D+]N\:]M>3M&DETGOKSI,'Z>KDNOP$SV^G<8.?H:@!H$DOOR9PQO
M2;SH$;?X>E#&;&M/WI'WX,-GLXH!#TNPMIX%(H@!:XR%#WLW0&<"& NP.]8@
M#$; ?,S]P=WE3?=-D:@%W,N1I,"\(%:7?]L\[&Q3.@7-+8G@3&&W8"MZP /P
MVZG..!^&) >9DYIJ$6QJU ^]'@H,,0R>X6Y88Z3ZP-<H-V"D15*-@9_1X>#G
M.%XZ%!UG$K&4",48=)@9 LR'D8?#65MXN@-NV_LP0=2@37EKK^65@;N%?.TS
M7(Y%"86H3BZ#CM3T)5:X;5EAP@<E\U7Z0^JJY=:I/!DY6,$1N7Q_;N>8^>C\
M//$'+WT^7KM$;;5S5&'A*T4=]:Z><F]$TIU"1UNP*R+0"/%Z(K/S,+76!C.A
ME)>JZ!Z?RQVZ*YW0M:Y!I?4Q2&-IE<-"5ZXU'B:H'5O.> SD3T% )EF\^(L<
M''E?[X!#.^ZU_Z<3>C@6OJ* IJ@/D:R0%QSH-Y#QHV3$OXK"^!9]4O3-'3LM
M]&KU8G$B=\$@U-]<P6[_O'MVQOB-^3YSZJ\FGS',QJ2?E'SV.[/4IX.BW/W%
M@NM4UT-A?]T6'LKA(H=R4G$J+"_!WJK7K<(IS=S,I5R]#5V3=AVNR=)WN?(N
M;8CNVZ5T3[98N?7&XB<;=^P_PA5(/1%*@2&WS'@<!K!F^-EPLM#1F7')R\&
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MUD,81.A5#]@9-PC!,,T,CN6J8Y@R,LY1$(I,VFW9-9**_]]QX!LY[JTL_<.
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M?1UP53U!*) 4*,X_DI7T6+J#+;V!%RKW"!9#Q"B34R-".E,-62$+(,PR"BI
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M ;Z(D(=_:ZUHX:XY%>-Y,9!XO_CS:O])#A5_U?MPCM":43_T>HSVSHTQ6N6
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M:6AK_3)-F KGUN5]V[$F .W*)@!95/6%V@ 4<<P7 #T_VJYV $>+K.VX;NT
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MX^"L5C'P_][/4YB)L3@'L[\2"_NPOQ(+^["_,K2VD=!:_D5F&4E;Y%#OF\,
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M].&SQYL/9B(H_ YL9=1R4:Y']U)1/.&)P,IT9VPAYD0R@T3^7&JS42@.47G
MDS('*1R#IL9W!>*&$<Z&N1QQJ)#[9WQQV\<+>>S_1IM 2!GFH\\(A2 Q.8UI
M@A6A!Z>(B93H+Q7T.BPPX<T_B"*B+CF'[NV@>RAHL$Y8*&^.B3+Q?0 S@(V8
MP4=?YLFM;5I<J['889I=6TG5>)B'3;(\^"?G,J"+Y@UQ("<GKL:H:UZVK5_^
MH@@<BR'94B F,?'Q/#T-D+]%GR$(VX@F5"D:P&]YO 3?*@=$TG4B;SD(CX3X
M$S\Q9Z$2?_&DFOK"[H<A915Q7?L+\X +4,=\\KUGUP9]]<W;&D;>$A/+!_HR
M<<DL+N^>F4ZX2PU?V-D6?8)M<'S.Q6&EV;S(<GW2LH^-'Q+,0"[>:!2 12P\
M>\H,,^+@8B(8R'\I$4@L=9YB*=![RJFHZ&E?@ I0.S8Q CH%4QYR !Z"ESM,
M6Y_N;H9F,)82/)YON@2'][04ZA"M%..2VX9+.ACM!&/=2J.=K;<Y?,[-FN,4
ML/+9%.O:+$YZBU%YJ>[V1,2&7^5?R@!V7HW]FCGQ+?$@K,CO5KHYV$7#1_J'
M/)C'O>0SD>?^_?ZW.*5=WCQS[8)?9=,YN1%)!A==.'O"P )%#A1B.MSPJJS%
MSVGLC9_3EKX-H+OS1[.V/W[./EE,]QB+*<[HNKB6)$93D+GU1/2'["W\@)B]
M(U?DB1@[#KY0,S\15XEO'>X<T]7C*H9I@?[A>BW3"[#* 8AG%1<J:%V*L=_"
M64NG,A]5EF9S<UF:*^0"-@XK2[.Q2I9F8]^R-!NK9&DV#C-+,Q-=)5GU\><T
MOV6:-E "O1(U1JYHVKN\S\:F\SZ#>$BK= ]D3WK2%M4EMH$:+9!O)<11=++^
M*(;.;0.,&8%X?_N@@:5Y3MU6)W]@ #CV #X 5(!ZPC#%E@R+4D\)%F@A&( /
MT!GYER;8I3]7I!84IK2YHVCQW^VLL\5_;^46_]WU]^,OOF39CY\+W</L^,V=
MTK+=^DZ _P_ZDEGGO/M]'_8(K+/+80AK+[O[A4)LG^.ANW0@:KKTN]Z9M6PV
MOS<=L<AQU%(>T&7,3\XZHK:Z2\*RKXT#<4<^;G<4W&*BR</8='D+SN &PX%X
M*<!+)A:5KM?_R#,I 5MSPT!_/#Q[#V,O"@"1#\_P^AE\(+<D0@L86= 7P'_?
MP.'77Q8T/Z)8]F?:.?E)521T$(EME-JJ#=1^4^9O]Y__F#+_#U%@%!-HHS!Y
M]JJ];"YKV;Y]2^W;D=Z852J4-W,T03*X=OFM0['DJEUS[]OT2J]=J;5*I;*O
M)+BJ9ME3&EV#AFF!7WI@&F9W[L[65,\7SQ\Q^[B4SY(Y )MC?07,4U) C8M.
M;AK,(4ZE.!(5).@P JR6^B?V<+KKG;%1>CC%U<SOY&:7.N;MO,TA>5(*IE)K
M-RO=-5N/I8I9(QF66B;6,CE]GS:F9<I!3H<_O&9C6-C:XT?G?>_?9>.N)O <
M4VQXA<O&W:NBMYE,]4JGT:CTRKCP/I+?FRX;=T^9:S"2+JJM+;KBQV@D-<$(
ML;P(,S[WTTI:RP:/T$Q*S%Z:VX9X(Z77LC)H'^IN]];_>^V,[DZET^IFBP57
MR2BOZ"68:!G*YBRJ;;YIB)[Y6!2U]F1%P.)P?!Y-174%H#YR5Z$5:MG*_">L
M*!!=BD6?PC!9P%]\FDJQOD58Z+^$2J]$J=L]WU\^K2H-S5M_/'BAZ>C?8[/6
M&R_\)P.2D6#9>UW]VC%TE4XOIQG:RD2AD70DH$NTC16QV.=$/";^.A2/#A+=
M 42]Z[/,%S:YX:2UM).][K22V$7%*QNC!AX-^^+YXB-\KF"+G^V32DZ1+,HH
M\!ZJM4QM+'YS"MV_>,LO8;)ON:57=LS)RE6_ _9HNG'%K^A_+DZ35_I;,2P;
M6"WT_( WYL">)9&#74N.K2SX3?5L1!>"++9:PM9=6L*F(WE7M6S=(ZEEZ[76
M6,O6[JY<R]9;?RW;3I<LR^,.N4*K+(\KR^.TIZ]$!R@.]#LL'2]IHZ0-T357
M^&*[W 0VE4!7-3(=_NH'YD]VN:&S?V*CH?=EF>?>W;Q*#^_4*CVIY5'CITUO
M\;"N!(\#*(=%+F7*;%D4N)Z;]]RZJU]\+R@XLG"O,C?:E7JG76DVLK'W Y1(
M^Y6Y$:Q$0*DL#>G[D->S$[I:0]Y%L]K+#A[9&[K:B_OY8S*FRR+"/2SPR)9H
M]5WKZF5J^WR"Z6J5'7NEN^J-1EFFL0O39RDQ':<RZS9+97;::9!EK<BAT>7A
MG^!0 Q=[&5HMZUJ*ZOC;&)I%ZE?VRC#$%D6-2J<,:NR2:E:P 3=+2T<?R-@+
M,;1@I,M@.3T-5J8G=0&L7<+B]6MC2_[%W&S6BVH[F]U6EAJ5I4:EE;W')SBZ
M8.S6S6\QKX\R:4O;^TU6U%4,RH.SO>N [59G8^6VI>6]G&:.R_*^R,XH/4!:
M.CC+>SX]S;.\"Q:>;<[R;E3KI>6]:\-V[S=X7';KX9_@Y[)-P1*)J<J'XYK
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M 1'9(PV1)HTR1X9(CN[%KM!8^X -0..GM0V) :N2U&V:'H]]\[TI"CE5ISU
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M0&K1^6M@H$EUEL#5XI]_LCUP*7]S^>AI#(7%\6OQ3K#ZXX8K<?5*HE%6G?*
M\/_C&N0B.T.+,H@&?PJU#'@9,9N\0UM4PYB^B\;J ]@;CXPJAWF# 5'RBW;
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MUL4'J]EJ=)L=8.&F8.%[?G??U^[NO\N[^\ODW?UUXNX>/AA0"(;3]=EU$?X
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MC?E&8Q=T-0D7\L.4[OD^SS+1KJRY9 BX9D?)@"SW; ?BXE1; CB%9WB9%OQ
M7CA+[IN"O(HM,*PF%E=O25 @XSZ"; MP2P/''H+(A/_.$&SL!2]BM=N^%%3(
M*>?VAT]T60$(,I2+0X;7I57  7?$GY31;AI#Q[0GA(+T7N1&:*,Z?LZXW*%K
M8)(3YBR^K4K !(X+NV9N0*[F,/*%J34U;1*UID*;PAK/@$KC+ =E @BPNR%
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MV1%]._R><,A)2<DIR"DI*"AI*2@H: \_*&B_FE#]5QP</ )0$6&#OX6'PP+
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M:&EO698CY]+8]B%;D 5XI()QEF4Y^A$$:*:C#U1"HF! ,0$1?H@0" 04%Q<
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M )!2DPK/\1N::E6_ 5B? M5?U@YO,YX\9W9;R*4S1S<*)7"A3/+3:U(JZW#
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M8^.TH;'<Z<+>L'*R7)(B'H$2KOWX.IF"KE(V*B#-H[8RK_,NC\I0BD]"B \
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M3ISG,S?I]25>\7R!GK8T]4@TB+R]U\GL99P($15KQ'[7MSR1^[ DZ1S1*6J
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M,#(R,3(S,5]D968N>&UL4$L! A0#%     @ _:*%5I2IE,5\G@  )2\) !4
M             ( !5HT  &)T;60M,C R,C$R,S%?;&%B+GAM;%!+ 0(4 Q0
M   ( /VBA5:1YY7]!7@  #;*!P 5              "  04L 0!B=&UD+3(P
M,C(Q,C,Q7W!R92YX;6Q02P$"% ,4    " #]HH563SLENR$"  #@!   $0
M            @ $]I $ 9#0W.38Y,&1E>#(S,2YH=&U02P$"% ,4    " #]
MHH56EU)CHT:0!  %E"8 $0              @ &-I@$ 9#0W.38Y,&1P;W-A
M;2YH=&U02P$"% ,4    " #]HH56KV6^#@\U  #6@@  $0
M@ $"-P8 9S0W.38Y,&<P,'HP,2YJ<&=02P4&      @ "  ( @  0&P&

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
